PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Elia, A; Constantinou, C; Clemens, MJ				Elia, A.; Constantinou, C.; Clemens, M. J.			Effects of protein phosphorylation on ubiquitination and stability of the translational inhibitor protein 4E-BP1	ONCOGENE			English	Article						calyculin A; eIF4E; protein degradation; protein phosphatases; protein synthesis	INITIATION-FACTOR 4E; NF-KAPPA-B; DNA-DAMAGING AGENT; MESSENGER-RNA; PHAS-I; DEPENDENT DEGRADATION; REPRESSOR 4E-BP1; CALYCULIN-A; CYCLIN D1; KINASE	The availability of the eukaryotic polypeptide chain initiation factor 4E (eIF4E) for protein synthesis is regulated by the 4E-binding proteins (4E-BPs), which act as inhibitors of cap-dependent mRNA translation. The ability of the 4E-BPs to sequester eIF4E is regulated by reversible phosphorylation at multiple sites. We show here that, in addition, 4E-BP1 is a substrate for polyubiquitination and that some forms of 4E-BP1 are simultaneously polyubiquitinated and phosphorylated. In Jurkat cells inhibition of proteasomal activity by MG132 enhances the level of hypophosphorylated, unmodified 4E-BP1 but only modestly increases the accumulation of high-molecular-weight, phosphorylated forms of 4E-BP1. In contrast, inhibition of protein phosphatase activity with calyculin A reduces the level of unmodified 4E-BP1 but strongly enhances the amount of phosphorylated, high-molecular-weight 4E-BP1. Turnover measurements in the presence of cycloheximide show that, whereas 4E-BP1 is normally a very stable protein, calyculin A decreases the apparent half-life of the normal-sized protein. Affinity chromatography on m(7)GTP-Sepharose indicates that the larger forms of 4E-BP1 bind very poorly to eIF4E. We suggest that the phosphorylation of 4E-BP1 may play a dual role in the regulation of protein synthesis, both reducing the affinity of 4E-BP1 for eIF4E and promoting the conversion of 4E-BP1 to alternative, polyubiquitinated forms.	[Elia, A.; Constantinou, C.; Clemens, M. J.] Univ London, Ctr Mol & Metab Signalling, Div Basic Med Sci, Translat Control Grp, London SW17 0RE, England	University of London	Clemens, MJ (corresponding author), Univ London, Ctr Mol & Metab Signalling, Div Basic Med Sci, Translat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sgul.ac.uk	Elia, Androulla/AAE-6854-2021					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Carroll M, 2006, MOL CELL BIOL, V26, P8586, DOI 10.1128/MCB.00955-06; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Fawcett J, 2001, J BIOL CHEM, V276, P11552, DOI 10.1074/jbc.M007988200; Fawcett J, 2001, ARCH BIOCHEM BIOPHYS, V385, P357, DOI 10.1006/abbi.2000.2160; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Graham B, 2005, CELL CYCLE, V4, P1342, DOI 10.4161/cc.4.10.2047; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Jeffrey IW, 2002, CANCER RES, V62, P2272; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Le Bouffant R, 2006, J CELL BIOCHEM, V99, P126, DOI 10.1002/jcb.20856; Li BG, 2000, INT J BIOCHEM CELL B, V32, P677, DOI 10.1016/S1357-2725(00)00010-8; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Lin SS, 2006, J BIOL CHEM, V281, P23003, DOI 10.1074/jbc.M602648200; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nimmanapalli R, 2003, CANCER RES, V63, P7950; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Othumpangat S, 2005, MOL CELL BIOCHEM, V279, P123, DOI 10.1007/s11010-005-8284-2; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ren Q, 2006, CANCER RES, V66, P5209, DOI 10.1158/0008-5472.CAN-05-4158; ROSENTHAL K, 1995, SEMIN AVIAN EXOT PET, V4, P1; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schneider R, 2005, INT J RADIAT ONCOL, V63, pS146, DOI 10.1016/j.ijrobp.2005.07.249; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tilleray V, 2006, FEBS LETT, V580, P1766, DOI 10.1016/j.febslet.2006.02.030; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135	74	52	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					811	822		10.1038/sj.onc.1210678	http://dx.doi.org/10.1038/sj.onc.1210678			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653084				2022-12-17	WOS:000252884500010
J	Fanelli, M; Caprodossi, S; Ricci-Vitiani, L; Porcellini, A; Tomassoni-Ardori, F; Amatori, S; Andreoni, F; Magnani, M; De Maria, R; Santoni, A; Minucci, S; Pelicci, PG				Fanelli, M.; Caprodossi, S.; Ricci-Vitiani, L.; Porcellini, A.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.; De Maria, R.; Santoni, A.; Minucci, S.; Pelicci, P. G.			Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment	ONCOGENE			English	Article						glioblastoma; DNA methyltransferases; DNA methylation; brain tumor; stem cells	CHROMOSOME INSTABILITY; DNMT3B; HYPOMETHYLATION; GENE; OVEREXPRESSION; FEATURES; REGIONS; CANCER; 3B	Cancer is generally characterized by loss of CG dinucleotides methylation resulting in a global hypomethylation and the consequent genomic instability. The major contribution to the general decreased methylation levels seems to be due to demethylation of heterochromatin repetitive DNA sequences. In human immunodeficiency, centromeric instability and facial anomalies syndrome, demethylation of pericentromeric satellite 2 DNA sequences has been correlated to functional mutations of the de novo DNA methyltransferase 3b (DNMT3b), but the mechanism responsible for the hypomethylated status in tumors is poorly known. Here, we report that human glioblastoma is affected by strong hypomethylation of satellite 2 pericentromeric sequences that involves the stem cell compartment. Concomitantly with the integrity of the DNMTs coding sequences, we report aberrations in DNA methyltrasferases expression showing upregulation of the DNA methyltransferase 1 (DNMT1) and downregulation of the de novo DNA methyltransferase 3a (DNMT3a). Moreover, we show that DNMT3a is the major de novo methyltransferase expressed in normal neural progenitor cells (NPCs) and its forced re-expression is sufficient to partially recover the methylation levels of satellite 2 repeats in glioblastoma cell lines. Thus, we speculate that DNMT3a decreased expression may be involved in the early post-natal inheritance of an epigenetically altered NPC population that could be responsible for glioblastoma development later in adult life.	[Fanelli, M.; Caprodossi, S.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.] Univ Urbino, Ctr Biotechnol, Mol Pathol Lab, I-61032 Urbino, Italy; [Caprodossi, S.; Minucci, S.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, Milan, Italy; [Ricci-Vitiani, L.; De Maria, R.] Inst Sup Sanita, Dept Hematol, Rome, Italy; [Porcellini, A.; Santoni, A.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; [Porcellini, A.; Santoni, A.] INM Neuromed, Dept Expt Med & Pathol, Rome, Italy	University of Urbino; IRCCS European Institute of Oncology (IEO); Istituto Superiore di Sanita (ISS); Sapienza University Rome; IRCCS Neuromed	Fanelli, M (corresponding author), Univ Urbino, Ctr Biotechnol, Mol Pathol Lab, Via Campanella 1, I-61032 Urbino, Italy.	mirco.fanelli@uniurb.it	Porcellini, Antonio/AAC-6097-2019; Ricci Vitiani, Lucia/J-8320-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; De Maria, Ruggero/S-6385-2019; Fanelli, Mirco/F-2665-2011; Porcellini, Antonio/E-1900-2011; Minucci, Saverio/J-9669-2012; santoni, angela/K-8997-2016; feng, jian/G-9313-2011; Francesca, Andreoni/G-7505-2012; Magnani, Mauro/A-1919-2008	Ricci Vitiani, Lucia/0000-0001-7336-5615; De Maria, Ruggero/0000-0003-2255-0583; Fanelli, Mirco/0000-0002-9649-8661; Porcellini, Antonio/0000-0001-6882-9518; santoni, angela/0000-0003-1206-7731; Francesca, Andreoni/0000-0002-4857-8210; Amatori, Stefano/0000-0003-3988-3480; Tomassoni Ardori, Francesco/0000-0002-8824-3693; Magnani, Mauro/0000-0001-6456-6626				Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Blanc JL, 2004, J NEURO-ONCOL, V68, P275, DOI 10.1023/B:NEON.0000033385.37098.85; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Caprodossi S, 2005, MOL BIOTECHNOL, V30, P231, DOI 10.1385/MB:30:3:231; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404; Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hassan KMA, 2001, HUM GENET, V109, P452; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PROSSER J, 1986, J MOL BIOL, V187, P145, DOI 10.1016/0022-2836(86)90224-X; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0; Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	30	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					358	365		10.1038/sj.onc.1210642	http://dx.doi.org/10.1038/sj.onc.1210642			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17653095				2022-12-17	WOS:000252256000012
J	Morimoto, K; Satoh-Yamaguchi, K; Hamaguchi, A; Inoue, Y; Takeuchi, M; Okada, M; Ikeda, W; Takai, Y; Imai, T				Morimoto, K.; Satoh-Yamaguchi, K.; Hamaguchi, A.; Inoue, Y.; Takeuchi, M.; Okada, M.; Ikeda, W.; Takai, Y.; Imai, T.			Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs	ONCOGENE			English	Article						Necl-5; poliovirus receptor; CD226; cancer cell; platelet; metastasis	IMMUNOGLOBULIN SUPERFAMILY; ADHESION; POLIOVIRUS; MIGRATION; DNAM-1; MEMBER; CD155; IDENTIFICATION; PROLIFERATION; INHIBITION	Necl-5 is an immunoglobulin (Ig)-like molecule that was originally identified as a poliovirus receptor and is often upregulated in cancer cells. We recently found that it colocalizes with integrin alpha(v)beta(3) at the leading edges of moving cells and enhances growth factor-induced cell movement and proliferation. Upon cell-cell contact, Necl-5 is removed from the cell surface by its trans-interaction with the cell adhesion molecule nectin-3, resulting in reduced cell movement and proliferation. Here, we investigated the role of Necl-5 in the interaction of cancer cells with platelets. Necl-5 was upregulated in CT26 cells, a colon adenocarcinoma cell line. When CT26 cells were injected into the tail vein of mice, they were arrested in the pulmonary vessels by adhering to platelets and subsequently metastasized to the lungs. Overexpression of Necl-5 in CT26 cells enhanced this metastasis, while inhibition of the trans-interaction of Necl-5 with CD226 by an anti-Necl-5 monoclonal antibody reduced the metastasis. Depletion of platelets by treatment with a rabbit anti-mouse platelet serum reduced the Necl-5-enhanced metastasis in mice. Thus, the trans-interaction of upregulated Necl-5 in cancer cells with its counter-receptor in platelets, probably CD226, is critical for efficient metastasis of cancer cells to the lungs.	[Morimoto, K.; Satoh-Yamaguchi, K.; Hamaguchi, A.; Inoue, Y.; Takeuchi, M.; Okada, M.; Imai, T.] KAN Res Inst Ic, Kobe MI R&D Ctr, Kobe, Hyogo 6500047, Japan; [Ikeda, W.; Takai, Y.] Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan	KAN Research Institute; Osaka University	Imai, T (corresponding author), KAN Res Inst Ic, Kobe MI R&D Ctr, 6-7-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	imai@kan.eisai.co.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; CRISSMAN JD, 1988, CANCER RES, V48, P4065; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; Fujito T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hirota T, 2005, ONCOGENE, V24, P2229, DOI 10.1038/sj.onc.1208409; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kojima H, 2003, J BIOL CHEM, V278, P36748, DOI 10.1074/jbc.M300702200; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470-2045(02)00789-1; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Sloan KE, 2005, CANCER RES, V65, P10930, DOI 10.1158/0008-5472.CAN-05-1890; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	31	52	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					264	273		10.1038/sj.onc.1210645	http://dx.doi.org/10.1038/sj.onc.1210645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637752				2022-12-17	WOS:000252256000002
J	Sheehan, KM; Gulmann, C; Eichler, GS; Weinstein, JN; Barrett, HL; Kay, EW; Conroy, RM; Liotta, LA; Petricoin, EF				Sheehan, K. M.; Gulmann, C.; Eichler, G. S.; Weinstein, J. N.; Barrett, H. L.; Kay, E. W.; Conroy, R. M.; Liotta, L. A.; Petricoin, E. F., III			Signal pathway pro. ling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition	ONCOGENE			English	Article						proteomics; protein microarray; colon cancer; stroma; microdissection	PHASE PROTEIN MICROARRAYS; GENE-EXPRESSION PROFILES; TISSUE INHIBITORS; CELL-LINES; CANCER; FIBROBLASTS; PROGRESSION; GROWTH; METALLOPROTEINASES; METASTASIS	Molecular crosstalk, including reciprocal stimulation, is theorized to take place between epithelial cancer cells and surrounding non-neoplastic stromal cells. This is the rationale for stromal therapy, which could eliminate support of a cancer by its genetically stable stroma. Epithelial-stromal crosstalk is so far poorly documented in vivo, and cell cultures and animal experiments may not provide accurate models. The current study details stromal-epithelial signalling pathways in 35 human colon cancers, and compares them with matched normal tissues using quantitative proteomic microarrays. Lysates prepared from separately microdissected epithelium and stroma were analysed using antibodies against 61 cell signalling proteins, most of which recognize activated phospho-isoforms. Analyses using unsupervised and supervised statistical methods suggest that cell signalling pathway profiles in stroma and epithelium appear more similar to each other in tumours than in normal colon. This supports the concept that coordinated crosstalk occurs between epithelium and stroma in cancer and suggests epithelial-mesenchymal transition. Furthermore, the data herein suggest that it is driven by cell proliferation pathways and that, specifically, several key molecules within the mitogen-activated protein kinase pathway may play an important role. Given recent findings of epithelial-mesenchymal transition in therapy-resistant tumour epithelium, these findings could have therapeutic implications for colon cancer.	[Sheehan, K. M.; Gulmann, C.; Barrett, H. L.] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland; [Sheehan, K. M.; Gulmann, C.] NIH, Natl Canc Inst, Canc Res Ctr, Pathol Lab,NCI FDA Clin Proteom Program, Bethesda, MD USA; [Sheehan, K. M.; Gulmann, C.; Barrett, H. L.; Kay, E. W.] Royal Coll Surgeons Ireland, Dept Pathol, Dublin 9, Ireland; [Eichler, G. S.; Weinstein, J. N.] NIH, Natl Canc Inst, Canc Res Ctr, Mol Pharmacol Lab, Bethesda, MD USA; [Conroy, R. M.] Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin, Ireland; [Liotta, L. A.; Petricoin, E. F., III] George Mason Univ, Ctr Appl Proteom & Mol Med, Manassas, VA USA; [Petricoin, E. F., III] US FDA, NCI, Clin Proteom Program, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Royal College of Surgeons - Ireland; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal College of Surgeons - Ireland; George Mason University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Gulmann, C (corresponding author), Beaumont Hosp, Dept Pathol, Dublin 9, Ireland.	christian_gulmann@hotmail.com	Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Weinstein, John/0000-0001-9401-6908; Sheehan, Katherine/0000-0002-8969-3610	NATIONAL CANCER INSTITUTE [Z01BC007349] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAUJO RP, 2004, DRUG DISCOV TODAY TH, V1, P425, DOI DOI 10.1016/j.ddstr.2004.11.004; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brigati C, 2002, CLIN EXP METASTAS, V19, P247, DOI 10.1023/A:1015587423262; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derycke L, 2005, CANCER BIOTHER RADIO, V20, P579, DOI 10.1089/cbr.2005.20.579; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gulmann C, 2006, J PATHOL, V208, P595, DOI 10.1002/path.1958; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019; Matrisian LM, 2001, CANCER RES, V61, P3844; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Notterman DA, 2001, CANCER RES, V61, P3124; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200; Sun YJ, 2005, MOL CANCER THER, V4, P51; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tomita T, 1996, DIS COLON RECTUM, V39, P1255, DOI 10.1007/BF02055119; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	52	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					323	331		10.1038/sj.onc.1210647	http://dx.doi.org/10.1038/sj.onc.1210647			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621268				2022-12-17	WOS:000252256000008
J	Wu, A; Chen, J; Baserga, R				Wu, A.; Chen, J.; Baserga, R.			Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes	ONCOGENE			English	Article						IRS-1; c-myc; cyclin D1; rRNS	SIMIAN-VIRUS-40 T-ANTIGEN; GROWTH-FACTOR RECEPTOR; IGF-I RECEPTOR; BETA-CATENIN; TRANSLOCATION; IRS-1; TRANSFORMATION; INSULIN-RECEPTOR-SUBSTRATE-1; PATHWAY	The insulin receptor substrate-1 (IRS-1) is a docking protein of the insulin-like growth factor-1 (IGF-1) receptor and of the insulin receptor. IRS-1 sends a strong mitogenic, anti-apoptotic signal and plays an important role in cell transformation and cancer. IRS-1 translocates to nuclei of cells, where it increases the activity of the rDNA, c-myc and cyclin D1 promoters. We show, by chromatin immunoprecipitation, occupancy by IRS-1 of the same promoters. Both promoter activation and promoter occupancy are IGF-1-dependent. In cells that respond to IGF-1 but in which IRS-1 does not translocate to nuclei, promoter occupancy is absent and promoter activation is absent or much reduced. Transcriptional activation of c-myc and cyclin D1 promoters by nuclear IRS-1 does not occur with a mutant, inactive IRS-1 protein ( deletion of the phosphotyrosine-binding domain, PTB) and does not require PI3- kinase activity. Taken together, these results indicate a novel mechanism by which nuclear IRS-1 activates cell cycle genes.	[Wu, A.; Chen, J.; Baserga, R.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NCI NIH HHS [CA08640, CA78890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Chang Q, 2002, CANCER RES, V62, P6035; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DeAngelis T, 2006, ONCOGENE, V25, P32, DOI 10.1038/sj.onc.1209013; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; del Rincon SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104; Drakas R, 2005, PROTEOMICS, V5, P132, DOI 10.1002/pmic.200400919; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Rowlands TM, 2003, P NATL ACAD SCI USA, V100, P11400, DOI 10.1073/pnas.1534601100; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wu A, 2005, J BIOL CHEM, V280, P2863, DOI 10.1074/jbc.M406138200	20	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					397	403		10.1038/sj.onc.1210636	http://dx.doi.org/10.1038/sj.onc.1210636			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17700539				2022-12-17	WOS:000252256000016
J	McBryan, J; Howlin, J; Kenny, PA; Shioda, T; Martin, F				McBryan, J.; Howlin, J.; Kenny, P. A.; Shioda, T.; Martin, F.			ER alpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis	ONCOGENE			English	Article						mammary gland; puberty; development; CITEDI; ER alpha	DUCTAL MORPHOGENESIS; BRANCHING MORPHOGENESIS; EPITHELIAL-CELLS; IN-VIVO; GROWTH; CITED1; TRANSCRIPTION; PROTEINS; REVEALS; DIFFERENTIATION	Expression microarray analysis identified over 930 genes regulated during puberty in the mouse mammary gland. Most prominent were genes whose expression increased in parallel with pubertal development and remained high thereafter. Members of the Wnt, transforming growth factor-beta and oestrogen-signalling pathways were significantly overrepresented. Comparison to expression data from CITED1 knockout mice identified a subset of oestrogen-responsive genes displaying altered expression in the absence of CITED1. Included in this subset are stanniocalcin2 (Stc2) and amphiregulin (Areg). Chromatin immunoprecipitation revealed that ER alpha binds to oestrogen response elements in both the Stc2 and Areg genes in the mammary gland during puberty. Additionally, CITED1 and ER alpha localize to the same epithelial cells of the pubertal mammary gland, supporting a role for interaction of these two proteins during normal development. In a human breast cancer data set, expression of Stc2, Areg and CITED1 parallel that of ER alpha. Similar to ERa, CITED1 expression correlates with good outcome in breast cancer, implying that potential maintenance of the ER alpha-CITED1 co-regulated signalling pathwayin breast tumours can indicate good prognosis.	Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Massachusetts Gen Hosp, Ctr Canc, Lab Tumour Biol, Charlestown, MA USA	University College Dublin; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Harvard University; Massachusetts General Hospital	Martin, F (corresponding author), Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	finian.martin@ucd.ie	Howlin, Jill/G-9665-2011; Kenny, Paraic/A-3120-2008	Howlin, Jill/0000-0002-2766-3002; McBryan, Jean/0000-0002-7568-2208				Allar MA, 2004, ENDOCRINOLOGY, V145, P2467, DOI 10.1210/en.2003-1641; Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Ball SM, 1998, ANAT REC, V250, P459, DOI 10.1002/(SICI)1097-0185(199804)250:4<459::AID-AR9>3.0.CO;2-S; Brisken C, 2000, GENE DEV, V14, P650; Clarke RB, 1997, CANCER RES, V57, P4987; Clarkson RWE, 2004, BREAST CANCER RES, V6, pR92, DOI 10.1186/bcr754; Crowley MR, 2000, DEV BIOL, V225, P407, DOI 10.1006/dbio.2000.9844; D'Cruz CM, 2002, MOL ENDOCRINOL, V16, P2034, DOI 10.1210/me.2002-0073; DANIEL C, 2000, METHODS MAMMARY GLAN; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Fournier MV, 2006, CANCER RES, V66, P7095, DOI 10.1158/0008-5472.CAN-06-0515; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Gass S, 2003, J MAMMARY GLAND BIOL, V8, P269, DOI 10.1023/B:JOMG.0000010029.85796.63; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; Howlin J, 2006, ONCOGENE, V25, P1532, DOI 10.1038/sj.onc.1209183; Howlin J, 2006, J MAMMARY GLAND BIOL, V11, P283, DOI 10.1007/s10911-006-9024-2; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Juncker-Jensen A, 2006, GROWTH HORM IGF RES, V16, P224, DOI 10.1016/j.ghir.2006.06.005; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Klopocki E, 2004, INT J ONCOL, V25, P641; Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Lincoln DW, 2005, FRONT BIOSCI-LANDMRK, V10, P506, DOI 10.2741/1546; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; Michaelson JS, 2005, ONCOGENE, V24, P2613, DOI 10.1038/sj.onc.1208208; Morris JS, 2006, J CELL PHYSIOL, V206, P16, DOI 10.1002/jcp.20427; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; PHANG TL, 2003, PC S BIOCOMPUT, V8, P351; Plisov S, 2005, J AM SOC NEPHROL, V16, P1632, DOI 10.1681/ASN.2004060476; Rudolph MC, 2003, J MAMMARY GLAND BIOL, V8, P287, DOI 10.1023/B:JOMG.0000010030.73983.57; Russo J, 2005, BREAST CANCER RES, V7, P131, DOI 10.1186/bcr1029; Shi GB, 2006, J BIOL CHEM, V281, P27426, DOI 10.1074/jbc.M602631200; Steimel A, 2004, EUR T ELECTR POWER, V14, P3, DOI 10.1002/etep.4; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Uehara N, 2006, ONCOL REP, V15, P903; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Werling RW, 2003, AM J SURG PATHOL, V27, P82, DOI 10.1097/00000478-200301000-00009; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733	45	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6406	6419		10.1038/sj.onc.1210468	http://dx.doi.org/10.1038/sj.onc.1210468			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17486082				2022-12-17	WOS:000249737600005
J	Li, Q; Dashwood, WM; Zhong, X; Nakagama, H; Dashwood, RH				Li, Q.; Dashwood, W. M.; Zhong, X.; Nakagama, H.; Dashwood, R. H.			Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1	ONCOGENE			English	Article						beta-catenin; Bcl-2; c-Myc; E2F1; wnt signaling; colorectal cancer	TRANSCRIPTION FACTOR; EXPRESSION; GENE; APOPTOSIS; CELLS; INHIBITION; ACTIVATION; EPIGALLOCATECHIN-3-GALLATE; MUTATION; ELEMENT	beta-Catenin/T-cell factor (Tcf) signaling is constitutively active in the majority of human colorectal cancers, and there are accompanying changes in Bcl-2 expression. Similarly, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine(PhIP)-induced colon tumors in the rat have increased beta-catenin and elevated Bcl-2. To examine the possible direct transcriptional regulation of rat Bcl-2 by beta-catenin/Tcf, we cloned and characterized the corresponding promoter region and found 70.1% similarity with its human counterpart, BCL2. Bcl- 2 promoter activity was increased in response to LiCl and exogenous b-catenin, including oncogenic mutants of beta-catenin found in PhIP-induced colon tumors. Protein/DNA arrays identified E2F1, but not beta-catenin/Tcf, as interactingmost strongly with the rat Bcl- 2 promoter. Exogenous E2F1 increased the promoter activity of rat Bcl- 2, except in mutants lacking the E2F1 sites. As expected, b-catenin induced its downstream target c-Myc, as well as E2F1 and Bcl- 2, and this was blocked by siRNA to c-Myc or E2F1. These findings suggest an indirect pathway for Bcl- 2 overexpression in PhIP-induced colon tumors involving beta-catenin, c-Myc and E2F1.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Natl Canc Ctr, Tokyo, Japan	Oregon State University; National Cancer Center - Japan	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst, Weniger 503, Corvallis, OR 97331 USA.	Rod.Dashwood@oregonstate.edu	Dashwood, Roderick/AAF-2025-2020; Dashwood, Roderick H/E-9090-2011	Li, Qingjie/0000-0003-1405-7000	NCI NIH HHS [CA65525, P01 CA090890-01A29001, R01 CA080176-05, R01 CA065525-09, P01 CA090890, P01 CA090890-01A20003, R01 CA080176, CA90890, CA80176, R29 CA065525, P01 CA090890-05, R01 CA065525, R01 CA065525-08] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210, P30 ES000210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R29CA065525, R01CA080176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; BEDI A, 1995, CANCER RES, V55, P1811; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Blumberg Stephen J, 2003, Vital Health Stat 1, P1; Dashwood RH, 1998, CANCER RES, V58, P1127; Dashwood WM, 2005, MUTAT RES-FUND MOL M, V591, P161, DOI 10.1016/j.mrfmmm.2005.03.029; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Fujiwara K, 2004, CARCINOGENESIS, V25, P1495, DOI 10.1093/carcin/bgh155; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; GROSS TM, 2000, DIABETES TECHNOL THE, V2, P19, DOI DOI 10.1089/15209150050214087; Harigai M, 1996, ONCOGENE, V12, P1369; Hayashi R, 1996, CANCER RES, V56, P4307; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang XH, 2003, INVEST OPHTH VIS SCI, V44, P347, DOI 10.1167/iovs.02-0198; Li QJ, 2004, J BIOL CHEM, V279, P45669, DOI 10.1074/jbc.M405025200; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Muller M J, 2001, Obes Rev, V2, P15; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ochiai M, 2003, AM J PATHOL, V163, P1607, DOI 10.1016/S0002-9440(10)63517-1; Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zeng GC, 2003, BBA-GENE STRUCT EXPR, V1625, P30, DOI 10.1016/S0167-4781(02)00573-0	32	52	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6194	6202		10.1038/sj.onc.1210438	http://dx.doi.org/10.1038/sj.onc.1210438			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404573	Green Accepted			2022-12-17	WOS:000249401300010
J	Sakamoto, S; Iijima, K; Mochizuki, D; Nakamura, K; Teshigawara, K; Kobayashi, J; Matsuura, S; Tauchi, H; Komatsu, K				Sakamoto, S.; Iijima, K.; Mochizuki, D.; Nakamura, K.; Teshigawara, K.; Kobayashi, J.; Matsuura, S.; Tauchi, H.; Komatsu, K.			Homologous recombination repair is regulated by domains at the N- and C-terminus of NBS1 and is dissociated with ATM functions	ONCOGENE			English	Article						NBS1; ATM; MRE11; homologous recombination; FHA/BRCT domains	FORKHEAD-ASSOCIATED DOMAIN; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; IONIZING-RADIATION; CELLULAR-RESPONSE; GAMMA-H2AX FOCI; MRE11 COMPLEX; HISTONE H2AX; CELLS; PATHWAY	The proteins responsible for radiation sensitive disorders, NBS1, kinase ataxia- telangiectasia-( A- T)- mutated ( ATM) and MRE11, interact through the C- terminus of NBS1 in response to the generation of DNA double- strand breaks ( DSBs) and are all implicated in checkpoint regulation and DSB repair, such as homologous recombination ( HR). We measured the ability of several NBS1 mutant clones and A- T cells to regulate HR repair using the DR- GFP or SCneo systems. ATM deficiency did not reduce the HR repair frequency of an induced DSB, and it was confirmed by findings that HR frequencies are only slightly affected by deletion of ATM- binding site at the extreme C-terminus of NBS1. In contrast, The HR- regulating ability is dramatically reduced by deletion of the MRE11- binding domain at the C- terminus of NBS1 and markedly inhibited by mutations in the FHA/ BRCT domains at the N- terminus. This impaired capability in HR is consistent with a failure to observe MRE11 foci formation. Furthermore, normal HR using sister chromatid was completely inhibited by the absence of FHA/ BRCT domains. These results suggested that the N- and C- terminal domains of NBS1 are the major regulatory domains for HR pathways, very likely through the recruitment and retention of the MRE11 nuclease to DSB sites in an ATM-independent fashion.	Ibaraki Univ, Dept Environm Sci, Ibaraki 3108512, Japan; Kyoto Univ, Ctr Radiat Biol, Dept Radiat Repair Dynam, Kyoto, Japan; Ibaraki Univ, Dept Environm Sci, Ibaraki, Japan; Lymphocyte Bank Co Ltd, Kyoto, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Hiroshima, Japan	Ibaraki University; Kyoto University; Ibaraki University; Hiroshima University	Tauchi, H (corresponding author), Ibaraki Univ, Dept Environm Sci, Ibaraki 3108512, Japan.	htauchi@mx.ibaraki.ac.jp; komatsu@house.rbc.kyoto-u.ac.jp	Matsuura, Shinya/U-4182-2017; Kobayashi, Junya/AAX-6390-2021	Matsuura, Shinya/0000-0001-5294-081X; Kobayashi, Junya/0000-0003-4645-7500; Sakamoto, Shuichi/0000-0001-9396-9475; Nakamura, Kyosuke/0000-0003-1809-639X				Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	27	52	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6002	6009		10.1038/sj.onc.1210428	http://dx.doi.org/10.1038/sj.onc.1210428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384674				2022-12-17	WOS:000249277200003
J	Cui, X; Zhang, L; Luo, J; Rajasekaran, A; Hazra, S; Cacalano, N; Dubinett, SM				Cui, X.; Zhang, L.; Luo, J.; Rajasekaran, A.; Hazra, S.; Cacalano, N.; Dubinett, S. M.			Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer	ONCOGENE			English	Article						STAT6; COX-2; NSCLC	TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; APOPTOSIS; TRANSCRIPTION; ACTIVATION; RESISTANCE; P300/CBP; IL-4	Cyclooxygenase-2 (COX-2) is frequently overexpressed in human cancers and contributes to the malignant phenotype. Our data indicate unphosphorylated signal transducers and activators of transcription 6 (STAT6) may transcriptionally upregulate COX-2 expression and protect against apoptosis in NSCLC cells. In A427 and H2122, NSCLC cell lines that constitutively express COX-2, only unphosphorylated STAT6 was detectable by western blot, thus, all of the following STAT6-dependent effects are attributed to the unphosphorylated protein. In both cell lines, small-interfering RNA-mediated knockdown of STAT6 or stable expression of dominant-negative STAT6 decreased COX-2 expression. In contrast, transfection with a phosphorylation-deficient mutant STAT6 increased COX-2 levels. Immunofluorescent staining revealed the presence of STAT6 in H2122 nuclei, suggesting a direct role in gene regulation for the unphosphorylated protein. Consistent with this hypothesis, unphosphorylated STAT6 increased luciferase expression from a COX-2 promoter reporter construct. STAT6 co-immunoprecipitated with the transcriptional co-activator, p300, and chromatin immunoprecipitation assays demonstrated that these proteins bind a consensus STAT6 binding site located within the COX-2 promoter. STAT6 DNA-binding specificity was confirmed by electrophoretic mobility shift assay. As COX-2 over-expression has been clearly linked to apoptosis resistance and other hallmarks of malignancy, these findings suggest a novel role of unphosphorylated STAT6 in the pathogenesis of non-small cell lung cancer.	Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Lung Canc Res Program Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dubinett, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Lung Canc Res Program Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, 37-131 CHS 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu			NCI NIH HHS [R01 CA111851, P50 CA90388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111851, P50CA090388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Gagarin D, 2005, J MOL CELL CARDIOL, V39, P453, DOI 10.1016/j.yjmcc.2005.01.015; Galka E, 2004, J SURG RES, V122, P14, DOI 10.1016/j.jss.2004.05.004; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Herschman HR, 1999, ADV EXP MED BIOL, V469, P3; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krysan K, 2004, CANCER RES, V64, P6359, DOI 10.1158/0008-5472.CAN-04-1681; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Pold M, 2004, CANCER RES, V64, P1853, DOI 10.1158/0008-5472.CAN-03-3262; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; Sheng HM, 1998, CANCER RES, V58, P362; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yang J, 2005, CANCER RES, V65, P939; Zeng R, 2002, J IMMUNOL, V168, P4567, DOI 10.4049/jimmunol.168.9.4567; Zhang MS, 2006, CANCER LETT, V243, P38, DOI 10.1016/j.canlet.2005.11.020	26	52	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4253	4260		10.1038/sj.onc.1210222	http://dx.doi.org/10.1038/sj.onc.1210222			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237818				2022-12-17	WOS:000247619900008
J	Del Bello, B; Moretti, D; Gamberucci, A; Maellaro, E				Del Bello, B.; Moretti, D.; Gamberucci, A.; Maellaro, E.			Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status	ONCOGENE			English	Article						apoptosis; cisplatin; melanoma cells; calpain; p53	KAPPA-B ACTIVATION; PROTEOLYTIC CLEAVAGE; PROTEASE FAMILIES; DEGRADATION; GLUTATHIONE; ALPHA; MODULATION; DEPLETION; MEMBRANE; RELEASE	The contribution of different proteolytic systems, in particular calpains and effector caspases, in apoptotic cell death is still controversial. In this paper, we show that during cisplatin-induced apoptosis of human metastatic melanoma cells, calpain activation, as measured in intact cells by two different fluorescent substrates, is an early event, taking place well before caspase-3/-7 activation, and progressively increasing during 48 h of treatment. Such activation appears to be independent from any intracellular calcium imbalance; in fact, an increase of cytosolic calcium along with emptying of the reticular stores occur only at very late stages, uniquely in frankly apoptotic, detached cells. Calpain activation proves to be an early and crucial event in the apoptotic machinery, as demonstrated by the significant protection of cell death in samples co-treated with the calpain inhibitors, MDL 28170, calpeptin and PD 150606, where a variable but significant reduction of both caspase-3/-7 activity and cell detachment is observed. Consistently, such a protective effect can be at least partially due to the impairment of cisplatin-induced p53 activation, occurring early in committed, preapoptotic cells. Furthermore, in late apoptotic cells, calpain activity is also responsible for the formation of a novel p53 proteolytic fragment (approximate to 26 kDa), whose function is so far to be elucidated.	Univ Siena, Dept Physiopathol & Expt Med, I-53100 Siena, Italy	University of Siena	Maellaro, E (corresponding author), Univ Siena, Dept Physiopathol & Expt Med, Via A Moro, I-53100 Siena, Italy.	maellaro@unisi.it	Gamberucci, Alessandra/P-5888-2017; Moretti, Daniele/G-4082-2011	Gamberucci, Alessandra/0000-0003-3373-0256; 				Arora AS, 1996, J CELL PHYSIOL, V167, P434, DOI 10.1002/(SICI)1097-4652(199606)167:3<434::AID-JCP7>3.0.CO;2-Q; Atencio IA, 2000, CELL GROWTH DIFFER, V11, P247; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Daniel KG, 2003, INT J MOL MED, V12, P247; Davies EV, 1998, BIOCHEM BIOPH RES CO, V248, P679, DOI 10.1006/bbrc.1998.9031; Del Bello B, 2004, EXP CELL RES, V293, P302, DOI 10.1016/j.yexcr.2003.10.024; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Gorka M, 2004, CELL BIOL INT, V28, P741, DOI 10.1016/j.cellbi.2004.07.003; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Kitagaki H, 2000, BIOSCI BIOTECH BIOCH, V64, P689, DOI 10.1271/bbb.64.689; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macho A, 1997, J IMMUNOL, V158, P4612; Maellaro E, 2003, BRIT J DERMATOL, V148, P1115, DOI 10.1046/j.1365-2133.2003.05301.x; Maellaro E, 2000, J CELL SCI, V113, P2671; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82; Melloni E, 1998, J BIOL CHEM, V273, P12827, DOI 10.1074/jbc.273.21.12827; Molinari M, 1996, ONCOGENE, V13, P2077; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Okorokov AL, 1997, ONCOL RES, V9, P267; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Schaecher K, 2004, NEUROCHEM RES, V29, P1443, DOI 10.1023/B:NERE.0000026410.56000.dd; Sedarous M, 2003, J BIOL CHEM, V278, P26031, DOI 10.1074/jbc.M302833200; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Trompier D, 2004, CANCER RES, V64, P4950, DOI 10.1158/0008-5472.CAN-04-0143; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wang JP, 2000, MOL CARCINOGEN, V29, P179, DOI 10.1002/1098-2744(200011)29:3<179::AID-MC7>3.0.CO;2-K; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; WU HY, 1994, J BIOL CHEM, V269, P20067; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; Zhu DM, 2000, CLIN CANCER RES, V6, P2456	59	52	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2717	2726		10.1038/sj.onc.1210079	http://dx.doi.org/10.1038/sj.onc.1210079			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17130844				2022-12-17	WOS:000246210600006
J	Jo, M; Thomas, KS; Takimoto, S; Gaultier, A; Hsieh, EH; Lester, RD; Gonias, SL				Jo, M.; Thomas, K. S.; Takimoto, S.; Gaultier, A.; Hsieh, E. H.; Lester, R. D.; Gonias, S. L.			Urokinase receptor primes cells to proliferate in response to epidermal growth factor	ONCOGENE			English	Article						urokinase receptor; epidermal growth factor; ERK; c-Src; STAT5b	C-SRC INTERACTIONS; PLASMINOGEN-ACTIVATOR; EGF RECEPTOR; TYROSINE KINASES; BREAST-CANCER; PHOSPHORYLATION; TRANSACTIVATION; BINDING; SIGNAL; INTEGRINS	Epidermal growth factor (EGF) express es mitogenic activity by a mechanism that requires the EGF receptor (EGFR). We report that murine embryonic. broblasts ( MEFs) prolifer ate in response to EGF only when these cells express the urokinase receptor (uPAR). EGFR expression was equivalent in uPAR-/- and uPAR+/+ MEFs. In response to EGF, these cells demonstrated equivalent overall EGFR tyrosine phosphorylation and ERK/MAP kinase activation; however, phosphorylation of Tyr-845 in the EGFR, which has been implicated in cell growth, was substantially decreased in uPAR-/-MEFs. STAT5b activation also was decreased. As Tyr- 845 is a c- Src target, we overexpressed c- Src in uPAR-/- MEFs and rescued EGF mitogenic activity. Rescue also was achieved by expressing murine but not human uPAR, suggesting a role for autocrine uPAR cell- signaling. In MDA-MB 231 breast cancer cells, EGF mitogenic activity was blocked by uPAR gene silencing, with antibodies that block uPA-binding to uPAR, and with a synthetic peptide that disrupts uPAR-dependent cell signaling. Again, c-Src overexpression rescued the mitogenic activity of EGF. We conclude that uPAR-dependent cell-signaling may prime cells to proliferate in response to EGF by promoting Tyr-845 phosphorylation and STAT5b activation. The importance of this pathway depends on the c-Src level in the cell.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of California System; University of California San Diego; University of Virginia	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu			NCI NIH HHS [CA-94900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Angelucci A, 2006, ENDOCR-RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; KOSHI S, 1997, TAIWAN J MATH, V1, P1; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; MAZZIERI R, 2006, ONCOGENE; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Monaghan-Benson E, 2006, J BIOL CHEM, V281, P9450, DOI 10.1074/jbc.M501901200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OREILLY DR, 1986, BIOL CELL, V57, P187, DOI 10.1111/j.1768-322X.1986.tb00475.x; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026	42	52	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2585	2594		10.1038/sj.onc.1210066	http://dx.doi.org/10.1038/sj.onc.1210066			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043637				2022-12-17	WOS:000245831200006
J	Iwakuma, T; Lozano, G				Iwakuma, T.; Lozano, G.			Crippling p53 activities via knock-in mutations in mouse models	ONCOGENE			English	Review						mutant p53; mouse model; knock-in mouse	LI-FRAUMENI-SYNDROME; GAIN-OF-FUNCTION; SUPPRESSOR PROTEIN P53; INDUCED DNA-DAMAGE; C-TERMINAL DOMAIN; EMBRYONIC LETHALITY; MUTANT P53; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL ACTIVATION; APOPTOTIC ACTIVITY	The tumor suppressor p53 is the most frequently mutated gene in human cancer. In vivo models have been generated using knock-in alleles in which missense mutations are introduced that mimic the kinds of mutations found in human cancers, or that abolish specific p53 functions. Critically, these studies examine the in vivo and physiological functions of p53. Studies indicate that p53 missense mutations in the DNA-binding domain identical with those inherited in the Li-Fraumeni syndrome, have distinct properties. Studies in mice with mutants that separate cell- cycle arrest and apoptosis functions of p53 show delayed onset of tumor development, suggesting that both p53 functions are crucial for suppressing tumors. Mice with mutations at post-translational modi. cation sites exhibit subtle effects on p53 activity and tumor development, indicating a fine-tuning mechanism of p53 activity in vivo. Importantly, each mutant mouse has a distinct phenotype, suggesting diverse and exquisite mechanisms of p53 regulation in different environments, different tissues and different genetic backgrounds. The generation of these mutant p53 knock-in mice has laid the groundwork for future studies to elucidate the in vivo physiological function of mutant p53 and to examine cooperating effects in combination with other alterations.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX USA; Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX USA.	gglozano@mdanderson.org			NCI NIH HHS [CA34936, CA82577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, R01CA082577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; BARTEK J, 1991, ONCOGENE, V6, P1699; Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; Deppert W, 2000, J CELL BIOCHEM, P115; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harper JW, 2004, CELL, V118, P2, DOI 10.1016/j.cell.2004.06.015; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Iwakuma T, 2005, CELL CYCLE, V4, P865, DOI 10.4161/cc.4.7.1800; Iwakuma T, 2004, ONCOGENE, V23, P7644, DOI 10.1038/sj.onc.1207793; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Johnson TM, 2005, CELL CYCLE, V4, P731, DOI 10.4161/cc.4.6.1696; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lai SL, 2000, J BIOMED SCI, V7, P64, DOI 10.1007/BF02255920; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Luo JL, 2001, CANCER RES, V61, P8158; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Powell B, 2000, CLIN CANCER RES, V6, P443; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Skaug V, 2000, CLIN CANCER RES, V6, P1031; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016	80	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2177	2184		10.1038/sj.onc.1210278	http://dx.doi.org/10.1038/sj.onc.1210278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401426				2022-12-17	WOS:000245394800006
J	Delarue, FL; Adnane, J; Joshi, B; Blaskovich, MA; Wang, DA; Hawker, J; Bizouarn, F; Ohkanda, J; Zhu, K; Hamilton, AD; Chellappan, S; Sebti, SM				Delarue, F. L.; Adnane, J.; Joshi, B.; Blaskovich, M. A.; Wang, D-A; Hawker, J.; Bizouarn, F.; Ohkanda, J.; Zhu, K.; Hamilton, A. D.; Chellappan, S.; Sebti, S. M.			Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter	ONCOGENE			English	Article						RhoB; farnesyltransferase inhibitors; geranylgeranyltransferase inhibitors; HDAC1 dissociation; HAT association; histone acetylation	FARNESYL-PROTEIN TRANSFERASE; HUMAN CANCER-CELLS; HUMAN TUMOR-GROWTH; GTPASE RHOB; ANTITUMOR-ACTIVITY; TRANSGENIC MICE; NUDE-MICE; K-RAS; N-RAS; PRENYLATION	Recently, we have shown that RhoB suppresses EGFR-, ErbB2-, Ras- and Akt-mediated malignant transformation and metastasis. In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs.	H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem, Tampa, FL USA; Univ S Florida, Dept Oncol, Tampa, FL USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL USA; Yale Univ, Dept Chem, New Haven, CT USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr,SRB3-DRDIS, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu	Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104; Zhu, Kuichun/0000-0002-3594-5616				Adnane J, 2002, CLIN CANCER RES, V8, P2225; Adnane J, 2000, ONCOGENE, V19, P5525, DOI 10.1038/sj.onc.1203920; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Benjamin D, 2001, NUCLEIC ACIDS RES, V29, P3603, DOI 10.1093/nar/29.17.3603; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Du W, 1999, CANCER RES, V59, P5492; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Holstein SA, 2002, BIOCHEMISTRY-US, V41, P13698, DOI 10.1021/bi026251x; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; Hunt JT, 2000, J MED CHEM, V43, P3587, DOI 10.1021/jm000248z; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Liu M, 1998, CANCER RES, V58, P4947; MAZIERES J, 2004, CLIN CANCER RES, V10, P2472; NAGASU T, 1995, CANCER RES, V55, P5310; Pan JX, 2005, CANCER RES, V65, P3671, DOI 10.1158/0008-5472.CAN-04-2744; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					633	640		10.1038/sj.onc.1209819	http://dx.doi.org/10.1038/sj.onc.1209819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909123	Bronze			2022-12-17	WOS:000243902200001
J	Zhang, G; Luo, X; Sumithran, E; Pua, VSC; Barnetson, RSC; Halliday, GM; Khachigian, LM				Zhang, G.; Luo, X.; Sumithran, E.; Pua, V. S. C.; Barnetson, R. St C.; Halliday, G. M.; Khachigian, L. M.			Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression	ONCOGENE			English	Article						c-Jun; squamous cell carcinoma; matrix metalloproteinases; angiogenesis; tumor growth	TRANSCRIPTION FACTOR; SKIN CARCINOGENESIS; TUMOR-GROWTH; DNA ENZYME; ANGIOGENESIS; ACTIVATION; AP-1; DEOXYRIBOZYMES; PROLIFERATION; PROGRESSION	Squamous cell carcinoma (SCC) is an invasive malignancy of epidermal keratinocytes. Surgical excision is currently the main treatment; however, this can cause scarring and disfigurement. There is accordingly, an acute need for alternative strategies to treat SCC. The transcription factor c-Jun is expressed in human SCC and another common form of invasive skin cancer, basal cell carcinoma together with the mitogenic marker-proliferating cell nuclear antigen. Here, we have employed DNAzymes (catalytic DNA molecules) targeting c-Jun (Dz13) to inhibit c-Jun expression in SCC cells. Dz13 inhibits SCC proliferation and suppresses solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. We further demonstrate that Dz13 inhibits c-Jun, together with matrix metalloproteinase (MMP)-2 and MMP-9 expression in the tumors, consistent with DNAzyme inhibition of MMP-2 and MMP-9 gelatinolytic activity by zymography. Dz13 also suppressed the expression of vascular endothelial growth factor and fibroblast growth factor-2 in the tumors. These findings demonstrate that c-Jun regulates SCC growth and suggest that DNAzymes targeting this transcription factor may potentially be useful as inhibitors of cutaneous carcinoma.	Univ New S Wales, Ctr Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia; Gribbles Pathol, Melbourne, Vic, Australia; Royal Prince Alfred Hosp, Dermatol Res Labs, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of New South Wales Sydney; University of Sydney; University of Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia.	l.khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Bernstein SC, 1996, DERMATOL SURG, V22, P243, DOI 10.1111/j.1524-4725.1996.tb00315.x; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1; Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Fuchs Shmuel, 2001, Int J Cardiovasc Intervent, V4, P3; Halliday GM, 2001, INT IMMUNOL, V13, P1147, DOI 10.1093/intimm/13.9.1147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Karamouzis M, 2004, EUR J CANCER, V40, P761, DOI 10.1016/j.ejca.2003.12.002; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Khachigian LM, 2000, J CLIN INVEST, V106, P1189, DOI 10.1172/JCI11620; Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kraus S, 1998, J AM ACAD DERMATOL, V38, P438, DOI 10.1016/S0190-9622(98)70502-X; Lowe HC, 2002, THROMB HAEMOSTASIS, V87, P134, DOI 10.1055/s-0037-1612956; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Patel BP, 2005, J SURG ONCOL, V90, P81, DOI 10.1002/jso.20240; Ro Young-Suck, 1995, Journal of Korean Medical Science, V10, P85; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; Schubert S, 2003, NUCLEIC ACIDS RES, V31, P5982, DOI 10.1093/nar/gkg791; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120	36	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7260	7266		10.1038/sj.onc.1209726	http://dx.doi.org/10.1038/sj.onc.1209726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16785994	Bronze			2022-12-17	WOS:000242244700004
J	Sung, YM; He, G; Hwang, DH; Fischer, SM				Sung, Y. M.; He, G.; Hwang, D. H.; Fischer, S. M.			Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development	ONCOGENE			English	Article						prostaglandin E2; EP2 transgenic mice; proliferation; angiogenesis; skin carcinogenesis	NF-KAPPA-B; MULTISTAGE CARCINOGENESIS; GROWTH-FACTOR; SUBTYPE EP4; MOUSE SKIN; EXPRESSION; CELLS; E-2; PROMOTION; APOPTOSIS	We previously showed that the EP2 knockout mice were resistant to chemically induced skin carcinogenesis. The purpose of this study was to investigate the role of the overexpression of the EP2 receptor in mouse skin carcinogenesis. To determine the effect of overexpression of EP2, we used EP2 transgenic (TG) mice and wild-type (WT) mice in a DMBA (7,12-dimethylbenz[alpha]anthracene)/TPA (12-O-tetradecanoylphorbol-13-acetate) two-stage carcinogenesis protocol. EP2 TG mice developed significantly more tumors compared with WT mice. Overexpression of the EP2 receptor increased TPA-induced keratinocyte proliferation both in vivo and in vitro. In addition, the epidermis of EP2 TG mice 48 h after topical TPA treatment was significantly thicker compared to that of WT mice. EP2 TG mice showed significantly increased cyclic adenosine monophosphate levels in the epidermis after prostaglandin E2 (PGE2) treatment. The inflammatory response to TPA was increased in EP2 TG mice, as demonstrated by an increased number of macrophages in the dermis. Tumors and 7 x TPA-treated and DMBA-TPA-treated ( 6 weeks) skins from EP2 TG mice produced more blood vessels than those of WT mice as determined by CD-31 immunostaining. Vascular endothelial growth factor (VEGF) protein expression was significantly increased in squamous cell carcinoma (SCC) samples from EP2 TG mice compared that of WT mice. There was, however, no difference in the number of apoptotic cells in tumors from WT and EP2 TG mice. Together, our results suggest that the overexpression of the EP2 receptor plays a significant role in the protumorigenic action of PGE2 in mouse skin.	Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; Univ Calif Davis, USDA, ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Agriculture (USDA); University of California System; University of California Davis	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	smficher@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA100140] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Conconi MT, 1996, ANN ANAT, V178, P229, DOI 10.1016/S0940-9602(96)80055-0; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Kawamori T, 2005, CARCINOGENESIS, V26, P353, DOI 10.1093/carcin/bgh322; Kitamura T, 2003, CANCER SCI, V94, P618, DOI 10.1111/j.1349-7006.2003.tb01492.x; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; Mutoh M, 2002, CANCER RES, V62, P28; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Seno H, 2002, CANCER RES, V62, P506; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2003, CANCER RES, V63, P5218; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sheng HM, 1998, CANCER RES, V58, P362; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Tiano HF, 2002, CANCER RES, V62, P3395; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Watanabe H, 1999, ANN ONCOL, V10, P136, DOI 10.1023/A:1008330012536; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	31	52	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5507	5516		10.1038/sj.onc.1209538	http://dx.doi.org/10.1038/sj.onc.1209538			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16607275				2022-12-17	WOS:000240370400004
J	Carujo, S; Estanyol, JM; Ejarque, A; Agell, N; Bachs, O; Pujol, MJ				Carujo, S.; Estanyol, J. M.; Ejarque, A.; Agell, N.; Bachs, O.; Pujol, M. J.			Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity	ONCOGENE			English	Article						SET; GAPDH; cyclin B; cdk1; cell cycle	TANDEM MASS-SPECTROMETRY; ACTIVATING FACTOR-I; GRANZYME-A; PHOSPHATASE 2A; CELL-CYCLE; DNA; IDENTIFICATION; COMPLEX; TRANSCRIPTION; REPLICATION	We report here that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) interacts in vitro and in vivo with the protein SET. This interaction is performed through the acidic domain of SET located at the carboxy terminal region. On analysing the functional relevance of SET-GAPDH interaction, we observed that GAPDH reverses in a dose-dependent manner, the inhibition of cyclin B-cdk1 activity produced by SET. Similarly to SET, GAPDH associates with cyclin B, suggesting that the regulation of cyclin B-cdk1 activity might be mediated not only by the interaction of GAPDH with SET but also with cyclin B. To analyse the putative role of GAPDH on cell cycle progression, HCT116 cells were transfected with a GAPDH expression vector. Results indicate that overexpression of GAPDH does not affect the timing of DNA replication but induces an increase in the number of mitosis, an advancement of the peak of cyclin B-cdk1 activity and an acceleration of cell cycle progression. All these results suggest that GAPDH might be involved in cell cycle regulation by modulating cyclin B-cdk1 activity.	Univ Barcelona, Fac Med, Dept Biol & Cellular & Anat Patol, E-08036 Barcelona, Spain	University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Biol & Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Carrascal M, 2002, PROTEOMICS, V2, P455, DOI 10.1002/1615-9861(200204)2:4<455::AID-PROT455>3.0.CO;2-E; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Krynetski EY, 2001, MOL PHARMACOL, V59, P367, DOI 10.1124/mol.59.2.367; Krynetski EY, 2003, CANCER RES, V63, P100; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakagawa T, 2003, J BIOL CHEM, V278, P20395, DOI 10.1074/jbc.M210824200; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shen HH, 2001, GENOMICS, V71, P21, DOI 10.1006/geno.2000.6397; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Vogel T, 1998, CYTOGENET CELL GENET, V81, P265, DOI 10.1159/000015042; VON LM, 1992, MOL CELL BIOL, V12, P3346; Wen CH, 2000, P NATL ACAD SCI USA, V97, P14524, DOI 10.1073/pnas.011446498; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	47	52	56	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4033	4042		10.1038/sj.onc.1209433	http://dx.doi.org/10.1038/sj.onc.1209433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474839				2022-12-17	WOS:000238802400004
J	Dolloff, NG; Shulby, SS; Nelson, AV; Stearns, ME; Johannes, GJ; Thomas, JD; Meucci, O; Fatatis, A				Dolloff, NG; Shulby, SS; Nelson, AV; Stearns, ME; Johannes, GJ; Thomas, JD; Meucci, O; Fatatis, A			Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor	ONCOGENE			English	Article						prostate cancer; metastasis; PDGF; EGF; Akt	IN-VIVO; EXPRESSION; INVOLVEMENT; PROGRESSION; MIGRATION; SURVIVAL; AKT	Prostate adenocarcinoma metastasizes to the skeleton more frequently than any other organ. An underlying cause of this phenomenon may be the ability of bone-produced factors to specifically select disseminated prostate cancer cells that are susceptible to their trophic effects. Platelet-derived growth factor ( PDGF), a potent mitogen for both normal and tumor cells, is produced in several tissues including bone, where it is synthesized by both osteoblasts and osteoclasts. Here, we show that PDGF causes a significantly stronger activation of the Akt/PKB survival pathway in bone-metastatic prostate cancer cells compared to nonmetastatic cells. Normal prostate epithelial cells and DU-145 prostate cells, originally derived from a brain metastasis, are not responsive to PDGF. In contrast, epidermal growth factor stimulates Akt to the same extent in all prostate cells tested. This difference in PDGF responsiveness depends on the higher expression of alpha-PDGFR in bone-metastatic compared to nonmetastatic prostate cells and the lack of alpha-PDGFR expression in normal and metastatic prostate cells derived from tissues other than bone. Thus, alpha-PDGFR expression might identify prostate cancer cells with the highest propensity to metastasize to the skeleton.	Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St,New Coll Bldg MS488, Philadelphia, PA 19102 USA.	af39@drexel.edu			NCI NIH HHS [CA076639, R01 CA076639, CA112096] Funding Source: Medline; NIDA NIH HHS [R01 DA015014-01, R01 DA019808-03, R01 DA015014-04, DA19808, R01 DA019808-02, R01 DA019808, R01 DA019808-01, R01 DA015014-02, R01 DA015014-03, R01 DA015014, DA15014] Funding Source: Medline; NIGMS NIH HHS [GM067892, R01 GM067892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019808, R01DA015014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FUDGE K, 1994, MODERN PATHOL, V7, P549; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Mundy GR, 2000, CANCER AND THE SKELETON, P1; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Russell PJ, 1998, CLIN CHEM, V44, P705; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Watson PH, 1996, J MOL ENDOCRINOL, V17, P45, DOI 10.1677/jme.0.0170045; Xu WP, 2003, CANCER RES, V63, P7777; Yang DH, 2000, CYTOKINE, V12, P1271, DOI 10.1006/cyto.2000.0707	19	52	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6848	6854		10.1038/sj.onc.1208815	http://dx.doi.org/10.1038/sj.onc.1208815			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007172	Green Accepted			2022-12-17	WOS:000232527800013
J	Marimpietri, D; Nico, B; Vacca, A; Mangieri, D; Catarsi, P; Ponzoni, M; Ribatti, D				Marimpietri, D; Nico, B; Vacca, A; Mangieri, D; Catarsi, P; Ponzoni, M; Ribatti, D			Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin	ONCOGENE			English	Article						angiogenesis; cytostatic; mTOR inhibitor; neuroblastoma; tumor progression; vessel growth	ENDOTHELIAL GROWTH-FACTOR; ANTIANGIOGENIC DRUGS; CELL PROLIFERATION; TUMOR ANGIOGENESIS; IN-VIVO; THERAPY; CANCER; TUMORIGENESIS; COMBINATION; EXPRESSION	The aim of this study was to evaluate the synergistic antiangiogenic effect of low dose of vinblastine (VBL) and rapamycin (RAP) in neuroblastoma (NB). Both in vitro (endothelial cells proliferation assay; TUNEL assay; phosphatidylserine exposure and cell cycle analysis) and in vivo (chick embryo chorioallantoic membrane, CAM) assays were used. Each compound alone was able to induce a significant dose- and time-response inhibition of in vitro endothelial cells (EC) growth. Interaction index evaluation indicates that a synergistic effect was found when both drugs were combined at very low doses. Comparable effects were obtained when EC were preincubated with conditioned medium (CM) derived from the human NB cell line HTLA-230. Morphological changes were induced by each drug, and their combination resulted in a clear and stronger effect. Apoptosis was demonstrated by the TUNEL assay and confirmed by Annexin V-FITC staining of EC treated with VBL, showing an increase in the percentage of cells with a G2-M and sub-G1 DNA content, whereas in those treated with RAP a block in the G1 cell fraction and inhibition of progression to the S phase were observed. Here too, the combination resulted in a synergistic cell cycle arrest and induction of apoptosis. Similar results were obtained in vivo with the CAM assay. The angiogenic responses induced by HTLA-230-derived CM, NB tumor xenografts, and human NB biopsy specimens were inhibited by each drug and more significantly by their combination. The observation that these well-known drugs display synergistic effects as antiangiogenics when administered frequently at very low dose may be of significance in the designing of new ways of treating NB.	Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy; G Gaslini Childrens Hosp, Differentiat Therapy Unit, Lab Oncol, I-16148 Genoa, Italy; Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70125 Bari, Italy; G Gaslini Childrens Hosp, Lab Pathophysiol Uremia, I-16148 Genoa, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, Piazza G Cesare 11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022; Marimpietri, Danilo/J-5975-2016; Marimpietri, Danilo/AAA-7283-2020; Catarsi, Paolo/J-4463-2016; Ponzoni, Mirco/J-7713-2016	Vacca, Angelo/0000-0002-4567-8216; Marimpietri, Danilo/0000-0001-6360-1661; Catarsi, Paolo/0000-0002-1862-8168; Ponzoni, Mirco/0000-0002-6164-4286; Mangieri, Domenica/0000-0003-4871-1701; Mangieri, Domenica/0000-0001-7350-9383				Abdollahi A, 2003, CANCER RES, V63, P8890; Baker CH, 2002, CANCER RES, V62, P1996; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bogenmann E, 1996, INT J CANCER, V67, P379, DOI 10.1002/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eggert A, 2000, CLIN CANCER RES, V6, P1900; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kaicker S, 2003, INT J ONCOL, V23, P1651; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Keselman HJ, 2004, PSYCHOL SCI, V15, P47, DOI 10.1111/j.0963-7214.2004.01501008.x; Kim ES, 2002, J PEDIATR SURG, V37, P518, DOI 10.1053/jpsu.2002.30855; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Nagabuchi E, 1997, J PEDIATR SURG, V32, P287, DOI 10.1016/S0022-3468(97)90196-2; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pastorino F, 2003, CANCER RES, V63, P86; PHILLIPS P, 1976, INT J CANCER, V17, P549, DOI 10.1002/ijc.2910170502; PONZONI M, 1995, CANCER RES, V55, P853; Ribatti D, 2002, EUR J CANCER, V38, P750, DOI 10.1016/S0959-8049(01)00337-9; Ribatti D, 1998, INT J CANCER, V77, P449; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Svensson A, 2002, PEDIATR RES, V51, P607, DOI 10.1203/01.PDR.0000013688.03134.5A; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Velde EAT, 2002, BRIT J SURG, V89, P1302, DOI 10.1046/j.1365-2168.2002.02183.x; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wassberg E, 1997, PEDIATR RES, V41, P327, DOI 10.1203/00006450-199703000-00004; WASSBERG E, 1997, AM J PATHOL, V1154, P395; Yokoyama Y, 2000, CANCER RES, V60, P2190	43	52	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6785	6795		10.1038/sj.onc.1208829	http://dx.doi.org/10.1038/sj.onc.1208829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007159				2022-12-17	WOS:000232527800006
J	Wendt, J; von Haefen, C; Hemmati, P; Belka, C; Dorken, B; Daniel, PT				Wendt, J; von Haefen, C; Hemmati, P; Belka, C; Dorken, B; Daniel, PT			TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway	ONCOGENE			English	Article						TRAIL; ionizing irradiation; Bax; apoptosis; mitochondrial pathway; synergy	NEGATIVE PROGNOSTIC-FACTOR; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; HUMAN-MELANOMA CELLS; MEDIATED APOPTOSIS; BREAST-CANCER; CHEMOTHERAPEUTIC DRUGS; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; CD95/FAS RECEPTOR	The death ligand TRAIL has been suggested as a suitable biological agent for the selective induction of cell death in cancer cells. Moreover, TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation (IR). Here, we show that synergy of TRAIL and IR, that is, crosssensitization between TRAIL and IR for induction of apoptosis, entirely depends on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to activate caspase-3 and - 9 when exposed to TRAIL and IR. In contrast, TRAIL sensitized for IR-induced apoptosis and vice versa upon reconstitution of Bax expression. Notably, both DU145 and HCT116 still express significant levels of the multidomain proapoptotic Bcl-2 homolog Bak. This indicates that Bak is not sufficient to mediate cross-sensitization and synergism between IR and TRAIL. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade upon DNA damage by IR.	Humboldt Univ, Charite, Univ Med Ctr, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Tubingen, Fac Med, Dept Radiat Oncol, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Daniel, PT (corresponding author), Humboldt Univ, Charite, Univ Med Ctr, Dept Hematol Oncol & Tumor Immunol, Campus Berlin,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ballestrero A, 2004, CLIN CANCER RES, V10, P1463, DOI 10.1158/1078-0432.CCR-1365-02; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bonavida B, 1999, INT J ONCOL, V15, P793; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; DHEIN J, 1992, J IMMUNOL, V149, P3166; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gliniak B, 1999, CANCER RES, V59, P6153; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LUCKINGFAMIRA KM, 1994, LEUKEMIA, V8, P1825; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	62	52	60	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4052	4064		10.1038/sj.onc.1208580	http://dx.doi.org/10.1038/sj.onc.1208580			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806163				2022-12-17	WOS:000229680300005
J	Levesque, AA; Kohn, EA; Bresnick, E; Eastman, A				Levesque, AA; Kohn, EA; Bresnick, E; Eastman, A			Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G(2) cell cycle checkpoints	ONCOGENE			English	Article						p53 tumor suppressor; topoisomerase I inhibitors; cell cycle checkpoints; UCN-01; cyclin B	CHK2 PROTEIN-KINASE; TRANSCRIPTIONAL REPRESSION; IONIZING-RADIATION; CANCER-CELLS; PHOSPHORYLATION; ACTIVATION; PATHWAY; 7-HYDROXYSTAUROSPORINE; REPLICATION; INHIBITOR	The topoisomerase I inhibitor SN38 arrests cell cycle progression primarilyin S or G(2) phases of the cell cycle in a p53-independent manner. The Chk1 inhibitor, 7-hydroxystaurosporine (UCN-01), overcomes both S and G(2) arrest preferentiallyin cells mutated for p53, driving cells through a lethal mitosis and thereby enhancing cytotoxicity. The mechanism by which p53 maintains S and G(2) arrest was investigated here. The p53 wild-type MCF10A cells were arrested in S phase by incubation with SN38 for 24 h. Subsequent incubation with UCN-01 failed to abrogate arrest. To examine the impact of p53, MCF10A cells were developed, which express the tetramerization domain of p53 to inhibit endogenous p53 function. These cells were attenuated in SN38-mediated induction of p21(WAF1), and UCN-01 induced S, but not G(2) progression. In contrast, MCF10A cells expressing short hairpin RNA to ablate p53 expression underwent both S and G(2) phase progression with UCN-01. The difference in G(2) progression was attributed to p53-mediated gene repression; the MCF10A cells expressing the tetramerization domain retained p53 protein and repressed both cyclin B and Chk1, while cells ablated for p53 did not repress these proteins. Hence, inhibition of p53 activator function permits S phase abrogation, while additional inhibition of p53 repressor function is required for abrogation of G(2) arrest. These studies provide a mechanistic explanation for how this therapeutic strategy can selectively target tumor cells.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA.	alan.eastman@dartmouth.edu	Levesque, Aime/GNM-9708-2022	Levesque, Aime/0000-0002-2907-229X	NCI NIH HHS [CA23108, CA82220] Funding Source: Medline; PHS HHS [T3209658] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA082220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Damia G, 2001, J BIOL CHEM, V276, P10641, DOI 10.1074/jbc.M007178200; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FAN SJ, 1995, CANCER RES, V55, P1649; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirose Y, 2001, CANCER RES, V61, P5843; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Husain A, 1997, CLIN CANCER RES, V3, P2089; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn EA, 2003, CANCER RES, V63, P31; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Park M, 2000, CANCER RES, V60, P542; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shao RG, 1997, CANCER RES, V57, P4029; Shieh SY, 2000, GENE DEV, V14, P289; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	42	52	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3786	3796		10.1038/sj.onc.1208451	http://dx.doi.org/10.1038/sj.onc.1208451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782134				2022-12-17	WOS:000229346300009
J	Berquin, IM; Pang, B; Dziubinski, ML; Scott, LM; Chen, YQ; Nolan, GP; Ethier, SP				Berquin, IM; Pang, B; Dziubinski, ML; Scott, LM; Chen, YQ; Nolan, GP; Ethier, SP			Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells	ONCOGENE			English	Article						YB-1; NSEP1; EGF; EGFR; breast cancer; expression cloning	GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; TOPOISOMERASE-II-ALPHA; GENE-EXPRESSION; NUCLEAR EXPRESSION; TUMOR PROGRESSION; FACTOR YB-1; IN-VITRO; DNA; ACTIVATION	The epidermal growth factor receptor ( EGFR) is linked to poor outcome in breast cancer, and resistance to hormonal therapy is often accompanied by activation of growth factor receptors. To investigate the mechanism(s) by which EGFR becomes activated in breast cancer, we screened a cDNA expression library for genes that mediate EGF-independent proliferation of human mammary epithelial cells (HMECs). We isolated the NSEP1 cDNA encoding Y-box-binding protein 1 (YB-1), a multifunctional transcriptional and translational regulator. This cDNA conferred growth factor independence to HMECs. YB-1-transduced cells overexpressed EGFR, but ErbB-2 (Her-2/neu) levels were unchanged. Moreover, EGFR was constitutively phosphorylated in the absence of exogenous ligand. In these cells, an EGFR-blocking antibody failed to inhibit proliferation, conditioned medium activity could not be detected, and the synthesis of EGFR ligands was reduced compared to parental cells. This suggests that EGFR is activated in a ligand-independent fashion. However, cell growth could be blocked with an ErbB kinase inhibitor, indicating that EGFR signaling plays a major role in YB-1-induced growth factor independence. Taken together, our results demonstrate that YB-1 overexpression can induce EGF independence in HMECs via activation of the EGFR pathway. This could represent one of the mechanisms by which YB-1 contributes to breast tumor aggressiveness.	Wake Forest Univ, Dept Pathol, Winston Salem, NC 27157 USA; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27157 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Wake Forest University; University of Michigan System; University of Michigan; Wake Forest University; Stanford University	Berquin, IM (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	iberquin@wfubmc.edu	Nolan, Garry/AAE-7903-2019; Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708; Nolan, Garry/0000-0002-8862-9043	NCI NIH HHS [R01 CA77416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2001, ONCOGENE, V20, P4019, DOI 10.1038/sj.onc.1204537; Brandt R, 2000, ONCOGENE, V19, P2129, DOI 10.1038/sj.onc.1203520; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fox SB, 1997, J MAMMARY GLAND BIOL, V2, P131, DOI 10.1023/A:1026399613946; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gu CD, 2001, ANTICANCER RES, V21, P2357; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kajino K, 2001, INTERVIROLOGY, V44, P311, DOI 10.1159/000050063; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kersting C, 2004, LAB INVEST, V84, P582, DOI 10.1038/labinvest.3700077; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Rubinstein DB, 2002, CANCER RES, V62, P4985; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SAKURA H, 1988, GENE, V73, P499; Salomon DS, 2000, CONT ENDOCRINOL, P137; Sartor CI, 1997, CANCER RES, V57, P978; Sato J D, 1983, Mol Biol Med, V1, P511; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shibao K, 1999, INT J CANCER, V83, P732; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wan YS, 2001, CELL SIGNAL, V13, P139, DOI 10.1016/S0898-6568(00)00146-7; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; Woods Ignatoski Kathleen M., 1999, Endocrinology, V140, P3615; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865	61	52	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3177	3186		10.1038/sj.onc.1208504	http://dx.doi.org/10.1038/sj.onc.1208504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735691				2022-12-17	WOS:000228728100011
J	Prandini, MH; Dreher, I; Bouillot, S; Benkerri, S; Moll, T; Huber, P				Prandini, MH; Dreher, I; Bouillot, S; Benkerri, S; Moll, T; Huber, P			The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis	ONCOGENE			English	Article						cadherin; endothelium; promoter regions; tumour angiogenesis; transgenic mice	VASCULAR-ENDOTHELIAL-CADHERIN; MAMMALIAN-CELLS; GENE PROMOTER; EXPRESSION; GROWTH; MOUSE; MEMBRANE; ANTIBODY; PROTEIN; MICE	Vascular endothelial (VE)-cadherin is exclusively expressed at interendothelial junctions of normal and tumour vessels. In this report, we characterized the transcriptional activity of the human VE-cadherin promoter. Transient transfection assays revealed that sequences at positions -1135/-744 and -166/-5 base pairs are critical for promoter activity in endothelial cells. We show that specific sequences in the proximal region interact with Ets and Sp1 family members. Transgenic mice were created and the human VE-cadherin promoter was able to confer correct temporal and spatial expression on the LacZ gene in embryos. In adults, the transgene was specifically and strongly expressed in the lung, heart, ovary, spleen and kidney glomeruli, whereas expression was weak or absent in the vasculature of other organs, including the brain, thymus, liver and skeletal muscle. Neovessels in tumour grafts and Matrigel implants harboured strong stainings, indicating that promoter activity is enhanced in angiogenic situations. Furthermore, Matrigel and transfection assays showed that VE-cadherin promoter is subjected to bFGF induction. Transgene expression was also noticed in extravascular sites of the central nervous system, suggesting that silencer elements may be located elsewhere in the gene. These results are a first step towards addressing the organ- and tumour-specific regulation of the VE-cadherin gene.	CEA Grenoble, CEA INSERM Joseph Fourier Univ EMI 0219, Dept Cellular Responses & Dynam, DVE,DRDC, F-38054 Grenoble, France; Cardion, Erkrath, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Huber, P (corresponding author), CEA Grenoble, CEA INSERM Joseph Fourier Univ EMI 0219, Dept Cellular Responses & Dynam, DVE,DRDC, 17 Rue Martyrs, F-38054 Grenoble, France.	phuber@cea.fr	Huber, Philippe/C-7971-2019	Huber, Philippe/0000-0002-4153-7694; BOUILLOT, Stephanie/0000-0001-7567-557X				Adachi H, 2002, J BIOL CHEM, V277, P24014, DOI 10.1074/jbc.M201854200; Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; Apostel F, 2002, BBA-GENE STRUCT EXPR, V1577, P384, DOI 10.1016/S0167-4781(02)00412-8; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Bronner C, 2002, ANTICANCER RES, V22, P605; Call GB, 2002, MOL CELL ENDOCRINOL, V189, P85, DOI 10.1016/S0303-7207(01)00744-4; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dancer A, 2003, GENE THER, V10, P1170, DOI 10.1038/sj.gt.3301981; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Gao XP, 2000, AM J PHYSIOL-LUNG C, V279, pL1218, DOI 10.1152/ajplung.2000.279.6.L1218; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Gill M, 2001, CIRC RES, V88, P167; GIMBRONE M A JR, 1978, TCA (Tissue Culture Association) Manual, V4, P813, DOI 10.1007/BF00918403; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gotsch U, 1997, J CELL SCI, V110, P583; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Hordijk PL, 1999, J CELL SCI, V112, P1915; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Liao F, 2002, CANCER RES, V62, P2567; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Palmer G, 2001, GENE, V279, P49, DOI 10.1016/S0378-1119(01)00747-8; Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2; PASSANITI A, 1992, LAB INVEST, V67, P519; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shiraishi M, 2002, BIOL CHEM, V383, P893, DOI 10.1515/BC.2002.096; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wong RK, 1999, AM J PHYSIOL-HEART C, V276, pH736; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	54	52	59	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2992	3001		10.1038/sj.onc.1208483	http://dx.doi.org/10.1038/sj.onc.1208483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735710	Green Submitted, Green Accepted			2022-12-17	WOS:000228649500008
J	Li, FZ; Ling, X; Huang, HY; Brattain, L; Apontes, P; Wu, JG; Binderup, L; Brattain, MG				Li, FZ; Ling, X; Huang, HY; Brattain, L; Apontes, P; Wu, JG; Binderup, L; Brattain, MG			Differential regulation of survivin expression and apoptosis by vitamin D-3 compounds in two isogenic MCF-7 breast cancer cell sublines	ONCOGENE			English	Article						vitamin D-3; survivin; apoptosis; p38 MAPK; MCF-7 breast cancer cell	BETA-INDUCED APOPTOSIS; RECEPTOR-TYPE II; GROWTH-INHIBITION; CRYSTAL-STRUCTURE; D ANALOGS; IN-VIVO; PROTEIN; GENE; IAP; FAMILY	Although both the antiapoptotic function of survivin and vitamin D-3 (VD3)-mediated cell growth inhibition and apoptosis have been extensively studied, it is not known whether survivin plays a role in VD3 compound-mediated cell growth inhibition and apoptosis induction. Using an isogenic model of MCF-7 breast adenocarcinoma cells (MCF-7E and MCF-7L sublines that are sensitive and resistant to VD3 compounds), we found that VD3 compounds effectively downregulated survivin in VD3-sensitive MCF-7E cells, which was associated with VD3-induced apoptosis. In contrast, VD3 compounds failed to downregulate survivin in VD3-resistant MCF-7L cells, which showed resistant to VD3-induced apoptosis. However, inhibition of survivin expression by small interfering RNA (siRNA) induced cell death per se and further sensitized VD3-induced apoptosis in MCF-7L cells, indicating that the inability of these cells to respond to VD3 is due to the failure to downregulate survivin. Forced expression of survivin not only blocked VD3-mediated G1 cell accumulation but also increased S and G2/M cell populations. VD3 treatment rapidly triggered the activation of p38 MAPK signaling in MCF-7E cells but not in MCF7L cells. Moreover, inhibition of p38 activation diminished VD3-mediated survivin inhibition and partially rescued VD3-induced cell death. We further showed that VD3 increased the expression of TGFbeta1 and TGFbeta receptor 2, and that blocking the function of TGFbeta receptor 2 diminished VD3 compound-mediated survivin downregulation. Thus, we propose that the VD3 compound-induced growth inhibition and apoptosis induction are at least partially dependent on survivin downregulation via VD3-induced TGFbeta signaling and the activation of p38 MAPK pathway. Targeting survivin through these pathways may lead to novel applications for cancer therapeutics. Published online 20 December 2004.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Li, Fengzhi/GXF-0115-2022		NATIONAL CANCER INSTITUTE [R01CA072001, R01CA109481, P30CA016056, R01CA038173, R37CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA38173, R01 CA109481, R01 CA72001, P30 CA016056, R01 CA109481-01, R01 CA072001, R01 CA038173, R37 CA038173, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blutt SE, 2000, CANCER RES, V60, P779; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Choi KS, 2003, CANCER GENE THER, V10, P87, DOI 10.1038/sj.cgt.7700531; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Diaz GD, 2000, CANCER RES, V60, P2304; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Getzenberg RH, 1997, UROLOGY, V50, P999, DOI 10.1016/S0090-4295(97)00408-1; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Hansen CM, 2000, CURR PHARM DESIGN, V6, P803, DOI 10.2174/1381612003400371; Hershberger PA, 1999, CANCER RES, V59, P2644; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; James SY, 1998, BRIT J PHARMACOL, V125, P953, DOI 10.1038/sj.bjp.0702103; Johnson CS, 2002, CANCER METAST REV, V21, P147, DOI 10.1023/A:1020836226594; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Ko Y, 1998, INT J ONCOL, V12, P87; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Narvaez CJ, 2001, J BIOL CHEM, V276, P9101, DOI 10.1074/jbc.M006876200; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Padgett RW, 1999, CANCER METAST REV, V18, P247, DOI 10.1023/A:1006325408261; PEEHL DM, 1994, CANCER RES, V54, P805; Pennati M, 2002, J CLIN INVEST, V109, P285; Reed JC, 1999, NAT CELL BIOL, V1, pE199, DOI 10.1038/70227; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shen CX, 2003, CANCER GENE THER, V10, P403, DOI 10.1038/sj.cgt.7700581; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wu GF, 1998, J BIOL CHEM, V273, P7749, DOI 10.1074/jbc.273.13.7749; Wu GF, 1997, ONCOGENE, V15, P1555, DOI 10.1038/sj.onc.1201329; Xia CY, 2002, MOL CANCER THER, V1, P687; Yang LM, 2001, J CELL PHYSIOL, V188, P383, DOI 10.1002/jcp.1125; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3	59	52	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1385	1395		10.1038/sj.onc.1208330	http://dx.doi.org/10.1038/sj.onc.1208330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608672	Green Accepted			2022-12-17	WOS:000227092600008
J	Petre-Draviam, CE; Williams, EB; Burd, CJ; Gladden, A; Moghadam, H; Meller, J; Diehl, JA; Knudsen, KE				Petre-Draviam, CE; Williams, EB; Burd, CJ; Gladden, A; Moghadam, H; Meller, J; Diehl, JA; Knudsen, KE			A central domain of cyclin D1 mediates nuclear receptor corepressor activity	ONCOGENE			English	Article						androgen receptor; TR beta 1; ER alpha; LxxLL; corepressor; prostate cancer	ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; DEPENDENT-KINASE; TRANSCRIPTIONAL ACTIVITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GENE-EXPRESSION; CO-REPRESSOR; ACTIVATION; PHOSPHORYLATION	Regulation of nuclear receptor activity is the focus of numerous ongoing studies to develop novel therapies for the treatment of hormone-related cancer. Although cyclin D1 functions to control the activity of several nuclear receptors, the region(s) of the protein responsible for such transcriptional comodulation remain poorly defined. Herein, we map the region of cyclin D1 required for binding and repression of the androgen receptor (AR) to a central, exclusively alpha-helical domain. Deletion of this domain disrupted AR binding and corepressor activity. Further investigations showed that this domain is sufficient for AR interaction and possesses the ability to bind histone deacetylase 3. Strikingly, overexpression of this repressor region attenuates cell cycle progression in prostatic adenocarcinoma cells. The requirement of this domain for nuclear receptor repression was conserved with respect to thyroid hormone receptor beta-1, whereas cyclin D1 activation of the estrogen receptor occurred independently of the central region. Together, these data identify a minimal repression module within cyclin D1 and demonstrate that the coactivator and corepressor functions of cyclin D1 are distinct. In addition, our data suggest that properties of the cyclin D1 central domain could be exploited to develop novel prostate cancer therapeutics.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Dept Biomed Engn, Cincinnati, OH 45267 USA; Univ Penn, Ctr Canc, Abramson Family Canc Res Ctr, Philadelphia, PA 19104 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.	Karen.Knudsen@uc.edu	Meller, Jaroslaw/A-1971-2011	Meller, Jaroslaw/0000-0002-1162-8253; Burd, Craig/0000-0002-6899-6751; Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [R01CA099996, R01CA093237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099996, CA93237] Funding Source: Medline; NICHD NIH HHS [HDO7200-15] Funding Source: Medline; NIEHS NIH HHS [P30-ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamczak R, 2004, PROTEINS, V56, P753, DOI 10.1002/prot.20176; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; BURD CJ, IN PRESS MOL ENDOCRI; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner LM, 1999, PROSTATE, V38, P40, DOI 10.1002/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; KATO J, 1993, GENE DEV, V7, P331; Khan OY, 2003, CURR OPIN DRUG DISC, V6, P692; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Knudsen KE, 1999, CANCER RES, V59, P2297; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Maruvada P, 2004, MOL BIOL CELL, V15, P1895, DOI 10.1091/mbc.e03-09-0636; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; POROLLO A, 2004, BIOINFORMATICS  0408; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schulze-Gahmen U, 2002, NAT STRUCT BIOL, V9, P177, DOI 10.1038/nsb756; SHAO ZH, 1995, ONCOGENE, V10, P221; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Summers M. D., 1987, TEX AGR EXP STA B, V1555; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	55	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					431	444		10.1038/sj.onc.1208200	http://dx.doi.org/10.1038/sj.onc.1208200			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558026				2022-12-17	WOS:000226279700014
J	Slee, EA; Gillotin, S; Bergamaschi, D; Royer, C; Llanos, S; Ali, S; Jin, BQ; Trigiante, G; Lu, X				Slee, EA; Gillotin, S; Bergamaschi, D; Royer, C; Llanos, S; Ali, S; Jin, BQ; Trigiante, G; Lu, X			The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization	ONCOGENE			English	Article						p53; iASPP; apoptosis	P53 TUMOR-SUPPRESSOR; APOPTOTIC FUNCTION; DNA-DAMAGE; INHIBITOR; PROTEINS; ANKYRIN; FAMILY; 53BP2; CELLS; DIE	ASPP1 and ASPP2 are both proteins that interact with p53 and enhance its ability to induce apoptosis by selectively elevating the expression of proapoptotic p53-responsive genes. iASPP(RAI) is a third member of the family that is the most conserved inhibitor of p53-mediated apoptosis. Here, we have described iASPP, a longer form of iASPP(RAI), which at 828 amino acids is more than twice the size of iASPP(RAI). Using two antibodies that recognize both iASPP and iASPP(RAI), we report that this longer form of iASPP is the predominant form of the molecule expressed in cells. Like iASPP(RAI), iASPP also binds to p53 and inhibits apoptosis induced by p53 overexpression. However, whereas iASPP(RAI) is predominantly nuclear, the N-terminus of iASPP is entirely cytoplasmic, and the longer iASPP is located in both the cytoplasm and the nucleus. The effect upon subcellular localization of the longer N-terminus of iASPP means that this new, longer form of the molecule may be subject to greater regulation and provides another layer in the control of p53-induced apoptosis.	Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China	Imperial College London; Ludwig Institute for Cancer Research; Air Force Military Medical University	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	x.lu@imperial.ac.uk	, Susana/AAA-9282-2019	Royer, Christophe/0000-0002-9882-7676; Bergamaschi, Daniele/0000-0002-3955-1091; Llanos, Susana/0000-0002-8555-9326; Gillotin, Sebastien/0000-0002-4129-4936; Lu, Xin/0000-0002-6587-1152				Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yap DBS, 2000, J BIOL CHEM, V275, P37296, DOI 10.1074/jbc.M004359200	18	52	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9007	9016		10.1038/sj.onc.1208088	http://dx.doi.org/10.1038/sj.onc.1208088			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489900				2022-12-17	WOS:000225492800001
J	Mongroo, PS; Johnstone, CN; Naruszewicz, I; Leung-Hagesteijn, C; Sung, RK; Carnio, L; Rustgi, AK; Hannigan, GE				Mongroo, PS; Johnstone, CN; Naruszewicz, I; Leung-Hagesteijn, C; Sung, RK; Carnio, L; Rustgi, AK; Hannigan, GE			beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer	ONCOGENE			English	Article						parvin; ILK; tumor suppression; PKB/GSK3b; EGF; breast cancer	CALPONIN HOMOLOGY DOMAINS; GLYCOGEN-SYNTHASE KINASE; FOCAL ADHESION PROTEIN; TUMOR-SUPPRESSOR PTEN; CYCLIN D1 GENE; CAENORHABDITIS-ELEGANS; EXPRESSION INCREASES; CHROMOSOME 22Q13; PROSTATE-CANCER; BINDING PROTEIN	We analysed breast tumors and breast cancer cell lines for the expression of beta-parvin (ParvB), an adaptor protein that binds to the integrin-linked kinase (ILK). Quantitative RT-PCR indicated that ParvB mRNA was downregulated, by at least 60%, in four of nine breast tumors, relative to patient-matched normal mammary gland tissue. We also found that ParvB protein levels were reduced by greater than or equal to90% in five of seven advanced tumors, relative to matched normal breast tissue. Conversely, ILK protein and kinase activity levels were elevated in these tumors, suggesting that downregulation of ParvB stimulates ILK signaling. Western blot analyses indicated very low levels of ParvB protein in MDA-MB-231 and MCF7 breast cancer cells, facilitating functional studies of the effects of ParvB on ILK signaling. Expression of ParvB in MDA-MB-231 and MCF7 cells increased cell adhesion to collagen. ParvB inhibited ILK kinase activity, anchorage-independent cell growth and in vitro matrigel invasion by MDA-MB-231 cells. EGF-induced phosphorylation of two ILK targets, PKB (Ser473) and glycogen synthase kinase 3beta (Ser9), was also inhibited by ParvB. These results indicated that ParvB inhibits ILK signaling downstream of receptor tyrosine kinases. Our results suggest that loss of ParvB expression is a novel mechanism for upregulating ILK activity in tumors.	Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Div Gastroenterol, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Hannigan, GE (corresponding author), Hosp Sick Children, Res Inst, Canc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hannigan@sickkids.ca	Hannigan, Greg/A-5092-2009					Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Barker N, 2000, BIOESSAYS, V22, P961; Cairns P, 1997, CANCER RES, V57, P4997; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Castells A, 2000, CANCER RES, V60, P2836; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Coffer PJ, 1998, BIOCHEM J, V335, P1; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Edwards Lincoln A, 2004, Cancer Treat Res, V119, P59; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Gimona M, 1998, CURR BIOL, V8, pR674; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HRESKO MC, 1994, J CELL BIOL, V124, P491, DOI 10.1083/jcb.124.4.491; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Korenbaum E, 2001, GENE, V279, P69, DOI 10.1016/S0378-1119(01)00743-0; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lin XY, 2003, CURR BIOL, V13, P922, DOI 10.1016/S0960-9822(03)00372-5; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marotta A, 2003, BRIT J CANCER, V88, P1755, DOI 10.1038/sj.bjc.6600939; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Olski TM, 2001, J CELL SCI, V114, P525; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Price JT, 1999, CANCER RES, V59, P5475; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Youssoufian H, 1998, BIOTECHNIQUES, V24, P198, DOI 10.2144/98242bm05; Yu X, 2000, J CELL SCI, V113, P2139; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	57	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8959	8970		10.1038/sj.onc.1208112	http://dx.doi.org/10.1038/sj.onc.1208112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467740				2022-12-17	WOS:000225354600011
J	Zhu, NX; Gu, LB; Findley, HW; Li, FZ; Zhou, MX				Zhu, NX; Gu, LB; Findley, HW; Li, FZ; Zhou, MX			An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy	ONCOGENE			English	Article						survivin variant; p53; apoptosis; leukemia	PRE-MESSENGER-RNA; ANTI-APOPTOSIS GENE; WILD-TYPE P53; BCL-X; EXPRESSION; IDENTIFICATION; CHECKPOINT; INHIBITOR; INDUCTION; CASPASE-9	Survivin is a unique member of the inhibitor of apoptosis protein family, and its expression is regulated by p53. Recent identification of several functionally divergent survivin variants augments the complexity of survivin action as well as its regulation. Here we report that survivin-2B ( retaining a part of intron 2 as a cryptic exon) is positively regulated by p53, and its overexpression plays a role in sensitizing leukemia cells to chemotherapeutic drug doxorubicin. Doxorubicin treatment activated p53, downregulated survivin and survivin-DeltaEx3 but upregulated survivin-2B in EU-3, an acute lymphocytic leukemia (ALL) cell line with wild-type (wt)-p53 phenotype. In contrast, doxorubicin treatment failed to induce these alterations in EU-6 cells, a mutant-p53 ALL cell line. To specify the role of wt-p53 in regulating survivin and its variants, a temperature-sensitive p53 mutant plasmid p53-143 was transfected into EU-4, a p53-null ALL cell line, to establish a subline EU-4/p53-143. When EU-4/p53-143 cell culture was shifted from 37.5 degreesC to the wt-p53-permissive temperature (32.5 degreesC), the expression of survivin and survivin-DEx3 was decreased whereas survivin-2B expression was increased, confirming the distinct regulatory effect of p53 on survivin and its variants. To clarify the role of survivin-2B in the process of apoptosis, survivin-2B cDNA was cloned into pcDNA3HA vector and transfected into EU-4 cells. Enforced expression of survivin-2B in EU-4 cells inhibited cell growth and sensitized these cells to doxorubicin-induced apoptosis. These results suggest that survivin-2B variant is a proapoptotic factor and its expression is upregulated by p53.	Emory Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol BMT, Atlanta, GA 30322 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Emory University; Roswell Park Cancer Institute	Zhou, MX (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol BMT, 2040 Ridgewood Dr NE, Atlanta, GA 30322 USA.	mzhou@emory.edu	Li, Fengzhi/GXF-0115-2022		NCI NIH HHS [R01 CA82323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 2000, BLOOD, V96, P1921; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HU H, 2003, ONCOL RES, V13, P429; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kato J, 2001, INT J CANCER, V95, P92; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Maxwell SA, 1999, APOPTOSIS, V4, P109, DOI 10.1023/A:1009618811038; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tu SP, 2003, CANCER RES, V63, P7724; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	31	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7545	7551		10.1038/sj.onc.1208038	http://dx.doi.org/10.1038/sj.onc.1208038			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334064				2022-12-17	WOS:000224176500011
J	Harrington, L				Harrington, L			Does the reservoir for self-renewal stem from the ends?	ONCOGENE			English	Review						stem/progenitor cell; self-renewal; telomeres; telomerase	HUMAN BONE-MARROW; TELOMERASE REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT GENE; DYSKERATOSIS-CONGENITA; TERMINAL TRANSFERASE; RNA COMPONENT; LIFE-SPAN; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; SERIAL TRANSPLANTATION	Stem cell research is a burgeoning field with an alluring potential for therapeutic intervention, and thus begs a critical understanding of the long-term consequences of stem cell replacement. Operationally, a stem cell may be defined as a rarely dividing cell with the capacity for self-renewal throughout the lifetime of the organism, and an ability to reconstitute its appropriate lineages via proliferation and differentiation. In many differentiated normal and cancer cell types, the maintenance of telomeres plays a pivotal role in their continued division potential. Taken together with the presence of the enzymatic activity responsible for telomere addition, telomerase, in several progenitor cell lineages, it is presumed that telomere maintenance will be critical for the replenishment of stem cells or their successors. The purpose of this review is to discuss the role of telomere length maintenance in self-renewal, and the consequent challenges and potential pitfalls to the manipulation of normal and cancer-derived stem cells.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Harrington, L (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, 620 Univ Ave,Room 932, Toronto, ON M5G 2C1, Canada.	leah@uhnres.utoronto.ca			NATIONAL INSTITUTE ON AGING [R01AG016629] Funding Source: NIH RePORTER; NIA NIH HHS [AG16629-04] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allain JE, 2002, P NATL ACAD SCI USA, V99, P3639, DOI 10.1073/pnas.062038599; Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Allsopp RC, 2003, NAT MED, V9, P369, DOI 10.1038/nm0403-369; Allsopp RC, 2002, ONCOGENE, V21, P3270, DOI 10.1038/sj.onc.1205314; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Baerlocher GM, 2002, CYTOMETRY, V47, P89, DOI 10.1002/cyto.10053; Banfi A, 2002, TISSUE ENG, V8, P901, DOI 10.1089/107632702320934001; Bessler M, 2004, CURR OPIN PEDIATR, V16, P23, DOI 10.1097/00008480-200402000-00006; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Darwin Charles, 1898, DESCENT MAN SELECTIO; Erdmann N, 2004, P NATL ACAD SCI USA, V101, P6080, DOI 10.1073/pnas.0401580101; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fogarty PF, 2003, LANCET, V362, P1628, DOI 10.1016/S0140-6736(03)14797-6; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenwood MJ, 2003, ARCH MED RES, V34, P489, DOI 10.1016/j.arcmed.2003.07.003; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Harley CB, 1997, CIBA F SYMP, V211, P129; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Hemann MT, 2001, MOL BIOL CELL, V12, P2023, DOI 10.1091/mbc.12.7.2023; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073; Kobune M, 2003, EXP HEMATOL, V31, P715, DOI 10.1016/S0301-472X(03)00177-2; Lansdorp PM, 1998, VOX SANG, V74, P91, DOI 10.1111/j.1423-0410.1998.tb05402.x; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KM, 2003, BIOCHEM BIOPH RES CO, V301, P1038, DOI 10.1016/S0006-291X(03)00086-X; Lendvay TS, 1996, GENETICS, V144, P1399; Limke TL, 2003, DEV NEUROSCI-BASEL, V25, P257, DOI 10.1159/000072273; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu Y, 2002, P NATL ACAD SCI USA, V99, P3597, DOI 10.1073/pnas.062549199; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Mason PJ, 2003, BIOESSAYS, V25, P126, DOI 10.1002/bies.10229; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365-2141.2003.04217.x; Miller MC, 2000, MOL CELL, V6, P827, DOI 10.1016/S1097-2765(05)00078-X; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Morales CP, 2003, GUT, V52, P327, DOI 10.1136/gut.52.3.327; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; Parsch D, 2004, J MOL MED-JMM, V82, P49, DOI 10.1007/s00109-003-0506-z; Pascolo E, 2002, J BIOL CHEM, V277, P15566, DOI 10.1074/jbc.M201266200; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Riha K, 2003, CHROMOSOME RES, V11, P263, DOI 10.1023/A:1022892010878; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Roth A, 2003, LEUKEMIA, V17, P2410, DOI 10.1038/sj.leu.2403177; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Samper E, 2002, BLOOD, V99, P2767, DOI 10.1182/blood.V99.8.2767; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Truckenmiller ME, 2002, EXP NEUROL, V175, P318, DOI 10.1006/exnr.2002.7898; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2001, INT J CANCER, V91, P644, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1103>3.0.CO;2-V; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vrana KE, 2003, P NATL ACAD SCI USA, V100, P11911, DOI 10.1073/pnas.2034195100; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Yin XX, 2004, BIOCHEM BIOPH RES CO, V315, P643, DOI 10.1016/j.bbrc.2003.01.102; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zimmermann S, 2003, LEUKEMIA, V17, P1146, DOI 10.1038/sj.leu.2402962	88	52	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7283	7289		10.1038/sj.onc.1207948	http://dx.doi.org/10.1038/sj.onc.1207948			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378088				2022-12-17	WOS:000223998800014
J	Flores, I; Murphy, DJ; Swigart, LB; Knies, U; Evan, GI				Flores, I; Murphy, DJ; Swigart, LB; Knies, U; Evan, GI			Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia	ONCOGENE			English	Article						Myc; epidermis; hyperplasia; differentiation; oncogene inactivation	TERMINALLY DIFFERENTIATING CELLS; B-INDUCED APOPTOSIS; C-MYC; STEM-CELLS; EPIDERMAL DIFFERENTIATION; MOUSE EPIDERMIS; EXPRESSION; P63; KERATINOCYTES; PROLIFERATION	The homeostatic integrity of skin epidermis is maintained by a balance between keratinocyte proliferation, on one hand, and terminal differentiation combined with outward migration and shedding, on the other. Perturbation of this balance in favor of proliferation can result in hyperplasia and, potentially, tumorigenesis. We have previously described a reversible transgenic mouse model of epidermal neoplasia in which expression of an acutely regulatable form of Myc, MycER(TAM), is targeted to epidermis via the involucrin promoter. In this model, sustained activation of MycER(TM) induces a complex neoplastic lesion involving marked hyperplasia of less-differentiated suprabasal cells, angiogenesis and overt papillomatosis. Subsequent deactivation of MycER(TAM) triggers complete papilloma regression. Here, we provide evidence that Myc-induced papillomas are self-limiting because of the eventual differentiation of MycER(TAM)-expressing keratinocytes. Thus, keratinocyte differentiation eventually prevails over Myc-induced proliferation. We also show that regression of Myc-induced papillomas following MycER(TAM) deactivation occurs through a combination of growth arrest and irreversible differentiation. Finally, we demonstrate that transient deactivation of Myc is sufficient to expel keratinocytes irreversibly from the proliferative compartment and render them refractory to the mitogenic influence of subsequent Myc reactivation. Such observations illustrate the potential utility of even short-term inhibition of oncogenic lesions in the treatment of cancer.	Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA; John Radcliffe Hosp, Inst Mol Med, Canc Res United Kingdom, Mol Oncol Labs, Oxford OX3 9DS, England	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Cancer Research UK; University of Oxford	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, 2340 Sutter St,Room S236, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Murphy, Daniel/V-1079-2019; Flores, Ignacio/E-8304-2016	Murphy, Daniel/0000-0002-5538-5468; Flores, Ignacio/0000-0001-8789-6396				Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liefer KM, 2000, CANCER RES, V60, P4016; MOORE JP, 1987, ONCOGENE RES, V2, P65; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; ROOP DR, 1988, CANCER RES, V48, P3245; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	26	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5923	5930		10.1038/sj.onc.1207796	http://dx.doi.org/10.1038/sj.onc.1207796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208685				2022-12-17	WOS:000222941100006
J	Cheng, HYY; Li, P; David, M; Smithgall, TE; Feng, LL; Lieberman, MW				Cheng, HYY; Li, P; David, M; Smithgall, TE; Feng, LL; Lieberman, MW			Arsenic inhibition of the JAK-STAT pathway	ONCOGENE			English	Article						arsenite; JAK; STAT3; SOCS; IL-6	ACTIVATED T-CELLS; SERINE PHOSPHORYLATION; PROLIFERATION; EXPRESSION; STRESS; SECRETION; APOPTOSIS; SIGNALS; LINES; IL-6	The Janus kinase (JAK)-signal transducer and activator of transcription ( STAT) pathway is an essential cascade for mediating normal functions of different cytokines in the development of the hematopoietic and immune systems. Chronic exposure to arsenic has been found to cause immunotoxicity and has been associated with the suppression of hematopoiesis ( anemia and leukopenia). Here, we report the novel finding of arsenic-mediated inactivation of the JAK-STAT signaling pathway by its direct interaction with JAK tyrosine kinase. Pretreatment with sodium arsenite strongly inhibited IL-6-inducible STAT3 tyrosine phosphorylation in HepG2 cells and did not affect its serine phosphorylation. As a result, sodium arsenite completely abolished STAT activity-dependent expression of suppressors of cytokine signaling ( SOCS). Both cellular and subcelluar experiments showed that the inhibition of JAK-STAT signaling resulted from JAK tyrosine kinase's direct interaction with arsenite, and that arsenic's suppression of JAK tyrosine kinase activity also occurred in the interferon gamma (IFNgamma) pathway. The ligand-independent inhibition by arsenic indicates that JAK was the direct target of arsenic action. Other inflammatory stimulants, stress agents, and metal cadmium failed to induce similar effects on the tyrosine phosphorylation of STAT3 as arsenic does. Our experiments also revealed that arsenic inactivation of the JAK-STAT pathway occurred independent of arsenic activation of MAP kinases. Taken together, our findings indicate that arsenic directly inhibits JAK tyrosine kinase activity and suggest that this direct interference in the JAK-STAT pathway may play a role in arsenic-associated pathogenesis.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Calif San Diego, UCSD Canc Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15261 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Olazam, Houston, TX 77030 USA.	mikel@bcm.tmc.edu			NIEHS NIH HHS [ES 10389] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010389] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHMAD S, 1995, ARCH INSECT BIOCHEM, V29, P135, DOI 10.1002/arch.940290205; Ahmed ST, 2000, J IMMUNOL, V165, P5227, DOI 10.4049/jimmunol.165.9.5227; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Barchowsky A, 1999, TOXICOL APPL PHARM, V159, P65, DOI 10.1006/taap.1999.8723; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P150; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P178; Bustamante J, 1997, TOXICOLOGY, V118, P129, DOI 10.1016/S0300-483X(96)03607-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Galicia G, 2003, INT IMMUNOPHARMACOL, V3, P671, DOI 10.1016/S1567-5769(03)00049-3; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ishitsuka K, 2002, LEUKEMIA LYMPHOMA, V43, P1107, DOI 10.1080/10428190290021461; Iwamoto T, 2000, ONCOGENE, V19, P4795, DOI 10.1038/sj.onc.1203829; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; *NAT RES COUNC SUB, 2001, ARS DRINK WAT, P82; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Vega L, 1999, IMMUNOPHARM IMMUNOT, V21, P203, DOI 10.3109/08923979909052758; WOODS JS, 1996, TOXICOLOGY METALS, P939; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Yu HS, 1998, ARCH DERMATOL RES, V290, P681, DOI 10.1007/s004030050373; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	33	52	58	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3603	3612		10.1038/sj.onc.1207466	http://dx.doi.org/10.1038/sj.onc.1207466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116095	Green Published			2022-12-17	WOS:000221101700012
J	Plug-DeMaggio, AW; Sundsvold, T; Wurscher, MA; Koop, JI; Klingelhutz, AJ; McDougall, JK				Plug-DeMaggio, AW; Sundsvold, T; Wurscher, MA; Koop, JI; Klingelhutz, AJ; McDougall, JK			Telomere erosion and chromosomal instability in cells expressing the HPV oncogene 16E6	ONCOGENE			English	Article						human papillomavirus; telomere erosion; HPV 16E6; chromosomal instability; tumorigenesis; anaphase bridges	HUMAN-PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; E6 ONCOPROTEIN; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; RECURRENT PATTERN; E7 ONCOPROTEIN; GENE-PRODUCT; HTERT GENE; INACTIVATION	Progression to advanced-stage cervical carcinomas is characterized by a recurrent pattern of chromosomal rearrangements. Structural chromosome rearrangements are generated through the fusion of broken chromosome ends. These chromosome breaks may be induced by mutagenic agents such as ionizing radiation, or chromosome ends may be exposed through extensive telomere shortening. The human papilloma virus oncogene 16E6 induces telomerase activity in human keratinocytes, a model system for cervical tumor formation. The present study explores the relationship between 16E6 expression, telomerase activity, and chromosomal instability. We show that the frequency of anaphase bridges is dependent on the level of telomerase activity in 16E6/E7-expressing clones, and is the result of telomere shortening. High frequencies of anaphase bridges, associated with low telomerase activity, correlate with increased chromosome instability. Anaphase bridge formation is also associated with the presence of micronuclei, which are shown to contain unstable chromosomes frequently involved in rearrangements. As anaphase bridges are observed in both high and low telomerase 16E6/E7 clones, but not in hTERT-expressing control clones, expression of 16E6 in these immortalized clones is not sufficient to stabilize shortened telomeres completely. We suggest a model in which HPV-induced tumorigenesis may be dependent on persistent bridge - breakage - fusion cycles that allow for continued genomic rearrangements.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Plug-DeMaggio, AW (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N, Seattle, WA 98109 USA.	ademaggi@fhcrc.org	Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, CANCER RES, V62, P7075; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; FORD JH, 1988, AM J HUM GENET, V43, P733; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MUNGER K, 1989, J VIROL, V63, P4417; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Plug-Demaggio AW, 2002, ONCOGENE, V21, P7507, DOI 10.1038/sj.onc.1205903; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	37	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3561	3571		10.1038/sj.onc.1207388	http://dx.doi.org/10.1038/sj.onc.1207388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077181				2022-12-17	WOS:000221101700007
J	Bao, BY; Hu, YC; Ting, HJ; Lee, YF				Bao, BY; Hu, YC; Ting, HJ; Lee, YF			Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells	ONCOGENE			English	Article						vitamin D; androgen; androgen receptor; prostate cancer	9-CIS RETINOIC ACID; D-RECEPTOR EXPRESSION; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; GENE-EXPRESSION; CDK INHIBITOR; LINE LNCAP; D ANALOGS; P21 GENE; DIFFERENTIATION	Epidemiological data on prostate cancer incidence has suggested that vitamin D deficiency may be a risk factor for prostate cancer. The antiproliferative activity of 1alpha, 25-dihydroxyvitamin D-3 (1,25-VD) and its analogues has been demonstrated in many prostate cancer models, yet the detailed mechanisms underlying this protective effect of vitamin D remain to be determined. Here, we demonstrate that two androgen receptor (AR)-positive prostate cancer cell lines, LNCaP and CWR22R, are more sensitive to the growth inhibitory effects of 1,25-VD compared to the AR-negative prostate cancer cell lines, PC-3 and DU 145. 1,25-VD treatment inhibited cyclin-dependent kinase 2 (cdk2) activity and induced G0/G1 arrest. Interestingly, we also found that 1,25-VD treatment induced the expression of AR, and that the onset of the G0/G1 arrest in LNCaP and CWR22R cells is correlated with the onset of increasing expression of AR. This implies that the antiproliferative actions of 1,25-VD in AR-positive prostate cancer might be mediated through AR. Furthermore, a reduction in 1,25-VD-mediated growth inhibition was observed when AR signaling was blocked by antiandrogens, AR RNA interference, or targeted disruption of AR. Taken together, our data suggest that the androgen/AR signaling plays an important role in the antiproliferative effects of 1,25-VD and restoration of androgen responsiveness by 1,25-VD might be beneficial for the treatment of hormone-refractory prostate cancer patients.	Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Chem Engn, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Lee, YF (corresponding author), Univ Rochester, Dept Urol, Rochester, NY 14642 USA.	yifen_lee@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020; Bao, Bo-Ying/D-1789-2012; Bao, Bo-Ying/H-4589-2019	Bao, Bo-Ying/0000-0001-5510-6513; Bao, Bo-Ying/0000-0001-5510-6513; Hu, Yueh-Chiang/0000-0002-7992-0525; Ting, Huei-Ju/0000-0003-3709-5755				BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Chlenski A, 2001, PROSTATE, V47, P66; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; Esquenet M, 1996, PROSTATE, V28, P182, DOI 10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hedlund TE, 1996, J STEROID BIOCHEM, V58, P277, DOI 10.1016/0960-0760(96)00030-1; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; PEEHL DM, 1994, CANCER RES, V54, P805; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077; SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhao XY, 2000, ENDOCRINOLOGY, V141, P2548, DOI 10.1210/en.141.7.2548; Zhao XY, 1997, ENDOCRINOLOGY, V138, P3290, DOI 10.1210/en.138.8.3290; Zhao XY, 1999, ENDOCRINOLOGY, V140, P1205, DOI 10.1210/en.140.3.1205; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3	44	52	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3350	3360		10.1038/sj.onc.1207461	http://dx.doi.org/10.1038/sj.onc.1207461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15048085				2022-12-17	WOS:000220975000009
J	Barsyte-Lovejoy, D; Mao, DYL; Penn, LZ				Barsyte-Lovejoy, D; Mao, DYL; Penn, LZ			c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism	ONCOGENE			English	Article						c-Myc oncogene; transcription; repression; growth arrest; RNA polymerase II	MEDIATED TRANSCRIPTIONAL REPRESSION; CDK INHIBITOR P15(INK4B); GROWTH ARREST GENES; DIHYDROFOLATE-REDUCTASE; ENDOPLASMIC-RETICULUM; FACTORS C/EBP; CAD PROMOTER; FACTOR MIZ-1; CELL-GROWTH; DNA-DAMAGE	The c-Myc cellular oncogene has diverse activities, including transformation, proliferation, and apoptosis. These activities are dependent on the ability of c-Myc to regulate gene transcription. c-Myc downregulates the GADD45a and GADD153 (DDTI3) genes that are induced in response to genotoxic stresses and that encode protein products with antiproliferative activities. We show that c-Myc represses the expression of GADD45a and GADD153 in response to thapsigargin, a nongenotoxic stress, as well as other endoplasmic reticulum ( ER) stress agents. c-Myc represses both the basal expression and the magnitude of ER stress induction of GADD gene transcription. This repression requires the minimal promoter region of GADD45a and GADD153 and is not dependent on the ER stress element or p53-binding sites in the regulatory regions of these genes. Further analysis by chromatin immunoprecipitation shows that c-Myc binds to the minimal promoter region of GADD45a and GADD153 in vivo. c-Myc-associated protein X (Max) is also bound to both GADD gene promoters, whereas c-Myc interacting zinc-finger protein 1(Miz-1) is bound to the GADD153, but not GADD45a, promoter. RNA polymerase II(RNAPII) is recruited to the GADD gene promoters in the presence and absence of c-Myc, which suggests that c-Myc represses these genes through a post-RNAPII recruitment mechanism.	Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459				Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Bowen H, 2003, J BIOL CHEM, V278, P36017, DOI 10.1074/jbc.M304301200; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen CH, 1996, ONCOGENE, V13, P1659; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Izumi H, 2001, J CELL SCI, V114, P1533; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; PRICE BD, 1992, CANCER RES, V52, P3814; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	52	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3481	3486		10.1038/sj.onc.1207487	http://dx.doi.org/10.1038/sj.onc.1207487			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021909				2022-12-17	WOS:000220975000023
J	Rother, K; Johne, C; Spiesbach, K; Haugwitz, U; Tschop, K; Wasner, M; Klein-Hitpass, L; Moroy, T; Mossner, J; Engeland, K				Rother, K; Johne, C; Spiesbach, K; Haugwitz, U; Tschop, K; Wasner, M; Klein-Hitpass, L; Moroy, T; Mossner, J; Engeland, K			Identification of Tcf-4 as a transcriptional target of p53 signalling	ONCOGENE			English	Article						p53; Tcf-4; promoter; repression; beta-catenin; DNA microarray	SUPPRESSOR PROTEIN P53; HOMOLOGY REGION CHR; BETA-CATENIN; CELL-CYCLE; TUMOR-SUPPRESSOR; DEPENDENT REPRESSION; GENE-EXPRESSION; BINDING; ACTIVATION; CANCER	T-cell factor (Tcf)-4 is a main transcription factor to pass on Wnt/beta-catenin signalling. The tumour suppressor protein p53 contributes as a transcription factor to cell-cycle arrest and apoptosis induction. Mutations of components in p53 and Wnt/beta-catenin signalling networks play a part in tumour formation. Here, we identify the Tcf-4 gene as a downstream effector of p53. Induction of wild-type p53 in a tet-off regulated human colon cell system leads to the reduction of Tcf-4 mRNA and protein levels. Also, mRNA of the Tcf-4 target gene uPAR is downregulated after p53 induction. Expression of a luciferase reporter controlled by the Tcf-4 promoter is repressed by wild-type p53, but not by a p53 mutant deficient in DNA binding. Such a regulation is seen in cell lines of different origin. These findings directly link Wnt/beta-catenin signalling and p53 tumour suppressor function and may provide a mechanism by which loss of p53 function contributes to progression in the adenoma/carcinoma sequence in colon tumours. Furthermore, since Tcf-4 is expressed in many tissues and downregulation of Tcf-4 by p53 is seen in several different cell types, this regulation likely plays a role in proliferation control of all tissues that can express p53 and Tcf-4.	Univ Leipzig, Max Burger Forschungszentrum, Med Klin & Poliklin 2, D-04103 Leipzig, Germany; Univ Essen Gesamthsch Klinikum, Inst Zellbiol, D-45122 Essen, Germany	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen	Engeland, K (corresponding author), Univ Leipzig, Max Burger Forschungszentrum, Med Klin & Poliklin 2, Johannisallee 30, D-04103 Leipzig, Germany.	engeland@medizin.uni-eipzig.de	Moroy, Tarik/D-9923-2011; Engeland, Kurt/AAW-9965-2020; Rother, Karen/GQI-3786-2022	Engeland, Kurt/0000-0003-3525-0440; Rother, Karen/0000-0002-0074-7329				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2000, ADV CANCER RES, V77, P1; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Clevers H, 2000, NAT CELL BIOL, V2, pE177, DOI 10.1038/35036424; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Duval A, 2000, CANCER RES, V60, P3872; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haugwitz U, 2002, NUCLEIC ACIDS RES, V30, P1967, DOI 10.1093/nar/30.9.1967; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MIYASHITA T, 1995, CELL, V80, P293; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Polakis P, 2000, GENE DEV, V14, P1837; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thiele A, 2001, J IMMUNOL, V167, P6786, DOI 10.4049/jimmunol.167.12.6786; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677	70	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3376	3384		10.1038/sj.onc.1207464	http://dx.doi.org/10.1038/sj.onc.1207464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990988				2022-12-17	WOS:000220975000012
J	Schedin, PJ; Eckel-Mahan, KL; McDaniel, SM; Prescott, JD; Brodsky, KS; Tentler, JJ; Gutierrez-Hartmann, A				Schedin, PJ; Eckel-Mahan, KL; McDaniel, SM; Prescott, JD; Brodsky, KS; Tentler, JJ; Gutierrez-Hartmann, A			ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells	ONCOGENE			English	Article						Ese-1; ETS; breast cancer; EMT; 3D culture; cadherin	ETS TRANSCRIPTION FACTOR; BREAST-CANCER; MATRIX METALLOPROTEINASES; PROGNOSTIC MARKER; GENE-EXPRESSION; MESSENGER-RNA; MURINE ETS-1; DOMAIN; GLAND; GROWTH	ESX is an epithelial-restricted member of a large family of transcription factors known as the Ets family. ESX expression has been shown to be correlated with Her2/neu proto-oncogene amplification in highly aggressive breast cancers and induced by Her2/neu in breast cell lines, but its role in tumorigenesis is unknown. Previously, we have shown that ESX enhances breast cell survival in colony-formation assays. In order to determine whether ESX can act as a transforming gene, we stably transfected MCF-12A human mammary epithelial cells with the ESX expression vector, pCGN2-HA-ESX. The MCF-12A cell line is immortalized, but nontransformed, and importantly, these cells fail to express endogenous ESX protein. We used pCGN2-HA-Ets-2 and pSVRas expression vectors as positive controls for transformation. Like HA-Ets-2 and V12-Ras, stable expression of ESX induced EGF-independent proliferation, serum-independent MAPK phosphorylation and growth in soft agar. Additionally, stable ESX expression conferred increased cell adhesion, motility and invasion in two-dimensional and transwell filter assays, and an epithelial to mesenchymal morphological transition. In three-dimensional cultures, parental and vector control (pCGN2) cells formed highly organized duct-like structures with evidence of cell polarity, ECM adhesion-dependent proliferation and cell survival, and lack of cellular invasion into surrounding matrix. Remarkably, the ESX stable cells formed solid, disorganized structures, with lack of cell polarity, loss of adhesion junctions and cytokeratin staining and loss of dependence on ECM adhesion for cell proliferation and survival. In addition, ESX cells invaded the surrounding matrix, indicative of a transformed and metastatic phenotype. Taken together, these data show that ESX expression alone confers a transformed and in vitro metastatic phenotype to otherwise normal MCF-12A cells.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; AMC Canc Res Ctr, Denver, CO 80214 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; AMC Cancer Research Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gutierrez-Hartmann, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.	schedinp@amc.org; a.gutierrez-hartmann@uchsc.edu	Schedin, Pepper/C-2532-2009; Gutierrez-Hartmann, Arthur/F-1295-2011	Eckel-Mahan, Kristin/0000-0001-8201-1675; Schedin, Pepper/0000-0003-4244-987X	NCI NIH HHS [R01 CA85944, P30 CA 46934] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085944, P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; Bemis LT, 2000, CANCER RES, V60, P3414; Benaud C, 1998, BREAST CANCER RES TR, V50, P97, DOI 10.1023/A:1006061115909; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BERNHARDT G, 1992, J CANCER RES CLIN, V118, P35, DOI 10.1007/BF01192309; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; Bonneton C, 1999, CELL MOTIL CYTOSKEL, V43, P288, DOI 10.1002/(SICI)1097-0169(1999)43:4<288::AID-CM2>3.0.CO;2-Y; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay ED, 1995, ACTA ANAT, V154, P8; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LIU E, 1992, ONCOGENE, V7, P1027; Mitas M, 2002, BRIT J CANCER, V86, P899, DOI 10.1038/sj.bjc.6600190; Neznanov N, 1999, CANCER RES, V59, P4242; O'Hagan RC, 1998, ONCOGENE, V16, P301, DOI 10.1038/sj.onc.1201547; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sapi E, 1998, CANCER RES, V58, P1027; Savagner P, 1994, Cancer Treat Res, V71, P229; Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Stossel TP, 1999, BIOCHEM SOC SYMP, V65, P267; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang B, 1997, ANTICANCER RES, V17, P4387; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089	56	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1766	1779		10.1038/sj.onc.1207391	http://dx.doi.org/10.1038/sj.onc.1207391			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14767472				2022-12-17	WOS:000220029300012
J	Li, CX; Chi, SM; He, NG; Zhang, XL; Guicherit, O; Wagner, R; Tyring, S; Xie, JW				Li, CX; Chi, SM; He, NG; Zhang, XL; Guicherit, O; Wagner, R; Tyring, S; Xie, JW			IFN alpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling	ONCOGENE			English	Article						hedgehog; smoothened; BCCs; PDGFR alpha; INF alpha; MEK; Fas	PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; MEDIATED APOPTOSIS; HUMAN HOMOLOG; PATCHED GENE; SOMATIC MUTATIONS; NEVUS SYNDROME; ONCOGENIC RAS; CARCINOMA; SKIN	Basal cell carcinoma (BCC), the most common form of human cancer, is understood to be associated with activation of the sonic hedgehog pathway, through loss-of-function mutations of tumor suppressor PTCH1 or gain-of-function mutations of smoothened. Interferon (IFN)-based therapy is quite effective in BCC treatment, but the molecular basis is not well understood. Here we report a novel mechanism by which IFNalpha mediates apoptosis in BCCs. In the presence of IFNalpha, we observed increased apoptosis in a BCC cell line ASZ001, in which PTC is null, and therefore with constitutive activation of the sonic hedgehog pathway. We demonstrate that SMO agonist Ag-1.4 mediates activation of extracellular signal-regulated kinase (Erk) phosphorylation, which is abrogated by IFNalpha in sonic hedgehog responsive C3H10T1/2 cells. In transient transfection experiments, we demonstrate that IFNalpha inhibits Erk phosphorylation and serum response element activation induced by expression of SMO, Gli1, PDGFRalpha and activated Raf, but not activated mitogen-activated Erk-regulating kinase (Mek), suggesting that IFNalpha targets mainly on Mek function. We further show that IFNalpha induces expression of Fas in BCC cells through interfering with Mek function. The role of the Fas-L/Fas signaling axis in IFNalpha-mediated apoptosis is demonstrated by the fact that addition of Fas-L neutralizing antibodies, just as caspase-8 inhibitor Z-IETD-FMK, effectively prevents IFNalpha-mediated apoptosis. Thus, our data indicate that IFNalpha-based BCC therapy induces Fas expression and apoptosis through interfering with Mek function.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Curis Inc, Cambridge, MA 02138 USA; Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77555 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Air Force Military Medical University	Xie, JW (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA.	jinxie@utmb.edu						Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; CHIMENTI S, 1995, DERMATOLOGY, V190, P214, DOI 10.1159/000246688; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; Epstein E, 2001, MED PEDIATR ONCOL, V36, P555, DOI 10.1002/mpo.1129; Fenton RG, 1998, CANCER RES, V58, P3391; Filipowicz E, 2002, CANCER, V94, P814, DOI 10.1002/cncr.10277; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GROB JJ, 1988, LANCET, V1, P878; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hottiger MO, 1999, GENE THER, V6, P1929, DOI 10.1038/sj.gt.3301036; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Larner A, 1996, BIOTHERAPY, V8, P175, DOI 10.1007/BF01877202; Lee SH, 1998, BRIT J DERMATOL, V139, P186; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Reifenberger J, 1998, CANCER RES, V58, P1798; Romerio F, 2002, FASEB J, V16, P1680, DOI 10.1096/fj.02-0120fje; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Vander Straten M, 2000, Adv Dermatol, V16, P299; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xie JW, 1997, GENE CHROMOSOME CANC, V18, P305	34	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1608	1617		10.1038/sj.onc.1207273	http://dx.doi.org/10.1038/sj.onc.1207273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647422				2022-12-17	WOS:000189219500015
J	Murray, PG; Qiu, GH; Fu, L; Waites, ER; Srivastava, G; Heys, D; Agathanggelou, A; Latif, F; Grundy, RG; Mann, JR; Starczynski, J; Crocker, J; Parkes, SE; Ambinder, RF; Young, LS; Tao, Q				Murray, PG; Qiu, GH; Fu, L; Waites, ER; Srivastava, G; Heys, D; Agathanggelou, A; Latif, F; Grundy, RG; Mann, JR; Starczynski, J; Crocker, J; Parkes, SE; Ambinder, RF; Young, LS; Tao, Q			Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma	ONCOGENE			English	Article						Hodgkin's lymphoma; RASSF1A; hypermethylation; tumor suppressor gene; Hodgkin/Reed-Sternberg cells	ABERRANT PROMOTER METHYLATION; BREAST CANCERS; CPG ISLAND; 3P21.3; HYPERMETHYLATION; CELL; PROTEIN; DISEASE; FAMILY; LUNG	Epigenetic inactivation of RASSF1A, a putative tumor suppressor with proapoptotic activity, is frequently observed in a number of solid tumors, including a variety of epithelial cancers, but has not been described in hematopoietic tumors. We have analysed the expression and methylation status of RASSF1A in Hodgkin's lymphoma (HL)-derived cell lines, primary HL tumors and serum samples from HL patients. RASSF1A transcription was detectable in only 2/6 HL cell lines. Methylation-specific PCR and bisulfite genomic sequencing revealed that the RASSF1A promoter was hypermethylated in all four RASSF1A-nonexpressing cell lines. 5-aza-2'-deoxycytidine treatment resulted in demethylation of the promoter and RASSF1A expression in these lines. Hypermethylation of RASSF1A was also detected in 34/52 (65%) primary HL tumors and in 2/22 serum samples from these patients. Microdissection of Hodgkin/ Reed - Sternberg (HRS) cells from several of these cases confirmed that the RASSF1A hypermethylation we detected in the analysis of whole tumor originated from the tumor cell population. Although hypermethylation of RASSF1A was detected in 5/6 non-Hodgkin's lymphoma (NHL)-derived cell lines, only rare primary NHL (1/10 of Burkitt's lymphoma, 1/12 of post-transplant lymphoma, 1/12 diffuse large B-cell lymphoma, 0/27 of nasal lymphoma, 0/8 follicular center cell lymphoma, 0/4 mantle cell lymphoma, 0/4 anaplastic large cell (Ki-1+) lymphoma, 0/2 MALT lymphoma) showed hypermethylation of the promoter. No methylation was detected in any of the 14 normal PBMC. These results point to an important role for epigenetic silencing of RASSF1A in the pathogenesis of HL. Inactivation of RASSF1A could be one mechanism by which HRS cells escape the apoptosis that should occur following nonproductive immunoglobulin gene rearrangements.	Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, Singapore 117597, Singapore; Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Childrens Hosp, Dept Oncol, Birmingham B4 6NH, W Midlands, England; Birmingham Heartlands Hosp, Dept Cellular Pathol, Birmingham B15 2TT, W Midlands, England; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Univ Birmingham, Div Canc Studies, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Johns Hopkins University; Johns Hopkins Medicine; University of Birmingham; University of Hong Kong; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; Johns Hopkins University; Johns Hopkins Medicine; Cancer Research UK; University of Birmingham	Murray, PG (corresponding author), Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, CRC MD11,Level 5,10 Med Dr, Singapore 117597, Singapore.	p.g.murray@bham.ac.uk; taoqia@jhs.com.sg	Young, Lawrence S/B-7213-2009; Tao, Qian/T-4743-2018; QIU, GUO-HUA/B-5806-2011; Ambinder, Richard/G-1607-2011; Fu, Li/F-7182-2010	Young, Lawrence S/0000-0003-3919-4298; Tao, Qian/0000-0001-5383-4808; QIU, GUO-HUA/0000-0001-6202-4284; Fu, Li/0000-0003-2643-6278				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee MG, 2001, CANCER RES, V61, P6688; Lee TL, 2002, CLIN CANCER RES, V8, P1761; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Morrissey C, 2001, CANCER RES, V61, P7277; MURRAY PG, 1992, J PATHOL, V166, P1, DOI 10.1002/path.1711660102; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Zou HZ, 2002, CLIN CANCER RES, V8, P188	23	52	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1326	1331		10.1038/sj.onc.1207313	http://dx.doi.org/10.1038/sj.onc.1207313			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961078				2022-12-17	WOS:000188892200019
J	Treff, NR; Pouchnik, D; Dement, GA; Britt, RL; Reeves, R				Treff, NR; Pouchnik, D; Dement, GA; Britt, RL; Reeves, R			High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells	ONCOGENE			English	Article						HMGA1; MCF-7 cells; Ras/ERK; caveolin; KIT ligand; cholesterol	GLOBAL GENE-EXPRESSION; CHROMOSOMAL-PROTEINS; IN-VIVO; HMG-I/Y; CHEMOTHERAPEUTIC INTERVENTION; TRANSDUCTION CASCADE; MALIGNANT PHENOTYPE; HMGI(Y) PROTEINS; EPITHELIAL-CELLS; GASTRIC CANCERS	High-mobility group (HMG) A1 proteins are gene regulatory factors whose overexpression is frequently observed in naturally occurring human cancers. The overexpression of transgenic HMGA1 proteins in cells results in neoplastic transformation and promotes progression to malignant cellular phenotypes. To understand the underlying molecular and biological events involved in these phenomena, we used oligonucleotide microarray analyses to generate an HMGA1a-induced expression profile for approximately 22 000 genes. This gene expression profile was generated using a well-characterized transgenic human MCF-7 mammary adenocarcinoma cell line in which overexpression of transgenic HMGA1 promotes a transition to a more malignant and metastatic phenotype. Microarray expression analyses, together with independent quantitative real-time reverse transcriptase polymerase chain reaction results, indicate that HMGA1a regulates genes involved in the Ras-extracellular signal-related kinase (Ras/ERK) mitogenic signaling pathway, including KIT ligand and caveolins 1 and 2. We also found that many cholesterol biosynthesis genes were decreased in cells overexpressing HMGA1a. Cholesterol depletion, decreased caveolin, and increased KIT ligand expression, are all independently associated with the activation of Ras/ERK signaling. Upon further analysis, we found that sensitivity to epidermal growth factor activation of ERK phosphorylation was significantly higher, and that cholesterol was significantly depleted, in cells overexpressing HMGA1a. The cumulative evidence indicates that one likely mechanism by which the HMGA1a protein promotes malignant changes in cells is through increased sensitivity to the activation of the Ras/ERK signaling pathway.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Reeves, R (corresponding author), Washington State Univ, Sch Mol Biosci, POB 644660, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu	Kim, Seongman/N-6910-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352, T32GM008336] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46352, T-32 GM008336] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe N, 2000, CANCER RES, V60, P3117; Bandiera A, 1998, CANCER RES, V58, P426; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Beckerbauer L, 2000, CHEM BIOL, V7, P805, DOI 10.1016/S1074-5521(00)00028-4; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Brandt S, 2003, ANTICANCER RES, V23, P223; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; BUSTIN M, 1996, PROG NUCL ACIDS RES, V54, P25; Caceres-Cortes JR, 2001, CANCER RES, V61, P6281; Charpentier AH, 2000, CANCER RES, V60, P5977; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Daoud SS, 2003, CANCER RES, V63, P2782; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Fedele M, 1996, CANCER RES, V56, P1896; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Giannini G, 1999, CANCER RES, V59, P2484; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; HEIDER JG, 1978, J LIPID RES, V19, P514; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; Kolch Walter, 2002, Expert Opin Pharmacother, V3, P709, DOI 10.1517/14656566.3.6.709; KOPP A, 1995, CANCER RES, V55, P4512; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lee S, 2002, CANCER LETT, V184, P197, DOI 10.1016/S0304-3835(02)00197-0; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LUNDBERG K, 1989, BIOCHIM BIOPHYS ACTA, V1009, P277, DOI 10.1016/0167-4781(89)90113-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nam ES, 2003, HISTOPATHOLOGY, V42, P466, DOI 10.1046/j.1365-2559.2003.01618.x; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; PIERANTONI GM, 2003, BIOCHEM J, V15, P145; Rajeswari MR, 2001, CANCER LETT, V173, P93, DOI 10.1016/S0304-3835(01)00688-7; RAM TG, 1993, CANCER RES, V53, P2655; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; REEVES R, 1990, J BIOL CHEM, V265, P8573; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; Zhang W, 2000, CANCER RES, V60, P6757	60	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					777	785		10.1038/sj.onc.1207167	http://dx.doi.org/10.1038/sj.onc.1207167			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737112				2022-12-17	WOS:000188304900016
J	Jiang, Y; Zhang, YK; Lees, E; Seghezzi, W				Jiang, Y; Zhang, YK; Lees, E; Seghezzi, W			AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer	ONCOGENE			English	Article						mitotic spindle checkpoint; mitotic kinase; cell cycle	ANAPHASE-PROMOTING COMPLEX; CENTROSOME AMPLIFICATION; KINASE AURORA2/AIK; DROSOPHILA-AURORA; BINDING DOMAIN; PROTEIN BUBR1; B KINASE; A KINASE; CANCERS; MITOSIS	AuroraA, a mitotic kinase, is reported to be amplified and overexpressed in a variety of human tumors. Active mutants of AuroraA can transform mouse fibroblasts and form tumors in nude mice. However, the mechanism behind this oncogenic potential remains elusive. In this study, we investigated the consequences of AuroraA overexpression and showed that increased AuroraA levels compromise the mitotic spindle checkpoint triggered by nocodazole, a microtubule polymerization inhibitor. This is accomplished by disrupting the proper assembly of the mitotic checkpoint complex at the level of the Cdc20-BubR1 interaction. As a result, the spindle checkpoint complex fails to form and cells progress through mitosis without proper arrest in response to nocodazole. This ability to override the mitotic spindle checkpoint was found to be independent of AuroraA kinase activity. We conclude that maintenance of a functional balance between AuroraA and mitotic checkpoint proteins is essential for the proper progression through mitosis. This study therefore offers a possible explanation of how deregulation of AuroraA can contribute to genetic instability and tumorigenesis.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Prot Design Labs Inc, Fremont, CA 94555 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Seghezzi, W (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	wolfgang.seghezzi@dnax.org						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CHAN CSM, 1993, GENETICS, V135, P677; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Hixon ML, 2000, FRONT BIOSCI, V5, pD50, DOI 10.2741/Hixon; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Khan SH, 1998, CANCER RES, V58, P396; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Reis RM, 2001, ACTA NEUROPATHOL, V101, P297; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	40	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8293	8301		10.1038/sj.onc.1206873	http://dx.doi.org/10.1038/sj.onc.1206873			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614453				2022-12-17	WOS:000186541500008
J	Wang, L; Soria, JC; Chang, YS; Lee, HY; Wei, QY; Mao, L				Wang, L; Soria, JC; Chang, YS; Lee, HY; Wei, QY; Mao, L			Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer	ONCOGENE			English	Article						minisatellite; tandem repeats; VNTR; hTERT; lung cancer	REVERSE-TRANSCRIPTASE; HTERT EXPRESSION; DNA; CELL; REARRANGEMENTS; POLYMORPHISMS; REPAIR; INSTABILITY; CARCINOMAS; EPITHELIUM	Chemoprevention has been widely explored as a promising strategy for controlling the incidence of lung cancer, the leading cause of cancer-related death. To maximize the benefit of lung cancer chemoprevention, it is important to identify individuals at high risk for the disease. The genetic background has been shown to play an important role in one's risk of developing lung cancer. We report here the identification of a polymorphic tandem repeats minisatellite (termed MNS16A) in the downstream region of the human telomerase gene. This minisatellite is located upstream of an antisense transcript from the human telomerase gene locus and was demonstrated to have promoter activity. The promoter activity was significantly lower in the construct containing the shorter repeats, suggesting that the MNS16A variant may have a relevance of functionality. To explore the role of this novel polymorphism in lung cancer, we conducted a pilot hospital-based case-control study by identifying the MNS16A genotype with genomic DNA from 53 lung cancer patients and 72 cancer-free controls. We found four different alleles and classified them as shorter (S) or longer (L) on the functional basis of the length of the repeats in the controls. The MNS16A genotype distributions of the SS, SL, and LL genotypes were 11, 32, and 57%, respectively, in the cases, and 14, 40, and 46%, respectively, in the controls. Compared with the SS+SL genotype, the LL genotype was associated with greater than twofold increased risk of lung cancer (odds ratio = 2.18; 95% confidence interval = 0.92, 5.20) after adjustment for age, sex, ethnicity, and smoking status, suggesting a potential role of MNS16A in lung cancer susceptibility. Larger studies are needed to verify our findings.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	lmao@mdanderson.org	Soria, Jean-Charles/F-3619-2014; Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358; Chang, Yoon Soo/0000-0003-3340-4223; Lee, Ho-Young/0000-0001-7556-9312	NATIONAL CANCER INSTITUTE [U01CA086390, P01CA091844] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; *AM CANC SOC INC, 2003, CANC FACTS FIG 2003, P2; Bouchardy C, 2001, LUNG CANCER-J IASLC, V32, P109, DOI 10.1016/S0169-5002(00)00215-4; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Dhaene K, 2000, VIRCHOWS ARCH, V437, P1, DOI 10.1007/s004280000189; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; HONMA M, 1994, MUTAT RES, V304, P167, DOI 10.1016/0027-5107(94)90208-9; Imai H, 1997, P NATL ACAD SCI USA, V94, P10817, DOI 10.1073/pnas.94.20.10817; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1987, NUCLEIC ACIDS RES, V15, P2823, DOI 10.1093/nar/15.7.2823; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEDWITH BJ, 1995, CARCINOGENESIS, V16, P1167, DOI 10.1093/carcin/16.5.1167; LEDWITH BJ, 1990, CANCER RES, V50, P5245; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; MATSUMURA Y, 1992, CANCER RES, V52, P2174; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PAQUETTE B, 1992, CANCER RES, V52, P5788; Shen HB, 2002, CANCER RES, V62, P4992; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; Spitz MR, 2001, CANCER RES, V61, P1354; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; Wang L, 2002, CLIN CANCER RES, V8, P2883; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yashima K, 1997, CANCER RES, V57, P2373	35	52	54	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7123	7129		10.1038/sj.onc.1206852	http://dx.doi.org/10.1038/sj.onc.1206852			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562040				2022-12-17	WOS:000185955000003
J	Harnois, T; Constantin, B; Rioux, A; Grenioux, E; Kitzis, A; Bourmeyster, N				Harnois, T; Constantin, B; Rioux, A; Grenioux, E; Kitzis, A; Bourmeyster, N			Differential interaction and activation of Rho family GTPases by p210(bcr-abl) and p190(bcr-abl)	ONCOGENE			English	Article						Bcr-Abl; Rho GTPases; signal transduction	CHRONIC MYELOGENOUS LEUKEMIA; GUANINE-NUCLEOTIDE EXCHANGE; BCR-ABL ONCOPROTEINS; TYROSINE PHOSPHORYLATION; PHILADELPHIA-CHROMOSOME; CELL-LINES; HEMATOPOIETIC-CELLS; RAS TRANSFORMATION; SIGNALING PATHWAY; PROTOONCOGENE VAV	The p210(bcr-abl) and p190(bcr-abl) fusion proteins, respectively responsible for chronic myelogenous leukemia and acute lymphoblastic leukemia, present deregulated tyrosine kinase activity and abnormal localization. The Dbl homology domain of Bcr, activating Rho GTPases, is present in p210(bcr-abl), but absent in p190(bcr-abl). We investigated the interaction of Bcr-Abl chimeras and Rho proteins by coimmunoprecipitation, pull-down experiments and GEF activity measurement. RhoA, Rac1 and Cdc42 interact in vivo with p210(bcr-abl) only. Moreover, the three types of GTPases are activated in vitro and in vivo by p210(bcr-abl). Nevertheless, Rac1 and Cdc42, but not RhoA, are activated by p190(bcr-abl) in vitro and in vivo. Part of this GEF activity of p190(bcr-abl) is probably attributable to p95(vav), which is complexed with both p190(bcr-abl) and p210(bcr-abl) in an activated form. p160(bcr), also in complex with Bcr-Abl, presents no GEF activity in p190(bcr-abl)-expressing cells. These results suggest that differential activation of Rho proteins should play a major role in BcrAbl-induced leukemogenesis.	CHU Poitiers, UPRES EA2622, Lab Genet Cellulaire & Mol, F-86021 Poitiers, France; CNRS, UMR 6558, Lab Biomembranes & Signalisat Cellulaire, F-86022 Poitiers, France	CHU Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Kitzis, A (corresponding author), CHU Poitiers, UPRES EA2622, Lab Genet Cellulaire & Mol, BP 577, F-86021 Poitiers, France.		Constantin, Bruno/AAH-6463-2021	Bourmeyster, Nicolas/0000-0002-9563-5142; RIOUX BILAN, Agnes/0000-0003-2798-8576; Constantin, Bruno/0000-0003-1668-581X				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHENG JC, 1995, CELL GROWTH DIFFER, V6, P139; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Crespo P, 1996, ONCOGENE, V13, P455; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; DRUKER B, 1992, BLOOD, V79, P2215; Eda M, 2001, J CELL SCI, V114, P3273; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hansen MDH, 2001, CURR BIOL, V11, P356, DOI 10.1016/S0960-9822(01)00091-4; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohguchi K, 1997, J BIOL CHEM, V272, P1990, DOI 10.1074/jbc.272.3.1990; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Rudolph MG, 2001, J BIOL CHEM, V276, P23914, DOI 10.1074/jbc.M011600200; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	56	52	56	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6445	6454		10.1038/sj.onc.1206626	http://dx.doi.org/10.1038/sj.onc.1206626			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508524				2022-12-17	WOS:000185535300014
J	Coppo, P; Dusanter-Fourt, I; Millot, G; Nogueira, MM; Dugray, A; Bonnet, ML; Mitjavila-Garcia, MT; Le Pesteur, D; Guilhot, F; Vainchenker, W; Sainteny, F; Turhan, AG				Coppo, P; Dusanter-Fourt, I; Millot, G; Nogueira, MM; Dugray, A; Bonnet, ML; Mitjavila-Garcia, MT; Le Pesteur, D; Guilhot, F; Vainchenker, W; Sainteny, F; Turhan, AG			Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells	ONCOGENE			English	Article						BCR-ABL; STAT3; embryonic stem cells	CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; CHRONIC MYELOID-LEUKEMIA; SIGNAL TRANSDUCERS; KINASE-ACTIVITY; SELF-RENEWAL; IN-VIVO; GENE; EXPRESSION; BCR/ABL	BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia (CML) arises in a primitive hematopoietic stem cell with both differentiation and self-renewal ability. To study the phenotypic effects of BCR-ABL in a clonal in vitro self-renewal and differentiation model, we have introduced BCR-ABL in the ES cell line CCE. The major effect of BCR-ABL expression was the persistence of primitive morphology of ES cells despite LIF deprivation, correlated with a constitutive activation of STAT3, the major self-renewal factor of ES cells, but no evidence of activation of STAT5. The enforced expression of BCR-ABL in an ES cell line, engineered to express a tetracycline-inducible dominant-negative form of a STAT3, triggered ES cell differentiation with an increased generation of hematopoietic cells expressing erythroid and megakaryocytic phenotypes. RT-PCR analysis for Oct4, Brachyury and beta-globin expression confirmed a delay of differentiation in BCR-ABL expressing clones, which could be entirely reversed upon activation of the dominant-negative form of STAT3. To study the possible relevance of STAT3 activation by BCR-ABL in human CML, Western blot analyses performed on the CD34+ cells, purified from CML patients at different stages of their disease, also demonstrated increased levels of STAT3 proteins phosphorylated both on tyrosine and serine residues. These results represent to our knowledge the first functional link between BCR-ABL oncogene and a self-renewal in the context of ES cells through constitutive activation of STAT3. Thus, the BCR-ABL embryonic stem cell model that we developed as well as the results obtained in human CML samples suggests a role for STAT3 in the pathogenesis of human CML.	Inst Gustave Roussy, INSERM, U362, Translat Res Cell Therapy Lab, F-94805 Villejuif, France; Hop Cochin, ICGM, INSERM, U363, F-75674 Paris, France; Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France; CHU Poitiers, Dept Oncol & Cell Therapy, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; UNICANCER; Gustave Roussy; CHU Poitiers	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, Translat Res Cell Therapy Lab, PR-1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dusanter-Fourt, Isabelle/P-4558-2017; Mitjavila-Garcia, Maria Teresa/L-8909-2018	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Nogueira, Maria Manuela/0000-0002-8353-1979; Guilhot, Francois/0000-0001-7222-487X; Vainchenker, William/0000-0003-4705-202X; TURHAN, Ali/0000-0002-4861-0137				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUGRAY A, 2001, LEUKEMIA, V14, P662; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4102	4110		10.1038/sj.onc.1206607	http://dx.doi.org/10.1038/sj.onc.1206607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821944				2022-12-17	WOS:000183707600013
J	Marchese, C; Maresca, V; Cardinali, G; Belleudi, F; Ceccarelli, S; Bellocci, M; Frati, L; Torrisi, MR; Picardo, M				Marchese, C; Maresca, V; Cardinali, G; Belleudi, F; Ceccarelli, S; Bellocci, M; Frati, L; Torrisi, MR; Picardo, M			UVB-induced activation and internalization of keratinocyte growth factor receptor	ONCOGENE			English	Article						UVB; keratinocyte growth factor receptor; oxidative stress; tyrosine phosphorylation	CULTURED HUMAN KERATINOCYTES; INDUCED EGF-RECEPTOR; HYDROGEN-PEROXIDE; ULTRAVIOLET-LIGHT; INDUCED APOPTOSIS; EXPRESSION; CELLS; KGF; INVOLVEMENT; MODULATION	Ultraviolet irradiation of mammalian cells induces several events that include activation of growth factor receptors and triggering of signal transduction pathway. Most of the UV responses are mediated by the production of reactive oxygen species (ROS) and can be blocked by antioxidants. In this study, we analysed the effect of UVB irradiation at physiologic doses and that of the prooxidant agent cumene hydroperoxide (CUH) on the activation of the receptor for keratinocyte growth factor (KGF), a key mediator of epithelial growth and differentiation. Exposure to both UVB (30-150 mJ/cm(2)) and CUH (200 muM of NIH3T3 KGFR (KGF receptors) transfectants caused a rapid tyrosine phosphorylation and activation of KGFR similar to that induced by KGF, and internalization of the activated receptor. The KGFR expression appeared unmodified by the treatments. Ultrastructural observations of both UVB- and CUH-treated cells showed a normal morphology of the plasma membranes and intracellular organelles. The antioxidant N-acetylcysteine inhibited UVB-induced receptor phosphorylation. The generation of an intracellular oxidative stress was detected as a decrease of catalase activity and of vitamin E, and reduced glutathione levels, whereas superoxide dismutase activity was not significantly modified. A peroxidation of polyunsaturated fatty acids of cell membranes was observed after both treatments, associated with the intracellular oxidative stress. Similar biochemical events were observed on NIH3T3 untransfected control cells, suggesting that KGFR activation follows intracellular generation of ROS and is not associated with a scavenging effect. Taken together our results demonstrate that exposure to UVB and to oxidant stimuli induces a rapid intracellular production of ROS, which in turn are capable of triggering KGFR activation and internalization, similar to those induced by KGF.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; IRCCS, Ist Dermatol Santa Maria & San Gallicano, Rome, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Marchese, C (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.		Picardo, Mauro/A-6978-2011; maresca, vittoria/J-3272-2016; Frati, Luigi/ABI-7437-2020; Cardinali, Giorgia/H-1814-2016; Ceccarelli, Simona/J-4086-2018; Marchese, Cinzia/J-1323-2018	Picardo, Mauro/0000-0003-4899-6639; maresca, vittoria/0000-0001-9239-6978; Cardinali, Giorgia/0000-0002-7527-9451; Ceccarelli, Simona/0000-0001-8789-7719; MARCHESE, CINZIA/0000-0002-9280-8917				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Claiborne A., 1985, CRC HDB METHODS OXYG, DOI DOI 10.1016/0531-5565(85)90021-X; COFFER PJ, 1995, ONCOGENE, V11, P561; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dimon-Gadal S, 1998, J BIOL CHEM, V273, P22833, DOI 10.1074/jbc.273.35.22833; Finch PW, 1997, AM J PATHOL, V151, P1619; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; FUCHS J, 1990, PHOTODERMATOL PHOTO, V7, P920; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Marchese C, 1997, CELL GROWTH DIFFER, V8, P989; Marchese C, 1998, J CELL SCI, V111, P3517; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; McGregor WG, 1999, J INVEST DERM SYMP P, V4, P1, DOI 10.1038/sj.jidsp.5640172; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; ONEIL P, 1998, J BIOCH, V24, P41; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; Peus D, 1999, FREE RADICAL BIO MED, V27, P1197, DOI 10.1016/S0891-5849(99)00198-7; Picardo M, 1996, J INVEST DERMATOL, V107, P322, DOI 10.1111/1523-1747.ep12363163; PICCOLI G, 1994, J CHROMATOGR A, V676, P239, DOI 10.1016/0021-9673(94)80465-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SHAOUL E, 1995, ONCOGENE, V10, P357; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; VESSEY DA, 1995, J INVEST DERMATOL, V104, P355, DOI 10.1111/1523-1747.ep12665382; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Zhou Y, 1996, Exp Dermatol, V5, P138, DOI 10.1111/j.1600-0625.1996.tb00108.x	41	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2422	2431		10.1038/sj.onc.1206301	http://dx.doi.org/10.1038/sj.onc.1206301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717419				2022-12-17	WOS:000182383500005
J	Becker, NA; Thorland, EC; Denison, SR; Phillips, LA; Smith, DI				Becker, NA; Thorland, EC; Denison, SR; Phillips, LA; Smith, DI			Evidence that instability within the FRA3B region extends four megabases	ONCOGENE			English	Article						common fragile sites; FRA3B; human papillomavirus; cervical cancer; viral integration	COMMON FRAGILE SITE; CELL CARCINOMA; FHIT GENE; VIRAL INTEGRATION; CERVICAL-CANCER; BROAD REGION; EXPRESSION; CLONING; DNA; METHYLATION	FRA3B is the most frequently expressed common fragile site localized within human chromosomal band 3p14.2, which is frequently deleted in many different cancers, including cervical cancer. Previous reports indicate aphidicolin-induced FRA3B instability occurs over similar to500 kb which is spanned by the 1.5 Mb fragile histidine triad (FHIT) gene. Recently an HPV16 cervical tumor integration, 2 Mb centromeric to the published FRA3B region, has been identified. FISH-based analysis with a BAC spanning the integration has demonstrated this integration occurs within the FRA3B region of instability. These data suggest that the unstable FRA3B region is much larger than previously reported. FISH-based analysis of aphidicolin-induced metaphase chromosomes allowed for a complete characterization of instability associated with FRA3B. This analysis indicates that fragility extends for 4 Mb. Within this region are a total of five genes, including FHIT. FRA3B gene expression analysis on a panel of cervical tumor-derived cell lines revealed that three of the five genes within FRA3B were aberrantly regulated. A similar analysis of genes outside of FRA3B indicated that the surrounding genes were not aberrantly expressed. These data provide additional support that regions of instability associated with CFSs and the genes contained within them, may play an important role in cancer development.	Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, 200 1St St Sw,Hilton 800, Rochester, MN 55905 USA.	smith.david@mayo.edu			NCI NIH HHS [CA 48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; CHOO KR, 1998, GENETIC BASIS HUMAN, P631; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Corbin S, 2002, CANCER RES, V62, P3477; Druck T, 1998, ONCOL RES, V10, P341; Fang JM, 2001, GENE CHROMOSOME CANC, V30, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1095>3.0.CO;2-F; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, CANCER GENET CYTOGEN, V31, P69, DOI 10.1016/0165-4608(88)90013-1; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gonzalez MV, 1998, J CLIN PATHOL, V51, P520, DOI 10.1136/jcp.51.7.520; Gostout BS, 1998, AM J OBSTET GYNECOL, V179, P56, DOI 10.1016/S0002-9378(98)70251-0; Greenspan DL, 1997, CANCER RES, V57, P4692; Hendricks DT, 1997, CANCER RES, V57, P2112; Herzog CR, 2001, MOL CARCINOGEN, V30, P159, DOI 10.1002/mc.1024; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kastury K, 1996, GENOMICS, V32, P225, DOI 10.1006/geno.1996.0109; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; POPESCU NC, 1990, HUM GENET, V84, P383; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; SANDBERG AA, 1990, CHROMOSOME HUMAN CAN; Sarkar G, 1993, PCR Methods Appl, V2, P318; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Tanaka H, 1998, CANCER RES, V58, P3429; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Thorland EC, 2000, CANCER RES, V60, P5916; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VERMA RS, 1989, HUMAN CHROMOSOMES MA; VERTINO PM, 1993, CANCER RES, V53, P1684; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Zimonjic DB, 1997, CANCER RES, V57, P1166; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	48	52	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8713	8722		10.1038/sj.onc.1205950	http://dx.doi.org/10.1038/sj.onc.1205950			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483524				2022-12-17	WOS:000179734400005
J	Chen, MW; Vacherot, F; de la Taille, A; Gil-Diez-de-Medina, S; Shen, RQ; Friedman, RA; Burchardt, M; Chopin, DK; Buttyan, R				Chen, MW; Vacherot, F; de la Taille, A; Gil-Diez-de-Medina, S; Shen, RQ; Friedman, RA; Burchardt, M; Chopin, DK; Buttyan, R			The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells	ONCOGENE			English	Article						prostate cancer; hormone-resistance; apoptosis; protocadherins; beta-catenin	ANDROGEN RECEPTOR MUTATIONS; IN-SITU HYBRIDIZATION; Y-CHROMOSOME GENES; PROTEIN; BCL-2; IDENTIFICATION; INDUCTION; CARCINOMA; CADHERIN; THERAPY	In order to identify gene products associated with the development of acquired therapeutic resistance by prostate cancer cells, we created two novel apoptosis-resistant prostate cancer cell lines, LNCaP-TR (phorbol-ester [TPA]-Resistant) and LNCaP-SSR (Serum Starvation-Resistant) by repeated transient exposure of cultured human LNCaP cells to apoptotic stimuli followed by expansion of surviving cell populations. These cell lines were found to be cross-resistant to the alternative selective agent and also hormone-resistant when xenografted into castrated male immunodeficient mice. RNA from the LNCaP-TR line was comparatively screened using a subtractive hybridization-PCR procedure. This allowed us to identify a 249 bp cDNA fragment that hybridized to a 4.8 kb mRNA preferentially expressed toy the apoptosis-resistant cells. Using RACE procedures, we cloned and sequenced the complete 4.8 kb cDNA. It is an unusual member of the protocadherin gene family containing two large overlapping open reading frames encoding homologous polypeptides, one having a signal sequence and the other lacking a signal sequence and we refer to it as protocadherin-PC. LNCaP cells directly transformed with protocadherin-PC cDNA were comparatively resistant to phorbol-ester induced apoptosis. Antibody recognition studies demonstrating the cytoplasmic nature of the protcadherin-PC translation product and its propensity to bind beta-catenin suggest that it might influence the apoptotic sensitivity of prostate cancer cells through a unique mechanism.	Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Comp & Informat Resource Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Univ Paris 07, INSERM, CHU Henri Mondor, Serv Urol,EMI 99 09,Assistance Publ Hop Paris, Paris, France	Columbia University; Columbia University; Columbia University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Buttyan, R (corresponding author), Herbert Irving Pavil,11th Floor,161 Ft Washington, New York, NY 10032 USA.	rb46@columbia.edu	Vacherot, Francis/R-6588-2018; de la taille, Alex/ABE-8422-2021	Vacherot, Francis/0000-0002-3677-1267; 				Blanco P, 2000, MAMM GENOME, V11, P906, DOI 10.1007/s003350010177; Brothman AR, 1997, CANCER GENET CYTOGEN, V95, P116, DOI 10.1016/S0165-4608(96)00302-0; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDDY S, 1998, HMMER USERS GUIDE BI; Furuya Y, 1996, CLIN CANCER RES, V2, P389; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Huggins C, 1941, CANCER RES, V1, P293; Karan D, 2001, CLIN CANCER RES, V7, P3472; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; Marcelli M, 2000, CANCER RES, V60, P944; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MURPHY GP, 1980, UROL CLIN N AM, V7, P631; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; RAFFO AJ, 1995, CANCER RES, V55, P4438; Resnick M I, 1975, Urol Clin North Am, V2, P141; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Shen R, 1997, Urol Oncol, V3, P67, DOI 10.1016/S1078-1439(97)00039-2; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; Takahashi S, 1996, CLIN CANCER RES, V2, P137; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tricoli JV, 1999, CANCER GENET CYTOGEN, V111, P1, DOI 10.1016/S0165-4608(98)00212-X; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yoshida K, 1999, GENOMICS, V62, P540, DOI 10.1006/geno.1999.6042; ZHANG XJ, 1994, BIOCHEM BIOPH RES CO, V198, P1189, DOI 10.1006/bbrc.1994.1168; [No title captured]	45	52	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7861	7871		10.1038/sj.onc.1205991	http://dx.doi.org/10.1038/sj.onc.1205991			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420223				2022-12-17	WOS:000178946000011
J	Lerman, C; Niaura, R				Lerman, C; Niaura, R			Applying genetic approaches to the treatment of nicotine dependence	ONCOGENE			English	Review						genetics; smoking; nicotine; treatment	SEROTONIN TRANSPORTER GENE; SUSTAINED-RELEASE BUPROPION; DOPAMINE-RECEPTOR GENE; TRYPTOPHAN-HYDROXYLASE GENE; RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; CIGARETTE-SMOKING; NASAL SPRAY; TRANSDERMAL NICOTINE; DEPRESSIVE SYMPTOMS	To advance the science of tobacco control, an enhanced understanding of the bio-behavioral basis of nicotine addiction is needed. In this study, we provide an overview of data from investigations of genetic factors in smoking behavior, discuss potential bio-behavioral mechanisms and effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessation treatment. The evidence to date is very consistent with respect to the significance of genetic contributions to smoking behavior. However, attempts to elucidate the role of specific genetic variants have met with mixed success. Explanations for the lack of consistency in the results of genetic association studies include biases in ascertainment, ethnic admixture, lack of attention to co-variates or modifiers of genetic risk, and the need for more refined phenotypes. As the field of genetics and smoking research progresses, increasing attention is being devoted to gene - environment interactions, with particular attention to the identification of genetic variants that may modify the effects of pharmacological treatment for smoking. With advances in molecular biology and genomics technology, individualized tailoring of smoking cessation therapy to genotype is within our grasp. Such research has the potential to improve treatment outcome, thereby reducing morbidity and mortality from smoking-related disease.	Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Brown Med Sch, Ctr Behav Med, Providence, RI 02903 USA; Brown Med Sch, Ctr Prevent Med, Providence, RI 02903 USA	University of Pennsylvania; University of Pennsylvania; Brown University; Brown University	Lerman, C (corresponding author), Univ Penn, Dept Psychiat, 3535 Mkt St,Suite 4100, Philadelphia, PA 19104 USA.	clerman@mail.med.upenn.edu	Niaura, Raymond/AAE-7319-2019	Niaura, Raymond/0000-0002-0856-3540	NCI NIH HHS [P50CA084719, R01 CA63562, P50 CA84718] Funding Source: Medline; NHLBI NIH HHS [R01 HL32318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063562, P50CA084718, P50CA084719] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; [Anonymous], 1991, JAMA, V266, P3133; Arinami T, 2000, EUR J PHARMACOL, V410, P215, DOI 10.1016/S0014-2999(00)00816-5; ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395; Audrain J., 1998, J APPL BIOBEHAV RES, V3, P29, DOI DOI 10.1111/J.1751-9861.1998.TB00042.X; Balfour DJK, 2001, INT J CLIN PRACT, V55, P53; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; Bierut LJ, 2000, AM J MED GENET, V90, P299, DOI 10.1002/(SICI)1096-8628(20000214)90:4<299::AID-AJMG7>3.0.CO;2-Y; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; Blondal T, 1997, EUR RESPIR J, V10, P1585, DOI 10.1183/09031936.97.10071585; Borrelli B, 1996, J CLIN PSYCHIAT, V57, P534; Bowles SV, 1999, PSYCHOSOM MED, V61, P104, DOI 10.1097/00006842-199901000-00117; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P161, DOI 10.1001/archpsyc.55.2.161; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; *CDC, 1994, 43 CDC; *CDCP, 2000, 49 CDCP; CEPEDABENITO A, 1993, J CONSULT CLIN PSYCH, V61, P822, DOI 10.1037/0022-006X.61.5.822; CHASSIN L, 1986, DEV PSYCHOL, V22, P327, DOI 10.1037/0012-1649.22.3.327; Choi WS, 1997, AM J PREV MED, V13, P385, DOI 10.1016/S0749-3797(18)30159-4; CINCIRIPINI PM, 1995, J CLIN PSYCHOPHARM, V15, P182, DOI 10.1097/00004714-199506000-00006; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008; CLONINGER CR, 1994, CURR OPIN NEUROBIOL, V4, P266, DOI 10.1016/0959-4388(94)90083-3; COHEN SJ, 1989, J AM DENT ASSOC, V118, P41, DOI 10.14219/jada.archive.1989.0018; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CONRAD KM, 1992, BRIT J ADDICT, V87, P1711; DALE LC, 1995, JAMA-J AM MED ASSOC, V274, P1353, DOI 10.1001/jama.274.17.1353; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; DAVID S, 2001, PRESENTATION SOC RES; Ebstein RP, 1997, MOL PSYCHIATR, V2, P472, DOI 10.1038/sj.mp.4000333; Eissenberg T, 2000, DRUG ALCOHOL DEPEN, V59, pS41; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; Fiore M C, 2000, Respir Care, V45, P1200; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FLAY BR, 1983, PEDIATRIC ADOLESCENT, P132; Flory JD, 1999, MOL PSYCHIATR, V4, P93, DOI 10.1038/sj.mp.4000466; FRIEDMAN LS, 1985, ADDICT BEHAV, V10, P1, DOI 10.1016/0306-4603(85)90048-6; GILBERT DG, 1995, BEHAV GENET, V25, P133, DOI 10.1007/BF02196923; Glassman AH, 2001, LANCET, V357, P1929, DOI 10.1016/S0140-6736(00)05064-9; Hall SM, 1996, J CONSULT CLIN PSYCH, V64, P1003, DOI 10.1037/0022-006X.64.5.1003; Hays JT, 2001, ANN INTERN MED, V135, P423, DOI 10.7326/0003-4819-135-6-200109180-00011; Heath AC, 1999, BEHAV GENET, V29, P395, DOI 10.1023/A:1021670703806; HEATH AC, 1993, ADDICT BEHAV, V18, P19, DOI 10.1016/0306-4603(93)90005-T; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Heinz A, 2000, NEUROPSYCHOPHARMACOL, V22, P133, DOI 10.1016/S0893-133X(99)00099-8; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; Hiatt RA, 1999, CANCER EPIDEM BIOMAR, V8, P957; HILLEMAN DE, 1994, J CLIN PHARMACOL, V34, P222, DOI 10.1002/j.1552-4604.1994.tb03989.x; HJALMARSON A, 1994, ARCH INTERN MED, V154, P2567, DOI 10.1001/archinte.154.22.2567; Hu S, 2000, MOL PSYCHIATR, V5, P181, DOI 10.1038/sj.mp.4000690; Hughes J R, 1999, Nicotine Tob Res, V1, P169, DOI 10.1080/14622299050011281; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; HUGHES JR, 1986, BEHAV THER, V17, P335, DOI 10.1016/S0005-7894(86)80066-1; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Hutchison KE, 2002, J ABNORM PSYCHOL, V111, P134, DOI 10.1037//0021-843X.111.1.134; JORENBY DE, 1995, JAMA-J AM MED ASSOC, V274, P1347, DOI 10.1001/jama.274.17.1347; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Jorm AF, 2000, AM J MED GENET, V96, P331, DOI 10.1002/1096-8628(20000612)96:3<331::AID-AJMG19>3.0.CO;2-0; Kandel DB, 2001, DRUG ALCOHOL DEPEN, V64, P233, DOI 10.1016/S0376-8716(01)00126-0; Kendler KS, 1999, PSYCHOL MED, V29, P299, DOI 10.1017/S0033291798008022; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; Killen JD, 1996, J CONSULT CLIN PSYCH, V64, P1060, DOI 10.1037/0022-006X.64.5.1060; King G, 1997, SOC SCI MED, V45, P1075, DOI 10.1016/S0277-9536(97)00035-X; King TK, 1997, ANN BEHAV MED, V19, P301, DOI 10.1007/BF02892295; Lando HA, 1996, AM J PUBLIC HEALTH, V86, P1786, DOI 10.2105/AJPH.86.12.1786; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Lerman C, 1999, HEALTH PSYCHOL, V18, P14, DOI 10.1037/0278-6133.18.1.14; Lerman C, 2000, MOL PSYCHIATR, V5, P189, DOI 10.1038/sj.mp.4000672; Lerman C, 1998, CANCER EPIDEM BIOMAR, V7, P253; Lerman C, 2001, AM J MED GENET, V105, P518, DOI 10.1002/ajmg.1476; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; LIPKUS IM, 1994, HEALTH PSYCHOL, V13, P149, DOI 10.1037/0278-6133.13.2.149; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; Madden PAF, 1999, BEHAV GENET, V29, P423, DOI 10.1023/A:1021674804714; Malhotra AK, 1996, MOL PSYCHIATR, V1, P388; Manuck SB, 1999, BIOL PSYCHIAT, V45, P603, DOI 10.1016/S0006-3223(98)00375-8; Masse LC, 1997, ARCH GEN PSYCHIAT, V54, P62; McKinney EF, 2000, PHARMACOGENETICS, V10, P483, DOI 10.1097/00008571-200008000-00001; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; Niaura R, 2001, PSYCHOL ADDICT BEHAV, V15, P13, DOI 10.1037/0893-164X.15.1.13; NIAURA R, 2002, IN PRESS J CONSULT C; NIELSEN DA, 1994, ARCH GEN PSYCHIAT, V51, P34; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; Noble EP, 1998, AM J MED GENET, V81, P257, DOI 10.1002/(SICI)1096-8628(19980508)81:3<257::AID-AJMG10>3.0.CO;2-E; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; Ockene Judith K., 1993, Annals of Behavioral Medicine, V15, P135; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; Oscarson M, 1998, FEBS LETT, V438, P201, DOI 10.1016/S0014-5793(98)01297-6; Paoletti P, 1996, EUR RESPIR J, V9, P643, DOI 10.1183/09031936.96.09040643; PEREZSTABLE EJ, 1990, AM J PUBLIC HEALTH, V80, P1500, DOI 10.2105/AJPH.80.12.1500; Perkins KA, 1996, EXP CLIN PSYCHOPHARM, V4, P166, DOI 10.1037/1064-1297.4.2.166; Perkins KA, 1999, PHARMACOL BIOCHEM BE, V64, P295, DOI 10.1016/S0091-3057(99)00085-4; Perkins KA, 2001, CNS DRUGS, V15, P391, DOI 10.2165/00023210-200115050-00005; Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623; Pickworth WB, 1996, J PHARMACOL EXP THER, V279, P450; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; Pierce JP, 1999, TOB CONTROL, V8, P37, DOI 10.1136/tc.8.1.37; Piper M E, 2001, Nicotine Tob Res, V3, P291; PIRIE PL, 1992, AM J PUBLIC HEALTH, V82, P1238, DOI 10.2105/AJPH.82.9.1238; Pomerleau C S, 1992, J Subst Abuse, V4, P143, DOI 10.1016/0899-3289(92)90014-O; Pomerleau CS, 1999, J ADDICT DIS, V18, P13, DOI 10.1300/J069v18n03_02; Pomerleau OF, 1998, PSYCHONEUROENDOCRINO, V23, P115, DOI 10.1016/S0306-4530(97)00074-7; Rigotti NA, 2000, JAMA-J AM MED ASSOC, V284, P699, DOI 10.1001/jama.284.6.699; Royce JM, 1997, SOC SCI MED, V44, P359, DOI 10.1016/S0277-9536(96)00149-9; Sabol SZ, 1999, HEALTH PSYCHOL, V18, P7, DOI 10.1037/0278-6133.18.1.7; Sargent JD, 2000, TOB CONTROL, V9, P163, DOI 10.1136/tc.9.2.163; SCHNEIDER NG, 1995, ADDICTION, V90, P1671, DOI 10.1046/j.1360-0443.1995.901216719.x; Schneider NG, 1996, CLIN PHARMACOL THER, V60, P568, DOI 10.1016/S0009-9236(96)90153-8; Shields PG, 1998, CANCER EPIDEM BIOMAR, V7, P453; Shiffman S, 2000, PSYCHOPHARMACOLOGY, V148, P33, DOI 10.1007/s002130050022; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; Silverman MA, 2000, AM J MED GENET, V96, P646, DOI 10.1002/1096-8628(20001009)96:5<646::AID-AJMG10>3.3.CO;2-N; Son BK, 1997, AM J EPIDEMIOL, V145, P110; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; Stallings MC, 1996, J PERS SOC PSYCHOL, V70, P127, DOI 10.1037/0022-3514.70.1.127; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; Sullivan P F, 1999, Nicotine Tob Res, V1 Suppl 2, pS51; Sullivan PF, 2001, AM J MED GENET, V105, P479, DOI 10.1002/ajmg.1433; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TONNESEN P, 1993, JAMA-J AM MED ASSOC, V269, P1268, DOI 10.1001/jama.269.10.1268; *TRIP, 1998, NAT CANC I TOB RES I; True WR, 1999, ARCH GEN PSYCHIAT, V56, P655, DOI 10.1001/archpsyc.56.7.655; *US DHHS, 1998, SURG GEN REP; VANDENBERGH D, 2002, IN PRESS NICOTINE TO; Vandenbergh DJ, 1997, MOL PSYCHIATR, V2, P417, DOI 10.1038/sj.mp.4000309; Voorhees CC, 1996, PREV MED, V25, P277, DOI 10.1006/pmed.1996.0057; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Walton R, 2001, TRENDS MOL MED, V7, P70, DOI 10.1016/S1471-4914(01)01915-3; Wetter DW, 1999, J CONSULT CLIN PSYCH, V67, P555, DOI 10.1037/0022-006X.67.4.555; Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-3289(94)90039-6	137	52	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7412	7420		10.1038/sj.onc.1205801	http://dx.doi.org/10.1038/sj.onc.1205801			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379882				2022-12-17	WOS:000178618000012
J	McWilliams, A; MacAulay, C; Gazdar, AF; Lam, S				McWilliams, A; MacAulay, C; Gazdar, AF; Lam, S			Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions	ONCOGENE			English	Review						lung neoplasms; diagnostic imaging; bronchoscopy	POSITRON-EMISSION-TOMOGRAPHY; ATYPICAL ADENOMATOUS HYPERPLASIA; ABERRANT PROMOTER METHYLATION; HIGH-RESOLUTION CT; CARCINOMA IN-SITU; BRONCHIAL EPITHELIUM; GENE-EXPRESSION; VIRTUAL BRONCHOSCOPY; CONFOCAL MICROSCOPY; ONCOGENE MUTATIONS	Current approaches for the therapy of lung cancer, the majority of which being advanced cancers, have failed to impact on long term survival. The key to improvement lies in the combination of early diagnosis and the introduction of novel targeted therapies. In this article we review some of the innovative approaches, both imaging and molecular, that are currently under investigation for early detection. Because lung cancers may arise in the central or peripheral compartments of the lung, newer approaches must target tumours arising in both of these compartments. Specimens available for analysis include sputa and blood. Detection of genetic changes in peripheral blood is a promising avenue being explored by several groups. Molecular techniques discussed include gene mutations, detection of nuclear riboprotein, methylation related silencing of genes and malignancy associated changes. Newer imaging technologies include autofluorescence bronchoscopy, virtual bronchoscopy, optical coherent tomography and confocal microscopy. Although the impact of these new technologies on survival has not been determined, they offer a wide range of exciting new approaches. In time they may completely revamp the present highly conservative and unsuccessful approaches to early diagnosis.	Univ Western Australia, Nedlands, WA 6009, Australia; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; British Columbia Canc Agcy, Lung Tumour Grp, Vancouver, BC V5Z 4E6, Canada	University of Western Australia; University of British Columbia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; British Columbia Cancer Agency	Lam, S (corresponding author), 600 W 10th Ave, Vancouver, BC 4E6, Canada.	slam@bccancer.bc.ca		MacAulay, Calum/0000-0003-4440-2792				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y; Aoki T, 2000, AM J ROENTGENOL, V174, P763, DOI 10.2214/ajr.174.3.1740763; Aquino SL, 1999, CLIN CHEST MED, V20, P725, DOI 10.1016/S0272-5231(05)70251-3; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; AUERBACH O, 1978, CANCER-AM CANCER SOC, V42, P483, DOI 10.1002/1097-0142(197808)42:2<483::AID-CNCR2820420216>3.0.CO;2-E; BAND PR, 1986, CANCER DETECT PREV, V9, P157; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bota S, 2001, AM J RESP CRIT CARE, V164, P1688, DOI 10.1164/ajrccm.164.9.2012147; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; Bury T, 1997, EUR RESPIR J, V10, P2529, DOI 10.1183/09031936.97.10112529; CORTESE DA, 1983, J THORAC CARDIOV SUR, V86, P373; Dawn S K, 2001, Respir Care, V46, P912; Dickensheets DL, 1996, OPT LETT, V21, P764, DOI 10.1364/OL.21.000764; DUHAYLONGSOD FG, 1995, ANN THORAC SURG, V60, P1348, DOI 10.1016/0003-4975(95)00754-9; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1986, J OCCUP ENVIRON MED, V28, P692, DOI 10.1097/00043764-198608000-00031; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Fry WA, 1996, CANCER, V77, P1947, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; GMITRO AF, 1993, OPT LETT, V18, P565, DOI 10.1364/OL.18.000565; Gupta NC, 1996, J NUCL MED, V37, P943; Gupta NC, 2001, CHEST, V120, P521, DOI 10.1378/chest.120.2.521; Haponik EF, 1999, CLIN CHEST MED, V20, P201, DOI 10.1016/S0272-5231(05)70135-0; HEELAN RT, 1984, RADIOLOGY, V151, P289, DOI 10.1148/radiology.151.2.6324279; Henderson Laura-Jane, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P638; Henschke CI, 2001, CANCER, V92, P153, DOI 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Herder GJM, 2001, J CLIN ONCOL, V19, P4271, DOI 10.1200/JCO.2001.19.22.4271; Hibi K, 1998, CANCER RES, V58, P5690; Hirsch FR, 2001, CLIN CANCER RES, V7, P5; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Izatt JA, 1996, IEEE J SEL TOP QUANT, V2, P1017, DOI 10.1109/2944.577331; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KANEKO M, 1997, CHEST, V112, pS62; KERR KM, 1997, PATHOLOGY LUNG TUMOR, P119; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; KOSS LG, 1964, ACTA CYTOL, V8, P104; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; Kurasono Y, 1998, VIRCHOWS ARCH, V432, P207, DOI 10.1007/s004280050157; Lacroix J, 2001, INT J CANCER, V92, P1; Lam S, 1999, JNCI-J NATL CANCER I, V91, P691, DOI 10.1093/jnci/91.8.691; Lam S, 2000, CANCER-AM CANCER SOC, V89, P2468; LAM S, 2000, LUNG CANCER, V29, P145; Lane P, 2001, PROC SPIE, V4251, P192, DOI 10.1117/12.427894; Lane PM, 2000, OPT LETT, V25, P1780, DOI 10.1364/OL.25.001780; Li XD, 2000, OPT LETT, V25, P1520, DOI 10.1364/OL.25.001520; Lonergan Kim, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P472; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Mac Manus MP, 2001, CANCER, V92, P886, DOI 10.1002/1097-0142(20010815)92:4<886::AID-CNCR1397>3.0.CO;2-V; MACAULAY C, 1995, ANAL QUANT CYTOL, V17, P55; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MCWILLIAMS A, 2001, IPA 8 WORLD C PHOT M, P40; MCWILLIAMS A, 2001, CHEST, V120, pS166; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; MELAMED MR, 1982, MORPHOGENESIS LUNG C, V1, P37; MILLER RR, 1990, AM J SURG PATHOL, V14, P904, DOI 10.1097/00000478-199010000-00002; Mori K, 2000, IEEE T MED IMAGING, V19, P103, DOI 10.1109/42.836370; MORI M, 1993, CANCER, V72, P2331, DOI 10.1002/1097-0142(19931015)72:8<2331::AID-CNCR2820720808>3.0.CO;2-E; Mori M, 1998, ULTRASTRUCT PATHOL, V22, P459, DOI 10.3109/01913129809032282; MUHM JR, 1983, RADIOLOGY, V148, P609, DOI 10.1148/radiology.148.3.6308709; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; NASIELL M, 1966, ACTA CYTOL, V10, P421; NASIELL M, 1987, LUNG CARCINOMAS, P207; NG ABP, 1983, ACTA CYTOL, V27, P397; Nieburgs H. E., 1959, T 7 ANN M INT SOC CY, P137; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Oda M, 1998, LUNG CANCER-J IASLC, V22, P23, DOI 10.1016/S0169-5002(98)00070-1; Palcic B., 1994, COMPENDIUM COMPUTERI, P157; Palmisano WA, 2000, CANCER RES, V60, P5954; Patz EF, 2000, CHEST, V117, P1568, DOI 10.1378/chest.117.6.1568; Payne PW, 1997, MAYO CLIN PROC, V72, P697; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215; RISSE EKJ, 1988, ACTA CYTOL, V32, P629; RISSE EKJ, 1987, ACTA CYTOL, V31, P159; Ritter JH, 1999, AM J CLIN PATHOL, V111, P587; Rollins AM, 1999, OPT LETT, V24, P1484, DOI 10.1364/OL.24.001484; Rollins AM, 1998, OPT EXPRESS, V3, P219, DOI 10.1364/OE.3.000219; ROSA UW, 1973, CHEST, V63, P203, DOI 10.1378/chest.63.2.203; Sabharwal YS, 1999, APPL OPTICS, V38, P7133, DOI 10.1364/AO.38.007133; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; SACCOMANNO G, 1982, SEMIN RESPIR MED, V4, P156, DOI 10.1055/s-2007-1012480; Seemann MD, 2001, LUNG CANCER-J IASLC, V32, P237, DOI 10.1016/S0169-5002(00)00228-2; SHIBUYA K, 2001, J CLIN EXP MED, V199, P593; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Smithpeter CL, 1998, APPL OPTICS, V37, P2749, DOI 10.1364/AO.37.002749; Sone S, 2001, BRIT J CANCER, V84, P25, DOI 10.1054/bjoc.2000.1531; Sone S, 2000, BRIT J RADIOL, V73, P137, DOI 10.1259/bjr.73.866.10884725; SONKA M, 1994, P SOC PHOTO-OPT INS, V2168, P73, DOI 10.1117/12.174425; Soria JC, 2002, CANCER RES, V62, P351; Summers RM, 1998, RADIOLOGY, V208, P331, DOI 10.1148/radiology.208.2.9680555; Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006; Thiberville Luc, 1997, European Respiratory Journal Supplement, V10, p425S; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; TOCKMAN MS, 1994, CHEST, V106, pS385, DOI 10.1378/chest.106.6_Supplement.385S; TOCKMAN MS, 1997, CLIN BIOL BASIS LUNG; Toyooka S, 2001, MOL CANCER THER, V1, P61; UMIKER WO, 1957, SURGERY, V41, P705; USUDA K, 1994, CANCER, V74, P2239, DOI 10.1002/1097-0142(19941015)74:8<2239::AID-CNCR2820740806>3.0.CO;2-P; Venmans BJW, 2000, CHEST, V117, P1572, DOI 10.1378/chest.117.6.1572; WAGNIERES G, 2002, FLUORESCENCE BIOMEDI; WHO, 2000, WORLD HLTH REP 2000, P164; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; WOOLNER LB, 1983, ATLAS EARLY LUNG CAN, P107; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611; Yang ZG, 2001, AM J ROENTGENOL, V176, P1399, DOI 10.2214/ajr.176.6.1761399; Yankelevitz DE, 2000, RADIOL CLIN N AM, V38, P267, DOI 10.1016/S0033-8389(05)70162-7; Yankelevitz DF, 1999, RADIOLOGY, V212, P561, DOI 10.1148/radiology.212.2.r99au33561; Yoshida J, 1998, CHEST, V114, P710, DOI 10.1378/chest.114.3.710; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	131	52	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6949	6959		10.1038/sj.onc.1205831	http://dx.doi.org/10.1038/sj.onc.1205831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362276				2022-12-17	WOS:000178640200009
J	Korus, M; Mahon, GM; Cheng, L; Whitehead, IP				Korus, M; Mahon, GM; Cheng, L; Whitehead, IP			p38 MAPK-mediated activation of NF-kappa B by the RhoGEF domain of Bcr	ONCOGENE			English	Article						Bcr; RhoGEF; Dbl proteins; NF-kappa B; p38 MAPK	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; RAC SIGNALING PATHWAYS; GTP-BINDING PROTEINS; DBL HOMOLOGY DOMAIN; C-ABL PROTEIN; PHILADELPHIA-CHROMOSOME; CELL-CYCLE; FOCAL ADHESIONS	The oncogenic fusion protein p210 Bcr-Abl is causally associated with virtually all cases of chronic myelogenous leukemia. The wild-type Bcr product has several recognizable structural and functional motifs including a domain that contains guanine nucleotide exchange activity for Rho family GTPases (DH/PH domain). Although this domain is retained within p210 Bcr-Abl, it has no known signaling activities in vivo. Here we report that a fragment of Bcr that encodes the isolated DH/PH domain is a potent activator of the NF-kappaB transcription factor. Within the context of full length Bcr, this activity is regulated by proximal flanking sequences that suppress the DH/PH domain encoded guanine nucleotide exchange activity. NF-kappaB activation by Bcr is not mediated by nuclear translocation, but rather by p38 mitogen-activated protein kinase (MAPK)-dependent modification of the RelA/p65 transactivation domain. Although we were able to demonstrate that Bcr can function as an exchange factor for Cdc42 in vivo, NF-kappaB activation appears to occur via a Cdc42-independent mechanism. These studies constitute direct evidence that the Bcr RhoGEF domain can function in vivo, and identify a new signaling activity that may contribute to the transforming potential of p210 Bcr-Abl.	Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Newark, NJ 07103 USA.				NATIONAL CANCER INSTITUTE [R29CA077493] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kin Y, 2001, J BIOL CHEM, V276, P39462, DOI 10.1074/jbc.M105484200; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Maru Y, 1999, BIOCHEM BIOPH RES CO, V260, P309, DOI 10.1006/bbrc.1999.0822; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RON D, 1991, NEW BIOL, V3, P372; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; WHITEHEAD JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, pF1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	63	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4601	4612		10.1038/sj.onc.1205678	http://dx.doi.org/10.1038/sj.onc.1205678			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096337				2022-12-17	WOS:000176625100002
J	Muthumani, K; Zhang, DH; Hwang, DS; Kudchodkar, S; Dayes, NS; Desai, BM; Malik, AS; Yang, JS; Chattergoon, MA; Maguire, HC; Weiner, DB				Muthumani, K; Zhang, DH; Hwang, DS; Kudchodkar, S; Dayes, NS; Desai, BM; Malik, AS; Yang, JS; Chattergoon, MA; Maguire, HC; Weiner, DB			Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines	ONCOGENE			English	Article						adCMV-vpr; p53; Bcl-2; caspase; cytochrome c; apoptosis	ADENOASSOCIATED VIRUS VECTORS; LATE GENE-EXPRESSION; VIRAL-PROTEIN-R; RECOMBINANT ADENOVIRUSES; CYTOCHROME-C; IN-VIVO; THERAPY; CANCER; CYCLE; MACROPHAGES	The targeted delivery of genes whose products arrest the cell cycle and/or induce apoptosis represent an important tool for the understanding and controlling forms of unregulated cell growth. The vpr gene product of HIV-1 has been reported to interfere with cell growth and induce apoptosis, but the mechanism of its action is not clearly understood. In order to study these important properties of Vpr, we created a recombinant adenovirus H5.010CMV-vpr (adCMV-vpr) as a tool to deliver the vpr gene to various cell lines to examine its biology. Vpr protein expression was confirmed by Western blot analysis in adCMV-vpr infected cells. We tested the effects of adCMV-vpr on cell growth of several tumor cell lines. Infection of both p53 positive and p53 deficient tumor cell lines with adCMV-vpr resulted in dramatic induction of cell death in short-term assays. We observed that apoptosis was induced through the mitochondrial pathway as we observed changes in the cytochrome c content accompanied by caspase 9 activation. As Bcl-2 is reported to interfere with apoptosis through the mitochondrial pathway, we examined the effect of adCMV-vpr in Bcl-2 over expressing cell lines. We observed that Bcl-2 overexpression does not inhibit adCMV-vpr induced apoptosis. The properties of adCMV-vpr inducing apoptosis through caspase 9 in a p53 pathway independent manner suggest that this is an important reagent. Such a vector may give insight into approaches designed to limit the growth of pathogenic human cells.	Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, Philadelphia, PA 19104 USA; Viral Genomix, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiner, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Muthumani, Kar/C-8252-2017; Muthumani, Kar/AAQ-4939-2020; Muthumani, Karuppiah/D-1092-2009; Weiner, David B/H-8579-2014	Muthumani, Kar/0000-0002-6807-2065; Muthumani, Kar/0000-0002-6807-2065; 				Athanasopoulos T, 2000, INT J MOL MED, V6, P363; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bonnet MC, 2000, IMMUNOL LETT, V74, P11, DOI 10.1016/S0165-2478(00)00244-3; BOON B, 1998, SCIENCE, V281, P266; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Brooks LA, 2000, CANCER RES, V60, P6875; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Fisher KJ, 1996, VIROLOGY, V217, P11, DOI 10.1006/viro.1996.0088; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; JOLLY D, 1994, CANCER GENE THER, V1, P51; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Komata T, 2000, GENE THER, V7, P2071, DOI 10.1038/sj.gt.3301327; Kunke D, 2000, CANCER GENE THER, V7, P766, DOI 10.1038/sj.cgt.7700178; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lynch CM, 1997, CIRC RES, V80, P497; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; MAY E, 1991, ONCOGENE, V6, P1363; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Muthumani K, 2000, DNA CELL BIOL, V19, P179, DOI 10.1089/104454900314564; Muthumani K, 2000, J LEUKOCYTE BIOL, V68, P366; NEWBOLD R, 1984, NATURE, V310, P628, DOI 10.1038/310628a0; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; PERKUS ME, 1995, J LEUKOCYTE BIOL, V58, P1; PLANCHON SM, 1995, CANCER RES, V55, P3706; Qazilbash MH, 1997, GENE THER, V4, P675, DOI 10.1038/sj.gt.3300444; Qi V, 2001, INT J HYPERTHER, V17, P38; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rozenszajn LA, 2000, EXP HEMATOL, V28, P1503, DOI 10.1016/S0301-472X(00)00589-0; Sawada H, 1996, CLIN EXP METASTAS, V14, P308; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; Stirewalt DEREK L., 2000, Hematology, V5, P15; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405	51	52	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4613	4625		10.1038/sj.onc.1205549	http://dx.doi.org/10.1038/sj.onc.1205549			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096338				2022-12-17	WOS:000176625100003
J	Jahn, T; Seipel, P; Coutinho, S; Urschel, S; Schwarz, K; Miething, C; Serve, H; Peschel, C; Duyster, J				Jahn, T; Seipel, P; Coutinho, S; Urschel, S; Schwarz, K; Miething, C; Serve, H; Peschel, C; Duyster, J			Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain	ONCOGENE			English	Article						c-kit; EGFP; signal transduction; PI3-kinase; Src	STEM-CELL-FACTOR; GREEN FLUORESCENT PROTEIN; RESONANCE ENERGY-TRANSFER; RECEPTOR TYROSINE KINASE; SRC FAMILY KINASES; PHOSPHATIDYLINOSITOL 3'-KINASE; ADAPTER PROTEIN; LIPID RAFTS; MAST-CELLS; ACTIVATION	In order to investigate activation and internalization of e-kit we created a functional c-kit-EGFP chimera by inserting EYFP (enhanced yellow fluorescent protein) within the extracellular domain of e-kit immediately downstream of the signal sequence, SS-EYFP-kit. This location was chosen because the C-terminal fusion of EGFP to c-kit unexpectedly caused constitutive activation of the c-kit tyrosine kinase. As analysed in fixed cells and by real time imaging in vivo, SCF induced activation led to internalization of the fusion construct and translocation to punctate structures resembling vesicles. Analysis of the internalization process by time lapse imaging revealed high mobility and discontinuous movement of these vesicles and their predominantly radial tracks. Two subsets of vesicles were observed: Traffic of the majority of vesicles was directed from the periphery to the center of the cell and most likely represents the internalization of activated receptor molecules via the endosomal pathway. However, some vesicular structures were observed to move towards the periphery of the cell and probably contain newly synthesized protein to replace internalized receptor molecules. The calculated velocity of moving vesicles ranged from 0.05 to 0.2 mum per se. Vesicle formation upon SCF induced dimerization of the receptor was strictly dependent on kinase activity of e-kit. Treatment of cells with phenylarsine oxide, an agent blocking receptor internalization, prior to SCF stimulation resulted in abrogation of the translocation of the chimera to vesicles whereas accumulation of vesicles was observed when cells were treated with proteasome inhibitors. Cholesterol depletion of the cell membrane by methyl-beta-cyclodextrin resulted in dose dependent reduction of receptor internalization indicating that c-kit may be present in lipid rafts or that intact lipid rafts are required for efficient internalization of the receptor. Using the induction of vesicular structures as a sign of efficient internalization of the receptor analysis of mutant e-kit constructs deficient either in activation of PI3-Kinase or Src revealed that internalization of e-kit is dependent on recruitment of Src but not PI3-Kinase.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Univ Munster, Dept Internal Med A, D-4400 Munster, Germany	Technical University of Munich; University of Munich; University of Munster	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.		Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Broudy VC, 1999, BLOOD, V94, P1979; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; Coutinho S, 2000, BLOOD, V96, P618; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Feng YQ, 1999, BIOCHEMISTRY-US, V38, P4553, DOI 10.1021/bi982224o; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KANUKURA Y, 1994, LEUKEMIA S1, V8, pS18; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Krystal GW, 1998, CANCER RES, V58, P4660; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LANGLEY KE, 1993, BLOOD, V81, P656; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Li Q, 1996, CANCER RES, V56, P4343; LIU L, 1994, J BIOL CHEM, V269, P16774; Longley BJ, 1997, P NATL ACAD SCI USA, V94, P9017, DOI 10.1073/pnas.94.17.9017; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MIYAZAWA K, 1994, BLOOD, V83, P137; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Shimizu YJ, 1996, J IMMUNOL, V156, P3443; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YEE NS, 1994, J BIOL CHEM, V269, P31991	40	52	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4508	4520		10.1038/sj.onc.1205559	http://dx.doi.org/10.1038/sj.onc.1205559			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085229				2022-12-17	WOS:000176476700005
J	Senyuk, V; Chakraborty, S; Mikhail, FM; Zhao, R; Chi, YQ; Nucifora, G				Senyuk, V; Chakraborty, S; Mikhail, FM; Zhao, R; Chi, YQ; Nucifora, G			The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells	ONCOGENE			English	Article						AML1; MDS1; EVI1; t(3;21); CtBP1; HDAC1	ACUTE PROMYELOCYTIC LEUKEMIA; STIMULATING FACTOR-RECEPTOR; PRIMARY MYELOID PROGENITORS; TERMINAL BINDING-PROTEIN; FUSION PROTEIN; HISTONE DEACETYLASES; MOLECULAR-CLONING; CO-REPRESSOR; AML1; GENE	The leukemia-associated fusion gene AML1/MDS1/EVI1 (AME) encodes a chimeric transcription factor that results from the (3;21)(q26;q22) translocation. This translocation is observed in patients with therapy-related myelodysplastic syndrome (MDS), with chronic myelogenous leukemia during the blast crisis (CML-BC), and with de novo or therapy-related acute myeloid leukemia (AML). AME is obtained by in-frame fusion of the AML1 and MDS1/EVI1 genes. We have previously shown that AME is a transcriptional repressor that induces leukemia in mice. In order to elucidate the role of AME in leukemic transformation, we investigated the interaction of AME with the transcription co-regulator CtBP1 and with members of the histone deacetylase (HDAC) family. In this report, we show that AME physically interacts in vivo with CtBP1 and HDACI and that these co-repressors require distinct regions of AME for interaction. By using reporter gene assays, we demonstrate that AME represses gene transcription by CtBP1-dependent and CtBP1-independent mechanisms. Finally, we show that the interaction between AME and CtBP1 is biologically important and is necessary for growth upregulation and abnormal differentiation of the murine hematopoietic precursor cell line 32Dc13 and of murine bone marrow progenitors.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Univ Alexandria, Dept Clin Pathol, Fac Med, Alexandria, Egypt	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Egyptian Knowledge Bank (EKB); Alexandria University	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,MC 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu			NCI NIH HHS [CA 67189, CA 72675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072675, R01CA067189, R29CA067189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HAST R, 1989, LEUKEMIA RES, V13, P173, DOI 10.1016/0145-2126(89)90142-2; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Keller SA, 2000, MOL CELL BIOL, V20, P7247, DOI 10.1128/MCB.20.19.7247-7258.2000; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANGENHUIJSEN MMAC, 1984, BRIT J HAEMATOL, V58, P227, DOI 10.1111/j.1365-2141.1984.tb06080.x; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; MIKHAIL FM, 2002, IN PRESS CANC GENET; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; RUBIN CM, 1990, BLOOD, V76, P2594; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zent C, 1996, CURR TOP MICROBIOL, V211, P243; Zent C., 1997, Leukemia (Basingstoke), V11, P273; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	41	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3232	3240		10.1038/sj.onc.1205436	http://dx.doi.org/10.1038/sj.onc.1205436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082639				2022-12-17	WOS:000175373600015
J	Mercer, K; Chiloeches, A; Huser, M; Kiernan, M; Marais, R; Pritchard, C				Mercer, K; Chiloeches, A; Huser, M; Kiernan, M; Marais, R; Pritchard, C			ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf	ONCOGENE			English	Article						A-Raf; knockout; ERK activation; oncogene transformation	PROTEIN-KINASE; B-RAF; EXPRESSION; PROTOONCOGENES; STIMULATE; LETHALITY; MICE	Previous studies have indicated an important role for the Raf family of protein kinases in controlling cellular responses to extracellular stimuli and activated oncogenes, through their ability to activate the MEK/ERKs. To investigate the specific role of A-Raf in this process we generated A-Raf deficient mouse embryonic fibroblasts (MEFs) and embryonic stem (ES) cells by gene targeting and characterized their ability to undergo proliferation, differentiation, apoptosis, ERK activation, and transformation by oncogenic Ras and Src. The A-Raf deficient cells are not disrupted for any of these processes, despite the fact that this protein is normally expressed at high levels in both cell types. This implies either that A-Raf plays no role in MEK/ERK activation, that its function is fully compensated by other Raf proteins or MEK kinases or that its role in MEK/ERK activation is highly tissue-specific. Interestingly, B-Raf and Raf-1 activity towards MEK as measured by the immunoprecipitation kinase cascade assay are both significantly increased in the A-Raf deficient MEFs.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Inst Canc Res, London SW3 6JB, England; Univ Plymouth, Dept Biol Sci, Plymouth PL4 8AA, Devon, England	University of Leicester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Plymouth	Pritchard, C (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk	Chiloeches, Antonio/Z-5993-2019; Dorner, Martin/C-5703-2013	Marais, Richard/0000-0001-7484-4183; Pritchard, Catrin/0000-0003-1859-4487; Antonio, Chiloeches Galvez/0000-0001-7162-330X; Dorner, Martin/0000-0002-8176-797X				BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Luckett JCA, 2000, CELL GROWTH DIFFER, V11, P163; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SLADEK TL, 1992, ONCOGENE, V7, P1305; STORM SM, 1990, ONCOGENE, V5, P345; Treinies I, 1999, MOL CELL BIOL, V19, P321; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000	23	52	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					347	355		10.1038/sj.onc.1205101	http://dx.doi.org/10.1038/sj.onc.1205101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821947				2022-12-17	WOS:000173311200003
J	Saintigny, Y; Lopez, BS				Saintigny, Y; Lopez, BS			Homologous recombination induced by replication inhibition, is stimulated by expression of mutant p53	ONCOGENE			English	Article						homologous recombination; replication inhibition; p53; RAD51	HUMAN RAD51 PROTEIN; CELL-CYCLE CHECKPOINT; G1 CHECKPOINT; BREAK REPAIR; MICE; DISSOCIATION; CHROMOSOMES; MECHANISMS; DEFICIENT; SEQUENCES	Cell cycle control, faithful DNA replication, repair and recombination are associated in a network of pathways controlling genome maintenance. In mammalian cells, inhibition of replication produces DNA breaks and induces RAD51-dependent recombination, in a late step. Here we examine whether the status of p53 affects this process in mouse L-cells containing a recombination substrate. We show that expression of the mutant (His175)p53 strongly stimulates recombination induced by aphidicolin, in a late step (kinetically related to the RAD51 step). Mutant p53 stimulates recombination induced by the replication elongation inhibitors (aphidicolin, hydroxyurea and Ara-C) but is without effect on recombination induced by the initiation inhibitors (mimosine and ciclopirox olamine). We compared the impact of several p53 mutations showing different effects on the G1 checkpoint and on recombination. We show that the mutant 1,273 p53 protein, which does not alter the G1 checkpoint, strongly stimulates recombination induced by elongation inhibitors. These results show that p53 can act on recombination induced by replication arrest independently of its role in the G1 checkpoint. An action of p53 via the RAD51 pathway is discussed.	CEA, UMR217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, UMR217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562				Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hyrien O, 2000, BIOCHIMIE, V82, P5, DOI 10.1016/S0300-9084(00)00344-8; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; ONNO M, 1992, ONCOGENE, V7, P2519; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Rothstein R, 2000, GENE DEV, V14, P1; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142	33	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					488	492		10.1038/sj.onc.1205040	http://dx.doi.org/10.1038/sj.onc.1205040			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821962	Green Published			2022-12-17	WOS:000173311200018
J	Radetzki, S; Kohne, CH; von Haefen, C; Gillissen, B; Strum, I; Dorken, B; Daniel, PT				Radetzki, S; Kohne, CH; von Haefen, C; Gillissen, B; Strum, I; Dorken, B; Daniel, PT			The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines	ONCOGENE			English	Article						Bak; Nbk; Bik; apoptosis; drug resistance; breast cancer	IN-VIVO; GENE BAX; DNA FRAGMENTATION; COLORECTAL-CANCER; PROTEIN FAMILY; OVARIAN-CANCER; TUMOR-GROWTH; CYTOCHROME-C; DEATH; EXPRESSION	We previously demonstrated that the forced expression of pro-caspase-3 can revert acquired chemoresistance in MT1-Adr breast cancer cells which show a defective activation of the mitochondrial pathway of apoptosis. We now asked whether the manipulation of mitochondrial apoptosis signaling can revert different types of drug resistance, i.e. the resistance due to impaired mitochondrial activation in the MT1-Adr cells and the resistance in MT3-Adr cells which is caused by increased expression of the Mdr-1/p-glycoprotein ABC transporter. Here we show that Bcl-2 overexpression is the underlying cause for the resistant phenotype in the MT1-Adr cells. Overexpression of the apoptosis-promoting Bax homologue Bak or the BH3 only protein Nbk/Bik reverts, as expected, acquired drug resistance in the MT1-Adr cells as recently demonstrated for pro-caspase-3. Moreover, we show that both apoptosis-promoters, Nbk/Bik and Bak, antagonize acquired chemoresistance for epirubicin-mediated apoptosis in MT3-Adr breast cancer cells. Neither drug uptake nor drug efflux were influenced by Bak or Nbk/Bik. Thus, our data show that manipulation of the downstream apoptosis signaling cascade by Bak and Nbk/Bik can overcome not only drug resistance due to mitochondrial apoptosis deficiency (in the MT1-Adr cells) but also classical, i.e. efflux-mediated, resistance for drug-induced cell death in the MT3-Adr cell line. Nbk/Bik and Bak could therefore be target genes to increase chemosensitivity and overcome different types of drug resistance.	Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Humboldt University of Berlin	Daniel, PT (corresponding author), Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.			Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BARGOU RC, 1995, EUR J IMMUNOL, V25, P770, DOI 10.1002/eji.1830250322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BOSANQUET AG, 2001, IN PRESS LEUKEMIA, V15; BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones NA, 1998, MOL PHARMACOL, V53, P819; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON C, 1995, SCIENCE, V279, P96; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480; Nunez G, 1996, ADV EXP MED BIOL, V406, P75; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Strobel T, 1998, CANCER RES, V58, P4776; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	52	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					227	238		10.1038/sj/onc/1205010	http://dx.doi.org/10.1038/sj/onc/1205010			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803466				2022-12-17	WOS:000173026200007
J	Roussel, MJS; Lanotte, M				Roussel, MJS; Lanotte, M			Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes	ONCOGENE			English	Article						APL; t(15;17) cell lines; mutation; phenotypes	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; 6-<3-ADAMANTYL-4-HYDROXYPHENYL>-2-NAPHTHALENE CARBOXYLIC-ACID; ARSENIC TRIOXIDE AS2O3; RETINOIC ACID; DOWN-REGULATION; IN-VITRO; APOPTOSIS; EXPRESSION; DIFFERENTIATION	Chromosomal translocations, leading to gene rearrangements that generate chimerical proteins, represent one of the initiating events of leukemia. Preleukemia cells eventually develop into overt leukemia by occurrence of secondary genetic alterations (tumor progression). The physiopathology of leukemia has made considerable progress during the last two decades, due to molecular biology investigations on the role played by the altered genes, during neoplasic hemopoiesis. In vitro studies have been facilitated by the establishment of stable leukemia cell lines bearing these gene rearrangements and secondary gene mutations. Investigations on acute promyelocytic leukemia (APL) have benefited from maturation sensitive and resistant cell lines (NB4 and UF-I) derived from APL patient's leukemia cells and bearing the t(15;17). The information concerning the NB4 cell line (responsiveness to retinoid/rexinoid, cAMP, arsenic, mutations causing resistance) is spread in an abundant literature. In this paper, we briefly recapitulate the cellular and molecular features of this cell line and its subclones with the aim of facilitating investigators in their choice of the most appropriate tool for their studies. As redundancy of several names given to NB4 sublines has sometimes created difficulties, we propose a nomenclature for the various NB4 sublines that most investigators certainly would be agreed with.	Hop St Louis, Ctr G Hayem, INSERM U 496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lanotte, M (corresponding author), Hop St Louis, Ctr G Hayem, INSERM U 496, 1 Ave Claude Vellefaux, F-75010 Paris, France.							Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; DERMIME S, 1993, BLOOD, V82, P1573; DERMIME S, 1995, LEUKEMIA LYMPHOMA, V16, P289, DOI 10.3109/10428199509049768; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kizaki M, 1999, INT J MOL MED, V4, P359; LANOTTE M, 1991, BLOOD, V77, P1080; Maksumova L, 2000, LEUKEMIA, V14, P1444, DOI 10.1038/sj.leu.2401856; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Naito K, 2000, LEUKEMIA, V14, P1436, DOI 10.1038/sj.leu.2401851; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Ponzanelli I, 2000, BLOOD, V95, P2672; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106	29	52	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7287	7291		10.1038/sj.onc.1204863	http://dx.doi.org/10.1038/sj.onc.1204863			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704857				2022-12-17	WOS:000171891900017
J	Toomey, NL; Deyev, VV; Wood, C; Boise, LH; Scott, D; Liu, LH; Cabral, L; Podack, ER; Barber, GN; Harrington, WJ				Toomey, NL; Deyev, VV; Wood, C; Boise, LH; Scott, D; Liu, LH; Cabral, L; Podack, ER; Barber, GN; Harrington, WJ			Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphoma	ONCOGENE			English	Article						Human Herpes Virus Type 8; Epstein Barr virus; TRAIL; apoptosis; lymphoma; FADD	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; SIGNALING COMPLEX DISC; EPSTEIN-BARR-VIRUS; LYMPHOPROLIFERATIVE DISORDERS; PROTEIN-KINASE; DEATH; ACTIVATION; THYMIDINE; RECEPTORS	Gammaherpes viruses are often detected in lymphomas arising in immunocompromised patients. We have found that Azidothymidine (AZT) alone induces apoptosis in Epstein Barr Virus (EBV) positive Burkitt's lymphoma (BL) cells but requires interferon alpha (IFN-alpha) to induce apoptosis in Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Lymphomas (PEL). Our analysis of a series of AIDS lymphomas revealed that IFN-alpha selectively induced very high levels of the Death Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas little or no induction was observed in primary EBV+ AIDS lymphomas and ERV-Burkitt's lines. AZT and IFN-alpha mediated apoptosis in PEL was blocked by stable overexpression of dominant negative Fas Associated Death Domain (FADD), decoy receptor 2 (DcR2), soluble TRAIL receptor fusion proteins (DR-4 and DR-5) and thymidine. Trimeric TRAIL (in place of IFN-alpha) similarly synergized with AZT to induce apoptosis in HHV-8 positive PEL cells. This is the first demonstration that IFN-alpha induces functional TRAIL in a malignancy that can be exploited to effect a suicide program. This novel antiviral approach to Primary Effusion lymphomas is targeted and may represent a highly effective and relatively non-toxic therapy.	Univ Miami, Sch Med, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Miami; University of Miami; University of Nebraska System; University of Nebraska Lincoln	Harrington, WJ (corresponding author), Univ Miami, Sch Med, Dept Med, Sylvester Comprehens Canc Ctr, Room 3400 D8-4,1475 NW 12th Ave, Miami, FL 33136 USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815; Wood, Charles/0000-0002-4256-1530	NATIONAL CANCER INSTITUTE [R01CA039201, R29CA077837, R01CA082274, R01CA080228] Funding Source: NIH RePORTER; NCI NIH HHS [CA80228, CA82274, CA77837, CA39201] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Cannon JS, 1999, J VIROL, V73, P4786, DOI 10.1128/JVI.73.6.4786-4793.1999; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DeMario MD, 1998, SEMIN ONCOL, V25, P492; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Findenig G, 1996, ONCOL RES, V8, P189; Gaidano G, 2000, J CLIN VIROL, V16, P215, DOI 10.1016/S1386-6532(99)00082-7; GAIDANO G, 1994, ANN HEMATOL, V69, P281, DOI 10.1007/BF01696556; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Goldsby RE, 1998, J PEDIAT HEMATOL ONC, V20, P282, DOI 10.1097/00043426-199807000-00002; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gustafson EA, 2000, J VIROL, V74, P684, DOI 10.1128/JVI.74.2.684-692.2000; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Knowles DM, 1999, MODERN PATHOL, V12, P200; Lee RK, 1999, CANCER RES, V59, P5514; Levine AM, 2000, SEMIN ONCOL, V27, P442; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mingari MC, 2000, HUM IMMUNOL, V61, P44, DOI 10.1016/S0198-8859(99)00158-5; Mullaney BP, 2000, ARCH PATHOL LAB MED, V124, P824; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Okano M, 2000, AM J MED SCI, V319, P392, DOI 10.1097/00000441-200006000-00009; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Raez L, 1999, AIDS RES HUM RETROV, V15, P713, DOI 10.1089/088922299310809; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Swinnen LJ, 2000, ANN ONCOL, V11, P45, DOI 10.1023/A:1008396821609; Swinnen LJ, 1999, SEMIN ONCOL, V26, P21; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zavaglia C, 2000, J CLIN GASTROENTEROL, V30, P234, DOI 10.1097/00004836-200004000-00006	44	52	53	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7029	7040		10.1038/sj.onc.1204895	http://dx.doi.org/10.1038/sj.onc.1204895			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704827				2022-12-17	WOS:000171739300006
J	Hellborg, F; Qian, W; Mendez-Vidal, C; Asker, C; Kost-Alimova, M; Wilhelm, M; Imreh, S; Wiman, KG				Hellborg, F; Qian, W; Mendez-Vidal, C; Asker, C; Kost-Alimova, M; Wilhelm, M; Imreh, S; Wiman, KG			Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein	ONCOGENE			English	Article						p53; human wig-1; zinc finger; growth suppression	GENOMIC HYBRIDIZATION ANALYSIS; DOUBLE-STRANDED-RNA; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; PROMOTES APOPTOSIS; CANDIDATE MEDIATOR; CANCER; LOCALIZATION; TUMORS	We previously identified a novel p53-induced mouse gene, wig-1, that encodes a 290 amino acid zinc finger protein (Varmeh-Ziaie et al., 1997). Here we have identified and characterized the human homolog of mouse wig-1. The human wig-1 protein is 87% identical to the mouse protein and contains three zinc finger domains and a putative nuclear localization signal. Human wig-1 mRNA and protein is induced following activation of wild type p53 expression in our BL41-ts p53 Burkitt lymphoma cells. Wig-l is also induced in MCF7 cells following treatment with the DNA-damaging agent mitomycin C. Northern blotting detected low levels of wig-1 mRNA in normal human tissues. Fluorescence in situ hybridization mapped wig-1 to human chromosome 3q26.3-27. FLAG-tagged human wig-1 localizes to the nucleus. Ectopic overexpression of human wig-1 inhibits tumor cell growth in a colony formation assay. These results suggest that human wig-1 has a role in the p53-dependent growth regulatory pathway.	Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	Klas.Wiman@mtc.ki.se	IBIS, REPRODUCCION/P-3399-2015; Wiman, Klas/AAB-8399-2021; Méndez-Vidal, Cristina/F-1366-2015	Wiman, Klas/0000-0002-7113-524X; Méndez-Vidal, Cristina/0000-0002-1282-1688; Wilhelm, Margareta/0000-0002-0516-9724				Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; Attardi LD, 2000, GENE DEV, V14, P704; Balsara BR, 1997, CANCER RES, V57, P2116; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chung DC, 1998, CANCER RES, V58, P3706; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; Fedorova L, 1997, EUR J HUM GENET, V5, P110, DOI 10.1159/000484744; Finerty PJ, 1999, BIOCHEMISTRY-US, V38, P4001, DOI 10.1021/bi9825293; Finerty PJ, 1997, J MOL BIOL, V271, P195, DOI 10.1006/jmbi.1997.1177; Forozan F, 2000, CANCER RES, V60, P4519; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; HALDAR S, 1994, CANCER RES, V54, P2095; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kruzelock RP, 1997, CANCER RES, V57, P106; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	38	52	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5466	5474		10.1038/sj.onc.1204722	http://dx.doi.org/10.1038/sj.onc.1204722			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571644				2022-12-17	WOS:000170781100007
J	Ishiguro, H; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y				Ishiguro, H; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y			Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney	ONCOGENE			English	Article						AXIN1; chromosome 3p22; colon cancer; lung cancer	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN MUTATIONS; WNT SIGNALING PATHWAY; NEGATIVE REGULATOR; HEPATOCELLULAR CARCINOMAS; COLORECTAL CARCINOMAS; CYCLIN D1; CANCER; ACTIVATION; APC	Axin, an important regulator of beta -catenin, is frequently mutated in human hepatocellular carcinomas (HCCs), and transduction of the wild-type Axin gene (AXIN1) induces apoptosis in HCC cells as well as in colon cancer cells. To investigate the detailed biological function of Axin, we searched on a cDNA microarray for genes whose expression was altered by transfer of wild-type AXIN1 into colon-cancer cell line LoVo. Among the genes showing altered expression, we focused on one, termed AXUD1 (AXIN1 up-regulated(1)), that revealed enhanced expression in response to exogeneously expressed AXIN1 but not to LacZ, a control gene. The AXUD1 gene consists of five exons and encodes a transcript with an open reading frame of 1767 bp. A 3.2-kb transcript of AXUD1 was expressed in all human tissues examined, most abundantly in lung, placenta, skeletal muscle, pancreas and leukocyte. By radiation-hybrid mapping we assigned its chromosomal location at 3p22, a region where frequent loss of heterozygosity has been reported in lung, renal, prostate, breast and cervical cancers. AXUD1 was frequently down-regulated in lung, kidney, liver and colon cancers compared with their corresponding normal tissues, suggesting that AXUD1 may have a tumor-suppressor function in those organs.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	University of Tokyo; RIKEN; Nagoya City University	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014; Tanaka, Toshihiro/J-9310-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Tanaka, Toshihiro/0000-0001-6201-9784				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Fujita M, 2000, CANCER RES, V60, P6683; Fukuchi T, 1998, CANCER RES, V58, P3526; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ishiguro H, 2000, JPN J CANCER RES, V91, P597, DOI 10.1111/j.1349-7006.2000.tb00987.x; Iwao K, 1998, CANCER RES, V58, P1021; Kawasoe T, 2000, CANCER RES, V60, P3354; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miano JM, 1997, GENE, V197, P215, DOI 10.1016/S0378-1119(97)00265-5; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura Y, 1997, NAT MED, V3, P499, DOI 10.1038/nm0597-499; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ono K, 2000, CANCER RES, V60, P5007; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Voeller HJ, 1998, CANCER RES, V58, P2520; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yokota J, 1989, Princess Takamatsu Symp, V20, P43; Zurawel RH, 1998, CANCER RES, V58, P896	35	52	57	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5062	5066		10.1038/sj.onc.1204603	http://dx.doi.org/10.1038/sj.onc.1204603			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526492				2022-12-17	WOS:000170439800017
J	Kozaki, K; Koshikawa, K; Tatematsu, Y; Miyaishi, O; Saito, H; Hida, T; Osada, H; Takahashi, T				Kozaki, K; Koshikawa, K; Tatematsu, Y; Miyaishi, O; Saito, H; Hida, T; Osada, H; Takahashi, T			Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis	ONCOGENE			English	Article						human lung cancer; metastasis; invasion; expression profiling; inflammation	EXPRESSION; ADENOCARCINOMAS; CHEMOKINES	This study established and characterized low-metastatic revertant and parental clones of a highly metastatic human lung cancer cell line, NCI-H460-LNM35 (hereafter referred to as LNM35), Expression-profiling analysis revealed that up-regulation of various proinflammatory cytokines and angiogenic chemotactic chemokines was present in LNM35, Further, while COX-2 itself is known to be inducible in inflammation, COX-2 expression levels correlated well with the capabilities of these clones for not only in vitro motility and invasion but also in vivo metastasis, and COX-2 inhibitors were shown for the first time to reduce lung cancer metastasis in vivo. These findings suggest that lung cancer cells may mimic inflammatory cells in the process of metastasis.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Internal Med, Nagoya, Aichi 4648681, Japan; Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan	Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014; Kozaki, Ken-ichi/M-6281-2014	Takahashi, Takashi/0000-0003-0615-7001; Kozaki, Ken-ichi/0000-0003-3286-819X				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BANI MR, 1991, JNCI-J NATL CANCER I, V83, P119, DOI 10.1093/jnci/83.2.119; GAZDAR A F, 1990, Current Opinion in Oncology, V2, P321; Hida T, 1998, CANCER RES, V58, P3761; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Kozaki K, 2000, CANCER RES, V60, P2535; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Wikenheiser KA, 1997, AM J RESP CELL MOL, V16, P713, DOI 10.1165/ajrcmb.16.6.9191473	20	52	60	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4228	4234		10.1038/sj.onc.1204561	http://dx.doi.org/10.1038/sj.onc.1204561			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464289				2022-12-17	WOS:000169857200013
J	Ishii, T; Kwon, H; Hiscott, J; Mosialos, G; Koromilas, AE				Ishii, T; Kwon, H; Hiscott, J; Mosialos, G; Koromilas, AE			Activation of the I kappa B alpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR	ONCOGENE			English	Article						cytokines; double-stranded RNA; protein phosphorylation; NF-kappa B; DNA-binding; transcription	EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; TUMOR-SUPPRESSOR P53; RIBOSOMAL S6 KINASE; MALIGNANT TRANSFORMATION; VIRAL-INFECTION; HA-RAS; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; APOPTOSIS	The interferon (IFN)-inducible double stranded (ds) RNA-activated protein kinase PKR plays an important role in protein synthesis by modulating the phosphorylation of the alpha -subunit of eukaryotic initiation fact 2 (eIF-2 alpha), In addition to translational control, PKR has been implicated in several signaling pathways leading to gene transcription. For example, PKR induces I kappaB alpha kinase (IKK) activity and I kappaB alpha phosphorylation leading to the induction of NF-kappaB-mediated gene transcription. Recent findings suggested that NF-kappaB activation by PKR does not require the catalytic activity of the kinase, Here, we provide novel evidence that induction of IKK and NF-kappaB activities proceeds independently of the dsRNA-binding properties of PKR and also verify the kinase-free role of PKR in this process. We also show that the effects of PKR mutants on IKK and NF-kappaB activation are independent of cell transformation but are dependent on the amount of the mutant PKR proteins expressed in cells. These data strongly support an indirect role of PKR in I kappaB alpha phosphorylation by modulating IKK activity through pathways that do not utilize the enzymatic and dsRNA-binding properties of PKR.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Fleming Biores Ctr, Athens, Greece	McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.				NATIONAL CANCER INSTITUTE [R29CA071705] Funding Source: NIH RePORTER; NCI NIH HHS [CA71705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLEMENS JM, 1977, J INTERFER CYTO RES, V17, P503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee R, 1997, VIROLOGY, V234, P277, DOI 10.1006/viro.1997.8642; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Nagai K, 1997, J VIROL, V71, P1718, DOI 10.1128/JVI.71.2.1718-1725.1997; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; WONG AHT, 2001, IN PRESS J BIOL CHEM; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	62	52	54	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1900	1912		10.1038/sj.onc.1204267	http://dx.doi.org/10.1038/sj.onc.1204267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313938				2022-12-17	WOS:000167908400011
J	Taneja, N; Tjalkens, R; Philbert, MA; Rehemtulla, A				Taneja, N; Tjalkens, R; Philbert, MA; Rehemtulla, A			Irradiation of mitochondria initiates apoptosis in a cell free system	ONCOGENE			English	Article						ionizing radiation; apoptosis; caspase; mitochondria; cytochrome c; Bcl-X-L	RADIATION-INDUCED APOPTOSIS; NF-KAPPA-B; IONIZING-RADIATION; CHEMOTHERAPEUTIC DRUGS; ACTIVATION; APAF-1; GENE; CRMA; FAS; PERMEABILITY	The ability to modulate the sensitivity of mammalian cells to ionizing radiation (IR) (e.g. using chemotherapeutics) is dependent on our understanding of the primary target and biochemical pathway that leads to IR-induced apoptosis. We demonstrate using a cell free assay that irradiation of mitochondria is a primary event that initiates IR-induced apoptosis. IR results in loss of mitochondrial membrane potential, opening of the permeability transition pore (PTP) and the release of cytochrome c (cyto c). Apaf-1 and ATP were required to initiate apoptosis upon release of cyto c from mitochondria, The importance of mitochondrial events in the initiation of IR-induced apoptosis was also supported by the observation that inhibition of caspase-9 by the overexpression of dominant negative mutants resulted in the inhibition of IR-induced apoptosis. In contrast, inhibition of caspase-8 had only a minor impact on IR-induced apoptosis, Over-expression of Bcl-X-L inhibited the initiation of IR-induced apoptosis due to its ability to prevent the loss of mitochondrial membrane potential, PTP opening and cytochrome c release, In a cell free assay for apoptosis, mitochondria as web as cytosol derived from Bcl-X-L over-expressing cells were less efficient at supporting apoptosis in response to IR suggesting multiple roles for Bcl-X-L in the regulation of apoptosis.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Toxicol Program, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rehemtulla, A (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA078041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R55ES008846, R01ES008846] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78041] Funding Source: Medline; NIEHS NIH HHS [ES 08846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Booker JK, 1998, J IMMUNOL, V161, P4536; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kataoka T, 1998, J IMMUNOL, V161, P3936; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Perkins CL, 2000, CANCER RES, V60, P1645; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rehemtulla Alnawaz, 1999, Neoplasia (New York), V1, P63, DOI 10.1038/sj.neo.7900013; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	40	52	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					167	177		10.1038/sj.onc.1204054	http://dx.doi.org/10.1038/sj.onc.1204054			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313941				2022-12-17	WOS:000166410900004
J	de Toledo, SM; Azzam, EI; Dahlberg, WK; Gooding, TB; Little, JB				de Toledo, SM; Azzam, EI; Dahlberg, WK; Gooding, TB; Little, JB			ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation	ONCOGENE			English	Article						MDM2; ATM; p53; ionizing radiation; UV	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; GENOTOXIC STRESS; MDM-2 ONCOGENE; UV IRRADIATION; IN-VIVO; PROTEIN; FIBROBLASTS; DEGRADATION	To further understand the mechanism(s) by which DNA damage activates p53, we analysed the expression levels of p53 and HDM2 (the human homolog of murine MDM2) in various human diploid fibroblast and tumor cell strains during the period that precedes activation of known downstream effecters of p53, In X-irradiated human cells, HDM2 protein was rapidly phosphorylated in serine/threonine residues in a p53, p14(ARF) and p73-independent manner. In p53 wild-type cells, HDM2 phosphorylation precedes a detectable increase in the levels of p53 and is not observed in ataxia telangiectasia (AT) fibroblasts, The transfection of AT cells with a vector expressing ATM restored the ability to rapidly phosphorylate HDM2 following X-irradiation, confirming a role for ATM in its phosphorylation, We also show that ATM complexes with HDM2, The DNA lesions signaling the early rapid phosphorylation of HDM2 are a result of X-ray and not UV-type damage. The ATM-promoted early covalent modification of HDM2 in X-irradiated human cells may provide a mechanism to activate p53.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Radiobiol Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Little, JB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Radiobiol Lab, Boston, MA 02115 USA.				NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DETOLEDO SM, 1995, INT J RADIAT BIOL, V67, P135, DOI 10.1080/09553009514550171; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KUBUTTAT MHG, 1997, NATURE, V387, P299; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Landers JE, 1997, CANCER RES, V57, P3562; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	49	52	52	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6185	6193		10.1038/sj.onc.1204020	http://dx.doi.org/10.1038/sj.onc.1204020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175332				2022-12-17	WOS:000166210500001
J	Xiao, GT; Sun, SC				Xiao, GT; Sun, SC			Activation of IKK alpha and IKK beta through their fusion with HTLV-I Tax protein	ONCOGENE			English	Article						I kappa B kinase; HTLV-I Tax; NF-kappa B; T-cell activation	NF-KAPPA-B; T-CELL LEUKEMIA; TRANSFORMING PROTEIN; KINASE COMPLEX; VIRUS TYPE-1; GAMMA; IDENTIFICATION; COMPONENT; REPEAT; MEKK1	Human T-cell leukemia virus type I (HTLV-I) Tax protein persistently stimulates the activity of I kappaB kinase (IKK), resulting in constitutive activation of the transcription factor NF-kappaB. Tax activation of IKK requires physical interaction of this viral protein with the IKK regulatory subunit, IKK gamma. The Tax/IKK gamma interaction allows Tax to engage the IKK catalytic subunits, IKK alpha and IKK beta, although it remains unclear whether this linker function of IKK gamma is sufficient for supporting the Tax-specific IKK activation. To address this question, we have examined the sequences of IKK gamma required for modulating the Tax/IKK signaling. We demonstrate that when fused to Tax, a small N-terminal fragment of IKK gamma, containing its minimal IKK alpha/beta -binding domain, is sufficient for bringing Tax to and activating the IKK catalytic subunits, Disruption of the IKK alpha/beta -binding activity of this domain abolishes its function in modulating the Tax/IKK signaling. We further demonstrate that direct fusion of Tax to IKK alpha and IKK beta leads to activation of these kinases. These findings suggest that the IKK gamma -directed Tax/TKK association serves as a molecular trigger for IKK activation.	Penn State Univ, Dept Microbiol & Immunol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Dept Microbiol & Immunol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [2R01 CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; XIAO G, 2000, IN PRESS J BIOL CHEM; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	30	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5198	5203		10.1038/sj.onc.1203894	http://dx.doi.org/10.1038/sj.onc.1203894			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064457				2022-12-17	WOS:000090124100009
J	Wijnhoven, SWP; Kool, HJM; Mullenders, LHF; van Zeeland, AA; Friedberg, EC; van der Horst, GTJ; van Steeg, H; Vrieling, H				Wijnhoven, SWP; Kool, HJM; Mullenders, LHF; van Zeeland, AA; Friedberg, EC; van der Horst, GTJ; van Steeg, H; Vrieling, H			Age-dependent spontaneous mutagenesis in Xpc mice defective in nucleotide excision repair	ONCOGENE			English	Article						nucleotide excision repair; Hprt; mutation; cancer; transgenic mice	DNA-REPAIR; INCREASED SUSCEPTIBILITY; PYRIMIDINE DIMERS; DHFR GENE; DAMAGE; ACCUMULATION; MUTATIONS; APOPTOSIS; INDUCTION; P53	DNA damages caused by cellular metabolites and environmental agents induce mutations, that may predispose to cancer. Nucleotide excision repair (NER) is a major cellular defence mechanism acting on a variety of DNA lesions. Here, we show that spontaneous mutant frequencies at the Hplt gene increased 30-fold in T-lymphocytes of 1 year old Xpc(-/-) mice, possessing only functional transcription-coupled repair (TCR), Hprt mutant frequencies in Xpa(-/-) and Csb(-/-) mice that both have a defect in this NER subpathway, remained low during ageing. In contrast to current models, the elevated mutation rate in Xpc(-/-) mice does not lead to an increased tumour incidence or premature ageing.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, MGC, NL-2333 AL Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Interuniv Inst Radiopathol & Radiat Protect, JA Cohen Inst, Leiden, Netherlands; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA; Natl Inst Publ Hlth & Environm, RIVM, Hlth Effects Res Lab, Dept Carcinogenesis Mutagenesis & Genet, NL-3720 BA Bilthoven, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Netherlands National Institute for Public Health & the Environment	Vrieling, H (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, MGC, POB 9503, NL-2300 RA Leiden, Netherlands.		van der Horst, Gijsbertus TJ/E-3661-2015; Vrieling, Harry/ABC-8068-2020	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Vrieling, Harry/0000-0002-3034-2664				Ananthaswamy HN, 1999, ONCOGENE, V18, P7395, DOI 10.1038/sj.onc.1203147; BERG RJW, 2000, IN PRESS CANC RES; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Cheo DL, 2000, CANCER RES, V60, P1580; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; de Vries A, 1997, CARCINOGENESIS, V18, P2327, DOI 10.1093/carcin/18.12.2327; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P99, DOI 10.1016/S0921-8777(99)00068-3; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KURAOKA I, 2000, IN PRESS P NATL ACAD; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Ljungman M, 1996, ONCOGENE, V13, P823; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Odagiri Y, 1998, NAT GENET, V19, P116, DOI 10.1038/468; Reis AM, 2000, CANCER RES, V60, P1571; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TATES AD, 1994, MUTAT RES-FUND MOL M, V309, P299, DOI 10.1016/0027-5107(94)90106-6; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANOOSTEN M, 2000, IN PRESS P NATL ACAD; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; WIJNHOVEN SWP, 2000, IN PRESS CANC RES; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	28	52	53	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5034	5037		10.1038/sj.onc.1203844	http://dx.doi.org/10.1038/sj.onc.1203844			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042691				2022-12-17	WOS:000089834300011
J	Wu, HY; Lan, ZD; Li, WQ; Wu, SC; Weinstein, J; Sakamoto, KM; Dai, W				Wu, HY; Lan, ZD; Li, WQ; Wu, SC; Weinstein, J; Sakamoto, KM; Dai, W			p55CDC/hCDC20 is associated with BUBR1 and may be a downstream target of the spindle checkpoint kinase	ONCOGENE			English	Article						spindle checkpoint; cell cycle; protein kinase; mitosis	CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; KINETOCHORE LOCALIZATION; PROTEIN-KINASE; BUDDING YEAST; CELLS; P55CDC; MITOSIS; CDC20; GENE; MAD2	Eukaryotic cells have evolved a mechanism that delays the progression of mitosis until condensed chromosomes are properly positioned on the mitotic spindle. We have been studying genes that regulated the spindle checkpoint in human cells. Enforced expression of human BUBR1, but not a BUBR1 mutant allele, enhances accumulation of mitotic cells. Yeast two-hybrid system and GST-pull-down analyses show that p55CDC/hCdc20, a protein known to link spindle checkpoint components such as MAD2 to anaphase promoting complex (APC), interacts with BUBR1, In addition, p55CDC is capable of pulling down BUBR1 in sf-9 cells infected with both p55CDC and His6-BUBR1 recombinant baculoviruses but not in the cells infected with p55CDC baculoviruses or with the baculoviral vector alone. Moreover, immunoprecipitation followed by Western blot analyses confirmed that native p55CDC is associated with BUBR1 in HeLa cells. Spindle checkpoint activation by nocodazole treatment enhances the association between p55CDC and His6-BUBR1, In nocodazole-arrested mitotic cells, both CDC16 and hyperphosphorylated CDC27, two APC components, preferentially associate with His6-BUBR1 resins, but not the control resins, Furthermore, BUBR1 phosphorylates p55CDC in vitro, and the phosphorylation of p55CDC by BUBR1 appears to be correlated with spindle checkpoint activation. Together, our studies strongly suggest that BUBR1 may target APC via p55CDC.	Amer Hlth Fdn, Valhalla, NY 10595 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat & Pathol, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90024 USA; Univ Cincinnati, Div Hematol Oncol, Cincinnati, OH USA	American Health Foundation; Amgen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Cincinnati	Dai, W (corresponding author), Amer Hlth Fdn, 1 Dana Rd, Valhalla, NY 10595 USA.			Sakamoto, Kathleen/0000-0003-0494-8838	NCI NIH HHS [CA74299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R13CA074299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bin OY, 1998, CELL GROWTH DIFFER, V9, P877; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Donadelli R, 1998, BIOCHEM BIOPH RES CO, V246, P881, DOI 10.1006/bbrc.1998.8713; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kao CT, 1996, ONCOGENE, V13, P1221; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350	25	52	52	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4557	4562		10.1038/sj.onc.1203803	http://dx.doi.org/10.1038/sj.onc.1203803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030144				2022-12-17	WOS:000089438200001
J	Berns, K; Hijmans, EM; Koh, E; Daley, GQ; Bernards, R				Berns, K; Hijmans, EM; Koh, E; Daley, GQ; Bernards, R			A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts	ONCOGENE			English	Article						c-myc; cell proliferation; cell cycle	CELL-CYCLE PROGRESSION; E CDK2 KINASE; ACTIVATES TRANSCRIPTION; RESPONSIVE GENES; IN-VIVO; S-PHASE; TRANSFORMATION; EXPRESSION; INHIBITION; PROTEINS	The c-myc gene is frequently over-expressed in human cancers and is involved in regulation of proliferation, differentiation and apoptosis, c-Myc is a transcription factor that acts primarily by regulating the expression of other genes. However, it has been very difficult to identify bona fide c-Myc target genes that explain its diverse biological activities. The recent generation of c-myc deficient Rat1A fibroblasts with a profound and stable growth defect provides a new system to search for genes that can substitute for c-myc in proliferation. In this study, we hale attempted to identify genes that rescue the slow growth phenotype of c-myc null cells through introduction of a series of potent cell cycle regulatory genes and several retroviral cDNA expression libraries. None of the candidate genes tested, including SV40 T-antigen and adenovirus E1A, caused reversal of the c-myc null growth defect. Furthermore, extensive screens with high-complexity retroviral cDNA libraries from three different tissue sources revealed that only c-myc and N-myc rescued the c-myc null slow-growth phenotype. Our data support the notion that there are no functional equivalents of the myc family of protooncogenes and also suggest that there are no c-Myc-activated gents that alone can substitute for c-Myc in control of cell proliferation.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423	NATIONAL CANCER INSTITUTE [R29CA076418] Funding Source: NIH RePORTER; NCI NIH HHS [CA76418-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	36	52	53	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3330	3334		10.1038/sj.onc.1203639	http://dx.doi.org/10.1038/sj.onc.1203639			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918589	Green Published			2022-12-17	WOS:000088019300011
J	Lindenboim, L; Yuan, JY; Stein, R				Lindenboim, L; Yuan, JY; Stein, R			Bcl-x(S) and Bax induce different apoptotic pathways in PC12 cells	ONCOGENE			English	Article						bcl-x(S); bax; bcl-2; Bcl-x(L); apoptosis; caspases; NGF	NERVE GROWTH-FACTOR; BCL-X-L; SYMPATHETIC NEURONS; PHOSPHATIDYLINOSITOL 3-KINASE; INDEPENDENT MECHANISMS; PROTEIN-KINASE; DEATH AGONIST; BH3 DOMAIN; FAMILY; INHIBITION	Apoptosis is regulated by the action of the Bcl-2 family of proteins, which includes anti- and pro-apoptotic members such as Bcl-x(S) and Bax. These proteins may differ from each other in structure, mechanism of action and interactions with anti-apoptotic signaling. The mechanism whereby Bax induces cell death has been studied in some cellular systems, but the mechanism of Bcl-x(S)-induced apoptosis is largely unknown. In this study we investigated and compared the apoptotic effects of Bcl-x(S) and Bax in the pheochromocytoma cell line, PC12 (a useful model system for studying neuronal apoptosis), and the extent to which they are protected by the survival factor, nerve growth factor (NGF), PC12 cells express endogenous Bcl-x(S), Bax and Bcl-x(L) proteins. Subcellular fractionation revealed that Bax is presented mainly in the cytosolic and the heavy membrane fractions, Bcl-x(S) is present only in the cytosol, and the anti-apoptotic protein Bcl-x(L) is located mainly in the heavy membrane fraction. In contrast to the cytosolic localization of endogenous Bcl-x(S), the exogenously overexpressed Bcl-x(S) is localized to the mitochondria, Overexpression of Bcl-x(S) or Bax induces cell death in the transfected cells. The cell death induced by overexpression of Bcl-x(S) was inhibited by coexpression of Bcl-x(S) with Bcl-2 or Bcl-x(L), or by treatment with the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoro-methylketone (Z-VAD-FMK) or with NGF. The Bcl-2 mutants Delta C22, which lacks the transmembrane domain, and G145A (mI-3) were able to inhibit the death-inducing effect of Bcl-x(S). These results therefore suggest that the apoptotic pathway induced by overexpression of Bcl-x(S) in PC12 cells can be controlled by Bcl-2 and Bcl-x(L), is mediated by caspases, and can be inhibited by the NGF signaling pathway. The Bax-induced cell death was inhibited by co-expression of Bax with Bcl-2 or Bcl-x(L), but was not inhibited by Z-VAD-FMK, NGF, or the Bcl-2 mI-3 or Delta C22 mutants. These results therefore suggest that Bax induces a caspase-independent cell death pathway which is blocked by Bcl-2 but not by the NGF signaling pathway. They further suggest that Bcl-x(S) and Bax induce different cell death pathways in PC12 cells.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Tel Aviv University; Harvard University; Harvard Medical School	Stein, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; Dole MG, 1996, CANCER RES, V56, P5734; Ealovega MW, 1996, CANCER RES, V56, P1965; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrell MJ, 1996, CLIN J PAIN, V12, P6, DOI 10.1097/00002508-199603000-00003; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Igase M, 1999, CLIN SCI, V96, P605, DOI 10.1042/CS19980279; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LINDENBOIM L, 1995, J NEUROCHEM, V64, P1054; Maroto R, 1997, J NEUROCHEM, V69, P514; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Martinou I, 1998, NEUROREPORT, V9, P15, DOI 10.1097/00001756-199801050-00004; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Middleton G, 1996, DEVELOPMENT, V122, P695; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orth R, 1997, J BIOL CHEM, V272, P8841; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spear N, 1997, J NEUROCHEM, V69, P53; StClair EG, 1997, J BIOL CHEM, V272, P29347; Stefanis L, 1998, J NEUROSCI, V18, P9204; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	68	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1783	1793		10.1038/sj.onc.1203495	http://dx.doi.org/10.1038/sj.onc.1203495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777212				2022-12-17	WOS:000086292500006
J	Yin, ZN; Spitz, MR; Babaian, RJ; Strom, SS; Troncoso, P; Kagan, J				Yin, ZN; Spitz, MR; Babaian, RJ; Strom, SS; Troncoso, P; Kagan, J			Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3	ONCOGENE			English	Article						chromosome 13; prostate cancer; loss of heterozygosity; tumor suppressor gene	ALLELIC LOSS; RETINOBLASTOMA GENE; FREQUENT LOSS; P53 PROTEIN; LOCI; CARCINOMA; HETEROZYGOSITY; DELETION; BRCA2; 13Q	We studied loss of heterozygosity (LOH) on human chromosome 13q in prostate cancer specimens to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the clinicopathological stage of the disease. Overall 13 (21%) of 61 specimens analysed had an allele loss on the long arm of chromosome 13, The most frequent (37%) LOH among the informative cases with allele losses was detected at the D13S284 locus on chromosome 13q14.3. A portion of the DNA segment that spans this locus and is flanked by the microsatellite loci D13S153 and D13S163 was lost in 85% of the specimens with allele losses and was designated as a LOH cluster region (LCR). The LCR spans more than 6 Mbp of DNA, The results suggest that a TSG relevant for the development of prostate cancer is located telomeric to the RE locus. There was a significant correlation (P=0.0024) between chromosome 13q LOH and advanced metastatic disease, suggesting that loss of 13q14.3 region is associated with prostate cancer progression, However, further research must be conducted to establish the identity and function of this putative TSG.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Sect Expt Lab Med, Box 054,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA68758-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, AJCC CANC STAGING MA; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOVA GS, 1993, CANCER RES, V53, P3869; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Brooks JD, 1996, CANCER RES, V56, P3814; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Cairns P, 1997, CANCER RES, V57, P4997; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooney KA, 1996, CANCER RES, V56, P1142; Cunningham JM, 1996, CANCER RES, V56, P4475; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LATIL A, 1995, B CANCER, V82, P589; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu Y, 1997, ONCOGENE, V15, P2463, DOI 10.1038/sj.onc.1201643; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1995, CANCER RES, V55, P5390; MASTERO R, 1996, CANCER RES, V56, P1146; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Mottaz AE, 1997, PROSTATE, V31, P209; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; PEI L, 1995, CANCER RES, V55, P1613; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Salem CE, 1997, J UROLOGY, V158, P510, DOI 10.1016/S0022-5347(01)64520-8; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Sigurdsson S, 1997, J MOL MED-JMM, V75, P758, DOI 10.1007/s001090050162; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Suzuki H, 1998, CANCER RES, V58, P204; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1997, CANCER RES, V57, P5221; TRAPMAN J, 1994, CANCER RES, V54, P6061; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; VISAKORPI T, 1995, CANCER RES, V55, P342; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weinstein IB, 1996, J CELL BIOCHEM, P23; YOO GH, 1994, CANCER RES, V54, P4603; ZAR JH, 1991, BIOSTATISTICAL ANAL; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	49	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7576	7583		10.1038/sj.onc.1203203	http://dx.doi.org/10.1038/sj.onc.1203203			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602517				2022-12-17	WOS:000084119600019
J	Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Shioya, H; Utsugisawa, Y; Shi, Y; Weichselbaum, R; Kufe, D				Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Shioya, H; Utsugisawa, Y; Shi, Y; Weichselbaum, R; Kufe, D			Function for p300 and not CBP in the apoptotic response to DNA damage	ONCOGENE			English	Article						ionizing radiation; apoptosis; p53 tumor suppressor	ABL TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; IONIZING-RADIATION; C-ABL; GROWTH ARREST; P53; BINDING; TRANSCRIPTION; EXPRESSION	The cellular response to ionizing radiation (IR) includes the induction of apoptosis, The p300/CBP proteins possess histone acetyltransferase activity and function as transcriptional coactivators of p53. We have prepared cells deficient in p300 or CBP to define the roles of these proteins in the cellular response to DNA damage, The present results demonstrate that p300, but not CBP, contributes to IR sensitivity of cells. The results also demonstrate that IR-induced apoptosis is impaired in the p300-, but not CBP-, deficient cells. These findings indicate that p300 functions in the apoptotic response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021		NCI NIH HHS [CA55241] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	31	52	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5714	5717		10.1038/sj.onc.1202930	http://dx.doi.org/10.1038/sj.onc.1202930			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523850				2022-12-17	WOS:000083016500012
J	Knudsen, KE; Weber, E; Arden, KC; Cavenee, WK; Feramisco, JR; Knudsen, ES				Knudsen, KE; Weber, E; Arden, KC; Cavenee, WK; Feramisco, JR; Knudsen, ES			The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death	ONCOGENE			English	Article						apoptosis; cyclin; phosphorylation; cell death; RB	GROWTH SUPPRESSION; PROTEIN; KINASE; PRB; RB; PHOSPHORYLATION; MUTANTS; BINDING; CANCER; DOMAIN	Studies aimed at examining the precise function(s) of the retinoblastoma tumor suppressor protein, RE, have been hindered by the rapid phosphorylation and inactivation of ectopically expressed RE which occurs in the majority of cell types, Therefore, ectopically expressed RE is a poor inhibitor of cellular proliferation, We have designed constitutively active RE proteins, PSM-RB, that cannot be inactivated by phosphorylation, Using these proteins, we show that unlike wild-type RE, PSM-RB proteins inhibit cell cycle progression in a broad range of tumor cell types. Furthermore, unlike p16(ink4a), PSM-RB is also a potent inhibitor of cell cycle progression in RB-deficient tumor cells. Surprisingly, we identified a tumor cell line that is resistant to the cell cycle inhibitory effects of PSM-RB. This finding challenges the hypothesis that RE must be inactivated in all cells for cell cycle progression to occur. Further characterization of this 'resistant' tumor line revealed that proliferation of these cells is still inhibited by PSM-RB. We show that this is due to PSM-RB-induced cell death. As such, these studies are the first to show that RE inhibits cellular proliferation through at least two distinct mechanisms - inhibition of cell cycle progression and induction of cell death.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.			Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [F32CA082034] Funding Source: NIH RePORTER; NCI NIH HHS [CA82034] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antelman D, 1997, ONCOGENE, V15, P2855, DOI 10.1038/sj.onc.1201465; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Knudsen ES, 1998, CANCER RES, V58, P2042; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	21	52	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5239	5245		10.1038/sj.onc.1202910	http://dx.doi.org/10.1038/sj.onc.1202910			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498874				2022-12-17	WOS:000082555700013
J	Stacey, DW; Hitomi, M; Kanovsky, M; Gan, L; Johnson, EM				Stacey, DW; Hitomi, M; Kanovsky, M; Gan, L; Johnson, EM			Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pura alpha	ONCOGENE			English	Article						Pura; cell cycle; checkpoint; microinjection; time lapse quantitative photometry	SINGLE-STRANDED-DNA; RETINOBLASTOMA GENE-PRODUCT; BINDING-PROTEIN; TRANSCRIPTION FACTOR; STIMULATES TRANSCRIPTION; MOLECULAR-CLONING; CONTROL ELEMENT; SEQUENCE; E2F; ASSOCIATION	Levels of Pur alpha, a protein implicated in control of both DNA replication and gene transcription, fluctuate during the cell cycle, being lowest in early S phase and highest just after mitosis. Here we have employed a new video time-lapse technique enabling us to determine the cell cycle position of each cell in an asynchronous culture at a given time and to ask whether introduction of Pur alpha protein at specific times can affect cell cycle progression. Approximately 80% of all NIH3T3 cells injected with Pur alpha were inhibited from passing through mitosis, Cells injected with Puree during S or G2 phases were efficiently blocked with a 4N (G2 phase) DNA level, as determined by quantitative DNA photometry of individual cells. Of the cells injected with Pur alpha. during G1 phase, 40% experienced a rapid cell death characterized by extreme cellular fragmentation. Of those G1 injected cells which remained viable, approximately equal numbers were arrested with either 2N or 4N DNA levels. Cells arrested by Pur alpha in G2 phase grew to cover a large surface area. These results link fluctuations in Pur alpha levels to aspects of cell cycle control.	Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, Cleveland, OH 44195 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Cleveland Clinic Foundation; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Stacey, DW (corresponding author), Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NCI NIH HHS [CA55219] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NINDS NIH HHS [NS35000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055219, R55CA055219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; Chang CF, 1996, J VIROL, V70, P4150, DOI 10.1128/JVI.70.6.4150-4156.1996; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lezon-Geyda K. A., 1997, FASEB Journal, V11, pA100; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MA ZW, 1995, CYTOGENET CELL GENET, V71, P64, DOI 10.1159/000134065; MAYOL X, 1993, ONCOGENE, V8, P2561; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; PINES J, 1991, COLD SPRING HARB SYM, V56, P449; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; QIN XQ, 1995, MOL CELL BIOL, V15, P742; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	41	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4254	4261		10.1038/sj.onc.1202795	http://dx.doi.org/10.1038/sj.onc.1202795			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435638				2022-12-17	WOS:000081542400009
J	Chariot, A; van Lint, C; Chapelier, M; Gielen, J; Merville, MP; Bours, V				Chariot, A; van Lint, C; Chapelier, M; Gielen, J; Merville, MP; Bours, V			CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein	ONCOGENE			English	Article						homeobox gene; CBP; coactivator; transcription; histone acetylation	RUBINSTEIN-TAYBI SYNDROME; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HOMEOBOX GENES; SYNERGISTIC ACTIVATION; MOLECULAR-CLONING; COACTIVATORS P300; ONCOPROTEIN; EXPRESSION; CBP/P300	Homeodomain-containing proteins are transcription factors regulating the coordinated expression of multiple target genes involved in development, differentiation and cellular transformation. In this study, we demonstrated that HOXB7, one member of this family, behaved as a transactivator in breast cancer cells. Deletion of either the HOXB7 N-terminal domain or the C-terminal acidic tail abolished this transcriptional effect, suggesting a combination of distinct functional transactivating domains. HOXB7 physically interacted both in vitro and in vivo with the coactivator CREB-binding protein (CBP). This interaction led to an enhanced transactivating potential and required the N-terminal of HOXB7 as well as two domains located at the C-terminal part of CBP. Moreover, trichostatin A, a deacetylase inhibitor, strongly enhanced the transcriptional properties of HOXB7. Our data therefore indicate that HOX proteins can directly interact with CBP and that acetylation/deacetylation may regulate their transcriptional properties.	Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium; Free Univ Brussels, Biol Chem Lab, Dept Mol Biol, Brussels, Belgium	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bours, V (corresponding author), Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium.			Chariot, Alain/0000-0002-1691-4347				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Care A, 1996, MOL CELL BIOL, V16, P4842; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chariot A, 1998, J CELL BIOCHEM, V71, P46; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DEGUCHI Y, 1991, BLOOD, V78, P445; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Magli MC, 1998, BIOTHERAPY, V10, P279, DOI 10.1007/BF02678548; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Sanlioglu S, 1998, J NEUROBIOL, V36, P559, DOI 10.1002/(SICI)1097-4695(19980915)36:4<559::AID-NEU9>3.0.CO;2-V; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimamoto T, 1998, INT J HEMATOL, V67, P339; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhang N, 1996, ONCOGENE, V13, P1781; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	56	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4007	4014		10.1038/sj.onc.1202776	http://dx.doi.org/10.1038/sj.onc.1202776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435624	Green Published			2022-12-17	WOS:000081327800011
J	Sunahara, M; Shishikura, T; Takahashi, M; Todo, S; Yamamoto, N; Kimura, H; Kato, S; Ishioka, C; Ikawa, S; Ikawa, Y; Nakagawara, A				Sunahara, M; Shishikura, T; Takahashi, M; Todo, S; Yamamoto, N; Kimura, H; Kato, S; Ishioka, C; Ikawa, S; Ikawa, Y; Nakagawara, A			Mutational analysis of p51A/TAp63 gamma, a p53 homolog, in non-small cell lung cancer and breast cancer	ONCOGENE			English	Article						p51; non-small cell lung cancer; mutation; p53	P73 GENE; CARCINOMA; ADENOCARCINOMA; YEAST	p51, a novel family member of human p53, is a recently identified candidate tumor suppressor gene mapped at chromosome 3q28, Like p53, p51 was found to activate p21(Waf1/Cip1) and to induce apoptosis, Since the DNA loss at 3q is reported in several cancers including non-small cell lung cancer (NSCLC), we screened for mutations in p51A (TAp63 gamma), an isoform of p51 with short C-terminal region, in 80 NSCLCs as well as 85 breast cancers by RT-PCR single strand conformation polymorphism (SSCP) analysis and DNA sequencing. In NSCLCs, p51 was expressed in most tumors at variable levels and we found three missense and one silent mutations: Gln31His (transactivation domain) in two tumors, Ala148Pro (DNA-binding domain) and Leu248Leu (DNA-binding domain). In the tumor with Ala148Pro or the silent mutation, only the mutant gene appeared to be expressed. The modified FASAY method to test the ability of yeast expressing p51A cDNA to grow in medium lacking histidine has revealed that Ala148Pro results in a loss of function, while Gln31His does not, In contrast to NSCLC, no mutation was observed in all 85 breast cancers by the similar method. Our results suggest that, because of infrequent mutation, p51 may not be a Knudson type tumor suppressor in most NSCLCs and breast cancers. Nevertheless, in at least a part of NSCLC, p51 may play a certain role in carcinogenesis in a tissue-specific manner.	Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan; Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Surg 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Chiba Univ, Sch Med, Inst Pulm Canc Res, Dept Surg, Chiba, Japan; Chiba Canc Ctr, Div Thorac Surg, Chuoh Ku, Chiba 2608717, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9800872, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan	Tokyo Medical & Dental University (TMDU); Chiba Cancer Center; Hokkaido University; Chiba University; Chiba Cancer Center; Tohoku University; Tohoku University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan.		Kato, Shunsuke/F-7607-2014; 井川, 俊太郎/L-5911-2015	Ishioka, Chikashi/0000-0002-3023-1227				COLES C, 1992, CANCER RES, V52, P5291; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; ISHIOKA C, 1995, ONCOGENE, V10, P1485; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; IZUO M, 1989, JPN J SURG, V19, P612; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KISHIMOTO Y, 1990, CANCER RES, V52, P4799; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; Nomoto S, 1998, CANCER RES, V58, P1380; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Petersen I, 1997, CANCER RES, V57, P2331; SATO S, 1994, CANCER RES, V54, P5652; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	22	52	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3761	3765		10.1038/sj.onc.1202972	http://dx.doi.org/10.1038/sj.onc.1202972			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391684				2022-12-17	WOS:000081140200010
J	Sachsenmaier, C; Sadowski, HB; Cooper, JA				Sachsenmaier, C; Sadowski, HB; Cooper, JA			STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation	ONCOGENE			English	Article						Src; STAT; PDGF; receptor tyrosine kinase; juxtamembrane	EPIDERMAL GROWTH-FACTOR; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; BETA-RECEPTOR; V-SRC; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INTERFERON-GAMMA; PROTEIN-KINASES; GENE-REGULATION	Activation of the platelet-derived growth factor (PDGF) receptor tyrosine kinase induces tyrosine phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins. Since the PDGF receptor also activates the Src tyrosine kinase, it is possible that Src mediates tyrosine phosphorylation of STATs in PDGF-treated cells. Consistent with a role for Src in STAT activation, we found that a PDGF receptor juxtamembrane tyrosine residue required for Src activation is necessary and sufficient for activation of STATs 1 and 3. To test the Src requirement further, we made other mutations in the PDGF receptor juxtamembrane region that increased or decreased Src binding. In epithelial and fibroblast cells, PDGF activated STAT1, 3 and 6 in the absence of detectable binding and activation of Src. In addition, PDGF induced C-myc RNA expression and DNA synthesis even though Src was not detectably activated. The activation of MAP kinase and the induction of c-fos gene expression both correlated with STAT but not Src activation by the receptor. We conclude that juxtamembrane tyrosine phosphorylation is necessary for both Src tyrosine kinase and STAT activation by the beta PDGF receptor, but that both processes are regulated independently by this region.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Fred Hutchinson Cancer Center; Cold Spring Harbor Laboratory	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A2-025,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [CA54786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELM MH, 1995, SCIENCE, V267, P1347; HERBST R, 1995, ONCOGENE, V10, P369; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Novak U, 1996, ONCOGENE, V13, P2607; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3583	3592		10.1038/sj.onc.1202694	http://dx.doi.org/10.1038/sj.onc.1202694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380880				2022-12-17	WOS:000080891700004
J	Chen, YQ; Hsieh, JT; Yao, FY; Fang, BL; Pong, RC; Cipriano, SC; Krepulat, F				Chen, YQ; Hsieh, JT; Yao, FY; Fang, BL; Pong, RC; Cipriano, SC; Krepulat, F			Induction of apoptosis and G2/M cell cycle arrest by DCC	ONCOGENE			English	Article						DCC; apoptosis; caspase; tumor suppressor gene; cell cycle; Cdk1	POLY(ADP-RIBOSE) POLYMERASE; COLORECTAL-CANCER; GENE; DEATH; IDENTIFICATION; CARCINOMAS; ADENOVIRUS; CLEAVAGE; PROTEASE; HOMOLOG	The Deleted in Colorectal Cancer gene (DCC) encodes a cell surface receptor that belongs to the Ig superfamily, Inactivation of the DCC gene has been implicated in human tumor progression. Howe, er, little is known about the biological function of the DCC protein. In the present study, we demonstrated that expression of DCC activated caspase-3 and programmed cell death, or induced G2/M cell cycle arrest in tumor cells, In some cell lines, apoptosis was evident within 24 h of DCC expression. Timing of the appearance of apoptotic cells coincided with that of the cleavage of poly (ADP-ribose) polymerase, a substrate of caspase-3, Expression of the apoptosis inhibitory gene Bcl-2 was not able to abrogate the DCC-induced apoptosis, In the G2/M cycle arrest cells, cdk1 activity was inhibited. Our results suggest that the DCC protein may transduce signals resulting in activation of caspases ok inhibition of Cdk1, These data provide a possible mechanism by which DCC suppresses tumorigenesis.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75235 USA; MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA	Wayne State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Chen, YQ (corresponding author), Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708	NATIONAL CANCER INSTITUTE [R21CA069845, R01CA073017] Funding Source: NIH RePORTER; NCI NIH HHS [R21CA69845, R01CA73017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHEN YQ, 1995, CANCER RES, V55, P4536; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAO X, 1993, CANCER RES, V53, P2723; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haldar S, 1996, CANCER RES, V56, P1253; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	33	52	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2747	2754		10.1038/sj.onc.1202629	http://dx.doi.org/10.1038/sj.onc.1202629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348349				2022-12-17	WOS:000080124900010
J	Prasad, GL; Masuelli, L; Raj, MHG; Harindranath, N				Prasad, GL; Masuelli, L; Raj, MHG; Harindranath, N			Suppression of src-induced transformed phenotype by expression of tropomyosin-1	ONCOGENE			English	Article						tropomyosin; src; oncogenes; transformation; tumor suppression; cytoskeleton	MAMMARY EPITHELIAL-CELLS; PROTEIN-TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; RAT FIBROBLASTS; C-SRC; CDNA; ACTIN; ORGANIZATION; CYTOSKELETON; ONCOGENE	Suppression of high M-r tropomyosins (TMs) is a common feature of transformed cells. Previous work from this laboratory has demonstrated that the isoform 1 of TM, TM1, acts as an anti-oncogene in ras-transformed murine fibroblasts. In this study, we have investigated whether TM1 is a ras-specific suppressor, or a general suppressor protein of the cellular transformation. V-src transformed fibroblasts, which express decreased TM1, were transduced with a full-length cDNA to overexpress TM1. Both the control and the transduced cells expressed v-src kinase at comparable levels. TM1 expressing (src-T1) cells grew at a lower rate in monolayer, exhibited well spread, flat morphology than the control cells. Enhanced expression of TM1 resulted in improved microfilamental architecture. More significantly, src-T1 cells completely failed to grow under anchorage independent conditions. These data demonstrate that TM1 is as an anti-oncogene of functionally diverse oncogenes, and it is a class II tumor suppressor protein.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA; Univ La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Louisiana State Univ, Med Ctr, Dept Obgyn & Biochem, New Orleans, LA 70112 USA; US FDA, CBER, Div Hematol Prod, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Sapienza University Rome; Louisiana State University System; US Food & Drug Administration (FDA)	Prasad, GL (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.		Masuelli, Laura/AGW-4259-2022	MASUELLI, Laura/0000-0001-8174-8034				BHATTACHARYA B, 1988, ONCOGENE RES, V3, P51; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; JAMMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KELLIE S, 1993, SYM SOC EXP BIOL, V47, P267; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MULLAUER L, 1993, ONCOGENE, V8, P2531; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OKAMURA H, 1994, ONCOGENE, V9, P2293; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; SCHAFER R, 1994, REV PHYSL BIOCH PHAR, V124, P30; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VANDEKERCKHOVE J, 1990, CURR OPIN CELL BIOL, V2, P241; Wang DZM, 1997, CANCER RES, V57, P2478; Wang FL, 1996, CANCER RES, V56, P3634; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113	45	52	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2027	2031		10.1038/sj.onc.1202264	http://dx.doi.org/10.1038/sj.onc.1202264			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208425				2022-12-17	WOS:000079191300013
J	Arriola, EL; Lopez, AR; Chresta, CM				Arriola, EL; Lopez, AR; Chresta, CM			Differential regulation of p21(waf-1/cip-1) and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop	ONCOGENE			English	Article						testicular neoplasms; p53; Mdm2; etoposide; apoptosis	WILD-TYPE P53; CYCLE CHECKPOINT PATHWAY; HUMAN TESTICULAR-TUMORS; GERM-CELL TUMORS; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVITY; ONCOPROTEIN MDM2; UV-RADIATION; DNA-DAMAGE; IN-VIVO	The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response, We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for >3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues, Global transcription is not inhibited: p21(saf-1/cip-1) and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent, When cells are treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated, Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, Manchester M13 9PT, Lancs, England	University of Manchester	Chresta, CM (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, B-38,Stopford Bldg, Manchester M13 9PT, Lancs, England.		Lopez, Andrea/GQQ-3059-2022					BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARBARESCHI M, 1995, UROL RES, V22, P349, DOI 10.1007/BF00296873; BERTRAND R, 1991, CANCER RES, V51, P6280; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chresta CM, 1996, CANCER RES, V56, P1834; CORDONCARDO C, 1994, CANCER RES, V54, P794; De Jong S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P638; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435; Guillou L, 1996, AM J PATHOL, V149, P1221; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; Ljungman M, 1996, ONCOGENE, V13, P823; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; RIOU JF, 1993, FEBS LETT, V334, P369, DOI 10.1016/0014-5793(93)80714-6; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; [No title captured]	56	52	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1081	1091		10.1038/sj.onc.1202391	http://dx.doi.org/10.1038/sj.onc.1202391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023685				2022-12-17	WOS:000078510600026
J	Notterman, D; Young, S; Wainger, B; Levine, AJ				Notterman, D; Young, S; Wainger, B; Levine, AJ			Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity	ONCOGENE			English	Article						p53; p21; G(2)/M; DNA; transactivation; nocodazole	CELL-CYCLE ARREST; WILD-TYPE P53; GROWTH SUPPRESSION; G(1) ARREST; ACTIVATION; APOPTOSIS; LACKING; DOMAIN; P21; IDENTIFICATION	The tumor suppressor p53 has been identified as a component of a mitotic spindle checkpoint. When exposed to a spindle-disrupting drug such as nocodazole, fibroblasts derived from mice having wild-type p53 are blocked with a 4N content of DNA, Conversely, fibroblasts from p53-deficient mice become polyploid, To learn if transcriptional activation of downstream genes by p53 plays a role in this putative checkpoint, three cell lines mere exposed to nocodazole, In one line, p53 protein is not expressed, while the other two cell lines over-express p53, In one of these two lines, the N-terminal transactivation domain is wild-type and in the second, this region contains a mutation that eliminates the ability of the protein to act as a transcription factor. Incubation with nocodazole of cells containing wild-type p53 results in accumulation of both 2N and 4N populations of cells. Under the same conditions, cells containing a transactivation-deficient mutant of p53 accumulate a 4N population of cells, but not a 2N population of cells. Cells entirely deficient in p53 protein become hyperdiploid, and display 8N to 16N DNA content. In all three cell lines, nocodazole elicited an initial increase in mitotic cells, but within 24 h the mitotic index returned to baseline. Expression patterns of cyclins B and D indicated that following entry into mitosis, the cells returned to a G(1) state but with 4N DNA content. Subsequent re-duplication of DNA beyond 4N is prevented in cells containing either wild-type or transcriptionally inactive p53 protein. In cells entirely lacking p53 protein, DNA is re-duplicated (without an intervening mitosis) and the cells become hyperdiploid. These experiments indicate that p53 does not participate in the transient mitotic arrest that follows spindle disruption, but is essential to prevent subsequent reduplication of DNA and the resulting hyperdiploid state. This function is intact in a mutant that is transcriptionally inactive.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Levine, AJ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Wainger, Brian/L-7553-2017					BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARBRE A, 1986, PRACTICAL PROTEIN CH, P227; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Starostik P, 1996, MOL CELL BIOL, V16, P3606; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335	33	52	52	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2743	2751		10.1038/sj.onc.1202210	http://dx.doi.org/10.1038/sj.onc.1202210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840938				2022-12-17	WOS:000077146700007
J	Floettmann, JL; Eliopoulos, AG; Jones, M; Young, LS; Rowe, M				Floettmann, JL; Eliopoulos, AG; Jones, M; Young, LS; Rowe, M			Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions	ONCOGENE			English	Article						Epstein-Barr virus; LMP-1; NF-kappa B; CD54; CD40; TNF-R	NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; TRANSIENT EXPRESSION; EPITHELIAL-CELLS; BINDING-SITES; ACTIVATION; GENE; INDUCTION; TRAF2; MEMBRANE-PROTEIN-1	The Epstein-Barr virus (EBV) encoded Latent Membrane Protein-1 (LMP1) mimics a constitutively active receptor molecule, and has been shown to activate NF-kappa B and the MAPK and JNK pathways, Two regions within the cytosolic domain of LMP1 have been found to effect cell signalling. One of these, the carboxy-terminal activation region-1 (CTAR1), binds members of the TRAF family of proteins, and the other (CTAR2) binds TRADD, suggesting that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor family of receptors, The ability to bind TRAFs, to activate NF-kappa B and the JNK pathway, to upregulate cellular genes such as CD54 (ICAM-1 adhesion molecule), and to affect cell growth and apoptosis has led to the suggestion that LMP1 signalling is similar to, or even identical to CD40, However, we now show that while ligand-induced CD40 signalling is impaired in the Jurkat T cell line, LMP1 was fully functional; therefore demonstrating that LMP1 and CD40 signalling differ, Mutated LMP1 genes, in which one or other of the CTAR1 and CTAR2 domains was non-functional, behaved more like CD40 in being unable to upregulate the CD54 cell surface marker in Jurkat cells, However, the CTAR1 domain of LMP1, which shared a TRAF-binding sequence motif with CD40, differed from CD40 in being unable to activate NF-kappa B in Jurkat, Cotransfection experiments with LMP1 mutants demonstrated that CTAR1 can cooperative with CTAR2 on separate LMP1 molecules, provided that they exist within the same oligomeric complex.	Cardiff Univ, Dept Med, Cardiff CF4 4XX, S Glam, Wales; Univ Birmingham, Sch Med, Inst Canc Studies, Birmingham B15 2TJ, W Midlands, England	Cardiff University; University of Birmingham	Rowe, M (corresponding author), Cardiff Univ, Dept Med, Heath Pk, Cardiff CF4 4XX, S Glam, Wales.		ELIOPOULOS, ARISTIDES/ABI-6632-2020; Rowe, Martin/B-2880-2009; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENRIQUEZ N, 1998, UNPUB; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PENG M, 1992, ONCOGENE, V7, P1775; PILON M, 1991, J IMMUNOL, V146, P1047; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	46	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2383	2392		10.1038/sj.onc.1202144	http://dx.doi.org/10.1038/sj.onc.1202144			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811470				2022-12-17	WOS:000076723300013
J	Iglesias, M; Yen, K; Gaiotti, D; Hildesheim, A; Stoler, MH; Woodworth, CD				Iglesias, M; Yen, K; Gaiotti, D; Hildesheim, A; Stoler, MH; Woodworth, CD			Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1 alpha	ONCOGENE			English	Article						apoptosis; cervical carcinoma; human; papillomavirus; interleukin-1; keratinocyte	EPITHELIAL-CELLS; GENE-EXPRESSION; DIFFERENTIAL REGULATION; GROWTH-FACTOR; DNA; CARCINOMA; RECEPTOR; PROLIFERATION; FIBROBLASTS; INFECTION	Interleukin-1 alpha. (IL-1 alpha) is a multifunctional cytokine that promotes inflammation, tissue remodeling and epithelial hyperplasia, Keratinocytes produce and sequester large amounts of biologically active IL-1 alpha which can be released after injury or infection. We show that high level expression of human papillomavirus (HPV) type 16 E6 and E7 oncoproteins enhanced release of IL-1 alpha from cultures of normal cervical keratinocytes (relative effectiveness E7>E6/E7 much greater than E6> control). The amount of IL-1 alpha. released was directly related to the ability of E7 or E6/E7 to stimulate apoptosis, E7 proteins that bound the retinoblastoma protein (Rb) strongly (HPV-16 and -18) induced more IL-1 alpha release than those that bound poorly (HPV-6 and an HPV-16 E7 24gly mutant). Furthermore, overexpression of the E2F-1 transcription factor, a downstream target of Rb, induced extensive apoptosis and IL-1 alpha release. Apoptosis and IL-1 alpha release in response to growth factor removal occurred in part through a p53-independent pathway as coexpression of E6 and downregulation of p53 did not prevent either response. Immunohistochemical analyses showed that IL-1 alpha. was expressed by keratinocytes in normal cervical epithelia, low and high grade dysplasias, and cervical carcinomas. However, HPV-16 E6/E7 RNA expression and apoptosis increased in parallel in proliferating keratinocytes in severe dysplasias and carcinomas suggesting that IL-1 alpha release is associated with progression to high grade disease. Thus, high level expression of the HPV-16 E7 protein sensitizes keratinocytes to apoptosis which results in release of IL-1 alpha.	NCI, Biol Lab, Bethesda, MD 20892 USA; NCI, Environm Epidemiol Branch, Bethesda, MD 20892 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22901 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia	Woodworth, CD (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bldg 37,Room 3B25, Bethesda, MD 20892 USA.							ANSEL JC, 1988, J IMMUNOL, V140, P2274; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; BRYAN D, 1995, CELL GROWTH DIFFER, V6, P1245; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CORREA P, 1992, CANCER RES, V52, P6735; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FAN TPD, 1993, BRIT J PHARMACOL, V110, P43, DOI 10.1111/j.1476-5381.1993.tb13769.x; Frazer IH, 1996, CURR OPIN IMMUNOL, V8, P484, DOI 10.1016/S0952-7915(96)80035-5; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Isacson C, 1996, CANCER RES, V56, P669; Kim CY, 1997, CANCER RES, V57, P4200; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUPPER TS, 1995, J INVEST DERMATOL, V105, pS62, DOI 10.1111/1523-1747.ep12316087; Li DQ, 1997, J CELL PHYSIOL, V172, P361, DOI 10.1002/(SICI)1097-4652(199709)172:3<361::AID-JCP10>3.0.CO;2-9; Merrick DT, 1996, CELL GROWTH DIFFER, V7, P1661; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montague JW, 1996, EXPERIENTIA, V52, P957, DOI 10.1007/BF01920104; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OBERYSZYN TM, 1993, MOL CARCINOGEN, V7, P238, DOI 10.1002/mc.2940070406; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Riethdorf L, 1996, AM J PATHOL, V149, P1469; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; ROSL F, 1994, J VIROL, V68, P2142; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shoji Y, 1996, J CLIN PATHOL, V49, P134, DOI 10.1136/jcp.49.2.134; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STONE KM, 1995, CLIN INFECT DIS   S1, V20, P591; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1993, AM J PATHOL, V142, P1544; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Woodworth CD, 1996, CELL GROWTH DIFFER, V7, P811; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	52	52	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1195	1205		10.1038/sj.onc.1202054	http://dx.doi.org/10.1038/sj.onc.1202054			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771962				2022-12-17	WOS:000075803300001
J	Brown, LA; Amores, A; Schilling, TF; Jowett, T; Baert, JL; de Launoit, Y; Sharrocks, AD				Brown, LA; Amores, A; Schilling, TF; Jowett, T; Baert, JL; de Launoit, Y; Sharrocks, AD			Molecular characterization of the zebrafish PEA3 ETS-domain transcription factor	ONCOGENE			English	Article						ETS-domain; PEA3; transcription factors; zebrafish	DNA-BINDING SPECIFICITIES; PROTEIN-PROTEIN; ONCOGENE FAMILY; FACTORS ELK-1; FACTOR ER81; MAP KINASE; MEMBER; ERM; CASCADES; DISTINCT	The PEA3 subfamily of ETS-domain proteins play important roles in regulating transcriptional activation and have been implicated in several tumorigenic processes. Here we describe the identification of a further member of this family from zebrafish which most likely represents a homologue of PEA3, A high degree of sequence conservation is observed in the ETS DNA-binding domain and acidic transcriptional activation domain. The DNA binding specificity of zebrafish PEA3 is virtually identical to that exhibited by mammalian family members and is autoregulated by cisacting inhibitory domains. Transcriptional activation by zebrafish PEA3 is potentiated by the ERK MAP kinase and protein kinase A pathways. During embryogenesis, PEA3 is expressed in complex spatial and temporal patterns in both mesodermal somites and ectodermal tissues including the brain, dorsal spinal chord and neural crest. Our characterisation of zebrafish PEA3 furthers our understanding of its molecular function and its expression profile suggests a novel role in cell patterning in the early vertebrate embryo.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Canc Res Fund, London WC2A 3PX, England; Inst Pasteur, Inst Biol, CNRS, UMR 319, F-59021 Lille, France	Newcastle University - UK; Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Sharrocks, AD (corresponding author), Zeneca Pharmaceut, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.			Amores, Angel/0000-0002-9307-3609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAERT JL, 1996, IN PRESS INT J CANC; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BROWN AL, 1997, UNPUB DEV BIOL; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELAUNOIT Y, 1997, IN PRESS BIOCH MOL M; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaya M, 1996, ONCOGENE, V12, P221; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Weinberg ES, 1996, DEVELOPMENT, V122, P271; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	48	52	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					93	104		10.1038/sj.onc.1201911	http://dx.doi.org/10.1038/sj.onc.1201911			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671318				2022-12-17	WOS:000074677800011
J	Johnson, MR; Valentine, C; Basilico, C; Mansukhani, A				Johnson, MR; Valentine, C; Basilico, C; Mansukhani, A			FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells	ONCOGENE			English	Article						fibroblast growth factor; estrogen receptor; MAP kinase; STAT1; MCF-7 growth inhibition; breast cancer	FIBROBLAST GROWTH-FACTOR; HUMAN BREAST-CANCER; RECEPTOR SUPERFAMILY; GENE-EXPRESSION; TRANSGENIC MICE; MAMMARY-GLAND; INDUCTION; PATHWAYS; FAMILY; KINASE	Normal breast tissue as well as most breast tumors are dependent on estrogen for growth, Breast tumors often progress to a hormone-independent state which is associated with poor prognosis, It has been proposed that activation of growth factor signaling pathways in the tumor cells may free them from hormonal control. Certain growth factors can mimic estrogen responses by activating the estrogen receptor via its phosphorylation by mitogen-activated protein (MAP) kinase, In this report, however, we show that fibroblast growth factor (FGF), despite activating MAP kinase, is growth-inhibitory for estrogen-dependent MCF-7 breast cancer cells, MCF-7 cells treated with FGFs exhibit slower growth than controls in both the presence and absence of estrogen, with a concomitant increase in the number of cells in G0/G1, Expression of a constitutively activated FGF receptor in these cells further decreases their growth rate, which is no longer influenced by FGF treatment. Activation of the FGF signaling pathway also reduces the induction of an estrogen-responsive CAT reporter plasmid by estrogen, an effect which appears to be independent of serine 118 in the estrogen receptor, a MAP kinase target site. The inhibitory effects of FGF are probably mediated through the sustained induction of the cyclin kinase inhibitor p21/WAF1/CIP1, which is upregulated at the mRNA and protein level by FGF, FGF treatment also results in the phosphorylation of STAT1, This upregulation of p21 and phosphorylation of STAT1 is not detectable in T47D breast cancer cells upon which FGF has no inhibitory effect.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Basilico, C (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.			Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA42568] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; Altucci L, 1996, ONCOGENE, V12, P2315; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHALBOS D, 1994, SEMIN CANCER BIOL, V5, P361; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fenig E, 1997, CLIN CANCER RES, V3, P135; GOMM JJ, 1991, CANCER RES, V51, P4685; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HORWITZ KB, 1978, CANCER RES, V38, P2434; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; Luqmani YA, 1996, EUR J CANCER, V32A, P518, DOI 10.1016/0959-8049(95)00563-3; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MCLESKEY SW, 1994, CANCER RES, V54, P523; MICHIELI P, 1994, CANCER RES, V54, P3391; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1990, CELL GROWTH DIFFER, V1, P225; ORNITZ DM, 1996, J BIOL CHEM, V271, P1592; Payson RA, 1996, ONCOGENE, V13, P47; PETERS G, 1991, SEMIN VIROL, V2, P319; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang HS, 1997, CANCER RES, V57, P1750; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2647	2656		10.1038/sj.onc.1201789	http://dx.doi.org/10.1038/sj.onc.1201789			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632141				2022-12-17	WOS:000073698200009
J	Sekiguchi, T; Hunter, T				Sekiguchi, T; Hunter, T			Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHKZ1 cells	ONCOGENE			English	Article						cell cycle; PCNA; tetracycline	DEPENDENT-KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; P53-MEDIATED G(1) ARREST; DNA-REPLICATION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; HUMAN FIBROBLASTS; PHASE-TRANSITION; NUCLEAR ANTIGEN; BINDING DOMAINS	p21(cip1/waf1/sdil) is universal cyclin-Cdk kinase inhibitor that has two functional domains; one binds and inhibits cyclin-Cdk activity and the other binds PCNA and thereby inhibits elongation by DNA polymerase. When transiently expressed in hamster BHK21 cells we found that human p21 was able to cause cell cycle arrest in G1 phase; this arrest was counteracted by coexpression of E2F-1 or SV40 large T antigen. To study the effect of p21 overexpression in vivo, BHK21 cell clones inducibly expressing human p21 (Tet-p21) driven by the tetracycline (Tet)-repressible promoter were established. The maximum induced p21 levels in the absence of Tet were estimated to be ten times that of endogenous hamster p21. As p21 levels rose following removal of Tet, p21-associated histone H1 kinase activity was increased and concomitantly cell growth and DNA synthesis were reduced. Tet-p21 BHK21 cells became arrested in G1 phase and lost colony forming ability irreversibly 2-4 days after removal of Tet. The induction of cyclin E- and cyclin A-associated kinase activities was diminished when G0-synchronized Tet-p21 BHK21 cells mere serum stimulated in the absence of Tet. Increased binding of p21 to PCNA and cyclin D1-Cdk4 was detected in induced cells. Overexpression of p21 led to cell death in BHK21 cells at 39.5 degrees C within 4 days.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CRISTOFALO VJ, 1989, EXP GERONTOL, V24, P367, DOI 10.1016/0531-5565(89)90044-2; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kobayashi T, 1995, ONCOGENE, V11, P2311; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tsao YP, 1995, BIOCHEM J, V312, P693, DOI 10.1042/bj3120693; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	71	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					369	380		10.1038/sj.onc.1201539	http://dx.doi.org/10.1038/sj.onc.1201539			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467962				2022-12-17	WOS:000071582100009
J	Scimeca, JC; Servant, MJ; Dyer, JO; Meloche, S				Scimeca, JC; Servant, MJ; Dyer, JO; Meloche, S			Essential role of calcium in the regulation of MAP kinase phosphatase-1 expression	ONCOGENE			English	Article						phosphatase; MAP kinase; gene expression; calcium	ACTIVATED PROTEIN-KINASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE CELLS; TYROSINE-PHOSPHATASE; HEAT-SHOCK; IN-VIVO; MITOGEN; PHOSPHORYLATION; TRANSCRIPTION	Mitogen-activated protein (MAP) kinase phosphatase-l (MKP-1) is a dual-specificity protein phosphatase encoded by an immediate-early gene responsive to growth factors and stress. The MKP-1 protein selectively inactivates MAP kinases in vitro by dephosphorylation of the regulatory Thr and Tyr residues. Little is known on the mechanisms that regulate MKP-1 gene expression. Here, we demonstrate that Ca2+ is both necessary and sufficient for the induction of MKP-1 gene expression. Treatment of Rat1 fibroblasts with the Ca2+ chelating agent BAPTA completely suppressed serum-induced MKP-1 expression in a dose- and time-dependent manner. The inhibitory effect of BAPTA was observed at the level of the protein and the mRNA. Importantly, Ca2+ chelation blocked the induction of MKP-1 expression in response to all stimuli tested and in different cell types. Increasing the intracellular concentration of Ca2+ with the ionophore A23187 was sufficient to induce MKP-1 mRNA and protein expression in rat fibroblasts. We also provide evidence that activation of MAP kinases is not an absolute requirement for induction of the MKP-1 gene. Exposure of rat fibroblasts to A23187 induced MKP-1 expression without activating the JNK and p38 MAP kinase pathways. Also, inhibition of the ERK pathway with the selective MEK inhibitor PD98059 did not interfere with serum-stimulated MKP-1 mRNA expression. These results will help define the regulatory mechanisms that govern MKP-1 gene transcription in target cells.	HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ H2W 1T8,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal; Universite de Montreal			; Scimeca, Jean-Claude/P-3830-2016	Dyer, Joseph-Omer/0000-0002-7570-9941; Scimeca, Jean-Claude/0000-0003-3773-6110				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEJONGE PC, 1983, BIOCHIM BIOPHYS ACTA, V722, P219, DOI 10.1016/0005-2728(83)90177-9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1993, J BIOL CHEM, V268, P26037; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FUKUDA M, 1995, ONCOGENE, V11, P239; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MILLAR JBA, 1995, GENE DEV, V9, P2217; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	76	52	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					717	725		10.1038/sj.onc.1201231	http://dx.doi.org/10.1038/sj.onc.1201231			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264412	Bronze			2022-12-17	WOS:A1997XP68300011
J	Jain, SK; Langdon, WY; Varticovski, L				Jain, SK; Langdon, WY; Varticovski, L			Tyrosine phosphorylation of p120(cbl) in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase	ONCOGENE			English	Article						BCR/abl tyrosine kinase; c-cbl; GRB2; PI 3-kinase	CHRONIC MYELOGENOUS LEUKEMIA; EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; BCR-ABL ONCOGENE; SIGNAL-TRANSDUCTION; PROTEIN PRODUCT; DOMAIN-BINDING; SH2 DOMAINS; V-CBL; PHOSPHOINOSITIDE 3-KINASE	Increased tyrosine kinase activity of abi oncogene in Philadelphia chromosome positive-leukemic cells leads to activation of p21(ras) and phosphatidylinositol 3'-kinase (PI 3-Kinase). The mechanism of activation of these signaling pathways is not understood, but numerous studies have focused on the identification and characterization of downstream substrates of BCR/abl tyrosine kinase as potential mediators of oncogenic signaling. It was recently found that the 120 kDa protein product of the c-cbl proto-oncogene is highly tyrosine phosphorylated and associates with BCR/abl in transformed hematopoietic cells. We have characterized further cbl's involvement in BCR/abl mediated tumorigenesis using growth factor independent BCR/abl transformed BaF3 cells. Our experiments show that, in contrast to other cell types, the in vivo interaction of cbl with GRB2 and p85 is significantly enhanced in BCR/abl transformed BaF3 cells and that tyrosine phosphorylation of cbl leads to a direct interaction with GRB2, p85 and abl SH2 domains. A 14-fold increase in cbl associated PI 3-kinase activity in BCR/abl transformed cells suggests that the binding of p85 SH2 domains to tyrosine phosphorylated cbl may contribute to PI 3-kinase activation. Domain analysis studies indicate that both SH3 domains of GRB2 bind to the proline rich region of cbl in quiescent BaF3 cells, whereas GRB2 SH2 domain interacts with a non-contiguous sequence of cbl in transformed cells. Although the interaction of cbl with GRB2 in transformed cells was facilitated by binding of GRB2 to BCR/abl, phosphorylation of cbl and its interaction with p190 BCR/abl remained unaltered in BaF3 cells transformed by p190Y177F BCRlabl mutant which is unable to bind GRB2 The current information and the data presented here suggest that, although cbl lacks src homology domains, it represents a novel intermediate protein which, by interaction with key SH-containing adaptor proteins, may participate in regulation of the Ras and PI 3-kinase pathways in BCR/abl transformed hematopoietic cells.	TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, BOSTON, MA 02135 USA; UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA	St. Elizabeth's Medical Center; Tufts University; University of Western Australia				Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [CA-53094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLESSO N, 1994, ONCOGENE, V9, P149; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG SW, 1995, ONCOGENE, V10, P1261; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Frank DA, 1996, LEUKEMIA, V10, P1724; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KIM TJ, 1995, J BIOL CHEM, V271, P1534; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, MOL CELL BIOL, V16, P45; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1996, ONCOGENE, V12, P839; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUSA M, 1992, J BIOL CHEM, V267, P22951; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	74	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	1997	14	18					2217	2228		10.1038/sj.onc.1201049	http://dx.doi.org/10.1038/sj.onc.1201049			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174058				2022-12-17	WOS:A1997WX93800011
J	Zinszner, H; Immanuel, D; Yin, Y; Liang, FX; Ron, D				Zinszner, H; Immanuel, D; Yin, Y; Liang, FX; Ron, D			A topogenic role for the oncogenic N-terminus of TLS: Nucleolar localization when transcription is inhibited	ONCOGENE			English	Article						hnRNP; gene expression; RNA-binding protein; immunofluorescence	RNA-BINDING PROTEIN; ACUTE MYELOID-LEUKEMIA; EWS/FLI-1 FUSION GENE; ROUND-CELL TUMOR; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MYXOID LIPOSARCOMA; COILED BODIES; SARCOMA; EWS	TLS (FUS) and the related gene EWS encode the N-terminal portion of many fusion oncoproteins involved in human sarcomas and leukemia. TLS is an RNA-binding nuclear protein that is identical to hnRNP P2 and may be implicated in mRNA metabolism. When RNA polymerase II is inhibited, TLS immunostaining in the nucleus is dramatically altered, from its normal diffuse nucleoplasmic pattern to accumulation in dense nuclease-resistant aggregates. Co-immunostaining with antibodies to fibrillarin or p80 coilin and immunoelectron microscopy revealed that the TLS associated with the nucleolus and are other known structures such as the coiled body or the interchromatin granule. Injection of cells with an oligodeoxynucleotide that disrupts splicing does not result in redistribution of TLS, indicating that the event is specific to inhibition of transcription. Oncoproteins that contain the N-terminal domain from either TLS, EWS or their Drosophila homologue, SARFH (CAZ), are also targeted to the same structure. These findings suggest a correlation between the topogenic and transforming activities of TLS and EWS N-termini and imply the existence of cellular targets that are shared by the germ-line encoded proteins and their oncogenic derivatives.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University; New York University; New York University; New York University				Ron, David/0000-0002-3014-5636; Liang, Fengxia/0000-0003-0037-4590	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; BRASCH K, 1992, EXP CELL RES, V202, P2211; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROWN AD, 1995, ONCOGENE, V10, P1749; CALVIO C, 1995, RNA, V1, P724; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Fujimura Y, 1996, ONCOGENE, V12, P159; HARDERS J, 1989, EMBO J, V8, P3941, DOI 10.1002/j.1460-2075.1989.tb08577.x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; KALLAND KH, 1991, NEW BIOL, V3, P389; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LESSNICK SL, 1995, ONCOGENE, V10, P423; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTH J, 1986, J MICROSC-OXFORD, V143, P125, DOI 10.1111/j.1365-2818.1986.tb02771.x; ROTH J, 1998, HISTOCHEMISTRY, V95, P132; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SPECTOR D, 1991, EMBO J, V10, P3476; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	52	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					451	461		10.1038/sj.onc.1200854	http://dx.doi.org/10.1038/sj.onc.1200854			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053842				2022-12-17	WOS:A1997WE36400008
J	Lu, QA; Kamps, MP				Lu, QA; Kamps, MP			Heterodimerization of Hox proteins with Pbx1 and oncoprotein E2a-Pbx1 generates unique DNA-binding specificities at nucleotides predicted to contact the N-terminal arm of the Hox homeodomain-demonstration of Hox-dependent targeting of E2a-Pbx1 in vivo	ONCOGENE			English	Article						E2a-Pbx1; oncoprotein; homeodomain; Hox	HOMEOBOX GENES; EXPRESSION; LEUKEMIA; EXTRADENTICLE; MOTIF; HOX-4.2; ELEMENT; FUSION; MICE; E2A	Hox proteins control genetic programs that orchestrate development, and a large subset of Hox proteins can bind DNA elements as heterodimers with the Pbx family of homeodomain proteins. A transcriptionally activated version of Phx1, E2a-Pbx1, is an oncoprotein in human pre-B cell leukemia that strongly suppresses differentiation and retains its ability to heterodimerize with Hox proteins. Because monomeric Hox proteins bind very similar DNA motifs, it is unclear how they activate diverse developmental programs. Here we demonstrate that heterodimers containing different Hox proteins and a common Pbx1 or E2a-Pbx1 partner bind different DNA motifs, Structural models suggest that the specificity of the Hox protein is altered by a conformation change involving residues in the N-terminal arm of the Hox homeodomain. Mutational analysis also supported the hypothesis that unique sequences in the N-terminal arm of the Hox homeodomain are at least partially responsible for mediating this specificity. lit vivo, Hox proteins directed E2a-Pbx1-mediated transactivation with moderate specificity to cognate Hox-Pbx motifs. Thus, the development specificity of individual Hox proteins may be mediated, in part, by differential targeting of cellular genes by Pbx1-Hox complexes. Likewise, through its function as a common heterodimer partner, oncoprotein E2a-Pbx1 may be able to interfere with multiple programs of development that are induced by the sequential or simultaneous expression of Hox proteins during hematopoiesis.	UNIV CALIF SAN DIEGO,DEPT PATHOL,SCH MED,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of California System; University of California San Diego; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA056876, P01CA050528] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876-05, 2 PO1 CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CARROLL AJ, 1984, BLOOD, V63, P721; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAWRENCE HJ, 1993, CELL GROWTH DIFFER, V4, P665; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MATHEWS CHE, 1991, BLOOD, V78, P2248; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETRINI M, 1992, BLOOD, V80, P185; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; ZENG WL, 1993, DEVELOPMENT, V118, P339	39	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					75	83		10.1038/sj.onc.1200799	http://dx.doi.org/10.1038/sj.onc.1200799			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010234	Bronze			2022-12-17	WOS:A1997WB76000007
J	Todd, MC; Xiang, RH; Garcia, DK; Kerbacher, KE; Moore, SL; Hensel, CH; Liu, P; Siciliano, MJ; Kok, K; vandenBerg, A; Veldhuis, P; Buys, CHCM; Killary, AM; Naylor, SL				Todd, MC; Xiang, RH; Garcia, DK; Kerbacher, KE; Moore, SL; Hensel, CH; Liu, P; Siciliano, MJ; Kok, K; vandenBerg, A; Veldhuis, P; Buys, CHCM; Killary, AM; Naylor, SL			An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo	ONCOGENE			English	Article						tumor suppressor gene; small cell lung cancer; human chromosome 3; positional cloning; homozygous deletion	CELL LUNG-CANCER; POLYMERASE CHAIN-REACTION; SHORT ARM; HOMOZYGOUS DELETION; DNA-SEQUENCE; ALLELIC LOSS; OVARIAN-CANCER; CARCINOMA; LINE; GENE	High frequencies of allelic loss on the short arm of chromosome 3 in small cell lung cancer (SCLC) and a number of other tumors suggest the existence of a tumor suppressor gene(s) within the deleted regions. Two small cell lung cancer lines, NCI H740 and GLC20, have been described which have homozygous deletions in the region 3p21.3. The deleted region overlaps with a 2 Mb fragment of human DNA present in the interspecies hybrid HA(3)BB9F, that suppresses tumor formation by mouse A9 fibrosarcoma cells. Human sequences from this cell hybrid were isolated using inter Alu PCR. From this starting point, a P1 contig was developed for the region of 450 Kb that is common to the homozygous deletions seen in the SCLC lines NCI H740 and GLC20 and is also present in HA(3)BB9F, the suppressed A9 hybrid. Individual P1 clones were assayed for their ability to suppress the tumorigenicity of the mouse fibrosarcoma cell line A9 as assayed by injection of transfected A9 cells into athymic nude mice. The introduction of one of the P1 clones into A9 cells resulted in suppression of tumor growth whereas two other P1 clones from the contig failed to suppress tumor formation in athymic nude mice. These data functionally delimit a tumor suppressor locus to a region of 80 kb within a P1 clone at 3p21.3.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; MD ANDERSON CANC INST,DEPT MOL GENET,HOUSTON,TX 77030; MD ANDERSON CANC INST,DEPT LAB MED,HOUSTON,TX 77030; UNIV GRONINGEN,DEPT MED GENET,GRONINGEN,NETHERLANDS	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Groningen			van den Berg, Anke/H-1718-2011; Liu, Paul/A-7976-2012; todd, martin/I-4143-2015	van den Berg, Anke/0000-0002-8894-2638; Liu, Paul/0000-0002-6779-025X; Moore, Shanna/0000-0001-5578-8868	NCI NIH HHS [CA56626, CA54174] Funding Source: Medline; PHS HHS [H600470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056626, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; ELNAGGAR AK, 1993, CANCER, V72, P881, DOI 10.1002/1097-0142(19930801)72:3<881::AID-CNCR2820720337>3.0.CO;2-Q; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HANSEN MF, 1987, P NATL ACAD SCI USA, V84, P9059; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; JONES MH, 1992, ONCOGENE, V7, P1631; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KRAUS C, 1994, GENOMICS, V23, P272, DOI 10.1006/geno.1994.1493; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1992, CANCER RES, V52, P1451; LEACH RJ, 1994, GENOMICS, V24, P549, DOI 10.1006/geno.1994.1665; LEDBETTER SA, 1990, GENOMICS, V6, P475, DOI 10.1016/0888-7543(90)90477-C; LIDEREAU R, 1989, J NATL CANCER I, V81, P1815; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LIU P, 1993, CANCER GENET CYTOGEN, V65, P93, DOI 10.1016/0165-4608(93)90213-6; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; POPESCU NC, 1988, CANCER RES, V48, P142; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RIMESSI P, 1994, ONCOGENE, V9, P3467; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIMIZU M, 1990, ONCOGENE, V5, P185; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG A, IN PRESS CYTOGENET C; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOTA J, 1988, ONCOGENE, V3, P471; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	56	52	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2387	2396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957080				2022-12-17	WOS:A1996VX10800011
J	Furuhata, T; Tokino, T; Urano, T; Nakamura, Y				Furuhata, T; Tokino, T; Urano, T; Nakamura, Y			Isolation of a novel GPI-anchored gene specifically regulated by p53; Correlation between its expression and anti-cancer drug sensitivity	ONCOGENE			English	Article						p53; GPI-anchored protein; anti-cancer drug; esophageal cancer	CELL-GROWTH; PROTEIN; SUPPRESSION; INHIBITOR; KINASES; THB; P21; DNA	We have identified a novel gene inducible by wild-type p53. A significant correlation between expression of this gene and p53 status in cells derived from esophageal cancers indicated that this gene is likely to be specifically regulated in a p53-dependent manner. As the predicted amino acid sequence showed a high degree of homology to the family of glycosyl-phosphatidylinositol (GPI)-anchored membrane proteins, we termed this gene GML (GPI-anchored molecule-like protein). Introduction of GML cDNA suppressed the growth of esophageal cancer cells in culture. A correlation between the presence of GML expression and the sensitivity of esophageal cancer cells to anti-cancer drugs implied that the gene product plays a significant role in the apoptotic pathway or cell-cycle regulation induced by p53 after DNA damage.	UNIV TOKYO, INST MED SCI, MOL MED LAB, TOKYO, JAPAN	University of Tokyo			Tokino, Takashi/AAI-9887-2021; Urano, Tomohiko/AFS-9574-2022					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUMLEY TP, 1992, J IMMUNOL, V149, P2615; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MIYASHITA T, 1995, CELL, V80, P293; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOKINO T, 1991, AM J HUM GENET, V48, P258; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	21	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1965	1970						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934543				2022-12-17	WOS:A1996VR79500016
J	Garcia, P; Cales, C				Garcia, P; Cales, C			Endoreplication in megakaryoblastic cell lines is accompanied by sustained expression of G1/S cyclins and downregulation of cdc25C	ONCOGENE			English	Article						cell cycle; endoreplication; megakaryocyte differentiation; cyclins; cdc2; cdc25C	DEPENDENT KINASE-4 CDK4; FISSION YEAST CDC25; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; ACTIVATING KINASE; DEVELOPMENTAL CONTROL; DNA-REPLICATION; MITOTIC INDUCER; G(1) CYCLINS	In most eukaryotic cells, a link between S and M phases of the cell cycle must be assured in order to maintain the ploidy of newly divided cells. However, in some cell types, e.g. the precursors of platelets megakaryocytes, extra S-phases can occur in the absence of concomitant mitoses, resulting in polyploidy, We have used two established cell lines with megakaryoblastic characteristics (HEL and MEG-01) to investigate the molecular events that lead these cells to bypass the regular control checkpoints that govern the interdependency of S and M phases. In the presence of the phorbol ester TPA, both cell lines stopped proliferating and displayed additional megakaryocytic features, including polyploidization. Analysis of key cell cycle regulatory factors implicated in the control of G1/S and G2/M transitions revealed a number of differences compared to normally cycling cells. Differentiating megakaryocytes were found to maintain high levels of cdk2, and cyclins E and A, This was accompanied by the appearance of the retinoblastoma protein in the hyperphosphorylated, functionally inactivated form, In addition, TPA-treated cells showed high levels of cyclin B and cdc2 proteins, however no activation of cdc2 was detected, This lack of cdc2 activation which should occur for entry into M phase appeared to be related to the down regulation of cdc25C phosphatase found in both differentiated HEL and MEG-01 cells, Together, our results suggest that in differentiating megakaryoblastic cells endoreplication is accompanied by sustained levels of cyclins A and E, and a lack of cdc2 activation, which is probably mediated through down regulation of cdc25C protein phosphatase.	UNIV AUTONOMA MADRID,CSIC,INST INVEST BIOMED,DEPT BIOQUIM,MADRID 28029,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Calés, Carmela/AAB-1595-2019	Garcia, Paloma/0000-0001-5582-8575; Cales, Carmela/0000-0002-6987-2259				BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; GREENBERG SM, 1990, BLOOD, V76, P533; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAYASHI S, 1993, DEVELOPMENT, V118, P105; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFFMAN R, 1989, BLOOD, V74, P1196; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Krishan A, 1990, Methods Cell Biol, V33, P121; KUTER DJ, 1992, BLOOD, V79, P619; LARRICK JW, 1980, J IMMUNOL, V125, P6; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORUZZI EV, 1993, BIOCHEM BIOPH RES CO, V196, P1248; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; NURSE P, 1994, CURR OPIN CELL BIOL, V6, P867; OGURA M, 1988, BLOOD, V72, P49; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBERTS JR, 1990, CANCER RES, V50, P710; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH AV, 1991, DEVELOPMENT, V112, P997; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STERN B, 1993, DEVELOPMENT, V117, P219; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VANDERLOO B, 1993, EUR J CLIN INVEST, V23, P621; VARMUZA S, 1988, DEVELOPMENT, V102, P127; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YEN A, 1993, CANCER RES, V53, P3085; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	75	52	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					695	703						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761290				2022-12-17	WOS:A1996VD43300004
J	Li, WQ; Michieli, P; Alimandi, M; Lorenzi, MV; Wu, YM; Wang, LH; Heidaran, MA; Pierce, JH				Li, WQ; Michieli, P; Alimandi, M; Lorenzi, MV; Wu, YM; Wang, LH; Heidaran, MA; Pierce, JH			Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells	ONCOGENE			English	Article						Sis; transformation; PKC-delta	PROTEIN-KINASE-C; SIMIAN SARCOMA-VIRUS; ALPHA-PDGF RECEPTOR; GROWTH-FACTOR; SIGNALING PATHWAYS; 3T3 CELLS; H-RAS; ACTIVATION; LOCALIZATION; SEQUENCE	In an effort to determine the role of protein kinase C-delta (PKC-delta) in cellular transformation mediated by the sis proto-oncogene, we cotransfected expression vectors containing cDNAs that encode for c-sis with an ATP binding mutant of PKC-delta (PKC-delta K376R) or wild type PKC-delta (PKC-delta WT) into NTH3T3 cells, Our results showed that expression of PKC-delta K376R severely impaired Sis-induced focus formation, whereas cotransfection of PKC-delta WT cDNA had no effect on Sis-mediated transformation, Consistent with this result, PKC-delta K376R expression also inhibited PDGF-BB-mediated anchorage-independent colony While cotransfection of a vector containing a dominant negative mutant of uas (N17 ras) cDNA potently inhibited Sis-induced transformation, the expression of PKC-delta K376R did not block transformation mediated by v-H-Ras or v-Raf, In addition, PDGF-BB-induced Raf and mitogen-activated protein kinase activation, which are known to be downstream molecules in the Ras cascade, were not affected by the expression of PKC-delta K376R, indicating that PKC-delta and Ras are segregated in mediating Sis-induced transformation. Interestingly, expression of PKC-delta K376R strongly reduced TPA responsive element (TRE) transactivation induced by PDGF stimulation, suggesting that activation of TRE-containing genes, which may be involved in Sis-mediated transformation, are negatively regulated by expression of PKC-delta K376R.	NIDR,IMMUNOL LAB,BETHESDA,MD 20892; CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Li, WQ (corresponding author), NCI,CELLULAR & MOL BIOL LAB,BLDG 37,ROOM 1E24,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871; Alimandi, Maurizio/0000-0002-1409-6803				BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BECKMANN R, 1994, EUR J BIOCHEM, V222, P335, DOI 10.1111/j.1432-1033.1994.tb18872.x; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALANG CK, 1994, ONCOGENE, V9, P2913; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KROOK A, 1993, MOL CELL BIOL, V13, P1471, DOI 10.1128/MCB.13.3.1471; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; Li W, 1996, CURR TOP MICROBIOL, V211, P55; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHARMA RV, 1993, AM J PHYSIOL, V264, pC71, DOI 10.1152/ajpcell.1993.264.1.C71; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1995, J BIOL CHEM, V270, P7033, DOI 10.1074/jbc.270.13.7033; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	38	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761294				2022-12-17	WOS:A1996VD43300008
J	Huynh, DP; Pulst, SM				Huynh, DP; Pulst, SM			Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells	ONCOGENE			English	Article						schwannomin; merlin; neurofibromatosis 2; antisense oligonucleotides; moesin; Schwann cell	E-CADHERIN; TYROSINE PHOSPHORYLATION; TYPE-2 NEUROFIBROMATOSIS; CYTOPLASMIC DOMAIN; UNITED-KINGDOM; BETA-CATENIN; PROTEIN; EZRIN; GENE; ASSOCIATION	Mutations in the neurofibromatosis 2 (NF2) gene are the predominant cause in the development of sporadic schwannomas and are also involved in the pathogenesis of meningiomas and ependymomas. The product of the NF2 gene, termed merlin or schwannnomin, is thought to act as a tumor suppressor protein. Although its protein sequence shows homology to proteins that are known to link the cytoskeleton to the cell membrane, no direct evidence for this function has been obtained, We used antisense phosphorothioate oligodeoxynucleotides (pODNs) complementary to the human NF2 cDNA sequence and transfected them into Schwann-like STS26T cells permeabilized by streptolysin O. Changes in cell morphology and attachment were observed at 12 to 24 h and continued up to 48 h post transfection. Cells were rounded and easily dislodged from the substratum at 12-24 h. These changes were reversible and cells became bipolar with thin protrusions and began to reattach to the substratum after 48 h. Normal morphology and adhesion were observed at 72 h post transfection. Morphological changes were due to suppression of schwannomin synthesis. Immunoprecipitations with anti-schwannomin antibodies showed schwannomin to be almost absent 3 h after treatment with antisense pODNs and to be significantly suppressed up to 12 h post transfection whereas beta-actin levels remained unchanged. The morphological changes were not the result of cell death, but resulted in increased cell proliferation. These data demonstrate that antisense oligonucleotides can be successfully employed to suppress schwannomin synthesis and indicate that schwannomin may belong to a class of tumor suppressor genes that provide a link between cell adhesion and tumorigenesis.	UNIV CALIF LOS ANGELES, SCH MED, NEUROGENET LAB, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROL, CSMC BURNS & ALLEN RES INST, LOS ANGELES, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NINDS NIH HHS [NS01428-01A1] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGOSTI CG, 1995, AM J HUM GENET, V57, P114; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARRY ELR, 1993, BIOTECHNIQUES, V15, P1016; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; DAHLBERG WK, 1993, INT J RADIAT BIOL, V63, P191, DOI 10.1080/09553009314550251; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; IRVING RM, 1993, ARCH OTOLARYNGOL, V119, P1222; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOIKE M, 1995, ONCOGENE, V10, P117; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MAUTNER V, NEUROSURGERY, V38, P880; MURTHY AE, 1995, AM J HUM GENET, V57, P113; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OKA H, 1993, CANCER RES, V53, P1696; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Sainz J, 1996, HUM GENET, V97, P121; SAINZ J, 1995, HUM MOL GENET, V4, P137, DOI 10.1093/hmg/4.1.137; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1830; SATO N, 1992, J CELL SCI, V103, P131; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	52	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					73	84						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700556				2022-12-17	WOS:A1996UX31900009
J	Mahajan, MA; Park, ST; Sun, XH				Mahajan, MA; Park, ST; Sun, XH			Association of a novel GTP binding protein, DRG, with TAL oncogenic proteins	ONCOGENE			English	Article						T cell leukemia; helix-loop-helix protein; GTP-binding protein; erythroid differentiation	LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; GENE SCL; EXPRESSION; MOTIF; TRANSLOCATION; TRANSCRIPTION	TAL1 is a basic helix-loop-helix (bHLH) protein involved in hematopoietic development. In T cell acute lymphoblastic leukemic cells, TAL1 is aberrantly overexpressed and is thought to contribute to oncogenesis. To identify proteins that interact with TAL1 in mediating leukemogenesis, we used TAL1 as a bait in a two-hybrid interaction screen, and isolated a cDNA clone that encodes a unique GTP binding protein, DRG. The interaction between DRG and TAL1 was confirmed both in vitro and in vivo, DRG was also shown to bind in vitro to two TAL1-related proteins, TAL2 and Lyl1. Mutational analyses showed that the HLH domain of TAL1 was necessary and sufficient for its interaction with the C-terminus of DRG. Furthermore, while DRG and E47 compete to interact with TAL1, TAL1 binds to DRG and E47 in a mutually exclusive manner. In rat embryonic fibroblast transformation assays, DRG stimulated the cotransforming activity of c-myc and I as. Based on these results, DRG appears to be a potential target for TAL-like oncoproteins.	NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University				Mahajan, Muktar/0000-0003-1024-6808	NIAID NIH HHS [AI-33597] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033597, R01AI033597] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AUSUBAL FM, 1994, CURRENT PROTOCOLS MO; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BOURNE HR, 1991, NATURE, V349, P118; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GOLDFARB AN, 1994, LEUKEMIA LYMPHOMA, V12, P157, DOI 10.3109/10428199409059586; GOLDFARB AN, 1992, BLOOD, V80, P2858; GREEN AR, 1991, ONCOGENE, V6, P475; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KUMAR S, 1993, INT J DEV BIOL, V37, P539; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PRENDERGAST GC, 1992, GENE DEV, V6, P2426; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P371, DOI 10.1016/0006-291X(92)91568-B; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P363, DOI 10.1016/0006-291X(92)91567-A; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	39	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2343	2350						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649774				2022-12-17	WOS:A1996UQ22000011
J	GAO, X; ZACHAREK, A; GRIGNON, DJ; SAKR, W; POWELL, IJ; PORTER, AT; HONN, KV				GAO, X; ZACHAREK, A; GRIGNON, DJ; SAKR, W; POWELL, IJ; PORTER, AT; HONN, KV			LOCALIZATION OF POTENTIAL TUMOR-SUPPRESSOR LOCI TO A LESS-THAN-2 MB REGION ON CHROMOSOME 17Q IN HUMAN PROSTATE-CANCER	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; DELETION MAPPING; TUMOR SUPPRESSOR GENE; POLYMERASE CHAIN REACTION; PROSTATIC CARCINOMA	BREAST-OVARIAN-CANCER; FAMILIAL BREAST; REPEAT POLYMORPHISM; ESOPHAGEAL CANCERS; LINKAGE ANALYSIS; ALLELIC LOSS; GENES; P53; CARCINOMA; DELETION	We recently demonstrated a high frequency of loss of heterozygosity (LOH) at the D17S856 and D17S855 (within the BRCA1 gene) loci in primary prostate cancer, suggesting that the BRCA1, gene and/or other tumor suppressor gene(s) located within the interval of the D17S856 and D17S855 loci and/or within the vicinity of this interval may be important in prostate cancer (Cancer Res., 55: 1002-1005, 1995). To further define the exact boundary of the deleted region (i.e., D17S856/D17S855) and to detect other possible LOH regions on the long arm of chromosome 17, we analysed 23 matched normal and tumor DNAs with 15 polymorphic microsatellite markers spanning chromosome 17q12-21. Eleven of 22 (50%) informative tumors showed allelic deletion at one or more of the loci studied. A minimal area of LOH was identified to extend from the proximal boundary at the D17S776 locus to the distal boundary at the D17S855 locus, spanning an estimated <2 Mb segment on chromosome 17q21. Our results suggest that a potential tumor suppressor gene(s) may reside in the <2 Mb region centromeric (inclusive) to the BRCA1 gene and that this tumor suppressor gene(s) may be involved in the formation of prostate cancer.	WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT UROL,DETROIT,MI 48202	Wayne State University; Wayne State University; Wayne State University								ANDERSON LA, 1993, GENOMICS, V17, P618, DOI 10.1006/geno.1993.1381; ARASON A, 1993, AM J HUM GENET, V52, P711; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BERGERHEIM USR, 1993, GENE CHROMOSOME CANC, V3, P215; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOVA GS, 1993, CANCER RES, V53, P3869; BRAWN PN, 1993, CANCER, V71, P2569, DOI 10.1002/1097-0142(19930415)71:8<2569::AID-CNCR2820710822>3.0.CO;2-R; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHIARODO A, 1991, CANCER RES, V51, P2498; CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; EASTON DF, 1993, AM J HUM GENET, V52, P678; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; FLEJTER WL, 1993, HUM MOL GENET, V2, P1080, DOI 10.1093/hmg/2.7.1080; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, INT J ONCOL, V6, P111; GAO X, 1993, CANCER RES, V53, P2723; GAO X, 1995, IN PRESS PATHOL ONCO; GAO X, 1995, CANCER MOL BIOL, V2, P475; GAO X, 1995, IN PRESS UROL; GAO X, 1994, CANCER MOL BIOL, V1, P297; GAO X, 1995, IN PRESS ONCOGENE; GAO XA, 1994, ONCOGENE, V9, P2999; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUANG Y, 1992, CANCER RES, V52, P6525; ILES DE, 1993, HUM MOL GENET, V2, P863; ISAACS WB, 1991, CANCER RES, V51, P4716; ISSHIKI K, 1994, ONCOGENE, V9, P1649; JACOBS IJ, 1993, CANCER RES, V53, P1218; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V26, P436; KEEN AJ, 1994, ONCOGENE, V9, P2083; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORI T, 1994, CANCER RES, V54, P3396; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; PEEHL DM, 1993, CANCER, V71, P1159, DOI 10.1002/1097-0142(19930201)71:3+<1159::AID-CNCR2820711439>3.0.CO;2-U; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V20, P1961; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROACH M, 1992, INT J RADIAT ONCOL, V24, P441, DOI 10.1016/0360-3016(92)91058-U; SAITO H, 1993, CANCER RES, V53, P3382; SIMARD J, 1994, NAT GENET, V8, P393; TARMIN L, 1994, CANCER RES, V54, P6094; TRAPMAN J, 1994, CANCER RES, V54, P6061; UCHIDA T, 1995, ONCOGENE, V10, P1019; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	71	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478543				2022-12-17	WOS:A1995RY96700003
J	SASTRY, L; LIN, WH; WONG, WT; DIFIORE, PP; SCOPPA, CA; KING, CR				SASTRY, L; LIN, WH; WONG, WT; DIFIORE, PP; SCOPPA, CA; KING, CR			QUANTITATIVE-ANALYSIS OF GRB2-SOS1 INTERACTION - THE N-TERMINAL SH3 DOMAIN OF GRB2 MEDIATES AFFINITY	ONCOGENE			English	Article						GRB2; SOS1; BIACORE; SPR; KINETICS	RECEPTOR TYROSINE KINASES; BIOSPECIFIC INTERACTION ANALYSIS; NUCLEOTIDE EXCHANGE FACTOR; SURFACE-PLASMON RESONANCE; PHOSPHORYLATED PEPTIDES; SIGNAL TRANSDUCTION; RAS; PROTEIN; BINDS; ASSOCIATION	Grb2 is an adaptor protein that links receptor and cytoplasmic tyrosine kinases to the Ras signalling pathway by binding the Ras-specific guanine nucleotide exchange factor, Sos1, through its SH3 domains, The Grb2-SH3 domain binding has been localized to the carboxy-terminal two hundred amino acids of Sos1 (Sos1-c). By using real time biospecific interaction analysis (BIAcore), we studied the kinetic parameters and binding affinity of the Grb2-Sos1-c interaction, The binding of Grb2 to Sos1-c is a high affinity interaction with a moderate association rate (9.45 x 10(4) per M per s), a slow dissociation rate (13.8 x 10(-5) s), and an affinity constant of 1.48 nM. BIAcore measurements on isolated N-terminal and C-terminal SH3 domains (NSH3 and CSH3) further indicate that the high affinity Grb2-Sos1-c interaction is primarily mediated through the NSH3 domain (K-d=1.68 nM). The CSH3 domain shows substantially reduced binding to Sos1-c in these measurements, Inhibition studies with BIAcore using proline rich peptides derived from the C-terminus of Sos1 show that there is a single major binding site for Grb2 in Sos1, This binding site is contained within the peptide N20, which corresponds to amino acids 1143-1162 of Sos1, This peptide completely blocks the Grb2-Sos1-c and NSH3-Sos1-c interactions with IC50 values of 8 mu M and 4 mu M respectively, The discrete interaction between the NSH3 domain and the N20 peptide may be amenable for drug discovery through screening or peptidomimetic approaches.	ONCOL INC, GAITHERSBURG, MD 20878 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; FAC MED & CHIRURG, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRANZOW R, 1902, BIOTECHNOLOGY, V10, P390; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIKI H, 1994, J BIOL CHEM, V269, P5489; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; 1991, BIACORE SYSTEM MANUA	31	52	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1107	1112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566970				2022-12-17	WOS:A1995RX18000013
J	FOURNIER, E; DUBREUIL, P; BIRNBAUM, D; BORG, JP				FOURNIER, E; DUBREUIL, P; BIRNBAUM, D; BORG, JP			MUTATION AT TYROSINE RESIDUE-1337 ABROGATES LIGAND-DEPENDENT TRANSFORMING CAPACITY OF THE FLT4 RECEPTOR	ONCOGENE			English	Article						ENDOTHELIUM; FLT4; PHOSPHORYLATION; RECEPTOR; SH2 DOMAIN; SHC	ENDOTHELIAL GROWTH-FACTOR; SH3 DOMAINS; SIGNAL TRANSDUCTION; KINASE; EXPRESSION; CELLS; VEGF; MOLECULES; BINDING	In humans, the FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which differ in their carboxy terminal regions. As compared to the short form, the long form has an additional stretch of 65 amino acids containing three tyrosine residues (Y1333, Y1337 and Y1363). Once expressed in fibroblast cells, only the long form is able to elicit both anchorage-independent growth in a soft agar assay and tumors in nude mice, and thus appears endowed,vith a potential ligand-dependent transforming capacity. Replacement of tyrosine 1337 by phenylalanine abrogates the transforming capacity of the long form. This residue was identified as a potential autophosphorylation site, and a docking site for a substrate important in the signal transduction specific of the long FLT4 isoform. We demonstrate that the GRB2 and SHC cytoplasmic substrates are involved in FLT4 signal transduction. SHC interaction could be crucial to FLT4-mediated transforming activity associated with the long isoform. Finally, trancripts for the two forms are detected in tissues positive for FLT4 gene expression.	INSERM, U119, ONCOL MOLEC LAB, F-13009 MARSEILLE, FRANCE; INSERM, U119, HEMATOL FONCTIONNELLE & MOLEC LAB, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			dubreuil, patrice/F-5346-2011; Borg, Jean-Paul/AAX-8096-2020; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Dubreuil, Patrice/0000-0003-1155-1150				APRELIKOVA O, 1992, CANCER RES, V52, P746; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORG JP, 1995, ONCOGENE, V10, P973; BORG JP, 1995, IN PRESS MOL ANAL MA; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROWN LF, 1993, AM J PATHOL, V143, P1255; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINNERTY H, 1993, ONCOGENE, V8, P2293; GALLAND F, 1993, ONCOGENE, V8, P1233; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HATVA E, 1995, AM J PATHOL, V146, P368; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PARK JE, 1994, J BIOL CHEM, V269, P25646; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	52	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					921	931						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675451				2022-12-17	WOS:A1995RU79800013
J	Barnard, D; Diaz, B; Hettich, L; Chuang, E; Zhang, XF; Avruch, J; Marshall, M				Barnard, D; Diaz, B; Hettich, L; Chuang, E; Zhang, XF; Avruch, J; Marshall, M			Identification of the sites of interaction between c-Raf-1 and Ras-GTP	ONCOGENE			English	Article						Oncogenes; RAS; RAF; Protein Interactions	KINASE SIGNALING PATHWAY; HA-RAS; RAF-1; ACTIVATION; BINDING; DOMAIN; ASSOCIATION; INHIBITION; PROTEINS; REGION	Specific sites of protein-protein interaction were identified in the 51-149 region of c-Raf-1 using contact epitope scanning and site-directed mutagenesis. Nineteen overlapping peptides based upon the primary sequence of the Ras binding domain of c-Raf-1 were tested for the ability to competitively inhibit complex formation between Ras-GTP and the c-Raf-1 N-terminus, A peptide containing c-Raf-1 residues 91-105 as well as five overlapping peptides covering a region extending from residues 118 to 143 interfered with Ras association, defining these sites as potential contact surfaces with Ras, Alanine scanning mutagenesis was used as a second probe for sites of Ras interaction with the c-Raf-1 N-terminus, Raf residues 64-67 and 80-103 were demonstrated as important for association with Ras-GTP with residues 66, 67, 84, 87, 89 and 91 identified as the most critical individual points of contact with the Ras protein, Alanine substitution of residues between 118-143 suggested only one potentially weak site of interaction defined by residues 120-125, The combined results of both peptide and mutagenic analyses suggest that the primary site of c-Raf-1 interaction,vith Ras maps to Raf residues 80-103, with secondary interactions occurring with residues 66 and 67 and possibly 120-125, Contact epitope scanning of the Ras effector region found maximum inhibition of Ras/Raf association with a peptide corresponding to Ras amino acids 37-51, A model is proposed for the GTP-dependent association of Ras and Raf.	Indiana Univ, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Dept Med, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Diabet Unit, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Med Serv, Boston, MA 02129 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07519] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE ML, 1992, SYNTHETIC PEPTIDES, P58; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	52	54	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1283	1290						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731678				2022-12-17	WOS:A1995QR65100004
J	WOODS, C; LEFEUVRE, C; STEWART, N; BACCHETTI, S				WOODS, C; LEFEUVRE, C; STEWART, N; BACCHETTI, S			INDUCTION OF GENOMIC INSTABILITY IN SV40-TRANSFORMED HUMAN-CELLS - SUFFICIENCY OF THE N-TERMINAL-147 AMINO-ACIDS OF LARGE T-ANTIGEN AND ROLE OF PRB AND P53	ONCOGENE			English	Article							HUMAN-DIPLOID FIBROBLASTS; WILD-TYPE P53; MOUSE EMBRYO FIBROBLASTS; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; CYCLE CHECKPOINT; DNA-SYNTHESIS; CHROMOSOMAL-ABERRATIONS; MONOCLONAL-ANTIBODIES	Genomic instability is an early event in the transformation of human cells by SV40 and may contribute, as a mutagenic process, to the generation of the rare cells which survive crisis and yield immortal populations. We have previously reported that expression of large T antigen is responsible for induction of chromosome aberrations and aneuploidy. In the present study we have demonstrated that the amino terminal 147 amino acids of the protein are as proficient as full length T antigen for this destabilization of the cell genome. Analysis of mutants within this region indicated that T antigens defective for binding to pRB or lacking the first 127 amino acids are significantly reduced in their ability to induce aneuploidy and/or aberrations, whereas a cytoplasmic T antigen is less severely impaired. In addition, we have shown that binding of T antigen to p53 is dispensable for genome destabilization but may be required for continued proliferation of genetically aberrant cells.	MCMASTER UNIV,DEPT PATHOL,MOLEC VIROL & IMMUNOL PROGRAMME,HAMILTON L8N 3Z5,ON,CANADA	McMaster University								ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; ANDERSON RW, 1988, J VIROL, V62, P285, DOI 10.1128/JVI.62.1.285-296.1988; ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BAUMANN EA, 1985, J VIROL, V54, P882, DOI 10.1128/JVI.54.3.882-885.1985; BOND JA, 1994, ONCOGENE, V9, P1885; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARNDEN DG, 1985, ISCN; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYFLICK L, 1965, EXP CELL RES, V37, P617; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACLEAN K, 1994, ONCOGENE, V9, P719; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RASHEED D, 1974, CANCER, V33, P1033; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAY FA, 1993, CARCINOGENESIS, V14, P1511, DOI 10.1093/carcin/14.8.1511; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	78	52	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2943	2950						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084597				2022-12-17	WOS:A1994PG82200020
J	FERNANDEZ, A; MARIN, MC; MCDONNELL, T; ANANTHASWAMY, HN				FERNANDEZ, A; MARIN, MC; MCDONNELL, T; ANANTHASWAMY, HN			DIFFERENTIAL SENSITIVITY OF NORMAL AND HA-RAS-TRANSFORMED C3H MOUSE EMBRYO FIBROBLASTS TO TUMOR-NECROSIS-FACTOR - INDUCTION OF BCL-2, C-MYC, AND MANGANESE SUPEROXIDE-DISMUTASE IN RESISTANT CELLS	ONCOGENE			English	Article							WILD-TYPE P53; FACTOR-MEDIATED CYTOTOXICITY; FACTOR-ALPHA; INTERFERON-GAMMA; MALIGNANT TRANSFORMATION; CHROMOSOMAL BREAKPOINT; ONCOGENE EXPRESSION; FOLLICULAR LYMPHOMA; DNA FRAGMENTATION; FACTOR RECEPTORS	In this study, we investigated the role of activated Ha-ras oncogene on the growth-regulatory properties of tumor necrosis factor (TNF) in C3H mouse embryo fibroblasts. TNF-resistant 10T1/2 cells transfected with an activated Ha-ras oncogene not only produced tumors in nude mice but also exhibited extreme sensitivity to cytolysis by TNF. TNF-induced cell death was mediated through apoptosis. The differential sensitivity of normal and Ha-ras transformed cells to TNF was not due to differences in the number of TNF receptors on their cell surface. However, TNF-resistant cells, but not sensitive cells, overexpressed bcl-2, c-myc, and manganese superoxide dismutase (MnSOD) mRNA following exposure to TNF. In addition, TNF treatment resulted in a marginal induction of p53 mRNA in both TNF-sensitive and resistant cells. These results suggest that TNF-induced cytotoxicity involves apoptosis and that TNF-induced over-expression of bcl-2, c-myc, and MnSOD genes is associated with TNF resistance in C3H mouse embryo fibroblasts.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA046523] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09255-02, R01-CA-46523] Funding Source: Medline; NCRR NIH HHS [RR5S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ASHER A, 1987, J IMMUNOL, V138, P963; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALKWILL FR, 1986, CANCER RES, V46, P3990; BARRETT K, 1991, EUR J IMMUNOL, V21, P1649, DOI 10.1002/eji.1830210710; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOSS JM, 1991, IMMUNOLOGY, V73, P309; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDEZ A, 1992, LYMPHOKINE CYTOK RES, V11, P79; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GONEN B, 1992, CANCER IMMUNOL IMMUN, V35, P388, DOI 10.1007/BF01789017; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; HENNET T, 1993, CANCER RES, V53, P1456; HIMENO T, 1992, INT J CANCER, V50, P458, DOI 10.1002/ijc.2910500322; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HSIO WL, 1984, SCIENCE, V226, P552; HUANG MN, 1990, BIOTECHNIQUES, V9, P711; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; ITOH N, 1993, J IMMUNOL, V151, P621; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEHMANN V, 1986, EUR J BIOCHEM, V158, P1, DOI 10.1111/j.1432-1033.1986.tb09712.x; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Maniatis T., 1982, MOL CLONING; MATHEWS N, 1987, IMMUNOLOGY, V62, P153; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MONOHARAN TH, 1985, CARCINOGENESIS, V6, P1295; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBAYE B, 1991, AM J PATHOL, V138, P447; RUBIN BY, 1988, CANCER RES, V48, P6006; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SATOMI N, 1988, J BIOL RESP MODIF, V7, P54; SELIGER B, 1988, J IMMUNOL, V141, P2138; SELIGER B, 1988, J CELL BIOCHEM, V38, P205, DOI 10.1002/jcb.240380308; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1989, ANTICANCER RES, V9, P1149; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; SUEN TC, 1990, LYMPHOKINE RES, V9, P15; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	75	52	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2009	2017						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208546				2022-12-17	WOS:A1994NR68500025
J	EZOE, K; LEE, ST; STRUNK, KM; SPRITZ, RA				EZOE, K; LEE, ST; STRUNK, KM; SPRITZ, RA			PTK1, A NOVEL PROTEIN-KINASE REQUIRED FOR PROLIFERATION OF HUMAN MELANOCYTES	ONCOGENE			English	Note							CELL-LINE; SEQUENCE; DOMAINS	We have identified and characterized PTK1, a novel human non-receptor protein kinase. Partial PTK1 cDNA was initially isolated by RT-PCR from mRNA of normal human melanocytes. Northern blot hybridization detected a 3.8-kb PTK1 mRNA in ah tissues and cell types studied. Nucleotide sequence analysis of a full-length PTK1 cDNA showed it to encode an 847-amino acid polypeptide with an amino-terminal SH3 domain, a kinase catalytic domain, a leucine zipper-like domain, and a carboxyl proline-rich domain. The PTK1 kinase domain contains motifs generally considered diagnostic of serine/threonine kinases but also contains amino acids highly conserved among the tyrosine kinases. This suggests that PTK1 is a serine/threonine kinase, but one very closely related to the tyrosine kinase superfamily. When normal human melanocytes were exposed to antisense PTK1 oligonucleotide, cell growth was inhibited, whereas a corresponding sense oligonucleotide had no inhibitory effect. These data indicate that PTK1 plays an important role in the proliferation of normal human melanocytes.	UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT PEDIAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784	NIAMS NIH HHS [AR39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BOLEN JB, 1993, ONCOGENE, V8, P2025; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE ST, 1993, ONCOGENE, V8, P3403; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TVEIT KM, 1980, BRIT J CANCER, V41, P724, DOI 10.1038/bjc.1980.134	14	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					935	938						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108137				2022-12-17	WOS:A1994MW55100030
J	HOEVER, M; CLEMENT, JH; WEDLICH, D; MONTENARH, M; KNOCHEL, W				HOEVER, M; CLEMENT, JH; WEDLICH, D; MONTENARH, M; KNOCHEL, W			OVEREXPRESSION OF WILD-TYPE P53 INTERFERES WITH NORMAL DEVELOPMENT IN XENOPUS-LAEVIS EMBRYOS	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; CELL-CYCLE CONTROL; PROTO-ONCOGENE; INSITU HYBRIDIZATION; MOUSE EMBRYOGENESIS; MESSENGER-RNAS; ANTIGEN; LOCALIZATION; EF-1-ALPHA; TRANSITION	We have cloned and sequenced a Xenopus p53 homologue which differs by one amino acid deletion from a previously published Xenopus sequence (Soussi et al., 1987). Transcription analysis revealed that this gene is activated during early oogenesis and that zygotic transcription initiates after midblastula transition. Transcripts are also present in all tested tissues of adult animals. Whole mount in situ hybridization with Xenopus oocytes and embryos revealed, that transcripts are ubiquitously distributed although some accumulation is observed in certain tissues. Microinjection of p53 mRNA into early cleavage stages effectively resulted in overexpression of p53 protein and interfered with normal development. Lethal defects until and during gastrulation and aberrant phenotypes of surviving embryos were probably caused by cleavage arrest or cleavage delay of injected cells with subsequent distortions of cell movements, induction processes and tissue differentiations.	UNIV ULM, BIOCHEM ABT, D-89069 ULM, GERMANY; UNIV SAARLAND, D-66421 HOMBURG, GERMANY	Ulm University; Saarland University			Montenarh, Mathias/AAB-6689-2020	Clement, Joachim H./0000-0002-6601-2456				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; KASTAN MB, 1991, CANCER RES, V51, P4279; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOHUN TJ, 1989, DEVELOPMENT, V107, P835; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; POTING A, 1990, DIFFERENTIATION, V44, P103; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VIZE PD, 1990, DEVELOPMENT, V110, P885; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	41	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					109	120						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302570				2022-12-17	WOS:A1994MW24700014
J	BUSCHER, D; DELLOSBARBA, P; HIPSKIND, RA; RAPP, UR; STANLEY, ER; BACCARINI, M				BUSCHER, D; DELLOSBARBA, P; HIPSKIND, RA; RAPP, UR; STANLEY, ER; BACCARINI, M			V-RAF CONFERS CSF-1 INDEPENDENT GROWTH TO A MACROPHAGE CELL-LINE AND LEADS TO IMMEDIATE-EARLY GENE-EXPRESSION WITHOUT MAP-KINASE ACTIVATION	ONCOGENE			English	Article							STIMULATING FACTOR-I; RECOMBINANT MURINE RETROVIRUS; PROTEIN-KINASE; C-FOS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; BINDING-SITES; BONE-MARROW; RECEPTOR	The BAC-1.2F5 macrophage cell line depends on CSF-1 for proliferation and survival. Phosphorylation and activation of the RAF-1 kinase are among the early events in CSF-1 signal transduction. To characterize the role of RAF-1 in CSF-1-induced proliferation, we overexpressed oncogenically activated RAF-1, cellular RAF-1 and RAF-1 kinase-defective mutant proteins in BAC-1.2F5 cells. We were unable to establish stable cell lines expressing either kinase-negative or full length RAF-1 proteins, implying that expression of these molecules is not tolerated in BAC-1.2F5 cells. Oncogenically activated RAF-1 induces CSF-1-independent growth in the absence of autocrine growth factor production. Autonomous growth is not associated with dedifferentiation, since v-raf-expressing macrophages perform the same immunological functions as control cells. Intriguingly, autonomous growth correlates with the suppression of CSF-1-mediated MAP-Kinase activation and with the low constitutive expression of a number of CSF-1-inducible genes, including fos, jun, ets2, and myc, but also the genes for the inflammatory cytokines TNF alpha and IL-1 beta. Many of these genes have AP-1 binding sites in their promoters, and the v-raf-expressing cells contain constitutive AP-1 binding activity. These data indicate that RAF-1, but not MAP-Kinase, is a key component in CSF-1 mitogenic signal transduction, and are consistent with a working hypothesis in which RAF-1 mediates transcriptional activation of genes via AP-1.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,DEPT IMMUNBIOL,HANNOVER,GERMANY; INST MOLEC BIOL,HANNOVER,GERMANY; UNIV FLORENCE,INST GEN PATHOL,FLORENCE,ITALY; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461	Fraunhofer Gesellschaft; University of Florence; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine			Dello Sbarba, Persio/AAX-9887-2020; Stanley, Evan R/J-9154-2013; Baccarini, Manuela/B-6481-2014	Stanley, Evan R/0000-0002-2910-2065; Baccarini, Manuela/0000-0002-3033-391X	NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BACCARINI M, 1990, GROWTH FACTORS DIFFE, P188; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECKER T, 1986, INFECT IMMUN, V54, P477, DOI 10.1128/IAI.54.2.477-486.1986; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIFFORD GE, 1987, J NATL CANCER I, V78, P121, DOI 10.1093/jnci/78.1.121; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOWE LR, 1992, CELL, V71, P535; KALTREIDER HB, 1986, AM REV RESPIR DIS, V133, P1097; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WITSELL AL, 1992, P NATL ACAD SCI USA, V89, P4754, DOI 10.1073/pnas.89.10.4754; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	73	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3323	3332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247534				2022-12-17	WOS:A1993MG78200016
J	SRIVASTAVA, S; WANG, SW; TONG, YA; PIROLLO, K; CHANG, EH				SRIVASTAVA, S; WANG, SW; TONG, YA; PIROLLO, K; CHANG, EH			SEVERAL MUTANT P53 PROTEINS DETECTED IN CANCER-PRONE FAMILIES WITH LI-FRAUMENI SYNDROME EXHIBIT TRANSDOMINANT EFFECTS ON THE BIOCHEMICAL-PROPERTIES OF THE WILD-TYPE P53	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; GERM-LINE; TRANSFORMED-CELLS; SIMIAN VIRUS-40; BREAST-CANCER; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; T-ANTIGEN; MUTATIONS; EXPRESSION	The identification of germ-line mutations in the p53 gene has provided a situation where comparable amounts of wild-type and mutant p53 co-exist in constitutional cells of certain individuals who are cancer-prone. Here we report the biochemical characteristics of several Li-Fraumeni syndrome associated mutant p53 proteins in order to assess the influence of germ-line mutant p53 on the functions of the wild-type p53. Unlike 248W mutant p53 protein, which was previously shown to have no effect on the wild-type p53 conformation (Milner & Medcalf, 1991; Cell 65, 765-774), germ-line associated mutant p53 proteins with residue 133T, 245D or 258K, converted the wild-type p53 conformation into the mutant conformation. Furthermore, lysates containing cotranslated wild-type p53 and these mutant p53 proteins were significantly impaired for DNA and SV40 large T antigen binding. These observations suggest that at least some germ-line p53 mutants might exhibit dominant effects on wild-type p53 functions and, like other mutant p53 proteins, the phenotype of germ-line mt p53 proteins might be variable depending on the particular mutation.	UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	SRIVASTAVA, S (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.			Wang, Shouwen/0000-0001-8484-1795	NATIONAL CANCER INSTITUTE [R29CA046455, R01CA045158] Funding Source: NIH RePORTER; NCI NIH HHS [CA46455, CA45158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BORRESEN AL, 1992, CANCER RES, V52, P3234; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1990, ONCOGENE, V5, P845; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAW JC, 1991, CANCER RES, V51, P6385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	53	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2449	2456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361758				2022-12-17	WOS:A1993LT36800016
J	HJERMSTAD, SJ; PETERS, KL; BRIGGS, SD; GLAZER, RI; SMITHGALL, TE				HJERMSTAD, SJ; PETERS, KL; BRIGGS, SD; GLAZER, RI; SMITHGALL, TE			REGULATION OF THE HUMAN C-FES PROTEIN-TYROSINE KINASE (P93C-FES) BY ITS SRC HOMOLOGY-2 DOMAIN AND MAJOR AUTOPHOSPHORYLATION SITE (TYR-713)	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; FUJINAMI SARCOMA-VIRUS; CYTOPLASMIC SIGNALING PROTEINS; SH2 DOMAINS; V-FES; TRANSFORMING ACTIVITY; CATALYTIC DOMAINS; LEUKEMIA-CELLS; MYELOID CELLS; EXPRESSION	The c-fes proto-oncogene product is expressed predominantly in hematopoietic cells of the myeloid lineage and has been implicated in the regulation of myeloid differentiation. The c-fes locus encodes a 93-kDa protein tyrosine kinase (p93c-fes) that possesses several structural features characteristic of the cytoplasmic class of protein tyrosine kinases, including a consensus sequence for autophosphorylation surrounding Tyr-713 and a src homology 2 (SH2) domain. To assess the effect of each of these potential regulatory sites on p93c-fes protein tyrosine kinase activity, we specifically deleted the c-fes SH2 domain using the polymerase chain reaction and replaced Tyr-713 with phenylalanine by oligonucleotide-directed mutagenesis (Y713F mutant). The resulting mutants were expressed in Escherichia coli and assayed for changes in protein tyrosine kinase activity using an immune complex kinase assay. Both mutations produced a marked decrease in the rate and extent of autophosphorylation and phosphorylation of the model substrate, enolase. To test whether the c-fes SH2 domain could interact with the autophosphorylated kinase domain, the SH2 domain was expressed as a fusion protein with glutathione S-transferase and immobilized on glutathione-agarose. The recombinant c-fes SH2 domain precipitated p93c-fes as readily as a monoclonal antibody. Binding of the SH2 domain to p93c-fes was completely dependent upon autophosphorylation, as a kinase-defective mutant of p93c-fes was not precipitated by the SH2 domain. High-affinity binding was also observed with recombinant SH2 domains from v-src and v-fps, raising the possibility of protein-protein interactions between various members of the cytoplasmic PTK family. These results indicate that the c-fes SH2 domain and consensus autophosphorylation site (Tyr-713) play major roles in the positive regulation of p93c-fes tyrosine kinase activity, possibly through intramolecular interaction.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, 600 S 42ND ST, OMAHA, NE 68198 USA; UNIV NEBRASKA, DEPT BIOCHEM & MOLEC BIOL, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, CANC PHARMACOL SECT, WASHINGTON, DC 20007 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska System; University of Nebraska Medical Center; Georgetown University				Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [NCI P30 CA36727-08, NCI CA 58667, NCI CA 54231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA054231, R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOULET I, 1992, ONCOGENE, V7, P703; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOEFFLER HP, 1981, CANCER RES, V41, P919; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VEILLETTE A, 1992, ONCOGENE, V7, P971; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WOOD ER, 1992, J BIOL CHEM, V267, P14138; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	46	52	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2283	2292						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687763				2022-12-17	WOS:A1993LP17100031
J	FLEMING, TP; MATSUI, T; HEIDARAN, MA; MOLLOY, CJ; ARTRIP, J; AARONSON, SA				FLEMING, TP; MATSUI, T; HEIDARAN, MA; MOLLOY, CJ; ARTRIP, J; AARONSON, SA			DEMONSTRATION OF AN ACTIVATED PLATELET-DERIVED GROWTH-FACTOR AUTOCRINE PATHWAY AND ITS ROLE IN HUMAN TUMOR-CELL PROLIFERATION INVITRO	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; SIS-TRANSFORMED-CELLS; V-SIS; FACTOR RECEPTORS; GENE; EXPRESSION; CDNA; STIMULATION; SURAMIN; CLONING	In tumor cells expressing platelet-derived growth factor (PDGF) ligand(s) and receptor(s), immunoblot analysis established tyrosine phosphorylation of PDGF receptors (PDGFRs) in the absence of any exogenous ligand, implying chronic receptor activation. Exposure to suramin resulted in diminished receptor autophosphorylation and/or up-regulation of receptor protein. In a subset of such tumor lines, there was a marked reduction in DNA synthesis in response to suramin or PDGF-neutralizing antiserum. These findings demonstrate that autocrine PDGF stimulation contributes to proliferation of some human tumors and that agents which interfere with ligand-receptor interactions at the cell surface can significantly interfere in this process.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Molloy, Christopher/A-6821-2013; Matsui, Toshimitsu/E-8065-2010	Molloy, Christopher/0000-0003-2964-6166; Matsui, Toshimitsu/0000-0002-2536-7584				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HELDIN CH, 1990, GROWTH FACTORS DIFFE, P267; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISTER M, 1991, J BIOL CHEM, V266, P16755; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	31	52	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1355	1359						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320245				2022-12-17	WOS:A1992HZ97100014
J	RITTLING, SR; DENHARDT, DT				RITTLING, SR; DENHARDT, DT			P53 MUTATIONS IN SPONTANEOUSLY IMMORTALIZED 3T12 BUT NOT 3T3 MOUSE EMBRYO CELLS	ONCOGENE			English	Article							MALIGNANT TRANSFORMATION; ACTIVATING MUTATIONS; SIMIAN VIRUS-40; GENE-MUTATIONS; RAS ONCOGENE; LUNG-CANCER; FIBROBLASTS; CULTURE; PROTEIN; LINES	We have asked whether p53 mutations are involved in the process of spontaneous immortalization of mouse embryo cells. Cells from Swiss mouse embryos were used to prepare 3T3 and 3T12 lines according to the protocol of Todaro & Green [(1963). J. Cell Biol., 17, 299-313]. After the cells emerged from crisis, p53 sequences were amplified by polymerase chain reaction (PCR) from both RNA and DNA. The sequence of the aggregated cDNA from each of six 3T3 lines showed no evidence of mutation. PCR-amplified p53 cDNA from two 3T3 lines was cloned, and individual clones in M13mp19 were partially sequenced. One cell line showed a single, non-coding nucleotide change in 2/8 independent clones. Nine cDNA clones from the second 3T3 lines were sequenced, and no single nucleotide changes appeared more than once. The mutations which appeared only once were not detected in clones of genomic DNA. Since these apparent mutations are probably reverse transcriptase or Taq polymerase errors, we conclude that both the 3T3 lines contained only wild-type p53. In two out of three independent 3T12 lines however, missense mutations were readily observed in the aggregate cDNA sequence. Restriction fragment length polymorphism and Southern blot analyses of the genomic DNA indicated that these cells were homozygous for the mutations. The p53 protein molecules in four cell lines were analysed by immunoprecipitation: one 3T12 line showed the pattern of antibody reactivity characteristic of some p53 mutants, while the others displayed the wild-type pattern. We conclude that p53 mutations arise and are strongly selected for during immortalization according to the 3T12 but not the 3T3 protocol.			RITTLING, SR (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,POB 1059,PISCATAWAY,NJ 08855, USA.				NIA NIH HHS [AG07972] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007972] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AARONSON SA, 1968, SCIENCE, V162, P24; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AUSUBEL FM, 1989, JCURRENT PROTOCOLS M; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CHIBA I, 1990, ONCOGENE, V5, P1603; CURATOLO L, 1984, IN VITRO CELL DEV B, V20, P597; DENHARDT DT, 1991, EXP CELL RES, V192, P128, DOI 10.1016/0014-4827(91)90167-S; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KELMAN Z, 1989, BLOOD, V74, P2318; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACIEIRACOELHO A, 1976, GERONTOLOGY, V22, P3, DOI 10.1159/000212121; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	52	52	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					935	942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349164				2022-12-17	WOS:A1992HP64200013
J	SCHROEDER, C; GIBSON, L; BEUG, H				SCHROEDER, C; GIBSON, L; BEUG, H			THE V-ERBA ONCOGENE REQUIRES COOPERATION WITH TYROSINE KINASES TO ARREST ERYTHROID-DIFFERENTIATION INDUCED BY LIGAND-ACTIVATED ENDOGENOUS C-ERBA AND RETINOIC ACID RECEPTOR	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR RECEPTOR; LEUKEMIA VIRUSES; GENE-EXPRESSION; CELLS; PROTEIN; TRANSFORMATION; TRANSCRIPTION	The v-erbA oncogene, a mutated version of the thyroid hormone receptor alpha (c-erbA/TR-alpha), cooperates with tyrosine kinase oncogenes in erythroblast transformation. Here we show that the ligand-activated, endogenous retinoic acid receptor (RAR-alpha), in cooperation with c-erbA/TR-alpha, efficiently reverses the transforming effect of kinase oncogenes, overcoming oncogene-induced self-renewal by triggering terminal differentiation of the transformed cells into healthy erythrocytes. This differentiation induction was accompanied by up-regulation of erythrocyte gene expression. Similarly, RAR-alpha and overexpressed exogenous c-erbA/TR-alpha efficiently abolished the differentiation arrest caused by v-erbA, while the low levels of endogenous TR-alpha had no effect. In contrast, transformation by v-erbA plus a kinase oncogene was not affected at all by ligand-activated endogenous or overexpressed exogenous TR-alpha and RAR-alpha. These results suggest that oncogene cooperation is required to protect leukemic erythroblasts from differentiation induction via endogenous, nuclear hormone receptors. Endogenous c-erbA/TR-alpha and RAR-alpha apparently cooperated in abolishing erythroblast self-renewal and inducing differentiation, since the respective ligands acted in a synergistic fashion, and overexpressed, non-ligand-bound c-erbA/TR-alpha suppressed endogenous RAR-alpha function in differentiation induction. Genetic evidence is presented that this functional cooperation requires the receptor dimerization domain, suggesting that TR-alpha/RAR-alpha heterodimers play a role in regulation of erythroid differentiation.	INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Gibson, Leonie/AAM-5917-2021	Gibson, Leonie/0000-0002-0904-8145				BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1985, PROC R SOC SER B-BIO, V226, P121, DOI 10.1098/rspb.1985.0086; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BEUG H, 1991, MYERS S NUCLEAR PROC, V15; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HOUSMAN D, 1980, COLD SPRING HARB SYM, V44, P1177, DOI 10.1101/SQB.1980.044.01.127; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Maniatis T., 1982, MOL CLONING; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROSS J, 1976, CELL, V8, P513, DOI 10.1016/0092-8674(76)90219-1; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	48	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					203	216						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347913				2022-12-17	WOS:A1992HG98200002
J	BLACK, EJ; STREET, AJ; GILLESPIE, DAF				BLACK, EJ; STREET, AJ; GILLESPIE, DAF			PROTEIN PHOSPHATASE 2A REVERSES PHOSPHORYLATION OF C-JUN SPECIFIED BY THE DELTA DOMAIN INVITRO - CORRELATION WITH ONCOGENIC ACTIVATION AND DEREGULATED TRANSACTIVATION ACTIVITY OF V-JUN	ONCOGENE			English	Article							OKADAIC ACID; AP-1; FOS; TRANSFORMATION; INHIBITOR; ENCODES	Chicken c-Jun proteins synthesized in vitro in reticulocyte extract consist of several electrophoretic isoforms resulting from phosphorylation which can be specifically reversed by purified protein phosphatase 2A (PP2A). Using the phosphatase inhibitors okadaic acid and microcystin-LR, we conclude that the isoforms seen in vitro represent a balance between the action of an unidentified kinase(s) which phosphorylates c-Jun and dephosphorylation by an endogenous PP2A-like phosphatase. c-Jun proteins are also subject to phosphorylation in vivo in chick embryo fibroblasts (CEF), which can be reversed by PP2A. In contrast, the viral Jun oncoprotein encoded by ASV17 is not subject to PP2A-sensitive phosphorylation in vitro and is hypophosphorylated in comparison with c-Jun in ASV17-transformed CEF. Hybrids between c-Jun and v-Jun demonstrate that differential phosphorylation in vitro is a consequence of deletion of 27 amino acids in the N-terminal third of v-Jun. The deletion is important for oncogenic activation and lies in a domain, termed delta, which regulates c-Jun transactivation function. PP2A-sensitive phosphorylation in vitro correlates with the differential responsiveness of c-Jun and v-Jun to a recently identified cell type-specific inhibitor of transactivation function.	BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND; UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, MRC PROTEIN PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	Beatson Institute; University of Dundee			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1987, ONCOGENE, V2, P79; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1989, MOL CELL BIOL, V9, P865, DOI 10.1128/MCB.9.2.865; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768	24	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1949	1958						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658706				2022-12-17	WOS:A1991GX11900002
J	BORDEREAUX, D; FICHELSON, S; TAMBOURIN, P; GISSELBRECHT, S				BORDEREAUX, D; FICHELSON, S; TAMBOURIN, P; GISSELBRECHT, S			ALTERNATIVE SPLICING OF THE EVI-1 ZINC FINGER GENE GENERATES MESSENGER-RNAS WHICH DIFFER BY THE NUMBER OF ZINC FINGER MOTIFS	ONCOGENE			English	Note									HOP COCHIN,INSERM,U152,IMMUNOL & ONCOL MALAD RETROVIRALES LAB,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CUYPERS HT, 1984, CELL, V37, P141; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HEARD JM, 1983, INT J CANCER, V32, P237, DOI 10.1002/ijc.2910320216; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; SOLA B, 1988, J VIROL, V62, P3973, DOI 10.1128/JVI.62.11.3973-3978.1988; SOLA B, 1986, J VIROL, V60, P718, DOI 10.1128/JVI.60.2.718-725.1986; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	19	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					925	927						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2113669				2022-12-17	WOS:A1990DP55300021
J	HERZOG, NK; SINGH, B; ELDER, J; LIPKIN, I; TRAUGER, RJ; MILLETTE, CF; GOLDMAN, DS; WOLFES, H; COOPER, GM; ARLINGHAUS, RB				HERZOG, NK; SINGH, B; ELDER, J; LIPKIN, I; TRAUGER, RJ; MILLETTE, CF; GOLDMAN, DS; WOLFES, H; COOPER, GM; ARLINGHAUS, RB			IDENTIFICATION OF THE PROTEIN PRODUCT OF THE C-MOS PROTO-ONCOGENE IN MOUSE TESTES	ONCOGENE			English	Article									SCRIPPS CLIN & RES FDN, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT ANAT & CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Scripps Research Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	HERZOG, NK (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015269] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NICHD NIH HHS [HD15269] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BLOUNT P, 1986, BRAIN RES, V382, P257, DOI 10.1016/0006-8993(86)91335-1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HUNTER T, 1986, ENZYMES, V17, P192; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SWAN D, 1982, J VIROL, V44, P752, DOI 10.1128/JVI.44.2.752-754.1982; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	24	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1988	3	2					225	229						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2970613				2022-12-17	WOS:A1988Q053400015
J	JANSSON, M; BEUG, H; GRAY, C; GRAF, T; VENNSTROM, B				JANSSON, M; BEUG, H; GRAY, C; GRAF, T; VENNSTROM, B			DEFECTIVE V-ERBB GENES CAN BE COMPLEMENTED BY V-ERBA IN ERYTHROBLAST AND FIBROBLAST TRANSFORMATION	ONCOGENE			English	Article											JANSSON, M (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,MEYERHOFSTR 1,D-6900 HEIDELBERG,FED REP GER.		Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1985, MODERN TRENDS HUMAN, V6, P290; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAHN P, 1986, IN PRESS MODERN TREN, V7; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; MANIATIS T, 1982, MOL CLONING LABORATO; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; PALMIERI S, 1982, VIROLOGY, V123, P296, DOI 10.1016/0042-6822(82)90263-X; PETTERSSON RF, 1983, GENE, V24, P15, DOI 10.1016/0378-1119(83)90127-0; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; ROYERPOKORA B, 1979, NATURE, V282, P750, DOI 10.1038/282750a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X	33	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					167	173						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2830578				2022-12-17	WOS:A1987J635200009
J	Xia, X; Wang, SC; Ni, B; Xing, SP; Cao, H; Zhang, ZZ; Yu, FR; Zhao, EH; Zhao, G				Xia, Xiang; Wang, Shuchang; Ni, Bo; Xing, Shunpeng; Cao, Hui; Zhang, Zizhen; Yu, Fengrong; Zhao, Enhao; Zhao, Gang			Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1 alpha positive feedback loop	ONCOGENE			English	Article							CELL-PROLIFERATION; INDUCIBLE FACTORS; INVASION; VESICLES; PLASMA; RNAS	Hypoxic tumor microenvironment(TME) is a universal feature in solid carcinoma and is associated with unfavorable prognosis. Tumor-derived exosomes are now significantly implicating in mediating cellular communication and interactions in TME. The aim of this study was to identify exosomal miR-301a-3p involved in gastric cancer(GC) progression and metastasis. Here, we found hypoxia promote GC exosomes release and miR-301a-3p expression in an HIF-1 alpha-dependent manner. In hypoxic TME, enriched miR-301a-3p could be transmitted between GC cells via exosomes and then contributed to inhibit HIF-1 alpha degradation through targeting PHD3, that were capable to hydroxylate HIF-1 alpha subunits to ubiquitinate degradation. This synergistical positive feedback loop between HIF-1 alpha and miR-301a-3p facilitated GC proliferation, invasion, migration, and epithelial-mesenchymal transition. In clinical samples, we further discovered circulating exosomal miR-301a-3p in serum was positively related with peritoneal metastasis. Collectively, these data indicate that GC cells could generate miR-301a-3p-rich exosomes in the hypoxic TME, which then help to HIF-1 alpha accumulation and promote GC malignant behaviors and metastasis. Exosomal miR-301a-3p/HIF-1 alpha signaling axis may serve as a promising predictor and potential therapeutic target of GC with metastasis.	[Xia, Xiang; Wang, Shuchang; Ni, Bo; Cao, Hui; Zhang, Zizhen; Yu, Fengrong; Zhao, Enhao; Zhao, Gang] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China; [Xing, Shunpeng] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Crit Care, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, FR; Zhao, EH; Zhao, G (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China.	yufengrongrj@163.com; zhaoenhao@renji.com; zhaogangrj@163.com			National Natural Science Foundation of China [81802313, 81972206]; Shanghai Sailing Program [17YF1415700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program	The National Natural Science Foundation of China (grant numbers: 81802313 and 81972206). Shanghai Sailing Program (Grant No. 17YF1415700). The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in the writing of the manuscript.	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Binenbaum Y, 2018, CANCER RES, V78, P5287, DOI 10.1158/0008-5472.CAN-18-0124; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Dassler-Plenker J, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188340; Fan Q, 2018, CANCER LETT, V414, P107, DOI 10.1016/j.canlet.2017.10.040; Ge XX, 2016, ONCOTARGET, V7, P24466, DOI 10.18632/oncotarget.8228; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Hu JH, 2018, PATHOL RES PRACT, V214, P2039, DOI 10.1016/j.prp.2018.09.008; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Khan MI, 2018, SEMIN CANCER BIOL, V49, P75, DOI 10.1016/j.semcancer.2017.05.008; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kroh EM, 2010, METHODS, V50, P298, DOI 10.1016/j.ymeth.2010.01.032; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Li XJ, 2018, CANCER LETT, V418, P211, DOI 10.1016/j.canlet.2018.01.031; Lordick F, 2017, ANN ONCOL, V28, P1767, DOI 10.1093/annonc/mdx051; Meng WR, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0982-6; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shao CC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0869-y; Strowitzki MJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050384; Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang M, 2013, J GASTROENTEROL, V48, P1023, DOI 10.1007/s00535-012-0733-6; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wang Z, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1761-y; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Xia X, 2017, AM J TRANSL RES, V9, P1886; Xia X, 2015, ONCOTARGET, V6, P21046, DOI 10.18632/oncotarget.4124; Xie F, 2019, ADV SCI, V6, DOI 10.1002/advs.201901779; Yin J, 2019, J CANCER, V10, P5964, DOI 10.7150/jca.35704; Yue X, 2019, MOL THER, V27, P1939, DOI 10.1016/j.ymthe.2019.07.011; Zong L, 2016, LANCET, V388, P2606, DOI 10.1016/S0140-6736(16)32226-7	46	51	55	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6231	6244		10.1038/s41388-020-01425-6	http://dx.doi.org/10.1038/s41388-020-01425-6		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32826951				2022-12-17	WOS:000561519300002
J	Guterres, AN; Villanueva, J				Guterres, Adam N.; Villanueva, Jessie			Targeting telomerase for cancer therapy	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; REVERSE-TRANSCRIPTASE; INHIBITOR IMETELSTAT; PEPTIDE VACCINE; BETA-1L ISOFORM; LUNG-CANCER; IN-VIVO; RECRUITMENT; LENGTH; CELLS	Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer cells which enables replicative immortality. In contrast, telomerase activity is silenced in most adult somatic cells. Thus, telomerase represents an attractive target for highly selective cancer therapeutics. However, development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. The discovery of prevalent mutations in theTERTpromoter region in many cancers and recent advances in telomerase biology has led to a renewed interest in targeting this enzyme. Here we discuss recent efforts targeting telomerase, including immunotherapies and direct telomerase inhibitors, as well as emerging approaches such as targetingTERTgene expression driven byTERTpromoter mutations. We also address some of the challenges to telomerase-directed therapies including potential therapeutic resistance and considerations for future therapeutic applications and translation into the clinical setting. Although much work remains to be done, effective strategies targeting telomerase will have a transformative impact for cancer therapy and the prospect of clinically effective drugs is boosted by recent advances in structural models of human telomerase.	[Guterres, Adam N.; Villanueva, Jessie] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Villanueva, Jessie] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute	Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.; Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	jvillanueva@wistar.org			NIH [R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815]; Department of Defense Melanoma Research Program [W81XWH-20-1-0356]; PA Department of Health; Martha W. Rogers Trust	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Melanoma Research Program; PA Department of Health; Martha W. Rogers Trust	L Work in our laboratory is supported by NIH grants R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815, the Department of Defense Melanoma Research Program (W81XWH-20-1-0356), the PA Department of Health and Martha W. Rogers Trust.	Akincilar SC, 2016, CANCER DISCOV, V6, P1276, DOI 10.1158/2159-8290.CD-16-0177; Armanios M, 2015, NEW ENGL J MED, V373, P965, DOI 10.1056/NEJMe1508740; Asai A, 2003, CANCER RES, V63, P3931; Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; Aviv A, 2017, TRENDS CANCER, V3, P253, DOI 10.1016/j.trecan.2017.02.005; Baell JB, 2016, J NAT PROD, V79, P616, DOI 10.1021/acs.jnatprod.5b00947; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Baerlocher GM, 2015, NEW ENGL J MED, V373, P920, DOI 10.1056/NEJMoa1503479; Bandaria JN, 2016, CELL, V164, P735, DOI 10.1016/j.cell.2016.01.036; Barthel FP, 2017, NAT GENET, V49, P349, DOI 10.1038/ng.3781; Bejarano L, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910292; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/NCHEM.1548, 10.1038/nchem.1548]; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan C, 2015, STRUCTURE, V23, P1934, DOI 10.1016/j.str.2015.08.006; Bullock M, 2019, THYROID, V29, P1623, DOI 10.1089/thy.2018.0314; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Chen L, 2018, CELL, V174, P218, DOI 10.1016/j.cell.2018.04.039; Chiappori AA, 2015, ANN ONCOL, V26, P354, DOI 10.1093/annonc/mdu550; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dilley RL, 2015, TRENDS CANCER, V1, P145, DOI 10.1016/j.trecan.2015.07.007; Drosopoulos WC, 2015, J CELL BIOL, V210, P191, DOI 10.1083/jcb.201410061; Duperret EK, 2018, MOL THER, V26, P435, DOI 10.1016/j.ymthe.2017.11.010; El-Daly H, 2005, BLOOD, V105, P1742, DOI 10.1182/blood-2003-12-4322; Gabler L, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0775-6; Garcia-Beccaria M, 2015, EMBO MOL MED, V7, P930, DOI 10.15252/emmm.201404497; Gillis AJ, 2008, NATURE, V455, P633, DOI 10.1038/nature07283; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, P949; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2003, MOL CELL BIOL, V23, P8450, DOI 10.1128/MCB.23.23.8450-8461.2003; Haycock PC, 2017, JAMA ONCOL, V3, P636, DOI 10.1001/jamaoncol.2016.5945; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2005, CLIN CANCER RES, V11, P217; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Jiang JS, 2018, CELL, V173, P1179, DOI 10.1016/j.cell.2018.04.038; Kanaya N, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-2744; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kim NW, 1994, SCIENCE, P266; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Kinde I, 2013, CANCER RES, V73, P7162, DOI 10.1158/0008-5472.CAN-13-2498; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Labussiere M, 2014, NEUROLOGY, V83, P1200, DOI 10.1212/WNL.0000000000000814; Lai TP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01291-z; Lee DD, 2019, J CLIN INVEST, V129, P223, DOI 10.1172/JCI121303; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Li YH, 2015, NAT CELL BIOL, V17, P1327, DOI 10.1038/ncb3240; Lilleby W, 2017, CANCER IMMUNOL IMMUN, V66, P891, DOI 10.1007/s00262-017-1994-y; Liu RY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03033-1; Liu W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04254-0; Ludlow AT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05582-x; Makowski MM, 2016, PROTEOMICS, V16, P417, DOI 10.1002/pmic.201500327; Mancini A, 2018, CANCER CELL, V34, P513, DOI 10.1016/j.ccell.2018.08.003; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; McKerlie M, 2012, NUCLEIC ACIDS RES, V40, P3975, DOI 10.1093/nar/gks035; Mender I, 2018, NEOPLASIA, V20, P826, DOI 10.1016/j.neo.2018.06.002; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Middleton G, 2014, LANCET ONCOL, V15, P829, DOI 10.1016/S1470-2045(14)70236-0; Min J, 2017, NUCLEIC ACIDS RES, V45, P2615, DOI 10.1093/nar/gkw1295; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Moye AL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8643; Mukherjee J, 2018, CANCER RES, V78, P2966, DOI 10.1158/0008-5472.CAN-17-2269; Nakashima M, 2013, J BIOL CHEM, V288, P33171, DOI 10.1074/jbc.M113.518175; Nandakumar J, 2012, NATURE, V492, P285, DOI 10.1038/nature11648; Napier CE, 2015, ONCOTARGET, V6, P16543, DOI 10.18632/oncotarget.3846; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262; Nitta E, 2011, BLOOD, V117, P4169, DOI 10.1182/blood-2010-08-297390; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; O'Sullivan RJ, 2014, NAT STRUCT MOL BIOL, V21, P167, DOI 10.1038/nsmb.2754; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Perera ON, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4409; Peto R, 2016, INT J EPIDEMIOL, V45, P621, DOI 10.1093/ije/dyv199; Ramamoorthy M, 2015, CANCER CELL, V28, P357, DOI 10.1016/j.ccell.2015.08.003; Raval A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131722; Reyes-Uribe P, 2018, ONCOGENE, V37, P4058, DOI 10.1038/s41388-018-0247-7; Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004; Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377; Sandri S, 2016, CANCER RES, V76, P2540, DOI 10.1158/0008-5472.CAN-15-2318; Sauerwald A, 2013, NAT STRUCT MOL BIOL, V20, P454, DOI 10.1038/nsmb.2530; Sayed ME, 2019, ONCOGENE, V38, P2937, DOI 10.1038/s41388-018-0639-8; Schmidt JC, 2015, GENE DEV, V29, P1095, DOI 10.1101/gad.263863.115; Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086; Sengupta S, 2018, MOL CANCER THER, V17, P1504, DOI 10.1158/1535-7163.MCT-17-0792; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shain AH, 2018, CANCER CELL, V34, pe4; Song YS, 2019, ENDOCR-RELAT CANCER, V26, P629, DOI 10.1530/ERC-17-0562; Spahr H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04388-1; Spiegl-Kreinecker S, 2018, NEURO-ONCOLOGY, V20, P1584, DOI 10.1093/neuonc/noy104; Stern JL, 2012, MOL CELL BIOL, V32, P2384, DOI 10.1128/MCB.00379-12; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; Sun CK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-180; Tauchi T, 2006, ONCOGENE, V25, P5719, DOI 10.1038/sj.onc.1209577; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Nguyen THD, 2018, NATURE, V557, P190, DOI 10.1038/s41586-018-0062-x; Thompson PA, 2013, CLIN CANCER RES, V19, P6578, DOI 10.1158/1078-0432.CCR-13-1117; Tong AS, 2015, CELL REP, V13, P1633, DOI 10.1016/j.celrep.2015.10.041; Ugel S, 2010, BLOOD, V115, P1374, DOI 10.1182/blood-2009-07-233270; Vallarelli AF, 2016, ONCOTARGET, V7, P53127, DOI 10.18632/oncotarget.10634; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Vonderheide RH, 2002, ONCOGENE, V21, P674, DOI 10.1038/sj.onc.1205074; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Xue HH, 2008, MOL CELL BIOL, V28, P4300, DOI 10.1128/MCB.01855-07; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Yuan XT, 2019, ONCOGENE, V38, P965, DOI 10.1038/s41388-018-0483-x; Zanetti M, 2017, NAT REV CLIN ONCOL, V14, P115, DOI 10.1038/nrclinonc.2016.67; Zeng XH, 2018, CELL REP, V23, P3031, DOI 10.1016/j.celrep.2018.05.020; Zhang CA, 2015, HUM MOL GENET, V24, P5356, DOI 10.1093/hmg/ddv252; Zhang G, 2018, CLIN CANCER RES, V24, P4771, DOI 10.1158/1078-0432.CCR-17-2773; Zhu X, 2016, SCI REP, V6, P518	127	51	51	12	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5811	5824		10.1038/s41388-020-01405-w	http://dx.doi.org/10.1038/s41388-020-01405-w		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32733068	Green Accepted			2022-12-17	WOS:000557084000002
J	Wolf, MM; Rathmell, WK; Beckermann, KE				Wolf, Melissa M.; Rathmell, W. Kimryn; Beckermann, Kathryn E.			Modeling clear cell renal cell carcinoma and therapeutic implications	ONCOGENE			English	Review							HYPOXIA-INDUCIBLE FACTORS; IN-VITRO; ANTIANGIOGENIC THERAPY; TUMOR ANGIOGENESIS; MAMMALIAN TARGET; XENOGRAFT MODELS; ORGANOID MODELS; GENETIC-BASIS; MOUSE MODELS; CANCER	Renal cell carcinoma (RCC) comprises a diverse group of malignancies arising from the nephron. The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by genetic mutations in factors governing the hypoxia signaling pathway, resulting in metabolic dysregulation, heightened angiogenesis, intratumoral heterogeneity, and deleterious tumor microenvironmental (TME) crosstalk. Identification of specific genetic variances has led to therapeutic innovation and improved survival for patients with ccRCC. Current barriers to effective long-term therapeutic success highlight the need for continued drug development using improved modeling systems. ccRCC preclinical models can be grouped into three broad categories: cell line, mouse, and 3D models. Yet, the breadth of important unanswered questions in ccRCC research far exceeds the accessibility of model systems capable of carrying them out. Accordingly, we review the strengths, weaknesses, and therapeutic implications of each model system that are relied upon today.	[Wolf, Melissa M.; Rathmell, W. Kimryn; Beckermann, Kathryn E.] Vanderbilt Univ, Dept Med, Div Hematol & Oncol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Beckermann, KE (corresponding author), Vanderbilt Univ, Dept Med, Div Hematol & Oncol, Med Ctr, Nashville, TN 37232 USA.	katy.beckermann@vumc.org		M Wolf, Melissa/0000-0003-2038-6978	NCI NIH HHS [K12 CA090625] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [5K12CA090625-19] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)		Bailey ST, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15770; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Baumans V, 2004, GENE THER, V11, pS64, DOI 10.1038/sj.gt.3302371; Beckermann KE, 2017, EXPERT REV CLIN IMMU, V13, P77, DOI 10.1080/1744666X.2016.1214575; Beksac AT, 2017, UROL ONCOL-SEMIN ORI, V35, P507, DOI 10.1016/j.urolonc.2017.05.006; Berlato C, 2017, J CLIN INVEST, V127, P801, DOI 10.1172/JCI82976; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Bouchard M, 2004, GENESIS, V38, P105, DOI 10.1002/gene.20008; Brodaczewska KK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0565-8; Brooks SA, 2014, EUR UROL, V66, P77, DOI 10.1016/j.eururo.2014.02.035; Bult CJ, 2019, NUCLEIC ACIDS RES, V47, pD801, DOI 10.1093/nar/gky1056; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Chappell JC, 2019, J CLIN INVEST, V129, P442, DOI 10.1172/JCI120855; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen QF, 2019, TRANSL ONCOL, V12, P987, DOI 10.1016/j.tranon.2019.04.020; Cheval L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046876; Chiang YC, 2018, CANCER RES, V78, P3135, DOI 10.1158/0008-5472.CAN-17-3460; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cuenod CA, 2006, ABDOM IMAGING, V31, P188, DOI 10.1007/s00261-005-0386-5; de Cubas AA, 2018, NAT REV UROL, V15, P599, DOI 10.1038/s41585-018-0052-7; de Velasco G, 2017, ONCOLOGIST, V22, P286, DOI 10.1634/theoncologist.2016-0078; Devaud C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108670; Dong, 2017, NAT COMMUN, V8; Dong YY, 2017, EUR UROL FOCUS, V3, P590, DOI 10.1016/j.euf.2016.08.005; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Espana-Agusti J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02245-1; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Finnberg NK, 2017, ONCOTARGET, V8, P66747, DOI 10.18632/oncotarget.19965; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Frew IJ, 2015, ANNU REV PATHOL-MECH, V10, P263, DOI 10.1146/annurev-pathol-012414-040306; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghatalia P, 2018, KIDNEY CANCER, V2, P23, DOI 10.3233/KCA-170021; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gioanni J, 1996, B CANCER, V83, P553; Grassi L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1453-0; Grisanzio C, 2011, J PATHOL, V225, P212, DOI 10.1002/path.2929; Gu YF, 2017, CANCER DISCOV, V7, P900, DOI 10.1158/2159-8290.CD-17-0292; Haake SM, 2017, CANCER-AM CANCER SOC, V123, P200, DOI 10.1002/cncr.30314; Haake SM, 2016, MOL CANCER RES, V14, P589, DOI 10.1158/1541-7786.MCR-16-0115; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harlander S, 2017, NAT MED, V23, P869, DOI 10.1038/nm.4343; Harshman LC, 2014, CLIN GENITOURIN CANC, V12, P335, DOI 10.1016/j.clgc.2014.03.003; Hartmann JT, 1999, ANTICANCER RES, V19, P1541; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Huang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068293; Hudes GR, 2009, CANCER, V115, P2313, DOI 10.1002/cncr.24239; Ideno N, 2019, LAB INVEST, V99, P1233, DOI 10.1038/s41374-018-0171-z; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Klinghammer K, 2017, CANCER TREAT REV, V55, P36, DOI 10.1016/j.ctrv.2017.02.009; Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kondo K, 2001, INT J CANCER, V91, P219, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S; KORHONEN M, 1994, CANCER RES, V54, P4532; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302; Lai YX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0470-7; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Magnen C, 2016, NAT REV CANCER, V16, P187, DOI 10.1038/nrc.2016.1; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee CM, 2009, ONCOGENE, V28, P1694, DOI 10.1038/onc.2009.12; Lee CH, 2017, NAT REV NEPHROL, V13, P69, DOI 10.1038/nrneph.2016.194; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Liao LL, 2015, CANCER GENET-NY, V208, P206, DOI 10.1016/j.cancergen.2015.02.008; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131; Lopez-Beltran A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00456; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Patel A, 2019, TRANSL ANDROL UROL, V8, pS156, DOI 10.21037/tau.2018.11.04; Pavia-Jimenez A, 2014, NAT PROTOC, V9, P1848, DOI 10.1038/nprot.2014.108; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pichler R, 2019, CANCERS, V11, DOI 10.3390/cancers11030422; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; PROCHAZKA M, 1992, P NATL ACAD SCI USA, V89, P3290, DOI 10.1073/pnas.89.8.3290; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Ricketts CJ, 2018, CELL REP, V23, P313, DOI [10.1016/j.celrep.2018.03.075, 10.1016/j.celrep.2018.06.032]; Rini B, 2015, LANCET ONCOL, V16, P676, DOI 10.1016/S1470-2045(15)70167-1; Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719; Rini BI, 2019, NEW ENGL J MED, V380, P2582, DOI 10.1056/NEJMc1905518; Rini BI, 2018, CLIN CANCER RES, V24, P4407, DOI 10.1158/1078-0432.CCR-18-0323; Rojas JD, 2019, IEEE T BIO-MED ENG, V66, P873, DOI 10.1109/TBME.2018.2860932; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Sanchez DJ, 2018, BBA-REV CANCER, V1870, P23, DOI 10.1016/j.bbcan.2018.06.003; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Santoni Matteo, 2018, Drugs Context, V7, P212528, DOI 10.7573/dic.212528; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schokrpur S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29032; Schor-Bardach R, 2009, RADIOLOGY, V251, P731, DOI 10.1148/radiol.2521081059; Schuetz AN, 2005, J MOL DIAGN, V7, P206, DOI 10.1016/S1525-1578(10)60547-8; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016444.90348.50; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Shuch B, 2015, EUR UROL, V67, P85, DOI 10.1016/j.eururo.2014.04.029; Shvarts O, 2006, UROLOGY, V68, P1132, DOI 10.1016/j.urology.2006.08.1073; Sivanand S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003643; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tiriac H, 2018, GASTROINTEST ENDOSC, V87, P1474, DOI 10.1016/j.gie.2017.12.032; Tratar UL, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00268; Turajlic S, 2018, CELL, V173, P595, DOI 10.1016/j.cell.2018.03.043; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Vallon V, 2001, J AM SOC NEPHROL, V12, P2003, DOI 10.1681/ASN.V12102003; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; WALLACE AC, 1972, CANCER, V29, P977, DOI 10.1002/1097-0142(197204)29:4<977::AID-CNCR2820290444>3.0.CO;2-P; Wang SS, 2014, P NATL ACAD SCI USA, V111, P16538, DOI 10.1073/pnas.1414789111; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Wiltrout RH, 1991, IMMUNOTHERAPY RENAL, P13; YAO M, 1988, CANCER RES, V48, P6753; Young MD, 2018, SCIENCE, V361, P594, DOI 10.1126/science.aat1699; Zhao CX, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0419-4; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	137	51	51	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3413	3426		10.1038/s41388-020-1234-3	http://dx.doi.org/10.1038/s41388-020-1234-3		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123314	Green Accepted			2022-12-17	WOS:000517738400002
J	Zhang, CY; Wang, HM; Liu, XM; Hu, YP; Ding, L; Zhang, X; Sun, QL; Li, YL				Zhang, Caiyan; Wang, Huimin; Liu, Xiaomin; Hu, Yanping; Ding, Lei; Zhang, Xing; Sun, Qiangling; Li, Yanli			Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; DOWN-REGULATION; STEM-CELLS; SPROUTY4; PROLIFERATION; MIGRATION; INVASION; PATHWAY; CONTRIBUTES; METHYLATION	Lung cancer is one of the most common malignant diseases globally, composed of non-small cell lung cancer (NSCLC, 85%) and small cell lung cancer (SCLC, 15%). MicroRNAs (miRNAs) are single-stranded noncoding RNAs having important roles in lung cancer development. miR-411-5p/3p were reported to be increased significantly in human NSCLC tissues and cell lines. Moreover, miR-411-5p/3p overexpression could accelerate cell proliferation and migration, and impede cell apoptosis in NSCLC cell lines. Mechanically, SPRY4 is confirmed a direct target of miR-411-5p/3p. Furthermore, our findings showed that miR-411-5p/3p promoted lung tumor growth in vivo, decreased SPRY4 expression dramatically, and induced EGFR, AKT signaling activation, as well as epithelial-mesenchymal transition (EMT) simultaneously in tumor tissues. In addition, we showed that miR-411-5p also targeted tumor suppressor TXNIP, involved in regulating positively cell cycle progress in SPC-A1 cells rather than in H1299. Whether cell specificity of low TXNIP mRNA level in H1299 is responsible for the different response to cell cycle between H1299 and SPC-A1 would need further explorations. Collectively, these results suggest that miR-411-5p/3p are required for NSCLC development by suppressing SPRY4 and TXNIP; thus, the miR-411-SPRY4-AKT axis might act as a promising target for lung cancer therapy clinically.	[Zhang, Caiyan; Wang, Huimin; Hu, Yanping; Ding, Lei; Li, Yanli] Shanghai Univ, Sch Life Sci, Lab Noncoding RNA & Canc, Shanghai 200444, Peoples R China; [Liu, Xiaomin; Zhang, Xing] Shanghai Univ, Sch Environm Sci & Engn, Shanghai 200444, Peoples R China; [Hu, Yanping] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China; [Sun, Qiangling] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Cent Lab, Shanghai 200030, Peoples R China	Shanghai University; Shanghai University; China Pharmaceutical University; Shanghai Jiao Tong University	Li, YL (corresponding author), Shanghai Univ, Sch Life Sci, Lab Noncoding RNA & Canc, Shanghai 200444, Peoples R China.	liyanli@shu.edu.cn	li, yanli/AAT-2012-2021; wang, hui/GRS-4730-2022; wang, huimin/HDM-8421-2022	li, yanli/0000-0002-2936-0339; DING, LEI/0000-0001-9556-9635; Zhang, Xing/0000-0003-4680-5085	NNSFC (National Natural Science Foundation of China) [91543123]	NNSFC (National Natural Science Foundation of China)(National Natural Science Foundation of China (NSFC))	This work is supported by NNSFC (National Natural Science Foundation of China, Training Program of the Major Research Plan) No. 91543123	Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Carter CA, 2016, CASE REP ONCOL, V9, P62, DOI 10.1159/000443725; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008-5472.CAN-16-1115; Cherni I, 2011, FUTURE ONCOL, V7, P1045, DOI [10.2217/FON.11.74, 10.2217/fon.11.74]; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Guo LF, 2016, MOL MED REP, V14, P2975, DOI 10.3892/mmr.2016.5645; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Heinrich EM, 2012, CIRC RES, V110, P1014, DOI 10.1161/CIRCRESAHA.111.243394; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Jiang L, 2016, INFLAMM RES, V65, P905, DOI 10.1007/s00011-016-0973-7; Jing HY, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0292-7; Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Li YL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.50; Li Yan, 2015, Asian Pac J Cancer Prev, V16, P2953; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Nadal E, 2014, CLIN CANCER RES, V20, P3107, DOI 10.1158/1078-0432.CCR-13-3348; Nie WW, 2015, ONCOTARGET, V6, P3003, DOI 10.18632/oncotarget.3096; Peter ME, 2010, CELL STEM CELL, V6, P4, DOI 10.1016/j.stem.2009.12.006; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Scrima M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030427; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; So WK, 2016, TUMOR BIOL, V37, P9197, DOI 10.1007/s13277-016-4790-y; Spangle JM, 2016, CELL REP, V15, P2692, DOI 10.1016/j.celrep.2016.05.046; Sun M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.225; Tennis MA, 2010, MOL CANCER RES, V8, P833, DOI 10.1158/1541-7786.MCR-09-0400; van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127; Vanas V, 2014, TUMOR BIOL, V35, P4447, DOI 10.1007/s13277-013-1587-0; Wang GD, 2015, AM J TRANSL RES, V7, P2000; Wang JH, 2006, PROSTATE, V66, P613, DOI 10.1002/pros.20353; Wang P, 2017, ONCOTARGET, V8, P57012, DOI 10.18632/oncotarget.18505; Wei M, 2017, ONCOTARGET, V8, P5323, DOI 10.18632/oncotarget.14142; Wu JY, 2017, CANCER LETT, V400, P18, DOI 10.1016/j.canlet.2017.04.021; Xia KK, 2015, BIOMED PHARMACOTHER, V70, P158, DOI 10.1016/j.biopha.2015.01.001; Yamamoto K, 2014, ONCOL REP, V32, P2365, DOI 10.3892/or.2014.3481; Zhang YD, 2016, BIOCHEM BIOPH RES CO, V476, P607, DOI 10.1016/j.bbrc.2016.06.006; Zhao ZJ, 2016, TUMOR BIOL, V37, P5551, DOI 10.1007/s13277-015-4425-8	44	51	51	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1892	1904		10.1038/s41388-018-0534-3	http://dx.doi.org/10.1038/s41388-018-0534-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390072	Green Published, hybrid			2022-12-17	WOS:000461164400008
J	Han, BC; Zhou, B; Qu, Y; Gao, BW; Xu, YL; Chung, S; Tanaka, H; Yang, W; Giuliano, AE; Cui, XJ				Han, Bingchen; Zhou, Bo; Qu, Ying; Gao, Bowen; Xu, Yali; Chung, Stacey; Tanaka, Hisashi; Yang, Wei; Giuliano, Armando E.; Cui, Xiaojiang			FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer	ONCOGENE			English	Article							NF-KAPPA-B; MESENCHYMAL TRANSITION; CELL MOTILITY; DNA-BINDING; INVASION; PROTEIN; IDENTIFICATION; SUBTYPES; METASTASIS; EXPRESSION	Triple-negative breast cancer (TNBC) has high rates of local recurrence and distant metastasis, partially due to its high invasiveness. The Forkhead box C1 (FOXC1) transcription factor has been shown to be specifically overexpressed in TNBC and associated with poor clinical outcome. How TNBC's high invasiveness is driven by FOXC1 and its downstream targets remains poorly understood. In the present study, pathway-specific PCR array assays revealed that WNT5A and matrix metalloproteinase-7 (MMP7) were upregulated by FOXC1 in TNBC cells. Interestingly, WNT5A mediates the upregulation of MMP7 by FOXC1 and the WNT5A-MMP7 axis is essential for FOXC1-induced invasiveness of TNBC cells in vitro. Xenograft models showed that the lung extravasation and metastasis of FOXC1-overexpressing TNBC cells were attenuated by knocking out WNT5A, but could be restored by MMP7 overexpression. Mechanistically, FOXC1 can bind directly to the WNT5A promoter region to activate its expression. Engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP), coupled with mass spectrometry, identified FOXC1-interacting proteins including a group of heterogeneous nuclear ribonucleoproteins involved in WNT5A transcription induction. Finally, we found that WNT5A activates NF-kappa B signaling to induce MMP7 expression. Collectively, these data demonstrate a FOXC1-elicited noncanonical WNT5A signaling mechanism comprising NF-kappa B and MMP7 that is essential for TNBC cell invasiveness, thereby providing implications toward developing an effective therapy for TNBC.	[Han, Bingchen; Zhou, Bo; Qu, Ying; Gao, Bowen; Chung, Stacey; Tanaka, Hisashi; Yang, Wei; Giuliano, Armando E.; Cui, Xiaojiang] Cedars Sinai Med Ctr, Dept Surg, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Xu, Yali] Beijing Union Med Coll Hosp, Dept Breast Surg, Beijing, Peoples R China	Cedars Sinai Medical Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Cui, XJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org	Tanaka, Hisashi/ABE-7637-2020; Yang, Wei/C-3047-2008; Yang, Wei/ABA-5268-2020	Tanaka, Hisashi/0000-0001-9223-4186; Yang, Wei/0000-0003-2575-3570; 	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063), and David Salomon Translational Breast Cancer Research Fund to Xiaojiang Cui, and the Fashion Footwear Charitable Foundation of New York, Inc., the Entertainment Industry Foundation, the Margie and Robert E. Petersen Foundation, and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Bunch H, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0040-x; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fujita T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103084; Fujita T, 2013, BIOCHEM BIOPH RES CO, V439, P132, DOI 10.1016/j.bbrc.2013.08.013; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Guan PP, 2015, ONCOTARGET, V6, P9140, DOI 10.18632/oncotarget.3274; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Han B, 2013, MOL BIOL BREAST CANC, P91; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Han SP, 2010, BIOCHEM J, V430, P379, DOI 10.1042/BJ20100396; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Honda K, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0031-0; Jang M, 2009, ONCOGENE, V28, P1529, DOI 10.1038/onc.2009.11; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim GE, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-959; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116; Morley S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12136; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nishita M, 2010, TRENDS CELL BIOL, V20, P346, DOI 10.1016/j.tcb.2010.03.001; Phoomak C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27853; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weng MT, 2013, PROTEIN CELL, V4, P807, DOI 10.1007/s13238-013-3056-3; Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097; Zhao Y, 2014, J BIOL CHEM, V289, P21028, DOI 10.1074/jbc.M113.546523	39	51	56	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1399	1408		10.1038/s41388-017-0021-2	http://dx.doi.org/10.1038/s41388-017-0021-2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29249801	Green Accepted			2022-12-17	WOS:000427279300010
J	Kim, M; Jang, K; Miller, P; Picon-Ruiz, M; Yeasky, TM; El-Ashry, D; Slingerland, JM				Kim, M.; Jang, K.; Miller, P.; Picon-Ruiz, M.; Yeasky, T. M.; El-Ashry, D.; Slingerland, J. M.			VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; BREAST-CANCER; E-CADHERIN; GENE-EXPRESSION; MIR-200 FAMILY; DOWN-REGULATION; TUMOR	Cancer stem cells (CSC) appear to have increased metastatic potential, but mechanisms underlying this are poorly defined. Here we show that VEGFA induction of Sox2 promotes EMT and tumor metastasis. In breast lines and primary cancer culture, VEGFA rapidly upregulates SOX2 expression, leading to SNAI2 induction, EMT, increased invasion and metastasis. We show Sox2 downregulates miR-452, which acts as a novel metastasis suppressor to directly target the SNAI2 3'-untranslated region (3'-UTR). VEGFA stimulates Sox2- and Slug-dependent cell invasion. VEGFA increases lung metastasis in vivo, and this is abrogated by miR-452 overexpression. Furthermore, SNAI2 transduction rescues metastasis suppression by miR-452. Thus, in addition to its angiogenic action, VEGFA upregulates Sox2 to drive stem cell expansion, together with miR-452 loss and Slug upregulation, providing a novel mechanism whereby cancer stem cells acquire metastatic potential. Prior work showed EMT transcription factor overexpression upregulates CSC. Present work indicates that stemness and metastasis are a two-way street: Sox2, a major mediator of CSC self-renewal, also governs the metastatic process.	[Kim, M.; Jang, K.; Miller, P.; Picon-Ruiz, M.; Yeasky, T. M.; El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA; [Kim, M.; Jang, K.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Slingerland, JM (corresponding author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Ruiz, Manuel Picón/I-3624-2015	Ruiz, Manuel Picón/0000-0002-9427-0946	Breast Cancer Research Foundation	Breast Cancer Research Foundation	This work was supported by funding from the Breast Cancer Research Foundation to JMS.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Adams J, 2000, CANCER RES, V60, P2898; Arias-Pulido H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-298; Azzam DJ, 2013, EMBO MOL MED, V5, P1502, DOI 10.1002/emmm.201302558; Bachelder RE, 2002, CANCER RES, V62, P7203; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Berns EMJJ, 2003, CLIN CANCER RES, V9, P1253; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; ETHIER SP, 1993, CANCER RES, V53, P627; Fang XF, 2010, OMICS, V14, P369, DOI 10.1089/omi.2010.0053; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Gonzalez-Moreno O, 2010, EXP CELL RES, V316, P554, DOI 10.1016/j.yexcr.2009.11.020; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gyorffy B, 2012, BREAST CANCER RES TR, V132, P1025, DOI 10.1007/s10549-011-1676-y; Hajra KM, 2002, CANCER RES, V62, P1613; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim LS, 2004, CLIN EXP METASTAS, V21, P107, DOI 10.1023/B:CLIN.0000024761.00373.55; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu LP, 2013, CLIN CANCER RES, V19, P3429, DOI 10.1158/1078-0432.CCR-12-3794; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Manders P, 2002, BRIT J CANCER, V87, P772, DOI 10.1038/sj.bjc.6600555; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Mercurio AM, 2005, J MAMMARY GLAND BIOL, V10, P283, DOI 10.1007/s10911-006-9001-9; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Montero AJ, 2012, CURR ONCOL REP, V14, P1, DOI 10.1007/s11912-011-0202-z; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Picon-Ruiz M, 2016, CANC RES, V76; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Qian PX, 2012, CANCER RES, V72, P6036, DOI 10.1158/0008-5472.CAN-12-1507; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sa-Nguanraksa D, 2015, MOL CLIN ONCOL, V3, P1103, DOI 10.3892/mco.2015.574; Senger DR, 2010, MOL BIOL CELL, V21, P377, DOI 10.1091/mbc.E09-07-0591; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shih T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Sullivan LA, 2010, MABS-AUSTIN, V2, P165, DOI 10.4161/mabs.2.2.11360; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127; Wander SA, 2013, BREAST CANCER RES TR, V138, P369, DOI 10.1007/s10549-012-2389-6; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang M, 2015, CANCER DISCOV, V5, P520, DOI 10.1158/2159-8290.CD-14-1101; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	103	51	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5199	5211		10.1038/onc.2017.4	http://dx.doi.org/10.1038/onc.2017.4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28504716	hybrid, Green Published			2022-12-17	WOS:000409371100011
J	Dumartin, L; Alrawashdeh, W; Trabulo, SM; Radon, TP; Steiger, K; Feakins, RM; di Magliano, MP; Heeschen, C; Esposito, I; Lemoine, NR; Crnogorac-Jurcevic, T				Dumartin, L.; Alrawashdeh, W.; Trabulo, S. M.; Radon, T. P.; Steiger, K.; Feakins, R. M.; di Magliano, M. P.; Heeschen, C.; Esposito, I.; Lemoine, N. R.; Crnogorac-Jurcevic, T.			ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; ANTERIOR GRADIENT 2; ONCOGENIC KRAS; CELLS; PROMOTES; INFLAMMATION; EXPRESSION; INDUCTION; OBESITY	The mechanisms of initiation of pancreatic ductal adenocarcinoma (PDAC) are still largely unknown. In the present study, we analysed the role of anterior gradient-2 (AGR2) in the earliest stages of pancreatic neoplasia. Immunohistochemical analysis of chronic pancreatitis (CP) and peritumoral areas in PDAC tissues showed that AGR2 was present in tubular complexes (TC) and early pancreatic intraepithelial neoplasia (PanINs). Moreover, AGR2 was also found in discrete subpopulations of non-transformed cells neighbouring these pre-neoplastic lesions. In primary cells derived from human patient-derived xenograft (PDX) model, flowcytometry revealed that AGR2 was overexpressed in pancreatic cancer stem cells (CSC) compared with non-stem cancer cells. In LSL-Kras(G12D); Pdx1-Cre (KC) mouse model Agr2 induction preceded the formation of pre-neoplastic lesions and their development was largely inhibited by Agr2 deletion in engineered LSL-Kras(G12D); Pdx1-Cre; Agr2(-/-)mice. In vitro, AGR2 expression was stimulated by tunicamycin-induced endoplasmic reticulum (ER) stress in both KRAS wild-type normal pancreas cells, as well as in KRAS mutated pancreatic cancer cells and was essential for ER homoeostasis. The unfolded protein response proteins GRP78, ATF6 and XBP1s were found expressed in CP and PDAC peritumoral tissues, but in contrast to AGR2, their expression was switched off during TC and PanIN formation. Real-time PCR and ELISA analyses showed that ER stress induced a pro-inflammatory phenotype in pancreatic normal, cancer and stellate cells. Moreover, AGR2 expression was inducible by paracrine transfer of ER stress and pro-inflammation between different pancreatic cell types. Our findings demonstrate that AGR2 induced in ER-stressed and inflammatory preneoplastic pancreas is a potential marker of cancer progenitor cells with an important functional role in PDAC initiation.	[Dumartin, L.; Alrawashdeh, W.; Radon, T. P.; Lemoine, N. R.; Crnogorac-Jurcevic, T.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England; [Trabulo, S. M.; Heeschen, C.] Queen Mary Univ London, Barts Canc Inst, Ctr Stem Cells Canc & Ageing, London, England; [Steiger, K.] Tech Univ Munich, Inst Pathol, Munich, Germany; [Feakins, R. M.] Royal London Hosp, Dept Histopathol, London, England; [di Magliano, M. P.] Univ Michigan, Dept Surg Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Esposito, I.] Heinrich Heine Univ Dusseldorf, Inst Pathol, Dusseldorf, Germany	University of London; Queen Mary University London; University of London; Queen Mary University London; Technical University of Munich; Barts Health NHS Trust; Royal London Hospital; University of Michigan System; University of Michigan; Heinrich Heine University Dusseldorf	Crnogorac-Jurcevic, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England.; Crnogorac-Jurcevic, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	t.c.jurcevic@qmul.ac.uk	Feakins, Roger/AAO-5570-2020; Feakins, Roger/J-6782-2019; Guba, Markus/M-4309-2019	Lemoine, Nick/0000-0001-8675-058X; Pasca di Magliano, Marina/0000-0001-9632-9035	CR-UK [A12008]; Cancer Research UK [12008] Funding Source: researchfish	CR-UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We would like to thank Profs David Tuveson and David Erle for providing us with KC and germline Agr2<SUP>-/-</SUP> transgenic mice, respectively and Prof Hemant Kocher for PS1 pancreatic stellate cells. We would also like to thank Julie Andow, Hagen Schmid and George Elia for their expert technical assistance. Grant Support: The work was supported by a grant A12008 from CR-UK (L. Dumartin, N.R. Lemoine and T. Crnogorac-Jurcevic).	Aichler M, 2012, J PATHOL, V226, P723, DOI 10.1002/path.3017; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Celli J, 2015, NAT REV MICROBIOL, V13, P71, DOI 10.1038/nrmicro3393; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Collins MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049707; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gupta A, 2013, J BIOL CHEM, V288, P4321, DOI 10.1074/jbc.M112.433086; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Hess DA, 2011, GASTROENTEROLOGY, V141, P1463, DOI 10.1053/j.gastro.2011.06.045; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Jorgensen E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-229; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kawasaki N, 2012, SCI REP-UK, V2, DOI 10.1038/srep00799; Kong B, 2018, GUT, V67, P146, DOI 10.1136/gutjnl-2015-310913; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Lugea A, 2011, GASTROENTEROLOGY, V140, P987, DOI 10.1053/j.gastro.2010.11.038; Ma SR, 2015, ONCOTARGET, V6, P8807, DOI 10.18632/oncotarget.3556; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Morris JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095486; Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Norris AM, 2013, ONCOGENE, V32, P3867, DOI 10.1038/onc.2012.394; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pandol SJ, 2010, DIGEST DIS, V28, P776, DOI 10.1159/000327212; Pandol SJ, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00008; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Roy N, 2015, GENE DEV, V29, P658, DOI 10.1101/gad.256628.114; Ryu J, 2013, BIOCHEM BIOPH RES CO, V430, P610, DOI 10.1016/j.bbrc.2012.11.105; Sah RP, 2014, J BIOL CHEM, V289, P27551, DOI 10.1074/jbc.M113.528174; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Whiteman HJ, 2007, CANCER RES, V67, P8633, DOI 10.1158/0008-5472.CAN-07-0545	46	51	55	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3094	3103		10.1038/onc.2016.459	http://dx.doi.org/10.1038/onc.2016.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27941872	Green Published, hybrid			2022-12-17	WOS:000402617900003
J	Sareddy, GR; Viswanadhapalli, S; Surapaneni, P; Suzuki, T; Brenner, A; Vadlamudi, RK				Sareddy, G. R.; Viswanadhapalli, S.; Surapaneni, P.; Suzuki, T.; Brenner, A.; Vadlamudi, R. K.			Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; HISTONE DEMETHYLASE; ER STRESS; GLIOBLASTOMA CELLS; LSD1; TARGET; MECHANISMS; GROWTH; HETEROGENEITY; CONTRIBUTES	Glioma stem cells (GSCs) have a central role in glioblastoma (GBM) development and chemo/radiation resistance, and their elimination is critical for the development of efficient therapeutic strategies. Recently, we showed that lysine demethylase KDM1A is overexpressed in GBM. In the present study, we determined whether KDM1A modulates GSCs stemness and differentiation and tested the utility of two novel KDM1A-specific inhibitors (NCL-1 and NCD-38) to promote differentiation and apoptosis of GSCs. The efficacy of KDM1A targeting drugs was tested on purified GSCs isolated from established and patient-derived GBMs using both in vitro assays and in vivo orthotopic preclinical models. Our results suggested that KDM1A is highly expressed in GSCs and knockdown of KDM1A using shRNA-reduced GSCs stemness and induced the differentiation. Pharmacological inhibition of KDM1A using NCL-1 and NCD-38 significantly reduced the cell viability, neurosphere formation and induced apoptosis of GSCs with little effect on differentiated cells. In preclinical studies using orthotopic models, NCL-1 and NCD-38 significantly reduced GSCs-driven tumor progression and improved mice survival. RNA-sequencing analysis showed that KDM1A inhibitors modulate several pathways related to stemness, differentiation and apoptosis. Mechanistic studies showed that KDM1A inhibitors induce activation of the unfolded protein response (UPR) pathway. These results strongly suggest that selective targeting of KDM1A using NCL-1 and NCD-38 is a promising therapeutic strategy for elimination of GSCs.	[Sareddy, G. R.; Viswanadhapalli, S.; Surapaneni, P.; Vadlamudi, R. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA; [Suzuki, T.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan; [Suzuki, T.] Japan Sci & Technol Agcy JST, CREST, Saitama, Japan; [Brenner, A.; Vadlamudi, R. K.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA; [Brenner, A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Hematol & Oncol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Kyoto Prefectural University of Medicine; Japan Science & Technology Agency (JST); Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sareddy, GR; Vadlamudi, RK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.	Sareddy@uthscsa.edu; Vadlamudi@uthscsa.edu		Viswanadhapalli, Suryavathi/0000-0002-7381-6962	AACR-AMGEN Inc. [14-40-11-SARE]; CPRIT training grant [RP140105]; NCI Grant [CA178499]; NATIONAL CANCER INSTITUTE [R01CA178499] Funding Source: NIH RePORTER	AACR-AMGEN Inc.; CPRIT training grant; NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the 2014 AACR-AMGEN Inc. fellowship in clinical/translational cancer research (Grant Number: 14-40-11-SARE) and CPRIT training grant (RP140105) awarded to GRS and NCI Grant CA178499 (RKV and AB).	Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Bai Y, 2014, GLIA, V62, P1687, DOI 10.1002/glia.22708; Bao SD, 2008, CANCER RES, V68, P6043, DOI 10.1158/0008-5472.CAN-08-1079; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Cho YM, 2009, EXP MOL MED, V41, P440, DOI 10.3858/emm.2009.41.6.049; Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229; Crespo I, 2015, AM J PATHOL, V185, P1820, DOI 10.1016/j.ajpath.2015.02.023; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364; Diaz-Villanueva JF, 2015, INT J MOL SCI, V16, P17193, DOI 10.3390/ijms160817193; Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ge WS, 2014, BIOMATERIALS, V35, P6015, DOI 10.1016/j.biomaterials.2014.04.055; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Khan IS, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14509; Kondo Y, 2014, CANCER SCI, V105, P363, DOI 10.1111/cas.12379; Kozono D, 2015, P NATL ACAD SCI USA, V112, pE4055, DOI 10.1073/pnas.1501967112; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Lee YS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/520578; Lei ZJ, 2015, ONCOGENE, V34, P3188, DOI 10.1038/onc.2015.129; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ogasawara D, 2013, ANGEW CHEM INT EDIT, V52, P8620, DOI 10.1002/anie.201303999; Ogasawara D, 2011, BIOORGAN MED CHEM, V19, P3702, DOI 10.1016/j.bmc.2010.12.024; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pajtler KW, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-19; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sareddy GR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24185; Sareddy GR, 2013, ONCOTARGET, V4, P18, DOI 10.18632/oncotarget.725; Sareddy GR, 2012, MOL CANCER THER, V11, P1174, DOI 10.1158/1535-7163.MCT-11-0960; Sato A, 2011, STEM CELLS, V29, P1942, DOI 10.1002/stem.753; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shao GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15344; Singh MM, 2011, NEURO-ONCOLOGY, V13, P894, DOI 10.1093/neuonc/nor049; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Ueda R, 2009, J AM CHEM SOC, V131, P17536, DOI 10.1021/ja907055q; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wang J, 2011, EURASIP J WIREL COMM, DOI 10.1155/2011/785437; Wang LW, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004021; Wang M., 2015, CAN J AGR ECON, V1, P1; Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016; Xie Q, 2015, ONCOTARGET, V6, P13241, DOI 10.18632/oncotarget.3676; Xu HM, 2014, J BIOL CHEM, V289, P26290, DOI 10.1074/jbc.M114.572560; Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Zhang XC, 2007, INT J DEV NEUROSCI, V25, P455, DOI 10.1016/j.ijdevneu.2007.08.007; Zhao X, 2015, ANIM BIOL, V65, P1, DOI 10.1163/15707563-00002455; Zhao ZK, 2012, WORLD J GASTROENTERO, V18, P6651, DOI 10.3748/wjg.v18.i45.6651	74	51	51	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2423	2434		10.1038/onc.2016.395	http://dx.doi.org/10.1038/onc.2016.395			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27893719	Green Accepted			2022-12-17	WOS:000400268900008
J	Jung, LA; Gebhardt, A; Koelmel, W; Ade, CP; Walz, S; Kuper, J; von Eyss, B; Letschert, S; Redel, C; d'Artista, L; Biankin, A; Zender, L; Sauer, M; Wolf, E; Evan, G; Kisker, C; Eilers, M				Jung, L. A.; Gebhardt, A.; Koelmel, W.; Ade, C. P.; Walz, S.; Kuper, J.; von Eyss, B.; Letschert, S.; Redel, C.; d'Artista, L.; Biankin, A.; Zender, L.; Sauer, M.; Wolf, E.; Evan, G.; Kisker, C.; Eilers, M.			OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors	ONCOGENE			English	Article							ANTI-APOPTOTIC FACTOR; DOMAIN-CONTAINING 3A; C-MYC; COLORECTAL TUMORIGENESIS; MITOCHONDRIAL DYNAMICS; UBIQUITIN RECEPTOR; BREAST-CANCER; DNA-BINDING; GENOME; CELLS	MYC genes have both essential roles during normal development and exert oncogenic functions during tumorigenesis. Expression of a dominant-negative allele of MYC, termed OmoMYC, can induce rapid tumor regression in mouse models with little toxicity for normal tissues. How OmoMYC discriminates between physiological and oncogenic functions of MYC is unclear. We have solved the crystal structure of OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in the same manner as the MYC/MAX heterodimer. OmoMYC attenuates both MYC-dependent activation and repression by competing with MYC/MAX for binding to chromatin, effectively lowering MYC/MAX occupancy at its cognate binding sites. OmoMYC causes the largest decreases in promoter occupancy and changes in expression on genes that are invaded by oncogenic MYC levels. A signature of OmoMYC-regulated genes defines subgroups with high MYC levels in multiple tumor entities and identifies novel targets for the eradication of MYC-driven tumors.	[Jung, L. A.; Gebhardt, A.; Ade, C. P.; von Eyss, B.; Redel, C.; Wolf, E.; Eilers, M.] Univ Wurzburg, Bioctr, Theodor Boveri Inst, D-97074 Wurzburg, Germany; [Jung, L. A.; Koelmel, W.; Kuper, J.; Kisker, C.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; [Walz, S.] Bioctr, Core Unit Bioinformat, Comprehens Canc Ctr, Wurzburg, Germany; [Letschert, S.; Sauer, M.] Univ Wurzburg, Bioctr, Dept Biotechnol & Biophys, Wurzburg, Germany; [d'Artista, L.; Zender, L.] Univ Tubingen, Dept Internal Med 1, Div Translat Gastrointestinal Oncol, Tubingen, Germany; [Biankin, A.] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Garscube Estate,Switchback Rd, Glasgow, Lanark, Scotland; [Biankin, A.] Glasgow Royal Infirm, West Scotland Pancreat Unit, Glasgow, Lanark, Scotland; [Biankin, A.] Univ NSW, South Western Sydney Clin Sch, Fac Med, Liverpool, NSW, Australia; [Evan, G.] Univ Cambridge, Dept Biochem, Cambridge, England	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Eberhard Karls University of Tubingen; University of Glasgow; University of Glasgow; University of Cambridge	Eilers, M (corresponding author), Univ Wurzburg, Bioctr, Theodor Boveri Inst, D-97074 Wurzburg, Germany.; Kisker, C (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany.	caroline.kisker@virchow.uni-wuerzburg.de; martin.eilers@biozentrum.uni-wuerzburg.de	von Eyss, Bjoern/P-1077-2019; Wolf, Elmar/AAY-8493-2021; Kisker, Caroline/T-1724-2019; Sauer, Markus/C-4378-2017	von Eyss, Bjoern/0000-0002-4731-6841; Wolf, Elmar/0000-0002-5299-6335; Sauer, Markus/0000-0002-1692-3219; Redel, Cornelia/0000-0002-3632-3317; Evan, Gerard/0000-0003-0412-1216; Kisker, Caroline/0000-0002-0216-6026; Jung, Lisa Anna/0000-0003-4149-1662; Biankin, Andrew/0000-0002-0362-5597	Worldwide Cancer Research; German Research Foundation [2341]; German National Academic Foundation; Cancer Research UK [12077, 19013, 22585, 17263, 22533] Funding Source: researchfish; Pancreatic Cancer UK [FLF2015_04_Glasgow] Funding Source: researchfish	Worldwide Cancer Research; German Research Foundation(German Research Foundation (DFG)); German National Academic Foundation; Cancer Research UK(Cancer Research UK); Pancreatic Cancer UK	We thank Laura Soucek for sharing results before publication, Agnes Elias and Werner Schmitz for help with protein purification, Hermann Schindelin for help with determining the structures of OmoMYC, Christopher Bombeck for help with generating the targeted shRNA library and Jens Siveke (Technical University of Munich) for kindly providing KPCs. The expert technical assistance of Barbara Bauer, Andre Kutschke, Angela Grun and Renate Metz is gratefully acknowledged. This work was supported by grants from Worldwide Cancer Research and the German Research Foundation via Research Group 2341 to ME, GE, LZ and CK, and a pre-doctoral fellowship from the German National Academic Foundation to LAJ. High-throughput-sequencing data are available at the Gene Expression Omnibus under the accession number GEO: GSE77328. We thank the European Synchrotron Radiation Facility for beamtime and the staff of ID23-1 for technical support. We thank the Helmholtz Zentrum Berlin for the allocation of beamtime and the staff of BL14.1 for technical support. Atomic coordinates have been deposited in the Protein Data Bank under accession codes 5I4Z (apo structure) and 5I50 (DNA-bound structure).	ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Anchoori RK, 2013, CANCER CELL, V24, P791, DOI 10.1016/j.ccr.2013.11.001; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chiang SF, 2012, INT J MOL MED, V29, P365, DOI 10.3892/ijmm.2011.849; Chung KY, 2011, HEPATOLOGY, V54, P307, DOI 10.1002/hep.24372; Cunningham JT, 2014, CELL, V157, P1088, DOI 10.1016/j.cell.2014.03.052; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Fang HY, 2010, J CELL SCI, V123, P1171, DOI 10.1242/jcs.062034; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Gilquin B, 2010, MOL CELL BIOL, V30, P1984, DOI 10.1128/MCB.00007-10; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guo JN, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0482-3; Hoffmann M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007644; Hong SL, 2000, GENE DEV, V14, P17; Huang KH, 2011, INT J MOL MED, V28, P9, DOI 10.3892/ijmm.2011.670; Husnjak K, 2008, NATURE, V453, P481, DOI 10.1038/nature06926; Jaenicke LA, 2016, MOL CELL, V61, P54, DOI 10.1016/j.molcel.2015.11.007; Killian A, 2006, GENE CHROMOSOME CANC, V45, P874, DOI 10.1002/gcc.20351; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Rohrmoser M, 2007, MOL CELL BIOL, V27, P3682, DOI 10.1128/MCB.00172-07; Ruggero D, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012336; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Scognamiglio R, 2016, CELL, V164, P668, DOI 10.1016/j.cell.2015.12.033; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Truitt ML, 2015, CELL, V162, P59, DOI 10.1016/j.cell.2015.05.049; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006	51	51	51	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1911	1924		10.1038/onc.2016.354	http://dx.doi.org/10.1038/onc.2016.354			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27748763	Green Accepted, Green Submitted			2022-12-17	WOS:000398898500003
J	Farmaki, E; Chatzistamou, I; Kaza, V; Kiaris, H				Farmaki, E.; Chatzistamou, I.; Kaza, V.; Kiaris, H.			A CCL8 gradient drives breast cancer cell dissemination	ONCOGENE			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-2; TUMOR-ASSOCIATED MACROPHAGES; HUMAN MONOCLONAL-ANTIBODY; CHEMOKINE LIGAND 2; CARLUMAB CNTO 888; METASTASIS; PROGRESSION; MICROENVIRONMENT; FIBROBLASTS; RECEPTORS	The migration of cancer cells towards gradients of chemoattractive factors represents a potential, yet elusive, mechanism that may contribute to cancer cell dissemination. Here we provide evidence for the maintenance of a gradient of increasing CCL8 concentration between the epithelium, the stroma and the periphery that is instrumental for breast cancer cells' dissemination. In response to signals elicited by the neoplastic epithelium, CCL8 production is enhanced in stromal fibroblasts at the tumor margins and in tissues at which breast cancer cells tend to metastasize such as the lungs and the brain. Manipulation of CCL8 activity influences the histology of the tumors and promotes major steps of the metastatic process such as invasion to adjacent stroma, intravasation and ultimately extravasation and seeding. These findings exemplify how gradients of chemoattractive factors such as CCL8, drive metastasis and suggest that interference with their operation may provide means for breast cancer management.	[Farmaki, E.; Kaza, V.; Kiaris, H.] Univ South Carolina, Dept Drug Discovery & Biomed Sci, CLS 713,715 Sumter St, Columbia, SC 29208 USA; [Chatzistamou, I.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Chatzistamou, I.] Univ Athens, Sch Dent, Dept Basic Sci, Athens, Greece; [Kiaris, H.] Univ Athens, Sch Med, Dept Biochem, Athens, Greece	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens	Kiaris, H (corresponding author), Univ South Carolina, Dept Drug Discovery & Biomed Sci, CLS 713,715 Sumter St, Columbia, SC 29208 USA.	kiarish@sccp.sc.edu		Kiaris, Hippokratis/0000-0002-8999-8289	NIH [5P30GM103336-02]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103336] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Professors I Roninson, E Broude and JE Schwarzbauer for useful comments and suggestions, and F Marini for sharing the EO771 cells. This study was supported by a pilot grant 5P30GM103336-02 from NIH.	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Bae JY, 2014, NEOPLASIA, V16, P928, DOI 10.1016/j.neo.2014.09.003; Barbai T, 2015, ONCOTARGET, V6, P29111, DOI 10.18632/oncotarget.5059; Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340; Bouquet F, 2011, CLIN CANCER RES, V17, P6754, DOI 10.1158/1078-0432.CCR-11-0544; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CASEY AE, 1951, P SOC EXP BIOL MED, V77, P358; Chatzistamou I, 2011, CELL ONCOL, V34, P483, DOI 10.1007/s13402-011-0044-6; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140; Das S, 2013, J EXP MED, V210, P1509, DOI 10.1084/jem.20111627; Fanti P, 2003, ENDOCRINE, V22, P161, DOI 10.1385/ENDO:22:2:161; Fenner J, 2014, SCI REP-UK, V4, DOI 10.1038/srep05512; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hollmen M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09188; Hu B, 2012, CELL, V149, P1207, DOI 10.1016/j.cell.2012.03.048; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Pitteri SJ, 2011, CANCER RES, V71, P5090, DOI 10.1158/0008-5472.CAN-11-0568; Rafii S, 2003, CANCER CELL, V4, P331, DOI 10.1016/S1535-6108(03)00278-2; Rajaram M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003789; Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Sandhu SK, 2013, CANCER CHEMOTH PHARM, V71, P1041, DOI 10.1007/s00280-013-2099-8; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Torres S, 2013, CLIN CANCER RES, V19, P6006, DOI 10.1158/1078-0432.CCR-13-1130; Trimis G, 2008, HUM MOL GENET, V17, P3596, DOI 10.1093/hmg/ddn252; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007	39	51	53	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6309	6318		10.1038/onc.2016.161	http://dx.doi.org/10.1038/onc.2016.161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27181207	Green Accepted			2022-12-17	WOS:000390247000004
J	Paranjape, AN; Soundararajan, R; Werden, SJ; Joseph, R; Taube, JH; Liu, H; Rodriguez-Canales, J; Sphyris, N; Wistuba, I; Miura, N; Dhillon, J; Mahajan, N; Mahajan, K; Chang, JT; Ittmann, M; Maity, SN; Logothetis, C; Tang, DG; Mani, SA				Paranjape, A. N.; Soundararajan, R.; Werden, S. J.; Joseph, R.; Taube, J. H.; Liu, H.; Rodriguez-Canales, J.; Sphyris, N.; Wistuba, I.; Miura, N.; Dhillon, J.; Mahajan, N.; Mahajan, K.; Chang, J. T.; Ittmann, M.; Maity, S. N.; Logothetis, C.; Tang, D. G.; Mani, S. A.			Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; BREAST-CANCER; NEUROENDOCRINE DIFFERENTIATION; AGGRESSIVE PHENOTYPE; KINASE INHIBITORS; RESISTANCE; METASTASIS; ACTIVATION; P38	Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are difficult to treat, and account for up to 30% of prostate cancer-related deaths every year. While existing therapies for prostate cancer such as androgen deprivation therapy (ADT), destroy the bulk of the AR-positive cells within the tumor, eradicating this population eventually leads to castration-resistance, owing to the continued survival of AR-/lo stem-like cells. In this study, we identified a critical nexus between p38MAPK signaling, and the transcription factor Forkhead Box Protein C2 (FOXC2) known to promote cancer stem-cells and metastasis. We demonstrate that prostate cancer cells that are insensitive to ADT, as well as high-grade/NE prostate tumors, are characterized by elevated FOXC2, and that targeting FOXC2 using a well-tolerated p38 inhibitor restores epithelial attributes and ADT-sensitivity, and reduces the shedding of circulating tumor cells in vivo with significant shrinkage in the tumor mass. This study thus specifies a tangible mechanism to target the AR-/lo population of prostate cancer cells with stem-cell properties.	[Paranjape, A. N.; Soundararajan, R.; Werden, S. J.; Joseph, R.; Taube, J. H.; Liu, H.; Rodriguez-Canales, J.; Sphyris, N.; Wistuba, I.; Mani, S. A.] UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,LSP9-2001, Houston, TX USA; [Miura, N.] Hamamatsu Univ, Sch Med, Dept Biochem, Hamamatsu, Shizuoka, Japan; [Dhillon, J.; Mahajan, N.; Mahajan, K.] Univ S Florida, Dept Oncol Sci, Moffitt Canc Ctr, Tampa, FL USA; [Chang, J. T.] UT Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Sch Med, Sch Biomed Informat, Houston, TX USA; [Ittmann, M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Maity, S. N.; Logothetis, C.] UT MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA; [Tang, D. G.] UT MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Sci Pk, Smithville, TX USA; [Mani, S. A.] UT MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX USA; [Mani, S. A.] UT MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Hamamatsu University School of Medicine; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mani, SA (corresponding author), UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,LSP9-2001, Houston, TX USA.	mani@mdanderson.org	Tang, Dean/AAI-3457-2020; Paranjape, Anurag N./P-1255-2018; SPHYRIS, NATHALIE/GQY-6349-2022; Liu, Hui/AAJ-4339-2020; Mani, Sendurai A./A-7244-2009	Tang, Dean/0000-0001-5029-1174; Paranjape, Anurag N./0000-0001-6119-0766; Liu, Hui/0000-0002-7669-9386; Mani, Sendurai A./0000-0002-5918-4276; Sphyris, Nathalie/0000-0003-1860-1958; Taube, Joseph/0000-0002-3636-5189; Joseph, Robiya/0000-0003-3214-890X; Mahajan, Kiran/0000-0001-7192-396X; Maity, Sankar/0000-0002-2387-6545	American Cancer Society M Patricia Alexander Research Scholar award; MDACC Prostate-SPORE [NIH R01 CA155243]; NATIONAL CANCER INSTITUTE [R01CA155243, P30CA016672] Funding Source: NIH RePORTER	American Cancer Society M Patricia Alexander Research Scholar award; MDACC Prostate-SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Neeraja Bhangre for technical assistance and Dr Sue-Hwa Lin for helpful discussions. This research was supported by grants from MDACC Prostate-SPORE, NIH R01 CA155243 and the American Cancer Society M Patricia Alexander Research Scholar award.	Aggarwal R, 2014, J NATL COMPR CANC NE, V12, P719, DOI 10.6004/jnccn.2014.0073; Aparicio A, 2011, PROSTATE, V71, P846, DOI 10.1002/pros.21301; Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499; Castillo V, 2014, INT J ONCOL, V45, P985, DOI 10.3892/ijo.2014.2529; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Cheriyan J, 2011, CIRCULATION, V123, P515, DOI 10.1161/CIRCULATIONAHA.110.971986; Cohen S, 2010, CURR OPIN RHEUMATOL, V22, P330, DOI 10.1097/BOR.0b013e3283378e6f; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Friedlander TW, 2014, INT J CANCER, V134, P2284, DOI 10.1002/ijc.28561; Gan L, 2011, PROSTATE, V71, P1158, DOI 10.1002/pros.21331; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367; Khandrika L, 2009, ONCOGENE, V28, P1248, DOI 10.1038/onc.2008.476; Koul Hari K, 2013, Genes Cancer, V4, P342, DOI 10.1177/1947601913507951; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Li P, 2014, EXP BIOL MED, V239, P813, DOI 10.1177/1535370214538727; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Ma B, 2014, J BIOL CHEM, V289, P11153, DOI 10.1074/jbc.M113.540237; MacNee W, 2013, THORAX, V68, P738, DOI 10.1136/thoraxjnl-2012-202744; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; Milone MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.165; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Nouri M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00370; Paranjape AN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-785; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Ricote M, 2006, APOPTOSIS, V11, P1969, DOI 10.1007/s10495-006-0086-9; Santoni M, 2014, BBA-REV CANCER, V1846, P630, DOI 10.1016/j.bbcan.2014.10.008; Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shida Y, 2007, BIOCHEM BIOPH RES CO, V353, P744, DOI 10.1016/j.bbrc.2006.12.077; Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tamaki H, 2014, ONCOTARGET, V5, P11399, DOI 10.18632/oncotarget.2550; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	47	51	53	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5963	5976		10.1038/onc.2015.498	http://dx.doi.org/10.1038/onc.2015.498			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	26804168	hybrid, Green Published			2022-12-17	WOS:000388509400004
J	Li, L; Fang, R; Liu, B; Shi, H; Wang, Y; Zhang, W; Zhang, X; Ye, L				Li, L.; Fang, R.; Liu, B.; Shi, H.; Wang, Y.; Zhang, W.; Zhang, X.; Ye, L.			Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth	ONCOGENE			English	Article							CHAPERONE-MEDIATED AUTOPHAGY; PROGNOSTIC-SIGNIFICANCE; ACETYLATION TARGETS; BINDING-PROTEIN; YAP PATHWAY; CELLS; KINASE; PROLIFERATION; EXPRESSION; RECEPTOR	Reduction or loss of tumor-suppressor mammalian STE20-like kinase 1 (MST1) in Hippo pathway contributes to the tumorigenesis. However, the mechanism leading to reduction of MST1 in cancers remains poorly understood. In this study, we explored the hypothesis that the oncoprotein hepatitis B X-interacting protein (HBXIP) is involved in the reduction of MST1 in breast cancer. Immunohistochemical analysis of tissue microarrays revealed that the expression of HBXIP was negatively associated with that of MST1 in 98 clinical breast tissue samples. Then we found that HBXIP could posttranslationally downregulate MST1 in breast cancer cells. Mechanistically, we identified that MST1 could be acetylated on its lysine 35 residue in the cells. Strikingly, the treatment with trichostatin A, an inhibitor of histone deacetylases (HDACs), markedly increased the levels of MST1 acetylation and protein in the cells. Interestingly, the oncoprotein HBXIP could significantly inhibit acetylation of MST1, resulting in the reduction of MST1 protein. Notably, we revealed that the HDAC6 could reduce the protein levels of MST1 through deacetylation modification of MST1 in the cells. Moreover, our data revealed that HBXIP upregulated HDAC6 at the levels of mRNA and protein by activating transcription factor nuclear factor-kappa B. Deacetylation of MST1 promoted the interaction of MST1 with HSC70 in the cells, resulting in a lysosome-dependent degradation of MST1 via chaperone-mediated autophagy (CMA). Functionally, the reduction of tumor-suppressor MST1 mediated by HBXIP promoted the growth of breast cancer cells in vitro and in vivo. Thus we conclude that the deacetylation of MST1 mediated by HBXIP-enhanced HDAC6 results in MST1 degradation in a CMA manner in promotion of breast cancer growth. Our finding provides new insights into the mechanism of tumor-suppressor MST1 reduction in breast cancer.	[Li, L.; Fang, R.; Liu, B.; Shi, H.; Wang, Y.; Zhang, W.; Ye, L.] Nankai Univ, Coll Life Sci, Dept Biochem, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China; [Zhang, X.] Nankai Univ, Coll Life Sci, Dept Canc Res, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Ye, L (corresponding author), Nankai Univ, Coll Life Sci, Dept Biochem, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.; Zhang, X (corresponding author), Nankai Univ, Coll Life Sci, Dept Canc Res, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.	zhangxd@nankai.edu.cn; yelihong@nankai.edu.cn	Fang, Runping/AAF-6835-2020		National Basic Research Program of China (973 Program) [2015CB553905]; National Natural Scientific Foundation of China [81372186, 81272218, 31470756]; Tianjin Natural Scientific Foundation [14JCZDJC32800]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Natural Scientific Foundation	This work was supported by grants from the National Basic Research Program of China (973 Program, No. 2015CB553905), the National Natural Scientific Foundation of China (Nos. 81372186, 81272218, 31470756) and Tianjin Natural Scientific Foundation (No. 14JCZDJC32800).	Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Cinar B, 2011, CANCER RES, V71, P4303, DOI 10.1158/0008-5472.CAN-10-4532; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Ding G, 2013, FEBS LETT, V587, P880, DOI 10.1016/j.febslet.2013.02.001; Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Hu N, 2011, J BIOL CHEM, V286, P13714, DOI 10.1074/jbc.M110.204131; Jeong H, 2009, CELL, V137, P60, DOI 10.1016/j.cell.2009.03.018; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631; Kuser-Abali G, 2014, EPIGENETICS-US, V9, P634, DOI 10.4161/epi.27957; Li H, 2015, J BIOL CHEM, V290, P22649, DOI 10.1074/jbc.M115.658468; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Li K, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012286, 10.1371/journal.pone.0010341]; Li SS, 2013, BIOCHEM J, V452, P281, DOI 10.1042/BJ20120680; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Lin XY, 2013, TUMOR BIOL, V34, P3239, DOI 10.1007/s13277-013-0895-8; Liu FB, 2014, CARCINOGENESIS, V35, P1144, DOI 10.1093/carcin/bgu021; Liu Q, 2013, INT J CANCER, V133, P1310, DOI 10.1002/ijc.28154; Liu SP, 2012, J BIOL CHEM, V287, P30228, DOI 10.1074/jbc.M112.343947; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Madonna R, 2014, J BIOL CHEM, V289, P19585, DOI 10.1074/jbc.M113.540559; Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Minoo P, 2007, MODERN PATHOL, V20, P331, DOI 10.1038/modpathol.3800740; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Park SJ, 2014, CANCER LETT, V354, P97, DOI 10.1016/j.canlet.2014.07.041; Perez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rausa FM, 2004, J BIOL CHEM, V279, P43070, DOI 10.1074/jbc.M407472200; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Salah Z, 2011, CANCER RES, V71, P2010, DOI 10.1158/0008-5472.CAN-10-3516; Seidel C, 2007, MOL CARCINOGEN, V46, P865, DOI 10.1002/mc.20317; Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596; Wang FZ, 2007, ACTA PHARMACOL SIN, V28, P431, DOI 10.1111/j.1745-7254.2007.00531.x; Wang P, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0435-8; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yue L, 2013, CARCINOGENESIS, V34, P927, DOI 10.1093/carcin/bgs399; Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005	52	51	55	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4048	4057		10.1038/onc.2015.476	http://dx.doi.org/10.1038/onc.2015.476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26657153				2022-12-17	WOS:000381020900003
J	Nagaoka, K; Fujii, K; Zhang, H; Usuda, K; Watanabe, G; Ivshina, M; Richter, JD				Nagaoka, K.; Fujii, K.; Zhang, H.; Usuda, K.; Watanabe, G.; Ivshina, M.; Richter, J. D.			CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis	ONCOGENE			English	Article							MESSENGER-RNA TRANSLATION; CYTOPLASMIC POLYADENYLATION; CELLULAR SENESCENCE; SYNAPTIC PLASTICITY; KNOCKOUT MICE; IN-VIVO; GROWTH; DIFFERENTIATION; MORPHOGENESIS; LOCALIZATION	In mouse mammary epithelial cells, cytoplasmic polyadenylation element binding protein 1 (CPEB1) mediates the apical localization of ZO-1 mRNA, which encodes a critical tight junction component. In mice lacking CPEB1 and in cultured cells from which CPEB has been depleted, randomly distributed ZO-1 mRNA leads to the loss of cell polarity. We have investigated whether this diminution of polarity results in an epithelial-to-mesenchyme (EMT) transition and possible increased metastatic potential. Here, we show that CPEB1-depleted mammary epithelial cells alter their gene expression profile in a manner consistent with an EMT and also become motile, which are made particularly robust when cells are treated with transforming growth factor-beta, an enhancer of EMT. CPEB1-depleted mammary cells become metastatic to the lung following injection into mouse fat pads while ectopically expressed CPEB1 prevents metastasis. Surprisingly, CPEB1 depletion causes some EMT/metastasis-related mRNAs to have shorter poly(A) tails while other mRNAs to have longer poly(A) tails. Matrix metalloproteinase 9 (MMP9) mRNA, which encodes a metastasis-promoting factor, undergoes poly(A) lengthening and enhanced translation upon CPEB reduction. Moreover, in human breast cancer cells that become progressively more metastatic, CPEB1 is reduced while MMP9 becomes more abundant. These data suggest that at least in part, CPEB1 regulation of MMP9 mRNA expression mediates metastasis of breast cancer cells.	[Nagaoka, K.; Fujii, K.; Zhang, H.; Usuda, K.; Watanabe, G.] Tokyo Univ Agr & Technol, Dept Vet Med, Lab Vet Physiol, Tokyo, Japan; [Ivshina, M.; Richter, J. D.] Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA	Tokyo University of Agriculture & Technology; University of Massachusetts System; University of Massachusetts Worcester	Nagaoka, K; Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	nagaokak@cc.tuat.ac.jp; joel.richter@umassmed.edu	Watanabe/G-1134-2013; Nagaoka, Kentaro/C-2019-2013	Watanabe/0000-0001-7611-4678; Nagaoka, Kentaro/0000-0003-1038-1380; Ivshina, Maria/0000-0002-0999-3470	NIH [GM46779]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046779] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grant GM46779 (to JDR).	Alarcon JM, 2004, LEARN MEMORY, V11, P318, DOI 10.1101/lm.72704; Alexandrov IM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002457; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Berger-Sweeney J, 2006, LEARN MEMORY, V13, P4, DOI 10.1101/lm.73706; Bestman JE, 2008, P NATL ACAD SCI USA, V105, P20494, DOI 10.1073/pnas.0806296105; Burns DM, 2011, NATURE, V473, P105, DOI 10.1038/nature09908; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; D'Ambrogio A, 2013, NAT REV CANCER, V13, P283, DOI 10.1038/nrc3485; D'Ambrogio A, 2012, CELL REP, V2, P1537, DOI 10.1016/j.celrep.2012.10.023; Du L, 2005, RNA, V11, P1340, DOI 10.1261/rna.2870505; Eliscovich C, 2008, NAT CELL BIOL, V10, P858, DOI 10.1038/ncb1746; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906; Groppo R, 2011, MOL CELL BIOL, V31, P2707, DOI 10.1128/MCB.05133-11; Grudzien-Nogalska E, 2014, J CELL SCI, V127, P2326, DOI 10.1242/jcs.144956; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Ivshina M, 2014, ANNU REV CELL DEV BI, V30, P393, DOI 10.1146/annurev-cellbio-101011-155831; Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013; Kim JH, 2006, MOL CELL, V24, P173, DOI 10.1016/j.molcel.2006.08.016; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kochanek DM, 2013, MOL CANCER RES, V11, P149, DOI 10.1158/1541-7786.MCR-12-0498; Licatalosi DD, 2008, NATURE, V456, P464, DOI 10.1038/nature07488; Lin CL, 2010, RNA, V16, P338, DOI 10.1261/rna.1779810; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Nagaoka K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1678; Nairismagi ML, 2012, ONCOGENE, V31, P4960, DOI 10.1038/onc.2011.650; Racki WJ, 2006, DEVELOPMENT, V133, P4527, DOI 10.1242/dev.02651; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shen WH, 2014, CELL REP, V6, P737, DOI 10.1016/j.celrep.2014.01.024; Tay J, 2001, DEV CELL, V1, P201, DOI 10.1016/S1534-5807(01)00025-9; Udagawa T, 2013, NAT MED, V19, P1473, DOI 10.1038/nm.3353; Udagawa T, 2012, MOL CELL, V47, P253, DOI 10.1016/j.molcel.2012.05.016; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304	40	51	52	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2893	2901		10.1038/onc.2015.350	http://dx.doi.org/10.1038/onc.2015.350			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411364	Green Accepted			2022-12-17	WOS:000377473700009
J	Cisowski, J; Sayin, VI; Liu, M; Karlsson, C; Bergo, MO				Cisowski, J.; Sayin, V. I.; Liu, M.; Karlsson, C.; Bergo, M. O.			Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF	ONCOGENE			English	Article							HUMAN-MELANOMA; RAS ONCOGENES; LUNG-CANCER; K-RAS; MUTATIONS; PATHWAY; BRAF(V600E); PROGRESSION; NRAS(Q61R); ACTIVATION	KRAS and BRAF are among the most commonly mutated oncogenes in human cancer that contribute to tumorigenesis in both distinct and overlapping tissues. However, KRAS and BRAF mutations are mutually exclusive; they never occur in the same tumor cell. The reason for the mutual exclusivity is unknown, but there are several possibilities. The two mutations could be functionally redundant and not create a selective advantage to tumor cells. Alternatively, they could be deleterious for the tumor cell and induce apoptosis or senescence. To distinguish between these possibilities, we activated the expression of BRAF(V600E) and KRAS(G12D) from their endogenous promoters in mouse lungs. Although the tumor-forming ability of BRAF(V600E) was higher than KRAS(G12D), KRAS(G12D) tumors were larger and more advanced. Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone. Moreover, several tumors expressed only one oncogene, suggesting negative selection against expression of both. Similarly, expression of both oncogenes in mouse embryonic fibroblasts essentially stopped proliferation. The expression of both oncogenes hyperactivated the MEK-ERK-cyclin D pathway but reduced proliferation by increasing the production of p15, p16 and p19 proteins encoded by the Ink4/Arf locus and thereby increased senescence-associated beta-galactosidase-positive cells. The data suggest that coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence.	[Cisowski, J.; Sayin, V. I.; Karlsson, C.; Bergo, M. O.] Univ Gothenburg, Inst Med, Sahlgrenska Canc Ctr, Dept Mol & Clin Med, Med Gatan 1G,POB 425, S-41390 Gothenburg, Sweden; [Sayin, V. I.] Univ Gothenburg, Inst Med, Wallenberg Lab, Dept Mol & Clin Med, S-41390 Gothenburg, Sweden; [Liu, M.] Univ Gothenburg, Inst Biomed, Dept Clin Chem & Transfus Med, S-41390 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Bergo, MO (corresponding author), Univ Gothenburg, Inst Med, Sahlgrenska Canc Ctr, Dept Mol & Clin Med, Med Gatan 1G,POB 425, S-41390 Gothenburg, Sweden.	martin.bergo@gu.se		Liu, Viktor/0000-0003-2865-034X	Swedish Cancer Society; Swedish Research Council; Goran Gustafsson Foundation; Swedish Children's Cancer Fund; BioCARE-a strategic research program at the University of Gothenburg; Ingabritt and Arne Lundberg's Research Foundation; Assar Gabrielsson Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Goran Gustafsson Foundation; Swedish Children's Cancer Fund; BioCARE-a strategic research program at the University of Gothenburg; Ingabritt and Arne Lundberg's Research Foundation; Assar Gabrielsson Foundation	We thank R Ister for technical assistance. This study was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Goran Gustafsson Foundation, the Swedish Children's Cancer Fund, BioCARE-a strategic research program at the University of Gothenburg, and Ingabritt and Arne Lundberg's Research Foundation (to MOB); and the Assar Gabrielsson Foundation (to VIS).	Alsina J, 2003, CLIN CANCER RES, V9, P6419; Andreadi C, 2012, GENE DEV, V26, P1945, DOI 10.1101/gad.193458.112; Borras E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-406; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goydos JS, 2005, J AM COLL SURGEONS, V200, P362, DOI 10.1016/j.jamcollsurg.2004.10.032; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Karreth FA, 2009, MOL CELL, V36, P477, DOI 10.1016/j.molcel.2009.10.017; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016; Monticone M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-92; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Sayin VI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055720; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Seth R, 2009, GUT, V58, P1234, DOI 10.1136/gut.2008.159137; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Vandal G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084745; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985	26	51	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1328	1333		10.1038/onc.2015.186	http://dx.doi.org/10.1038/onc.2015.186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028035				2022-12-17	WOS:000371763100013
J	Wang, L; Yang, H; Lei, Z; Zhao, J; Chen, Y; Chen, P; Li, C; Zeng, Y; Liu, Z; Liu, X; Zhang, HT				Wang, L.; Yang, H.; Lei, Z.; Zhao, J.; Chen, Y.; Chen, P.; Li, C.; Zeng, Y.; Liu, Z.; Liu, X.; Zhang, H-T			Repression of TIF gamma by SOX2 promotes TGF-beta-induced epithelial-mesenchymal transition in non-small-cell lung cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTION FACTORS; MULTIPLE ROLES; GROWTH; METASTASIS; EXPRESSION; TIF1-GAMMA; SMAD4; PROGRESSION; SURVIVAL	TIF1 gamma is a novel regulator of transforming growth factor (TGF)-beta/Smad signaling. Our previous studies show that dysregulated expression of transcriptional intermediary factor 1 gamma (TIF1 gamma) and abnormal TGF-beta/Smad signaling are implicated in non-small-cell lung cancer (NSCLC) separately. However, how TIF1 gamma contributes to NSCLC by controlling TGF-beta/Smad signaling is poorly understood. Here, we investigated the mechanistic role of TIF1 gamma in TGF-beta-induced epithelial-mesenchymal transition (EMT), as well as a link between TIF1 gamma and SOX2 in NSCLC. We show that TIF1 gamma is a downstream target of SOX2 in NSCLC cells. SOX2 overexpression negatively regulated TIF1 gamma promoter activity and thereby attenuated TIF1 gamma mRNA and protein expression levels; SOX2 knockdown significantly enhanced TIF1 gamma promoter activity and augmented TIF1 gamma expression. Moreover, TIF1 gamma mRNA expression was downregulated in human NSCLC tissues and negatively correlated with SOX2 protein, which was upregulated in NSCLC tissues. Importantly, knockdown of TIF1 gamma or SOX2 overexpression augmented SMAD4 (human Mad (mothers against decapentaplegic)-related homologous protein 4)-dependent transcriptional responses, and enhanced TGF-beta-induced EMT and human NSCLC cell invasion; knockdown of SOX2 impaired TGF-beta-induced EMT and NSCLC cell invasion. In an in vivo model of metastasis, knockdown of TIF1 gamma promotes NSCLC cell metastasis. In addition, our data suggested that TIF1 gamma inhibited TGF-beta-induced EMT through competing with SMAD4 in NSCLC cells. Taken together, our findings reveal a new mechanism by which SOX2-mediated transcription repression of TIF1 gamma promotes TGF-beta-induced EMT in NSCLC.	[Wang, L.; Yang, H.; Lei, Z.; Liu, X.; Zhang, H-T] Soochow Univ, Coll Med, Lab Canc Mol Genet, 199 Renai Rd,Sinosingapore Ind Pk, Suzhou 215123, Peoples R China; [Wang, L.; Yang, H.; Lei, Z.; Zhao, J.; Li, C.; Zeng, Y.; Liu, Z.; Liu, X.; Zhang, H-T] Suzhou Key Lab Mol Canc Genet, Suzhou, Peoples R China; [Zhao, J.; Li, C.; Zeng, Y.; Liu, Z.] Soochow Univ, Dept Thorac & Cardiovasc Surg, Affiliated Hosp 1, Coll Med, Suzhou, Peoples R China; [Chen, Y.] Soochow Univ, Coll Med, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Suzhou, Peoples R China; [Chen, P.] Genome Scale Biol, Res Programs Unit, Syst Biol Lab, Haartmaninkatu 8, Helsinki, Finland; [Chen, P.] Univ Helsinki, Fac Med, Inst Biomed Biochem & Dev Biol, Haartmaninkatu 8, Helsinki, Finland	Soochow University - China; Soochow University - China; Soochow University - China; University of Helsinki	Zhang, HT (corresponding author), Soochow Univ, Coll Med, Lab Canc Mol Genet, 199 Renai Rd,Sinosingapore Ind Pk, Suzhou 215123, Peoples R China.	htzhang@suda.edu.cn	Zhang, Hong-Tao/P-9661-2017; Chen, Ping/AAL-8264-2020; Lei, Zhe/AGZ-4963-2022	Zhang, Hong-Tao/0000-0003-4182-421X; Chen, Ping/0000-0002-8068-1891; 	National Natural Science Foundation of China [81372277, 81171894, 81201575]; Jiangsu Province's Key Provincial Talents Program [RC2011106]; '333' Project of Jiangsu Province Government; Graduate Innovation Project of Jiangsu Province [CXZZ13_0830]; Soochow Scholar Project of Soochow University; Suzhou Key Laboratory for Molecular Cancer Genetics [SZS201209]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province's Key Provincial Talents Program; '333' Project of Jiangsu Province Government; Graduate Innovation Project of Jiangsu Province; Soochow Scholar Project of Soochow University; Suzhou Key Laboratory for Molecular Cancer Genetics; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	We are grateful for participation and cooperation from the patients with NSCLC. This work was supported in part by the grants from National Natural Science Foundation of China (81372277, 81171894 and 81201575), Jiangsu Province's Key Provincial Talents Program (RC2011106), '333' Project of Jiangsu Province Government, Graduate Innovation Project of Jiangsu Province (CXZZ13_0830), Soochow Scholar Project of Soochow University, Suzhou Key Laboratory for Molecular Cancer Genetics (SZS201209) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Aucagne R, 2011, J CLIN INVEST, V121, P2361, DOI 10.1172/JCI45213; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Fang WT, 2014, INT J CANCER, V135, P809, DOI 10.1002/ijc.28734; Fattet L, 2013, J CELL SCI, V126, P3713, DOI 10.1242/jcs.126748; Feng J, 2012, AM J CLIN PATHOL, V138, P230, DOI 10.1309/AJCPDHQFNYJZ01YG; Gontan C, 2008, DEV BIOL, V317, P296, DOI 10.1016/j.ydbio.2008.02.035; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hesling C, 2011, EMBO REP, V12, P665, DOI 10.1038/embor.2011.78; Jeon HS, 2010, J THORAC ONCOL, V5, P417, DOI 10.1097/JTO.0b013e3181ce3afd; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Lei Z, 2014, FASEB J, V28, P2696, DOI 10.1096/fj.13-247288; Lei Z, 2009, CANCER RES, V69, P7046, DOI 10.1158/0008-5472.CAN-08-4602; Li XF, 2013, CANCER LETT, V336, P379, DOI 10.1016/j.canlet.2013.03.027; Liu KC, 2013, CELL SIGNAL, V25, P1264, DOI 10.1016/j.cellsig.2013.02.013; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Nakatsugawa M, 2011, LAB INVEST, V91, P1796, DOI 10.1038/labinvest.2011.140; Park C, 2002, LUNG CANCER-J IASLC, V38, P143, DOI 10.1016/S0169-5002(02)00182-4; Pirozzi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021548; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Qian Q, 2014, INT J ONCOL, V44, P874, DOI 10.3892/ijo.2014.2255; Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629; Szymanowska-Narloch A, 2013, ADV MED SCI-POLAND, V58, P196, DOI 10.2478/ams-2013-0025; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Vincent DF, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000575; Wang Longqiang, 2013, Zhongguo Fei Ai Za Zhi, V16, P227, DOI 10.3779/j.issn.1009-3419.2013.05.02; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Xu Wei, 2013, Zhongguo Fei Ai Za Zhi, V16, P591, DOI 10.3779/j.issn.1009-3419.2013.11.05; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Zhang HT, 2004, CLIN CANCER RES, V10, P2359, DOI 10.1158/1078-0432.CCR-0959-3; Zhao J, 2008, J CANCER RES CLIN, V134, P919, DOI 10.1007/s00432-008-0392-4; Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18	47	51	58	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					867	877		10.1038/onc.2015.141	http://dx.doi.org/10.1038/onc.2015.141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961934				2022-12-17	WOS:000370332200007
J	Cao, K; Wang, G; Li, W; Zhang, L; Wang, R; Huang, Y; Du, L; Jiang, J; Wu, C; He, X; Roberts, AI; Li, F; Rabson, AB; Wang, Y; Shi, Y				Cao, K.; Wang, G.; Li, W.; Zhang, L.; Wang, R.; Huang, Y.; Du, L.; Jiang, J.; Wu, C.; He, X.; Roberts, A. I.; Li, F.; Rabson, A. B.; Wang, Y.; Shi, Y.			Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity	ONCOGENE			English	Article							T-CELLS; MEDIATED APOPTOSIS; TRANSCRIPTION FACTORS; MOLECULAR-MECHANISMS; CANCER PROGRESSION; CYCLOSPORINE-A; EXPRESSION; THERAPY; TUMORS; ANTIBODY	The poor efficacy of the in vivo anti-tumor immune response has been partially attributed to ineffective T-cell responses mounted against the tumor. Fas-FasL-dependent activation-induced cell death (AICD) of T cells is believed to be a major contributor to compromised anti-tumor immunity. The molecular mechanisms of AICD are well-investigated, yet the possibility of regulating AICD for cancer therapy remains to be explored. In this study, we show that histone deacetylase inhibitors (HDACIs) can inhibit apoptosis of CD4(+) T cells within the tumor, thereby enhancing anti-tumor immune responses and suppressing melanoma growth. This inhibitory effect is specific for AICD through suppressing NFAT1-regulated FasL expression on activated CD4(+) T cells. In gld/gld mice with mutation in FasL, the beneficial effect of HDACIs on AICD of infiltrating CD4(+) T cells is not seen, confirming the critical role of FasL regulation in the anti-tumor effect of HDACIs. Importantly, we found that the co-administration of HDACIs and anti-CTLA4 could further enhance the infiltration of CD4(+) T cells and achieve a synergistic therapeutic effect on tumor. Therefore, our study demonstrates that the modulation of AICD of tumor-infiltrating CD4(+) T cells using HDACIs can enhance anti-tumor immune responses, uncovering a novel mechanism underlying the anti-tumor effect of HDACIs.	[Cao, K.; Wang, G.; Li, W.; Huang, Y.; Du, L.; Li, F.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ Med, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, Shanghai, Peoples R China; [Zhang, L.; Roberts, A. I.; Rabson, A. B.; Shi, Y.] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Zhang, L.; Shi, Y.] Soochow Univ, Affiliated Hosp 1, Inst Translat Med, Suzhou 215123, Peoples R China; [Wang, R.] Cedars Sinai Med Ctr, Dept Med, Urooncol Res, Los Angeles, CA 90048 USA; [Jiang, J.; Wu, C.; He, X.] Soochow Univ, Affiliated Hosp 3, Changzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Soochow University - China; Cedars Sinai Medical Center; Soochow University - China	Shi, Y (corresponding author), Soochow Univ, Affiliated Hosp 1, Inst Translat Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	yingwang@sibs.ac.cn; yfshi@suda.edu.cn	HUANG, YIN/AAH-6871-2020; Du, Liming/M-8227-2019; cao, kai/AAG-6833-2021; Shi, Yufang/AAE-4431-2020	HUANG, YIN/0000-0001-5602-9871; Shi, Yufang/0000-0001-8964-319X; wang, ying/0000-0002-2571-9367; Du, Liming/0000-0002-0527-3556; cao, kai/0000-0002-7939-7279	Scientific Innovation Project of the Chinese Academy of Science [XDA 01040107, XDA 01040110]; Programs of National Natural Science of China [81330046]; Ministry of Science and Technology of China [2015CB964400]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Municipal Key Projects of Basic Research [12JC1409200]; Shanghai Rising-Star Program [14QA1404200]; Robert Wood Johnson Foundation [67038]	Scientific Innovation Project of the Chinese Academy of Science; Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Municipal Key Projects of Basic Research; Shanghai Rising-Star Program; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	This work was supported by grants from the Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107 and XDA 01040110), the Programs of National Natural Science of China (81330046), the Ministry of Science and Technology of China (2015CB964400), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Municipal Key Projects of Basic Research (12JC1409200), Shanghai Rising-Star Program (14QA1404200). The Child Health Institute of New Jersey is supported by a grant from the Robert Wood Johnson Foundation (grant number 67038).	Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bolger TA, 2005, J NEUROSCI, V25, P9544, DOI 10.1523/JNEUROSCI.1826-05.2005; Boni A, 2008, BLOOD, V112, P4746, DOI 10.1182/blood-2008-07-169797; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Butler LM, 2000, CANCER RES, V60, P5165; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Devadas S, 2006, IMMUNITY, V25, P237, DOI 10.1016/j.immuni.2006.06.011; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jacobson M.D., 1996, BIOCH SCI, V21, P83, DOI DOI 10.1016/S0968-0004(96)20008-8; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Liu FY, 2012, J BIOL CHEM, V287, P25530, DOI 10.1074/jbc.M112.356279; Maecker HL, 2002, CANCER CELL, V2, P139, DOI 10.1016/S1535-6108(02)00095-8; Manicassainy S, 2007, J IMMUNOL, V178, P312, DOI 10.4049/jimmunol.178.1.312; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; MERION RM, 1984, NEW ENGL J MED, V310, P148, DOI 10.1056/NEJM198401193100303; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreira JMA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-30; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Swann JB, 2007, J CLIN INVEST, V117, P1137, DOI 10.1172/JCI31405; Tanaka T, 2002, CANCER LETT, V181, P165, DOI 10.1016/S0304-3835(01)00799-6; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Wang RX, 1998, J IMMUNOL, V161, P2201; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Xu GW, 2007, CELL RES, V17, P759, DOI 10.1038/cr.2007.52; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yu P, 2006, LAB INVEST, V86, P231, DOI 10.1038/labinvest.3700389; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029	49	51	51	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5960	5970		10.1038/onc.2015.46	http://dx.doi.org/10.1038/onc.2015.46			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25745993	Green Published, hybrid			2022-12-17	WOS:000366113500003
J	Hernanda, PY; Chen, K; Das, AM; Sideras, K; Wang, W; Li, J; Cao, W; Bots, SJA; Kodach, LL; de Man, RA; Ijzermans, JNM; Janssen, HLA; Stubbs, AP; Sprengers, D; Bruno, MJ; Metselaar, HJ; Hagen, TLM; Kwekkeboom, J; Peppelenbosch, MP; Pan, Q				Hernanda, P. Y.; Chen, K.; Das, A. M.; Sideras, K.; Wang, W.; Li, J.; Cao, W.; Bots, S. J. A.; Kodach, L. L.; de Man, R. A.; Ijzermans, J. N. M.; Janssen, H. L. A.; Stubbs, A. P.; Sprengers, D.; Bruno, M. J.; Metselaar, H. J.; Ten Hagen, T. L. M.; Kwekkeboom, J.; Peppelenbosch, M. P.; Pan, Q.			SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEINS; GROWTH-FACTOR-BETA; TGF-BETA; COLORECTAL-CANCER; SIGNALING PATHWAYS; PANCREATIC-CANCER; SUPPRESSOR GENE; CELL-MIGRATION; EXPRESSION; LIVER	Further understanding of the molecular biology and pathogenesis of hepatocellular carcinoma (HCC) is crucial for future therapeutic development. SMAD4, recognized as an important tumor suppressor, is a central mediator of transforming growth factor beta (TGFB) and bone morphogenetic protein (BMP) signaling. This study investigated the role of SMAD4 in HCC. Nuclear localization of SMAD4 was observed in a cohort of 140 HCC patients using tissue microarray. HCC cell lines were used for functional assay in vitro and in immune-deficient mice. Nuclear SMAD4 levels were significantly increased in patient HCC tumors as compared with adjacent tissues. Knockdown of SMAD4 significantly reduced the efficiency of colony formation and migratory capacity of HCC cells in vitro and was incompatible with HCC tumor initiation and growth in mice. Knockdown of SMAD4 partially conferred resistance to the anti-growth effects of BMP ligand in HCC cells. Importantly, simultaneous elevation of SMAD4 and phosphorylated SMAD2/3 is significantly associated with poor patient outcome after surgery. Although high levels of SMAD4 can also mediate an antitumor function by coupling with phosphorylated SMAD1/5/8, this signaling, however, is absent in majority of our HCC patients. In conclusion, this study revealed a highly non-canonical tumor-promoting function of SMAD4 in HCC. The drastic elevation of nuclear SMAD4 in sub-population of HCC tumors highlights its potential as an outcome predictor for patient stratification and a target for personalized therapeutic development.	[Hernanda, P. Y.; Chen, K.; Sideras, K.; Wang, W.; Li, J.; Cao, W.; Bots, S. J. A.; Kodach, L. L.; de Man, R. A.; Janssen, H. L. A.; Sprengers, D.; Bruno, M. J.; Metselaar, H. J.; Kwekkeboom, J.; Peppelenbosch, M. P.; Pan, Q.] Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Dept Gastroenterol & Hepatol, NL-3015 CE Rotterdam, Netherlands; [Hernanda, P. Y.; Chen, K.; Sideras, K.; Wang, W.; Li, J.; Cao, W.; Bots, S. J. A.; Kodach, L. L.; de Man, R. A.; Janssen, H. L. A.; Sprengers, D.; Bruno, M. J.; Metselaar, H. J.; Kwekkeboom, J.; Peppelenbosch, M. P.; Pan, Q.] Postgrad Sch Mol Med, NL-3015 CE Rotterdam, Netherlands; [Hernanda, P. Y.] Wijaya Kusuma Univ, Biomol Res Ctr, Lab Med Genet, Surabaya, Indonesia; [Chen, K.] Zhejiang Sci Tech Univ, Coll Life Sci, BioX Ctr, Hangzhou, Zhejiang, Peoples R China; [Das, A. M.; Ten Hagen, T. L. M.] Erasmus Univ, Med Ctr, Dept Surg, Lab Expt Surg Oncol Sect Surg Oncol, NL-3015 CE Rotterdam, Netherlands; [Ijzermans, J. N. M.] Erasmus Univ, Med Ctr, Dept Surg, NL-3015 CE Rotterdam, Netherlands; [Janssen, H. L. A.] Univ Hlth Network, Div Gastroenterol, Toronto, ON, Canada; [Stubbs, A. P.] Erasmus Univ, Med Ctr, Dept Bioinformat, NL-3015 CE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Zhejiang Sci-Tech University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Erasmus University Rotterdam; Erasmus MC	Pan, Q (corresponding author), Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Dept Gastroenterol & Hepatol, Room Na 617,sGravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	q.pan@erasmusmc.nl	Peppelenbosch, Maikel P./U-5304-2019	Sideras, Kostandinos/0000-0002-4698-2105; Pan, Qiuwei/0000-0001-9982-6184; hernanda, pratika yuhyi/0000-0003-2025-2136; Peppelenbosch, Maikel/0000-0001-9112-6028; Kodach, Liudmila/0000-0003-2487-3204	Daniel den Hoed Foundation; Netherlands Organization for Scientific Research (NWO/ZonMw) [916-13-032]; Dutch Digestive Foundation (MLDS) [CDG 1304]; European Association for the Study of the Liver (EASL); Science and Technology Department Commonwealth Technology Applied Research Project of Zhejiang Province, China [2012F82G2060018]; National Nature Science Foundation of China [81272687]	Daniel den Hoed Foundation; Netherlands Organization for Scientific Research (NWO/ZonMw)(Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Health Research and Development); Dutch Digestive Foundation (MLDS); European Association for the Study of the Liver (EASL); Science and Technology Department Commonwealth Technology Applied Research Project of Zhejiang Province, China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank the support from the Daniel den Hoed Foundation for a Centennial Award fellowship (to Q Pan), the Netherlands Organization for Scientific Research (NWO/ZonMw) for a VENI grant (no. 916-13-032) (to Q Pan), the Dutch Digestive Foundation (MLDS) for a career development grant (no. CDG 1304) (to Q Pan) and the European Association for the Study of the Liver (EASL) for a Sheila Sherlock Fellowship (to Q Pan). Support from the Science and Technology Department Commonwealth Technology Applied Research Project (no. 2012F82G2060018) of Zhejiang Province, China and the National Nature Science Foundation of China (No. 81272687) (to K Chen) is gratefully acknowledged. We thank Dr Ron Smits from Erasmus Medical Center Rotterdam for critical reading of the manuscript and thank Dr Jie Xu from the Animal Care at Hangzhou Normal University, Hangzhou, China for helping with the animal experiments.	Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Argani P, 2001, CANCER, V91, P1332; Caputo V, 2012, AM J HUM GENET, V90, P161, DOI 10.1016/j.ajhg.2011.12.011; Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561; Chiu CY, 2012, MOL CANCER RES, V10, P415, DOI 10.1158/1541-7786.MCR-11-0293; Das AM, 2014, ANGIOGENESIS, V17, P163, DOI 10.1007/s10456-013-9385-2; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; Hernanda PY, 2013, CARCINOGENESIS, V34, P2330, DOI 10.1093/carcin/bgt210; Hiwatashi K, 2009, ANN SURG ONCOL, V16, P3176, DOI 10.1245/s10434-009-0614-2; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Itatani Y, 2013, GASTROENTEROLOGY, V145, P1064, DOI 10.1053/j.gastro.2013.07.033; Kang YK, 2002, HUM PATHOL, V33, P877, DOI 10.1053/hupa.2002.127444; Kocabayoglu Peri, 2013, Front Biosci (Schol Ed), V5, P217; Kodach LL, 2008, CANCER, V112, P300, DOI 10.1002/cncr.23160; Kodach LL, 2007, GASTROENTEROLOGY, V133, P1272, DOI 10.1053/j.gastro.2007.08.021; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li Q, 2013, CANCER SCI, V104, P398, DOI 10.1111/cas.12093; Maegdefrau U, 2012, EXP MOL PATHOL, V92, P74, DOI 10.1016/j.yexmp.2011.10.004; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Matsuzaki K, 2007, HEPATOLOGY, V46, P48, DOI 10.1002/hep.21672; Matsuzaki K, 2013, CYTOKINE GROWTH F R, V24, P385, DOI 10.1016/j.cytogfr.2013.06.002; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Mullauer L, 1996, HEPATOLOGY, V23, P840, DOI 10.1002/hep.510230427; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Pan QW, 2008, ACTA ONCOL, V47, P135, DOI 10.1080/02841860701403053; Pan QW, 2011, FEBS LETT, V585, P1025, DOI 10.1016/j.febslet.2011.02.035; Pedroza-Gonzalez A, 2013, HEPATOLOGY, V57, P183, DOI 10.1002/hep.26013; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Sakai H, 2012, CLIN EXP METASTAS, V29, P327, DOI 10.1007/s10585-012-9453-9; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Tangkijvanich P, 2000, J CLIN GASTROENTEROL, V31, P302, DOI 10.1097/00004836-200012000-00007; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; van Horssen R, 2006, J CELL BIOCHEM, V99, P1536, DOI 10.1002/jcb.20994; Virtanen S, 2011, EXP CELL RES, V317, P2136, DOI 10.1016/j.yexcr.2011.06.001; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wang L, 2012, INT J CANCER, V131, P1941, DOI 10.1002/ijc.27444; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yao L, 2012, ASIAN PAC J CANCER P, V13, P1297, DOI 10.7314/APJCP.2012.13.4.1297; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhang LX, 2012, CANCER RES, V72, P4276, DOI 10.1158/0008-5472.CAN-12-1013	52	51	53	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5055	5068		10.1038/onc.2014.425	http://dx.doi.org/10.1038/onc.2014.425			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531314				2022-12-17	WOS:000361693300006
J	Ubertini, V; Norelli, G; D'Arcangelo, D; Gurtner, A; Cesareo, E; Baldari, S; Gentileschi, MP; Piaggio, G; Nistico, P; Soddu, S; Facchiano, A; Bossi, G				Ubertini, V.; Norelli, G.; D'Arcangelo, D.; Gurtner, A.; Cesareo, E.; Baldari, S.; Gentileschi, M. P.; Piaggio, G.; Nistico, P.; Soddu, S.; Facchiano, A.; Bossi, G.			Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist	ONCOGENE			English	Article							CANCER-RELATED INFLAMMATION; NECROSIS-FACTOR-ALPHA; LI-FRAUMENI-SYNDROME; KAPPA-B ACTIVATION; REGULATORY REGIONS; GENE-EXPRESSION; IL-1 RECEPTOR; TUMOR MALIGNANCY; MESSENGER-RNA; IN-VIVO	The TP53 tumor-suppressor gene is frequently mutated in human cancer. Missense mutations can add novel functions (gain-of-function, GOF) that promote tumor malignancy. Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN). We show that mutp53 but not wild-type (wt) p53 suppresses the sIL-1Ra production in conditioned media of cancer cells. Moreover, mutp53, but not wtp53, binds physically the sIL-1Ra promoter and the protein-protein interaction with the transcriptional corepressor MAFF (v-MAF musculoaponeurotic fibrosarcoma oncogene family, protein F) is required for mutp53-induced sIL-1Ra suppression. Remarkably, when exposed to IL-1 beta (IL-1 beta) inflammatory stimuli, mutp53 sustains a ready-to-be-activated in vitro and in vivo cancer cells' response through the sIL-1Ra repression. Taken together, these results identify sIL-1Ra as a novel mutp53 target gene, whose suppression might be required to generate a chronic pro-inflammatory tumor microenvironment through which mutp53 promotes tumor malignancy.	[Ubertini, V.; Norelli, G.; Gurtner, A.; Baldari, S.; Gentileschi, M. P.; Piaggio, G.; Nistico, P.; Soddu, S.] Regina Elena Inst Canc Res, Expt Oncol Labs, I-00158 Rome, Italy; [D'Arcangelo, D.; Cesareo, E.; Facchiano, A.] IRCCS, Ist Dermopat Immacolata IDI, Rome, Italy; [Bossi, G.] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Bossi, G (corresponding author), Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Via Messi Oro 156, I-00158 Rome, Italy.	bossi@ifo.it	Baldari, Silvia/AAA-5959-2021; D'Arcangelo, Daniela/K-6533-2016; Bossi, Gianluca/ABH-6846-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; gurtner, aymone/AAB-8843-2020; Gurtner, Aymone/J-7217-2018; Bossi, Gianluca/B-9394-2017; Bossi, Gianluca/G-8375-2016; Piaggio, Giulia/AAD-7336-2022; Nisticò, Paola/B-2862-2018; Piaggio, Giulia/J-7214-2018; Maria Pia, Gentileschi/J-2637-2017; Facchiano, Antonio/J-4744-2012; Facchiano, Antonio/K-5984-2016	Baldari, Silvia/0000-0001-7982-9468; D'Arcangelo, Daniela/0000-0002-7862-3289; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; gurtner, aymone/0000-0002-7661-9059; Gurtner, Aymone/0000-0002-7661-9059; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Nisticò, Paola/0000-0003-4409-2261; Piaggio, Giulia/0000-0003-2114-1892; Facchiano, Antonio/0000-0002-4243-2392; Facchiano, Antonio/0000-0002-4243-2392	Associazione Italiana Ricerca sul Cancro (AICR) (IG) [8804, 13234]; Associazione Italiana Ricerca sul Cancro (AICR) (MFAG) [11752]; Associazione Italiana Ricerca sul Cancro (AICR) (RC) [3.5-2013]	Associazione Italiana Ricerca sul Cancro (AICR) (IG)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana Ricerca sul Cancro (AICR) (MFAG)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana Ricerca sul Cancro (AICR) (RC)(Fondazione AIRC per la ricerca sul cancro)	We thank Dr S Bacchetti, Dr FL Graham and Dr G D'Orazi for critical reading of the manuscript; Dr C Gabay for providing pRa-1680-Luc vector; and Dr G Tolstonog for ENCODE in silico analyses on the sIL-1Ra promoter. This work was supported with grants from Associazione Italiana Ricerca sul Cancro (AICR) to GB (IG no. 8804), AG (MFAG no. 11752), PG (IG no. 13234), and AF (RC 3.5-2013). We thank the Proteomic Facility for Complex Potein Muxture (CPM) Analisys at ISS, Rome.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146; Apte RN, 2008, IMMUNOL REV, V222, P222, DOI 10.1111/j.1600-065X.2008.00615.x; Bar J, 2009, ONCOGENE, V28, P933, DOI 10.1038/onc.2008.445; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161; CHIRIVI RGS, 1993, CANCER RES, V53, P5051; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; D'Arcangelo D, 2002, CIRC RES, V91, pE4, DOI 10.1161/01.RES.0000036753.50601.E9; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Dunn E, 2001, TRENDS IMMUNOL, V22, P533, DOI 10.1016/S1471-4906(01)02034-8; Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603; Fischer A, 2005, MOL CELL BIOL, V25, P8960, DOI 10.1128/MCB.25.20.8960-8970.2005; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813; Jenkins JK, 1997, J IMMUNOL, V158, P748; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Kimura T, 1999, BIOCHEM BIOPH RES CO, V264, P86, DOI 10.1006/bbrc.1999.1487; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Notterman DA, 2001, CANCER RES, V61, P3124; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Puhlmann M, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-37; Quante T, 2012, CELL CYCLE, V11, P3290, DOI 10.4161/cc.21646; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; SMITH MF, 1992, J IMMUNOL, V149, P2000; Streicher KL, 2007, MOL CANCER RES, V5, P847, DOI 10.1158/1541-7786.MCR-06-0427; ULICH TR, 1992, AM J PATHOL, V141, P61; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; WU S, 1994, GYNECOL ONCOL, V53, P59, DOI 10.1006/gyno.1994.1088; Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224	44	51	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2493	2504		10.1038/onc.2014.191	http://dx.doi.org/10.1038/onc.2014.191			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998848				2022-12-17	WOS:000354190400008
J	Wu, DW; Wu, TC; Wu, JY; Cheng, YW; Chen, YC; Lee, MC; Chen, CY; Lee, H				Wu, D-W; Wu, T-C; Wu, J-Y; Cheng, Y-W; Chen, Y-C; Lee, M-C; Chen, C-Y; Lee, H.			Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression	ONCOGENE			English	Article						PXN; Bcl-2; cisplatin-based chemotherapy; NSCLC	OVARIAN-CANCER; REGULATES ADHESION; PREDICTS SURVIVAL; GROWTH; INVASION; PROLIFERATION; SENSITIVITY; CARCINOMA; APOPTOSIS; RELAPSE	Paxillin (PXN) is required for receptor tyrosine kinase-mediated ERK activation, and the activation of the Raf/MEK/ERK cascade has been linked with Bcl-2 expression. We hypothesized that phosphorylation of PXN by the EGFR/Src pathway might contribute to cisplatin resistance via increased Bcl-2 expression. We show that cisplatin resistance was dependent on PXN expression, as evidenced by PXN overexpression in TL-13 and TL-10 cells and PXN knockdown in H23 and CL1-5 cells. Specific inhibitors of signaling pathways indicated that the phosphorylation of PXN at Y118 and Y31 via the Src pathway was responsible for cisplatin resistance. We further demonstrated that ERK activation was also dependent on this PXN phosphorylation. Bcl-2 transcription was upregulated by phosphorylated PXN-mediated ERK activation via increased binding of phosphorylated CREB to the Bcl-2 promoter. A subsequent increase in Bcl-2 levels by a PXN/ERK axis was responsible for the resistance to cisplatin. Animal models further confirmed the findings of in vitro cells indicating that xenograft tumors induced by TL-13-overexpressing cells were successfully suppressed by cisplatin combined with Src or ERK inhibitor compared with treatment of cisplatin, Src inhibitor or ERK inhibitor alone. A positive correlation of phosphorylated PXN with phosphorylated ERK and Bcl-2 was observed in lung tumors from NSCLC patients. Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors. Collectively, PXN phosphorylation might contribute to cisplatin resistance via activating ERK-mediated Bcl-2 transcription. Therefore, we suggest that Src or ERK inhibitor might be helpful to improve the sensitivity for cisplatin-based chemotherapy in NSCLC patients with PXN-positive tumors.	[Wu, D-W; Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Wu, T-C] Chung Shan Med Univ, Dept Internal Med, Taichung, Taiwan; [Wu, J-Y] Buddhist Tzu Chi Taichung Gen Hosp, Div Thorac Surg, Taichung, Taiwan; [Wu, J-Y] Tzu Chi Univ, Coll Med, Hualien, Taiwan; [Chen, Y-C] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taichung, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Thorac Surg, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Chung Shan Medical University; Buddhist Tzu Chi General Hospital; Tzu Chi University; Taipei Medical University; Taichung Veterans General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Room 5,12F,3,Pk St, Taipei, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [NSC-100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (NSC-100-2314-B-038-043-MY3) of Taiwan, ROC.	Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Arany I, 2005, KIDNEY INT, V68, P1573, DOI 10.1111/j.1523-1755.2005.00569.x; Bai LF, 2012, INT J CANCER, V130, P2693, DOI 10.1002/ijc.26303; Bendardaf R, 2008, ONCOL REP, V20, P999, DOI 10.3892/or_00000101; Bertotti A, 2010, CLIN CANCER RES, V16, P3933, DOI 10.1158/1078-0432.CCR-10-0106; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Bray K, 2009, MOL CANCER RES, V7, P1487, DOI 10.1158/1541-7786.MCR-09-0166; Creson TK, 2009, J MOL NEUROSCI, V37, P123, DOI 10.1007/s12031-008-9122-2; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jagadeeswaran R, 2008, CANCER RES, V68, P132, DOI 10.1158/0008-5472.CAN-07-1998; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004; Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3; Low SY, 2012, CANCER LETT, V314, P166, DOI 10.1016/j.canlet.2011.09.025; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044; Sen A, 2010, J BIOL CHEM, V285, P28787, DOI 10.1074/jbc.M110.134064; Sheibani N, 2008, J CELL PHYSIOL, V214, P655, DOI 10.1002/jcp.21256; Shintani Y, 2011, ANN THORAC SURG, V92, P1794, DOI 10.1016/j.athoracsur.2011.07.032; Sorenson CM, 2004, J BIOL CHEM, V279, P11368, DOI 10.1074/jbc.M310079200; Subramanian M, 2007, J IMMUNOL, V179, P2330, DOI 10.4049/jimmunol.179.4.2330; Sung WW, 2011, CLIN CANCER RES, V17, P5991, DOI 10.1158/1078-0432.CCR-11-0227; Tabassam FH, 2011, AM J PHYSIOL-GASTR L, V301, pG601, DOI 10.1152/ajpgi.00375.2010; Turner CE, 2000, J CELL SCI, V113, P4139; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Yang TM, 2009, AM J RESP CELL MOL, V41, P14, DOI 10.1165/rcmb.2008-0320OC; Yoon H, 2011, BIOCHEM BIOPH RES CO, V405, P333, DOI 10.1016/j.bbrc.2010.11.130; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143; Zou W, 2012, J BONE MINER RES, V27, P2490, DOI 10.1002/jbmr.1706	43	51	52	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4385	4395		10.1038/onc.2013.389	http://dx.doi.org/10.1038/onc.2013.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24096476	Bronze			2022-12-17	WOS:000341157800003
J	Ciarapica, R; De Salvo, M; Carcarino, E; Bracaglia, G; Adesso, L; Leoncini, PP; Dall'Agnese, A; Walters, ZS; Verginelli, F; De Sio, L; Boldrini, R; Inserra, A; Bisogno, G; Rosolen, A; Alaggio, R; Ferrari, A; Collini, P; Locatelli, M; Stifani, S; Screpanti, I; Rutella, S; Yu, Q; Marquez, VE; Shipley, J; Valente, S; Mai, A; Miele, L; Puri, PL; Locatelli, F; Palacios, D; Rota, R				Ciarapica, R.; De Salvo, M.; Carcarino, E.; Bracaglia, G.; Adesso, L.; Leoncini, P. P.; Dall'Agnese, A.; Walters, Z. S.; Verginelli, F.; De Sio, L.; Boldrini, R.; Inserra, A.; Bisogno, G.; Rosolen, A.; Alaggio, R.; Ferrari, A.; Collini, P.; Locatelli, M.; Stifani, S.; Screpanti, I.; Rutella, S.; Yu, Q.; Marquez, V. E.; Shipley, J.; Valente, S.; Mai, A.; Miele, L.; Puri, P. L.; Locatelli, F.; Palacios, D.; Rota, R.			The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)	ONCOGENE			English	Article						EZH2; FBXO32; histone methyltransferases; PAX3-FOXO1; rhabdomyosarcoma; Polycomb proteins	COMBINED EPIGENETIC THERAPY; SKELETAL-MUSCLE; GENE-EXPRESSION; INHIBITOR 3-DEAZANEPLANOCIN; TRANSCRIPTION FACTORS; HISTONE METHYLATION; SELF-RENEWAL; CELLS; ATROPHY; DIFFERENTIATION	The Polycomb group (PcG) proteins regulate stem cell differentiation via the repression of gene transcription, and their deregulation has been widely implicated in cancer development. The PcG protein Enhancer of Zeste Homolog 2 (EZH2) works as a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) by methylating lysine 27 on histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. In skeletal muscle progenitors, EZH2 prevents an unscheduled differentiation by repressing muscle-specific gene expression and is downregulated during the course of differentiation. In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precursors, EZH2 is abnormally expressed and its downregulation in vitro leads to muscle-like differentiation of RMS cells of the embryonal variant. However, the role of EZH2 in the clinically aggressive subgroup of alveolar RMS, characterized by the expression of PAX3-FOXO1 oncoprotein, remains unknown. We show here that EZH2 depletion in these cells leads to programmed cell death. Transcriptional derepression of F-box protein 32 (FBXO32) (Atrogin1/MAFbx), a gene associated with muscle homeostasis, was evidenced in PAX3-FOXO1 RMS cells silenced for EZH2. This phenomenon was associated with reduced EZH2 occupancy and H3K27me3 levels at the FBXO32 promoter. Simultaneous knockdown of FBXO32 and EZH2 in PAX3-FOXO1 RMS cells impaired the pro-apoptotic response, whereas the overexpression of FBXO32 facilitated programmed cell death in EZH2-depleted cells. Pharmacological inhibition of EZH2 by either 3-Deazaneplanocin A or a catalytic EZH2 inhibitor mirrored the phenotypic and molecular effects of EZH2 knockdown in vitro and prevented tumor growth in vivo. Collectively, these results indicate that EZH2 is a key factor in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells working, at least in part, by repressing FBXO32. They also suggest that the reducing activity of EZH2 could represent a novel adjuvant strategy to eradicate high-risk PAX3-FOXO1 alveolar RMS.	[Ciarapica, R.; De Salvo, M.; Bracaglia, G.; Adesso, L.; Leoncini, P. P.; Verginelli, F.; De Sio, L.; Stifani, S.; Locatelli, F.; Rota, R.] IRCCS, Osped Pediat Bambino Gesu, Dept Oncohematol, Rome, Italy; [Carcarino, E.; Dall'Agnese, A.; Puri, P. L.; Palacios, D.] IRCCS Fdn Santa Lucia, Rome, Italy; [Walters, Z. S.; Shipley, J.] Inst Canc Res, Div Mol Pathol & Canc Therapeut, Sutton, Surrey, England; [Boldrini, R.] IRCCS, Osped Pediat Bambino Gesu, Dept Pathol, Rome, Italy; [Inserra, A.] IRCCS, Osped Pediat Bambino Gesu, Dept Surg, Rome, Italy; [Bisogno, G.; Rosolen, A.] Univ Padua, Dept Pediat, Oncohematol Unit, Padua, Italy; [Alaggio, R.] Univ Padua, Med DIMED, Pathol Unit, Padua, Italy; [Ferrari, A.] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy; [Collini, P.] Fdn IRCCS Ist Nazl Tumori, Anat Pathol Unit 2, Milan, Italy; [Locatelli, M.] IRCCS, Osped Pediat Bambino Gesu, Sci Directorate, Rome, Italy; [Stifani, S.] McGill Univ, Ctr Neuronal Survival, Montreal Neurol Inst, Montreal, PQ, Canada; [Screpanti, I.] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy; [Yu, Q.] Genome Inst Singapore, Agcy Sci Technol & Res, Singapore, Singapore; [Marquez, V. E.] Natl Canc Inst, CCR, Frederick Natl Lab Canc Res, Chem Biol Lab, Frederick, MD USA; [Valente, S.; Mai, A.] Univ Roma La Sapienza, Fdn Cenci Bolognetti, Ist Pasteur, Dipartimento Chim & Tecnol Farmaco, Rome, Italy; [Miele, L.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Puri, P. L.] Sanford Burnham Med Res Inst, Muscle Dev & Regenerat Program, La Jolla, CA USA; [Locatelli, F.] Univ Pavia, Dipartimento Sci Pediat, I-27100 Pavia, Italy	IRCCS Bambino Gesu; IRCCS Santa Lucia; University of London; Institute of Cancer Research - UK; IRCCS Bambino Gesu; IRCCS Bambino Gesu; University of Padua; University of Padua; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Bambino Gesu; McGill University; Sapienza University Rome; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fondazione Cenci Bolognetti; Sapienza University Rome; University of Mississippi; University of Mississippi Medical Center; Sanford Burnham Prebys Medical Discovery Institute; University of Pavia	Rota, R (corresponding author), IRCCS, Osped Pediat Bambino Gesu, Dept Oncohematol, Rome, Italy.	d.palacios@hsantalucia.it; rossella.rota@opbg.net	Mai, Antonello/AAC-2144-2019; Adesso, Laura/AAA-7708-2020; Rota, Rossella/AAB-2497-2019; Valente, Sergio/K-2198-2016; Rutella, Sergio/AAF-9187-2020; Locatelli, Mattia/AAA-6241-2020; Inserra, Alessandro/H-3120-2012; Rutella, Sergio/AAF-9210-2020; Marquez, Victor/AAP-3549-2021; Palacios, Daniela/AAA-7608-2019; verginelli, federica/HGU-3834-2022; Collini, Paola/K-7354-2016; Leoncini, Pier Paolo/AAH-9343-2019; alaggio, rita/AAC-2348-2019; Ferrari, Andrea/R-1028-2016; Palacios, Daniela/K-4698-2016; Bisogno, Gianni/K-9282-2016	Adesso, Laura/0000-0003-2121-4924; Rota, Rossella/0000-0002-9408-7711; Valente, Sergio/0000-0002-2241-607X; Rutella, Sergio/0000-0003-1970-7375; Palacios, Daniela/0000-0002-2207-2369; verginelli, federica/0000-0002-8762-8815; Collini, Paola/0000-0002-6158-210X; alaggio, rita/0000-0003-3915-3816; Ferrari, Andrea/0000-0002-4724-0517; Palacios, Daniela/0000-0002-2207-2369; Mai, Antonello/0000-0001-9176-2382; Miele, Lucio/0000-0002-5853-7287; Bisogno, Gianni/0000-0003-4462-5523; Shipley, Janet/0000-0001-6748-8678; Yu, Qiang/0000-0003-2132-8278; Walters, Zoe/0000-0002-1835-5868	Associazione Italiana per la Ricerca sul Cancro (AIRC) [10338]; Italian Ministry of Health Ricerca Corrente; Association for International Cancer Research (AICR-UK) [12-0168]; AIRC 5 per mille; NIH Intramural Research Program, National Cancer Institute, CCR; Cancer Research UK [C5066/A10399]; Sarcoma UK; Progetto IIT-Sapienza [A2]; FIRB [RBFR10ZJQT]; FP7 Project [BLUEPRINT/282510]; Worldwide Cancer Research [12-0168] Funding Source: researchfish	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health Ricerca Corrente(Ministry of Health, Italy); Association for International Cancer Research (AICR-UK); AIRC 5 per mille(Fondazione AIRC per la ricerca sul cancro); NIH Intramural Research Program, National Cancer Institute, CCR; Cancer Research UK(Cancer Research UK); Sarcoma UK; Progetto IIT-Sapienza; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); FP7 Project; Worldwide Cancer Research	We thank E Giorda for fluorescence-activated cell sorting analysis. Myogenin (Wright WE) and MHC (Fishman DA) antibodies were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242, USA. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, 10338) and Italian Ministry of Health Ricerca Corrente (RR); Association for International Cancer Research (AICR-UK, 12-0168) (DP); AIRC 5 per mille (FL); NIH Intramural Research Program, National Cancer Institute, CCR (VEM); Cancer Research UK (C5066/A10399) (ZSW); Sarcoma UK (ZSW, JS); Progetto IIT-Sapienza A2, FIRB RBFR10ZJQT and FP7 Project BLUEPRINT/282510 (AM). SS is a Chercheur National of the Fonds de la Recherche en Sante du Quebec.	Benoit YD, 2013, J CELL PHYSIOL, V228, P764, DOI 10.1002/jcp.24224; Boumber Y, 2011, ONCOLOGY-NY, V25, P220; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bray M, 2000, ANTIVIR RES, V45, P135, DOI 10.1016/S0166-3542(00)00066-8; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Cheng LL, 2012, CLIN CANCER RES, V18, P4201, DOI 10.1158/1078-0432.CCR-12-0036; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Crose LES, 2012, CLIN CANCER RES, V18, P3780, DOI 10.1158/1078-0432.CCR-10-3063; Davicioni E, 2010, J CLIN ONCOL, V28, P1240, DOI 10.1200/JCO.2008.21.1268; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fiskus W, 2012, CLIN CANCER RES, V18, P6227, DOI 10.1158/1078-0432.CCR-12-0873; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Gannon OM, 2013, CLIN CANCER RES, V19, P428, DOI 10.1158/1078-0432.CCR-12-2505; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hunt LC, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-17; Jiang YL, 2013, J CELL PHYSIOL, V228, P1989, DOI 10.1002/jcp.24365; Juan AH, 2011, GENE DEV, V25, P789, DOI 10.1101/gad.2027911; Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008; Kalushkova A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011483; Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Lagirand-Cantaloube J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004973; Lanzuolo C, 2012, ANNU REV GENET, V46, P561, DOI 10.1146/annurev-genet-110711-155603; Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921; Lee MH, 2011, CANCER RES, V71, P3921, DOI 10.1158/0008-5472.CAN-10-3358; Mai A, 2007, CHEMMEDCHEM, V2, P987, DOI 10.1002/cmdc.200700023; Marchesi I, 2012, CELL CYCLE, V11, P3828, DOI 10.4161/cc.22025; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Momparler RL, 2012, LEUKEMIA RES, V36, P1049, DOI 10.1016/j.leukres.2012.03.001; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; Mousavi K, 2012, MOL CELL, V45, P255, DOI 10.1016/j.molcel.2011.11.019; Ogata T, 2009, MECH AGEING DEV, V130, P328, DOI 10.1016/j.mad.2009.02.001; Okada A, 2008, MUSCLE NERVE, V38, P1246, DOI 10.1002/mus.21110; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Puri PL, 2000, GENE DEV, V14, P574; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Ramirez-Peinado S, 2011, CANCER RES, V71, P6796, DOI 10.1158/0008-5472.CAN-11-0759; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Serra C, 2007, MOL CELL, V28, P200, DOI 10.1016/j.molcel.2007.08.021; Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Valente S, 2012, BIOCHIMIE, V94, P2308, DOI 10.1016/j.biochi.2012.06.003; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vekony H, 2008, J CLIN PATHOL, V61, P744, DOI 10.1136/jcp.2007.054262; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Walters ZS, 2014, ONCOGENE, V33, P1148, DOI 10.1038/onc.2013.46; Wang C, 2011, CANCER RES, V72, P315; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wong CF, 2008, J BIOL CHEM, V283, P9836, DOI 10.1074/jbc.M709614200; Woodhouse S, 2013, J CELL SCI, V126, P565, DOI 10.1242/jcs.114843; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Xie P, 2009, J BIOL CHEM, V284, P5488, DOI 10.1074/jbc.M806487200; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498	73	51	52	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4173	4184		10.1038/onc.2013.471	http://dx.doi.org/10.1038/onc.2013.471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24213577	hybrid, Green Accepted			2022-12-17	WOS:000340595700008
J	Choi, C; Helfman, DM				Choi, C.; Helfman, D. M.			The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2	ONCOGENE			English	Article						K-Ras; ERK; stress fiber; motility; lung metastasis signature; PI3K	BREAST-CANCER METASTASIS; SIGNALING PATHWAYS; DOWN-REGULATION; CROSS-TALK; IN-VITRO; INHIBITION; ACTIVATION; EXPRESSION; FIBROBLASTS; RHOA	MDA-MB-231 LM2 (herein referred to as LM2) is a derivative of MDA-MB-231 cells that was selected for its ability to metastasize to lung tissue in vivo. We investigated cellular properties of LM2 including actin cytoskeleton organization, motility and signaling pathways that drive the expression of genes associated with the lung metastasis signature. Parental cells exhibit well-developed stress fibers, whereas LM2 had poorly organized stress fibers. LM2 exhibited higher levels of K-Ras protein and corresponding higher levels of phosphorylated ERK compared with parental cells. The Ras-ERK pathway was responsible for the disruption of stress fibers because inhibition of MEK with UO126 or small interfering RNA (siRNA) against K-Ras or ERK1/2 resulted in restoration of stress fibers and focal adhesions. We observed that the K-Ras-ERK pathway is important for the expression of genes associated with the lung metastasis signature. Paradoxically, inhibition of the Ras-ERK pathway did not result in inhibition of cell motility but was accompanied by activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Inhibition of both ERK and PI3K pathways was required to inhibit motility of LM2 cells. These results suggest that both ERK and PI3K pathways drive motile functions of metastatic LM2 cells and genes associated with the lung metastasis signature.	[Choi, C.; Helfman, D. M.] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Helfman, D. M.] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Helfman, DM (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 335 Gwahangno, Taejon 305701, South Korea.	dhelfman@kaist.ac.kr	Helfman, David M./C-2058-2011		WCU Program through the National Research Foundation of Korea - Ministry of Education Science and Technology [R31-2008-000-10071-0]; National Research Foundation of Korea [R1A-1A-2007-709]	WCU Program through the National Research Foundation of Korea - Ministry of Education Science and Technology; National Research Foundation of Korea(National Research Foundation of Korea)	We thank Jooyoung Yi and Sunyoung Lim for technical assistance. MDA-MB-231 parental, LM2 and BrM2 cells were kindly provided by Dr Joan Massague. DMH is supported by the WCU Program through the National Research Foundation of Korea funded by the Ministry of Education Science and Technology (R31-2008-000-10071-0) and grant from the National Research Foundation of Korea (R1A-1A-2007-709).	Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; Makrodouli E, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-118; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tourkina E, 2008, AM J PHYSIOL-LUNG C, V294, pL843, DOI 10.1152/ajplung.00295.2007; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wang XQ, 2009, MOL BIOL CELL, V20, P791, DOI 10.1091/mbc.E08-07-0732; Won JK, 2012, J MOL CELL BIOL, V4, P153, DOI 10.1093/jmcb/mjs021; Yamashita Y, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-20	33	51	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3668	3676		10.1038/onc.2013.341	http://dx.doi.org/10.1038/onc.2013.341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23995792				2022-12-17	WOS:000338942900006
J	Guo, Q; Su, N; Zhang, J; Li, X; Miao, Z; Wang, G; Cheng, M; Xu, H; Cao, L; Li, F				Guo, Q.; Su, N.; Zhang, J.; Li, X.; Miao, Z.; Wang, G.; Cheng, M.; Xu, H.; Cao, L.; Li, F.			PAK4 kinase-mediated SCG10 phosphorylation involved in gastric cancer metastasis	ONCOGENE			English	Article						PAK4; SCG10; phosphorylation; gastric cancer; metastasis	ANCHORAGE-INDEPENDENT GROWTH; NEURONAL GROWTH; CELL-MIGRATION; POOR-PROGNOSIS; STATHMIN; EXPRESSION; PROLIFERATION; INVASION; OVEREXPRESSION; MICROTUBULES	Superior cervical ganglia 10 (SCG10), as a microtubule (MT) destabilizer, maintains MT homeostasis and has a critical role in neuronal development, but its function in tumorigenesis has not been characterized. In the present study, we demonstrated that p21-activated kinase 4 (PAK4)-mediated SCG10 phosphorylation regulates MT homeostasis in metastatic gastric cancer. Our results indicate that SCG10 is a physiological substrate of PAK4, which is phosphorylated on serine 50 (Ser50) in a PAK4-dependent manner. Phosphorylated SCG10 regulated MT dynamics to promote gastric cancer cell migration and invasion in vitro and metastasis in a xenograft mouse models. Inhibiting PAK4, either by LCH-7749944 or RNA interference, resulted in the inhibition of Ser50 phosphorylation and a blockade to cell invasion, suggesting that PAK4-SCG10 signaling occurs in gastric cancer cell invasion. Moreover, we demonstrated a strong positive correlation between PAK4 and phospho-Ser50 SCG10 expression in gastric cancer samples. We also showed that high expression of SCG10 phospho-Ser50 is highly correlated to an aggressive phenotype of clinical gastric cancer. These findings revealed a novel function of SCG10 in promoting invasive potential of gastric cancer cells, suggesting that blocking PAK4-mediated SCG10 phosphorylation might be a potential therapeutic strategy for metastasis of gastric cancer.	[Guo, Q.; Su, N.; Zhang, J.; Li, X.; Wang, G.; Cao, L.; Li, F.] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, Shenyang 110001, Peoples R China; [Guo, Q.; Su, N.; Zhang, J.; Li, X.; Wang, G.; Cao, L.; Li, F.] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China; [Miao, Z.; Xu, H.] China Med Univ, Hosp 1, Dept Surg Oncol & Gen Surg, Shenyang 110001, Peoples R China; [Cheng, M.] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; Shenyang Pharmaceutical University	Li, F (corresponding author), China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, 92 Beier Rd, Shenyang 110001, Peoples R China.	fli@mail.cmu.edu.cn		Li, Feng/0000-0001-5868-7456; Wang, Guiling/0000-0001-7304-1610	National Natural Science Foundation of China [90813038, 31171360, 81230077, 81130042]; Doctoral fund of Ministry of Education of China [20102104110016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral fund of Ministry of Education of China(Ministry of Education, China)	We thank Yongxi Song, Jianhua Wu and Feng Zhao for their technical assistance with the animal experiments. We are grateful to Gary M Bokoch, Audrey Minden and Bruce Mayer for providing essential expression vectors. This work was supported by grants from the National Natural Science Foundation of China (Nos 90813038, 31171360, 81230077 and 81130042) and Doctoral fund of Ministry of Education of China (No. 20102104110016).	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Ahn HK, 2011, TRANSL ONCOL, V4, P345, DOI 10.1593/tlo.11145; Begum A, 2009, CANCER SCI, V100, P1908, DOI 10.1111/j.1349-7006.2009.01252.x; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Chen G, 2003, MOL CELL PROTEOMICS, V2, P107, DOI 10.1074/mcp.M200055-MCP200; Ghosh R, 2007, PROSTATE, V67, P1038, DOI 10.1002/pros.20601; Grenningloh G, 2004, J NEUROBIOL, V58, P60, DOI 10.1002/neu.10279; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kim JH, 2008, TUMOR BIOL, V29, P41, DOI 10.1159/000132570; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li XF, 2005, J BIOL CHEM, V280, P41192, DOI 10.1074/jbc.M506884200; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Liu Y, 2010, ONCOGENE, V29, P5883, DOI 10.1038/onc.2010.329; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Mak GWY, 2011, CANCER RES, V71, P2949, DOI 10.1158/0008-5472.CAN-10-4046; MCCARTY KS, 1986, CANCER RES, V46, P4244; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Paradis V, 2010, AM J PATHOL, V177, P1791, DOI 10.2353/ajpath.2010.100166; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Takahashi M, 2002, CANCER RES, V62, P6598; Tararuk T, 2006, J CELL BIOL, V173, P265, DOI 10.1083/jcb.200511055; Togano T, 2005, J NEUROSCI RES, V80, P475, DOI 10.1002/jnr.20462; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Westerlund N, 2011, NAT NEUROSCI, V14, P305, DOI 10.1038/nn.2755; Whale AD, 2013, ONCOGENE, V32, P2114, DOI 10.1038/onc.2012.233; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008; Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033; Zhang J, 2012, CANCER LETT, V317, P24, DOI 10.1016/j.canlet.2011.11.007	42	51	57	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3277	3287		10.1038/onc.2013.296	http://dx.doi.org/10.1038/onc.2013.296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23893240				2022-12-17	WOS:000338443400007
J	Zhu, X; Guo, Y; Yao, S; Yan, Q; Xue, M; Hao, T; Zhou, F; Zhu, J; Qin, D; Lu, C				Zhu, X.; Guo, Y.; Yao, S.; Yan, Q.; Xue, M.; Hao, T.; Zhou, F.; Zhu, J.; Qin, D.; Lu, C.			Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway	ONCOGENE			English	Article						KSHV vIL-6; angiogenesis; tumorigenesis; signal pathway	LYTIC CYCLE REPLICATION; IMMUNODEFICIENCY-VIRUS REPLICATION; IN-VITRO; T-CELLS; TYPE-1; ACTIVATION; AIDS; INFECTION; GP130; INDUCTION	Kaposi's sarcoma-associated herpesvirus (KSHV) is the cause of Kaposi's sarcoma (KS), which is the most common AIDS-associated malignancy. KS is characterized by neovascularization and spindle cell proliferation. The interaction between HIV-1 and KSHV has a central role in promoting the aggressive manifestations of KS in AIDS patients; however, the pathogenesis underlying AIDS-related KS (AIDS-KS) remains unknown. Herein, we examined the potential of HIV-1 negative factor (Nef) to impact KSHV viral interleukin-6 (vIL-6)-induced angiogenesis and tumorigenesis. In vitro experiments showed that exogenous Nef penetrated vIL-6-expressing endothelial cells. Both internalized and ectopic expression of Nef in endothelial cells and fibroblasts synergized with vIL-6 to promote vascular tube formation and cell proliferation. Using a chicken chorioallantoic membrane (CAM) model, we demonstrated that Nef synergistically promotes vIL-6-induced angiogenesis and tumorigenesis. Animal experiments further showed that Nef facilitates vIL-6-induced angiogenesis and tumor formation in athymic nu/nu mice. Mechanistic studies indicated that Nef synergizes with vIL-6 to enhance angiogenesis and tumorigenesis by activating the AKT pathway in the CAM model, as well as nude mice. LY294002, a specific inhibitor of phosphatidylinositol-3-kinase (PI3K), significantly impaired the ability of Nef to promote vIL-6-induced tumorigenesis in an allograft model of nude mice. Our data provide first-line evidence that Nef may contribute to the pathogenesis underlying AIDS-KS in synergy with vIL-6. These novel findings also suggest that targeting the PI3K/AKT signal may be a potentially effective therapeutic approach in AIDS-KS patients.	[Zhu, X.; Lu, C.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, X.; Lu, C.] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, X.; Guo, Y.; Yan, Q.; Xue, M.; Hao, T.; Zhou, F.; Qin, D.; Lu, C.] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, X.] Jiangsu Prov Hosp Tradit Chinese Med, Dept Lab Med, Nanjing, Jiangsu, Peoples R China; [Yao, S.] Quzhou Coll Technol, Sch Med, Quzhou, Peoples R China; [Zhu, J.] Univ Pittsburgh, Inst Canc, Canc Virol Program, Pittsburgh, PA USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University of Chinese Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lu, C (corresponding author), Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210029, Jiangsu, Peoples R China.	diqin@njmu.edu.cn; clu@njmu.edu.cn		yuanyuan, guo/0000-0002-5122-8545	National Basic Research Program of China (973 Program) [2011CB504803]; National Natural Science Foundation of China [81171552, 30972619, 30900064, 31270199]; Ph.D Programs Foundation of Ministry of Education of China [20123234110006]; Natural Science Foundation of Ministry of Education of Jiangsu Province [10KJA310032, 09KJB310007]; Research Fund for the Doctoral Program of Higher Education of China (New Teacher Fund) [20093234120004]; China Postdoctoral Science Foundation [2012M511304]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ph.D Programs Foundation of Ministry of Education of China(Ministry of Education, China); Natural Science Foundation of Ministry of Education of Jiangsu Province; Research Fund for the Doctoral Program of Higher Education of China (New Teacher Fund); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Basic Research Program of China (973 Program) (2011CB504803), National Natural Science Foundation of China (81171552, 30972619, 30900064, 31270199), the Ph.D Programs Foundation of Ministry of Education of China (20123234110006), Natural Science Foundation of Ministry of Education of Jiangsu Province (great project 10KJA310032 and grant 09KJB310007), Research Fund for the Doctoral Program of Higher Education of China (New Teacher Fund, grant 20093234120004) and China Postdoctoral Science Foundation (2012M511304).	AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Blum L, 1997, AIDS, V11, P1653; Boshoff C, 2001, PHILOS T R SOC B, V356, P517, DOI 10.1098/rstb.2000.0778; BOVI PD, 1986, CANCER RES, V46, P6333; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen XY, 2009, NEOPLASIA, V11, P1272, DOI 10.1593/neo.09494; Choi J, 2005, J VIROL, V79, P11194, DOI 10.1128/JVI.79.17.11194-11204.2005; Choi J, 2005, J VIROL, V79, P264, DOI 10.1128/JVI.79.1.264-276.2005; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Ensoli B, 1996, EUR J CANCER PREV, V5, P410; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Guo HG, 2004, J VIROL, V78, P9336, DOI 10.1128/JVI.78.17.9336-9342.2004; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Harrington W, 1997, LANCET, V349, P774; He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004; Husain M, 2005, AIDS, V19, P1975, DOI 10.1097/01.aids.0000191918.42110.27; Junkin M, 2011, BIOMATERIALS, V32, P1848, DOI 10.1016/j.biomaterials.2010.11.009; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Leonard JA, 2011, J VIROL, V85, P6867, DOI 10.1128/JVI.00229-11; Linnemann T, 2002, VIROLOGY, V294, P246, DOI 10.1006/viro.2002.1365; Macreadie IG, 1998, J BIOMED SCI, V5, P203, DOI 10.1007/BF02253470; Marecki JC, 2006, AM J RESP CRIT CARE, V174, P437, DOI 10.1164/rccm.200601-005OC; Meads MB, 2004, J BIOL CHEM, V279, P51793, DOI 10.1074/jbc.M407382200; Merat R, 2002, INT J CANCER, V97, P791, DOI 10.1002/ijc.10086; Mercader M, 2000, AM J PATHOL, V156, P1961, DOI 10.1016/S0002-9440(10)65069-9; Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Morris VA, 2008, J VIROL, V82, P8771, DOI 10.1128/JVI.00766-08; Morris VA, 2012, VIROLOGY, V428, P112, DOI 10.1016/j.virol.2012.03.013; Mullberg J, 2000, J IMMUNOL, V164, P4672, DOI 10.4049/jimmunol.164.9.4672; Peter F, 1998, IMMUNITY, V9, P433, DOI 10.1016/S1074-7613(00)80626-3; Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302; Qin D, 2008, CELL MICROBIOL, V10, P713, DOI 10.1111/j.1462-5822.2007.01079.x; Qin D, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-240; Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; Suthaus J, 2011, EUR J CELL BIOL, V90, P495, DOI 10.1016/j.ejcb.2010.10.016; Tang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031652; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; Voelkel NF, 2008, AIDS, V22, pS49, DOI 10.1097/01.aids.0000327516.55041.01; Wan XY, 1999, J VIROL, V73, P8268, DOI 10.1128/JVI.73.10.8268-8278.1999; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753; Zeng Y, 2007, J VIROL, V81, P2401, DOI 10.1128/JVI.02024-06; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269; Zhu XL, 2011, J MOL BIOL, V410, P1035, DOI 10.1016/j.jmb.2011.03.055	62	51	53	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1986	1996		10.1038/onc.2013.136	http://dx.doi.org/10.1038/onc.2013.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604117				2022-12-17	WOS:000334346300011
J	Becker, TM; Boyd, SC; Mijatov, B; Gowrishankar, K; Snoyman, S; Pupo, GM; Scolyer, RA; Mann, GJ; Kefford, RF; Zhang, XD; Rizos, H				Becker, T. M.; Boyd, S. C.; Mijatov, B.; Gowrishankar, K.; Snoyman, S.; Pupo, G. M.; Scolyer, R. A.; Mann, G. J.; Kefford, R. F.; Zhang, X. D.; Rizos, H.			Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor	ONCOGENE			English	Article						MAPK; B-RAF; STAT3; Mcl-1; anoikis	HUMAN-MELANOMA CELLS; DNA-BINDING ACTIVITY; SERINE PHOSPHORYLATION; MCL-1 EXPRESSION; FAMILY KINASES; INHIBITION; CANCER; APOPTOSIS; SRC; ACTIVATION	Approximately 50% of melanomas depend on mutant B-RAF for proliferation, metastasis and survival. The inhibition of oncogenic B-RAF with highly targeted compounds has produced remarkable albeit short-lived clinical responses in B-RAF mutant melanoma patients. Reactivation of signaling downstream of B-RAF is frequently associated with acquired resistance to B-RAF inhibitors, and the identification of B-RAF targets may provide new strategies for managing melanoma. Oncogenic B-RAF(V600E) is known to promote the stabilizing phosphorylation of the anti-apoptotic protein Mcl-1, implicated in melanoma survival and chemoresistance. We now show that B-RAFV600E signaling also induces the transcription of Mcl-1 in melanocytes and melanoma. We demonstrate that activation of STAT3 serine-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation. Consequently, suppression of STAT3 activity disrupted B-RAF(V600E)-mediated induction of Mcl-1 and reduced melanoma cell survival. We propose that STAT3 has a central role in the survival and contributes to chemoresistance of B-RAF(V600E) melanoma.	[Becker, T. M.; Boyd, S. C.; Mijatov, B.; Gowrishankar, K.; Snoyman, S.; Pupo, G. M.; Mann, G. J.; Kefford, R. F.; Rizos, H.] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2145, Australia; [Scolyer, R. A.; Mann, G. J.; Kefford, R. F.] Melanoma Inst Australia, Sydney, NSW, Australia; [Zhang, X. D.] Univ Newcastle, Immunol & Oncol Unit, Newcastle, NSW 2300, Australia	University of Sydney; Westmead Institute for Medical Research; Melanoma Institute Australia; University of Newcastle	Becker, TM (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2145, Australia.	therese.becker@sydney.edu.au	zhang, xian/GYA-0290-2022; zhang, xu/GRX-9733-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GYE-3558-2022; Scolyer, Richard/AAE-8511-2019; Rizos, Helen/AAE-5010-2020; Mann, Graham J/G-4758-2014	Scolyer, Richard/0000-0002-8991-0013; Rizos, Helen/0000-0002-2094-9198; Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229; Powter, Branka/0000-0003-2814-456X; Becker, Therese/0000-0002-5636-9902; Zhang, Xu Dong/0000-0001-9457-8003	National Health and Medical Research Council of Australia (NHMRC) [633004]; Cancer Institute New South Wales [10/TPG/1-02]; Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales, Research Fellowship; NHMRC Senior Research Fellowship	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales; Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales, Research Fellowship; NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by the Program Grant 633004 and project grants of the National Health and Medical Research Council of Australia (NHMRC), Translational Research Program Grant 10/TPG/1-02 of the Cancer Institute New South Wales and an infrastructure grant to Westmead Millennium Institute by the Health Department of NSW through Sydney West Area Health Service. Westmead Institute for Cancer Research is the recipient of capital grant funding from the Australian Cancer Research Foundation. HR is a recipient of a Cancer Institute New South Wales, Research Fellowship and a NHMRC Senior Research Fellowship. RAS is a recipient of a Cancer Institute New South Wales, Research Fellowship.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Alshamsan A, 2011, TRANSL ONCOL, V4, P178, DOI 10.1593/tlo.11100; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Becker TM, 2010, J INVEST DERMATOL, V130, P2144, DOI 10.1038/jid.2010.117; Bill MA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-165; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Burdelya L, 2005, J IMMUNOL, V174, P3925, DOI 10.4049/jimmunol.174.7.3925; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500; Curtis LM, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B89; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Ding YL, 2006, CANCER-AM CANCER SOC, V106, P1123, DOI 10.1002/cncr.21727; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Fuh B, 2009, BRIT J CANCER, V100, P106, DOI 10.1038/sj.bjc.6604793; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Hong DS, 2008, J CLIN ONCOL, V26; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Jensen TO, 2011, CANCER, V118, P2476; Jiang CC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.48; Kong LY, 2010, CLIN CANCER RES, V16, P2550, DOI 10.1158/1078-0432.CCR-10-0279; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin L, 2009, ONCOGENE, V28, P961, DOI 10.1038/onc.2008.448; Lin L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-217; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Long GV, 2010, 35 EUR SOC MED ONC E; McMurray JS, 2006, CHEM BIOL, V13, P1123, DOI 10.1016/j.chembiol.2006.11.001; Messina Jane L, 2008, Cancer Control, V15, P196; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; OCONNOR TJ, 1995, CELL GROWTH DIFFER, V6, P123; Paraiso K, 2012, PIGM CELL MELANOMA R, P878; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; Shepherd C, 2010, CURR ONCOL REP, V12, P146, DOI 10.1007/s11912-010-0095-2; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tang LR, 1998, CLIN CANCER RES, V4, P1865; Venkatasubbarao K, 2005, CANCER RES, V65, P2861, DOI 10.1158/0008-5472.CAN-04-2396; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Wellbrock C, 2010, BIOCHEM PHARMACOL, V80, P561, DOI 10.1016/j.bcp.2010.03.019; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wong RPC, 2008, ONCOL REP, V19, P933; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhuang LQ, 2007, MODERN PATHOL, V20, P416, DOI 10.1038/modpathol.3800750	54	51	51	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1158	1166		10.1038/onc.2013.45	http://dx.doi.org/10.1038/onc.2013.45			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23455323				2022-12-17	WOS:000331933800009
J	Wang, X; Sun, Y; Wong, J; Conklin, DS				Wang, X.; Sun, Y.; Wong, J.; Conklin, D. S.			PPAR gamma maintains ERBB2-positive breast cancer stem cells	ONCOGENE			English	Article						PPAR gamma; HER2/neu positive; stem cells	ACTIVATED-RECEPTOR-GAMMA; FATTY-ACID SYNTHASE; INHIBIT GROWTH; EXPRESSION; RESISTANCE; ERBB2; HER2; CARCINOMA; SURVIVAL; LIGAND	Overexpression of the adverse prognostic marker ERBB2 occurs in 30% of breast cancers and is associated with aggressive disease and poor outcomes. Our recent findings have shown that NR1D1 and the peroxisome proliferator-activated receptor-gamma (PPAR gamma)-binding protein (PBP) act through a common pathway in upregulating several genes in the de novo fatty acid synthesis network, which is highly active in ERBB2-positive breast cancer cells. NR1D1 and PBP are functionally related to PPARg, a well-established positive regulator of adipogenesis and lipid storage. Here, we report that inhibition of the PPARg pathway reduces the aldehyde dehydrogenase (ALDH)-positive population in ERBB2-positive breast cancer cells. Results from in vitro tumorsphere formation assays demonstrate that the PPARg antagonists GW9662 and T0070907 decrease tumorsphere formation in ERBB2-positive cells, but not other breast cells. We show that the mechanism by which GW9662 treatment causes a reduction in ALDH-positive population cells is partially due to ROS, as it can be rescued by treatment with N-acetyl-cysteine. Furthermore, global gene expression analyses show that GW9662 treatment suppresses the expression of several lipogenic genes, including ACLY, MIG12, FASN and NR1D1, and the stem-cell related genes KLF4 and ALDH in BT474 cells. Antagonist treatment also decreases the level of acetylation in histone 3 and histone 4 in BT474 cells, compared with MCF7 cells. In vivo, GW9662 pre-treatment inhibits the tumor-seeding ability of BT474 cells. Together, these results show that the PPARg pathway is critical for the cancer stem cell properties of ERBB2-positive breast cancer cells.	[Wang, X.; Sun, Y.; Wong, J.; Conklin, D. S.] SUNY Albany, Canc Res Ctr, Dept Biomed Sci, Rensselaer, NY 12144 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Conklin, DS (corresponding author), SUNY Albany, Canc Res Ctr, Dept Biomed Sci, CRC 305,1 Discovery Dr, Rensselaer, NY 12144 USA.	dconklin@albany.edu		Conklin, Douglas/0000-0003-4922-4307	NCI [1R01CA136658]; NATIONAL CANCER INSTITUTE [R01CA136658] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jan Baumann and other members of the UAlbany CRC for helpful suggestions. This work was supported by NCI 1R01CA136658 to DSC.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; [Anonymous], 2011, PHARMACOGENOMICS, V12, P12; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Baumann J., 2012, BREAST CANC RECENT A, P17; Bedard PL, 2009, J MAMMARY GLAND BIOL, V14, P55, DOI 10.1007/s10911-009-9116-x; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161; Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Christgen Matthias, 2012, Methods Mol Biol, V878, P201, DOI 10.1007/978-1-61779-854-2_13; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505; Dressman MA, 2003, CANCER RES, V63, P2194; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Ferguson EM, 2006, MOL REPROD DEV, V73, P1195, DOI 10.1002/mrd.20494; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Glazer RI, 2008, PPAR RES, V2008, DOI 10.1155/2008/247379; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; He X, 2012, ANN ONCOL, V23, P1771, DOI 10.1093/annonc/mdr534; Kauraniemi P, 2006, ENDOCR-RELAT CANCER, V13, P39, DOI 10.1677/erc.1.01147; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kourtidis A, 2010, CANCER RES, V70, P1783, DOI 10.1158/0008-5472.CAN-09-1550; Kourtidis A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2240; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kuniyasu H, 2008, PPAR RES, V2008, DOI 10.1155/2008/529720; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu H, 2003, BREAST CANCER RES TR, V79, P63, DOI 10.1023/A:1023366117157; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Oliveras-Ferraros C, 2010, BIOCHEM BIOPH RES CO, V397, P27, DOI 10.1016/j.bbrc.2010.05.041; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Pignatelli M, 2001, J CELL SCI, V114, P4117; Rageul J, 2009, INT J CANCER, V125, P2802, DOI 10.1002/ijc.24683; Reka AK, 2010, MOL CANCER THER, V9, P3221, DOI 10.1158/1535-7163.MCT-10-0570; Robbins GT, 2012, FRONT BIOSCI-LANDMRK, V17, P1816, DOI 10.2741/4021; Sebastiani V, 2006, ANTICANCER RES, V26, P2983; Silva SD, 2004, ORAL ONCOL, V40, P688, DOI 10.1016/j.oraloncology.2004.01.004; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Sutton-McDowall ML, 2012, THERIOGENOLOGY, V77, P1632, DOI 10.1016/j.theriogenology.2011.12.008; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008-5472.CAN-09-2067; Tsao T, 2010, CANCER RES, V70, P4949, DOI 10.1158/0008-5472.CAN-09-1962; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu L, 2012, BLOOD, V119, P115, DOI 10.1182/blood-2011-06-363093; Yang ZB, 2003, CLIN CANCER RES, V9, P3198; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yuan HY, 2012, ONCOTARGET, V3, P345; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zu XY, 2012, RECENT PAT ANTI-CANC, V7, P154, DOI 10.2174/157489212799972954	61	51	55	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5512	5521		10.1038/onc.2013.217	http://dx.doi.org/10.1038/onc.2013.217			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23770845	Green Published			2022-12-17	WOS:000328276400002
J	Ma, G; Yasunaga, J; Fan, J; Yanagawa, S; Matsuoka, M				Ma, G.; Yasunaga, J.; Fan, J.; Yanagawa, S.; Matsuoka, M.			HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells	ONCOGENE			English	Article						HTLV-1; HBZ; Tax; DAPLE; Wnt signaling pathway; Wnt5a	NF-KAPPA-B; VIRUS TYPE-1; BETA-CATENIN; SIGNALING PATHWAY; TGF-BETA; TRANSCRIPTION FACTOR; VIRAL TRANSCRIPTION; BINDING PROTEIN; ISOMERASE PIN1; IN-VIVO	Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). HTLV-1 bZIP factor (HBZ), the viral gene transcribed from the antisense strand, is consistently expressed in ATL cells and promotes their proliferation. In this study, we found that a Wnt pathway-related protein, disheveled-associating protein with a high frequency of leucine residues (DAPLE), interacts with both HTLV-1 Tax and HBZ. In the presence of DAPLE, Tax activated canonical Wnt signaling. Conversely, HBZ markedly suppressed canonical Wnt activation induced by either Tax/DAPLE or beta-catenin. As a mechanism of HBZ-mediated Wnt suppression, we found that HBZ targets lymphoid enhancer-binding factor 1, one of the key transcription factors of the pathway, and impairs its DNA-binding ability. We also observed that the canonical Wnt pathway was not activated in HTLV-1-infected cells, whereas the representative of noncanonical Wnt ligand, Wnt5a, which antagonizes canonical Wnt signaling, was overexpressed. HBZ was able to induce Wnt5a transcription by enhancing its promoter activity through the TGF-beta pathway. Importantly, knocking down of Wnt5a in ATL cells repressed cellular proliferation and migration. Our results implicate novel roles of HBZ in ATL leukemogenesis through dysregulation of both the canonical and noncanonical Wnt pathways.	[Ma, G.; Yasunaga, J.; Fan, J.; Matsuoka, M.] Kyoto Univ, Inst Virus Res, Lab Virus Control, Kyoto 6068507, Japan; [Yanagawa, S.] Kyoto Univ, Inst Virus Res, Lab Gene Anal, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Yasunaga, J (corresponding author), Kyoto Univ, Inst Virus Res, Lab Virus Control, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	jyasunag@virus.kyoto-u.ac.jp		Matsuoka, Masao/0000-0002-0473-754X; Yasunaga, Jun-ichirou/0000-0002-7939-2080	Ministry of Education, Science, Sports, and Culture of Japan; Takeda Science Foundation; Grants-in-Aid for Scientific Research [22114003, 221S0001] Funding Source: KAKEN	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H Miyoshi for providing lentiviral packaging vectors and L Kingsbury for proofreading of this manuscript. This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan to MM, and a grant from the Takeda Science Foundation to JY.	Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Badiglian L, 2009, ONCOL REP, V21, P313, DOI 10.3892/or_00000223; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Clerc I, 2008, J BIOL CHEM, V283, P23903, DOI 10.1074/jbc.M803116200; Da Forno PD, 2008, CLIN CANCER RES, V14, P5825, DOI 10.1158/1078-0432.CCR-07-5104; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Driessens G, 2011, J IMMUNOL, V186, P784, DOI 10.4049/jimmunol.1001562; Fan J, 2005, CANCER RES, V65, P6927, DOI 10.1158/0008-5472.CAN-04-3495; Franchini G, 2003, INT J HEMATOL, V78, P280, DOI 10.1007/BF02983552; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Groen RWJ, 2008, CANCER RES, V68, P6969, DOI 10.1158/0008-5472.CAN-08-1322; Hagiya K, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-19; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Kuo YL, 2006, EMBO J, V25, P1741, DOI 10.1038/sj.emboj.7601054; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Lemasson I, 2007, J VIROL, V81, P1543, DOI 10.1128/JVI.00480-06; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McDonald SL, 2009, BRIT J CANCER, V101, P209, DOI 10.1038/sj.bjc.6605174; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Oshita A, 2003, GENES CELLS, V8, P1005, DOI 10.1111/j.1365-2443.2003.00692.x; Peloponese JM, 2009, J VIROL, V83, P3238, DOI 10.1128/JVI.01824-08; Pise-Masison CA, 2009, BLOOD, V113, P4016, DOI 10.1182/blood-2008-08-175901; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250; Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Shackelford J, 2003, P NATL ACAD SCI USA, V100, P15572, DOI 10.1073/pnas.2636947100; Shibamoto S, 1998, GENES CELLS, V3, P659; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Sukarawan W, 2010, AM J PATHOL, V176, P461, DOI 10.2353/ajpath.2010.090478; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Tezuka N, 2007, BIOCHEM BIOPH RES CO, V356, P648, DOI 10.1016/j.bbrc.2007.03.019; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Watashi K, 2008, J VIROL, V82, P9928, DOI 10.1128/JVI.01017-08; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496; Yanagawa S, 2000, FEBS LETT, V474, P189, DOI 10.1016/S0014-5793(00)01601-X; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zhao TJ, 2011, BLOOD, V118, P1865, DOI 10.1182/blood-2010-12-326199; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729; Zhi HJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002025	61	51	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4222	4230		10.1038/onc.2012.450	http://dx.doi.org/10.1038/onc.2012.450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045287	Green Submitted			2022-12-17	WOS:000324168000004
J	To, MD; Rosario, RD; Westcott, PMK; Banta, KL; Balmain, A				To, M. D.; Rosario, R. D.; Westcott, P. M. K.; Banta, K. L.; Balmain, A.			Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis	ONCOGENE			English	Article						Ras; Hras; Kras; Nras; skin carcinogenesis; lung carcinogenesis	MOUSE SKIN; SPINDLE CARCINOMAS; HUMAN CANCER; PAS1 LOCUS; K-RAS; PROGRESSION; MUTATIONS; EXPRESSION; TUMORS; SUSCEPTIBILITY	Ras oncogenes (Hras, Kras and Nras) are important drivers of carcinogenesis. However, tumors with Ras mutations often show loss of the corresponding wild-type (WT) allele, suggesting that proto-oncogenic forms of Ras can function as a suppressor of carcinogenesis. In vitro studies also suggest that WT Ras proteins can suppress the tumorigenic properties of alternate mutant Ras family members, but in vivo evidence for these heterologous interactions is lacking. We have investigated the genetic interactions between different combinations of mutant and WT Ras alleles in vivo using carcinogen-induced lung and skin carcinogenesis in mice with targeted deletion of different Ras family members. The major suppressor effect of WT Kras is observed only in mutant Kras-driven lung carcinogenesis, where loss of one Kras allele led to increased tumor number and size. Deletion of one Hras allele dramatically reduced the number of skin papillomas with Hras mutations, consistent with Hras as the major target of mutation in these tumors. However, skin carcinoma numbers were very similar, suggesting that WT Hras functions as a suppressor of progression from papillomas to invasive squamous carcinomas. In the skin, the Kras proto-oncogene functions cooperatively with mutant Hras to promote papilloma development, although the effect is relatively small. In contrast, the Hras proto-oncogene attenuated the activity of mutant Kras in lung carcinogenesis. Interestingly, loss of Nras increased the number of mutant Kras-induced lung tumors, but decreased the number of mutant Hras-induced skin papillomas. These results show that the strongest suppressor effects of WT Ras are only seen in the context of mutation of the cognate Ras protein, and only relatively weak effects are detected on tumor development induced by mutations in alternative family members. The data also underscore the complex and context-dependent nature of interactions between proto-oncogenic and oncogenic forms of different Ras family members during tumor development.	[To, M. D.] Univ Calif San Francisco, Dept Surg, Thorac Oncol Program, San Francisco, CA 94115 USA; [To, M. D.; Rosario, R. D.; Westcott, P. M. K.; Banta, K. L.; Balmain, A.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94115 USA; [Westcott, P. M. K.; Balmain, A.] Univ Calif San Francisco, Pharmaceut Sci & Pharmacogen Program, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	To, MD (corresponding author), Univ Calif San Francisco, Dept Surg, Thorac Oncol Program, 2340 Sutter St,Room N219, San Francisco, CA 94115 USA.	mto@cc.ucsf.edu; abalmain@cc.ucsf.edu			NCI [CA111834-01, CA84244]; NIH [T32 GM007175]; National Science Foundation Graduate Research Fellowship; Nan Tucker McEvoy Research Fund in Thoracic Oncology; Barbara Bass Bakar Chair in Cancer Genetics; NATIONAL CANCER INSTITUTE [U01CA084244, R01CA111834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007175] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); Nan Tucker McEvoy Research Fund in Thoracic Oncology; Barbara Bass Bakar Chair in Cancer Genetics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Motoya Katsuki and Dr Hiroki Nagase for the Hras<SUP>KO</SUP> mice, and Dr Tyler Jacks for the LSL-Kras<SUP>G12D</SUP> mice. This work was supported by NCI Grants CA111834-01 and CA84244 to AB. PMKW is supported by NIH Training Grant T32 GM007175 and a National Science Foundation Graduate Research Fellowship. MDT acknowledges the support from the Nan Tucker McEvoy Research Fund in Thoracic Oncology. AB acknowledges support from the Barbara Bass Bakar Chair in Cancer Genetics.	BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Diaz R, 2005, INT J CANCER, V113, P241, DOI 10.1002/ijc.20563; Diaz R, 2002, CANCER RES, V62, P4514; Dworkin AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001136; Hager JH, 2004, CANCER RES, V64, P2406, DOI 10.1158/0008-5472.CAN-03-3522; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Manenti G, 2008, ONCOGENE, V27, P5753, DOI 10.1038/onc.2008.194; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Nagase H, 2003, CANCER RES, V63, P4849; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Quinlan MP, 2008, CELL CYCLE, V7, P1332, DOI 10.4161/cc.7.10.5927; Sweet-Cordero A, 2006, GENE CHROMOSOME CANC, V45, P338, DOI 10.1002/gcc.20296; To MD, 2008, NAT GENET, V40, P1240, DOI 10.1038/ng.211; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; To MD, 2011, MOL CANCER RES, V9, P1339, DOI 10.1158/1541-7786.MCR-11-0219; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	29	51	51	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4028	4033		10.1038/onc.2012.404	http://dx.doi.org/10.1038/onc.2012.404			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22945650	Green Submitted, Green Accepted			2022-12-17	WOS:000323748100011
J	Franzetti, GA; Laud-Duval, K; Bellanger, D; Stern, MH; Sastre-Garau, X; Delattre, O				Franzetti, G-A; Laud-Duval, K.; Bellanger, D.; Stern, M-H; Sastre-Garau, X.; Delattre, O.			MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor	ONCOGENE			English	Article						Ewing sarcoma; EWS-FLI1; CD99; microRNAs; miR-30a-5p	MESENCHYMAL PROGENITOR CELLS; SARCOMA CELLS; TRANSCRIPTION FACTOR; FUSION PROTEINS; STEM-CELLS; EXPRESSION; MICRORNAS; IDENTIFICATION; CANCER; GENE	Ewing sarcoma is a pediatric bone tumor characterized in 85% of cases by the fusion between EWS and FLI1 genes that results in the expression of the EWS-FLI1 aberrant transcription factor. Histologically, the Ewing tumor expresses high levels of the CD99 membrane glycoprotein. It has been recently described that CD99 expression contributes to the Ewing tumor oncogenesis by modulating growth and differentiation of tumor cells. Different studies have also shown that overexpression of EWS-FLI1 induces CD99 expression in non-Ewing cells. At the opposite, the knockdown of EWS-FLI1 expression by siRNA approaches has no significant effect on CD99 mRNA level in Ewing cells. Here, by in vivo and in vitro studies, we show that while EWS-FLI1 inhibition has only slight effects on the amount of CD99 transcript, it induces a dramatic decrease of the CD99 protein expression level, hence suggesting post-transcriptional regulations, possibly mediated by microRNAs. To further investigate this issue, we identified a set of 91 miRNAs that demonstrate EWS-FLI1 modulation, three of them being predicted to bind CD99 3' untranslated region (3'UTR). Among these, we show that miR-30a-5p has the ability to interact with the 3'UTR region of CD99 and to regulate its expression. Moreover, the re-expression of miRNA-30a-5p in Ewing cell line induces decreased cell proliferation and invasion. In this study, we therefore show that miR-30a-5p constitutes a major functional link between EWS-FLI1 and CD99, two critical biomarkers and therapeutic targets in Ewing sarcoma.	[Franzetti, G-A; Laud-Duval, K.; Bellanger, D.; Stern, M-H; Delattre, O.] Inst Curie, Ctr Rech, INSERM U830, F-75248 Paris 05, France; [Franzetti, G-A; Laud-Duval, K.; Bellanger, D.; Stern, M-H; Delattre, O.] Inst Curie, Ctr Rech, F-75248 Paris 05, France; [Sastre-Garau, X.] Grp Hosp Pitie Salpetriere, Inst Curie, Serv Pathol, F-75634 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Delattre, O (corresponding author), Inst Curie, Ctr Rech, INSERM U830, 26 Rue Ulm, F-75248 Paris 05, France.	Olivier.delattre@curie.fr	Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272; delattre, olivier/0000-0002-8730-2276; Sastre-Garau, Xavier/0000-0001-5992-2083	Ligue Nationale Contre le Cancer (Equipe labelise); INCa [2009-1-PLBIO-04-IC-1]; Courir pour Mathieu; Dans les pas du Geant; Olivier Chape; Les Bagouzamanon; les Amis de Claire; Ministere de l'Enseignement Superieur et de la Recherche (France)	Ligue Nationale Contre le Cancer (Equipe labelise); INCa(Institut National du Cancer (INCA) France); Courir pour Mathieu; Dans les pas du Geant; Olivier Chape; Les Bagouzamanon; les Amis de Claire; Ministere de l'Enseignement Superieur et de la Recherche (France)	We thank the members of the cytometry plateform of tumor biology department of the Institut Curie for the cell selection by FACS. This work was supported by grants from the Ligue Nationale Contre le Cancer (Equipe labelise), the INCa (no 2009-1-PLBIO-04-IC-1), and the following associations: Courir pour Mathieu, Dans les pas du Geant, Olivier Chape, Les Bagouzamanon and les Amis de Claire. Georges-Alain Franzetti is a recipient of a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche (France).	Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; Boeva V, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq217; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Bremond A, 2009, BLOOD, V113, P347, DOI 10.1182/blood-2008-02-137745; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Chansky HA, 2001, CANCER RES, V61, P3586; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erkizan HV, 2010, CLIN CANCER RES, V16, P4077, DOI 10.1158/1078-0432.CCR-09-2261; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Guillon N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004932; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30; Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Melot T, 2001, EUR J BIOCHEM, V268, P3483, DOI 10.1046/j.1432-1327.2001.02251.x; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Sanchez G, 2008, CELL CYCLE, V7, P2299, DOI 10.4161/cc.6445; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Scotlandi K, 2000, CANCER RES, V60, P5134; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zaragosi LE, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-r64; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607	54	51	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3915	3921		10.1038/onc.2012.403	http://dx.doi.org/10.1038/onc.2012.403			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22986530				2022-12-17	WOS:000323210200014
J	Ivanov, SV; Panaccione, A; Brown, B; Guo, Y; Moskaluk, CA; Wick, MJ; Brown, JL; Ivanova, AV; Issaeva, N; El-Naggar, AK; Yarbrough, WG				Ivanov, S. V.; Panaccione, A.; Brown, B.; Guo, Y.; Moskaluk, C. A.; Wick, M. J.; Brown, J. L.; Ivanova, A. V.; Issaeva, N.; El-Naggar, A. K.; Yarbrough, W. G.			TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior	ONCOGENE			English	Article						TrkC; Bcl2; neurotrophin-3; migration; salivary adenoid cystic carcinoma; invasion	SALIVARY-GLAND TUMORS; TYROSINE KINASE RECEPTOR; ETV6-NTRK3 GENE FUSION; CELL-PROLIFERATION; NEUROTROPHIN RECEPTORS; NEUROBLASTOMA-CELLS; MYOEPITHELIAL CELLS; SOMATIC MUTATIONS; BREAST-CANCER; EXPRESSION	Treatment options for adenoid cystic carcinoma (ACC) of the salivary gland, a slowly growing tumor with propensity for neuroinvasion and late recurrence, are limited to surgery and radiotherapy. Based on expression analysis performed on clinical specimens of salivary cancers, we identified in ACC expression of the neurotrophin-3 receptor TrkC/NTRK3, neural crest marker SOX10, and other neurologic genes. Here, we characterize TrkC as a novel ACC marker, which was highly expressed in 17 out of 18 ACC primary-tumor specimens, but not in mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma. Expression of the TrkC ligand NT-3 and Tyr-phosphorylation of TrkC detected in our study suggested the existence of an autocrine signaling loop in ACC with potential therapeutic significance. NT-3 stimulation of U2OS cells with ectopic TrkC expression triggered TrkC phosphorylation and resulted in Ras, Erk 1/2 and Akt activation, as well as VEGFR1 phosphorylation. Without NT-3, TrkC remained unphosphorylated, stimulated accumulation of phospho-p53 and had opposite effects on p-Akt and p-Erk 1/2. NT-3 promoted motility, migration, invasion, soft-agar colony growth and cytoskeleton restructuring in TrkC-expressing U2OS cells. Immunohistochemical analysis demonstrated that TrkC-positive ACC specimens also show high expression of Bcl2, a Trk target regulated via Erk 1/2, in agreement with activation of the TrkC pathway in real tumors. In normal salivary gland tissue, both TrkC and Bcl2 were expressed in myoepithelial cells, suggesting a principal role for this cell lineage in the ACC origin and progression. Sub-micromolar concentrations of a novel potent Trk inhibitor AZD7451 completely blocked TrkC activation and associated tumorigenic behaviors. Pre-clinical studies on ACC tumors engrafted in mice showed efficacy and low toxicity of AZD7451, validating our in vitro data and stimulating more research into its clinical application. In summary, we describe in ACC a previously unrecognized pro-survival neurotrophin signaling pathway and link it with cancer progression.	[Ivanov, S. V.; Panaccione, A.; Ivanova, A. V.; Issaeva, N.; Yarbrough, W. G.] Yale Univ, Sch Med, Dept Surg, Otolaryngol Sect, New Haven, CT 06510 USA; [Panaccione, A.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Brown, B.] Vanderbilt Univ, Sch Med, Dept Otolaryngol, Nashville, TN 37212 USA; [Brown, B.] Vanderbilt Univ, Sch Med, Barry Baker Lab Head & Neck Oncol, Nashville, TN 37212 USA; [Guo, Y.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA; [Moskaluk, C. A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Wick, M. J.] South Texas Accelerated Res Therapeut, Sun Antonio, TX USA; [Brown, J. L.] AstraZeneca R&D Boston, Waltham, MA USA; [El-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Yarbrough, W. G.] Smilow Canc Hosp, H&N Dis Ctr, New Haven, CT USA; [Yarbrough, W. G.] Yale Canc Ctr, Mol Virol Program, New Haven, CT USA	Yale University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Virginia; AstraZeneca; University of Texas System; UTMD Anderson Cancer Center; Yale University	Ivanov, SV (corresponding author), Yale Phys Bldg,800 Howard Ave,4th Floor, New Haven, CT 06519 USA.	sergey.ivanov@yale.edu; wendell.yarbrough@yale.edu	Issaeva, Natalia/K-4577-2019	Issaeva, Natalia/0000-0001-5483-6610; Ivanov, Sergey/0000-0001-9770-7237	Adenoid Cystic Carcinoma Research Foundation; NIH from the National Institute of Dental and Craniofacial Research [5RC1DE020332-02]; Vanderbilt Ingram Cancer Center; Vanderbilt Bill Wilkerson Center for Otolaryngology and Communication Sciences; Robert J Kleberg Jr and Helen C Kleberg Foundation; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [RC1DE020332] Funding Source: NIH RePORTER	Adenoid Cystic Carcinoma Research Foundation; NIH from the National Institute of Dental and Craniofacial Research; Vanderbilt Ingram Cancer Center; Vanderbilt Bill Wilkerson Center for Otolaryngology and Communication Sciences; Robert J Kleberg Jr and Helen C Kleberg Foundation; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by funds from the Adenoid Cystic Carcinoma Research Foundation to SI and WGY and by the NIH Challenge Grant 5RC1DE020332-02 from the National Institute of Dental and Craniofacial Research to WGY. This work was also supported in part by the Vanderbilt Ingram Cancer Center, the Vanderbilt Bill Wilkerson Center for Otolaryngology and Communication Sciences, the Robert J Kleberg Jr and Helen C Kleberg Foundation, and by an endowment to the Barry Baker Laboratory for Head and Neck Oncology.	Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Azevedo RS, 2008, HEAD NECK PATHOL, V2, P257, DOI 10.1007/s12105-008-0074-1; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Bartkowska K, 2007, DEVELOPMENT, V134, P4369, DOI 10.1242/dev.008227; Bohm J, 2008, AM J PATHOL, V173, P1455, DOI 10.2353/ajpath.2008.071039; Bouzas-Rodriguez J, 2010, J CLIN INVEST, V120, P850, DOI 10.1172/JCI41013; Buzanska L, 2010, TOXICOLOGY, V270, P35, DOI 10.1016/j.tox.2009.06.005; Chummun S, 2001, BRIT J PLAST SURG, V54, P476, DOI 10.1054/bjps.2001.3636; DARDICK I, 1985, HEAD NECK SURG, V7, P395, DOI 10.1002/hed.2890070509; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Edsjo A, 2001, CELL GROWTH DIFFER, V12, P39; Fagiani E, 2007, CANCER RES, V67, P3064, DOI 10.1158/0008-5472.CAN-06-2301; Fernandez RM, 2009, ANN HUM GENET, V73, P19, DOI 10.1111/j.1469-1809.2008.00479.x; FITZPATRICK PJ, 1986, INT J RADIAT ONCOL, V12, P1743, DOI 10.1016/0360-3016(86)90314-7; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Goldberg L, 2006, CANCER RES, V66, P11709, DOI 10.1158/0008-5472.CAN-06-1878; Hardy G, 1998, SADJ, V53, P371; Harel L, 2010, DEV NEUROBIOL, V70, P298, DOI 10.1002/dneu.20769; HUBNER G, 1971, CANCER-AM CANCER SOC, V27, P1255, DOI 10.1002/1097-0142(197105)27:5<1255::AID-CNCR2820270533>3.0.CO;2-1; Jaglin XH, 2009, NAT GENET, V41, P746, DOI 10.1038/ng.380; JAO W, 1976, CANCER, V37, P1322, DOI 10.1002/1097-0142(197603)37:3<1322::AID-CNCR2820370313>3.0.CO;2-7; Jin W, 2008, J BIOL CHEM, V283, P1391, DOI 10.1074/jbc.M705052200; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Katayama K, 2009, PLOS ONE, V4, pA151, DOI 10.1371/journal.pone.0007786; Katoh M, 2011, CURR PHARM BIOTECHNO, V12, P160, DOI 10.2174/138920111794295710; Kelsh RN, 2006, BIOESSAYS, V28, P788, DOI 10.1002/bies.20445; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Kumar S, 1998, J NEUROSCI RES, V54, P754, DOI 10.1002/(SICI)1097-4547(19981215)54:6<754::AID-JNR3>3.0.CO;2-K; Kummoona R, 2008, J ORAL PATHOL MED, V37, P345, DOI 10.1111/j.1600-0714.2007.00624.x; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Lavoie JF, 2005, J BIOL CHEM, V280, P29199, DOI 10.1074/jbc.M502364200; Marchetti D, 2007, J EXP CLIN CANC RES, V26, P5; Marchetti D, 2003, PATHOL ONCOL RES, V9, P147, DOI 10.1007/BF03033729; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Mehlen P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3151pe47; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Montano X, 2009, ONCOGENE, V28, P3787, DOI 10.1038/onc.2009.143; Moskaluk CA, 2011, LAB INVEST, V91, P1480, DOI 10.1038/labinvest.2011.105; Nikoletopoulou V, 2010, NATURE, V467, P59, DOI 10.1038/nature09336; Phuchareon J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006040; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rajan N, 2011, ONCOGENE, V30, P4243, DOI 10.1038/onc.2011.133; REGEZI JA, 1977, OTOLARYNG CLIN N AM, V10, P297; Rottner K, 2010, TRENDS CELL BIOL, V20, P650, DOI 10.1016/j.tcb.2010.08.014; Sakamoto Y, 2001, ONCOL REP, V8, P477; Sanchez-Mejias A, 2009, J MED GENET, V46, P862, DOI 10.1136/jmg.2009.067819; Sinnappah-Kang ND, 2005, INT J ONCOL, V27, P617; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Slebos RJC, 2006, CLIN CANCER RES, V12, P701, DOI 10.1158/1078-0432.CCR-05-2017; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sundram U, 2003, MODERN PATHOL, V16, P802, DOI 10.1097/01.MP.0000081726.49886.CF; Tauszig-Delamasure S, 2011, EXPERT OPIN THER TAR, V15, P847, DOI 10.1517/14728222.2011.575361; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Wang T, 2008, J MED CHEM, V51, P4672, DOI 10.1021/jm800343j; Wang T, 2009, EXPERT OPIN THER PAT, V19, P305, DOI 10.1517/13543770902721261; Wood Laura D, 2006, Hum Mutat, V27, P1060, DOI 10.1002/humu.9452; Wu SM, 2010, STEM CELL RES, V4, P38, DOI 10.1016/j.scr.2009.09.002; Zandi R, 2007, CELL SIGNAL, V19, P2013, DOI 10.1016/j.cellsig.2007.06.023; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	65	51	53	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3698	3710		10.1038/onc.2012.377	http://dx.doi.org/10.1038/onc.2012.377			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	23027130				2022-12-17	WOS:000322904400005
J	Abhari, BA; Cristofanon, S; Kappler, R; von Schweinitz, D; Humphreys, R; Fulda, S				Abhari, B. A.; Cristofanon, S.; Kappler, R.; von Schweinitz, D.; Humphreys, R.; Fulda, S.			RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex	ONCOGENE			English	Article						apoptosis; IAP inhibitor; TRAIL; RIP1; neuroblastoma	NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TESTING STAGE 1; CANCER-CELLS; DNA-DAMAGE; RECEPTOR; ANTAGONISTS; NECROSIS; CIAP1; IDENTIFICATION	Inhibitor of apoptosis (IAP) proteins represent promising therapeutic targets due to their high expression in many cancers. Here, we report that small-molecule IAP inhibitors at subtoxic concentrations cooperate with monoclonal antibodies against TRAIL receptor 1 (Mapatumumab) or TRAIL-R2 (Lexatumumab) to induce apoptosis in neuroblastoma cells in a highly synergistic manner (combination index <0.1). Importantly, we identify receptor-activating protein 1 (RIP1) as a critical mediator of this synergism. RIP1 is required for the formation of a RIP1/FADD/caspase-8 complex that drives caspase-8 activation, cleavage of Bid into tBid, mitochondrial outer membrane permeabilization, full activation of caspase-3 and caspase-dependent apoptosis. Indeed, knockdown of RIP1 abolishes formation of the RIP1/FADD/caspase-8 complex, caspase activation and apoptosis upon combination treatment. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 inhibits IAP inhibitor- and TRAIL receptor-triggered apoptosis. In contrast, overexpression of the dominant-negative superrepressor I kappa B alpha-SR or addition of the tumor necrosis factor (TNF)alpha-blocking antibody Enbrel do not interfere with cotreatment-induced apoptosis, pointing to a nuclear factor-kappa B- and TNF alpha-independent mechanism. Of note, IAP inhibitor also sensitizes primary cultured neuroblastoma cells for TRAIL receptor-mediated loss of viability, underscoring the clinical relevance. By identifying RIP1 as a critical mediator of IAP inhibitor- mediated sensitization for Mapatumumab- or Lexatumumab-induced apoptosis, our findings provide new insights into the synergistic interaction of IAP inhibitors together with TRAIL receptor agonists.	[Abhari, B. A.; Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Kappler, R.; von Schweinitz, D.] Univ Munich, Dr von Haunerschen Childrens Hosp, Dept Pediat Surg, Munich, Germany; [Humphreys, R.] Human Genome Sci Inc, Oncol Res Dept, Rockville, MD USA	Goethe University Frankfurt; University of Munich; GlaxoSmithKline; Human Genome Sciences Inc	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417; Kappler, Roland/0000-0002-8581-2803	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); IAP6/18	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); IAP6/18	We thank X Wang for providing RIP3 antibody and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bellail AC, 2010, J CELL MOL MED, V14, P1303, DOI 10.1111/j.1582-4934.2009.00777.x; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chao B, 2006, inventors; Tetrapeptide analogs. United States patent, Patent No. PCT/US2005/024700; Chou T.C., 1991, SYNERGISM ANTAGONISM, P61; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2006, CANCER RES, V66, P10016, DOI 10.1158/0008-5472.CAN-05-4079; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Loder S, 2012, LEUKEMIA, V26, P1020, DOI 10.1038/leu.2011.353; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Naumann I, 2011, CLIN CANCER RES, V17, P3204, DOI 10.1158/1078-0432.CCR-10-2451; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Palacios C, 2010, CANCER LETT, V287, P207, DOI 10.1016/j.canlet.2009.06.012; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Smith MA, 2010, PEDIATR BLOOD CANCER, V54, P307, DOI 10.1002/pbc.22188; Stadel D, 2010, CLIN CANCER RES, V16, P5734, DOI 10.1158/1078-0432.CCR-10-0985; Straub CS, 2011, CURR TOP MED CHEM, V11, P291; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	41	51	51	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3263	3273		10.1038/onc.2012.337	http://dx.doi.org/10.1038/onc.2012.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890322				2022-12-17	WOS:000321301600006
J	Wendt, MK; Schiemann, BJ; Parvani, JG; Lee, YH; Kang, Y; Schiemann, WP				Wendt, M. K.; Schiemann, B. J.; Parvani, J. G.; Lee, Y-H; Kang, Y.; Schiemann, W. P.			TGF-beta stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer	ONCOGENE			English	Article						EMT; FAK; metastasis; Pyk2; signal transduction; TGF-beta	FOCAL ADHESION KINASE; GROWTH-FACTOR-BETA; PROTEIN-TYROSINE KINASE; CELL-PROLIFERATION; SIGNALING EVENTS; BONE METASTASIS; UP-REGULATION; SRC; FAK; INHIBITION	Epithelial-mesenchymal transition (EMT) programs are essential in promoting breast cancer invasion, systemic dissemination and in arousing proliferative programs in breast cancer micrometastases, a reaction that is partially dependent on focal adhesion kinase (FAK). Many functions of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question as to whether Pyk2 also participates in driving the metastatic outgrowth of disseminated breast cancer cells. In addressing this question, we observed Pyk2 expression to be (i) significantly upregulated in recurrent human breast cancers; (ii) differentially expressed across clonal isolates of human MDA-MB-231 breast cancer cells in a manner predictive for metastatic outgrowth, but not for invasiveness; and (iii) dramatically elevated in ex vivo cultures of breast cancer cells isolated from metastatic lesions as compared with cells that produced the primary tumor. We further show that metastatic human and murine breast cancer cells robustly upregulate their expression of Pyk2 during EMT programs stimulated by transforming growth factor-beta (TGF-beta). Genetic and pharmacological inhibition of Pyk2 demonstrated that the activity of this protein tyrosine kinase was dispensable for the ability of breast cancer cells to undergo invasion in response to TGF-beta, and to form orthotopic mammary tumors in mice. In stark contrast, Pyk2-deficiency prevented TGF-beta from stimulating the growth of breast cancer cells in 3D-organotypic cultures that recapitulated pulmonary microenvironments, as well as inhibited the metastatic outgrowth of disseminated breast cancer cells in the lungs of mice. Mechanistically, Pyk2 expression was inversely related to that of E-cadherin, such that elevated Pyk2 levels stabilized beta 1 integrin expression necessary to initiate the metastatic outgrowth of breast cancer cells. Thus, we have delineated novel functions for Pyk2 in mediating distinct elements of the EMT program and metastatic cascade regulated by TGF-beta, particularly the initiation of secondary tumor outgrowth by disseminated cells. Oncogene (2013) 32, 2005-2015; doi:10.1038/onc.2012.230; published online 18 June 2012	[Wendt, M. K.; Schiemann, B. J.; Parvani, J. G.; Lee, Y-H; Schiemann, W. P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Case Western Reserve University; Princeton University	Schiemann, WP (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	william.schiemann@case.edu		Kang, Yibin/0000-0002-1626-6730; Wendt, Mike/0000-0002-3665-7413	National Institutes of Health [CA129359]; Susan G Komen for the Cure Foundation [BCTR0706967]; Department of Defense [BC084561]; Case Comprehensive Cancer Center [P30 CA043703]; American Cancer Society [PF-09-120-01]; NATIONAL CANCER INSTITUTE [R01CA129359, P30CA043703] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); Case Comprehensive Cancer Center; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Pfizer for generously providing the small molecule inhibitors against FAK and Pyk2. Members of the Schiemann Laboratory are thanked for critical reading of the manuscript. WPS was supported in part by grants from the National Institutes of Health (CA129359), the Susan G Komen for the Cure Foundation (BCTR0706967), the Department of Defense (BC084561), and pilot funding from the Case Comprehensive Cancer Center (P30 CA043703), while MKW was supported by a fellowship from the American Cancer Society (PF-09-120-01).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Behmoaram E, 2008, AM J PATHOL, V173, P1540, DOI 10.2353/ajpath.2008.080292; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Burdick AD, 2006, CARCINOGENESIS, V27, P2331, DOI 10.1093/carcin/bgl083; Carelli S, 2006, LUNG CANCER, V53, P263, DOI 10.1016/j.lungcan.2006.06.001; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dahl U, 1996, DEVELOPMENT, V122, P2895; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fan HP, 2011, J BIOL CHEM, V286, P18573, DOI 10.1074/jbc.M110.200717; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Galliher Amy J, 2006, Future Oncol, V2, P743, DOI 10.2217/14796694.2.6.743; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; ILLC D, 1995, NATURE, V377, P539; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim SJ, 2004, J KOREAN MED SCI, V19, P710, DOI 10.3346/jkms.2004.19.5.710; Korpal M, 2009, NAT MED; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lim ST, 2010, J BIOL CHEM, V285, P1743, DOI 10.1074/jbc.M109.064212; Lipinski CA, 2010, EXPERT OPIN THER TAR, V14, P95, DOI 10.1517/14728220903473194; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sun CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018878; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Ungefroren H, 2011, CURR CANCER DRUG TAR, V11, P524, DOI 10.2174/156800911795538075; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weis SM, 2008, J CELL BIOL, V181, P43, DOI 10.1083/jcb.200710038; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Wendt MK, 2011, JOVE-J VIS EXP, DOI 10.3791/3245; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; Wendt MK, 2009, J BIOL CHEM, V284, P34145, DOI 10.1074/jbc.M109.023614; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	58	51	54	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2005	2015		10.1038/onc.2012.230	http://dx.doi.org/10.1038/onc.2012.230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710711	Green Accepted			2022-12-17	WOS:000317919900002
J	Castoria, G; Giovannelli, P; Lombardi, M; De Rosa, C; Giraldi, T; de Falco, A; Barone, MV; Abbondanza, C; Migliaccio, A; Auricchio, F				Castoria, G.; Giovannelli, P.; Lombardi, M.; De Rosa, C.; Giraldi, T.; de Falco, A.; Barone, M. V.; Abbondanza, C.; Migliaccio, A.; Auricchio, F.			Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells	ONCOGENE			English	Article						estradiol receptor; tyrosine phosphorylation; Src; nuclear export; cell cycle; breast cancer	HUMAN ESTROGEN-RECEPTOR; FORKHEAD TRANSCRIPTION FACTORS; DNA-SYNTHESIS; PROGESTERONE-RECEPTOR; PROTEIN-KINASE; MCF-7 CELLS; IN-VITRO; ACTIVATION; ALPHA; BINDING	We report that in breast cancer cells, tyrosine phosphorylation of the estradiol receptor alpha (ERalpha) by Src regulates cytoplasmic localization of the receptor and DNA synthesis. Inhibition of Src or use of a peptide mimicking the ERalpha p-Tyr537 sequence abolishes ERalpha tyrosine phosphorylation and traps the receptor in nuclei of estradiol-treated MCF-7 cells. An ERalpha mutant carrying a mutation of Tyr537 to phenylalanine (ER537F) persistently localizes in nuclei of various cell types. In contrast with ERalpha wt, ER537F does not associate with Ran and its interaction with Crm1 is insensitive to estradiol. Thus, independently of estradiol, ER537F is retained in nuclei, where it entangles FKHR-driving cell cycle arrest. Chromatin immunoprecipitation analysis reveals that overexpression of ER537F in breast cancer cells enhances FKHR interaction with cyclin D1 promoter. This mutant also counteracts cell transformation by the activated forms of Src or PI3-K. In conclusion, in addition to regulating receptor localization, ERalpha phosphorylation by Src is required for hormone responsiveness of DNA synthesis in breast cancer cells.	[Castoria, G.; Giovannelli, P.; Lombardi, M.; De Rosa, C.; Giraldi, T.; de Falco, A.; Abbondanza, C.; Migliaccio, A.; Auricchio, F.] Univ Naples 2, Dept Gen Pathol, I-80138 Naples, Italy; [Barone, M. V.] ELFID, Naples, Italy	Universita della Campania Vanvitelli	Migliaccio, A (corresponding author), Univ Naples 2, Dept Gen Pathol, Via L De Crecchio 7, I-80138 Naples, Italy.	antimo.migliaccio@unina2.it	Migliaccio, Antimo/AAB-3376-2019; Castoria, Gabriella/I-3349-2019; Giovannelli, Pia/J-7931-2019	Castoria, Gabriella/0000-0002-0576-4494; Giovannelli, Pia/0000-0002-2488-917X; Migliaccio, Antimo/0000-0002-4197-2055; BARONE, Maria Vittoria/0000-0001-6190-4917; ABBONDANZA, Ciro/0000-0001-5346-4835	Italian Association for Cancer Research (A.I.R.C.) [IG 5389]; A.I.R.C.	Italian Association for Cancer Research (A.I.R.C.)(Fondazione AIRC per la ricerca sul cancro); A.I.R.C.(Fondazione AIRC per la ricerca sul cancro)	This work was funded by the Italian Association for Cancer Research (A.I.R.C.; Grant No. IG 5389). PG is supported by a fellowship from A.I.R.C.	Abbondanza C, 2012, J CELL PHYSIOL, V227, P964, DOI 10.1002/jcp.22803; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arnold SF, 1997, BIOCHEM BIOPH RES CO, V235, P336, DOI 10.1006/bbrc.1997.6779; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; AURICCHIO F, 1981, BIOCHEM J, V198, P699, DOI 10.1042/bj1980699; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Blake Richard A., 2000, AMERICA, V181, P20; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; Castoria G, 1996, INT J CANCER, V65, P574, DOI 10.1002/(SICI)1097-0215(19960301)65:5<574::AID-IJC4>3.0.CO;2-#; Castoria G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017218; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Erenburg I, 1997, MOL ENDOCRINOL, V11, P2004, DOI 10.1210/me.11.13.2004; Haendeler J, 2003, MOL CELL BIOL, V23, P4598, DOI 10.1128/MCB.23.13.4598-4610.2003; He X, 2010, ONCOGENE, V29, P2238, DOI 10.1038/onc.2009.513; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kaspar JW, 2010, J BIOL CHEM, V285, P153, DOI 10.1074/jbc.M109.040022; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284; Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MIGLIACCIO A, 1992, INT J CANCER, V51, P733, DOI 10.1002/ijc.2910510512; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Morelli C, 2010, MOL CELL BIOL, V30, P857, DOI 10.1128/MCB.00824-09; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossi M, 2011, J BIOL CHEM, V286, P8507, DOI 10.1074/jbc.M110.179523; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427	55	51	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4868	4877		10.1038/onc.2011.642	http://dx.doi.org/10.1038/onc.2011.642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266855				2022-12-17	WOS:000311210700007
J	Li, Y; Deng, C; Hu, X; Patel, B; Fu, X; Qiu, Y; Brand, M; Zhao, K; Huang, S				Li, Y.; Deng, C.; Hu, X.; Patel, B.; Fu, X.; Qiu, Y.; Brand, M.; Zhao, K.; Huang, S.			Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis	ONCOGENE			English	Article						TAL1/SCL; LSD1; H3K4 demethylation; serine phosphorylation; epigenetic regulation; leukemogenesis	T-CELL LEUKEMIA; CHROMOSOME-TRANSLOCATION; GENE-EXPRESSION; SCL GENE; TRANSCRIPTION; DIFFERENTIATION; PHOSPHORYLATION; PROLIFERATION; DEMETHYLASE; DISRUPTION	TAL1/SCL is a hematopoietic-specific oncogene and its activity is regulated by associated transcriptional co-activators and corepressors. Dysregulation of TAL1 activity has been associated with T-cell leukemogenesis. However, it remains unclear how the interactions between TAL1 and corepressors versus co-activators are properly regulated. Here, we reported that protein kinase A (PKA)-mediated phosphorylation regulates TAL1 interaction with the lysine-specific demethylase (LSD1) that removes methyl group from methylated Lys 4 on histone H3 tails. Phosphorylation of serine 172 in TAL1 specifically destabilizes the TAL1-LSD1 interaction leading to promoter H3K4 hypermethylation and activation of target genes that have been suppressed in normal and malignant hematopoiesis. Knockdown of TAL1 or LSD1 led to a derepression of the TAL1 target genes in T-cell acute lymphoblast leukemia (T-ALL) Jurkat cells, which is accompanied by elevating promoter H3K4 methylation. Similarly, treatment of PKA activator forskolin resulted in derepression of target genes by reducing its interaction with LSD1 while PKA inhibitor H89 represses them by suppressing H3K4 methylation levels. Consistent with the dual roles of TAL1 in transcription, TAL1-associated LSD1 is decreased while recruitment of hSET1 is increased at the TAL1 targets during erythroid differentiation. This process is accompanied by a dramatic increase in H3K4 methylation. Thus, our data revealed a novel interplay between PKA phosphorylation and TAL1-mediated epigenetic regulation that regulates hematopoietic transcription and differentiation programs during hematopoiesis and leukemogenesis. Oncogene (2012) 31, 5007-5018; doi:10.1038/onc.2012.8; published online 6 February 2012	[Li, Y.; Hu, X.; Fu, X.] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China; [Qiu, Y.] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Qiu, Y.; Huang, S.] Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA; [Brand, M.] Ottawa Hosp, Sprott Ctr Stem Cell Res, Res Inst, Ottawa, ON, Canada; [Zhao, K.] NHLBI, Syst Biol Ctr, NIH, Bethesda, MD 20892 USA; [Li, Y.; Deng, C.; Hu, X.; Patel, B.; Huang, S.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	Jilin University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Ottawa; Ottawa Hospital Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida	Huang, S (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	sumingh@ufl.edu	Li, Ying/L-7292-2019	, Yi/0000-0002-3282-6072	National Institute of Health [R01HL090589, R01HL091929, R01HL091929-01A1S1, R01HL095674]; NIH [5T32-CA9126-34]; Intramural Research programs, National Heart Lung Blood Institute and National Institute of Health; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090589, ZICHL006058, ZIAHL005801, R01HL095674, ZIAHL006031, R01HL091929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056009] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research programs, National Heart Lung Blood Institute and National Institute of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to members of the Huang laboratory for their suggestions and comments. This work was supported by grants from the National Institute of Health (SH, R01HL090589, R01HL091929 and R01HL091929-01A1S1-the ARRA Administrative supplement; YQ, R01HL095674). BP is supported by NIH T32 training grant (5T32-CA9126-34). KZ is supported by the Intramural Research programs, National Heart Lung Blood Institute and National Institute of Health.	APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Begley CG, 1999, BLOOD, V93, P2760; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cai Y, 2009, BIOCHEM BIOPH RES CO, V390, P295, DOI 10.1016/j.bbrc.2009.09.111; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Martinez MC, 2006, BLOOD, V108, P3012, DOI 10.1182/blood-2006-04-019109; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; Condorelli GL, 1996, CANCER RES, V56, P5113; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Demers C, 2007, MOL CELL, V27, P573, DOI 10.1016/j.molcel.2007.06.022; Dey S, 2010, MOL CELL BIOL, V30, P2181, DOI 10.1128/MCB.01441-09; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Hansson A, 2003, BIOCHEM BIOPH RES CO, V312, P1073, DOI 10.1016/j.bbrc.2003.11.030; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Hu X, 2009, EPIGENETICS-US, V4, P257, DOI 10.4161/epi.4.6.9711; Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Izraeli S, 2004, BRIT J HAEMATOL, V126, P3, DOI 10.1111/j.1365-2141.2004.04986.x; Kassouf MT, 2010, GENOME RES, V20, P1064, DOI 10.1101/gr.104935.110; Kusy S, 2010, J EXP MED, V207, P2141, DOI 10.1084/jem.20100745; Lacombe J, 2010, BLOOD, V115, P792, DOI 10.1182/blood-2009-01-201384; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Li XG, 2010, BLOOD, V115, P2028, DOI 10.1182/blood-2009-07-236059; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Palamarchuk A, 2005, CANCER RES, V65, P4515, DOI 10.1158/0008-5472.CAN-05-0751; Palii CG, 2011, EMBO J, V30, P494, DOI 10.1038/emboj.2010.342; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Robb L, 1997, BIOESSAYS, V19, P607, DOI 10.1002/bies.950190711; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Sanchez MJ, 2001, DEVELOPMENT, V128, P4815; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200; Shank-Calvo JA, 2006, ONCOGENE, V25, P3023, DOI 10.1038/sj.onc.1209326; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Tripic T, 2009, BLOOD, V113, P2191, DOI 10.1182/blood-2008-07-169417; WADMAN IA, 1994, ONCOGENE, V9, P3713; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050	59	51	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5007	5018		10.1038/onc.2012.8	http://dx.doi.org/10.1038/onc.2012.8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310283	Green Accepted			2022-12-17	WOS:000311888600005
J	Casar, B; He, Y; Iconomou, M; Hooper, JD; Quigley, JP; Deryugina, EI				Casar, B.; He, Y.; Iconomou, M.; Hooper, J. D.; Quigley, J. P.; Deryugina, E. I.			Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells	ONCOGENE			English	Article						CDCP1; plasmin; cleavage; colonization; apoptosis; signaling	DOMAIN-CONTAINING PROTEIN-1; PROTEASE-ACTIVATED RECEPTORS; CUB-DOMAIN; TYROSINE PHOSPHORYLATION; PKC-DELTA; SRC; CARCINOMA; MIGRATION; ADHESION; PLASMIN	The CUB domain-containing protein-1 (CDCP1) is a transmembrane molecule that has recently been implicated in cancer progression. In this study we have established a novel mechanism for initiation of CDCP1-mediated signaling in vivo and demonstrated that specific 135 -> 70-kDa processing of cell-surface CDCP1 by extracellular serine proteases is a prerequisite for CDCP1-dependent survival of cancer cells during metastasis. The in vivo cleavage of CDCP1 triggers a survival program involving recruitment of Src and PKC delta, Src-mediated phosphorylation of cell-surface-retained 70-kDa CDCP1, activation of Akt and suppression of PARP1-induced apoptosis. We demonstrate in vivo that phosphorylated Src, PKC delta and Akt all constitute activated elements of a CDCP1-signaling axis during tissue colonization of tumor cells. Preventing in vivo cleavage of CDCP1 with unique anti-CDCP1 antibodies, serine protease inhibitors or genetic modulation of the cleavage site in the CDCP1 molecule completely abrogated survival signaling associated with the 70-kDa CDCP1, and induced PARP1 cleavage and PARP1-mediated apoptosis, ultimately resulting in substantial inhibition of tissue colonization by tumor cells. The lack of CDCP1 cleavage in the lung tissue of plasminogen-knockout mice along with a coordinated reduction in tumor cell survival in a lung retention model, and importantly rescue of both by in vivo supplied plasmin, indicated that plasmin is the crucial serine pr otease executing in vivo cleavage of cell-surface CDCP1 during early stages of lung colonization. Together, our findings indicate that in vivo blocking of CDCP1 cleavage upstream from CDCP1-induced pro-survival signaling provides a potential mechanism for therapeutic intervention into metastatic disease. Oncogene ( 2012) 31, 3924-3938; doi:10.1038/onc.2011.555; published online 19 December 2011	[Casar, B.; Quigley, J. P.; Deryugina, E. I.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [He, Y.; Iconomou, M.; Hooper, J. D.] Mater Med Res Inst, Brisbane, Qld, Australia	Scripps Research Institute; Mater Research	Deryugina, EI (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,SP3030-3120, La Jolla, CA 92037 USA.	deryugin@scripps.edu	CASAR, BERTA/M-2291-2014; Hooper, John/C-1481-2016	CASAR, BERTA/0000-0002-3058-5631; HE, Yaowu/0000-0002-7828-263X; Hooper, John/0000-0003-1054-8486	NCI NIH HHS [R01 CA 105412, R01 CA105412, R01 CA 129484, R01 CA129484] Funding Source: Medline; NCRR NIH HHS [RR 025774, UL1 RR025774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105412, R01CA129484] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Gray K, 2008, FEBS LETT, V582, P907, DOI 10.1016/j.febslet.2008.02.026; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Landis RC, 2001, ANN THORAC SURG, V72, P2169, DOI 10.1016/S0003-4975(01)02821-1; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Schmidt A, 2005, J BIOL CHEM, V280, P34441, DOI 10.1074/jbc.M501903200; Shi XL, 2004, MOL CANCER RES, V2, P395; Spassov DS, 2011, CELL CYCLE, V10, P1225, DOI 10.4161/cc.10.8.15343; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Wortmann A, 2011, J BIOL CHEM; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	30	51	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3924	3938		10.1038/onc.2011.555	http://dx.doi.org/10.1038/onc.2011.555			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22179830	Green Accepted			2022-12-17	WOS:000308342800002
J	Ghiam, AF; Cairns, RA; Thoms, J; Dal Pra, A; Ahmed, O; Meng, A; Mak, TW; Bristow, RG				Ghiam, A. F.; Cairns, R. A.; Thoms, J.; Dal Pra, A.; Ahmed, O.; Meng, A.; Mak, T. W.; Bristow, R. G.			IDH mutation status in prostate cancer	ONCOGENE			English	Letter							GLIOMAS		[Ghiam, A. F.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; Univ Toronto, Toronto, ON M4X 1K9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Ghiam, AF (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada.	rob.bristow@rmp.uhn.on.ca	Dal Pra, Alan/AAM-9352-2021; Cairns, Rob A/A-3232-2009; Dal Pra, Alan/AAN-9511-2020	Dal Pra, Alan/0000-0002-1648-6557; Cairns, Rob A/0000-0001-9540-7927; Bristow, Robert/0000-0002-8553-9544				Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Chan Norman, 2007, Future Oncol, V3, P329, DOI 10.2217/14796694.3.3.329; Ishkanian AS, 2009, PROSTATE, V69, P1091, DOI 10.1002/pros.20959; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Park SW, 2009, INT J CANCER, V125, P2485, DOI 10.1002/ijc.24647; Prensner JR, 2011, NAT MED, V17, P291, DOI 10.1038/nm0311-291; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yen KE, 2010, ONCOGENE, V29, P6409, DOI 10.1038/onc.2010.444	9	51	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	33					3826	3826		10.1038/onc.2011.546	http://dx.doi.org/10.1038/onc.2011.546			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120718				2022-12-17	WOS:000307924900009
J	Ali, AY; Abedini, MR; Tsang, BK				Ali, A. Y.; Abedini, M. R.; Tsang, B. K.			The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation	ONCOGENE			English	Article						cisplatin resistance; apoptosis; ovarian cancer; PPM1D; Chk1; p53	DNA-DAMAGE-RESPONSE; CANCER-CELLS; WIP1 PHOSPHATASE; TUMOR-SUPPRESSOR; 7-HYDROXYSTAUROSPORINE UCN-01; P53-INDUCED PHOSPHATASE; P53-DEFICIENT CELLS; INHIBITORY PROTEIN; CHK1; PHOSPHORYLATION	Cisplatin (CDDP: cis-diamminedichloroplatinum) resistance is a major hurdle in the treatment of human ovarian cancer (OVCA). A better understanding of the mechanisms of CDDP resistance can greatly improve therapeutic outcome for patients. A determinant of CDDP sensitivity in OVCA, p53, is activated by checkpoint kinase 1 (Chk1) in response to DNA damage. Although the oncogenic phosphatase protein phosphatase magnesium-dependent 1 (PPM1D) can deactivate both p53 and Chk1 through site-specific dephosphorylation, whether PPM1D has a role in CDDP resistance is unknown. Here, using pair-matched wild-type p53 CDDP-sensitive (OV2008) and -resistant (C13*) cells, and p53-compromised CDDP-resistant cells (A2780cp, OCC-1, OVCAR-3 and SKOV3), we have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cells in response to CDDP; (ii) PPM1D, but not phosphoinositide-3-kinase-related kinase (ataxia telangiectasia and Rad3 related protein (ATR)), is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53. Our findings establish for the first time that PPM1D confers CDDP resistance in OVCA cells through attenuating CDDP-induced, Chk1-mediated, p53-dependent apoptosis. These findings extend the current knowledge on the molecular and cellular basis of cisplatin resistance and offer the rationale for PPMID as a potential target for treatment of chemoresistant OVCA. Oncogene (2012) 31, 2175-2186; doi:10.1038/onc.2011.399; published online 19 September 2011	[Tsang, B. K.] Univ Ottawa, Ottawa Hosp Res Inst, Dept Obstet & Gynaecol, Chron Dis Program, Ottawa, ON K1Y 4E9, Canada; [Ali, A. Y.; Abedini, M. R.; Tsang, B. K.] Univ Ottawa, Dept Cellular Med, Ottawa, ON K1Y 4E9, Canada; [Ali, A. Y.; Abedini, M. R.; Tsang, B. K.] Univ Ottawa, Dept Mol Med, Ottawa, ON K1Y 4E9, Canada; [Abedini, M. R.] Birjand Univ Med Sci, Dept Physiol & Pharmacol, Birjand, Iran; [Tsang, B. K.] Univ Ottawa, Dept Obstet & Gynaecol, Ottawa, ON K1Y 4E9, Canada; [Tsang, B. K.] Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotechnol, World Class Univ WCU Biomodulat Major, Seoul, South Korea	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; Seoul National University (SNU)	Tsang, BK (corresponding author), Univ Ottawa, Ottawa Hosp Res Inst, Dept Obstet & Gynaecol, Chron Dis Program, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca	amiri, omolbanin/G-4425-2017; Darmian, Faezeh Vahedi/AAF-7755-2019	amiri, omolbanin/0000-0002-3815-5716; Tsang, Benjamin K./0000-0003-1213-3946	Canadian Institutes of Health Research [MOP-15691]; World Class University (WCU) through the National Research Foundation of Korea [R31-10056]; Ministry of Education, Science and Technology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); World Class University (WCU) through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the Canadian Institutes of Health Research (MOP-15691), the World Class University (WCU) program (R31-10056) through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Canadian Cancer Society, 2009, CAN CANC STAT; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Carrassa L, 2004, CELL CYCLE, V3, P1177; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Choi J, 2000, GENOMICS, V64, P298, DOI 10.1006/geno.2000.6134; Chuman Y, 2008, PROTEIN PEPTIDE LETT, V15, P938, DOI 10.2174/092986608785849236; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JEKUNEN AP, 1994, CANCER RES, V54, P2680; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jurvansuu J, 2007, J MOL BIOL, V372, P397, DOI 10.1016/j.jmb.2007.06.077; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu XB, 2005, CELL CYCLE, V4, P1060; Lu XB, 2004, CELL CYCLE, V3, P1363, DOI 10.4161/cc.3.11.1241; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; MISTRY P, 1992, CANCER RES, V52, P6188; Ouyang GL, 2009, CELL BIOL INT, V33, P1237, DOI 10.1016/j.cellbi.2009.08.011; Pan Y, 2009, CANCER BIOL THER, V8, P1559, DOI 10.4161/cbt.8.16.8955; Perego P, 2003, INT J CANCER, V105, P617, DOI 10.1002/ijc.11140; Perego P, 1996, CANCER RES, V56, P556; Playle LC, 2002, BRIT J CANCER, V87, P352, DOI 10.1038/sj.bjc.6600492; Qu YH, 2005, MOL BIOL CELL, V16, P1684; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rong JJ, 2010, CANCER LETT, V296, P55, DOI 10.1016/j.canlet.2010.03.016; Sasaki H, 2000, CANCER RES, V60, P5659; Shao RG, 1997, CANCER RES, V57, P4029; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Wagner JM, 2009, MOL PHARMACOL, V76, P208, DOI 10.1124/mol.109.055178; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yang X, 2008, BRIT J CANCER, V98, P803, DOI 10.1038/sj.bjc.6604223; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yazlovitskaya EM, 2003, ANTICANCER RES, V23, P2275; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhang XN, 2009, CANCER RES, V69, P7960, DOI 10.1158/0008-5472.CAN-09-0634; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	55	51	53	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2175	2186		10.1038/onc.2011.399	http://dx.doi.org/10.1038/onc.2011.399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927021				2022-12-17	WOS:000303415900006
J	Brennan, D; Peltonen, S; Dowling, A; Medhat, W; Green, KJ; Wahl, JK; Del Galdo, F; Mahoney, MG				Brennan, D.; Peltonen, S.; Dowling, A.; Medhat, W.; Green, K. J.; Wahl, J. K., III; Del Galdo, F.; Mahoney, M. G.			A role for caveolin-1 in desmoglein binding and desmosome dynamics	ONCOGENE			English	Article						carcinogenesis; caveolin; caveolae; desmoglein; keratinocyte	PLASMA-MEMBRANE; LIPID RAFTS; SIGNAL-TRANSDUCTION; CELL-MIGRATION; BREAST-CANCER; GENE FAMILY; MOUSE SKIN; IN-VIVO; EXPRESSION; GROWTH	Desmoglein-2 (Dsg2) is a desmosomal cadherin that is aberrantly expressed in human skin carcinomas. In addition to its well-known role in mediating intercellular desmosomal adhesion, Dsg2 regulates mitogenic signaling that may promote cancer development and progression. However, the mechanisms by which Dsg2 activates these signaling pathways and the relative contribution of its signaling and adhesion functions in tumor progression are poorly understood. In this study we show that Dsg2 associates with caveolin-1 (Cav-1), the major protein of specialized membrane microdomains called caveolae, which functions in both membrane protein turnover and intracellular signaling. Sequence analysis revealed that Dsg2 contains a putative Cav-1-binding motif. A permeable competing peptide resembling the Cav-1 scaffolding domain bound to Dsg2, disrupted normal Dsg2 staining and interfered with the integrity of epithelial sheets in vitro. Additionally, we observed that Dsg2 is proteolytically processed; resulting in a 95-kDa ectodomain shed product and a 65-kDa membrane-spanning fragment, the latter of which localizes to lipid rafts along with full-length Dsg2. Disruption of lipid rafts shifted Dsg2 to the non-raft fractions, leading to the accumulation of these proteins. Interestingly, Dsg2 proteolytic products are elevated in vivo in skin tumors from transgenic mice overexpressing Dsg2. Collectively, these data are consistent with the possibility that accumulation of truncated Dsg2 protein interferes with desmosome assembly and/or maintenance to disrupt cell-cell adhesion. Furthermore, the association of Dsg2 with Cav-1 may provide a mechanism for regulating mitogenic signaling and modulating the cell-surface presentation of an important adhesion molecule, both of which could contribute to malignant transformation and tumor progression. Oncogene (2012) 31, 1636-1648; doi:10.1038/onc.2011.346; published online 15 August 2011	[Mahoney, M. G.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; [Peltonen, S.] Univ Turku, Dept Dermatol, Turku, Finland; [Peltonen, S.] Turku Univ Hosp, FIN-20520 Turku, Finland; [Green, K. J.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Green, K. J.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wahl, J. K., III] Univ Nebraska Med Ctr, Dept Oral Biol, Lincoln, NE USA; [Del Galdo, F.] Univ Leeds, LMBU, Leeds Inst Mol Med, Scleroderma Res Ctr, Leeds, W Yorkshire, England	Jefferson University; University of Turku; University of Turku; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Leeds	Mahoney, MG (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, 233 S 10th St,Suite 428 BLSB, Philadelphia, PA 19107 USA.	my.mahoney@jefferson.edu	Peltonen, Sirkku/C-3133-2008; Del+Galdo, Francesco/ABD-9872-2021	Peltonen, Sirkku/0000-0003-0990-1430; Del+Galdo, Francesco/0000-0002-8528-2283; Medhat, Walid/0000-0002-6704-2171	National Institutes of Health [R01 AR47938, R01 DE01905, R01 CA122151]; NATIONAL CANCER INSTITUTE [R01CA122151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Dr Abhilasha Gupta for critically reading the paper and insightful discussions. This work was supported by grants from the National Institutes of Health to M Mahoney (R01 AR47938), J Wahl (R01 DE01905) and K Green (R01 CA122151).	Allen E, 1996, J CELL BIOL, V133, P1367, DOI 10.1083/jcb.133.6.1367; Andl CD, 2001, J INVEST DERMATOL, V117, P1068, DOI 10.1046/j.0022-202x.2001.01528.x; Arribas J, 2006, CANCER METAST REV, V25, P57, DOI 10.1007/s10555-006-7889-6; Bech-Serra JJ, 2006, MOL CELL BIOL, V26, P5086, DOI 10.1128/MCB.02380-05; Biedermann K, 2005, J PATHOL, V207, P199, DOI 10.1002/path.1821; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brennan D, 2009, CELL ADHES MIGR, V3, P148, DOI 10.4161/cam.3.2.7539; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Chen ST, 2004, INT J MOL MED, V14, P577; Cheng X, 2004, J DERMATOL, V31, P171, DOI 10.1111/j.1346-8138.2004.tb00654.x; Cirillo N, 2008, J CELL BIOCHEM, V103, P598, DOI 10.1002/jcb.21431; Del Galdo F, 2008, CURR OPIN RHEUMATOL, V20, P713, DOI 10.1097/BOR.0b013e3283103d27; Delva E, 2008, J BIOL CHEM, V283, P18303, DOI 10.1074/jbc.M710046200; Denault Jean-Bernard, 2008, V414, P191; Denning MF, 1998, EXP CELL RES, V239, P50, DOI 10.1006/excr.1997.3890; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Eshkind L, 2002, EUR J CELL BIOL, V81, P592, DOI 10.1078/0171-9335-00278; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1994, J BIOL CHEM, V269, P30745; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gassmann MG, 2000, EXP CELL RES, V258, P23, DOI 10.1006/excr.2000.4904; Harada H, 1996, ACTA DERM-VENEREOL, V76, P417; Keim SA, 2008, HYBRIDOMA, V27, P249, DOI 10.1089/hyb.2008.0020; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Klessner JL, 2009, MOL BIOL CELL, V20, P328, DOI 10.1091/mbc.E08-04-0356; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Kurzen H, 2003, J CUTAN PATHOL, V30, P621, DOI 10.1034/j.1600-0560.2003.00122.x; Lajoie P, 2010, INT REV CEL MOL BIO, V282, P135, DOI 10.1016/S1937-6448(10)82003-9; Laughlin RC, 2004, INFECT IMMUN, V72, P5349, DOI 10.1128/IAI.72.9.5349-5357.2004; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Lorch JH, 2007, CANCER RES, V67, P727, DOI 10.1158/0008-5472.CAN-06-2162; Mahoney MG, 2002, EXP DERMATOL, V11, P115, DOI 10.1034/j.1600-0625.2002.110203.x; Mahoney MG, 2006, EXP DERMATOL, V15, P101, DOI 10.1111/j.1600-0625.2006.00391.x; Nava P, 2007, MOL BIOL CELL, V18, P4565, DOI 10.1091/mbc.E07-05-0426; Okamoto CT, 1998, ADV DRUG DELIVER REV, V29, P215, DOI 10.1016/S0169-409X(97)00080-X; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Rupinder SK, 2007, VASC PHARMACOL, V46, P383, DOI 10.1016/j.vph.2007.01.006; Santiago-Josefat B, 2007, J BIOL CHEM, V282, P8325, DOI 10.1074/jbc.M608826200; SCHAFER S, 1994, EXP CELL RES, V211, P391, DOI 10.1006/excr.1994.1103; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trojan L, 2005, ANTICANCER RES, V25, P183; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Whittock NV, 2003, J INVEST DERMATOL, V120, P970, DOI 10.1046/j.1523-1747.2003.12257.x; Zheng XJ, 2003, BBA-MOL CELL RES, V1643, P25, DOI 10.1016/j.bbamcr.2003.08.006	61	51	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1636	1648		10.1038/onc.2011.346	http://dx.doi.org/10.1038/onc.2011.346			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841821	Green Published, Green Accepted			2022-12-17	WOS:000302231400003
J	Heffernan-Stroud, LA; Helke, KL; Jenkins, RW; De Costa, AM; Hannun, YA; Obeid, LM				Heffernan-Stroud, L. A.; Helke, K. L.; Jenkins, R. W.; De Costa, A-M; Hannun, Y. A.; Obeid, L. M.			Defining a role for sphingosine kinase 1 in p53-dependent tumors	ONCOGENE			English	Article						ceramide; sphingosine-1-phosphate; p53; sphingosine kinase; cancer; senescence	PROGRAMMED CELL-DEATH; CERAMIDE-INDUCED APOPTOSIS; TANDEM MASS-SPECTROMETRY; BIOACTIVE SPHINGOLIPIDS; QUANTITATIVE-ANALYSIS; GENOTOXIC STRESS; HIGH EXPRESSION; DOWN-REGULATION; MICE DEFICIENT; CYCLE ARREST	p53 is a crucial tumor suppressor that is mutated or deleted in a majority of cancers. Exactly how p53 prevents tumor progression has proved elusive for many years; however, this information is crucial to define targets for chemotherapeutic development that can effectively restore p53 function. Bioactive sphingolipids have recently emerged as important regulators of proliferative, apoptotic and senescent cellular processes. In this study, we demonstrate that the enzyme sphingosine kinase 1 (SK1), a critical enzyme in the regulation of the key bioactive sphingolipids ceramide, sphingosine and sphingosine-1-phosphate (S1P), serves as a key downstream target for p53 action. Our results show that SK1 is proteolysed in response to genotoxic stress in a p53-dependent manner. p53 null mice display elevation of SK1 levels and a tumor-promoting dysregulation of bioactive sphingolipids in which the anti-growth sphingolipid ceramide is decreased and the pro-growth sphingolipid S1P is increased. Importantly, deletion of SK1 in p53 null mice completely abrogated thymic lymphomas in these mice and prolonged their life span by similar to 30%. Deletion of SK1 also significantly attenuated the formation of other cancers in p53 heterozygote mice. The mechanism of p53 tumor suppression by loss of SK1 is mediated by elevations of sphingosine and ceramide, which in turn were accompanied by increased expression of cell cycle inhibitors and tumor cell senescence. Thus, targeting SK1 may restore sphingolipid homeostasis in p53-dependent tumors and provide insights into novel therapeutic approaches to cancer. Oncogene (2012) 31, 1166-1175; doi:10.1038/onc.2011.302; published online 18 July 2011	[Obeid, L. M.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA; [Heffernan-Stroud, L. A.; Obeid, L. M.] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29403 USA; [Helke, K. L.] Med Univ S Carolina, Dept Comparat Med Lab Anim Resources, Charleston, SC 29403 USA; [Jenkins, R. W.; Hannun, Y. A.; Obeid, L. M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA; [De Costa, A-M] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; [Obeid, L. M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St, Charleston, SC 29403 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847; Helke, Kris/0000-0001-9746-0764	Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX000156]; NIH/NIGMS [R01 GM062887]; NIH/NCI [P01 CA097132-project 3, P01 CA097132-project 1]; American Heart Association [AHA 081509E]; NIH MSTP [GM08716]; MUSC Hollings Cancer Center Abney Foundation; NIH/NIEHS [T32 ES012878, F30ES017379]; NCI [IPO1CA097132, P30 CA 138313]; NIH/NCRR SC COBRE [P20 RR017677]; NIH [C06 RR018823]; National Center for Research Resources; NATIONAL CANCER INSTITUTE [P30CA138313, P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012878, F30ES017379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887, T32GM008716] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000156] Funding Source: NIH RePORTER	Biomedical Laboratory Research and Development Service of the VA Office of Research and Development; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Heart Association(American Heart Association); NIH MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MUSC Hollings Cancer Center Abney Foundation; NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCRR SC COBRE; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported, in part, by Award Number I01BX000156 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development, NIH/NIGMS R01 GM062887, NIH/NCI P01 CA097132-project 3 (to LMO). NIH/NCI P01 CA097132-project 1 (to YAH). American Heart Association Pre-Doctoral Fellowship AHA 081509E (to RWJ), NIH MSTP Training Grant GM08716 (to RWJ, AMDC, LAHS), MUSC Hollings Cancer Center Abney Foundation Scholarship (to RWJ, LAHS), NIH/NIEHS TG T32 ES012878, and NIH/NIEHS National Research Service Award Individual Predoctoral Fellowship F30ES017379 (to LAHS). Liquid chromatography-mass spectrometry analysis of sphingolipids was performed by Lipidomics Shared Resource, MUSC (Methods 2006, 39: 82-91) supported by NCI Grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20 RR017677 as specified in Supplementary Information. Laboratory space in the CRI building of MUSC was supported by the NIH, Grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. Refer to Supplementary Information for individual acknowledgements and the VA disclaimer.	Akao Y, 2006, BIOCHEM BIOPH RES CO, V342, P1284, DOI 10.1016/j.bbrc.2006.02.070; Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805; Bayerl MG, 2008, LEUKEMIA LYMPHOMA, V49, P948, DOI 10.1080/10428190801911654; Bergelin N, 2009, ENDOCRINOLOGY, V150, P2055, DOI 10.1210/en.2008-0625; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Bielawski J, 2009, METHODS MOL BIOL, V579, P443, DOI 10.1007/978-1-60761-322-0_22; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; CHAO R, 1992, J BIOL CHEM, V267, P23459; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2003, PHARMACOL RES, V47, P439, DOI 10.1016/S1043-6618(03)00053-7; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Debacq-Chainiaux F, 2010, ADV EXP MED BIOL, V694, P126; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Assaad W, 2003, BIOCHEM J, V376, P725, DOI 10.1042/BJ20030888; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Heffernan-Stroud LA, 2011, ADV ENZYME REGUL, V51, P219, DOI 10.1016/j.advenzreg.2010.10.003; Hengst JA, 2010, BIOORG MED CHEM LETT, V20, P7498, DOI 10.1016/j.bmcl.2010.10.005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kim SS, 2002, ONCOGENE, V21, P2020, DOI 10.1038/sj.onc.1205037; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Long JS, 2010, MOL CELL BIOL, V30, P3827, DOI 10.1128/MCB.01133-09; Lopez-Marure R, 2000, EUR J BIOCHEM, V267, P4325, DOI 10.1046/j.1432-1327.2000.01436.x; Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993; Lozano G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001115; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mathews TP, 2010, J MED CHEM, V53, P2766, DOI 10.1021/jm901860h; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103; Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958; Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Pruett ST, 2008, J LIPID RES, V49, P1621, DOI 10.1194/jlr.R800012-JLR200; Pruschy M, 1999, BRIT J CANCER, V80, P693, DOI 10.1038/sj.bjc.6690411; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Ryland LK, 2011, CANCER BIOL THER, V11, P138, DOI 10.4161/cbt.11.2.14624; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Taha TA, 2005, J BIOL CHEM, V280, P17196, DOI 10.1074/jbc.M413744200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Taha TA, 2006, BBA-BIOMEMBRANES, V1758, P2027, DOI 10.1016/j.bbamem.2006.10.018; Vadas M, 2008, BBA-MOL CELL BIOL L, V1781, P442, DOI 10.1016/j.bbalip.2008.06.007; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yoon CH, 2009, MOL CANCER RES, V7, P361, DOI 10.1158/1541-7786.MCR-08-0069; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	72	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1166	1175		10.1038/onc.2011.302	http://dx.doi.org/10.1038/onc.2011.302			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765468	Green Accepted			2022-12-17	WOS:000300945900009
J	Park, JH; Lee, JY; Shin, DH; Jang, KS; Kim, HJ; Kong, G				Park, J-H; Lee, J-Y; Shin, D-H; Jang, K-S; Kim, H-J; Kong, Gu			Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1 alpha mediated by the PTEN/PI3K/Akt pathway	ONCOGENE			English	Article						Mel-18; polycomb group proteins; Akt; angiogenesis	INDUCIBLE FACTOR 1-ALPHA; FORKHEAD TRANSCRIPTION FACTOR; REGULATES CELL-PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER; SUPPRESSOR PROTEIN; UBIQUITIN LIGASE; VEGF EXPRESSION; POOR-PROGNOSIS; HYPOXIA	Mel-18 has been implicated in several processes in tumor progression, in which the Akt pathway is involved as an important key molecular event. However, the function of Mel-18 in human cancers has not been fully established yet. Here, we examined the effect of Mel-18 on tumor angiogenesis in human breast cancer, and found that Mel-18 was a novel regulator of HIF-1 alpha. Mel-18 negatively regulated the HIF-1 alpha expression and its target gene VEGF transcription during both normoxia and hypoxia. We demonstrated that Mel-18 regulated the HIF-1 alpha expression and activity via the PI3K/Akt pathway. Loss of Mel-18 downregulated Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression, consequently activating the PI3K/Akt/MDM2 pathway, and leading to an increase of HIF-1 alpha protein level. Mel-18 modulated the HIF-1 alpha transcriptional activity via regulating the cytoplasmic retention of FOXO3a, a downstream effector of Akt, and recruitment of HIF-1 alpha/CBP complex to the VEGF promoter. Furthermore, our data shows that Mel-18 blocked tumor angiogenesis both in vitro and in vivo. Mel-18 overexpression inhibited in vitro tube formation in human umbilical endothelial cells (HUVECs). Xenografts in NOD/SCID mice derived from stably Mel-18 knocked down MCF7 human breast cancer cells showed increased tumor volume, microvessel density, and phospho-Akt and HIF-1a expression levels. In conclusion, our findings provide that Mel-18 is a novel regulator of tumor angiogenesis through regulating HIF-1 alpha and its target VEGF expressions mediated by the PTEN/PI3K/Akt pathway, suggesting a new tumor-suppressive role of Mel-18 in human breast cancer. Oncogene (2011) 30, 4578-4589; doi: 10.1038/onc.2011.174; published online 23 May 2011	[Park, J-H; Shin, D-H; Jang, K-S; Kim, H-J; Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; [Lee, J-Y; Kong, Gu] Hanyang Univ, IBBR, Seoul 133791, South Korea	Hanyang University; Hanyang University	Kong, G (corresponding author), Hanyang Univ, Coll Med, Dept Pathol, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr	Jang, Kiseok/P-2048-2015	Jang, Kiseok/0000-0002-6585-3990	National Research Foundation of Korea (NRF); Korean government (MEST) [2010K001350, 2010-0020534]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2010K001350 and 2010-0020534).	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Davis R, 2009, ONCOL REP, V22, P1473, DOI 10.3892/or_00000589; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Fang J, 2007, CELL SIGNAL, V19, P2487, DOI 10.1016/j.cellsig.2007.07.025; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Jung JH, 2010, BIOCHEM BIOPH RES CO, V400, P523, DOI 10.1016/j.bbrc.2010.08.086; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196; Li W, 2008, ONCOL REP, V20, P713, DOI 10.3892/or_00000064; Li XY, 2007, ACTA BIOCH BIOPH SIN, V39, P745, DOI 10.1111/j.1745-7270.2007.00337.x; Ma JC, 2009, MOL CELL BIOCHEM, V331, P161, DOI 10.1007/s11010-009-0154-x; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 2001, EXP NEPHROL, V9, P235; Merritt WM, 2010, MOL CANCER THER, V9, P985, DOI 10.1158/1535-7163.MCT-09-0967; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Tan M, 2008, ONCOGENE, V27, P1404, DOI 10.1038/sj.onc.1210780; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian T, 2010, CARCINOGENESIS, V31, P1211, DOI 10.1093/carcin/bgq085; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Vemula S, 2010, BLOOD, V115, P1785, DOI 10.1182/blood-2009-08-237222; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Zhong H, 2000, CANCER RES, V60, P1541	48	51	55	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 10	2011	30	45					4578	4589		10.1038/onc.2011.174	http://dx.doi.org/10.1038/onc.2011.174			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21602890				2022-12-17	WOS:000296890700005
J	Watt, SA; Pourreyron, C; Purdie, K; Hogan, C; Cole, CL; Foster, N; Pratt, N; Bourdon, JC; Appleyard, V; Murray, K; Thompson, AM; Mao, X; Mein, C; Bruckner-Tuderman, L; Evans, A; McGrath, JA; Proby, CM; Foerster, J; Leigh, IM; South, AP				Watt, S. A.; Pourreyron, C.; Purdie, K.; Hogan, C.; Cole, C. L.; Foster, N.; Pratt, N.; Bourdon, J-C; Appleyard, V.; Murray, K.; Thompson, A. M.; Mao, X.; Mein, C.; Bruckner-Tuderman, L.; Evans, A.; McGrath, J. A.; Proby, C. M.; Foerster, J.; Leigh, I. M.; South, A. P.			Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma	ONCOGENE			English	Article						cutaneous squamous cell carcinoma; primary cell culture; gene expression analysis; therapeutic targets; PLK1	POLO-LIKE KINASE; GENE-EXPRESSION PATTERNS; CHRONIC MYELOID-LEUKEMIA; NONMELANOMA SKIN-CANCER; EPITHELIAL-CELLS; ANALYSIS DEFINES; BREAST-CANCER; IN-VIVO; LINES; IDENTIFICATION	Identifying therapeutic targets for cancer treatment relies on consistent changes within particular types or sub-types of malignancy. The ability to define either consistent changes or sub-types of malignancy is often masked by tumor heterogeneity. To elucidate therapeutic targets in cutaneous squamous cell carcinoma (cSCC), the most frequent skin neoplasm with malignant potential, we have developed an integrated approach to gene expression profiling beginning with primary keratinocytes in culture. Candidate drivers of cSCC development were derived by first defining a set of in vitro cancer genes and then comparing their expression in a range of clinical data sets containing normal skin, cSCC and the benign hyper-proliferative condition psoriasis. A small interfering RNA (siRNA) screen of the resulting 21 upregulated genes has yielded targets capable of reducing xenograft tumor volume in vivo. Small-molecule inhibitors for one target, Polo-like kinase-1 (PLK1), are already in clinical trials for other malignancies, and our data show efficacy in cSCC. Another target, C20orf20, is identified as being overexpressed in cSCC, and siRNA-mediated knockdown induces apoptosis in vitro and reduces tumor growth in vivo. Thus, our approach has shown established and uncharacterized drivers of tumorigenesis with potent efficacy as therapeutic targets for the treatment of cSCC. Oncogene (2011) 30, 4666-4677; doi:10.1038/onc.2011.180; published online 23 May 2011	[Watt, S. A.; Pourreyron, C.; Hogan, C.; Cole, C. L.; Bourdon, J-C; Appleyard, V.; Murray, K.; Thompson, A. M.; Proby, C. M.; Foerster, J.; Leigh, I. M.; South, A. P.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Div Med Sci, Dundee DD1 9SY, Scotland; [Purdie, K.; Mao, X.] Inst Cell & Mol Sci, Ctr Cutaneous Res, London, England; [Foster, N.; Pratt, N.] Ninewells Hosp Dundee, Dept Human Genet, Dundee, Scotland; [Mein, C.] Queen Mary Univ London, Genome Ctr, London, England; [Bruckner-Tuderman, L.] Univ Med Ctr Freiburg, Dept Dermatol, Freiburg, Germany; [Bruckner-Tuderman, L.] Freiburg Inst Adv Studies, Sch Life Sci LifeNet, Freiburg, Germany; [Evans, A.] Ninewells Hosp Dundee, Dept Pathol, Dundee, Scotland; [McGrath, J. A.] Kings Coll London, St Johns Inst Dermatol, St Thomas Hosp, Div Genet & Mol Med,Genet Skin Dis Grp,Sch Med, London, England	University of Dundee; University of London; Queen Mary University London; University of London; Queen Mary University London; University of Freiburg; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	South, AP (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Div Med Sci, Dundee DD1 9SY, Scotland.	a.p.south@dundee.ac.uk	Pourreyron, Celine/AAE-7362-2020; JC, Bourdon/A-4439-2008; McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	JC, Bourdon/0000-0003-4623-9386; McGrath, John/0000-0002-3708-9964; Mein, Charles/0000-0003-0811-9658	DebRA, the dystrophic epidermolysis bullosa research association; Cancer Research UK [13044] Funding Source: researchfish	DebRA, the dystrophic epidermolysis bullosa research association; Cancer Research UK(Cancer Research UK)	Funding: This work was funded by DebRA, the dystrophic epidermolysis bullosa research association (http://www.debra.org.uk/).	Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Braakhuis BJM, 2010, CURR OPIN OTOLARYNGO, V18, P67, DOI 10.1097/MOO.0b013e32833693ce; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Cai SQ, 2005, J DERMATOL, V32, P354, DOI 10.1111/j.1346-8138.2005.tb00906.x; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Cheng H, 2010, CIRC RES, V106, P21, DOI 10.1161/CIRCRESAHA.109.206920; Creighton C, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r46; Cunningham J, 2002, BRIT J HAEMATOL, V119, P1062, DOI 10.1046/j.1365-2141.2002.03940.x; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; EPSTEIN E, 1984, J DERMATOL SURG ONC, V10, P418; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fine JD, 2009, J AM ACAD DERMATOL, V60, P203, DOI 10.1016/j.jaad.2008.09.035; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Gleixner KV, 2010, CANCER RES, V70, P1513, DOI 10.1158/0008-5472.CAN-09-2181; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa T, 2007, GENES CELLS, V12, P811, DOI 10.1111/j.1365-2443.2007.01089.x; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Nindl I, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-30; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Purdie KJ, 2007, GENE CHROMOSOME CANC, V46, P661, DOI 10.1002/gcc.20447; Purdie KJ, 2009, J INVEST DERMATOL, V129, P1562, DOI 10.1038/jid.2008.408; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Romanowska M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009701; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Schmit TL, 2009, J INVEST DERMATOL, V129, P2843, DOI 10.1038/jid.2009.172; Schmit TL, 2009, CELL CYCLE, V8, P2697, DOI 10.4161/cc.8.17.9413; Schoffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009-0010; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Sharma SV, 2010, NAT REV CANCER, V10, P241, DOI 10.1038/nrc2820; SMITH HS, 1981, CANCER RES, V41, P4637; South AP, 2003, J CELL SCI, V116, P3303, DOI 10.1242/jcs.00636; Staples MP, 2006, MED J AUSTRALIA, V184, P6, DOI 10.5694/j.1326-5377.2006.tb00086.x; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Van Haren R, 2009, BRIT J DERMATOL, V161, P1278, DOI 10.1111/j.1365-2133.2009.09338.x; Veness MJ, 2007, HEAD NECK-J SCI SPEC, V29, P621, DOI 10.1002/hed.20576; Wallis S, 2000, MOL BIOL CELL, V11, P1077, DOI 10.1091/mbc.11.3.1077; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Welsh JB, 2001, CANCER RES, V61, P5974; Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40; Yamaguchi K, 2010, BRIT J CANCER, V102, P325, DOI 10.1038/sj.bjc.6605500	56	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	46					4666	4677		10.1038/onc.2011.180	http://dx.doi.org/10.1038/onc.2011.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21602893	Green Published, hybrid			2022-12-17	WOS:000297252100006
J	Rodriguez, MI; Gonzalez-Flores, A; Dantzer, F; Collard, J; de Herreros, AG; Oliver, FJ				Rodriguez, M. I.; Gonzalez-Flores, A.; Dantzer, F.; Collard, J.; de Herreros, A. G.; Oliver, F. J.			Poly(ADP-ribose)-dependent regulation of Snail1 protein stability	ONCOGENE			English	Article						snail1; E-cadherin; PARP-1; poly(ADP-ribosyl)ation; EMT; melanoma	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; TUMOR-CELLS; DNA-DAMAGE; TGF-BETA; POLYMERASE; CANCER; PROGRESSION; PARP-1	Snail1 is a master regulator of the epithelial-mesenchymal transition (EMT) and has been implicated in key tumor biological processes such as invasion and metastasis. It has been previously shown that poly(ADP-ribose) polymerase-1 (PARP-1) knockdown, but not PARP inhibition, down-regulates the expression of Snail1. In this study we have characterized a novel regulatory mechanism controlling Snail1 protein expression through poly(ADP-ribosyl)ation. The effect is not only limited to repression of Snail1 transcription but also to downregulated Snail1 protein stability. PARP-1 (but not PARP-2) poly(ADP) ribosylates Snail1, both in vivo and in vitro, and interacts with Snail1, an association that is sensitive to PARP inhibitors. PARP inhibition has also clear effects on EMT phenotype of different tumor cells, including Snail1 downregulation, E-cadherin upregulation, decreased cell elongation and invasiveness. Therefore, this study reveals a new regulatory mechanism of Snail1 activation through poly(ADP-ribosyl) ation with consequences in malignant transformation through EMT. Oncogene (2011) 30, 4365-4372; doi: 10.1038/onc.2011.153; published online 16 May 2011	[Rodriguez, M. I.; Gonzalez-Flores, A.; Oliver, F. J.] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18100, Spain; [Dantzer, F.] Ecole Super Biotechnol Strasbourg, Dept Integr Genome, UMR 7175, Strasbourg, France; [Collard, J.] Netherlands Canc Inst, Amsterdam, Netherlands; [de Herreros, A. G.] IMIM Hosp del Mar, Programa Recerca Canc, Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Netherlands Cancer Institute; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Oliver, FJ (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Avda Conocimiento S-N, Granada 18100, Spain.	joliver@ipb.csic.es	Lara, María Isabel Rodríguez/A-1961-2017; Dantzer, Françoise/O-2126-2016; de Herreros, A Garcia/H-3104-2014; Oliver, Javier/S-1725-2018	Lara, María Isabel Rodríguez/0000-0002-2270-0070; de Herreros, A Garcia/0000-0001-5270-0808; Oliver, Javier/0000-0001-8468-1998; Dantzer, Francoise/0000-0003-0945-8483	CSIC; Junta de Andalucia; Ecole Superieure de Biotechnologie de Strasbourg, Strasbourg, France; Ministerio de Ciencia; Netherlands Cancer Institute, Amsterdam, The Netherlands; Ministerio de Ciencia e Innovacion [SAF2006-01094, SAF2009-13281-C02-01]; Fundacion La Caixa [BM06-219-0]; Junta de Andalucia [P07-CTS-0239]; Ministerio de Educacion y Ciencia [SAF2007-64597, SAF2006-03399]; la Fundacion Cientifica de la Asociacion Espanola contra el Cancer	CSIC; Junta de Andalucia(Junta de Andalucia); Ecole Superieure de Biotechnologie de Strasbourg, Strasbourg, France; Ministerio de Ciencia(Spanish Government); Netherlands Cancer Institute, Amsterdam, The Netherlands(Netherlands Government); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion La Caixa(La Caixa Foundation); Junta de Andalucia(Junta de Andalucia); Ministerio de Educacion y Ciencia(Spanish Government); la Fundacion Cientifica de la Asociacion Espanola contra el Cancer	We acknowledge Laura Lopez for her technical assistance. MIR is recipient of a postdoctoral fellowship financed by the program JAE-Doc of CSIC. She was also funded by Junta de Andalucia Short-Term Fellowships to stay at the Departement Integrite du Genome' de I'UMR 7175, Ecole Superieure de Biotechnologie de Strasbourg, Strasbourg, France and Ministerio de Ciencia 'Programa Jose Castillejo' to stay at the Department of Cell Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands. This work was supported by Ministerio de Ciencia e Innovacion SAF2006-01094; SAF2009-13281-C02-01, Fundacion La Caixa BM06-219-0; and Junta de Andalucia P07-CTS-0239 to FJO; Ministerio de Educacion y Ciencia SAF2007-64597 and 'Ministerio de Ciencia y Tecnologia' (SAF2006-03399) and 'la Fundacion Cientifica de la Asociacion Espanola contra el Cancer' to AGH.	Aguilar-Quesada R, 2007, CURR MED CHEM, V14, P1179, DOI 10.2174/092986707780597998; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Hassa PO, 2008, FRONT BIOSCI-LANDMRK, V13, P3046, DOI 10.2741/2909; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Lasfar A, 2010, CARCINOGENESIS, V31, P1710, DOI 10.1093/carcin/bgq155; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Peinado H, 2005, CELL CYCLE, V4, P1749, DOI 10.4161/cc.4.12.2224; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sarrio D, 2004, ONCOGENE, V23, P3272, DOI 10.1038/sj.onc.1207439; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375	34	51	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4365	4372		10.1038/onc.2011.153	http://dx.doi.org/10.1038/onc.2011.153			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21577210				2022-12-17	WOS:000296356400007
J	Abdeen, SK; Salah, Z; Maly, B; Smith, Y; Tufail, R; Abu-Odeh, M; Zanesi, N; Croce, CM; Nawaz, Z; Aqeilan, RI				Abdeen, S. K.; Salah, Z.; Maly, B.; Smith, Y.; Tufail, R.; Abu-Odeh, M.; Zanesi, N.; Croce, C. M.; Nawaz, Z.; Aqeilan, R. I.			Wwox inactivation enhances mammary tumorigenesis	ONCOGENE			English	Article						WWOX; WW domains; breast cancer; triple negative; tumor suppressor	BREAST-CANCER; E6-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR; EXPRESSION; GENE; IDENTIFICATION; ESTROGEN; GROWTH	Breast cancer is the leading cause of cancer-related death in women worldwide. Expression of the WWOX tumor suppressor is absent or reduced in a large proportion of breast tumors suggesting that loss of WWOX may contribute to breast tumorigenesis. Wwox-deficient mice die by 3-4 weeks of age precluding adult tumor analysis. To evaluate the effect of WWOX-altered expression on mammary tumor formation, the Wwox-heterozygous allele was back crossed onto the C3H mammary tumor-susceptible genetic background (Wwox(C3H) +/-) and incidence of mammary tumor formation was evaluated. Although 50% of the female Wwox(C3H) +/- mice developed mammary carcinomas, only 7% of Wwox(C3H) +/- mice did. Intriguingly, mammary tumors in Wwox(C3H) +/- mice frequently lost WWOX protein expression suggesting a genetic predisposition toward mammary tumorigenesis. Immunohistochemical staining of hormone receptors revealed loss of estrogen receptor-a (ER) and progesterone receptor in the majority of these tumors. In vitro, depletion of WWOX in MCF7 ER-positive cells led to reduced ER expression and reduced sensitivity to tamoxifen and estrogen treatment and was associated with enhanced survival and anchorage-independent growth. Finally, cDNA array analyses of murine normal mammary epithelial cells and mammary tumors identified 163 significantly downreguated and 129 upregulated genes in the tumors. The majority of differentially expressed genes were part of pathways involved in cellular movement, cell-to-cell signaling and interaction, cellular development, cellular growth and proliferation and cell death. These changes in gene expression of mouse mammary tumors in Wwox(C3H) +/- mice resemble, at least in part, human breast cancer development. Our findings demonstrate the critical role that the WWOX tumor suppressor gene has in preventing tumorigenesis in breast cancer. Oncogene (2011) 30, 3900-3906; doi:10.1038/onc.2011.115; published online 18 April 2011	[Abdeen, S. K.; Salah, Z.; Abu-Odeh, M.; Aqeilan, R. I.] Hebrew Univ Jerusalem, Dept Immunol & Canc Res IMRIC, Lautenberg Ctr Gen & Tumor Immunol, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Maly, B.] Hebrew Univ Jerusalem, Dept Expt Pathol, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Smith, Y.] Hebrew Univ Jerusalem, Genom Data Anal Unit, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Tufail, R.; Nawaz, Z.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL USA; [Zanesi, N.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Miami; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Aqeilan, RI (corresponding author), Hebrew Univ Jerusalem, Dept Immunol & Canc Res IMRIC, Lautenberg Ctr, POB 12272, IL-91120 Jerusalem, Israel.	aqeilan@cc.huji.ac.il	Aqeilan, Rami/R-4443-2016; Young, Richard A/F-6495-2012; Aqeilan, Rami/AAT-7785-2020	Aqeilan, Rami/0000-0002-6034-023X; Young, Richard A/0000-0001-8855-8647; 	NIH [R01DK060907]; Israeli Science Foundation [1331/08]; Israel Cancer Research Funds (ICRF); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060907, R01DK079217] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Israeli Science Foundation(Israel Science Foundation); Israel Cancer Research Funds (ICRF); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to all the Aqeilan's lab members for helpful suggestions and technical assistance. This research was supported by grants from NIH (R01DK060907) to ZN and RIA, Israeli Science Foundation (#1331/08) to RIA and Israel Cancer Research Funds (ICRF) to ZS.	Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008-5472.CAN-07-1081; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilian RI, 2007, CANCER RES, V67, P9330, DOI 10.1158/0008-5472.CAN-07-2147; Bednarek AK, 2000, CANCER RES, V60, P2140; Del Mare S, 2009, J CELL BIOCHEM, V108, P737, DOI 10.1002/jcb.22298; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; Guler G, 2009, CANCER-AM CANCER SOC, V115, P899, DOI 10.1002/cncr.24103; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Klein A, 2007, INT J CANCER, V121, P683, DOI 10.1002/ijc.22630; Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008-5472.CAN-09-4602; Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Radmacher MD, 2000, J NATL CANCER I, V92, P48, DOI 10.1093/jnci/92.1.48; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Salah Z, 2010, FUTURE ONCOL, V6, P249, DOI [10.2217/fon.09.152, 10.2217/FON.09.152]; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Turner BC, 2002, CANCER RES, V62, P4054	23	51	53	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	36					3900	3906		10.1038/onc.2011.115	http://dx.doi.org/10.1038/onc.2011.115			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21499303				2022-12-17	WOS:000294687200007
J	Pode-Shakked, N; Harari-Steinberg, O; Haberman-Ziv, Y; Rom-Gross, E; Bahar, S; Omer, D; Metsuyanim, S; Buzhor, E; Jacob-Hirsch, J; Goldstein, RS; Mark-Danieli, M; Dekel, B				Pode-Shakked, N.; Harari-Steinberg, O.; Haberman-Ziv, Y.; Rom-Gross, E.; Bahar, S.; Omer, D.; Metsuyanim, S.; Buzhor, E.; Jacob-Hirsch, J.; Goldstein, R. S.; Mark-Danieli, M.; Dekel, B.			Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target	ONCOGENE			English	Article						frizzled7; wnt pathway; stem cells; Wilms' tumor; sensitive; resistant	FREQUENT EPIGENETIC INACTIVATION; STEM-CELLS; BETA-CATENIN; CANCER; GENES; IDENTIFICATION; MODEL; ACTIVATION; WTX	Wilms' tumor (WT), the most frequent renal solid tumor in children, has been linked to aberrant Wnt signaling. Herein, we demonstrate that different WTs can be grouped according to either sensitivity or resistance to an antibody (Ab) specific to frizzled7 (FZD7), a Wnt receptor. In the FZD7-sensitive WT phenotype, the Ab induced cell death of the FZD7(+) fraction, which in turn depleted primary WT cultures of their clonogenic and sphere-forming cells and decreased in vivo proliferation and survival on xenografting to the chick chorio-allantoic-membrane. In contrast, FZD7-resistant WT in which no cell death was induced showed a different intracellular route of the Ab-FZD7 complex compared with sensitive tumors and accumulation of beta-catenin. This coincided with a low sFRP1 and DKK1 (Wnt inhibitors) expression pattern, restored epigenetically with de-methylating agents, and lack of beta-catenin or WTX mutations. The addition of exogenous DKK1 and sFRP1 to the tumor cells enabled the sensitization of FZD7-resistant WT to the FZD7 Ab. Finally, although extremely difficult to achieve because of dynamic cellular localization of FZD7, sorting of FZD7(+) cells from resistant WT, showed them to be highly clonogenic/proliferative, overexpressing WT 'stemness' genes, emphasizing the importance of targeting this fraction. FZD7 Ab therapy alone or in combination with Wnt pathway antagonists may have a significant role in the treatment of WT via targeting of a tumor progenitor population. Oncogene (2011) 30, 1664-1680; doi:10.1038/onc.2010.549; published online 17 January 2011	[Pode-Shakked, N.; Harari-Steinberg, O.; Haberman-Ziv, Y.; Bahar, S.; Omer, D.; Metsuyanim, S.; Buzhor, E.; Mark-Danieli, M.; Dekel, B.] Safra Childrens Hosp, Pediat Stem Cell Res Inst, Tel Hashomer, Israel; [Pode-Shakked, N.; Harari-Steinberg, O.; Haberman-Ziv, Y.; Bahar, S.; Omer, D.; Metsuyanim, S.; Buzhor, E.; Mark-Danieli, M.; Dekel, B.] Sheba Med Ctr, Sheba Ctr Regenerat Med, Tel Hashomer, Israel; [Pode-Shakked, N.; Haberman-Ziv, Y.; Bahar, S.; Omer, D.; Buzhor, E.; Dekel, B.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Rom-Gross, E.] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Pediat Surg, Jerusalem, Israel; [Metsuyanim, S.; Jacob-Hirsch, J.] Sheba Med Ctr, Ctr Canc Res, Tel Hashomer, Israel; [Goldstein, R. S.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center; Bar Ilan University	Dekel, B (corresponding author), Edmond & Lili Safra Childrens Hosp, Sheba Med Ctr, Pediat Stem Cell Res Inst, IL-52621 Tel Hashomer, Israel.	benjamin.dekel@gmail.com	Goldstein, Ronald/H-5765-2011		ISF [1139/07]; ICRF; TAU Cancer Biology Research Center; TAU Stem Cell Research Center; Schreiber Foundation; Brettler Foundation; Sackler School of Medicine; Tel Aviv University	ISF(Israel Science Foundation); ICRF; TAU Cancer Biology Research Center; TAU Stem Cell Research Center; Schreiber Foundation; Brettler Foundation; Sackler School of Medicine; Tel Aviv University	We thank Lior Zangi, Tsahi Neuman and Igor Grinberg for technical assistance. This work was supported by ISF grant number 1139/07, ICRF Clinical Career Development Award, TAU Cancer Biology Research Center and TAU Stem Cell Research Center, The Schreiber and Brettler Foundations, Sackler School of Medicine, Tel Aviv University (BD). This work is part of the requirements toward a PhD degree, Sackler School of Medicine, Tel Aviv University (NPS).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528; Dekel B, 2006, J AM SOC NEPHROL, V17, P3300, DOI 10.1681/ASN.2005020195; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Feinberg Andrew P, 2003, Methods Mol Biol, V222, P239; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Galmozzi E, 2006, CURR MED CHEM, V13, P603, DOI 10.2174/092986706776055661; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365-2141.2008.07242.x; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Koesters R, 1999, CANCER RES, V59, P3880; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Metsuyanim S, 2008, STEM CELLS, V26, P1808, DOI 10.1634/stemcells.2007-0322; Metsuyanim S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006709; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259; Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155; Pfeiffer P, 2007, ONCOGENE, V26, P3661, DOI 10.1038/sj.onc.1210377; Pode-Shakked N, 2009, J CELL MOL MED, V13, P1792, DOI 10.1111/j.1582-4934.2008.00607.x; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Rashidi H, 2009, BIOESSAYS, V31, P459, DOI 10.1002/bies.200800168; Ren X, 2007, CELL DEATH DIFFER, V14, P2076, DOI 10.1038/sj.cdd.4402220; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Robison Leslie L, 2005, Minn Med, V88, P45; Schedl A, 2007, NAT REV GENET, V8, P791, DOI 10.1038/nrg2205; Schmidt-Ott KM, 2008, KIDNEY INT, V74, P1004, DOI 10.1038/ki.2008.322; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Spreafico F, 2009, EXPERT REV ANTICANC, V9, P693, DOI 10.1586/ERA.09.45; Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259; Taizi M, 2006, EXP HEMATOL, V34, P1698, DOI 10.1016/j.exphem.2006.07.005; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; Wittmann S, 2008, GENE CHROMOSOME CANC, V47, P386, DOI 10.1002/gcc.20544; Zirn B, 2006, GENE CHROMOSOME CANC, V45, P565, DOI 10.1002/gcc.20319	43	51	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1664	1680		10.1038/onc.2010.549	http://dx.doi.org/10.1038/onc.2010.549			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21472018				2022-12-17	WOS:000289239400005
J	Lui, VWY; Wong, EYL; Ho, K; Ng, PKS; Lau, CPY; Tsui, SKW; Tsang, CM; Tsao, SW; Cheng, SH; Ng, MHL; Ng, YK; Lam, EKY; Hong, B; Lo, KW; Mok, TSK; Chan, ATC; Mills, GB				Lui, V. W. Y.; Wong, E. Y. L.; Ho, K.; Ng, P. K. S.; Lau, C. P. Y.; Tsui, S. K. W.; Tsang, C-M; Tsao, S-W; Cheng, S. H.; Ng, M. H. L.; Ng, Y. K.; Lam, E. K. Y.; Hong, B.; Lo, K. W.; Mok, T. S. K.; Chan, A. T. C.; Mills, G. B.			Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death	ONCOGENE			English	Article						c-Met tyrosine kinase inhibitor; TIGAR; NADPH	NASOPHARYNGEAL CARCINOMA; ACTIVATION; RECEPTOR; INVASION; CANCER	c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers. Oncogene (2011) 30, 1127-1134; doi:10.1038/onc.2010.490; published online 8 November 2010	[Lui, V. W. Y.; Wong, E. Y. L.; Ho, K.; Lau, C. P. Y.; Lam, E. K. Y.; Hong, B.; Mok, T. S. K.; Chan, A. T. C.] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, State Key Lab Oncol S China, Canc Signaling Lab,Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Ng, P. K. S.; Tsui, S. K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Tsang, C-M; Tsao, S-W] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Cheng, S. H.; Ng, M. H. L.; Lo, K. W.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Ng, Y. K.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Texas System; UTMD Anderson Cancer Center	Chan, ATC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Sha Tin, Hong Kong, Peoples R China.	anthony@clo.cuhk.edu.hk	Ng, Yuen-Keng/ABC-3906-2020; Mok, Tony Shu Kam/B-2310-2019; Chan, Anthony Tak Cheung/R-3940-2018; Tsui, Stephen Kwok-Wing/E-4385-2015; Cheng, Suk Hang/A-6177-2009; Lui, Vivian W. Y./I-5458-2016; Hong, Bo/ABA-3687-2021	Ng, Yuen-Keng/0000-0003-4491-5221; Mok, Tony Shu Kam/0000-0002-8251-0551; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Cheng, Suk Hang/0000-0002-2880-2289; Lui, Vivian W. Y./0000-0001-6918-1573; Hong, Bo/0000-0001-8117-5029; Lo, Kwok Wai/0000-0002-3488-6124	Research Grant Council, Hong Kong Government [471607]; Head and Neck SPORE [P50 CA097007]; CCSG [P30CA16672];  [2006.1.027];  [2007.1.025];  [2009.1.012]; NATIONAL CANCER INSTITUTE [P50CA097007, P30CA016672, P50CA098258] Funding Source: NIH RePORTER	Research Grant Council, Hong Kong Government(Hong Kong Research Grants Council); Head and Neck SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCSG; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Amgen, Inc. (USA) for the kind provision of the novel c-Met tyrosine kinase inhibitor, AM7. This study was supported by Research Grant Council, Hong Kong Government (471607) and Direct Grants for Research (2006.1.027; 2007.1.025; 2009.1.012) to VWYL. GBM is supported by Head and Neck SPORE P50 CA097007 and CCSG grant P30CA16672.	Anderson KE, 2006, CANC EPIDEMIOLOGY PR, P721; Bellon SF, 2008, J BIOL CHEM, V283, P2675, DOI 10.1074/jbc.M705774200; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Lui VWY, 2009, CARCINOGENESIS, V30, P2085, DOI 10.1093/carcin/bgp253; Lui VWY, 2007, MOL PHARMACOL, V71, P1435, DOI 10.1124/mol.106.032284; Lui VWY, 2010, BIOCHEM PHARMACOL, V79, P1772, DOI 10.1016/j.bcp.2010.02.012; Lui VWY, 2009, INT J CANCER, V125, P1884, DOI 10.1002/ijc.24567; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Qian CN, 2002, CANCER RES, V62, P589; Stabile LP, 2004, GENE THER, V11, P325, DOI 10.1038/sj.gt.3302169; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; WONG JH, 2009, CANC LETT; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103	19	51	53	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1127	1134		10.1038/onc.2010.490	http://dx.doi.org/10.1038/onc.2010.490			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21057531	Green Accepted			2022-12-17	WOS:000287964100011
J	Preston, RS; Philp, A; Claessens, T; Gijezen, L; Dydensborg, AB; Dunlop, EA; Harper, KT; Brinkhuizen, T; Menko, FH; Davies, DM; Land, SC; Pause, A; Baar, K; van Steensel, MAM; Tee, AR				Preston, R. S.; Philp, A.; Claessens, T.; Gijezen, L.; Dydensborg, A. B.; Dunlop, E. A.; Harper, K. T.; Brinkhuizen, T.; Menko, F. H.; Davies, D. M.; Land, S. C.; Pause, A.; Baar, K.; van Steensel, M. A. M.; Tee, A. R.			Absence of the Birt-Hogg-Dube gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility	ONCOGENE			English	Article						Birt-Hogg-Dube; HIF; folliculin; warburg effect	RENAL-CELL CARCINOMA; MAMMALIAN TARGET; FUMARATE HYDRATASE; CANCER; ACTIVATION; EXPRESSION; AMPK; MTOR; PHOSPHORYLATION; RAPAMYCIN	Under conditions of reduced tissue oxygenation, hypoxia-inducible factor (HIF) controls many processes, including angiogenesis and cellular metabolism, and also influences cell proliferation and survival decisions. HIF is centrally involved in tumour growth in inherited diseases that give rise to renal cell carcinoma (RCC), such as Von Hippel-Lindau syndrome and tuberous sclerosis complex. In this study, we examined whether HIF is involved in tumour formation of RCC in Birt-Hogg-Dube syndrome. For this, we analysed a Birt-Hogg-Dube patient-derived renal tumour cell line (UOK257) that is devoid of the Birt-Hogg-Dube protein (BHD) and observed high levels of HIF activity. Knockdown of BHD expression also caused a threefold activation of HIF, which was not as a consequence of more HIF1 alpha or HIF2 alpha protein. Transcription of HIF target genes VEGF, BNIP3 and CCND1 was also increased. We found nuclear localization of HIF1 alpha and increased expression of VEGF, BNIP3 and GLUT1 in a chromophobe carcinoma from a Birt-Hogg-Dube patient. Our data also reveal that UOK257 cells have high lactate dehydrogenase, pyruvate kinase and 3-hydroxyacyl-CoA dehydrogenase activity. We observed increased expression of pyruvate dehydrogenase kinase 1 (a HIF gene target), which in turn leads to increased phosphorylation and inhibition of pyruvate dehydrogenase. Together with increased protein levels of GLUT1, our data reveal that UOK257 cells favour glycolytic rather than lipid metabolism (a cancer phenomenon termed the 'Warburg effect'). UOK257 cells also possessed a higher expression level of the L-lactate influx monocarboxylate transporter 1 and consequently utilized L-lactate as a metabolic fuel. As a result of their higher dependency on glycolysis, we were able to selectively inhibit the growth of these UOK257 cells by treatment with 2-deoxyglucose. This work suggests that targeting glycolytic metabolism may be used therapeutically to treat Birt-Hogg-Dube-associated renal lesions. Oncogene (2011) 30, 1159-1173; doi:10.1038/onc.2010.497; published online 8 November 2010	[Preston, R. S.; Dunlop, E. A.; Harper, K. T.; Davies, D. M.; Tee, A. R.] Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; [Philp, A.; Baar, K.] Univ Calif Davis, Davis, CA 95616 USA; [Claessens, T.; Gijezen, L.; Brinkhuizen, T.; van Steensel, M. A. M.] Maastricht Univ, Med Ctr, Dept Dermatol, Maastricht, Netherlands; [Claessens, T.; Gijezen, L.; Brinkhuizen, T.; van Steensel, M. A. M.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Dydensborg, A. B.; Pause, A.] McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada; [Menko, F. H.] VU Med Ctr Amsterdam, Dept Clin Genet, Amsterdam, Netherlands; [Land, S. C.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Cardiovasc & Lung Biol, Div Med Sci, Dundee DD1 9SY, Scotland	Cardiff University; University of California System; University of California Davis; Maastricht University; Maastricht University; McGill University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Dundee	Tee, AR (corresponding author), Cardiff Univ, Inst Med Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk	/J-6218-2019; van Steensel, Maurice A.M./V-3852-2019	/0000-0002-9209-7561; Tee, Andrew/0000-0002-5577-4631; Davies, Mark/0000-0002-0688-3129; Baar, Keith/0000-0001-9337-6186; van Steensel, Maurice/0000-0002-7507-2442; Philp, Andrew/0000-0003-3860-4136; Land, Stephen/0000-0001-9216-5969	Association for International Cancer Research [06-914/915]; Wellcome Trust [088032/Z/08/Z]; Dutch Cancer Society [UM2009-4352, UM2010-4609]; Engineering and Physical Sciences Research Council [EP/E008925/1]; Biotechnology and Biological Sciences Research Council [BB/F002084/1]; BBSRC [BB/F002084/1] Funding Source: UKRI; EPSRC [EP/E008925/1] Funding Source: UKRI; Worldwide Cancer Research [06-0914] Funding Source: researchfish	Association for International Cancer Research; Wellcome Trust(Wellcome TrustEuropean Commission); Dutch Cancer Society(KWF Kankerbestrijding); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Worldwide Cancer Research	This work was supported by The Association for International Cancer Research Career Development Fellowship (No 06-914/915) (to A Tee). The Myrovlytis Trust supports the labs of A Tee, M v Steensel and A Pause and Partnership for Cures supports A Tee and Mv Steensel. Funding was also provided by the Wellcome Trust (No 088032/Z/08/Z) (to S Land) and the Dutch Cancer Society (grants UM2009-4352 to M v Steensel and UM2010-4609 to T Brinkhuizen). M Kamps, A van Marion and V Winnepenninckx (all of the MUMC) provided valuable assistance with immunohistochemistry. Funding was also provided by the Engineering and Physical Sciences Research Council (EP/E008925/1) and the Biotechnology and Biological Sciences Research Council (BB/F002084/1) (to K Baar). We also thank Wales Gene Park.	Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; Bratslavsky G, 2007, CLIN CANCER RES, V13, P4667, DOI 10.1158/1078-0432.CCR-06-2510; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Deldicque L, 2007, AM J PHYSIOL-CELL PH, V293, pC1263, DOI 10.1152/ajpcell.00162.2007; Dunlop EA, 2009, CELL SIGNAL, V21, P827, DOI 10.1016/j.cellsig.2009.01.012; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Galgani JE, 2008, AM J PHYSIOL-ENDOC M, V295, pE1009, DOI 10.1152/ajpendo.90558.2008; Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hartman TR, 2009, ONCOGENE, V28, P1594, DOI 10.1038/onc.2009.14; Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hemminki K, 2002, CARCINOGENESIS, V23, P809, DOI 10.1093/carcin/23.5.809; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Khoo SK, 2002, J MED GENET, V39, P906, DOI 10.1136/jmg.39.12.906; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu MY, 2003, CANCER RES, V63, P2675; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Rapisarda A, 2002, CANCER RES, V62, P4316; Robey R.B., 2005, DRUG DISCOV TODAY DI, V2, P239, DOI [10.1016/j.ddmec.2005.05.021, DOI 10.1016/J.DDMEC.2005.05.021, DOI 10.1016/j.ddmec.2005.05.021]; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; SLEGTENHORST MV, 2007, J BIOL CHEM, V282, P24583; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; SUAREZ RK, 1986, AM J PHYSIOL, V251, pR537, DOI 10.1152/ajpregu.1986.251.3.R537; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356; Woodward ER, 2008, CLIN CANCER RES, V14, P5925, DOI 10.1158/1078-0432.CCR-08-0608; YANG Y, 2007, CANC GENET CYTOGEN, V96, P336	44	51	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1159	1173		10.1038/onc.2010.497	http://dx.doi.org/10.1038/onc.2010.497			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057536	Green Accepted			2022-12-17	WOS:000288202400003
J	Bhatia, B; Hsieh, M; Kenney, AM; Nahle, Z				Bhatia, B.; Hsieh, M.; Kenney, A. M.; Nahle, Z.			Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma	ONCOGENE			English	Article						sonic hedgehog; medulloblastoma; E2F1; Rb; lipogenesis; metabolism	FATTY-ACID SYNTHASE; ACTIVATED PROTEIN-KINASE; REDUCES FOOD-INTAKE; N-MYC; CYCLE PROGRESSION; E2F1 EXPRESSION; HUMAN HOMOLOG; MICE LACKING; PROLIFERATION; INHIBITION	Deregulation of the Rb/E2F tumor suppressor complex and aberrantion of Sonic hedgehog (Shh) signaling are documented across the spectrum of human malignancies. Exaggerated de novo lipid synthesis is also found in certain highly proliferative, aggressive tumors. Here, we show that in Shh-driven medulloblastomas, Rb is inactivated and E2F1 is upregulated, promoting lipogenesis. Extensive lipid accumulation and elevated levels of the lipogenic enzyme fatty acid synthase (FASN) mark those tumors. In primary cerebellar granule neuron precursors (CGNPs), proposed Shh-associated medulloblastoma cells-of-origin, Shh signaling triggers E2F1 and FASN expression, whereas suppressing fatty acid oxidation (FAO), in a smoothened-dependent manner. In the developing cerebellum, E2F1 and FASN co-localize in proliferating CGNPs. in vivo and in vitro, E2F1 is required for FASN expression and CGNP proliferation, and E2F1 knockdown impairs Shh-mediated FAO inhibition. Pharmacological blockade of Rb inactivation and/or lipogenesis inhibits CGNP proliferation, drives medulloblastoma cell death and extends survival of medulloblastoma-bearing animals In vivo. These findings identify a novel mechanism through which Shh signaling links cell cycle progression to lipid synthesis, through E2F1-dependent regulation of lipogenic enzymes. These findings pertinent to the etiology of tumor metabolism also underscore the key role of the Shh-->E2F1-->FASN axis in regulating de novo lipid synthesis in cancers, and as such its value as a global therapeutic target in hedgehog-dependent and/or Rb-inactivated tumors. Oncogene (2011) 30, 410-422; doi: 10.1038/onc.2010.454; published online 4 October 2010	[Bhatia, B.; Kenney, A. M.] Weill Cornell Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; [Hsieh, M.; Nahle, Z.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Nahle, Z (corresponding author), Weill Cornell Med Coll, Dept Cardiothorac Surg, 1300 York Ave, New York, NY 10021 USA.	zan2003@med.cornell.edu			Lung Cancer Center and the division of thoracic surgery at Weill Cornell Medical College; NIH [NINDS R01NS061070]; Memorial Sloan-Kettering Brain Tumor Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	Lung Cancer Center and the division of thoracic surgery at Weill Cornell Medical College; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Memorial Sloan-Kettering Brain Tumor Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Michael J Klein and the Pathology and Laboratory Medicine group at the Hospital for Special Surgery and MSKCC microcyteometry facility. We also thank Lori A Mainwaring, Cedric Dray, Cemille Guldal, Elisa DeStanchina and Fajun Yang for helpful discussions. These studies were funded by the Lung Cancer Center and the division of thoracic surgery at Weill Cornell Medical College (ZN), the NIH (NINDS R01NS061070) (AMK) and the Memorial Sloan-Kettering Brain Tumor Center (BB).	Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bhatia B, 2009, CANCER RES, V69, P7224, DOI 10.1158/0008-5472.CAN-09-1299; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cooper-Kuhn CM, 2002, MOL CELL NEUROSCI, V21, P312, DOI 10.1006/mcne.2002.1176; Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Djouadi F, 2003, MOL GENET METAB, V78, P112, DOI 10.1016/S1096-7192(03)00017-9; Dowell P, 2005, ANNU REV BIOCHEM, V74, P515, DOI 10.1146/annurev.biochem.73.011303.074027; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Eberhart CG, 2008, CANCER CELL, V14, P105, DOI 10.1016/j.ccr.2008.07.011; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Ferretti E, 2006, ONCOGENE, V25, P7267, DOI 10.1038/sj.onc.1209716; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hepker J, 1997, DEVELOPMENT, V124, P549; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ho KS, 2002, CURR OPIN NEUROBIOL, V12, P57, DOI 10.1016/S0959-4388(02)00290-8; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Marino S, 2000, GENE DEV, V14, P994; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; MENENDEZ JA, 2009, BIOCH BIOPHYS ACTA; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Olson MV, 2007, CANCER RES, V67, P4005, DOI 10.1158/0008-5472.CAN-06-2973; Orita H, 2008, CLIN CANCER RES, V14, P2458, DOI 10.1158/1078-0432.CCR-07-4177; Orita H, 2007, CLIN CANCER RES, V13, P7139, DOI 10.1158/1078-0432.CCR-07-1186; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	67	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					410	422		10.1038/onc.2010.454	http://dx.doi.org/10.1038/onc.2010.454			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20890301	Green Accepted			2022-12-17	WOS:000286621600004
J	Marshall, GM; Bell, JL; Koach, J; Tan, O; Kim, P; Malyukova, A; Thomas, W; Sekyere, EO; Liu, T; Cunningham, AM; Tobias, V; Norris, MD; Haber, M; Kavallaris, M; Cheung, BB				Marshall, G. M.; Bell, J. L.; Koach, J.; Tan, O.; Kim, P.; Malyukova, A.; Thomas, W.; Sekyere, E. O.; Liu, T.; Cunningham, A. M.; Tobias, V.; Norris, M. D.; Haber, M.; Kavallaris, M.; Cheung, B. B.			TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells	ONCOGENE			English	Article						TRIM16; EBBP; neuroblastoma; vimentin; E2F1; tumour suppressor	B-BOX PROTEIN; HIGH-RISK NEUROBLASTOMA; RING FINGER; 13-CIS-RETINOIC ACID; UBIQUITIN LIGASE; BINDING DOMAIN; RETINOIC ACID; BREAST-CANCER; EXPRESSION; FAMILY	The family of tripartite-motif (TRIM) proteins are involved in diverse cellular processes, but are often characterized by critical protein-protein interactions necessary for their function. TRIM16 is induced in different cancer types, when the cancer cell is forced to proceed down a differentiation pathway. We have identified TRIM16 as a DNA-binding protein with histone acetylase activity, which is required for the retinoic acid receptor beta(2) transcriptional response in retinoid-treated cancer cells. In this study, we show that overexpressed TRIM16 reduced neuroblastoma cell growth, enhanced retinoid-induced differentiation and reduced tumourigenicity in vivo. TRIM16 was only expressed in the differentiated ganglion cell component of primary human neuroblastoma tumour tissues. TRIM16 bound directly to cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. TRIM16 reduced cell motility and this required downregulation of vimentin. Retinoid treatment and enforced overexpression caused TRIM16 to translocate to the nucleus, and bind to and downregulate nuclear E2F1, required for cell replication. This study, for the first time, demonstrates that TRIM16 acts as a tumour suppressor, affecting neuritic differentiation, cell migration and replication through interactions with cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. Oncogene (2010) 29, 6172-6183; doi:10.1038/onc.2010.340; published online 23 August 2010	[Marshall, G. M.; Bell, J. L.; Koach, J.; Tan, O.; Kim, P.; Malyukova, A.; Thomas, W.; Sekyere, E. O.; Liu, T.; Norris, M. D.; Haber, M.; Kavallaris, M.; Cheung, B. B.] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia; [Marshall, G. M.] Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW, Australia; [Cunningham, A. M.] UNSW, Sch Womens & Childrens Hlth, Fac Med, Kensington, NSW, Australia; [Tobias, V.] Sydney Childrens Hosp, S Eastern Area Lab Serv, Randwick, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney	Cheung, BB (corresponding author), Univ NSW, Lowy Canc Res Ctr, Mol Carcinogenesis Program, Childrens Canc Inst Australia, High St,POB 81, Randwick, NSW 2031, Australia.	bcheung@ccia.unsw.edu.au	Kavallaris, Maria/J-5240-2014; Liu, Tao/A-3922-2015	Liu, Tao/0000-0001-6244-7316; Tan, Owen/0000-0002-0303-7138; Cheung, Belamy/0000-0001-8784-860X; Bell, Jessica/0000-0002-8875-0943; Haber, Michelle/0000-0003-2036-8817; Norris, Murray/0000-0002-0632-4589	National Health and Medical Research Council, Australia; Cancer Institute NSW	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW	This research was supported by programme grants from the National Health and Medical Research Council, Australia. This research project was also supported by an Early Career Development Fellowship from the Cancer Institute NSW. The Children's Cancer Institute Australia for Medical Research is affiliated with the University of NSW and Sydney Children's Hospital. We thank Ms Tala Kaplinovsky of the Westfield Research Laboratory at Sydney Children's Hospital for help with using confocal microscopy. We thank Mr Andrew Gayagay of the Paediatric Anatomical Pathology, SEALS for help with preparation of patient samples.	Beer HD, 2002, J BIOL CHEM, V277, P20740, DOI 10.1074/jbc.M111233200; BORDEN KLB, 1993, FEBS LETT, V335, P255, DOI 10.1016/0014-5793(93)80741-C; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Cao TY, 1998, J CELL SCI, V111, P1319; Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Cheung BB, 2006, J BIOL CHEM, V281, P18246, DOI 10.1074/jbc.M600879200; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson DG, 2006, CURR MOL MED, V6, P731; Joshi VV, 2000, PEDIATR DEVEL PATHOL, V3, P184, DOI 10.1007/s100240050024; KATSETOS CD, 1991, LAB INVEST, V64, P45; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lalonde JP, 2004, J BIOL CHEM, V279, P8181, DOI 10.1074/jbc.M306751200; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Liu HLC, 1998, MOL ENDOCRINOL, V12, P1733, DOI 10.1210/me.12.11.1733; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Mrosek M, 2008, BIOCHEMISTRY-US, V47, P10722, DOI 10.1021/bi800733z; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Muley PD, 2008, DEV NEUROBIOL, V68, P1441, DOI 10.1002/dneu.20670; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Raif A, 2009, CANCER LETT, V277, P82, DOI 10.1016/j.canlet.2008.11.030; Rexhepaj E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2187; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vichi A, 2005, P NATL ACAD SCI USA, V102, P1945, DOI 10.1073/pnas.0409800102; Vora HH, 2009, INT J BIOL MARKER, V24, P38, DOI 10.1177/172460080902400106; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yabe JT, 2003, CELL MOTIL CYTOSKEL, V56, P193, DOI 10.1002/cm.10137	39	51	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	46					6172	6183		10.1038/onc.2010.340	http://dx.doi.org/10.1038/onc.2010.340			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729920	hybrid, Green Published			2022-12-17	WOS:000284356500009
J	Tian, L; Peng, G; Parant, JM; Leventaki, V; Drakos, E; Zhang, Q; Parker-Thornburg, J; Shackleford, TJ; Dai, H; Lin, SY; Lozano, G; Rassidakis, GZ; Claret, FX				Tian, L.; Peng, G.; Parant, J. M.; Leventaki, V.; Drakos, E.; Zhang, Q.; Parker-Thornburg, J.; Shackleford, T. J.; Dai, H.; Lin, S-Y; Lozano, G.; Rassidakis, G. Z.; Claret, F. X.			Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair	ONCOGENE			English	Article						DNA repair; DNA damage; null mutation; embryonic lethality; Rad51	RAD51 RECOMBINATION PROTEIN; HOMOLOGOUS RECOMBINATION; EXPRESSION; P53; DEGRADATION; ACTIVATION; P27(KIP1); OVEREXPRESSION; PROLIFERATION; LOCALIZATION	Jun activation domain-binding protein 1 (JAB1) is a multifunctional protein that participates in the control of cell proliferation and the stability of multiple proteins. JAB1 overexpression has been implicated in the pathogenesis of human cancer. JAB1 regulates several key proteins and thereby produces varied effects on cell cycle progression, genome stability and cell survival. However, the biological significance of JAB1 activity in these cellular signaling pathways is unclear. Therefore, we developed mice that were deficient in Jab1 and analyzed the null embryos and heterozygous cells. This disruption of Jab1 in mice resulted in early embryonic lethality due to accelerated apoptosis. Loss of Jab1 expression sensitized both mouse primary embryonic fibroblasts and osteosarcoma cells to gamma-radiation-induced apoptosis, with an increase in spontaneous DNA damage and homologous recombination (HR) defects, both of which correlated with reduced levels of the DNA repair protein Rad51 and elevated levels of p53. Furthermore, the accumulated p53 directly binds to Rad51 promoter, inhibits its activity and represents a major mechanism underlying the HR repair defect in Jab1-deficient cells. These results indicate that Jab1 is essential for efficient DNA repair and mechanistically link Jab1 to the maintenance of genome integrity and to cell survival. Oncogene (2010) 29, 6125-6137; doi:10.1038/onc.2010.345; published online 30 August 2010	[Tian, L.; Peng, G.; Zhang, Q.; Shackleford, T. J.; Dai, H.; Lin, S-Y; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Peng, G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Leventaki, V.; Drakos, E.; Rassidakis, G. Z.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Parker-Thornburg, J.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Claret, FX (corresponding author), Univ Texas MD Anderson, Dept Syst Biol, Div Canc Med, 7435 Fannin St,Unit 950, Houston, TX 77054 USA.	fxclaret@mdanderson.org	Rassidakis, George/V-9553-2019; Claret, Francois X/R-2104-2016; Leventaki, Vasiliki/N-8175-2018	Claret, Francois X/0000-0003-4629-6495; Shackleford, Terry/0000-0002-3621-2289	National Institutes of Health [RO1 CA90853, CA16672]; Susan G Komen for the Cure; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jeffrey Medeiros's laboratory for providing technical help, Dina Lev and Zhi-Xiang Xu for kindly providing the pRad51-luciferase reporter, Rad51 and p53 constructs and Dr Bert Vogelstein for sharing PG13-luc and MG15-Luc plasmids. We also thank Christine Wogan for assistance with the manuscript preparation. This research was supported by the National Institutes of Health Grant RO1 CA90853, the Susan G Komen for the Cure and the NIH Core Grant CA16672.	Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Dong YY, 2005, CLIN CANCER RES, V11, P259; Doronkin S, 2002, DEVELOPMENT, V129, P5053; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; Harada K, 2006, ANTICANCER RES, V26, P1615; Harari-Steinberg O, 2007, GENES CELLS, V12, P183, DOI 10.1111/j.1365-2443.2007.01049.x; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kouvaraki MA, 2003, CANCER RES, V63, P2977; KOUVARAKI MA, 2006, CANCER RES, V66, P6589; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Oron E, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100150; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Pierce AJ, 2005, METH MOL B, V291, P373; Raderschall E, 2002, CANCER RES, V62, P219; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Russell JS, 2003, CANCER RES, V63, P7377; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2004, J BIOL CHEM, V279, P43013, DOI 10.1074/jbc.M406559200; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Zhang QX, 2005, FEBS LETT, V579, P3932, DOI 10.1016/j.febslet.2005.06.012	47	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6125	6137		10.1038/onc.2010.345	http://dx.doi.org/10.1038/onc.2010.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20802511	Green Accepted			2022-12-17	WOS:000284356500005
J	Lee, GH; Yan, C; Shin, SJ; Hong, SC; Ahn, T; Moon, A; Park, SJ; Lee, YC; Yoo, WH; Kim, HT; Kim, DS; Chae, SW; Kim, HR; Chae, HJ				Lee, G-H; Yan, C.; Shin, S-J; Hong, S-C; Ahn, T.; Moon, A.; Park, S. J.; Lee, Y. C.; Yoo, W. H.; Kim, H-T; Kim, D-S; Chae, S-W; Kim, H-R; Chae, H-J			BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function	ONCOGENE			English	Article						BI-1; cancer; metastasis; NHE; acidic pH	INTRACELLULAR PH REGULATION; NA+/H+ EXCHANGER; EXTRACELLULAR PH; EPITHELIAL-CELLS; MATRIX-METALLOPROTEINASE; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; PROSTATE-CANCER; SKELETAL-MUSCLE; DOWN-REGULATION	The anti-apoptotic protein, BAX inhibitor-1 (BI-1), has a role in cancer/tumor progression. BI-1-overexpressing HT1080 and B16F10 cells produced higher lung weights and tumor volumes after injection into the tail veins of mice. Transfection of BI-1 siRNA into cells before injection blocked lung metastasis. in vitro, the overexpression of BI-1 increased cell mobility and invasiveness, with highly increased glucose consumption and cytosolic accumulation of lactate and pyruvate, but decreased mitochondrial O(2) consumption and ATP production. Glucose metabolism-associated extracellular pH also decreased as cells excreted more H(+), and sodium hydrogen exchanger (NHE) activity increased, probably as a homeostatic mechanism for intracellular pH. These alterations activated MMP 2/9 and cell mobility and invasiveness, which were reversed by the NHE inhibitor, 5-(N-ethyl-N-isopropyl) amiloride (EIPA), suggesting a role for NHE in cancer metastasis. In both in vitro and in vivo experiments, C-terminal deleted (CDBI-1) cells showed similar results to control cells, suggesting that the C-terminal motif is required for BI-1-associated alterations of glucose metabolism, NHE activation and cancer metastasis. These findings strongly suggest that BI-1 reduces extracellular pH and regulates metastasis by altering glucose metabolism and activating NHE, with the C-terminal tail having a pivotal role in these processes. Oncogene (2010) 29, 2130-2141; doi: 10.1038/onc.2009.491; published online 1 February 2010	[Chae, H-J] Chonbuk Natl Univ, Dept Pharmacol & Res, Sch Med, Res Ctr Pulm Disorder, Jeonju 561181, Chonbuk, South Korea; [Lee, G-H; Yan, C.; Kim, D-S; Chae, S-W; Chae, H-J] Chonbuk Natl Univ, Dept Pharmacol & Cardiovasc Res Ctr, Jeonju 561181, Chonbuk, South Korea; [Shin, S-J; Hong, S-C] Chonbuk Natl Univ, Dept Microbiol, Sch Med, Jeonju 561181, Chonbuk, South Korea; [Ahn, T.] Chonnam Natl Univ, Coll Vet Med, Dept Biochem, Kwangju, South Korea; [Moon, A.] Duksung Womens Univ, Sch Pharm, Seoul, South Korea; [Park, S. J.; Lee, Y. C.] Chonbuk Natl Univ, Dept Internal Med, Jeonju 561181, Chonbuk, South Korea; [Park, S. J.; Lee, Y. C.] Chonbuk Natl Univ, Airway Remodeling Lab, Sch Med, Jeonju 561181, Chonbuk, South Korea; [Yoo, W. H.] Chonbuk Natl Univ, Dept Internal Med, Div Rheumatol, Jeonju 561181, Chonbuk, South Korea; [Kim, H-T] Chonbuk Natl Univ, Sch Med, Dept Anat, Jeonju 561181, Chonbuk, South Korea; [Kim, H-R] Wonkwang Univ, Sch Dent, Dept Dent Pharmacol, Iksan, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Chonnam National University; Duksung Women's University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Wonkwang University	Chae, HJ (corresponding author), Chonbuk Natl Univ, Dept Pharmacol & Res, Sch Med, Res Ctr Pulm Disorder, San2-20, Jeonju 561181, Chonbuk, South Korea.	hrkimdp@wonkwang.ac.kr; hjchae@chonbuk.ac.kr		Hong, Seong-Tshool/0000-0001-8254-6581; HyoungTae, Kim/0000-0002-2482-6064	Ministry of Education, Science and Technology, South Korea; Ministry for Health, Welfare and Family Affairs, Republic of Korea [A084144]	Ministry of Education, Science and Technology, South Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by the Research Program for New Drug Target Discovery grant from the Ministry of Education, Science and Technology, South Korea and partly supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084144).	Alrefai WA, 2001, AM J PHYSIOL-CELL PH, V281, pC1551, DOI 10.1152/ajpcell.2001.281.5.C1551; BENNETT AF, 1982, BIOCHEMISTRY-US, V21, P4407, DOI 10.1021/bi00261a033; BEREITERHAHN J, 1988, CELL MOTIL CYTOSKEL, V10, P528, DOI 10.1002/cm.970100409; Bhujwalla ZM, 2002, NMR BIOMED, V15, P114, DOI 10.1002/nbm.743; Bolduc N, 2002, FEBS LETT, V532, P111, DOI 10.1016/S0014-5793(02)03650-5; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Boyd RS, 1999, BRIT J CANCER, V80, P315, DOI 10.1038/sj.bjc.6690357; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DELCARMEN G, 2005, EUR J GYNAECOL ONCOL, V26, P501; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Dohm CP, 2006, J MOL NEUROSCI, V29, P1, DOI 10.1385/JMN:29:1:1; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; Harguindey S, 2005, BBA-REV CANCER, V1756, P1, DOI 10.1016/j.bbcan.2005.06.004; Harima Y, 2004, INT J RADIAT ONCOL, V60, P237, DOI 10.1016/j.ijrobp.2004.02.047; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Hille C, 2007, J EXP BIOL, V210, P1463, DOI 10.1242/jeb.001529; Honegger KJ, 2006, P NATL ACAD SCI USA, V103, P803, DOI 10.1073/pnas.0503562103; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jones LE, 2004, CLIN CANCER RES, V10, P2832, DOI 10.1158/1078-0432.CCR-1157-03; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kim MS, 2003, CANCER RES, V63, P5454; Klein M, 2000, J GEN PHYSIOL, V115, P599, DOI 10.1085/jgp.115.5.599; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LAGARDE AE, 1988, J CELL BIOCHEM, V36, P249, DOI 10.1002/jcb.240360306; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Provent P, 2007, CANCER RES, V67, P7638, DOI 10.1158/0008-5472.CAN-06-3459; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623, DOI 10.1152/ajpcell.1994.267.6.C1623; ROTIN D, 1989, CANCER RES, V49, P205; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Schornack PA, 2003, NEOPLASIA, V5, P135, DOI 10.1016/S1476-5586(03)80005-2; Stacpoole Peter W., 2003, Current Gene Therapy, V3, P239, DOI 10.2174/1566523034578320; Steffan JJ, 2009, TRAFFIC, V10, P737, DOI 10.1111/j.1600-0854.2009.00904.x; Stellingwerff T, 2003, AM J PHYSIOL-ENDOC M, V284, pE589, DOI 10.1152/ajpendo.00418.2002; Stephens FB, 2007, J PHYSIOL-LONDON, V581, P431, DOI 10.1113/jphysiol.2006.125799; TANNOCK IF, 1989, CANCER RES, V49, P4373; Thomas SH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002103; Wahl ML, 2000, J CELL PHYSIOL, V183, P373, DOI 10.1002/(SICI)1097-4652(200006)183:3<373::AID-JCP10>3.0.CO;2-S; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9	55	51	52	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2130	2141		10.1038/onc.2009.491	http://dx.doi.org/10.1038/onc.2009.491			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20118983				2022-12-17	WOS:000276402800011
J	Punj, V; Matta, H; Schamus, S; Tamewitz, A; Anyang, B; Chaudhary, PM				Punj, V.; Matta, H.; Schamus, S.; Tamewitz, A.; Anyang, B.; Chaudhary, P. M.			Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a	ONCOGENE			English	Article						KSHV; vFLIP; K13; NF-kB; CXCR4; mir-146a	NF-KAPPA-B; MICROVASCULAR ENDOTHELIAL-CELLS; CELLULAR MICRORNA MIR-146A; GENE-EXPRESSION; LYTIC REPLICATION; INDUCED APOPTOSIS; KINASE COMPLEX; ACTIVATION; HUMAN-HERPESVIRUS-8; TRANSFORMATION	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV)encoded viral FLICE inhibitory protein (vFLIP) K13 is a potent activator of the nuclear factor-kappa B (NF-kappa B) pathway. In this study, we show that infection with KHSV and ectopic expression of K13, but not its NF-kappa B-defective mutant, suppressed the expression of CXCR4. Suppression of CXCR4 by KSHV and K13 was associated with upregulated expression of miR-146a, a microRNA that is known to bind to the 3'-untranslated region of CXCR4 mRNA. Reporter studies identified two NF-kappa B sites in the promoter of miR-146a that were essential for its activation by K13. Accordingly, ectopic expression of K13, but not its NF-kappa B-defective mutant or other vFLIPs, strongly stimulated the miR-146a promoter activity, which could be blocked by specific genetic and pharmacological inhibitors of the NF-kappa B pathway. Finally, expression of CXCR4 was downregulated in clinical samples of KS and this was accompanied by an increased expression of miR-146a. Our results show that K13-induced NF-kappa B activity suppresses CXCR4 through upregulation of miR-146a. Downregulation of CXCR4 expression by K13 may contribute to KS development by promoting premature release of KSHV-infected endothelial progenitors into the circulation. Oncogene (2010) 29, 1835-1844; doi:10.1038/onc.2009.460; published online 21 December 2009	[Punj, V.; Matta, H.; Schamus, S.; Tamewitz, A.; Anyang, B.; Chaudhary, P. M.] Univ Pittsburgh, Dept Med, Div Hematol Oncol, Hillman Canc Ctr,Canc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chaudhary, PM (corresponding author), Univ Pittsburgh, Dept Med, Div Hematol Oncol, Hillman Canc Ctr,Canc Inst, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		National Institutes of Health [CA85177, CA124621]; Leukemia & Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA085177, R01CA124621] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr David Baltimore (California Institute of Technology) for the miR-146a promoter reporter constructs, Dr Parkash Gill for SLK cells, the NIH AIDS Research and Reference Reagent Program for CXCR4 antibodies and the Cancer Specimen Resources at the University of California, San Francisco and George Washington University, Washington, for providing patient samples. This work was supported by grants from the National Institutes of Health (CA85177 and CA124621) and the Leukemia & Lymphoma Society.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary Preet M., 2008, V1, P186, DOI 10.1159/000141519; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Dorak T, 2006, REAL TIME PCR; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2008, ONCOGENE, V27, P5243, DOI 10.1038/onc.2008.150; Matta H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Motsch N, 2007, RNA BIOL, V4, P131, DOI 10.4161/rna.4.3.5206; Naranatt PP, 2004, CANCER RES, V64, P72, DOI 10.1158/0008-5472.CAN-03-2767; Pellet C, 2006, J INVEST DERMATOL, V126, P621, DOI 10.1038/sj.jid.5700083; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Poole LJ, 2002, J VIROL, V76, P3395, DOI 10.1128/JVI.76.7.3395-3420.2002; Punj V, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-50; Punj V, 2009, BLOOD, V113, P5660, DOI 10.1182/blood-2008-10-186403; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sakakibara S, 2009, J VIROL, V83, P2140, DOI 10.1128/JVI.01871-08; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 2000, J ANTIMICROB CHEMOTH, V45, P15, DOI 10.1093/jac/45.suppl_4.15; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thurau M, 2009, J VIROL, V83, P598, DOI 10.1128/JVI.00629-08; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Williams AE, 2008, BIOCHEM SOC T, V36, P1211, DOI 10.1042/BST0361211; Xu YY, 2007, J GEN VIROL, V88, P46, DOI 10.1099/vir.0.82375-0; Ye FC, 2008, J VIROL, V82, P4235, DOI 10.1128/JVI.02370-07; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067	49	51	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1835	1844		10.1038/onc.2009.460	http://dx.doi.org/10.1038/onc.2009.460			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023696	Green Accepted			2022-12-17	WOS:000276022800012
J	Lee, Y; Kim, SJ; Park, HD; Park, EH; Huang, SM; Jeon, SB; Kim, JM; Lim, DS; Koh, SS				Lee, Y.; Kim, S. J.; Park, H. D.; Park, E. H.; Huang, S. M.; Jeon, S. B.; Kim, J-M; Lim, D-S; Koh, S. S.			PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression	ONCOGENE			English	Article						PAUF; pancreatic cancer; metastasis; CXCR4; signaling	CHEMOKINE RECEPTOR CXCR4; EPIDERMAL-GROWTH-FACTOR; PROSTATE-CANCER; TUMOR-CELLS; MOUSE MODEL; BREAST; INVASION; CARCINOMA; MIGRATION; INCREASES	Pancreatic cancer is characterized by early metastatic spread, but the process of tumor cell dissemination is largely unknown. In this study we show that the soluble protein pancreatic adenocarcinoma upregulated factor (PAUF) has an important role in the metastasis and progression of the disease. Variations in the level of PAUF, either by overexpression or knockdown, resulted in altered migration, invasion and proliferation capacity of pancreatic cancer cells. Moreover, depletion of PAUF in metastatic cells dramatically abrogated the spread of the cells to distant organs in an orthotopic xenograft mouse model. PAUF elicited the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and AKT intracellular signaling cascades and consequently their downstream transcription factors in an autocrine manner. Genome-wide expression analysis revealed that C-X-C chemokine receptor type 4 (CXCR4) expression was induced by PAUF overexpression but was repressed by PAUF knockdown. The PAUF-mediated increase in cancer cell motility was attenuated by the CXCR4 inhibitor, AMD3100, or by anti-CXCR4 antibody. Furthermore, immunohistochemical analysis of pancreatic tumor tissues clearly showed a significant positive correlation between PAUF and CXCR4 expression. Collectively, these findings indicate that PAUF enhances the metastatic potential of pancreatic cancer cells, at least in part, by upregulating CXCR4 expression.	[Lee, Y.; Kim, S. J.; Park, E. H.; Koh, S. S.] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon 305806, South Korea; [Lee, Y.; Park, H. D.; Lim, D-S] Korea Adv Inst Sci & Technol, Natl Res Lab, Dept Biol Sci, Taejon 305701, South Korea; [Kim, S. J.; Koh, S. S.] Univ Sci & Technol, Sch Sci, Taejon, South Korea; [Park, H. D.; Jeon, S. B.] LG Life Sci Ltd, Taejon, South Korea; [Huang, S. M.; Kim, J-M] Chungnam Natl Univ, Dept Pathol, Canc Res Inst, Coll Med, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); LG Life Sciences Ltd; Chungnam National University	Koh, SS (corresponding author), Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, 111 Gwahangno, Taejon 305806, South Korea.	daesiklim@kaist.ac.kr; sskoh@kribb.re.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555	Ministry of Education, Science and Technology, Korea	Ministry of Education, Science and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the 21st Century Frontier Functional Human Genome Project of the Ministry of Education, Science and Technology, Korea. We thank CK Jung and MG Kang for statistical analysis, SH Kim for the luciferase reporter plasmids and HJ Hong for critiques of our work.	Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Benovic JL, 2004, CANCER CELL, V6, P429, DOI 10.1016/j.ccr.2004.10.017; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gao RP, 2005, GASTROENTEROLOGY, V129, P1019, DOI 10.1053/j.gastro.2005.06.067; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Koizumi K, 2007, CANCER SCI, V98, P1652, DOI 10.1111/j.1349-7006.2007.00606.x; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Marchesi F, 2004, CANCER RES, V64, P8420, DOI 10.1158/0008-5472.CAN-04-1343; Marshall J, 2006, CANCER-AM CANCER SOC, V107, P1207, DOI 10.1002/cncr.22133; Mashino K, 2002, CANCER RES, V62, P2937; Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Okada Y, 2004, CLIN EXP METASTAS, V21, P285, DOI 10.1023/B:CLIN.0000046131.24625.54; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Saur D, 2005, GASTROENTEROLOGY, V129, P1237, DOI 10.1053/j.gastro.2005.06.056; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sung B, 2008, CANCER RES, V68, P8938, DOI 10.1158/0008-5472.CAN-08-2155; Taichman RS, 2002, CANCER RES, V62, P1832; Tong ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540; Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745; Wehler T, 2006, ONCOL REP, V16, P1159; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zlotnik A, 2008, J PATHOL, V215, P211, DOI 10.1002/path.2350; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024	54	51	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					56	67		10.1038/onc.2009.298	http://dx.doi.org/10.1038/onc.2009.298			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19784070				2022-12-17	WOS:000273373500006
J	Li, JJ; Liu, DP; Liu, GT; Xie, D				Li, J-J; Liu, D-P; Liu, G-T; Xie, D.			EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor	ONCOGENE			English	Article						ephrinA5; EGFR; c-Cbl; glioma	C-CBL; EPH RECEPTORS; TYROSINE KINASES; GENE-EXPRESSION; CANCER CELLS; T-CELLS; PHOSPHORYLATION; BINDING; LIGAND; TUMORIGENICITY	Eph receptors, the largest subfamily of receptor tyrosine kinases, and their ephrin ligands play important roles in nervous system development. Recently, they have been implicated in tumorigenesis of different cancers. In this study, we showed that the expression of ephrinA5 was dramatically downregulated in primary gliomas compared with normal tissues. Forced expression of ephrinA5 reduced tumorigenicity of human glioma U373 cells. Epidermal growth factor receptor (EGFR), which frequently acts as an oncoprotein in glioma, was greatly decreased in ephrinA5-transfected glioma cells, and the two molecules exhibited a mutually exclusive expression pattern in primary glioma samples. We found that ephrinA5 enhanced c-Cbl binding to EGFR, thus promoted ubiquitylation and degradation of the receptor. Either ephrinA5-Fc or EphA2-Fc treatment simulating bidirectional signaling of Eph/ephrin system resulted in EGFR decrease. This study discovered that ephrinA5 acted as a tumor suppressor in glioma, and its negative regulation of EGFR contributed to the suppressive effects. In addition to identifying a novel mechanism underlying tumor suppressor activity of ephrinA5, we also showed cross-talk between different receptor tyrosine kinase families in glioma. These.ndings may improve therapeutic strategies for glioma.	[Xie, D.] Chinese Acad Sci, Mol Oncol Lab, Inst Nutr Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Li, J-J] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; [Liu, G-T] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Cedars Sinai Medical Center	Xie, D (corresponding author), Chinese Acad Sci, Mol Oncol Lab, Inst Nutr Sci, Shanghai Inst Biol Sci, 294 Tai Yuan Rd, Shanghai 200031, Peoples R China.	dxie@sibs.ac.cn		Xie, Dong/0000-0002-1150-8657				Bolz J, 2004, J NEUROBIOL, V59, P82, DOI 10.1002/neu.10346; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Finne EF, 2004, BIOCHEM J, V379, P39, DOI 10.1042/BJ20031619; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grossmann AH, 2004, FEBS LETT, V577, P555, DOI 10.1016/j.febslet.2004.10.054; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Huberman AD, 2005, NAT NEUROSCI, V8, P1013, DOI 10.1038/nn1505; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li ZB, 2007, PLOS BIOL, V5, P212, DOI 10.1371/journal.pbio.0050035; Liu DP, 2007, INT J ONCOL, V30, P865; Liu XW, 2000, J BIOL CHEM, V275, P7280, DOI 10.1074/jbc.275.10.7280; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Nicholas MK, 2006, CLIN CANCER RES, V12, P7261, DOI 10.1158/1078-0432.CCR-06-0874; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Otal R, 2006, NEUROSCIENCE, V141, P109, DOI 10.1016/j.neuroscience.2006.03.052; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; Sharfe N, 2003, J IMMUNOL, V170, P6024, DOI 10.4049/jimmunol.170.12.6024; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; XU J, 1993, J BIOL CHEM, V268, P16065; Yarden RI, 2001, J CELL BIOCHEM, P232	36	51	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1759	1768		10.1038/onc.2009.15	http://dx.doi.org/10.1038/onc.2009.15			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19270726				2022-12-17	WOS:000265640400003
J	Gonzalez, L; Zambrano, A; Lazaro-Trueba, I; Lopez, E; Gonzalez, JJA; Martin-Perez, J; Aranda, A				Gonzalez, L.; Zambrano, A.; Lazaro-Trueba, I.; Lopez, E.; Gonzalez, J. J. A.; Martin-Perez, J.; Aranda, A.			Activation of the unliganded estrogen receptor by prolactin in breast cancer cells	ONCOGENE			English	Article						prolactin; estrogen receptor; transcriptional activation; breast cancer cells	CYCLIN D1; C-MYC; MAMMARY-GLAND; GROWTH-FACTOR; PROGESTERONE-RECEPTOR; ENDOCRINE RESISTANCE; HORMONE RECEPTORS; TYROSINE KINASE; GENE-EXPRESSION; IN-VIVO	Both prolactin (PRL) and estrogen (E2) are involved in the pathogenesis and progression of mammary neoplasia, but the mechanisms by which these hormones interact to exert their effects in breast cancer cells are not well understood. We show here that PRL is able to activate the unliganded estrogen receptor (ER). In breast cancer cells, PRL activates a reporter plasmid containing estrogen response elements (EREs) and induces the ER target gene pS2. These actions are blocked by the antagonist ICI 182,780, showing that ER is required for the PRL-mediated effect. Moreover, PRL leads to phosphorylation of ER alpha in serine-118 (P-ER alpha), a modification related to the potentiation of ligand-independent transcriptional activation. In addition, PRL mimics the effect of E2 on target gene expression by inducing cyclical recruitment of ER alpha and P-ER alpha to ERE-containing promoters, resulting in recruitment of co-activators and acetylation of histone H3. Finally, PRL induces expression of c-Myc and Cyclin D1 and leads to increased cell proliferation, which is specifically antagonized by ICI 182,780 or ERa depletion. These results show that ligand-independent ER alpha activation appears to be an important component of the proliferative and transcriptional actions of PRL in breast cancer cells.	[Martin-Perez, J.; Aranda, A.] CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Martin-Perez, J (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	jmartin@iib.uam.es; aaranda@iib.uam.es	Zambrano, Alberto/Q-6188-2019; Martin-Perez, Jorge/A-3522-2008; Zambrano, Alberto/A-1580-2013; Aranda, Ana/ABG-8820-2020	Zambrano, Alberto/0000-0001-5677-2999; Martin-Perez, Jorge/0000-0002-2292-0057; Zambrano, Alberto/0000-0001-5677-2999; Aranda, Ana/0000-0002-8338-9589; Gonzalez, Lorena/0000-0002-0575-7833	Ministerio de Educacion y Ciencia [SAF2006-00371, BFU2007-62402]; Fondo de Investigaciones Sanitarias [RD06/0020/0036, PIO40682]; Fundacion MMA; CRESCENDO [FP6-018652]	Ministerio de Educacion y Ciencia(Spanish Government); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion MMA; CRESCENDO(European Commission)	This work was supported by grants SAF2006-00371 and BFU2007-62402 from the Ministerio de Educacion y Ciencia, RD06/0020/0036 and PIO40682 from the Fondo de Investigaciones Sanitarias, by a grant from the Fundacion MMA and by the EU Project CRESCENDO (FP6-018652).	Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Carroll JS, 2002, CANCER RES, V62, P3126; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GINSBURG E, 1995, CANCER RES, V55, P2591; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Lipfert L, 2006, MOL ENDOCRINOL, V20, P516, DOI 10.1210/me.2005-0190; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; McNeil CM, 2006, J STEROID BIOCHEM, V102, P147, DOI 10.1016/j.jsbmb.2006.09.028; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Murphy L, 2004, CLIN CANCER RES, V10, P1354, DOI 10.1158/1078-0432.CCR-03-0112; Murphy LC, 2006, J STEROID BIOCHEM, V102, P139, DOI 10.1016/j.jsbmb.2006.09.021; MURPHY LJ, 1984, CANCER RES, V44, P1963; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Santos MDL, 2007, ENDOCR-RELAT CANCER, V14, P1021, DOI 10.1677/ERC-07-0144; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; SHAFIE S, 1977, CANCER RES, V37, P792; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Wang Y, 2007, CANCER RES, V67, P3698, DOI 10.1158/0008-5472.CAN-06-4000; Weitsman GE, 2006, CANCER RES, V66, P10162, DOI 10.1158/0008-5472.CAN-05-4111; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	57	51	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1298	1308		10.1038/onc.2008.473	http://dx.doi.org/10.1038/onc.2008.473			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19169277	Green Submitted			2022-12-17	WOS:000264116000002
J	Lodyga, M; De Falco, V; Bai, XH; Kapus, A; Melillo, RM; Santoro, M; Liu, M				Lodyga, M.; De Falco, V.; Bai, X-H; Kapus, A.; Melillo, R. M.; Santoro, M.; Liu, M.			XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway	ONCOGENE			English	Article						adaptor protein; protein tyrosine phosphorylation; thyroid cancer; RET/PTC; phosphatidylinositol 3-kinase; PKB/AKT	THYROID PAPILLARY CARCINOMAS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RET PROTOONCOGENE; SH2 DOMAINS; PHOSPHOINOSITIDE 3-KINASE; MAP KINASE; CELL LINE; RAS	XB130 is a recently cloned 130kDa-adaptor protein and Src kinase substrate, structurally similar to actin-filament-associated protein. Here we show that XB130 is predominantly expressed in the thyroid. Given that XB130 is a thyroid-specific tyrosine kinase substrate, we asked whether it is targeted by RET/PTC, a genetically rearranged, constitutively active, thyroid-specific tyrosine kinase that plays a pathogenic role in papillary thyroid cancer. RET/PTC induced robust tyrosine phosphorylation of XB130, which promoted its subsequent association with the p85 alpha subunit of phosphatidylinositol 3-kinase (PI 3-kinase). We identified tyrosine 54 of XB130 as the major target of RET/PTC-mediated phosphorylation and a critical binding site for the SH2 domains of p85 alpha. Importantly, downregulation of XB130 in TPC1 papillary thyroid cancer cells, harboring the RET/PTC1 kinase, strongly reduced Akt activity without altering ERK1/2 phosphorylation, and concomitantly inhibited cell-cycle progression and survival in suspension. In conclusion, XB130 is a novel substrate of the RET/PTC kinase that links RET/PTC signaling to PI 3-kinase activation, and thereby plays an important role in sustaining proliferation and survival of thyroid tumor cells.	[Lodyga, M.; Bai, X-H; Liu, M.] Univ Hlth Network, Toronto Gen Hosp, Div Cellular & Mol Biol, Toronto, ON M5G 1L7, Canada; [De Falco, V.; Melillo, R. M.; Santoro, M.] Inst Endocrinol & Oncol Sperimentale CNR G Salvat, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; [Kapus, A.; Liu, M.] Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Toronto	Liu, M (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Div Cellular & Mol Biol, TMDT 2-814,101 Coll St, Toronto, ON M5G 1L7, Canada.	masantor@unina.it; mingyao.liu@utoronto.ca	melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015	DE FALCO, VALENTINA/0000-0002-8972-7921; Liu, Mingyao/0000-0002-9188-8417; MELILLO, Rosa Marina/0000-0002-9233-5275	AstraZeneca [ZD6474]; Canadian Institutes of Health Research [MOP-13270, MOP-42546]; European Union [FP636495]; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	AstraZeneca(AstraZeneca); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); European Union(European Commission); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Dr B Han and Dr D Winer for technical assistance. We thank AJ Ryan, AstraZeneca for the ZD6474 inhibitor. We also thank Dr S Asa and JM Hershman for human thyroid cell lines, Dr G Pelicci for GST- fusion proteins and Dr M Chiariello for the Src mutant. This work was supported by operating grants (MOP-13270, MOP-42546) from Canadian Institutes of Health Research, a grant from the Italian Association for Cancer Research, MIUR, Alleanza contro iL Cancro and the European Union Contract FP636495 (GENRISK-T).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Carlomagno F, 2002, CANCER RES, V62, P7284; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; De Falco V, 2005, ONCOGENE, V24, P6303, DOI 10.1038/sj.onc.1208776; de Martimprey H, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1094; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Iavarone C, 2006, J BIOL CHEM, V281, P10567, DOI 10.1074/jbc.M513397200; Iwashita T, 1996, ONCOGENE, V12, P481; Jung HS, 2005, MOL ENDOCRINOL, V19, P2748, DOI 10.1210/me.2005-0122; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Lodyga M, 2002, AM J PHYSIOL-LUNG C, V283, pL265, DOI 10.1152/ajplung.00492.2001; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Mai KT, 2001, THYROID, V11, P859, DOI 10.1089/105072501316973118; Mariggio S, 2007, CANCER RES, V67, P11769, DOI 10.1158/0008-5472.CAN-07-1997; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200	40	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					937	949		10.1038/onc.2008.447	http://dx.doi.org/10.1038/onc.2008.447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19060924				2022-12-17	WOS:000263457400001
J	Hoskins, EE; Morris, TA; Higginbotham, JM; Spardy, N; Cha, E; Kelly, P; Williams, DA; Wikenheiser-Brokamp, KA; Duensing, S; Wells, SI				Hoskins, E. E.; Morris, T. A.; Higginbotham, J. M.; Spardy, N.; Cha, E.; Kelly, P.; Williams, D. A.; Wikenheiser-Brokamp, K. A.; Duensing, S.; Wells, S. I.			Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture	ONCOGENE			English	Article						Fanconi anemia; human papillomavirus; keratinocyte; organotypic raft culture	GENE-EXPRESSION; DNA; PROTEIN; RADIOSENSITIVITY; IDENTIFICATION; CANCER; SUSCEPTIBILITY; PATHOGENESIS; INSTABILITY; PATHWAY	Fanconi anemia (FA) is a recessive genome instability syndrome characterized by heightened cellular sensitivity to DNA damage, aplastic anemia and cancer susceptibility. Leukemias and squamous cell carcinomas (SCCs) are the most predominant FA-associated cancers, with the latter exhibiting markedly early disease onset and aggressiveness. Although studies of hematopoietic cells derived from FA patients have provided much insight into bone marrow deficiencies and leukemogenesis, molecular transforming events in FA-deficient keratinocytes, which are the cell type of origin for SCC, are poorly understood. We describe here the growth and molecular properties of FANCA-deficient versus FANCA-corrected HPV E6/E7 immortalized keratinocytes in monolayer and organotypic epithelial raft culture. In response to DNA damage, FANCA-deficient patient-derived keratinocyte cultures displayed a G2/M phase arrest, senescence and apoptosis. Organotypic raft cultures exhibited DNA repair-associated defects with more 53BP1 foci and TdT-mediated dNTP nick end labeling-positive cells over their corrected counterparts. Interestingly, together with reduced rates of DNA damage, FA correction resulted in a marked decrease in epithelial thickness and the presence of fewer cell layers. The observed FANCA-mediated suppression of hyperplasia correlated with the detection of fewer cells transiting through the cell cycle in the absence of gross differentiation abnormalities or apoptotic differences. Importantly, the knockdown of either FANCA or FANCD2 in HPV-positive keratinocytes was sufficient for increasing epithelial hyperplasia. Our findings support a new role for FA pathways in the maintenance of differentiation-dependent cell cycle exit, with the implication that FA deficiencies may contribute to the high risk of FA patients for developing HPV-associated SCC.	[Hoskins, E. E.; Morris, T. A.; Higginbotham, J. M.; Wells, S. I.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Hematol Oncol, Cincinnati, OH 45229 USA; [Spardy, N.; Cha, E.; Duensing, S.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Kelly, P.] Wyeth Pharmaceut, Cambridge, MA USA; [Williams, D. A.] Harvard Univ, Childrens Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02115 USA; [Wikenheiser-Brokamp, K. A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Pathol & Lab Med & Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pfizer; Harvard University; Boston Children's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wells, SI (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Hematol Oncol, TCHRF Room S7-206,MLC 7013,3333 Burnet Ave, Cincinnati, OH 45229 USA.	susanne.wells@cchmc.org			Public Health Service [CA102357, HL081499]; Translational Research Initiative at CCHMC; Fanconi Anemia Research Fund; NIH/NCI [R01 CA112598]; KAW-B [HL079193]; NATIONAL CANCER INSTITUTE [R01CA112598, R01CA102357] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081499, R01HL079193] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Translational Research Initiative at CCHMC; Fanconi Anemia Research Fund; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); KAW-B; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Paul Andreassen, Ruhikanta Meetei, Qishen Pang, James Mulloy, Harmut Geiger, Yi Zheng and Stella Davies for helpful discussions and critical comments on the manuscript. We thank members of the Fanconi Anemia Comprehensive Care Center (FACCC), particularly Lars Wagner, Richard Harris and Robin Mueller for human tissue samples, as well as Susan Radtke for regulatory support. We thank the patients of the FACCC for samples. We are grateful to Denis Lee and Paul Lambert for expert advice on the organotypic raft system, as well as to Maureen Hoatlin for the FANCA and to James Lessard for the monoclonal actin antibody. We thank Christopher Baum for the retroviral SF91 expression vector, and Neeraj Singh for generation of the SF91-18E6/E7 retroviral construct. We thank the flow cytometry core facility and Dan Marmer for assistance with flow sorting. Vector supernatant was provided by the CCHMC Viral Vector Core and Translational Trials Development and Support Lab. This research was supported by Public Health Service Grant CA102357, a grant from the Translational Research Initiative at CCHMC and a grant from the Fanconi Anemia Research Fund to SIW. SD and NS are supported by NIH/NCI R01 CA112598. DAW was supported by Public Health Service Grant HL081499. KAW-B was supported by HL079193.	Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Alter BP, 2002, RADIOTHER ONCOL, V62, P345, DOI 10.1016/S0167-8140(01)00474-1; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bremer M, 2003, STRAHLENTHER ONKOL, V179, P748, DOI 10.1007/s00066-003-1099-8; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Chandra S, 2005, MOL THER, V12, P976, DOI 10.1016/j.ymthe.2005.04.021; de Oca RM, 2005, BLOOD, V105, P1003, DOI 10.1182/blood-2003-11-3997; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dorsman JC, 2007, CELL ONCOL, V29, P211; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Guardiola P, 2004, BLOOD, V103, P73, DOI 10.1182/blood-2003-06-2146; Hanenberg H, 2002, EXP HEMATOL, V30, P410, DOI 10.1016/S0301-472X(02)00782-8; Hoskins EE, 2008, ONCOGENE, V27, P4798, DOI 10.1038/onc.2008.121; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Kutler DI, 2003, J NATL CANCER I, V95, P1718, DOI 10.1093/jnci/djg091; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Marcou Y, 2001, RADIOTHER ONCOL, V60, P75, DOI 10.1016/S0167-8140(01)00370-X; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Nakahara T, 2005, J VIROL, V79, P13150, DOI 10.1128/JVI.79.20.13150-13165.2005; Niedernhofer LJ, 2005, CELL, V123, P1191, DOI 10.1016/j.cell.2005.12.009; Pagano G, 2005, EUR J HAEMATOL, V75, P93, DOI 10.1111/j.1600-0609.2005.00507.x; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Sims AE, 2007, NAT STRUCT MOL BIOL, V14, P564, DOI 10.1038/nsmb1252; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Tamary H, 2007, PEDIATR HEMAT ONCOL, V24, P87, DOI 10.1080/08880010601123240; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; van Zeeburg HJT, 2005, CANCER RES, V65, P1271, DOI 10.1158/0008-5472.CAN-04-3665; van Zeeburg HJT, 2004, JNCI-J NATL CANCER I, V96, P968, DOI 10.1093/jnci/djh178; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159	41	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					674	685		10.1038/onc.2008.416	http://dx.doi.org/10.1038/onc.2008.416			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015634	Green Accepted			2022-12-17	WOS:000263076400005
J	Bar, J; Feniger-Barish, R; Lukashchuk, N; Shaham, H; Moskovits, N; Goldfinger, N; Simansky, D; Perlman, M; Papa, M; Yosepovich, A; Rechavi, G; Rotter, V; Oren, M				Bar, J.; Feniger-Barish, R.; Lukashchuk, N.; Shaham, H.; Moskovits, N.; Goldfinger, N.; Simansky, D.; Perlman, M.; Papa, M.; Yosepovich, A.; Rechavi, G.; Rotter, V.; Oren, M.			Cancer cells suppress p53 in adjacent fibroblasts	ONCOGENE			English	Article						p53; stroma; tumor suppression; CAFs; genotoxic stress	STROMAL CELLS; TUMOR-SUPPRESSOR; CARCINOMA; GROWTH; TP53; MUTATIONS	The p53 tumor suppressor serves as a crucial barrier against cancer development. In tumor cells and their progenitors, p53 suppresses cancer in a cell-autonomous manner. However, p53 also possesses non-cell-autonomous activities. For example, p53 of stromal fibroblasts can modulate the spectrum of proteins secreted by these cells, rendering their microenvironment less supportive of the survival and spread of adjacent tumor cells. We now report that epithelial tumor cells can suppress p53 induction in neighboring fibroblasts, an effect reproducible by tumor cell-conditioned medium. The ability to suppress fibroblast p53 activation is acquired by epithelial cells in the course of neoplastic transformation. Specifically, stable transduction of immortalized epithelial cells by mutant H-Ras and p53-specific short inhibitory RNA endows them with the ability to quench fibroblast p53 induction. Importantly, human cancer-associated fibroblasts are more susceptible to this suppression than normal fibroblasts. These findings underscore a mechanism whereby epithelial cancer cells may overcome the non-cell-autonomous tumor suppressor function of p53 in stromal fibroblasts.	[Bar, J.] Chaim Sheba Med Ctr, Canc Res Ctr, Dept Oncol, IL-52621 Tel Hashomer, Israel; [Bar, J.; Rechavi, G.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Lukashchuk, N.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Shaham, H.; Moskovits, N.; Goldfinger, N.; Rotter, V.; Oren, M.] Weizmann Inst Sci, IL-76100 Rehovot, Israel; [Simansky, D.] Chaim Sheba Med Ctr, Dept Thorac Surg, IL-52621 Tel Hashomer, Israel; [Perlman, M.; Yosepovich, A.] Chaim Sheba Med Ctr, Inst Pathol, IL-52621 Tel Hashomer, Israel; [Papa, M.] Chaim Sheba Med Ctr, Dept Surg C, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Beatson Institute; Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Bar, J (corresponding author), Ottawa Hosp Canc Ctr, Div Med Oncol, Gen Campus,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	bar.jair@gmail.com	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	Flight Attendant Medical Research Institute (FAMRI); National Cancer Institute [R37 CA40099]; Koschitzky family; Tel Aviv University Cancer Biology Research Center; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute (FAMRI); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Koschitzky family; Tel Aviv University Cancer Biology Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J Schachter and Dr B Kaufman for helpful discussions. This work was supported in part by a Center of Excellence grant from the Flight Attendant Medical Research Institute (FAMRI), and by grant R37 CA40099 from the National Cancer Institute. JB was supported also by the Koschitzky family donation to the breast cancer unit of CSMC, and by a Van Bates grant from the Tel Aviv University Cancer Biology Research Center.	Bar J, 2004, ONCOGENE, V23, P2128, DOI 10.1038/sj.onc.1207325; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campbell IG, 2008, NEW ENGL J MED, V358, P1634, DOI 10.1056/NEJMc086024; Dudley AC, 2008, BRIT J CANCER, V99, P118, DOI 10.1038/sj.bjc.6604465; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Logunov DY, 2008, ONCOGENE, V27, P4521, DOI 10.1038/onc.2008.103; Milyavsky M, 2003, CANCER RES, V63, P7147; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Olumi AF, 1999, CANCER RES, V59, P5002; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Roukos DH, 2008, NEW ENGL J MED, V358, P1636; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wernert N, 2001, ANTICANCER RES, V21, P2259	22	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					933	936		10.1038/onc.2008.445	http://dx.doi.org/10.1038/onc.2008.445			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060923	Green Accepted			2022-12-17	WOS:000263320000015
J	Fukukawa, C; Nagayama, S; Tsunoda, T; Toguchida, J; Nakamura, Y; Katagiri, T				Fukukawa, C.; Nagayama, S.; Tsunoda, T.; Toguchida, J.; Nakamura, Y.; Katagiri, T.			Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma	ONCOGENE			English	Article						Frizzled; synovial sarcoma; JNK; cytoskeleton; anchorage-independent growth; Rac	BETA-CATENIN; DISHEVELLED PHOSPHORYLATION; SIGNALING CASCADE; GENE-EXPRESSION; PROTEIN; KINASE; RAC; RHO; TRANSLOCATION; BINDING	We previously reported that Frizzled homologue 10 (FZD10), a member of the Wnt signal receptor family, was highly and specifically upregulated in synovial sarcoma and played critical roles in its cell survival and growth. We here report a possible molecular mechanism of the FZD10 signaling in synovial sarcoma cells. We found a significant enhancement of phosphorylation of the Dishevelled (Dvl)2/Dvl3 complex as well as activation of the Rac1-JNK cascade in synovial sarcoma cells in which FZD10 was overexpressed. Activation of the FZD10-Dvls -Rac1 pathway induced lamellipodia formation and enhanced anchorage-independent cell growth cells. FZD10 overexpression also caused the destruction of the actin cytoskeleton structure, probably through the down-regulation of the RhoA activity. Our results have strongly implied that FZD10 transactivation causes the activation of the non-canonical Dvl-Rac1-JNK pathway and plays critical roles in the development/progression of synovial sarcomas.	[Katagiri, T.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; [Tsunoda, T.] Inst Phys & Chem Res, RIKEN, SNP Res Ctr, Lab Med Informat, Yokohama, Kanagawa, Japan; [Toguchida, J.] Kyoto Univ, Inst Frontier Med Sci, Kyoto, Japan	University of Tokyo; RIKEN; Kyoto University	Katagiri, T (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tkatagi@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012; Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bryja V, 2007, J CELL SCI, V120, P586, DOI 10.1242/jcs.03368; Bryja V, 2007, CELL SIGNAL, V19, P610, DOI 10.1016/j.cellsig.2006.08.011; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Coindre JM, 2003, CANCER-AM CANCER SOC, V98, P2700, DOI 10.1002/cncr.11840; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukukawa C, 2008, CANCER SCI, V99, P432, DOI 10.1111/j.1349-7006.2007.00701.x; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habu S, 1998, SURG TODAY, V28, P401, DOI 10.1007/s005950050149; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamel M, 2006, ENDOTHELIUM-J ENDOTH, V13, P157, DOI 10.1080/10623320600760191; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hiraga H, 1999, J BONE JOINT SURG AM, V81A, P558, DOI 10.2106/00004623-199904000-00014; Hosono T, 2005, JPN J CLIN ONCOL, V35, P274, DOI 10.1093/jjco/hyi073; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Koike J, 1999, BIOCHEM BIOPH RES CO, V262, P39, DOI 10.1006/bbrc.1999.1161; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; McGilbray TT, 2003, LANCET ONCOL, V4, P283, DOI 10.1016/S1470-2045(03)01075-1; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Nagayama S, 2002, CANCER RES, V62, P5859; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nunnally AP, 2004, DEV GENES EVOL, V214, P144, DOI 10.1007/s00427-004-0386-4; Ochi N, 2004, ORL-J OTO-RHIN-LARYN, V66, P42, DOI 10.1159/000077233; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Shannon BA, 2005, ARCH PATHOL LAB MED, V129, P238; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Szuhai K, 2004, CANCER GENET CYTOGEN, V153, P48, DOI 10.1016/j.cancergencyto.2003.12.012; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P93, DOI 10.1016/0165-4608(86)90153-6; Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022-5030.2005; Wechezak AR, 2005, J CELL PHYSIOL, V202, P867, DOI 10.1002/jcp.20176; WEISS SW, 2001, ENZINGER WEISSS SOFT; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wiggan O, 2002, J CELL SCI, V115, P531; Williams DH, 2004, J UROLOGY, V171, P2376, DOI 10.1097/01.ju.0000125319.92634.9b	50	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1110	1120		10.1038/onc.2008.467	http://dx.doi.org/10.1038/onc.2008.467			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137009				2022-12-17	WOS:000263722900006
J	Mashima, T; Sato, S; Sugimoto, Y; Tsuruo, T; Seimiya, H				Mashima, T.; Sato, S.; Sugimoto, Y.; Tsuruo, T.; Seimiya, H.			Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions	ONCOGENE			English	Article						low pH; acyl-CoA synthetase; lipid metabolism; microenvironment; midkine	HUMAN HEPATOCELLULAR-CARCINOMA; PROLIFERATOR-ACTIVATED RECEPTOR; HUMAN-MELANOMA CELLS; GENE-EXPRESSION; THERAPEUTIC TARGET; DRUG-RESISTANCE; GROWTH-FACTOR; SOLID TUMORS; MIDKINE; CANCER	Extracellular acidosis (low pH) is a tumor microenvironmental stressor that has a critical function in the malignant progression and met astatic dissemination of tumors. To survive under stress conditions, tumor cells must evolve resistance to stress-induced toxicity. Acyl-CoA synthetase 5 (ACSL5) is a member of the ACS family, which converts fatty acid to acyl-CoA. ACSL5 is frequently overexpressed in malignant glioma, whereas its functional significance is still unknown. Using retrovirus-mediated stable gene transfer ( gain of function) and small interfering RNA-mediated gene silencing ( loss of function), we show here that ACSL5 selectively promotes human glioma cell survival under extracellular acidosis. ACSL5 enhanced cell survival through its ACS catalytic activity. To clarify the genome-wide changes in cell signaling pathways by ACSL5, we performed cDNA microarray analysis and identified an ACSL5-dependent gene expression signature. The analysis revealed that ACSL5 was critical to the expression of tumor-related factors including midkine (MDK), a heparin-binding growth factor frequently overexpressed in cancer. Knockdown of MDK expression significantly attenuated ACSL5-mediated survival under acidic state. These results indicate that ACSL5 is a critical factor for survival of glioma cells under acidic tumor microenvironment, thus providing novel molecular basis for cancer therapy.	[Seimiya, H.] Japanese Fdn Canc Res, Div Mol Biotherapy, Ctr Canc Chemotherapy, Koto Ku, Tokyo 1358550, Japan; [Sato, S.] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo 1358550, Japan; [Sugimoto, Y.] Keio Univ, Dept Chemotherapy, Fac Pharm, Tokyo, Japan; [Sugimoto, Y.] Japanese Fdn Canc Res, Div Gene Therapy, Ctr Canc Chemotherapy, Tokyo 1358550, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Keio University; Japanese Foundation for Cancer Research	Seimiya, H (corresponding author), Japanese Fdn Canc Res, Div Mol Biotherapy, Ctr Canc Chemotherapy, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	hseimiya@jfcr.or.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 2001, CANCER RES, V61, P8429; Caviglia JM, 2004, J BIOL CHEM, V279, P11163, DOI 10.1074/jbc.M311392200; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Gassler N, 2005, J PATHOL, V207, P295, DOI 10.1002/path.1831; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Jia HL, 2007, CLIN CANCER RES, V13, P1133, DOI 10.1158/1078-0432.CCR-06-1025; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; KADOMATSU K, 2004, CANC LETT, V204, P1391; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liang YC, 2005, WORLD J GASTROENTERO, V11, P2557, DOI 10.3748/wjg.v11.i17.2557; Maeda S, 2007, BRIT J CANCER, V97, P405, DOI 10.1038/sj.bjc.6603879; Mashek DG, 2006, J BIOL CHEM, V281, P945, DOI 10.1074/jbc.M507646200; Mashima T, 2005, DRUG RESIST UPDATE, V8, P339, DOI 10.1016/j.drup.2005.11.001; Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; Mishima K, 2001, CANCER RES, V61, P5349; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; OBrien T, 1996, CANCER RES, V56, P2515; Ohtsubo T, 1997, CANCER RES, V57, P3910; Reichert M, 2002, CANCER, V95, P1113, DOI 10.1002/cncr.10767; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; Schoonjans K, 1996, J LIPID RES, V37, P907; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sung YK, 2003, CANCER SCI, V94, P421, DOI 10.1111/j.1349-7006.2003.tb01458.x; Sung YK, 2007, EXP MOL MED, V39, P477, DOI 10.1038/emm.2007.52; Takei Y, 2001, CANCER RES, V61, P8486; TANNOCK IF, 1989, CANCER RES, V49, P4373; Tao QG, 2007, JNCI-J NATL CANCER I, V99, P1668, DOI 10.1093/jnci/djm208; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Tong Y, 2007, J NEUROCHEM, V100, P1097, DOI 10.1111/j.1471-4159.2006.04276.x; UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797; van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972; VAUPEL P, 1989, CANCER RES, V49, P6449; Xie SH, 1997, CANCER RES, V57, P2295; Yamashita Y, 2000, ONCOGENE, V19, P5919, DOI 10.1038/sj.onc.1203981; Ye C, 1999, BRIT J CANCER, V79, P179, DOI 10.1038/sj.bjc.6690030; Yeh CS, 2006, CANCER LETT, V233, P297, DOI 10.1016/j.canlet.2005.03.050	50	51	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					9	19		10.1038/onc.2008.355	http://dx.doi.org/10.1038/onc.2008.355			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806831				2022-12-17	WOS:000262294100002
J	Jiang, H; Vogt, PK				Jiang, H.; Vogt, P. K.			Constitutively active Rheb induces oncogenic transformation	ONCOGENE			English	Article						Rheb; PI 3-kinase; Akt; TOR; S6-kinase; 4E-binding protein	PROTEIN-KINASE B; CELL-CYCLE PROGRESSION; SMALL GTPASE-RHEB; MAMMALIAN TARGET; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; PROTEASOMAL DEGRADATION; NUCLEAR-LOCALIZATION; RAPAMYCIN MTOR; RAF KINASE; ACTIVATION	Rheb (Ras-homolog enriched in brain) is a component of the phosphatidylinositol 3-kinase (PI3K) target of rapamycin (TOR) signa ling pathway, functioning as a positive regulator of TOR. Constitutively active mutants of Rheb induce oncogenic transformation in cell culture. The transformed cells are larger and contain more protein than their normal counterparts. They show constitutive phosphorylation of the ribosomal protein S6 kinase and the eukaryotic initiation factor 4E-binding protein 1, two downstream targets of TOR. The TOR-specific inhibitor rapamycin strongly interferes with transformation induced by constitutively active Rheb, suggesting that TOR activity is essential for the oncogenic effects of mutant Rheb. Rheb-induced transformation is also dependent on a C-terminal farnesylation signal that mediates localization to a cellular membrane. An engineered N-terminal myristylation signal can substitute for the farnesylation. Immunofluorescence localizes wild-type and mutant Rheb to vesicular structures in the cytoplasm, overlapping with the endoplasmic reticulum.	[Jiang, H.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Jiang, H (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC 239, La Jolla, CA 92037 USA.	hjiang@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	National Cancer Institute; NATIONAL CANCER INSTITUTE [P01CA078045, R01CA107094, R01CA078230] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lynn Ueno, Dr Marco Gymnopoulos, Dr Peiging Sun and Dr William B Kiosses (Core Microscopy, The Scripps Research Institute) for expert technical assistance. This study was supported by grants from the National Cancer Institute. This article is numbered 19286 in the Scripps Research Institute.	Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Aoki M, 2004, Curr Top Microbiol Immunol, V279, P321; Bader AG, 2008, ONCOGENE, V27, P1179, DOI 10.1038/sj.onc.1210719; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Basso AD, 2005, J BIOL CHEM, V280, P31101, DOI 10.1074/jbc.M503763200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Briaud I, 2005, J BIOL CHEM, V280, P2282, DOI 10.1074/jbc.M412179200; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hers I, 2005, BIOCHEM J, V388, P713, DOI 10.1042/BJ20041531; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2006, J BIOL CHEM, V281, P25447, DOI 10.1074/jbc.M605273200; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Mach KE, 2000, GENETICS, V155, P611; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sonderegger CK, 2003, ONCOGENE, V22, P1749, DOI 10.1038/sj.onc.1206308; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yan LJ, 2006, J BIOL CHEM, V281, P19793, DOI 10.1074/jbc.C600028200; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	80	51	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5729	5740		10.1038/onc.2008.180	http://dx.doi.org/10.1038/onc.2008.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18521078	Green Accepted			2022-12-17	WOS:000259487100008
J	Gouyer, V; Fontaine, D; Dumont, P; de Wever, O; Fontayne-Devaud, H; Leteurtre, E; Truant, S; Delacour, D; Drobecq, H; Kerckaert, JP; de Launoit, Y; Bracke, M; Gespach, C; Desseyn, JL; Huet, G				Gouyer, V.; Fontaine, D.; Dumont, P.; de Wever, O.; Fontayne-Devaud, H.; Leteurtre, E.; Truant, S.; Delacour, D.; Drobecq, H.; Kerckaert, J-P; de launoit, Y.; Bracke, M.; Gespach, C.; Desseyn, J-L; Huet, G.			Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells	ONCOGENE			English	Article						mucinous differentiation; CXCR4; CKB; GRB10; CSPG4/NG2; BMP-7	PROSTATE-CANCER; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; PLASMINOGEN-ACTIVATOR; TISSUE INHIBITOR; OVARIAN-CANCER; EXPRESSION; GROWTH; GENE; PROGRESSION	From the conditioned medium of the human colon carcinoma cells, HT-29 5M21 ( CM-5M21), expressing a spontaneous invasive phenotype, tumor-associated trypsin inhibitor ( TATI) was identified and characterized by proteomics, cDNA microarray approaches and functional analyses. Both CM-5M21 and recombinant TATI, but not the K18Y-TATI mutant at the protease inhibitor site, trigger collagen type I invasion by several human adenoma and carcinoma cells of the colon and breast, through phosphoinositide-3-kinase, protein kinase C and Rho-GTPases/Rho kinase-dependent pathways. Conversely, the proinvasive action of TATI in parental HT29 cells was alleviated by the TATI antibody PSKAN2 and the K18Y-TATI mutant. Stable expression of K18Y-TATI in HT-29 5M21 cells downregulated tumor growth, angiogenesis and the expression of several metastasis-related genes, including CSPG4 ( 13.8-fold), BMP-7 ( 9.7-fold), the BMP antagonist CHORDIN ( 5.2-fold), IGFBP-2 and IGF2 ( 9.6- and 4.6-fold). Accordingly, ectopic expression of KY-TATI inhibited the development of lung metastases from HT-29 5M21 tumor xenografts in immunodeficient mice. These findings identify TATI as an autocrine transforming factor potentially involved in early and late events of colon cancer progression, including local invasion of the primary tumor and its metastatic spread. Targeting TATI, its molecular partners and effectors may bring novel therapeutic applications for high-grade human solid tumors in the digestive and urogenital systems.	[Gouyer, V.; Fontaine, D.; Fontayne-Devaud, H.; Leteurtre, E.; Truant, S.; Kerckaert, J-P; Desseyn, J-L; Huet, G.] Ctr Rech Jean Pierre Aubert, INSERM, U837, Fac Med, F-59045 Lille, France; [Gouyer, V.; Fontaine, D.; Dumont, P.; Fontayne-Devaud, H.; Leteurtre, E.; Truant, S.; Drobecq, H.; Kerckaert, J-P; de launoit, Y.; Desseyn, J-L; Huet, G.] NW Canceropole, Lille, France; [Gouyer, V.; Leteurtre, E.; Truant, S.; Huet, G.] CHRU, Lille, France; [Dumont, P.; Drobecq, H.; de launoit, Y.] Inst Biol Lille, UMR 8161, Lille, France; [de Wever, O.; Bracke, M.] Ghent Univ Hosp, Expt Cancerol Lab, Ghent, Belgium; [Delacour, D.] Univ Marburg, Dept Cell Biol & Cell Pathol, Marburg, Germany; [Gespach, C.] INSERM, U673, Paris, France; [Gespach, C.] Univ Paris 06, Hop St Antoine, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Ghent University; Ghent University Hospital; Philipps University Marburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Huet, G (corresponding author), Ctr Rech Jean Pierre Aubert, INSERM, U837, Fac Med, Pl Verdun, F-59045 Lille, France.	huet@lille.inserm.fr	Gouyer, Valérie/R-4984-2018; Desseyn, Jean-Luc/M-5070-2018; de wever, olivier/J-3094-2013	Gouyer, Valérie/0000-0002-4223-7060; Desseyn, Jean-Luc/0000-0001-6876-8049; de wever, olivier/0000-0002-5453-760X; Drobecq, Herve/0000-0002-4081-1575; de Launoit, Yvan/0000-0003-1837-9808				Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Antila R, 2006, GYNECOL ONCOL, V101, P97, DOI 10.1016/j.ygyno.2005.09.046; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balasubramani M, 2006, CANCER RES, V66, P763, DOI 10.1158/0008-5472.CAN-05-3771; BARTELT DC, 1977, ARCH BIOCHEM BIOPHYS, V179, P189, DOI 10.1016/0003-9861(77)90103-5; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x; Delacour D, 2005, J CELL BIOL, V169, P491, DOI 10.1083/jcb.200407073; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fountoulakis M, 1998, ELECTROPHORESIS, V19, P1819, DOI 10.1002/elps.1150191046; Gouyer V, 2005, CANCER-AM CANCER SOC, V103, P1676, DOI 10.1002/cncr.20965; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Harbeck N, 2007, CRIT REV CL LAB SCI, V44, P179, DOI 10.1080/10408360601040970; Hu KM, 2007, IMMUNOL LETT, V113, P19, DOI 10.1016/j.imlet.2007.07.004; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; Kebache S, 2007, J BIOL CHEM, V282, P21873, DOI 10.1074/jbc.M611066200; KIKUCHI N, 1989, J BIOCHEM-TOKYO, V106, P1059, DOI 10.1093/oxfordjournals.jbchem.a122964; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Lee YC, 2007, EUR J CANCER, V43, P736, DOI 10.1016/j.ejca.2006.11.020; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.0.CO;2-C; Loberg RD, 2007, CANCER RES, V67, P9417, DOI 10.1158/0008-5472.CAN-07-1286; Louvet C, 2000, ANTI-CANCER DRUG, V11, P579, DOI 10.1097/00001813-200008000-00010; Makagiansar IT, 2007, J CELL BIOL, V178, P155, DOI 10.1083/jcb.200612084; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P; Monti P, 2003, CANCER RES, V63, P7451; Nguyen QD, 2005, ONCOGENE, V24, P8240, DOI 10.1038/sj.onc.1208990; Nyberg P, 2006, EXP CELL RES, V312, P1219, DOI 10.1016/j.yexcr.2005.12.024; OHMACHI Y, 1993, INT J CANCER, V55, P728, DOI 10.1002/ijc.2910550505; Paju A, 2006, CRIT REV CL LAB SCI, V43, P103, DOI 10.1080/10408360500523852; Paju A, 2004, CLIN CANCER RES, V10, P4761, DOI 10.1158/1078-0432.CCR-0204-03; Paju A, 2007, EUR UROL, V52, P1670, DOI 10.1016/j.eururo.2007.01.096; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Stenman UH, 2002, CLIN CHEM, V48, P1206; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011; TURPEINEN U, 1988, BIOCHEM J, V254, P911, DOI 10.1042/bj2540911; van der Zee M, 2006, P NATL ACAD SCI USA, V103, P16307, DOI 10.1073/pnas.0605154103; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983; Yan RL, 2007, INT J CANCER, V121, P2301, DOI 10.1002/ijc.22933; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174; Yasuda T, 1998, J BIOL CHEM, V273, P34413, DOI 10.1074/jbc.273.51.34413; YASUDA T, 1993, GENE, V131, P275	50	51	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4024	4033		10.1038/onc.2008.42	http://dx.doi.org/10.1038/onc.2008.42			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18317448				2022-12-17	WOS:000257325100002
J	Kawase, T; Ichikawa, H; Ohta, T; Nozaki, N; Tashiro, F; Ohki, R; Taya, Y				Kawase, T.; Ichikawa, H.; Ohta, T.; Nozaki, N.; Tashiro, F.; Ohki, R.; Taya, Y.			p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis	ONCOGENE			English	Article						p53; exonuclease; apoptosis; p53 phosphorylation	DNA-DAMAGE; NUCLEOLAR LOCALIZATION; CANDIDATE MEDIATOR; IONIZING-RADIATION; PHOSPHORYLATION; STRESS; ROLES; DEGRADATION; DOMAINS; POINT	DNA degradation is one of the biochemical hallmarks detected in apoptotic cells, and several nucleases have been reported to function cooperatively in this process. It has also been suggested that different sets of nucleases are activated by different stimuli, and induce distinct patterns of DNA degradation. Here we report that apoptosis-enhancing nuclease ( AEN) is a novel direct target gene of p53. AEN is induced by p53 with various DNA damage, and its expression is regulated by the phosphorylation status of p53. We demonstrate that AEN is a typical exonuclease with conserved exonuclease domains Exo I-III, and it targets both single- and double-stranded DNA and RNA. AEN induces apoptosis by itself, and the conserved domains are essential for both AEN nuclease activity and its apoptosis-inducing ability. AEN possesses nuclear and nucleolar localization signals, and it translocates from the nucleolus to nucleoplasm upon apoptosis induction. We also show the dislocation of nucleophosmin in conjunction with the translocation of AEN to the nucleoplasm, indicating the ability of AEN in nucleolus disruption. In addition, AEN is shown to be required for efficient DNA fragmentation in p53-dependent apoptosis. These results suggest that AEN is an important downstream mediator of p53 in apoptosis induction.	[Ohki, R.] Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Tokyo 1040045, Japan; [Ohta, T.] Natl Canc Ctr, Res Inst, Ctr Med Genom, Tokyo 1040045, Japan; [Nozaki, N.] Kanagawa Dent Coll, Dept Biochem & Mol Biol, Kanagawa, Japan; [Kawase, T.; Tashiro, F.] Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Chiba, Japan; [Kawase, T.; Ohki, R.; Taya, Y.] Japan Sci & Technol Agcy, SORST, Chiba, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Kanagawa Dental College; Tokyo University of Science; Japan Science & Technology Agency (JST)	Ohki, R (corresponding author), Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rohki@gan2.res.ncc.go.jp			Direct For Mathematical & Physical Scien [1041698] Funding Source: National Science Foundation	Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162; Kawane K, 2006, NATURE, V443, P998, DOI 10.1038/nature05245; Kurki S, 2004, CELL CYCLE, V3, P976; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee JH, 2005, BIOCHEM BIOPH RES CO, V337, P39, DOI 10.1016/j.bbrc.2005.08.264; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Parrish JZ, 2006, CHROMOSOMA, V115, P89, DOI 10.1007/s00412-005-0038-0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Schaetzlein S, 2007, CELL, V130, P863, DOI 10.1016/j.cell.2007.08.029; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; TOUNEKTI O, 1995, EXP CELL RES, V217, P506, DOI 10.1006/excr.1995.1116; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	40	51	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3797	3810		10.1038/onc.2008.32	http://dx.doi.org/10.1038/onc.2008.32			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264133				2022-12-17	WOS:000256904700004
J	Tsuchida, R; Das, B; Yeger, H; Koren, G; Shibuya, M; Thorner, P; Baruchel, S; Malkin, D				Tsuchida, R.; Das, B.; Yeger, H.; Koren, G.; Shibuya, M.; Thorner, Ps; Baruchel, S.; Malkin, D.			Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling	ONCOGENE			English	Article						osteosarcoma; cisplatin; tumorigenic SP; VEGF/Flt1 autocrine	ENDOTHELIAL GROWTH-FACTOR; HUMAN OSTEOBLAST CELLS; PROSTATE-CANCER CELLS; HUMAN TUMOR-CELLS; IN-VITRO; VEGF; TRANSFORMATION; PHENOTYPE; CHEMOTHERAPY; INDUCTION	The cellular and molecular mechanisms of tumor progression following chemotherapy are largely unknown. Here, we demonstrate that cisplatin ( CDDP) treatment upregulates VEGF and Flt1 expression leading to the survival and expansion of a highly tumorigenic fraction of side-population (SP) cells in osteosarcoma (HOS), neuroblastoma (SK-N-BE2) and rhabdomyosarcoma (RH-4) cell lines. In all three lines, we show that CDDP treatment increases levels of VEGF and Flt1 expression, and induces enhanced clonogenic capacity and increased expression of the 'stemness'-associated genes Nanog, Bmi-1 and Oct-4 in the SP fraction. In HOS, these changes are associated with the transformation of a non-tumorigenic osteosarcoma SP fraction to a highly tumorigenic phenotype. Inhibition of Flt1 led to complete reduction of tumorigenicity in the HOS SP fraction, and reduction of clonogenic capacity and expression of stemness genes in the SK-N-BE(2) and RH-4 SP fractions. Treatment with U0126, a specific inhibitor of MAPK/ERK1,2 completely downregulates CDDP-induced VEGF and Flt1 expression and induction/expansion of SP fraction in all three cell lines, indicating that these effects are mediated through MAPK/ERK1,2 signaling. In conclusion, we report a novel mechanism of CDDP-induced tumor progression, whereby the activation of VEGF/Flt1 autocrine signaling leads to the survival and expansion of a highly tumorigenic SP fraction.	[Tsuchida, R.; Das, B.; Baruchel, S.; Malkin, D.] Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; [Das, B.; Koren, G.; Baruchel, S.; Malkin, D.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Yeger, H.; Thorner, Ps] Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; [Yeger, H.; Thorner, Ps] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Shibuya, M.] Univ Tokyo, Inst Med Sci, Dept Genet, Div Genet, Tokyo, Japan; [Baruchel, S.; Malkin, D.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Malkin, D.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Tokyo; University of Toronto; University of Toronto	Malkin, D (corresponding author), Hosp Sick Children, Dept Pediat, Div Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	david.malkin@sickkids.ca	Malkin, David/AAW-8715-2021; Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Behrends M, 2000, AM J PHYSIOL-HEART C, V279, pH1111, DOI 10.1152/ajpheart.2000.279.3.H1111; Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Cara S, 2001, ANN ONCOL, V12, P23, DOI 10.1023/A:1008389706725; COLE S, 2004, DRUG RESISTANCE; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575; Das B, 2003, EUR J CANCER, V39, P2556, DOI 10.1016/j.ejca.2003.07.002; DAS B, 2007, STEM CELLS; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; Gee MFW, 2005, ONCOGENE, V24, P8025, DOI 10.1038/sj.onc.1208939; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hirschmann-Jax C, 2005, CELL CYCLE, V4, P203; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Miller AC, 1998, ENVIRON HEALTH PERSP, V106, P465, DOI 10.1289/ehp.98106465; Miller AC, 2001, CARCINOGENESIS, V22, P115, DOI 10.1093/carcin/22.1.115; Miura K, 2005, BIOCHEM CELL BIOL, V83, P36, DOI 10.1139/O04-106; Montanaro F, 2004, EXP CELL RES, V298, P144, DOI 10.1016/j.yexcr.2004.04.010; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Qi L, 2003, ANTICANCER RES, V23, P3917; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; RICHMAN CM, 1976, BLOOD, V47, P1031; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Setoguchi T, 2004, CELL CYCLE, V3, P414; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; Steiner HH, 2004, J NEURO-ONCOL, V66, P129, DOI 10.1023/B:NEON.0000013495.08168.8f; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y	40	51	53	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3923	3934		10.1038/onc.2008.38	http://dx.doi.org/10.1038/onc.2008.38			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18332870				2022-12-17	WOS:000257089000004
J	Liu, D; Evans, I; Britton, G; Zachary, I				Liu, D.; Evans, I.; Britton, G.; Zachary, I.			The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis	ONCOGENE			English	Article						nuclear receptors; Nur77; protein kinase C; broblast growth factor	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAY; FOCAL ADHESION KINASE; FACTOR EGR3; TYROSINE PHOSPHORYLATION; PROSTACYCLIN PRODUCTION; REGULATORY FACTORS; ACTIVATION; CELLS	Early growth response 3 (Egr3) is a member of a zinc-finger transcription factor subfamily, which we previously found to be strongly upregulated by vascular endothelial growth factor (VEGF)-A in an oligonucleotide microarray screen of endothelial cells. Here, we show that Egr3 is the predominant Egr family member upregulated by VEGF in endothelial cells at 45 min, and that VEGF induced a rapid increase in Egr-dependent transcriptional activation mediated via its major signalling receptor, VEGFR2/KDR, and the protein kinase C (PKC) pathway. VEGF-induced Egr3 gene expression was also mediated in part via a PKC-dependent activation of protein kinase D. Inhibition of Egr3 gene expression by RNA interference was effective in inhibiting basal and VEGF-induced Egr3 gene expression, and it also inhibited VEGF-mediated endothelial cell proliferation, migration and tubulogenesis. These findings indicate that Egr3 has an essential downstream role in VEGF-mediated endothelial functions leading to angiogenesis and may have particular relevance for adult angiogenic processes involved in vascular repair and neovascular disease.	[Liu, D.; Evans, I.; Britton, G.; Zachary, I.] UCL, BHF Labs, Dept Med, London WC1E 6JJ, England; [Liu, D.] UCL, Dept Med, Ark Therapeut Ltd, London, England	University of London; University College London; University of London; University College London	Zachary, I (corresponding author), UCL, BHF Labs, Dept Med, Rayne Bldg 5 Univ St, London WC1E 6JJ, England.	I.Zachary@ucl.ac.uk	Evans, Ian/C-8533-2009	Evans, Ian/0000-0002-0468-8274	British Heart Foundation [RG/06/003/21131] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Carter JH, 2007, J IMMUNOL, V178, P3038, DOI 10.4049/jimmunol.178.5.3038; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649; Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P164, DOI 10.1006/bbrc.2001.4761; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Levkovitz Y, 2001, J NEUROSCI, V21, P45, DOI 10.1523/JNEUROSCI.21-01-00045.2001; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Mercier G, 2001, MOL BRAIN RES, V97, P137, DOI 10.1016/S0169-328X(01)00311-4; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Donovan KJ, 1998, J NEUROCHEM, V70, P1241; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Safford M, 2005, NAT IMMUNOL, V6, P472, DOI 10.1038/ni1193; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tourtellotte WG, 1998, NAT GENET, V20, P87, DOI 10.1038/1757; Tourtellotte WG, 2001, DEV BIOL, V232, P388, DOI 10.1006/dbio.2001.0202; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Xi HK, 2004, J IMMUNOL, V173, P340, DOI 10.4049/jimmunol.173.1.340; Xi HK, 2004, J IMMUNOL, V172, P964, DOI 10.4049/jimmunol.172.2.964; Xi HK, 2006, IMMUNITY, V24, P813, DOI 10.1016/j.immuni.2006.03.023; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	38	51	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2989	2998		10.1038/sj.onc.1210959	http://dx.doi.org/10.1038/sj.onc.1210959			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059339				2022-12-17	WOS:000255681700006
J	Kivi, N; Greco, D; Auvinen, P; Auvinen, E				Kivi, N.; Greco, D.; Auvinen, P.; Auvinen, E.			Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression	ONCOGENE			English	Article						HPV; papillomavirus; E5; microarray; cell adhesion; cell motility	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; MATRIX METALLOPROTEINASES; CYCLE PROGRESSION; EPITHELIAL-CELLS; E7 GENE; TRANSFORMATION; IMMORTALIZATION; TRANSDUCTION; INVASION	We investigated the effects of the human papillomavirus type 16 E5 oncogene on cellular gene expression in human epithelial cells using cDNA microarray. In a genome-wide microarray assay, the expression of 179 genes was found to be significantly altered due to E5 expression. The expression of lamin A/C was downregulated at protein level. The expression of protein kinase C-delta and phosphoinositide-3-kinase proteins was found to be upregulated. We also observed increased motility of E5-expressing cells. We conclude that the E5 protein affects several cellular pathways involved in cell adhesion, cell motility and mitogenic signaling. These alterations may together lead to inhibition of apoptosis and facilitate the establishment of persistent infection in the epithelium.	[Kivi, N.; Auvinen, E.] Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; [Kivi, N.; Auvinen, E.] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; [Greco, D.; Auvinen, P.] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Kivi, N (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, PO 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	niina.kivi@helsinki.fi	Auvinen, Petri/AAP-8117-2021; Greco, Dario/T-7113-2019; Auvinen, Petri/D-5044-2009	Greco, Dario/0000-0001-9195-9003; Auvinen, Petri/0000-0002-3947-4778; Auvinen, Eeva/0000-0002-2094-985X				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Auvinen E, 2004, ARCH VIROL, V149, P1745, DOI 10.1007/s00705-004-0325-8; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; Bravo IG, 2005, ARCH VIROL, V150, P231, DOI 10.1007/s00705-004-0420-x; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Buness A, 2005, BIOINFORMATICS, V21, P554, DOI 10.1093/bioinformatics/bti052; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CASTRONOVO V, 1993, INVAS METAST, V13, P1; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen SL, 1996, ARCH VIROL, V141, P791, DOI 10.1007/BF01718155; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Czech MP, 2003, ANNU REV PHYSIOL, V65, P791, DOI 10.1146/annurev.physiol.65.092101.142522; DEMETER LM, 1992, CANCER RES, V52, P1561; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; Duerst RJ, 2003, VIRAL IMMUNOL, V16, P475, DOI 10.1089/088282403771926300; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Ivetac I, 2005, MOL BIOL CELL, V16, P2218, DOI 10.1091/mbc.e04-09-0799; Kim SH, 2006, CELL MOL LIFE SCI, V63, P930, DOI 10.1007/s00018-005-5561-x; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Leykauf K, 2004, J GEN VIROL, V85, P1427, DOI 10.1099/vir.0.79844-0; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGER K, 1989, J VIROL, V63, P4417; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Rajeevan MS, 2001, J MOL DIAGN, V3, P26, DOI 10.1016/S1525-1578(10)60646-0; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Werner JA, 2002, CLIN EXP METASTAS, V19, P275, DOI 10.1023/A:1015531319087; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002	55	51	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2532	2541		10.1038/sj.onc.1210916	http://dx.doi.org/10.1038/sj.onc.1210916			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982485				2022-12-17	WOS:000255057000003
J	Borczuk, AC; Papanikolaou, N; Toonkel, RL; Sole, M; Gorenstein, LA; Ginsburg, ME; Sonett, JR; Friedman, RA; Powell, CA				Borczuk, A. C.; Papanikolaou, N.; Toonkel, R. L.; Sole, M.; Gorenstein, L. A.; Ginsburg, M. E.; Sonett, J. R.; Friedman, R. A.; Powell, C. A.			Lung adenocarcinoma invasion in TGFbRII-deficient cells is mediated by CCL5/RANTES	ONCOGENE			English	Article						lung adenocarcinoma; bronchioloalveolar carcinoma; neoplasm invasiveness; RANTES; TGF-beta; disease progression	FACTOR-BETA RECEPTOR; BREAST-CARCINOMA; GENE-EXPRESSION; CCL5 RANTES; CANCER; CCR5; METASTASIS; PROGRESSION; ANTAGONIST; ACTIVATION	Recently, we identified a lung adenocarcinoma signature that segregated tumors into three clades distinguished by histological invasiveness. Among the genes differentially expressed was the type II transforming growth factor-beta receptor (TGF beta RII), which was lower in adenocarcinoma mixed subtype and solid invasive subtype tumors compared with bronchioloalveolar carcinoma. We used a tumor cell invasion system to identify the chemokine CCL5 (RANTES, regulated on activation, normal T-cell expressed and presumably secreted) as a potential downstream mediator of TGF-beta signaling important for lung adenocarcinoma invasion. We specifically hypothesized that RANTES is required for lung cancer invasion and progression in TGFbRII-repressed cells. We examined invasion in TGFbRII-deficient cells treated with two inhibitors of RANTES activity, Met-RANTES and a CCR5 receptor-blocking antibody. Both treatments blocked invasion induced by TGFbRII knockdown. In addition, we examined the clinical relevance of the RANTES-CCR5 pathway by establishing an association of RANTES and CCR5 immunostaining with invasion and outcome in human lung adenocarcinoma specimens. Moderate or high expression of both RANTES and CCR5 was associated with an increased risk for death, P = 0.014 and 0.002, respectively. In conclusion, our studies indicate RANTES signaling is required for invasion in TGFbRII-deficient cells and suggest a role for CCR5 inhibition in lung adenocarcinoma prevention and treatment.	[Borczuk, A. C.] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; [Papanikolaou, N.; Toonkel, R. L.; Sole, M.; Powell, C. A.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Gorenstein, L. A.; Ginsburg, M. E.; Sonett, J. R.] Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Friedman, R. A.] Columbia Univ Coll Phys & Surg, Dept Biomed Informat, New York, NY 10032 USA; [Friedman, R. A.; Powell, C. A.] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Powell, CA (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, 630 W,168th St,Box 91, New York, NY 10032 USA.	cap6@columbia.edu	BORCZUK, alain/AHA-5172-2022; Powell, Charles A/C-8663-2011; Borczuk, Alain/AAI-8226-2021; Borczuk, Alain/AFU-5278-2022	Powell, Charles A/0000-0003-3509-891X; Borczuk, Alain/0000-0001-6807-8064; Borczuk, Alain/0000-0001-6807-8064; toonkel, rebecca/0000-0001-8339-2107	NATIONAL CANCER INSTITUTE [R01CA120174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA120174-02, 1R01CA120174, R01 CA120174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azenshtein E, 2002, CANCER RES, V62, P1093; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Biswas S, 2004, CANCER RES, V64, P4687, DOI 10.1158/0008-5472.CAN-03-3255; Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Culley FJ, 2006, J VIROL, V80, P8151, DOI 10.1128/JVI.00496-06; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gustin JA, 2004, AM J PHYSIOL-CELL PH, V286, pC547, DOI 10.1152/ajpcell.00332.2002; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Jang SB, 2002, MOL CELLS, V14, P35; Luboshits G, 1999, CANCER RES, V59, P4681; Ma B, 2005, J CLIN INVEST, V115, P3460, DOI 10.1172/JCI24858; Moran CJ, 2002, CLIN CANCER RES, V8, P3803; Nakazaki Y, 2006, MOL THER, V14, P599, DOI 10.1016/j.ymthe.2006.04.014; Nissinen R, 2003, J RHEUMATOL, V30, P1928; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Remmelink M, 2005, INT J ONCOL, V26, P247; Sakurai H, 2004, AM J SURG PATHOL, V28, P198, DOI 10.1097/00000478-200402000-00007; Schwabe RF, 2003, AM J PHYSIOL-GASTR L, V285, pG949, DOI 10.1152/ajpgi.00215.2003; Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306; van Deventer HW, 2005, CANCER RES, V65, P3374, DOI 10.1158/0008-5472.CAN-04-2616	24	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					557	564		10.1038/sj.onc.1210662	http://dx.doi.org/10.1038/sj.onc.1210662			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653092	Green Accepted			2022-12-17	WOS:000252426100016
J	Zhang, B; Chambers, KJ; Faller, DV; Wang, S				Zhang, B.; Chambers, K. J.; Faller, D. V.; Wang, S.			Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation	ONCOGENE			English	Article						ER; prohibitin; brg1; brm; HDAC; HAT	SWI-SNF COMPLEX; CHROMATIN REMODELING COMPLEX; E2F-DEPENDENT GENE-TRANSCRIPTION; HISTONE DEACETYLASE ACTIVITY; BREAST-CANCER CELLS; RETINOBLASTOMA PROTEIN; GLUCOCORTICOID-RECEPTOR; MUSCLE DIFFERENTIATION; GROWTH ARREST; CYCLE ARREST	The SWI/SNF complex participates as a co-activator in the transcriptional regulation of certain genes. Conversely, we and others have recently established that Brg1 and Brm, the central components of SWI/SNF, act instead as co-repressors for E2F-mediated transcriptional repression, and for the transcription of certain other promoters. We report here that Brg-1 and Brm can switch their mode of function at same promoter between activation and repression by ligand-directed differential coordination with BAF155, BAF170, HDAC1, p300 and prohibitin. This ligand and context-dependent reprogramming of the SWI/SNF complex allows it to differentially serve as either a co-repressor or a co-activator of transcription at the same promoter.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Wang, S (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, R-906,715 Albany St, Boston, MA 02118 USA.	sw184@bu.edu			NATIONAL CANCER INSTITUTE [R01CA101992, R03CA102940] Funding Source: NIH RePORTER; NCI NIH HHS [CA101992, 1R03CA102940-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banchio C, 2006, J BIOL CHEM, V281, P10010, DOI 10.1074/jbc.M513503200; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Brehm A, 1999, BRIT J CANCER, V80, P38; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Foster KSJ, 2006, ONCOGENE, V25, P4605, DOI 10.1038/sj.onc.1209496; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Goodwin GH, 1997, GENE, V184, P27, DOI 10.1016/S0378-1119(96)00569-0; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lin HY, 2005, STEROIDS, V70, P444, DOI 10.1016/j.steroids.2005.03.001; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031; Matsuda KI, 2002, MOL ENDOCRINOL, V16, P2215, DOI 10.1210/me.2002-0110; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Panteleeva I, 2004, ANN NY ACAD SCI, V1030, P656, DOI 10.1196/annals.1329.076; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roche KC, 2004, ONCOGENE, V23, P8185, DOI 10.1038/sj.onc.1208025; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Zhao LH, 2005, ACTA BIOCH BIOPH SIN, V37, P440, DOI 10.1111/j.1745-7270.2005.00061.x	54	51	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7153	7157		10.1038/sj.onc.1210509	http://dx.doi.org/10.1038/sj.onc.1210509			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486062				2022-12-17	WOS:000250715000009
J	Lin, J; Sun, T; Ji, L; Deng, W; Roth, J; Minna, J; Arlinghaus, R				Lin, J.; Sun, T.; Ji, L.; Deng, W.; Roth, J.; Minna, J.; Arlinghaus, R.			Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1	ONCOGENE			English	Article						c-Abl; FUS1; NSCLC; lung cancer; imatinib	HOMOZYGOUS DELETION REGION; EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE; IN-VIVO; PROTEIN; BCR; FAMILY; VITRO; EXON; CRK	In lung cancer, frequent loss of one allele of chromosome 3p is seen in both small cell lung cancer and non-small cell lung cancer (NSCLC), providing evidence of tumor suppressor genes (TSGs) in this chromosomal region. The mechanism of Fus1 tumor suppressor activity is unknown. We have found that a Fus1 peptide inhibits the Ab1 tyrosine kinase in vitro (IC50 35 mu M). The inhibitory Fus1 sequence was derived from a region that was deleted in a mutant FUS1 gene (FUS1 (1-80)) detected in some lung cancer cell lines. Importantly, a stearic acid-modified form of this peptide was required for the inhibition, but stearic acid alone was not inhibitory. Two NSCLC cell lines, which lack expression of wild-type Fus1, contain activated c-Abl. Forced expression of an inducible FUS1 cDNA in H1299 NSCLC cells decreased levels of activated c-Abl and inhibited its tyrosine kinase activity. Similarly, treatment of c-Abl immune complexes with the inhibitory Fus1 peptide also reduced the level of c-Abl in these immune complexes. The size and number of colonies of the NSCLC cell line, H1299, in soft agar was strongly inhibited by the Abl kinase inhibitor imatinib mesylate. Co-expression of FUS1 and c-ABL in COS1 cells blocked activation of c-Abl tyrosine kinase. In contrast, coexpression of mutant FUS1(1-80) with c-ABL had little inhibitory activity against c-Abl. These findings provide strong evidence that c-Abl is a possible target in NSCLC patients that have reduced expression of Fus1 in their tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Arlinghaus, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NCI NIH HHS [P50CA70907, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Buchdunger E, 1996, CANCER RES, V56, P100; Das AK, 2006, CANCER RES, V66, P9601, DOI 10.1158/0008-5472.CAN-06-2627; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Girard L, 2000, CANCER RES, V60, P4894; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ito I, 2004, CANCER GENE THER, V11, P733, DOI 10.1038/sj.cgt.7700756; Ji L, 2002, CANCER RES, V62, P2715; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Ling XY, 2003, CANCER RES, V63, P298; Liu JX, 1996, CANCER RES, V56, P5120; LIU JX, 1993, ONCOGENE, V8, P101; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; *US CANC STAT WORK, 2004, UC CANC STAT 2001 IN; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang M, 2004, ACTA PHARMACOL SIN, V25, P61; Zhang Peilin, 2003, Mol Cancer, V2, P1	29	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					6989	6996		10.1038/sj.onc.1210500	http://dx.doi.org/10.1038/sj.onc.1210500			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486070	Green Accepted			2022-12-17	WOS:000250412200004
J	Wang, N; Lin, KK; Lu, Z; Lam, KS; Newton, R; Xu, X; Yu, Z; Gill, GN; Andersen, B				Wang, N.; Lin, K. K.; Lu, Z.; Lam, K. S.; Newton, R.; Xu, X.; Yu, Z.; Gill, G. N.; Andersen, B.			The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells	ONCOGENE			English	Article						breast cancer; lim domain; LMO; proliferation; apoptosis; HDAC	BONE MORPHOGENETIC PROTEIN-7; CANCER PROGRESSION; DOMAIN; RECEPTOR; GROWTH; GLAND; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; INVASION	The nuclear LIM-only protein 4 (LMO4) is upregulated in breast cancer, especially estrogen receptor-negative tumors, and its overexpression in mice leads to hyperplasia and tumor formation. Here, we show that deletion of LMO4 in the mammary glands of mice leads to impaired lobuloalveolar development due to decreased epithelial cell proliferation. With the goal of discovering potential LMO4-target genes, we also developed a conditional expression system in MCF-7 cells for both LMO4 and a dominant negative (DN) form of its co-regulator, cofactor of LIM domains (Clim/Ldb/Nli). We then used DNA microarrays to identify genes responsive to LMO4 and DN-Clim upregulation. One of the genes common to both data sets was bone morphogenic protein 7 (BMP7), whose expression is also significantly correlated with LMO4 transcript levels in a large dataset of human breast cancers, suggesting that BMP7 is a bona. de target gene of LMO4 in breast cancer. Inhibition of BMP7 partially blocks the effects of LMO4 on apoptosis, indicating that BMP7 mediates at least some functions of LMO4. Gene transfer studies show that LMO4 regulates the BMP7 promoter, and chromatin immunoprecipitation studies show that LMO4 and its cofactor Clim2 are recruited to the BMP7 promoter. Furthermore, we demonstrate that HDAC2 recruitment to the BMP7 promoter is inhibited by upregulation of LMO4 and that HDAC2 knockdown upregulates the promoter. These studies suggest a novel mechanism of action for LMO4: LMO4, Clim2 and HDAC2 are part of a transcriptional complex, and increased LMO4 levels can disrupt the complex, leading to decreased HDAC2 recruitment and increased promoter activity.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Lin, Kevin/C-1959-2009; Lu, ZX/G-4586-2010	Lin, Kevin/0000-0003-4305-8352	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44882] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Dean C, 2004, DEVELOPMENT, V131, P4155, DOI 10.1242/dev.01285; Deane JE, 2004, EMBO J, V23, P3589, DOI 10.1038/sj.emboj.7600376; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gruvberger S, 2001, CANCER RES, V61, P5979; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kusumegi T, 2004, J BIOCHEM MOL TOXIC, V18, P1, DOI 10.1002/jbt.20004; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lee SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/j.mcn.2004.04.010; Lu Z, 2006, ONCOGENE, V25, P2920, DOI 10.1038/sj.onc.1209318; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Monroe DG, 2000, MOL CELL BIOL, V20, P4626, DOI 10.1128/MCB.20.13.4626-4634.2000; Mousses S, 2002, CANCER RES, V62, P1256; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rabbitts TH, 1999, CANCER RES, V59, p1794S; Ryan DP, 2006, J MOL BIOL, V359, P66, DOI 10.1016/j.jmb.2006.02.074; Singh RR, 2005, CANCER RES, V65, P10594, DOI 10.1158/0008-5472.CAN-05-2268; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288	36	51	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6431	6441		10.1038/sj.onc.1210465	http://dx.doi.org/10.1038/sj.onc.1210465			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452977				2022-12-17	WOS:000249737600007
J	Creighton, CJ				Creighton, C. J.			A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors	ONCOGENE			English	Article						akt pathway; mTOR; human breast cancer; gene expression pro. ling; meta-analysis	CELLS IN-VITRO; EXPRESSION SIGNATURE; TARGETED THERAPIES; CANCER; AKT; TAMOXIFEN; ACTIVATION; PATTERNS; ESTROGEN; SURVIVAL	The Akt pathway is commonly deregulated in many cancers. Clinical trials are currently underway to test the effectiveness of breast cancer treatment by inhibition of various Akt pathway intermediates. A set of genes induced by Akt in a transgenic mouse model, a subset of which were sensitive to mammalian target of rapamycin (mTOR) inhibitor RAD001, was examined in five public gene expression pro. le data sets of clinical breast tumor specimens (representing > 1000 different samples in all). In each of the clinical data sets, the Akt mouse model genes as a group were significantly overexpressed in human tumors having high levels of AKT1 mRNA. The subset of genes both upregulated by Akt and dependent on mTOR activity were associated with estrogen receptor-negative status, higher grade, increasing tumor size and poor prognosis in multiple patient cohorts; these associations were either not present or not as strong for the Akt-induced, mTOR-independent genes or for AKT1 expression alone. The genes shown here to be relevant to Akt-mTOR both experimentally and pathologically have the potential for use in a molecular diagnostic to determine which patients should receive mTOR antagonist treatment.	Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, Houston, TX 77030 USA	Baylor College of Medicine	Creighton, CJ (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, 1 Baylor Plaza MS 305, Houston, TX 77030 USA.	creighto@bcm.tmc.edu						Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Johnston SRD, 2006, CLIN CANCER RES, V12, p1061S, DOI 10.1158/1078-0432.CCR-05-2125; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lehmann U, 2001, METHODS, V25, P409, DOI 10.1006/meth.2001.1263; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tian L, 2005, P NATL ACAD SCI USA, V102, P13544, DOI 10.1073/pnas.0506577102; Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	23	51	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4648	4655		10.1038/sj.onc.1210245	http://dx.doi.org/10.1038/sj.onc.1210245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17213801				2022-12-17	WOS:000248037900005
J	Sutton, KM; Hayat, S; Chau, NM; Cook, S; Pouyssegur, J; Ahmed, A; Perusinghe, N; Le Floch, R; Yang, J; Ashcroft, M				Sutton, K. M.; Hayat, S.; Chau, N-M; Cook, S.; Pouyssegur, J.; Ahmed, A.; Perusinghe, N.; Le Floch, R.; Yang, J.; Ashcroft, M.			Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1	ONCOGENE			English	Article						hypoxia-inducible factor 1(HIF-1); hypoxia; growth factor; ERK1/2 signalling; small molecule inhibitor	INDUCIBLE FACTOR 1-ALPHA; GROWTH-FACTOR EXPRESSION; ACTIVATED PROTEIN-KINASE; MAP KINASE; FACTOR-I; FACTOR (HIF)-1-ALPHA; CANCER-THERAPY; BREAST-CANCER; FACTOR-1-ALPHA; ANGIOGENESIS	The transcription factor hypoxia-inducible factor 1 (HIF-1) plays a pivotal role in tumour growth and progression, and HIF-1 is regulated through a number of signalling pathways. Here, we investigated the involvement of the mitogen-activated protein kinase (MAPK) signalling pathway in HIF-1 regulation. We found that overexpression of wild-type (WT) extracellular signal regulated protein kinase 1 (ERK1) greatly potentiated HIF-1 activation in hypoxia and HIF-1 alpha induced in response to insulin growth-like factor 1 (IGF-1). Conversely, treatment of tumour cells with the MEK1/2 inhibitors PD98059 or U0216, or expression of a dominant-negative form of ERK1 blocked HIF-1 activation in hypoxia without affecting HIF-1 alpha induction, localization or binding of HIF-1 beta. Interestingly however, the highly selective MEK1/2 inhibitor PD184352 did not inhibit HIF-1 activity or vascular endothelial growth factor (VEGF) induced in response to hypoxia but blocked HIF-1a protein and HIF-1 activity induced by IGF-1 stimulation without affecting HIF-1 alpha mRNA levels. Finally, we found that ERK5 phosphorylation status was not significantly affected by hypoxia in the presence or absence of PD184352. Taken together, our data suggest that although ERK1/2 signalling is important for HIF-1 alpha induction and HIF-1 activity in response to IGF-1, it is dispensable for the induction of HIF-1 alpha and activation of HIF-1 in response to hypoxia.	Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; Babraham Inst, MAP Kinase Grp, Mol Signalling Lab, Signalling Programme, Cambridge, England; Inst Signalling Dev Biol & Canc Res, Nice, France; Inst Canc Res, Microscopy Facil, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cancer Research UK; University of London; Institute of Cancer Research - UK	Ashcroft, M (corresponding author), Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	margaret.ashcroft@icr.ac.uk	Yang, Jun/N-2309-2018	Yang, Jun/0000-0002-4233-3220				Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blancher C, 2001, CANCER RES, V61, P7349; Blancher C, 2000, CANCER RES, V60, P7106; Bos R, 2005, HISTOPATHOLOGY, V46, P31, DOI 10.1111/j.1365-2559.2005.02045.x; Carroll Veronica A., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009117; Chau NM, 2005, CANCER RES, V65, P4918, DOI 10.1158/0008-5472.CAN-04-4453; Dokladda K, 2005, FEBS LETT, V579, P236, DOI 10.1016/j.febslet.2004.11.084; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee E, 2002, MOL CELLS, V14, P9; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 2003, CURR PHARM DESIGN, V9, P531, DOI 10.2174/1381612033391469; Michiels C, 2001, IUBMB LIFE, V52, P49, DOI 10.1080/15216540252774766; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wallace EM, 2005, CURR TOP MED CHEM, V5, P215, DOI 10.2174/1568026053507723; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 1999, CANCER RES, V59, P5830	40	51	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3920	3929		10.1038/sj.onc.1210168	http://dx.doi.org/10.1038/sj.onc.1210168			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213817				2022-12-17	WOS:000247144500002
J	Chen, SY; Cai, C; Fisher, CJ; Zheng, Z; Omwancha, J; Hsieh, CL; Shemshedini, L				Chen, S-Y; Cai, C.; Fisher, C. J.; Zheng, Z.; Omwancha, J.; Hsieh, C-L; Shemshedini, L.			c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation	ONCOGENE			English	Article						androgen receptor; c-Jun; coactivation proliferation	TRANSCRIPTIONAL ACTIVITY; RESPONSE ELEMENT; SERINE-PROTEASE; AMINO-TERMINUS; TMPRSS2 GENE; EXPRESSION; PROGRESSION; ACTIVATION; LNCAP; DIMERIZATION	Androgens and the androgen receptor (AR) are involved in the growth and progression of prostate cancer. Our previous studies suggest that the proto-oncoprotein c-Jun is an AR coactivator that stimulates AR transactivation by mediating receptor dimerization and subsequent DNA binding. To study the physiological relevance of this c-Jun activity on AR, we have generated stable LNCaP cell lines expressing different levels of c-Jun. These cell lines exhibit a direct correlation between endogenous c-Jun levels and AR transcriptional activity and expression of endogenous androgen-regulated genes. Disruption by antisense RNA of endogenous c-Jun expression in LNCaP cells strongly compromises the androgen-dependent proliferation of these cells. In contrast, expression of a c-Jun mutant, which is fully active in coactivation of AR but deficient in AP-1 transactivation, significantly enhances androgen-dependent proliferation. This. nding indicates that the coactivation function of c-Jun is sufficient for regulating androgen-induced growth of LNCaP cells. c-Jun also enhances AR transactivtion in androgen-independent LNCaP cells, which closely mimic hormone-refractory prostate cancer cells in gene expression and growth behavior. Importantly, siRNA-mediated repression of endogenous c-Jun expression results in markedly reduced growth of these cells, strongly suggesting an important biological role for c-Jun in hormone-efractory prostate cancer.	Univ Toledo, Dept Sci Biol, Toledo, OH 43603 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Sci Biol, 2801,W Bancroft Ave, Toledo, OH 43603 USA.	lshemsh@utnet.utoledo.edu	CHEN, Shaoyong/ABF-3357-2021; Cai, Changmeng/AAE-6835-2020	Cai, Changmeng/0000-0002-8701-2586				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Acevedo ML, 2004, ESSAYS BIOCHEM, V40, P73, DOI 10.1042/bse0400073; Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Debes JD, 2002, CANCER RES, V62, P5632; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Haelens A, 2003, BIOCHEM J, V369, P141, DOI 10.1042/BJ20020912; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; Korkmaz CG, 2004, J ENDOCRINOL, V182, P377, DOI 10.1677/joe.0.1820377; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lin BY, 1999, CANCER RES, V59, P4180; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Linja MJ, 2004, J STEROID BIOCHEM, V92, P255, DOI 10.1016/j.jsbmb.2004.10.012; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUURMANS ALG, 1988, PROSTATE, V12, P55, DOI 10.1002/pros.2990120108; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Song LN, 2004, MOL ENDOCRINOL, V18, P70, DOI 10.1210/me.2003-0189; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tillman K, 1998, ENDOCRINE, V9, P193, DOI 10.1385/ENDO:9:2:193; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vaarala MH, 2001, INT J CANCER, V94, P705, DOI 10.1002/ijc.1526; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Zheng Z, 2006, J BIOL CHEM, V281, P4002, DOI 10.1074/jbc.M509260200; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	60	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7212	7223		10.1038/sj.onc.1209705	http://dx.doi.org/10.1038/sj.onc.1209705			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732317				2022-12-17	WOS:000242046900010
J	Lin, YT; Chen, Y; Wu, G; Lee, WH				Lin, Y-T; Chen, Y.; Wu, G.; Lee, W-H			Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control	ONCOGENE			English	Article						mitosis; kinetochores; spindle checkpoint; chromosome segregation and microtubule	MITOTIC CHECKPOINT; BUDDING YEAST; CELL-CYCLE; MICROTUBULE ATTACHMENT; MAMMALIAN-CELLS; NDC80 COMPLEX; MOLECULAR ANALYSIS; OUTER KINETOCHORE; DROSOPHILA ZW10; GENE-PRODUCT	Faithful chromosome segregation is essential for maintaining the genomic integrity, which requires coordination among chromosomes, kinetochores, centrosomes and spindles during mitosis. Previously, we discovered a novel coiled-coil protein, highly expressed in cancer 1 (Hec1), which is indispensable for this process. However, the precise underlying mechanism remains unclear. Here, we show that Hec1 directly interacts with human ZW10 interacting protein (Zwint-1), a binding partner of Zeste White 10 ( ZW10) that is required for chromosome motility and spindle checkpoint control. In mitotic cells, Hec1 transiently forms complexes with Zwint-1 and ZW10 in a temporal and spatial manner. Although the three proteins have variable cell cycle-dependent expression profiles, they can only be co-immunoprecipitated during M phase. Immunofluorescent study showed that Hec1 and Zwint-1 co-localize at kinetochores beginning at prophase and that ZW10 joins them later at prometaphase. Depletion of Hec1 impairs the recruitment of both Zwint-1 and ZW10 to kinetochores, while depletion of Zwint-1 abrogates the kinetochore localization of ZW10 but not Hec1. The results suggest that the localization of Hec1 at kinetochores is required for the sequential recruitment of Zwint-1 and ZW10. Disrupting this recruitment by inhibiting the expression of Hec1 or Zwint-1 causes chromosome missegregation, spindle checkpoint failure, and eventually cell death upon cytokinesis. Taken together, these results, at least in part, provide a molecular basis to explain how Hec1 plays a crucial role for spindle checkpoint control and faithful chromosome segregation.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX USA	University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu			NCI NIH HHS [CA 107568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Bharadwaj R, 2004, J BIOL CHEM, V279, P13076, DOI 10.1074/jbc.M310224200; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Emanuele MJ, 2005, MOL BIOL CELL, V16, P4882, DOI 10.1091/mbc.E05-03-0239; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; McEwen BF, 1998, CHROMOSOMA, V107, P366, DOI 10.1007/s004120050320; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikami Y, 2005, MOL CELL BIOL, V25, P1958, DOI 10.1128/MCB.25.5.1958-1970.2005; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Starr DA, 2000, J CELL SCI, V113, P1939; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang HM, 2004, J BIOL CHEM, V279, P54590, DOI 10.1074/jbc.M407588200; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Xiao J, 2001, J BIOL CHEM, V276, P6105, DOI 10.1074/jbc.M008893200; Zheng L, 1999, MOL CELL BIOL, V19, P5417; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	73	51	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6901	6914		10.1038/sj.onc.1209687	http://dx.doi.org/10.1038/sj.onc.1209687			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16732327				2022-12-17	WOS:000241732300001
J	Domchek, SM; Weber, BL				Domchek, S. M.; Weber, B. L.			Clinical management of BRCA1 and BRCA2 mutation carriers	ONCOGENE			English	Review						BRCA1; BRCA2; oophorectomy; breast cancer; ovarian cancer; management	BREAST-CANCER RISK; HORMONE-REPLACEMENT THERAPY; SURGICAL ADJUVANT BREAST; BILATERAL PROPHYLACTIC OOPHORECTOMY; REDUCING SALPINGO-OOPHORECTOMY; ORAL-CONTRACEPTIVE USE; OVARIAN-CANCER; POSTMENOPAUSAL WOMEN; INHERITED MUTATIONS; ENDOMETRIAL CANCER	The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.	Univ Penn, Abramson Canc Ctr, Canc Risk Evaluat Program, Philadelphia, PA 19104 USA; GlaxoSmithKline Inc, Philadelphia, PA USA	University of Pennsylvania; GlaxoSmithKline	Domchek, SM (corresponding author), Univ Penn, Abramson Canc Ctr, Canc Risk Evaluat Program, 3400 Spruce St, Philadelphia, PA 19104 USA.	susan.domchek@uphs.upenn.edu						Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andrieu N, 2006, JNCI-J NATL CANCER I, V98, P535, DOI 10.1093/jnci/djj132; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Aziz S, 2001, GYNECOL ONCOL, V80, P341, DOI 10.1006/gyno.2000.6095; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Carcangiu ML, 2004, INT J GYNECOL PATHOL, V23, P35, DOI 10.1097/01.pgp.0000101082.35393.84; Casey MJ, 2005, GYNECOL ONCOL, V97, P457, DOI 10.1016/j.ygyno.2005.01.039; Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310; Colgan TJ, 2002, GYNECOL ONCOL, V85, P397, DOI 10.1006/gyno.2002.6638; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; COMCHEK SM, 2006, LANCET ONCOL, V7, P223; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Eitan R, 2006, GYNECOL ONCOL, V102, P315, DOI 10.1016/j.ygyno.2005.12.021; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Friedman E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1387; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Haffty BG, 2002, LANCET, V359, P1471, DOI 10.1016/S0140-6736(02)08434-9; Hartmann LC, 2001, JNCI-J NATL CANCER I, V93, P1633, DOI 10.1093/jnci/93.21.1633; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Jernstrom H, 2004, JNCI-J NATL CANCER I, V96, P1094, DOI 10.1093/jnci/djh211; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kramer JL, 2005, J CLIN ONCOL, V23, P8629, DOI 10.1200/JCO.2005.02.9199; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lavie O, 2004, GYNECOL ONCOL, V92, P521, DOI 10.1016/j.ygyno.2003.11.009; Leach MO, 2005, LANCET, V365, P1769, DOI 10.1016/S0140-6736(05)66481-1; Lu KH, 2000, J CLIN ONCOL, V18, P2728, DOI 10.1200/JCO.2000.18.14.2728; McEwen AR, 2004, GYNECOL ONCOL, V92, P992, DOI 10.1016/j.ygyno.2003.12.003; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Milne RL, 2005, CANCER EPIDEM BIOMAR, V14, P350, DOI 10.1158/1055-9965.EPI-04-0376; Modan B, 2001, NEW ENGL J MED, V345, P235, DOI 10.1056/NEJM200107263450401; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Narod SA, 2006, LANCET ONCOL, V7, P402, DOI 10.1016/S1470-2045(06)70624-6; Pierce LJ, 2006, J CLIN ONCOL, V24, P2437, DOI 10.1200/JCO.2005.02.7888; Pierce LJ, 2000, J CLIN ONCOL, V18, P3360, DOI 10.1200/JCO.2000.18.19.3360; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; Powell CB, 2005, J CLIN ONCOL, V23, P127, DOI 10.1200/JCO.2005.04.109; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 2005, J CLIN ONCOL, V23, P7804, DOI 10.1200/JCO.2004.00.8151; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rutter JL, 2003, JNCI-J NATL CANCER I, V95, P1072, DOI 10.1093/jnci/95.14.1072; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; Schwartz MD, 2004, J CLIN ONCOL, V22, P1823, DOI 10.1200/JCO.2004.04.086; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; Whittemore AS, 2004, BRIT J CANCER, V91, P1911, DOI 10.1038/sj.bjc.6602239	66	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5825	5831		10.1038/sj.onc.1209881	http://dx.doi.org/10.1038/sj.onc.1209881			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998496				2022-12-17	WOS:000240765900002
J	Pazzaglia, S; Tanori, M; Mancuso, M; Gessi, M; Pasquali, E; Leonardi, S; Oliva, MA; Rebessi, S; Di Majo, V; Covelli, V; Giangaspero, F; Saran, A				Pazzaglia, S.; Tanori, M.; Mancuso, M.; Gessi, M.; Pasquali, E.; Leonardi, S.; Oliva, M. A.; Rebessi, S.; Di Majo, V.; Covelli, V.; Giangaspero, F.; Saran, A.			Two-hit model for progression of medulloblastoma preneoplasia in Patched heterozygous mice	ONCOGENE			English	Article						medulloblastoma; preneoplasia; Patched; hedgehog; ionizing radiation; LOH	IONIZING-RADIATION; KNOCKOUT MICE; LARGE DELETIONS; MOUSE MODEL; CELL-LINES; HPRT LOCUS; TUMORIGENESIS; GROWTH; CEREBELLUM; MUTATION	Inactivation of one Ptc1 allele predisposes humans and mice to spontaneous medulloblastoma development, and irradiation of newborn Ptc1 heterozygous mice results in dramatic increase of medulloblastoma incidence. While a role for loss of wild-type (wt) Ptc1 (LOH) in radiation-induced medulloblastomas from Ptc1(neo67/+) mice is well established, the importance of this event in spontaneous medulloblastomas is still unclear. Here, we demonstrate that biallelic Ptc1 loss plays a crucial role in spontaneous medulloblastomas, as shown by high rate of wt Ptc1 loss in spontaneous tumors. In addition, remarkable differences in chromosomal events involving the Ptc1 locus in spontaneous and radiation-induced medulloblastomas suggest distinct mechanisms for Ptc1 loss. To assess when, during tumorigenesis, Ptc1 loss occurs, we characterized cerebellar abnormalities that precede tumor appearance in Ptc1(neo67/+) mice. We show that inactivation of only one copy of Ptc1 is sufficient to give rise to abnormal cerebellar proliferations with different degree of altered cell morphology, but lacking potential to progress to neoplasia. Furthermore, we identify biallelic Ptc1 loss as the event causally related to the transition from the preneoplastic stage to full blown medulloblastoma. These results underscore the utility of the Ptc1(neo67/+) mouse model for studies on the mechanisms of medulloblastoma and for development of new therapeutic strategies.	ENEA, CR Casaccia, Biotechnol Unit, I-00060 Rome, Italy; Natl Neurol Inst C Besta, Div Neuropathol, Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; INM Neuromed, Isernia, Italy; ENEA, CR Casaccia, Radiat Protect Unit, I-00060 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Italian National Agency New Technical Energy & Sustainable Economics Development; IRCCS Istituto Neurologico Besta; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Neuromed; Italian National Agency New Technical Energy & Sustainable Economics Development; Sapienza University Rome	Pazzaglia, S (corresponding author), ENEA, CR Casaccia, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Giangaspero, Felice/AAH-9253-2020; Oliva, Maria Antonietta/AAE-9115-2020; Giangaspero, Felice/Z-4961-2019; Gessi, Marco/K-2572-2018	Giangaspero, Felice/0000-0001-5382-2380; Oliva, Maria Antonietta/0000-0003-3460-696X; Giangaspero, Felice/0000-0001-5382-2380; Saran, Anna/0000-0002-5587-064X				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Chintagumpala M, 2001, CURR OPIN ONCOL, V13, P154, DOI 10.1097/00001622-200105000-00004; Corcoran RB, 2001, J NEURO-ONCOL, V53, P307, DOI 10.1023/A:1012260318979; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Eberhart CG, 2003, BRAIN PATHOL, V13, P376; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HUTCHINSON F, 1995, J MOL BIOL, V254, P372, DOI 10.1006/jmbi.1995.0624; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Kinzler KW, 1997, NATURE, V386, P763; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; NELSON SL, 1995, RADIAT RES, V141, P2, DOI 10.2307/3579083; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Pazzaglia S, 2006, CANCER LETT, V234, P124, DOI 10.1016/j.canlet.2005.03.047; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2000, MOL CARCINOGEN, V27, P219, DOI 10.1002/(SICI)1098-2744(200003)27:3<219::AID-MC9>3.0.CO;2-S; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Ponomareva ON, 2002, CANCER RES, V62, P1518; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Turker MS, 1997, MUTAT RES-FUND MOL M, V374, P201, DOI 10.1016/S0027-5107(96)00230-8; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wetmore C, 2000, CANCER RES, V60, P2239; Yamada Y, 1996, RADIAT RES, V145, P481, DOI 10.2307/3579070; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	30	51	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5575	5580		10.1038/sj.onc.1209544	http://dx.doi.org/10.1038/sj.onc.1209544			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16636673				2022-12-17	WOS:000240370400011
J	Geserick, C; Tejera, A; Gonzalez-Suarez, E; Klatt, P; Blasco, MA				Geserick, C.; Tejera, A.; Gonzalez-Suarez, E.; Klatt, P.; Blasco, M. A.			Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-beta signaling	ONCOGENE			English	Article						telomerase; immortalization; proliferation; gene expression profiling; transforming growth factor-beta	KRUPPEL-LIKE FACTOR-4; CATALYTIC SUBUNIT; GENE-EXPRESSION; DOWN-REGULATION; LIFE-SPAN; DIFFERENTIAL REGULATION; TRANSGENIC MICE; CANCER; IDENTIFICATION; SENESCENCE	Here, we show that ectopic expression of the catalytic subunit of mouse telomerase (mTert) confers a growth advantage to primary murine embryonic fibroblasts (MEFs), which have very long telomeres, as well as facilitates their spontaneous immortalization and increases their colony-forming capacity upon activation of oncogenes. We demonstrate that these telomere length-independent growth-promoting effects of mTert overexpression require catalytically active mTert, as well as the formation of mTert/Terc complexes. The gene expression profile of mTert-overexpressing MEFs indicates that telomerase enhances growth in these cells through the repression of growth-inhibiting genes of the transforming growth factor-beta (TGF-beta) signaling network. We functionally validate this result by showing that mTert abrogates the growth-inhibitory effect of TGF-beta in MEFs, thus demonstrating that telomerase increments the proliferative potential of primary mouse embryonic fibroblasts by targeting the TGF-beta pathway.	Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, Melchor Fernandez Almagro,3, E-28029 Madrid, Spain.	mblasco@cnio.es	Gonzalez-Suarez, Eva/L-6298-2014; Tejera, Agueda M./AAU-2000-2021; Blasco, Maria A./M-1694-2014; Tejera, Agueda/L-1946-2015; Tejera, Agueda/Z-1938-2019	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Blasco, Maria A./0000-0002-4211-233X; Tejera, Agueda M/0000-0002-6703-9466				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Cayuela ML, 2005, EMBO REP, V6, P268, DOI 10.1038/sj.embor.7400359; Chen ZY, 2005, MOL PHARMACOL, V68, P1203, DOI 10.1124/mol.105.014944; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Gonzalez-Suarez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Keeton AB, 2003, ENDOCRINOLOGY, V144, P5402, DOI 10.1210/en.2003-0592; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kopp JB, 1996, LAB INVEST, V74, P991; Krag S, 2000, LAB INVEST, V80, P1855, DOI 10.1038/labinvest.3780196; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liao L, 2005, BIOCHEM BIOPH RES CO, V336, P854, DOI 10.1016/j.bbrc.2005.08.180; Lim JY, 2005, J MOL CELL CARDIOL, V39, P627, DOI 10.1016/j.yjmcc.2005.06.016; LIM RW, 1995, BBA-MOL CELL RES, V1266, P91, DOI 10.1016/0167-4889(94)00226-5; Liu JH, 2003, AM J PHYSIOL-LUNG C, V285, pL1106, DOI 10.1152/ajplung.00180.2003; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Mulsow JJW, 2005, ANN SURG, V242, P880, DOI 10.1097/01.sla.0000189606.58343.cd; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Ryu MS, 2004, EXP CELL RES, V299, P159, DOI 10.1016/j.yexcr.2004.05.014; Sachsinger J, 2001, CANCER RES, V61, P5580; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Simmen RCM, 2004, J BIOL CHEM, V279, P29286, DOI 10.1074/jbc.M403139200; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Sun LH, 2003, MOL BIOL REP, V30, P249, DOI 10.1023/A:1026370726763; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wang T, 2005, J BIOL CHEM, V280, P12593, DOI 10.1074/jbc.M410982200; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon YS, 2005, ONCOGENE, V24, P1895, DOI 10.1038/sj.onc.1208262; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	74	51	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4310	4319		10.1038/sj.onc.1209465	http://dx.doi.org/10.1038/sj.onc.1209465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501597				2022-12-17	WOS:000239240100006
J	Sawai, H; Okada, Y; Funahashi, H; Matsuo, Y; Takahashi, H; Takeyama, H; Manabe, T				Sawai, H.; Okada, Y.; Funahashi, H.; Matsuo, Y.; Takahashi, H.; Takeyama, H.; Manabe, T.			Integrin-linked kinase activity is associated with interleukin-1a-induced progressive behavior of pancreatic cancer and poor patient survival	ONCOGENE			English	Article						integrins; integrin-linked kinase; interleukin; pancreatic cancer	EXPRESSION; APOPTOSIS; ILK; BETA-1-INTEGRIN; ADENOCARCINOMA; ACTIVATION; INHIBITION; GROWTH; PHOSPHORYLATION; MIGRATION	Cancer cell adhesion and invasion into extracellular matrix are regulated by integrin-linked kinase ( ILK) activity in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner. In this study, we demonstrated that ILK and beta(1)-integrin play important roles in interleukin (IL)-1 alpha-induced enhancement of adhesion and invasion of pancreatic cancer cells through p38 mitogen-activated protein kinase ( MAPK) signaling pathway and activator protein-1 (AP-1) activation. Alteration of ILK kinase activity controlled IL-1 alpha-induced p38 MAPK phosphorylation and its downstream AP-1 activation with subsequent regulation of pancreatic cancer cell adhesion and invasion. Overexpressed ILK enhances the IL-1 alpha-induced p38 MAPK phosphorylation more strongly through glycogen synthase kinase 3 (GSK-3) activation, and subsequently induces AP-1 activation, which promotes aggressive capabilities of pancreatic cancer cells. In contrast, knockdown of ILK kinase activity inhibits the IL-1 alpha-induced activation of MAPK/AP-1 pathway via inhibition of GSK-3 phosphorylation. In immunohistochemical analysis, statistically significant association between strong expression of ILK and poor prognosis of pancreatic cancer patients were observed, and strong expression of ILK in cancerous tissues can be a significant prognostic indicator of pancreatic cancer patients. Our results suggest that ILK is involved with aggressive capability in pancreatic cancer and that these regulations can be helpful to understand biological processes for a better translational treatment for pancreatic cancer patients.	Nagoya City Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Sawai, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.	cb8h-swi@asahi-net.or.jp	Sawai, Hirozumi/AAZ-1639-2020	Sawai, Hirozumi/0000-0002-2534-5959				Ahmed N, 2005, BRIT J CANCER, V92, P1475, DOI 10.1038/sj.bjc.6602495; Ahmed N, 2004, CLIN CANCER RES, V10, P2415, DOI 10.1158/1078-0432.CCR-03-0042; Buda A, 2003, GUT, V52, P729, DOI 10.1136/gut.52.5.729; Chen P, 2004, INT J CANCER, V111, P881, DOI 10.1002/ijc.20340; Chua YJ, 2005, J CLIN ONCOL, V23, P4532, DOI 10.1200/JCO.2005.17.954; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Park S, 2004, J CELL BIOCHEM, V91, P973, DOI 10.1002/jcb.10768; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Sawai H, 2003, DIGEST DIS SCI, V48, P1241, DOI 10.1023/A:1024276821731; Sawai H, 2003, ONCOLOGY-BASEL, V65, P167, DOI 10.1159/000072343; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Stocken DD, 2005, BRIT J CANCER, V92, P1372, DOI 10.1038/sj.bjc.6602513; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; van Golen CM, 2003, ONCOGENE, V22, P2664, DOI 10.1038/sj.onc.1206362; Vellon L, 2005, ONCOGENE, V24, P3759, DOI 10.1038/sj.onc.1208452; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025	40	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3237	3246		10.1038/sj.onc.1209356	http://dx.doi.org/10.1038/sj.onc.1209356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407822				2022-12-17	WOS:000237951200002
J	Ahsan, MK; Masutani, H; Yamaguchi, Y; Kim, YC; Nosaka, K; Matsuoka, M; Nishinaka, Y; Maeda, M; Yodoi, J				Ahsan, MK; Masutani, H; Yamaguchi, Y; Kim, YC; Nosaka, K; Matsuoka, M; Nishinaka, Y; Maeda, M; Yodoi, J			Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2	ONCOGENE			English	Article						HTLV-I; ATL; TBP-2/ VDUP1; DNA-methylation; histone deacetylation; interleukin-2	UP-REGULATED PROTEIN-1; VIRUS TYPE-I; LEUKEMIA; CANCER; GROWTH; LINES; D-3; IDENTIFICATION; TRANSFORMATION; METHYLATION	The transition from interleukin-2 (IL-2)-dependent to IL-2-independent growth is considered one of the key steps in the transformation of human T-cell leukemia virus type-I (HTLV-I)-infected T cells. The expression of thioredoxin-binding protein-2 (TBP-2) is lost during the transition of HTLV-I-infected T-cell lines. Here, we analysed the mechanism of loss of TBP-2 expression and the role of TBP-2 in IL-2-dependent growth in the in vitro model to investigate multistep transformation of HTLV-I. CpGs in the TBP-2 gene are methylated in IL-2-independent but not in IL-2-dependent cells. Sequential treatment with 5-aza-2'-deoxycytidine and a histone deacetylase inhibitor augmented histone acetylation and TBP-2 expression, suggesting that loss of TBP-2 expression is due to DNA methylation and histone deacetylation. In IL-2-dependent cells, a basal level of TBP-2 expression was maintained by IL-2 associated with cellular growth, whereas TBP-2 expression was upregulated on deprivation of IL-2 associated with growth suppression. Overexpression of TBP-2 in IL-2-independent cells suppressed the growth and partially restored responsiveness to IL-2. Knockdown of TBP-2 caused the IL-2-dependent cells to show partial growth without IL- 2. These results suggested that epigenetic silencing of the TBP-2 gene results in a loss of responsiveness to IL- 2, contributing to uncontrolled IL- 2- independent growth in HTLV-I-infected T-cell lines.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Res Ctr Acquired Immunofef Syndrome, Sakyo Ku, Kyoto, Japan	Kyoto University; Kyoto University	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827; Matsuoka, Masao/0000-0002-0473-754X				Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Maeda M, 1992, Hum Cell, V5, P70; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MAKINO S, 1992, IMMUNOLOGY, V76, P578; Masutani H, 2002, METHOD ENZYMOL, V347, P279; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Nishinaka Y, 2004, CANCER RES, V64, P1287, DOI 10.1158/0008-5472.CAN-03-0908; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nosaka K, 2000, CANCER RES, V60, P1043; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Satoh A, 2003, CANCER RES, V63, P8606; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; TAGAYA Y, 1989, EMBO J, V13, P2244; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; YODOI J, 1974, NEW ENGL J MED, V290, P572; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	29	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2181	2191		10.1038/sj.onc.1209256	http://dx.doi.org/10.1038/sj.onc.1209256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16314839				2022-12-17	WOS:000236581200005
J	Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP				Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP			Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; transgenic mouse models; NPM/RAR alpha; PML/RAR alpha; PLZF/RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; ACUTE MYELOGENOUS LEUKEMIA; CYTOPLASMIC NUCLEOPHOSMIN; PROTEINS; GENE; INTERACTS; MODELS; APL	Recurrent chromosomal translocations involving the RAR alpha locus on chromosome 17 are the hallmark of acute promyelocytic leukemia (APL). The RARa gene fuses to variable partners (PML, PLZF, NPM, NuMA and STAT5B: X genes) leading to the expression of APL-specific fusion proteins with identical RARa moieties. To analyse whether the variable X moiety could affect the activity of the fusion protein in vivo, we generated and characterized, on a comparative basis, NPM/RAR alpha transgenic mice ( TM) in which the fusion gene is expressed under the control of a human Cathepsin G ( hCG) minigene. We compared the features of the leukemia observed in these TM with those in hCG-PML/RAR alpha and hCG-PLZF/RAR alpha TM. In all three transgenic models, leukemia developed after a variably long latency, with variable penetrance. However, the three leukemias displayed distinct cytomorphological features. hCG-NPM/RAR alpha leukemic cells resembled monoblasts. This phenotype contrasts with what was observed in the hCG-PML/RAR alpha TM model in which the leukemic phase was characterized by the proliferation of promyelocytic blasts. Similarly, hCG-PLZF/RAR alpha TM displayed a different phenotype where terminally differentiated myeloid cells predominated. Importantly, the NPM/RAR alpha oncoprotein was found to localize in the nucleolus, unlike PML/RAR alpha and PLZF/RAR alpha, thus possibly interfering with the normal function of NPM. Similarly to what was observed in human APL patients, we found that NPM/RAR alpha and PML/RAR alpha, but not PLZF/RAR alpha leukemia, was responsive to all-trans retinoic acid ( ATRA) or As2O3 treatments. Taken together, our results underscore the critical relevance of the X moiety in dictating the biology of the disease and the activity of the APL fusion oncoprotein.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pathol, Mem Sloan Kettering Inst, New York, NY 10021 USA; Univ Sao Paulo, Div Hematol, Dept Internal Med, Med Sch Ribeirao Preto, Sao Paulo, Brazil; Columbia Univ, Dept Pathol, New York, NY USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA	Memorial Sloan Kettering Cancer Center; Universidade de Sao Paulo; Columbia University; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pathol, Mem Sloan Kettering Inst, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Rego, Eduardo M/A-1058-2012; Rego, Eduardo/AFS-7973-2022; Rego, Eduardo M./Y-5572-2019; Cattoretti, Giorgio/H-2340-2011	Rego, Eduardo M/0000-0003-1567-4086; Rego, Eduardo/0000-0003-1567-4086; Rego, Eduardo M./0000-0003-1567-4086; Kogan, Scott/0000-0002-2395-8479; Cattoretti, Giorgio/0000-0003-3799-3221; TRIBIOLI, CARLA/0000-0003-2544-476X	NATIONAL CANCER INSTITUTE [R01CA074031] Funding Source: NIH RePORTER; NCI NIH HHS [CA-74031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; BRUNNING RD, 2001, PATHOLOGY GENETICS T, P75; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Degos L, 2003, BRIT J HAEMATOL, V122, P539, DOI 10.1046/j.1365-2141.2003.04460.x; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2005, NEW ENGL J MED, V352, P291, DOI 10.1056/NEJMe048337; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEUSEL JW, 1993, BLOOD, V81, P1614; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Redner RL, 2000, BLOOD, V95, P2683; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Sainty D, 2000, BLOOD, V96, P1287; SIRULNIK A, 2003, BEST PRACT RES CLIN, V17, P71; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	26	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1974	1979		10.1038/sj.onc.1209216	http://dx.doi.org/10.1038/sj.onc.1209216			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16331271				2022-12-17	WOS:000236224800014
J	Yang, F; Foekens, JA; Yu, J; Sieuwerts, AM; Timmermans, M; Klijn, JGM; Atkins, D; Wang, Y; Jiang, Y				Yang, F; Foekens, JA; Yu, J; Sieuwerts, AM; Timmermans, M; Klijn, JGM; Atkins, D; Wang, Y; Jiang, Y			Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways	ONCOGENE			English	Article						breast tumors; laser microdissection; DNA microarray; gene profiling; estrogen receptor	GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; EXPRESSION PROFILES; CANCER CELLS; CAPTURE MICRODISSECTION; CDNA MICROARRAY; MESSENGER-RNA; EPH RECEPTORS; P-CADHERIN; IDENTIFICATION	About 70-80% of breast cancers express estrogen receptor alpha (ER-alpha), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size, and histological grade, ER status is considered as one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. To investigate genes and pathways that are associated with ER status and epithelial cells in breast tumor, we applied laser capture microdissection (LCM) technology to capture epithelial tumor cells from 28 lymph node-negative breast tumor samples, in which 17 patients had ER-alpha + tumors, and 11 patients have ER-alpha- tumors. Gene expression profiles were analysed on Affymetrix Hu133A GeneChip. Meanwhile, gene profiles using total RNA isolated from bulk tumors of the same 28 patients were also generated. In total, 146 ;genes and 112 genes with significant P-value and having significant differential expression between ER-alpha + and ER-alpha- tumors were identified from the LCM data set and bulk tissue data set, respectively. A total of 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathways may play roles related to ER. The gene pro. ling with LCM-captured tumor cells provides a unique approach to study epithelial tumor cells and to gain an insight into signaling pathways associated with ER.	Veridex LLC, Johnson & Johnson Co, San Diego, CA 92121 USA; Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands	Johnson & Johnson; Johnson & Johnson USA; Erasmus University Rotterdam; Erasmus MC	Jiang, Y (corresponding author), Veridex LLC, Johnson & Johnson Co, 3210 Merryfield Row, San Diego, CA 92121 USA.	jjiang2@vrxus.jnj.com						Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FOEKENS JA, 1989, CANCER RES, V49, P5823; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Gruvberger S, 2001, CANCER RES, V61, P5979; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Kamme F, 2004, METH MOLEC MED, P215; Khoo C, 1997, PROTEIN EXPRES PURIF, V9, P379, DOI 10.1006/prep.1996.0709; Kim H, 2001, BIOCHEM SOC T, V29, P216, DOI 10.1042/BST0290216; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Luzzi V, 2003, J MOL DIAGN, V5, P9, DOI 10.1016/S1525-1578(10)60445-X; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Malbert-Colas L, 2003, PFLUG ARCH EUR J PHY, V447, P35, DOI 10.1007/s00424-003-1152-6; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Matsui H, 2003, ANTICANCER RES, V23, P195; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Mokbel K, 2003, CURR MED RES OPIN, V19, P683, DOI 10.1185/030079903125002397; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Nishidate T, 2004, INT J ONCOL, V25, P797; Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795; Parl F.F., 2000, ESTROGENS ESTROGEN R; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polacek DC, 2003, PHYSIOL GENOMICS, V13, P147, DOI 10.1152/physiolgenomics.00173.2002; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Seth A, 2003, ANTICANCER RES, V23, P2043; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Sun JM, 2005, EXP CELL RES, V302, P96, DOI 10.1016/j.yexcr.2004.08.015; Tamini Y, 2004, INVEST OPHTH VIS SCI, V45, P3904, DOI 10.1167/iovs.04-0628; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Weisz A, 2004, J CELL PHYSIOL, V200, P440, DOI 10.1002/jcp.20039; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wu KM, 2003, J BIOL CHEM, V278, P51673, DOI 10.1074/jbc.M310021200; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yim SH, 2003, TOXICOL PATHOL, V31, P295, DOI 10.1080/01926230309753	47	51	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1413	1419		10.1038/sj.onc.1209165	http://dx.doi.org/10.1038/sj.onc.1209165			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16261164				2022-12-17	WOS:000235708200015
J	D'Costa, AM; Robinson, JK; Maududi, T; Chaturvedi, V; Nickoloff, BJ; Denning, MF				D'Costa, AM; Robinson, JK; Maududi, T; Chaturvedi, V; Nickoloff, BJ; Denning, MF			The proapoptotic tumor suppressor protein kinase C-delta is lost in human squamous cell carcinomas	ONCOGENE			English	Article						protein kinase C-delta; skin cancer; squamous cell carcinoma; tumor suppressor gene	GROWTH-FACTOR RECEPTOR; RADIATION-INDUCED APOPTOSIS; INDUCED CUTANEOUS DAMAGE; PKC-DELTA; HUMAN KERATINOCYTES; TRANSGENIC MICE; RAS ONCOGENE; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; PHORBOL ESTER	Protein kinase C (PKC)-delta is proapoptotic in human keratinocytes, and is downregulated or inactivated in keratinocytes expressing the activated Ha-ras oncogene, making it a candidate tumor suppressor gene for squamous cell carcinoma (SCC). We evaluated the significance of PKC-delta loss in transformed human keratinocytes using tumorigenic HaCaT Ras II-4 cells that have significantly reduced PKC-delta levels. Re-expression of PKC-delta by retro virus transduction caused an increase in apoptosis and growth inhibition in culture. The growth inhibition induced by PKC-delta could be partially reversed by Bcl-(xL) expression, indicating that apoptosis was in part responsible for PKC-delta-induced growth inhibition. PKC-delta re-expression suppressed the tumor-igenicity of HaCaT Ras II-4 cells in nude mice (P < 0.05), and the small tumors that did form contained elevated levels of activated caspase-3, indicating increased apoptosis. In addition, we found that 29% (12/42) of human Bowen's disease ( squamous carcinoma in situ) or SCC cases had absent or reduced PKC-delta when compared to the surrounding normal epidermis. These results indicate that PKC-delta inhibits transformed keratinocyte growth by inducing apoptosis, and that PKC-delta may function as a tumor suppressor in human SCCs where its loss in cells harboring activated ras could provide a growth advantage by conferring resistance to apoptosis.	Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Skin Canc Res Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Skin Canc Res Program, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Skin Canc Res Program, 2160 S 1st Ave,Room 304, Maywood, IL 60153 USA.	mdennin@lumc.edu			NCI NIH HHS [CA83784] Funding Source: Medline; NIAMS NIH HHS [AR47814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashton KJ, 2003, ARCH DERMATOL, V139, P876, DOI 10.1001/archderm.139.7.876; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BOUKAMP P, 1990, CANCER RES, V50, P2840; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURNS FJ, 1976, CANCER RES, V36, P1422; Cataldi A, 2002, J CELL BIOCHEM, V86, P553, DOI 10.1002/jcb.10251; Chida K, 2003, CANCER RES, V63, P2404; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; Dlugosz AA, 1997, CANCER RES, V57, P3180; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; Dobler M, 1999, INT J ONCOL, V14, P571; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Einspahr Janine G., 1999, Neoplasia (New York), V1, P468, DOI 10.1038/sj.neo.7900061; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; Frey MR, 2001, BIOCHEM PHARMACOL, V61, P1093, DOI 10.1016/S0006-2952(01)00596-2; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; Hansen LA, 2000, CANCER RES, V60, P3328; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Jansen AP, 2001, CANCER RES, V61, P808; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LEE E, 1992, CARCINOGENESIS, V13, P2367, DOI 10.1093/carcin/13.12.2367; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu JH, 2003, CANCER RES, V63, P1153; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; Papp H, 2004, CELL MOL LIFE SCI, V61, P1095, DOI 10.1007/s00018-004-4014-2; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wheeler DL, 2005, PHOTOCHEM PHOTOBIOL, V81, P9, DOI 10.1562/2004-08-12-RA-271.1; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Wheeler DL, 2003, CANCER RES, V63, P6547; Wheeler DL, 2002, ONCOGENE, V21, P3620, DOI 10.1038/sj.onc.1205451; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	64	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					378	386		10.1038/sj.onc.1209065	http://dx.doi.org/10.1038/sj.onc.1209065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158048				2022-12-17	WOS:000234714100006
J	Lu, Z; Luo, RZ; Peng, H; Huang, M; Nishmoto, A; Hunt, KK; Helin, K; Liao, WSL; Yu, Y				Lu, Z; Luo, RZ; Peng, H; Huang, M; Nishmoto, A; Hunt, KK; Helin, K; Liao, WSL; Yu, Y			E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer	ONCOGENE			English	Article						ARHI; tumor suppressor gene; transcriptional regulation; E2F; HDAC; breast cancer	CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTORS; HISTONE H3; IN-VIVO; E2F; EXPRESSION; CARCINOGENESIS; REPLICATION; METHYLATION; REPRESSION	ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor - trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F - HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.	UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA; European Inst Oncol, Dept Expt Oncol, Milan, Italy; Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; IRCCS European Institute of Oncology (IEO); University of Copenhagen; University of Texas System; UTMD Anderson Cancer Center	Yu, Y (corresponding author), UT MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 354, Houston, TX 77030 USA.	yyu@mdanderson.org	Lu, Zhen/E-5221-2015; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097	NCI NIH HHS [CA 64602, CA 80957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; Hisatomi H, 2002, ONCOLOGY-BASEL, V62, P136, DOI 10.1159/000048259; Lu Z H, 2001, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V23, P324; Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; Shi Zonggao, 2002, Zhonghua Zhongliu Zazhi, V24, P475; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang L, 2003, CLIN CANCER RES, V9, P3660; Weber F, 2005, J CLIN ENDOCR METAB, V90, P1149, DOI 10.1210/jc.2004-1447; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Yuan JH, 2003, CANCER RES, V63, P4174; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	27	51	51	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					230	239		10.1038/sj.onc.1209025	http://dx.doi.org/10.1038/sj.onc.1209025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158053				2022-12-17	WOS:000234583600007
J	Yu, QY; Ciemerych, MA; Sicinski, P				Yu, QY; Ciemerych, MA; Sicinski, P			Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins	ONCOGENE			English	Article						D-cyclins; oncogenic transformation; Ras; Myc	TRANSCRIPTIONAL INDUCTION; EXPRESSION; GENE; TRANSFORMATION; KINASE; PATHWAYS; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; SEQUESTRATION	D-type cyclins serve as cell cycle recipients of several oncogenic pathways. The specific sequences of the promoters of the cyclin D genes are thought to render particular D-cyclins responsive to specific oncogenic pathways. For instance, the Ras oncogene was postulated to signal through cyclin D1, while Myc can impact the cell cycle machinery by transcriptionally upregulating cyclin D2. In the current study we engineered mouse fibroblasts to express only cyclin D1, only D2, or only D3. These 'single-cyclin' cells allowed us to rigorously test the ability of cyclin D1, D2, or D3, when expressed on their own, to serve as recipients of the Ras- and Myc-driven oncogenic pathways. We found that each of the D-cyclins was sufficient to drive oncogenic proliferation of mouse fibroblasts. This, together with our recent observations that cells lacking all three D-cyclins show greatly reduced susceptibility to the oncogenic action of Ras and Myc, reveals that the Ras and Myc oncogenes can impact the core cell cycle machinery through all three D-cyclins.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Cell Biol, Beijing 100034, Peoples R China; Univ Warsaw, Inst Zool, Dept Embryol, PL-02089 Warsaw, Poland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Peking University; University of Warsaw	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	peter_sicinski@dfci.harvard.edu		Ciemerych, Maria A./0000-0003-0387-4179	NCI NIH HHS [R01 CA83688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083688] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002-0356; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Terada Y, 2003, J AM SOC NEPHROL, V14, P1223, DOI 10.1097/01.ASN.0000060577.94532.06; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Yang M, 1998, BIOCHEM MOL BIOL INT, V44, P51; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	43	51	52	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7114	7119		10.1038/sj.onc.1208853	http://dx.doi.org/10.1038/sj.onc.1208853			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16103884				2022-12-17	WOS:000232833200013
J	Chien, J; Staub, J; Avula, R; Zhang, HY; Liu, WG; Hartmann, LC; Kaufmann, SH; Smith, DI; Shridhar, V				Chien, J; Staub, J; Avula, R; Zhang, HY; Liu, WG; Hartmann, LC; Kaufmann, SH; Smith, DI; Shridhar, V			Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; methylation; tumor suppressor; apoptosis; proliferation	DNA METHYLATION; TUMOR-SUPPRESSOR; CARCINOMA CELLS; X-CHROMOSOME; EARLY-STAGE; EXPRESSION; GENE; PROTEIN; DIFFERENTIATION; IDENTIFICATION	Epigenetic silencing by hypermethylation of CpGs represents a mechanism of inactivation of tumor suppressors. Here we report on the cloning of a novel candidate tumor suppressor gene TCEAL7 inactivated by methylation in ovarian cancer. TCEAL codes for a 1.35 kb transcript that was previously reported to be downregulated in ovarian cancer by cDNA microarray and suppression subtraction cDNA (SSH) analyses. This report focuses on the elucidation of mechanisms associated with TCEAL7 downregulation. Expression of TCEAL7 is downregulated in a majority of ovarian tumors and cancer cell lines but induced by 5-aza-2'- deoxycytidine treatment in a dose-dependant manner, implicating methylation as a mechanism of TCEAL7 inactivation. Sequence analyses of bisufite-modified genomic DNA from somatic cell hybrids with either the active or the inactive human X chromosome reveal that TCEAL7 is subjected to X chromosome inactivation. Loss of TCEAL7 expression in primary tumors and cell lines correlates with methylation of a CpG site within the promoter. In vitro methylation of the CpG site suppresses promoter activity whereas selective demethylation of the SmaI site attenuates the suppression. Finally, re-expression of TCEAL7 in cancer cell lines induces cell death and reduces colony formation effciency. These data implicate TCEAL7 as a cell death regulatory protein that is frequently inactivated in ovarian cancers and suggest that it may function as a tumor suppressor.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Chien, Jeremy/AID-8939-2022	Kaufmann, Scott/0000-0002-4900-7145; Chien, Jeremy/0000-0003-4744-8374				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brown AL, 1999, HUM MOL GENET, V8, P611, DOI 10.1093/hmg/8.4.611; Brown CJ, 1997, AM J HUM GENET, V61, P5, DOI 10.1086/513914; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Deng DJ, 2003, WORLD J GASTROENTERO, V9, P26, DOI 10.3748/wjg.v9.i1.26; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 2002, SCIENCE, V297, P1807; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Hatakeyama C, 2004, CLIN GENET, V66, P327, DOI 10.1111/j.1399-0004.2004.00310.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kleymenova EV, 1998, ONCOGENE, V16, P713, DOI 10.1038/sj.onc.1201583; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Mukai J, 2002, J BIOL CHEM, V277, P13973, DOI 10.1074/jbc.M106342200; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Persengiev SP, 1997, NEUROREPORT, V8, P2091, DOI 10.1097/00001756-199707070-00001; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; Saitoh F, 1995, ANTICANCER RES, V15, P2137; Shridhar V, 2001, CANCER RES, V61, P4258; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Song SH, 2001, CANCER RES, V61, P4628; Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Williams JW, 2002, MOL REPROD DEV, V61, P281, DOI 10.1002/mrd.10100; Yang QS, 2002, BIOCHEM GENET, V40, P1, DOI 10.1023/A:1014565320998; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	38	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5089	5100		10.1038/sj.onc.1208700	http://dx.doi.org/10.1038/sj.onc.1208700			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870691				2022-12-17	WOS:000230816900008
J	Demidenko, ZN; Rapisarda, A; Garayoa, M; Giannakakou, P; Melillo, G; Blagosklonny, MV				Demidenko, ZN; Rapisarda, A; Garayoa, M; Giannakakou, P; Melillo, G; Blagosklonny, MV			Accumulation of hypoxia-inducible factor-1 alpha is limited by transcription-dependent depletion	ONCOGENE			English	Article						HIF-1; hypoxia; p53; the proteasome; degradation	TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU PROTEIN; PROLYL HYDROXYLASES; TOPOISOMERASE-I; HIF-ALPHA; HIF-1-ALPHA; OXYGEN; P53; INHIBITION; PATHWAY	In the presence of oxygen and iron, hypoxia- inducible factor (HIF-1 alpha) is rapidly degraded via the prolyl hydroxylases (PHD)/VHL pathways. Given striking similarities between p53 and HIF-1 alpha regulation, we previously suggested that HIF-1 transcriptionally initiates its own degradation and therefore inhibitors of transcription must induce HIF-1 alpha. Under normoxia, while inducing p53, inhibitors of transcription did not induce HIF-1 alpha. Under hypoxia or low iron (DFX), inhibitors of transcription dramatically super- induced HIF-1 alpha. Removal of inhibitors resulted in outburst of the HIF-1-dependent transcription followed by depletion of HIF-1 alpha. Although hypoxia/ DFX induced PHD3, we excluded the PHD/VHL pathway in the regulation of HIF-1 alpha under hypoxia/DFX. The transcription-dependent degradation of HIF-1 alpha under hypoxia occurs via the proteasome and is accelerated by protein acetylation. Thus, HIF-1 alpha is regulated by two distinct mechanisms. Under normoxia, HIF-1 alpha is degraded via the classic PHD/VHL pathway, is expressed at low levels and therefore does not activate the feedback loop. But under hypoxia, HIF-1 alpha accumulates and transcriptionally activates its own degradation that is independent from the PHD/VHL pathway.	New York Med Coll, Brander Canc Res Inst, Valhalla, NY USA; SAID Frederick Inc, NCI, Tumor Hypoxia Lab, Frederick, MD USA; Univ Navarra, Fac Med & Ciencias, Dept Histol & Anat Patol, Navarra, Spain; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	New York Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Navarra; Emory University	Blagosklonny, MV (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	Blagosklonny@hotmail.com	Garayoa, Mercedes/O-6039-2017	Garayoa, Mercedes/0000-0003-2194-2841; Giannakakou, Paraskevi/0000-0001-7378-262X				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; de Azevedo WF, 2002, BIOCHEM BIOPH RES CO, V293, P566; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Haupt Y, 2004, CELL CYCLE, V3, P884; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin SK, 2004, MOL PHARMACOL, V66, P612; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Rapisarda A, 2004, CELL CYCLE, V3, P172; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Salnikow K, 2000, CANCER RES, V60, P5630; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Turcotte S, 2004, AM J PHYSIOL-RENAL, V286, pF338, DOI 10.1152/ajprenal.00254.2003; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	42	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4829	4838		10.1038/sj.onc.1208636	http://dx.doi.org/10.1038/sj.onc.1208636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897903				2022-12-17	WOS:000230477900010
J	Busson, M; Carazo, A; Seyer, P; Grandemange, P; Casas, F; Pessemesse, L; Rouault, JP; Wrutniak-Cabello, C; Cabello, G				Busson, M; Carazo, A; Seyer, P; Grandemange, P; Casas, F; Pessemesse, L; Rouault, JP; Wrutniak-Cabello, C; Cabello, G			Coactivation of nuclear receptors and myogenic factors induces the major BTG1 influence on muscle differentiation	ONCOGENE			English	Article						BTG1; coactivator; myoblast; myogenic factors; nuclear receptors	THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL ACTIVATION; PROTEIN METHYLTRANSFERASE; MYOBLAST DIFFERENTIATION; NERVOUS-SYSTEM; RETINOIC ACID; TRIIODOTHYRONINE; FAMILY; GENE; COMPONENT	The btg1 (B-cell translocation gene 1) gene coding sequence was isolated from a translocation break point in a case of B-cell chronic lymphocytic leukaemia. We have already shown that BTG1, considered as an antiproliferative protein, strongly stimulates myoblast differentiation. However, the mechanisms involved in this influence remained unknown. In cultured myoblasts, we found that BTG1 stimulates the transcriptional activity of nuclear receptors (T3 and all-trans retinoic acid receptors but not RXRalpha and PPARgamma), c-Jun and myogenic factors (CMD1, Myf5, myogenin). Immunoprecipitation experiments performed in cells or using in vitro-synthesized proteins and GST pull-down assays established that BTG1 directly interacts with T3 and all-trans retinoic acid receptors and with avian MyoD ( CMD1). These interactions are mediated by the transactivation domain of each transcription factor and the A box and C-terminal part of BTG1. NCoR presence induces the ligand dependency of the interaction with nuclear receptors. Lastly, deletion of BTG1 interacting domains abrogates its ability to stimulate nuclear receptors and CMD1 activity, and its myogenic influence. In conclusion, BTG1 is a novel important coactivator involved in the regulation of myoblast differentiation. It not only stimulates the activity of myogenic factors, but also of nuclear receptors already known as positive myogenic regulators.	INRA, UMR 866, Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Hop Debrousse, INSERM, U418, F-69322 Lyon 05, France	INRAE; Universite de Montpellier; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cabello, G (corresponding author), INRA, UMR 866, Differenciat Cellulaire & Croissance, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr		Francois, Casas/0000-0002-5535-8195				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2000, FEBS LETT, V478, P4, DOI 10.1016/S0014-5793(00)01814-7; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Daury L, 2001, ONCOGENE, V20, P7998, DOI 10.1038/sj.onc.1204967; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Matsuda S, 1996, ONCOGENE, V12, P705; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Prevot D, 2001, J BIOL CHEM, V276, P9640, DOI 10.1074/jbc.M008201200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; ROWE A, 1991, DEVELOPMENT, V111, P771; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SNEDECOR GW, 1961, STAT METHODS, P534; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	44	51	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1698	1710		10.1038/sj.onc.1208373	http://dx.doi.org/10.1038/sj.onc.1208373			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674337				2022-12-17	WOS:000227345100006
J	Coll, MAL; Perera, S; Shi, W; Filmus, J				Coll, MAL; Perera, S; Shi, W; Filmus, J			A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells	ONCOGENE			English	Article						anoikis; c-Src; caveolin-1; IEC-18; colon cancer	HUMAN BREAST-CANCER; C-SRC; INDUCED APOPTOSIS; TYROSINE KINASES; DOWN-REGULATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; ACTIVATED RAS; DEATH; ADHESION	Detachment of epithelial cells from the basement membrane ( BM) induces apoptosis, a phenomenon now widely known as anoikis. Studies in mammary and intestinal epithelial cells have shown that the loss of attachment to the BM rapidly triggers reversible proapoptotic events from which the cells can recover if they reattach within a certain period. Thus, cells seem to be transiently protected from the initial detachment-induced proapoptotic events. The molecular mechanisms underlying such transient protection against anoikis are unknown. In this paper, we present evidence indicating that detachment of intestinal epithelial cells triggers a transient, yet significant increase in the activity of the tyrosine kinases c-Src and c-Fyn, and that this activation of Src-family kinases (SFK) contributes to the transient protection against anoikis in these cells. The protective signals from SFK are mediated by the PI3K pathway, and caveolin-1. In addition, we show that the MEK1-ERK1/2 pathway acts in a synergistic manner with SFK to protect intestinal epithelial cells from anoikis.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Filmus, J (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Mol & Cellular Biol, 2075 Bayview Ave,S Wing,Room S218, Toronto, ON M4N 3M5, Canada.	jorge.filmus@sw.ca		Perera, Sheron/0000-0001-8048-0611; Loza Coll, Mariano/0000-0002-3123-1229				Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Carver LA, 2003, CANCER RES, V63, P6571; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Ishida K, 2003, BIOCHEM BIOPH RES CO, V300, P201, DOI 10.1016/S0006-291X(02)02790-0; JAMAL HH, 1994, ONCOGENE, V9, P417; Krestow JK, 1999, BIOCHEM BIOPH RES CO, V260, P48, DOI 10.1006/bbrc.1999.0863; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin EH, 2004, EXP CELL RES, V293, P1, DOI 10.1016/j.yexcr.2003.09.008; LOZA CM, 2002, ONCOGENE, V21, P2908; Maher PA, 2000, EXP CELL RES, V260, P189, DOI 10.1006/excr.2000.5009; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Quaroni A, 1980, Methods Cell Biol, V21B, P403; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reed BH, 2004, CURR BIOL, V14, P372, DOI 10.1016/j.cub.2004.02.029; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; STRANGE R, 1992, DEVELOPMENT, V115, P49; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	50	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1727	1737		10.1038/sj.onc.1208379	http://dx.doi.org/10.1038/sj.onc.1208379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674335				2022-12-17	WOS:000227345100009
J	Abounader, R; Reznik, T; Colantuoni, C; Martinez-Murillo, F; Rosen, EM; Laterra, J				Abounader, R; Reznik, T; Colantuoni, C; Martinez-Murillo, F; Rosen, EM; Laterra, J			Regulation of c-Met-dependent gene expression by PTEN	ONCOGENE			English	Article						receptor tyrosine kinase; tumor suppressor; hepatocyte growth factor; scatter factor; microarrays; epidermal growth factor receptor	FACTOR/HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR EXPRESSION; TUMOR-SUPPRESSOR PTEN; HUMAN GLIOBLASTOMA; PTEN/MMAC1; MUTATIONS; PATHWAYS; RECEPTOR; 3-KINASE/AKT; MULTIFORME	Receptor tyrosine kinases (RTK) and the tumor suppressor PTEN co-regulate oncogenic cell signaling pathways. How these interactions influence gene transcription is inadequately understood. We used expression microarrays to investigate the effects of PTEN on gene expression changes caused by activating c-Met in human glioblastoma cells. c-Met activation by scatter factor/hepatocyte growth factor (SF/HGF) altered the expression of 27-fold more genes in PTEN-null U-373MG cells than in PTEN homozygous primary normal human astrocytes (523 vs 19 genes). Restoring wt-PTEN in U-373MG cells dramatically altered patterns of c-Met regulated gene expression. This effect was varied depending on the specific gene in question. PTEN reduced the number of c-Met regulated transcripts from 931 to 502, decreased the relative number of genes upregulated by c-Met from 46 to 25%, and increased the relative number of downregulated genes from 54 to 75%. PTEN and c-Met co-regulated many genes involved in cell growth regulation such as oncogenes, growth factors, transcription factors, and constituents of the ubiquitin pathway. c-Met activation in PTEN-null ( but not PTEN reconstituted) cells led to upregulation of the EGFR agonist TGFalpha and subsequently to EGFR activation. Using PTEN mutants, we found that PTEN's transcriptional effects were either lipid-phosphatase dependent, protein-phosphatase dependent, or phosphatase-independent. These results show that PTEN has critical and mechanistically complex effects on RTK-regulated gene transcription. These findings expand our understanding of tumor promoter/suppressor inter-relationships and downstream transcriptional effects of PTEN loss and c-Met overexpression in malignant gliomas.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Lombardi Canc Ctr, Dept Oncol, Washington, DC USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Abounader, R (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway,Room 400, Baltimore, MD 21205 USA.	abounader@kennedykrieger.org; laterra@kennedykrieger.org		Colantuoni, Carlo/0000-0001-6818-6380	NINDS NIH HHS [R01 NS045209, R01 NS032148, R01 NS43987] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045209, R01NS043987, R01NS032148] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Abounader R, 2001, J NEUROCHEM, V76, P1497, DOI 10.1046/j.1471-4159.2001.00158.x; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bowers DC, 2000, CANCER RES, V60, P4277; Cheney IW, 1998, CANCER RES, V58, P2331; Colantuoni C, 2002, BIOTECHNIQUES, V32, P1316, DOI 10.2144/02326mt02; Davies MPA, 1999, BRIT J CANCER, V79, P1542, DOI 10.1038/sj.bjc.6690246; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Koochekpour S, 1997, CANCER RES, V57, P5391; Laterra J, 1997, LAB INVEST, V76, P565; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Sano T, 1999, CANCER RES, V59, P1820; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	29	51	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9173	9182		10.1038/sj.onc.1208146	http://dx.doi.org/10.1038/sj.onc.1208146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516982				2022-12-17	WOS:000225638000002
J	del Rincon, SV; Guo, Q; Morelli, C; Shiu, HY; Surmacz, E; Miller, WH				del Rincon, SV; Guo, Q; Morelli, C; Shiu, HY; Surmacz, E; Miller, WH			Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism	ONCOGENE			English	Article						retinoic acid; IRS-1; ubiquitin; PKC; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; BREAST-CANCER CELLS; PROTEIN-KINASE-C; ACUTE PROMYELOCYTIC LEUKEMIA; BRONCHIAL EPITHELIAL-CELLS; GROWTH-FACTOR; CYCLIN D1; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; 3T3-L1 ADIPOCYTES	Insulin receptor substrate-1 (IRS-1) mediates signaling from the insulin-like growth factor type-I receptor. We found that all-trans retinoic acid ( RA) decreases IRS-1 protein levels in MCF-7, T47-D, and ZR75.1 breast cancer cells, which are growth arrested by RA, but not in the RA-resistant MDA-MB-231 and MDA-MB-468 cells. Based on prior reports of ubiquitin-mediated degradation of IRS-1, we investigated the ubiquitination of IRS-1 in RA-treated breast cancer cells. Two proteasome inhibitors, MG-132 and lactacystin, blocked the RA-mediated degradation of IRS-1, and RA increased ubiquitination of IRS-1 in the RA-sensitive breast cancer cells. In addition, we found that RA increases serine phosphorylation of IRS-1. To elucidate the signaling pathway responsible for this phosphorylation event, pharmacologic inhibitors were used. Two PKC inhibitors, but not a MAPK inhibitor, blocked the RA-induced degradation and serine phosphorylation of IRS-1. We demonstrate that RA activates PKC-delta in the sensitive, but not in the resistant cells, with a time course that is consistent with the RA-induced decrease of IRS-1. We also show that: ( 1) RA-activated PKC-delta phosphorylates IRS-1 in vitro, ( 2) PKC-delta and IRS-1 interact in RA-treated cells, and ( 3) mutation of three PKC-delta serine sites in IRS-1 to alanines results in no RA-induced in vitro phosphorylation of IRS-1. Together, these results indicate that RA regulates IRS-1 levels by the ubiquitin - proteasome pathway, involving a PKC-sensitive mechanism.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Calabria, Postgrad Sch Clin Pathol, I-87036 Cosenza, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Lady Davis Institute; McGill University; McGill University; McGill University; University of Calabria; Jefferson University	Miller, WH (corresponding author), Lady Davis Inst, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	wmiller@ldi.jgh.mcgill.ca	Morelli, Catia/AAE-1886-2019	Morelli, Catia/0000-0002-9407-0805				Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Brouillard F, 2003, J BIOL CHEM, V278, P39509, DOI 10.1074/jbc.M307123200; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Chang Q, 2002, CANCER RES, V62, P6035; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Gonzalez C, 2001, JOP, V2, P140; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Huang XD, 2002, J CLIN ENDOCR METAB, V87, P255, DOI 10.1210/jc.87.1.255; Ito T, 1996, MOL CELL BIOL, V16, P943; IWAO K, 1999, NUCL ACIDS S SER, V42, P207; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rosenauer A, 1998, CANCER RES, V58, P5110; Salerno M, 1999, INT J CANCER, V81, P299; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SMITH LK, 1993, BIOCHEM BIOPH RES CO, V196, P767, DOI 10.1006/bbrc.1993.2315; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yoshida H, 1996, CANCER RES, V56, P2945; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200	55	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9269	9279		10.1038/sj.onc.1208104	http://dx.doi.org/10.1038/sj.onc.1208104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516986				2022-12-17	WOS:000225638000012
J	Wiederhold, T; Lee, MF; James, M; Neujahr, R; Smith, N; Murthy, A; Hartwig, J; Gusella, JF; Ramesh, V				Wiederhold, T; Lee, MF; James, M; Neujahr, R; Smith, N; Murthy, A; Hartwig, J; Gusella, JF; Ramesh, V			Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2	ONCOGENE			English	Article						NF2; merlin; tumor suppressor; Grb2; cytoskeleton	ALDRICH-SYNDROME PROTEIN; HUMAN SCHWANNOMA CELLS; TYPE-2 GENE-PRODUCT; NEUROFIBROMATOSIS TYPE-2; TERMINAL DOMAIN; SH3 DOMAINS; F-ACTIN; N-WASP; NHE-RF; MEMBRANE	Neurofibromatosis 2 (NF2) is a dominantly inherited disorder characterized by bilateral vestibular schwannomas and meningiomas. Merlin, the neurofibromatosis 2 tumor suppressor protein, is related to the ERM ( ezrin, radixin, moesin) proteins and, like its family members, is thought to play a role in plasma membrane-cytoskeletal interactions. We report a novel protein as a merlin-specific binding partner that we have named magicin ( merlin and Grb2 interacting cytoskeletal protein) and show that the two proteins interact in vitro and in vivo as well as colocalize beneath the plasma membrane. Magicin is a 24 kDa protein that is expressed in many cell lines and tissues. Magicin, similar to merlin, associates with the actin cytoskeleton as determined by cofractionation, immunofluorescence and electron microscopy. Analysis of the magicin sequence reveals binding motifs for the adaptor protein Grb2. Employing affinity binding, blot overlay and co-immunoprecipitation assays, we demonstrate an interaction between Grb2 and magicin. In addition, merlin is capable of forming a ternary complex with magicin and Grb2. These results support a role for merlin in receptor-mediated signaling at the cell surface, and may have implications in the regulation of cytoskeletal reorganization.	Massachusetts Gen Hosp, Mol Neurosci Unit, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Div Expt Med, Longwood Med Res Ctr, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurosci Unit, Bldg 149,13th St,Rm6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; JANNATIPOUR M, 2001, J BIOL CHEM, V29, P29; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Liu CH, 2002, BIOCHEM BIOPH RES CO, V290, P602, DOI 10.1006/bbrc.2001.6119; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; Mayer BJ, 2001, J CELL SCI, V114, P1253; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Neill GW, 2001, BIOCHEM J, V358, P727, DOI 10.1042/0264-6021:3580727; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251	47	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8815	8825		10.1038/sj.onc.1208110	http://dx.doi.org/10.1038/sj.onc.1208110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467741				2022-12-17	WOS:000225165100011
J	Adachi, K; Toyota, M; Sasaki, Y; Yamashita, T; Ishida, S; Ohe-Toyota, M; Maruyama, R; Hinoda, Y; Saito, T; Imai, K; Kudo, R; Tokino, T				Adachi, K; Toyota, M; Sasaki, Y; Yamashita, T; Ishida, S; Ohe-Toyota, M; Maruyama, R; Hinoda, Y; Saito, T; Imai, K; Kudo, R; Tokino, T			Identification of SCN3B as a novel p53-inducible proapoptotic gene	ONCOGENE			English	Article						p53; SCN3B; apoptosis; ER	ADENOVIRUS-MEDIATED TRANSFER; KINASE C-ABL; DNA-DAMAGE; ENDOPLASMIC-RETICULUM; APOPTOTIC RESPONSE; SODIUM-CHANNELS; DIRECT TARGET; CANCER-CELLS; P53; P73	Tumor suppressor p53 is a transcription factor that induces growth arrest and/or apoptosis in response to cellular stress. To identify novel p53-inducible genes, we compared the expression of genes in normal mouse embryo fibroblasts (MEFs) to p53-null cells by cDNA representational difference analysis. We report here that expression of endogenous sodium channel subunit beta 3 (SCN3B) is upregulated in mouse embryonic fibroblasts by DNA damage in a p53-dependent manner. In addition, we found that SCN3B levels are upregulated in human cancer cell lines by DNA damaging agents, as well as by overexpression of p53, but not significantly by p63 or p73. Furthermore, we identified two putative p53-binding sites upstream of the first exon (RE1) and in the third intron (RE2). The p53 protein can directly interact with the putative p53-binding sites in vivo, as assessed by chromatin immunoprecipitation. A reporter gene assay revealed that these two p53-binding sites are functional response elements. The SCN3B protein appears to be localized to the endoplasmic reticulum (ER). Introduction of the SCN3B gene into T98G and Saos2 cells potently suppressed colony formation. Furthermore, we found that adenovirus-mediated transfer of SCN3B induced apoptosis when combined with anticancer agents. The results presented here suggest that SCN3B mediates a p53-dependent apoptotic pathway and may be a candidate for gene therapy combined with anticancer drugs.	Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Sch Med, Dept Obstet & Gynecol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Yamaguchi Univ, Sch Med, Div Clin Lab, Ube, Yamaguchi 7558505, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Yamaguchi University	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Sasaki, Yasushi/0000-0002-3500-8059				Agami R, 1999, NATURE, V399, P809; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gong JG, 1999, NATURE, V399, P806; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; MIYASHITA T, 1995, CELL, V80, P293; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Sasaki Y, 2000, J CLIN LAB ANAL, V14, P314, DOI 10.1002/1098-2825(20001212)14:6<314::AID-JCLA11>3.0.CO;2-O; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	29	51	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7791	7798		10.1038/sj.onc.1208067	http://dx.doi.org/10.1038/sj.onc.1208067			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334053				2022-12-17	WOS:000224331600005
J	Lessard, J; Faubert, A; Sauvageau, G				Lessard, J; Faubert, A; Sauvageau, G			Genetic programs regulating HSC specification, maintenance and expansion	ONCOGENE			English	Review						hematopoiesis; HSC; self-renewal	HEMATOPOIETIC STEM-CELLS; COLONY-FORMING CELLS; CREB-BINDING-PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW TRANSPLANTATION; TRANSCRIPTION FACTOR GATA-2; FETAL LIVER HEMATOPOIESIS; POLYCOMB-GROUP GENES; IKAROS MUTANT MICE; LONG-TERM	All mature blood cells originate from a small population of self-renewing pluripotent hematopoietic stem cells (HSCs). The capacity to self-renew characterizes all stem cells, whether normal or neoplastic. Interestingly, recent studies suggest that self-renewal is essential for tumor cell maintenance, implicating that this process has therapeutic relevance. Unfortunately, the molecular bases for self-renewal of vertebrate cells remain poorly defined. This article will focus on the developmental mechanisms underlying fetal and adult HSC homeostasis. Specifically, distinctions between genetic programs regulating HSC specification (identity), self-renewal (in both fetal and adult) and differentiation/commitment will be discussed with a special emphasis on transcriptional and chromatin regulators.	Univ Montreal, Lab Mol Genet Hematopoiet Stem Cells, Res Inst Immunol & Canc IRIC, Montreal, PQ H3C 3J7, Canada; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Dept Med, Montreal, PQ H3C 3J7, Canada; Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ H1T 2M2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ, Canada	Universite de Montreal; Stanford University; Universite de Montreal; McGill University	Sauvageau, G (corresponding author), Univ Montreal, Lab Mol Genet Hematopoiet Stem Cells, Res Inst Immunol & Canc IRIC, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Dimri GP, 2002, CANCER RES, V62, P4736; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; Gailani M R, 1999, Adv Dermatol, V14, P261; Garcia MJ, 2002, AM J PATHOL, V161, P1007, DOI 10.1016/S0002-9440(10)64261-7; GARDNER RV, 1988, EXP HEMATOL, V16, P49; Geiger H, 2002, NAT IMMUNOL, V3, P329, DOI 10.1038/ni0402-329; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HARRISON DE, 1990, J EXP MED, V172, P431, DOI 10.1084/jem.172.2.431; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; Harrison DE, 1997, EXP HEMATOL, V25, P293; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Iscove NN, 1997, CURR BIOL, V7, P805, DOI 10.1016/S0960-9822(06)00341-1; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; JONES RJ, 1989, BLOOD, V73, P397; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kung AL, 2000, GENE DEV, V14, P272; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; LALA PK, 1978, J EXP MED, V148, P1468, DOI 10.1084/jem.148.6.1468; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LEPAULT F, 1993, BLOOD, V81, P950; LERNER C, 1990, EXP HEMATOL, V18, P114; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Liu Y, 2001, J BIOL CHEM, V276, P17985, DOI 10.1074/jbc.M100678200; Lopez RA, 2002, P NATL ACAD SCI USA, V99, P602, DOI 10.1073/pnas.022412699; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; MAUCH P, 1989, BLOOD, V74, P872; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MULDER AH, 1987, EXP HEMATOL, V15, P99; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; OH IH, 2003, ASH ABSTR, P325; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Oike Y, 1999, BLOOD, V93, P2771; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; PHILLIPS RL, 1992, P NATL ACAD SCI USA, V89, P11607, DOI 10.1073/pnas.89.23.11607; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Polakis P, 2000, GENE DEV, V14, P1837; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Rebel VI, 1996, EXP HEMATOL, V24, P638; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Tokimasa S, 2001, EXP HEMATOL, V29, P93, DOI 10.1016/S0301-472X(00)00620-2; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANBEKKUM DW, 1979, BLOOD CELLS, V5, P143; VANDERLOO JCM, 1994, BLOOD, V83, P1769; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANZANT G, 1991, EXP HEMATOL, V19, P941; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; VISSER JWM, 1988, BLOOD CELLS, V14, P369; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weissman IL, 2002, IMMUNOL REV, V185, P159, DOI 10.1034/j.1600-065X.2002.18514.x; WORTON RG, 1969, J EXP MED, V130, P91, DOI 10.1084/jem.130.1.91; WU AM, 1968, P NATL ACAD SCI USA, V59, P1209, DOI 10.1073/pnas.59.4.1209; WU AM, 1968, J EXP MED, V127, P455, DOI 10.1084/jem.127.3.455; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yoder MC, 1997, P NATL ACAD SCI USA, V94, P6776, DOI 10.1073/pnas.94.13.6776; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	127	51	53	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7199	7209		10.1038/sj.onc.1207940	http://dx.doi.org/10.1038/sj.onc.1207940			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378080				2022-12-17	WOS:000223998800006
J	Martin-Oliva, D; O'Valle, F; Munoz-Gamez, JA; Valenzuela, MT; Nunez, MI; Aguilar, M; de Almodovar, JMR; del Moral, RG; Oliver, FJ				Martin-Oliva, D; O'Valle, F; Munoz-Gamez, JA; Valenzuela, MT; Nunez, MI; Aguilar, M; de Almodovar, JMR; del Moral, RG; Oliver, FJ			Crosstalk between PARP-1 and NF-kappa B modulates the promotion of skin neoplasia	ONCOGENE			English	Article						skin carcinogenesis; PARP-1; NF-kappa B; inflammation	NITRIC-OXIDE SYNTHASE; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; DEFICIENT MICE; HUMAN CANCER; FACTOR-ALPHA; EXPRESSION; CELLS; CARCINOGENESIS	Poly (ADP-ribose) polymerase-1 (PARP-1)-deficient mice are protected against septic shock, type I diabetes, stroke and inflammation. It is now accepted that inflammation and related events, such as activation of NF-kappaB, are key components in the initiation and progression of epithelial cancer and in particular in the neoplastic transformation of keratinocytes and skin carcinogenesis. Here, we report that PARP-1-deficient mice display a strikingly reduced susceptibility to skin carcinogenesis. In parp-1(-/-) mice, development of papilloma-like premalignant lesions induced with DMBA and TPA, is strongly delayed and the final number of tumor-bearing mice and total tumor number were significantly reduced. In addition, epidermis of parp-1(-/-) mice did not show increased proliferation rates after treatment with carcinogen. Deregulated NF-kappaB is a hallmark for tumorigenesis together with the concomitant release of early inflammatory mediators. In the absence of PARP-1, NF-kappaB activation and induction kappaB-target genes did not take place during the promotion of tumor development. These results suggest that PARP-1 abolition impairs the promotion of skin carcinogenesis interfering with the activation of NF-kappaB and might have an important implication in targeting PARP-1 as a new antineoplastic therapeutic approach.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Hosp, Granada, Spain; Univ Granada, Dept Pathol, E-18071 Granada, Spain; Univ Granada, Dept Radiol & Phys Med, E-18071 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada; University of Granada	Oliver, FJ (corresponding author), CSIC, Inst Parasitol & Biomed, C Ventanilla 11, Granada 18001, Spain.	joliver@ipb.csic.es	Martín-Oliva, David/L-8472-2014; Oliver, Javier/S-1725-2018; OValle, Francisco/AAA-9151-2019; Núñez, María Isabel/L-9924-2014	Martín-Oliva, David/0000-0002-8095-5442; Oliver, Javier/0000-0001-8468-1998; Núñez, María Isabel/0000-0001-8159-7969; Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072				Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bauerle PA, 1996, CELL, V87, P13; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMURCIA JM, 1997, P NATL ACAD SCI USA, V94, P73037; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Musgrave BL, 1999, EXP CELL RES, V252, P96, DOI 10.1006/excr.1999.4631; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PANDOLFI F, 1992, CANCER, V69, P1165; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Tucker PC, 2001, FASEB J, V15, P2241, DOI 10.1096/fj.01-0133com; Velasco M, 1997, J BIOL CHEM, V272, P23025, DOI 10.1074/jbc.272.37.23025; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Weinberg WC, 1999, CANCER RES, V59, P2050; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	42	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5275	5283		10.1038/sj.onc.1207696	http://dx.doi.org/10.1038/sj.onc.1207696			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077172				2022-12-17	WOS:000222491600003
J	Ding, Y; Wang, L; Su, LK; Frey, JA; Shao, RP; Hunt, KK; Yan, DH				Ding, Y; Wang, L; Su, LK; Frey, JA; Shao, RP; Hunt, KK; Yan, DH			Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer	ONCOGENE			English	Article						IFIX; interferon; HIN-200; p21(CIP1); breast cancer	DEATH-DOMAIN-FOLD; CARCINOMA CELL-LINES; INDUCED APOPTOSIS; PYRIN DOMAIN; TUMOR SUPPRESSION; CDK INHIBITORS; CYCLE CONTROL; EXPRESSION; GROWTH; FAMILY	We identified IFIX as a new member of the hematopoietic interferon (IFN)-inducible nuclear protein with the 200-amino-acid repeat (HIN-200) family. Six different alternatively spliced forms of mRNA are transcribed from the IFIX gene, which are predicted to encode six different isoforms of IFIX proteins (IFIXalpha1, alpha2, beta1, beta2, gamma1, and gamma2). The IFIX proteins are primarily localized in the nucleus. They share a common N-terminal region that contains a predicted pyrin domain and a putative nuclear localization signal. Unlike IFIXalpha and IFIXbeta, IFIXgamma isoforms do not have the 200-amino-acid signature motif. Interestingly, the expression of IFIX was reduced in most human breast tumors and breast cancer cell lines. Expression of IFIXalpha1, the longest isoform of IFIX, in human breast cancer cell lines reduced their anchorage-dependent and -independent growth in vitro and tumor-igenicity in nude mice. Moreover, a liposome-mediated IFIXalpha1 gene transfer suppressed the growth of already-formed tumors in a breast cancer xenograft model. IFIXalpha1 appears to suppress the growth of breast cancer cells in a pRB- and p53-independent manner by increasing the expression of the cyclin-dependent kinase inhibitor p21(CIp1), which leads to the reduction of the kinase activity of both Cdk2 and p34(Cdc2). Together, our results show that IFIXalpha1 possesses a tumor-suppressor activity and suggest IFIXalpha1 may be used as a therapeutic agent in cancer treatment.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Yan, DH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyan@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Choubey D, 2000, FEBS LETT, V474, P38, DOI 10.1016/S0014-5793(00)01571-4; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Coradini D, 1998, ANTICANCER RES, V18, P177; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Ding Y, 2002, CLIN CANCER RES, V8, P3290; Doree M, 2002, J CELL SCI, V115, P2461; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fang M, 2000, ANTICANCER RES, V20, P103; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Nadal A, 1997, J PATHOL, V183, P156; Naldini A, 2002, J CELL PHYSIOL, V191, P290, DOI 10.1002/jcp.10101; PRICE JE, 1990, CANCER RES, V50, P717; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; Wen Y, 2000, CANCER RES, V60, P42; Wen Y, 2001, CANCER RES, V61, P7142; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yin F, 2001, ANTICANCER RES, V21, P413; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang JF, 1996, P NATL ACAD SCI USA, V93, P4513, DOI 10.1073/pnas.93.9.4513; ZHANG RD, 1991, INVAS METAST, V11, P204; Zhou YH, 2002, CANCER INVEST, V20, P348, DOI 10.1081/CNV-120001180; Zou YY, 2002, CANCER RES, V62, P8	39	51	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4556	4566		10.1038/sj.onc.1207592	http://dx.doi.org/10.1038/sj.onc.1207592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15122330				2022-12-17	WOS:000221799000005
J	Taniuchi, I; Littman, DR				Taniuchi, I; Littman, DR			Epigenetic gene silencing by Runx proteins	ONCOGENE			English	Article						Runx; CD4; silencing; epigenetics	T-LYMPHOCYTE DEVELOPMENT; ACUTE MYELOID-LEUKEMIA; CD4 SILENCER; CELL DEVELOPMENT; EXPRESSION; REPRESSION; DELETION; DOMAIN; AML1; DIFFERENTIATION	Runx family proteins have the potential for either activating or suppressing gene expression in a context-dependent manner. There are several mechanisms by which transcriptional repression can occur. A wide range of locus inactivation, that is often called gene silencing, is thought to be achieved by chromatin modi. cations. Recently, Runx family proteins were found to have an essential role in either temporal transcriptional repression or irreversible epigenetic silencing at the CD4 locus through binding to a CD4 silencer at different stages of development. These findings link Runx function to epigenetic gene regulation, and shed new light on the mechanisms by which Runx represses target gene expression.	RIKEN, Res Ctr Allergy & Immunol, Lab Transcript Regulat, Yokohama, Kanagawa 2300045, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 812, Japan; PREST, JST, Kawaguchi, Japan; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA	RIKEN; Kyushu University; Howard Hughes Medical Institute; New York University	Taniuchi, I (corresponding author), RIKEN, Res Ctr Allergy & Immunol, Lab Transcript Regulat, Yokohama, Kanagawa 2300045, Japan.	taniuchi@rcai.riken.jp	Taniuchi, Ichiro/N-6399-2015	Taniuchi, Ichiro/0000-0002-9853-9068				Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; Donda A, 1996, EUR J IMMUNOL, V26, P493, DOI 10.1002/eji.1830260232; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; Ellmeier W, 2002, IMMUNITY, V16, P623, DOI 10.1016/S1074-7613(02)00309-6; Festenstein R, 2000, CURR OPIN GENET DEV, V10, P199, DOI 10.1016/S0959-437X(00)00060-5; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Garefalaki A, 2002, IMMUNITY, V16, P635, DOI 10.1016/S1074-7613(02)00308-4; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kioussis D, 2002, NAT REV IMMUNOL, V2, P909, DOI 10.1038/nri952; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Leung RKM, 2001, NAT IMMUNOL, V2, P1167, DOI 10.1038/ni733; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; TANIUCHI I, 2004, IN PRESS ADV IMMUNOL; VONBOEHMER H, 1993, IMMUNOL REV, V135, P67; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Zou YR, 2001, NAT GENET, V29, P332, DOI 10.1038/ng750	31	51	51	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4341	4345		10.1038/sj.onc.1207671	http://dx.doi.org/10.1038/sj.onc.1207671			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156191				2022-12-17	WOS:000221586000020
J	EL Naaman, C; Grum-Schwensen, B; Mansouri, A; Grigorian, M; Santoni-Rugiu, E; Hansen, T; Kriajevska, M; Schafer, BW; Heizmann, CW; Lukanidin, E; Ambartsumian, N				EL Naaman, C; Grum-Schwensen, B; Mansouri, A; Grigorian, M; Santoni-Rugiu, E; Hansen, T; Kriajevska, M; Schafer, BW; Heizmann, CW; Lukanidin, E; Ambartsumian, N			Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene	ONCOGENE			English	Article						animal models; Mts1(S100A4); p53; tumor development; tumor suppressor activity	TUMOR-SUPPRESSOR GENE; PROTEIN S100A4 P9KA; BINDING PROTEIN; WILD-TYPE; P53; EXPRESSION; CALCIUM; TARGET; CELLS; TP53	Metastasis-promoting Mts1(S100A4) protein belongs to the S100 family of Ca2+-binding proteins. A mouse strain with a germ-line inactivation of the S100A4 gene was generated. The mice were viable and did not display developmental abnormalities in the postnatal period. However, an abnormal sex ratio was observed in the litters with the S100A4-/- genotype, raising the possibility of a certain level of embryonic lethality in this strain. In all, 10% of 10-14-month-old S100A4-null animals developed tumors. This is a characteristic feature of mouse strains with inactivated tumor suppressor genes. Spontaneous tumors of S100A4-/- mice were p53 positive. Recently, we have shown that S100A4 interacts with p53 tumor suppressor protein and induces apoptosis. We proposed that impairment of this interaction could affect the apoptosis-promoting function of p53 that is involved in its tumor suppressor activity. The frequency of apoptosis in the spleen of S100A4-/- animals after whole-body gamma-irradiation was reduced compared to the wild-type animals. The same was true for the transcriptional activation of the p53 target genes - waf/p21/cip1 and bax. Taken together, these observations indicate that spontaneous tumors in S100A4-/- mice are a result of functional destabilization of p53 tumor suppressor gene.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen, Denmark; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	Danish Cancer Society; Max Planck Society; Rigshospitalet; University of Copenhagen; University of Zurich	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	na@cancer.dk	Hansen, Thomas/GWZ-2858-2022; Santoni-Rugiu, Eric/H-4913-2019; Hansen, Thomas Folkmann/O-5965-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Hansen, Thomas Folkmann/0000-0001-6703-7762; Santoni-Rugiu, Eric/0000-0002-2283-3535; Grum-Schwensen, Birgitte/0000-0001-6677-1869; Schafer, Beat/0000-0001-5988-2915				Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Buzard GS, 1996, MUTAT RES-REV GENET, V365, P43, DOI 10.1016/S0165-1110(96)90011-1; Cazorla M, 1998, MOL CARCINOGEN, V21, P251, DOI 10.1002/(SICI)1098-2744(199804)21:4<251::AID-MC4>3.0.CO;2-N; Chen DS, 1996, BIOCHEM SOC T, V24, pS352, DOI 10.1042/bst024352s; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; Christensen CRL, 1998, CANCER RES, V58, P1238; Cohn MA, 2001, NUCLEIC ACIDS RES, V29, P3335, DOI 10.1093/nar/29.16.3335; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Duddy SK, 1999, TOXICOL APPL PHARM, V156, P106, DOI 10.1006/taap.1999.8631; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Fei PW, 2002, CANCER RES, V62, P7316; Feng G, 2001, CANCER RES, V61, P7999; FORD HL, 1995, ONCOGENE, V10, P1597; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hsieh HL, 2002, J CELL SCI, V115, P3149; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; Klingelhofer J, 1997, DEV DYNAM, V210, P87, DOI 10.1002/(SICI)1097-0177(199710)210:2<87::AID-AJA2>3.0.CO;2-5; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; Mandinova A, 1998, J CELL SCI, V111, P2043; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; Mansouri A, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P478; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; Meuwissen R, 2001, EXP CELL RES, V264, P100, DOI 10.1006/excr.2000.5146; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Passey RJ, 1999, J IMMUNOL, V163, P2209; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Pelc P, 2003, HISTOPATHOLOGY, V42, P387, DOI 10.1046/j.1365-2559.2003.01588.x; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Ridinger K, 1998, BBA-MOL CELL RES, V1448, P254, DOI 10.1016/S0167-4889(98)00137-2; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAUER B, 1993, METHOD ENZYMOL, V225, P890; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Teratani T, 2002, BIOCHEM BIOPH RES CO, V291, P623, DOI 10.1006/bbrc.2002.6494; TURUSOV V, 1994, PATHOLOGY TUMORS LAB, V2; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WETERMAN MAJ, 1993, CANCER RES, V53, P6061; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	75	51	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3670	3680		10.1038/sj.onc.1207420	http://dx.doi.org/10.1038/sj.onc.1207420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116098				2022-12-17	WOS:000221101700019
J	Costa, FF; Verbisck, NV; Salim, ACM; Ierardi, DF; Pires, LC; Sasahara, RM; Sogayar, MC; Zanata, SM; Mackay, A; O'Hare, M; Soares, F; Simpson, AJG; Camargo, AA				Costa, FF; Verbisck, NV; Salim, ACM; Ierardi, DF; Pires, LC; Sasahara, RM; Sogayar, MC; Zanata, SM; Mackay, A; O'Hare, M; Soares, F; Simpson, AJG; Camargo, AA			Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors	ONCOGENE			English	Article						ADAM23; methylation; cell adhesion; downregulation; breast tumor	DNA METHYLATION; CELL-ADHESION; CPG ISLAND; METALLOPROTEASE DOMAIN; MEMBRANE-PROTEINS; SUPPRESSOR GENES; DISINTEGRIN-LIKE; CANCER; EXPRESSION; FAMILY	Altered cell adhesion is causally involved in tumor progression, and the identification of novel adhesion molecules altered in tumors is crucial for our understanding of tumor biology and for the development of new prognostic and therapeutic strategies. Here, we provide evidence for the epigenetic downregulation in breast tumors of the A Desintegrin And Metalloprotease domain 23 gene ( ADAM 23), a member of a new family of surface molecules with roles in cell - cell adhesion and/or cell matrix interactions. W e examined the mRNA expression and methylation status of the 50 upstream region of the ADAM23 gene in different breast tumor cell lines as well as in primary breast tumors. We found ADAM23 50 hypermethylation in eight out of 12 (66.7%) tumor cell lines and in nine out of 13 (69.2%) primary tumors. Promoter hypermethylation was strongly associated with reductions in both mRNA and protein expression, with a threshold of 40 - 60% of modified CpG dinucleotides being required for the complete silencing of ADAM23 mRNA expression. Treatment of MCF-7 and SKBR-3 cell lines with 5'-Aza-2'-deoxycytidine led to a reactivation of ADAM23 mRNA expression and a marked decrease in the methylation level. It is worth noting that primary breast tumors with a more advanced grade showed a higher degree of methylation, suggesting that the adhesion molecule ADAM23 may be downregulated during the progression of breast cancer.	Ludwig Inst Canc Res, Lab Mol Biol & Genom, BR-01509010 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; Univ Fed Parana, Neurobiol Lab, BR-80060000 Curitiba, Parana, Brazil; Univ Coll, Ludwig Inst Canc Res, Breast Canc Lab, London, England; Hosp ACCamargo, Dept Patol, Sao Paulo, Brazil	Ludwig Institute for Cancer Research; Universidade de Sao Paulo; Universidade Federal do Parana; Ludwig Institute for Cancer Research; University of London; University College London; A.C.Camargo Cancer Center	Camargo, AA (corresponding author), Ludwig Inst Canc Res, Lab Mol Biol & Genom, Rua Prof Antonio Prudente 109,4th Floor, BR-01509010 Sao Paulo, Brazil.	anamaria@compbio.ludwig.org.br	Zanata, Silvio/AAC-9670-2021; Camargo, Anamaria A/E-9388-2012; Verbisck, Newton Valerio/I-1356-2012; Simpson, Amelia/HGB-1823-2022; Sogayar, Mari C/B-3980-2017	Zanata, Silvio/0000-0003-2818-6954; Camargo, Anamaria A/0000-0002-6076-9597; Verbisck, Newton Valerio/0000-0001-9817-7223; Sogayar, Mari C/0000-0003-4805-4609; Soares, Fernando Augusto/0000-0003-1647-7842; Soares, Fernando/0000-0002-1212-9093				Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1; Moss ML, 2001, DRUG DISCOV TODAY, V6, P417, DOI 10.1016/S1359-6446(01)01738-X; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Radice D, 2003, PHARMACOECONOMICS, V21, P383, DOI 10.2165/00019053-200321060-00003; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sagane K, 1998, BIOCHEM J, V334, P93, DOI 10.1042/bj3340093; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714	36	51	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1481	1488		10.1038/sj.onc.1207263	http://dx.doi.org/10.1038/sj.onc.1207263			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14661055	Bronze			2022-12-17	WOS:000189035800016
J	Ueda, R; Iizuka, Y; Yoshida, K; Kawase, T; Kawakami, Y; Toda, M				Ueda, R; Iizuka, Y; Yoshida, K; Kawase, T; Kawakami, Y; Toda, M			Identification of a human glioma antigen, SOX6, recognized by patients' sera	ONCOGENE			English	Article						glioma; tumor antigen; CT antigen; SOX6; SEREX; IgG response	IMMUNE-RESPONSES; NERVOUS-SYSTEM; BRAIN-TUMORS; GENE SOX6; PROTEIN; TESTIS; SRY; LYMPHOCYTES; EXPRESSION; MOUSE	To identify tumor antigens for glioma, a human testis cDNA library was screened by serological identification of antigens by recombinant expression cloning with sera from glioma patients. In this screening, the most frequently isolated antigen was SOX6, an Sry-related high-mobility group (HMG) box-containing gene. SOX6 is a transcriptional factor that is specifically expressed in the developing central nervous system and in the early stages of chondrogenesis in mouse embryos. IgG antibodies against SOX6 were detected in sera from 12 of 36 glioma patients (33.3%), 0 of 14 patients with other brain disease (0%), and one of 54 other cancer patients (1.9%). In sera from 37 healthy individuals, no IgG responses against SOX6 were detected, except in an elderly female. Furthermore, Western blot and ELISA analyses with sera from glioma patients revealed that the DNA-binding domain, the HMG box of SOX6, might be a dominant epitope of IgGs against SOX6. RT-PCR and Northern blot analysis revealed that the SOX6 gene was more highly expressed in glioma tissues than in normal adult tissues, except testis. Western blot analysis with an anti-SOX6 antibody demonstrated that the SOX6 protein was expressed in glioma tissues, but not in normal adult brain tissue. Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analysed expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in non-neoplastic tissues from the cerebral cortex. In summary, these results indicate that the developmentally regulated transcription factor SOX6 is aberrantly expressed in glioma and specifically recognized by IgGs from glioma patients' sera.	Keio Univ, Sch Med, Dept Neurosurg, Neuroimmunol Res Grp,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University	Toda, M (corresponding author), Keio Univ, Sch Med, Dept Neurosurg, Neuroimmunol Res Grp,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	todam@sc.itc.keio.ac.jp	nakamura, asuka/S-7235-2016; Toda, Masahiro/L-2268-2013; Kawakami, Yutaka/E-7429-2013; Yoshida, Kazunari/L-2255-2013	Kawakami, Yutaka/0000-0003-4836-2855; 				Almqvist PM, 2002, J HISTOCHEM CYTOCHEM, V50, P147, DOI 10.1177/002215540205000203; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Cohen-Barak G, 2001, GENE, V265, P157, DOI 10.1016/S0378-1119(01)00346-8; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fischer U, 2001, CLIN EXP IMMUNOL, V126, P206, DOI 10.1046/j.1365-2249.2001.01635.x; Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Narahara M, 2002, BIOL PHARM BULL, V25, P705, DOI 10.1248/bpb.25.705; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PRADOS MD, 1992, INT J RADIAT ONCOL, V23, P3, DOI 10.1016/0360-3016(92)90537-R; ROBBINS PF, 1994, CANCER RES, V54, P3124; Sahin U, 2000, CLIN CANCER RES, V6, P3916; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; TAKAHASHI K, 1995, CANCER RES, V55, P3478; Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; Xia Y, 2000, CANCER RES, V60, P6303; Yamashita A, 2000, FEBS LETT, V481, P147, DOI 10.1016/S0014-5793(00)01987-6	33	51	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1420	1427		10.1038/sj.onc.1207252	http://dx.doi.org/10.1038/sj.onc.1207252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14691456	Green Submitted			2022-12-17	WOS:000189035800009
J	Wang, Q; Wieder, R				Wang, Q; Wieder, R			All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells	ONCOGENE			English	Article						apoptosis; JNK; retinoic acid; Taxotere; breast cancer	ACTIVATED PROTEIN-KINASE; RECEPTOR-ALPHA; INDUCED APOPTOSIS; SIGNALING PATHWAYS; GROWTH-INHIBITION; TUMOR-CELLS; LNCAP CELLS; EXPRESSION; PHOSPHORYLATION; PROLIFERATION	Taxotere is a cytotoxin effective in treating breast and prostate cancer. It stabilizes microtubules and causes catastrophic cell cycle arrest in G2/M. Taxanes also initiate apoptosis by activating signal pathways, such as the jun N-terminal kinase (JNK) pathway. Strategies aimed at potentiating cell death signaling may improve their efficacy while lessening the potential side effects. We reported that all-trans retinoic acid (ATRA) potentiated taxane-mediated cell death. Here we investigated whether ATRA potentiates cell death signaling through the JNK pathway. Activation of JNK by Taxotere 0.01, 0.1 and 1.0 muM was observed at 24h in adherent cells and increased at 48h. Taxotere 0.001 muM-induced JNK activation started after 48h and increased at 72h. The timing and intensity of PARP cleavage was similar to that of JNK activation. JNK activation and PARP cleavage induced by 30 nM Taxotere at 48h were reversed by curcumin, PD169316 and SP600125, JNK inhibitors in order of progressive specificity. None of these inhibitors had an effect on p38 or ERK phosphorylation. All three inhibitors reversed Taxotere-induced phosphorylation of Bcl-2. ATRA induced JNK activation at 24, 48 and 72h. Incubating cells with ATRA 0.01 muM for 3 days prior to Taxotere treatment potentiated Taxotere-induced JNK activation 24 and 48h later, an effect sustained for 72h. Cytotoxicities from 3-day ATRA 0.01 muM incubations were synergistic with subsequent 1-h Taxotere 0.01, 0.1 and 1.0 muM incubations in breast cancer cell lines MCF-7 and MDA-MB-231 and in prostate cancer cell lines LNCaP and PC-3, and additive in breast cancer cell line SK-Br-3. These data demonstrate the potentiation of Taxotere-induced cell death by ATRA pretreatment in breast and prostate cancer cells, and support a mechanism through accentuated and sustained JNK activation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wieder, R (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, MSB I-596,185 S Orange Ave, Newark, NJ 07103 USA.	wiederro@umdnj.edu						Aapro M, 1996, ANTI-CANCER DRUG, V7, P33, DOI 10.1097/00001813-199608002-00009; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Consolini R, 1998, J CLIN ONCOL, V16, P907, DOI 10.1200/JCO.1998.16.3.907; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; DAWSON MI, 1995, CANCER RES, V55, P4446; Fenig E, 1997, CLIN CANCER RES, V3, P135; Fitzgerald P, 1997, CANCER RES, V57, P2642; Flicker SH, 1997, CANCER LETT, V115, P63, DOI 10.1016/S0304-3835(97)04715-0; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; GRECO WR, 1995, PHARMACOL REV, V47, P331; Grunt TW, 1998, BRIT J CANCER, V78, P79, DOI 10.1038/bjc.1998.446; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Jones HE, 1997, PROSTATE, V30, P174; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Li MT, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-16; Liang JY, 1999, PROSTATE, V38, P228; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Masuda M, 2002, JPN J CANCER RES, V93, P329, DOI 10.1111/j.1349-7006.2002.tb02176.x; Moos PJ, 1998, CELL GROWTH DIFFER, V9, P687; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Nabholtz J M, 2000, Expert Opin Pharmacother, V1, P187, DOI 10.1517/14656566.1.2.187; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Petras J, 2000, LAT AM PERSPECT, V27, P3, DOI 10.1177/0094582X0002700501; Rishi AK, 1996, CANCER RES, V56, P5246; Schneider SM, 2000, CANCER RES, V60, P5479; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Sun SY, 1999, CANCER RES, V59, P2829; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Torres K, 1998, CANCER RES, V58, P3620; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang H, 2001, FEBS LETT, V503, P91, DOI 10.1016/S0014-5793(01)02699-0; Wang Q, 2000, CANCER RES, V60, P2040; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wanner R, 2002, J MOL MED, V80, P61, DOI 10.1007/s00109-001-0288-0; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Wieder R, 1999, PRACT APPROACH SER, V215, P1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XC, 1997, CANCER RES, V57, P4992; Yang CPH, 2002, BBA-MOL CELL RES, V1590, P76, DOI 10.1016/S0167-4889(02)00200-8; Yokoo T, 1997, AM J PHYSIOL-RENAL, V273, pF206, DOI 10.1152/ajprenal.1997.273.2.F206; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zheng A, 2000, ACTA HAEMATOL-BASEL, V103, P135, DOI 10.1159/000041036; Zou CP, 1998, CLIN CANCER RES, V4, P1345	56	51	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					426	433		10.1038/sj.onc.1207040	http://dx.doi.org/10.1038/sj.onc.1207040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724571				2022-12-17	WOS:000188098300013
J	Huang, MC; Lee, HY; Yeh, CC; Kong, Y; Zaloudek, CJ; Goetzl, EJ				Huang, MC; Lee, HY; Yeh, CC; Kong, Y; Zaloudek, CJ; Goetzl, EJ			Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA(2))	ONCOGENE			English	Article						vascular endothelial growth factor; urokinase-type plasminogen activator; lysophospholipids; lipid mediators; ovarian cancer	VASCULAR-PERMEABILITY FACTOR; PROSTATE-CANCER CELLS; SIGNAL-TRANSDUCTION; FACTOR VEGF; LYSOPHOSPHOLIPASE-D; ASCITES-FORMATION; SPLICE VARIANTS; EXPRESSION; TUMORS; GENE	The lipid growth factor lysophosphatidic acid (LPA) is produced by ovarian cancer cells in quantities sufficient to attain concentrations of up to 10 muM. An autocrine circuit was demonstrated when ovarian cancer cells, but not normal ovarian surface epithelial cells, were proven to express LPA(2) (Edg-4) and LPA(3) (Edg-7) G protein-coupled receptors for LPA. Human LPA(2) now has been expressed transgenically in C57BL/6 mouse ovaries under direction of the alpha-inhibin large promoter. Human LPA(2) mRNA and protein were detected in all transgenic (TG) mouse ovaries at levels far higher than in other tissues and at least fivefold higher than in cultured lines of human ovarian cancer cells, with the expected sex cord-stromal distribution. Most LPA(2) TG ovaries produced significantly higher levels than non-TG ovaries of type A, but not type B, vascular endothelial growth factor (VEGF), isomers of VEGF-A, and urokinase-type plasminogen activator (uPA). Many LPA(2) TG ovaries had elevated expression of VEGF receptors 1 and 2, and a depressed level of type 2 PA inhibitor. Thus, the LPA-LPA(2) circuit regulates ovarian cells both directly and through increases in protein growth factor systems.	Univ Calif San Francisco, Med Ctr, Dept Med Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med Microbiol & Immunol, UB8B,Box 0711,533 Parnassus Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu		Lee, Hsinyu/0000-0002-1477-0183				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Dolezalova H, 2003, J CELL BIOCHEM, V88, P732, DOI 10.1002/jcb.10394; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fujimoto J, 1998, CANCER-AM CANCER SOC, V83, P2528, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2528::AID-CNCR18>3.0.CO;2-N; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Goetzl EJ, 1999, CANCER RES, V59, P5370; Hazelton D, 1999, CLIN CANCER RES, V5, P823; Hsu SY, 1996, ENDOCRINOLOGY, V137, P4837, DOI 10.1210/en.137.11.4837; Hu LM, 2002, AM J PATHOL, V161, P1917, DOI 10.1016/S0002-9440(10)64467-7; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Luo JC, 1998, CANCER RES, V58, P2652; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Orre M, 1999, INT J CANCER, V84, P101, DOI 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5; Qi C, 1998, J CELL PHYSIOL, V174, P261, DOI 10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Stimpfl M, 2002, CLIN CANCER RES, V8, P2253; TIGYI G, 2002, MOL CELLULAR BIOL LI, V1582, P1; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Yukita A, 2000, ANTICANCER RES, V20, P155; Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434-999-0373-0; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	42	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					122	129		10.1038/sj.onc.1206986	http://dx.doi.org/10.1038/sj.onc.1206986			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712217				2022-12-17	WOS:000187895300013
J	Ludwig, DL; Pereira, DS; Zhu, ZP; Hicklin, DJ; Bohlen, P				Ludwig, DL; Pereira, DS; Zhu, ZP; Hicklin, DJ; Bohlen, P			Monoclonal antibody therapeutics and apoptosis	ONCOGENE			English	Review						cancer; receptor tyrosine kinase; anti-angiogenesis; TRAIL; immunoglobulin; ErbB	ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMAS; FACTOR RECEPTOR BLOCKADE; HUMAN-BREAST-CANCER; COMPLEMENTARITY-DETERMINING REGIONS; PROTEIN-KINASE-A; PHASE I/II TRIAL; IN-VIVO; ANTITUMOR-ACTIVITY; TYROSINE KINASE	The potential for disease-specific targeting and low toxicity profiles have made monoclonal antibodies attractive therapeutic drug candidates. Antibody-mediated target cell killing is frequently associated with immune effector mechanisms such as antibody-directed cellular cytotoxicity, but they can also be induced by apoptotic processes. Antibody-directed mechanisms, including antigen crosslinking, activation of death receptors, and blockade of ligand-receptor growth or survival pathways, can elicit the induction of apoptosis in targeted cells. Depending on their mechanism of action, monoclonal antibodies can induce targeted cell-specific killing alone or can enhance target cell susceptibility to chemo- or radiotherapeutics by effecting the modulation of antiapoptotic pathways. This review will focus on the mechanisms by which antibodies are capable of eliciting programmed cell death either directly or indirectly within tumor cells.	ImClone Syst Inc, New York, NY 10014 USA	Eli Lilly	Ludwig, DL (corresponding author), ImClone Syst Inc, 180 Varick St, New York, NY 10014 USA.	dale@imclone.com						ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Bagshawe KD, 1996, ADV DRUG DELIVER REV, V22, P365, DOI 10.1016/S0169-409X(96)00443-7; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Baselga J, 2002, ONCOLOGIST, V7, P2; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Benini S, 2001, CLIN CANCER RES, V7, P1790; Bianco C, 2000, CLIN CANCER RES, V6, P4343; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; Bruns CJ, 2002, INT J CANCER, V102, P101, DOI 10.1002/ijc.10681; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; Dearden C, 2002, BIODRUGS, V16, P283, DOI 10.2165/00063030-200216040-00004; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Ekedahl J, 2002, EXP CELL RES, V279, P277, DOI 10.1006/excr.2002.5608; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Findley HW, 1999, LEUKEMIA, V13, P147, DOI 10.1038/sj.leu.2401280; FischerColbrie J, 1997, ANTICANCER RES, V17, P613; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Hu LM, 2002, AM J PATHOL, V161, P1917, DOI 10.1016/S0002-9440(10)64467-7; Huang SM, 1999, INVEST NEW DRUG, V17, P259, DOI 10.1023/A:1006384521198; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoue K, 2000, CLIN CANCER RES, V6, P2635; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kandasamy K, 2002, CANCER RES, V62, P4929; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Keppler-Hafkemeyer A, 2000, INT J CANCER, V87, P86, DOI 10.1002/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Kozin SV, 2001, CANCER RES, V61, P39; Kreitman R. J., 2001, Current Pharmaceutical Biotechnology, V2, P313, DOI 10.2174/1389201013378635; Kreitman RJ, 1999, BLOOD, V94, P3340, DOI 10.1182/blood.V94.10.3340.422k19_3340_3348; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Lee S, 2002, CANCER RES, V62, P5703; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu BL, 2001, ONCOGENE, V20, P3726, DOI 10.1038/sj.onc.1204490; Mallat Z, 2000, BRIT J PHARMACOL, V130, P947, DOI 10.1038/sj.bjp.0703407; Maloney DG, 2001, ANTI-CANCER DRUG, V12, pS1; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; MAUNG ZT, 1994, BRIT J HAEMATOL, V88, P105, DOI 10.1111/j.1365-2141.1994.tb04984.x; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Milas L, 2000, CLIN CANCER RES, V6, P701; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MIYASHITA T, 1993, BLOOD, V81, P151; Monks NR, 2001, BRIT J CANCER, V85, P764, DOI 10.1054/bjoc.2001.1947; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Napier MP, 2000, CLIN CANCER RES, V6, P765; NICHOLSON S, 1989, LANCET, V1, P182; Nor JE, 2001, CANCER RES, V61, P2183; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Overholser JP, 2000, CANCER, V89, P74, DOI 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Peltenburg LTC, 2000, Q J NUCL MED, V44, P355; Penuel E, 2001, SEMIN ONCOL, V28, P36, DOI 10.1053/sonc.2001.29711; Pietras RJ, 1999, CANCER RES, V59, P1347; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; POSEY J, 2002, AM SOC CLIN ONCOL, V21, pA17; Press OW, 2000, BLOOD, V96, P2934; Presta Leonard G., 2002, Current Pharmaceutical Biotechnology, V3, P237, DOI 10.2174/1389201023378256; Prewett M, 1999, CANCER RES, V59, P5209; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rosen Lee S, 2002, Cancer Control, V9, P36; Rowan W, 1998, IMMUNOLOGY, V95, P427; Sasaki M, 2003, INT J ONCOL, V22, P181; Sato J D, 1983, Mol Biol Med, V1, P511; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Senter PD, 2001, ADV DRUG DELIVER REV, V53, P247, DOI 10.1016/S0169-409X(01)00206-X; Shaheen RM, 2001, INT J ONCOL, V18, P221; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sheridan M T, 1997, Radiat Oncol Investig, V5, P180, DOI 10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.3.CO;2-Z; SHIBUYA M, 1990, ONCOGENE, V5, P519; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Sievers EL, 2000, CANCER CHEMOTH PHARM, V46, pS18, DOI 10.1007/PL00014043; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soffer SZ, 2001, J PEDIATR SURG, V36, P1177, DOI 10.1053/jpsu.2001.25747; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tortora G, 1999, CLIN CANCER RES, V5, P875; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; van der Kolk LE, 2002, LEUKEMIA, V16, P1735, DOI 10.1038/sj.leu.2402559; Vaughan TJ, 1998, NAT BIOTECHNOL, V16, P535, DOI 10.1038/nbt0698-535; VOLM M, 1992, ANTICANCER RES, V12, P11; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Ward E S, 1995, Ther Immunol, V2, P77; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Yakes FM, 2002, CANCER RES, V62, P4132; YARNOLD S, 1994, CANCER RES, V54, P506; Zhang LL, 2002, CANCER RES, V62, P2034; Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881	143	51	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9097	9106		10.1038/sj.onc.1207104	http://dx.doi.org/10.1038/sj.onc.1207104			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663488				2022-12-17	WOS:000187043600013
J	Bos, R; van Diest, PJ; van der Groep, P; Greijer, AE; Hermsen, MA; Heijnen, I; Meijer, GA; Baak, JPA; Pinedo, HM; van der Wall, E; Shvarts, A				Bos, R; van Diest, PJ; van der Groep, P; Greijer, AE; Hermsen, MA; Heijnen, I; Meijer, GA; Baak, JPA; Pinedo, HM; van der Wall, E; Shvarts, A			Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D-1 and hypoxia-inducible factor-1 alpha (HIF-1 alpha)	ONCOGENE			English	Article						BCL-6; HIF-1 alpha; cyclin D-1; oncogenes; breast cancer	D1; DIFFERENTIATION; OVEREXPRESSION	B-cell lymphoma gene (BCL-6) upregulation contributes to immortalization of mouse embryo fibroblast and primary B cells via upregulation of cyclin D-1. As cyclin D-1 overexpression is a common phenomenon in different cancers, BCL-6 protein overexpression may not be restricted to lymphomas. In this study, expression of BCL-6 was investigated by immunohistochemistry on paraffin-embedded specimens from 150 breast cancer patients and 10 specimens of normal breast tissue. The results showed BCL-6 overexpression (greater than or equal to10% of cells) in 24/150 (16%) breast cancer patients, whereas in normal breast low expression (<1%) of BCL-6 was observed. In linear regression analysis BCL-6 expression was associated with cyclin D-1 (r = 0.197, P = 0.016). Further, in chi(2) analyses, BCL-6-positivity was associated with overexpression of p53 (P = 0.016), and hypoxia-inducible factor-1 alpha (P < 0.001). Involvement of BCL-6 in breast carcinogenesis is further underscored by comparative genomic hybridization analysis that showed gains at the BCL-6 locus (3q27) in 14/86 (16%) breast cancer tissues. The cases with amplification in BCL-6 showed an increased (25%) incidence of BCL-6 protein overexpression. Thus, this study is the first to show that BCL-6 oncogene activation plays a role in cancers other than lymphomas.	Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; SiR Hosp, Dept Pathol, Stavanger, Norway	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Shvarts, A (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	a.shvarts@vumc.nl	Bos, Reinhard/AAS-1726-2020	Bos, Reinhard/0000-0003-1094-5596; Meijer, Gerrit/0000-0003-0330-3130				Bindra RS, 2002, CANCER RES, V62, P3014; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; de Jong JS, 1999, J CLIN PATHOL-MOL PA, V52, P78, DOI 10.1136/mp.52.2.78; Dunphy CH, 2001, LEUKEMIA LYMPHOMA, V41, P585, DOI 10.3109/10428190109060349; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Hermsen MAJA, 1998, J PATHOL, V186, P356; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ree HJ, 2003, HUM PATHOL, V34, P610, DOI 10.1016/S0046-8177(03)00086-8; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; vanDiest PJ, 1997, AM J PATHOL, V150, P705; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Ye BH, 2000, CANCER INVEST, V18, P356, DOI 10.3109/07357900009012179; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zhong H, 1999, CANCER RES, V59, P5830	19	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8948	8951		10.1038/sj.onc.1206995	http://dx.doi.org/10.1038/sj.onc.1206995			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654791				2022-12-17	WOS:000186982200016
J	Johnston, JB; Kabore, AF; Strutinsky, J; Hu, XJ; Paul, JT; Kropp, DM; Kuschak, B; Begleiter, A; Gibson, SB				Johnston, JB; Kabore, AF; Strutinsky, J; Hu, XJ; Paul, JT; Kropp, DM; Kuschak, B; Begleiter, A; Gibson, SB			Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia	ONCOGENE			English	Article						apoptosis; death receptors; chronic lymphocytic leukemia; TRAIL; chemotherapeutic drugs	TRAIL-INDUCED APOPTOSIS; LIGAND-INDUCED APOPTOSIS; MULTIPLE-MYELOMA; IN-VITRO; TRAIL/APO2L-INDUCED APOPTOSIS; DRUG-RESISTANCE; CYTOTOXIC DRUGS; TUMOR-CELLS; EXPRESSION; ACTIVATION	The standard treatments for chronic lymphocytic leukemia (CLL) include the alkylating agent chlorambucil (CLB) and the nucleoside analog fludarabine (F-ara-AMP, Flu). Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) is a death receptor ligand that induces apoptosis preferentially in tumors. However, CLL cells seem to be resistant to TRAIL-induced apoptosis. The TRAIL apoptotic signaling pathway has also been implicated in genotoxin-induced apoptosis through upregulation of TRAIL death receptors DR4 and DR5. In the present study, we demonstrate that the treatment of primary CLL cells with CLB or Flu increases the mRNA, protein and cell surface expression levels of DR4 and DR5 in a dose-dependent manner. In contrast to CLL cells, drug treatment fails to increase significantly the expression of DR4 or DR5 in normal lymphocytes. CLL cells are, however, resistant to TRAIL-induced apoptosis compared to B-cell lines. In contrast, combinational treatment using CLB or Flu with TRAIL (100 ng/ml) gave a synergistic apoptotic response. Furthermore, TRAIL is readily detectable on the cell surface of CLL cells, but TRAIL expression fails to increase following drug treatment. Preventing TRAIL from interacting with DR4 and DR5 decreases CLB-induced apoptosis in CLL cells. A similar, but less marked effect is observed with Flu. These findings indicate the involvement of the TRAIL apoptotic pathway in the mechanism of action of chemotherapy, and this mechanism could be utilized to sensitize CLL cells to TRAIL-induced apoptosis.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.			Gibson, Spencer/0000-0003-0119-732X				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; BEGLEITER A, 1995, LEUKEMIA, V9, P1875; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; Dighiero G, 2000, NEW ENGL J MED, V343, P1799, DOI 10.1056/NEJM200012143432410; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Gibson EM, 2002, CANCER RES, V62, P488; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gottardi D, 1996, BRIT J HAEMATOL, V94, P612, DOI 10.1046/j.1365-2141.1996.d01-1856.x; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Johnston JB, 1997, LEUKEMIA LYMPHOMA, V26, P435, DOI 10.3109/10428199709050881; JOHNSTON JB, 1999, WINTROBES CLIN HEMAT, P2405; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; Levesque MC, 2001, LEUKEMIA, V15, P1305, DOI 10.1038/sj.leu.2402192; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Pepper C, 1999, BRIT J HAEMATOL, V107, P611, DOI 10.1046/j.1365-2141.1999.01726.x; Plasilova M, 2002, LEUKEMIA, V16, P67, DOI 10.1038/sj.leu.2402338; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Ravi R, 2002, CANCER RES, V62, P1583; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; SAYERS TJ, 2003, BLOOD, V13, P13; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Vrhovac R, 1998, BLOOD, V91, P4694, DOI 10.1182/blood.V91.12.4694.412k09_4694_4700; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Zhao HX, 1998, BLOOD, V92, P1031	49	51	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8356	8369		10.1038/sj.onc.1207004	http://dx.doi.org/10.1038/sj.onc.1207004			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614459				2022-12-17	WOS:000186541500014
J	Aasen, T; Hodgins, MB; Edward, M; Graham, SV				Aasen, T; Hodgins, MB; Edward, M; Graham, SV			The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression	ONCOGENE			English	Article						gap junctions; connexins; cell-cell communication; papillomavirus; tumourigenesis; organotypic culture	HUMAN-PAPILLOMAVIRUS TYPE-16; CELL-CELL COMMUNICATION; INTERCELLULAR COMMUNICATION; GROWTH-CONTROL; HUMAN KERATINOCYTES; CARCINOMA CELLS; DOWN-REGULATION; HUMAN BREAST; E-CADHERIN; EXPRESSION	Disruption of gap junctional intercellular communication (GJIC) and/or connexins (gap junction proteins) is frequently reported in malignant cell lines and tumours. Certain human papillomaviruses (HPV) associated with the development of cancers, especially of the cervix, have previously been reported to downregulate GJIC in vitro. There is also evidence for reduced gap junctions in cervical dysplasia. However, many squamous hyperproliferative conditions, including HPV-induced warts, often show extensive upregulation of certain connexins. The association between HPV and GJIC, and the mechanism and consequence of deregulated GJIC in cervical tumour progression, remains unclear. Therefore, using a variety of nonmalignant and malignant cell lines and an organotypic raft-culture system, we investigated the relationship between HPV, gap junctions and tumour progression. Established cervical tumour cell lines carrying HPV were unable to communicate via gap junctions (when assayed by dye-transfer techniques). This correlated with lack of connexin protein expression, while transfection with connexins 26 or 43 led to functional gap junction membrane plaques. On the other hand, immortal but nonmalignant cell lines that contained episomal or integrated HPV-16, but required feeder-layer and growth-factor support, were consistently well coupled, and expressed multiple connexins at membrane junctions. In vitro selection of feeder-layer and growth-factor-independent variants eventually lead to loss of GJIC, which correlated with loss of membrane and increased cytoplasmic connexin 43 localization. However, this was preceded by loss of differentiation and stromal invasion, as assayed on the organotypic raft-culture model. Using this model, a comparison between noncoupled, well-coupled and connexin-transfected cell lines revealed no firm correlation between GJIC and dysplasia, but GJIC appeared to favour increased stratification. These findings demonstrate that loss of GJIC is frequent, but appears to occur more as a consequence of, rather than being the cause of, epithelial dysplasia, and may be influenced by, but is not directly attributable to, HPV.	Univ Glasgow, Div Canc Sci & Mol Pathol, Sect Squamous Cell Biol & Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Div Virol, IBLS, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow; University of Glasgow	Hodgins, MB (corresponding author), Univ Glasgow, Div Canc Sci & Mol Pathol, Sect Squamous Cell Biol & Dermatol, Robertson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	m.b.hodgins@clinmed.gla.ac.uk	Aasen, Trond/B-5279-2013	Aasen, Trond/0000-0003-0763-2695; Graham, Sheila/0000-0002-7140-8279	Wellcome Trust [064140] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Bhattacharyya T, 1998, MED MYCOL, V36, P15, DOI 10.1080/02681219880000031; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; Budunova IV, 1996, MOL CARCINOGEN, V15, P202; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Eiberger J, 2001, CELL COMMUN ADHES, V8, P163, DOI 10.3109/15419060109080717; ENNAJI MM, 1995, CELL MOL BIOL, V41, P481; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1993, J CELL SCI, V106, P463; FITZGERALD DJ, 1994, CARCINOGENESIS, V15, P1859, DOI 10.1093/carcin/15.9.1859; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Graeber SHM, 1998, EXP CELL RES, V243, P142, DOI 10.1006/excr.1998.4130; Habermann H, 2002, J UROLOGY, V167, P655, DOI 10.1016/S0022-5347(01)69118-3; Hernandez-Blazquez FJ, 2001, EXP CELL RES, V270, P235, DOI 10.1006/excr.2001.5342; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Holden PR, 1997, CARCINOGENESIS, V18, P15, DOI 10.1093/carcin/18.1.15; Huang RP, 1998, CANCER RES, V58, P5089; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2000, CARCINOGENESIS, V21, P311; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laird DW, 1999, CANCER RES, V59, P4104; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lesueur F, 2002, BIOCHEM BIOPH RES CO, V294, P108, DOI 10.1016/S0006-291X(02)00451-5; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Lucke T, 1999, J INVEST DERMATOL, V112, P354, DOI 10.1046/j.1523-1747.1999.00512.x; Manthey D, 2001, J MEMBRANE BIOL, V181, P137, DOI 10.1007/s00232-001-0017-1; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Martin PEM, 2001, J CELL SCI, V114, P3845; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; MCNUTT NS, 1971, J CELL BIOL, V51, P805, DOI 10.1083/jcb.51.3.805; MCNUTT NS, 1969, SCIENCE, V165, P597, DOI 10.1126/science.165.3893.597; MESNIL M, 1995, CANCER RES, V55, P629; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Naus CCG, 1999, ADV EXP MED BIOL, V468, P373; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Omori Y, 2001, MUTAT RES-FUND MOL M, V477, P191, DOI 10.1016/S0027-5107(01)00120-8; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Piechocki MP, 1999, CARCINOGENESIS, V20, P401, DOI 10.1093/carcin/20.3.401; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Richard G, 2002, AM J HUM GENET, V70, P1341, DOI 10.1086/339986; Risek B, 1998, J CELL SCI, V111, P1395; Saito T, 1998, ONCOGENE, V17, P1673, DOI 10.1038/sj.onc.1202092; Saito T, 2001, INT J CANCER, V93, P317, DOI 10.1002/ijc.1350; Saitoh M, 1997, CARCINOGENESIS, V18, P1319, DOI 10.1093/carcin/18.7.1319; Saunders MM, 2001, CANCER RES, V61, P1765; Sawey MJ, 1996, MOL CARCINOGEN, V17, P49, DOI 10.1002/(SICI)1098-2744(199610)17:2<49::AID-MC1>3.3.CO;2-8; Shore L, 2001, BIOCHEM J, V357, P489, DOI 10.1042/0264-6021:3570489; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tomakidi P, 2000, CELL TISSUE RES, V301, P323, DOI 10.1007/s004410000231; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Van Geel M, 2002, BRIT J DERMATOL, V146, P938, DOI 10.1046/j.1365-2133.2002.04893.x; VESSEY CJ, 1995, J PATHOL, V176, P151, DOI 10.1002/path.1711760208; Wiszniewski L, 2001, CELL COMMUN ADHES, V8, P409, DOI 10.3109/15419060109080762; Yamakage K, 1998, MOL CARCINOGEN, V23, P121, DOI 10.1002/(SICI)1098-2744(199810)23:2<121::AID-MC9>3.0.CO;2-P; Yamakage K, 2000, J INVEST DERMATOL, V114, P289, DOI 10.1046/j.1523-1747.2000.00873.x; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	81	51	56	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7969	7980		10.1038/sj.onc.1206709	http://dx.doi.org/10.1038/sj.onc.1206709			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970745				2022-12-17	WOS:000185388200012
J	Rangatia, J; Vangala, RK; Singh, SM; Zada, AAP; Elsasser, A; Kohlmann, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G				Rangatia, J; Vangala, RK; Singh, SM; Zada, AAP; Elsasser, A; Kohlmann, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G			Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBP alpha DNA binding via leucine zipper domain interaction	ONCOGENE			English	Article						C/EBP alpha; c-Jun; AML	TRANSCRIPTION-FACTOR; PROTEIN-ALPHA; BCR-ABL; GRANULOCYTIC DIFFERENTIATION; LINEAGE COMMITMENT; DOWN-REGULATION; PU.1; MUTATIONS; REGULATOR; GENE	Transcription factor C/EBPalpha induces normal myeloid differentiation, inactivation of C/EBPalpha leads to a differentiation block in acute myeloid leukemias (AML), and overexpression of C/EBPalpha results in ANIL growth arrest and differentiation. Recent reports suggest that C/EBPalpha is activated or inactivated via protein-protein interactions. We previously reported that C/EBPalpha needs to inactivate the proto-oncogene c-Jun via leucine zipper domain interaction in order to induce granulocytic differentiation. We, therefore, hypothesized that c-Jun expression might be elevated in AML and subsequently inactivate C/EBPalpha. In fact, compared to normal bone marrow mononuclear cells, c-Jun expression is increased in AML patient samples (Affymetrix expression microarray analysis, n = 166). c-Jun binds to C/EBPalpha via the leucine zipper domains and prevents C/EBPalpha from DNA binding. Inactivation of C/EBPalpha by c-Jun is necessary for c-Jun to induce proliferation because c-Jun-induced proliferation can be prevented by ectopic overexpression of C/EBPalpha. The dominant-negative 30-kDa C/EBPalpha protein, found in AML, fails to downregulate c-Jun mRNA expression in AML patient samples. Thus, our data suggest a model for AML in which c-Jun promotes proliferation and prevents differentiation by inhibiting C/EBPalpha DNA binding via leucine zipper domain interaction. It might depend on the expression levels of C/EBPalpha and c-Jun, if inhibition of C/EBPalpha by c-Jun or if inhibition of c-Jun by C/EBPalpha is more predominant: proliferation versus differentiation; AML versus normal myeloid development.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; GSF Res Ctr, Munich, Germany; Harvard Univ, Sch Med, Inst Med, Boston, MA USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.			Tenen, Daniel/0000-0002-6423-3888				Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; ELSAESSER A, 2003, IN PRESS ONCOGENE; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; MILLER M, 2003, J BIOL CHEM     0210; MIZUKI M, 2002, BLOOD           1205; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2002, BLOOD, V100, P2717, DOI 10.1182/blood-2002-03-0990; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; van Waalwijk van Doorn-Khosravani SB, 2002, HEMATOL J, V3, P324; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	31	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4760	4764		10.1038/sj.onc.1206664	http://dx.doi.org/10.1038/sj.onc.1206664			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879022				2022-12-17	WOS:000184157000018
J	Levine, JJ; Stimson-Crider, KM; Vertino, PM				Levine, JJ; Stimson-Crider, KM; Vertino, PM			Effects of methylation on expression of TMS1/ASC in human breast cancer cells	ONCOGENE			English	Article						DNA methylation; methyltransferase; apoptosis; ASC; gene regulation; transcription	RECRUITMENT DOMAIN PROTEIN; DNA METHYLATION; CPG ISLAND; GENE; TRANSCRIPTION; REPRESSION; PROMOTER; HYPERMETHYLATION; LEUKEMIA; COMPLEX	Gene silencing associated with aberrant methylation of promoter region CpG islands is one mechanism in which tumor suppressor genes are inactivated in human cancers. Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1) (also called ASC), which is aberrantly methylated and silenced in human breast cancers. To further investigate the mechanism of TMS1 silencing, we defined the transcription initiation site and detailed the DNA methylation pattern of the TMS1 CpG island in normal breast epithelial cells, breast cancer cell lines, and primary tumors. We find that in normal cells, the TMS1 CpG island lies within a 1.2kb unmethylated domain, the 5' boundary of which is in close proximity to the transcription initiation site. In breast cancer cell lines, this boundary appeared to be unstable in that methylation tended to accumulate in the 5' end of the CpG island relative to normal epithelial cells. In contrast, the 3' methylation boundary remained intact. Gene silencing was not correlated with the methylation of specific CpG sites nor the inability to transactivate the TMS1 promoter, but was correlated with the percentage of alleles in the population exhibiting dense methylation across the entire CpG island. Using 5-aza-deoxycytidine to reactivate TMS1 in methylated and silent cell lines, and a cassette methylation strategy to determine the impact of methylation on different parts of the promoter, we find that demethylation of a small region immediately surrounding the transcription start site is critical to TMS1 expression. Our data support the idea that gene silencing and dense methylation are tightly coupled events that affect individual chromosomal copies of TMS1 in an all-or-none manner. The transition to this stably repressed state may be facilitated by spreading of methylation into the proximal promoter and direct effects of methylation on TMS1 transcription.	Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Vertino, PM (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365-B Clifton Rd NE,Room B5119, Atlanta, GA 30322 USA.	pvertin@emory.edu		Crider, Krista/0000-0001-6997-5955	NCI NIH HHS [1R01 CA77337] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Conway KE, 2000, CANCER RES, V60, P6236; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Dammann R, 2001, CANCER RES, V61, P3105; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Han L, 2001, MOL CELL BIOL, V21, P3416, DOI 10.1128/MCB.21.10.3416-3424.2001; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kass Stefan U., 1993, Biochemical Society Transactions, V21, p9S; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kinoshita H, 2000, CANCER RES, V60, P3623; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Mann JR, 2000, CRIT REV EUKAR GENE, V10, P241; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; McConnell BB, 2000, CANCER RES, V60, P6243; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WANG L, 2002, J BIOL CHEM, V17, P17; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	40	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3475	3488		10.1038/sj.onc.1206430	http://dx.doi.org/10.1038/sj.onc.1206430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776200				2022-12-17	WOS:000183128500015
J	Senchenko, V; Liu, J; Braga, E; Mazurenko, N; Loginov, W; Seryogin, Y; Bazov, I; Protopopov, A; Kisseljov, FL; Kashuba, V; Lerman, MI; Klein, G; Zabarovsky, ER				Senchenko, V; Liu, J; Braga, E; Mazurenko, N; Loginov, W; Seryogin, Y; Bazov, I; Protopopov, A; Kisseljov, FL; Kashuba, V; Lerman, MI; Klein, G; Zabarovsky, ER			Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas	ONCOGENE			English	Article						quantitative real-time PCR; human chromosome 3p; tumor suppressor genes; NotI linking clone; loss of heterozygosity; cervical carcinoma	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; LUNG-CANCER; 3P DELETIONS; SHORT ARM; INTRAEPITHELIAL NEOPLASIA; EPIGENETIC INACTIVATION; ALLELIC LOSS; HETEROZYGOSITY; FREQUENT	We report chromosome 3p deletion mapping of 32 cervical carcinoma (CC) biopsies using 26 microsatellite markers located in frequently deleted 3p regions to detect loss of heterozygosity and homozygous loss. In addition, two STS markers (NLJ-003 and NL3-001) located in the 3p21.3 telomeric (3p21.3T) and 3p21.3 centromeric (3p21.3C) regions, respectively, were used for quantitative real-time PCR as TaqMan probes. We show that quantitative real-time PCR is reliable and sensitive and allows discriminating between 0, 1 and 2 marker copies per human genome. For the first time, frequent (five of 32 cases, i.e. 15.6%) homozygous deletions were demonstrated in CCs in both 3p21.3T and 3p21.3C regions. The smallest region homozygously deleted in 3p21.3C was located between D3S1568 (CACNA2D2 gene) and D3S4604 (SEMA3F gene) and contains 17 genes previously defined as lung cancer candidate Tumor suppressor genes (TSG(s)). The smallest region homozygously deleted in 3p21.3T was flanked by D3S1298 and NL1-024 (D3S4285), excluding DLEC1 and MYD88 as candidate TSGs involved in cervical carcinogenesis. Overall, this region contains five potential candidates, namely GOLGA4, APRG1, ITGA9, HYA22 and VILL, which need to be analysed. The data showed that aberrations of either NLJ-003 or NL3-001 were detected in 29 cases (90.6%) and most likely have a synergistic effect (P<0.01). The study also demonstrated that aberrations in 3p21.3 were complex and in addition to deletions, may involve gene amplification as well. The results strongly suggest that 3p21.3T and 3p21.3C regions harbor genes involved in the origin and/or development of CCs and imply that those genes might be multiple TSG(s).	Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; Russian State Genet Ctr, Moscow 113545, Russia; Russian Acad Med Sci, Blokhin Canc Res Ctr, Moscow 115478, Russia; NCI, Canc Causing Genes Sect, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Karolinska Institutet; Research Center of Biotechnology RAS; Russian Academy of Sciences; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Kashuba, Vladimir I/N-3732-2017; Kashuba, Vladimir/AAO-7742-2020; Zabarovsky, Eugene R/A-6645-2010; Loginov, Vytaliy I/J-9738-2018; Senchenko, Vera N/C-8992-2014; Braga, Eleonora A./P-5574-2016	Kashuba, Vladimir I/0000-0001-9416-8282; Loginov, Vytaliy I/0000-0003-2668-8096; Senchenko, Vera N/0000-0002-3119-515X; Braga, Eleonora/0000-0001-5188-4094; Bazov, Igor/0000-0003-4388-1656	PHS HHS [N01-C0-56000] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; ANGELONI D, 2001, SOURCEBOOK ASBESTOS, V23, P169; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Boulay JL, 1999, BIOTECHNIQUES, V27, P228, DOI 10.2144/99272bm03; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Braga E. A., 1997, Molekulyarnaya Biologiya (Moscow), V31, P985; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cairns JP, 1998, CLIN CANCER RES, V4, P441; Chiang PW, 1999, CLIN CANCER RES, V5, P1381; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; de Nooij-van Dalen AG, 1998, GENE CHROMOSOME CANC, V21, P30, DOI 10.1002/(SICI)1098-2264(199801)21:1<30::AID-GCC5>3.0.CO;2-9; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Fouret PJ, 1998, PATHOBIOLOGY, V66, P306, DOI 10.1159/000028038; Guo ZM, 2000, INT J CANCER, V86, P518, DOI 10.1002/(SICI)1097-0215(20000515)86:4<518::AID-IJC12>3.0.CO;2-Y; Guo ZM, 1998, ANTICANCER RES, V18, P707; Guo ZM, 2001, MODERN PATHOL, V14, P54, DOI 10.1038/modpathol.3880256; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Helland A, 2000, INT J CANCER, V88, P217; Herzog CR, 2001, MOL CARCINOGEN, V30, P159, DOI 10.1002/mc.1024; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Kashuba VI, 1999, GENE, V239, P259, DOI 10.1016/S0378-1119(99)00411-4; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kisseljov F, 1996, INT J CANCER, V69, P484, DOI 10.1002/(SICI)1097-0215(19961220)69:6<484::AID-IJC12>3.3.CO;2-G; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Larson AA, 1997, CANCER RES, V57, P4082; Larson AA, 1997, CANCER RES, V57, P4171; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lerman MI, 2000, CANCER RES, V60, P6116; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; LIVAK KJ, 1995, PCR METH APPL, V4, P357; MANTEL N, 1967, CANCER RES, V27, P209; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Mazurenko N, 1999, ONCOL REP, V6, P859; Muller CY, 1998, J NATL CANCER I, V90, P433, DOI 10.1093/jnci/90.6.433; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Protopopov A, 2003, CANCER RES, V63, P404; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; Rader JS, 1996, ONCOGENE, V13, P2737; SAMOYLOVA EV, 1995, INT J CANCER, V61, P337, DOI 10.1002/ijc.2910610311; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Varella-Garcia M, 1998, CANCER RES, V58, P4701; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1997, CANCER RES, V57, P3154; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	52	51	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2984	2992		10.1038/sj.onc.1206429	http://dx.doi.org/10.1038/sj.onc.1206429			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771950				2022-12-17	WOS:000182824800014
J	Zhang, YF; Homer, C; Edwards, SJ; Hananeia, L; Lasham, A; Royds, J; Sheard, P; Braithwaite, AW				Zhang, YF; Homer, C; Edwards, SJ; Hananeia, L; Lasham, A; Royds, J; Sheard, P; Braithwaite, AW			Nuclear localization of Y-box factor YB1 requires wild-type p53	ONCOGENE			English	Article						YB1; p53; nuclear localization	MDR1 GENE-EXPRESSION; BINDING-PROTEIN YB-1; TRANSCRIPTIONAL TARGET; MONOCLONAL-ANTIBODY; POTENTIAL MEDIATOR; CELL-PROLIFERATION; APOPTOSIS; DOMAIN; TRANSACTIVATION; ACTIVATION	Nuclear localization and high levels of the Y-box binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we explore a role for p53 in the nuclear localization of YB1. We report that various genotoxic stresses induce nuclear localization of YB1 in a small proportion of treated cells, but only in cells with wild-type p53. We go on to show directly that functional p53 is required for YB1 to translocate to the nucleus. Tumor-associated p53 mutants however are attenuated for YB1 nuclear localization as are mutants mutated in the proline-rich domain of p53. These data link the DNA-damage response of p53 to YB1 nuclear translocation. In addition, we find that YB1 inhibits p53-induced cell death and its ability to transactivate promoters of genes involved in cell death signaling. Together these data suggest that some forms of p53 cause YB1 to accumulate in the nucleus, which in turn inhibits p53 activity. These results provide a possible explanation for the correlation of nuclear YB1 with drug resistance and poor prognosis in some tumor types, and for the first time implicate p53 in the process of nuclear translocation.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Genesis Res & Dev Corp Ltd, Auckland, New Zealand; Univ Otago, Sch Med Sci, Dept Physiol, Dunedin, New Zealand	University of Otago; University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, Box 913, Dunedin, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz		Edwards, Sara/0000-0002-3468-1217				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; Dix BR, 2000, CANCER RES, V60, P2666; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Prives C, 1999, J PATHOL, V187, P112; Robles AI, 2001, CANCER RES, V61, P6660; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; STEIN U, 2001, J BIOL CHEM, V21, P21; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Vater CA, 1996, ONCOGENE, V13, P739; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	51	51	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2782	2794		10.1038/sj.onc.1206357	http://dx.doi.org/10.1038/sj.onc.1206357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743601				2022-12-17	WOS:000182569300009
J	Shah, RNH; Ibbitt, JC; Alitalo, K; Hurst, HC				Shah, RNH; Ibbitt, JC; Alitalo, K; Hurst, HC			FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1 alpha	ONCOGENE			English	Article						FGFR4; pancreatic cancer; HNF1; intronic enhancer	FIBROBLAST GROWTH-FACTORS; TRANSCRIPTION FACTORS; MULTIGENE FAMILY; FACTOR RECEPTORS; GENE; EXPRESSION; HOMEOPROTEIN; MUTATIONS; PROMOTERS; DIVERSITY	Fibroblast growth factor receptor 4 (FGFR4) is expressed in 50-70% of pancreatic carcinomas (PC) and a similar proportion of derived cell tines. Here we determine the sites of FGFR4 transcriptional initiation which show a pattern characteristic of genes with GC-rich, TATA-less promoters. We have examined the chromatin structure around the FGFR4 gene in a panel of expressing and non-expressing PC tines using the DNase I hypersensitive site assay. One region of hypersensitivity, located largely within intron 1, was found to be greatly extended in expressing cells. Subsequent functional analyses using reporter assays demonstrated that this region was able to act as a cell-specific enhancer, only showing significant activity in PC tines expressing endogenous FGFR4. Transcription factors able to bind to the enhancer were investigated using footprinting and mobility shift assays and two binding sites for Sp1 proteins and two sites able to bind hepatic nuclear factor 1 (HNF1) proteins were identified. Further reporter assays using constructs mutated in each binding site demonstrated that HNF1 binding was essential for enhancer activity in expressing cells, an observation that correlated with the increased abundance of HNF1alpha in these same cells as measured by Western blotting. Finally we show that exogenous expression of HNF1 factors in an FGFR4 non-expressing line led to an induction of enhancer activity in reporter assays and also activated expression of the endogenous gene. We conclude that HNF1alpha is a major determinant of FGFR4 expression in PC.	Hammersmith Hosp, ICSM, Canc Res UK Mol Oncol Unit, London W12 0NN, England; Biomedicum Helsinki, Helsinki 00014, Finland	Cancer Research UK; Imperial College London; University of Helsinki	Hurst, HC (corresponding author), Hammersmith Hosp, ICSM, Canc Res UK Mol Oncol Unit, London W12 0NN, England.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ARMSTRONG E, 1992, GENE CHROMOSOME CANC, V4, P94, DOI 10.1002/gcc.2870040116; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bange J, 2002, CANCER RES, V62, P840; Becker M, 2000, BIOCHEM BIOPH RES CO, V276, P493, DOI 10.1006/bbrc.2000.3483; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Jang JH, 2001, CANCER RES, V61, P3541; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; KOBRIN MS, 1993, CANCER RES, V53, P937; Kostrzewa M, 1998, MAMM GENOME, V9, P131, DOI 10.1007/s003359900703; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Le Bras S, 1998, DIABETES, V47, P1236, DOI 10.2337/diabetes.47.8.1236; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; Li JX, 2000, GENE DEV, V14, P464; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miralles F, 1999, P NATL ACAD SCI USA, V96, P6267, DOI 10.1073/pnas.96.11.6267; OHATA T, 1995, BRIT J CANCER, V72, P824; Ornitz DM, 2001, GENOME BIOL, V2; Parakati R, 2002, J BIOL CHEM, V277, P9278, DOI 10.1074/jbc.M108411200; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264	37	51	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8251	8261		10.1038/sj.onc.1206020	http://dx.doi.org/10.1038/sj.onc.1206020			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447688				2022-12-17	WOS:000179323900003
J	Robinson, SJ; Healy, E				Robinson, SJ; Healy, E			Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix	ONCOGENE			English	Article						melanocortin 1 receptor; melanoma; proliferation; fibronectin	STIMULATING HORMONE IMMUNOREACTIVITY; INHIBITS EXPERIMENTAL METASTASIS; 1 RECEPTOR MC1R; MSH RECEPTOR; HUMAN MELANOCYTES; COAT COLOR; ALPHA-MELANOTROPIN; FAIR SKIN; RISK; EXPRESSION	Pigmentation is a significant determinant of individual susceptibility to cutaneous melanoma, with fair skinned subjects at highest risk of developing this neoplasm. Melanocortin 1 receptor (MC1R) gene variants alter pigment synthesis in vivo, and are causally associated with red hair and fair skin in humans. MC1R variants are more frequent in subjects with melanoma, and increase the risk of developing this tumour in sporadic and familial cases. MC1R variants may predispose to melanoma as a result of alterations in skin pigmentation (which affords less protection against incident ultraviolet radiation). However, melanoma cells synthesize and release alpha-melanocyte stimulating hormone (alphaMSH, the ligand for MC1R), therefore MC1R variants could alter the autocrine effects of alphaMSH on melanoma cell behaviour, thereby affecting early melanoma development and progression via non-pigmentary mechanisms. B16G4F melanoma cells, which are functionally null at Mc1r, were stably transfected with wild type and variant (Arg151Cys, Arg160Trp, and Asp294His) human MC1R. At similar MO receptor numbers per cell, aMSH increased intracellular cAMP in wild type MC1R transfected melanoma cells, but the cAMP response was compromised in the variant MCIR transfected clones. In growth inhibition experiments, alphaMSH significantly reduced growth of wild type MC1R transfected cells, but had no effect on cells transfected with variant MC1R. In addition, binding to fibronectin was significantly reduced by alphaMSH in the wild type transfectants whereas this was not observed in the variant transfected clones; binding to laminin was not affected by aMSH in this cell tine. These results provide evidence for differences in melanoma cell behaviour secondary to MC1R variants, and suggest an alternative non-pigmentary mechanism whereby MC1R variants could modify melanoma susceptibility or progression.	Univ Southampton, Southampton Gen Hosp, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Healy, E (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Mailpoint 825, Southampton SO16 6YD, Hants, England.	ehealy@soton.ac.uk		Healy, Eugene/0000-0001-5591-6970	MRC [G116/122] Funding Source: UKRI; Medical Research Council [G116/122] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abdel-Malek ZA, 2001, CELL MOL LIFE SCI, V58, P434, DOI 10.1007/PL00000868; Andersen GN, 2001, CLIN EXP IMMUNOL, V126, P441, DOI 10.1046/j.1365-2249.2001.01604.x; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Box NF, 2001, J INVEST DERMATOL, V116, P224, DOI 10.1046/j.1523-1747.2001.01224.x; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Chluba-de Tapia J, 1996, J CELL SCI, V109, P2023; CHLUBADETAPIA J, 1995, J RECEPT SIGNAL TR R, V15, P43; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; CROMBIE IK, 1979, BRIT J CANCER, V40, P185, DOI 10.1038/bjc.1979.165; Flanagan N, 2000, HUM MOL GENET, V9, P2531, DOI 10.1093/hmg/9.17.2531; GHANEM G, 1989, PIGM CELL RES, V2, P519, DOI 10.1111/j.1600-0749.1989.tb00248.x; HAAKE AR, 1999, DERMATOLOGY GEN MED, P70; Harding RM, 2000, AM J HUM GENET, V66, P1351, DOI 10.1086/302863; Haycock JW, 1999, J INVEST DERMATOL, V113, P560, DOI 10.1046/j.1523-1747.1999.00739.x; Healy E, 2001, HUM MOL GENET, V10, P2397, DOI 10.1093/hmg/10.21.2397; Healy E, 2000, LANCET, V355, P1072, DOI 10.1016/S0140-6736(00)02042-0; Hedley SJ, 1998, BRIT J DERMATOL, V138, P536; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; Jiang JW, 1995, PIGM CELL RES, V8, P314, DOI 10.1111/j.1600-0749.1995.tb00680.x; Jimenez-Cervantes C, 2001, J INVEST DERMATOL, V117, P156, DOI 10.1046/j.0022-202x.2001.01393.x; KAIDBEY KH, 1979, J AM ACAD DERMATOL, V1, P249, DOI 10.1016/S0190-9622(79)70018-1; Karjalainen JM, 1998, BRIT J CANCER, V77, P1917, DOI 10.1038/bjc.1998.318; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Kijas JMH, 2001, GENETICS, V158, P779; KLUNGLAND H, 1995, MAMM GENOME, V6, P636, DOI 10.1007/BF00352371; LEGROS F, 1981, CANCER RES, V41, P1539; Loir B, 1998, EUR J CANCER, V34, P424, DOI 10.1016/S0959-8049(97)10016-8; Luger TA, 2000, ANN NY ACAD SCI, V917, P232; LUNEC J, 1990, PATHOBIOLOGY, V58, P193, DOI 10.1159/000163583; Marklund L, 1996, MAMM GENOME, V7, P895, DOI 10.1007/s003359900264; Morandini R, 1998, J CELL PHYSIOL, V175, P276, DOI 10.1002/(SICI)1097-4652(199806)175:3<276::AID-JCP5>3.0.CO;2-L; MORETTI S, 1990, J INVEST DERMATOL, V95, P320, DOI 10.1111/1523-1747.ep12485060; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Murata J, 1997, INVAS METAST, V17, P82; NESBIT M, 1994, INVAS METAST, V14, P131; Newton JM, 2000, MAMM GENOME, V11, P24, DOI 10.1007/s003350010005; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; RAMPEN FHJ, 1988, ARCH DERMATOL, V124, P885, DOI 10.1001/archderm.124.6.885; RAMSAY JA, 1995, J INVEST DERMATOL, V105, P22, DOI 10.1111/1523-1747.ep12312431; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Smalley K, 2000, FEBS LETT, V476, P198, DOI 10.1016/S0014-5793(00)01726-9; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; SOLCA FF, 1993, FEBS LETT, V322, P177, DOI 10.1016/0014-5793(93)81563-F; Takeuchi S, 1996, BBA-GENE STRUCT EXPR, V1308, P164, DOI 10.1016/0167-4781(96)00100-5; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; THODY AJ, 1993, ANN NY ACAD SCI, V680, P381, DOI 10.1111/j.1749-6632.1993.tb19696.x; Vage DI, 1997, NAT GENET, V15, P311, DOI 10.1038/ng0397-311; Vage DI, 1999, MAMM GENOME, V10, P39, DOI 10.1007/s003359900939; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; WEINSTOCK MA, 1991, AM J EPIDEMIOL, V133, P240, DOI 10.1093/oxfordjournals.aje.a115868	58	51	51	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8037	8046		10.1038/sj.onc.1205913	http://dx.doi.org/10.1038/sj.onc.1205913			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439754				2022-12-17	WOS:000179097200013
J	Guo, Y; Stacey, DW; Hitomi, M				Guo, Y; Stacey, DW; Hitomi, M			Post-transcriptional regulation of cyclin D1 expression during G2 phase	ONCOGENE			English	Article						cell cycle; Ras; cyclin D1; in situ hybridization; single cell-based analysis; post-transcriptional regulation	INITIATION-FACTOR 4E; HISTONE MESSENGER-RNA; IN-SITU HYBRIDIZATION; CELL-CYCLE; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; NIH3T3 CELLS; RAS; PROGRESSION	During continuous proliferation, cyclin D1 protein is induced to high levels in a Ras-dependent manner as cells progress from S phase to G2 phase. To understand the mechanism of the Ras-dependent cyclin D1 induction, cyclin D1 mRNA levels were determined by quantitative image analysis following fluorescent in situ hybridization. Although a slight increase in mRNA expression levels was detected during the S/G2 transition, this increase could not explain the more robust induction of cyclin D1 protein levels. This suggested the involvement of post-transcriptional regulation as a mechanism of cyclin D1 protein induction. To directly test this hypothesis, the cyclin D1 transcription rate was determined by run-on assays. The transcription rate of cyclin D1 stayed steady during the synchronous transition from S the G2 phase. We further demonstrated that cyclin D1 protein levels could increase during G2 phase in the absence of new mRNA synthesis. alpha-Amanitin, a transcription inhibitor, did not suppress cyclin D1 protein elevation as the cells progressed from S to G2 phase, even though the inhibitor was able to completely block cyclin D1 protein induction during reentry into the cell cycle from quiescence. The half life of cyclin D1 protein was shortest during S phase indicating that a change in protein stability might play a role in post-translational induction of cyclin D1 in G2 phase. These data indicate a fundamental difference in the regulation of cyclin D1 production during continuous cell cycle progression and re-initiation of the cell cycle.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, NC2-150,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NCI NIH HHS [CA92194] Funding Source: Medline; NIGMS NIH HHS [GM 52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPH S, 1993, J CELL SCI, V105, P113; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dirks RW, 1996, HISTOCHEM CELL BIOL, V106, P151; DIRKS RW, 1995, HISTOCHEM CELL BIOL, V104, P391, DOI 10.1007/BF01458133; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kotelnikov V, 1997, CLIN CANCER RES, V3, P669; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Palakurthi SS, 2000, CANCER RES, V60, P2919; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Raap A K, 1997, Methods Mol Biol, V75, P367; Ramljak D, 2000, CARCINOGENESIS, V21, P1537, DOI 10.1093/carcin/21.8.1537; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shu JY, 1996, ONCOGENE, V13, P2421; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Srivastava R A, 1994, Methods Mol Biol, V31, P281; Stacey DW, 2000, MOL CELL BIOL, V20, P9127, DOI 10.1128/MCB.20.24.9127-9137.2000; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	57	51	52	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7545	7556		10.1038/sj.onc.1205907	http://dx.doi.org/10.1038/sj.onc.1205907			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386817				2022-12-17	WOS:000178618200010
J	Timms, JF; White, SL; O'Hare, MJ; Waterfield, MD				Timms, JF; White, SL; O'Hare, MJ; Waterfield, MD			Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells	ONCOGENE			English	Article						ErbB-2; cell cycle; cdk inhibitors; cdk2; luminal epithelial	PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; CANCER CELLS; INDUCED APOPTOSIS; CDK INHIBITORS; MESSENGER-RNA; D1 EXPRESSION; KINASE; P27(KIP1); GROWTH	Most breast cancers arise from luminal epithelial cells and 25-30% of these tumours overexpress the ErbB-2 receptor. Herein, a non-transformed, immortalized cell system was used to investigate the effects of ErbB-2 overexpression in luminal epithelial cells. The phenotypic consequence of ErbB-2 overexpression is a shortening of the G1 phase of the cell cycle and early S phase entry, which leads to hyperproliferation. We show that this effect was mediated through the up-regulation of cdk6 and cyclins D1 and E, and enhanced degradation and relocalization of P27(Kip1). These changes were effected predominantly through enhanced MAPK signalling, resulting in cdk2 hyperactivation. PI3K signalling also participated in cell cycle progression, since PI3K and MAPK coordinately regulated changes in cyclin D1 and cdk6 expression. Cdk4 activity was not required for cell cycle progression in these cells, and was constitutively inhibited through its association with p16(INK4A). MAPK-dependent induction of p21(Cip1) was also necessary for G1 phase progression, although its degradation by the proteasome was required for S phase entry. These data provide new insights into the complex molecular mechanisms underlying mitogenic cell cycle control in luminal epithelial cells, the cell type relevant to primary breast cancer, and show how ErbB-2 overexpression subverts this normal control.	Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Breast Canc Lab, Dept Surg, Royal Free & Univ Coll Med Sch, London W1W 7EJ, England	Ludwig Institute for Cancer Research; University of London; University College London	Timms, JF (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	jtimms@ludwig.ucl.ac.uk	Timms, John/A-1556-2010	Timms, John/0000-0002-4507-835X				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	64	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6573	6586		10.1038/sj.onc.1205847	http://dx.doi.org/10.1038/sj.onc.1205847			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242655				2022-12-17	WOS:000178202300003
J	Blagosklonny, MV				Blagosklonny, MV			Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs	ONCOGENE			English	Article						p53; mitosis; G2 arrest; checkpoints; paclitaxel	G(2) ARREST; DNA-DAMAGE; P53; CANCER; UCN-01; KINASE; P21(WAF1/CIP1); APOPTOSIS; PATHWAYS; THERAPY	By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells. However, DOX still protects a subset of tumor cell lines lacking wt p53 (HL60 and Jurkat leukemia cells), thus limiting the utility of protection of cells with wt p53 (e.g., normal cells). The present work overcomes this obstacle by adding an abrogator of p53-independent checkpoint (e.g., UCN-01) to the DOX-PTX sequence. By inhibiting a p53-independent pathway, UCN-01 overrode DOX-induced G2 arrest and instead induced G1 arrest in HL60 and Jurkat, thus propelling these p53-deficient cells from G2 to G1. Once they entered mitosis, cells were killed by PTX. Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. Unlike previous approaches, this strategy is intended to increase selectivity, not the cytotoxicity of PTX. This rational sequence of agents that induces p53-dependent and abrogates p53-independent arrest represents a cancer-selective strategy for treatment of p53-deficient tumors.	New York Med Coll, Brander Canc Res Inst, Dept Med, Hawthorne, NY 10532 USA	New York Medical College	Blagosklonny, MV (corresponding author), New York Med Coll, Brander Canc Res Inst, Dept Med, 19 Bradhurst Ave, Hawthorne, NY 10532 USA.							An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1999, LEUKEMIA, V13, P2031, DOI 10.1038/sj.leu.2401623; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 2001, INT J ONCOL, V19, P257; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li W, 1999, MOL PHARMACOL, V55, P1988; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; Smith APL, 2002, CELL CYCLE, V1, P16, DOI 10.4161/cc.1.1.96; Torres K, 1998, CANCER RES, V58, P3620; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1996, NATURE, V381, P643; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455	26	51	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6249	6254		10.1038/sj.onc.1205793	http://dx.doi.org/10.1038/sj.onc.1205793			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214265				2022-12-17	WOS:000177829000001
J	Ru, HY; Chen, RL; Lu, WC; Chen, JHS				Ru, HY; Chen, RL; Lu, WC; Chen, JHS			hBUB1 defects in leukemia and lymphoma cells	ONCOGENE			English	Article						mitosis checkpoint; hBUB1; chromosome instability; lymphoma; leukemia	SACCHAROMYCES-CEREVISIAE; CHECKPOINT; INSTABILITY; CANCER; GENES	Tumorigenesis is a multi-step process involving a series of changes of cellular genes. Most solid tumors and hematopoietic malignancies often show abnormal chromosome numbers, the aneuploidy. The chromosomal aneuploidy keeps cells in the state of chromosomal instability (CIN) that will increase the mutation rate of cells affected and thus push them deeper into the process of tumorigenesis. The yeast genetic studies showed that normal distribution of chromosome during mitosis is under the surveillance of a set of genes, the spindle assembly checkpoint genes, that include the BUB and MAD gene groups and MPS. In some colorectal cancers with CIN it was found to have hBUB1 gene mutated and the mutated gene functions dominantly. We have examined a series of breast cancer cell lines with or without CIN for the hBUB1 gene mutation and found none. However, we detected various degrees of deletion in the coding sequences of the hBUB1 gene in cells from T lymphoblastic leukemia cell lines, Molt3 and Molt4, and cells from some acute lymphoblastic leukemia and Hodgkin's lymphoma patients. So far the lesions of deletion are in the kinetochore localization domain of the hBUB1 gene that may explain why the deletion lesions in the BUB1 gene cause aneuploidy in lymphoma and lymphoma cells. The deletions are heterozygous in nature. Like the mutated hBUB1 gene in colorectal cancer, the mutant hBUB1 cDNA from lymphoblastic leukemia cells behaves dominantly.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; Tzu Chi Univ, Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Dept Pediat, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JHS (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd,Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw	LU, Wei-Cheng/O-5577-2017	Chen, Rong-Long/0000-0003-0290-9886				Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOEB LA, 1991, CANCER RES, V51, P3075; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057	16	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4673	4679		10.1038/sj.onc.1205585	http://dx.doi.org/10.1038/sj.onc.1205585			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096343				2022-12-17	WOS:000176625100008
J	Vecsey-Semjen, B; Becker, KT; Sinski, A; Blennow, E; Vietor, I; Zatlouka, K; Beug, H; Wagner, E; Huber, LA				Vecsey-Semjen, B; Becker, KT; Sinski, A; Blennow, E; Vietor, I; Zatlouka, K; Beug, H; Wagner, E; Huber, LA			Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers	ONCOGENE			English	Article						colon cancer; cell line; Wnt signaling; APC; E-cadherin; p53	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; BETA-CATENIN; GASTRIC-CANCER; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; RAPID DETECTION; CYCLIN D1; APC GENE; C-MYC	A major obstacle to obtaining more detailed insights into the diversity of phenotypic and molecular changes occurring in colon cancer cells is the lack of low-passage colon cancer cell lines, which would still closely reflect the phenotype of the colon cancer cells in vivo. Here, we characterize eight novel, low passage number human colon carcinoma cell lines, originating from colorectal cancers extensively characterized in the clinics. All cell lines closely resemble the original tumors with respect to phenotype, markers and detectable genetic changes. Cell morphology and marker expression is highly variable, ranging from fully polarized cells correctly expressing all basolateral epithelial markers, to cells with mesenchymal characteristics and a complete loss; of polarity due to delocalization or loss of junction complex proteins. The alterations in phenotype and epithelial marker expression correspond to changes already detectable in the primary tumor in vivo. Seven of the cell lines show chromosomal instability, while one cell line is characterized by microsatellite instability. p53 associated with K-ras mutations were detected in three cell, lines. Hitherto non-described E-cadherin mutations were found at both alleles in one cell line whereas in another cell line the E-cadherin protein was down-regulated. A stabilizing beta-catenin mutation (S45F) appears in the same cell line that carried the mutated E-cadherin gene. Six cell lines carried APC mutations, which in five of the lines led to an activated beta-catenin/Tcf/LEF signaling pathway.. In accordance with beta-catenin/Tcf/LEF activation, the cell lines show increased migration and invasiveness. Our results show that the characterized, low-passage cell lines mirror the diversity of the individual tumors from which they were derived. Through molecular analyses of these cell lines we demonstrate that tumorgenicity events are much more diverse in human colon cancer than expected, despite the common origin of the tumors from a small patient group with similar tumor grading and clinical prognosis.	IMP, Res Inst Mol Pathol, Vienna, Austria; Tech Univ Munich, Dept Pathol, D-8000 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; Boehringer Ingelheim Austria GmbH, Live Vaccine Div, Vienna, Austria; Karolinska Hosp, Dept Clin Genet, S-10401 Stockholm, Sweden; Graz Univ, Inst Pathol, Graz, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Boehringer Ingelheim; Karolinska Institutet; Karolinska University Hospital; University of Graz	Wagner, E (corresponding author), IMP, Res Inst Mol Pathol, Vienna, Austria.	ernst.wagner@cup.uni-muenchen.de; huber@nt.imp.univie.ac.at	Wagner, Ernst/A-7435-2012; Wagner, Ernst/ABB-5976-2020; Huber, Lukas Alfons/AAM-3499-2021; Becker, Karl-Friedrich/D-3636-2015	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Huber, Lukas Alfons/0000-0003-1116-2120; Becker, Karl-Friedrich/0000-0002-6801-4498				ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Becker K F, 1999, Hum Mutat, V13, P171, DOI 10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU14>3.0.CO;2-Z; Becker KF, 1996, TRENDS GENET, V12, P250, DOI 10.1016/S0168-9525(96)90032-3; BECKER KF, 2002, IN PRESS J PATHOL; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; CHANTRET I, 1994, J CELL SCI, V107, P213; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dietmaier W, 1997, CANCER RES, V57, P4749; Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Guerrero S, 2000, CANCER RES, V60, P6750; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han AC, 2000, ARCH PATHOL LAB MED, V124, P1147; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANDFORD H, 1890, T PATHOLOGICAL SOC L, V41, P133; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Hartmann C, 1999, INT J ONCOL, V15, P975; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hsu MY, 2000, J CELL SCI, V113, P1535; JEN J, 1994, CANCER RES, V54, P5523; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KAHN S, 1987, ANTICANCER RES, V7, P639; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; Klein G, 1998, ADV CANCER RES, V72, P1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lochter A, 1999, MATRIX BIOL, V18, P455, DOI 10.1016/S0945-053X(99)00036-0; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mo YY, 1996, CANCER RES, V56, P2633; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagase H, 1996, JPN J CANCER RES, V87, P1025, DOI 10.1111/j.1349-7006.1996.tb03104.x; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oh JH, 1999, INT J CANCER, V81, P902, DOI 10.1002/(SICI)1097-0215(19990611)81:6<902::AID-IJC11>3.0.CO;2-T; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pricolo VE, 1996, AM J SURG, V171, P41, DOI 10.1016/S0002-9610(99)80071-3; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; REICHMANN E, 1994, SEMIN CANCER BIOL, V5, P157; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sadot E, 1998, J NEUROCHEM, V70, P428; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vietor I, 2001, EMBO REP, V2, P306, DOI 10.1093/embo-reports/kve066; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Yamamoto H, 2001, CANCER RES, V61, P3139; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x	77	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4646	4662		10.1038/sj.onc.1205577	http://dx.doi.org/10.1038/sj.onc.1205577			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096341				2022-12-17	WOS:000176625100006
J	Allsopp, RC; Weissman, IL				Allsopp, RC; Weissman, IL			Replicative senescence of hematopoietic stem cells during serial transplantation: does telomere shortening play a role?	ONCOGENE			English	Article						telomere; hematopoietic stem cell; senescence; transplantation	TERMINAL TRANSFERASE; END-REPLICATION; IMMORTAL CELLS; LIFE-SPAN; CHROMOSOMES; TETRAHYMENA; EXPRESSION; EXTENSION; DNA; PROLIFERATION	Hematopoietic stem cells (HSC) have a finite proliferative lifespan, based upon the limited number of times they can be serially transplanted in mice. Telomeres have been shown to shorten during the division of many normal somatic cells in humans, and the attrition of telomeres has been shown to ultimately cause replicative senescence in vitro for a number of different human cell strains. Whereas most human cell types have little to no detectable levels of telomerase activity, hematopoietic cells, including HSC, express low to moderate levels of telomerase, and yet telomeres shorten considerably during replicative aging of these cells. Here we consider the role telomerase may play in the hematopoietic system as well as the effect that over-expression of telomerase reverse transcriptase may have on the replicative capacity of hematopoietic stem cells during transplantation.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University	Allsopp, RC (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	rallsopp@cmgm.Stanford.edu			NCI NIH HHS [CA 86065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed S, 1998, GENETICS, V150, P643; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Effros RB, 1998, AM J HUM GENET, V62, P1003, DOI 10.1086/301845; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; GUERRINI AM, 1993, HUM MOL GENET, V2, P455, DOI 10.1093/hmg/2.4.455; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kruk PA, 1996, BIOCHEM BIOPH RES CO, V224, P487, DOI 10.1006/bbrc.1996.1054; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yasumoto S, 1996, ONCOGENE, V13, P433	52	51	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3270	3273		10.1038/sj.onc.1205314	http://dx.doi.org/10.1038/sj.onc.1205314			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032768				2022-12-17	WOS:000175633300003
J	Weber, HO; Samuel, T; Rauch, P; Funk, JO				Weber, HO; Samuel, T; Rauch, P; Funk, JO			Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways	ONCOGENE			English	Article						INK4a/ARF; p53; p21; 14-3-3 sigma; DNA tumor virus	P19(ARF) TUMOR-SUPPRESSOR; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; MDM2; P14(ARF); CANCER; P21; P16(INK4A); PRODUCT	The tumor suppressor ARF is transcribed from the INK4a/ARF locus in partly overlapping reading frames with the CDK inhibitor p16(Ink4a). ARF is able to antagonize the MDM2-mediated ubiquitination and degradation of p53, leading to either cell cycle arrest or apoptosis, depending on the cellular context. However, recent data point to additional p53-independent functions of mouse p19(ARF). Little is known about the dependency of human p14(ARF) function on p53 and its downstream genes. Therefore, we analysed the mechanism of p14(ARF)-induced cell cycle arrest in several human cell types. Wild-type HCT116 colon carcinoma cells (p53(+/+)p21(CIP1+/+) 14-3-3sigma(+/+)), but not p53(-/-) counterparts, underwent G(1) and G(2) cell cycle arrest following infection with a p14(ARF)-adenovirus. In p21(CIP1-/-) cells, p14(ARF) did not induce G(1) or G(2) arrest, while 14-3-3sigma(-/-) counterparts were mainly arrested in G(1), pointing to essential roles of p21(CIP1) in G(1) and G(2) arrest and cooperative roles of p21 and 14-3-3sigma in ARF-mediated G(2) arrest. Our data demonstrate a strict p53 and p21(CIP1) dependency of p14(ARF)-induced cell cycle arrest in human cells.	Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, D-91052 Erlangen, Germany; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA	University of Erlangen Nuremberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Funk, JO (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, Hartmannstr 14, D-91052 Erlangen, Germany.							Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERMEKING H, 1997, MOL CELL, V1, P1; Herzinger T, 1995, ONCOGENE, V11, P2051; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Modestou M, 2001, CANCER RES, V61, P3145; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	51	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3207	3212		10.1038/sj.onc.1205429	http://dx.doi.org/10.1038/sj.onc.1205429			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082636				2022-12-17	WOS:000175373600012
J	Williamson, EA; Dadmanesh, F; Koeffler, HP				Williamson, EA; Dadmanesh, F; Koeffler, HP			BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						BRCA1; p27(Kip1); transcriptional regulation	TUMOR-SUPPRESSOR BRCA1; BREAST-CANCER; CELL-CYCLE; DNA-REPAIR; GENE-EXPRESSION; CDK-INHIBITOR; PROTEIN; ACTIVATION; PROMOTER; ARREST	The p27(Kip1) is a member of the universal cyclin-dependent kinase inhibitor family. Previously, immunochemical analysis of a series of breast cancer cell lines demonstrated a correlation between the expression of P27(Kip1) and the breast cancer susceptibility gene BRCA1. BRCA1 has a number of activities including DNA repair, growth inhibition and as a transcription factor. Here we demonstrate that BRCA1 transactivates expression of p27(Kip1). This transactivation is dependent on the presence of a functional C-terminal transactivation domain. Promoter-deletion analysis identified the presence of a putative BRCA1-responsive element located at position -615 to -511 of the p27(Kip1) promoter. These results suggest that the transcriptional regulation of p27(Kip1) by BRCA1 may be a mechanism for BRCA1- induced growth inhibition.	Univ Calif Los Angeles, Sch Med, Dept Med, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Anat Pathol, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Williamson, EA (corresponding author), Cedars Sinai Med Ctr, Dept Med Hematol Oncol, Davis Res Bldg,Room 5016,8700 Beverly Blvd, Los Angeles, CA 90048 USA.							Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Ciaparrone M, 1998, CANCER RES, V58, P114; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ELSTNER E, 2002, IN PRESS BREAST CANC; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; HALLIGAN BD, 1995, GENE, V161, P217, DOI 10.1016/0378-1119(95)00299-L; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hu YF, 2000, J BIOL CHEM, V275, P40910, DOI 10.1074/jbc.C000607200; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Katayose Y, 1997, CANCER RES, V57, P5441; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Masciullo V, 1999, CANCER RES, V59, P3790; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spirin KS, 1996, CANCER RES, V56, P2400; StCroix B, 1996, NAT MED, V2, P1204; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3199	3206		10.1038/sj.onc.1205461	http://dx.doi.org/10.1038/sj.onc.1205461			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082635				2022-12-17	WOS:000175373600011
J	Hiromura, K; Pippin, JW; Blonski, MJ; Roberts, JM; Shankland, SJ				Hiromura, K; Pippin, JW; Blonski, MJ; Roberts, JM; Shankland, SJ			The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation	ONCOGENE			English	Article						apoptosis; cell cycle; cyclin dependent kinase; mesangial cell	NUCLEAR EXPORT; BCL-2 FAMILY; IN-VITRO; CDK2; ACTIVATION; INHIBITION; P27(KIP1); DEATH; ROSCOVITINE; MECHANISMS	Apoptosis is closely linked to proliferation. In this study we showed that inducing apoptosis in mouse mesangial cells with ultraviolet (UV) irradiation was associated with increased cyclin A-cyclin dependent kinase (CDK) 2 activity. Inhibiting CDK2 activity with Roscovitine or dominant negative mutant reduced apoptosis. Because apoptosis typically begins in the cytoplasm, we tested the hypothesis that the subcellular localization of CDK2 determines the proliferative or apoptotic fate of the cell. Our results showed that cyclin A-CDK2 was nuclear in proliferating cells. However, inducing apoptosis in proliferating cells with UV irradiation was associated with a decrease in nuclear cyclin A and CDK2 protein levels. This coincided with an increase in protein and kinase activity for cyclin A-CDK2 in the cytoplasm. Translocation of cyclin A-CDK2 also occurred in p53(-/-) mesangial cells. Finally, we showed that caspase-3 activity was significantly reduced by inhibiting CDK2 activity with Roscovitine. In summary, our results show that apoptosis is associated with an increase in cytoplasmic cyclin A-CDK2 activity, which is p53 independent and upstream of caspase-3. We propose that the subcellular localization of CDK2 determines the proliferative or apoptotic fate of the cell.	Univ Washington, Sch Med, Div Nephrol, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Shankland, SJ (corresponding author), Univ Washington, Sch Med, Div Nephrol, Dept Med, Box 356521, Seattle, WA 98195 USA.	stuartjs@u.washington.edu			NIDDK NIH HHS [DK51096, DK56799, DK34198, DK47659, DK52121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034198, R01DK051096, P50DK047659, R01DK034198, R01DK056799, R01DK052121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2001, CIRC RES, V88, P408, DOI 10.1161/01.res.88.4.408; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Baptist M, 1996, J CELL PHYSIOL, V166, P256; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DANNO K, 1982, BRIT J DERMATOL, V107, P423, DOI 10.1111/j.1365-2133.1982.tb00385.x; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V253, P609, DOI 10.1006/bbrc.1998.9825; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miller LJ, 1998, SCIENCE, V281, P1301, DOI 10.1126/science.281.5381.1301; Minn AJ, 1998, ADV IMMUNOL, V70, P245, DOI 10.1016/S0065-2776(08)60388-0; Mooney A, 1997, J IMMUNOL, V159, P3949; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; NISHIOKA WK, 1994, J EXP MED, V179, P769, DOI 10.1084/jem.179.2.769; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; Reed SI, 1997, CANCER SURV, V29, P7; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; Shankland SJ, 2000, AM J PHYSIOL-RENAL, V278, pF515, DOI 10.1152/ajprenal.2000.278.4.F515; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Syljuasen RG, 1999, RADIAT RES, V152, P328, DOI 10.2307/3580333; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yao SL, 1996, CANCER RES, V56, P4551; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	44	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1750	1758		10.1038/sj.onc.1205238	http://dx.doi.org/10.1038/sj.onc.1205238			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896606				2022-12-17	WOS:000174214200013
J	Kawabe, T; Suganuma, M; Ando, T; Kimura, M; Hori, H; Okamoto, T				Kawabe, T; Suganuma, M; Ando, T; Kimura, M; Hori, H; Okamoto, T			Cdc25C interacts with PCNA at G2/M transition	ONCOGENE			English	Article						cell cycle; G2; M checkpoint; Cdc25C; PCNA; MPF	CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; PROTEIN-KINASE; HUMAN HOMOLOG; CHECKPOINT; REPLICATION; CYCLE; DAMAGE; BINDING; YEAST	Cdc25 activates maturation promoting factor (MPF) and promotes mitosis by removing the inhibitory phosphate from the Tyr-15 of Cdc2 in human cells. In this study, we searched the interacting protein(s) of human Cdc25C using the yeast two-hybrid screen and identified proliferating cell nuclear antigen (PCNA) as an interacting partner of Cdc25C. The interaction between Cdc25C and PCNA was confirmed in vitro and in vivo. Co-immunoprecipitation analyses using human T cell line, Jurkat, further revealed that Cdc25C interacted with PCNA transiently when cells began to enter mitosis. Immunofluorescence analysis also showed that Cdc25C and PCNA were transiently co-localized in the nucleus at the beginning of M phase. Together with the previous observations of the interaction between various cdc/cyclin and PCNA, our findings strongly suggested a potential role of PCNA at the G2 to M phase transition of cell cycle.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp						ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Gowdy PM, 1998, J CELL SCI, V111, P3401; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hindges R, 1997, BIOL CHEM, V378, P345; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDSAY HD, 1997, EMBO J, V16, P545; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Suganuma M, 1999, CANCER RES, V59, P5887; SZEPESI A, 1994, BLOOD, V84, P3413; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; ZENG XR, 1994, J BIOL CHEM, V269, P24027; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	53	51	53	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1717	1726		10.1038/sj.onc.1205229	http://dx.doi.org/10.1038/sj.onc.1205229			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896603				2022-12-17	WOS:000174214200010
J	Brennan, P; Mehl, AM; Jones, M; Rowe, M				Brennan, P; Mehl, AM; Jones, M; Rowe, M			Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells	ONCOGENE			English	Article						cyclin; survival; LY294002; PKB; latent membrane protein-1; EBNAZA	EPSTEIN-BARR-VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; LATENT MEMBRANE-PROTEIN; KINASE-B ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; BURKITTS-LYMPHOMA; C-MYC; BAD PHOSPHORYLATION; DOWN-REGULATION; CYCLE ARREST	B-cell lymphoma, which is increasing world wide, includes such varied conditions as post-transplant lymphoproliferative disease (PTLD) and Burkitt's lymphoma. This study has characterized a role for the signalling molecule phosphatidylinositol 3-kinase, PI3K, in the regulation of growth and survival of immortalized B-lymphocytes. Burkitt's lymphoma cells die rapidly following inhibition of PI3K with LY294002, a chemical inhibitor. Furthermore, Epstein-Barr virus (EBV) immortalized B-cells, lymphoblastoid cell lines, which are a model of PTLD, do not die but are growth inhibited. This growth inhibition is due to an accumulation at G1 phase of the cell cycle and is paralleled by a loss of E2F transcriptional activity, which is essential for cell cycle entry. An active form of PI3K promotes E2F transcriptional activity in lymphoblastoid cell lines. Treatment of LCL with LY294002 causes a reduction of the expression of both cyclin D2 and cyclin D3, two key cyclins required for cell cycle progression but does not affect the expression of the EBV latent genes, EBNA2A or LMP-1. LY294002 also causes an increase in p27kip1, a cyclin dependent kinase inhibitor and results in the dephosphorylation of members of the pocket protein family. These data describe a mechanism by which PI3K plays a role in B-lymphocyte growth and suggests that a pathway from PI3K to D-type cyclin expression may provide diagnostic or treatment opportunities.	Cardiff Univ, Sect Infect & Immun, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Brennan, P (corresponding author), Cardiff Univ, Sect Infect & Immun, Tenovus Bldg, Cardiff CF14 4XX, S Glam, Wales.	brennanp@cf.ac.uk	Brennan, Paul/B-9210-2009; Brennan, Paul/ABB-9196-2021; Rowe, Martin/B-2880-2009	Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499; Rowe, Martin/0000-0003-4139-7326				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brennan P, 2001, SEMIN CANCER BIOL, V11, P415, DOI 10.1006/scbi.2001.0408; Butler MP, 1999, GENE CHROMOSOME CANC, V24, P322, DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Chung TDK, 2000, PROSTATE, V42, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Fais F, 1996, INT J CANCER, V68, P810, DOI 10.1002/(SICI)1097-0215(19961211)68:6<810::AID-IJC20>3.0.CO;2-2; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gold MR, 2000, IMMUNOL REV, V176, P47; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Griffiths PD, 1999, J MED VIROL, V59, P496, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;496::AID-JMV12&gt;3.0.CO;2-U; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hinton HJ, 1999, J IMMUNOL, V162, P7002; *IARC W, 1997, EPST VIR KAP SARC HE, V70, P47; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jones KD, 1999, BLOOD, V94, P2871; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MILNER AE, 1993, ONCOGENE, V8, P3385; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; Nalesnik MA, 1998, SPRINGER SEMIN IMMUN, V20, P325, DOI 10.1007/BF00838047; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALMERO I, 1993, ONCOGENE, V8, P1049; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Rowe M, 2001, Methods Mol Biol, V174, P229; Rowe M, 1998, SPRINGER SEMIN IMMUN, V20, P389, DOI 10.1007/BF00838051; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tosato G, 1998, SPRINGER SEMIN IMMUN, V20, P405, DOI 10.1007/BF00838052; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; YOUNG LS, 1987, J GEN VIROL, V68, P2853, DOI 10.1099/0022-1317-68-11-2853	58	51	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1263	1271		10.1038/sj.onc.1205182	http://dx.doi.org/10.1038/sj.onc.1205182			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850846				2022-12-17	WOS:000173729400014
J	Clarke, P; Meintzer, SM; Spalding, AC; Johnson, GL; Tyler, KL				Clarke, P; Meintzer, SM; Spalding, AC; Johnson, GL; Tyler, KL			Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection	ONCOGENE			English	Article						apoptosis; TRAIL; reovirus; caspase 8; chemotherapy	INFLUENZA-VIRUS INFECTION; NECROSIS-FACTOR-ALPHA; TUMORICIDAL ACTIVITY; SIGNALING PATHWAY; DEATH RECEPTORS; MOLECULAR-BASIS; LIGAND; EXPRESSION; ACTIVATION; MODULATION	TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis in susceptible cells by binding to death receptors 4 (DR4) and 5 (DR5). TRAIL preferentially induces apoptosis in transformed cells and the identification of mechanisms by which TRAIL-induced apoptosis can be enhanced may lead to novel cancer chemotherapeutic strategies. Here we show that reovirus infection induces apoptosis in cancer cell lines derived from human breast, lung and cervical cancers. Reovirus-induced apoptosis is mediated by TRAIL and is associated with the release of TRAIL from infected cells. Reovirus infection synergistically and specifically sensitizes cancer cell lines to killing by exogenous TRAIL. This sensitization both enhances the susceptibility of previously resistant cell lines to TRAIL-induced apoptosis and reduces the amount of TRAIL needed to kill already sensitive lines. Sensitization is not associated with a detectable change in the expression of TRAIL. receptors in reovirus-infected cells. Sensitization is associated with an increase in the activity of the death receptor-associated initiator caspase. caspase 8, and is inhibited by the peptide IETD-fmk, suggesting that reovirus sensitizes cancer cells to TRAIL-induced apoptosis in a caspase 8-dependent manner. Reovirus-induced sensitization of cells to TRAIL is also associated with increased cleavage of PARP, a substrate of the effector caspases 3 and 7.	Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Tyler, KL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B 182, 4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014071] Funding Source: NIH RePORTER; NIA NIH HHS [1RO1AG14071] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; DeBiasi RL, 2001, J VIROL, V75, P351, DOI 10.1128/JVI.75.1.351-361.2001; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; DUKE RC, 1992, CURRENT PROTOCOLS IM; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Jelachich ML, 2001, J VIROL, V75, P5930, DOI 10.1128/JVI.75.13.5930-5938.2001; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kaplan D, 1998, J VIROL, V72, P6279, DOI 10.1128/JVI.72.8.6279-6282.1998; Keane MM, 1999, CANCER RES, V59, P734; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; OBERHAUS SM, 1998, CURRENT TOPICS MICRO, V233; Ozoren N, 2000, CANCER RES, V60, P6259; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Sedger LM, 1999, J IMMUNOL, V163, P920; Sieg S, 1996, J VIROL, V70, P8747, DOI 10.1128/JVI.70.12.8747-8751.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TYLER KL, 1985, NEUROLOGY, V35, P88, DOI 10.1212/WNL.35.1.88; Tyler KL, 1996, J VIROL, V70, P7984, DOI 10.1128/JVI.70.11.7984-7991.1996; TYLER KL, 1995, J VIROL, V69, P6972, DOI 10.1128/JVI.69.11.6972-6979.1995; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	43	51	54	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6910	6919		10.1038/sj.onc.1204842	http://dx.doi.org/10.1038/sj.onc.1204842			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687970				2022-12-17	WOS:000171641000012
J	Jazaeri, AA; Nunes, KJ; Dalton, MS; Xu, MH; Shupnik, MA; Rice, LW				Jazaeri, AA; Nunes, KJ; Dalton, MS; Xu, MH; Shupnik, MA; Rice, LW			Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression	ONCOGENE			English	Article						ER-alpha; ER-beta; PR; PR-B; endometrial cancer; MMMT	ESTROGEN-RECEPTOR-BETA; PROGESTERONE-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNAS; CANCER-CELLS; ALPHA; ACTIVATION; REGULATOR	Both the estrogen receptor (ER) and the progesterone receptor (PR) have two subtypes: ER-alpha and beta, and PR-A and -B, respectively. These subtypes differ in function and expression, and recent reports have correlated changes in the normal proportions of these isoforms with neoplastic states. We investigated ER and PR isoform expression in normal pre- and post-menopausal endometrium, well-differentiated endometrial adenocarcinoma, and poorly differentiated malignant mixed mullerian tumors (MMMTs). Semi-quantitative RT-PCR and immunoblotting were used to measure receptor mRNA and protein expression. Estrogen receptor-alpha/beta mRNA ratios were significantly higher in postmenopausal (27.3) compared to premenopausal endometrium (4.9) mainly as a result of lower ER-beta expression in the former. Compared to age-matched postmenopausal controls, the ER-alpha/beta ratio was reduced in both grade I adenocarcinoma and MMMT specimens (3.3 and 6.8, respectively), due to a selective loss of ER-alpha. The relative abundance of PR-A and PR-B mRNA remained unchanged between all tissue subtypes. Total PR protein, however, was significantly reduced in MMMTs compared to all other groups. Thus, sex steroid receptor expression is significantly and differentially altered in well-differentiated and poorly-differentiated endometrial cancers. Both cancers exhibit decreased ER-alpha expression and the MMMTs also demonstrate a significant loss of PR protein.	Univ Virginia, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Div Endocrinol, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Rice, LW (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Box 800712, Charlottesville, VA 22906 USA.	Lwr9y@virginia.edu	Jazaeri, Amir/I-3458-2015; Jazaeri, Amir/A-2400-2008	Jazaeri, Amir/0000-0003-4335-4151; 	NCI NIH HHS [K08 CA73668-01] Funding Source: Medline; NICHD NIH HHS [U54 HD 28934] Funding Source: Medline; NIDDK NIH HHS [R01 DK57082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA073668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057082] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; ANTUNES CMF, 1979, NEW ENGL J MED, V300, P9, DOI 10.1056/NEJM197901043000103; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; COSTA MJ, 1994, MODERN PATHOL, V7, P619; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FECHNER RE, 1974, CANCER-AM CANCER SOC, V34, P444, DOI 10.1002/1097-0142(197408)34:2<444::AID-CNCR2820340232>3.0.CO;2-J; Foley EF, 2000, CANCER RES, V60, P245; Graham JD, 1996, J STEROID BIOCHEM, V56, P93; Gray L A Sr, 1977, Obstet Gynecol Surv, V32, P619, DOI 10.1097/00006254-197709000-00023; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUSBERG SB, 1971, AM J OBSTET GYNECOL, V111, P633, DOI 10.1016/0002-9378(71)90965-3; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Ing NH, 1996, BIOL REPROD, V54, P591, DOI 10.1095/biolreprod54.3.591; Jazaeri O, 1999, GYNECOL ONCOL, V74, P38, DOI 10.1006/gyno.1999.5404; Kumar NS, 1998, CANCER RES, V58, P1860; Matsuzaki S, 1999, MOL HUM REPROD, V5, P559, DOI 10.1093/molehr/5.6.559; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Pujol P, 1998, CANCER RES, V58, P5367; Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0; Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051; SOPER JT, 1984, AM J OBSTET GYNECOL, V150, P342, DOI 10.1016/S0002-9378(84)80135-0; SUTTON GP, 1986, OBSTET GYNECOL, V68, P709; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Zelmanowicz A, 1998, GYNECOL ONCOL, V69, P253, DOI 10.1006/gyno.1998.4941	31	51	55	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6965	6969		10.1038/sj.onc.1204809	http://dx.doi.org/10.1038/sj.onc.1204809			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687977				2022-12-17	WOS:000171641000019
J	Miralem, T; Steinberg, R; Price, D; Avraham, H				Miralem, T; Steinberg, R; Price, D; Avraham, H			VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells	ONCOGENE			English	Article						VEGF; breast cancer; cell signaling; mitogenic response; cell migration	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHATIDYLINOSITOL 3-KINASE; FIBROBLAST-GROWTH; TYROSINE KINASE; VEGF RECEPTORS; IV COLLAGEN; INHIBITING FACTORS; BINDING DOMAIN; HEPARIN	The expression of VEGF and the relapse-free survival rate of breast cancer patients are inversely related. While VEGF induces the proliferation and migration of vascular endothelial cells, its function in breast cancer cells is not well studied. We reported previously that fibronectin increased VEGF-dependent migration in breast cancer cells. Since VEGF has an extracellular matrix (ECTM)-binding domain and possesses binding affinity for heparin, we sought to determine the effects of VEGF in breast cancer cells and the role of heparin and/ or fibronectin in VEGF-induced signaling. Cells grown on plastic were compared to those grown on fibronectin or to those grown on plastic in the presence of heparin, and analysed for intracellular signaling, proliferation and migration in response to VEGF(165). Both heparin and fibronectin enhanced the binding of VEGF to T47D cells. After treatment with VEGF, [H-3]thymidine incorporation, c-fos induction, and the number of migrating cells were significantly higher (similar to twofold) in cells grown on fibronectin or in cells grown on plastic in the presence of heparin when compared to those grown on plastic only. Likewise, tyrosine phosphorylation of VEGF receptors, MAPK activity and PI3-kinase activity were all severalfold higher in cells seeded on fibronectin or in the presence of heparin as compared to cells exposed to VEGF alone. VEGF-dependent c-fos induction was found to be regulated through a MAPK-dependent, but PI3-kinase-independent pathway. In contrast, the migration of T47D cells in response to VEGF, in the presence of ECM, was regulated through PI3-kinase. Therefore, VEGF requires ECM components to induce a mitogenic response and cell migration in T47D breast cancer cells.	Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, H (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu	Mordwinkin, Nicholas M/A-4347-2010; Miralem, Tihomir/F-7576-2013	Avraham, Hava/0000-0002-7545-3640; Miralem, Tihomir/0000-0001-7705-0442	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NIAMS NIH HHS [AR21 CA 87290-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHN NG, 1990, J BIOL CHEM, V265, P11487; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; Blancher C, 2000, CANCER RES, V60, P7106; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; De Jong JS, 1998, J PATHOL, V184, P44; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Derman MP, 1996, J BIOL CHEM, V271, P4251; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GRINNELL F, 1979, CELL, V17, P117, DOI 10.1016/0092-8674(79)90300-3; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HALPER J, 1990, EXP CELL RES, V187, P324, DOI 10.1016/0014-4827(90)90099-V; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; HICKS K, 1989, BIOCHEM BIOPH RES CO, V164, P1323, DOI 10.1016/0006-291X(89)91814-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; Joukov V, 1996, EMBO J, V15, P290; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livant DL, 2000, J CLIN INVEST, V105, P1537, DOI 10.1172/JCI8527; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; Miralem T, 1996, AM J PHYSIOL-RENAL, V270, pF960, DOI 10.1152/ajprenal.1996.270.6.F960; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; ORMEROD EJ, 1985, HISTOCHEM J, V17, P1155, DOI 10.1007/BF01002540; PAOLELLA G, 1988, NUCLEIC ACIDS RES, V16, P3545, DOI 10.1093/nar/16.8.3545; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; SHIBUYA M, 1999, CURR TOP MICROBIOL, P237; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Speirs V, 1999, BRIT J CANCER, V80, P898, DOI 10.1038/sj.bjc.6690438; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshiji H, 1996, CANCER RES, V56, P2013; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	80	51	54	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5511	5524		10.1038/sj.onc.1204753	http://dx.doi.org/10.1038/sj.onc.1204753			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571649	Bronze			2022-12-17	WOS:000170781100012
J	Luciano, F; Ricci, JE; Auberger, P				Luciano, F; Ricci, JE; Auberger, P			Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation	ONCOGENE			English	Article						apoptosis; Src kinases; caspases; T and B lymphocytes	PROTEIN-TYROSINE KINASES; FAS-MEDIATED APOPTOSIS; CELL-DEATH; HEMATOPOIETIC-CELLS; DOWN-REGULATION; DEFICIENT MICE; T-LYMPHOCYTES; B-CELLS; RECEPTOR; ACTIVATION	The members of the Src kinase family are expressed in a wide variety of tissues, but some of them such as Blk, Hck, Fgr, Lck and Lyn are found primarily in hematopoietic cells. In the present study, we have undertaken experiments to test whether Src kinase cleavage and relocation is a general mechanism during induction of apoptosis. Our results indicate that Fyn and Lyn are efficiently cleaved in their unique region in hernatopoietic cells undergoing apoptosis. Fyn cleavage occurred in Fas-stimulated Jurkat T cells but Fyn and Lyn were also processed in the SKW6.4 B cell line. Inhibition of caspases by Z-VAD-fmk or Ac-DEVD-CHO totally prevented Fyn and Lyn cleavage in both intact cells and in vitro. Fyn and Lyn but not Lek, Src and Hck were processed in vitro by human recombinant caspase 3 and by cellular extracts prepared from Fas-stimulated cells. Single mutation of Asp 19 or Asp 18 in the unique N-terminal domains of Fyn and Lyn respectively abolished their cleavage and relocation into the cytoplasm of apoptotic cells. When immunoprecipitated from COS cells N-terminal deleted Src kinases exhibited increased enzymatic kinase activity toward enolase. Thus, cleavage of Fyn and Lyn during induction of apoptosis represents a new mechanism for the regulation of Src kinases that may have important functional and physiological consequences.	Fac Med, Equipe Labellisee Ligue Natl Canc, INSERM U526, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), Fac Med, Equipe Labellisee Ligue Natl Canc, INSERM U526, IFR50,Ave Valombrose, F-06107 Nice 2, France.		luciano, frederic/P-6264-2016; Ricci, Jean Ehrland/I-7117-2016; RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013	luciano, frederic/0000-0001-9253-4998; Ricci, Jean Ehrland/0000-0003-1585-8117; RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; Katsuta H, 1998, J IMMUNOL, V160, P1547; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KRUEGER J, 1991, ONCOGENE, V6, P933; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; RICCI JE, 2001, IN PRESS FASEB J; RUDD CE, 1991, ADV EXP MED BIOL, V292, P85; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SUDOL M, 1993, ONCOGENE, V8, P823; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILLMAN CL, 1991, BLOOD, V77, P726; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; ZHAO YH, 1991, ONCOGENE, V6, P1725	46	51	51	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4935	4941		10.1038/sj.onc.1204661	http://dx.doi.org/10.1038/sj.onc.1204661			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526478				2022-12-17	WOS:000170439800003
J	Kozlova, NI; Morozevich, GE; Chubukina, AN; Berman, AE				Kozlova, NI; Morozevich, GE; Chubukina, AN; Berman, AE			Integrin alpha v beta 3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells	ONCOGENE			English	Article						integrins; apoptosis; anoikis; extracellular matrix	ENDOTHELIAL-CELLS; MELANOMA-CELLS; EXPRESSION; SURVIVAL; ACTIVATION; ADHESION; MATRIX; ANGIOGENESIS; INDUCTION; COLLAGEN	A population of cells surviving during prolonged incubation in suspension (anoikis-negative cells) were selected from the original anoikis-positive human intestinal carcinoma cell line Caco-2. Anoikis-negative cells are characterized by a strong transcriptional downregulation of the alphav-integrin chain as detected by FACS analysis, RT-PCR and Northern blotting. This finding suggested that ow-integrin generates a signal stimulating apoptosis of Caco-2 cells upon their detachment from the extracellular matrix. Two lines of evidence supporting this suggestion were provided. First, activation of the alphav beta3 integrin on Caco-2 cells by their treatment with an alphav beta3-specific monoclonal antibody resulted in marked stimulation of anoikis. Second, treatment of Caco-2 cells with alphav-specific antisense oligonucleotide resulted in downregulation of the expression of alphav chain and in elevated resistance of these cells to anoikis. Thus, for the first time, our data prove that alphav beta3 integrin can be an active transducer of apoptosis-stimulating signals generated in response to disruption of the cell-matrix contacts.	Russian Acad Med Sci, Inst Biomed Chem, Moscow 119832, Russia	Russian Academy of Medical Sciences; Institute of Biomedical Chemistry	Berman, AE (corresponding author), Russian Acad Med Sci, Inst Biomed Chem, Pogodinskaya Str 10, Moscow 119832, Russia.		Kozlova, Nadezda/ABD-7878-2020; Morozevich, Galina/ABD-7858-2020; EBerman, Albert/F-5042-2017					Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; Berman A E, 2000, Membr Cell Biol, V13, P207; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Danen EHJ, 1996, BIOCHEM BIOPH RES CO, V226, P75, DOI 10.1006/bbrc.1996.1313; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Eble J.A., 1997, MOL B INT U, P1; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kuzuya M, 1999, EXP CELL RES, V248, P498, DOI 10.1006/excr.1999.4422; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miao JY, 1997, BIOCHEM BIOPH RES CO, V233, P182, DOI 10.1006/bbrc.1997.6422; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morozevich GE, 1998, VOP MED KHIM, V44, P77; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	36	51	54	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4710	4717		10.1038/sj.onc.1204619	http://dx.doi.org/10.1038/sj.onc.1204619			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498793				2022-12-17	WOS:000170208600011
J	Chattopadhyay, A; Chiang, CW; Yang, E				Chattopadhyay, A; Chiang, CW; Yang, E			BAD/BCL-(xL) heterodimerization leads to bypass of G0/G1 arrest	ONCOGENE			English	Article						BAD; BCL-(xL); apoptosis; cell cycle arrest	DEATH AGONIST BAD; CELL-CYCLE ENTRY; BH3 DOMAIN; BCL-2 EXPRESSION; MICE DEFICIENT; PROTEIN; PHOSPHORYLATION; PROGRESSION; APOPTOSIS; FAMILY	The pro-apoptotic molecule BAD binds BCL-x(L) or BCL2 and inactivates their survival function. In addition to their anti-apoptotic function, BCL2 and BCL-xL also delay cell cycle entry from quiescence. We found that the BH3-only molecule BAD also exerted a cell cycle effect. BAD expression resulted in failure to cell cycle block in growth arrest conditions. In low serum and in confluence, fibroblasts constitutively or inducibly expressing BAD persisted in S phase, continued to incorporate BrdU, and exhibited sustained cyclin E/cdk2 activity. Mutation analysis indicated that the cell cycle effect of BAD was not dependent on its phosphorylation status or subcellular localization, but strictly co-segregated with BCL-xL binding. bclx(-/-) MEFs expressing BAD and bad(-/-) MEFs both arrested in G0/G1 in low serum similar to wild-type controls, suggesting that the ability to overcome the G0/G1 checkpoint resulted from the presence of BAD/BCL-x(L) heterodimers, rather than the absence of BCL-xL or BAD. These data provide evidence that in addition to regulating apoptosis, the BAD/BCLx(L) heterodimer has a novel cell cycle function.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yang, E (corresponding author), Vanderbilt Univ Sch Med, 525 MRB 2, Nashville, TN 37232 USA.	elizabeth.yang@mcmail.vanderbilt.edu			NCI NIH HHS [CA68485, 1RO1 CA78443] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA078443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lind EF, 1999, J IMMUNOL, V162, P5374; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	45	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4507	4518		10.1038/sj.onc.1204584	http://dx.doi.org/10.1038/sj.onc.1204584			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494146				2022-12-17	WOS:000170074900008
J	Celiker, MY; Wang, M; Atsidaftos, E; Liu, X; Liu, YE; Jiang, Y; Valderrama, E; Goldberg, ID; Shi, YE				Celiker, MY; Wang, M; Atsidaftos, E; Liu, X; Liu, YE; Jiang, Y; Valderrama, E; Goldberg, ID; Shi, YE			Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA	ONCOGENE			English	Article						TIMP-4; Wilms' tumor; gene therapy; growth inhibition; tumorigenesis	IN-VIVO; PROGELATINASE-A; GENE-TRANSFER; PROMOTING ACTIVITY; STROMAL CELLS; EXPRESSION; CANCER; METASTASIS; OVEREXPRESSION; SUPPRESSION	Extracellular matrix (ECM) degrading matrix metalloproteinases (MMPs) lead to ECM turnover, a key event in cancer growth and progression. The tissue inhibitors of matrix metalloproteinases (TIMPs) Limit the activity of MMPs, which suggests their use for cancer gene therapy. Here we report that systemic administration of naked TIMP-4 DNA significantly inhibited Wilms' tumor growth in nude mice. TIMP-4, whose expression was lost in Wilms' tumor, inhibited the growth of G401 Wilms' tumor tells at a concentration lower than those required for MMP inhibition. This inhibition was associated with internalization of exogenous recombinant TIMP-4, Electroporation-mediated intramuscular injection of TIMP-4 expression plasmid resulted in sustained plasma TIMP-4 levels and significant tumor suppression. Our data demonstrate a tumor suppressive effect of TIMP-4 against Wilms' tumor and the potential utility of intramuscular delivery of TIMP gene for treatment of kidney derived cancers.	Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Schneider Childrens Hosp, Long Isl Jewish Med Ctr, Div Pediat Hematol Oncol, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Med, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Pathol, New Hyde Park, NY 11040 USA	Northwell Health; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Northwell Health; Northwell Health; Northwell Health	Shi, YE (corresponding author), Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, New Hyde Park, NY 11040 USA.				NCI NIH HHS [CA68064-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; BACCALAO R, 1995, HDB BIOL CONFOCAL MI, P311; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRANCINI G, 1993, CANCER EPIDEM BIOMAR, V2, P125; GARVIN AJ, 1993, AM J PATHOL, V142, P375; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Heppner KJ, 1996, AM J PATHOL, V149, P273; Imren S, 1996, CANCER RES, V56, P2891; Jiang YF, 2001, CANCER RES, V61, P2365; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Liu YLE, 1997, J BIOL CHEM, V272, P20479, DOI 10.1074/jbc.272.33.20479; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; PYKE C, 1993, AM J PATHOL, V142, P359; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	33	51	60	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4337	4343		10.1038/sj.onc.1204508	http://dx.doi.org/10.1038/sj.onc.1204508			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466614				2022-12-17	WOS:000169912600007
J	Mori, N; Matsumoto, Y; Okumoto, M; Suzuki, N; Yamate, J				Mori, N; Matsumoto, Y; Okumoto, M; Suzuki, N; Yamate, J			Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis	ONCOGENE			English	Article						apoptosis susceptibility; susceptibility to radiation lymphomagenesis; genetic variation in DNA-PKcs; DNA double-strand breaks repair	SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; RECOMBINANT CONGENIC STRAINS; V(D)J RECOMBINATION; X-IRRADIATION; NONSENSE MUTATION; SCID MUTATION; BREAK REPAIR; MICE; THYMOCYTES	DNA double-strand breaks (DSBs) induced by ionizing radiation enforce cells to die, if unrepaired; while if misrepaired, DSBs may cause malignant transformation. The DSB repair system predominant in mammals requires DNA-dependent protein kinase (DNA-PK), Previously, we identified the apoptosis susceptibility gene Radiation-induced apoptosis 1 (Rapop1) on mouse chromosome 16, The STS/A (STS) allele at Rapop1 leads to decreased sensitivity to apoptosis in the BALB/cHeA (BALB/c) background. In the present study, we established Rapop1 congenic strains C,S-RI and C.S-R1L, which contain the STS genome in a 0.45 cM interval critical for Rapop1 in common in the BALB/c background. Within the segment critical for Rapop1, Prkdc encoding the catalytic subunit of DNA-PK (DNA-PKcs) was assigned. Two variations T6,418C and G11,530A, which induce amino acid substitutions C2,140R downstream from the putative leucine zipper motif and V3,844M near the kinase domain, respectively, were found between BALB/c and STS for Prkdc. The majority of inbred strains such as C57BL/6J carried the STS allele at Prkdc; a few strains including 129/SvJ and C.B17 carried the BALB/c allele. DNA-PK activity as well as DNA-PKcs expression was profoundly diminished in BALB/c and 129/SvJ mice as compared with C57BL/6 and C.S-R1 mice. In the crosses (C.S-R1 x BALB/c)F-1 x 129/SvJ and (C.S-R1 x BALB/c)F-1 x C.B17, enhanced apoptosis occurred in the absence of the wildtype allele at Prkdc. C.S-R1 and C.S-R1L were both less sensitive to radiation lymphomagenesis than BALB/ c, Our study provides strong evidence for Prkdc as a candidate for Rapop1 and a susceptibility gene for radiation lymphomagenesis as well.	Adv Sci & Technol Res Inst, Dept Appl Biosci, Osaka 5998570, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Pathol, Osaka 5998570, Japan; Univ Tokyo, Grad Sch Med, Dept Radiat Oncol, Bunkyo Ku, Tokyo 1130033, Japan	Japan Advanced Institute of Science & Technology (JAIST); Osaka Metropolitan University; University of Tokyo	Mori, N (corresponding author), Adv Sci & Technol Res Inst, Dept Appl Biosci, Osaka 5998570, Japan.		Matsumoto, Yoshihisa/G-3430-2017	Matsumoto, Yoshihisa/0000-0002-0758-290X				Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CUSTER RP, 1985, AM J PATHOL, V120, P464; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Kamisaku H, 1997, INT J RADIAT BIOL, V72, P191, DOI 10.1080/095530097143419; Kienker LJ, 2000, NUCLEIC ACIDS RES, V28, P2752, DOI 10.1093/nar/28.14.2752; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; Lund J, 1999, MAMM GENOME, V10, P438, DOI 10.1007/s003359901019; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Matsumoto Y, 1999, J RADIAT RES, V40, P183, DOI 10.1269/jrr.40.183; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MORI N, 1991, J RADIAT RES, V32, P277, DOI 10.1269/jrr.32.277; Mori N, 1998, MAMM GENOME, V9, P377, DOI 10.1007/s003359900773; MORI N, 1992, INT J RADIAT BIOL, V62, P153, DOI 10.1080/09553009214551961; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; Okayasu R, 2000, CANCER RES, V60, P4342; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1995, EXP ANIM TOKYO, V44, P43, DOI 10.1538/expanim.44.43; Park YG, 2000, CANCER LETT, V148, P95, DOI 10.1016/S0304-3835(99)00321-3; Peterson SR, 1997, J BIOL CHEM, V272, P10227; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Prise KM, 1998, INT J RADIAT BIOL, V74, P173, DOI 10.1080/095530098141564; SAKATA K, 2000, IN PRESS INT J RAD O; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Weil MM, 1996, RADIAT RES, V146, P646, DOI 10.2307/3579380; Weil MM, 1996, INT J RADIAT BIOL, V70, P579, DOI 10.1080/095530096144789; YAMADA T, 1988, INT J RADIAT BIOL, V53, P65, DOI 10.1080/09553008814550431; YOKORO K, 1986, RAD CARCINOG, P138	42	51	52	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3609	3619		10.1038/sj.onc.1204497	http://dx.doi.org/10.1038/sj.onc.1204497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439324				2022-12-17	WOS:000169400200002
J	Ludes-Meyers, JH; Liu, YM; Munoz-Medellin, D; Hilsenbeck, SG; Brown, PH				Ludes-Meyers, JH; Liu, YM; Munoz-Medellin, D; Hilsenbeck, SG; Brown, PH			AP-1 blockade inhibits the growth of normal and malignant breast cells	ONCOGENE			English	Article						AP-1; breast cancer; signal transduction; human mammary epithelial cells; carcinogenesis	MAMMARY EPITHELIAL-CELLS; C-JUN; INDUCED TRANSFORMATION; DELETION MUTANT; P53 MUTATIONS; CANCER CELLS; EXPRESSION; LINES; ACTIVATION; INDUCTION	We have previously demonstrated that basal AP-1 transcriptional activity is high in normal human mammary epithelial cells, intermediate in immortal breast cells, and relatively low in breast cancer cells. In this study we investigated whether differences in AP-1 transcriptional activity reflect differences in breast cells' dependence on AP-I for proliferation. The cJun dominant negative, TAM-67, was used to determine the effect of AP-1 blockade on the growth of normal, immortal and malignant breast cells. We first showed that TAM-67 inhibits AP-1 activity in normal and malignant breast cells. We then determined whether this AP-1 inhibitor affected colony forming efficiency of the immortalized and malignant breast cells. The AP-I inhibitor reduced colony formation of immortal breast cells by over 50% (by 58% in 184B5 cells and 62% in MCF10A cells), and reduced colony formation in the breast cancer cell line MCF7 by 43%, but did not reduce colony formation in the other breast cancer cell lines (T47D, MDA MB231 and MDA MB 435), We also determined the effect of AP-1 blockade on the growth of normal breast cells using a single cell proliferation assay. Using this assay, the growth of normal breast cells was extremely sensitive to AP-1 blockade, while immortal breast cells were moderately sensitive. We next directly tested the effect of TAM-67 expression on the growth of MCF7 breast cancer cells, using cells stably transfected with TAM-67 under the control of a doxycycline-inducible promoter. Upon induction, TAM-67 was expressed and AP-1 activity was inhibited in these cells. We then measured the growth of these cells in the presence or absence of TAM-67, The results of these studies show that the growth of MCF7 cells was suppressed by the AP-1 inhibitor, TAM-67. These results demonstrate that normal and immortalized breast cells, and some breast cancer cells (such as MCF7), require AP-1 to transduce proliferative signals, while other breast cancer cells (such as T47D, MDA MB231 and MDA MB 435) do not. These studies suggest that the AP-1 transcription factor is a potential target for future agents for the prevention or treatment of breast cancer.	Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Alkek 570-N,MS 600,1 Baylor Plaza, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NATIONAL CANCER INSTITUTE [T32CA070091] Funding Source: NIH RePORTER; NCI NIH HHS [CA70091] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BERENBLUM I, 1947, BRIT J CANCER, V1, P379, DOI 10.1038/bjc.1947.35; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katayose D, 1995, CLIN CANCER RES, V1, P889; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PETRAK D, 1994, J IMMUNOL, V153, P2046; Smith LM, 1997, CANCER RES, V57, P3046; SOULE HD, 1990, CANCER RES, V50, P6075; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRIPATHY D, 1993, ACTIVATED ONCOGENES, P15; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041	32	51	53	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2771	2780		10.1038/sj.onc.1204377	http://dx.doi.org/10.1038/sj.onc.1204377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420689				2022-12-17	WOS:000168712000005
J	Sablina, AA; Chumakov, PM; Levine, AJ; Kopnin, BP				Sablina, AA; Chumakov, PM; Levine, AJ; Kopnin, BP			p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling	ONCOGENE			English	Article						p53; cell cycle checkpoints; cell adhesion; microtubules	CELL-CYCLE CHECKPOINT; TUMOR-SUPPRESSOR P53; FOCAL ADHESIONS; DNA-DAMAGE; PHOSPHORYLATE P53; PROTEIN-KINASE; BAX GENE; IN-VIVO; PATHWAYS; ARREST	The p53 tumor suppressor is activated in response to various stresses driving the cells into growth arrest or apoptosis. We have addressed the question of how disintegration of microtubule system induces activation of p53. Depolymerization of microtubules by colcemid in rat and human quiescent fibroblasts resulted in accumulation of transcriptionally active p53 that caused cell-cycle arrest at the G1/S boundary. The p53 activation correlated with prominent activation of Erk1/2 MAP kinases that resulted from colcemid-stimulated development of focal adhesions. Inhibition of focal contacts development hy plating of cells onto poly-L-lysine abrogated both Erk1/2 and p53 activations in colcemid-treated cells, while plating of cells onto fibronectin caused transient up-regulation of p53 even in the absence of colcemid. Pre-treatment of cells with the specific MEK1 inhibitor PD098059 also attenuated colcemid-induced p53 activation and G1 cell cycle arrest. Cell types which either failed to develop focal adhesions in response to colcemid treatment (human MCF-7 epithelial cells), or lacked colcemid-induced sustained Erk activation (primary mouse embryo fibroblasts and 12(1) cells) showed virtually no p53 up-regulation in response to disruption of microtubules during G0/G1. Our results indicate that p53 activation is not triggered by disintegration of microtubule system by itself, but rather originates from some of the consequences of such disintegration, in particular, from the development of focal adhesions leading to activation of Erk signaling pathway.	Russian Canc Res Ctr, Inst Cancerogenesis, Moscow, Russia; RAS, VA Engelhardt Mol Biol Inst, Moscow, Russia; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Princeton University	Chumakov, PM (corresponding author), RAS, VA Engelhardt Mol Biol Inst, Moscow, Russia.		Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019; Sablina, Anna/P-2818-2019; Sablina, Anna/B-2217-2017	Kopnin, Boris/0000-0003-3100-2212; Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; Chehab NH, 2000, GENE DEV, V14, P278; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Harris CC, 1996, ENVIRON HEALTH PERSP, V104, P435, DOI 10.2307/3432799; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Khan SH, 1998, CANCER RES, V58, P396; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pletjushkina OJ, 1998, CELL ADHES COMMUN, V5, P121, DOI 10.3109/15419069809040286; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; RITTLING SR, 1992, ONCOGENE, V7, P935; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sablina AA, 1998, J CELL SCI, V111, P977; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542	45	51	54	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					899	909		10.1038/sj.onc.1204156	http://dx.doi.org/10.1038/sj.onc.1204156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314025				2022-12-17	WOS:000167097000001
J	Hubinger, G; Muller, E; Scheffrahn, I; Schneider, C; Hildt, E; Singer, BB; Sigg, I; Graf, J; Bergmann, L				Hubinger, G; Muller, E; Scheffrahn, I; Schneider, C; Hildt, E; Singer, BB; Sigg, I; Graf, J; Bergmann, L			CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299	ONCOGENE			English	Article						CD30; TNF receptor; cell cycle arrest; anaplastic large cell lymphoma (ALCL)	TNF RECEPTOR SUPERFAMILY; KAPPA-B ACTIVATION; NEGATIVE SELECTION; HODGKINS-DISEASE; FACTORS TRAFS; T-CELLS; DEATH; APOPTOSIS; INDUCTION; CD30	One of the major characteristics of anaplastic large cell lymphomas (ALCL) is the expression of the Ki-1/CD30 antigen. While the receptor mediates NF-kappaB-activation in Hodgkin's lymphomas, some data suggest the CD30-mediated apoptosis of other CD30-expressing cells. We were able to demonstrate that activation of CD30 leads to different effects regarding cell proliferation of the ALCL-derived cell lines Karpas 299 and JB6, Western and Northern blotting analysis re, revealed that CD30-induced growth inhibition of Karpas 299 cells correlated with a strong upregulation of the cell cycle inhibitor p21(CIP1/WAF1). We found a non activating point mutation at codon 273 in exon 8 of the p53 gene in Karpas 299 cells which indicates an p53-independent mechanism for induced p21 expression. Abundant p21 protein expression resulted in hypophosphorylation of the retinoblastoma protein (Rb) and inhibition of the proliferating cell nuclear antigen (PCNA). CD30-stimulated cells showed no indications of apoptotic cell death, like genomic DNA fragmentation or cleavage of the caspase3 target protein poly (ADP-ribose) polymerase (PARP), Our results indicate that CD30 is able to mediate an p21-associated cell cycle arrest in ALCL with possible implications for prognosis and clinical treatment.	Karolinska Inst, Dept Cellular & Mol Biol, Stockholm, Sweden; Robert Koch Inst, Dept Mol Biol, D-1000 Berlin, Germany; Univ Frankfurt, Dept Internal Med 3, D-6000 Frankfurt, Germany; Univ Ulm, Dept Internal Med 3, Ulm, Germany	Karolinska Institutet; Robert Koch Institute; Goethe University Frankfurt; Ulm University	Hubinger, G (corresponding author), Univ Ulm Klinikum, Dept Internal Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Singer, Bernhard B./AAP-9999-2020; Hildt, Eberhard/A-1040-2015					Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baker SJ, 1996, ONCOGENE, V12, P1; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chiarle R, 1999, J IMMUNOL, V163, P194; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FALINI B, 1995, BLOOD, V85, P1; Givol I, 1998, ONCOGENE, V16, P3115, DOI 10.1038/sj.onc.1201849; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Marches R, 1999, P NATL ACAD SCI USA, V96, P8711, DOI 10.1073/pnas.96.15.8711; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Singer BB, 2000, CANCER RES, V60, P1236; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	37	51	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					590	598		10.1038/sj.onc.1204128	http://dx.doi.org/10.1038/sj.onc.1204128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313991				2022-12-17	WOS:000166755000006
J	Melillo, RM; Carlomagno, F; De Vita, G; Formisano, P; Vecchio, G; Fusco, A; Billaud, M; Santoro, M				Melillo, RM; Carlomagno, F; De Vita, G; Formisano, P; Vecchio, G; Fusco, A; Billaud, M; Santoro, M			The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret	ONCOGENE			English	Article						Ret; tyrosine kinase; IRS-1; P13-K	PROTEIN-KINASE B; TYROSINE PHOSPHORYLATION; NEUROTROPHIC FACTOR; DOCKING SITE; PTB DOMAINS; ACTIVATION; MUTATIONS; SURVIVAL; INTERLEUKIN-4; PROLIFERATION	Tyrosine 1062 of Ret, which represents an intracytoplasmic docking site for multiple signaling molecules, is essential for Ret-mediated activation of phosphatidylinositol 3-Kinase (PI3-K), PI3-K, in turn, has been implicated in inducing cell survival and neoplastic transformation mediated by Ret, We have examined the mechanisms by which Ret stimulates PD-K. Here me show that the Insulin Receptor Substrate-1 (IRS-1) is tyrosine phosphorylated and associated with the p85 regulatory subunit of PI3-K in response to Ret activation. IRS-1 coimmunoprecipitates with Ret and co-expression of IRS-1 results in the potentiation of Ret-mediated activation of Akt(PKB), a bona fide effector of PI3-K, The association with the PTB domain of IRS-1 depends on the phosphorylation of tyrosine 1062 of Ret, The deletion of asparagine 1059 (delN1059) and the substitution of leucine 1061 (L1061P), two Ret mutations identified in families affected by congenital megacolon (Hirscbsprungs disease), impair the binding of IRS-1 to Ret as well as Ret-mediated Akt(PKB) stimulation. Finally, me show that Shc, which was previously identified as another ligand of Y1062 of Ret, competes with IRS-1 for the binding to Ret pY1062. All together, these findings suggest that IRS-1 is a component of the signaling pathway which leads to Ret-mediated PI3-K activation, a pathway which can be targeted by Hirschsprung-associated Ret mutations. The alternative binding of Shc and IRS-1 to Ret pY1062 can be a system to modulate the activation of different intracellular signaling pathways and to elicit different biological responses following net activation.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; CNRS, UMR5641, Genet Lab, F-69373 Lyon 08, France	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Centre National de la Recherche Scientifique (CNRS)	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		melillo, rosa marina/O-5255-2015; De Vita, Gabriella/H-4422-2011; Billaud, Marc N/M-6954-2013; Formisano, Pietro/J-4237-2018	De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197; Formisano, Pietro/0000-0001-7020-6870; MELILLO, Rosa Marina/0000-0002-9233-5275				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BESSET V, 2000, IN PRESS J BIOL CHEM; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Vita G, 2000, CANCER RES, V60, P3916; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 1999, CANCER RES, V59, P1120; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Siegal G, 1999, NAT STRUCT BIOL, V6, P7, DOI 10.1038/4873; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; van der Geer P, 1999, ONCOGENE, V18, P3071, DOI 10.1038/sj.onc.1202879; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, RECENT PROG HORM RES, V53, P119; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	55	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					209	218		10.1038/sj.onc.1204049	http://dx.doi.org/10.1038/sj.onc.1204049			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313948				2022-12-17	WOS:000166410900008
J	Raffo, AJ; Kim, AL; Fine, RL				Raffo, AJ; Kim, AL; Fine, RL			Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis	ONCOGENE			English	Article						p53; Bax; nuclear complexes; apoptosis; chemotherapy	PROGRAMMED CELL-DEATH; WILD-TYPE P53; BAX GENE; P53-DEPENDENT APOPTOSIS; 3'-TO-5' EXONUCLEASE; IN-VIVO; MELANOMA; INHIBITION; EXCLUSION; PROTEIN	Mechanisms by which chemotherapeutic agents induce apoptosis are not completely understood. Current knowledge of the actual pharmacologic effects of chemotherapy and their biochemical mechanisms are better understood than the downstream events, which initiate the apoptotic cascade. The chemotherapeutic agent cisplatin causes DNA damage and can induce apoptosis in several types of human cancers. We found the formation of previously unreported nuclear complexes between the tumor suppressor protein p53 and the pro-apoptotic protein Bax, in human melanoma cell lines induced into apoptosis following cisplatin exposure. These detergent resistant complexes were detected: after wild type (wt) p53 and Bax increased in the nucleus; at the same time when active cytoplasmic apoptosis related protease, caspase 3/CPP32 appeared; and prior to the detection of apoptotic DNA fragmentation. Three channel fluorescence laser scanning confocal image microscopy revealed that the nuclear Bax/p53 complexes remained in the nucleus and localized proximal to DNA fragmentation sites as assayed by TUNEL after cisplatin exposure. Two human melanoma cell lines, expressing wt p53, were induced into apoptosis after cisplatin exposure, however they differed in the timing of this induction. In both cell lines the formation of nuclear Bax/p53 co-immunoprecipitable complexes correlated with the timing of the induction of apoptosis, The degree of apoptosis induced by different concentrations of cisplatin correlated with the amount of nuclear Bax/p53 complexes. The coimmunoprecipitation of Bax and p53 was found regardless of the antibodies tested and was specific since Bcl-x(L)/p53 complexes were not detected. Additionally, the human prostate cancer cell line, LNCaP, also formed nuclear Bax/p53 complexes only after apoptosis was induced by paclitaxel.	Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA	Columbia University	Fine, RL (corresponding author), Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, 650 W 168th St,Black Bldg,Room BB-20-25, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13696-27, 5 P30 CA13696] Funding Source: Medline; NCRR NIH HHS [1S10 RR10506] Funding Source: Medline; NIAMS NIH HHS [P30AR 44535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Dennis LK, 1999, ARCH DERMATOL, V135, P275, DOI 10.1001/archderm.135.3.275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hall HI, 1999, J AM ACAD DERMATOL, V40, P35, DOI 10.1016/S0190-9622(99)70562-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1999, BIOCHEM PHARMACOL, V57, P143, DOI 10.1016/S0006-2952(98)00272-X; Janus F, 1999, MOL CELL BIOL, V19, P2155; Knippschild U, 1996, ONCOGENE, V12, P1755; Kobayashi T, 1998, ONCOGENE, V16, P1587, DOI 10.1038/sj.onc.1201681; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martin DS, 1997, CANCER INVEST, V15, P372, DOI 10.3109/07357909709039742; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakao Y, 1998, JPN J CANCER RES, V89, P1020, DOI 10.1111/j.1349-7006.1998.tb00491.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	36	51	61	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6216	6228		10.1038/sj.onc.1203995	http://dx.doi.org/10.1038/sj.onc.1203995			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175336				2022-12-17	WOS:000166210500005
J	De Luca, A; Arra, C; D'Antonio, A; Casamassimi, A; Losito, S; Ferraro, P; Ciardiello, F; Salomon, DS; Normanno, N				De Luca, A; Arra, C; D'Antonio, A; Casamassimi, A; Losito, S; Ferraro, P; Ciardiello, F; Salomon, DS; Normanno, N			Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts	ONCOGENE			English	Article						TGF alpha; amphiregulin; cripto; colon carcinoma; antisense	MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-A; FACTOR-ALPHA; IMMUNOHISTOCHEMICAL DETECTION; ANTISENSE OLIGONUCLEOTIDES; ANTITUMOR-ACTIVITY; COLORECTAL TUMORS; FACTOR FAMILY; CANCER CELLS; AMPHIREGULIN	A majority of human colon carcinomas coexpress the epidermal growth factor (ECF)-related peptides transforming growth factor alpha (TGF alpha), amphiregulin (AR) and CRIPTO-1 (CR). We have synthesized novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against TGF alpha. AR and CR, We screened the EGF-related (AS MBOs) for their ability to inhibit the anchorage independent growth of GEO human colon carcinoma cells. Tbe MBOs that showed a high in vitro efficacy were then used for in vitro experiments. TGF alpha, AR and CR AS MBOs were able to inhibit the growth of CEO tumor xenografts in nude mice in a dose-dependent manner. Furthermore, the AS MBOs were able to specifically inhibit the expression of the target mRNAs and proteins in the tumor xenografts. A more significant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO, Finally, tumors from mice treated with TGF alpha, AR and CR AS MBOs showed a significant reduction of microvessel count, as compared with tumors from untreated mice or from mire treated with a single AS MBO, These data suggest that combinations of AS oligonucleotides directed against different growth factors might represent a novel, experimental therapy approach of colon carcinomas.	ITN Fdn Pascale, Novel Therapeut Approaches Sect Oncol Sperimental, I-80131 Naples, Italy; ITN Fdn Pascale, Anim Fac, I-80131 Naples, Italy; Anat Pathol ULSS 3, I-36061 Bassano Del Grappa, VI, Italy; ITN Fdn, Anat Patol, I-80131 Naples, Italy; Univ Naples Federico II, Dip Endocrinol & Oncol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy; NCI, LTIB, Tumor Growth Factor Sect, NIH, Bethesda, MD 20892 USA	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Normanno, N (corresponding author), ITN Fdn Pascale, Novel Therapeut Approaches Sect Oncol Sperimental, I-80131 Naples, Italy.		De Luca, Antonella/J-8737-2016; Casamassimi, Amelia/AAD-2816-2020; Normanno, Nicola/AAT-1107-2021; losito, Nunzia/Y-6339-2018	De Luca, Antonella/0000-0001-5762-447X; Casamassimi, Amelia/0000-0002-6010-4261; losito, Nunzia/0000-0001-9045-0328; Arra, Claudio/0000-0003-3162-2091; Ciardiello, Fortunato/0000-0002-3369-4841; Normanno, Nicola/0000-0002-7158-2605	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4; Agrawal S, 1998, ANTISENSE NUCLEIC A, V8, P135, DOI 10.1089/oli.1.1998.8.135; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; Ciardiello F, 1996, JNCI-J NATL CANCER I, V88, P1770, DOI 10.1093/jnci/88.23.1770; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CIARDIELLO F, 1993, INT J CANCER, V54, P952, DOI 10.1002/ijc.2910540615; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Ebert AD, 1999, CANCER RES, V59, P4502; Fontanini G, 1998, CLIN CANCER RES, V4, P241; GAGLIARDI G, 1994, INT J ONCOL, V4, P865; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MODRELL B, 1992, GROWTH FACTORS, V7, P195; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; NORMANNO N, 1993, INT J ONCOL, V2, P903; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Normanno N, 1996, CLIN CANCER RES, V2, P601; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; Qi C., 1994, BRIT J CANCER, V69, P19896; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; STROMBERG K, 1994, INT J GYNECOL PATHOL, V13, P342, DOI 10.1097/00004347-199410000-00008; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325	37	51	52	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5863	5871		10.1038/sj.onc.1203979	http://dx.doi.org/10.1038/sj.onc.1203979			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127817	Bronze			2022-12-17	WOS:000165563100005
J	Kawakami, Y; Kitamoto, M; Nakanishi, T; Yasui, W; Tahara, E; Nakayama, J; Ishikawa, F; Tahara, H; Ide, T; Kajiyama, G				Kawakami, Y; Kitamoto, M; Nakanishi, T; Yasui, W; Tahara, E; Nakayama, J; Ishikawa, F; Tahara, H; Ide, T; Kajiyama, G			Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues	ONCOGENE			English	Article						human telomerase reverse transcriptase; hepatocellular carcinoma; immunohistochemical detection	DISEASED PEDIATRIC LIVER; DNA POLYMERASE-ALPHA; MONOCLONAL-ANTIBODY; HEPATOCELLULAR-CARCINOMA; PROGENITOR CELLS; IMMUNOHISTOCHEMICAL DETECTION; PROLIFERATING HEPATOCYTES; DUCTULAR HEPATOCYTES; CATALYTIC COMPONENT; IMMORTAL CELLS	Although telomerase activity in hepatocellular carcinoma (HCC) increases in accordance with degree of histological undifferentiation, it is unknown whether the level of telomerase activity in HCC reflects of the degree of activity in individual cells or the frequency of telomerase-positive HCC cells. Non-cancerous liver tissues exhibit low but significant levels of telomerase activity, but the nature of telomerase-positive cells in these tissues is unclear, In this study, we performed immunohistochemical staining using specific antibody against telomerase reverse transcriptase (hTERT) protein in 15 HCC samples and 13 adjacent non-cancerous liver tissues, There were hTERT-positive hepatocytes, though very low frequency, in non-cancerous liver tissues. The frequencies in hTERT positive hepatocytes were very well correlated with clinicopathological parameters and telomerase activity levels: the average frequencies of chronic hepatitis was 0.2%, liver cirrhosis 0.2%, well-differentiated HCC 3.0%, moderately differentiated HCC 28%, and poorly differentiated HCC 95%, The intensity of staining varied among cells within a given specimen, and correlation with degree of histological undifferentiation was less obvious. Portions of migrating lymphocytes and biliary epithelial cells were also hTERT-positive. These findings indicate that the upregulation of telomerase activity with degree of undifferentiation of HCC is mainly due to the increase in frequency of hTERT positive HCC cells.	Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Minami Ku, Hiroshima 7348551, Japan; Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2260027, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Tokyo Institute of Technology	Ide, T (corresponding author), Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Ishikawa, Fuyuki/AAU-4056-2021; Nakayama, Jun-ichi/C-6003-2011	Ishikawa, Fuyuki/0000-0002-5580-2305; Nakayama, Jun-ichi/0000-0002-5597-8239				Baumann U, 1999, HEPATOLOGY, V30, P112, DOI 10.1002/hep.510300140; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crosby HA, 1998, AM J PATHOL, V152, P771; Crosby HA, 1998, HEPATOLOGY, V28, P980, DOI 10.1002/hep.510280412; Demetris AJ, 1996, AM J PATHOL, V149, P439; DEVOS R, 1992, AM J PATHOL, V140, P1441; DUNSFORD HA, 1985, AM J PATHOL, V118, P218; DUNSFORD HA, 1989, CANCER RES, V49, P4894; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; ELMORE LW, 1991, CANCER RES, V51, P5752; EVARTS RP, 1989, CANCER RES, V49, P1541; GOLDLUST A, 1995, EPILEPSY RES, V22, P1, DOI 10.1016/0920-1211(95)00028-9; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Haque S, 1996, LAB INVEST, V75, P699; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; KAWAKITA N, 1992, AM J PATHOL, V140, P513; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Nakamura Y, 1999, MOL CARCINOGEN, V26, P312, DOI 10.1002/(SICI)1098-2744(199912)26:4<312::AID-MC10>3.3.CO;2-1; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Novikoff PM, 1996, AM J PATHOL, V148, P1473; Ogami M, 1999, LAB INVEST, V79, P15; Ohyashiki K, 1997, CANCER RES, V57, P2100; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Roskams T, 1996, HISTOPATHOLOGY, V28, P291, DOI 10.1046/j.1365-2559.1996.d01-438.x; Ruck P, 1996, AM J PATHOL, V148, P321; SEKI S, 1990, HUM PATHOL, V21, P1020, DOI 10.1016/0046-8177(90)90251-Y; SEKI S, 1991, HEPATOLOGY, V14, P781, DOI 10.1002/hep.1840140507; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Takahashi S, 2000, EUR J CANCER, V36, P496, DOI 10.1016/S0959-8049(99)00284-1; Takaishi H, 2000, CANCER, V88, P312, DOI 10.1002/(SICI)1097-0142(20000115)88:2<312::AID-CNCR10>3.3.CO;2-I; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 1998, JPN J CANCER RES, V89, P1099, DOI 10.1111/j.1349-7006.1998.tb00502.x; Yasui W, 1996, J PATHOL, V180, P122, DOI 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	41	51	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3888	3893		10.1038/sj.onc.1203733	http://dx.doi.org/10.1038/sj.onc.1203733			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951582				2022-12-17	WOS:000088614300007
J	Rodriguez, MI; Finbow, ME; Alonso, A				Rodriguez, MI; Finbow, ME; Alonso, A			Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation	ONCOGENE			English	Article						papillomavirus; receptors; membrane proteins; vacuolar H+-ATPase; endosomes; recycling	PORE-FORMING PROTEIN; EPITHELIAL-CELL LINE; BOVINE PAPILLOMAVIRUS; TRANSFORMING PROTEIN; TYPE-16 DNA; GENE-EXPRESSION; ONCOPROTEIN; KERATINOCYTES; SITE; COMMUNICATION	Human papillomavirus type 16 E5 protein (HPV16 E5) upregulates ligand-mediated activation of the epidermal growth factor receptor (EGFR) in transfected human keratinocytes. HPV16 E5 binds to the 16 kDa proteolipid (subunit c) of the vacuolar H+-ATPase (16K), responsible for endosomal acidification, and this binding has been suggested to be responsible for increased recycling of the EGFRs, Using mutant deletions we show here that amino acids 53-78, but not 79-83 are necessary for binding to the 16K proteolipid, EGF treatment of cells expressing wild type or mutants of the E5 protein show that deletion of the last carboxy terminal 5 amino acids results in loss of ES-mediated EGFR overactivation, Thus, our results show that the binding capacity of HPV16 E5 to 16K can be dissociated from the effect of the viral protein on EGFR activation.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Helmholtz Association; German Cancer Research Center (DKFZ); Beatson Institute	Alonso, A (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld-242, D-69120 Heidelberg, Germany.		García, Isabel Rodríguez/AAG-2211-2019; Rodríguez, Isabel/L-9327-2013	García, Isabel Rodríguez/0000-0001-7213-1411; Rodríguez, Isabel/0000-0001-7213-1411				ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; BauerHofmann R, 1996, VIROLOGY, V217, P33, DOI 10.1006/viro.1996.0090; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; DURST M, 1987, ONCOGENE, V1, P251; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; FINBOW ME, 1991, MOL CARCINOGEN, V4, P441, DOI 10.1002/mc.2940040605; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; NEAL MA, 1995, J INVEST DERMATOL, V105, P668; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PIM D, 1992, ONCOGENE, V7, P27; PIRISI L, 1987, J VIROL, V57, P572; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	38	51	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3727	3732		10.1038/sj.onc.1203718	http://dx.doi.org/10.1038/sj.onc.1203718			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949926				2022-12-17	WOS:000088568400004
J	Hori, T; Takaori-Kondo, A; Kamikubo, Y; Uchiyama, T				Hori, T; Takaori-Kondo, A; Kamikubo, Y; Uchiyama, T			Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor	ONCOGENE			English	Article						protein kinase; tumor suppressor; cell cycle; mitosis; phosphorylation	MYOTONIC-DYSTROPHY KINASE; CELL-CYCLE; GENE DBF2; ENCODES; SEQUENCE	A novel human protein kinase, designated kpm, was identified and molecularly cloned. The isolated cDNA done had an open reading frame consisting of 1088 amino acid residues with a putative kinase domain located near the carboxy-terminus. Homology search revealed that kpm belongs to a subfamily of serine/threonine protein kinases including warts/lats, a Drosophila tumor suppressor. Among these, kpm is most homologous to, but distinct from, recently reported LATS1, a human homolog of DI Drosophila warts/lats. Northern blot analysis disclosed that kpm is expressed as a 6.0 kb transcript in most of the tissues examined and also as an additional shorter 4.0 kb transcript in testis, Western blotting using polyclonal rabbit anti-kpm antibody detected kpm protein as a band with an apparent M-r of 150 kD. Immune complex kinase assay of HA-tagged kpm showed that kpm had kinase activity and phosphorylated itself in vitro. Studies with synchronized HeLa cells indicated that kpm protein was expressed relatively constantly throughout the cell cycle and underwent significant phosphorylation at mitotic phase. These results suggest that kpm plays a role in cell cycle progression during mitosis and its deletion or dysfunction might be involved in certain types of human cancers.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hori, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Kawaracho, Kyoto 6068507, Japan.							HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KOEFFLER HP, 1980, BLOOD, V56, P265; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; VALLEJO AN, 1995, COLD SPRING HARBOR L; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XU TA, 1995, DEVELOPMENT, V121, P1053; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	21	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3101	3109		10.1038/sj.onc.1203659	http://dx.doi.org/10.1038/sj.onc.1203659			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871863				2022-12-17	WOS:000087903900008
J	Jove, R				Jove, R			Preface: STAT signaling	ONCOGENE			English	Editorial Material						signal transducer and activator of transcription; STAT			H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.								0	51	55	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2466	2467		10.1038/sj.onc.1203549	http://dx.doi.org/10.1038/sj.onc.1203549			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851044				2022-12-17	WOS:000087459400001
J	Boutillier, AL; Trinh, E; Loeffler, JP				Boutillier, AL; Trinh, E; Loeffler, JP			Caspase-dependent cleavage of the retinoblastoma protein is an early step in neuronal apoptosis	ONCOGENE			English	Article						apoptosis; cerebellar neuron; retinoblastoma protein; caspase; CPP32	CEREBELLAR GRANULE NEURONS; ICE-LIKE PROTEASE; TUMOR-SUPPRESSOR PROTEIN; CELL-DEATH; ICE/CED-3 PROTEASE; SIGNALING PATHWAY; MDM2 ONCOPROTEIN; FAMILY PROTEINS; GENE-PRODUCT; DEGRADATION	Rb-deficient embryos (Rb-/-) show abnormal degeneration of neurons and die at mid-gestation, suggesting that RE may protect against apoptosis. Having previously shown that cyclin D1 accumulates during K+-induced apoptosis of granule neurons, we chose to investigate the role of RB under these conditions. We show that RB is cleaved in its C-terminus during the onset of neuronal apoptosis. Caspase 3-like activity increases following K+ deprivation and the time course correlates with RB cleavage and apoptosis, Although the use of a specific caspase 3-like inhibitor (z-DEBD.fmk) delays RB cleavage and reduces DNA fragmentation, data implicate other caspases in these processes. However K+ deprivation induces a gradual production of the active p20 subunit of caspase 3 (CPP32) that coincides with RB disappearance at the cellular level. Nuclear detection of a transfected HA-tagged caspase cleavage-resistant RB mutant (DEAG/D to DEAA/D) revealed a significant decrease in apoptosis of neurons expressing the RB mutant (less than 5%) relative to the wild type form of RB (40%) during K+ deprivation. Taken together, these data show that caspase-dependent cleavage of RB is an early permissive step of the apoptosis-inducing signaling pathway in neurons, They indicate a major role of RB in neuronal protection.	CNRS, UMR 7519, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), CNRS, UMR 7519, 21 Rue Rene Descartes, F-67084 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; Armstrong RC, 1997, J NEUROSCI, V17, P553; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DOU QP, 1998, FRONT BIOSCI, V3, P419; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GALLO V, 1987, J NEUROSCI, V7, P2203; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KONDO S, 1995, ONCOGENE, V10, P2001; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Lynch T, 1997, MOL PSYCHIATR, V2, P227, DOI 10.1038/sj.mp.4000242; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Schulz JB, 1996, J NEUROSCI, V16, P4696; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; Sohm F, 1999, ONCOGENE, V18, P2762, DOI 10.1038/sj.onc.1202634; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	56	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2171	2178		10.1038/sj.onc.1203532	http://dx.doi.org/10.1038/sj.onc.1203532			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822366				2022-12-17	WOS:000086974100001
J	Orsetti, B; Courjal, F; Cuny, M; Rodriguez, C; Theillet, C				Orsetti, B; Courjal, F; Cuny, M; Rodriguez, C; Theillet, C			17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification	ONCOGENE			English	Article						breast; cancer; chromosome; imbalance; CGH; amplification	COMPARATIVE GENOMIC HYBRIDIZATION; RENAL-CELL CARCINOMAS; IN-SITU; TUMORS; HUMAN-CHROMOSOME-17; CHROMOSOME-17Q; DUPLICATION; COINCIDES; PATTERNS; LOCUS	Chromosome 17q is frequently rearranged in breast cancer. Allelotyping studies have proposed the existence of at least four regions of allelic imbalance (AI). Here we present a study combining allelotyping using 19 CA repeat markers mapping in the 17q21-25 region and molecular cytogenetics (CGH and FISH). Allelotyping,vas undertaken on 178 pairs of cognate tumor and normal DNA in order to determine the number of regions of AI and define the shortest overlaps. AI ranged from 34-54% of the informative cases according to the marker and, overall, 66% of the tumors presented Al: at one of the markers tested. Analysis of the patterns of imbalances revealed at least five common regions of imbalance respectively defined by markers: D17S855, which is intragenic of BRCA1 (SRO 1), D17S1607 (SRO 2), D17S1855 (SRO 3), between D17S789 and D17S785 (SRO 4) and D17S784 (SRO 5). In order to characterize the nature of the genetic events revealed by allelotyping we performed CGH analysis on a subset of 43 tumors presenting variable patterns of imbalance. CGH showed that AI at 17q could represent four different types of genetic events: loss of chromosome 17, gain of 17q, gain of 17q22-q24, loss of 17q11-q21 and/or 17q25-qter. Some of these anomalies could occur concomitantly within the same tumor. Since 35% of the tumors analysed by CGH presented gains, these data indicated that All at 17q were not solely indicative of losses of genetic material and could also represent DNA amplification. Gains were most commonly observed in the 17q23-q24 regions. This suggested that AI in SRO 2 and SRO 3 corresponded to DNA amplification, To assess this, we isolated BAC clones by PCR screening for markers D17S1607 and D17S1855 and used these in FISH experiments on six breast tumor cell lines and 14 breast cancer specimens. FISH results showed that both D17S1607 and D17S1855 were frequently involved in DNA amplification (8-30 copies). Altogether, our data show that allelotyping can be efficiently used in amplicon mapping. Clinico-pathological correlations indicated that imbalance at 17q preferentially occurred in high grade, PR- and ERBB2 amplified tumors.	Ctr Rech CRLC Val Aurelle Paul Lamarque, Equipe Genome & Canc, CNRS, UMR 5535, F-34298 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Theillet, C (corresponding author), Ctr Rech CRLC Val Aurelle Paul Lamarque, Equipe Genome & Canc, CNRS, UMR 5535, F-34298 Montpellier 5, France.		Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Benitez J, 1997, CANCER RES, V57, P4217; Bugert P, 1998, INT J CANCER, V76, P337, DOI 10.1002/(SICI)1097-0215(19980504)76:3<337::AID-IJC9>3.0.CO;2-W; Courjal F, 1997, CANCER RES, V57, P4368; Courjal F, 1997, CANCER RES, V57, P4360; CROPP CS, 1993, CANCER RES, V53, P5617; DEVILEE P, 1991, CANCER RES, V51, P1020; Fletcher J, 1994, Methods Mol Biol, V29, P51; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; ISOLA JJ, 1995, AM J PATHOL, V147, P905; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kenck C, 1997, ONCOGENE, V14, P1093, DOI 10.1038/sj.onc.1200915; Kuukasjarvi T, 1997, GENE CHROMOSOME CANC, V18, P94, DOI 10.1002/(SICI)1098-2264(199702)18:2<94::AID-GCC3>3.3.CO;2-5; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MUNN KE, 1995, ONCOGENE, V10, P1653; Munn KE, 1996, BRIT J CANCER, V73, P636, DOI 10.1038/bjc.1996.110; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; Plummer SJ, 1997, GENOMICS, V45, P140, DOI 10.1006/geno.1997.4906; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RIED T, 1995, CANCER RES, V55, P5415; THEILE M, 1995, ONCOGENE, V10, P439; Wolf M, 1997, CANCER GENET CYTOGEN, V93, P33, DOI 10.1016/S0165-4608(96)00291-9	28	51	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6262	6270		10.1038/sj.onc.1203006	http://dx.doi.org/10.1038/sj.onc.1203006			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597224				2022-12-17	WOS:000083934100009
J	Davis, PL; Miron, A; Andersen, LM; Iglehart, JD; Marks, JR				Davis, PL; Miron, A; Andersen, LM; Iglehart, JD; Marks, JR			Isolation and initial characterization of the BRCA2 promoter	ONCOGENE			English	Article						BRCA2; transcription; promoter	SUSCEPTIBILITY GENE BRCA2; TRANSCRIPTION FACTOR USF; MAMMARY EPITHELIAL-CELLS; SPORADIC BREAST-CANCER; MAJOR LATE PROMOTER; DNA-REPAIR; C-MYC; COOPERATIVE INTERACTION; OVARIAN CANCERS; MAMMALIAN-CELLS	The hereditary breast cancer susceptibility gene, BRCA2, is considered to be a tumor suppressor gene that may be involved in the cellular response to DNA damage, The transcript for this gene is cell cycle regulated with mRNA levels reaching a peak just before the onset of DNA synthesis. In order to define the mechanisms by which BRCA2 is transcriptionally regulated, we have begun to study upstream regulatory sequences, In this report, we define a minimal promoter region that has strong activity in human breast epithelial cells, Deletions of this sequence narrowed the strong basal activity to a region extending from - 66 to + 129 with respect to the BRCA2 transcriptional start site. This sequence demonstrated cell cycle regulated activity with kinetics similar to the endogenous transcript. Examination of the sequence revealed several consensus binding sites for transcription factors including an E-box, E2F and Ets recognition motifs. Electrohoretic mobility shift assays revealed specific protein binding to two sequences upstream of the start site; the palindromic E-box and an Ets/E2F site, Site-directed mutagenesis of either of these sites reduced both the basal activity in log phase cells and the cell cycle regulated activity of the promoter. Mutational inactivation of both sites within the same construct effectively eliminated promoter activity. Antibodies to candidate transcription factors used in super shift experiments revealed specific interactions between the BRCA2 promoter and the basic region/helix-loop-helix containing USE-I and 2 proteins and Elf-1, an Ets domain protein, Binding of these factors depended upon the presence of intact recognition sequences. The USF factors were shown to bind predominantly as a heterodimeric complex of USF-1 and 2 while Elf-1 bound the promoter when it was not occupied by USF, Co-transfection studies with USP proteins and the varicella tester IE62 protein provide evidence for the involvement of endogenous and exogenous USF in the activation of the BRCA2 promoter. We propose that interactions between USF-1, USF-2 and Elf-1 play an important role in the transcriptional regulation of the BRCA2 gene.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Canc Genet Lab, Durham, NC 27710 USA	Duke University; Duke University	Marks, JR (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 3873, Durham, NC 27710 USA.				NCI NIH HHS [CA-73802, CA-68438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068438, R01CA073802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bertwistle D, 1997, CANCER RES, V57, P5485; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davis P, 1996, ONCOGENE, V13, P1315; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Dobrovic A, 1997, CANCER RES, V57, P3347; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Phillips KW, 1997, LAB INVEST, V76, P419; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Spillman MA, 1996, ONCOGENE, V13, P1639; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TYLER JK, 1993, NUCLEIC ACIDS RES, V21, P513, DOI 10.1093/nar/21.3.513; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	60	51	52	2	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6000	6012		10.1038/sj.onc.1202990	http://dx.doi.org/10.1038/sj.onc.1202990			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557089				2022-12-17	WOS:000083359100006
J	Gallagher, WM; Argentini, M; Sierra, V; Bracco, L; Debussche, L; Conseiller, E				Gallagher, WM; Argentini, M; Sierra, V; Bracco, L; Debussche, L; Conseiller, E			MBP1: a novel mutant p53-specific protein partner with oncogenic properties	ONCOGENE			English	Article						mutant p53; MBP1; fibulin; gain of function	CELL-LINES; FUNCTION MUTATIONS; 2-HYBRID SYSTEM; P53 PROTEIN; WILD-TYPE; GENE; GROWTH; RAS; CANCER; YEAST	Using a least two-hybrid screening strategy with a common tumour-derived p53 mutant as bait, we identified several mutant p53-interacting partners including the known proteins wild-type (nt) p53, hUBC9 and GBP/PIAS1. In addition, a novel protein partner was identified which we have termed MBP1, for Mutant p53-binding Protein 1. MBP1 is a new member of the emerging fibulin gene family, which currently comprises fibulin-1, fibulin-2 and S1-5. Expression of MBP1 mRNA is differentially regulated both temporally during development of the mouse embryo and in a tissue-specific manner within the adult. Specific interaction between MBP1 and mutant p53 was illustrated by both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells. MBP1 displayed the following order of binding specificity towards different p53 forms: H175 > G281 > H273 greater than or equal to W248 > wt p53. Thus, MBP1 appears to bind preferentially to p53 mutants of the 'structural' rather than 'contact' class, reflecting a potential bias towards those mutants having a significant alteration in conformation from that assumed by wt p53. We propose that MBP1 is the product of a candidate oncogene as rates of both neoplastic transformation and tumour cell growth were shown to be significantly enhanced when the protein is ectopically overexpressed. Furthermore, MBP1 may play a role in determining if a 'gain of function' effect is seen with certain p53 mutants.	Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, F-94403 Vitry, France; IGBMC, F-67404 Illkirch, France; ExonHit Therapeut, F-75013 Paris, France	Sanofi-Aventis; Institut National de la Sante et de la Recherche Medicale (Inserm)	Conseiller, E (corresponding author), Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, 13 Quai Jules Guesde,BP14, F-94403 Vitry, France.			Gallagher, William/0000-0002-4307-5999				Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Delahunty M, 1995, Connect Tissue Res, V31, P283, DOI 10.3109/03008209509010824; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLAY C, 1995, METHOD ENZYMOL, V255, P389; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HSIAO M, 1994, AM J PATHOL, V145, P702; IWABUCHI K, 1993, ONCOGENE, V8, P1693; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nelson Vanessa, 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P695; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Saltzman A, 1998, FEBS LETT, V425, P431, DOI 10.1016/S0014-5793(98)00287-7; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Toh H, 1992, Mediators Inflamm, V1, P223, DOI 10.1155/S0962935192000346; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	39	51	54	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3608	3616		10.1038/sj.onc.1202937	http://dx.doi.org/10.1038/sj.onc.1202937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380882				2022-12-17	WOS:000080891700006
J	Graham, SM; Oldham, SM; Martin, CB; Drugan, JK; Zohn, IE; Campbell, S; Der, CJ				Graham, SM; Oldham, SM; Martin, CB; Drugan, JK; Zohn, IE; Campbell, S; Der, CJ			TC21 and Ras share indistinguishable transforming and differentiating activities	ONCOGENE			English	Article						Ras-related; JNK; PC12 pheochromocytoma cells; C2 myoblasts	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; KAPPA-B ACTIVATION; NIH 3T3 CELLS; R-RAS; ONCOGENIC RAS; HA-RAS; INDEPENDENT PATHWAYS; PLASMA-MEMBRANE; FAMILY MEMBERS	Constitutively activated mutants of the Ras-related protein TC21/R-Ras2 cause tumorigenic transformation of NIH3T3 cells. However, unlike Ras, TC21 fails to bind to and activate the Raf-1 serine-threonine kinase, Thus, whereas Ras transformation is critically dependent on Raf-1 TC21 activity is promoted by activation of Raf-independent signaling pathways. In the present study, we have further compared the functions of Ras and TC21, First we determined the basis for the inability of TC21 to activate Raf-1, Whereas Ras can interact with the two distinct Ras-binding sequences in NH2-terminus of Raf-2, designated RBS1 and Raf-Cys, TC21 could only bind Raf-Cys, Thus, the inability of TC21 to bind to RBS1 may prevent it from promoting the translocation of Raf-1 to the plasma membrane. Second, we found that TC21 is an activator of the JNK and p38, but not ERK, mitogen-activated protein kinase cascades and that TC21 transforming activity was dependent on Rac function. Thus, like Ras, TC21 may activate a Rac/JNK pathway, Third, we determined if TC21 could cause the same biological consequences as Ras in three distinct cell types. Like Ras, activated TC21 caused transformation of RIE-1 rat intestinal epithelial cells and terminal differentiation of PC12 pheochromocytoma cells. Finally, activated TC21 blocked serum starvation-induced differentiation of C2 myoblasts, whereas dominant negative TC21 greatly accelerated this differentiation process. Therefore, TC21 and Ras share indistinguishable biological activities in all cell types that we have evaluated. These results support the importance of Raf-independent pathways in mediating the actions of Ras and TC21.	Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.			Zohn, Irene/0000-0001-7688-682X; campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA070308, R29CA064569, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA64569, CA70308, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1992, CANCER BIOL, V3, P199; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAMPBELL SL, 1998, IN PRESS ONCOGENE; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CARBONI JM, 1995, ONCOGENE, V10, P1905; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1996, ONCOGENE, V12, P169; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILL CS, 1993, CELL, V73, P385; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLDHAM SM, 1998, IN PRESS ONCOGENE; OLSEN EN, 1987, MOL CELL BIOL, V7, P2104; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	94	51	54	2	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2107	2116		10.1038/sj.onc.1202517	http://dx.doi.org/10.1038/sj.onc.1202517			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321735				2022-12-17	WOS:000079346200008
J	Liu, WH; Yung, BYM				Liu, WH; Yung, BYM			Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23	ONCOGENE			English	Article						nucleophosmin/B23; apoptosis; telomerase activity	NUCLEOLAR PHOSPHOPROTEIN B23; HELA-CELLS; RNA-SYNTHESIS; PROTEIN B23; HUMAN FIBROBLASTS; IMMORTAL CELLS; ACTINOMYCIN-D; NUMATRIN B23; TRANSLOCATION; GROWTH	Vanadate (10 mu M), a potent inhibitor of tyrosine phosphatase, added simultaneously potentiated BuONa-induced (1 mM) apoptosis, The steady-state level of nucleophosmin/B23 mRNA and the total cellular nucleophosmin/B23 protein decreased during the BuONa/vanadate-induced apoptosis. Stabilization and promotor transcriptional activity assays indicate that the decrease in nucleophosmin/B23 mRNA in BuONa/vanadate-treated HL-60 cells was transcriptionally regulated. A decline in telomerase activity was observed in HL-60 cells treated with BuONa/vanadate for 24-96 h. There was virtually no decline of nucleophosmin/B23 mRNA nor the telomerase activities during the growth arrest by serum-starvation. The decrease in nucleophosmin/B23 mRNA expression and telomerase activity in HL-60 cells subsequent to BuONa/vanadate treatment can thus be attributed to cellular apoptosis rather than the growth arrest induced by BuONa/vanadate. Nucleophosmin/BW antisense oligomer treatment significantly potentiated BuONa-induced apoptosis and inhibition of telomerase activity. Results of this study suggest that nucleophosmin/B23 is one of the key elements in the down-regulation of nucleolar function for cellular apoptosis and mortalization.	Chang Gung Univ, Coll Med, Dept Pharmacol, Canc Biochem Lab, Tao Yuan 333, Taiwan	Chang Gung University	Yung, BYM (corresponding author), Chang Gung Univ, Coll Med, Dept Pharmacol, Canc Biochem Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196				Albanell J, 1996, CANCER RES, V56, P1503; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BERNHARD W, 1968, ULTRASTRUCT BIOL, V3, P81; Bestilny LJ, 1996, CANCER RES, V56, P3796; BUSCH H, 1963, CANCER RES, V23, P313; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chang ST, 1996, BIOCHEM BIOPH RES CO, V221, P594, DOI 10.1006/bbrc.1996.0641; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FONAGY A, 1992, CANCER RES, V52, P5250; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HIYAMA E, 1995, CANCER RES, V55, P3258; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WU MH, 1995, BIOCHEM J, V305, P987, DOI 10.1042/bj3050987; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1986, CANCER RES, V46, P922; YUNG BYM, 1992, INT J CANCER, V52, P317, DOI 10.1002/ijc.2910520227	46	51	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3055	3064		10.1038/sj.onc.1202234	http://dx.doi.org/10.1038/sj.onc.1202234			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881708				2022-12-17	WOS:000077427800013
J	Cohen, PA; Mani, JC; Lane, DP				Cohen, PA; Mani, JC; Lane, DP			Characterization of a new intrabody directed against the N-terminal region of human p53	ONCOGENE			English	Article						p53 tumour suppressor; single-chain antibody; transactivation	TUMOR-SUPPRESSOR PROTEIN; SINGLE-CHAIN ANTIBODY; DNA-BINDING ACTIVITY; WILD-TYPE P53; INTRACELLULAR EXPRESSION; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; PHOSPHORYLATION SITES; FILAMENTOUS PHAGE; KINETIC-ANALYSIS	Genes encoding the rearranged immunoglobulin heavy and light chain variable regions of DO-1, a monoclonal antibody directed against human p53, have been used to construct a single-chain antibody, DO-1 recognizes an N-terminal epitope in the region involved in the transactivation function of p53 and the binding of Mdm2. The DO-1 single chain scFv expressed in the periplasm of E. coli or at the surface of the filamentous phage M13 retained the immunological specificity and affinity of the full length antibody. Furthermore, the DO-1 recombinant antibody was able to inhibit the in vitro binding of Hdm2, and was shown to be a powerful protecting agent of p53's DNA binding activity at 37 degrees C. The DO-1 single-chain antibody has been used to construct single-chain intracellular antibodies (intrabodies) for expression in the cytoplasm and the nucleus of mammalian cells. These anti-p53 intrabodies were additionally modified by addition of a C-kappa domain to increase cytoplasmic and nuclear stability, Here we show that expression of the DO-1 single-chain antibody in the H1299 cell line results in an inhibition of p53's transactivation function, The DO-1 intrabody is a useful tool to study those functions of p53 driven by the N-terminal region of the protein.	Univ Dundee, Inst Med Sci, Dept Biochem, CRC,Cell Transformat Res Grp, Dundee DD1 4HN, Scotland; CNRS, UMR 9921, UFR Pharm, F-34060 Montpellier 01, France	University of Dundee; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lane, DP (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, CRC,Cell Transformat Res Grp, Dundee DD1 4HN, Scotland.		Cohen, Pascale/I-5875-2012; Lane, David P/C-4920-2008	Cohen, Pascale/0000-0001-7016-9598; Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BIOCCA S, 1993, BIOCHEM BIOPH RES CO, V197, P422, DOI 10.1006/bbrc.1993.2496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DUAN LX, 1994, HUM GENE THER, V5, P1315, DOI 10.1089/hum.1994.5.11-1315; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hecker D, 1996, ONCOGENE, V12, P953; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Jannot CB, 1996, ONCOGENE, V13, P275; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEONARDO AD, 1994, GENE DEV, V8, P2540; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; Maki CG, 1996, CANCER RES, V56, P2649; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; MARSTON NJ, 1994, ONCOGENE, V9, P2707; Mayo LD, 1997, CANCER RES, V57, P5013; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MILLER SPL, 1992, MOL CELL BIOL, V12, P5041; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VARHAVSKY A, 1992, CELL, V69, P725; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H	83	51	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	1998	17	19					2445	2456		10.1038/sj.onc.1202190	http://dx.doi.org/10.1038/sj.onc.1202190			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824155				2022-12-17	WOS:000076927300004
J	DiGiovanna, MP; Lerman, MA; Coffey, RJ; Muller, WJ; Cardiff, RD; Stern, DF				DiGiovanna, MP; Lerman, MA; Coffey, RJ; Muller, WJ; Cardiff, RD; Stern, DF			Active signaling by Neu in transgenic mice	ONCOGENE			English	Article						HER-2/Neu/ErbB-2; transgenic mice; phosphorylation; breast cancer; activation; transforming growth factor-alpha (TGF alpha)	EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-TUMORS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; POINT MUTATION; MAMMARY-TUMORS; PROTOONCOGENE PRODUCT; ONCOGENIC ACTIVATION; METASTATIC DISEASE; CELLULAR-RESPONSE	Transgenic mice engineered to overexpress the HER-2/neu/erbB-2 protooncogene under the control of a mammary-specific promoter develop mammary tumors and are a model for human breast cancer. Signal transduction by Neu was examined in situ in the tumors of these transgenic mice. This was accomplished using the PN2A monoclonal antibody, which recognizes Neu only in the phosphorylated, and therefore actively signaling, state. Immunohistochemistry using PN2A demonstrated that Neu actively signals in the tumors of Neu transgenic mice. Expression of Neu was always accompanied by co-overexpression of the endogenous epidermal growth factor receptor. Qualitatively similar results were found in mammary tumors from mice bitransgenic for the neu and transforming growth factor-alpha genes (both driven by the mouse mammary tumor virus promoter). Early mammary lesions demonstrated distinctive patterns of Neu activation relative to expression levels. Overexpression and activation were separable both temporally and spatially. These results refine the multi-step model for the role of Neu in mammary neoplasia and establish phosphorylation-state specific antibodies as a powerful tool for investigating tumor progression.	Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; McMaster Univ, Inst Mol Biol, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Sch Med, Dept Pathol, Livermore, CA 95616 USA	Yale University; Yale University; Yale University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; McMaster University; University of California System; University of California Davis	DiGiovanna, MP (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, 333 Cedar St, New Haven, CT 06510 USA.		Lerman, Melissa/AGG-2451-2022	Lerman, Melissa/0000-0003-1378-5292	NATIONAL CANCER INSTITUTE [R01CA045708, R01CA046413] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46413, R01-CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DeckardJanatpour K, 1997, INT J ONCOL, V11, P235; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DiGiovanna MP, 1996, BRIT J CANCER, V74, P802, DOI 10.1038/bjc.1996.439; DiGiovanna MP, 1997, ANAL BIOCHEM, V247, P167, DOI 10.1006/abio.1997.9919; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gulliford TJ, 1997, ONCOGENE, V15, P2219, DOI 10.1038/sj.onc.1201595; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; Krane IM, 1996, ONCOGENE, V12, P1781; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1990, ONCOGENE, V5, P953; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; RIESE DJ, IN PRESS BIOESSAYS; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIMMELPENNING H, 1992, VIRCHOWS ARCH A, V420, P433, DOI 10.1007/BF01600515; SEGATTO O, 1990, New Biologist, V2, P187; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	49	51	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1877	1884		10.1038/sj.onc.1202091	http://dx.doi.org/10.1038/sj.onc.1202091			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778054				2022-12-17	WOS:000076303300014
J	Husmann, K; Sers, C; Fietze, E; Mincheva, A; Lichter, P; Schafer, R				Husmann, K; Sers, C; Fietze, E; Mincheva, A; Lichter, P; Schafer, R			Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12	ONCOGENE			English	Article						expression genetics; cellular transformation; RAS; oncogenic signalling; transcriptional target	HRAS-TRANSFORMED CELLS; BREAST-CANCER CELLS; LYSYL OXIDASE; WILMS TUMOR; H-RAS; DIFFERENTIAL DISPLAY; PROTEIN-KINASE; MESSENGER-RNAS; EXPRESSION; GROWTH	The H-rev107 tumour suppressor was isolated as a gene specifically expressed in rat fibroblasts resistant toward malignant transformation by the activated HRAS gene (Sers et al., 1997; Hajnal et al., 1994), Here we describe the human homologue of the rat H-rev107 gene. The predicted rat and human proteins are highly conserved exhibiting an overall amino acid identity of 83%, The HREV107-1 gene is ubiquitously expressed with the exception of haematopoetic cells and tissues, In contrast, H-REV107-1 mRNA was found only in eight of 27 cell lines derived from mammary carcinoma, lung carcinoma, gastric carcinoma, kidney carcinoma, melanoma, neuroblastoma and other tumours, The H-REV107-1 protein was not detectable in any of these tumour cells. Loss of H-REV107-1 expression was not restricted to cultured human tumour cell lines, but also found in primary squamous cell carcinomas. Gross structural aberrations of the H-REV107-1 gene were absent in tumorigenic cell lines. Thus, the block to H-REV107-1 expression is achieved both at the level of transcription and translation. By fluorescence in situ hybridisation the human H-REV107-1 gene was localised to chromosome 11q11-12.	Univ Zurich, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland; Humboldt Univ, Univ Hosp Charite, Inst Pathol, D-10117 Berlin, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Schafer, R (corresponding author), Univ Zurich, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010	Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOAK AM, 1994, AM J RESP CELL MOL, V11, P751, DOI 10.1165/ajrcmb.11.6.7946403; BOS JL, 1989, CANCER RES, V49, P4682; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Gioeli D, 1997, CANCER RES, V57, P1157; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JANES PW, 1994, ONCOGENE, V9, P3601; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATZ E, 1986, J NATL CANCER I, V77, P909; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIESS M, 1995, ONCOGENE, V10, P61; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NEGRINI M, 1994, CANCER RES, V54, P1331; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; PENG JW, 1990, CANCER GENET CYTOGEN, V45, P101; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Szpirer C, 1996, MAMM GENOME, V7, P701, DOI 10.1007/s003359900211; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	55	51	52	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1305	1312		10.1038/sj.onc.1202060	http://dx.doi.org/10.1038/sj.onc.1202060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771974				2022-12-17	WOS:000075803300013
J	Hock, B; Bohme, B; Karn, T; Feller, S; Rubsamen-Waigmann, H; Strebhardt, K				Hock, B; Bohme, B; Karn, T; Feller, S; Rubsamen-Waigmann, H; Strebhardt, K			Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions	ONCOGENE			English	Article						Eph-related kinases; HEK2; SH2-domains; signal transduction	COMMISSURAL AXONS; C-CRK; EPH; BINDING; PROTEIN; FAMILY; ACTIVATION; PROMOTES; GUIDANCE; DOMAIN	HEK2 belongs to the family of EPH-related receptor tyrosine kinases (RTK) which are involved in axonal pathfinding and the formation of the embryonic body plan. The knowledge about intracellular pathways of signal transduction mediated by EPH-related receptors is still limited, Many of the known key players of cellular signalling contain Src homology 2 (SH2) domains, which recognize phosphotyrosine motifs in RTKs, Thus, we examined the interactions of various SH2-containing molecules like PLC-gamma 1, rasGAP, p85 subunit of PI3-kinase, Src, Fyn, Crk, Nck, GrbZ and Shc with HEK2 using in vitro binding assays, immunoprecipitations and yeast Two-Hybrid assays. We found that rasGAP, Crk and Fyn bind in a SH2-dependent manner to autophosphorylated HEK2, rasGAP, which contains two SH2- and one SH3-domain, was shown to associate with its N-terminal SH2-domain to HEK2, Furthermore, we demonstrated that a single amino acid substitution (Y614F) clearly reduces the phosphotyrosine content of HEK2 and abrogates its ability to bind rasGAP, Crk and Fyn indicating that this residue functions as major phosphorylation and multi-docking site. The conservation of this predicted binding site among various EPH-related RTKs provides evidence that Fyn, Crk and rasGAP are key players in signal transduction of at least a subset of these receptors.	Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Med Inst Strahlenkunde & Zellforsch MSZ, Lab Mol Onkol, D-97078 Wurzburg, Germany; Bayer AG, Inst Virol, D-42096 Wuppertal, Germany	Bayer AG	Strebhardt, K (corresponding author), Chemotherapeut Forschungsinst, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Strebhardt, Klaus/E-8765-2011; karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOHME B, 1993, ONCOGENE, V8, P2857; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; Ellis C, 1996, ONCOGENE, V12, P1727; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FOX GM, 1995, ONCOGENE, V10, P897; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; KARN T, 1993, ONCOGENE, V8, P3433; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	51	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					255	260		10.1038/sj.onc.1201907	http://dx.doi.org/10.1038/sj.onc.1201907			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674711				2022-12-17	WOS:000074706700015
J	Lee, H; Maihle, NJ				Lee, H; Maihle, NJ			Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues	ONCOGENE			English	Article						c-erbB3; alternative processing; truncated growth factor receptors; gene structure; epidermal growth factor receptor homologues	GROWTH-FACTOR RECEPTOR; GENE ENCODES; CAENORHABDITIS-ELEGANS; MONOCLONAL-ANTIBODY; TYROSINE KINASE; TRUNCATED FORM; LET-23 GENE; PROTEIN; TUMORS; DOMAIN	ErbB-3 is a member of the epidermal growth factor receptor (EGFR/ErbB) family. In addition to the previously reported 6.2 kb full-length and 1.4 kb truncated c-erbB3 transcripts, we have observed a 1.7 kb c-erbB3 human transcript in Northern blots that specifically hybridizes to a probe of the extracellular domain of the receptor. Using 3'-RACE we have isolated four novel c-erbB3 cDNA clones of 1.6, 1.7, 2.1 and 2.3 kb from a human ovarian carcinoma-derived cell line. All four alternate transcripts are synthesized by readthrough of an intron and use of an alternative polyadenylation signal within this intron. Identical c-erbB3 transcripts are expressed in normal human placental tissues. Expression of these alternate transcripts is tissue-specific as indicated by Northern blot and RNase protection analyses. Fibroblasts transfected with expression vectors carrying these alternate c-erbB3 cDNA clones stably express truncated ErbB-3 products. Three of these four cDNA clones express a receptor product that is secreted. Immunoprecipitation analysis of primary cultures of human ovarian carcinomas also demonstrate the expression of a 90 kDa ErbB-3 related protein that is secreted. Furthermore, we demonstrate conservation of the exon-intron junctions between members of the erbB gene family in those regions of the gene encoding the extracellular domain. This gene structure is also conserved in the c-erbB1 homologues of Drosophila and C. elegans. Growth regulatory roles for related truncated ErbB products recently have been reported. It is, therefore, possible that the products of these four alternate c-erbB3 transcripts may also play important growth regulatory roles in normal and transformed cells.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maihle, NJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.				NCI NIH HHS [CA65800, CA09441, CA57534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009441, R01CA057534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1980, CELL, V20, P381; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BUICK RN, 1985, CANCER RES, V45, P3668; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CLIFFORD R, 1994, GENETICS, V137, P531; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; Frohman Michael A., 1994, P14; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MAIHLE NJ, 1991, P NATL ACAD SCI USA, V88, P1825, DOI 10.1073/pnas.88.5.1825; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P1970; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLET A, 1995, ONCOGENE, V10, P319; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sakai T, 1996, J MOL BIOL, V256, P548, DOI 10.1006/jmbi.1996.0107; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SIMPSON BJB, 1995, BRIT J CANCER, V71, P758, DOI 10.1038/bjc.1995.147; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	30	51	68	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3243	3252		10.1038/sj.onc.1201866	http://dx.doi.org/10.1038/sj.onc.1201866			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681822				2022-12-17	WOS:000074343600004
J	Matsuoka, M; Tani, K; Asano, S				Matsuoka, M; Tani, K; Asano, S			Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19(Ink4D) and p21(Cip1) in mouse macrophages	ONCOGENE			English	Article						p19(Ink4D); p21(Cip1); interferon-alpha	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; TGF-BETA; PROTEIN-KINASE; POTENTIAL MEDIATOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; GROWTH ARREST; G(1) CYCLINS	The mechanism of cell cycle arrest induced by interferon-alpha (IFN-alpha) was analysed using a mouse macrophage cell line, BAC1.2F5A. IFN-alpha added in media before mid-G1 prohibited cells from entering S phase. The blockage of G1/S transition was associated with diminuition of both cyclin D1/cdk4- and cyclin E/cdk2-associated kinase activities. G1 cyclin-associated kinase activities were down-regulated quickly after the addition of IFN-alpha. Cells treated with IFN-alpha contained excess amounts of cdk inhibitors which down-regulated G1 cyclin/cdk-associated kinase activities in the proliferating cells and this action was counteracted by exogenously-supplied recombinant cgclin D2/cdk4 complexes, In parallel, accumulation of p19(Ink4D) and p21(Cip1), and their attachment to cdks mere upregulated quickly after the addition of IFN-alpha. Expression of p19(Ink4D) and p21(Cip1) was potentiated transcriptionally. We concluded that increased attachment of upregulated cdk inhibitors including p19(Ink4D) and p21(Cip1) to G1 cyclin/cdk complexes contributed to diminuition of G1 cyclin/cdk-associated kinase activities and resulting G1 phase arrest during the early phase of treatment with IFN-alpha.	Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, Tokyo 108, Japan	University of Tokyo	Matsuoka, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1411; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAVARONE A, 1997, NATURE, V387, P417; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, ONCOGENE, V9, P2261; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V368, P753; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PESTKA S, 1987, ANN REV BIOCH, V56, P72; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3453; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU J, 1995, MOL CELL BIOL, V14, P8018	66	51	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2075	2086		10.1038/sj.onc.1201745	http://dx.doi.org/10.1038/sj.onc.1201745			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572488				2022-12-17	WOS:000073177200005
J	Lembo, M; Sacchi, C; Zappador, C; Bellomo, G; Gaboli, M; Pandolfi, PP; Gariglio, M; Landolfo, S				Lembo, M; Sacchi, C; Zappador, C; Bellomo, G; Gaboli, M; Pandolfi, PP; Gariglio, M; Landolfo, S			Inhibition of cell proliferation by the interferon-inducible 204 gene, a member of the Ifi 200 cluster	ONCOGENE			English	Article						interferon; interferon-inducible genes; p204; cell cycle; growth inhibition	TUMOR-SUPPRESSOR GENES; CONSTITUTIVE EXPRESSION; RETINOBLASTOMA PROTEIN; CYCLE PROGRESSION; TRANSGENIC MICE; INFLUENZA-VIRUS; 3T3 CELLS; GROWTH; TRANSCRIPTION; ARREST	The role of the IFN-inducible p204 as growth regulator was investigated by transfecting an expression vector constitutively expressing p204 into several cell lines, Like PRE and p107, p204 is a potent growth inhibitor in sensitive cells, as demonstrated by the cell focus assay, Since stable transfectants of sensitive lines constitutively overexpressing p204 could not be established in vitro, we inserted the 204 cDNA into a vector bearing an heavy-metal-inducible promoter, Here we show that proliferation of B6MEF fibroblasts lacking endogenous p204 is strongly inhibited by transient p204 expression in the nucleus, p204 delays G(1) progression into the S-phase and cells accumulate with a DNA content equivalent to cells arrested in late G(1). Moreover, the role of p204 in the control of cell growth in vivo was investigated by generating transgenic mice in which the Ifi 204 gene was constitutively expressed in all tissues, To this end, expression vectors bearing the 204 cDNA under the control of the SV40 viral promoter were constructed, The overexpression of the p204 transgene achieved by injecting fertilized mouse eggs with these vectors was compatible with embryo development up to the four-cell stage in an in vitro follow-up of 4.5 days, However, no viable animals with an intact copy of the transgene were obtained, suggesting that high and constitutive levels of p204 expression can impair normal embryo development, These findings indicate that p204 plays a negative role in growth regulation and provide new information about the molecular mechanisms exploited by IFNs to inhibit cell proliferation.	Med Sch Torino, Dept Microbiol & Publ Hlth, Turin, Italy; Med Sch Novara, Dept Med Sci, Novara, Italy; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; CNR, Ctr Immunogenet & Expt Oncol, I-10126 Turin, Italy	University of Eastern Piedmont Amedeo Avogadro; Memorial Sloan Kettering Cancer Center; Consiglio Nazionale delle Ricerche (CNR)	Landolfo, S (corresponding author), Med Sch Torino, Dept Microbiol & Publ Hlth, Turin, Italy.			Gariglio, Marisa/0000-0002-5187-0140				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; Demaeyer E., 1988, INTERFERONS OTHER RE; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FRIESEN HJ, 1981, ARCH BIOCHEM BIOPHYS, V206, P432, DOI 10.1016/0003-9861(81)90111-9; GARIGLIO M, 1992, VIROLOGY, V187, P115, DOI 10.1016/0042-6822(92)90300-E; GARIGLIO M, 1994, EUR J BIOCHEM, V221, P731, DOI 10.1111/j.1432-1033.1994.tb18786.x; Gariglio M, 1996, J CELL BIOCHEM, V60, P83, DOI 10.1002/(SICI)1097-4644(19960101)60:1<83::AID-JCB11>3.3.CO;2-#; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOGAN B, 1994, MANIPULATING MOUSE E, P226; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Min W, 1996, MOL CELL BIOL, V16, P359; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Sambrook J, 1989, MOL CLONING LAB MANU; SEN GC, 1992, J BIOL CHEM, V267, P5017; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	56	51	52	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1543	1551		10.1038/sj.onc.1201677	http://dx.doi.org/10.1038/sj.onc.1201677			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569021				2022-12-17	WOS:000072743200004
J	Ohnishi, T; Wang, XJ; Ohnishi, K; Takahashi, A				Ohnishi, T; Wang, XJ; Ohnishi, K; Takahashi, A			p53-dependent induction of WAF1 by cold shock in human glioblastoma cells	ONCOGENE			English	Article						p53; WAF1; signal transduction; cold shock; non-genotoxic stress	GROWTH ARREST; P53; APOPTOSIS; PROTEINS	Induction of WAF1 expression was investigated in human glioblastoma cell lines differing in p53 gene statuses after cold shock treatment, Accumulation of both wild-type (wt) and mutant p53 (mp53) was induced by cold shock at 4 degrees C for 60 min, however, WAF1 accumulation was induced by cold shock in A-172 cells carrying the wtp53 but not in T98G cells carrying the mp53, Inactivation of wtp53 by a dominant negative p53 mutant (p53Trp248) abolished cold shock-induced WAF1 expression in A-172 transfectant cells, Furthermore, no WAF1 expression was induced by cold shock in p530-deficient human osteosarcoma Saos-2 cells. Northern blot analysis showed that the WAF1 but not p53 gene was activated by cold shock only in A-172 cells, These findings suggest that WAF1 expression is cold shock-inducible in human glioblastoma cells, and that this induction may be due to signal transduction mediated by p53 in response to non-genotoxic stress, cold shock.	Nara Med Univ, Dept Biol, Nara 634, Japan	Nara Medical University	Ohnishi, T (corresponding author), Nara Med Univ, Dept Biol, 840 Shijo Cho, Nara 634, Japan.			Takahashi, Akihisa/0000-0002-9960-2153				AOKI H, 1997, IN PRESS MOL CARCINO; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DROBNIS EZ, 1993, J EXP ZOOL, V265, P432, DOI 10.1002/jez.1402650413; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRUMAN II, 1992, J CELL PHYSIOL, V153, P112, DOI 10.1002/jcp.1041530115; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Ohtsubo T, 1997, CANCER RES, V57, P3910; Ota T, 1996, PHOTOCHEM PHOTOBIOL, V64, P984, DOI 10.1111/j.1751-1097.1996.tb01865.x; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WANG X, 1997, IN PRESS EXP CELL RE; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179	19	51	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1507	1511		10.1038/sj.onc.1201663	http://dx.doi.org/10.1038/sj.onc.1201663			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525749				2022-12-17	WOS:000072572400015
J	Kohn, KW				Kohn, KW			Functional capabilities of molecular network components controlling the mammalian G1/S cell cycle phase transition	ONCOGENE			English	Article						molecular reaction network modeling; molecular reaction diagrams; computer simulation of reaction networks; cell cycle models; G1/S phase transition; E2F; retinoblastoma protein	UBIQUITIN-PROTEASOME PATHWAY; SPINDLE-ASSEMBLY CHECKPOINT; TRANSCRIPTION FACTOR E2F-1; S-PHASE; NITROGEN-MUSTARD; DNA-SYNTHESIS; RETINOBLASTOMA PROTEIN; INCREASED EXPRESSION; MITOTIC OSCILLATOR; INHIBITS GROWTH	The molecular interactions implicated in the mammalian G1/S cell cycle phase transition comprise a highly nonlinear network which can produce seemingly paradoxical results and make intuitive interpretations unreliable, A new approach to this problem is presented, consisting of (1) a convention of unambiguous reaction diagrams, (2) a convenient computer simulation method, and (3) a quasi-evolutionary method of probing the functional capabilities of simplified components of the network, Simulations were carried out for a sequence of hypothetical primordial systems, beginning with the simplest plausibly functional system, The complexity of the system was then increased in small steps, such that functionality was added at each step, The results suggested new functional concepts: (1) Rb-family proteins could store E2F in a manner analogous to the way a condenser stores electric charge, and, upon phosphorylation, release a large wave of active E2F; (2) excessive or premature cyclin-dependent kinase activities could paradoxically impair E2F activity during the G1/S transition period, The results show how network simulations, carried out by means of the methods described, can assist in the design and interpretation of experiments probing the control of the G1/S phase transition.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kohn, KW (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA.							Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOU QP, 1993, CANCER RES, V53, P1493; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINGERT HJ, 1988, CANCER RES, V48, P4375; FINGERT HJ, 1986, CANCER RES, V46, P2463; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; Goldbeter A., 1996, BIOCH OSCILLATIONS C; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; HYVER C, 1990, BIOSYSTEMS, V24, P86; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAUFFMAN S, 1975, J THEOR BIOL, V55, P47, DOI 10.1016/S0022-5193(75)80108-1; KHOLODENKO BN, 1995, TRENDS BIOCHEM SCI, V20, P52, DOI 10.1016/S0968-0004(00)88955-0; KOHN KW, 1997, COMPUTER MODELING CO; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LOCK RB, 1992, CANCER RES, V52, P1817; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521; NOVAK B, 1993, J THEOR BIOL, V165, P101, DOI 10.1006/jtbi.1993.1179; NOVAK B, 1993, J CELL SCI, V106, P1153; NOVAK B, 1995, J THEOR BIOL, V173, P283, DOI 10.1006/jtbi.1995.0063; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OConnor PM, 1997, CANCER SURV, V29, P151; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1988, UCLA S MOL CELL BIOL, V58, P157; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; TYSON JJ, 1991, P NATL ACAD SCI USA, V88, P7328, DOI 10.1073/pnas.88.16.7328; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZARAKOWSKA R, 1997, J BIOL CHEM, V272, P12738	66	51	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1065	1075		10.1038/sj.onc.1201608	http://dx.doi.org/10.1038/sj.onc.1201608			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519880				2022-12-17	WOS:000072335900012
J	Caricasole, AAD; van Schaik, RHN; Zeinstra, LM; Wierikx, CDJ; van Gurp, RJHLM; van den Pol, M; Looijenga, LHJ; Oosterhuis, JW; Pera, MF; Ward, A; de Bruijn, D; Kramer, P; de Jong, FH; van den Eijnden-van Raaij, AJM				Caricasole, AAD; van Schaik, RHN; Zeinstra, LM; Wierikx, CDJ; van Gurp, RJHLM; van den Pol, M; Looijenga, LHJ; Oosterhuis, JW; Pera, MF; Ward, A; de Bruijn, D; Kramer, P; de Jong, FH; van den Eijnden-van Raaij, AJM			Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours	ONCOGENE			English	Article						teratocarcinoma; germ cell tumour; TGF beta; embryonal carcinoma	EMBRYONAL CARCINOMA-CELLS; BETA SUPERFAMILY; ADULT TESTIS; ACTIVIN-A; TUMORS; RECEPTORS; MEMBERS	We describe the cloning and initial characterization of a novel cDNA from human embryonal carcinoma CEC) cells, This cDNA, which we named human growth differentiation factor 3 (hGDF3), encodes the homologue of mouse GDF3, a TGF beta superfamily member belonging to the Growth/Differentiation Factors. We have analysed the expression of hGDF3 in human embryonal carcinoma cell lines and in primary testicular germ cell tumours of adolescents and adults (TGCTs), Expression of hGDF3 in human EC cell lines is stem cell-specific, is down-regulated upon RA-mediated differentiation and is increased upon culture of the cells in the presence of activin A, In TGCTs, hGDF3 expression is low in seminomas, while expression in non-seminomas is readily detectable and appears to be associated with the EC and yolk sac components in the tumours, We have also mapped the hGDF3 locus to the short arm of human chromosome 12, a region consistently overrepresented in human testicular germ cell rumours, Thus, hGDF3 represents an embryonal carcinoma stem cell-associated marker both in vitro and in vivo.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Erasmus Univ, Dept Endocrinol & Reprod, NL-3000 DR Rotterdam, Netherlands; Acad Hosp Rotterdam, Dr Daniel Den Hoed Canc Ctr, Expt Pathooncol Lab, NL-3075 EA Rotterdam, Netherlands; Monash Univ, Med Ctr, Inst Reprod & Dev, Clayton, Vic 3168, Australia; Univ Bath, Sch Biol & Biochem, Bath BA2 7AY, Avon, England; Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Monash University; University of Bath	Caricasole, AAD (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		van Schaik, Ron H.N./G-6816-2013; de Bruijn, D.R.H./L-4233-2015; Looijenga, Leendert/B-8145-2019; PERA, MARTIN/A-9812-2012; De Jong, Frank H/A-9876-2011	Looijenga, Leendert/0000-0002-8146-1911; PERA, MARTIN/0000-0001-6239-0428; De Jong, Frank H/0000-0003-3578-1065; Ward, Andrew/0000-0001-8311-5695				ANDREWS P, 1987, TERATOCARCINOMAS EMB; ANDREWS PW, 1994, LAB INVEST, V71, P243; BAARENDS WM, 1995, ENDOCRINOLOGY, V136, P5614, DOI 10.1210/en.136.12.5614; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; DAMJANOV I, 1993, LAB INVEST, V68, P220; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; DEJONG FH, 1993, BIOCHEM BIOPH RES CO, V192, P1334, DOI 10.1006/bbrc.1993.1562; DEJONG FH, 1994, FRONTIERS ENDOCRINOL, V3; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JONES CM, 1992, MOL ENDOCRINOL, V6, P1961, DOI 10.1210/me.6.11.1961; KEITZ ATV, 1994, UROLOGY, V5, P28; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; PERA MF, 1988, DIFFERENTIATION, V39, P139, DOI 10.1111/j.1432-0436.1988.tb00089.x; PERA MF, 1987, INT J CANCER, V40, P334, DOI 10.1002/ijc.2910400309; Sambrook J, 1989, MOL CLONING LAB MANU; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; SINKE RJ, 1992, GENOMICS, V12, P206, DOI 10.1016/0888-7543(92)90367-2; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H; VANSCHAIK RHN, 1997, IN PRESS BR J CANC; White T.J., 1990, PCR PROTOCOLS GUIDE, P315, DOI [10.1016/0307-4412(91), DOI 10.1016/0307-4412(91)]; ZHANG J, 1989, HUM GENET, V83, P359, DOI 10.1007/BF00291381	26	51	80	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					95	103		10.1038/sj.onc.1201515	http://dx.doi.org/10.1038/sj.onc.1201515			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467948				2022-12-17	WOS:000071236800012
J	Zhang, LR; Kharbanda, S; Chen, D; Bullocks, J; Miller, DL; Ding, IYF; Hanfelt, J; McLeskey, SW; Kern, FG				Zhang, LR; Kharbanda, S; Chen, D; Bullocks, J; Miller, DL; Ding, IYF; Hanfelt, J; McLeskey, SW; Kern, FG			MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice	ONCOGENE			English	Article						estrogen independence; antiestrogen resistance; angiogenesis; metastasis; fibroblast growth factors	FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; ESTROGEN-DEPLETED CONDITIONS; HUMAN MAMMARY-GLAND; CANCER-CELLS; FACTOR-I; EPITHELIAL-CELLS; FACTOR RECEPTORS; FACTOR FAMILY; CONSTITUTIVE ACTIVATION	FGF-1 is expressed in a high proportion of breast tumors, While overexpression of FGF-4 in the MCF-7 breast carcinoma cell line confers the ability to form spontaneously metastasizing tumors in ovariectomized nude mice without estrogen supplementation and in mice that receive tamoxifen pellets, the response of a cell to individual FGFs can be controlled at multiple levels, and the significance of FGF-1 expression in human breast tumors is uncertain, To study the role of FGF-1, MCF-7 human breast cancer carcinoma cells, previously transfected with bacterial beta-galactosidase, were retransfected with FGF-1 expression vectors, FGF-1 transfectants formed large, vascularized tumors in ovariectomized nude mice without estrogen supplementation as web as in mice that received tamoxifen pellets, Lymphatic and pulmonary micrometastases were detected as deposits of X-gal-stained cells as early as 17 days after cell inoculation whereas no metastases were detected in estrogen-supplemented mice bearing similar-sized control tumors, When compared with controls, both clonal and polyclonal populations of FGF-1 overexpressing cells exhibited increased anchorage-independent growth and decreased population doubling times in estrogen-depleted or 4-hydroxytamoxifen containing medium, These results suggest that FGF signaling may be important in the transition of breast cancer cells from hormone-dependent to hormone-independent and from nonmetastatic to metastatic.	GEORGETOWN UNIV, MED CTR, SCH NURSING, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Georgetown University					NCI NIH HHS [P50CA53185, R01-CA50376, R29-CA6614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLAM SB, 1988, ONCOGENE, V3, P129; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BROWN KJ, 1995, J CELL BIOCHEM, V58, P6, DOI 10.1002/jcb.240580103; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DING IY, 1992, P ANN M AM ASS CANC, V33, pA1610; ENGEL LW, 1978, CANCER RES, V38, P4327; Fenig E, 1997, CLIN CANCER RES, V3, P135; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLOVER JF, 1988, CANCER RES, V48, P3693; GOMM JJ, 1991, CANCER RES, V51, P4685; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IMAGAWA W, 1994, BIOCHEM BIOPH RES CO, V204, P1165, DOI 10.1006/bbrc.1994.2585; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KE YQ, 1993, J CELL SCI, V106, P135; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MCLESKEY SW, 1993, CANCER RES, V53, P2168; McLeskey SW, 1996, BRIT J CANCER, V73, P1053, DOI 10.1038/bjc.1996.204; MCLESKEY SW, 1994, CANCER RES, V54, P523; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X; SOMMERS CL, 1990, CANCER RES, V50, P67; SPIRITO P, 1991, CIRCULATION, V84, P322, DOI 10.1161/01.CIR.84.1.322; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRYDOM DJ, 1986, BIOCHEMISTRY-US, V25, P945, DOI 10.1021/bi00353a001; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TOI M, 1994, JPN J CANCER RES, V85, P1045, DOI 10.1111/j.1349-7006.1994.tb02904.x; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VISSCHER DW, 1995, MODERN PATHOL, V8, P665; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	88	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2093	2108		10.1038/sj.onc.1201386	http://dx.doi.org/10.1038/sj.onc.1201386			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366526				2022-12-17	WOS:A1997YC28400010
J	Panagopoulos, I; Lassen, C; Isaksson, M; Mitelman, F; Mandahl, N; Aman, P				Panagopoulos, I; Lassen, C; Isaksson, M; Mitelman, F; Mandahl, N; Aman, P			Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia	ONCOGENE			English	Article						chromosome translocations; DNA sequence; breakpoints; tumors	ACUTE PROMYELOCYTIC LEUKEMIA; RNA-BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; MOLECULAR ANALYSIS; FUSION; ONCOGENE; CHOP; ERG; RECOMBINATION; CELL	We have sequenced the breakpoint regions in one acute myeloid leukemia (AML) with t(16;21)(pll;q22) resulting in the formation of a FUS/ERG hybrid gene and in four myxoid liposarcomas (MLS), three of which had the t(12;16) (q13:p11) and translocation a FUS/CHOP fusion gene and one with t(12;22;20)(q13;q12;q11) and an EWS/CHOP hybrid gene. The breakpoints were localized to intron 7 of FUS, intron 1 of CHOP, an intronic sequence of ERG and intron 7 of EWS. In two MLS cases with t(12;16) and in the AML, the breaks in intron 7 of FUS had occurred close to each other, a few nucleotides downstream from a TG dinucleotide repeat region. The break in the two MLS had occurred in the same ATGGTG hexamer and in the AML 40 nucleotides upstream from the hexamer. The third case of t(12;16) MLS had a break upstream and near a TC-dinucleotide repeat region and a sequence similar to the chi bacterial recombination element was found to flank the breakpoint. In the MLS with the EWS/ CHOP hybrid gene, the break in intron 7 of EWS had occurred close to an Alu sequence. Similarly, in all 4 MLS, the breaks in intron 1 of CHOP mere near an Alu sequence. No Alu or other repetitive sequences were found 250 bp upstream or downstream from the break in the ERG intron involved in the AML case. In the AML, the MLS with ESW/CHOP and in one MLS with FUS/CHOP there were one, two and six, respectively, nucleotide identity between the contributing germline sequences in the breakpoint. In the other two MLS cases, two and three extra nucleotides of unknown origin were inserted between the FUS and CHOP sequences. At the junction and/or in its close vicinity, identical oligomers, frequently containing a trinucleotide TGG, were found in both partner genes. Our data thus show that all four genes-PUS, EWS, CHOP and ERG-contain characteristic motifs in the breakpoint regions which may serve as specific recognition sites for DNA-binding proteins and have functional importance in the recombination events taking place between the chromosomes. Different sequence motifs may, however, play a role in each individual case.			Panagopoulos, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Mitelman, Felix/0000-0002-3757-7212; Aman, Pierre/0000-0002-1482-8875; Panagopoulos, Ioannis/0000-0003-2159-5341				ADACHI M, 1990, ONCOGENE, V5, P1653; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BHAGIRATH T, 1995, GENE CHROMOSOME CANC, V13, P126, DOI 10.1002/gcc.2870130209; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOMER PH, 1995, LEUKEMIA, V9, P1305; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; FELIX CA, 1995, CANCER RES, V55, P4287; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JAEGER U, 1993, BLOOD, V81, P1833; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KAGAN J, 1993, HEMATOL PATHOL, V7, P159; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J, 1989, MOL CLONING LAB MANU; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; SPITZNER JR, 1989, NUCLEIC ACIDS RES, V18, P1; YOSHIDA H, 1995, GENE CHROMOSOME CANC, V12, P37, DOI 10.1002/gcc.2870120107	33	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1357	1362		10.1038/sj.onc.1201281	http://dx.doi.org/10.1038/sj.onc.1201281			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315104				2022-12-17	WOS:A1997XV84500014
J	Thompson, MA; Flegg, R; Westin, EH; Ramsay, RG				Thompson, MA; Flegg, R; Westin, EH; Ramsay, RG			Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines	ONCOGENE			English	Article						c-myb; transcriptional attenuation; colon tumour cells	NONPOLYPOSIS COLORECTAL-CANCER; MESSENGER-RNA; MULTIPLE MECHANISMS; REPLICATION ERRORS; SUPPRESSOR PROTEIN; ADENOMATOUS POLYPS; SODIUM-BUTYRATE; GENE; DIFFERENTIATION; ELONGATION	In the hemopoietic system c-myb expression is required for proliferation of immature cells and its downregulation is required for differentiation. In colonic mucosa c-myb expression occurs at levels comparable to immature hemopoietic cells. Inhibition of c-myb expression in colon cell lines, using anti-sense oligonucleotides, indicates that c-myb expression is required for proliferation. However, the mechanism of c-myb regulation during colon cell differentiation has not been explored. Using the LIM1215 and CaCo-2 colon carcinoma cell lines induced to differentiate with sodium butyrate, we demonstrate that c-myb mRNA is down-regulated as an early event in differentiation by a mechanism involving transcriptional attenuation in intron 1. By analogy with procaryotic and eucaryotic genes, transcriptional attenuation probably occurs in a region containing nineteen consecutive thymidine residues. Computer prediction of the secondary structure of the nascent mRNA chain encoded by this region suggests a strong potential for stem-loop formation. Sequence analysis of several colon tumour cell lines reveals mutations in this region that may disrupt transcriptional attenuation and result in the increased c-myb expression observed in colon tumours and tumour cell lines.	PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Peter Maccallum Cancer Center; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Virginia Commonwealth University			Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; AUGERON C, 1984, CANCER RES, V44, P3961; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BOISE LH, 1992, ONCOGENE, V7, P1817; Bubb VJ, 1996, ONCOGENE, V12, P2641; CHEN JS, 1995, CANCER RES, V55, P174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DENG G, 1992, CANCER RES, V52, P3378; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FERRAO P, 1995, ONCOGENE, V11, P1631; GAMET L, 1992, INT J CANCER, V52, P286, DOI 10.1002/ijc.2910520222; GRECO C, 1994, ANTICANCER RES, V14, P1433; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBS SM, 1994, ONCOGENE, V9, P227; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KIM HG, 1994, AM J PATHOL, V145, P148; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUMM A, 1995, SCIENCE, V269, P1400, DOI 10.1126/science.7660121; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LOTHE RA, 1993, CANCER RES, V53, P5849; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MELANI C, 1991, CANCER RES, V51, P2897; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PATHAK S, 1989, CELL MOL BIOL COLON, P139; PINTO M, 1983, BIOL CELL, V47, P323; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SPENCER CA, 1990, ONCOGENE, V5, P777; STROBL L, 1992, EMBO J, V9, P3307; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weston K M, 1990, Semin Cancer Biol, V1, P371; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; WHITEHEAD RH, 1986, GUT, V27, P1447; WU C, 1994, ONCOGENE, V9, P991; XU L, 1995, ONCOGENE, V11, P1865; XU L, 1991, MOL CELL BIOL, V11, P7006; YOKATA J, 1986, SCIENCE, V231, P261; YOUNG J, 1993, ONCOGENE, V8, P671; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	63	51	54	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1715	1723		10.1038/sj.onc.1201007	http://dx.doi.org/10.1038/sj.onc.1201007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135073				2022-12-17	WOS:A1997WR89300010
J	Servillo, G; Penna, L; Foulkes, NS; Magni, MV; DellaFazia, MA; SassoneCorsi, P				Servillo, G; Penna, L; Foulkes, NS; Magni, MV; DellaFazia, MA; SassoneCorsi, P			Cyclic AMP signalling pathway and cellular proliferation: Induction of CREM during liver regeneration	ONCOGENE			English	Article						cAMP; CREM; CREB; liver regeneration; proliferation; early response	PROTO-ONCOGENE EXPRESSION; LONG-TERM DESENSITIZATION; GENE-TRANSCRIPTION; TYROSINE AMINOTRANSFERASE; PARTIAL-HEPATECTOMY; GROWTH-FACTOR; RAT-LIVER; BINDING; CAMP; PHOSPHORYLATION	The CREM gene encodes both activators and repressors of cAMP-induced gene expression, An isoform of CREM encodes the powerful transcriptional repressor ICER (Inducible cAMP Early Repressor), which has been shown to be inducible by virtue of an alternative, intronic promoter, The CREM gene belongs to the early response class and displays a characteristic neuroendocrine cell- and tissue-specific expression, To date ICER inducibility has in non-replicating, terminally differentiated In this paper we document a robust induction of CREM expression in the regenerating rat liver after partial hepatectomy. This represents the first link of inducible CREM expression to the phenomenon of cellular proliferation, Furthermore, it represents the first example of transcriptional activation of a cAMP-responsive factor in the regenerating liver, This has significant physiological relevance since the adenylate cyclase signalling pathway is strongly implicated in liver regeneration, Finally, we show that the repressor ICER is inducible in the hepatoma cell line H35 upon activation of the adenylate cyclase and phosphorylation of the activator CREB.	INST GENET & BIOL MOL & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV PERUGIA, MONTELUCE POLICLIN, INST PATOL GEN, I-06100 PERUGIA, ITALY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Perugia			Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Servillo, Giuseppe/0000-0001-7960-7689; Della Fazia, Maria Agnese/0000-0002-5373-8477				BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELLAFAZIA MA, 1992, BIOCHEM BIOPH RES CO, V182, P753, DOI 10.1016/0006-291X(92)91796-S; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; EKANGER R, 1989, J BIOL CHEM, V264, P4374; Fausto Nelson, 1994, P1059; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; GARCIASAINZ JA, 1989, AM J PHYSIOL, V256, pC384, DOI 10.1152/ajpcell.1989.256.2.C384; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOUSLAY MD, 1986, BIOCHEM SOC T, V14, P183, DOI 10.1042/bst0140183; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LALLI E, 1994, J BIOL CHEM, V269, P17359; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEFFERT HL, 1988, LIVER BIOL PATHOBIOL, P833; MACMANUS JP, 1972, BIOCHEM BIOPH RES CO, V49, P1201, DOI 10.1016/0006-291X(72)90596-7; Maniatis T, 1989, MOL CLONING; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; TAUB R, 1987, J BIOL CHEM, V262, P10893; TOMLINSON S, 1985, CLIN ENDOCRINOL, V23, P595, DOI 10.1111/j.1365-2265.1985.tb01120.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1601	1606		10.1038/sj.onc.1200996	http://dx.doi.org/10.1038/sj.onc.1200996			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129151				2022-12-17	WOS:A1997WQ54800011
J	Bennett, JD; Farlie, PG; Watson, RJ				Bennett, JD; Farlie, PG; Watson, RJ			E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts	ONCOGENE			English	Article						B-myb; E2F; cell cycle; transcription repression; p107; p130	CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; GROWTH-REGULATION; S-PHASE; IN-VIVO; E2F-CYCLIN-A COMPLEX; FAMILY PROTEINS; GENE PROMOTER; EXPRESSION; ASSOCIATION	We have previously shown in mouse NIH3T3 fibroblasts that transcription of the B-myb gene, which encodes a transcription factor required for S phase entry, is repressed through a promoter E2F site in G(0)/early G(1). Transcription repression at this stage of the cell cycle was correlated with binding of a specific p107/E2F complex to this site, We report here, however, that transfection of cells with the known components of this complex, p107, E2F-4 and DP-1, did not repress the B-myb promoter in cycling NIH3T3 cells, although p107 inhibited transcription transactivation by E2F-4/DP-1. To establish definitively the contribution of E2F to repression, the effects of further mutations within and surrounding the E2F site were examined, It was evident that E2F binding and repression were closely correlated, lending greater weight to the contention that E2F itself is implicated in this activity, These studies also identified a closely linked site, designated the downstream repression site (DRS), which was not required for E2F binding or transactivation but which was necessary for repression, These findings indicated that E2F-dependent repression and activation are independently regulated phenomena and suggest that repression involves additional interactions determined by the promoter context.	LUDWIG INST CANC RES,IMPERIAL COLL,SCH MED ST MARYS,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGMEIER C, 1993, NUCLEIC ACIDS ERS, V21, P4998; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PORCU P, 1994, ONCOGENE, V9, P2125; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLF DA, 1995, ONCOGENE, V10, P2067; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	51	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1073	1082						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806697				2022-12-17	WOS:A1996VG76600021
J	Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronovo, V				Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronovo, V			Isolation from a multigene family of the active human gene of the metastasis-associated multifunctional protein 37LRP/p40 at chromosome 3p21.3	ONCOGENE			English	Article						37 kD laminin receptor precursor; 3p21.3; Alu sequences; p40 ribosome-associated protein; small nuclear RNA E2 gene	AFFINITY LAMININ RECEPTOR; SMALL NUCLEOLAR RNAS; CELL LUNG-CANCER; RIBOSOMAL-PROTEIN; MESSENGER-RNA; TRANSLATIONAL CONTROL; BINDING-PROTEIN; MAMMALIAN-CELLS; CARCINOMA-CELLS; ALU RNA	The 37 kD precursor of the 67 kD laminin receptor (37LRP) is a polypeptide whose expression is consistently upregulated in aggressive carcinoma. Interestingly, the 37LRP appears to be a multifunctional protein involved in the translational machinery and has also been identified as p40 ribosome-associated protein. Although highly conserved cDNAs corresponding to this polypeptide have been isolated from several species including vertebrates, invertebrates, plants and prokaryotes, characterization of any of the corresponding active genes has never been reported. In this study, we have cloned an intron-containing fragment which permitted us to isolate the active 37LRP/p40 human gene. This gene contains seven exons and six introns. Ribonuclease protection experiments suggest multiple transcription start sites. The promoter area does not bear a TATA box but contains four Sp1 sites. The first intron is also GC rich containing five Sp1 sites. Intron 4 contains the full sequence of the small nuclear RNA E2 and two Alu sequences are found in intron 3. Fluorescent in situ hybridization localized the 37LRP/p40 active gene on chromosome 3 in the locus 3p21.3 which, interestingly, is a hot spot for genetic alterations in several cancers and particularly in small cell lung carcinoma.	IST TUMORI,MILAN,ITALY; NCI,MOL PATHOL SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Belotti, Dorina/AAA-8077-2020; sozzi, gabriella/G-8259-2011	Belotti, Dorina/0000-0002-3868-9144; sozzi, gabriella/0000-0001-9360-6914				ANTOINE M, 1992, HUM MOL GENET, V1, P565, DOI 10.1093/hmg/1.8.565; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; AXELOS M, 1993, PLANT PHYSIOL, V103, P299, DOI 10.1104/pp.103.1.299; BIGNON C, 1991, GENOMICS, V10, P481, DOI 10.1016/0888-7543(91)90336-D; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; CARRITT B, 1992, CANCER RES, V52, P1536; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CASTRONOVO V, 1989, J NATL CANCER I, V81, P781, DOI 10.1093/jnci/81.10.781; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHEN LC, 1994, CANCER RES, V54, P3021; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIES B, 1993, GENOMICS, V15, P68, DOI 10.1006/geno.1993.1011; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; DEFALCO S, 1993, GENE, V126, P227, DOI 10.1016/0378-1119(93)90371-9; ELLIS S, 1994, FASEB J, V8, pA1312; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; FAUTSCH MP, 1991, J BIOL CHEM, V266, P23288; FERNANDEZ MT, 1991, BIOCHEM BIOPH RES CO, V175, P84, DOI 10.1016/S0006-291X(05)81203-3; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HEPPELLPARTON AC, 1992, GENE CHROMOSOME CANC, V4, P228, DOI 10.1002/gcc.2870040307; HERNNDEZ MG, 1994, J BIOL CHEM, V269, P20744; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; JACKERS P, 1996, IN PRESS BIOCH BIOPH; KEPPEL E, 1991, J CELL SCI, V100, P789; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LOPEZRIBOT JL, 1994, INFECT IMMUN, V62, P742; LUBINSKI J, 1994, CANCER RES, V54, P3710; MAKRIDES S, 1988, NUCLEIC ACIDS RES, V16, P2349, DOI 10.1093/nar/16.5.2349; MARAIA RJ, 1993, MOL CELL BIOL, V13, P4233, DOI 10.1128/MCB.13.7.4233; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MIOZZO M, 1990, GENE CHROMOSOME CANC, V2, P163, DOI 10.1002/gcc.2870020213; MOSCOW JA, 1994, CARCINOGENESIS, V15, P2769, DOI 10.1093/carcin/15.12.2769; NAG MK, 1993, P NATL ACAD SCI USA, V90, P9001, DOI 10.1073/pnas.90.19.9001; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; ROSENTHAL ET, 1995, J CELL SCI, V108, P245; ROWE SM, 1995, CANCER RES, V55, P2743; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SHIRAISHI M, 1995, ONCOGENE, V10, P1453; SINNETT D, 1992, J MOL BIOL, V226, P689, DOI 10.1016/0022-2836(92)90626-U; SIYANOVA EY, 1991, DOKL AKAD NAUK SSSR, V313, P227; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TOHGO A, 1994, FEBS LETT, V340, P133, DOI 10.1016/0014-5793(94)80188-6; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P3829, DOI 10.1093/nar/17.10.3829; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WESTENDORF J M, 1990, Journal of Cell Biology, V111, p93A; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485	60	51	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					495	503						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760291				2022-12-17	WOS:A1996VB32800007
J	Paulin, FEM; West, MJ; Sullivan, NF; Whitney, RL; Lyne, L; Willis, AE				Paulin, FEM; West, MJ; Sullivan, NF; Whitney, RL; Lyne, L; Willis, AE			Aberrant translational control of the c-myc gene in multiple myeloma	ONCOGENE			English	Article						c-myc; translational control; multiple myeloma	MESSENGER-RNA TRANSLATION; 5' UNTRANSLATED REGION; PLASMA-CELLS; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; NONCODING REGION; 1ST EXON; P53 GENE; EXPRESSION; ONCOGENE	We demonstrate a 10- to 25-fold increase in the amount of c-myc protein in several independent cell lines derived from patients with multiple myeloma (MM). This is not accompanied by a corresponding increase in the overall level of the c-my mRNA. There is, however, a 3.4-fold increase in the amount of c-myc mRNA associated with the polysomes in these cell Lines without any detectable change in either the polysome size or the rate of translation elongation, thus suggesting that there is an increase in the extent of mobilisation of c-myc mRNA to the polysomes in MM. Analysis of the 5' untranslated region of c-myc has revealed the presence of a mutation, in all of the MM cell lines examined, in a region which has been implicated previously in the translational control of this mRNA species. These data suggest aberrant translational control of the c-myc gene in cell lines derived from patients with MM, which may contribute towards pathogenesis of the disease.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; NUVENTURES LTD,NEWCASTLE TYNE NE2 4HE,TYNE & WEAR,ENGLAND; JESSOP HOSP WOMEN,DEPT OBSTET & GYNAECOL,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND	University of Leicester				West, Michelle/0000-0002-9497-9365; Willis, Anne/0000-0002-1470-8531				BARKER HF, 1992, BRIT J HAEMATOL, V81, P331, DOI 10.1111/j.1365-2141.1992.tb08236.x; CORRADINI P, 1993, BLOOD, V81, P2708; CROCE CM, 1985, BLOOD, V65, P1; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Davidson E. H., 1986, GENE ACTIVITY EARLY; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; GREIL R, 1991, BLOOD, V78, P180; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HATA H, 1993, BLOOD, V81, P3357; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JOHANNES G, 1992, J BIOL CHEM, V267, P10108; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAZARUS P, 1992, ONCOGENE, V7, P1037; Lewis J P, 1984, Hematol Oncol, V2, P307; MAZARS GR, 1992, ONCOGENE, V7, P1015; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1993, BLOOD, V81, P128; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1989, ONCOGENE, V4, P815; PETTERSSON M, 1992, BLOOD, V79, P495; PORTIER M, 1992, ONCOGENE, V7, P2539; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SULLIVAN NF, 1989, ONCOGENE, V4, P1509; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; VANCAMP B, 1990, BLOOD, V76, P377; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; West MJ, 1995, ONCOGENE, V11, P2515	42	51	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					505	513						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760292				2022-12-17	WOS:A1996VB32800008
J	Eshleman, JR; Markowitz, SD; Donover, PS; Lang, EZ; Lutterbaugh, JD; Li, GM; Longley, M; Modrich, P; Veigl, ML; Sedwick, WD				Eshleman, JR; Markowitz, SD; Donover, PS; Lang, EZ; Lutterbaugh, JD; Li, GM; Longley, M; Modrich, P; Veigl, ML; Sedwick, WD			Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability	ONCOGENE			English	Article						replication errors (RER); repetitive sequences; nucleic acid; genomic instability; colon cancer; HPRT	GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; MISMATCH REPAIR; COLORECTAL-CANCER; HUMAN FIBROBLASTS; HPRT GENE; MUTATIONS; DNA; FRAMESHIFT	Colon cancer and an increasing number of other cancers have been found to exhibit instability of DNA microsatellite sequences. Such tumors have been designated as replication errors (RER) tumors. However, as microsatellites are only rarely found within coding regions of the genome, instability of these sequences cannot directly contribute to carcinogenesis. Recently, we have shown RER colon cancers also demonstrate a marked 100-fold increase in mutation rates measured within an expressed gene, hprt, suggesting the mutator phenotype in these tumors extends beyond microsatellite sequences. To determine whether the RER phenotype indeed destabilizes non-repetitive DNA sequences we have sequenced hprt gene mutations recovered from the RER colon cancer cell line RKO. Greater than 10% of hprt mutants proved to be a single 3 bp deletion located in a nonrepetitive ATTAT sequence motif. Additionally, 1-4 bp deletions or insertions were found to be randomly located throughout the hprt gene. Lastly, one third of hprt mutations proved to be transitions or transversions. The microsatellite instability demonstrated in RKO is thus a global mutator phenotype which destabilizes DNA sequences both inside and outside of repetitive sequence elements and which augments base substitutions as well as frameshifts. These findings extend the characteristics of mutations associated with RER tumors and suggest additional mechanisms by which mutator phenotypes may alter target oncogenes and tumor suppressor genes.	UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,IRELAND CANC CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Case Western Reserve University; Duke University; Howard Hughes Medical Institute			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [P01CA051183, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA4370301, CA57208, P01 CA51183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDERSSON B, 1992, ENVIRON MOL MUTAGEN, V20, P89, DOI 10.1002/em.2850200204; BAO CY, 1995, MUTAT RES-FUND MOL M, V326, P1, DOI 10.1016/0027-5107(94)00152-U; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANKE M, 1994, BIOTECHNIQUES, V17, P858; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LITT M, 1989, AM J HUM GENET, V44, P397; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORRIS T, 1993, SOMAT CELL MOLEC GEN, V19, P9, DOI 10.1007/BF01233950; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OLLER AR, 1994, GENETICS, V138, P263; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARK MS, 1995, RADIAT RES, V141, P11, DOI 10.2307/3579084; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STEINGRIMSDOTTIR H, 1992, NUCLEIC ACIDS RES, V20, P1201, DOI 10.1093/nar/20.6.1201; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANG JL, 1991, CARCINOGENESIS, V12, P71, DOI 10.1093/carcin/12.1.71	42	51	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1425	1432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622858				2022-12-17	WOS:A1996UF07600006
J	Takeda, S; Kondo, M; Kumada, T; Koshikawa, T; Ueda, R; Nishio, M; Osada, H; Suzuki, H; Nagatake, M; Washimi, O; Takagi, K; Takahashi, T; Nakao, A; Takahashi, T				Takeda, S; Kondo, M; Kumada, T; Koshikawa, T; Ueda, R; Nishio, M; Osada, H; Suzuki, H; Nagatake, M; Washimi, O; Takagi, K; Takahashi, T; Nakao, A; Takahashi, T			Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinomas and underlying disease	ONCOGENE			English	Article						genomic imprinting; IGF2; H19; hepatocellular carcinoma; hepatocarcinogenesis	II GENE; HEPATITIS-C; WILMS-TUMOR; P53 GENE; INTERFERON; TISSUES; RELAXATION; IGF2; RNA	It has been well documented that the liver is an exceptional organ in which the monoallelic expression of insulin-like growth factor 2 (IGF2) due to genomic imprinting is relaxed during the postnatal period, resulting in biallelic expression thereafter. In the present study, changes in the status of genomic imprinting were examined in 15 hepatocellular carcinomas (HCCs) as well as in 29 liver biopsies of chronic hepatitis or liver cirrhosis without clinical evidence of HCC, following screening for heterozygotes with an ApaI polymorphism in IGF2 in 34 HCCs and 80 such non-HCC cases. Extreme allelic-expression imbalance, leading to restoration of monoallelic IGF2 expression, was observed in 15 (100%) of 15 informative HCCs for the polymorphism with this monoallelic IGF2 expression appearing to be non-random from the paternal allele. Interestingly, the same allelic-expression imbalance was also present in a significant fraction of noncancerous liver specimens of patients with underlying disease known to be associated with HCC development. In contrast, the status of genomic imprinting of H19, another gene closely mapped at 11p15 under opposite imprinting, was strictly maintained in seven (100%) of seven cases informative for an RsaI polymorphism of H19. Together with the previous reports on altered genomic imprinting of IGF2 and H19 in embryonal lesions such as Wilms tumors as well as in lung cancers, the results suggest that perturbations of imprinting status occur as locus and tumor-type specific events in the development of human cancers.	AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT PATHOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT CLIN LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; OGAKI MUNICIPAL HOSP,DEPT INTERNAL MED,OGAKI 503,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University; Ogaki Municipal Hospital			Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROWN AL, 1986, J BIOL CHEM, V261, P3144; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIES SM, 1994, CANCER RES, V54, P2560; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KANAI K, 1992, LANCET, V339, P1543, DOI 10.1016/0140-6736(92)91311-U; KAWAKITA N, 1992, AM J PATHOL, V140, P513; KONDO M, 1995, ONCOGENE, V10, P1193; KONDO M, 1994, ONCOGENE, V9, P3063; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NAKAJIMA T, 1994, J GASTROENTEROL, V29, P450, DOI 10.1007/BF02361242; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; NISHIDA N, 1993, CANCER RES, V53, P368; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANAKA K, 1991, CANCER RES, V51, P2842; TSAI JF, 1994, INT J CANCER, V56, P619, DOI 10.1002/ijc.2910560502; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZHANG X, 1994, CANCER RES, V54, P4177	33	51	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1589	1592						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622877				2022-12-17	WOS:A1996UF07600025
J	Laget, MP; Defossez, PA; Albagli, O; Baert, JL; Dewitte, F; Stehelin, D; deLaunoit, Y				Laget, MP; Defossez, PA; Albagli, O; Baert, JL; Dewitte, F; Stehelin, D; deLaunoit, Y			Two functionally distinct domains responsible for transactivation by the Ets family member ERM	ONCOGENE			English	Article						Ets gene; ERM; DNA-binding; transactivation	TRANSCRIPTIONAL ACTIVATION DOMAINS; HOMEODOMAIN-DNA INTERACTIONS; GENE FAMILY; C-FOS; CRYSTAL-STRUCTURE; LEUKEMIA-VIRUS; V-ETS; BINDING; PROTEIN; C-ETS-1	The recently cloned human Ets transcription factor ERM is closely related to the ER81 and PEA3 genes. Here, we report the functional analysis of the DNA-binding and transactivation properties of ERM. Specific DNA-binding by ERM requires the ETS domain, conserved in all members of the Ets family and is inhibited by an 84 residue long central region and the carboxy-terminal tail. Two fragments of ERM are transferrable activation domains: alpha, which sits in the 72 first residues and encompasses the acidic domain conserved between ERM, ER81 and PEA3, and the carboxy-terminal tail which also bears a DNA-binding inhibition function. Deletion of alpha strongly reduces transactivation by ERM. Moreover, alpha and the carboxyterminal tail exhibit functional synergism, suggesting that they activate transcription through different mechanisms. In support of this idea, we demonstrate that VP16 squelches transactivation by alpha but not by the carboxyterminal tail. This result also indicates that alpha and VP16 may share common limiting cofactors. alpha and the carboxy-terminal tail do not seem to be conserved within the whole Ets family, indicating that the specificity of ERM may rely on interactions with distinct cofactors.	INST PASTEUR,CNRS,URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Defossez, Pierre-Antoine/0000-0002-6463-9263				ALBAGLI O, 1994, ONCOGENE, V9, P3259; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CHEN ZQ, 1992, SCIENCE, V250, P1416; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JEON IS, 1995, ONCOGENE, V10, P1229; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAO VN, 1993, ONCOGENE, V8, P2167; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	72	51	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1325	1336						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649835				2022-12-17	WOS:A1996UC06700018
J	Neyns, B; Katesuwanasing, D; Vermeij, J; Bourgain, C; Vandamme, B; Amfo, K; Lissens, W; DeSutter, P; HooghePeters, E; DeGreve, J				Neyns, B; Katesuwanasing, D; Vermeij, J; Bourgain, C; Vandamme, B; Amfo, K; Lissens, W; DeSutter, P; HooghePeters, E; DeGreve, J			Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium	ONCOGENE			English	Article						proto-oncogene; c-jun; jun-B; jun-D; ovarian cancer; normal ovarian surface epithelium	PROTO-ONCOGENE FAMILY; C-JUN; CELL-GROWTH; P53 GENE; FOS; AP-1; HER-2/NEU; MEMBER; TUMORS; MYC	The jun genes (c-jun, jun-B and jun-D) play a role in critical cell functions such as proliferation, differentiation and apoptosis. We documented jun expression at the mRNA and protein level in human ovarian cancer tissues (n = 28), surface epithelial cells of normal ovaries (n = 14) and ovarian cancer cell lines (n = 6). Almost all of ovarian tumors as well as normal ovaries concomitantly express c-jun, jun-B and jun-D mRNA. Immunohistochemistry was less sensitive and revealed nuclear c-Jun and Jun-B proteins in the malignant epithelial cells of respectively 38% and 11% of ovarian tumors and in the surface epithelium of a normal premenopausal ovary. In cultured ovarian cancer cells, c-jun and jun-B expression is inducible by serum and TPA and is therefore not constitutive. The c-jun and jun-B proteins therefore play a role both in differentiation of the normal ovarian surface epithelium, as well as in the proliferation of epithelial ovarian cancer cells. High jun-B expression relates to a more malignant phenotype both in vitro and in vivo. The jun-D gene is suppressed in ovarian cancer cells as compared to normal ovarian surface epithelial cells in situ and in vitro. Downregulation of jun-D might therefore be part of the malignant ovarian epithelial cell phenotype.	FREE UNIV BRUSSELS, LAB MED ONCOL, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, DEPT HAEMATOL & MED ONCOL, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, NFWO, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, EXPTL PATHOL LAB, B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, MED GENET LAB, B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, DEPT GYNECOL, B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, LAB FUNDAMENTAL & CLIN PHARMACOL, B-1090 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Lissens, Willy/B-2892-2013; De Greve, Jacques/J-4939-2012; Neyns, Bart/ABG-3145-2021; Neyns, Bart/AAA-8267-2021	Lissens, Willy/0000-0003-3875-9955; De Greve, Jacques/0000-0002-2389-0742; Neyns, Bart/0000-0003-0658-5903; 				ALLUM WH, 1987, BRIT J CANCER, V56, P785, DOI 10.1038/bjc.1987.288; AMFO K, 1995, ONCOGENE, V11, P351; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUERSPERG A, 1994, OVARIAN CANCER, V3; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; AUWERX J, 1992, ONCOGENE, V7, P2271; BAUKNECHT T, 1993, CANCER, V71, P419, DOI 10.1002/1097-0142(19930115)71:2<419::AID-CNCR2820710224>3.0.CO;2-6; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BERCHUCK A, 1992, HEMATOL ONCOL CLIN N, V6, P813; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERGER I, 1991, ONCOGENE, V6, P561; BIGSBY RM, 1994, ENDOCRINOLOGY, V134, P1820, DOI 10.1210/en.134.4.1820; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CARTER R, 1994, ONCOGENE, V9, P2675; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHATTON B, 1994, ONCOGENE, V9, P375; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COHEN DR, 1993, ONCOGENE, V8, P443; DEGREVE J, 1990, P AM ASSOC CANC RES, V31, P131; DEGROOT RP, 1992, ONCOGENE, V7, P2281; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; ICHIKAWA Y, 1994, CANCER RES, V54, P33; JONES DJ, 1987, BRIT J CANCER, V56, P779, DOI 10.1038/bjc.1987.287; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KHAN I, 1993, PROSTAGLANDINS, V46, P139, DOI 10.1016/0090-6980(93)90039-A; KOO AS, 1992, J UROLOGY, V148, P1314, DOI 10.1016/S0022-5347(17)36899-4; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUK PA, 1990, LAB INVEST, V63, P132; MAGRISSO IJ, 1993, LAB INVEST, V69, P674; MARTI A, 1994, ONCOGENE, V9, P1213; MATTEI MG, 1990, ONCOGENE, V5, P151; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MILNER BJ, 1993, CANCER RES, V53, P2128; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MOTTA PM, 1980, J SUBMICR CYTOL PATH, V12, P407; NEPHEW KP, 1993, ENDOCRINOLOGY, V133, P419, DOI 10.1210/en.133.1.419; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; OKAMOTO A, 1991, CANCER RES, V51, P5171; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RUBIN SC, 1994, CANCER, V73, P1456, DOI 10.1002/1097-0142(19940301)73:5<1456::AID-CNCR2820730522>3.0.CO;2-L; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; SINGLETON TP, 1994, CANCER-AM CANCER SOC, V73, P1460, DOI 10.1002/1097-0142(19940301)73:5<1460::AID-CNCR2820730523>3.0.CO;2-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH MJ, 1992, BLOOD, V79, P2107; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; TASHIRO H, 1992, INT J CANCER, V50, P828, DOI 10.1002/ijc.2910500528; TSAO SW, 1991, ANTICANCER RES, V11, P1975; TYSON FL, 1991, AM J OBSTET GYNECOL, V165, P640, DOI 10.1016/0002-9378(91)90300-G; VANDAMME B, 1992, CANCER RES, V52, P6646; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; Young R.C., 1993, CANC PRINCIPLES PRAC, P1226	58	51	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1247	1257						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649827				2022-12-17	WOS:A1996UC06700010
J	Hoehn, GT; Stokland, T; Amin, S; Ramirez, M; Hawkins, AL; Griffin, CA; Small, D; Civin, CI				Hoehn, GT; Stokland, T; Amin, S; Ramirez, M; Hawkins, AL; Griffin, CA; Small, D; Civin, CI			Tnk1: A novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34(+)/Lin(-)/CD38(-) stem/progenitor cells	ONCOGENE			English	Article						Tnk1; tyrosine kinase; signal transduction; Ack; SH3 domain; stem cell	HUMAN-BONE MARROW; SIGNAL TRANSDUCTION; INSITU HYBRIDIZATION; HEMATOPOIETIC STEM; ANTIGENIC ANALYSIS; PROGENITOR CELLS; PROTO-ONCOGENE; W-LOCUS; RECEPTOR; P56LCK	Degenerate PCR was employed to identify novel tyrosine kinase genes from an enriched population of human umbilical cord blood hematopoietic stem/progenitor cells. One novel tyrosine kinase gene, designated Tnk1, was cloned, The sequence of the complete Tnk1 coding region predicts a 72 kD protein. Comparison of Tnk1 to available sequences in protein databases reveals that it is most homologous to Ack, an intracellular tyrosine kinase which associates with the GTP-bound form of p21cdc42Hs. Like Ack, Tnk1 consists of an N-terminal kinase domain, a putative SH3 domain immediately C-terminal to the kinase domain, and a proline-rich C-terminal region. Analysis of Tnk1 mRNA expression demonstrates that Tnk1 is expressed in all cord blood, bone marrow and adult blood sub-populations, as well as in most of the leukemia cell lines examined (16 of 20). Hybridization to fetal multi-tissue Northern blots detected several different Tnk1 transcripts in all fetal tissues examined. In contrast, a single Tnk1 transcript was detected in only five of 16 adult tissues examined (prostate, testis, ovary, small intestine and colon). Fluorescence in situ hybridization (FISH) analysis of metaphase chromosomes localized the Tnk1 gene to the short arm of chromosome 17 (17p13.1), near the p53 locus. Thus, Tnk1 is a novel tyrosine kinase that may be involved in signalling pathways utilized broadly during fetal development, more selectively in adult tissues and in cells of the lymphohematopoietic system.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University			Ramirez, Manuel/H-7710-2015	Ramirez, Manuel/0000-0003-0332-6973; Small, Donald/0000-0002-3072-243X	NATIONAL CANCER INSTITUTE [T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [NIH CA60441] Funding Source: Medline; NHLBI NIH HHS [NIHCA-06973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BIEGEL JA, 1992, CANCER RES, V52, P3391; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROXMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109, DOI 10.1073/pnas.89.9.4109; CARDOSO AA, 1993, P NATL ACAD SCI USA, V90, P8707, DOI 10.1073/pnas.90.18.8707; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GORE SD, 1995, EXP HEMATOL, V23, P413; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUANG S, 1992, NATURE, V360, P745, DOI 10.1038/360745a0; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOKEN MR, 1987, BLOOD, V70, P1316; LU L, 1993, BLOOD, V81, P41; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCDONALD JD, 1994, GENOMICS, V23, P229, DOI 10.1006/geno.1994.1481; MCGINNIS JF, 1995, J NEUROSCI RES, V40, P165, DOI 10.1002/jnr.490400204; MORRIS C, 1995, ONCOGENE, V10, P1009; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OGAWA M, 1993, BLOOD, V81, P2844; OLIVEIRA L, 1994, GENOMICS, V22, P478, DOI 10.1006/geno.1994.1415; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHERR CJ, 1990, BLOOD, V75, P1; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TOMBRANTINK J, 1994, GENOMICS, V19, P266, DOI 10.1006/geno.1994.1057; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	50	51	55	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					903	913						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632913				2022-12-17	WOS:A1996TW68600022
J	Kataoka, K; Noda, M; Nishizawa, M				Kataoka, K; Noda, M; Nishizawa, M			Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins	ONCOGENE			English	Article						Maf; Jun; Fos; AP-1; NF-E2; transformation	AVIAN TRANSFORMING RETROVIRUS; DNA-BINDING SPECIFICITY; YA SUBUNIT GENE; LEUCINE ZIPPER; C-JUN; TRANSCRIPTIONAL ACTIVATION; V-MAF; EMBRYO FIBROBLASTS; RESPONSIVE ELEMENT; YEAST GCN4	The v-maf oncogene encodes a nuclear bZip protein which specifically recognizes relatively long palindromic sequences related to an AP-1 site. In this study, we investigated the relationship of transactivation and transformation activity of Maf. The amino-terminal two thirds of the molecule were dispensable for its DNA-binding activity but conferred its transactivation potential. Transactivation activities of a set of deletion mutants correlated well with their cell transforming abilities. However, a point mutant associated with enhanced oncogenic activity was not more effective in transactivation than the wild type, suggesting that some other function(s) of Maf is also important for its transforming ability. We also examined the effect of other bZip proteins on the transactivation activity of Maf. Three small Maf family proteins (MafK, MafF and MafG), which are missing the transactivation domain of v-Maf, competitively inhibited transactivation by Maf. Co-expression of Jun or Fos also affected the transactivation potential of Maf by forming Maf/Jun or Maf/Fos heterodimers of distinct DNA-binding specificities. In addition to these factors, we noticed the presence of a strong endogenous transactivating activity associated with a sequence related to an NF-E2 site rather than the typical AP-1 site in fibroblast cells. These results indicate that AP-1 site-like cis-regulatory elements of eukaryotic genes are regulated by multiple sets of bZip dimers with different DNA-binding and transactivation properties.	JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHATTON B, 1994, ONCOGENE, V9, P375; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATAOKA K, 1994, MOL CELL BIOL, V14, P700; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGAN IM, 1993, ONCOGENE, V8, P1135; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OKUDA A, 1987, J BIOL CHEM, V262, P3858; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P2198, DOI 10.1093/nar/22.12.2198; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WONG WY, 1992, ONCOGENE, V7, P2077; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	45	51	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					53	62						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552399				2022-12-17	WOS:A1996TQ01400007
J	Conzen, SD; Cole, CN				Conzen, SD; Cole, CN			The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts	ONCOGENE			English	Article						SV40 large T antigen; immortalization; senescence; apoptosis	LARGE TUMOR-ANTIGEN; P53 BINDING; GENE; MUTANTS; CELLS; DNA; VIRUS; E1A; IDENTIFICATION; ADENOVIRUS-E1A	Simian virus 40 (SV40) is a small DNA tumor virus whose early region gene product, large T antigen, is sufficient to immortalize primary rodent cells and transform established rodent cell lines, Three functional domains of large T antigen are required for transformation of the rat embryo fibroblast REF 52 cell line: the extreme amino-terminal region, a domain which binds p105(Rb) family members, and the bipartite p53-binding region, Many studies have attempted to define the activities and regions of SV40 large T antigen required for immortalization of mouse embryo fibroblasts (MEFs), In most of these studies, investigators have used survival of T antigen-expressing primary MEF colonies at the time when control MEFs undergo senescence as a measurement of 'immortalization' and concluded that immortalization of MEFs is correlated with large T antigen's ability to sequester the human tumor suppressor gene product p53 and separable from its p105(Rb)-binding or N terminal functions, In order to more rigorously define the regions of SV40 large T antigen required for escape from senescence, individual T antigen-expressing primary MEF colonies were systematically subcultured for >60 population doublings beyond the time of control MEF senescence under conditions known to limit the number of spontaneously immortalized cells, We found that although interaction of T antigen with p53 was sufficient to substantially extend the lifespan of MEFs, all three SV40 large T antigen domains required for REF 52 transformation were necessary to immortalize primary MEFs, These results indicate that p53 inactivation alone is insufficient to immortalize primary MEFs; rather, immortalization requires multiple activities of T antigen which are also required for efficient transformation.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Cole, Charles/GRR-1551-2022		NCI NIH HHS [CA39259, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039259, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; COLBY WW, 1982, P NATL ACAD SCI-BIOL, V79, P5189, DOI 10.1073/pnas.79.17.5189; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; LOWE S, 1994, P NATL ACAD SCI USA, V91, P1026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAULBECKER C, 1992, J VIROL, V4, P2195; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P324; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE AE, 1994, GENE DEV, V15, P667; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOODS C, 1994, ONCOGENE, V9, P2943; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZHU J, 1992, J VIROL, V65, P6872; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	40	51	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2295	2302						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570180				2022-12-17	WOS:A1995TK70200013
J	KUROKAWA, M; OGAWA, S; TANAKA, T; MITANI, K; YAZAKI, Y; WITTE, ON; HIRAI, H				KUROKAWA, M; OGAWA, S; TANAKA, T; MITANI, K; YAZAKI, Y; WITTE, ON; HIRAI, H			THE AML1 EVI-1 FUSION PROTEIN IN THE T(3-21) TRANSLOCATION EXHIBITS TRANSFORMING ACTIVITY ON RAT1 FIBROBLASTS WITH DEPENDENCE ON THE EVI-1 SEQUENCE	ONCOGENE			English	Article						AMLI/EVI-1; TRANSFORMATION; FIBROBLAST; API ACTIVATION; C-JUN	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; ZINC FINGER PROTEIN; C-JUN; TRANSCRIPTION FACTOR; MESSENGER-RNA; PHILADELPHIA-CHROMOSOME; PRE-B; T(15-17) TRANSLOCATION	The t(3;21) (q26;q22) chromosomal translocation associated with blastic crisis of chronic myelogenous leukemia (CML) results in the formation of a chimeric protein fusing the amino-terminal DNA-binding domain encoded by the AML1 gene to the carboxyl-terminal-encoding portion of the Evi-1 gene. In order to evaluate transforming activity of this protein, AML1/Evi-1 was introduced into Rat1 fibroblasts, Cells expressing the fusion product formed macroscopic colonies in soft agar, indicating that AML1/Evi-1 is a transforming gene. It was also demonstrated that introduction of AML1/Evi-1 into the Rat1 clones harboring BCR/ABL also conferred enhanced capacity for anchorage independent growth, Analyses of deletion mutants of AML1/Evi-1 revealed that removal of the second zinc finger domain within the Evi-1 sequence totally abrogated the ability of AML1/Evi-1 to transform Rat1 cells. We showed that the transforming effect is correlated with the AP-1 activation induced by AML1/Evi-1. Furthermore, me demonstrated that c-jan is transcriptionally activated in Rat1 cells transformed by AML1/Evi-1, suggesting that c-jun expression is under control of AML1/Evi-1. These results indicate that the oncogenic effect of the t(3;21) translocation is caused by the generation of a chimeric transcriptional factor and that AML1/Evi-1 could perform a pivotal role in leukemic progression of CML.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of Tokyo; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			Tanaka, Tomoyuki U/A-4775-2008					ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHEN Z, 1991, CANCER GENET CYTOGEN, V57, P153, DOI 10.1016/0165-4608(91)90146-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COYLE T, 1988, AM J HEMATOL, V27, P56, DOI 10.1002/ajh.2830270113; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KANTARJIAN HM, 1993, BLOOD, V82, P691; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS J, 1992, BLOOD, V80, P2953; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1990, BLOOD, V76, P2594; RUBIN CM, 1987, BLOOD, V70, P1338; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHNEIDER NR, 1991, ANN GENET-PARIS, V34, P256; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SONOBE MH, 1991, ONCOGENE, V6, P1531; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	76	51	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675444				2022-12-17	WOS:A1995RU79800003
J	KATOH, M; HIRAI, M; SUGIMURA, T; TERADA, M				KATOH, M; HIRAI, M; SUGIMURA, T; TERADA, M			CLONING AND CHARACTERIZATION OF MST, A NOVEL (PUTATIVE) SERINE THREONINE KINASE WITH SH3 DOMAIN	ONCOGENE			English	Note						SERINE THREONINE KINASE; SH3 DOMAIN; LEUCINE ZIPPER DOMAIN	RECEPTOR TYROSINE KINASE; EXPRESSION CLONING; MESSENGER-RNAS; GENE; PROTEINS; FAMILY; ZIPPER; WELL	Protein kinases play a key role in cell growth regulation. We have isolated a cDNA fragment of the MST gene from the MKN28 gastric cancer cell line cDNA pool by degenerate polymerase chain reaction. MST-cDNAs were cloned from the human brain cDNA library. Nucleotide sequence analysis indicated that the MST gene encodes a novel putative non-receptor type of serine/threonine kinase with Src homology 3 (SH3) domain, two leucine zipper domains and proline rich domain. The deduced amino acid sequence corresponding to a part of kinase domain and leucine zipper domains of MST (amino acid codons 244-461) is almost identical to the published partial amino acid sequence of MLK2. MST is the first non-receptor type of serine/threonine kinase containing SH3 domain, leucine zipper domain and proline rich domain other than PTK1/Sprk. The MST gene was moderately expressed in brain, skeletal muscle and testis as a 3.8 kb mRNA, and the MST gene has been mapped to human chromosome 19q13.1-q13.2.	NATL CANC CTR, RES INST, DIV GENET, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, GRAD SCH SCI, DEPT ANTHROPOL, BUNKYO KU, TOKYO 113, JAPAN	National Cancer Center - Japan; University of Tokyo								DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; GALLO KA, 1994, J CELL BIOCH S1, V50, P278; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; KATOH M, 1993, JPN J CANCER RES, V84, P117, DOI 10.1111/j.1349-7006.1993.tb02843.x; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KATOH M, 1993, GASTROENTEROL JPN, V28, P739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE ST, 1993, ONCOGENE, V8, P3403; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHEECKEREN W, 1992, NUCLEIC ACIDS RES, V14, P3721; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	21	51	55	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1447	1451						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731697				2022-12-17	WOS:A1995QR65100024
J	CHANG, CC; ZHANG, JD; LOMBARDI, L; NERI, A; DALLAFAVERA, R				CHANG, CC; ZHANG, JD; LOMBARDI, L; NERI, A; DALLAFAVERA, R			MECHANISM OF EXPRESSION AND ROLE IN TRANSCRIPTIONAL CONTROL OF THE PROTOONCOGENE NFKB-2/LYT-10	ONCOGENE			English	Article							NF-KAPPA-B; CELL-CYCLE CONTROL; DNA-BINDING; P65 SUBUNIT; GENE-PRODUCT; REL; HOMOLOGY; CLONING; P50; ACTIVATION	The NFKB-2 gene (previously LYT-10, NF-kappa Bp100 or NF-kappa Bp97) codes for a NF-kappa B/rel related protein which is highly homologous to NFKB-1 (previously NF-kappa Bp105) within its rel, poly-glycine and ankyrin domains. The NFKB-2 gene is a candidate proto-oncogene since it is involved in lymphoma-associated chromosomal aberrations. In order to gain insight into the physiological function and role in tumorigenesis of NFKB-2, we have analysed its mechanism of expression and role in transcriptional regulation. We report that, contrary to previous studies, a single 3.2 kb mRNA species and its 100 kD (p100) primary translation product is detectable in all cell types tested. A second NFKB-2 protein, p52, corresponding to the amino-terminal half (rel domain) of NFKB-2 p100, is detectable in the same cell types and derives from the post-translational processing of p100. While p100 is constitutively localized in the cytoplasm, NF-kappa B induction by TPA treatment of Hela cells is associated with cytoplasmic/nuclear translocation of NFKB-2 p52 and its appearance within DNA-binding NF-kappa B complexes. NFKB-2 p52 differs from NFKB-1p50 in its differential affinity for kappa B sequences: by itself it binds H2/HLA-kappa B sites more efficiently than HIV/ IgK-kappa B sites, while it can bind both sites efficiently,when complexed with Rel-A(p65). Transient co-transfection of expression and reporter plasmids in cells devoid of endogenous NF-kappa B activity showed that p52 has no intrinsic transcriptional activation capabilities: it can stimulate Rel-A(p65)-driven transcription by formation of p65/p52 heterodimers, whereas, overexpressed, it down-regulates p65-dependent transcription by formation of inactive p52/p52 homodimers. These results indicate that the NFKB-2 gene codes for an inducible NF-kappa B transcription factor with the capability of differentially regulating NF-kappa B transcription depending on its abundance in,the nucleus.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,SERV EMATOL,MILAN,ITALY	Columbia University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Neri, Antonino/I-9690-2014	Neri, Antonino/0000-0001-9047-5912	NCI NIH HHS [CA 44029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUERLE PA, 1988, SCIENCE, V242, P540; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V344, P36; BROWNELL E, 1989, ONCOGENE, V4, P935; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GRILLI M, 1992, INT REV CYTOL, V48, P1; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P75; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAKSELA K, UNPUB; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	41	51	52	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					923	933						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108136				2022-12-17	WOS:A1994MW55100029
J	MURPHY, C; KRETSCHMER, C; BIESINGER, B; BECKERS, J; JUNG, J; DESROSIERS, RC; MULLERHERMELINK, HK; FLECKENSTEIN, BW; RUTHER, U				MURPHY, C; KRETSCHMER, C; BIESINGER, B; BECKERS, J; JUNG, J; DESROSIERS, RC; MULLERHERMELINK, HK; FLECKENSTEIN, BW; RUTHER, U			EPITHELIAL TUMORS INDUCED BY A HERPESVIRUS ONCOGENE IN TRANSGENIC MICE	ONCOGENE			English	Article							SAIMIRI STRAINS; SMALL RNAS; EXPRESSION; REGION; GENE; TRANSFORMATION; IDENTIFICATION; CONSEQUENCES; STP-C488; GENOME	To investigate the role of herpesviral genes in tumourigenesis, transgenic mice were generated expressing STP-C, a transformation associated protein of the lymphoma inducing herpesvirus saimiri. Epithelial tumours developed in the salivary gland, pancreas, thymus and liver of transgenic mice within the first weeks of life. Thus, the target cells for tumour formation in the transgenic mice were surprisingly different from those of the herpesvirus from which the oncogene was derived. Our results identify STP-C as a herpesvirus oncogene sufficient for tumour induction without the cooperation of other viral gene products. Furthermore, the results demonstrate pleiotropic transforming capabilities of the STP-C oncogene and suggest that the specificity of lymphoma induction by the virus is determined by factors other than the oncogene itself.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV WURZBURG, INST PATHOL, D-97080 WURZBURG, GERMANY; UNIV ERLANGEN NURNBERG, INST KLIN & MOLEK VIROL, D-91054 ERLANGEN, GERMANY; HARVARD UNIV, SCH MED, NEW ENGLAND REG PRIMATE RES CTR, SOUTHBOROUGH, MA 01772 USA	European Molecular Biology Laboratory (EMBL); University of Wurzburg; University of Erlangen Nuremberg; Harvard University			Beckers, Johannes/K-7237-2012	Beckers, Johannes/0000-0001-7874-3822				ALBRECHT JC, 1992, NUCLEIC ACIDS RES, V20, P1810; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AZEN EA, 1984, SCIENCE, V226, P967, DOI 10.1126/science.6095444; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODEMER W, 1986, J VIROL, V60, P114, DOI 10.1128/JVI.60.1.114-123.1986; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FIELDS BN, 1990, FIELDS VIROLOGY, P1373; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; GODDARD MJ, 1991, J CLIN PATHOL, V44, P660, DOI 10.1136/jcp.44.8.660; HOGAN B, 1986, MANIPULATING MOUSE E, P230; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1992, J VIROL, V66, P1777, DOI 10.1128/JVI.66.3.1777-1780.1992; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDES C, 1990, EXP PATHOL-JENA, V40, P239, DOI 10.1016/S0232-1513(11)80308-7; MEDVECZKY MM, 1989, J VIROL, V63, P3601, DOI 10.1128/JVI.63.9.3601-3611.1989; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MELENDEZ LV, 1968, LAB ANIM CARE, V18, P374; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MURTHY S, 1986, EMBO J, V5, P1625, DOI 10.1002/j.1460-2075.1986.tb04405.x; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; RUTHER U, 1989, PROG NUCLEIC ACID RE, V36, P235; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587	30	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					221	226						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302583				2022-12-17	WOS:A1994MW24700027
J	MCCUBREY, JA; SMITH, SR; ALGATE, PA; DEVENTE, JE; WHITE, MK; STEELMAN, LS				MCCUBREY, JA; SMITH, SR; ALGATE, PA; DEVENTE, JE; WHITE, MK; STEELMAN, LS			RETROVIRAL INFECTION CAN ABROGATE THE FACTOR-DEPENDENCY OF HEMATOPOIETIC-CELLS BY AUTOCRINE AND NONAUTOCRINE MECHANISMS DEPENDING ON THE PRESENCE OF A FUNCTIONAL VIRAL ONCOGENE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; V-SRC; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; AUTONOMOUS GROWTH; GENE-EXPRESSION; ABELSON VIRUS; INTERLEUKIN-3; LINE; TRANSFORMATION	The mechanisms responsible for abrogation of the growth factor-dependency of a hematopoietic cell line were investigated. FDC-P1 cells were infected with retroviral constructs containing the neo gene and either a wild-type or a temperature-sensitive v-src oncogene. v-src(wt) abrogated the factor-dependency of these cells since each G418r colony gave rise to factor-independent cells and no autocrine growth factor activity was detected. Moreover, the vast majority (<99%) of cells infected with the v-src(ts) mutant gave rise to conditional factor-independent cells. Therefore a functional v-src gene product was required for growth factor-independence which occurred by a non-autocrine mechanism. A minority of factor-independent cells which arose after v-src(ts) infection, grew at the non-permissive temperature and one-half secreted granulocyte/macrophage-colony stimulating factor (GM-CSF) which supports the growth of the parental cells. Since the v-src(ts) viral stock contained a helper virus, Murine Leukemia Virus (MuLV), the ability of this virus to relieve factor-dependency was examined. A low frequency of factor-independent transformants was recovered after MuLV infection and one-half secreted GM-CSF. Therefore, retroviruses such as MuLV which lack an oncogene, can transform cells by stimulating autocrine growth factor secretion. Subsequent experiments performed with helper-free v-src preparations indicated that they could abrogate factor-dependency directly by a non-autocrine mechanism. These results demonstrate that a hematopoietic cell line can be transformed by two different mechanisms after retroviral infection and may be relevant for understanding hematopoietic cell transformation after persistent viral infection.			MCCUBREY, JA (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858, USA.			McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [NCI RO1CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1993, ONCOGENE, V8, P1221; ANDERSON SM, 1990, ONCOGENE, V5, P317; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1802; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARBERS K, 1981, P NATL ACAD SCI-BIOL, V78, P7609, DOI 10.1073/pnas.78.12.7609; IHLE JN, 1987, J IMMUNOL, V138, P3051; IHLE JN, 1983, J IMMUNOL, V131, P282; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KITAMURA T, 1991, CELL, V66, P165; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1991, ONCOGENE RES, V6, P1; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NICOLA NA, 1986, J BIOL CHEM, V261, P2384; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALASZYNSKI EW, 1984, J IMMUNOL, V132, P1872; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WYKE JA, 1973, VIROLOGY, V53, P152, DOI 10.1016/0042-6822(73)90474-1	44	51	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2905	2915						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414494				2022-12-17	WOS:A1993MC09300003
J	HAMAGUCHI, M; XIAO, H; UEHARA, Y; OHNISHI, Y; NAGAI, Y				HAMAGUCHI, M; XIAO, H; UEHARA, Y; OHNISHI, Y; NAGAI, Y			HERBIMYCIN-A INHIBITS THE ASSOCIATION OF P60(V-SRC) WITH THE CYTOSKELETAL STRUCTURE AND WITH PHOSPHATIDYLINOSITOL-3' KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; CHICKEN-EMBRYO FIBROBLASTS; GTPASE-ACTIVATING PROTEIN; INSOLUBLE CELLULAR MATRIX; PLASMA-MEMBRANE MATRIX; SRC GENE-PRODUCT; TYROSINE KINASES; TRANSFORMING PROTEIN; CELLS; PHOSPHORYLATION	To search for the biochemical prerequisites for morphological transformation by p60v-src, we examined the effect of herbimycin A, a potent inhibitor of cell transformation. on chicken embryonic fibroblasts transformed by Rous sarcoma virus. A small dose of herbimycin (0.1-0.3 mug ml-1) was enough to convert the cell morphology to a normal phenotype with a concomitant reassembly of microfilament bundles. In the cells treated with the drug, the majority of the substrates for p60v-src remained phosphorylated and p60v-src was myristylated, membrane associated and fairly active as a protein kinase. Under the same conditions, however, the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3' kinase was strongly inhibited, suggesting that the interactions of p60v-src with the cellular structure and the enzyme were indispensable for morphological transformation.	NATL INST HLTH,DEPT ANTIBIOT,TOKYO 141,JAPAN	National Institute of Health Sciences - Japan	HAMAGUCHI, M (corresponding author), NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,TURUMAI CHO 65,SHOUWA KU,NAGOYA,AICHI 466,JAPAN.							BEUG H, 1978, CELL, V45, P105; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HAMAGUCHI M, 1985, VIROLOGY, V147, P295, DOI 10.1016/0042-6822(85)90132-1; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V77, P1311; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOCKER AW, 1986, J VIROL, V58, P876; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	40	51	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					559	564						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382356				2022-12-17	WOS:A1993KN00800005
J	TONG, JH; DONG, S; GENG, JP; HUANG, W; WANG, ZY; SUN, GL; CHEN, SJ; CHEN, Z; LARSEN, CJ; BERGER, R				TONG, JH; DONG, S; GENG, JP; HUANG, W; WANG, ZY; SUN, GL; CHEN, SJ; CHEN, Z; LARSEN, CJ; BERGER, R			MOLECULAR-REARRANGEMENTS OF THE MYL GENE IN ACUTE PROMYELOCYTIC LEUKEMIA (APL, M3) DEFINE A BREAKPOINT CLUSTER REGION AS WELL AS SOME MOLECULAR VARIANTS	ONCOGENE			English	Article							TRANS RETINOIC ACID; RECEPTOR-ALPHA GENE; CHROMOSOME-TRANSLOCATION; PRE-B; DIFFERENTIATION	Genomic DNA probes generated from the retinoic acid receptor alpha (RARA) gene located on chromosome 17 and from the MYL gene located on chromosome 15 were used to study the chromosome 15 breakpoints resulting from the t(15; 17) translocation in 26 patients with acute promyelocytic leukemia (APL). In 20 out of 22 patients with a detectable MYL rearrangement, the breakpoints were clustered within a 4.4 kb segment designated MYL(bcr).The two remaining patients exhibited a more 5' rearrangement at about 10 kb upstream of the MYL(bcr) region, implying the lack of at least one MYL gene exon in the resulting MYL-RARA fusion gene. The variation of chromosome breakpoints within the MYL gene may explain size heterogeneity previously observed in some MYL-RARA fusion transcripts expressed in APL cells.	SHANGHAI MED UNIV 2,SHANGHAI RUI JIN HOSP,SHANGHAI INST HEMATOL,MOLEC BIOL LAB,SHANGHAI 200025,PEOPLES R CHINA; INST GENET MOLEC,CNRS,INSERM,U301,F-75010 PARIS,FRANCE; INST GENET MOLEC,CNRS,SDI 15954 1,F-75010 PARIS,FRANCE	Shanghai Jiao Tong University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BIONDI A, 1991, BLOOD, V77, P1418; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG KS, 1991, LEUKEMIA, V5, P200; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN Z, 1991, LEUKEMIA, V5, P288; CHOMIENNE C, 1990, BLOOD, V76, P1710; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Maniatis T., 1982, MOL CLONING; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002	24	51	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					311	316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312695				2022-12-17	WOS:A1992HG98200016
J	DOUGLAS, JL; GOPALAKRISHNAN, S; QUINLAN, MP				DOUGLAS, JL; GOPALAKRISHNAN, S; QUINLAN, MP			MODULATION OF TRANSFORMATION OF PRIMARY EPITHELIAL-CELLS BY THE 2ND EXON OF THE AD5 E1A12S GENE	ONCOGENE			English	Article							ADENOVIRUS E1A; GROWTH-FACTOR; FUNCTIONAL DOMAINS; E1A-12S PROTEIN; TERMINAL REGION; DNA FRAGMENTS; TYPE-5; SEQUENCES; INDUCTION; PRODUCTS	Expression of the Ad5 E1A first exon is necessary and sufficient to cooperate with an activated RAS oncogene to transform primary epithelial cells. The second exon, although necessary for immortalization and induction of an epithelial cell growth factor, is not essential for co-transformation with T24 RAS. To determine whether the second exon has a role in the cooperation of ElA with an activated RAS gene, we have performed an extensive mutational analysis of this region. All of the deletion and point mutants that we have generated and analyzed retained the ability to enable the transformants to grow in serum-free media and in soft agar. A region in the C-terminus of the E1A polypeptide encoded by nucleotides 1437-1488 appears to modulate the level of transformation. Co-transfections of T24 RAS and EIA genes with mutations that bring about specific amino acid substitutions or deletions in the C-terminus result in enhanced transformation. There is an increase in the number of transformed foci and they appear earlier. A single amino acid change can bring about this phenotype, which is dominant over wild type. Thus, it seems that expression of the wild-type second exon retards or suppresses transformation. The hypertransforming phenotype does not correlate with any differences in the expression of the mutated E1A or the co-cotransfected RAS gene. The C-terminus encodes a nuclear localization signal for E1A, however the subcellular localization of the mutant polypeptides does not affect their co-transforming ability.	UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; EGAN C, 1989, ONCOGENE, V4, P383; Flint S. J, 1981, DNA TUMOR VIRUSES; FRISCH SM, 1990, ONCOGENE, V5, P75; GALLIMORE PH, 1974, J MOL BIOL, V8, P49; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORAN E, 1986, J VIROL, V57, P764; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; REICH R, 1988, CANCER RES, V48, P3307; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	46	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2093	2103						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945414				2022-12-17	WOS:A1991GX11900021
J	ZHAO, X; BATTEN, B; SINGH, B; ARLINGHAUS, RB				ZHAO, X; BATTEN, B; SINGH, B; ARLINGHAUS, RB			REQUIREMENT OF THE C-MOS PROTEIN-KINASE FOR MURINE MEIOTIC MATURATION	ONCOGENE			English	Note									UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; OHIO STATE UNIV,DEPT ANAT,COLUMBUS,OH 43210	University of Texas System; UTMD Anderson Cancer Center; Ohio State University					NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1988, ONCOGENE, V3, P159; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG NK, 1988, ONCOGENE, V3, P225; Hogan B., 1986, MANIPULATING MOUSE E; KESHET E, 1988, ONCOGENE, V2, P235; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37	29	51	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1727	1730						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2176285				2022-12-17	WOS:A1990EL40100017
J	CHEN, L; OBRYAN, JP; SMITH, HS; LIU, E				CHEN, L; OBRYAN, JP; SMITH, HS; LIU, E			OVEREXPRESSION OF MATRIX GLA PROTEIN MESSENGER-RNA IN MALIGNANT HUMAN BREAST CELLS - ISOLATION BY DIFFERENTIAL CDNA HYBRIDIZATION	ONCOGENE			English	Article									UNIV N CAROLINA, LINEBERGER CANC RES CTR, CB 7295, CHAPEL HILL, NC 27599 USA; PACIFIC MED CTR, GERALDINE BRUSH CANC RES INST, SAN FRANCISCO, CA 94115 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; California Pacific Medical Center; University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008	O'Bryan, John/0000-0001-5386-1080	NCI NIH HHS [P0I CA44768, R01-CA49240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049240, P01CA044768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BENZ CC, 1989, JNCI-J NATL CANCER I, V81, P1704, DOI 10.1093/jnci/81.22.1704; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; DAIRKEE SH, 1987, BREAST CANCER RES TR, V10, P11, DOI 10.1007/BF01806130; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVITA VT, 1982, CANCER PRINCIPLES PR, P914; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER JD, 1988, J BIOL CHEM, V263, P11033; GASIC GJ, 1984, CANCER METAST REV, V3, P99, DOI 10.1007/BF00047657; GORELIK E, 1987, CANCER RES, V47, P809; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALE JE, 1988, J BIOL CHEM, V263, P5820; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; KIEFER MC, 1988, NUCLEIC ACIDS RES, V16, P5213, DOI 10.1093/nar/16.11.5213; KORNBLIHTT AR, 1983, P NATL ACAD SCI-BIOL, V80, P3218, DOI 10.1073/pnas.80.11.3218; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIU E, 1988, ONCOGENE, V3, P323; MACKAY J, 1988, LANCET, V2, P1384; Maniatis T., 1982, MOL CLONING; MOLL R, 1984, J MOL BIOL, V179, P257; NEUBAUER BL, 1986, J UROLOGY, V135, P163, DOI 10.1016/S0022-5347(17)45554-6; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; PRICE PA, 1985, J BIOL CHEM, V260, P4971; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWCHUK A, 1986, J PEDIATR SURG, V21, P1119, DOI 10.1016/0022-3468(86)90022-9; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; SMITH HS, 1979, CANCER RES, V39, P4138; SMITH HS, 1983, BIOCHIM BIOPHYS ACTA, V738, P103, DOI 10.1016/0304-419X(84)90009-X; SMITH HS, 1984, BIOCHIM BIOPHYS ACTA, V41, P4637; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; THORNES D, 1989, EUR J SURG ONCOL, V15, P431; TRASK D K, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P444	41	51	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1990	5	9					1391	1395						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216462				2022-12-17	WOS:A1990EC24100017
J	KURY, FD; SCHNEEBERGER, C; SLIUTZ, G; KUBISTA, E; SALZER, H; MEDL, M; LEODOLTER, S; SWOBODA, H; ZEILLINGER, R; SPONA, J				KURY, FD; SCHNEEBERGER, C; SLIUTZ, G; KUBISTA, E; SALZER, H; MEDL, M; LEODOLTER, S; SWOBODA, H; ZEILLINGER, R; SPONA, J			DETERMINATION OF HER-2/NEU AMPLIFICATION AND EXPRESSION IN TUMOR-TISSUE AND CULTURED-CELLS USING A SIMPLE, PHENOL FREE METHOD FOR NUCLEIC-ACID ISOLATION	ONCOGENE			English	Editorial Material									UNIV VIENNA,DEPT OBSTET & GYNECOL 1,DIV MOLEC ENDOCRINOL,SPITALGASSE 23,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,LUDWIG BOLTZMANN INST PRENATAL & EXPTL GENOME ANAL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT OTOLARYNGOL,A-1090 VIENNA,AUSTRIA; KRANKENHAUS STADT VIENNA LAINZ,A-1130 VIENNA,AUSTRIA	University of Vienna; Ludwig Boltzmann Institute; University of Vienna; University of Vienna				Zeillinger, Robert/0000-0001-6771-4591				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; ANDERSSON K, 1985, PLASMID, V13, P78, DOI 10.1016/0147-619X(85)90059-9; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; Carter C., 1983, BIOTECHNIQUES, V1, P142; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Favaloro J, 1980, Methods Enzymol, V65, P718; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HIGGINS SJ, 1978, BIOCHEM J, V174, P543, DOI 10.1042/bj1740543; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIRKES PE, 1985, ANAL BIOCHEM, V148, P376, DOI 10.1016/0003-2697(85)90242-8; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; ZARLENGA DS, 1987, ANAL BIOCHEM, V162, P569, DOI 10.1016/0003-2697(87)90435-0; ZEILLINGER R, 1989, ONCOGENE, V4, P109; ZHOU DJ, 1988, ONCOGENE, V2, P279	22	51	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1403	1408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699198				2022-12-17	WOS:A1990EC24100019
J	Green, NH; Galvan, DL; Badal, SS; Chang, BH; LeBleu, VS; Long, JY; Jonasch, E; Danesh, FR				Green, Nathanael H.; Galvan, Daniel L.; Badal, Shawn S.; Chang, Benny H.; LeBleu, Valerie S.; Long, Jianyin; Jonasch, Eric; Danesh, Farhad R.			MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma	ONCOGENE			English	Article							ONE-CARBON METABOLISM; CANCER; SERINE; TRANSLATION; GLYCINE; HIF-2; N-6-METHYLADENOSINE	One-carbon metabolism plays a central role in a broad array of metabolic processes required for the survival and growth of tumor cells. However, the molecular basis of how one-carbon metabolism may influence RNA methylation and tumorigenesis remains largely unknown. Here we show MTHFD2, a mitochondrial enzyme involved in one-carbon metabolism, contributes to the progression of renal cell carcinoma (RCC) via a novel epitranscriptomic mechanism that involves HIF-2 alpha. We found that expression of MTHFD2 was significantly elevated in human RCC tissues, and MTHFD2 knockdown strongly reduced xenograft tumor growth. Mechanistically, using an unbiased methylated RNA immunoprecipitation sequencing (meRIP-Seq) approach, we found that MTHFD2 plays a critical role in controlling global N-6-methyladenosine (m(6)A) methylation levels, including the m(6)A methylation of HIF-2 alpha mRNA, which results in enhanced translation of HIF-2 alpha. Enhanced HIF-2 alpha translation, in turn, promotes the aerobic glycolysis, linking one-carbon metabolism to HIF-2 alpha-dependent metabolic reprogramming through RNA methylation. Our findings also suggest that MTHFD2 and HIF-2 alpha form a positive feedforward loop in RCC, promoting metabolic reprograming and tumor growth. Taken together, our results suggest that MTHFD2 links RNA methylation status to the metabolic state of tumor cells in RCC.	[Green, Nathanael H.; Danesh, Farhad R.] Baylor Coll Med, Dept Pharmacol & Chem Biol, Houston, TX 77030 USA; [Green, Nathanael H.; Galvan, Daniel L.; Badal, Shawn S.; Long, Jianyin; Danesh, Farhad R.] Univ Texas MD Anderson Canc Ctr, Sect Nephrol, Houston, TX 77030 USA; [Chang, Benny H.] Baylor Coll Med, Dept Med & Mol & Cellular Biol, Houston, TX 77030 USA; [LeBleu, Valerie S.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Jonasch, Eric] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Danesh, FR (corresponding author), Baylor Coll Med, Dept Pharmacol & Chem Biol, Houston, TX 77030 USA.; Danesh, FR (corresponding author), Univ Texas MD Anderson Canc Ctr, Sect Nephrol, Houston, TX 77030 USA.	fdanesh@mdanderson.org	Galvan, Daniel L./L-2768-2019	Galvan, Daniel L./0000-0001-7541-6252; Danesh, Farhad/0000-0001-6849-5239	 [R01-DK078900];  [R01-DK091310]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078900, R01DK091310] Funding Source: NIH RePORTER	; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	FRD: R01-DK078900; R01-DK091310	American Cancer Society, 2018, CANC FACTS FIG 2018; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; GEBHARD RL, 1987, J LIPID RES, V28, P1177; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Komata M, 2014, METHODS MOL BIOL, V1164, P33, DOI 10.1007/978-1-4939-0805-9_4; Koufaris C, 2016, J PROTEOME RES, V15, P2618, DOI 10.1021/acs.jproteome.6b00188; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Long JY, 2010, J BIOL CHEM, V285, P23455, DOI 10.1074/jbc.M110.136168; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Martinez-Saez O, 2017, CRIT REV ONCOL HEMAT, V111, P117, DOI 10.1016/j.critrevonc.2017.01.013; Massari F, 2015, CANCER TREAT REV, V41, P767, DOI 10.1016/j.ctrv.2015.07.002; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Noone A.M., 2018, SEER CANC STAT REV 1; Pikman Y, 2016, J EXP MED, V213, P1285, DOI 10.1084/jem.20151574; Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sheppard NG, 2015, SCI REP-UK, V5, DOI 10.1038/srep15029; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Tedeschi PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.393; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	51	50	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6211	6225		10.1038/s41388-019-0869-4	http://dx.doi.org/10.1038/s41388-019-0869-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31289360	Green Accepted			2022-12-17	WOS:000482210100005
J	So, D; Shin, HW; Kim, J; Lee, M; Myeong, J; Chun, YS; Park, JW				So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Myeong, Jongyun; Chun, Yang-Sook; Park, Jong-Wan			Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense	ONCOGENE			English	Article							EXTRACELLULAR VESICLES; CELL-DEATH; MITOCHONDRIAL DAMAGE; LONGEVITY PROTEIN; INFLAMMASOME; PYROPTOSIS; TRANSCRIPTION; DEACETYLASE; PATHWAY; MICROVESICLES	Mammalian cells are equipped with antiviral innate immunity. To survive and grow, human papilloma virus (HPV)-infected cervical cancer cells must overcome this host defense system. However, the precise mechanism whereby cervical cancer cells evade the immunity is not fully understood. We noted that Sirtuin 1 (SIRT1) is overexpressed in HPV-infected cervical cancer cells and hypothesized that SIRT1 counteracts antiviral immunity. Here, we found that cervical cancer cells undergo massive death by SIRT1 knockdown, but this effect is reversed by SIRT1 restoration. SIRT1-knocked-down cells showed representative features of pyroptosis, as well as highly expressed absent in melanoma 2 (AIM2) and its downstream genes related to the inflammasome response. Mechanistically, SIRT1 repressed the NF-kappa B-driven transcription of the AIM2 gene by destabilizing the RELB mRNA. Interestingly, pyroptotic death signaling in SIRT1-knocked-down cells was transmitted to naive cervical cancer cells, which was mediated by extracellular vesicles carrying AIM2 inflammasome proteins. Furthermore, the growth of cervical cancer xenografts was significantly inhibited by either SIRT1-targeting siRNAs or SIRT1-knockdown-derived extracellular vesicles. Immunohistochemical analyses showed that SIRT1 expression correlated with poor clinical outcomes in cervical cancer. In conclusion, SIRT1 enabled HPV-infected cervical cancer cells to continue growing by nullifying AIM2 inflammasome-mediated immunity. Without SIRT1, cervical cancer cells could no longer survive because of the derepression of the AIM2 inflammasome. SIRT1 could therefore be a target for the effective treatment of cervical cancer.	[So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Chun, Yang-Sook; Park, Jong-Wan] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea; [So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea; [So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Myeong, Jongyun; Chun, Yang-Sook; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea; [So, Daeho; Shin, Hyun-Woo; Kim, Jiyoung; Lee, Mingyu; Myeong, Jongyun; Chun, Yang-Sook; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea; [Chun, Yang-Sook] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 03080, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, JW (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea.	parkjw@snu.ac.kr		SHIN, HYUN-WOO/0000-0002-4038-9992; Park, Jong-Wan/0000-0003-4676-5191	National Research Foundation of Korea [2016R1A2A1A05005082]	National Research Foundation of Korea(National Research Foundation of Korea)	We thank Dr. Ja Eun Kim (Kyung Hee University) for giving the plasmids for SIRT1 and mutants, and Dr. Woo Ho Kim (Seoul National University) for providing cervical cancer tissue arrays. This work was supported by a grant from the National Research Foundation of Korea (2016R1A2A1A05005082; to JWP).	Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Allison SJ, 2009, AGING-US, V1, P316, DOI 10.18632/aging.100028; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bergsbaken T, 2011, J IMMUNOL, V187, P2748, DOI 10.4049/jimmunol.1100477; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Boyer SN, 1996, CANCER RES, V56, P4620; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Chen IF, 2006, MOL CANCER THER, V5, P1, DOI 10.1158/1535-7163.MCT-05-0310; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Davidson S, 2011, CRIT REV ONCOL HEMAT, V79, P24, DOI 10.1016/j.critrevonc.2010.07.002; Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gadducci A, 2010, ONCOL LETT, V1, P3, DOI 10.3892/ol_00000001; Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; In HY, 2007, P NATL ACAD SCI USA, V105, P3374; Kamura T, 2013, TAIWAN J OBSTET GYNE, V52, P161, DOI 10.1016/j.tjog.2013.04.003; Koh WJ, 2013, J NATL COMPR CANC NE, V11, P320, DOI 10.6004/jnccn.2013.0043; Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154; Man SM, 2016, EUR J IMMUNOL, V46, P269, DOI 10.1002/eji.201545839; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Rathinam VAK, 2011, VIROLOGY, V411, P153, DOI 10.1016/j.virol.2011.02.003; Reinholz M, 2013, ARCH DERMATOL RES, V305, P723, DOI 10.1007/s00403-013-1375-0; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Singh S, 2015, TUMOR BIOL, V36, P6159, DOI 10.1007/s13277-015-3300-y; Small W, 2017, CANCER-AM CANCER SOC, V123, P2404, DOI 10.1002/cncr.30667; Tetta C, 2013, ENDOCRINE, V44, P11, DOI 10.1007/s12020-012-9839-0; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Velez-Perez A, 2017, HUM PATHOL, V59, P102, DOI 10.1016/j.humpath.2016.09.019; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang J, 2016, INT J SCI, V5, P133; Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111; Zhang DY, 2009, J BIOL CHEM, V284, P20917, DOI 10.1074/jbc.M109.020073; ZIMMERMAN EM, 1969, J CELL PHYSIOL, V74, P67, DOI 10.1002/jcp.1040740110	45	50	55	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5191	5204		10.1038/s41388-018-0339-4	http://dx.doi.org/10.1038/s41388-018-0339-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29844574				2022-12-17	WOS:000445093100004
J	Rada, M; Nallanthighal, S; Cha, J; Ryan, K; Sage, J; Eldred, C; Ullo, M; Orsulic, S; Cheon, DJ				Rada, Miran; Nallanthighal, Sameera; Cha, Jennifer; Ryan, Kerry; Sage, Jessica; Eldred, Catherine; Ullo, Maria; Orsulic, Sandra; Cheon, Dong-Joo			Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer	ONCOGENE			English	Article							NF-KAPPA-B; CELL LUNG-CANCER; EXTRACELLULAR-MATRIX; LINKED INHIBITOR; GENE SIGNATURE; ACTIVATION; PROMOTES; COL11A1; SRC; CHEMORESISTANCE	Although, cisplatin resistance is a major challenge in the treatment of ovarian cancer, the precise mechanisms underlying cisplatin resistance are not fully understood. Collagen type XI alpha 1 (COL11A1), a gene encoding a minor fibrillar collagen of the extracellular matrix, is identified as one of the most upregulated genes in cisplatin-resistant ovarian cancer and recurrent ovarian cancer. However, the exact functions of COL11A1 in cisplatin resistance are unknown. Here we demonstrate that COL11A1 binds to integrin alpha 1 beta 1 and discoidin domain receptor 2 (DDR2) and activates downstream signaling pathways to inhibit cisplatin-induced apoptosis in ovarian cancer cells. Mechanistically, we show that COL11A1 activates Src-PI3K/Akt-NF-kB signaling to induce the expression of three inhibitor apoptosis proteins (IAPs), including XIAP, BIRC2, and BIRC3. Genetic and pharmacological inhibition of XIAP, BIRC2, and BIRC3 is sufficient to restore cisplatin-induced apoptosis in ovarian cancer cells in the presence of COL11A1 in ovarian cancer cells and xenograft mouse models, respectively. We also show that the components of COL11A1-integrin alpha 1 beta 1/DDR2-Src-PI3K/Akt-NF-kB-IAP signaling pathway serve as poor prognosis markers in ovarian cancer patients. Taken together, our results suggest novel mechanisms by which COL11A1 confers cisplatin resistance in ovarian cancer. Our study also uncovers IAPs as promising therapeutic targets to reduce cisplatin resistance in ovarian cancer, particularly in recurrent ovarian cancer expressing high levels of COL11A1.	[Rada, Miran; Nallanthighal, Sameera; Cha, Jennifer; Ryan, Kerry; Sage, Jessica; Eldred, Catherine; Ullo, Maria; Cheon, Dong-Joo] Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA; [Cha, Jennifer] Rensselaer Polytech Inst, Sch Sci, Troy, NY 12180 USA; [Orsulic, Sandra] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA	Albany Medical College; Rensselaer Polytechnic Institute; Cedars Sinai Medical Center	Cheon, DJ (corresponding author), Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA.	cheond@mail.amc.edu	Rada, Miran/AFC-7022-2022; Rada, Miran/AAO-8034-2021	Rada, Miran/0000-0002-8220-7982; 	Albany Medical College; Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Award; AACR Gertrude B. Elion Cancer Research Award	Albany Medical College; Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Award; AACR Gertrude B. Elion Cancer Research Award	We thank Drs. Robert C. Bast, Michael DiPersio, and Paula McKeown-Longo for insightful discussions and critical readings of the manuscript; Dr. Nikki Cheng for CAF cells. D.-J.C. is supported by the startup fund from the Albany Medical College, the Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Award, and the AACR Gertrude B. Elion Cancer Research Award.	Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Armstrong T, 2004, CLIN CANCER RES, V10, P7427, DOI 10.1158/1078-0432.CCR-03-0825; Asselin E, 2001, CANCER RES, V61, P1862; Cai Q, 2011, J MED CHEM, V54, P2714, DOI 10.1021/jm101505d; Castells M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.384; Cheon DJ, 2014, BIOMARK MED, V8, P523, DOI 10.2217/bmm.14.16; Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256; Chien J, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00251; Choi YE, 2009, J BIOL CHEM, V284, P12772, DOI 10.1074/jbc.M807550200; Cohen E, 2013, ANTICANCER RES, V33, P379; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Garcia-Pravia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078327; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hatton O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042610; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Janzen DM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8956; Jia DY, 2016, CANCER LETT, V382, P203, DOI 10.1016/j.canlet.2016.09.001; Jin H, 2015, ONCOL RES, V22, P167, DOI 10.3727/096504015X14298122915664; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; Konecny GE, 2009, BRIT J CANCER, V101, P1699, DOI 10.1038/sj.bjc.6605381; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li WY, 2011, J THORAC ONCOL, V6, P1801, DOI 10.1097/JTO.0b013e318226b4a6; Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Pramanik KC, 2013, CARCINOGENESIS, V34, P2061, DOI 10.1093/carcin/bgt154; Raglow Z, 2015, CANCER LETT, V357, P448, DOI 10.1016/j.canlet.2014.12.011; Sasaki H, 2000, CANCER RES, V60, P5659; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shen LH, 2016, ONCOL REP, V36, P877, DOI 10.3892/or.2016.4869; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Teng P-N, 2013, BRIT J CANCER, V110, P123; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wu WS, 2016, ONCOTARGET, V7, P52281, DOI 10.18632/oncotarget.10739; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Xu HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052209	50	50	50	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4809	4820		10.1038/s41388-018-0297-x	http://dx.doi.org/10.1038/s41388-018-0297-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29769618				2022-12-17	WOS:000443146000004
J	Gerlach, D; Tontsch-Grunt, U; Baum, A; Popow, J; Scharn, D; Hofmann, MH; Engelhardt, H; Kaya, O; Beck, J; Schweifer, N; Gerstberger, T; Zuber, J; Savarese, F; Kraut, N				Gerlach, Daniel; Tontsch-Grunt, Ulrike; Baum, Anke; Popow, Johannes; Scharn, Dirk; Hofmann, Marco H.; Engelhardt, Harald; Kaya, Onur; Beck, Janina; Schweifer, Norbert; Gerstberger, Thomas; Zuber, Johannes; Savarese, Fabio; Kraut, Norbert			The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; SMALL NUCLEAR RIBONUCLEOPROTEIN; P-TEFB; SELECTIVE-INHIBITION; CELL IDENTITY; PROTEIN BRD4; C-MYC; ELONGATION; CANCER	Bromodomain and extra-terminal (BET) protein inhibitors have been reported as treatment options for acute myeloid leukemia (AML) in preclinical models and are currently being evaluated in clinical trials. This work presents a novel potent and selective BET inhibitor (BI 894999), which has recently entered clinical trials (NCT02516553). In preclinical studies, this compound is highly active in AML cell lines, primary patient samples, and xenografts. HEXIM1 is described as an excellent pharmacodynamic biomarker for target engagement in tumors as well as in blood. Mechanistic studies show that BI 894999 targets super-enhancer-regulated oncogenes and other lineage-specific factors, which are involved in the maintenance of the disease state. BI 894999 is active as monotherapy in AML xenografts, and in addition leads to strongly enhanced antitumor effects in combination with CDK9 inhibitors. This treatment combination results in a marked decrease of global p-Ser2 RNA polymerase II levels and leads to rapid induction of apoptosis in vitro and in vivo. Together, these data provide a strong rationale for the clinical evaluation of BI 894999 in AML.	[Gerlach, Daniel; Tontsch-Grunt, Ulrike; Baum, Anke; Popow, Johannes; Scharn, Dirk; Hofmann, Marco H.; Engelhardt, Harald; Kaya, Onur; Beck, Janina; Schweifer, Norbert; Gerstberger, Thomas; Savarese, Fabio; Kraut, Norbert] Boehringer Ingelheim RCV GmbH & Co KG, A-1120 Vienna, Austria; [Zuber, Johannes] Vienna BioCtr VBC, Res Inst Mol Pathol IMP, A-1030 Vienna, Austria; [Zuber, Johannes] Med Univ Vienna, Vienna BioCtr VBC, A-1030 Vienna, Austria	Boehringer Ingelheim; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna; Vienna Biocenter (VBC)	Savarese, F; Kraut, N (corresponding author), Boehringer Ingelheim RCV GmbH & Co KG, A-1120 Vienna, Austria.	fabio.savarese@boehringer-ingelheim.com; norbert.kraut@boehringer-ingelheim.com	Zuber, Johannes/E-7517-2011	Zuber, Johannes/0000-0001-8810-6835; Gerlach, Daniel/0000-0001-9338-3765; Hofmann, Marco/0000-0001-7557-1156				Aftimos PG, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2504; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Bartholomeeusen K, 2012, J BIOL CHEM, V287, P36609, DOI 10.1074/jbc.M112.410746; Berenguer-Daize C, 2016, INT J CANCER, V139, P2047, DOI 10.1002/ijc.30256; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561; Bres V, 2008, CURR OPIN CELL BIOL, V20, P334, DOI 10.1016/j.ceb.2008.04.008; Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Coude MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Devaraj SGT, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3686; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; Dukler N, 2017, NAT GENET, V49, P2, DOI 10.1038/ng.3759; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; GRECO WR, 1995, PHARMACOL REV, V47, P331; Gressel S, 2017, ELIFE, V6, DOI 10.7554/eLife.29736; Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449; Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jonkers I, 2015, NAT REV MOL CELL BIO, V16, P167, DOI 10.1038/nrm3953; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lee YS, 2015, MOL CANCER THER, V14, pC202; Lin XY, 2017, MOL CANCER THER, V16, P388, DOI 10.1158/1535-7163.MCT-16-0475; Liu PY, 2014, J BIOL CHEM, V289, P9918, DOI 10.1074/jbc.M113.539015; Liu W, 2013, CELL, V155, P1581, DOI 10.1016/j.cell.2013.10.056; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Moreno N, 2017, ONCOTARGET, V8, P84986, DOI 10.18632/oncotarget.18583; Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521; Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Rudolph D, 2015, J PHARMACOL EXP THER, V352, P579, DOI 10.1124/jpet.114.221150; Sarosiek KA, 2013, MOL CELL, V51, P751, DOI 10.1016/j.molcel.2013.08.048; Schuller R, 2016, MOL CELL, V61, P305, DOI 10.1016/j.molcel.2015.12.003; Shahbazi J, 2016, CLIN CANCER RES, V22, P2534, DOI 10.1158/1078-0432.CCR-15-1666; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Siegel MB, 2015, ONCOTARGET, V6, P18921, DOI 10.18632/oncotarget.4214; Simo-Riudalbas L, 2015, BRIT J PHARMACOL, V172, P2716, DOI 10.1111/bph.12844; Waizenegger IC, 2016, MOL CANCER THER, V15, P354, DOI 10.1158/1535-7163.MCT-15-0617; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yao WL, 2015, ONCOTARGET, V6, P34669, DOI 10.18632/oncotarget.5785; Yeh TC, 2017, CLIN CANCER RES, V23, P1025, DOI 10.1158/1078-0432.CCR-16-1658; Yokoyama Y, 2016, CANCER RES, V76, P6320, DOI 10.1158/0008-5472.CAN-16-0854; Zhang WS, 2012, J BIOL CHEM, V287, P43137, DOI 10.1074/jbc.M112.413047; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	63	50	52	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2687	2701		10.1038/s41388-018-0150-2	http://dx.doi.org/10.1038/s41388-018-0150-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29491412	hybrid, Green Published			2022-12-17	WOS:000432545100006
J	Heilmann, K; Toth, R; Bossmann, C; Klimo, K; Plass, C; Gerhauser, C				Heilmann, K.; Toth, R.; Bossmann, C.; Klimo, K.; Plass, C.; Gerhauser, C.			Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MAMMALIAN EXPRESSION ATLAS; ENGINEERED MOUSE MODELS; TUMOR-SUPPRESSOR GENE; MAMMARY ADENOCARCINOMA; CPG METHYLATION; BONE METASTASIS; SEQUENCING DATA; SEQ EXPERIMENTS; STEM-CELLS	The majority of long noncoding RNAs (lncRNAs) is still poorly characterized with respect to function, interactions with protein-coding genes, and mechanisms that regulate their expression. As for protein-coding RNAs, epigenetic deregulation of lncRNA expression by alterations in DNA methylation might contribute to carcinogenesis. To provide genome-wide information on lncRNAs aberrantly methylated in breast cancer we profiled tumors of the C3(1) SV40TAg mouse model by MCIp-seq (Methylated CpG Immunoprecipitation followed by sequencing). This approach detected 69 lncRNAs differentially methylated between tumor tissue and normal mammary glands, with 26 located in antisense orientation of a protein-coding gene. One of the hypomethylated lncRNAs, 1810019D21Rik (now called Esrp2-antisense (as)) was identified in proximity to the epithelial splicing regulatory protein 2 (Esrp2) that is significantly elevated in C3(1) tumors. ESRPs were shown previously to have a dual role in carcinogenesis. Both gain and loss have been associated with poor prognosis in human cancers, but the mechanisms regulating expression are not known. Indepth analyses indicate that coordinate overexpression of Esrp2 and Esrp2-as inversely correlates with DNA methylation. Luciferase reporter gene assays support co-expression of Esrp2 and the major short Esrp2-as variant from a bidirectional promoter, and transcriptional regulation by methylation of a proximal enhancer. Ultimately, this enhancer-based regulatory mechanism provides a novel explanation for tissue-specific expression differences and upregulation of Esrp2 during carcinogenesis. Knockdown of Esrp2-as reduced Esrp2 protein levels without affecting mRNA expression and resulted in an altered transcriptional profile associated with extracellular matrix (ECM), cell motility and reduced proliferation, whereas overexpression enhanced proliferation. Our findings not only hold true for the murine tumor model, but led to the identification of an unannotated human homolog of Esrp2-as which is significantly upregulated in human breast cancer and associated with poor prognosis.	[Heilmann, K.; Toth, R.; Bossmann, C.; Klimo, K.; Plass, C.; Gerhauser, C.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, BW, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gerhauser, C (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, BW, Germany.	c.gerhauser@dkfz.de	Toth, Reka/AAB-1695-2020	Toth, Reka/0000-0002-6096-1052; Gerhauser, Clarissa/0000-0002-5792-3901; Plass, Christoph/0000-0003-2554-3952	DKFZ Helmholtz International Graduate School for Cancer Research	DKFZ Helmholtz International Graduate School for Cancer Research	KH was supported by a Ph.D. scholarship provided by the DKFZ Helmholtz International Graduate School for Cancer Research. We are grateful to Megumio Onishi Seebacher for providing barcoded oligonucleotide sequences, the Genome and Proteome core facility of the DKFZ for providing technical support and excellent MCIp-seq and RNA-seq services, and Lorena Salgueiro and Rocio Sotillo Roman for their instant support in isolating murine mammary epithelial cells and fibroblasts. We further want to thank Oliver Mucke and Monika Helf for excellent technical assistance, and Thomas Risch, Maiwen Caudron-Herger, Odilia Popanda and Dieter Weichenhan for helpful discussion. The results reported here are in part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21; Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035; Baer C, 2015, INT J CANCER, V137, P1352, DOI 10.1002/ijc.29491; Bai YG, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0079-7; Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7; Batts TD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027841; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bennett CN, 2010, TOXICOL PATHOL, V38, P88, DOI 10.1177/0192623309357074; Bennett CN, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2125; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434; Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515; Deloria AJ, 2016, ONCOTARGET, V7, P73800, DOI 10.18632/oncotarget.12070; Di Palma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.262; Diederichs S, 2014, TRENDS GENET, V30, P121, DOI 10.1016/j.tig.2014.01.004; Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105; Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Gottgens EL, 2016, INT REV CEL MOL BIO, V327, P163, DOI 10.1016/bs.ircmb.2016.06.003; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012; Guil S, 2012, NAT STRUCT MOL BIOL, V19, P1068, DOI 10.1038/nsmb.2428; Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayakawa A, 2016, ADV EXP MED BIOL, V925, P33; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Hu GZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107016; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huang HY, 2013, CLIN CANCER RES, V19, P2861, DOI 10.1158/1078-0432.CCR-12-2641; Hwang JA, 2013, ONCOTARGET, V4, P2317, DOI 10.18632/oncotarget.1464; Hynes RO, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a004903; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Iwakiri M, 2009, NEUROPATHOLOGY, V29, P263, DOI 10.1111/j.1440-1789.2008.00978.x; Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Lee C, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-37; Li AM, 2013, BIOCHEM BIOPH RES CO, V436, P486, DOI 10.1016/j.bbrc.2013.05.131; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LI Y, 2015, SCI REP UK, V5; Lienhard M, 2014, BIOINFORMATICS, V30, P284, DOI 10.1093/bioinformatics/btt650; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003; Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082; Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566; Pappa G, 2007, CARCINOGENESIS, V28, P1471, DOI 10.1093/carcin/bgm044; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Punj V, 2010, CLIN CANCER RES, V16, P1140, DOI 10.1158/1078-0432.CCR-09-2463; Qin D, 2015, CELL MOL BIOL LETT, V20, P323, DOI 10.1515/cmble-2015-0021; Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47; Reaves DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091747; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sahu A, 2015, TRENDS CANCER, V1, P93, DOI 10.1016/j.trecan.2015.08.010; Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Sonnet Miriam, 2013, Methods Mol Biol, V971, P201, DOI 10.1007/978-1-62703-269-8_11; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun H, 2016, J CELL MOL MED, V20, P1234, DOI 10.1111/jcmm.12783; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tseng YY, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.974467; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5; Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851; Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Xu Z, 2014, ONCOGENE, V33, P2836, DOI 10.1038/onc.2013.243; Yang F, 2017, CELL MOL LIFE SCI, V74, P951, DOI 10.1007/s00018-016-2334-7; Yao Y, 2010, CARCINOGENESIS, V31, P382, DOI 10.1093/carcin/bgp308; Yarmishyn AA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S9-S7; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu HS, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-251; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011; Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77	119	50	54	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6446	6461		10.1038/onc.2017.246	http://dx.doi.org/10.1038/onc.2017.246			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759043	hybrid, Green Published			2022-12-17	WOS:000415622900008
J	Zhao, L; Ji, G; Le, X; Luo, Z; Wang, C; Feng, M; Xu, L; Zhang, Y; Lau, WB; Lau, B; Yang, Y; Lei, L; Yang, H; Xuan, Y; Chen, Y; Deng, X; Yi, T; Yao, S; Zhao, X; Wei, Y; Zhou, S				Zhao, L.; Ji, G.; Le, X.; Luo, Z.; Wang, C.; Feng, M.; Xu, L.; Zhang, Y.; Lau, W. B.; Lau, B.; Yang, Y.; Lei, L.; Yang, H.; Xuan, Y.; Chen, Y.; Deng, X.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.			An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; TUMOR MICROENVIRONMENT; EXPRESSION; INVASION; PROMOTES; FIBROBLASTS; GROWTH; MODEL	Epithelial ovarian cancer (EOC) is one of the most common gynecological cancers, with diagnosis often at a late stage. Metastasis is a major cause of death in patients with EOC, but the underlying molecular mechanisms remain obscure. Here, we utilized an integrated approach to find potential key transcription factors involved in ovarian cancer metastasis and identified STAT4 as a critical player in ovarian cancer metastasis. We found that activated STAT4 was overexpressed in epithelial cells of ovarian cancer and STAT4 overexpression was associated with poor outcome of ovarian cancer patients, which promoted metastasis of ovarian cancer in both in vivo and in vitro. Although STAT4 mediated EOC metastasis via inducing epithelial-to-mesenchymal transition (EMT) of ovarian cancer cells in vivo, STAT4 failed to induce EMT directly in vitro, suggesting that STAT4 might mediate EMT process via cancer-stroma interactions. Further functional analysis revealed that STAT4 overexpression induced normal omental fibroblasts and adipose- and bone marrow-derived mesenchymal stem cells to obtain cancer-associated fibroblasts (CAF)-like features via induction of tumor-derived Wnt7a. Reciprocally, increased production of CAF-induced CXCL12, IL6 and VEGFA within tumor microenvironment could enable peritoneal metastasis of ovarian cancer via induction of EMT program. In summary, our study established a model that STAT4 promotes ovarian cancer metastasis via tumor-derived Wnt7a-induced activation of CAFs.	[Zhao, L.; Ji, G.; Le, X.; Zhang, Y.; Xuan, Y.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.] Sichuan Univ, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women, Chengdu 610041, Peoples R China; [Zhao, L.; Ji, G.; Le, X.; Zhang, Y.; Xuan, Y.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.] Sichuan Univ, Children Minist Educ, West China Second Hosp, Chengdu 610041, Peoples R China; [Zhao, L.; Ji, G.; Le, X.; Zhang, Y.; Xuan, Y.; Yi, T.; Yao, S.; Zhao, X.; Wei, Y.; Zhou, S.] Sichuan Univ, State Key Lab Biotherapy, Collaborat Innovat Ctr, West China Hosp, Chengdu 610041, Peoples R China; [Luo, Z.; Wang, C.] Sichuan Univ, Coll Biol Sci, Chengdu, Peoples R China; [Feng, M.; Xu, L.] Sichuan Univ, West China Second Hosp, Dept Pathol, Chengdu, Peoples R China; [Lau, W. B.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA; [Lau, B.] Affiliate Stanford Univ, Kaiser Santa Clara Med Ctr, Dept Surg Emergency Med, Santa Clara, CA USA; [Yang, Y.; Lei, L.] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China; [Yang, H.] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China; [Chen, Y.; Deng, X.] Sichuan Univ, West China Hosp, Dept Surg Gastroenterol, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Jefferson University; Sichuan University; Sichuan University; Sichuan University	Zhao, L (corresponding author), Sichuan Univ, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women, Chengdu 610041, Peoples R China.; Zhao, L (corresponding author), Sichuan Univ, Children Minist Educ, West China Second Hosp, Chengdu 610041, Peoples R China.; Zhao, L (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Collaborat Innovat Ctr, West China Hosp, Chengdu 610041, Peoples R China.	taotaovip2005@163.com		Lau, Wayne Bond/0000-0002-8064-8290; Zhou, Shengtao/0000-0001-8322-5536; Zhang, Yaguang/0000-0002-9216-1834	National Natural Science Foundation of China [81402396]; Sichuan Science-Technology Soft Sciences Project [2016ZR0086]; Yi Yao Foundation [14H0563]; West China Second Hospital, Sichuan University [KS021]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Science-Technology Soft Sciences Project; Yi Yao Foundation; West China Second Hospital, Sichuan University	This work was supported by grants from the National Natural Science Foundation of China (grant #81402396), Sichuan Science-Technology Soft Sciences Project (grant #2016ZR0086), Yi Yao Foundation (grant #14H0563) and Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021).	Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633; Baumann C, 2015, P NATL ACAD SCI USA, V112, P4056, DOI 10.1073/pnas.1418549112; Charlet J, 2016, MOL CELL, V62, P422, DOI 10.1016/j.molcel.2016.03.033; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Cheng JM, 2015, J BIOL REG HOMEOS AG, V29, P85; Cordero AB, 2010, JOVE-J VIS EXP, V42, P2125, DOI DOI 10.3791/2125;42; Gandellini P, 2015, SEMIN CANCER BIOL, V35, P96, DOI 10.1016/j.semcancer.2015.08.008; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kim KW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0197-8; King ML, 2015, ONCOGENE, V34, P3452, DOI 10.1038/onc.2014.277; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Litvinov IV, 2014, CELL CYCLE, V13, P2975, DOI 10.4161/15384101.2014.947759; Luo ZY, 2016, CANCER LETT, V377, P174, DOI 10.1016/j.canlet.2016.04.038; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Nick AM, 2015, NAT REV CLIN ONCOL, V12, P239, DOI 10.1038/nrclinonc.2015.26; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, P1; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Roider HG, 2009, BIOINFORMATICS, V25, P435, DOI 10.1093/bioinformatics/btn627; Sharon Y, 2013, JOVE-J VIS EXP, DOI 10.3791/4425; Shen HJ, 2016, CELL, V165, P331, DOI 10.1016/j.cell.2016.02.064; Tang LJ, 2015, CELL PHYSIOL BIOCHEM, V37, P143, DOI 10.1159/000430340; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Wubetu GY, 2014, ANN SURG ONCOL, V21, pS721, DOI 10.1245/s10434-014-3861-9; Xu XF, 2014, MOL CANCER THER, V13, P1729, DOI 10.1158/1535-7163.MCT-13-0982; Yoshioka S, 2012, MOL CANCER RES, V10, P469, DOI 10.1158/1541-7786.MCR-11-0177; Yu KH, 2016, MOL CELL PROTEOMICS, V15, P2525, DOI 10.1074/mcp.O116.059253; Zhou ST, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M112.017988; Zhou XY, 2014, CELL PHYSIOL BIOCHEM, V33, P1003, DOI 10.1159/000358671	35	50	52	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3384	3396		10.1038/onc.2016.487	http://dx.doi.org/10.1038/onc.2016.487			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114283				2022-12-17	WOS:000403340700003
J	Pixberg, CF; Raba, K; Muller, F; Behrens, B; Honisch, E; Niederacher, D; Neubauer, H; Fehm, T; Goering, W; Schulz, WA; Flohr, P; Boysen, G; Lambros, M; De Bono, JS; Knoefel, WT; Sproll, C; Stoecklein, NH; Neves, RPL				Pixberg, C. F.; Raba, K.; Muller, F.; Behrens, B.; Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.; Goering, W.; Schulz, W. A.; Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.; Knoefel, W. T.; Sproll, C.; Stoecklein, N. H.; Neves, R. P. L.			Analysis of DNA methylation in single circulating tumor cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN EXPRESSION; BREAST-CANCER; MIR-200 FAMILY; PROMOTER METHYLATION; ADHESION MOLECULE; REPRESSORS ZEB1; CPG ISLAND; GENE; BISULFITE	Direct analysis of circulating tumor cells (CTCs) can inform on molecular mechanisms underlying systemic spread. Here we investigated promoter methylation of three genes regulating epithelial-to-mesenchymal transition (EMT), a key mechanism enabling epithelial tumor cells to disseminate and metastasize. For this, we developed a single-cell protocol based on agaroseembedded bisulfite treatment, which allows investigating DNA methylation of multiple loci via a multiplex PCR (multiplexedscAEBS). We established our assay for the simultaneous analysis of three EMT-associated genes miR-200c/141, miR-200b/a/429 and CDH1 in single cells. The assay was validated in solitary cells of GM14667, MDA-MB-231 and MCF-7 cell lines, achieving a DNA amplification efficiency of 70% with methylation patterns identical to the respective bulk DNA. Then we applied multiplexedscAEBS to 159 single CTCs from 11 patients with metastatic breast and six with metastatic castration-resistant prostate cancer, isolated via CellSearch (EpCAM(pos)/CKpos/CD45(neg)/DAPI(pos)) and subsequent FACS sorting. In contrast to CD45(pos) white blood cells isolated and processed by the identical approach, we observed in the isolated CTCs methylation patterns resembling more those of epithelial-like cells. Methylation at the promoter of microRNA-200 family was significantly higher in prostate CTCs. Data from our single-cell analysis revealed an epigenetic heterogeneity among CTCs and indicates tumor-specific active epigenetic regulation of EMT-associated genes during blood-borne dissemination.	[Pixberg, C. F.; Muller, F.; Behrens, B.; Knoefel, W. T.; Stoecklein, N. H.; Neves, R. P. L.] Univ Hosp, Dept Gen Visceral & Paediat Surg, Dusseldorf, Germany; [Pixberg, C. F.; Raba, K.; Muller, F.; Behrens, B.; Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.; Goering, W.; Schulz, W. A.; Knoefel, W. T.; Sproll, C.; Stoecklein, N. H.; Neves, R. P. L.] Heinrich Heine Univ Dusseldorf, Fac Med, Dusseldorf, Germany; [Raba, K.] Univ Hosp, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany; [Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.] Univ Hosp, Dept Obstet & Gynecol, Dusseldorf, Germany; [Goering, W.; Schulz, W. A.] Univ Hosp, Dept Urol, Dusseldorf, Germany; [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Inst Canc Res, Div Canc Therapeut, London, England; [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Inst Canc Res, Div Clin Studies, London, England; [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London, England; [Sproll, C.] Univ Hosp, Dept Oral Maxillo & Plast Facial Surg, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Stoecklein, NH (corresponding author), Heinrich Heine Univ Dusseldorf, Univ Hosp, Dept Gen Visceral & Paediat Surg, Moorenstr 5, D-40225 Dusseldorf, Germany.	nikolas.stoecklein@uni-duesseldorf.de	Neves, Rui/AAF-9626-2021; Boysen, Gunnar/U-3272-2019; Schulz, Wolfgang/N-3402-2019; Neubauer, Hans/C-4467-2016; Raba, Katharina/B-8697-2017	Neves, Rui/0000-0002-4515-739X; Boysen, Gunnar/0000-0001-8364-9881; Schulz, Wolfgang/0000-0002-2196-463X; Neubauer, Hans/0000-0002-3467-4105; Raba, Katharina/0000-0001-8818-4219; Fehm, Tanja/0000-0002-4926-0108; de Bono, Johann S/0000-0002-2034-595X; Muller, Fabienne/0000-0002-5845-6305	Dusseldorf School of Oncology (Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe); EU grant reference EU FP7 project CTCTrap [305341]; Deutsche Krebshilfe [109600]; Innovative Medicines Initiative Joint Undertaking (IMI JU); CANCER-ID [115749]; Dusseldorf School of Oncology (Medical Faculty HHU Dusseldorf); Deutsche Krebshilfe (NHS); MRC [G0601308] Funding Source: UKRI; Medical Research Council [G0601308] Funding Source: researchfish	Dusseldorf School of Oncology (Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe); EU grant reference EU FP7 project CTCTrap; Deutsche Krebshilfe(Deutsche Krebshilfe); Innovative Medicines Initiative Joint Undertaking (IMI JU); CANCER-ID; Dusseldorf School of Oncology (Medical Faculty HHU Dusseldorf); Deutsche Krebshilfe (NHS); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	KR, BB, EH, DN, HN, TF, WTK, CS, NHS and RPLN are members of the Disseminated Cancer Cell Network (DCC Net) Dusseldorf. This work was supported by the Dusseldorf School of Oncology (funded by the Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe and the Medical Faculty HHU Dusseldorf) (to CFP), by an EU grant reference EU FP7 project CTCTrap (Grant #305341 to JSDB), the Deutsche Krebshilfe (Grant #109600 to CS and NHS) and the Innovative Medicines Initiative Joint Undertaking (IMI JU) in conjunction with CANCER-ID (Grant Agreement #115749 to NHS).	Alberter B, 2016, EXPERT REV MOL DIAGN, V16, P25, DOI 10.1586/14737159.2016.1121099; Allard WJ, 2015, CLIN CANCER RES, V21, P2883, DOI 10.1158/1078-0432.CCR-14-2559; Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brambert PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117310; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Carmona FJ, 2014, CANCER RES, V74, P5608, DOI 10.1158/0008-5472.CAN-13-3659; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096; Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551; Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107; Friedlander TW, 2014, INT J CANCER, V134, P2284, DOI 10.1002/ijc.28561; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Genereux DP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn691; Geuns E, 2003, HUM MOL GENET, V12, P2873, DOI 10.1093/hmg/ddg315; Geuns E, 2007, EUR J HUM GENET, V15, P352, DOI 10.1038/sj.ejhg.5201759; Geuns E, 2007, J MED GENET, V44, P144, DOI 10.1136/jmg.2006.044149; Gires O, 2014, CELL MOL LIFE SCI, V71, P4393, DOI 10.1007/s00018-014-1693-1; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; HAYATSU H, 1970, BIOCHEMISTRY-US, V9, P2858, DOI 10.1021/bi00816a016; Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Larson CJ, 2004, CYTOM PART A, V62A, P46, DOI 10.1002/cyto.a.20073; Lianidou ES, 2016, MOL ONCOL, V10, P431, DOI 10.1016/j.molonc.2016.01.011; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Magbanua MJM, 2014, CANCER METAST REV, V33, P757, DOI 10.1007/s10555-014-9503-7; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Neves RPL, 2014, CLIN CHEM, V60, P1290, DOI 10.1373/clinchem.2014.222331; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Pal SK, 2015, CLIN GENITOURIN CANC, V13, P130, DOI 10.1016/j.clgc.2014.08.014; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pixberg CF, 2015, GENES-BASEL, V6, P1053, DOI 10.3390/genes6041053; Polioudaki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1386-7; Polzer B, 2014, EMBO MOL MED, V6, P1371, DOI 10.15252/emmm.201404033; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Rao CG, 2005, INT J ONCOL, V27, P49; Rossi E, 2010, CLIN CANCER RES, V16, P5233, DOI 10.1158/1078-0432.CCR-10-1449; Schwartzman O, 2015, NAT REV GENET, V16, P716, DOI 10.1038/nrg3980; SHAPIRO R, 1973, J BIOL CHEM, V248, P4060; Sieuwerts AM, 2009, J NATL CANCER I, V101, P61, DOI 10.1093/jnci/djn419; Spiliotaki M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0485-8; Steinert G, 2014, CANCER RES, V74, P1694, DOI 10.1158/0008-5472.CAN-13-1885; Stoecklein NH, 2016, EXPERT REV MOL DIAGN, V16, P147, DOI 10.1586/14737159.2016.1123095; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; TIERLING S, BISULFITE SEQUENCING; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	76	50	51	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3223	3231		10.1038/onc.2016.480	http://dx.doi.org/10.1038/onc.2016.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068321				2022-12-17	WOS:000402869800002
J	Shi, Z; Jiao, S; Zhou, Z				Shi, Z.; Jiao, S.; Zhou, Z.			STRIPAK complexes in cell signaling and cancer	ONCOGENE			English	Review							PROTEIN PHOSPHATASE 2A; 8P11 MYELOPROLIFERATIVE SYNDROME; MEMBRANE-ASSOCIATED PROTEIN; CALMODULIN-BINDING PROTEIN; ORGAN SIZE CONTROL; STRIATIN-INTERACTING PHOSPHATASE; SARCOLEMMAL-ASSOCIATED PROTEINS; STE20-LIKE KINASE MST3; MALFORMATION 3 CCM3; TUMOR-SUPPRESSOR	Striatin-interacting phosphatase and kinase (STRIPAK) complexes are striatin-centered multicomponent supramolecular structures containing both kinases and phosphatases. STRIPAK complexes are evolutionarily conserved and have critical roles in protein (de) phosphorylation. Recent studies indicate that STRIPAK complexes are emerging mediators and regulators of multiple vital signaling pathways including Hippo, MAPK (mitogen-activated protein kinase), nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are extensively involved in a variety of fundamental biological processes ranging from cell growth, differentiation, proliferation and apoptosis to metabolism, immune regulation and tumorigenesis. Growing evidence correlates dysregulation of STRIPAK complexes with human diseases including cancer. In this review, we summarize the current understanding of the assembly and functions of STRIPAK complexes, with a special focus on cell signaling and cancer.	[Shi, Z.; Jiao, S.; Zhou, Z.] Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,State Key Lab Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China; [Shi, Z.] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China; [Zhou, Z.] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Tongji University; ShanghaiTech University	Zhou, Z (corresponding author), Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,State Key Lab Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zczhou@sibcb.ac.cn	Shi, Zhubing/F-9490-2010	Shi, Zhubing/0000-0002-9624-4960	973 Program of the Ministry of Science and Technology of China [2012CB910204]; National Natural Science Foundation of China [31270808, 31300734, 31470736, 31470868, 91442125, 91542125]; Science and Technology Commission of Shanghai Municipality [13ZR1446400]; 'Cross and Cooperation in Science and Technology Innovation Team' project of the Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences [2014KIP202]	973 Program of the Ministry of Science and Technology of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); 'Cross and Cooperation in Science and Technology Innovation Team' project of the Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences(Knowledge Innovation Program of the Chinese Academy of SciencesChinese Academy of Sciences)	This work was supported by the 973 Program of the Ministry of Science and Technology of China (2012CB910204), the National Natural Science Foundation of China (31270808, 31300734, 31470736, 31470868, 91442125, 91542125), the Science and Technology Commission of Shanghai Municipality (13ZR1446400) and the 'Cross and Cooperation in Science and Technology Innovation Team' project of the Chinese Academy of Sciences, and the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2014KIP202).	AL Zeyadi M, 2015, BIOTECHNOL BIOTEC EQ, V29, P111, DOI 10.1080/13102818.2014.989179; Andreazza S, 2015, CELL REP, V11, P1266, DOI 10.1016/j.celrep.2015.04.033; Ashton-Beaucage D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001809; Bai SW, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-54; Baillat G, 2002, J BIOL CHEM, V277, P18961, DOI 10.1074/jbc.M108818200; Baillat G, 2001, MOL BIOL CELL, V12, P663, DOI 10.1091/mbc.12.3.663; Bailly YJR, 2007, CEREBELLUM, V6, P344, DOI [10.1080/14734220701225912, 10.1080/147342207012259120]; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Bartoli M, 1998, J BIOL CHEM, V273, P22248, DOI 10.1074/jbc.273.35.22248; Beck AH, 2010, ONCOGENE, V29, P845, DOI 10.1038/onc.2009.381; Bergametti F, 2005, AM J HUM GENET, V76, P42, DOI 10.1086/426952; Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013; Boada-Romero E, 2013, EMBO J, V32, P566, DOI 10.1038/emboj.2013.8; Breitman M, 2008, BBA-MOL CELL RES, V1783, P1792, DOI 10.1016/j.bbamcr.2008.04.017; Byers JT, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-48; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Ceccarelli DF, 2011, J BIOL CHEM, V286, P25056, DOI 10.1074/jbc.M110.213777; Cha JD, 2011, ORAL SURG ORAL MED O, V111, P594, DOI 10.1016/j.tripleo.2010.11.020; Chen CB, 2009, BIOSCIENCE REP, V29, P405, DOI 10.1042/BSR20090096; Chen CC, 2014, J BIOL CHEM, V289, P9651, DOI 10.1074/jbc.M113.529297; Chen HW, 2002, MOL CELL BIOL, V22, P1792, DOI 10.1128/MCB.22.6.1792-1803.2002; Chen YK, 2012, MOL BIOL CELL, V23, P4383, DOI 10.1091/mbc.E12-05-0365; Chen YK, 2012, J NEUROSCI, V32, P1043, DOI 10.1523/JNEUROSCI.4405-11.2012; Cheung J, 2001, GENOMICS, V78, P7, DOI 10.1006/geno.2001.6651; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cooper WN, 2009, ONCOGENE, V28, P2988, DOI 10.1038/onc.2009.152; Cornils H, 2011, MOL CELL BIOL, V31, P1382, DOI 10.1128/MCB.01216-10; Coutinho P, 2014, ENDOCRINOLOGY, V155, P2233, DOI 10.1210/en.2013-1834; Couzens AL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004712; Crawley SW, 2014, J CELL BIOL, V207, P441, DOI 10.1083/jcb.201407015; Dadgostar H, 2003, FEBS LETT, V553, P403, DOI 10.1016/S0014-5793(03)01072-X; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Fidalgo M, 2012, J BIOL CHEM, V287, P11556, DOI 10.1074/jbc.M111.320259; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Frost A, 2012, CELL, V149, P1339, DOI 10.1016/j.cell.2012.04.028; Gaillard S, 2001, FEBS LETT, V508, P49, DOI 10.1016/S0014-5793(01)03020-4; Glatter T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.75; Gloerich M, 2012, NAT CELL BIOL, V14, P793, DOI 10.1038/ncb2537; Gordon J, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-54; Goudreault M, 2009, MOL CELL PROTEOMICS, V8, P157, DOI 10.1074/mcp.M800266-MCP200; Grand EK, 2004, GENE CHROMOSOME CANC, V40, P78, DOI 10.1002/gcc.20023; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210; Guo T, 2013, CELL RES, V23, P1201, DOI 10.1038/cr.2013.120; Guzzo RM, 2005, AM J PHYSIOL-HEART C, V288, pH1810, DOI 10.1152/ajpheart.01015.2004; Guzzo RM, 2004, BIOCHEM J, V381, P599, DOI 10.1042/BJ20031723; Guzzo RM, 2004, J CELL SCI, V117, P2271, DOI 10.1242/jcs.01079; Haeberle AM, 2006, J COMP NEUROL, V495, P336, DOI 10.1002/cne.20895; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Hao Q, 2014, J STRUCT BIOL, V186, P224, DOI 10.1016/j.jsb.2014.04.005; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hata Y, 2013, MAR DRUGS, V11, P896, DOI 10.3390/md11030896; Hauri S, 2013, MOL SYST BIOL, V9, DOI 10.1002/msb.201304750; Henderson JL, 2015, J MED CHEM, V58, P419, DOI 10.1021/jm5014055; Hergovich A, 2011, CELL SIGNAL, V23, P1433, DOI 10.1016/j.cellsig.2011.04.007; Horn T, 2011, NAT METHODS, V8, P341, DOI 10.1038/NMETH.1581; Hsieh JY, 2013, NUCLEIC ACIDS RES, V41, P9753, DOI 10.1093/nar/gkt666; Huang J, 2005, EMBO J, V24, P4018, DOI 10.1038/sj.emboj.7600863; Hwang JY, 2014, INT J BIOCHEM CELL B, V47, P118, DOI 10.1016/j.biocel.2013.11.021; Hyodo T, 2012, J BIOL CHEM, V287, P25019, DOI 10.1074/jbc.M112.372342; Ikeda M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000300; Ishikawa T, 2012, CIRC-ARRHYTHMIA ELEC, V5, P1098, DOI 10.1161/CIRCEP.111.969972; Ito M, 2010, J INNATE IMMUN, V2, P607, DOI 10.1159/000317690; Jackson CC, 2010, HUM PATHOL, V41, P461, DOI 10.1016/j.humpath.2009.11.003; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kachidian P, 1998, NEUROSCIENCE, V85, P111, DOI 10.1016/S0306-4522(97)00593-9; Kazmierczak-Baranska J, 2015, FEBS LETT, V589, P222, DOI 10.1016/j.febslet.2014.12.003; Kean MJ, 2011, J BIOL CHEM, V286, P25065, DOI 10.1074/jbc.M110.214486; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042734; Koontz LM, 2013, DEV CELL, V25, P388, DOI 10.1016/j.devcel.2013.04.021; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lant B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7449; Li XF, 2011, J BIOL CHEM, V286, P26138, DOI 10.1074/jbc.M110.211250; Lin A, 2010, AM J PATHOL, V176, P108, DOI 10.2353/ajpath.2010.090256; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; Lin ZH, 2014, INT J ONCOL, V45, P629, DOI 10.3892/ijo.2014.2455; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Ma X, 2007, LIFE SCI, V81, P1141, DOI 10.1016/j.lfs.2007.08.006; Ma X, 2007, MOL BIOL CELL, V18, P1965, DOI 10.1091/mbc.E06-07-0608; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Madsen CD, 2015, NAT CELL BIOL, V17, P68, DOI 10.1038/ncb3083; Marion JD, 2013, J BIOL CHEM, V288, P18612, DOI 10.1074/jbc.M112.440859; Mills AM, 2011, AM J SURG PATHOL, V35, P583, DOI 10.1097/PAS.0b013e318211abd6; Moens SJB, 2012, CIRCULATION, V126, P1993, DOI 10.1161/CIRCULATIONAHA.112.124529; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moqrich A, 1998, GENOMICS, V51, P136, DOI 10.1006/geno.1998.5342; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; MURO Y, 1995, BIOCHEM BIOPH RES CO, V207, P1029, DOI 10.1006/bbrc.1995.1288; Nelson S, 2013, J CELL SCI, V126, P873, DOI 10.1242/jcs.100479; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Peng S, 2015, CLIN EXP IMMUNOL, V182, P57, DOI 10.1111/cei.12658; Pojoga LH, 2012, AM J HYPERTENS, V25, P243, DOI 10.1038/ajh.2011.197; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Record CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011905; Ribeiro PS, 2010, MOL CELL, V39, P521, DOI 10.1016/j.molcel.2010.08.002; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231; Sakuma C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6180; Salin P, 1998, J COMP NEUROL, V397, P41; Schmitt DC, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.116; Schulte J, 2010, J NEUROSCI, V30, P5189, DOI 10.1523/JNEUROSCI.5823-09.2010; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shi ZB, 2015, ACTA BIOCH BIOPH SIN, V47, P29, DOI 10.1093/abbs/gmu107; Shi ZB, 2013, STRUCTURE, V21, P449, DOI 10.1016/j.str.2013.01.007; Shih PY, 2014, J CELL SCI, V127, P3521, DOI 10.1242/jcs.149476; Song H, 2010, BIOCHEM BIOPH RES CO, V391, P969, DOI 10.1016/j.bbrc.2009.11.175; Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003; Sugden PH, 2013, BIOCHEM J, V454, P13, DOI 10.1042/BJ20130219; Sukotjo C, 2003, J BIOL CHEM, V278, P51527, DOI 10.1074/jbc.M309616200; Sukotjo C, 2002, J DENT RES, V81, P229, DOI 10.1177/154405910208100402; Sung V, 2003, CANCER RES, V63, P3356; Suwanwela J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016204; ten Klooster JP, 2009, DEV CELL, V16, P551, DOI 10.1016/j.devcel.2009.01.016; Trammell MA, 2008, J CELL SCI, V121, P1284, DOI 10.1242/jcs.017210; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Wagh V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.273; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Wang YG, 1999, SCI CHINA SER C, V42, P323, DOI 10.1007/BF03183610; Wielowieyski PA, 2000, J BIOL CHEM, V275, P38474, DOI 10.1074/jbc.M007682200; Wigle JT, 1997, J BIOL CHEM, V272, P32384, DOI 10.1074/jbc.272.51.32384; Xiao S, 2000, BLOOD, V96, P699; Xiong WP, 2015, MOL ENDOCRINOL, V29, P460, DOI 10.1210/me.2014-1332; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang M, 2013, STRUCTURE, V21, P680, DOI 10.1016/j.str.2013.02.015; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zheng XJ, 2010, J CLIN INVEST, V120, P2795, DOI 10.1172/JCI39679; Zou Q, 2015, J EXP MED, V212, P1323, DOI 10.1084/jem.20150110	143	50	51	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4549	4557		10.1038/onc.2016.9	http://dx.doi.org/10.1038/onc.2016.9			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876214				2022-12-17	WOS:000382336300001
J	Gupta, SC; Singh, R; Asters, M; Liu, J; Zhang, X; Pabbidi, MR; Watabe, K; Mo, YY				Gupta, S. C.; Singh, R.; Asters, M.; Liu, J.; Zhang, X.; Pabbidi, M. R.; Watabe, K.; Mo, Y-Y			Regulation of breast tumorigenesis through acid sensors	ONCOGENE			English	Article							SENSING ION CHANNELS; NADPH-OXIDASE; CANCER GENOMICS; CALCIUM; CA2+; ACTIVATION; PH; METASTASIS; CELLS; ROS	The low extracellular pH in the microenvironment has been shown to promote tumor growth and metastasis; however, the underlying mechanism is poorly understood. Particularly, little is known how the tumor cell senses the acidic signal to activate the acidosis-mediated signaling. In this study, we show that breast cancer cells express acid-sensing ion channel 1 (ASIC1), a proton-gated cation channel primarily expressed in the nervous system. RNA interference, knockout and rescue experiments demonstrate a critical role for ASIC1 in acidosis-induced reactive oxidative species and NF-kappa B activation, two key events for tumorigenesis. Mechanistically, ASIC1 is required for acidosis-mediated signaling through calcium influx. We show that as a cytoplasmic membrane protein, ASIC1 is also associated with mitochondria, suggesting that ASIC1 may regulate mitochondrial calcium influx. Importantly, interrogation of the Cancer Genome Atlas breast invasive carcinoma data set indicates that alterations of ASIC1 alone or combined with other 4 ASIC genes are significantly correlated with poor patient survival. Furthermore, ASIC1 inhibitors cause a significant reduction of tumor growth and tumor load. Together, these results suggest that ASIC1 contributes to breast cancer pathogenesis in response to acidic tumor microenvironments, and ASIC1 may serve as a prognostic marker and a therapeutic target for breast cancer.	[Gupta, S. C.; Singh, R.; Asters, M.; Liu, J.; Mo, Y-Y] Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Room G651, Jackson, MS 39216 USA; [Gupta, S. C.; Singh, R.] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; [Zhang, X.] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA; [Pabbidi, M. R.; Mo, Y-Y] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, Jackson, MS 39216 USA; [Watabe, K.] Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; Wake Forest University	Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Room G651, Jackson, MS 39216 USA.	ymo@umc.edu	Mo, Yin-Yuan/R-8255-2019; Gupta, Subash/AAF-2563-2019; Singh, Ramesh/S-4568-2017	Gupta, Subash/0000-0002-0418-1940; Singh, Ramesh/0000-0001-5052-7925	National Institutes of Health [R01 CA154989]; UMMC's Intramural Research Support Program; COBRE grant [GM103328]; NATIONAL CANCER INSTITUTE [R01CA154989] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UMMC's Intramural Research Support Program; COBRE grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Parminder J.S. Vig at UMMC for providing mouse brain tissues. This work is supported in part by a grant from the National Institutes of Health R01 CA154989 (YM) and a grant from UMMC's Intramural Research Support Program (SCG). Imaging Core of Center for Psychiatric Neuroscience at UMMC is supported by COBRE grant GM103328.	Abbey CK, 2004, P NATL ACAD SCI USA, V101, P11438, DOI 10.1073/pnas.0404396101; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Benarroch EE, 2014, NEUROLOGY, V82, P628, DOI 10.1212/WNL.0000000000000134; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chu XP, 2012, CURR DRUG TARGETS, V13, P263, DOI 10.2174/138945012799201685; Damaghi M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00370; Drago I, 2011, EMBO J, V30, P4119, DOI 10.1038/emboj.2011.337; El Jamali A, 2008, FREE RADICAL BIO MED, V44, P868, DOI 10.1016/j.freeradbiomed.2007.11.020; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Feissner RF, 2009, FRONT BIOSCI-LANDMRK, V14, P1197, DOI 10.2741/3303; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Giorgio V, 2010, BBA-BIOENERGETICS, V1797, P1113, DOI 10.1016/j.bbabio.2009.12.006; Granfeldt D, 2002, J LEUKOCYTE BIOL, V71, P611; Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514; Gupta SC, 2013, J BIOL CHEM, V288, P32343, DOI 10.1074/jbc.M113.455188; Hashim AI, 2011, NMR BIOMED, V24, P582, DOI 10.1002/nbm.1644; Ho TT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1198; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Jagnandan D, 2007, J BIOL CHEM, V282, P6494, DOI 10.1074/jbc.M608966200; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Pandey D, 2011, MOL PHARMACOL, V80, P407, DOI 10.1124/mol.110.070193; Peppicelli S, 2013, CLIN EXP METASTAS, V30, P957, DOI 10.1007/s10585-013-9595-4; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Schaefer L, 2000, FEBS LETT, V471, P205, DOI 10.1016/S0014-5793(00)01403-4; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Viola HM, 2007, CIRC RES, V100, P1036, DOI 10.1161/01.RES.0000263010.19273.48; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wang G, 2006, HYPERTENSION, V48, P482, DOI 10.1161/01.HYP.0000236647.55200.07; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2013, NAT REV NEUROSCI, V14, P461, DOI 10.1038/nrn3529; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu L, 2000, CANCER RES, V60, P4610; Ye JH, 2007, BIOCHEM BIOPH RES CO, V355, P986, DOI 10.1016/j.bbrc.2007.02.061; Zha XM, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-1; Zhang A, 2013, CELL RES, V23, P340, DOI 10.1038/cr.2012.164	52	50	50	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4102	4111		10.1038/onc.2015.477	http://dx.doi.org/10.1038/onc.2015.477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686084	Green Accepted			2022-12-17	WOS:000381020900008
J	Schneider, MR; Yarden, Y				Schneider, M. R.; Yarden, Y.			The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors	ONCOGENE			English	Review							EPIDERMAL-GROWTH-FACTOR; FACTOR-RECEPTOR MUTATIONS; KINASE DOMAIN MUTATIONS; BREAST-CANCER; EGF RECEPTOR; LUNG-CANCER; MICE LACKING; QUANTITATIVE-ANALYSIS; HUMAN GLIOBLASTOMAS; CARDIAC DEVELOPMENT	The epidermal growth factor receptor (EGFR) and a coreceptor denoted HER2/ERBB2 are frequently overexpressed or mutated in solid tumors, such as carcinomas and gliomas. In line with driver roles, cancer drugs intercepting EGFR or HER2 currently outnumber therapies targeting other hubs of signal transduction. To explain the roles for EGFR and HER2 as prime drivers and targets, we take lessons from invertebrates and refer to homeostatic regulation of several mammalian tissues. The model we infer ascribes to the EGFR-HER2 module pivotal functions in rapid clonal expansion of progenitors called transient amplifying cells (TACs). Accordingly, TACs of tumors suffer from replication stress, and hence accumulate mutations. In addition, several lines of evidence propose that in response to EGF and related mitogens, TACs might undergo dedifferentiation into tissue stem cells, which might enable entry of oncogenic mutations into the stem cell compartment. According to this view, antibodies or kinase inhibitors targeting EGFR-HER2 effectively retard some solid tumors because they arrest mutation- enriched TACs and possibly inhibit their dedifferentiation. Deeper understanding of the EGFR-HER2 module and relations between cancer stem cells and TACs will enhance our ability to control a broad spectrum of human malignancies.	[Schneider, M. R.] Ludwig Maximilians Univ Munchen, Gene Ctr, Inst Mol Anim Breeding & Biotechnol, Feodor Lynen Str 25, D-81377 Munich, Germany; [Yarden, Y.] Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel	University of Munich; Weizmann Institute of Science	Schneider, MR (corresponding author), Ludwig Maximilians Univ Munchen, Gene Ctr, Inst Mol Anim Breeding & Biotechnol, Feodor Lynen Str 25, D-81377 Munich, Germany.; Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel.	Marlon.schneider@lmu.de; Yosef.yarden@weizmann.ac.il		Schneider, Marlon/0000-0002-9570-3491	German Research Foundation (DFG); Else-Kroner-Fresenius Stiftung; Fritz Thyssen Foundation; Wilhelm Sander-Stiftung; European Research Council; Dr Miriam and Sheldon G Adelson Medical Research Foundation; family of Mr Marvin Tanner	German Research Foundation (DFG)(German Research Foundation (DFG)); Else-Kroner-Fresenius Stiftung; Fritz Thyssen Foundation; Wilhelm Sander-Stiftung; European Research Council(European Research Council (ERC)European Commission); Dr Miriam and Sheldon G Adelson Medical Research Foundation; family of Mr Marvin Tanner	We thank Lilach Gilboa and Maik Dahlhoff for insightful discussions. MRS is supported by the German Research Foundation (DFG), the Else-Kroner-Fresenius Stiftung, the Fritz Thyssen Foundation and the Wilhelm Sander-Stiftung. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. Currently, he is Research Professor of the Israel Cancer Research Fund. We would like to acknowledge financial support from the European Research Council, the Dr Miriam and Sheldon G Adelson Medical Research Foundation and the family of Mr Marvin Tanner.	Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Aguirre A, 2010, NATURE, V467, P323, DOI 10.1038/nature09347; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bashir O, 2003, CLIN SCI, V105, P323, DOI 10.1042/CS20030023; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Clevers H, 2013, CELL, V152, P1198, DOI 10.1016/j.cell.2013.02.030; D'Uva G, 2015, NAT CELL BIOL, V17, P627, DOI 10.1038/ncb3149; Dahlhoff M, 2008, FEBS LETT, V582, P2911, DOI 10.1016/j.febslet.2008.07.026; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Doan PL, 2013, NAT MED, V19, P295, DOI 10.1038/nm.3070; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Doupe DP, 2013, BIOESSAYS, V35, P443, DOI 10.1002/bies.201200166; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Erickson SL, 1997, DEVELOPMENT, V124, P4999; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Frederick L, 2000, CANCER RES, V60, P1383; Fuentealba LC, 2012, CELL STEM CELL, V10, P698, DOI 10.1016/j.stem.2012.05.012; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galvez-Contreras AY, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00258; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Genetos DC, 2010, CELL TISSUE RES, V340, P81, DOI 10.1007/s00441-010-0929-0; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gomez-Gaviro MV, 2012, P NATL ACAD SCI USA, V109, P1317, DOI 10.1073/pnas.1016199109; Gonzalez-Perez O, 2011, BRAIN RES REV, V67, P147, DOI 10.1016/j.brainresrev.2011.01.001; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Grompe M, 2014, CELL STEM CELL, V15, P257, DOI 10.1016/j.stem.2014.08.004; Gupta Bhagwati P, 2012, WormBook, P1, DOI 10.1895/wormbook.1.152.1; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hechtman JF, 2012, ARCH PATHOL LAB MED, V136, P691, DOI 10.5858/arpa.2011-0168-RS; Heinmoller P, 2003, CLIN CANCER RES, V9, P5238; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Hsu YC, 2014, NAT MED, V20, P847, DOI 10.1038/nm.3643; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Iyer R, 2004, RADIOTHER ONCOL, V72, P283, DOI 10.1016/j.radonc.2004.07.012; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jeong EG, 2006, INT J CANCER, V119, P2986, DOI 10.1002/ijc.22257; Jeuken J, 2009, BRAIN PATHOL, V19, P661, DOI 10.1111/j.1750-3639.2009.00320.x; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kalman B, 2013, NEUROMOL MED, V15, P420, DOI 10.1007/s12017-013-8229-y; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kitade M, 2013, GENE DEV, V27, P1706, DOI 10.1101/gad.214601.113; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kovacs E, 2015, ANNU REV BIOCHEM, V84, P739, DOI 10.1146/annurev-biochem-060614-034402; Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood-2004-09-3645; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Kurppa K, 2009, PIGM CELL MELANOMA R, V22, P708, DOI 10.1111/j.1755-148X.2009.00635.x; Kwak EL, 2006, CLIN CANCER RES, V12, P4283, DOI 10.1158/1078-0432.CCR-06-0189; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; LIBERMANN TA, 1985, J CELL SCI, P161; LIM RW, 1984, J CELL BIOL, V98, P739, DOI 10.1083/jcb.98.2.739; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARCHBANK T, 1995, CLIN SCI, V89, P117, DOI 10.1042/cs0890117; Mazouzi A, 2014, EXP CELL RES, V329, P85, DOI 10.1016/j.yexcr.2014.09.030; Mazzoleni S, 2010, CANCER RES, V70, P7500, DOI 10.1158/0008-5472.CAN-10-2353; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Morante J, 2008, CURR BIOL, V18, P553, DOI 10.1016/j.cub.2008.02.075; Nagane M, 1996, CANCER RES, V56, P5079; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Ninomiya M, 2006, NEUROSCI LETT, V403, P63, DOI 10.1016/j.neulet.2006.04.039; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Panupinthu N, 2014, ONCOGENE, V33, P2846, DOI 10.1038/onc.2013.259; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pastrana E, 2009, P NATL ACAD SCI USA, V106, P6387, DOI 10.1073/pnas.0810407106; Pellettieri J, 2007, ANNU REV GENET, V41, P83, DOI 10.1146/annurev.genet.41.110306.130244; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Pines G, 2010, ONCOGENE, V29, P5850, DOI 10.1038/onc.2010.313; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pinto AC, 2013, BREAST, V22, pS152, DOI 10.1016/j.breast.2013.07.029; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Ponti G, 2013, P NATL ACAD SCI USA, V110, pE1045, DOI 10.1073/pnas.1219563110; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942; Schneider MR, 2014, SEMIN CELL DEV BIOL, V28, P1, DOI 10.1016/j.semcdb.2014.02.003; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; Sun Y, 2005, NEURON, V45, P873, DOI 10.1016/j.neuron.2005.01.045; Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005-0176; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Teng YHF, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2857; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Tong CK, 2014, NEURON, V81, pe221; Troyer KL, 2001, GASTROENTEROLOGY, V121, P68, DOI 10.1053/gast.2001.25478; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Yan M, 2015, CANCER METAST REV, V34, P157, DOI 10.1007/s10555-015-9552-6; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Yasugi T, 2010, DEVELOPMENT, V137, P3193, DOI 10.1242/dev.048058; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zeineldin R, 2010, J HISTOCHEM CYTOCHEM, V58, P529, DOI 10.1369/jhc.2010.955104; Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094; Zwang Yaara, 2009, Traffic, V10, P349, DOI 10.1111/j.1600-0854.2008.00870.x	167	50	51	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2949	2960		10.1038/onc.2015.372	http://dx.doi.org/10.1038/onc.2015.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434585	Green Accepted			2022-12-17	WOS:000377474500001
J	Nagaraja, AS; Dorniak, PL; Sadaoui, NC; Kang, Y; Lin, T; Armaiz-Pena, G; Wu, SY; Rupaimoole, R; Allen, JK; Gharpure, KM; Pradeep, S; Zand, B; Previs, RA; Hansen, JM; Ivan, C; Rodriguez-Aguayo, C; Yang, P; Lopez-Berestein, G; Lutgendorf, SK; Cole, SW; Sood, AK				Nagaraja, A. S.; Dorniak, P. L.; Sadaoui, N. C.; Kang, Y.; Lin, T.; Armaiz-Pena, G.; Wu, S. Y.; Rupaimoole, R.; Allen, J. K.; Gharpure, K. M.; Pradeep, S.; Zand, B.; Previs, R. A.; Hansen, J. M.; Ivan, C.; Rodriguez-Aguayo, C.; Yang, P.; Lopez-Berestein, G.; Lutgendorf, S. K.; Cole, S. W.; Sood, A. K.			Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis	ONCOGENE			English	Article							BREAST-CANCER; BETA-BLOCKERS; TUMOR-METASTASIS; STRESS; EXPRESSION; CYCLOOXYGENASE-2; NOREPINEPHRINE; CARCINOMA; INVASION; OUTCOMES	Adrenergic stimulation adversely affects tumor growth and metastasis, but the underlying mechanisms are not well understood. Here, we uncovered a novel mechanism by which catecholamines induce inflammation by increasing prostaglandin E2 (PGE2) levels in ovarian cancer cells. Metabolic changes in tumors isolated from patients with depression and mice subjected to restraint stress showed elevated PGE2 levels. Increased metabolites, PTGS2 and PTGES protein levels were found in Skov3-ip1 and HeyA8 cells treated with norepinephrine (NE), and these changes were shown to be mediated by ADRB2 receptor signaling. Silencing PTGS2 resulted in significantly decreased migration and invasion in ovarian cancer cells in the presence of NE and decreased tumor burden and metastasis in restraint stress orthotopic models. In human ovarian cancer samples, concurrent increased ADRB2, PTGS2 and PTGES expression was associated with reduced overall and progression-free patient survival. In conclusion, increased adrenergic stimulation results in increased PGE2 synthesis via ADRB2-Nf-kappa B-PTGS2 axis, which drives tumor growth and metastasis.	[Nagaraja, A. S.; Dorniak, P. L.; Sadaoui, N. C.; Kang, Y.; Armaiz-Pena, G.; Wu, S. Y.; Rupaimoole, R.; Allen, J. K.; Gharpure, K. M.; Pradeep, S.; Zand, B.; Previs, R. A.; Hansen, J. M.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1352,1515 Holcombe Blvd, Houston, TX 77030 USA; [Lin, T.; Yang, P.] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA; [Ivan, C.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNAi & Noncoding RNA, Houston, TX 77030 USA; [Lutgendorf, S. K.] Univ Iowa, Dept Psychol, Obstet & Gynecol, Iowa City, IA 52242 USA; [Lutgendorf, S. K.] Univ Iowa, Urol, Iowa City, IA USA; [Lutgendorf, S. K.] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Cole, S. W.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Mol Biol Inst, Norman Cousins Ctr,Dept Med,Div Hematol Oncol, Los Angeles, CA 90095 USA; [Cole, S. W.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Iowa; University of Iowa; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1352,1515 Holcombe Blvd, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Canc Biol, Unit 1352,1515 Holcombe Blvd, Houston, TX 77030 USA.	asood@mdanderson.org	Nagaraja, Archana Sidalaghatta/AAE-2205-2021; Nagaraja, Archana/AAE-8529-2021; Sood, Anoop Kumar/A-7344-2013; Rupaimoole, Rajesha/K-3272-2016	Sood, Anoop Kumar/0000-0001-5702-4108; Nagaraja, Archana/0000-0002-2851-9272; Previs, Rebecca/0000-0001-8087-9120; Gharpure, Kshipra/0000-0003-4954-5696; Armaiz-Pena, Guillermo N/0000-0002-9081-5339; Rupaimoole, Rajesha/0000-0002-4795-7921; Ivan, Cristina/0000-0002-4848-0168; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723	United States National Institutes of Health [CA116778, CA104825, CA140933, CA109298, CPRIT RP140106, CPRIT RP110595, NIH CA 109298, P50CA083639, P50CA098258, AG017265, AG033590]; NIH [HHSN261200800001E]; Breast Cancer Research Foundation; United States Department of Defense [OC073399, W81XWH-10-1-0158, BC085265]; Marcus Foundation; Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; CPRIT Graduate Scholar Fellowship; Altman-Goldstein Discovery fellowship; Ovarian Cancer Research Fund, Inc.; Cancer Prevention and Research Institute of Texas [RP101502, RP101489]; NCI-DHHS-NIH T32 training grant [T32 CA101642]; National Cancer Institute Network on Biobehavioral Pathways in Cancer; NATIONAL CANCER INSTITUTE [R01CA193249, P50CA098258, P50CA083639, R01CA109298, T32CA101642, R01CA116778, R01CA104825, R01CA177909, P30CA016672, R01CA140933] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017265, R37AG033590] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; United States Department of Defense(United States Department of Defense); Marcus Foundation; Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; CPRIT Graduate Scholar Fellowship; Altman-Goldstein Discovery fellowship; Ovarian Cancer Research Fund, Inc.; Cancer Prevention and Research Institute of Texas; NCI-DHHS-NIH T32 training grant; National Cancer Institute Network on Biobehavioral Pathways in Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank the following for funding support: the United States National Institutes of Health (CA116778, CA104825, CA140933, CA109298, CPRIT RP140106, CPRIT RP110595, NIH CA 109298, P50CA083639, P50CA098258, AG017265, AG033590), NIH under Contract No. HHSN261200800001E and the Breast Cancer Research Foundation, the United States Department of Defense (OC073399, W81XWH-10-1-0158, and BC085265); the Marcus Foundation; the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; the RGK Foundation; the Gilder Foundation; the Blanton-Davis Ovarian Cancer Research Program and the Betty Anne Asche Murray Distinguished Professorship (AKS). ASN is supported in part by the CPRIT Graduate Scholar Fellowship. KMG is supported by the Altman-Goldstein Discovery fellowship. SYW is supported by the Ovarian Cancer Research Fund, Inc., and by Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489). RAP, BZ and JH are supported by the NCI-DHHS-NIH T32 training grant (T32 CA101642). We thank Laila Dahmoush at the University of Iowa for her help analyzing patient tumor slides. This research was supported by the National Cancer Institute Network on Biobehavioral Pathways in Cancer. We also thank Erica Goodoff at MD Anderson for help with scientific editing.	Athanassiadou P, 2008, PATHOL RES PRACT, V204, P241, DOI 10.1016/j.prp.2007.11.004; Benish M, 2008, ANN SURG ONCOL, V15, P2042, DOI 10.1245/s10434-008-9890-5; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Costanzo ES, 2005, CANCER-AM CANCER SOC, V104, P305, DOI 10.1002/cncr.21147; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Gosain A, 2006, J TRAUMA, V60, P736, DOI 10.1097/01.ta.0000196802.91829.cc; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kruk J, 2004, CANCER DETECT PREV, V28, P399, DOI 10.1016/j.cdp.2004.07.009; Lin Y, 2014, MOL MED REP, V9, P2499, DOI 10.3892/mmr.2014.2131; Lutgendorf SK, 2012, J CLIN ONCOL, V30, P2885, DOI 10.1200/JCO.2011.39.4411; Lutgendorf SK, 2011, BRAIN BEHAV IMMUN, V25, P250, DOI 10.1016/j.bbi.2010.10.012; Lutgendorf SK, 2009, BRAIN BEHAV IMMUN, V23, P176, DOI 10.1016/j.bbi.2008.04.155; Matsumoto Y, 2001, INT J MOL MED, V8, P31; Qiu X, 2014, ENDOCR-RELAT CANCER, V21, P533, DOI 10.1530/ERC-13-0450; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; Sethi J, 2010, METHOD FIND EXP CLIN, V32, P233, DOI 10.1358/mf.2010.32.4.1423889; Shakhar G, 1998, J IMMUNOL, V160, P3251; Sivamani RK, 2009, PLOS MED, V6, P105, DOI 10.1371/journal.pmed.1000012; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang HM, 2013, ANN ONCOL, V24, P1312, DOI 10.1093/annonc/mds616; Weiner J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040221; Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005	29	50	50	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2390	2397		10.1038/onc.2015.302	http://dx.doi.org/10.1038/onc.2015.302			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257064	Green Accepted			2022-12-17	WOS:000376165000011
J	Shi, Y; Yang, Y; Hoang, B; Bardeleben, C; Holmes, B; Gera, J; Lichtenstein, A				Shi, Y.; Yang, Y.; Hoang, B.; Bardeleben, C.; Holmes, B.; Gera, J.; Lichtenstein, A.			Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress	ONCOGENE			English	Article							RIBOSOME ENTRY SITE; UNFOLDED PROTEIN RESPONSE; RAPAMYCIN; KINASE; ACTIVATION; EXPRESSION; INITIATION; INDUCE; GENE	Protein translation is inhibited by the unfolded protein response (UPR)-induced eIF-2 alpha phosphorylation to protect against endoplasmic reticulum (ER) stress. In addition, we found additional inhibition of protein translation owing to diminished mTORC1 (mammalian target of rapamycin complex1) activity in ER-stressed multiple myeloma (MM) cells. However, c-myc protein levels and myc translation was maintained. To ascertain how c-myc was maintained, we studied myc IRES (internal ribosome entry site) function, which does not require mTORC1 activity. Myc IRES activity was upregulated in MM cells during ER stress induced by thapsigargin, tunicamycin or the myeloma therapeutic bortezomib. IRES activity was dependent on upstream MAPK (mitogen-activated protein kinase) and MNK1 (MAPK-interacting serine/threonine kinase 1) signaling. A screen identified hnRNP A1 (A1) and RPS25 as IRES-binding trans-acting factors required for ER stress-activated activity. A1 associated with RPS25 during ER stress and this was prevented by an MNK inhibitor. In a proof of principle, we identified a compound that prevented binding of A1 to the myc IRES and specifically inhibited myc IRES activity in MM cells. This compound, when used alone, was not cytotoxic nor did it inhibit myc translation or protein expression. However, when combined with ER stress inducers, especially bortezomib, a remarkable synergistic cytotoxicity ensued with associated inhibition of myc translation and expression. These results underscore the potential for targeting A1-mediated myc IRES activity in MM cells during ER stress.	VA West LA Hosp Hematol Oncol, West LA VA Hosp, UCLA Greater Los Angeles VA Healthcare Ctr, Div Hematol Oncol, W111H, Los Angeles, CA USA; VA West LA Hosp Hematol Oncol, West LA VA Hosp, Jonsson Comprehens Canc Ctr, W111H, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center	Lichtenstein, A (corresponding author), VA West LA Hosp Hematol Oncol, West LA VA Hosp, Div Hematol Oncol, UCLA Greater Los Angeles VA Healthcare Ctr, W111H,11301 Wilshire Blvd,Bldg 500,Room 4237, Los Angeles, CA 90073 USA.; Lichtenstein, A (corresponding author), VA West LA Hosp Hematol Oncol, West LA VA Hosp, Jonsson Comprehens Canc Ctr, W111H,11301 Wilshire Blvd,Bldg 500,Room 4237, Los Angeles, CA 90073 USA.	Alan.lichtenstein@med.va.gov		Holmes, Brent/0000-0002-2768-2991; Gera, Joseph/0000-0002-2908-6894	NIH [RO1CA168700, 2RO1CA111448, RO1CA132778, R21CA168491]; Veteran's Administration; Multiple Myeloma Research Foundation; NATIONAL CANCER INSTITUTE [R21CA168491, R01CA132778, R01CA111448, R01CA168700] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veteran's Administration(US Department of Veterans Affairs); Multiple Myeloma Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grants RO1CA168700, 2RO1CA111448, RO1CA132778 and R21CA168491 and research funds of the Veteran's Administration and Multiple Myeloma Research Foundation	Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bliskovsky V, 2003, P NATL ACAD SCI USA, V100, P14982, DOI 10.1073/pnas.2431627100; Bodescot M, 1996, GENE, V174, P115, DOI 10.1016/0378-1119(96)00464-7; Bommert KS, 2013, LEUKEMIA, V27, P441, DOI 10.1038/leu.2012.185; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Damiano F, 2013, BIOCHEM J, V449, P543, DOI 10.1042/BJ20120906; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Denys A, 2004, FEBS LETT, V564, P177, DOI 10.1016/S0014-5793(04)00361-8; Dibrov SM, 2003, P NATL ACAD SCI USA, V100, P14982; Gera JF, 2002, METHOD ENZYMOL, V350, P499, DOI 10.1016/S0076-6879(02)50981-2; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; Kuehl WM, 2012, BLOOD, V120, P2351, DOI 10.1182/blood-2012-08-445262; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liang SH, 2006, BIOCHEM J, V393, P201, DOI 10.1042/BJ20050374; Lin JY, 2008, J GEN VIROL, V89, P2540, DOI 10.1099/vir.0.2008/003673-0; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Martin J, 2008, J BIOL CHEM, V283, P23274; Nakamura RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048194; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Paulin FEM, 1996, ONCOGENE, V13, P505; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi Y, 2013, ONCOGENE, V32, P190, DOI 10.1038/onc.2012.43; Shi YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094011; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Suzuki A, 2005, ONCOGENE, V24, P6936, DOI 10.1038/sj.onc.1208844	35	50	51	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1015	1024		10.1038/onc.2015.156	http://dx.doi.org/10.1038/onc.2015.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961916	Green Accepted			2022-12-17	WOS:000370823300007
J	Liu, Y; Ye, X; Zhang, JB; Ouyang, H; Shen, Z; Wu, Y; Wang, W; Wu, J; Tao, S; Yang, X; Qiao, K; Zhang, J; Liu, J; Fu, Q; Xie, Y				Liu, Y.; Ye, X.; Zhang, J-B; Ouyang, H.; Shen, Z.; Wu, Y.; Wang, W.; Wu, J.; Tao, S.; Yang, X.; Qiao, K.; Zhang, J.; Liu, J.; Fu, Q.; Xie, Y.			PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing beta-catenin expression and nuclear translocation	ONCOGENE			English	Article							CELL-PROLIFERATION; GENE; LIVER; TRANSCRIPTION; GROWTH; METASTASIS; MODULATION; MUTATIONS; SURVIVAL; PROTEIN	Aberrant activation of the Wnt/beta-catenin pathway is frequent in hepatocellular carcinoma (HCC) and contributes to HCC initiation and progression. This abnormal activation may result from somatic mutations in the genes of the Wnt/beta-catenin pathway and/or dysregulation of the Wnt/beta-catenin pathway. The mechanism for the latter remains poorly understood. Prospero-related homeobox 1 (PROX1) is a downstream target of the Wnt/beta-catenin pathway in human colorectal cancer and elevated PROX1 expression promotes malignant progression. However, the Wnt/beta-catenin pathway does not regulate PROX1 expression in the liver and HCC cells. Here we report that PROX1 promotes HCC cell proliferation in vitro and tumor growth in HCC xenograft mice. PROX1 and beta-catenin levels are positively correlated in tumor tissues as well as in cultured HCC cells. PROX1 can upregulate beta-catenin transcription by stimulating the beta-catenin promoter and enhance the nuclear translocation of beta-catenin in HCC cells, which leads to the activation of the Wnt/beta-catenin pathway. Moreover, we show that increase in PROX1 expression renders HCC cells more resistant to sorafenib treatment, which is the standard therapy for advanced HCC. Overall, we have pinpointed PROX1 as a critical factor activating the Wnt/beta-catenin pathway in HCC, which promotes HCC proliferation and sorafenib resistance.	[Liu, Y.; Ye, X.; Ouyang, H.; Shen, Z.; Wu, Y.; Wang, W.; Wu, J.; Tao, S.; Yang, X.; Qiao, K.; Zhang, J.; Liu, J.; Fu, Q.; Xie, Y.] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Key Lab Med Mol Virol MOE, Shanghai 200032, Peoples R China; [Liu, Y.; Ye, X.; Ouyang, H.; Shen, Z.; Wu, Y.; Wang, W.; Wu, J.; Tao, S.; Yang, X.; Qiao, K.; Zhang, J.; Liu, J.; Fu, Q.; Xie, Y.] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, MOH, Shanghai 200032, Peoples R China; [Liu, Y.] Fudan Univ, Dept Surg, Huashan Hosp, Shanghai 200032, Peoples R China; [Zhang, J-B] Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; [Zhang, J-B] Fudan Univ, Key Lab Carcinogenesis & Canc Invas MOE, Shanghai 200032, Peoples R China; [Ouyang, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Fu, Q.] Binzhou Med Univ, Dept Immunol, Yantai 264003, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Binzhou Medical University	Liu, J (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Key Lab Med Mol Virol MOE, Yixueyuan Rd 138, Shanghai 200032, Peoples R China.	liujing212@fudan.edu.cn; qiangfu11@fudan.edu.cn; yhxie@fudan.edu.cn			National Key Project for Infectious Diseases [2012ZX10002-006, 2012ZX10004-503, 2012ZX10002012-003]; National Basic Research Program [2012CB519002]; Natural Science Foundation of China [31071143, 31170148, 81472226, 81372654, 81370730]; Shanghai Municipal Health Committee [GWDTR201216]; Nature Science Foundation from Shandong province [ZR2011HQ006]; Municipal Science and Technology Committee [13ZR1407100]	National Key Project for Infectious Diseases; National Basic Research Program(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Health Committee; Nature Science Foundation from Shandong province; Municipal Science and Technology Committee	We thank Prof RH Dashwood of Oregon State University and Prof Long Yu of Fudan University for kindly providing the beta-catenin promoter luciferase reporters. This work is supported by the grants from the National Key Project for Infectious Diseases (2012ZX10002-006, 2012ZX10004-503, 2012ZX10002012-003), National Basic Research Program (2012CB519002), Natural Science Foundation of China (31071143, 31170148, 81472226, 81372654 and 81370730), Shanghai Municipal Health Committee (GWDTR201216), Nature Science Foundation from Shandong province (ZR2011HQ006) and Municipal Science and Technology Committee (13ZR1407100).	Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Burke Z, 2002, MECH DEVELOP, V118, P147, DOI 10.1016/S0925-4773(02)00240-X; Chai H, 2010, INT J CLIN EXP PATHO, V3, P408; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cui J, 2001, J CANCER RES CLIN, V127, P577, DOI 10.1007/s004320100259; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Elsir T, 2012, CANCER METAST REV, V31, P793, DOI 10.1007/s10555-012-9390-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Guigon CJ, 2010, ENDOCRINOLOGY, V151, P5528, DOI 10.1210/en.2010-0475; Han L, 2010, BRAIN RES, V1366, P9, DOI 10.1016/j.brainres.2010.09.097; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Iyer R, 2010, EXPERT OPIN PHARMACO, V11, P1943, DOI 10.1517/14656566.2010.496453; Kaltezioti V, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000565; Kamiya A, 2008, HEPATOLOGY, V48, P252, DOI 10.1002/hep.22303; Karalay O, 2011, P NATL ACAD SCI USA, V108, P5807, DOI 10.1073/pnas.1013456108; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322; Lai TY, 2011, ONCOL REP, V26, P415, DOI 10.3892/or.2011.1323; Lavado A, 2007, DEV DYNAM, V236, P518, DOI 10.1002/dvdy.21024; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Liu GY, 2012, HEPATOLOGY, V55, P1830, DOI 10.1002/hep.25564; Liu YF, 2013, HEPATOLOGY, V58, P692, DOI 10.1002/hep.26398; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ouyang HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062192; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Qin J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009; Riazi AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005698; Risebro CA, 2009, DEVELOPMENT, V136, P495, DOI 10.1242/dev.030007; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Song KH, 2006, J BIOL CHEM, V281, P10081, DOI 10.1074/jbc.M513420200; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhu XD, 2008, J CLIN ONCOL, V26, P2707, DOI 10.1200/JCO.2007.15.6521	34	50	51	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5524	5535		10.1038/onc.2015.7	http://dx.doi.org/10.1038/onc.2015.7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25684142				2022-12-17	WOS:000364594000002
J	Rohatgi, RA; Janusis, J; Leonard, D; Bellve, KD; Fogarty, KE; Baehrecke, EH; Corvera, S; Shaw, LM				Rohatgi, R. A.; Janusis, J.; Leonard, D.; Bellve, K. D.; Fogarty, K. E.; Baehrecke, E. H.; Corvera, S.; Shaw, L. M.			Beclin 1 regulates growth factor receptor signaling in breast cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE COMPLEXES; EARLY ENDOSOMES; AUTOPHAGY; GENE; TUMORIGENESIS; TRAFFICKING; TRANSFERRIN; METASTASIS; MATURATION; MEMBRANE	Beclin 1 is a haploinsufficient tumor suppressor that is decreased in many human tumors. The function of beclin 1 in cancer has been attributed primarily to its role in the degradative process of macroautophagy. However, beclin 1 is a core component of the vacuolar protein sorting 34 (Vps34)/class III phosphatidylinositoI-3 kinase (PI3KC3) and Vps15/p150 complex that regulates multiple membrane-trafficking events. In the current study, we describe an alternative mechanism of action for beclin 1 in breast cancer involving its control of growth factor receptor signaling. We identify a specific stage of early endosome maturation that is regulated by beclin 1, the transition of APPL1-containing phosphatidyIinositol 3-phosphate-negative (PI3P(-)) endosomes to PI3P(+) endosomes. Beclin 1 regulates PI3P production in response to growth factor stimulation to control the residency time of growth factor receptors in the PI3P(-)/APPL(+)-signaling-competent compartment. As a result, suppression of BECN1 sustains growth factor-stimulated AKT and ERK activation resulting in increased breast carcinoma cell invasion. In human breast tumors, beclin 1 expression is inversely correlated with AKT and ERK phosphorylation. Our data identify a novel role for beclin 1 in regulating growth factor signaling and reveal a mechanism by which loss of beclin 1 expression would enhance breast cancer progression.	[Rohatgi, R. A.; Janusis, J.; Baehrecke, E. H.; Shaw, L. M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Leonard, D.; Corvera, S.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; [Bellve, K. D.; Fogarty, K. E.] Univ Massachusetts, Sch Med, Biomed Imaging Grp, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Shaw, LM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01605 USA.	leslie.shaw@umassmed.edu			National Institute of Health (NIH) [CA142782, CA177167, DK60564, CA159314]; NATIONAL CANCER INSTITUTE [R01CA159314, R01CA142782, R01CA177167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK060564] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institute of Health (NIH) grants CA142782 and CA177167 (LMS), DK60564 (SC) and CA159314 (EHB). We thank Lawrence M Lifshitz and Clive Standley of the UMass Biomedical Imaging Group for their contributions to the programs used to analyze the TESM data. We thank Sha Zhu for assistance with cloning, Usha Acharya for assistance with the PI3P lipid measurements and Chung-Cheng Hsieh for statistical advice.	Arboleda MJ, 2003, CANCER RES, V63, P196; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dong M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0355-0; Dutta Dipannita, 2012, Cell Logist, V2, P203; Er EE, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004015; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; Hayakawa A, 2006, P NATL ACAD SCI USA, V103, P11928, DOI 10.1073/pnas.0508832103; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033; Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Lee MH, 2008, BIOCHEMISTRY-US, V47, P11682, DOI 10.1021/bi801451f; Leonard D, 2008, J CELL SCI, V121, P3445, DOI 10.1242/jcs.031484; Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98; Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Lorincz P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/851349; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Navaroli DM, 2012, P NATL ACAD SCI USA, V109, pE471, DOI 10.1073/pnas.1115495109; Pankratz SL, 2009, J BIOL CHEM, V284, P2031, DOI 10.1074/jbc.M804776200; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Platta HW, 2011, CURR OPIN CELL BIOL, V23, P393, DOI 10.1016/j.ceb.2011.03.008; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Resnik JL, 1998, CANCER RES, V58, P1159; Ryu JY, 2014, CELL REP, V7, P1227, DOI 10.1016/j.celrep.2014.04.006; Schenck A, 2008, CELL, V133, P486, DOI 10.1016/j.cell.2008.02.044; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Shravage BV, 2013, DEVELOPMENT, V140, P1321, DOI 10.1242/dev.089490; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; Wang JR, 2013, J INEQUAL APPL, P1, DOI 10.1186/1029-242X-2013-308; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zoncu R, 2009, CELL, V136, P1110, DOI 10.1016/j.cell.2009.01.032	47	50	55	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5352	5362		10.1038/onc.2014.454	http://dx.doi.org/10.1038/onc.2014.454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25639875	Green Accepted			2022-12-17	WOS:000363479200005
J	Liu, G; Yu, FX; Kim, YC; Meng, Z; Naipauer, J; Looney, DJ; Liu, X; Gutkind, JS; Mesri, EA; Guan, KL				Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Naipauer, J.; Looney, D. J.; Liu, X.; Gutkind, J. S.; Mesri, E. A.; Guan, K-L			Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; ORGAN SIZE CONTROL; PRIMARY EFFUSION LYMPHOMA; YES-ASSOCIATED PROTEIN; SCF-BETA-TRCP; GENE-EXPRESSION; CELL-PROLIFERATION; YAP PATHWAY; TEAD/TEF FAMILY; GROWTH-CONTROL	Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic virus and the culprit behind the human disease Kaposi sarcoma (KS), an AIDS-defining malignancy. KSHV encodes a viral G-protein-coupled receptor (vGPCR) critical for the initiation and progression of KS. In this study, we identified that YAP/TAZ, two homologous oncoproteins inhibited by the Hippo tumor suppressor pathway, are activated in KSHV-infected cells in vitro, KS-like mouse tumors and clinical human KS specimens. The KSHV-encoded vGPCR acts through Gq/11 and G12/13 to inhibit the Hippo pathway kinases Lats1/2, promoting the activation of YAP/TAZ. Furthermore, depletion of YAP/TAZ blocks vGPCR-induced cell proliferation and tumorigenesis in a xenograft mouse model. The vGPCR-transformed cells are sensitive to pharmacologic inhibition of YAP. Our study establishes a pivotal role of the Hippo pathway in mediating the oncogenic activity of KSHV and development of KS, and also suggests a potential of using YAP inhibitors for KS intervention.	[Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Guan, K-L] Shandong Univ, Sch Life Sci, Jinan 250100, Peoples R China; [Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Guan, K-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Liu, G.; Yu, F-X; Kim, Y. C.; Meng, Z.; Guan, K-L] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Naipauer, J.; Mesri, E. A.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Naipauer, J.; Mesri, E. A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Viral Oncol Program,Miami Ctr AIDS Res, Miami, FL 33136 USA; [Looney, D. J.] Univ Calif San Diego, VA San Diego Healthcare Syst, Dept Med, La Jolla, CA 92093 USA; [Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	Shandong University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Miami; University of Miami; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Guan, KL (corresponding author), Univ Calif San Diego, Dept Pharmacol, RM4010,2880 Torrey Pines Scenic Dr, La Jolla, CA 92093 USA.	kuguan@ucsd.edu	Gutkind, J. Silvio/J-1201-2016; Liu, Xiangguo/G-1091-2010; Liu, Guangbo/O-7636-2016; Guan, Kun-Liang/ADK-7088-2022	Gutkind, J. Silvio/0000-0002-5150-4482; Liu, Guangbo/0000-0001-5623-8227; Liu, Xiangguo/0000-0002-1879-3817; Yu, Fa-Xing/0000-0003-4834-9335; Kim, Young Chul/0000-0002-6782-2186; Naipauer, Julian/0000-0001-6842-6815	NIH/NCI [P30 CA23100]; NIAID [P30 AI36214, R01CA132809, R01GM51586]; Chinese Scholarship Council; NIH [CA136387]; Miami CFAR Grant [P30AI073961]; NATIONAL CANCER INSTITUTE [R01CA136387, P30CA023100, R01CA132809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, P30AI073961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Chinese Scholarship Council(China Scholarship Council); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Miami CFAR Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank AIDS and Cancer Specimen Resource at the University of California, San Francisco (particularly Ronald Honrada, Andrew Ma and Michael McGrath) for providing the tissue microarrays and carrying out the HHV-8 staining. We also thank Jenna Jewell, Steve Plouffe and Fabian Flores for critical reading of this manuscript, and Drs Dirk Dittmer, Carsten Gram Hansen and Toshiro Moroishi for insightful discussions. EAM and JN would like to thank Santas Rosario and Darlah Lopez Rodriguez for their help with the infection systems. This study was supported by grants from NIH/NCI P30 CA23100, NIAID P30 AI36214, R01CA132809, R01GM51586 (to KLG) and the Chinese Scholarship Council (to GL). EAM and JN were supported by NIH Grants CA136387 and Miami CFAR Grant P30AI073961.	Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cavallin LE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004154; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Edelman DC, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-78; Feng H, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000157; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hermans P, 2000, HIV Med, V1, P137, DOI 10.1046/j.1468-1293.2000.00027.x; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; Kaplan LD, 2013, HEMATOL-AM SOC HEMAT, P103, DOI 10.1182/asheducation-2013.1.103; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Leung HJ, 2012, ANTIMICROB AGENTS CH, V56, P5794, DOI 10.1128/AAC.01126-12; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma Q, 2013, ANTIOXID REDOX SIGN, V18, P80, DOI 10.1089/ars.2012.4584; Marinissen MJ, 2006, J BIOL CHEM, V281, P11332, DOI 10.1074/jbc.M512199200; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Martin D, 2011, CANCER CELL, V19, P805, DOI 10.1016/j.ccr.2011.05.005; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; St JM, 1999, NAT GENET, V21, P182; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strassburger K, 2012, DEV BIOL, V367, P187, DOI 10.1016/j.ydbio.2012.05.008; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vieira J, 2004, VIROLOGY, V325, P225, DOI 10.1016/j.virol.2004.03.049; von Gise A, 2012, P NATL ACAD SCI USA, V109, P2394, DOI 10.1073/pnas.1116136109; Wen KW, 2010, CANCER LETT, V289, P140, DOI 10.1016/j.canlet.2009.07.004; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	67	50	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3536	3546		10.1038/onc.2014.281	http://dx.doi.org/10.1038/onc.2014.281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195862	Green Accepted, Green Submitted			2022-12-17	WOS:000357434900006
J	Gurgis, FMS; Yeung, YT; Tang, MXM; Heng, B; Buckland, M; Ammit, AJ; Haapasalo, J; Haapasalo, H; Guillemin, GJ; Grewal, T; Munoz, L				Gurgis, F. M. S.; Yeung, Y. T.; Tang, M. X. M.; Heng, B.; Buckland, M.; Ammit, A. J.; Haapasalo, J.; Haapasalo, H.; Guillemin, G. J.; Grewal, T.; Munoz, L.			The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1 beta-driven IL-6 secretion in glioblastoma cells	ONCOGENE			English	Article							PROTEIN-KINASE 2; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; RICH ELEMENTS; HUR; CYTOKINE; EXPRESSION; GLIOMA; INHIBITORS; GROWTH	The microenvironment of glioblastoma (GBM) contains high levels of inflammatory cytokine interleukin 6 (IL-6), which contributes to promote tumour progression and invasion. The common epidermal growth factor receptor variant III (EGFRvIII) mutation in GBM is associated with significantly higher levels of IL-6. Furthermore, elevated IL-1 beta levels in GBM tumours are also believed to activate GBM cells and enhance IL-6 production. However, the crosstalk between these intrinsic and extrinsic factors within the oncogene-microenvironment of GBM causing overproduction of IL-6 is poorly understood. Here, we show that EGFRvIII potentiates IL-1 beta-induced IL-6 secretion from GBM cells. Importantly, exacerbation of IL-6 production is most effectively attenuated in EGFRvIII-expressing GBM cells with inhibitors of p38 mitogen-activated protein kinase (p38 MAPK) and MAPK-activated protein kinase 2 (MK2). Enhanced IL-6 production and increased sensitivity toward pharmacological p38 MAPK and MK2 inhibitors in EGFRvIII-expressing GBM cells is associated with increased MK2-dependent nuclear-cytoplasmic shuttling and accumulation of human antigen R (HuR), an IL-6 mRNA-stabilising protein, in the cytosol. IL-1 beta-stimulated activation of the p38 MAPK-MK2-HuR pathway significantly enhances IL-6 mRNA stability in GBM cells carrying EGFRvIII. Further supporting a role for the p38 MAPK-MK2-HuR pathway in the development of inflammatory environment in GBM, activated MK2 is found in more than 50% of investigated GBM tissues and correlates with lower grade and secondary GBMs. Taken together, p38 MAPK-MK2-HuR signalling may enhance the potential of intrinsic (EGFRvIII) and extrinsic (IL-1 beta) factors to develop an inflammatory GBM environment. Hence, further improvement of brain-permeable and anti-inflammatory inhibitors targeting p38 MAPK, MK2 and HuR may combat progression of lower grade gliomas into aggressive GBMs.	[Gurgis, F. M. S.; Yeung, Y. T.; Tang, M. X. M.; Munoz, L.] Univ Sydney, Sch Med Sci Pharmacol, Sydney, NSW 2006, Australia; [Yeung, Y. T.; Ammit, A. J.; Grewal, T.] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Heng, B.; Guillemin, G. J.] Macquarie Univ, Australian Sch Adv Med, N Ryde, NSW 2109, Australia; [Buckland, M.] Univ Sydney, Sch Med Sci Pathol, Sydney, NSW 2006, Australia; [Haapasalo, J.; Haapasalo, H.] Tampere Univ Hosp, Dept Pathol, Tampere, Finland; [Haapasalo, J.; Haapasalo, H.] Tampere Univ Hosp, Fimlab Labs, Tampere, Finland; [Haapasalo, J.] Tampere Univ Hosp, Neurosurg Unit, Tampere, Finland	University of Sydney; University of Sydney; Macquarie University; University of Sydney; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital	Munoz, L (corresponding author), Univ Sydney, Sch Med Sci Pharmacol, Sydney, NSW 2006, Australia.	lenka.munoz@sydney.edu.au	Guillemin, Gilles J/C-3878-2015; Yeung, Yiu/AAH-6863-2021	Guillemin, Gilles J/0000-0001-8105-4470; Grewal, Thomas/0000-0002-7937-8887; Heng, Ruiwen Benjamin/0000-0002-0247-2920; Ammit, Alaina/0000-0003-0555-2544	National Foundation for Medical Research and Innovation; National Health and Medical Research Council of Australia [510294, 1025637]; University of Sydney [2010-02681]; Australian Research Council [FT120100397]; Tour de Cure; University of Sydney Brown Fellowship	National Foundation for Medical Research and Innovation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney(University of Sydney); Australian Research Council(Australian Research Council); Tour de Cure; University of Sydney Brown Fellowship	This study was supported by grants from National Foundation for Medical Research and Innovation and the University of Sydney Brown Fellowship to LM. TG acknowledges support from the National Health and Medical Research Council of Australia (510294) and the University of Sydney (2010-02681). GJG is supported by the Australian Research Council (FT120100397) and Tour de Cure. AJA is supported by the National Health and Medical Research Council of Australia (1025637). We would like to thank Maggie Lee for technical assistance with immunohistochemistry and Myriam Gorospe for pHuR(S202) antibody.	Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bolognani F, 2012, J NEURO-ONCOL, V106, P531, DOI 10.1007/s11060-011-0707-1; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Brzezinska AA, 2009, IMMUNOLOGY, V127, P386, DOI 10.1111/j.1365-2567.2008.02980.x; Cheng CY, 2010, BRIT J PHARMACOL, V160, P1595, DOI 10.1111/j.1476-5381.2010.00858.x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Doller A, 2008, CELL SIGNAL, V20, P2165, DOI 10.1016/j.cellsig.2008.05.007; Fernau NS, 2010, J BIOL CHEM, V285, P3896, DOI 10.1074/jbc.M109.081430; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Gurgis FMS, 2014, MOL PHARMACOL, V85, P345, DOI 10.1124/mol.113.090365; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Li L, 2009, NEURO-ONCOLOGY, V11, P9, DOI 10.1215/15228517-2008-081; Liao WL, 2011, J BIOL CHEM, V286, P35499, DOI 10.1074/jbc.M111.263582; Lin WN, 2011, BRIT J PHARMACOL, V163, P1691, DOI 10.1111/j.1476-5381.2011.01312.x; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Miyata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059095; Mourey RJ, 2010, J PHARMACOL EXP THER, V333, P797, DOI 10.1124/jpet.110.166173; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Munoz L, 2010, EUR J PHARMACOL, V635, P212, DOI 10.1016/j.ejphar.2010.02.037; Munoz L, 2010, ANAL BIOCHEM, V401, P125, DOI 10.1016/j.ab.2010.02.016; Nabors LB, 2001, CANCER RES, V61, P2154; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Ramgolam VS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014450; Schulz I, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-86; Spooren A, 2011, BIOCHEM PHARMACOL, V81, P1004, DOI 10.1016/j.bcp.2011.01.019; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016; Wang SB, 2008, J LEUKOCYTE BIOL, V83, P982, DOI 10.1189/jlb.0907641; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yeung YT, 2013, BRIT J PHARMACOL, V168, P591, DOI 10.1111/bph.12008; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289	38	50	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2934	2942		10.1038/onc.2014.225	http://dx.doi.org/10.1038/onc.2014.225			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088200	Bronze			2022-12-17	WOS:000355324300012
J	Jiang, N; Hjorth-Jensen, K; Hekmat, O; Iglesias-Gato, D; Kruse, T; Wang, C; Wei, W; Ke, B; Yan, B; Niu, Y; Olsen, JV; Flores-Morales, A				Jiang, N.; Hjorth-Jensen, K.; Hekmat, O.; Iglesias-Gato, D.; Kruse, T.; Wang, C.; Wei, W.; Ke, B.; Yan, B.; Niu, Y.; Olsen, J. V.; Flores-Morales, A.			In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth	ONCOGENE			English	Article							ANDROGEN RECEPTOR; HIPPO PATHWAY; LNCAP MODEL; PHOSPHORYLATION; PTEN; MTOR; INHIBITOR; PROGRESSION; ACTIVATION; EXPRESSION	Prostate cancer remains a leading cause of cancer-related mortality worldwide owing to our inability to treat effectively castration-resistant tumors. To understand the signaling mechanisms sustaining castration-resistant growth, we implemented a mass spectrometry-based quantitative proteomic approach and use it to compare protein phosphorylation in orthotopic xenograft tumors grown in either intact or castrated mice. This investigation identified changes in phosphorylation of signaling proteins such as MEK, LYN, PRAS40, YAP1 and PAK2, indicating the concomitant activation of several oncogenic pathways in castration-resistant tumors, a notion that was confirmed by tumor transcriptome analysis. Further analysis demonstrated that the activation of mTORC1, PAK2 and the increased levels of YAP1 in castration-resistant tumors can be explained by the loss of androgen inhibitory actions. The analysis of clinical samples demonstrated elevated levels of PAK2 and YAP1 in castration-resistant tumors, whereas knockdown experiments in androgen-independent cells demonstrated that both YAP1 and PAK2 regulate cell colony formation and cell invasion activity. PAK2 also influenced cell proliferation and mitotic timing. Interestingly, these phenotypic changes occur in the absence of obvious alterations in the activity of AKT, MAPK or mTORC1 pathways, suggesting that PAK2 and YAP1 may represent novel targets for the treatment of castration-resistant prostate cancer. Pharmacologic inhibitors of PAK2 (PF-3758309) and YAP1 (Verteporfin) were able to inhibit the growth of androgen-independent PC3 xenografts. This work demonstrates the power of applying high-resolution mass spectrometry in the proteomic profiling of tumors grown in vivo for the identification of novel and clinically relevant regulatory proteins.	[Jiang, N.; Hjorth-Jensen, K.; Hekmat, O.; Iglesias-Gato, D.; Kruse, T.; Olsen, J. V.; Flores-Morales, A.] Univ Copenhagen, Dept Hlth Sci, Novo Nordisk Fdn Ctr Prot Res, Fac Hlth & Med Sci, Copenhagen, Denmark; [Jiang, N.; Wang, C.; Wei, W.; Ke, B.; Yan, B.; Niu, Y.] Tianjin Med Univ, Tianjin Inst Urol, Tianjin, Peoples R China	University of Copenhagen; Tianjin Medical University	Niu, Y (corresponding author), Tianjin Inst Urol, 23 Pingjiang Rd, Tianjin 300211, Peoples R China.	Amilcar.Flores@cpr.ku.dk; niuyuanjie9317@163.com; Amilcar.Flores@cpr.ku.dk	Olsen, Jesper/ABH-4638-2020; Hekmat, Omid/AAU-4182-2021; Iglesias-Gato, Diego/R-1794-2016	Olsen, Jesper/0000-0002-4747-4938; Iglesias-Gato, Diego/0000-0002-8982-9936	Novo Nordisk Foundation, Movember; Danish Council for Independent Research; Science Foundation of Tianjin [11JCZDJC19700, 09ZCZDSF04300]; National Natural Science Foundation of China [2012CB518304, 2012DFG32220]; Novo Nordisk Fonden [NNF12OC0002286] Funding Source: researchfish	Novo Nordisk Foundation, Movember; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Science Foundation of Tianjin(Natural Science Foundation of Tianjin); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Novo Nordisk Fonden(Novo Nordisk Foundation)	This work was supported by grants to AF-M from the Novo Nordisk Foundation, Movember and the Danish Council for Independent Research. JN and NY are supported by the Science Foundation of Tianjin (No.: 11JCZDJC19700) and 09ZCZDSF04300 and the National Natural Science Foundation of China Grant numbers: 2012CB518304 and 2012DFG32220.	Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chuan YC, 2010, ONCOGENE, V29, P1531, DOI 10.1038/onc.2009.442; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Crawford ED, 2009, UROLOGY, V73, P4, DOI 10.1016/j.urology.2009.03.001; D'Antonio JM, 2008, PROSTATE, V68, P698, DOI 10.1002/pros.20677; Das Thakur M, 2010, CURR BIOL, V20, P657, DOI 10.1016/j.cub.2010.02.035; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Drake JM, 2013, P NATL ACAD SCI USA, V110, pE4762, DOI 10.1073/pnas.1319948110; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hekmat O, 2013, J PROTEOME RES, V12, P4136, DOI 10.1021/pr400457u; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Lundby A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1871; Ma L, 2007, CANCER RES, V67, P7106, DOI 10.1158/0008-5472.CAN-06-4798; Mann M, 2013, MOL CELL, V49, P583, DOI 10.1016/j.molcel.2013.01.029; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Nakabayashi M, 2012, BJU INT, V110, P1729, DOI 10.1111/j.1464-410X.2012.11456.x; Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Olsen JV, 2013, MOL CELL PROTEOMICS, V12, P3444, DOI 10.1074/mcp.O113.034181; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Olsen JV, 2009, MOL CELL PROTEOMICS, V8, P2759, DOI 10.1074/mcp.M900375-MCP200; Pan CP, 2009, MOL CELL PROTEOMICS, V8, P2796, DOI 10.1074/mcp.M900285-MCP200; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Saramaki O, 2007, FRONT BIOSCI-LANDMRK, V12, P3287, DOI 10.2741/2312; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327; Schayowitz A, 2010, BRIT J CANCER, V103, P1001, DOI 10.1038/sj.bjc.6605882; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; THALMANN GN, 1994, CANCER RES, V54, P2577; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VISAKORPI T, 1994, EUR J CANCER, V30A, P129, DOI 10.1016/S0959-8049(05)80037-1; Ye Diana Zi, 2012, Cell Logist, V2, P105; Zhang G, 2012, J CELL SCI, V125, P3243, DOI 10.1242/jcs.104208; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	55	50	52	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2764	2776		10.1038/onc.2014.206	http://dx.doi.org/10.1038/onc.2014.206			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065596				2022-12-17	WOS:000354979500009
J	Jansson, MD; Damas, ND; Lees, M; Jacobsen, A; Lund, AH				Jansson, M. D.; Damas, N. D.; Lees, M.; Jacobsen, A.; Lund, A. H.			miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2	ONCOGENE			English	Article							NEGATIVE REGULATOR; CELL-PROLIFERATION; GROWTH ARREST; MICRORNA; CANCER; P21(WAF1/CIP1); MODULATION; ACTIVATION; LOOP	MicroRNAs (miRNAs) regulate many key cancer-relevant pathways and may themselves possess oncogenic or tumor-suppressor functions. Consequently, miRNA dysregulation has been shown to be a prominent feature in many human cancers. The p53 tumor suppressor acts as a negative regulator of cell proliferation in response to stress and represents the most commonly lost and mutated gene in human cancers. The function of p53 is inhibited by the MDM2 oncoprotein. Using a high-throughput screening approach, we identified miR-339-5p as a regulator of the p53 pathway. We demonstrate that this regulation occurs via the ability of miR-339-5p to target directly the 3'-untranslated region of MDM2 mRNA, reducing MDM2 expression and thus promoting p53 function. Consequently, overexpression of miR-339-5p positively impacts on p53-governed cellular responses such as proliferation arrest and senescence, whereas inhibition of miR-339-5p function perturbs the p53 response in cancer cells, allowing an increased proliferation rate. In addition, miR-339-5p expression is downregulated in tumors harboring wild-type TP53, suggesting that reduction of miR-339-5p level helps to suppress the p53 response in p53-competent tumor cells. Furthermore, we show that a negative correlation between miR-339-5p and MDM2 expression exists in human cancer, implying that the interaction is important for cancer development.	[Jansson, M. D.; Damas, N. D.; Lees, M.; Lund, A. H.] Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark; [Jansson, M. D.; Damas, N. D.; Lees, M.; Lund, A. H.] Univ Copenhagen, Ctr Epigenet, DK-2200 Copenhagen, Denmark; [Jacobsen, A.] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA	University of Copenhagen; University of Copenhagen; Memorial Sloan Kettering Cancer Center	Lund, AH (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	anders.lund@bric.ku.dk	Lund, Anders H./F-4786-2014; Skanderup, Anders Jacobsen/K-1081-2013	Lund, Anders H./0000-0002-7407-3398; Skanderup, Anders Jacobsen/0000-0001-6847-4980; Jansson, Martin/0000-0002-6946-145X; Djodij Damas, Nkerorema/0000-0002-1192-7704	Danish National Advanced Technology Foundation; Danish National Research Foundation; Novo Nordisk Foundation; Lundbeck Foundation; Danish Cancer Society; Danish Medical Research Council; Lundbeck Foundation [R108-2012-10312, R100-2011-8756] Funding Source: researchfish	Danish National Advanced Technology Foundation; Danish National Research Foundation(Danmarks Grundforskningsfond); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden)	Work in the authors' laboratory was supported by the Danish National Advanced Technology Foundation, the Danish National Research Foundation, the Novo Nordisk Foundation, the Lundbeck Foundation and the Danish Cancer Society. Dr Jansson was supported by a grant from the Danish Medical Research Council. We acknowledge the The Cancer Genome Atlas Research Network for our use of their publically available tumor data sets. We thank Bert Vogelstein and Kristian Helin for cell lines.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burns DM, 2011, NATURE, V473, P105, DOI 10.1038/nature09908; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; FOX MH, 1980, CYTOMETRY, V1, P71, DOI 10.1002/cyto.990010114; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kheir TB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-29; Kumar M, 2011, ONCOGENE, V30, P843, DOI 10.1038/onc.2010.457; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30; Lize M, 2010, CELL DEATH DIFFER, V17, P452, DOI 10.1038/cdd.2009.188; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo Y, 2012, ONCOGENE, V31, P306, DOI 10.1038/onc.2011.244; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Vispe S, 2009, MOL CANCER THER, V8, P2780, DOI 10.1158/1535-7163.MCT-09-0549; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542; Xiao JN, 2011, EMBO J, V30, P524, DOI 10.1038/emboj.2010.347; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063142	46	50	55	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1908	1918		10.1038/onc.2014.130	http://dx.doi.org/10.1038/onc.2014.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882579				2022-12-17	WOS:000352725600005
J	Kim, G; Ouzounova, M; Quraishi, AA; Davis, A; Tawakkol, N; Clouthier, SG; Malik, F; Paulson, AK; D'Angelo, RC; Korkaya, S; Baker, TL; Esen, ES; Prat, A; Liu, S; Kleer, CG; Thomas, DG; Wicha, MS; Korkaya, H				Kim, G.; Ouzounova, M.; Quraishi, A. A.; Davis, A.; Tawakkol, N.; Clouthier, S. G.; Malik, F.; Paulson, A. K.; D'Angelo, R. C.; Korkaya, S.; Baker, T. L.; Esen, E. S.; Prat, A.; Liu, S.; Kleer, C. G.; Thomas, D. G.; Wicha, M. S.; Korkaya, H.			SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model	ONCOGENE			English	Article						breast cancer; triple negative subtype; p53; PTEN; inflammatory cytokine; IL6	SOCS3; CELLS; GENE; MECHANISMS; IDENTIFICATION; ACTIVATION; EXPRESSION; RESISTANCE; THERAPY; DISEASE	Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesions have been implicated in progression to invasive ductal carcinomas. A recent molecular and mutational analysis of breast cancers revealed that inactivation of tumor suppressors, p53 and PTEN, are strongly associated with triple negative breast cancer. In addition, these tumor suppressors have important roles in regulating self-renewal in normal and malignant stem cells. To investigate their role in breast carcinogenesis, we knocked down these genes in human mammary cells and in non-transformed MCF10A cells. p53 and PTEN knockdown synergized to activate pro-inflammatory interleukin-6 (IL6)/Stat3/nuclear factor kappa B signaling. This resulted in generation of highly metastatic epithelial-to-mesenchymal transition-like cancer stem cells resulting in tumors whose gene expression profile mimicked that found in basal/claudin-low molecular subtype within the triple negative breast tumors. Constitutive activation of this loop in transformed cells was dependent on proteolytic degradation of suppressor of cytokine signaling 3 (SOCS3) resulting in low levels of this protein in basal/claudin-low cell lines and primary tumors. In non-transformed cells, transient activation of the IL6 inflammatory loop induced SOCS3 expression leading to pathway inactivation. In transformed cells, enforced expression of SOCS3 or interfering with IL6 pathway via IL6R blockade inhibited tumor growth and metastasis in mouse xenograft models. Furthermore, circulating tumor cells were significantly reduced in tumor-bearing animals when treated with anti-IL6R antibodies. These studies uncover important connections between inflammation and carcinogenesis and suggest that blocking pro-inflammatory cytokines may be utilized as an attractive strategy to target triple negative breast tumors, which currently lacks molecularly targeted therapies.	[Kim, G.; Ouzounova, M.; Quraishi, A. A.; Davis, A.; Tawakkol, N.; Clouthier, S. G.; Malik, F.; Paulson, A. K.; D'Angelo, R. C.; Korkaya, S.; Baker, T. L.; Esen, E. S.; Liu, S.; Wicha, M. S.; Korkaya, H.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Kim, G.] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, Songnam 463712, Gyeonggi, South Korea; [Malik, F.] Indian Inst Integrat Med, Dept Canc Pharmacol, Jammu, India; [Prat, A.] Vall dHebron Inst Oncol, Translat Genom Grp, Barcelona, Spain; [Kleer, C. G.; Thomas, D. G.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; Pochon Cha University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM); Vall d'Hebron Institut d'Oncologia (VHIO); University of Michigan System; University of Michigan	Korkaya, H (corresponding author), Georgia Regents Univ, Ctr Canc, Dept Biochem & Mol Biol, 1410 Laney Walker Blvd CN2136, Augusta, GA 30912 USA.	hkorkaya@gru.edu	Ouzounova, Maria/B-7189-2014; Korkaya, Hasan/GRY-1016-2022; Wicha, Max/AAE-7268-2019; Liu, Suling/N-2796-2013; esen, elif serap/GPP-6880-2022; Paulson, Amanda/AAX-2334-2021; liu, suling/AAF-5249-2019; Korkaya, Hasan/ABD-6282-2020	Ouzounova, Maria/0000-0001-8934-3461; Liu, Suling/0000-0002-0475-0242; liu, suling/0000-0002-0475-0242; Korkaya, Hasan/0000-0002-0719-5862; Malik, Fayaz/0000-0001-5475-6610	NIH [CA101860, CA129765]; Breast Cancer Research Foundation; GRU Cancer Center; Komen grant [KG11230]; NATIONAL CANCER INSTITUTE [U01CA154224, R01CA125577, R01CA129765, R01CA101860] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; GRU Cancer Center; Komen grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH grants; CA101860 and CA129765 and Breast Cancer Research Foundation grant to MSW and by the GRU Cancer Center and the Komen grant; KG11230 to HK.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dandrea M, 2009, NUCLEIC ACIDS RES, V37, P6681, DOI 10.1093/nar/gkp723; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Ohsugi Y, 2008, EXPERT OPIN BIOL TH, V8, P669, DOI 10.1517/14712598.8.5.669 ; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasi W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-178; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Sommer U, 2005, J BIOL CHEM, V280, P31478, DOI 10.1074/jbc.M506008200; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Ying MZ, 2010, J CANCER RES CLIN, V136, P1617, DOI 10.1007/s00432-010-0819-6; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093	33	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					671	680		10.1038/onc.2014.4	http://dx.doi.org/10.1038/onc.2014.4			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531711	Bronze, Green Accepted			2022-12-17	WOS:000348853800001
J	Lin, C; Song, L; Liu, A; Gong, H; Lin, X; Wu, J; Li, M; Li, J				Lin, C.; Song, L.; Liu, A.; Gong, H.; Lin, X.; Wu, J.; Li, M.; Li, J.			Overexpression of AKIP1 promotes angiogenesis and lymphangiogenesis in human esophageal squamous cell carcinoma	ONCOGENE			English	Article						AKIP1; angiogenesis; lymphangiogenesis; VEGF-C	ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; NF-KAPPA-B; VEGF-C; TUMOR LYMPHANGIOGENESIS; CANCER-CELLS; GENE-EXPRESSION; UP-REGULATION; IN-VIVO; SURVIVAL	A-kinase-interacting protein 1 (AKIP1) is found to be overexpressed in breast and prostate cancers, suggesting that AKIP1 might act as a potent oncogenic protein. However, the clinical significance and biological role of AKIP1 in cancer progression remain largely unknown. Herein, we report that AKIP1 is markedly overexpressed in esophageal squamous cell carcinoma (ESCC) cell lines and clinical ESCC samples. AKIP1 expression significantly correlates with ESCC progression and patients' shorter survival time. Furthermore, we find that overexpressing AKIP1 induces, whereas silencing AKIP1 reduces, ESCC angiogenesis and lymphangiogenesis both in vitro and in vivo. Moreover, we demonstrate that AKIP1 transcriptionally upregulates vascular endothelial growth factor-C (VEGF-C) via interaction with its promoter through cooperation with multiple transcriptional factors, including SP1, AP2 and nuclear factor-kappa B (NF-kappa B). Importantly, significant correlation between levels of AKIP1 and VEGF-C is observed in a cohort of human ESCC, as well as in non-small cell lung cancer, hepatocellular carcinoma and ovarian cancer. Hence, these findings indicate an important role for AKIP1 in ESCC angiogenesis and lymphangiogenesis, and uncover a novel mechanism for the upregulation of VEGF-C in cancers.	[Lin, C.; Song, L.; Lin, X.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Dept Expt Res, Guangzhou 510080, Guangdong, Peoples R China; [Lin, C.; Liu, A.; Gong, H.; Li, J.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China; [Wu, J.; Li, M.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China; [Wu, J.; Li, M.; Li, J.] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn	Lin, Chuyong/AAA-9931-2020; Song, LB/AAL-1968-2020; Liu, Aibin/S-7252-2019	Lin, Chuyong/0000-0003-4887-5386; Liu, Aibin/0000-0003-1600-8288	Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); Natural Science Foundation of China [81325013, 81071780, 81030048, 91229101, U1201121, 81272196, 81272198]; Science and Technology Department of Guangdong Province [S2011020002757, S2012020010946]; Ministry of Education of China [20130171110085, 20120171110055]	Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Guangdong Province; Ministry of Education of China(Ministry of Education, China)	This work was supported by the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2012), Natural Science Foundation of China (81325013, 81071780, 81030048, 91229101, U1201121, 81272196 and 81272198), the Science and Technology Department of Guangdong Province (S2011020002757 and S2012020010946) and Ministry of Education of China (20130171110085, 20120171110055).	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; BLOT WJ, 2006, CANC EPIDEMIOLOGY PR, P697, DOI DOI 10.1093/ACPROF:OSO/9780195149616.003.0036; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Chien MH, 2009, CARCINOGENESIS, V30, P2005, DOI 10.1093/carcin/bgp244; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feng YK, 2011, EUR J CANCER, V47, P2353, DOI 10.1016/j.ejca.2011.05.006; Gao N, 2008, J BIOL CHEM, V283, P7834, DOI 10.1074/jbc.M710285200; Gao N, 2010, J BIOL CHEM, V285, P28097, DOI 10.1074/jbc.M110.116566; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hosch SB, 2001, J CLIN ONCOL, V19, P1970, DOI 10.1200/JCO.2001.19.7.1970; Joukov V, 1996, EMBO J, V15, P290; Karpanen T, 2001, CANCER RES, V61, P1786; Kimura H, 1999, DIS ESOPHAGUS, V12, P205; Kitadai Y, 2004, ONCOL REP, V11, P315; Kitching R, 2003, BBA-GENE STRUCT EXPR, V1625, P116, DOI 10.1016/S0167-4781(02)00562-6; Krzystek-Korpacka M, 2007, CANCER LETT, V249, P171, DOI 10.1016/j.canlet.2006.08.011; Kubota Y, 2009, FRONT BIOSCI-LANDMRK, V14, P3872, DOI [10.2735/3495, 10.2741/3495]; Kumar B, 2011, ANGIOGENESIS, V14, P371, DOI 10.1007/s10456-011-9221-5; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/ijc.10706, 10.1002/jhc.10706]; Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mariette C, 2003, CANCER-AM CANCER SOC, V97, P1616, DOI 10.1002/cncr.11228; Miebach S, 2006, J NEURO-ONCOL, V76, P39, DOI 10.1007/s11060-005-3674-6; Ooki A, 2007, WORLD J SURG, V31, P2184, DOI 10.1007/s00268-007-9198-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; Sato T, 2006, INT J ONCOL, V28, P1043; Scavelli C, 2004, LEUKEMIA, V18, P1054, DOI 10.1038/sj.leu.2403355; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sobin LH, 1997, TNM CLASSIFICATION M, P54; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Tanigawa N, 1997, CANCER, V79, P220; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Zhang HL, 2010, DIS ESOPHAGUS, V23, P53, DOI 10.1111/j.1442-2050.2009.00971.x; Zhang Y, 2012, GASTROENTEROLOGY, V142, P521, DOI 10.1053/j.gastro.2011.11.023	46	50	53	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					332	341		10.1038/onc.2013.559	http://dx.doi.org/10.1038/onc.2013.559			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413079				2022-12-17	WOS:000348145500007
J	Tanaka, I; Osada, H; Fujii, M; Fukatsu, A; Hida, T; Horio, Y; Kondo, Y; Sato, A; Hasegawa, Y; Tsujimura, T; Sekido, Y				Tanaka, I.; Osada, H.; Fujii, M.; Fukatsu, A.; Hida, T.; Horio, Y.; Kondo, Y.; Sato, A.; Hasegawa, Y.; Tsujimura, T.; Sekido, Y.			LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade	ONCOGENE			English	Article						malignant nnesothelioma; Hippo pathway; YAP; AJUBA; LATS2	SCAFFOLD PROTEINS; GROWTH-CONTROL; MITOTIC PROGRESSION; YAP PATHWAY; CANCER; DROSOPHILA; FOXM1; TRANSCRIPTION; ORGANIZATION; APOPTOSIS	Malignant mesothelioma (MM) is one of the most aggressive neoplasms usually associated with asbestos exposure and is highly refractory to current therapeutic modalities. MMs show frequent activation of a transcriptional coactivator Yes-associated protein (YAP), which is attributed to the neurofibromatosis type 2 (NF2)-Hippo pathway dysfunction, leading to deregulated cell proliferation and acquisition of a malignant phenotype. However, the whole mechanism of disordered YAP activation in MMs has not yet been well clarified. In the present study, we investigated various components of the NF2-Hippo pathway, and eventually found that MM cells frequently showed downregulation of LIM-domain protein AJUBA, a binding partner of large tumor suppressor type 2 (LATS2), which is one of the last-step kinases of the NF2-Hippo pathway. Although loss of AJUBA expression was independent of the alteration status of other Hippo pathway components, MM cell lines with AJUBA inactivation showed a more dephosphorylated (activated) level of YAP. Immunohistochemical analysis showed frequent downregulation of AJUBA in primary MMs, which was associated with YAP constitutive activation. We found that AJUBA transduction into MM cells significantly suppressed promoter activities of YAP-target genes, and the suppression of YAP activity by AJUBA was remarkably canceled by knockdown of LATS2. In connection with these results, transduction of AJUBA-expressing lentivirus significantly inhibited the proliferation and anchorage-independent growth of the MM cells that harbored ordinary LATS family expression. Taken together, our findings indicate that AJUBA negatively regulates YAP activity through the LATS family, and inactivation of AJUBA is a novel key mechanism in MM cell proliferation.	[Tanaka, I.; Osada, H.; Fujii, M.; Fukatsu, A.; Kondo, Y.; Sekido, Y.] Aichi Canc Ctr, Res Inst, Dept Thorac Oncol Oncol, Nagoya, Aichi 4648681, Japan; [Tanaka, I.; Hasegawa, Y.] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4648601, Japan; [Osada, H.; Fukatsu, A.; Sekido, Y.] Nagoya Univ, Grad Sch Med, Dept Canc Genet, Program Funct Construct Med, Nagoya, Aichi 4648601, Japan; [Hida, T.; Horio, Y.] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan; [Sato, A.; Tsujimura, T.] Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo 6638501, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center; Hyogo College of Medicine	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Kanokoden 1-1, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Hasegawa, Yoshinori/I-1277-2012; Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848; Horio, Yoshitsugu/0000-0003-4661-6399	KAKENHI [24650650, 25290053]; Ministry of Health, Labor and Welfare of Japan; P-DIRECT; Takeda Science Foundation; Foundation for Promotion of Cancer Research	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); P-DIRECT; Takeda Science Foundation(Takeda Science Foundation (TSF)); Foundation for Promotion of Cancer Research	This work was supported in part by KAKENHI (24650650,25290053), Grants-in-Aid for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor and Welfare of Japan, P-DIRECT and the Takeda Science Foundation (YS). We thank Dr Adi F Gazdar for the cell lines and Mari Kizuki and Miwako Nishizawa for their excellent technical assistance. IT was supported by the Foundation for Promotion of Cancer Research.	Abe Y, 2006, FEBS LETT, V580, P782, DOI 10.1016/j.febslet.2005.12.096; Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Badouel C, 2009, CURR OPIN CELL BIOL, V21, P837, DOI 10.1016/j.ceb.2009.09.010; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Das Thakur M, 2010, CURR BIOL, V20, P657, DOI 10.1016/j.cub.2010.02.035; Delgermaa V, 2011, B WORLD HEALTH ORGAN, V89, P716, DOI 10.2471/BLT.11.086678; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Feng YF, 2005, MOL CELL BIOL, V25, P4010, DOI 10.1128/MCB.25.10.4010-4022.2005; Ferrand A, 2009, BIOL CELL, V101, P221, DOI 10.1042/BC20080060; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Locasale JW, 2007, P NATL ACAD SCI USA, V104, P13307, DOI 10.1073/pnas.0706311104; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Pass HI, 2004, CURR PROB CANCER, V28, P85; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Sasaki H, 2010, DEV GROWTH DIFFER, V52, P263, DOI 10.1111/j.1440-169X.2009.01158.x; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Shaw AS, 2009, NAT REV IMMUNOL, V9, P47, DOI 10.1038/nri2473; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111	48	50	53	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					73	83		10.1038/onc.2013.528	http://dx.doi.org/10.1038/onc.2013.528			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24336325				2022-12-17	WOS:000349740100007
J	Delehouze, C; Godl, K; Loaec, N; Bruyere, C; Desban, N; Oumata, N; Galons, H; Roumeliotis, TI; Giannopoulou, EG; Grenet, J; Twitchell, D; Lahti, J; Mouchet, N; Galibert, MD; Garbis, SD; Meijer, L				Delehouze, C.; Godl, K.; Loaec, N.; Bruyere, C.; Desban, N.; Oumata, N.; Galons, H.; Roumeliotis, T. I.; Giannopoulou, E. G.; Grenet, J.; Twitchell, D.; Lahti, J.; Mouchet, N.; Galibert, M-D; Garbis, S. D.; Meijer, L.			CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells	ONCOGENE			English	Article						cyclin-dependent kinase; casein kinase 1; roscovitine; CR8; MYCN; neuroblastoma	CYCLIN-DEPENDENT KINASE; RNA-POLYMERASE-II; DRUG DISCOVERY; CDK INHIBITORS; BREAST-CANCER; INTRACELLULAR TARGETS; THERAPEUTIC TARGETS; PYRIDOXAL KINASE; DUAL-SPECIFICITY; K/CDK12 COMPLEX	To understand the mechanisms of action of (R)-roscovitine and (S)-CR8, two related pharmacological inhibitors of cyclin-dependent kinases (CDKs), we applied a variety of '-omics' techniques to the human neuroblastoma SH-SY5Y and IMR32 cell lines: (1) kinase interaction assays, (2) affinity competition on immobilized broad-spectrum kinase inhibitors, (3) affinity chromatography on immobilized (R)-roscovitine and (S)-CR8, (4) whole genome transcriptomics analysis and specific quantitative PCR studies, (5) global quantitative proteomics approach and western blot analysis of selected proteins. Altogether, the results show that the major direct targets of these two molecules belong to the CDKs (1,2,5,7,9,12), DYRKs, CLKs and CK1s families. By inhibiting CDK7, CDK9 and CDK12, these inhibitors transiently reduce RNA polymerase 2 activity, which results in downregulation of a large set of genes. Global transcriptomics and proteomics analysis converge to a central role of MYC transcription factors downregulation. Indeed, CDK inhibitors trigger rapid and massive downregulation of MYCN expression in MYCN-amplified neuroblastoma cells as well as in nude mice xenografted IMR32 cells. Inhibition of casein kinase 1 may also contribute to the antitumoral activity of (R)-roscovitine and (S)-CR8. This dual mechanism of action may be crucial in the use of these kinase inhibitors for the treatment of MYC-dependent cancers, in particular neuroblastoma where MYCN amplification is a strong predictor factor for high-risk disease.	[Delehouze, C.; Loaec, N.; Bruyere, C.; Oumata, N.; Meijer, L.] Ctr Perharidy, Hotel Rech, ManRos Therapeut, F-29680 Roscoff, France; [Godl, K.] Evotec Munchen GmbH, Martinsried, Germany; [Loaec, N.; Desban, N.; Meijer, L.] CNRS, Prot Phosphorylat & Human Dis Grp, Roscoff, Bretagne, France; [Galons, H.] Univ Paris 05, INSERM U648, Lab Chim Organ 2, Paris, France; [Roumeliotis, T. I.; Garbis, S. D.] Univ Southampton, Inst Life Sci, Ctr Prote & Metabol Res, Southampton, Hants, England; [Giannopoulou, E. G.] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY USA; [Grenet, J.; Twitchell, D.; Lahti, J.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; [Mouchet, N.; Galibert, M-D] Univ Rennes 1, CNRS, UMR 6290, Inst Genet & Dev Rennes Equipe Express Gen & Onco, Rennes, France	Evotec; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southampton; Cornell University; St Jude Children's Research Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes 1	Meijer, L (corresponding author), Ctr Perharidy, Hotel Rech, ManRos Therapeut, F-29680 Roscoff, France.	herve.galons@univ-paris5.fr; S.D.Garbis@soton.ac.uk; meijer@manros-therapeutics.com	Mouchet, Nicolas/AAP-6126-2020; MEIJER, Laurent/ABE-7465-2021; Garbis, Spiros D/L-3099-2013; Giannopoulou, Evgenia/K-9576-2019	Mouchet, Nicolas/0000-0002-2849-9953; Garbis, Spiros D/0000-0002-1050-0805; , laurent/0000-0003-3511-4916	EEC (FP6 Life Sciences & Health PRO-KINASE Project); Canceropole Grand-Ouest; Association France-Alzheimer Finistere; Association pour la Recherche sur le Cancer [ARC-1092]; Ligue Nationale contre le Cancer (Comite Grand-Ouest); Polycystic Kidney Disease Foundation; Fondation Jerome Lejeune; Conseil Regional de Bretagne ('Fonds de Maturation'); Institut National contre le Cancer (INCa) GLIOMER program; CCCDK8 program; EEC (TEMPO Research Project); NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765] Funding Source: NIH RePORTER	EEC (FP6 Life Sciences & Health PRO-KINASE Project); Canceropole Grand-Ouest; Association France-Alzheimer Finistere; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale contre le Cancer (Comite Grand-Ouest); Polycystic Kidney Disease Foundation; Fondation Jerome Lejeune; Conseil Regional de Bretagne ('Fonds de Maturation')(Region Bretagne); Institut National contre le Cancer (INCa) GLIOMER program; CCCDK8 program; EEC (TEMPO Research Project); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This article is dedicated to the memory of Jill Lahti and Vincent Kidd. We are grateful to Jacint Boix and Jean Benard, for the neuroblastoma cell lines. This research was supported by grants from the EEC (FP6 Life Sciences & Health PRO-KINASE and TEMPO Research Projects), the 'Canceropole Grand-Ouest', the 'Association France-Alzheimer Finistere', the 'Association pour la Recherche sur le Cancer' (ARC-1092), the 'Ligue Nationale contre le Cancer (Comite Grand-Ouest)', the Polycystic Kidney Disease Foundation, the Fondation Jerome Lejeune, the 'Conseil Regional de Bretagne' ('Fonds de Maturation' 2009) and the 'Institut National contre le Cancer' (INCa) GLIOMER and CCCDK8 programs.	Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Aldoss IT, 2009, EXPERT OPIN INV DRUG, V18, P1957, DOI 10.1517/13543780903418445; Azevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI DOI 10.1111/J.1432-1033.1997.0518A.X; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baumli S, 2012, STRUCTURE, V20, P1788, DOI 10.1016/j.str.2012.08.011; Becker F, 2004, CHEM BIOL, V11, P211, DOI 10.1016/j.chembiol.2004.02.001; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bettayeb K, 2008, MOL CANCER THER, V7, P2713, DOI 10.1158/1535-7163.MCT-08-0080; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Blazek D, 2012, CELL CYCLE, V11, P1049, DOI 10.4161/cc.11.6.19678; Blazek D, 2011, GENE DEV, V25, P2158, DOI 10.1101/gad.16962311; Breuer D, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-94; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chen Y, 2013, SURGERY, V153, P4, DOI 10.1016/j.surg.2012.03.030; Cheng SWG, 2012, MOL CELL BIOL, V32, P4691, DOI 10.1128/MCB.06267-11; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Cirillo D, 2011, CURR MED CHEM, V18, P2854, DOI 10.2174/092986711796150496; Conradt L, 2011, NEOPLASIA, V13, P1026, DOI 10.1593/neo.111016; Dai Q, 2012, J BIOL CHEM, V287, P25344, DOI 10.1074/jbc.M111.321760; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Debdab M, 2011, J MED CHEM, V54, P4172, DOI 10.1021/jm200274d; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Eglen R, 2011, PHARMACOL THERAPEUT, V130, P144, DOI 10.1016/j.pharmthera.2011.01.007; Eglen RM, 2009, ASSAY DRUG DEV TECHN, V7, P22, DOI 10.1089/adt.2008.164; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Faisal A, 2011, MOL CANCER THER, V10, P2115, DOI 10.1158/1535-7163.MCT-11-0333; Galons H, 2013, EXPERT OPIN THER PAT, V23, P945, DOI 10.1517/13543776.2013.789861; Garrofe-Ochoa X, 2011, APOPTOSIS, V16, P660, DOI 10.1007/s10495-011-0603-3; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Goldstein DM, 2008, NAT REV DRUG DISCOV, V7, P391, DOI 10.1038/nrd2541; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Grotzer MA, 2009, CURR CANCER DRUG TAR, V9, P176, DOI 10.2174/156800909787580962; Grunwald V, 2002, CANCER RES, V62, P6141; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Hsieh WS, 2009, CLIN CANCER RES, V15, P1435, DOI 10.1158/1078-0432.CCR-08-1748; Hui ABY, 2009, CLIN CANCER RES, V15, P3716, DOI 10.1158/1078-0432.CCR-08-2790; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Johnson N, 2010, EXPERT OPIN THER TAR, V14, P1199, DOI 10.1517/14728222.2010.525221; Jorda R, 2012, CURR PHARM DESIGN, V18, P2974, DOI 10.2174/138161212800672804; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; Kohoutek J, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-12; Krystof V, 2012, CURR PHARM DESIGN, V18, P2883, DOI 10.2174/138161212800672750; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lee JH, 2012, BIOCHIP J, V6, P362, DOI 10.1007/s13206-012-6408-9; Loven J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 2006, MONOGRAPHS ENZYME IN, V2, P187; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Misra RN, 2004, J MED CHEM, V47, P1719, DOI 10.1021/jm0305568; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Oumata N, 2008, J MED CHEM, V51, P5229, DOI 10.1021/jm800109e; Oumata N, 2009, ORG PROCESS RES DEV, V13, P641, DOI 10.1021/op800284k; Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324; Petrelli A, 2008, CURR MED CHEM, V15, P422; Popowycz F, 2009, J MED CHEM, V52, P655, DOI 10.1021/jm801340z; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; Sharma K, 2009, NAT METHODS, V6, P741, DOI [10.1038/nmeth.1373, 10.1038/NMETH.1373]; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Squires MS, 2010, MOL CANCER THER, V9, P920, DOI 10.1158/1535-7163.MCT-09-1071; Tahtouh T, 2012, J MED CHEM, V55, P9312, DOI 10.1021/jm301034u; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; Tanramluk D, 2009, CHEM BIOL DRUG DES, V74, P16, DOI 10.1111/j.1747-0285.2009.00832.x; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Trova MP, 2009, BIOORG MED CHEM LETT, V19, P6613, DOI 10.1016/j.bmcl.2009.10.011; Trova MP, 2009, BIOORG MED CHEM LETT, V19, P6608, DOI 10.1016/j.bmcl.2009.10.025; Via MC, 2011, KINASE TARGETED THER, P124; Wang LM, 2010, MINI-REV MED CHEM, V10, P1058, DOI 10.2174/1389557511009011058; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Weinmann H, 2005, CHEMBIOCHEM, V6, P455, DOI 10.1002/cbic.200500034; Wesierska-Gadek J, 2011, EXPERT OPIN INV DRUG, V20, P1611, DOI 10.1517/13543784.2011.628985; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	92	50	52	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5675	5687		10.1038/onc.2013.513	http://dx.doi.org/10.1038/onc.2013.513			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24317512	Green Accepted			2022-12-17	WOS:000346089300003
J	Cioce, M; Ganci, F; Canu, V; Sacconi, A; Mori, F; Canino, C; Korita, E; Casini, B; Alessandrini, G; Cambria, A; Carosi, MA; Blandino, R; Panebianco, V; Facciolo, F; Visca, P; Volinia, S; Muti, P; Strano, S; Croce, CM; Pass, HI; Blandino, G				Cioce, M.; Ganci, F.; Canu, V.; Sacconi, A.; Mori, F.; Canino, C.; Korita, E.; Casini, B.; Alessandrini, G.; Cambria, A.; Carosi, M. A.; Blandino, R.; Panebianco, V.; Facciolo, F.; Visca, P.; Volinia, S.; Muti, P.; Strano, S.; Croce, C. M.; Pass, H. I.; Blandino, G.			Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma	ONCOGENE			English	Article						mesothelioma; OCT4; mir-145; mesothelial cysts; chemoresistance; senescence	EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; HETEROCHROMATIN FORMATION; INHIBITS PROLIFERATION; ADENOCARCINOMA CELLS; PLURIPOTENCY FACTORS; LUNG ADENOCARCINOMA; CELLULAR SENESCENCE; GLIOMA-CELLS; OCT4	We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused very low levels in MPM cell lines and specimens. Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via specific binding to its 30-UTR. Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells. In line with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on clonogenicity and replicative senescence. This further supports the relevance of the mir-145-OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced senescence and that induced by the re-expression of mir-145 are discussed.	[Cioce, M.; Canino, C.; Pass, H. I.] NYU, Dept Cardiothorac Surg, Langone Med Ctr, New York, NY USA; [Ganci, F.; Canu, V.; Sacconi, A.; Korita, E.; Blandino, G.] Italian Natl Canc Inst Regina Elena, Translat Oncogen Unit, Rome, Italy; [Mori, F.; Strano, S.] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Rome, Italy; [Casini, B.; Carosi, M. A.; Visca, P.] Italian Natl Canc Inst, Dept Pathol, Rome, Italy; [Alessandrini, G.; Facciolo, F.] Regina Elena Inst Canc Res, Unit Thorac Surg, Rome, Italy; [Cambria, A.; Blandino, R.; Panebianco, V.] San Vincenzo Hosp, Dept Surg Oncol, Taormina, Italy; [Volinia, S.; Croce, C. M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Volinia, S.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Muti, P.] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	New York University; NYU Langone Medical Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; McMaster University	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Translat Oncogen Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	blandino@ifo.it	Strano, Sabrina/K-9654-2016; sacconi, andrea/J-3669-2018; Cioce, Mario/R-9734-2017; Ganci, Federica/K-9857-2016; Canu, Valeria/K-9333-2016; Volinia, Stefano/A-3029-2010; Young, Richard A/F-6495-2012; Muti, Paola/AAD-9108-2020; Visca, Paolo/J-9547-2018; Volinia, Stefano/AAA-9264-2019	sacconi, andrea/0000-0002-8276-0438; Cioce, Mario/0000-0001-8129-6664; Ganci, Federica/0000-0002-8010-2183; Canu, Valeria/0000-0001-9085-7320; Volinia, Stefano/0000-0003-0910-3893; Young, Richard A/0000-0001-8855-8647; Visca, Paolo/0000-0001-8484-6991; Volinia, Stefano/0000-0003-0910-3893; CASINI, BEATRICE/0000-0002-9038-0179; Alessandrini, Gabriele/0000-0002-4380-7627; Facciolo, Francesco/0000-0002-7137-8946; Pass, Harvey/0000-0003-3222-3471; strano, sabrina/0000-0002-6341-4230	INAIL (Italian Workers' Compensation Authority); NATIONAL CANCER INSTITUTE [U01CA152758, P30CA016087] Funding Source: NIH RePORTER	INAIL (Italian Workers' Compensation Authority); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge INAIL (Italian Workers' Compensation Authority) for grant support (to GB).	Adammek M, 2013, FERTIL STERIL, V99, P1346, DOI 10.1016/j.fertnstert.2012.11.055; Basu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052188; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Bonifacio LN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012519; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Calin GA, 2006, LEUKEMIA RES, V30, P653, DOI 10.1016/j.leukres.2005.10.017; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Casarsa C, 2011, CANCER LETT, V302, P136, DOI 10.1016/j.canlet.2011.01.009; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chen Z, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-151; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086; Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597; Du ZH, 2009, GLIA, V57, P724, DOI 10.1002/glia.20800; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Granville L, 2005, ARCH PATHOL LAB MED, V129, P1428; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Hazarika M, 2005, CLIN CANCER RES, V11, P982; Jean D, 2012, ARCH PATHOL LAB MED, V136, P277, DOI 10.5858/arpa.2011-0215-RA; Ji XH, 2008, CURR TOP MICROBIOL, V320, P99; Kai K, 2010, LUNG CANCER, V70, P146, DOI 10.1016/j.lungcan.2010.04.020; Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113; Kaufman AJ, 2008, EXPERT REV ANTICANC, V8, P293, DOI 10.1586/14737140.8.2.293; Klinge CM, 2011, MOL CANCER THER, V10, P2062, DOI 10.1158/1535-7163.MCT-11-0381; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6; Lee HK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054652; Linn Douglas E, 2010, Genes Cancer, V1, P908, DOI 10.1177/1947601910388271; Lu Y, 2013, ONCOL REP, V29, P67, DOI 10.3892/or.2012.2084; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Nakanishi H, 2014, ONCOGENE, V33, P702, DOI 10.1038/onc.2013.13; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Pass HI, 2010, CANCER RES, V70, P1916, DOI 10.1158/0008-5472.CAN-09-3993; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Pignot G, 2013, INT J CANCER, V132, P2479, DOI 10.1002/ijc.27949; Rodier Francis, 2013, Methods Mol Biol, V965, P165, DOI 10.1007/978-1-62703-239-1_10; Romanov VS, 2012, BIOCHEMISTRY-MOSCOW+, V77, P575, DOI 10.1134/S000629791206003X; Rudd RM, 2010, BRIT MED BULL, V93, P105, DOI 10.1093/bmb/ldp047; Samardzija C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-37; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Schramm A, 2010, EUR J CARDIO-THORAC, V37, P566, DOI 10.1016/j.ejcts.2009.08.027; Speranza MC, 2012, ONCOTARGET, V3, P724; Tang GL, 2008, BBA-GENE REGUL MECH, V1779, P655, DOI 10.1016/j.bbagrm.2008.06.006; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Wajapeyee Narendra, 2013, Methods Mol Biol, V965, P373, DOI 10.1007/978-1-62703-239-1_25; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Wu YJ, 2011, CANCER-AM CANCER SOC, V117, P3989, DOI 10.1002/cncr.25944; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang JJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-211	57	50	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5319	5331		10.1038/onc.2013.476	http://dx.doi.org/10.1038/onc.2013.476			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24240684	Green Accepted, Green Submitted			2022-12-17	WOS:000345120600002
J	Huang, Y; Yu, P; Li, W; Ren, G; Roberts, AI; Cao, W; Zhang, X; Su, J; Chen, X; Chen, Q; Shou, P; Xu, C; Du, L; Lin, L; Xie, N; Zhang, L; Wang, Y; Shi, Y				Huang, Y.; Yu, P.; Li, W.; Ren, G.; Roberts, A. I.; Cao, W.; Zhang, X.; Su, J.; Chen, X.; Chen, Q.; Shou, P.; Xu, C.; Du, L.; Lin, L.; Xie, N.; Zhang, L.; Wang, Y.; Shi, Y.			p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation	ONCOGENE			English	Article						mesenchymal stem cells; p53; immunomodulation; iNOS	NITRIC-OXIDE; INFILTRATING LYMPHOCYTES; GENETIC ALTERATIONS; STROMAL CELLS; MUTANT P53; T-CELLS; CANCER; MUTATIONS; CARCINOMA; EXPRESSION	p53 is one of the most studied genes in cancer biology, and mutations in this gene may be predictive for the development of many types of cancer in humans and in animals. However, whether p53 mutations in non-tumor stromal cells can affect tumor development has received very little attention. In this study, we show that B16F0 melanoma cells form much larger tumors in p53-deficient mice than in wild-type mice, indicating a potential role of p53 deficiency in non-tumor cells of the microenvironment. As mesenchymal stem cells (MSCs) are attracted to tumors and form a major component of the tumor microenvironment, we examined the potential role of p53 status in MSCs in tumor development. We found that larger tumors resulted when B16F0 melanoma cells were co-injected with bone marrow MSCs derived from p53-deficient mice rather than MSCs from wild-type mice. Interestingly, this tumor-promoting effect by p53-deficient MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the immune response has a critical role. Indeed, in the presence of inflammatory cytokines, p53-deficient MSCs expressed more inducible nitric oxide synthase (iNOS) and exhibited greater immunosuppressive capacity. Importantly, tumor promotion by p53-deficient MSCs was abolished by administration of S-methylisothiourea, an iNOS inhibitor. Therefore, our data demonstrate that p53 status in tumor stromal cells has a key role in tumor development by modulating immune responses.	[Huang, Y.; Yu, P.; Li, W.; Cao, W.; Zhang, X.; Su, J.; Chen, X.; Chen, Q.; Shou, P.; Xu, C.; Du, L.; Lin, L.; Xie, N.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Shanghai Inst Biol Sci, Inst Hlth Sci,Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China; [Ren, G.; Roberts, A. I.; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Ren, G.; Roberts, A. I.; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Shanghai Inst Biol Sci, Inst Hlth Sci,Key Lab Stem Cell Biol, 225 S Chongqing Rd,1 Bldg, Shanghai 200025, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	Yu, Pengfei/AHC-3497-2022; Li, Wenzhao/H-4235-2016; Xu, Chunliang/R-7065-2018; Shi, Yufang/AAE-4431-2020; Su, Juanjuan/C-4040-2018; Shou, Peishun/J-7985-2014; HUANG, YIN/AAH-6871-2020; Du, Liming/M-8227-2019	Yu, Pengfei/0000-0002-3894-5697; Li, Wenzhao/0000-0002-3878-3333; Shi, Yufang/0000-0001-8964-319X; Su, Juanjuan/0000-0002-6159-1954; Shou, Peishun/0000-0001-7685-7471; HUANG, YIN/0000-0001-5602-9871; Chen, Qing/0000-0002-2088-0370; wang, ying/0000-0002-2571-9367; Du, Liming/0000-0002-0527-3556	Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; Chinese Academy of Sciences [XDA01040107, KSCX1-YW-22-04]; NSFC [31010103908]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences); NSFC(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630), Scientific Innovation Project of the Chinese Academy of Sciences (XDA01040107 and KSCX1-YW-22-04) and International Cooperation and Exchanges NSFC (31010103908). We are also grateful to Yikun Yao (IHS, CAS) for his assistance and suggestions.	Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146; Andersen MH, 2009, J CLIN INVEST, V119, P2245, DOI 10.1172/JCI38739; Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brito C, 1999, J IMMUNOL, V162, P3356; Brown GC, 1997, BIOCHEM SOC T, V25, P901, DOI 10.1042/bst0250901; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1476, DOI 10.4161/onci.21940; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1297, DOI 10.4161/onci.21659; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussain SP, 2008, CANCER RES, V68, P7130, DOI 10.1158/0008-5472.CAN-08-0410; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Matsumoto N, 2003, BRIT J CANCER, V89, P707, DOI 10.1038/sj.bjc.6601141; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Moinfar F, 2000, CANCER RES, V60, P2562; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nakano O, 2001, CANCER RES, V61, P5132; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Paterson RF, 2003, CANCER, V98, P1830, DOI 10.1002/cncr.11747; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Roninson IB, 2003, CANCER RES, V63, P2705; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharma MD, 2009, BLOOD, V113, P6102, DOI 10.1182/blood-2008-12-195354; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Simelyte E, 2005, ARTHRITIS RHEUM-US, V52, P1876, DOI 10.1002/ART.21099; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; STRETCH JR, 1991, CANCER RES, V51, P5976; Studeny M, 2002, CANCER RES, V62, P3603; Suzuki YJ, 2010, ANTIOXID REDOX SIGN, V12, P323, DOI 10.1089/ars.2009.2887; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tuhkanen H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216	77	50	54	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3830	3838		10.1038/onc.2013.355	http://dx.doi.org/10.1038/onc.2013.355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975435				2022-12-17	WOS:000339394100009
J	Lin, MZ; Marzec, KA; Martin, JL; Baxter, RC				Lin, M. Z.; Marzec, K. A.; Martin, J. L.; Baxter, R. C.			The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents	ONCOGENE			English	Article						EGFR; IGFBP-3; breast cancer; DNA-PK; DNA-damaging therapy	DOUBLE-STRAND BREAK; FACTOR RECEPTOR; NUCLEAR EGFR; RECURRENT GLIOBLASTOMA; TUMOR SUPPRESSION; EPITHELIAL-CELLS; LIPID RAFTS; PHASE-II; EXPRESSION; KINASE	Following exposure to radiation and chemotherapeutic agents, the epidermal growth factor receptor (EGFR) can modulate the repair of DNA double-strand breaks (DSB) by forming protein complexes that include the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). This is one of the key mechanism by which tumors become resistant to DNA-damaging therapies. Our previous studies have shown that insulin-like growth factor binding protein-3 (IGFBP-3) is a substrate for DNA-PKcs, and can transactivate EGFR. We therefore questioned whether IGFBP-3 might interact with the EGFR - DNA-PK complex that regulates the DNA damage response. The aim of this study was to delineate the role of IGFBP-3 in the response of breast cancer cells to DSB-inducing chemotherapeutic agents. In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib. Enhanced association among IGFBP-3, EGFR and DNA-PKcs, following the exposure to DNA-damaging drugs was supported by both co-immunoprecipitation analysis and direct visualization by proximity ligation assay. The activation of DNA-PKcs at Ser2056, DNA repair as measured by a nonhomologous end-joining assay, and the increase in EGFR and DNA-PKcs interaction induced by DNA-damaging agents, were all decreased by IGFBP-3 silencing, suggesting that IGFBP-3 has an obligatory role in the DNA repair response to DNA-damaging therapy. In conclusion, IGFBP-3 co-translocation to the nucleus of breast cancer cells and its formation of a complex with DNA-PKcs and EGFR in response to DNA damage shows its potential involvement in the regulation of DNA repair. This suggests the possibility of a therapeutic approach for sensitizing breast cancer to chemo-or radiotherapy by targeting the DNA repair function of IGFBP-3.	[Lin, M. Z.; Marzec, K. A.; Martin, J. L.; Baxter, R. C.] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Hormones & Canc Div, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Baxter, RC (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Hormones & Canc Div, St Leonards, NSW 2065, Australia.	robert.baxter@sydney.edu.au	Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Marzec, Kamila/0000-0002-3051-2205	RCB from the Australian Research Council [DP0984232]	RCB from the Australian Research Council(Australian Research Council)	This work was supported by Grant Number DP0984232 to RCB from the Australian Research Council.	Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Andrin C, 2004, J BIOL CHEM, V279, P25017, DOI 10.1074/jbc.M401805200; Andrin C, 2012, NUCLEUS-PHILA, V3, P384, DOI 10.4161/nucl.21055; Arnes JB, 2009, J CLIN PATHOL, V62, P139, DOI 10.1136/jcp.2008.056291; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; Butt AJ, 2004, J CLIN ENDOCR METAB, V89, P1950, DOI 10.1210/jc.2003-030914; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; Chuang ST, 2008, J UROLOGY, V179, P445, DOI 10.1016/j.juro.2007.09.106; Ciardiello F, 2006, BRIT J CANCER, V94, P1604, DOI 10.1038/sj.bjc.6603141; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Cobb LJ, 2006, CANCER RES, V66, P10878, DOI 10.1158/0008-5472.CAN-06-0585; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; Dennison GJ, 2008, BREAST CANCER RES, V10, pS21, DOI 10.1186/bcr1924; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2010, STRAHLENTHER ONKOL, V186, P1, DOI 10.1007/s00066-009-2026-4; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Dominguez-Brauer C, 2010, CELL CYCLE, V9, P86, DOI 10.4161/cc.9.1.10350; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; GRKOVIC S, 2012, ONCOGENE, DOI DOI 10.1038/0NC.2012.264; Hanzal-Bayer MF, 2007, FEBS LETT, V581, P2098, DOI 10.1016/j.febslet.2007.03.019; Hasty P, 2008, CELL CYCLE, V7, P1139, DOI 10.4161/cc.7.9.5807; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Irwin ME, 2011, J CELL PHYSIOL, V226, P2316, DOI 10.1002/jcp.22570; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kinzler KW, 1997, NATURE, V386, P763; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Martin JL, 2007, ENDOCRINOLOGY, V148, P2532, DOI 10.1210/en.2006-1335; Martin JL, 2009, J BIOL CHEM, V284, P25542, DOI 10.1074/jbc.M109.007120; Martin JL, 2003, J BIOL CHEM, V278, P2969, DOI 10.1074/jbc.M210739200; McIntosh J, 2010, J BIOL CHEM, V285, P38788, DOI 10.1074/jbc.M110.177311; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Micutkova L, 2012, INT J CANCER, V130, P1544, DOI 10.1002/ijc.26149; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; O'Han MK, 2009, GROWTH FACTORS, V27, P394, DOI 10.3109/08977190903185032; Paharkova-Vatchkova V, 2010, ENDOCR-RELAT CANCER, V17, P293, DOI 10.1677/ERC-09-0106; Probst-Hensch NM, 2010, CLIN CANCER RES, V16, P1025, DOI 10.1158/1078-0432.CCR-09-0957; Putti TC, 2005, MODERN PATHOL, V18, P26, DOI 10.1038/modpathol.3800255; Reardon DA, 2010, J NEURO-ONCOL, V96, P219, DOI 10.1007/s11060-009-9950-0; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Rinaldi S, 2006, ENDOCR-RELAT CANCER, V13, P593, DOI 10.1677/erc.1.01150; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; Santer FR, 2006, CANCER RES, V66, P3024, DOI 10.1158/0008-5472.CAN-05-2013; Schedlich LJ, 2003, ENDOCRINOLOGY, V144, P1984, DOI 10.1210/en.2002-220798; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang XQ, 2006, J INVEST DERMATOL, V126, P951, DOI 10.1038/sj.jid.5700282; Williams AC, 2000, CANCER RES, V60, P22; Xi YG, 2006, MOL CANCER THER, V5, P3078, DOI 10.1158/1535-7163.MCT-06-0424; Xue A, 2008, PANCREAS, V36, P160, DOI 10.1097/MPA.0b013e31815750f0; Yarden RI, 2012, INT J BIOCHEM CELL B, V44, P1761, DOI 10.1016/j.biocel.2012.06.026; Yoon JH, 2012, BIOCHEM PHARMACOL, V83, P747, DOI 10.1016/j.bcp.2011.12.029; Yu H, 1996, BRIT J CANCER, V74, P1242, DOI 10.1038/bjc.1996.523	67	50	52	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					85	96		10.1038/onc.2012.538	http://dx.doi.org/10.1038/onc.2012.538			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178489	Bronze			2022-12-17	WOS:000329212000010
J	Savary, K; Caglayan, D; Caja, L; Tzavlaki, K; Bin Nayeem, S; Bergstrom, T; Jiang, Y; Uhrbom, L; Forsberg-Nilsson, K; Westermark, B; Heldin, CH; Ferletta, M; Moustakas, A				Savary, K.; Caglayan, D.; Caja, L.; Tzavlaki, K.; Bin Nayeem, S.; Bergstrom, T.; Jiang, Y.; Uhrbom, L.; Forsberg-Nilsson, K.; Westermark, B.; Heldin, C-H; Ferletta, M.; Moustakas, A.			Snail depletes the tumorigenic potential of glioblastoma	ONCOGENE			English	Article						BMP; glioblastoma multiforme; glioma-initiating cells; invasiveness; snail	GROWTH-FACTOR-BETA; NEURAL STEM-CELLS; HIGH-GRADE GLIOMA; INITIATING CELLS; MESENCHYMAL TRANSITION; RECEPTOR; BRAIN; DIFFERENTIATION; PROGRESSION; SUPPRESSES	Glioblastoma multiforme (GBM) is an aggressive brain malignancy characterized by high heterogeneity and invasiveness. It is increasingly accepted that the refractory feature of GBM to current therapies stems from the existence of few tumorigenic cells that sustain tumor growth and spreading, the so-called glioma-initiating cells (GICs). Previous studies showed that cytokines of the bone morphogenetic protein (BMP) family induce differentiation of the GICs, and thus act as tumor suppressors. Molecular pathways that explain this behavior of BMP cytokines remain largely elusive. Here, we show that BMP signaling induces Smad-dependent expression of the transcriptional regulator Snail in a rapid and sustained manner. Consistent with its already established promigratory function in other cell types, we report that Snail silencing decreases GBM cell migration. Consequently, overexpression of Snail increases GBM invasiveness in a mouse xenograft model. Surprisingly, we found that Snail depletes the GBM capacity to form gliomaspheres in vitro and to grow tumors in vivo, both of which are important features shared by GICs. Thus Snail, acting downstream of BMP signaling, dissociates the invasive capacity of GBM cells from their tumorigenic potential.	[Savary, K.; Caja, L.; Bin Nayeem, S.; Heldin, C-H; Moustakas, A.] Uppsala Univ, Biomed Ctr, Sci Life Lab, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; [Caglayan, D.; Bergstrom, T.; Jiang, Y.; Uhrbom, L.; Forsberg-Nilsson, K.; Westermark, B.; Ferletta, M.] Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden; [Tzavlaki, K.; Moustakas, A.] Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Biomed Ctr, Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University; Uppsala University	Ferletta, M (corresponding author), Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.	Maria.Ferletta@igp.uu.se; Aris.Moustakas@LICR.uu.se	Forsberg-Nilsson, Karin/D-9604-2019; Caja, Laia/J-4618-2019	Forsberg-Nilsson, Karin/0000-0003-0692-6245; Caja, Laia/0000-0002-8786-8763; Westermark, Bengt/0000-0001-7153-5545	Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discovery Program; Goran Gustafsson Foundation; Swedish Cancer Society	Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discovery Program; Goran Gustafsson Foundation; Swedish Cancer Society(Swedish Cancer Society)	We thank: J Grawe, Uppsala University FACS facility; M Kastemar for tumor sampling; I Alafuzoff for tumor pathology; A Ahgren, M Vanlandewijck for tumor immunohistochemistry; H Goransson-Kultima, A Andersson, Uppsala University Microarray facility; A Ostman (Karolinska Institute) for encouragement; M Brenner, A Cano for reagents; K Sampath (Curis, Inc,) for BMP7; T Gahman and A Shiau (Ludwig Institute for Cancer Research, San Diego, USA) for GW6604 and DMH1 inhibitor synthesis; S Thuault, E-J Tan, K Kahata and other group members for discussion. Funding of the authors' work was provided by the Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discovery Program, the Goran Gustafsson Foundation and the Swedish Cancer Society.	Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chirasani SR, 2010, BRAIN, V133, P1961, DOI 10.1093/brain/awq128; de Gouville AC, 2005, BRIT J PHARMACOL, V145, P166, DOI 10.1038/sj.bjp.0706172; Ferletta M, 2011, INT J CANCER, V129, P45, DOI 10.1002/ijc.25647; Franco DL, 2010, J CELL SCI, V123, P3467, DOI 10.1242/jcs.068692; Fukuda S, 2007, MOL CELL BIOL, V27, P4931, DOI 10.1128/MCB.02435-06; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kim MY, 2010, NEUROSCIENCE, V170, P8, DOI 10.1016/j.neuroscience.2010.07.020; Kowanetz M, 2008, J CELL BIOL, V182, P655, DOI 10.1083/jcb.200804107; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; Maire CL, 2010, STEM CELLS, V28, P1611, DOI 10.1002/stem.480; McLendon RE, 2011, J ONCOL, V2011; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Myung J, 2010, NEUROPATHOLOGY, V30, P224, DOI 10.1111/j.1440-1789.2009.01072.x; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Rich JN, 2003, FRONT BIOSCI-LANDMRK, V8, pE245, DOI 10.2741/992; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Westermark Bengt, 1995, Current Opinion in Oncology, V7, P220, DOI 10.1097/00001622-199505000-00005; Yamada N, 1996, BRIT J CANCER, V73, P624, DOI 10.1038/bjc.1996.108; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301	45	50	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5409	5420		10.1038/onc.2013.67	http://dx.doi.org/10.1038/onc.2013.67			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23524585	hybrid, Green Published			2022-12-17	WOS:000327177600004
J	Kliese, N; Gobrecht, P; Pachow, D; Andrae, N; Wilisch-Neumann, A; Kirches, E; Riek-Burchardt, M; Angenstein, F; Reifenberger, G; Riemenschneider, MJ; Meese, E; Panayotova-Dimitrova, D; Gutmann, DH; Mawrin, C				Kliese, N.; Gobrecht, P.; Pachow, D.; Andrae, N.; Wilisch-Neumann, A.; Kirches, E.; Riek-Burchardt, M.; Angenstein, F.; Reifenberger, G.; Riemenschneider, M. J.; Meese, E.; Panayotova-Dimitrova, D.; Gutmann, D. H.; Mawrin, C.			miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells	ONCOGENE			English	Article						miRNA; meningioma; invasion; collagen type 5	EXPRESSION; GENE; GROWTH; BRAIN; LINE; ESTABLISHMENT; MICRORNA-145; INVASIVENESS; MUTATIONS; TARGET	Meningiomas are frequent, mostly benign intracranial or spinal tumors. A small subset of meningiomas is characterized by histological features of atypia or anaplasia that are associated with more aggressive biological behavior resulting in increased morbidity and mortality. Infiltration into the adjacent brain tissue is a major factor linked to higher recurrence rates. The molecular mechanisms of progression, including brain invasion are still poorly understood. We have studied the role of micro-RNA 145 (miR-145) in meningiomas and detected significantly reduced miR-145 expression in atypical and anaplastic tumors as compared with benign meningiomas. Overexpression of miR-145 in IOMM-Lee meningioma cells resulted in reduced proliferation, increased sensitivity to apoptosis, reduced anchorage-independent growth and reduction of orthotopic tumor growth in nude mice as compared with control cells. Moreover, meningioma cells with high miR-145 levels had impaired migratory and invasive potential in vitro and in vivo. PCR-array studies of miR145-overexpressing cells suggested that collagen type V alpha (COL5A1) expression is downregulated by miR-145 overexpression. Accordingly, COL5A1 expression was significantly upregulated in atypical and anaplastic meningiomas. Collectively, our data indicate an important anti-migratory and anti-proliferative function of miR-145 in meningiomas.	[Kliese, N.; Gobrecht, P.; Pachow, D.; Andrae, N.; Wilisch-Neumann, A.; Kirches, E.; Mawrin, C.] Otto Von Guericke Univ, Inst Neuropathol, D-39120 Magdeburg, Germany; [Riek-Burchardt, M.] Leibniz Inst Neurobiol, Project Grp Neuropharmacol, Magdeburg, Germany; [Angenstein, F.] Leibniz Inst Neurobiol, Lab Noninvas Anim Imaging, Magdeburg, Germany; [Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Riemenschneider, M. J.] Regensburg Univ Hosp, Dept Neuropathol, Regensburg, Germany; [Meese, E.] Univ Saarland, Dept Human Genet, Homburg, Germany; [Panayotova-Dimitrova, D.] Heidelberg Univ, Dept Dermatol, Heidelberg, Germany; [Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Otto von Guericke University; Leibniz Institut fur Neurobiologie (LIN); Leibniz Institut fur Neurobiologie (LIN); Heinrich Heine University Dusseldorf; University of Regensburg; Saarland University; Ruprecht Karls University Heidelberg; Washington University (WUSTL)	Mawrin, C (corresponding author), Otto Von Guericke Univ, Inst Neuropathol, Leipziger St 44, D-39120 Magdeburg, Germany.	christian.mawrin@med.ovgu.de	Meese, Eckart Ulrich/ABD-1983-2021; Reifenberger, Guido/AAE-3599-2019	Gutmann, David/0000-0002-3127-5045	Wilhelm Sander-Stiftung [2010.017.1]	Wilhelm Sander-Stiftung	The skillful technical work of Ines Schellhase, Ines Meyer and Sandra Hartmann is highly appreciated. We thank Professor Till Acker (University of Giessen) for help with the morphometric quantification of tumor infiltration in mice and Grit Werner for her help with MR imaging. The work was supported by the Wilhelm Sander-Stiftung (grant #2010.017.1).	BLACK PM, 1993, NEUROSURGERY, V32, P643, DOI 10.1227/00006123-199304000-00023; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; DePaepe A, 1997, AM J HUM GENET, V60, P547; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Haase D, 2010, NEURO-ONCOLOGY, V12, P844, DOI 10.1093/neuonc/noq004; Kilic T, 2002, NEUROSURGERY, V51, P183, DOI 10.1227/01.NEU.0000017466.25827.18; Kirches E, 2011, LAB INVEST, V91, P1766, DOI 10.1038/labinvest.2011.130; Koo S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-143; La Rocca G, 2009, CELL CYCLE, V8, P2255, DOI 10.4161/cc.8.14.9026; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; Mawrin C, 2010, BRAIN PATHOL, V20, P200, DOI 10.1111/j.1750-3639.2009.00267.x; NITTA H, 1990, HISTOL HISTOPATHOL, V5, P267; Nordqvist ACS, 2001, J NEUROSURG, V95, P839, DOI 10.3171/jns.2001.95.5.0839; Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M; Puttmann S, 2005, LAB INVEST, V85, P1163, DOI 10.1038/labinvest.3700307; Ragel BT, 2008, SURG NEUROL, V70, P295, DOI 10.1016/j.surneu.2007.06.031; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Schittenhelm J, 2006, NEUROPATH APPL NEURO, V32, P525, DOI 10.1111/j.1365-2990.2006.00761.x; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Stuart JE, 2011, J NEUROPATH EXP NEUR, V70, P1, DOI 10.1097/NEN.0b013e3182018f1c; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Symoens S, 2009, HUM MUTAT, V30, pE395, DOI 10.1002/humu.20887; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TANAKA K, 1989, CANCER, V64, P2243, DOI 10.1002/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S; Watson MA, 2002, AM J PATHOL, V161, P665, DOI 10.1016/S0002-9440(10)64222-8; Wenstrup RJ, 2006, J BIOL CHEM, V281, P12888, DOI 10.1074/jbc.M511528200; Zaman MS, 2010, BRIT J CANCER, V103, P256, DOI 10.1038/sj.bjc.6605742	30	50	52	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4712	4720		10.1038/onc.2012.468	http://dx.doi.org/10.1038/onc.2012.468			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108408	hybrid			2022-12-17	WOS:000325072200013
J	Bhattacharya, S; HuangFu, WC; Dong, G; Qian, J; Baker, DP; Karar, J; Koumenis, C; Diehl, JA; Fuchs, SY				Bhattacharya, S.; HuangFu, W-C; Dong, G.; Qian, J.; Baker, D. P.; Karar, J.; Koumenis, C.; Diehl, J. A.; Fuchs, S. Y.			Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses	ONCOGENE			English	Article						interferon; tumor microenvironment; integrated stress response; PERK; GCN2; IFNAR1	I-INTERFERON; PROTEIN-KINASE; DOWN-REGULATION; IFNAR1 CHAIN; ALPHA; HYPOXIA; PERK; PHOSPHORYLATION; DEGRADATION; CELLS	Viral and pharmacological inducers of protein kinase RNA-activated (PKR)-like ER kinase (PERK) were shown to accelerate the phosphorylation-dependent degradation of the IFNAR1 chain of the Type 1 interferon (IFN) receptor and to limit cell sensitivity to IFN. Here we report that hypoxia can elicit these effects in a PERK-dependent manner. The altered fate of IFNAR1 affected by signaling downstream of PERK depends on phosphorylation of eIF2 alpha (eukaryotic translational initiation factor 2-alpha) and ensuing activation of p38 alpha kinase. Activators of other eIF2 alpha kinases such as PKR or GCN2 (general control nonrepressed-2) are also capable of eliminating IFNAR1 and blunting IFN responses. Modulation of constitutive PKR activity in human breast cancer cells stabilizes IFNAR1 and sensitizes these cells to IFNAR1-dependent anti-tumorigenic effects. Although downregulation of IFNAR1 and impaired IFNAR1 signaling can be elicited in response to amino-acid deficit, the knockdown of GCN2 in melanoma cells reverses these phenotypes. We propose that, in cancer cells and the tumor microenvironment, activation of diverse eIF2 alpha kinases followed by IFNAR1 downregulation enables multiple cellular components of tumor tissue to evade the direct and indirect anti-tumorigenic effects of Type 1 IFN.	[Bhattacharya, S.; HuangFu, W-C; Dong, G.; Qian, J.; Fuchs, S. Y.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Bhattacharya, S.; HuangFu, W-C; Dong, G.; Qian, J.; Fuchs, S. Y.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Baker, D. P.] Biogen Idec Inc, Cambridge, MA USA; [Karar, J.; Koumenis, C.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Biogen; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 380 S Univ Ave,Hill 316, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu	Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	'Training in Tumor Virology' Grant [2-T32-CA-557726-06]; NIH [CA92900, CA142425, CA94214, CA104838]; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA094214, R01CA142425, R01CA092900, P01CA104838] Funding Source: NIH RePORTER	'Training in Tumor Virology' Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Herlyn, R Kaufman, A Koromilas, A Nebreda, D Ron and Z Ronai for reagents, Dr Yong Zhang for technical help, and the members of Fuchs, Diehl and Koumenis labs for discussion. The support to SB from the 'Training in Tumor Virology' Grant 2-T32-CA-557726-06 is greatly appreciated. This work was supported by the NIH Grants CA92900 and CA142425 (to SYF), CA94214 (to CK), CA104838 (to JAD) and by a grant with the Pennsylvania Department of Health (to JAD, CK, and SYF). The Department specifically disclaims responsibility for any analyses, interpretation or conclusions.	Bhattacharya S, 2011, BLOOD, V118, P4179, DOI 10.1182/blood-2010-12-325373; Bhattacharya S, 2011, J BIOL CHEM, V286, P22069, DOI 10.1074/jbc.M111.238766; Bhattacharya S, 2010, J BIOL CHEM, V285, P2318, DOI 10.1074/jbc.M109.071498; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Blalock WL, 2010, J CELL PHYSIOL, V223, P572, DOI 10.1002/jcp.22092; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Bobrovnikova-Marjon E, 2012, MOL CELL BIOL, V32, P2268, DOI 10.1128/MCB.00063-12; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Brassard DL, 2002, J LEUKOCYTE BIOL, V71, P565; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Diehl JA, 2011, GASTROENTEROLOGY, V141, P38, DOI 10.1053/j.gastro.2011.05.018; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Eggermont AMM, 2001, EUR J CANCER, V37, P2147, DOI 10.1016/S0959-8049(01)00272-6; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Folkman J, 1992, Semin Cancer Biol, V3, P89; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Hamanaka RB, 2009, ONCOGENE, V28, P910, DOI 10.1038/onc.2008.428; HuangFu WC, 2012, ONCOGENE, V31, P161, DOI 10.1038/onc.2011.221; Huangfu Wei-Chun, 2010, Genes Cancer, V1, P725, DOI 10.1177/1947601910382901; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; Li YZ, 2004, ARCH IMMUNOL THER EX, V52, P156; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Liu JH, 2009, MOL CELL BIOL, V29, P6401, DOI 10.1128/MCB.00478-09; Liu JH, 2009, CELL HOST MICROBE, V5, P72, DOI 10.1016/j.chom.2008.11.008; Liu Y, 2010, NEOPLASIA, V12, P61, DOI 10.1593/neo.91354; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Noman MZ, 2011, CRIT REV IMMUNOL, V31, P357, DOI 10.1615/CritRevImmunol.v31.i5.10; Nussbaum JM, 2003, CANCER LETT, V196, P207, DOI 10.1016/S0304-3835(03)00276-3; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PFEFFER LM, 1980, J CELL BIOL, V85, P9, DOI 10.1083/jcb.85.1.9; Pindel A, 2011, J INTERF CYTOK RES, V31, P59, DOI 10.1089/jir.2010.0099; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qian J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002065; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Ye JB, 2009, CURR MOL MED, V9, P411, DOI 10.2174/156652409788167096; Zheng H, 2011, BLOOD, V118, P4003, DOI 10.1182/blood-2011-06-359745; Zheng H, 2011, MOL CELL BIOL, V31, P710, DOI 10.1128/MCB.01154-10	49	50	50	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4214	4221		10.1038/onc.2012.439	http://dx.doi.org/10.1038/onc.2012.439			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045272	Green Accepted			2022-12-17	WOS:000324168000003
J	Herranz, D; Maraver, A; Canamero, M; Gomez-Lopez, G; Inglada-Perez, L; Robledo, M; Castelblanco, E; Matias-Guiu, X; Serrano, M				Herranz, D.; Maraver, A.; Canamero, M.; Gomez-Lopez, G.; Inglada-Perez, L.; Robledo, M.; Castelblanco, E.; Matias-Guiu, X.; Serrano, M.			SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency	ONCOGENE			English	Article						SIRT1; c-MYC; PTEN; thyroid cancer; prostate cancer	C-MYC; ONCOPROTEIN; BIOGENESIS; MUTATION; MOUSE; P53	Current genetic evidence in mice indicates that SIRT1 has potent tumor suppressor activity in a variety of cancer models, with no evidence yet for SIRT1 oncogenic activity in vivo. We report here that transgenic Sirt1 expression is oncogenic in murine thyroid and prostate carcinogenesis initiated by Pten-deficiency. Based on mRNA expression analyses of pre-tumoral murine thyroids, we find that SIRT1 increases c-MYC transcriptional programs. Moreover, we show higher c-MYC protein levels in murine thyroid cancers from Sirt1 transgenic mice. Similarly, SIRT1 is overexpressed in human thyroid cancers and it is positively correlated with c-MYC protein levels. Finally, we show in cultured thyroid cancer cells that SIRT1 stabilizes c-MYC protein. These results implicate SIRT1 as a new candidate target for the treatment of thyroid carcinomas.	[Herranz, D.; Maraver, A.; Serrano, M.] Spanish Natl Canc Res Ctr CNIO, Tumor Suppress Grp, E-28029 Madrid, Spain; [Canamero, M.] Spanish Natl Canc Res Ctr CNIO, Comparat Pathol Unit, E-28029 Madrid, Spain; [Gomez-Lopez, G.] Spanish Natl Canc Res Ctr CNIO, Bioinformat Unit, E-28029 Madrid, Spain; [Inglada-Perez, L.; Robledo, M.] Spanish Natl Canc Res Ctr CNIO, CIBERER, E-28029 Madrid, Spain; [Inglada-Perez, L.; Robledo, M.] Spanish Natl Canc Res Ctr CNIO, Hereditary Endocrine Canc Grp, E-28029 Madrid, Spain; [Castelblanco, E.; Matias-Guiu, X.] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Irblleida, Lleida, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Universitat de Lleida; University Hospital Arnau de Vilanova	Serrano, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Robledo, Mercedes/O-2230-2013; Inglada-Perez, Lucia/Z-3020-2019; Maraver, Antonio/G-2666-2015; Gomez-Lopez, Gonzalo/D-9123-2016; inglada-perez, lucia/H-5378-2015; matias-guiu, xavier/C-3039-2009; Herranz, Daniel/L-6986-2017; Serrano, Manuel/H-2634-2015; /AAI-3238-2021; E, Esmeralda Castelblanco/A-7588-2011	Robledo, Mercedes/0000-0001-6256-5902; Gomez-Lopez, Gonzalo/0000-0002-4146-0551; matias-guiu, xavier/0000-0002-7201-6605; Herranz, Daniel/0000-0003-1768-5969; Serrano, Manuel/0000-0001-7177-9312; E, Esmeralda Castelblanco/0000-0002-2061-6270; INGLADA, LUCIA/0000-0001-9523-2717; Inglada-Perez, Lucia/0000-0001-9814-4368; Maraver, Antonio/0000-0002-5527-5680	CNIO; Spanish Ministry of Science (SAF); Spanish Ministry of Science (CONSOLIDER); European Research Council (ERC); 'Marcelino Botin' Foundation; AXA Foundation; 'Ramon Areces' Foundation; Spanish Ministry of Health; CIBERER;  [RD09/0076/00059]	CNIO; Spanish Ministry of Science (SAF)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Science (CONSOLIDER)(Ministry of Science and Innovation, Spain (MICINN)); European Research Council (ERC)(European Research Council (ERC)European Commission); 'Marcelino Botin' Foundation; AXA Foundation; 'Ramon Areces' Foundation; Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); CIBERER; 	We thank Maribel Munoz and Gema Iglesias for excellent mouse handling. Work in the laboratory of MS is funded by the CNIO and by grants from the Spanish Ministry of Science (SAF and CONSOLIDER), the European Research Council (ERC Advanced Grant), the 'Marcelino Botin' Foundation, the AXA Foundation and the 'Ramon Areces' Foundation. AM is funded by a 'Miguel Servet' grant from the Spanish Ministry of Health. LI-P is supported by CIBERER. Human tumor samples were obtained with the support of Xarxa Catalana de Bancs de Tumors, the Tumor Bank Platform of RTICC, and project RD09/0076/00059.	Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chen X, 2008, COLD SH Q B, V73, P203, DOI 10.1101/sqb.2008.73.026; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Herranz D, 2010, NAT REV CANCER, V10, P819, DOI 10.1038/nrc2962; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Lin CJ, 2009, CANCER RES, V69, P7491, DOI 10.1158/0008-5472.CAN-09-0813; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; ROMANO MI, 1993, HORM RES, V39, P161, DOI 10.1159/000182718; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Smith KN, 2010, CELL STEM CELL, V7, P343, DOI 10.1016/j.stem.2010.06.023; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167	25	50	52	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4052	4056		10.1038/onc.2012.407	http://dx.doi.org/10.1038/onc.2012.407			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986535				2022-12-17	WOS:000323748100014
J	Hu, Q; Lu, YY; Noh, H; Hong, S; Dong, Z; Ding, HF; Su, SB; Huang, S				Hu, Q.; Lu, Y-Y; Noh, H.; Hong, S.; Dong, Z.; Ding, H-F; Su, S-B; Huang, S.			Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression	ONCOGENE			English	Article						uPA; ILF3; transcription; miRNA	MESSENGER-RNA STABILITY; GENE-EXPRESSION; SIGNALING PATHWAYS; NUCLEAR FACTOR; KAPPA-B; CANCER; RECEPTOR; NF90; TRANSCRIPTION; METASTASIS	Sustained urokinase-type plasminogen activator (uPA) expression is detected in aggressive breast tumors. Although uPA can be transiently upregulated by diverse extracellular stimuli, sustained, but not transiently upregulated uPA expression contributes to breast cancer invasion/metastasis. Unfortunately, how sustained uPA expression is achieved in invasive/metastatic breast cancer cells is unknown. Here, we show that sustained and transiently upregulated uPA expression are regulated by distinct mechanisms. Using a collection of transcription factor-targeted small-interfering RNAs, we discovered that interleukin enhancer-binding factor 3 (ILF3) is required for sustained uPA expression. Two discrete mechanisms mediate ILF3 action. The first is that ILF3 activates uPA transcription by binding to the CTGTT sequence in the nucleotides - 1004B similar to - 1000 of the uPA promoter; the second is that ILF3 inhibits the processing of uPA mRNA-targeting primary microRNAs (pri-miRNAs). Knockdown of ILF3 led to significant reduction in in vitro cell growth/migration/invasion and in vivo breast tumor development. Importantly, immunohistochemistry (IHC) showed that nuclear ILF3, but not cytoplasmic ILF3 staining correlates with elevated uPA level and higher grades of human breast tumor specimens. Nuclear localization of ILF3 highlights the role of ILF3 in sustained uPA expression as a transcription activator and pri-miRNA processing blocker. In conclusion, this study shows that ILF3 promotes breast tumorigenicity by regulating sustained uPA expression.	[Hu, Q.; Noh, H.; Hong, S.; Huang, S.] Georgia Hlth Sci Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Lu, Y-Y; Su, S-B; Huang, S.] Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China; [Dong, Z.] Georgia Hlth Sci Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; [Ding, H-F] Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA; [Ding, H-F; Huang, S.] Georgia Hlth Sci Univ, Ctr Canc, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Shanghai University of Traditional Chinese Medicine; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Huang, S (corresponding author), Georgia Hlth Sci Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	shuang@georgiahealth.edu		Ding, Han-Fei/0000-0001-5702-3439	NIH [CA093926]; NSF of China [81 073 134]; Shanghai Eastern Scholar Fund; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF of China(National Natural Science Foundation of China (NSFC)); Shanghai Eastern Scholar Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by funding from NIH CA093926 (SH), NSF of China Fund 81 073 134 (SBS) and Shanghai Eastern Scholar Fund (SH). We would like to thank Dr Michael Mathews for providing ILF3 splicing isoform constructs.	Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; Annecke K, 2008, ADV CLIN CHEM, V45, P31, DOI 10.1016/S0065-2423(07)00002-9; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Crippa MP, 2007, INT J BIOCHEM CELL B, V39, P690, DOI 10.1016/j.biocel.2006.10.008; Das R, 2004, J BIOL CHEM, V279, P11051, DOI 10.1074/jbc.M310256200; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Dunn SE, 2001, CANCER RES, V61, P1367; Foekens JA, 2000, CANCER RES, V60, P636; Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08; Guo NL, 2008, CLIN CANCER RES, V14, P8213, DOI 10.1158/1078-0432.CCR-08-0095; Guo Y, 2012, ONCOL REP, V27, P286, DOI 10.3892/or.2011.1483; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Harbeck Nadia, 2004, Clin Breast Cancer, V5, P348, DOI 10.3816/CBC.2004.n.040; HUANG SA, 1994, J BIOL CHEM, V269, P28764; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; KAO PN, 1994, J BIOL CHEM, V269, P20691; Kiesler P, 2010, J BIOL CHEM, V285, P8256, DOI 10.1074/jbc.M109.041004; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Li Y, 2008, MOL CELL BIOL, V28, P4275, DOI 10.1128/MCB.00369-08; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Mahanivong C, 2007, MOL CARCINOGEN, V46, P165, DOI 10.1002/mc.20249; Mazumdar A, 2001, CANCER RES, V61, P400; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Noh Hyangsoon, 2011, Genes Cancer, V2, P140, DOI 10.1177/1947601911408888; Pei Y, 2008, J IMMUNOL, V180, P222, DOI 10.4049/jimmunol.180.1.222; PRICE JE, 1990, CANCER RES, V50, P717; Reichman TW, 2003, J MOL BIOL, V332, P85, DOI 10.1016/S0022-2836(03)00885-4; Sakamoto S, 2009, MOL CELL BIOL, V29, P3754, DOI 10.1128/MCB.01836-08; Shi LF, 2007, J EXP MED, V204, P971, DOI 10.1084/jem.20052078; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; Vumbaca F, 2008, MOL CELL BIOL, V28, P772, DOI 10.1128/MCB.02078-06; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9	46	50	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3933	3943		10.1038/onc.2012.414	http://dx.doi.org/10.1038/onc.2012.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986534	Green Accepted			2022-12-17	WOS:000323748100002
J	Pust, S; Klokk, TI; Musa, N; Jenstad, M; Risberg, B; Erikstein, B; Tcatchoff, L; Liestol, K; Danielsen, HE; van Deurs, B; Sandvig, K				Pust, S.; Klokk, T. I.; Musa, N.; Jenstad, M.; Risberg, B.; Erikstein, B.; Tcatchoff, L.; Liestol, K.; Danielsen, H. E.; van Deurs, B.; Sandvig, K.			Flotillins as regulators of ErbB2 levels in breast cancer	ONCOGENE			English	Article						ErbB2 receptor tyrosine kinase; flotillin; breast cancer; endocytosis; downregulation	SIGNALING NETWORK; EPITHELIAL-CELLS; MAMMALIAN-CELLS; UP-REGULATION; IN-SITU; PHASE-I; RECEPTOR; KINASE; PROTEINS; GELDANAMYCIN	Amplification and overexpression of the receptor tyrosine kinase ErbB2 occur in up to 30% of human breast cancers, and high ErbB2 levels are correlated with poor prognosis for breast cancer patients. In contrast to the epithelial growth factor receptor (ErbB1), ErbB2 is not downregulated by ligand-induced mechanisms. Here we show that flotillins are involved in the stabilization of ErbB2 at the plasma membrane. In SKBR3 breast cancer cells and breast cancer tissue, a positive correlation between flotillin and ErbB2 expression levels could be demonstrated. Moreover, the tissue microarray analyses of biopsies from 194 patients diagnosed with carcinomas of the breast showed that flotillin-2 emerged as a potential predictor of prognosis in breast cancer. Depletion of flotillin-1 and flotillin-2 leads to internalization and degradation of ErbB2. Furthermore, flotillin-1 and -2 were found to be in a molecular complex with ErbB2 and Hsp90. The depletion of one of these proteins results in disruption of this complex, followed by destabilization of ErbB2 at the membrane, and its internalization and degradation. As a consequence, ErbB2-triggered downstream signalling is inhibited. Our data demonstrate a novel mechanism for interfering with ErbB2 signalling, which potentially can have clinical impact.	[Pust, S.; Klokk, T. I.; Musa, N.; Tcatchoff, L.; Sandvig, K.] Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway; [Pust, S.; Klokk, T. I.; Musa, N.; Jenstad, M.; Risberg, B.; Tcatchoff, L.; Liestol, K.; Danielsen, H. E.; Sandvig, K.] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway; [Jenstad, M.; Risberg, B.; Danielsen, H. E.] Oslo Univ Hosp, Inst Med Informat, N-0379 Oslo, Norway; [Risberg, B.] Oslo Univ Hosp, Dept Pathol, N-0379 Oslo, Norway; [Erikstein, B.] Oslo Univ Hosp, N-0379 Oslo, Norway; [van Deurs, B.] Univ Copenhagen, Fac Hlth Sci, Dept Cellular & Mol Med, Copenhagen, Denmark; [Sandvig, K.] Univ Oslo, Fac Math & Nat Sci, Dept Mol Biosci, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Copenhagen; University of Oslo	Sandvig, K (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway.	ksandvig@radium.uio.no	Pust, Sascha/M-3201-2013; Danielsen, Havard e/A-7540-2014; Danielsen, Havard/AAK-8489-2020	Pust, Sascha/0000-0002-0178-2206; Asp, Nagham Theres/0000-0002-2143-1470	South-Eastern Norway Regional Health Authority (Helse Sor-Ost); Norwegian Research Council; Norwegian Cancer Society	South-Eastern Norway Regional Health Authority (Helse Sor-Ost); Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Cancer Society(Norwegian Cancer Society)	We thank Wanja Kildal, Anne-Mari Gjestvang Pedersen and Anne Engen for their expert technical assistance. We thank Gisou van der Goot (EPFL, Lausanne, Switzerland) for providing the polyclonal flotillin-1 antibody used in confocal microscopy. We thank Ornulf Borgan for assistance with the analysis of the results from the breast tissue samples. We thank the South-Eastern Norway Regional Health Authority (Helse Sor-Ost), the Norwegian Research Council and the Norwegian Cancer Society for financial support.	Allred DC, 1998, MODERN PATHOL, V11, P155; Amaddii M, 2012, J BIOL CHEM, V287, P7265, DOI 10.1074/jbc.M111.287599; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Baulida J, 1996, J BIOL CHEM, V271, P5251; Cicenas J, 2006, EUR J CANCER, V42, P636, DOI 10.1016/j.ejca.2005.11.012; Citri A, 2004, CELL CYCLE, V3, P51; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Gomez V, 2010, J BIOL CHEM, V285, P20683, DOI 10.1074/jbc.M110.130591; Hazarika P, 2004, CANCER RES, V64, P7361, DOI 10.1158/0008-5472.CAN-04-0823; Jones KL, 2009, LANCET ONCOL, V10, P1179, DOI 10.1016/S1470-2045(09)70315-8; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Lerdrup M, 2006, J CELL SCI, V119, P85, DOI 10.1242/jcs.02707; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Modi S, 2006, CLIN BREAST CANCER, V7, P270, DOI 10.3816/CBC.2006.n.040; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Pust S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008844; Saslowsky DE, 2010, J CLIN INVEST, V120, P4399, DOI 10.1172/JCI42958; Schulte T, 1997, DEVELOPMENT, V124, P577; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Spears M, 2012, BREAST CANCER RES TR, V132, P463, DOI 10.1007/s10549-011-1606-z; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Tomasovic A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029739; Vassilieva EV, 2009, BIOCHEM BIOPH RES CO, V379, P460, DOI 10.1016/j.bbrc.2008.12.118; Wu YY, 2010, CANCER RES, V70, P5475, DOI 10.1158/0008-5472.CAN-10-0176; Wu YY, 1999, INT J ONCOL, V14, P1021; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-479; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	43	50	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3443	3451		10.1038/onc.2012.357	http://dx.doi.org/10.1038/onc.2012.357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22869152				2022-12-17	WOS:000322014900005
J	Gopisetty, G; Xu, J; Sampath, D; Colman, H; Puduvalli, VK				Gopisetty, G.; Xu, J.; Sampath, D.; Colman, H.; Puduvalli, V. K.			Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation	ONCOGENE			English	Article						CD133; glioma Stem Cell; Sp1; Myc; promoter methylation; epigenetic regulation	DNA METHYLATION; CPG METHYLATION; HEMATOPOIETIC STEM; CHROMOSOMAL-PROTEIN; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; GENE-EXPRESSION; BINDING-SITES; C-MYC; TRANSCRIPTION	Tumor stem cells, postulated to be the source cells for malignancies, have been identified in several cancers using cell-surface expression of markers including CD133, a pentaspan membrane protein. CD133+ve cells form neurospheres, exhibit self-renewal and differentiation, and are tumorigenic. However, despite its association with stem cells, a causal relationship of CD133 to tumorigenesis remains to be defined. Hypothesizing that specific epigenetic and transcription factors implicated in driving the stem cell state may concurrently regulate CD133 expression in stem cells, we analyzed the structure and regulation of CD133 promoter in glioma stem cells and glioma cell lines. Initially, a minimal promoter region was identified by analyzing the activity of CD133 promoter-driven luciferase-expressing 5'-and 3'-deletion-constructs upstream of the transcription start site. This region contained a CpG island that was hypermethylated in CD133-ve glioma stem cells (GSC) and glioma cells but unmethylated in CD133+ve ones. Of several predicted TF-binding sites in this region, the role of tandem Sp1 (-242 and -221) and two Myc (-541 and -25)-binding sites were examined. Overexpression of Sp1 or Myc increased CD133 minimal promoter-driven luciferase activity and CD133 levels in GSC and in glioma cell line. Mithramycin, a Sp1 inhibitor, decreased minimal promoter activity and downregulated CD133 levels in GSC. Gel-shift assays demonstrated direct binding of Sp1 to their predicted sites that was competitively inhibited by oligonucleotide-binding-site sequences and supershifted by anti-Sp1 confirming the interaction. Sp1 and Myc-antibody chromatin immunoprecipitation (ChIP) analysis in GSC showed enrichment of regions with Sp1 and Myc-binding sites. In CD133-ve cells, ChIP analysis showed binding of the methyl-DNA-binding proteins, MBD1, MBD2 and MeCP2 to the methylated CpG island and repression of transcription. These results demonstrate that Sp1 and Myc regulate CD133 transcription in GSC and that promoter methylation and methyl-DNA-binding proteins cause repression of CD133 by excluding transcription-factor binding.	[Gopisetty, G.; Xu, J.; Colman, H.; Puduvalli, V. K.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77035 USA; [Sampath, D.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77035 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Puduvalli, VK (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 431, Houston, TX 77035 USA.	vpuduval@mdanderson.org	Sampath, Deepa/J-3298-2016; Colman, Howard/L-5433-2019; Sampath, Deepa/T-5069-2019; Puduvalli, Vinay K/A-2411-2016; Gopisetty, Gopal/ABB-6470-2020	Sampath, Deepa/0000-0002-4366-8436	Gregory Jungeblut Brain Tumor Research Fund; Dr Marnie Rose Foundation; Chuoke Brain Tumor Fund; NATIONAL CANCER INSTITUTE [P30CA016672, K24CA160777] Funding Source: NIH RePORTER	Gregory Jungeblut Brain Tumor Research Fund; Dr Marnie Rose Foundation; Chuoke Brain Tumor Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the Gregory Jungeblut Brain Tumor Research Fund, The Dr Marnie Rose Foundation and the Chuoke Brain Tumor Fund for providing funding support for this project.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BEDNARIK DP, 1991, NEW BIOL, V3, P969; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049; Cheng LP, 2004, FEBS LETT, V565, P195, DOI 10.1016/j.febslet.2004.03.097; Clouaire T, 2010, NUCLEIC ACIDS RES, V38, P4620, DOI 10.1093/nar/gkq228; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Elsaba TMA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010714; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marsden CG, 2009, METHODS MOL BIOL, V590, P363, DOI 10.1007/978-1-60327-378-7_23; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Neuzil J, 2007, BIOCHEM BIOPH RES CO, V355, P855, DOI 10.1016/j.bbrc.2007.01.159; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Parisi F, 2007, NUCLEIC ACIDS RES, V35, P1098, DOI 10.1093/nar/gkl1157; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Shmelkov SV, 2005, INT J BIOCHEM CELL B, V37, P715, DOI 10.1016/j.biocel.2004.08.010; Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Weigmann A, 1997, P NATL ACAD SCI USA, V94, P12425, DOI 10.1073/pnas.94.23.12425; Wu DY, 2006, CELL RES, V16, P319, DOI 10.1038/sj.cr.7310040; Yi JM, 2008, CANCER RES, V68, P8094, DOI 10.1158/0008-5472.CAN-07-6208; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	50	50	52	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3119	3129		10.1038/onc.2012.331	http://dx.doi.org/10.1038/onc.2012.331			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22945648	Green Accepted			2022-12-17	WOS:000321004600002
J	Jafarnejad, SM; Ardekani, GS; Ghaffari, M; Martinka, M; Li, G				Jafarnejad, S. M.; Ardekani, G. S.; Ghaffari, M.; Martinka, M.; Li, G.			Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion	ONCOGENE			English	Article						Sox4; Dicer; melanoma; invasion; miRNA	SOX4 EXPRESSION; PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTOR; METASTASIS; APOPTOSIS; GENE; IDENTIFICATION; MIGRATION; BIOLOGY; DROSHA	We previously reported reduced expression of Sox4 in metastatic melanoma and its role in suppression of cell migration and invasion through inhibition of nuclear factor (NF)-kappa B p50. Sox4 can also bind to the promoter sequence of Dicer, a microRNA (miRNA) biogenesis factor. Interestingly, altered expression of Dicer was also observed in cancers. However, the potential mechanisms that regulate Dicer expression and its potential significance in melanoma progression are unknown. Here, we studied the regulation of Dicer expression by Sox4 and its role in suppression of melanoma invasion. Our data showed that Sox4 positively regulates Dicer expression by binding to its promoter sequences and enhancing its activity. We found that knockdown of Dicer enhances the matrigel invasion of melanoma cells by at least twofold. In addition, we revealed that overexpression of exogenous Dicer reverts the enhanced melanoma cell invasion upon Sox4 knockdown. Furthermore, we examined the expression of Dicer protein in a large set of melanocytic lesions (n = 514) at different stages by tissue microarray and found that Dicer expression is inversely correlated with melanoma progression (P < 0.0001). Consistently, reduced Dicer expression was correlated with a poorer overall and disease-specific 5-year survival of patients (P = 0.015 and 0.0029, respectively). In addition, we found a significant correlation between expression of Sox4 and Dicer proteins in melanoma biopsies (P = 0.009), further indicating the regulation of Dicer expression by Sox4. Finally, we revealed that knockdown of Sox4 induces a major change in the expression pattern of miRNAs in melanoma cells, mainly due to reduced expression of Dicer. Our results pinpoint the regulation of Dicer expression by Sox4 in melanoma and the critical role of Dicer in suppression of melanoma invasion. Our findings on Sox4-regulated miRNA biogenesis pathway may aid toward the development of novel targeted therapeutic approaches for melanoma. Oncogene (2013) 32, 2131-2139; doi:10.1038/onc.2012.239; published online 11 June 2012	[Jafarnejad, S. M.; Ardekani, G. S.; Li, G.] Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada; [Ghaffari, M.] Univ British Columbia, Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Martinka, M.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Pathol, Vancouver, BC V6H 3Z6, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@mail.ubc.ca		Jafarnejad, Seyed Mehdi/0000-0002-5129-7081	Canadian Institutes of Health Research [MOP-93810, MOP-110974, CCI-117958]; Canadian Dermatology Foundation; University of British Columbia Graduate Fellowship; Canadian Institutes of Health Research-Skin Research Training Centre Trainee Awards	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; University of British Columbia Graduate Fellowship; Canadian Institutes of Health Research-Skin Research Training Centre Trainee Awards(Canadian Institutes of Health Research (CIHR))	The authors would like to thank Dr Ian J MacRae for providing the pCDNA3-Flag-Dicer construct, Stephanie Smith, Kate Orchard, Ronald Wong, Ladan Fazli, Larry Tan, Cecilia Sjoestroem, Liang L Liu and Yabin Cheng for technical assistance and Drs Michael Cox, Aziz Ghahary and Vincent Duronio for helpful discussions. This work was supported by grants from the Canadian Institutes of Health Research (MOP-93810, MOP-110974 and CCI-117958) and the Canadian Dermatology Foundation to GL. SMJ is a recipient of University of British Columbia Graduate Fellowship. SMJ and GSA are recipients of Canadian Institutes of Health Research-Skin Research Training Centre Trainee Awards.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34; Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Faber C, 2011, EUR J CANCER, V47, P1414, DOI 10.1016/j.ejca.2011.01.006; Faggad A, 2010, J PATHOL, V220, P382, DOI 10.1002/path.2658; Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Jafarnejad SM, 2010, AM J PATHOL, V177, P2741, DOI 10.2353/ajpath.2010.100377; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Levy C, 2010, CELL, V141, P994, DOI 10.1016/j.cell.2010.05.004; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020494; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566; Sand M, 2010, CANCER INVEST, V28, P649, DOI 10.3109/07357901003630918; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Sekine S, 2009, GASTROENTEROLOGY, V136, P2304, DOI 10.1053/j.gastro.2009.02.067; Spatz A, 2010, CURR OPIN ONCOL, V22, P163, DOI 10.1097/CCO.0b013e328337fe8f; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Wong RPC, 2007, MOL CANCER THER, V6, P1692, DOI 10.1158/1535-7163.MCT-07-0134; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Wu JF, 2011, MED ONCOL, V28, P804, DOI 10.1007/s12032-010-9520-5	39	50	53	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2131	2139		10.1038/onc.2012.239	http://dx.doi.org/10.1038/onc.2012.239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689055	Green Accepted			2022-12-17	WOS:000318062800002
J	Ferguson, J; Arozarena, I; Ehrhardt, M; Wellbrock, C				Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C.			Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion	ONCOGENE			English	Article						melanoma; MEK; SRC; MMP-2; invasion; combination therapy	MMP-2 EXPRESSION; FACTOR RECEPTOR; KINASE; MIGRATION; ACTIVATION; DASATINIB; ADHESION; PROTEIN; RESISTANCE; INTEGRIN	The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas, and targeting MEK as a central kinase of this pathway is currently tested in clinical trials. However, dose-limiting side effects are observed, and MEK inhibitors that sufficiently reduce ERK activation in patients show a low clinical response. Apart from dose limitations, a reason for the low response to MEK targeting drugs is thought to be the upregulation of counteracting signalling cascades as a direct response to MEK inhibition. Therefore, understanding the biology of melanoma cells and the effects of MEK inhibition on these cells will help to identify new combinatorial approaches that are more potent and allow for lower concentrations of the drug being used. We have discovered that in melanoma cells MEK inhibition by selumetinib (AZD6244, ARRY-142886) or PD184352, while efficiently suppressing proliferation, stimulates increased invasiveness. Inhibition of MEK suppresses actin-cortex contraction and increases integrin-mediated adhesion. Most importantly, and surprisingly, MEK inhibition results in a significant increase in matrix metalloproteases (MMP)-2 and membrane-type 1-MMP expression. All together, MEK inhibition in melanoma cells induces a 'mesenchymal' phenotype that is characterised by protease-driven invasion. This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion. Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma. Oncogene (2013) 32, 86-96; doi:10.1038/onc.2012.25; published online 6 February 2012	[Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C.] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Wellbrock, C (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Claudia.Wellbrock@manchester.ac.uk	Arozarena, Imanol/A-5981-2017	Arozarena, Imanol/0000-0001-6349-2442; Wellbrock, Claudia/0000-0002-3825-6381	Cancer Research UK [C11591/A10202]	Cancer Research UK(Cancer Research UK)	We thank Astra Zeneca (Macclesfield) for providing us with selumetinib and saracatinib, John Humphries (Manchester) for providing help, advice and the reagents (MB13) for the integrin analyses, Chistoph Ballestrem (Manchester) for the vinculin antibody and Stephen Taylor (Manchester) for support with microscopy. This work was funded by Cancer Research UK (grant no C11591/A10202).	AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bass MD, 2008, J CELL BIOL, V181, P1013, DOI 10.1083/jcb.200711129; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Dong MY, 2010, ANTICANCER RES, V30, P4405; Dummer R, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.9033; Eustace AJ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-53; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Fornier MN, 2011, ANN ONCOL, V22, P2575, DOI 10.1093/annonc/mdr018; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Geissinger E, 2002, CANCER RES, V62, P4820; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Green TP, 2009, MOL ONCOL, V3, P248, DOI 10.1016/j.molonc.2009.01.002; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Homsi J, 2009, MELANOMA RES, V19, P167, DOI 10.1097/CMR.0b013e328304974c; Huang JH, 2003, J BIOL CHEM, V278, P48367, DOI 10.1074/jbc.M308213200; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Itoh Y, 2006, IUBMB LIFE, V58, P589, DOI 10.1080/15216540600962818; Johnson ML, 2011, J THORAC ONCOL, V6, P1128, DOI 10.1097/JTO.0b013e3182161508; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Lee JH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-116; Lee SH, 2010, ONCOGENE, V29, P5182, DOI 10.1038/onc.2010.251; Meierjohann S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-201; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Pullikuth AK, 2010, MOL CELL BIOL, V30, P3233, DOI 10.1128/MCB.01178-09; Puzanov I, 2011, MOL ONCOL, V5, P116, DOI 10.1016/j.molonc.2011.01.005; Renouf DJ, 2010, INVEST NEW DRUGS; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Tower GB, 2002, BBA-MOL BASIS DIS, V1586, P265, DOI 10.1016/S0925-4439(01)00105-3; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; Wellbrock C, 2010, BIOCHEM PHARMACOL, V80, P561, DOI 10.1016/j.bcp.2010.03.019; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zheng YH, 2009, MOL CELL, V35, P11, DOI 10.1016/j.molcel.2009.06.013	52	50	52	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					86	96		10.1038/onc.2012.25	http://dx.doi.org/10.1038/onc.2012.25			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310287	Bronze, Green Accepted			2022-12-17	WOS:000313029500009
J	Dallosso, AR; Oster, B; Greenhough, A; Thorsen, K; Curry, TJ; Owen, C; Hancock, AL; Szemes, M; Paraskeva, C; Frank, M; Andersen, CL; Malik, K				Dallosso, A. R.; Oster, B.; Greenhough, A.; Thorsen, K.; Curry, T. J.; Owen, C.; Hancock, A. L.; Szemes, M.; Paraskeva, C.; Frank, M.; Andersen, C. L.; Malik, K.			Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways	ONCOGENE			English	Article						colorectal cancer; protocadherin; epigenetic silencing; Wnt; mTOR	DNA METHYLATION; MICROSATELLITE INSTABILITY; GAMMA-PROTOCADHERINS; HOMOPHILIC INTERACTION; CYTOPLASMIC DOMAIN; TUMOR-SUPPRESSOR; HUMAN BREAST; CANCER; GENE; CARCINOMA	Loss of tumour suppressor gene function can occur as a result of epigenetic silencing of large chromosomal regions, referred to as long-range epigenetic silencing (LRES), and genome-wide analyses have revealed that LRES is present in many cancer types. Here we utilize Illumina Beadchip methylation array analysis to identify LRES across 800 kb of chromosome 5q31 in colorectal adenomas and carcinomas (n = 34) relative to normal colonic epithelial DNA (n = 6). This region encompasses 53 individual protocadherin (PCDH) genes divided among three gene clusters. Hypermethylation within these gene clusters is asynchronous; while most PCDH hypermethylation occurs early, and is apparent in adenomas, PCDHGC3 promoter methylation occurs later in the adenoma-carcinoma transition. PCDHGC3 was hypermethylated in 17/28 carcinomas (60.7%) according to methylation array analysis. Quantitative real-time reverse transcription-polymerase chain reaction showed that PCDHGC3 is the highest expressed PCDH in normal colonic epithelium, and that there was a strong reciprocal relationship between PCDHGC3 methylation and expression in carcinomas (R = -0.84). PCDH LRES patterns are reflected in colorectal tumour cell lines; adenoma cell lines are not methylated at PCDHGC3 and show abundant expression at the mRNA and protein level, while the expression is suppressed in hypermethylated carcinoma cell lines (R = -0.73). Short-interfering RNA-mediated reduction of PCDHGC3 led to a decrease of apoptosis in RG/C2 adenoma cells, and overexpression of PCDHGC3 in HCT116 cells resulted in the reduction of colony formation, consistent with tumour suppressor capabilities for PCDHGC3. Further functional analysis showed that PCDHGC3 can suppress Wnt and mammalian target of rapamycin signalling in colorectal cancer cell lines. Taken together, our data suggest that the PCDH LRES is an important tumour suppressor locus in colorectal cancer, and that PCDHGC3 may be a strong marker and driver for the adenoma-carcinoma transition. Oncogene (2012) 31, 4409-4419; doi: 10.1038/onc.2011.609; published online 16 January 2012	[Oster, B.; Thorsen, K.; Andersen, C. L.] Aarhus Univ Hosp, Dept Mol Med, DK-8200 Skejby, Denmark; [Dallosso, A. R.; Curry, T. J.; Owen, C.; Hancock, A. L.; Szemes, M.; Malik, K.] Univ Bristol, Sch Cellular & Mol Med, Canc Epigenet Lab, Bristol BS8 1TD, Avon, England; [Greenhough, A.; Paraskeva, C.] Univ Bristol, Sch Cellular & Mol Med, Colorectal Canc Lab, Bristol, Avon, England; [Frank, M.] Univ Freiburg, Inst Biol 1, Freiburg, Germany	Aarhus University; University of Bristol; University of Bristol; University of Freiburg	Andersen, CL (corresponding author), Aarhus Univ Hosp, Dept Mol Med, DK-8200 Skejby, Denmark.	cla@ki.au.dk; k.t.a.malik@bristol.ac.uk	Andersen, Claus L/C-1477-2017; Greenhough, Alexander/Y-6728-2019; Greenhough, Alexander/J-9308-2012; Andersen, Claus Lindbjerg/A-9217-2012	Greenhough, Alexander/0000-0002-8306-811X; Greenhough, Alexander/0000-0002-8306-811X; Andersen, Claus Lindbjerg/0000-0002-7406-2103; Dallosso, Anthony/0000-0002-1460-2550; Malik, Karim/0000-0002-8965-200X	Wellcome Trust VIP award; Cancer Research UK [C20791/A12743, C19/A11975]; Kidney Research UK; Cancer and Leukaemia in Childhood-Sargent Trust; John and Birthe Meyer Foundation; Lundbeck Foundation; European Union [SYSCOL HEALTHF5-2010-258236]; Cancer Research UK [12743, 11975] Funding Source: researchfish; Kidney Research UK [RP42/2009] Funding Source: researchfish	Wellcome Trust VIP award(Wellcome Trust); Cancer Research UK(Cancer Research UK); Kidney Research UK(Kidney Research UK (KRUK)); Cancer and Leukaemia in Childhood-Sargent Trust; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); European Union(European Commission); Cancer Research UK(Cancer Research UK); Kidney Research UK(Kidney Research UK (KRUK))	This work was supported by a Wellcome Trust VIP award, Cancer Research UK Grants C20791/A12743 and C19/A11975, Kidney Research UK and the Cancer and Leukaemia in Childhood-Sargent Trust. Further funding was from the John and Birthe Meyer Foundation, the Lundbeck Foundation and The European Union's Seventh Framework Program (SYSCOL HEALTHF5-2010-258236). We thank Dr Greg Phillips for the antibody towards the gamma-PCDH constant domain, Professor Moon for reporter plasmids and Professor Vogelstein for mutant HCT116 cells. We also thank Dr Andrea Buda, Dr Katy Petherick, Dr Zsombor Melegh, Dr Newton Wong and Professor Andrew Silver for helpful discussions and comments.	Ahuja N, 1997, CANCER RES, V57, P3370; Ashton GH, 2010, DEV CELL, V19, P259, DOI 10.1016/j.devcel.2010.07.015; Bass T, 2007, DEV GENES EVOL, V217, P337, DOI 10.1007/s00427-007-0145-4; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745; Elder DJE, 1996, CANCER RES, V56, P2273; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fernandez-Monreal M, 2009, MOL CELL NEUROSCI, V40, P344, DOI 10.1016/j.mcn.2008.12.002; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Greenhough A, 2010, ONCOGENE, V29, P3398, DOI 10.1038/onc.2010.94; Greenspan EJ, 2006, CARCINOGENESIS, V27, P1316, DOI 10.1093/carcin/bgi373; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; Han MH, 2010, MOL CELL PROTEOMICS, V9, P71, DOI 10.1074/mcp.M900343-MCP200; Hanson HH, 2010, J BIOL CHEM, V285, P20982, DOI 10.1074/jbc.M109.092031; Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Javierre BM, 2011, MOL CANCER RES, V9, P1139, DOI 10.1158/1541-7786.MCR-10-0515; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kobayashi Y, 2011, GENOME RES, V21, P1017, DOI 10.1101/gr.119487.110; Lin CY, 2010, J BIOL CHEM, V285, P41675, DOI 10.1074/jbc.M110.179895; Lind GE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-85; Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; O'Leary R, 2011, MOL BIOL CELL, V22, P4362, DOI 10.1091/mbc.E11-04-0283; OBATA S, 1995, J CELL SCI, V108, P3765; Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951; PARASKEVA C, 1989, CANCER RES, V49, P1282; Paz MF, 2003, CANCER RES, V63, P1114; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schalm SS, 2010, P NATL ACAD SCI USA, V107, P13894, DOI 10.1073/pnas.1007182107; Schmidt WM, 2007, MOL CARCINOGEN, V46, P766, DOI 10.1002/mc.20307; Schreiner D, 2010, P NATL ACAD SCI USA, V107, P14893, DOI 10.1073/pnas.1004526107; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Wang XZ, 2009, J BIOL CHEM, V284, P2880; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wong JJL, 2011, MODERN PATHOL, V24, P396, DOI 10.1038/modpathol.2010.212; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154	57	50	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4409	4419		10.1038/onc.2011.609	http://dx.doi.org/10.1038/onc.2011.609			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249255	Green Accepted			2022-12-17	WOS:000309591300007
J	Liao, YC; Ruan, JW; Lua, I; Li, MH; Chen, WL; Wang, JRY; Kao, RH; Chen, JH				Liao, Y. C.; Ruan, J. W.; Lua, I.; Li, M. H.; Chen, W. L.; Wang, J. R. Y.; Kao, R. H.; Chen, J. H.			Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling	ONCOGENE			English	Article						hPTTG1; GEF-H1; RhoA; tumour metastasis; cytoskeleton regulation	TUMOR-TRANSFORMING GENE; TRANSCRIPTIONAL ACTIVATION FUNCTION; SISTER-CHROMATID SEPARATION; NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; HUMAN SECURIN; ACTIN CYTOSKELETON; BINDING-FACTOR; PTTG; EXPRESSION	Human pituitary tumour-transforming gene 1 (hPTTG1) is an oncogenic transcription factor that is overexpressed in many tumour types, especially tumours with metastatic abilities. However, how hPTTG1 overexpression drives metastasis is not yet clear. As a transcription factor, hPTTG1 may promote metastasis by activating target genes that are involved in the metastatic process. Here, we showed that Rho guanine nucleotide exchange factor-H1 (GEF-H1) was transcriptionally activated by hPTTG1, thereby promoting breast cancer metastasis. Luciferase reporter analyses and chromatin immunoprecipitation (ChIP) assays showed that hPTTG1 directly bound and activated the GEF-H1 gene promoter. In this study, RNA interference-mediated knockdown of hPTTG1 in highly metastatic breast tumour cells decreased GEF-H1 expression and RhoA activation, thereby reducing cell motility and invasion, and interfering with cytoskeletal remodelling in vitro, and impairing the tumour metastasis in vivo. The restoration of GEF-H1 expression in hPTTG1-knockdown cells rescued the hPTTG1-knockdown effects on cytoskeletal changes in vitro and tumour metastasis in vivo. Conversely, ectopic expression of hPTTG1 in non-metastatic breast tumour cells induced cytoskeletal rearrangements, and allowed these cells to metastasise in a mouse model by orthotopic implantation. In human tumour samples, hPTTG1 expression was also correlated to GEF-H1 expression in aggressive breast carcinoma. Altogether, these findings definitively establish a role for hPTTG1 in activating the GEF-H1/RhoA pathway as a newly identified mechanism in breast cancer metastasis. Oncogene (2012) 31, 3086-3097; doi: 10.1038/onc.2011.476; published online 17 October 2011	[Lua, I.; Chen, J. H.] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien 97004, Hualien County, Taiwan; [Liao, Y. C.; Ruan, J. W.; Chen, J. H.] Tzu Chi Univ, Inst Med Sci, Hualien 97004, Hualien County, Taiwan; [Li, M. H.] Buddhist Tzu Chi Gen Hosp, Dept Pathol, Hualien, Taiwan; [Chen, W. L.] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Wang, J. R. Y.; Kao, R. H.] Buddhist Tzu Chi Gen Hosp, Dept Hematol Oncol, Taipei, Taiwan	Tzu Chi University; Tzu Chi University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; National Defense Medical Center; Buddhist Tzu Chi General Hospital	Chen, JH (corresponding author), Tzu Chi Univ, Dept Mol Biol & Human Genet, Rm D416,701,Sec 3,Zhongyang Rd, Hualien 97004, Hualien County, Taiwan.	noli401029@gmail.com	Ruan, Jhen-Wei/N-2624-2017; Ruan, Jhen-Wei/G-6647-2014	Ruan, Jhen-Wei/0000-0002-0636-1937; 	National Science Council of Taiwan [NSC96-2320-B-320-013-MY3]; National Health Research Institutes of Taiwan [NHRI-EX99-9928BI]; Tzu-Chi Foundation	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan); Tzu-Chi Foundation	Ms Lily Chen, Ms Vicky Chang and Ms Shi-Rong Lin provided expert technical assistance. We thank Dr Lu-Hai Wang's suggestions during the preparation of this manuscript. This study was supported by grants from the National Science Council of Taiwan (NSC96-2320-B-320-013-MY3), the National Health Research Institutes of Taiwan (NHRI-EX99-9928BI) and also partially by the Tzu-Chi Foundation.	Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Birkenfeld J, 2008, TRENDS CELL BIOL, V18, P210, DOI 10.1016/j.tcb.2008.02.006; Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07-12-1269; Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105; Chesnokova V, 2010, MOL CELL ENDOCRINOL, V326, P55, DOI 10.1016/j.mce.2010.02.012; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; del Peso L, 1997, ONCOGENE, V15, P3047; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Ito T, 2008, CANCER RES, V68, P3214, DOI 10.1158/0008-5472.CAN-07-3043; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Ogbagabriel S, 2005, MODERN PATHOL, V18, P985, DOI 10.1038/modpathol.3800382; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ridley AJ, 2001, J CELL SCI, V114, P2713; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Smith VE, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001699; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Tong YG, 2009, J MOL ENDOCRINOL, V43, P179, DOI 10.1677/JME-08-0176; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wittmann T, 2001, J CELL SCI, V114, P3795; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	46	50	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3086	3097		10.1038/onc.2011.476	http://dx.doi.org/10.1038/onc.2011.476			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002306	Green Published, hybrid			2022-12-17	WOS:000305705900007
J	Garcia, CB; Shaffer, CM; Alfaro, MP; Smith, AL; Sun, J; Zhao, Z; Young, PP; VanSaun, MN; Eid, JE				Garcia, C. B.; Shaffer, C. M.; Alfaro, M. P.; Smith, A. L.; Sun, J.; Zhao, Z.; Young, P. P.; VanSaun, M. N.; Eid, J. E.			Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2	ONCOGENE			English	Article						cancer; differentiation; gene expression	GENE-EXPRESSION; DIFFERENTIATION; POLYCOMB; GROWTH; ADULT; PROTEINS; NEUROGENESIS; PROGENITORS; ACTIVATION; INHIBITORS	Cell identity is determined by its gene expression programs. The ability of a cell to change its identity and produce cell types outside its lineage is achieved by the activity of transcription controllers capable of reprogramming differentiation gene networks. The synovial sarcoma (SS)-associated protein, SYT-SSX2, reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells (BMMSCs) by dictating their commitment to a pro-neural lineage. It fulfills this function by directly targeting an extensive array of neural-specific genes as well as genes of developmental pathway mediators. Concomitantly, the ability of both myoblasts and BMMSCs to differentiate into their normal myogenic and adipogenic lineages was compromised. SS is believed to arise in mesenchymal stem cells where formation of the t(X/18) translocation product, SYT-SSX, constitutes the primary event in the cancer. SYT-SSX is therefore believed to initiate tumorigenesis in its target stem cell. The data presented here allow a glimpse at the initial events that likely occur when SYT-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation. In addition, we identified the fibroblast growth factor receptor gene, Fgfr2, as one occupied and upregulated by SYT-SSX2. Knockdown of FGFR2 in both BMMSCs and SS cells abrogated their growth and attenuated their neural phenotype. These results support the notion that the SYT-SSX2 nuclear function and differentiation effects are conserved throughout sarcoma development and are required for its maintenance beyond the initial phase. They also provide the stem cell regulator, FGFR2, as a promising candidate target for future SS therapy. Oncogene (2012) 31, 2323-2334; doi:10.1038/onc.2011.418; published online 26 September 2011	[Garcia, C. B.; Smith, A. L.; Zhao, Z.; VanSaun, M. N.; Eid, J. E.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Shaffer, C. M.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA; [Alfaro, M. P.; Young, P. P.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Sun, J.; Zhao, Z.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37232 USA; [Young, P. P.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Eid, JE (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 740 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	josiane.eid@vanderbilt.edu		Garcia, Christina/0000-0001-7892-0120	Alex's Lemonade Stand Foundation; Sarcoma Foundation of America; NCRR of the NIH [P40RR017447]; NATIONAL CANCER INSTITUTE [T32CA009592, P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR017447] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Sarcoma Foundation of America; NCRR of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funding was provided by the Alex's Lemonade Stand Foundation (Innovation Award) and the Sarcoma Foundation of America. Microarrays were performed at the Vanderbilt Functional Genomics Shared Resource core supported by the VICC (P30 CA68485), the VDCC (P30 DK58404) and the Vanderbilt Vision Center (P30 EY08126). Some of the materials used in this work were provided by the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White through a grant from NCRR of the NIH (grant no. P40RR017447). We thank BV Mary and H Trinity for assistance; T Ito and M Ladanyi for SYO-1 cells and A Sandelin and S Wilhite for technical support.	Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105; Asp P, 2011, P NATL ACAD SCI USA, V108, pE149, DOI 10.1073/pnas.1102223108; Barco R, 2007, MOL BIOL CELL, V18, P4003, DOI 10.1091/mbc.E07-05-0496; Barco R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005060; Chadashvili T, 2006, J COMP NEUROL, V498, P1, DOI 10.1002/cne.21009; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ever L, 2005, CURR OPIN NEUROBIOL, V15, P29, DOI 10.1016/j.conb.2005.01.005; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Gurdon JB, 2008, SCIENCE, V322, P1811, DOI 10.1126/science.1160810; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Huang W, 2007, FRONT BIOSCI-LANDMRK, V12, P3068, DOI 10.2741/2296; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; Ishibe T, 2008, CLIN ORTHOP RELAT R, V466, P2147, DOI 10.1007/s11999-008-0343-z; Katoh M, 2008, INT J ONCOL, V33, P233, DOI 10.3892/ijo_00000001; Katoh Y, 2009, INT J MOL MED, V23, P307, DOI 10.3892/ijmm_00000132; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Maric D, 2007, J NEUROSCI, V27, P1836, DOI 10.1523/JNEUROSCI.5141-06.2007; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Mateos-Langerak J, 2008, ADV GENET, V61, P45, DOI 10.1016/S0065-2660(07)00002-8; Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9; Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018-008-8429-z; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Villegas SN, 2010, J CELL BIOCHEM, V110, P10, DOI 10.1002/jcb.22536; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	42	50	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2323	2334		10.1038/onc.2011.418	http://dx.doi.org/10.1038/onc.2011.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21996728	Green Accepted			2022-12-17	WOS:000303610800007
J	Ganguly, SS; Fiore, LS; Sims, JT; Friend, JW; Srinivasan, D; Thacker, MA; Cibull, ML; Wang, C; Novak, M; Kaetzel, DM; Plattner, R				Ganguly, S. S.; Fiore, L. S.; Sims, J. T.; Friend, J. W.; Srinivasan, D.; Thacker, M. A.; Cibull, M. L.; Wang, C.; Novak, M.; Kaetzel, D. M.; Plattner, R.			c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression	ONCOGENE			English	Article						c-Abl; Arg; melanoma; invasion; STAT3; MMP	TYROSINE KINASE; BREAST-CANCER; MATRIX-METALLOPROTEINASE; CLINICAL-EFFICACY; FAMILY KINASES; GROWTH-FACTOR; IMATINIB; EXPRESSION; INHIBITION; THERAPY	Despite 35 years of clinical trials, there is little improvement in 1-year survival rates for patients with metastatic melanoma, and the disease is essentially untreatable if not cured surgically. The paucity of chemotherapeutic agents that are effective for treating metastatic melanoma indicates a dire need to develop new therapies. Here, we found a previously unrecognized role for c-Abl and Arg in melanoma progression. We demonstrate that the kinase activities of c-Abl and Arg are elevated in primary melanomas (60%), in a subset of benign nevi (33%) and in some human melanoma cell lines. Using siRNA and pharmacological approaches, we show that c-Abl/Arg activation is functionally relevant because it is required for melanoma cell proliferation, survival and invasion. Significantly, we identify the mechanism by which activated c-Abl promotes melanoma invasion by showing that it transcriptionally upregulates matrix metalloproteinase-1 (MMP-1), and using rescue approaches we demonstrate that c-Abl promotes invasion through a STAT3-MMP-1 pathway. Additionally, we show that c-Abl and Arg are not merely redundant, as active Arg drives invasion in a STAT3-independent manner, and upregulates MMP-3 and MT1-MMP, in addition to MMP-1. Most importantly, c-Abl and Arg not only promote in vitro processes important for melanoma progression, but also promote metastasis in vivo, as inhibition of c-Abl/Arg kinase activity with the c-Abl/Arg inhibitor, nilotinib, dramatically inhibits metastasis in a mouse model. Taken together, these data identify c-Abl and Arg as critical, novel, drug targets in metastatic melanoma, and indicate that nilotinib may be useful in preventing metastasis in patients with melanomas harboring active c-Abl and Arg. Oncogene (2012) 31, 1804-1816; doi: 10.1038/onc.2011.361; published online 5 September 2011	[Ganguly, S. S.; Fiore, L. S.; Sims, J. T.; Friend, J. W.; Srinivasan, D.; Thacker, M. A.; Novak, M.; Kaetzel, D. M.; Plattner, R.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Sch Med, Lexington, KY 40536 USA; [Cibull, M. L.] Univ Kentucky, Dept Pathol, Sch Med, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Dept Biostat, Sch Med, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Lucille P Markey Canc Ctr, Sch Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Dept Mol & Biomed Pharmacol, Sch Med, 800 Rose St,Combs Res Bldg,Room 209, Lexington, KY 40536 USA.	rplat2@uky.edu			NIH [CA116784, CA83237]; NIH/NCI [1R01CA116784]; NATIONAL CANCER INSTITUTE [R01CA116784, P30CA177558, R01CA083237, R01CA166499] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Plattner's and Dr Kaetzel's work are supported by NIH CA116784 and CA83237, respectively. All of the other authors declare no potential conflict of interest.; We thank Patty Cross, J Anthony Brandon, Holly Bennett and Jennifer Strange for assistance with IHC, IVIS imaging, isolation of GST-STAT3 and cell sorting, respectively; John D'Orazio for primary melanocytes; Meenhard Herlyn for WM melanoma cell lines and for genotyping WM cell lines; Suyan Huang for A375; Fernando deCastro for IHC advice and Paul Manley (Novartis, Switzerland) for STI571 and nilotinib, and advice regarding their use. This work was supported by NIH/NCI grant 1R01CA116784.	Allington TM, 2011, CELLS TISSUES ORGANS, V193, P98, DOI 10.1159/000320163; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Bachmeier BE, 2005, EXP CELL RES, V305, P83, DOI 10.1016/j.yexcr.2004.12.019; Berwick M, 2009, DERMATOL CLIN, V27, P205, DOI 10.1016/j.det.2008.12.002; Blackburn JS, 2009, ONCOGENE, V28, P4237, DOI 10.1038/onc.2009.272; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Candelaria M, 2005, MED ONCOL, V22, P1, DOI 10.1385/MO:22:1:001; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Deininger MW, 2008, CLIN CANCER RES, V14, P4027, DOI 10.1158/1078-0432.CCR-07-5015; DeMatteo R, 2009, ANN SURG ONCOL, V16, P799, DOI 10.1245/s10434-009-0316-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fanjul-Fernandez M, 2010, BBA-MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furlan A, 2011, CELL DEATH DIFFER; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofmann UB, 2009, CLIN CANCER RES, V15, P324, DOI 10.1158/1078-0432.CCR-08-2243; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Kabbarah O, 2005, CANCER CELL, V8, P439, DOI 10.1016/j.ccr.2005.11.008; Kong YY, 2010, ARCH PATHOL LAB MED, V134, P1740, DOI 10.1043/2009-0418-RAR.1; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; le Coutre P, 2004, CANCER CHEMOTH PHARM, V53, P313, DOI 10.1007/s00280-003-0741-6; Li X, 2010, CELL DEATH DIFFER, V17, P1277, DOI 10.1038/cdd.2010.8; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; Lin Kimberly, 2010, Genes Cancer, V1, P409; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Mayorga ME, 2006, MELANOMA RES, V16, P127, DOI 10.1097/01.cmr.0000215039.30812.9b; Mouawad R, 2010, CRIT REV ONCOL HEMAT, V74, P27, DOI 10.1016/j.critrevonc.2009.08.005; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Ogawa Y, 2008, J DERMATOL SCI, V51, P190, DOI 10.1016/j.jdermsci.2008.03.011; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Raby BN, 2001, INT J CANCER, V93, P644, DOI 10.1002/ijc.1380; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Redondo P, 2004, J INVEST DERMATOL, V123, P1208, DOI 10.1111/j.0022-202X.2004.23496.x; Santos FPS, 2009, LEUKEMIA LYMPHOMA, V50, P16, DOI 10.3109/10428190903383427; Satzger I, 2010, DERMATOLOGY, V220, P77, DOI 10.1159/000265558; Shepherd C, 2010, CURR ONCOL REP, V12, P146, DOI 10.1007/s11912-010-0095-2; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Smalley KSM, 2009, CANCER RES, V69, P3241, DOI 10.1158/0008-5472.CAN-08-4305; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Tsareva SA, 2007, NEOPLASIA, V9, P279, DOI 10.1593/neo.06820; Ugurel S, 2005, BRIT J CANCER, V92, P1398, DOI 10.1038/sj.bjc.6602529; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200	53	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1804	1816		10.1038/onc.2011.361	http://dx.doi.org/10.1038/onc.2011.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21892207	Green Accepted			2022-12-17	WOS:000302785200006
J	Zhang, JS; Koenig, A; Harrison, A; Ugolkov, AV; Fernandez-Zapico, ME; Couch, FJ; Billadeau, DD				Zhang, J-S; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Couch, F. J.; Billadeau, D. D.			Mutant K-Ras increases GSK-3 beta gene expression via an ETS-p300 transcriptional complex in pancreatic cancer	ONCOGENE			English	Article						GSK-3 beta; K-Ras; MAPK; ETS; pancreatic cancer	GLYCOGEN-SYNTHASE KINASE-3-BETA; FACTOR-KAPPA-B; PROSTATE-CANCER; SIGNALING PATHWAYS; COLORECTAL-CANCER; BINDING-PROTEIN; CELL-SURVIVAL; C-MYC; ETS-1; FAMILY	Glycogen synthase kinase-3 beta (GSK-3 beta) is overexpressed in a number of human malignancies and has been shown to contribute to tumor cell proliferation and survival. Although regulation of GSK-3 beta activity has been extensively studied, the mechanisms governing GSK-3 beta gene expression are still unknown. Using pancreatic cancer as a model, we find that constitutively active Ras signaling increases GSK-3 beta gene expression via the canonical mitogen-activated protein kinase signaling pathway. Analysis of the mechanism revealed that K-Ras regulates the expression of this kinase through two highly conserved E-twenty six (ETS) binding elements within the proximal region. Furthermore, we demonstrate that mutant K-Ras enhances ETS2 loading onto the promoter, and ETS requires its transcriptional activity to increase GSK-3 beta gene transcription in pancreatic cancer cells. Lastly, we show that ETS2 cooperates with p300 histone acetyltransferase to remodel chromatin and promote GSK-3 beta expression. Taken together, these results provide a general mechanism for increased expression of GSK-3 beta in pancreatic cancer and perhaps other cancers, where Ras signaling is deregulated. Oncogene (2011) 30, 3705-3715; doi:10.1038/onc.2011.90; published online 28 March 2011	[Zhang, J-S; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Billadeau, D. D.] Mayo Clin, Div Oncol Res, Schulze Ctr Novel Therapeut, Coll Med, Rochester, MN 55905 USA; [Zhang, J-S; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Billadeau, D. D.] Mayo Clin, Dept Immunol, Schulze Ctr Novel Therapeut, Coll Med, Rochester, MN 55905 USA; [Koenig, A.] Univ Marburg, Dept Gastroenterol & Endocrinol, Marburg, Germany; [Couch, F. J.] Mayo Clin, Div Expt Pathol & Lab Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Philipps University Marburg; Mayo Clinic	Zhang, JS (corresponding author), Mayo Clin, Div Oncol Res, Schulze Ctr Novel Therapeut, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	zhang.jinsan@mayo.edu; billadeau.daniel@mayo.edu	Ugolkov, Andrey/T-3012-2019; Harrison, Andrew M./I-3708-2013	Harrison, Andrew M./0000-0003-0063-9421	Mayo Clinic Pancreatic Cancer SPORE [CA102701]; German Cancer Society; NATIONAL CANCER INSTITUTE [P20CA102701, P50CA102701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK084567] Funding Source: NIH RePORTER	Mayo Clinic Pancreatic Cancer SPORE; German Cancer Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Mayo Clinic Pancreatic Cancer SPORE grant CA102701 (DDB and MEF-Z). DDB is a Leukemia and Lymphoma Scholar. AK is supported by a Mildred-Scheel fellowship of German Cancer Society.	Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bilim V, 2009, BRIT J CANCER, V101, P2005, DOI 10.1038/sj.bjc.6605437; Billadeau DD, 2007, PANCREATOLOGY, V7, P398, DOI 10.1159/000108955; Cao Q, 2006, CELL RES, V16, P671, DOI 10.1038/sj.cr.7310078; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fauquette V, 2005, BIOCHEM J, V386, P35, DOI 10.1042/BJ20040706; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Gutierrez-Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hollenhorst PC, 2004, NUCLEIC ACIDS RES, V32, P5693, DOI 10.1093/nar/gkh906; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Ito H, 2004, CANCER RES, V64, P7439, DOI 10.1158/0008-5472.CAN-04-1177; Ito T, 1998, MODERN PATHOL, V11, P209; Ito Y, 2002, ONCOL REP, V9, P853; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jedlicka P, 2008, HISTOL HISTOPATHOL, V23, P1417, DOI 10.14670/HH-23.1417; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kobberup S, 2007, DEV DYNAM, V236, P3100, DOI 10.1002/dvdy.21292; Koenig A, 2010, GASTROENTEROLOGY, V138, P1189, DOI 10.1053/j.gastro.2009.10.045; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Lau KF, 1999, GENOMICS, V60, P121, DOI 10.1006/geno.1999.5875; Lefter LP, 2009, CANCER GENE THER, V16, P137, DOI 10.1038/cgt.2008.65; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Li R, 2009, ANTICANCER RES, V29, P2077; Li YY, 2009, CANCER SCI, V100, P396, DOI 10.1111/j.1349-7006.2008.01059.x; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Narod SA, 2008, BRIT J CANCER, V99, P847, DOI 10.1038/sj.bjc.6604558; Nelson ML, 2010, P NATL ACAD SCI USA, V107, P10026, DOI 10.1073/pnas.0915137107; Ougolkov AV, 2006, CLIN CANCER RES, V12, P5074, DOI 10.1158/1078-0432.CCR-06-0196; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Polakis P, 2000, GENE DEV, V14, P1837; Rowley M, 2011, GASTROENTEROLOGY; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001	47	50	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3705	3715		10.1038/onc.2011.90	http://dx.doi.org/10.1038/onc.2011.90			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441955	Green Accepted			2022-12-17	WOS:000294244500006
J	Goding, CR				Goding, C. R.			A picture of Mitf in melanoma immortality	ONCOGENE			English	Editorial Material							PROLIFERATION; SENESCENCE; CELLS	The Mitf gene has a key role in melanocytes and melanoma by regulating cell cycle progression, survival and differentiation. Two papers in this issue of Oncogene (Cheli et al., 2011; Strub et al., 2011) reveal that low-Mitf cells can initiate tumors with high efficiency, and that Mitf blocks senescence by regulating genes implicated in S-phase progression and mitosis. Oncogene (2011) 30, 2304-2306; doi: 10.1038/onc.2010.641; published online 31 January 2011	Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford OX3 7DQ, England	Ludwig Institute for Cancer Research; University of Oxford	Goding, CR (corresponding author), Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Old Rd Campus,Res Bldg, Oxford OX3 7DQ, England.	colin.goding@ludwig.ox.ac.uk		Goding, Colin/0000-0002-1614-3909				Arnheiter H, 2010, PIGM CELL MELANOMA R, V23, P729, DOI 10.1111/j.1755-148X.2010.00759.x; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P27, DOI 10.1111/j.1755-148X.2007.00433.x; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045	10	50	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2304	2306		10.1038/onc.2010.641	http://dx.doi.org/10.1038/onc.2010.641			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21278792				2022-12-17	WOS:000290789200002
J	Chien, WW; Domenech, C; Catallo, R; Kaddar, T; Magaud, JP; Salles, G; Ffrench, M				Chien, W. W.; Domenech, C.; Catallo, R.; Kaddar, T.; Magaud, J-P; Salles, G.; Ffrench, M.			Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway	ONCOGENE			English	Article						p(16INK4a); CDK1; cell cycle; microRNA; E2F; post-transcriptional regulation	ACUTE LYMPHOBLASTIC-LEUKEMIA; LUNG-CANCER CELLS; MESSENGER-RNAS; PROLIFERATION; ACTIVATION; REPRESSION; APOPTOSIS; PROTEINS; TRANSFORMATION; TRANSCRIPTION	The p(16INK4a) protein regulates cell cycle progression mainly by inhibiting the activity of G1-phase cyclin-dependent kinases (CDKs) 4 and 6, the subsequent retinoblastoma protein (pRb) phosphorylation and E2F transcription factor release. The p(16INK4a) protein can also repress the activity of other transcription factors, such as c-myc, nuclear factor-kappaB and c-Jun/AP1. Here, we report that, in two p16(-/-), pRb(WT) and p53(WT) cell lines (MCF7 and U87), p(16INK4a) overexpression induces a dramatic decrease in CDK1 protein expression. In response to p(16INK4a), the decreased rate of CDK1 protein synthesis, its unchanged protein half- life, unreduced CDK1 mRNA steady- state levels and mRNA half- life allow us to hypothesize that p(16INK4a) could regulate CDK1 expression at the post- transcriptional level. This CDK1 downregulation is mediated by the 30-untranslated region (30UTR) of CDK1 mRNA as shown by translational inhibition in luciferase assays and is associated with a modified expression balance of microRNAs (miRNAs) that potentially regulate CDK1, analyzed by TaqMan Human microRNA Array. The p16INK4a-induced expression of two miRNAs (miR-410 and miR-650 chosen as an example) in MCF7 cells is confirmed by individual reverse transcriptionqPCR. Furthermore, we show the interaction of miR-410 or miR-650 with CDK1-30UTR by luciferase assays. Endogenous CDK1 expression decreases upon both miRNA overexpression and increases with their simultaneous inhibition. The induction of miR-410, but not miR-650 could be related to the pRb/ E2F pathway. These results demonstrate the post-transcriptional inhibition of CDK1 by p(16INK4a). We suggest that p(16INK4a) may regulate gene expression by modifying the functional equilibrium of transcription factors and consequently the expression balance of miRNAs. Oncogene (2011) 30, 1880-1891; doi: 10.1038/onc. 2010.570; published online 20 December 2010	[Ffrench, M.] Univ Lyon 1, CNRS, UMR ENS HCL 5239, Lab Pathol Cellules Lymphoides,Fac Med Lyon Sud, F-69495 Oullins, Rhone Alpes, France; [Magaud, J-P; Ffrench, M.] Hosp Civils Lyon, CHLS, Hematol Lab, Pierre Benite, France; [Salles, G.] Hosp Civils Lyon, CHLS, Serv Hematol, Pierre Benite, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CHU Lyon; CHU Lyon	Ffrench, M (corresponding author), Univ Lyon 1, CNRS, UMR ENS HCL 5239, Lab Pathol Cellules Lymphoides,Fac Med Lyon Sud, 165 Chemin Grand Revoyet, F-69495 Oullins, Rhone Alpes, France.	martine.ffrench@chu-lyon.fr	Salles, Gilles/Z-2336-2019; Holt, Janet E/B-2415-2013	Salles, Gilles/0000-0002-9541-8666; 	Ligue contre le Cancer of Saone-et-Loire and Rhone; Fondation pour la Recherche Medicale; Canceropole Lyon-Auvergne-Rhone-Alpes	Ligue contre le Cancer of Saone-et-Loire and Rhone; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Canceropole Lyon-Auvergne-Rhone-Alpes	This work was supported by the Ligue contre le Cancer of Saone-et-Loire and Rhone, by the Fondation pour la Recherche Medicale and by the Canceropole Lyon-Auvergne-Rhone-Alpes.	Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Baghdassarian N, 1999, CELL GROWTH DIFFER, V10, P405; Baghdassarian N, 1998, EXP CELL RES, V240, P263, DOI 10.1006/excr.1998.3942; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; Chen RW, 2008, BLOOD, V112, P822, DOI 10.1182/blood-2008-03-142182; Chien WW, 2010, CELL CYCLE, V9, P3286, DOI 10.4161/cc.9.16.12600; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Cox CV, 2007, BLOOD, V109, P674, DOI 10.1182/blood-2006-06-030445; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hara E, 1996, MOL CELL BIOL, V16, P859; Harada H, 1999, CANCER RES, V59, P3783; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Kaddar T, 2009, BIOL CELL, V101, P511, DOI 10.1042/BC20080213; Kamb A, 1994, Nat Genet, V8, P23; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Leclerc Guy J, 2002, Cancer Cell Int, V2, P1, DOI 10.1186/1475-2867-2-1; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Moser JJ, 2007, J NEUROSCI RES, V85, P3619, DOI 10.1002/jnr.21439; Nalabothula N, 2007, INT J ONCOL, V30, P669; Nishiwaki E, 2000, MOL CELL BIOL, V20, P7726, DOI 10.1128/MCB.20.20.7726-7734.2000; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Souza-Rodrigues E, 2007, PROTEOMICS, V7, P4102, DOI 10.1002/pmic.200700133; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang B, 2005, J IMMUNOL, V175, P4274, DOI 10.4049/jimmunol.175.7.4274; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	50	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1880	1891		10.1038/onc.2010.570	http://dx.doi.org/10.1038/onc.2010.570			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21170085				2022-12-17	WOS:000289777700004
J	Liu, Y; Chen, N; Cui, X; Zheng, X; Deng, L; Price, S; Karantza, V; Minden, A				Liu, Y.; Chen, N.; Cui, X.; Zheng, X.; Deng, L.; Price, S.; Karantza, V.; Minden, A.			The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis	ONCOGENE			English	Article						Pak4; mammary epithelial cells; breast cancer; apoptosis; cell survival	ANCHORAGE-INDEPENDENT GROWTH; EPITHELIAL ACINI; CELL POLARITY; CANCER; APOPTOSIS; RECEPTOR; ACTIVATION; SURVIVAL; BINDING; MODEL	The Pak4 serine/threonine kinase is highly expressed in many cancer cell lines and human tumors. Although several studies have addressed the role for Pak4 in transformation of fibroblasts, most human cancers are epithelial in origin. Epithelial cancers are associated not only with changes in cell growth but also with changes in the cellular organization within the three-dimensional (3D) architecture of the affected tissues. In this study we used immortalized mouse mammary epithelial cells (iMMECs) as a model system to study the role for Pak4 in mammary tumorigenesis. iMMECs are an excellent model system for studying breast cancer, as they can grow in 3D-epithelial cell culture, in which they form acinar structures that recapitulate in vivo mammary morphogenesis. Although Pak4 is expressed at low levels in wild-type iMMECs, it is overexpressed in response to oncogenes, such as oncogenic Ras and Her2/neu. In this study we found that overexpression of Pak4 in iMMECs leads to changes in 3D acinar architecture that are consistent with oncogenic transformation. These include decreased central acinar cell death, abrogation of lumen formation, cell polarity alterations and deregulation of acinar size and cell number. Furthermore, iMMECs overexpressing Pak4 form tumors when implanted into the fat pads of athymic mice. Our results suggest that overexpression of Pak4 triggers events that are important for the transformation of mammary epithelial cells. This is likely to be owing to the ability of Pak4 to inhibit apoptosis and promote cell survival and thus subsequent uncontrolled proliferation, and to its ability to deregulate cell shape and polarity. Oncogene (2010) 29, 5883-5894; doi:10.1038/onc.2010.329; published online 9 August 2010	[Liu, Y.; Cui, X.; Zheng, X.; Minden, A.] Rutgers State Univ, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA; [Chen, N.; Price, S.; Karantza, V.] Canc Inst New Jersey, Dept Med, New Brunswick, NJ USA; [Chen, N.; Karantza, V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Med Oncol, Dept Internal Med, Piscataway, NJ 08854 USA; [Deng, L.] Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Minden, A (corresponding author), Rutgers State Univ, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Ernest Mario Sch Pharm, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	aminden@rci.rutgers.edu	Chen, Ning/AAM-9513-2021	Chen, Ning/0000-0002-8191-6744	 [R01 CA076342];  [R00 CA133181]; NATIONAL CANCER INSTITUTE [R00CA133181, R01CA076342] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Chung S Yang and Dr Zhihong Yang for providing human colon cancer cell lines. This work was supported by R01 CA076342 to AM and R00 CA133181 to VK.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chandramouly G, 2007, J CELL SCI, V120, P1596, DOI 10.1242/jcs.03439; Chen SY, 2008, COMMUN COMPUT PHYS, V4, pI; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Degenhardt K, 2006, CLIN CANCER RES, V12, P5298, DOI 10.1158/1078-0432.CCR-06-0439; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Konska G, 1998, INT J ONCOL, V12, P361; Li XF, 2005, J BIOL CHEM, V280, P41192, DOI 10.1074/jbc.M506884200; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	22	50	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	44					5883	5894		10.1038/onc.2010.329	http://dx.doi.org/10.1038/onc.2010.329			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697354	Green Accepted			2022-12-17	WOS:000283843400003
J	Tanaka, T; Rabbitts, TH				Tanaka, T.; Rabbitts, T. H.			Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth	ONCOGENE			English	Article						antibody fragment; cancer; lung tumourigenesis; RAS signalling; therapy	SIGNAL-TRANSDUCTION; ONCOGENIC RAS; MOUSE MODEL; LUNG; TUMORIGENICITY; BINDING; ACTIVATION; EXPRESSION; ADDICTION; PATHWAYS	RAS mutations are the most common gain-of-function change in human cancer and promise to be a critical therapy target. As a new approach, we have used a surrogate to drug the 'undruggable' (that is, RAS-effector protein-protein interactions inside cancer cells) in preclinical mouse models of RAS-dependent cancers. Using this novel reagent, we have specifically targeted RAS signalling in a transgenic mouse model of lung cancer by directly blockading RAS-effector interactions with an antibody fragment that binds to activated RAS, and show that the interaction of RAS and effectors, such as phosphoinositide 3-kinase and RAF, is necessary for tumour initiation. Further, interference with oncogenic RAS-effector interactions result in control of tumour growth in human cancer cells but, crucially, does not necessarily cause tumour regression. These findings support the concept that ablating RAS-dependent signalling in cancer will have chemo-preventive effects that confer a chronic state in cancer and suggest that mutant RAS-targeted therapies may require conjoint targeting of other molecules and/or current cancer therapeutic strategies (for example, radiotherapy and chemotherapy) to be curative. In this context, our findings suggest that the oncogene addiction model is not universally correct in its central thesis that cancer cell death is inevitable after loss of oncogenic protein function. Oncogene (2010) 29, 6064-6070; doi:10.1038/onc.2010.346; published online 6 September 2010	[Tanaka, T.; Rabbitts, T. H.] Univ Leeds, Leeds Inst Mol Med, Sect Expt Therapeut, St Jamess Univ Hosp, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Rabbitts, TH (corresponding author), Univ Leeds, Leeds Inst Mol Med, Sect Expt Therapeut, St Jamess Univ Hosp, Wellcome Trust Brenner Bldg,Beckett St, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council; University of Leeds; Medical Research Council [G0901686, G0600914] Funding Source: researchfish; MRC [G0600914, G0901686] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Leeds; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by grants from the Medical Research Council and the University of Leeds. We wish to thank Dr. Anton Berns for the conditional, Cre-dependent K-Ras<SUP>V12</SUP> transgenic mouse line. We also thank Dr Jeffrey A Whitsett for pCC10CAT-2300 for constructing the CC10 transgenic cassette. We are indebted to Debra Evans, Deborah Carter, Gillian Cardwell for animal husbandry, to Lesley Drynan for expert assistance and to Mike Shires for histology.	Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gatenby RA, 2009, NATURE, V459, P508, DOI 10.1038/459508a; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weir B, 2004, CANCER CELL, V6, P433, DOI 10.1016/j.ccr.2004.11.004	27	50	54	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6064	6070		10.1038/onc.2010.346	http://dx.doi.org/10.1038/onc.2010.346			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20818422				2022-12-17	WOS:000284108700008
J	Gao, X; Pang, J; Li, LY; Liu, WP; Di, JM; Sun, QP; Fang, YQ; Liu, XP; Pu, XY; He, D; Li, MT; Su, ZL; Li, BY				Gao, X.; Pang, J.; Li, L-Y; Liu, W-P; Di, J-M; Sun, Q-P; Fang, Y-Q; Liu, X-P; Pu, X-Y; He, D.; Li, M-T; Su, Z-L; Li, B-Y			Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer	ONCOGENE			English	Article						prostate cancer; proteomics; collapsin response mediator protein-4; metastasis-suppressor gene; methylation	UNC-33-LIKE PHOSPHOPROTEIN GENE; LYMPH-NODE METASTASIS; GROWTH CONE COLLAPSE; TRANSCRIPTION FACTORS; METHYLATION; PROMOTER; INVASION; CELLS; MICROMETASTASES; NEUROBLASTOMA	Metastasis is the chief cause of mortality from cancer, but the mechanisms leading to metastasis are poorly understood. We used a proteomics approach to screen for metastasis-associated proteins and found that collapsin response mediator protein-4 (CRMP4) expression was inversely associated with the lymph node metastasis of prostate cancer (PCa). Subsequent in vitro and in vivo studies revealed that overexpression of CRMP4 not only suppressed the invasion ability of PCa cells, but also strongly inhibited tumor metastasis in an animal model. Furthermore, methylation of a CpG island within the promoter region of the CRMP4 gene is responsible for downregulation of CRMP4 expression. Thus, in this study, we show new function of CRMP4 as a metastasis-suppressor in PCa. The findings provide new mechanistic insights into metastasis and therapeutic potential for this most common male cancer. Oncogene (2010) 29, 4555-4566; doi: 10.1038/onc.2010.213; published online 14 June 2010	[Gao, X.; Pang, J.; Li, L-Y; Liu, W-P; Di, J-M; Sun, Q-P; Fang, Y-Q; Liu, X-P; Pu, X-Y] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China; [He, D.; Su, Z-L] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China; [Li, M-T] Sun Yat Sen Univ, Prote Ctr, Zhongshan Sch Medcine, Guangzhou 510275, Guangdong, Peoples R China; [Li, B-Y] Univ Kansas, Med Ctr, Dept Urol, Kansas City, KS 66103 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Kansas; University of Kansas Medical Center	Gao, X (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Tianhe Rd 600, Guangzhou 510630, Guangdong, Peoples R China.	Xin.Gao.zsu@gmail.com	Pang, Jun/AAY-3407-2021	Pang, Jun/0000-0003-0024-9415; li, liaoyuan/0000-0002-5328-6802	Chinese National Natural Science Foundation [30772178, 30973011, 30901496]; Guangdong Provincial Science and Technology Research [7117362]; Chinese Ministry of Health; Chinese National Hi-Tech Research and Development Program [2007AA021906]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Research; Chinese Ministry of Health; Chinese National Hi-Tech Research and Development Program(National High Technology Research and Development Program of China)	We thank Professor Quentin Liu (State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University) for providing excellent technical assistances. Special thanks to Professor Zhou Zhu (Johns Hopkins University, School of Medicine, USA) for valuable suggestions and critical reading of this paper. This work was supported by Chinese National Natural Science Foundation 30772178, 30973011, 30901496, Key Project of Guangdong Provincial Science and Technology Research 7117362, Key Project of Chinese Ministry of Health and Chinese National Hi-Tech Research and Development Program 2007AA021906.	Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433; Burton JB, 2008, NAT MED, V14, P882, DOI 10.1038/nm.1727; Cai CQ, 2008, ONCOGENE, V27, P3201, DOI 10.1038/sj.onc.1210983; Cathcart MC, 2008, J PHARMACOL EXP THER, V326, P51, DOI 10.1124/jpet.107.134221; Chi AS, 2009, ONCOLOGIST, V14, P621, DOI 10.1634/theoncologist.2008-0272; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de Boer M, 2009, NEW ENGL J MED, V361, P653, DOI 10.1056/NEJMoa0904832; Deo RC, 2004, EMBO J, V23, P9, DOI 10.1038/sj.emboj.7600021; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fu HJ, 2007, J PROTEOME RES, V6, P2435, DOI 10.1021/pr060615g; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jackson D, 2006, PROTEOMICS, V6, P3901, DOI 10.1002/pmic.200500794; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Klein CA, 2008, SCIENCE, V321, P1785, DOI 10.1126/science.1164853; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Matsuo T, 2000, J BIOL CHEM, V275, P16560, DOI 10.1074/jbc.M001312200; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Miyake H, 2007, CLIN CANCER RES, V13, P1192, DOI 10.1158/1078-0432.CCR-05-2706; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Paris PL, 2004, HUM MOL GENET, V13, P1303, DOI 10.1093/hmg/ddh155; Rinker-Schaeffer CW, 2006, CLIN CANCER RES, V12, P3882, DOI 10.1158/1078-0432.CCR-06-1014; Rosslenbroich V, 2005, EXP CELL RES, V310, P434, DOI 10.1016/j.yexcr.2005.08.005; Schewe DM, 2005, CLIN CANCER RES, V11, P8538, DOI 10.1158/1078-0432.CCR-05-0786; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Shaffer DR, 2006, NAT MED, V12, P14, DOI 10.1038/nm0106-14; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Shih JY, 2003, CLIN EXP METASTAS, V20, P69, DOI 10.1023/A:1022598604565; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Uzawa K, 2002, CLIN CANCER RES, V8, P828; Wang LH, 1997, J NEUROCHEM, V69, P2261; Yacoub M, 2009, HISTOPATHOLOGY, V55, P392, DOI 10.1111/j.1365-2559.2009.03406.x; Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105; Zilberman D, 2007, NAT GENET, V39, P442, DOI 10.1038/ng0407-442	47	50	53	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2010	29	32					4555	4566		10.1038/onc.2010.213	http://dx.doi.org/10.1038/onc.2010.213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20543870				2022-12-17	WOS:000280862300006
J	Shibata, T; Kokubu, A; Miyamoto, M; Hosoda, F; Gotoh, M; Tsuta, K; Asamura, H; Matsuno, Y; Kondo, T; Imoto, I; Inazawa, J; Hirohashi, S				Shibata, T.; Kokubu, A.; Miyamoto, M.; Hosoda, F.; Gotoh, M.; Tsuta, K.; Asamura, H.; Matsuno, Y.; Kondo, T.; Imoto, I.; Inazawa, J.; Hirohashi, S.			DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung	ONCOGENE			English	Article						lung cancer; cancer stem cell; DEK; neuroendocrine	COMPARATIVE GENOMIC HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; CANCER STEM-CELLS; CHROMOSOMAL TRANSLOCATION; PROTEIN DEK; HEPATOCELLULAR-CARCINOMA; PROTOONCOGENE; EXPRESSION; CHROMATIN; DIFFERENTIATION	Lung cancer shows diverse histological subtypes. Large-cell neuroendocrine cell carcinoma and small-cell lung carcinoma show similar histological features and clinical behaviors, and can be classified as high-grade neuroendocrine carcinoma (HGNEC) of the lung. Here we elucidated the molecular classification of pulmonary endocrine tumors by copy-number profiling. We compared alterations of copy number with the clinical outcome of HGNEC and identified a chromosomal gain of the DEK oncogene locus (6p22.3) that was significantly associated with poor prognosis. We further confirmed that DEK overexpression was associated with poor prognosis in a larger set of HGNEC. Downregulation of DEK by small hairpin RNA led to a marked reduction of in vitro colony formation, in vivo tumorigenicity and chemo-resistance, and was associated with loss of lung cancer stem cell markers. Gene expression profiling revealed that DEK downregulation was associated with altered expression of transcriptional regulators, which specifically include known targets of interchromosomal translocations in hematopoietic tumors, and knockdown of these epigenetic modifiers affected colony formation activity. Our study showed that DEK overexpression, partly through an increase in its gene dose, mediates the activity of global transcriptional regulators and is associated with tumor initiation activity and poor prognosis in HGNEC. Oncogene (2010) 29, 4671-4681; doi:10.1038/onc.2010.217; published online 14 June 2010	[Shibata, T.; Kokubu, A.; Miyamoto, M.; Hosoda, F.; Hirohashi, S.] Natl Canc Ctr, Canc Genom Project, Res Inst, Chuo Ku, Tokyo 1040045, Japan; [Shibata, T.; Gotoh, M.; Hirohashi, S.] Natl Canc Ctr, Div Pathol, Res Inst, Chuo Ku, Tokyo 1040045, Japan; [Tsuta, K.] Natl Canc Ctr, Clin Lab Div, Chuo Ku, Tokyo, Japan; [Asamura, H.] Natl Canc Ctr, Div Thorac Surg, Chuo Ku, Tokyo, Japan; [Matsuno, Y.] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan; [Kondo, T.] Natl Canc Ctr, Proteome Bioinfomat Project, Res Inst, Chuo Ku, Tokyo 1040045, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Grad Sch Biomed Sci, Tokyo, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Ctr Excellence Program Frontier Res Mol Destruct, Tokyo, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Hokkaido University; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Shibata, T (corresponding author), Natl Canc Ctr, Canc Genom Project, Res Inst, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tashibat@ncc.go.jp	imoto, Issei/D-8065-2012; Shibata, Tatsuhiro/AAO-1278-2021; Kondo, Tadashi/I-4819-2019; Imoto, Issei/AAD-5799-2020; Shibata, Tatsuhiro/ABA-8234-2020	Kondo, Tadashi/0000-0001-6405-7792; 	Ministry of Health, Labor and Welfare of Japan; New Energy and Industrial Technology Development Organization (NEDO), Japan; National Institute of Biomedical Innovation (NiBio)	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); New Energy and Industrial Technology Development Organization (NEDO), Japan(New Energy and Industrial Technology Development Organization (NEDO)); National Institute of Biomedical Innovation (NiBio)(National Institute of Biomedical Innovation)	We thank Dr Weixia Peng for the initial work of array CGH and Dr Yukihiro Yoshida for the help of clinical data analysis. We thank Dr S Diane Hayward at the Johns Hopkins University for generously providing the CBF1 reporter constructs (4xwtCBF1Luc and 4xmtCBF1Luc). This work was supported in part by Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan, a grant from the New Energy and Industrial Technology Development Organization (NEDO), Japan and a grant for the program for promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio).	Alexiadis V, 2000, GENE DEV, V14, P1308; Asamura H, 2006, J CLIN ONCOL, V24, P70, DOI 10.1200/JCO.2005.04.1202; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; Cavellan E, 2006, J BIOL CHEM, V281, P16264, DOI 10.1074/jbc.M600233200; Cleary J, 2005, J BIOL CHEM, V280, P31760, DOI 10.1074/jbc.M500884200; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; D'Adda T, 2005, MODERN PATHOL, V18, P795, DOI 10.1038/modpathol.3800353; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Fujita K, 2009, J HUM GENET, V54, P355, DOI 10.1038/jhg.2009.40; Gamble MJ, 2007, NAT STRUCT MOL BIOL, V14, P548, DOI 10.1038/nsmb1248; Glinsky GV, 2008, J CLIN ONCOL, V26, P2846, DOI 10.1200/JCO.2008.17.0266; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gustafsson BI, 2008, CANCER-AM CANCER SOC, V113, P5, DOI 10.1002/cncr.23542; Han SY, 2009, PATHOL INT, V59, P443, DOI 10.1111/j.1440-1827.2009.02392.x; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Jiang TY, 2009, CANCER RES, V69, P845, DOI 10.1158/0008-5472.CAN-08-2762; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Kappes F, 2004, MOL CELL BIOL, V24, P6011, DOI 10.1128/MCB.24.13.6011-6020.2004; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Ko SI, 2006, FEBS LETT, V580, P3217, DOI 10.1016/j.febslet.2006.04.081; Kondoh N, 1999, CANCER RES, V59, P4990; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Soares LMM, 2006, SCIENCE, V312, P1961, DOI 10.1126/science.1128659; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Peacock CD, 2008, J CLIN ONCOL, V26, P2883, DOI 10.1200/JCO.2007.15.2702; Peng WX, 2005, CANCER SCI, V96, P661, DOI 10.1111/j.1349-7006.2005.00092.x; Pina C, 2008, CELL STEM CELL, V2, P264, DOI 10.1016/j.stem.2008.01.013; Righi L, 2007, VIRCHOWS ARCH, V451, pS51, DOI 10.1007/s00428-007-0445-0; Sammons M, 2006, J BIOL CHEM, V281, P26802, DOI 10.1074/jbc.M600915200; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200; Shibata T, 2005, CLIN CANCER RES, V11, P6177, DOI 10.1158/1078-0432.CCR-05-0293; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Sriuranpong V, 2001, CANCER RES, V61, P3200; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Travis W.D., 2004, PATHOLOGY GENETICS T, P341; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Walch AK, 1998, AM J PATHOL, V153, P1089, DOI 10.1016/S0002-9440(10)65653-2; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330	54	50	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4671	4681		10.1038/onc.2010.217	http://dx.doi.org/10.1038/onc.2010.217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543864				2022-12-17	WOS:000281127400006
J	Sidhu, SS; Nawroth, R; Retz, M; Lemjabbar-Alaoui, H; Dasari, V; Basbaum, C				Sidhu, S. S.; Nawroth, R.; Retz, M.; Lemjabbar-Alaoui, H.; Dasari, V.; Basbaum, C.			EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis	ONCOGENE			English	Article						CD147; EMMPRIN; beta-catenin; Wnt; lung cancer	MATRIX-METALLOPROTEINASE INDUCER; FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN; COLORECTAL-CANCER; GROWTH-FACTOR; STEM-CELLS; WNT; EXPRESSION; CD147; ACTIVATION	Advances in the field of tumor biology have identified that tumor cells co-opt developmental signaling pathways of embryonic stem cells and thus gain the ability to proliferate, differentiate and alter cell-cell interactions. One such pathway is the Wnt/beta-catenin signaling pathway. High levels of EMMPRIN expression have been shown to correlate with poor prognosis and metastasis in a broad range of tumors. Although a variety of functions are attributed to EMMPRIN in tumorigenesis, the specific mechanism(s) through which it can exert its effects have not been elucidated, until now. In this study, we identify EMMPRIN as a novel regulator of the canonical Wnt/beta-catenin signaling pathway in lung cancer. Increasing EMMPRIN expression levels in lung cancer epithelial cells upregulated the beta-catenin signaling pathway and silencing EMMPRIN inhibited beta-catenin signaling, cell migration, proliferation, anchorage-independent growth and tumor growth in a mouse tumor xenograft model. These results provide a compelling rationale for targeting EMMPRIN for anticancer therapies. Understanding the molecular mechanisms driving EMMPRIN-induced lung tumorigenesis will provide enormous benefits in developing new therapeutic treatments for this and other forms of cancer. Oncogene ( 2010) 29, 4145-4156; doi: 10.1038/onc.2010.166; published online 31 May 2010	[Sidhu, S. S.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA; [Sidhu, S. S.] Univ Calif San Francisco, Dept Med, Div Allergy Immunol, San Francisco, CA 94143 USA; [Sidhu, S. S.; Nawroth, R.; Retz, M.; Lemjabbar-Alaoui, H.; Dasari, V.; Basbaum, C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Sidhu, S. S.; Nawroth, R.; Retz, M.; Lemjabbar-Alaoui, H.; Dasari, V.; Basbaum, C.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Nawroth, R.; Retz, M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D-8000 Munich, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Technical University of Munich	Sidhu, SS (corresponding author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, HSE 1350,513 Parnassus Ave, San Francisco, CA 94143 USA.	ssidhu@ucsf.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	National Institutes of Health [PPG P01 HL024136]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the National Institutes of Health (PPG P01 HL024136). The authors would like to thank Anatol Sucher for technical support and Dr Zena Werb for critical reading of the paper. The authors also dedicate this paper to the memory of Dr Carol Basbaum (mentor and friend).	Als AB, 2007, CLIN CANCER RES, V13, P4407, DOI 10.1158/1078-0432.CCR-07-0109; Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9; Bartscherer K, 2008, EMBO REP, V9, P977, DOI 10.1038/embor.2008.167; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Betsuyaku T, 2003, AM J RESP CRIT CARE, V168, P222, DOI 10.1164/rccm.200301-103OC; BISWAS C, 1995, CANCER RES, V55, P434; Bonner AE, 2003, J MED GENET, V40, P408, DOI 10.1136/jmg.40.6.408; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Daniel VC, 2006, RESPIROLOGY, V11, P234, DOI 10.1111/j.1440-1843.2006.00838.x; Davidson B, 2003, CLIN EXP METASTAS, V20, P161, DOI 10.1023/A:1022696012668; Deora AA, 2005, P NATL ACAD SCI USA, V102, P16245, DOI 10.1073/pnas.0504419102; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023; Gagliardi M, 2008, TRAFFIC, V9, P1, DOI 10.1111/j.1600-0854.2007.00662.x; Guo HM, 1997, J BIOL CHEM, V272, P24; Huang ZQ, 2008, BIOCHEM BIOPH RES CO, V374, P517, DOI 10.1016/j.bbrc.2008.07.058; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Klein CA, 2002, NAT BIOTECHNOL, V20, P387, DOI 10.1038/nbt0402-387; Koornstra JJ, 2005, CANCER EPIDEM BIOMAR, V14, P1608, DOI 10.1158/1055-9965.EPI-05-0112; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar-Alaoui H, 2010, ONCOGENE, V29, P635, DOI 10.1038/onc.2009.365; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lowy AM, 2006, CANCER RES, V66, P4734, DOI 10.1158/0008-5472.CAN-05-4268; McEntee MF, 1999, CARCINOGENESIS, V20, P635, DOI 10.1093/carcin/20.4.635; Millimaggi D, 2007, NEOPLASIA, V9, P349, DOI 10.1593/neo.07133; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morrisey EE, 2003, AM J PATHOL, V162, P1393, DOI 10.1016/S0002-9440(10)64271-X; Nabeshima K, 2006, PATHOL INT, V56, P359, DOI 10.1111/j.1440-1827.2006.01972.x; Nawroth R, 2008, UROLOGE, V47, P1152, DOI 10.1007/s00120-008-1828-9; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Reimers N, 2004, CLIN CANCER RES, V10, P3422, DOI 10.1158/1078-0432.CCR-03-0610; Renno T, 2002, J IMMUNOL, V168, P4946, DOI 10.4049/jimmunol.168.10.4946; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Riethdorf S, 2006, INT J CANCER, V119, P1800, DOI 10.1002/ijc.22062; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070; Sienel W, 2008, MODERN PATHOL, V21, P1130, DOI 10.1038/modpathol.2008.102; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Sun JX, 2001, CANCER RES, V61, P2276; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tang Y, 2006, MOL CANCER RES, V4, P371, DOI 10.1158/1541-7786.MCR-06-0042; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Van Scoyk M, 2008, TRANSL RES, V151, P175, DOI 10.1016/j.trsl.2007.12.011; Wang WJ, 2008, CHEMOTHERAPY, V54, P291, DOI 10.1159/000151225; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Yang JM, 2006, J BIOL CHEM, V281, P9719, DOI 10.1074/jbc.M508421200; Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200; Yurchenko V, 2005, J BIOL CHEM, V280, P17013, DOI 10.1074/jbc.M412851200	63	50	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4145	4156		10.1038/onc.2010.166	http://dx.doi.org/10.1038/onc.2010.166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20514014				2022-12-17	WOS:000280151500003
J	Wen, KW; Damania, B				Wen, K. W.; Damania, B.			Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1	ONCOGENE			English	Article						KSHV; K1; heat shock proteins; Hsp90; Hsp40; lytic replication	SARCOMA-ASSOCIATED HERPESVIRUS; MULTICENTRIC CASTLEMANS-DISEASE; HEAT-SHOCK PROTEINS; KAPOSIS-SARCOMA; DNA-SEQUENCES; SIGNALING PATHWAY; STEROID-RECEPTOR; GENE-PRODUCT; IN-VIVO; GELDANAMYCIN	Kaposi sarcoma-associated herpesvirus (KSHV) is a member of the gammaherpesvirus family. It is the etiological agent of three different human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman disease. The far left end of the KSHV genome encodes a unique transmembrane glycoprotein called K1. K1 possesses the ability to transform rodent fibroblasts and block apoptosis. K1 has also been shown to activate the PI3K/Akt/mTOR pathway in different cells. Using tandem affinity purification, we identified heat shock protein 90 beta (Hsp90 beta) and endoplasmic reticulum-associated Hsp40 (Erdj3/DnaJB11), as cellular binding partners of K1. Interactions of K1 with Hsp90 beta and Hsp40 were confirmed by co-immunoprecipitation in both directions. Furthermore, K1 also interacted with the Hsp90 alpha isoform. We report that small-interfering RNAs directed against Hsp90 and Hsp40/Erdj3, as well as pharmacological inhibitors of Hsp90, dramatically reduced K1 expression, suggesting that K1 is a client protein of these chaperones. In addition, both Hsp90 and Hsp40/Erdj3 were essential for K1's antiapoptotic function. Finally, we report that the Hsp90 inhibitors, 17-AAG and 17-DMAG, can suppress the proliferation of KSHV-positive PEL cell lines and exhibited IC(50) values of 50 nM and below. Oncogene (2010) 29, 3532-3544; doi:10.1038/onc.2010.124; published online 26 April 2010	[Wen, K. W.; Damania, B.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Wen, K. W.; Damania, B.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Damania, B (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	damania@med.unc.edu			NIH [CA096500]; University of Pennsylvania [P30-AI045008]; NIAID [T32-AI007001]; MSTP [T32-GM008719]; NATIONAL CANCER INSTITUTE [R01CA096500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007001, P30AI045008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MSTP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Prasanna Bhende for help with immunohistochemistry and cell-cycle analysis and Stuart Krall for technical assistance. We thank Dr Jae Jung for providing us with the anti-K1 antibody and members of the Damania and Dittmer lab for informative discussions. We also thank the UNC Proteomics Center for processing of the protein samples and subsequent mass spectroscopy analysis. BD is a Leukemia & Lymphoma Society Scholar, American Heart Association established investigator, and a Burroughs Wellcome Fund Investigator in Infectious Disease. This work was supported by grant CA096500 from NIH and a University of Pennsylvania CFAR pilot project grant (P30-AI045008) to BD. KWW was supported in part by NIAID training Grant T32-AI007001 and MSTP Grant T32-GM008719. BD is a Leukemia & Lymphoma Society Scholar and Burroughs Welcome Fund Investigator in Infectious Disease.	Berkova Z, 2009, JNCI-J NATL CANCER I, V101, P399, DOI 10.1093/jnci/djn516; Bowser BS, 2002, J VIROL, V76, P12574, DOI 10.1128/JVI.76.24.12574-12583.2002; Burch AD, 2005, J VIROL, V79, P10740, DOI 10.1128/JVI.79.16.10740-10749.2005; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANDRIANI S, 2010, J VIROL MAR; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Damania B, 1999, J VIROL, V73, P5123, DOI 10.1128/JVI.73.6.5123-5131.1999; Damania B, 2000, J VIROL, V74, P2721, DOI 10.1128/JVI.74.6.2721-2730.2000; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Gessain A, 1996, BLOOD, V87, P414; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; Hollingshead M, 2005, CANCER CHEMOTH PHARM, V56, P115, DOI 10.1007/s00280-004-0939-2; Ivy P. S., 2004, ONCOLOGY HUNTINGT, V18, P619; Ivy PS, 2004, ONCOLOGY-NY, V18, P610; Lagunoff M, 1997, VIROLOGY, V236, P147, DOI 10.1006/viro.1997.8713; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Lee BS, 2000, J EXP MED, V192, P11, DOI 10.1084/jem.192.1.11; Lee BS, 2005, J VIROL, V79, P12173, DOI 10.1128/JVI.79.19.12173-12184.2005; Lee BS, 2003, J VIROL, V77, P8072, DOI 10.1128/JVI.77.14.8072-8086.2003; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; Lee H, 1998, MOL CELL BIOL, V18, P5219, DOI 10.1128/MCB.18.9.5219; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li W, 2007, EMBO J, V26, P1221, DOI 10.1038/sj.emboj.7601579; Livingston CM, 2008, J VIROL, V82, P6324, DOI 10.1128/JVI.00455-08; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Ohji G, 2006, J BIOCHEM, V139, P129, DOI 10.1093/jb/mvj008; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Pedersen CB, 2003, J BIOL CHEM, V278, P47449, DOI 10.1074/jbc.M309514200; Picard D, 2004, NAT CELL BIOL, V6, P479, DOI 10.1038/ncb0604-479; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Prakash O, 2005, BLOOD, V105, P3987, DOI 10.1182/blood-2004-07-2781; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Samaniego F, 2001, J Natl Cancer Inst Monogr, P15; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Shen Y, 2005, MOL BIOL CELL, V16, P40, DOI 10.1091/mbc.E04-05-0434; Shinozaki F, 2006, J BIOL CHEM, V281, P16361, DOI 10.1074/jbc.M600891200; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Tomlinson CC, 2008, J VIROL, V82, P6514, DOI 10.1128/JVI.02637-07; Trentin L, 2008, BLOOD, V112, P4665, DOI 10.1182/blood-2008-02-139139; Wang L, 2006, CANCER RES, V66, P3658, DOI 10.1158/0008-5472.CAN-05-3680; Wang L, 2004, CANCER RES, V64, P2774, DOI 10.1158/0008-5472.CAN-03-3653; Wang SZ, 2007, BLOOD, V109, P2174, DOI 10.1182/blood-2006-02-003178; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Xu WP, 2003, CANCER RES, V63, P7777; Zhang C, 2005, PLANT PHYSIOL BIOCH, V43, P13, DOI 10.1016/j.plaphy.2004.10.006	55	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3532	3544		10.1038/onc.2010.124	http://dx.doi.org/10.1038/onc.2010.124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418907	Green Accepted, Green Submitted			2022-12-17	WOS:000278835400008
J	van Eekelen, M; Sasportas, LS; Kasmieh, R; Yip, S; Figueiredo, JL; Louis, DN; Weissleder, R; Shah, K				van Eekelen, M.; Sasportas, L. S.; Kasmieh, R.; Yip, S.; Figueiredo, J-L; Louis, D. N.; Weissleder, R.; Shah, K.			Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors	ONCOGENE			English	Article						brain tumor; glioma; human neural stem cells; TSP-1; endothelial cells; angiogenesis; in vivo imaging	IN-VIVO; MALIGNANT GLIOMA; THERAPY; CANCER; ABT-510; GROWTH; APOPTOSIS; ENDOSTATIN; INHIBITOR; MIGRATION	Novel therapeutic agents combined with innovative modes of delivery and non-invasive imaging of drug delivery, pharmacokinetics and efficacy are crucial in developing effective clinical anticancer therapies. In this study, we have created and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that comprises unique regions of three type-I-repeats of TSP-1 and used engineered human neural stem cells (hNSC) to provide sustained on-site delivery of secretable aaTSP-1 to tumor-vasculature. We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microvascular endothelial cells co-cultured with established glioma cells and CD133+ glioma-initiating cells. Using human glioma cells and hNSC engineered with different combinations of fluorescent and bioluminescent marker proteins and employing multi-modality imaging techniques, we show that aaTSP-1 targets the vascular-component of gliomas and a single administration of hNSC-aaTSP-1 markedly reduces tumor vessel-density that results in inhibition of tumor-progression and increased survival in mice bearing highly malignant human gliomas. We also show that therapeutic hNSC do not proliferate and remain in an un-differentiated state in the brains of glioma-bearing mice. This study provides a platform for accelerated development of future cell-based therapies for cancer. Oncogene (2010) 29, 3185-3195; doi: 10.1038/onc.2010.75; published online 22 March 2010	[van Eekelen, M.; Sasportas, L. S.; Kasmieh, R.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA USA; [van Eekelen, M.; Sasportas, L. S.; Kasmieh, R.; Figueiredo, J-L; Weissleder, R.; Shah, K.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Louis, D. N.; Shah, K.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Yip, S.; Louis, D. N.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Yip, S.; Louis, D. N.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Figueiredo, J-L; Weissleder, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Shah, K (corresponding author), Harvard Univ, Mol Neurotherapy & Imaging Lab, Massachusetts Gen Hosp, Dept Radiol & Neurol,Med Sch, Rm 5403,149,13th St, Charlestown, MA 02129 USA.	kshah@helix.mgh.harvard.edu	Yip, Stephen/E-9994-2012; van Eekelen, Mark/A-6225-2010	Yip, Stephen/0000-0002-8514-9861; /0000-0003-0828-4143	American Cancer Society; Goldhirsh foundation; Alliance for Cancer Gene Therapy [P50 CA86355, R21CA131980]; NATIONAL CANCER INSTITUTE [P50CA086355, R21CA131980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071197] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Goldhirsh foundation; Alliance for Cancer Gene Therapy; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by American Cancer Society (KS), Goldhirsh foundation (KS), Alliance for Cancer Gene Therapy (KS), P50 CA86355 (KS, RW), R21CA131980 (KS). We thank Dr Rainer Koehler for his help with intravital microscopy and Dr Claudio Vinegoni for his help with processing images. We also thank Dr Jack Lawler (Beth Israel Deaconess Hospital, Boston) for providing us with TSP-1 cDNA construct and Dr Paul van Bergen en Henegouwen (Utrecht University, The Netherlands) for his constructive comments.	Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Anderson JC, 2007, CANCER BIOL THER, V6, P454, DOI 10.4161/cbt.6.3.3630; ASAISHI K, 1981, CANCER RES, V41, P1898; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Capillo M, 2003, CLIN CANCER RES, V9, P377; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Corsten MF, 2008, LANCET ONCOL, V9, P376, DOI 10.1016/S1470-2045(08)70099-8; Drixler TA, 2000, CANCER RES, V60, P1761; Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001; Ehtesham M, 2002, CANCER RES, V62, P7170; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Guerin C, 1997, EXS, V79, P47; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoekstra R, 2006, EUR J CANCER, V42, P467, DOI 10.1016/j.ejca.2005.08.040; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kisker O, 2001, CANCER RES, V61, P7669; Kock N, 2007, NEOPLASIA, V9, P435, DOI 10.1593/neo.07223; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Liu P, 2003, LEUKEMIA RES, V27, P701, DOI 10.1016/S0145-2126(02)00346-6; Markovic SN, 2007, AM J CLIN ONCOL-CANC, V30, P303, DOI 10.1097/01.coc.0000256104.80089.35; Montet X, 2007, RADIOLOGY, V242, P751, DOI 10.1148/radiol.2423052065; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Rusk A, 2006, CLIN CANCER RES, V12, P7444, DOI 10.1158/1078-0432.CCR-06-0109; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Shah K, 2004, CANCER RES, V64, P3236, DOI 10.1158/0008-5472.CAN-03-3516; Shah K, 2003, ONCOGENE, V22, P6865, DOI 10.1038/sj.onc.1206748; Shah K, 2008, J NEUROSCI, V28, P4406, DOI 10.1523/JNEUROSCI.0296-08.2008; Tang Y, 2003, HUM GENE THER, V14, P1247, DOI 10.1089/104303403767740786; Tuettenberg J, 2006, CRIT REV ONCOL HEMAT, V59, P181, DOI 10.1016/j.critrevonc.2006.01.004; Verhaegen M, 2002, ANAL CHEM, V74, P4378, DOI 10.1021/ac025742k; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088; Zhang XF, 2007, CANCER LETT, V247, P143, DOI 10.1016/j.canlet.2006.04.003	37	50	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3185	3195		10.1038/onc.2010.75	http://dx.doi.org/10.1038/onc.2010.75			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305695	Green Accepted			2022-12-17	WOS:000278321100002
J	Wu, Y; Wang, YY; Nakamoto, Y; Li, YY; Baba, T; Kaneko, S; Fujii, C; Mukaida, N				Wu, Y.; Wang, Y. Y.; Nakamoto, Y.; Li, Y-Y; Baba, T.; Kaneko, S.; Fujii, C.; Mukaida, N.			Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver	ONCOGENE			English	Article						serine/threonine kinase; apoptosis; cell cycle; Bad	NF-KAPPA-B; SERINE/THREONINE KINASE-ACTIVITY; BAD-MEDIATED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CHEMICAL HEPATOCARCINOGENESIS; PROTEIN-KINASE; GROWTH-FACTOR; CANCER CELLS; C-MYC; ACTIVATION	Pim-3, a proto-oncogene with serine/threonine kinase activity, was enhanced in hepatocellular carcinoma (HCC) tissues. To address the roles of Pim-3 in HCC development, we prepared transgenic mice that express human Pim-3 selectively in liver. The mice were born at a Mendelian ratio, were fertile and did not exhibit any apparent pathological changes in the liver until 1 year after birth. Pim-3-transgenic mouse-derived hepatocytes exhibited accelerated cell cycle progression. The administration of a potent hepatocarcinogen, diethylnitrosamine (DEN), induced accelerated proliferation of liver cells in Pim-3 transgenic mice in the early phase, compared with that observed for wild-type mice. Treatment with DEN induced lipid droplet accumulation with increased proliferating cell numbers 6 months after the treatment. Eventually, wild-type mice developed HCC with a frequency of 40% until 10 month after the treatment. Lipid accumulation was accelerated in Pim-3 transgenic mice with higher proliferating cell numbers, compared with that observed for wild-type mice. Pim-3 transgenic mice developed HCC with a higher incidence (80%) and a heavier burden, together with enhanced intratumoral CD31-positive vascular areas, compared with that observed for wild-type mice. These observations indicate that Pim-3 alone cannot cause, but can accelerate HCC development when induced by a hepatocarcinogen, such as DEN. Oncogene (2010) 29, 2228-2237; doi: 10.1038/onc.2009.504; published online 18 January 2010	[Wu, Y.; Wang, Y. Y.; Li, Y-Y; Baba, T.; Fujii, C.; Mukaida, N.] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9200934, Japan; [Wu, Y.] Sichuan Univ, W China Hosp, Dept Hematol, Chengdu 610064, Sichuan, Peoples R China; [Wu, Y.] Sichuan Univ, W China Hosp, Hematol Res Lab, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China; [Wu, Y.] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610064, Sichuan, Peoples R China; [Nakamoto, Y.; Kaneko, S.] Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa 9200934, Japan; [Li, Y-Y] Fudan Univ, Canc Hosp, Researcher Ctr, Shanghai 200433, Peoples R China	Kanazawa University; Sichuan University; Sichuan University; Sichuan University; Kanazawa University; Fudan University	Mukaida, N (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	naofumim@kenroku.kanazawa-u.ac.jp	Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851; Fujii, Chifumi/0000-0001-8735-5274				Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; BRAUN L, 1989, CANCER RES, V49, P1554; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chung J, 2007, LAB INVEST, V87, P540, DOI 10.1038/labinvest.3700550; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Fujii C, 2005, INT J CANCER, V114, P209, DOI 10.1002/ijc.20719; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; HOSONO S, 1993, ONCOGENE, V8, P491; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Li YY, 2006, CANCER RES, V66, P6741, DOI 10.1158/0008-5472.CAN-05-4272; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Manna SK, 2000, J IMMUNOL, V165, P5962, DOI 10.4049/jimmunol.165.10.5962; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Otani K, 2005, GASTROENTEROLOGY, V128, P96, DOI 10.1053/j.gastro.2004.10.045; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Popivanova BK, 2007, CANCER SCI, V98, P321, DOI 10.1111/j.1349-7006.2007.00390.x; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; ROBERTS RA, 1999, CARCINOGENESIS, V20, P1297; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Udalova IA, 2001, BIOCHEM BIOPH RES CO, V289, P25, DOI 10.1006/bbrc.2001.5929; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; Wang Y, 2009, INT J CANCER, V124, P540, DOI 10.1002/ijc.23995; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Wu Y, 2008, J IMMUNOL, V181, P6384, DOI 10.4049/jimmunol.181.9.6384; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang XQ, 2006, INT J CANCER, V118, P1869, DOI 10.1002/ijc.21596; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zheng HC, 2008, J CANCER RES CLIN, V134, P481, DOI 10.1007/s00432-007-0310-1; Zheng YY, 2007, HEPATOLOGY, V45, P16, DOI 10.1002/hep.21445	43	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2228	2237		10.1038/onc.2009.504	http://dx.doi.org/10.1038/onc.2009.504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101231	Green Submitted			2022-12-17	WOS:000276685200008
J	Xie, J; Litman, R; Wang, S; Peng, M; Guillemette, S; Rooney, T; Cantor, SB				Xie, J.; Litman, R.; Wang, S.; Peng, M.; Guillemette, S.; Rooney, T.; Cantor, S. B.			Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to pol eta-dependent bypass	ONCOGENE			English	Article						BRCA1; FANCJ; DNA repair	DNA-POLYMERASE-ETA; HOMOLOGY-DIRECTED REPAIR; FANCONI-ANEMIA PATHWAY; BREAST-CANCER; HELICASE BRIP1; PROTEIN; DAMAGE; BRCA1; CELLS; BACH1	BRCA1 and the DNA helicase FANCJ (also known as BACH1 or BRIP1) have common functions in breast cancer suppression and DNA repair. However, the functional significance of the direct interaction between BRCA1 and FANCJ remains unclear. Here, we have discovered that BRCA1 binding to FANCJ regulates DNA damage repair choice. Thus, when FANCJ binding to BRCA1 is ablated, the molecular mechanism chosen for the repair of damaged DNA is dramatically altered. Specifically, a FANCJ protein that cannot be phosphorylated at serine 990 or bind BRCA1 inhibits DNA repair via homologous recombination and promotes pol eta-dependent bypass. Furthermore, the pol eta-dependent bypass promoted by FANCJ requires the direct binding to the mismatch repair (MMR) protein, MLH1. Together, our findings implicate that in human cells BRCA1 binding to FANCJ is critical to regulate DNA repair choice and promote genomic stability. Moreover, unregulated FANCJ function could be associated with cancer and/or chemoresistance. Oncogene (2010) 29, 2499-2508; doi:10.1038/onc.2010.18; published online 22 February 2010	[Xie, J.; Litman, R.; Wang, S.; Peng, M.; Guillemette, S.; Rooney, T.; Cantor, S. B.] Univ Massachusetts, UMASS Mem Canc Ctr, Dept Canc Biol, Womens Cancers Program,Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University Massachusetts Worcester Hospital	Cantor, SB (corresponding author), UMASS Med Sch, Dept Canc Biol, 364 Plantat St,LRB Rm 415, Worcester, MA 01605 USA.	Sharon.Cantor@umassmed.edu			NIH [R01 CA129514-01A1]; NATIONAL CANCER INSTITUTE [R01CA129514] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Larry Thompson, Alan Lehmann, and Roger Greenberg for critical comments. We also thank Maria Jasin for the DR-U2OS cells and Alan Lehmann for the XPV-vector and pol eta-complemented lines as well as pol eta-GFP construct, Hans Joenje for FA-J cells, and Claire Baldwin for readership comments. This study was supported by NIH R01 CA129514-01A1 and from charitable contributions from Mr and Mrs Edward T Vitone Jr.	Albertella MR, 2005, CANCER RES, V65, P9799, DOI 10.1158/0008-5472.CAN-05-1095; Alt A, 2007, SCIENCE, V318, P967, DOI 10.1126/science.1148242; Barber LJ, 2008, CELL, V135, P261, DOI 10.1016/j.cell.2008.08.016; Barbour L, 2003, MUTAT RES-FUND MOL M, V532, P137, DOI 10.1016/j.mrfmmm.2003.08.014; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cantor SB, 2006, CELL CYCLE, V5, P164, DOI 10.4161/cc.5.2.2338; Delacote F, 2007, MUTAT RES-FUND MOL M, V615, P125, DOI 10.1016/j.mrfmmm.2006.11.028; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Dupaigne P, 2008, MOL CELL, V29, P243, DOI 10.1016/j.molcel.2007.11.033; Eelen G, 2008, ONCOGENE, V27, P4233, DOI 10.1038/onc.2008.51; Gupta R, 2005, J BIOL CHEM, V280, P25450, DOI 10.1074/jbc.M501995200; Hinz JM, 2006, DNA REPAIR, V5, P875, DOI 10.1016/j.dnarep.2006.05.039; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kawamoto T, 2005, MOL CELL, V20, P793, DOI 10.1016/j.molcel.2005.10.016; Kim HT, 2008, MOL CELLS, V25, P457; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Niedernhofer LJ, 2005, CELL, V123, P1191, DOI 10.1016/j.cell.2005.12.009; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Papouli E, 2005, MOL CELL, V19, P123, DOI 10.1016/j.molcel.2005.06.001; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Peng M, 2007, EMBO J, V26, P3238, DOI 10.1038/sj.emboj.7601754; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902; Shen X, 2009, MOL CELL, V35, P716, DOI 10.1016/j.molcel.2009.06.034; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Sommers JA, 2009, J BIOL CHEM, V284, P7505, DOI 10.1074/jbc.M809019200; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	43	50	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2499	2508		10.1038/onc.2010.18	http://dx.doi.org/10.1038/onc.2010.18			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20173781	Green Accepted			2022-12-17	WOS:000277169400005
J	Lacoste, S; Wiechec, E; Silva, AGD; Guffei, A; Williams, G; Lowbeer, M; Benedek, K; Henriksson, M; Klein, G; Mai, S				Lacoste, S.; Wiechec, E.; Silva, A. G. dos Santos; Guffei, A.; Williams, G.; Lowbeer, M.; Benedek, K.; Henriksson, M.; Klein, G.; Mai, S.			Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells	ONCOGENE			English	Article						Epstein-Barr virus; genomic instability; telomere dysfunction; nuclear organization	PROMOTES GENOMIC INSTABILITY; NEGATIVE BURKITTS-LYMPHOMA; STRONG TELOMERASE ACTIVITY; LATENT GENES; GROWTH PHENOTYPE; HODGKINS-DISEASE; TUMOR-CELLS; DNA-DAMAGE; LYMPHOCYTES; LINES	The Epstein-Barr virus (EBV) is carried by more than 90% of the adult world population and has been implicated in several human malignancies. Its ability to induce unlimited in vitro proliferation of B cells is frequently used to generate lymphoblastoid cell lines (LCLs). In this study, we have investigated the evolution of two LCLs up to 25 weeks after EBV infection. LCLs were karyotyped once a month by spectral karyotyping (SKY). LCLs but not mitogen-activated B cells showed evidence of DNA damage and DNA damage response within the first 2 weeks. After 4 weeks, the former, but not the latter, showed a high level of non-clonal structural aberrations, mainly deletions, fragments, dicentric chromosomes and unbalanced translocations. Genomic instability decreased thereafter over time. Nonrandom aneuploidy 12 weeks after infection showed clonal evolution in culture. After 25 weeks post-infection, most cells exhibited karyotypic stability. Chromosomal aberrations were compatible with telomere dysfunction, although in the absence of telomere shortening. The telomere capping protein TRF2 was partially displaced from telomeres in EBV-infected cells, suggesting an EBV-mediated uncapping problem. In conclusion, this study suggests that DNA damage and telomere dysfunction contribute to EBV-related chromosomal instability in early LCLs. Oncogene (2010) 29, 503-515; doi: 10.1038/onc.2009.359; published online 2 November 2009	[Lacoste, S.; Silva, A. G. dos Santos; Guffei, A.; Mai, S.] Univ Manitoba, Manitoba Inst Cell Biol, Dept Physiol, Winnipeg, MB R3E 0V9, Canada; [Wiechec, E.] Univ Aarhus, Dept Human Genet, Aarhus C, Denmark; [Williams, G.] Hlth Sci Ctr, Hematopathol Lab, Dept Pathol, Winnipeg, MB, Canada; [Lowbeer, M.; Benedek, K.; Henriksson, M.; Klein, G.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	University of Manitoba; Aarhus University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Karolinska Institutet	Mai, S (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Dept Physiol, 675 McDermot Ave,Rm ON6046, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017; Silva, Amanda/G-4992-2010; Henriksson, Marie Arsenian/F-5010-2015	Mai, Sabine/0000-0002-5797-2201; Arsenian Henriksson, Marie/0000-0001-6376-7792	Canadian Cancer Society; National Cancer Institute of Canada; Swedish Cancer Society; Canadian Institutes of Health; Manitoba Health Research Council	Canadian Cancer Society(Canadian Cancer Society (CCS)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Swedish Cancer Society(Swedish Cancer Society); Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council	We thank Mary Cheang for statistical analyses, and Ludger Klewes, Brenda Kuschak and Sabine Hombach-Klonisch for technical help. This study was supported by the Canadian Cancer Society and the National Cancer Institute of Canada (SM), the Swedish Cancer Society (GK), the Canadian Institutes of Health Research Strategic Training Program 'Innovative Technologies in Multidisciplinary Health Research Training' fellowships (SL and EW) and by a Manitoba Health Research Council post-doctoral fellowship (SL).	Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Belfiore MC, 2007, CANCER LETT, V254, P236, DOI 10.1016/j.canlet.2007.03.010; Caporali A, 2007, ONCOGENE, V26, P1398, DOI 10.1038/sj.onc.1209928; Cerimele F, 2005, P NATL ACAD SCI USA, V102, P175, DOI 10.1073/pnas.0408381102; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; CIOBANU N, 1986, MT SINAI J MED, V53, P627; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; De Vos WH, 2009, CYTOM PART A, V75A, P428, DOI 10.1002/cyto.a.20699; Diehl V, 1977, Haematol Blood Transfus, V20, P289; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Gargouri B, 2009, MOL CELL BIOCHEM, V324, P55, DOI 10.1007/s11010-008-9984-1; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GORDON J, 1986, IMMUNOLOGY, V58, P591; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; GUNVEN P, 1970, NATURE, V228, P1053, DOI 10.1038/2281053a0; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1973, NATL CANCER I MONOGR, P79; HENLE W, 1966, J BACTERIOL, V92, P269, DOI 10.1128/JB.92.1.269-271.1966; HENLE W, 1973, CANCER RES, V33, P1419; Henle W., 1979, EPSTEINBARR VIRUS, P61; Hopwood PA, 2002, TRANSPLANTATION, V74, P194, DOI 10.1097/00007890-200207270-00009; Hu BT, 1999, EUR J IMMUNOL, V29, P3745, DOI 10.1002/(SICI)1521-4141(199911)29:11<3745::AID-IMMU3745>3.0.CO;2-1; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Jeon JP, 2007, CANCER GENET CYTOGEN, V173, P122, DOI 10.1016/j.cancergencyto.2006.10.010; JONCAS J, 1974, CAN MED ASSOC J, V110, P33; Jung D, 2001, IMMUNOL INVEST, V30, P157, DOI 10.1081/IMM-100104023; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kim SH, 2004, CYTOGENET GENOME RES, V105, P292, DOI 10.1159/000078201; Knecht H, 2009, LEUKEMIA, V23, P565, DOI 10.1038/leu.2008.314; Konishi A, 2008, GENE DEV, V22, P1221, DOI 10.1101/gad.1634008; Lassoued S, 2008, MOL CELL BIOCHEM, V313, P179, DOI 10.1007/s11010-008-9755-z; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; MAI S, 2002, FISH PRACTICAL APPRO, P55; Mochida A, 2005, ARCH VIROL, V150, P2139, DOI 10.1007/s00705-005-0557-2; Nagele RG, 2001, J CELL SCI, V114, P377; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; Nilsson K, 1992, Hum Cell, V5, P25; NILSSON K, 1975, INT J CANCER, V15, P321, DOI 10.1002/ijc.2910150217; O'Nions J, 2004, J GEN VIROL, V85, P881, DOI 10.1099/vir.0.19704-0; Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905; OKANO M, 1990, AM J PATHOL, V137, P517; Okubo M, 2001, CANCER GENET CYTOGEN, V129, P30, DOI 10.1016/S0165-4608(01)00420-4; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PURTILO DT, 1980, LANCET, V1, P300; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; ROONEY CM, 1986, BRIT J HAEMATOL, V62, P413, DOI 10.1111/j.1365-2141.1986.tb02952.x; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; STEEL CM, 1977, NATURE, V270, P729, DOI 10.1038/270729a0; Sugimoto M, 1999, MECH AGEING DEV, V107, P51, DOI 10.1016/S0047-6374(98)00131-6; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Takahashi T, 2003, DNA CELL BIOL, V22, P727, DOI 10.1089/104454903770946700; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THOMAS JA, 1989, LANCET, V1, P1075; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Vermolen BJ, 2005, CYTOM PART A, V67A, P144, DOI 10.1002/cyto.a.20159; WALTER J, 1992, INT J CANCER, V50, P265, DOI 10.1002/ijc.2910500217; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; Weierich C, 2003, CHROMOSOME RES, V11, P485, DOI 10.1023/A:1025016828544; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; YOUNG LS, 1991, LANCET, V337, P1617, DOI 10.1016/0140-6736(91)93322-Z	74	50	50	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					503	515		10.1038/onc.2009.359	http://dx.doi.org/10.1038/onc.2009.359			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881539				2022-12-17	WOS:000274084600004
J	Said, N; Frierson, HF; Chernauskas, D; Conaway, M; Motamed, K; Theodorescu, D				Said, N.; Frierson, H. F., Jr.; Chernauskas, D.; Conaway, M.; Motamed, K.; Theodorescu, D.			The role of SPARC in the TRAMP model of prostate carcinogenesis and progression	ONCOGENE			English	Article						prostate neoplasms; SPARC/osteonectin; mice; TRAMP	CELL LUNG-CANCER; OVARIAN-CANCER; EXTRACELLULAR-MATRIX; TRANSGENIC MOUSE; CYSTEINE SPARC; POOR-PROGNOSIS; NULL MICE; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; ENHANCED GROWTH	SPARC (Secreted Protein Acidic and Rich in Cysteine), is a matricellular glycoprotein that is produced by tumor and/or neighboring stroma. In human prostate cancer, SPARC immunoreactivity is highest in metastatic lesions but distinct contributions of tumoral and stromal SPARC to tumorigenesis and progression are unclear. To determine the role of SPARC in primary prostate tumorigenesis, we crossed SPARC-null (SP-/-) with TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice. TRAMP(+)/SP-/- mice exhibited accelerated cancer development and progression. Compared to their TRAMP(+)/SP-/- counterparts, TRAMP(+)/SP+/+ tumors had fewer proliferating cells, and decreased cyclins A and D1 with increased p21(Cip) and p27(Kip). Similar effects on proliferation and cell-cycle regulators were observed in human prostate cancer cell lines, transiently transfected with pSPARC. TRAMP(+)/SP-/- tumors exhibited decreased stromal collagen, enhanced matrix metalloproteinase activity and increased vascular endothelial growth factor, proinflammatory cytokines. To determine the contribution of stromal SPARC, we evaluated subcutaneous tumor growth of TRAMP cell lines in syngeneic SP+/+ and SP-/- mice. Enhanced growth, decreased stromal collagen and increased proteolysis were noted in SP-/- mice. Our findings demonstrate that both tumor and stromal SPARC are limiting for primary prostate tumorigenesis and progression, through effects on the cell cycle and the creation of a less favorable tumor microenvironment. Oncogene (2009) 28, 3487-3498; doi: 10.1038/onc.2009.205; published online 13 July 2009	[Theodorescu, D.] Univ Virginia, Hlth Sci Ctr, Dept Urol, Charlottesville, VA 22908 USA; [Said, N.; Chernauskas, D.; Theodorescu, D.] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Frierson, H. F., Jr.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; [Conaway, M.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA; [Motamed, K.] Univ Virginia, Med Coll Georgia, Vasc Biol Ctr, Charlottesville, VA 22908 USA; [Theodorescu, D.] Univ Virginia, Paul Mellon Urol Canc Inst, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Urol, Box 800422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NIH [CA104106, K01-CA089689]; Georgia Cancer Coalition [GCC0023]; NATIONAL CANCER INSTITUTE [P01CA104106, K01CA089689] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH CA104106 (DT) and Georgia Cancer Coalition grant GCC0023 (KM) and the National Institutes of Health grants K01-CA089689 (KM).	Aycock RL, 2004, J INVEST DERMATOL, V123, P592, DOI 10.1111/j.0022-202X.2004.23316.x; Basu A, 1999, CELL GROWTH DIFFER, V10, P721; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555-007-9109-4; Cheetham S, 2008, BRIT J CANCER, V98, P1810, DOI 10.1038/sj.bjc.6604377; Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330; Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608; Chlenski A, 2007, ONCOGENE, V26, P4513, DOI 10.1038/sj.onc.1210247; Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357; Comstock CES, 2007, BRIT J CANCER, V96, P970, DOI 10.1038/sj.bjc.6603615; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Jacob K, 1999, CANCER RES, V59, P4453; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kato Y, 2005, INT J MOL MED, V16, P263; Kelloff GJ, 2006, CLIN CANCER RES, V12, P3661, DOI 10.1158/1078-0432.CCR-06-1104; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807; Koukourakis MI, 2003, CANCER RES, V63, P5376; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAITLAND N, 2008, METASTASIS PROSTATE, P21; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Pan MR, 2008, EXP BIOL MED, V233, P456, DOI 10.3181/0709-RM-257; Pienta KJ, 2008, PROSTATE, V68, P629, DOI 10.1002/pros.20726; Podhajcer OL, 2008, CANCER METAST REV, V27, P523, DOI 10.1007/s10555-008-9135-x; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rodriguez-Jimenez FJ, 2007, ONCOL REP, V17, P1301; Roy S, 2007, MOL CANCER THER, V6, P2696, DOI 10.1158/1535-7163.MCT-07-0104; SAGE H, 1989, J MOL CELL CARDIOL, V21, P13, DOI 10.1016/0022-2828(89)90833-X; Said N, 2005, AM J PATHOL, V167, P1739, DOI 10.1016/S0002-9440(10)61255-2; Said N, 2007, MOL CANCER RES, V5, P1015, DOI 10.1158/1541-7786.MCR-07-0001; Said N, 2007, AM J PATHOL, V170, P1054, DOI 10.2353/ajpath.2007.060903; Said NA, 2007, NEOPLASIA, V9, P23, DOI 10.1593/neo.06658; Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202; Sansom OJ, 2007, GUT, V56, P1410, DOI 10.1136/gut.2006.116921; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Schultz C, 2002, CANCER RES, V62, P6270; Seraj MJ, 2001, CLIN CANCER RES, V7, P1516; Socha MJ, 2009, NEOPLASIA, V11, P126, DOI 10.1593/neo.81146; Sova P, 2006, CANCER EPIDEM BIOMAR, V15, P114, DOI 10.1158/1055-9965.EPI-05-0323; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Suzuki M, 2005, BRIT J CANCER, V92, P942, DOI 10.1038/sj.bjc.6602376; Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289; Wong SY, 2008, CLIN EXP METASTAS, V25, P109, DOI 10.1007/s10585-007-9126-2; Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024; Yamashita K, 2003, CANCER, V97, P2412, DOI 10.1002/cncr.11368; Yang EN, 2007, INT J CANCER, V121, P567, DOI 10.1002/ijc.22706	60	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3487	3498		10.1038/onc.2009.205	http://dx.doi.org/10.1038/onc.2009.205			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19597474				2022-12-17	WOS:000270478300006
J	Tanikawa, C; Furukawa, Y; Yoshida, N; Arakawa, H; Nakamura, Y; Matsuda, K				Tanikawa, C.; Furukawa, Y.; Yoshida, N.; Arakawa, H.; Nakamura, Y.; Matsuda, K.			XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway	ONCOGENE			English	Article						XEDAR; P53; FAS; colorectal cancer; anoikis; TNFR	FOCAL-ADHESION KINASE; ECTODERMAL DYSPLASIA RECEPTOR; NF-KAPPA-B; P53-DEPENDENT APOPTOSIS; SOMATIC MUTATIONS; DNA-DAMAGE; P53 GENE; EXPRESSION; ACTIVATION; CANCER	Colorectal cancers with mutations in the p53 gene have an invasive property, but its underlying mechanism is not fully understood. Through the screening of two data sets of the genome-wide expression pro. le, one for p53-introduced cells and the other for the numbers of cancer tissues, we report here X-linked ectodermal dysplasia receptor (XEDAR), a member of the TNFR superfamily, as a novel p53 target that has a crucial role in colorectal carcinogenesis. p53 upregulated XEDAR expression through two p53-binding sites within intron 1 of the XEDAR gene. We also found a significant correlation between decreased XEDAR expressions and p53 gene mutations in breast and lung cancer cell lines (P=0.0043 and P=0.0122, respectively). Furthermore, promoter hypermethylation of the XEDAR gene was detected in 20 of 20 colorectal cancer cell lines (100%) and in 6 of 12 colorectal cancer tissues (50%), respectively. Thus, the XEDAR expression was suppressed to <25% of surrounding normal tissues in 12 of 18 colorectal cancer tissues (66.7%) due to either its epigenetic alterations and/or p53 mutations. We also found that XEDAR interacted with and subsequently caused the accumulation of FAS protein, another member of p53-inducible TNFR. Moreover, XEDAR negatively regulated FAK, a central component of focal adhesion. As a result, inactivation of XEDAR resulted in the enhancement of cell adhesion and spreading, as well as resistance to p53-induced apoptosis. Taken together, our findings showed that XEDAR is a putative tumor suppressor that could prevent malignant transformation and tumor progression by regulating apoptosis and anoikis. Oncogene (2009) 28, 3081-3092; doi:10.1038/onc.2009.154; published online 22 June 2009	[Matsuda, K.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; [Furukawa, Y.] Univ Tokyo, Div Clin Genome Res, Tokyo 1088639, Japan; [Yoshida, N.] Univ Tokyo, Inst Med Sci, Div Gene Express & Regulat, Tokyo 1088639, Japan; [Arakawa, H.] Natl Canc Ctr, Res Inst, Canc Med & Biophys Div, Tokyo 104, Japan	University of Tokyo; University of Tokyo; University of Tokyo; National Cancer Center - Japan	Matsuda, K (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	koichima@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013; Matsuda, Koichi/D-4597-2011	Arakawa, Hirofumi/0000-0001-6077-0638; Matsuda, Koichi/0000-0001-7292-2686; Tanikawa, Chizu/0000-0003-4759-4793	Japan Society for the Promotion of Science and Ministry of education, culture, sports, science and technology of Japan [18687012]	Japan Society for the Promotion of Science and Ministry of education, culture, sports, science and technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Katagiri for helpful discussion and A Takahashi K Makino for her technical assistance. This work was supported partly by grant #18687012 from Japan Society for the Promotion of Science and Ministry of education, culture, sports, science and technology of Japan (to KM). CT is a JSPS Research Fellow.	Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Diez M, 2000, ANTICANCER RES, V20, P3907; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Furutani M, 1997, CANCER LETT, V111, P191, DOI 10.1016/S0304-3835(96)04509-0; Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P373, DOI 10.1002/mc.20395; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kitahara O, 2001, CANCER RES, V61, P3544; Lark AL, 2003, CLIN CANCER RES, V9, P215; Lee SH, 1999, CANCER RES, V59, P5683; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Liu XG, 2005, CANCER RES, V65, P9169, DOI 10.1158/0008-5472.CAN-05-0939; Matsuda K, 2002, CANCER RES, V62, P2883; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Newton K, 2004, MOL CELL BIOL, V24, P1608, DOI 10.1128/MCB.24.4.1608-1613.2004; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENS LV, 1995, CANCER RES, V55, P2752; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Sinha SK, 2004, J BIOL CHEM, V279, P41873, DOI 10.1074/jbc.M407363200; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Takakuwa T, 2002, ONCOGENE, V21, P4702, DOI 10.1038/sj.onc.1205571; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	39	50	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3081	3092		10.1038/onc.2009.154	http://dx.doi.org/10.1038/onc.2009.154			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543321				2022-12-17	WOS:000269319000007
J	Lee, JY; Kang, MB; Jang, SH; Qian, T; Kim, HJ; Kim, CH; Kim, Y; Kong, G				Lee, J-Y; Kang, M-B; Jang, S-H; Qian, T.; Kim, H-J; Kim, C-H; Kim, Y.; Kong, G.			Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition	ONCOGENE			English	Article						Id-1; PTEN; p53; breast cancer	CELL-CYCLE PROGRESSION; BETA-CATENIN; EXPRESSION; P53; TRANSCRIPTION; PATHWAY	Inhibitor of differentiation-1 (Id-1) has been accepted as a putative oncogene to promote oncogenic processes through inactivation of tumor suppressors and activation of growth promoting pathways. Here, we show that Id-1 activates the Akt pathway by inhibition of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) transcription through downregulation of p53. Id-1 negatively regulated both p53 and PTEN at the transcriptional level. In promoter assay with serial deletion and chromatin immunoprecipitation assay, the binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation. This led to Akt phosphorylation at Ser473 and the activation of the Akt-mediated canonical Wnt signaling pathway. The glycogen synthase kinase-3 beta phosphorylation at Ser9, stabilization and nuclear localization of beta-catenin, T-cell factor (TCF)/lymphoid enhancer factor transactivation activity and cyclin D1 expression were enhanced by Id-1. On the other hand, Akt-mediated p27(Kip1) phosphorylation at Thr157 and its cytosolic localization were also increased in Id-1 overexpressing MCF7 cells. In conclusion, our results disclose Id-1 as a novel PTEN inhibitor that could activate the Akt pathway and its downstream effectors, the Wnt/TCF pathway and p27(Kip1) phosphorylation and suggest that the oncogenic function of Id-1 may be partly attributed to its PTEN inhibition in human breast carcinogenesis.	[Lee, J-Y; Kang, M-B; Jang, S-H; Qian, T.; Kim, H-J; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, Seoul 133791, South Korea; [Kim, C-H] Sungkyunkwan Univ, Dept Biol Sci, Kyonggi Do, South Korea; [Kim, Y.] Hanyang Univ, Dept Biochem, Coll Med, Seoul 133791, South Korea	Hanyang University; Sungkyunkwan University (SKKU); Hanyang University	Kong, G (corresponding author), Hanyang Univ, Dept Pathol, Coll Med, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr			Korean Government (MOEHRD) [KRF-2007-314-E00041]	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government)	This work was supported by a Korea Research Foundation Grant (KRF-2007-314-E00041) funded by the Korean Government (MOEHRD, Basic Research Promotion Fund).	BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Chung TW, 2003, CANCER RES, V63, P3453; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Jang KS, 2006, CANCER LETT, V244, P203, DOI 10.1016/j.canlet.2005.12.016; Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vikhanskaya F, 2007, NUCLEIC ACIDS RES, V35, P2093, DOI 10.1093/nar/gkm099; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang XM, 2007, J BIOL CHEM, V282, P33284, DOI 10.1074/jbc.M705089200	22	50	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					824	831		10.1038/onc.2008.451	http://dx.doi.org/10.1038/onc.2008.451			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19079342				2022-12-17	WOS:000263320000005
J	Wotton, S; Terry, A; Kilbey, A; Jenkins, A; Herzyk, P; Cameron, E; Neil, JC				Wotton, S.; Terry, A.; Kilbey, A.; Jenkins, A.; Herzyk, P.; Cameron, E.; Neil, J. C.			Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival	ONCOGENE			English	Article						Runx; adhesion; survival; microarray; transcription	DEPENDENT ACTIVATION; FUSION PROTEIN; REPRESSION; LEUKEMIA; CBFA1; DISRUPTION; RESISTANCE; EXPRESSION; MOLECULES; MECHANISM	The Runx genes are important in development and cancer, where they can act either as oncogenes or tumour suppressors. We compared the effects of ectopic Runx expression in established fibroblasts, where all three genes produce an indistinguishable phenotype entailing epithelioid morphology and increased cell survival under stress conditions. Gene array analysis revealed a strongly overlapping transcriptional signature, with no examples of opposing regulation of the same target gene. A common set of 50 highly regulated genes was identified after further filtering on regulation by inducible RUNX1-ER. This set revealed a strong bias toward genes with annotated roles in cancer and development, and a preponderance of targets encoding extracellular or surface proteins, reflecting the marked effects of Runx on cell adhesion. Furthermore, in silico prediction of resistance to glucocorticoid growth inhibition was confirmed in fibroblasts and lymphoid cells expressing ectopic Runx. The effects of fibroblast expression of common RUNX1 fusion oncoproteins (RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11) were also tested. Although two direct Runx activation target genes were repressed (Ncam1 and Rgc32), the fusion proteins appeared to disrupt the regulation of downregulated targets (Cebpd, Id2 and Rgs2) rather than impose constitutive repression. These results elucidate the oncogenic potential of the Runx family and reveal novel targets for therapeutic inhibition.	[Wotton, S.; Terry, A.; Kilbey, A.; Jenkins, A.; Cameron, E.; Neil, J. C.] Univ Glasgow, Inst Comparat Med, Mol Oncol Lab, Fac Vet Med, Glasgow G61 1QH, Lanark, Scotland; [Herzyk, P.] Univ Glasgow, Inst Biomed & Life Sci, Sir Henry Wellcome Funct Genom Facil, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Wotton, S (corresponding author), Univ Glasgow, Inst Comparat Med, Mol Oncol Lab, Fac Vet Med, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	S.Wotton@vet.gla.ac.uk; j.c.neil@vet.gla.ac.uk			Cancer Research, UK; Leukaemia Research Fund of Great Britain	Cancer Research, UK(Cancer Research UK); Leukaemia Research Fund of Great Britain	We thank Scott Hiebert (Vanderbilt Cancer Centre, TN, USA) for RUNX1/ETO and CBFB-MYH11 plasmids, Alan Friedman (Johns Hopkins University, MD, USA) for the AML-ER plasmid and Olivier Bernard (INSERM, Paris, France) for the TEL/RUNX1 construct. We are grateful to Torsten Schaller for the murine Runx3 cDNA and to Monica Stewart and Karen Blyth for helpful comments. This work was supported by a programme grant from Cancer Research, UK, and the Leukaemia Research Fund of Great Britain.	Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; Bianchini R, 2006, J PHARMACOL EXP THER, V319, P887, DOI 10.1124/jpet.106.108480; Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; BLYTH K, 1995, ONCOGENE, V10, P1717; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Breitling Rainer, 2005, Journal of Bioinformatics and Computational Biology, V3, P1171, DOI 10.1142/S0219720005001442; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fukushima-Nakase Y, 2005, BLOOD, V105, P4298, DOI 10.1182/blood-2004-08-3372; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Javed A, 2000, J CELL SCI, V113, P2221; Jeffery IB, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-359; Jiang HM, 2005, MOL CELL BIOL, V25, P10675, DOI 10.1128/MCB.25.24.10675-10683.2005; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Miething C, 2007, P NATL ACAD SCI USA, V104, P4594, DOI 10.1073/pnas.0604716104; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; Terry A, 2004, GENE, V336, P115, DOI 10.1016/j.gene.2004.04.015; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wotton S, 2002, CANCER RES, V62, P7181; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729	47	50	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5856	5866		10.1038/onc.2008.195	http://dx.doi.org/10.1038/onc.2008.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18560354	Green Accepted			2022-12-17	WOS:000259722400009
J	Westhoff, MA; Zhou, S; Bachem, MG; Debatin, KM; Fulda, S				Westhoff, M. A.; Zhou, S.; Bachem, M. G.; Debatin, K. M.; Fulda, S.			Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells	ONCOGENE			English	Article						cell adhesion-mediated drug resistance; glioblastoma; apoptosis	GAP JUNCTIONAL COMMUNICATION; DE-NOVO; TUMOR MICROENVIRONMENT; GLYCYRRHETINIC ACID; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; STEM-CELLS; IN-VITRO; BRAIN; SURVIVAL	The failure of malignant cells to undergo apoptosis is a major obstacle in cancer therapy, and thus identifying the underlining molecules involved therein is imperative for improving patient survival. An important mechanism of drug resistance is cell adhesion-mediated drug resistance (CAM-DR). In this study we identify a novel switch by which glioblastoma multiforme (GBM) cells alter the mode of CAM-DR. In the absence of a microenvironmental cue provided by components of the extracellular matrix (ECM), GBM cells are able to employ an alternative, but equally effective, mode of CAM-DR by forming spheres via cell-cell interactions. Intriguingly, when inhibiting cell-cell interactions in the absence of ECM components, either by low cell density or by inhibition of gap junctions (intercellular connexin tunnels) through chemical inhibition with carbenoxyolone or coincubation with the connexin-mimicking Gap27 Cx37,43 peptide, GBM cells were sensitized to tumor necrosis factor-related apoptosis- inducing ligand- and CD95-induced apoptosis. By demonstrating that GBM cells can alternate from one form of CAM-DR (cell-substrate tethering) to another (homocellular cell-cell adhesion) and that inhibition of both forms is necessary for apoptosis sensitization, our findings not only have important implications for novel approaches to restore defective apoptosis programs, but also reveal a novel role of gap junctions in GBM.	[Westhoff, M. A.; Debatin, K. M.; Fulda, S.] Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany; [Zhou, S.; Bachem, M. G.] Univ Ulm, Dept Clin Chem, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Fulda, S (corresponding author), Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Westhoff, Mike-Andrew/ABA-9272-2021; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Westhoff, Mike-Andrew/0000-0003-3256-7100; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; Ministry of Science; Research and Arts of Baden-Wurttemberg; IZKF Ulm; Wilhelm-Sander-Stiftung; Else-Kroner-Fresenius-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Ministry of Science(Ministry of Science, ICT & Future Planning, Republic of Korea); Research and Arts of Baden-Wurttemberg; IZKF Ulm; Wilhelm-Sander-Stiftung; Else-Kroner-Fresenius-Stiftung	We thank M Adam-Jager and S Piater for expert technical assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, the Ministry of Science, Research and Arts of Baden-Wurttemberg, IZKF Ulm, Wilhelm-Sander-Stiftung and Else-Kroner-Fresenius-Stiftung (to SF and KMD).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Calaora V, 2001, J NEUROSCI, V21, P4740, DOI 10.1523/JNEUROSCI.21-13-04740.2001; Cheng AW, 2004, DEV BIOL, V272, P203, DOI 10.1016/j.ydbio.2004.04.031; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Elliott Tony, 2002, Expert Rev Anticancer Ther, V2, P449, DOI 10.1586/14737140.2.4.449; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Fulda S, 1997, CANCER RES, V57, P3823; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; GLADSON CL, 1995, J CELL SCI, V108, P947; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; Green LM, 2005, RADIAT RES, V163, P172, DOI 10.1667/RR3297; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Hazlehurst LA, 2003, CANCER RES, V63, P7900; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Huang RP, 1998, CANCER RES, V58, P5089; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Krysko DV, 2005, APOPTOSIS, V10, P459, DOI 10.1007/s10495-005-1875-2; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Levin V A, 1999, Neuro Oncol, V1, P69, DOI 10.1093/neuonc/1.1.69; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Oloumi A, 2000, CANCER RES, V60, P5747; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Schmid-Kotsas A, 1999, AM J PATHOL, V155, P1749, DOI 10.1016/S0002-9440(10)65490-9; Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood-2003-12-4218; Shain KH, 2001, MOL CANCER THER, V1, P69; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; SUTHERLAND RM, 1972, BRIT J RADIOL, V45, P788, DOI 10.1259/0007-1285-45-538-788; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Wei CJ, 2005, J BIOL CHEM, V280, P19925, DOI 10.1074/jbc.M412921200; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhang W, 1999, CANCER RES, V59, P1994	41	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5169	5181		10.1038/onc.2008.148	http://dx.doi.org/10.1038/onc.2008.148			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469856				2022-12-17	WOS:000258915100001
J	Perotti, D; Gamba, B; Sardella, M; Spreafico, F; Terenziani, M; Collini, P; Pession, A; Nantron, M; Fossati-Bellani, F; Radice, P				Perotti, D.; Gamba, B.; Sardella, M.; Spreafico, F.; Terenziani, M.; Collini, P.; Pession, A.; Nantron, M.; Fossati-Bellani, F.; Radice, P.		AIEOP Wilms Tumor Study Grp	Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors	ONCOGENE			English	Article						Wilms' tumor; WTX; mutation analysis; tumor suppressor; chromosome X	BETA-CATENIN; MUTATIONS; HETEROZYGOSITY; RELAXATION; CANCER; LOCUS; 16Q	For many years the precise genetic etiology of the majority of Wilms' tumors has remained unexplained. Recently, the WTX gene, mapped to chromosome Xq11.1, has been reported to be lost or mutated in approximately one-third of Wilms' tumors. Moreover, in female cases, the somatically inactivated alleles were found to invariantly derive from the active chromosome X. Consequently, WTX has been proposed as a 'one-hit' tumor suppressor gene. To provide further insights on the contribution of WTX to the development of the disease, we have examined 102 Wilms' tumors, obtained from 43 male and 57 female patients. Quantitative PCR analyses detected WTX deletions in 5 of 45 (11%) tumors from males, whereas loss of heterozygosity at WTX-linked microsatellites was observed in 9 tumors from 50 informative females (19%). However, in the latter group, using a combination of HUMARA assay and bisulfite-modified DNA sequencing, we found that the deletion affected the active chromosome X only in two cases (4%). Sequence analyses detected an inactivating somatic mutation of WTX in a single tumor, in which a strongly reduced expression of the mutant allele respect to the wildtype allele was observed, a finding not consistent with its localization on the active chromosome X. Overall, a functional somatic nullizygosity of the WTX gene was ascertained only in seven of the Wilms' tumors included in the study ( approximately 7%). Our findings indicate that previously reported estimates on the proportion of Wilms' tumors due to WTX alterations should be reconsidered.	[Spreafico, F.; Terenziani, M.; Fossati-Bellani, F.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy; [Collini, P.] Fdn IRCCS Ist Nazl Tumori, Dept Anat Pathol, I-20133 Milan, Italy; [Pession, A.] Policlin St Orsola Malpighi, Dept Pediat Oncol & Hematol, Bologna, Italy; [Nantron, M.] Ist Giannina Gaslini, Dept Pediat Hematol & Oncol, Genoa, Italy; [Radice, P.] IFOM Fdn Ist FIRC Oncol Mol, Milan, Italy; [Perotti, D.; Gamba, B.; Sardella, M.; Radice, P.] Fdn IRCCS Ist Nazl Tumori, Genet Susceptibil Canc Unit, Dept Expt Oncol & Labs, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Genoa; IRCCS Istituto Giannina Gaslini; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan	Perotti, D (corresponding author), Fdn IRCCS Ist Nazl Tumori, Genet Susceptibil Canc Unit, Dept Expt Oncol & Labs, Via Venezian 1, I-20133 Milan, Italy.	daniela.perotti@istitutotumori.mi.it	Terenziani, Monica/B-9562-2017; Pession, Andrea/O-3200-2013; Perotti, Daniela/C-2013-2017; Collini, Paola/K-7354-2016; Spreafico, Filippo/K-7813-2016; Radice, Paolo/O-3119-2013	Terenziani, Monica/0000-0002-7080-6718; Pession, Andrea/0000-0002-0379-9562; Perotti, Daniela/0000-0002-6703-2889; Collini, Paola/0000-0002-6158-210X; Spreafico, Filippo/0000-0002-5587-3509; Radice, Paolo/0000-0001-6298-4111	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Fukuzawa R, 2007, J CLIN PATHOL, V60, P1013, DOI 10.1136/jcp.2006.043083; GRUNDY PE, 1994, CANCER RES, V54, P2331; Han M, 2007, GENE CHROMOSOME CANC, V46, P909, DOI 10.1002/gcc.20476; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Hoglund M, 2004, CANCER GENET CYTOGEN, V150, P9, DOI 10.1016/j.cancergencyto.2003.08.017; Huff V, 2007, CANCER CELL, V11, P105, DOI 10.1016/j.ccr.2007.01.011; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Little SE, 2004, J CLIN ONCOL, V22, P4140, DOI 10.1200/JCO.2004.02.136; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; MAW MA, 1992, CANCER RES, V52, P3094; Nusse R, 2007, SCIENCE, V316, P988, DOI 10.1126/science.1143337; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Perotti D, 2005, J PEDIAT HEMATOL ONC, V27, P197, DOI 10.1097/01.mph.0000161270.22313.2f; Perotti D, 2004, HUM MUTAT, V24, P400, DOI 10.1002/humu.20096; Perotti D, 2005, J PEDIAT HEMATOL ONC, V27, P521, DOI 10.1097/01.mph.0000184309.22583.66; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RADICE P, 1995, GENOMICS, V27, P497, DOI 10.1006/geno.1995.1082; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; RUTESHOUSER EC, 2007, GENE CHROMOSOME CANC, V43, P172; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Vernon EG, 2003, ONCOGENE, V22, P1371, DOI 10.1038/sj.onc.1206332	31	50	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4625	4632		10.1038/onc.2008.93	http://dx.doi.org/10.1038/onc.2008.93			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391980				2022-12-17	WOS:000258077300011
J	Kralova, J; Dvorak, M; Koc, M; Kral, V				Kralova, J.; Dvorak, M.; Koc, M.; Kral, V.			p38 MAPK plays an essential role in apoptosis induced by photoactivation of a novel ethylene glycol porphyrin derivative	ONCOGENE			English	Article						porphyrin; photoactivation; apoptosis; p38 MAPK; caspase; lysosome	CYTOCHROME-C RELEASE; ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; MEDIATED PHOTODYNAMIC THERAPY; SIGNAL-REGULATED KINASE; CARCINOMA A431 CELLS; BID CLEAVAGE; SUBCELLULAR-LOCALIZATION; BCL-2 PHOSPHORYLATION; LYSOSOMAL PHOTODAMAGE	In this study, we provide evidence that photostimulation of various cancer cells preloaded with a new photosensitizing compound, tetrakis-meso-(4-ethyleneglycol- 2,3,5,6-tetra. fluorophenyl) porphyrin (PORF-TEG), results in rapid activation of the cell death machinery. PORF-TEG, although primarily localized in lysosomes, induces mitochondria-driven apoptosis. The induction of apoptosis is accompanied by immediate and sustained activation of p38 mitogen-activated protein kinase (MAPK) and transient activation of c-Jun N-terminal kinase (JNK). Conversely, the inhibition of p38 by PD 169316 or SB202190 and by the p38a dominant-negative mutant as well as the deletion of the p38a gene (MEFs-KO) protected cells from apoptosis, whereas inhibition of JNK did not. Activation of the p38 signaling pathway occurs upstream of caspase activation. In addition, preincubation of cells with scavengers of reactive oxygen species attenuated p38 and caspase activation and increased cell survival, thus connecting reactive oxygen species formation with the activation of the p38 pathway. Later events included degradation of Bcl-2, activation of tBid, and cleavage of Bad and Mcl-1. The data suggest a key role for p38 MAPK in PORF-TEG-photoinduced apoptosis.	[Kralova, J.; Dvorak, M.; Koc, M.] Acad Sci Czech Republic, Inst Mol Genet, Dept Mol Virol, CR-14220 Prague 4, Czech Republic; [Kral, V.] Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Chemistry & Technology, Prague	Kralova, J (corresponding author), Acad Sci Czech Republic, Inst Mol Genet, Dept Mol Virol, Videnska 1083, CR-14220 Prague 4, Czech Republic.	kralova@img.cas.cz	Kralova, Jarmila/G-3834-2014; Dvořák, Michal/I-9939-2014; Koc, Michal/D-1234-2014; Kral, Vladimir/I-9518-2017; Dvorak, Michal/G-5861-2014	Kralova, Jarmila/0000-0002-4735-8857; Koc, Michal/0000-0003-0928-4196; Kral, Vladimir/0000-0001-5034-4184; 				Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; De Chiara G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hishita T, 2001, CANCER RES, V61, P2878; Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273; Ichinose S, 2006, INT J ONCOL, V29, P349; Ishisaka R, 2001, J BIOCHEM-TOKYO, V129, P35, DOI 10.1093/oxfordjournals.jbchem.a002833; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kessel D, 2000, PHOTOCHEM PHOTOBIOL, V71, P196, DOI 10.1562/0031-8655(2000)071<0196:DOTART>2.0.CO;2; Kessel D, 2002, PHOTOCH PHOTOBIO SCI, V1, P837, DOI 10.1039/b206046a; Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Klotz LO, 1998, CANCER RES, V58, P4297; Kralova J, 2003, J MED CHEM, V46, P2049, DOI 10.1021/jm021060d; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546; Oh SH, 2004, TOXICOL APPL PHARM, V194, P221, DOI 10.1016/j.taap.2003.09.011; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Saczko J, 2007, FOLIA BIOL-PRAGUE, V53, P7; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tong ZM, 2003, J PHOTOCH PHOTOBIO B, V71, P77, DOI 10.1016/j.jphotobiol.2003.08.001; Tong ZM, 2002, CANCER RES, V62, P5528; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558; Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277; Yu WP, 2001, CANCER RES, V61, P6569; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	48	50	51	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3010	3020		10.1038/sj.onc.1210960	http://dx.doi.org/10.1038/sj.onc.1210960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059338				2022-12-17	WOS:000255681700008
J	Persson, F; Winnes, M; Andren, Y; Wedell, B; Dahlenfors, R; Asp, J; Mark, J; Enlund, F; Stenman, G				Persson, F.; Winnes, M.; Andren, Y.; Wedell, B.; Dahlenfors, R.; Asp, J.; Mark, J.; Enlund, F.; Stenman, G.			High-resolution array CGH analysis of salivary gland tumors reveals fusion and amplification of the FGFR1 and PLAG1 genes in ring chromosomes	ONCOGENE			English	Article						array-CGH; gene amplification; fusion oncogene; FGFR1; PLAG1; salivary gland tumor	COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL EXPRESSION; PLEOMORPHIC ADENOMAS; IN-VITRO; CANCER; REARRANGEMENTS; TRANSLOCATION; DELETIONS; PROTEIN; BREAST	We have previously identified a subgroup of pleomorphic salivary gland adenomas with ring chromosomes of uncertain derivation. Here, we have used spectral karyotyping (SKY), fluorescence in situ hybridization (FISH) and high-resolution oligonucleotide array-CGH to determine the origin and content of these rings and to identify genes disrupted as a result of ring formation. Of 16 tumors with rings, 11 were derived from chromosome 8, 3 from chromosome 5 and 1 each from chromosomes 1, 6 and 9. Array-CGH revealed that 10/11 r(8) consisted of amplification of a 19Mb pericentromeric segment with recurrent breakpoints in FGFR1 in 8p12 and in PLAG1 in 8q12.1. Molecular analyses revealed that ring formation consistently generated novel FGFR1-PLAG1 gene fusions in which the 5'-part of FGFR1 is linked to the coding sequence of PLAG1. An alternative mechanism of PLAG1 activation was found in tumors with copy number gain of an intact PLAG1 gene. Rings derived from chromosomes 1, 5, 6 or 9 did not result in gene fusions, but rather resulted in losses indicative of the involvement of putative tumor suppressor genes on 8p, 5p, 5q and/or 6q. Our findings also reveal a novel mechanism by which FGFR1 contributes to oncogenesis and further illustrate the versatility of the FGFR1 and PLAG1 genes tumorigenesis.	[Persson, F.; Winnes, M.; Andren, Y.; Wedell, B.; Asp, J.; Enlund, F.; Stenman, G.] Sahlgrens Univ Hosp, Dept Pathol, Lundberg Lab Canc Res, SE-41345 Gothenburg, Sweden; [Dahlenfors, R.; Mark, J.] Cent Hosp Skovde, Dept Pathol, Skovde, Sweden	Sahlgrenska University Hospital	Stenman, G (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, Lundberg Lab Canc Res, SE-41345 Gothenburg, Sweden.	goran.stenman@llcr.med.gu.se	Asp, Julia/AAE-5624-2019	Enlund, Fredrik/0000-0003-0030-9393				Abbott JJ, 2006, MODERN PATHOL, V19, P1512, DOI 10.1038/modpathol.3800695; Asp J, 2006, GENE CHROMOSOME CANC, V45, P820, DOI 10.1002/gcc.20346; Astrom AK, 1999, CANCER RES, V59, P918; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Brennan C, 2004, CANCER RES, V64, P4744, DOI 10.1158/0008-5472.CAN-04-1241; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; EVESON JW, 2005, WHO CLASSIFICATION T, P254; Geurts JMW, 1997, CANCER RES, V57, P13; Gisselsson D, 1999, HUM GENET, V104, P315, DOI 10.1007/s004390050960; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Hoffman MP, 2002, DEVELOPMENT, V129, P5767, DOI 10.1242/dev.00172; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kost-Alimova M, 2003, P NATL ACAD SCI USA, V100, P6622, DOI 10.1073/pnas.0430971100; Kost-Alimova M, 2007, SEMIN CANCER BIOL, V17, P19, DOI 10.1016/j.semcancer.2006.11.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARK J, 1988, CANCER GENET CYTOGEN, V33, P229, DOI 10.1016/0165-4608(88)90033-7; Mark J, 1997, CANCER GENET CYTOGEN, V95, P9, DOI 10.1016/S0165-4608(96)00204-X; MARK J, 1983, ACTA PATH MICRO IM A, V91, P397; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164; Roijer E, 2002, AM J PATHOL, V160, P433, DOI 10.1016/S0002-9440(10)64862-6; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Sjogren H, 2000, CANCER RES, V60, P6832; Stenman G, 2005, SEMIN CANCER BIOL, V15, P224, DOI 10.1016/j.semcancer.2005.01.002; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Voz ML, 2004, ONCOGENE, V23, P179, DOI 10.1038/sj.onc.1207013; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84	38	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3072	3080		10.1038/sj.onc.1210961	http://dx.doi.org/10.1038/sj.onc.1210961			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059337				2022-12-17	WOS:000255681700015
J	Hajji, N; Wallenborg, K; Vlachos, P; Nyman, U; Hermanson, O; Joseph, B				Hajji, N.; Wallenborg, K.; Vlachos, P.; Nyman, U.; Hermanson, O.; Joseph, B.			Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells	ONCOGENE			English	Article						NSCLC; apoptosis; HDAC inhibitor; AIF; Bcl-xL	HISTONE DEACETYLASE INHIBITORS; CANCER CELLS; ANTICANCER AGENTS; EXPRESSION; RESISTANT; BCL-2; AMPLIFICATION; THERAPY; PROTEIN; POINT	Commonly used regimens in cancer therapy rely on the induction of apoptotic cell death, and drug resistance can be attributed, at least in part, to a disabled apoptotic program. Non-small cell lung carcinomas (NSCLC), exhibit an intrinsic resistance to chemotherapy. Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells. Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducingfactor (AIF)-dependent death pathway. Importantly, AIF proved to be required for the effects of TSA/VP16 as RNA knockdown of AIF resulted in a complete abolishment of TSA/VP16-induced apoptotic cell death in drug-resistant NSCLC cells. Our results thus provide evidence for the requirement of both caspase-dependent and caspase-independent apoptotic pathways in TSA/VP16-mediated death of drug-resistant NSCLC cells, and extend previous suggestions that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be valuable in the treatment of NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.	[Hajji, N.; Vlachos, P.; Nyman, U.; Joseph, B.] Karolinska Inst, Inst Environm Med, Div Toxicol & Neurotoxicol, SE-17177 Stockholm, Sweden; [Wallenborg, K.; Hermanson, O.] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol & Neurotoxicol, Box 210, SE-17177 Stockholm, Sweden.	bertrand.joseph@ki.se	hajji, nabil/AAV-1435-2020; Nyman, Ulrika/D-3708-2013; , Ola/AAF-5126-2021	Hermanson, Ola/0000-0001-9320-7921				Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Choi YH, 2005, INT J ONCOL, V27, P473; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Henderson C, 2003, DRUG RESIST UPDATE, V6, P247, DOI 10.1016/S1368-7646(03)00067-0; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Karczmarek-Borowska B, 2006, LUNG CANCER, V51, P61, DOI 10.1016/j.lungcan.2005.08.010; Komatsu N, 2006, ONCOL REP, V15, P187; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/713803693; La Thangue NB, 2004, J CHEMOTHERAPY, V16, P64, DOI 10.1179/joc.2004.16.Supplement-1.64; Lei XY, 2007, ACTA BIOCH BIOPH SIN, V39, P344, DOI 10.1111/j.1745-7270.2007.00286.x; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Pham NA, 2001, EXP CELL RES, V264, P345, DOI 10.1006/excr.2000.5148; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016; Schniewind Bodo, 2006, J Carcinog, V5, P25, DOI 10.1186/1477-3163-5-25; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yu XD, 2002, J NATL CANCER I, V94, P504; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	36	50	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3134	3144		10.1038/sj.onc.1210976	http://dx.doi.org/10.1038/sj.onc.1210976			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071312				2022-12-17	WOS:000255897600006
J	Caramel, J; Medjkane, S; Quignon, F; Delattre, O				Caramel, J.; Medjkane, S.; Quignon, F.; Delattre, O.			The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors	ONCOGENE			English	Article						SNF5/INI1; rhabdoid tumor suppressor; differentiation; SWI/SNF; adipocyte	CHROMATIN-REMODELING COMPLEX; SWI/SNF COMPLEX; BETA ISOFORM; CELL-CYCLE; SNF5; HSNF5/INI1; SUPPRESSOR; MUTATIONS; TRANSCRIPTION; BINDING	ATP-dependent SWI/SNF chromatin remodeling complexes regulate cell-cycle and play critical roles in a variety of differentiation pathways. The core subunit SNF5/INI1 is a tumor suppressor that is inactivated in a highly aggressive childhood cancer of unknown cellular origin, termed malignant rhabdoid tumor (MRT). The highly undifferentiated phenotype of this tumor suggests that the loss-of-function of hSNF5/INI1 impairs specific differentiation programs of the MRT parental cell. Based on the hypothesis that these programs might be reinitialized upon hSNF5/INI1 re-expression in MRTs, we show that some MRT cell lines can differentiate toward the adipogenic lineage. We further show that the knock down of the SNF5/INI1 subunit abrogates adipocyte differentiation of murine 3T3-L1 preadipocytes and of human mesenchymal stem cells. Finally, we provide evidence that hSNF5/INI1 cooperates with C/EBP beta and PPAR gamma 2 transcriptional regulators to activate the expression of adipocyte-specific genes. These data indicate that not only the ATPase subunit of the SWI/SNF complex, but also SNF5/INI1 is required for adipocyte differentiation. They further show that MRT cell lines harbor an adipogenic differentiation potential and that the tumor suppressor role of the SNF5/INI1 subunit may rely on its ability to regulate the balance between cell proliferation and differentiation.	[Caramel, J.; Medjkane, S.; Quignon, F.; Delattre, O.] Inst Curie, INSERM, U830, Sect Rech,Unite Genet & Biol Canc, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite	Delattre, O (corresponding author), Inst Curie, INSERM, U830, Sect Rech,Unite Genet & Biol Canc, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr	Quignon, Frédérique/P-4249-2017	delattre, olivier/0000-0002-8730-2276; Caramel, Julie/0000-0002-8883-918X; Medjkane, Souhila/0000-0001-7973-7707				Albanese P, 2006, EUR J CANCER, V42, P2326, DOI 10.1016/j.ejca.2006.03.028; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Chai JJ, 2007, CANCER RES, V67, P3002, DOI 10.1158/0008-5472.CAN-06-4207; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20-3-205; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hata K, 2005, MOL CELL BIOL, V25, P1971, DOI 10.1128/MCB.25.5.1971-1979.2005; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kashiwagi M, 2007, DEVELOPMENT, V134, P1571, DOI 10.1242/dev.001750; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krabbe C, 2005, APMIS, V113, P831, DOI 10.1111/j.1600-0463.2005.apm_3061.x; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee MC, 2002, NEUROPATHOLOGY, V22, P252, DOI 10.1046/j.1440-1789.2002.00458.x; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Medjkane S, 2004, CANCER RES, V64, P3406, DOI 10.1158/0008-5472.CAN-03-3004; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Saladin R, 1999, CELL GROWTH DIFFER, V10, P43; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	40	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2035	2044		10.1038/sj.onc.1210847	http://dx.doi.org/10.1038/sj.onc.1210847			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922027				2022-12-17	WOS:000254359100008
J	Cheng, Z; Ke, Y; Ding, X; Wang, F; Wang, H; Ahmed, K; Liu, Z; Xu, Y; Aikhionbare, F; Yan, H; Liu, J; Xue, Y; Powell, M; Liang, S; Reddy, SE; Hu, R; Huang, H; Jin, C; Yao, X				Cheng, Z.; Ke, Y.; Ding, X.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Xu, Y.; Aikhionbare, F.; Yan, H.; Liu, J.; Xue, Y.; Powell, M.; Liang, S.; Reddy, S. E.; Hu, R.; Huang, H.; Jin, C.; Yao, X.			Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response	ONCOGENE			English	Article						UV irradiation; DNA damage; TIP60; sumoylation; p53	HISTONE ACETYLTRANSFERASE; PROTEIN; P53; ACETYLATION; NUCLEAR; REPAIR	The histone acetyltransferase TIP60 regulates the DNA damage response following genotoxic stress by acetylating histone and remodeling chromatin. However, the molecular mechanisms underlying the TIP60-dependent response to UV-induced DNA damage remain poorly understood. To systematically analyse proteins that regulate TIP60 activity in response to UVirradiation, we performed a proteomic analysis of proteins selectively bound to TIP60 in response to UVirradiation using mass spectrometry and identified a novel regulatory mechanism by which TIP60 orchestrates transcriptional activation of p53-dependent checkpoint response in UV-irradiated cells. The initial step of this pathway involves UV-induced association of TIP60 with SUMO-conjugation enzymes and site-specific sumoylation of TIP60 at lysines 430 and 451 via Ubc9. This sumoylation initiates the relocation of TIP60 from nucleoplasm to the promyelocytic leukemia body, which is essential for the UV-irradiated DNA damage repair response via a p53-dependent pathway. Significantly, inhibition of TIP60 sumoylation by overexpression of non-sumoylatable mutant abrogates the p53-dependent DNA damage response, demonstrating the importance of TIP60 sumoylation in response to UV irradiation. Our biochemical characterization demonstrated that the sumoylation of TIP60 augments its acetyltransferase activity in vitro and in vivo. Thus, this study shed new light on the function and regulation of TIP60 activity in UV-irradiated DNA damage response.	[Cheng, Z.; Ke, Y.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Yan, H.; Liu, J.; Jin, C.; Yao, X.] Hefei Natl Lab, Hefei, Peoples R China; [Ding, X.; Wang, F.; Aikhionbare, F.; Powell, M.; Reddy, S. E.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Ding, X.; Yao, X.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Xu, Y.; Huang, H.] Zhejiang Univ, Dept Hematol, Hangzhou, Peoples R China; [Liang, S.] Hunan Normal Univ, Lab Protein chem, Changsha, Peoples R China; [Hu, R.] Fudan Univ, Dept Endocrinol, Shanghai 200433, Peoples R China	Morehouse School of Medicine; Beijing University of Chinese Medicine; Zhejiang University; Hunan Normal University; Fudan University	Yao, X (corresponding author), Univ Sci & Technol China, Lab Cell Dynam, Hefei 230026, Peoples R China.	yaoxb@ustc.edu.cn	Xue, Yu/G-5929-2011	Xue, Yu/0000-0002-9403-6869; Wang, Hongmei/0000-0002-5881-2488	NCRR NIH HHS [G-12-RR03034] Funding Source: Medline; NIDDK NIH HHS [DK56292] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1718; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHELTER P, 2003, NATURE, V425, P188; Shieh SY, 2000, GENE DEV, V14, P289; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Zhou FF, 2005, FEBS LETT, V579, P3369, DOI 10.1016/j.febslet.2005.04.076	22	50	55	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					931	941		10.1038/sj.onc.1210710	http://dx.doi.org/10.1038/sj.onc.1210710			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17704809				2022-12-17	WOS:000252946300005
J	Mizumachi, T; Suzuki, S; Naito, A; Carcel-Trullols, J; Evans, TT; Spring, PM; Oridate, N; Furuta, Y; Fukuda, S; Higuchi, M				Mizumachi, T.; Suzuki, S.; Naito, A.; Carcel-Trullols, J.; Evans, T. T.; Spring, P. M.; Oridate, N.; Furuta, Y.; Fukuda, S.; Higuchi, M.			Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells	ONCOGENE			English	Article						docetaxel; drug resistance; head and neck cancer; mitochondrial DNA; Fo-ATPase	BREAST-CANCER; OXIDATIVE STRESS; REACTIVE OXYGEN; P-GLYCOPROTEIN; APOPTOSIS; EXPRESSION; DEATH; DETERMINES; CARCINOMA; SYNTHASE	Docetaxel is one of the most effective chemotherapeutic agents against cancer; nevertheless, some patients develop resistance. Unfortunately, their causes and mechanisms remain unknown. We created docetaxel-resistant DRHEp2 from human laryngeal cancer HEp2 and investigated the roles of mitochondrial DNA (mtDNA) and reactive oxygen species (ROS) on docetaxel resistance. DRHEp2 had greatly increased mtDNA content. Reduction of mtDNA content in DRHEp2 by ethidium bromide treatment reduced the resistance. These results indicate the possible roles of mtDNA-coded enzymes in mitochondrial respiratory chain (MRC) in resistant mechanisms. Oligomycin A, an Fo-ATPase inhibitor, eliminated docetaxel resistance in DRHEp2; in contrast, inhibitors of other MRC did not. RNA interference targeted to Fo-ATPase d-subunit restored docetaxel-induced cytotoxicity to DRHEp2. These results indicate the roles of Fo-ATPase for resistant mechanisms. Docetaxel induced ROS generation in HEp2 but not in DRHEp2 and antioxidant pyrrolidine dithiocarbamate eliminated docetaxel-induced cytotoxicity, suggesting roles of ROS in docetaxel-induced cell death. Furthermore, inhibition of Fo-ATPase by Oligomycin A induced docetaxel-mediated ROS generation in DRHEp2. Taken together, DRHEp2 acquired docetaxel resistance through increasing Fo-ATPase, which led to diminish docetaxel-induced ROS generation and subsequently inhibited cell death. In conclusion, mtDNA plays an important role in developing docetaxel resistance through the reduction of ROS generation by regulating Fo-ATPase.	[Mizumachi, T.; Suzuki, S.; Naito, A.; Carcel-Trullols, J.; Evans, T. T.; Higuchi, M.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Mizumachi, T.; Suzuki, S.; Oridate, N.; Furuta, Y.; Fukuda, S.] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan; [Spring, P. M.] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Hokkaido University; University of Arkansas System; University of Arkansas Medical Sciences	Higuchi, M (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	mhiguchi@uams.edu	Fukuda, Satoshi/A-8433-2012; Suzuki, Seigo/G-5378-2012; Oridate, Nobuhiko/ABC-4116-2020; Oridate, Nobuhiko/G-5365-2012; Mizumachi, Takatsugu/G-5479-2012	Oridate, Nobuhiko/0000-0002-6968-3028; 	NCI NIH HHS [R01 CA100846, R01 CA100846-04, R01 CA100846-01A1, R01 CA100846-02, R01 CA100846-06, R01 CA100846-05, R01 CA100846-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Alexandre J, 2006, INT J CANCER, V119, P41, DOI 10.1002/ijc.21685; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BISSERY MC, 1995, ANTI-CANCER DRUG, V6, P339, DOI 10.1097/00001813-199506000-00001; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Caporossi D, 2003, FREE RADICAL BIO MED, V35, P1355, DOI 10.1016/j.freeradbiomed.2003.08.008; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Higuchi M, 2006, ONCOGENE, V25, P1437, DOI 10.1038/sj.onc.1209190; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kirkland RA, 2007, EXP NEUROL, V204, P458, DOI 10.1016/j.expneurol.2006.09.013; Lee CF, 2005, ANN NY ACAD SCI, V1042, P246, DOI 10.1196/annals.1338.027; Li YC, 2004, CHEMOTHERAPY, V50, P55, DOI 10.1159/000077803; Lievre A, 2005, J CLIN ONCOL, V23, P3517, DOI 10.1200/JCO.2005.07.044; Liu B, 2001, J SURG RES, V99, P179, DOI 10.1006/jsre.2001.6126; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Qian W, 2005, AM J PHYSIOL-CELL PH, V289, pC1466, DOI 10.1152/ajpcell.00265.2005; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Schaaf GJ, 2002, FREE RADICAL RES, V36, P835, DOI 10.1080/1071576021000005267; Schrijvers D, 2005, CURR OPIN ONCOL, V17, P218, DOI 10.1097/01.cco.0000158735.91723.0e; Shalli K, 2005, FASEB J, V19, P1299, DOI 10.1096/fj.04-3178fje; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; WILS P, 1994, BIOCHEM PHARMACOL, V48, P1528, DOI 10.1016/0006-2952(94)90580-0; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	30	50	54	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					831	838		10.1038/sj.onc.1210681	http://dx.doi.org/10.1038/sj.onc.1210681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17637738	Green Accepted			2022-12-17	WOS:000252884500012
J	Zhao, Y; Hamza, M; Leong, H; Lim, CB; Pan, YF; Cheung, E; Soo, KC; Iyer, N				Zhao, Y.; Hamza, Ms; Leong, H. S.; Lim, C-B; Pan, Y-F; Cheung, E.; Soo, K-C; Iyer, Ng			Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells	ONCOGENE			English	Article						KLF5; survival kinase; 5FU; bad phosphorylation	KLF5 TRANSCRIPTION FACTOR; FACTOR FAMILY; GENE; REGULATORS; GROWTH; AKT; PROLIFERATION; ACTIVATION; ONCOGENES; PATHWAY	Although Kruppel-like factor 5 (KLF5) is a transcription factor that has been implicated in pathways critical to carcinogenesis, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. Here, we describe a novel role for KLF5 in a p53-independent apoptotic pathway. Using RNA-interference technology, we show that cells deficient in KLF5 have increased sensitivity to DNA damage, regardless of p53 status. Both p53 and p53-dependent factors are unaffected by KLF5 depletion. Instead, the apoptotic phenotype consequent to damage is associated with reduced bad phosphorylation, and downregulation of Pim1. Consistently, transfection of wild-type Pim1 is sufficient to rescue this phenotype. Previous data have shown a number of putative Sp1-binding consensus sequences on the Pim1 promoter. Remarkably, chromatin immunoprecipitation studies show that KLF5 binds to the Pim1 promoter, and that binding increases soon after damage. These results identify a novel, p53-independent apoptotic pathway through which KLF5 functions in response to DNA damage. Therapeutic deregulation of this pathway could be used to modulate chemosensitivity.	[Zhao, Y.; Leong, H. S.; Lim, C-B; Soo, K-C; Iyer, Ng] Natl Canc Ctr, Wee Kim Wee Lab Surg Oncol, Dept Surg Oncol, Singapore 169610, Singapore; [Hamza, Ms; Pan, Y-F; Cheung, E.] Genome Inst Singapore, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Iyer, N (corresponding author), Natl Canc Ctr, Wee Kim Wee Lab Surg Oncol, Dept Surg Oncol, 11 Hosp Dr, Singapore 169610, Singapore.	gopaliyer@yahoo.com	Hamza, Sabry/B-8184-2011; Zhao, Yan/A-2197-2011	Pan, You-Fu/0000-0002-9996-8892; Zhao, Yan/0000-0003-0397-4049				Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CN, 2005, J CLIN ONCOL, V23, P7286, DOI 10.1200/JCO.2004.00.2253; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Nagai R, 2003, ADV EXP MED BIOL, V538, P57; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rainio EM, 2005, VIROLOGY, V333, P201, DOI 10.1016/j.virol.2005.01.001; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	34	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					1	8		10.1038/sj.onc.1210625	http://dx.doi.org/10.1038/sj.onc.1210625			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17603560				2022-12-17	WOS:000252118700001
J	Capel, E; Flejou, JF; Hamelin, R				Capel, E.; Flejou, J-F; Hamelin, R.			Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis	ONCOGENE			English	Article						microsatellite instability; HNPCC; MLH1; promoter; methylation	MICROSATELLITE INSTABILITY; DNA; HMLH1; CPG; CANCER; HYPERMETHYLATION; PREDISPOSITION; MUTATIONS; REGION; TUMORS	About 15% of colorectal cancers are called MSI because they demonstrate microsatellite instability. In most sporadic MSI cases, the DNA mismatch repair (MMR) defect is due to methylation of the MLH1 promoter. In hereditary MSI cases, it is the consequence of germline mutations of one of the MMR genes. We analysed the MLH1 promoter for methylation using the methylation-specific PCR technique. With a previously described and widely used primer set, a number of samples with an intact MMR system were found to have methylated MLH1 promoter, a finding normally associated with lack of MLH1 expression. Another primer set, specific for a more proximal region of the promoter, gave results that correlated more closely with loss of MLH1 expression. We then conducted a survey of the literature on the subject, and a total of 161 articles were examined. Although it was shown as early as 1999 that absence of MLH1 expression correlated with methylation of the proximal but not distal regions of the MLH1 promoter, 60% of published studies analysed nonspecific regions. Our findings suggest that these studies are likely to have wrongly estimated the association between methylation of the MLH1 gene and the lack of its protein expression.	INSERM, U762, F-75010 Paris, France; Univ Paris 06, IFR65, Paris, France; Hop St Antoine, Serv Anat Pathol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Hamelin, R (corresponding author), INSERM, U762, 27 rue Juliette Dodu, F-75010 Paris, France.	richard.hamelin@cephb.fr		Capel, Emilie/0000-0001-8396-2843				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Deng GR, 1999, CANCER RES, V59, P2029; Eads CA, 1999, CANCER RES, V59, P2302; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Grady WM, 2001, CANCER RES, V61, P900; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Kane MF, 1997, CANCER RES, V57, P808; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamamoto H, 2001, CANCER RES, V61, P3139	28	50	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7596	7600		10.1038/sj.onc.1210581	http://dx.doi.org/10.1038/sj.onc.1210581			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546041				2022-12-17	WOS:000251282100013
J	Kanazawa, T; Iwashita, T; Kommareddi, P; Nair, T; Misawa, K; Misawa, Y; Ueda, Y; Tono, T; Carey, TE				Kanazawa, T.; Iwashita, T.; Kommareddi, P.; Nair, T.; Misawa, K.; Misawa, Y.; Ueda, Y.; Tono, T.; Carey, T. E.			Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors	ONCOGENE			English	Article						g protein-coupled receptors; mitogen-activated protein kinase; cyclin-dependent kinase inhibitor; head and neck neoplasm	PROTEIN-KINASE; CANCER CELLS; HEAD; ARREST; 18Q; P27; EXPRESSION; RAS	Galanin receptor 1(GALR1) maps to a common region of 18q loss in head and neck squamous cell carcinomas and is frequently inactivated by methylation. To investigate effects of GALR1 and its signaling pathways, we stably expressed hemaglutinin-tagged GALR1 in a human oral carcinoma cell line (UM-SCC-1-GALR1) that expresses no endogenous GALR1. In transfected cells, galanin induced activation of the extracellular-regulated protein kinase-1/2 (ERK1/2) and suppressed proliferation. Galanin stimulation mediated decreased expression of cyclin D1 and increased expression of the cyclin-dependent kinase inhibitors (CKI), p27(Kip1) and p57(Kip2). Pretreatment with the ERK1/2-specitic inhibitor U0126 prevented these galanin-induced effects. Phosphatidylinositol 3-kinase (PI3K) pathway activation did not differ in UM-SCC-1-GALR1 and UM-SCC-1-mock cells after galanin treatment. Pertussis toxin and LY294002 inhibition demonstrated that galanin and GALR1 induce ERK1/2 activation via God, not the PI3K pathway-linked to the G beta gamma subunit. Galanin and GALR1 also inhibit colony formation and tumor growth in vivo. Our results implicate GALR1, a Gi protein-coupled receptor, as a tumor suppressor gene that inhibits cell proliferation via ERK1/2 activation.	Univ Michigan, Dept Otolaryngol Head & Neck Surg, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Ryukyus, Dept Otolaryngol Head & Neck Surg, Okinawa, Japan; Hamamatsu Univ Sch Med, Dept Otolaryngol, Hamamatsu, Shizuoka 43131, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of the Ryukyus; Hamamatsu University School of Medicine	Carey, TE (corresponding author), Univ Michigan, Dept Otolaryngol, 1301 E Ann St,6020 KHRI, Ann Arbor, MI 48109 USA.	careyte@umich.edu		Carey, Thomas/0000-0002-5202-7518	NATIONAL CANCER INSTITUTE [P50CA097248, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P30DC005188] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97248, P30 CA46592] Funding Source: Medline; NIDCD NIH HHS [P30 DC005188, P30 DC05188] Funding Source: Medline; NIDCR NIH HHS [R01 DE12477] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akervall J, 2003, CLIN CANCER RES, V9, P1750; Berger A, 2004, ENDOCRINOLOGY, V145, P500, DOI 10.1210/en.2003-0649; Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2; Cody JD, 1997, AM J MED GENET, V71, P420, DOI 10.1002/(SICI)1096-8628(19970905)71:4<420::AID-AJMG9>3.3.CO;2-A; Dixon BS, 2002, AM J PHYSIOL-CELL PH, V283, pC193, DOI 10.1152/ajpcell.00289.2001; Esposito V, 1997, CANCER RES, V57, P3381; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Han JH, 2005, J BIOL CHEM, V280, P31548, DOI 10.1074/jbc.M503431200; Henson BS, 2005, J BIOL CHEM, V280, P22564, DOI 10.1074/jbc.M414589200; Hoffmann MJ, 2005, INT J CANCER, V114, P406, DOI 10.1002/ijc.20749; Kong SM, 2000, CANCER RES, V60, P249; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; Lu XY, 2005, NEUROPEPTIDES, V39, P165, DOI 10.1016/j.npep.2004.12.013; Massarelli E, 2005, CANCER-AM CANCER SOC, V103, P952, DOI 10.1002/cncr.20879; Masuda T, 2002, CANCER RES, V62, P3819; MISAWA K, 2004, P AM ASSOC CANC RES, V44, P4271; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Otis M, 2005, ENDOCRINOLOGY, V146, P633, DOI 10.1210/en.2004-0935; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Seufferlein T, 1996, CANCER RES, V56, P5758; Takebayashi S, 2000, CANCER RES, V60, P3397; Takebayashi S, 2004, GENE CHROMOSOME CANC, V41, P145, DOI 10.1002/gcc.20066; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102	32	50	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5762	5771		10.1038/sj.onc.1210384	http://dx.doi.org/10.1038/sj.onc.1210384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17384686				2022-12-17	WOS:000248885100008
J	Morgan-Lappe, S; Woods, KW; Li, Q; Anderson, MG; Schurdak, ME; Luo, Y; Giranda, VL; Fesik, SW; Leverson, JD				Morgan-Lappe, S; Woods, KW; Li, Q; Anderson, MG; Schurdak, ME; Luo, Y; Giranda, VL; Fesik, SW; Leverson, JD			RNAi-based screening of the human kinome identies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors	ONCOGENE			English	Article						siRNA; Akt; kinome; multitargeted inhibitors	INOSITOL PHOSPHATE MULTIKINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; INTERFERING RNAS; MAMMALIAN-CELLS; CANCER-THERAPY; HUMAN HOMOLOG; DNA-PK; PATHWAY; EXPRESSION	Tumors comprise genetically heterogeneous cell populations, whose growth and survival depend on multiple signaling pathways. This has spurred the development of multitargeted therapies, including small molecules that can inhibit multiple kinases. A major challenge in designing such molecules is to determine which kinases to inhibit in each cancer to maximize efficacy and therapeutic index. We describe an approach to this problem implementing RNA interference technology. In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. siRNAs targeting casein kinase I gamma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-mediated cell killing, and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation. Small molecules targeting CSNK1G3 and/or IPMK in addition to Akt may thus exhibit increased efficacy and have the potential for improved therapeutic index.	Abbott Labs, Canc Res, Abbott Pk, IL 60064 USA; Abbott Labs, Adv Technol, Abbott Pk, IL USA	Abbott Laboratories; Abbott Laboratories	Leverson, JD (corresponding author), Abbott Labs, Canc Res, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	joel.leverson@abbott.com		Schurdak, Mark/0000-0002-1146-3268				Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Caffrey JJ, 2001, FEBS LETT, V499, P6, DOI 10.1016/S0014-5793(01)02500-5; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Deininger MWN, 2004, CANCER CELL, V6, P108, DOI 10.1016/j.ccr.2004.08.006; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Kusuda J, 1998, CYTOGENET CELL GENET, V83, P101, DOI 10.1159/000015143; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Melnikova I, 2004, NAT REV DRUG DISCOV, V3, P993, DOI 10.1038/nrd1600; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mouritzen P, 2004, BIOTECHNIQUES, V37, P492, DOI 10.2144/04373AF02; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Piccolo E, 2004, ONCOGENE, V23, P1754, DOI 10.1038/sj.onc.1207296; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	48	50	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1340	1348		10.1038/sj.onc.1209169	http://dx.doi.org/10.1038/sj.onc.1209169			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247451				2022-12-17	WOS:000235708200007
J	Iwanaga, R; Komori, H; Ishida, S; Okamura, N; Nakayama, K; Nakayama, KI; Ohtani, K				Iwanaga, R; Komori, H; Ishida, S; Okamura, N; Nakayama, K; Nakayama, KI; Ohtani, K			Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners	ONCOGENE			English	Article						cell cycle; E2F; target gene; p27(Kip1); growth stimulation	S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F; DNA-REPLICATION; CHECKPOINT RESPONSE; MICROARRAY ANALYSIS; TUMOR-SUPPRESSOR; IN-VIVO; EXPRESSION; APOPTOSIS; GROWTH	The transcription factor E2F mediates cell cycle-dependent expression of genes important for cell proliferation in response to growth stimulation. To further understand the role of E2F, we utilized a sensitive subtraction method to explore new E2F1 targets, which are expressed at low levels and might have been unrecognized in previous studies. We identified 33 new E2F1-inducible genes, including checkpoint genes Claspin and Rad51ap1, and four genes with unknown function required for cell cycle progression. Moreover, we found three groups of E2F1-inducible genes that were not induced by growth stimulation. At least, two groups of genes were directly induced by E2F1, indicating that E2F1 can regulate expression of genes not induced during the cell cycle. One included Neogenin, WASF1 and SGEF genes, which may have a role in differentiation or development. The other was the cyclin-dependent kinase inhibitor p27(Kip1), which was involved in suppression of inappropriate cell cycle progression induced by deregulated E2F. E2F1-responsive regions of these genes were located more upstream than those of typical E2F targets and did not have typical E2F sites. These results indicate that there are groups of E2F1 targets, which are regulated in a distinct manner from that of typical E2F targets.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 158, Japan; Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Lab Microbiol & Immunol, Bunkyo Ku, Tokyo, Japan; Tohoku Univ, Grad Sch Med, Dept Dev Biol, Ctr Translat & Adv Anim Res Human Dis,Aoba Ku, Sendai, Miyagi 980, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Tokyo Medical & Dental University (TMDU); National Institute of Health Sciences - Japan; Tokyo Medical & Dental University (TMDU); Tohoku University; Kyushu University	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp						Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; BALZER HJ, 1994, NUCLEIC ACIDS RES, V22, P2853, DOI 10.1093/nar/22.14.2853; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito E, 1999, GENE, V228, P93, DOI 10.1016/S0378-1119(99)00022-0; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Qi H, 2003, ENDOCRINOLOGY, V144, P1742, DOI 10.1210/en.2002-220984; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shieh SY, 2000, GENE DEV, V14, P289; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	34	50	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1786	1798		10.1038/sj.onc.1209210	http://dx.doi.org/10.1038/sj.onc.1209210			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288221				2022-12-17	WOS:000236013700010
J	Ichwan, SJA; Yamada, S; Sumrejkanchanakij, P; Ibrahim-Auerkari, E; Eto, K; Ikeda, MA				Ichwan, SJA; Yamada, S; Sumrejkanchanakij, P; Ibrahim-Auerkari, E; Eto, K; Ikeda, MA			Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells	ONCOGENE			English	Article						p53; phosphorylation; p53 resistance; apoptosis; tumor suppressor	INTERACTING PROTEIN KINASE-2; TRANSCRIPTIONAL ACTIVITY; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; POTENTIAL MEDIATOR; UV-RADIATION; IN-VIVO; ACTIVATION; PATHWAY	To investigate whether dysregulation of p53 phosphorylation confers tumor resistance to p53, we analysed the effects of wild-type p53 on oral squamous cell carcinoma (SCC) cell lines carrying various mutations of p53. Introduction of exogenous p53 neither induced apoptosis nor suppressed colony formation in HSC-3 cells lacking any detectable p53 and HSC-4 cells expressing mutant p53R248Q protein. Consistently, exogenous p53 did not induce proapoptotic p53-target genes in these p53-resistant cells. We found that phosphorylation of exogenous p53 on serine 46 (Ser46) was severely impaired in HSC-3 but not HSC-4 cells. A mutant mimicking Ser46-phosphorylation (p53S46D) enhanced proapoptotic Noxa promoter activity, and overcame the resistance to p53-mediated apoptosis and growth suppression in HSC-3 cells. Conversely, a mutant defective for Ser46-phosphorylation (p53S46A) failed to suppress the growth of p53-sensitive HSC-2 cells. In contrast to HSC-3 cells, p53S46D had no effect on HSC-4 cells, and inhibition of endogenous p53R248Q by siRNA restored p53-mediated apoptosis in HSC-4 cells, indicating a dominant-negative effect of p53R248Q protein on wild-type p53 function. These results demonstrate that the defect in Ser46 phosphorylation accounts for the p53 resistance of HSC-3 cells, and provide evidence for a mechanism underlying the acquisition of p53 resistance in oral SCC.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Sect Maxillofacial Surg, Tokyo, Japan; Chulalongkorn Univ, Fac Dent, Dept Anat, Bangkok, Thailand; Univ Indonesia, Fac Dent, Dept Oral Biol, Jakarta, Indonesia	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Chulalongkorn University; University of Indonesia	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	mikeda.emb@tmd.ac.jp	Auerkari, Elza Ibrahim/F-7406-2017; Ichwan, Solachuddin/E-6027-2016; ARIEF, SOLACHUDDIN JAUHARI/K-3011-2019	Auerkari, Elza Ibrahim/0000-0002-5680-7925; Ichwan, Solachuddin/0000-0002-2780-2455; 				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohtani S, 2004, MOL CANCER THER, V3, P93; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prives C, 1999, J PATHOL, V187, P112; Restle A, 2005, ONCOGENE, V24, P4380, DOI 10.1038/sj.onc.1208639; Rodicker F, 2003, CANCER RES, V63, P2737; SAKAI E, 1992, ONCOGENE, V7, P927; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Tamamori-Adachi M, 2003, CIRC RES, V92, pE12, DOI 10.1161/01.RES.0000049105.15329.1C; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	43	50	50	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1216	1224		10.1038/sj.onc.1209158	http://dx.doi.org/10.1038/sj.onc.1209158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247456				2022-12-17	WOS:000235537500009
J	DeAngelis, T; Chen, J; Wu, A; Prisco, M; Baserga, R				DeAngelis, T; Chen, J; Wu, A; Prisco, M; Baserga, R			Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling	ONCOGENE			English	Article						T antigen; growth factor signaling; transformation	GROWTH-FACTOR-I; BREAST-CANCER CELLS; RIBOSOMAL GENE-TRANSCRIPTION; MOUSE EMBRYO FIBROBLASTS; LARGE TUMOR-ANTIGEN; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; HEMATOPOIETIC-CELLS; SIMIAN VIRUS-40	Previous work has shown that the Simian Virus 40 T antigen (T antigen) cannot transform mouse embryo. fibroblasts (MEFs) that do not express the type 1 insulin-like growth factor receptor (IGF-IR). We have now investigated the mechanism(s) by which the transforming activity of T antigen is affected by IGF-IR signaling. We demonstrate that transformation by T antigen of MEFs and several other cell lines requires an insulin receptor substrate-1 (IRS-1) phosphorylated on tyrosines. If IRS-1 is not expressed, or is serine phosphorylated or otherwise inactive, T antigen fails to transform cells in culture. For instance, while T antigen cannot transform 32D myeloid cells (that do not express IRS-1), its transforming activity is restored by the expression of a wild-type IRS-1, but not of an IRS-1 mutated at the PI3K binding sites. The importance of IRS-1 activation of PI3K in T-antigen transformation is supported by the. finding that a constitutively activated p110 subunit of PI3K, a target of IRS-1, overcomes the inability of T antigen to transform MEFs with a serine phosphorylated IRS-1. Taken together, these results indicate that the IRS-1/PI3K signaling is one of the mechanisms regulating transformation by the SV40 T antigen. We propose that the requirement for a tyrosyl-phosphorylated IRS-1 provides a mechanism to explain the failure of T antigen to transform MEFs with deleted IGF- IR genes.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020956] Funding Source: NIH RePORTER; NCI NIH HHS [CA89640] Funding Source: Medline; NIA NIH HHS [AG 20956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Baserga Renato, 2004, VVolume 42, P235; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; CASTLES CG, 1993, CANCER RES, V53, P5934; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LIEBERMAN I, 1963, J BIOL CHEM, V238, P2141; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 2001, ONCOGENE, V20, P4842, DOI 10.1038/sj.onc.1204649; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SANTOS M, 1982, J CELL BIOCHEM, V19, P127, DOI 10.1002/jcb.240190204; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOPRANO KJ, 1979, P NATL ACAD SCI USA, V76, P3885, DOI 10.1073/pnas.76.8.3885; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VALENTINIS B, 1994, ONCOGENE, V9, P825; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White Robert J., 2004, VVolume 42, P371; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	61	50	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					32	42		10.1038/sj.onc.1209013	http://dx.doi.org/10.1038/sj.onc.1209013			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170362				2022-12-17	WOS:000234406400004
J	Hosoda, M; Ozaki, T; Miyazaki, K; Hayashi, S; Furuya, K; Watanabe, K; Nakagawa, T; Hanamoto, T; Todo, S; Nakagawara, A				Hosoda, M; Ozaki, T; Miyazaki, K; Hayashi, S; Furuya, K; Watanabe, K; Nakagawa, T; Hanamoto, T; Todo, S; Nakagawara, A			UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination	ONCOGENE			English	Article						E3 ligase; p53; p73; ubiquitin; UFD2a	KINASE C-ABL; APOPTOTIC RESPONSE; P53-RELATED PROTEIN; REGULATES P73; P53; REGION; DOMAIN; DELTA-NP73; P73-ALPHA; FAMILY	p73 protein level is kept extremely low in mammalian cultured cells and its stability may be regulated by not only the ubiquitin/proteasome-dependent proteolysis but also through other unidentified mechanisms. Here, we found for the first time that p73 is physically as well as functionally associated with the U-box-type E3/E4 ubiquitin ligase UFD2a. The immunoprecipitation experiments demonstrated that this interaction is mediated by the COOH-terminal region of p73 alpha containing SAM domain. During the cisplatin-induced apoptosis in SHSY5Y neuroblastoma cells, p73a accumulated at a protein level, whereas the endogenous UFD2a was significantly reduced in response to cisplatin. Ectopic expression of UFD2a decreased the half-life of p73 alpha in association with a significant inhibition of the p73 alpha-mediated transactivation as well as proapoptotic activity. Downregulation of endogenous UFD2a by antisense strategy resulted in a remarkable accumulation of p73a. Unexpectedly, UFD2a-mediated degradation of p73 alpha was sensitive to the proteasomal inhibitor, however, UFD2a did not affect the ubiquitination levels of p73 alpha. Taken together, our present findings imply that UFD2a might promote the proteasomal turnover of p73 in a ubiquitination-independent manner, and also suggest that UFD2a might play an important role in the regulation of cisplatin-induced apoptosis mediated by p73.	Chiba Canc Ctr, Inst Res, Div Biochem, Chuo Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Inst Res, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Hosoda, Mitsuchika/A-7534-2012					Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Mahoney JA, 2002, BIOCHEM J, V361, P587, DOI 10.1042/0264-6021:3610587; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura Y, 1997, EUR J CANCER, V33, P1986, DOI 10.1016/S0959-8049(97)00333-X; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Osada M, 2001, BIOCHEM BIOPH RES CO, V283, P1135, DOI 10.1006/bbrc.2001.4905; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Schultz J, 1997, PROTEIN SCI, V6, P249; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Stiewe T, 2002, CANCER RES, V62, P3598; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tsai KKC, 2003, CANCER RES, V63, P3418; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu LQ, 2004, ONCOGENE, V23, P4032, DOI 10.1038/sj.onc.1207538; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	43	50	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7156	7169		10.1038/sj.onc.1208872	http://dx.doi.org/10.1038/sj.onc.1208872			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170377				2022-12-17	WOS:000232990100005
J	Yan, Y; Spieker, RS; Kim, M; Stoeger, SM; Cowan, KH				Yan, Y; Spieker, RS; Kim, M; Stoeger, SM; Cowan, KH			BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation	ONCOGENE			English	Article						BRCA1; Cdc2; Cdc25C; Chk1; ERK1/2 and Wee1	DNA-DAMAGE RESPONSE; 14-3-3 PROTEIN-BINDING; TYROSINE PHOSPHORYLATION; IONIZING IRRADIATION; CANCER SUSCEPTIBILITY; CARCINOMA-CELLS; WEE1 KINASE; S-PHASE; BRCA1; CHECKPOINT	Germline mutations in the BRCA1 gene are associated with an increased susceptibility to the development of breast and ovarian cancers. Evidence suggests that BRCA1 protein plays a key role in mediating DNA damage-induced checkpoint responses. Several studies have shown that ectopic expression of BRCA1 in human cells can trigger cellular responses similar to those induced by DNA damage, including G2/M cell cycle arrest and apoptosis. While the effects of ectopic BRCA1 expression on the G2/M transition and apoptosis have been extensively studied, the factors that dictate the balance between these two responses remain poorly understood. We have recently shown that ectopic expression of BRCA1 in MCF-7 human breast cancer cells resulted in activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and G2/M cell cycle arrest. Furthermore, inhibition of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-specific inhibitors resulted in increased apoptosis, suggesting a potential role of ERK1/2 kinases in BRCA1-mediated G2/M checkpoint response. In this study, we assessed the role of ERK1/2 kinases in the regulation of BRCA1-mediated G2/M cell cycle arrest. Results indicate that BRCA1-induced G2/M cell cycle arrest and ERK1/2 activation correlate with changes in the level and/or activity of several key regulators of the G2/M checkpoint, including activation of Chk1 and Wee1 kinases, induction of 14-3-3, and down-regulation of Cdc25C. Furthermore, inhibition of ERK1/2 kinases using MEK1/2-specific inhibitors results in a marked attenuation of the BRCA1-induced G2/M arrest. Biochemical studies established that ERK1/2 inhibition abolished the effects of BRCA1 on components of the G2/M checkpoint, including regulation of Cdc25C expression and activation of Wee1 and Chk1 kinases. These results implicate a critical role of ERK1/2 signaling in the regulation of BRCA1 function on controlling the G2/M checkpoint responses.	Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA	University of Nebraska System; University of Nebraska Medical Center; Children's National Health System	Cowan, KH (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	kcowan@unmc.edu			NCI NIH HHS [P30 CA036727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen JJ, 2000, CANCER RES, V60, P5037; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deng CX, 2000, BIOESSAYS, V22, P728; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gatei M, 2000, CANCER RES, V60, P3299; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kawabe T, 2004, MOL CANCER THER, V3, P513; KHARBANDA S, 1994, CANCER RES, V54, P1412; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qin J, 2003, RADIAT RES, V159, P139, DOI 10.1667/0033-7587(2003)159[0139:MAOTDD]2.0.CO;2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yang XH, 1999, BREAST CANCER RES TR, V54, P1, DOI 10.1023/A:1006189906896; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837	52	50	54	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3285	3296		10.1038/sj.onc.1208492	http://dx.doi.org/10.1038/sj.onc.1208492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735702				2022-12-17	WOS:000228881800007
J	Berton, TR; Mitchell, DL; Guo, RF; Johnson, DG				Berton, TR; Mitchell, DL; Guo, RF; Johnson, DG			Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation	ONCOGENE			English	Article						E2F1; UV radiation; apoptosis; DNA repair; p53	NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; MOUSE SKIN CARCINOGENESIS; GLOBAL GENOMIC REPAIR; TUMOR-SUPPRESSOR P53; XERODERMA-PIGMENTOSUM; CELL-CYCLE; IN-VIVO; MICE LACKING; S-PHASE	The E2F1 transcription factor regulates the expression of genes involved in cell proliferation, apoptosis and DNA repair. Following DNA damage, E2F1 is phosphorylated and stabilized, but the physiological role of E2F1 in the response to DNA damage is unclear. We find that mice lacking E2F1 have increased levels of epidermal apoptosis compared to wild-type mice following exposure to ultraviolet B (UVB) radiation. Moreover, transgenic overexpression of E2F1 in basal layer keratinocytes suppresses apoptosis induced by UVB. Inhibition of UVB-induced apoptosis by E2F1 is unexpected given that most studies have demonstrated a proapoptotic function for E2F1. E2F1-mediated suppression of apoptosis does not involve alterations in mitogen-activated protein kinase activation or Bcl-2 downregulation in response to UVB and is independent of p53. Instead, inhibition of UVB-induced apoptosis by E2F1 correlates with a stimulation of DNA repair. Mice lacking E2F1 are impaired for the removal of DNA photoproducts, while E2F1 transgenic mice repair UVB-induced DNA damage at an accelerated rate compared to wild-type mice. These findings suggest that E2F1 participates in the response to UVB by promoting DNA repair and suppressing apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389,1808 Pk Rd 1C, Smithville, TX 78957 USA.	djohnson@mdanderson.org	Guo, Ruifeng/D-1270-2010	Johnson, David/0000-0002-6223-1790	NATIONAL CANCER INSTITUTE [T32CA009480, R01CA079648, P30CA016672, U01CA105345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [CA79648, CA16672, U01CA105345, CA09480] Funding Source: Medline; NIEHS NIH HHS [ES07784, U01ES11047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; BERG RJW, 1993, CANCER RES, V53, P4212; Berg RJW, 2000, CANCER RES, V60, P2858; Berton TP, 2001, J INVEST DERMATOL, V117, P1171, DOI 10.1046/j.0022-202x.2001.01536.x; Berton TR, 1998, MOL CARCINOGEN, V23, P175, DOI 10.1002/(SICI)1098-2744(199811)23:3<175::AID-MC6>3.0.CO;2-B; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BODE AM, 2003, SCI STKE, pRE2; Brash DE, 2001, J INVEST DERMATOL, V117, P1234, DOI 10.1046/j.0022-202x.2001.01554.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Huang YY, 1997, CANCER RES, V57, P3640; IANAI A, 2004, J BIOL CHEM, V279, P30380; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Isoherranen K, 1999, ARCH DERMATOL RES, V291, P212, DOI 10.1007/s004030050396; KANJILAL S, 1993, CANCER RES, V53, P2961; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; Meng RD, 1999, INT J ONCOL, V14, P5; Mitchell DL, 1999, CANCER RES, V59, P2875; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nichols AF, 2003, NUCLEIC ACIDS RES, V31, P562, DOI 10.1093/nar/gkg152; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Powers JT, 2004, MOL CANCER RES, V2, P203; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8; Washio F, 1999, BRIT J DERMATOL, V140, P1031; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Young LC, 2003, J INVEST DERMATOL, V121, P435, DOI 10.1046/j.1523-1747.2003.12450.x; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	89	50	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2449	2460		10.1038/sj.onc.1208462	http://dx.doi.org/10.1038/sj.onc.1208462			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735727				2022-12-17	WOS:000228180600003
J	Krasnoselsky, AL; Whiteford, CC; Wei, JS; Bilke, S; Westermann, F; Chen, QR; Khan, J				Krasnoselsky, AL; Whiteford, CC; Wei, JS; Bilke, S; Westermann, F; Chen, QR; Khan, J			Altered expression of cell cycle genes distinguishes aggressive neuroblastoma	ONCOGENE			English	Article						cDNA microarray; gene expression; principal component analysis; neuroblastoma; MYCN; gene ontology	PROLIFERATIVE ACTIVITY; MYCN; AMPLIFICATION; DIFFERENTIATION; IDENTIFICATION; PREDICTION; INDUCTION	In this study, gene expression pro. ling was performed on 103 neuroblastoma (NB) tumors, stages 1-4 with and without MYCN amplification, using cDNA microarrays containing 42578 elements. Using principal component analysis (PCA) to analyse the relationships among these samples, we confirm that the global patterns of gene expression reflect the phenotype of the tumors. To explore the biological processes that may contribute to increasing aggressive phenotype of the tumors, we utilized a statistical approach based on PCA. We identified a specific subset of the cell cycle and/or chromosome segregation genes that distinguish stage 4 NB tumors from all lower stage tumors, including stage 3. Furthermore, the control of the kinetochore assembly emerges from the Gene Ontology analysis as one of the key biological processes associated with an aggressive NB phenotype. Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors.	Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Gaithersburg, MD 20877 USA; German Canc Res Ctr, Dept Tumour Genet B030, D-69120 Heidelberg, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; German Cancer Research Center (DKFZ)	Khan, J (corresponding author), Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Room 134E,8717 Grovemont Circle, Gaithersburg, MD 20877 USA.	khanjav@mail.nih.gov	Westermann, Frank/F-7509-2013; Khan, Javed/P-9157-2014		NATIONAL CANCER INSTITUTE [Z01SC010366, ZIASC010366] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaminos M, 2003, CANCER RES, V63, P4538; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; COHN SL, 1990, AM J PATHOL, V136, P1043; DOMINICI C, 1992, ANTICANCER RES, V12, P59; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; McArdle L, 2004, CARCINOGENESIS, V25, P1599, DOI 10.1093/carcin/bgh173; Mora J, 2003, CANCER LETT, V197, P119, DOI 10.1016/S0304-3835(03)00094-6; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; Sugihara E, 2004, ONCOGENE, V23, P1005, DOI 10.1038/sj.onc.1207216; Takita J, 2004, GENE CHROMOSOME CANC, V40, P120, DOI 10.1002/gcc.20021; Tonini GP, 2003, CANCER LETT, V197, P69, DOI 10.1016/S0304-3835(03)00081-8; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Zar JH., 1999, BIOSTATISTICAL ANAL; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	32	50	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1533	1541		10.1038/sj.onc.1208341	http://dx.doi.org/10.1038/sj.onc.1208341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15592497				2022-12-17	WOS:000227218200006
J	Lee, KS; Park, JE; Asano, S; Park, CJ				Lee, KS; Park, JE; Asano, S; Park, CJ			Yeast polo-like kinases: functionally conserved multitask mitotic regulators	ONCOGENE			English	Review						yeast; polo kinase; G2/M transition; anaphase onset; mitosis exit; cytokinesis	SISTER-CHROMATID SEPARATION; CELL-CYCLE PROGRESSION; DNA-DAMAGE CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE CDC5; XENOPUS EGG EXTRACTS; COHESIN SUBUNIT SCC1; KINESIN-LIKE PROTEIN; IN-VITRO REGULATION; FISSION YEAST	The polo-like kinases (Plks) are a conserved subfamily of Ser/Thr protein kinases that play pivotal roles in regulating various cellular and biochemical events at multiple stages of M phase. Genetic and biochemical data revealed that both the budding yeast and the fission yeast polo kinase homologs (Cdc5 and Plo1, respectively) bear remarkable functional similarities with those in metazoan organisms, suggesting that the role of Plks is largely conserved throughout evolution. Thus, studies on Plks in genetically amenable lower eucaryotic organisms may yield valuable insights into the function of Plks in higher eucaryotic organisms. In this review, common properties and distinct functions of Cdc5 and Plo1 will be discussed and compared to properties and functions of Plks in higher eucaryotic organisms.	NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, KS (corresponding author), NCI, Lab Metab, Ctr Canc Res, NIH, 9000 Rockville Pike,Bldg 37,Rm 3118, Bethesda, MD 20892 USA.	kyunglee@mail.nih.gov						Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bardin AJ, 2003, MOL CELL BIOL, V23, P5018, DOI 10.1128/MCB.23.14.5018-5030.2003; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Botstein D, 1997, MOL BIOL CELL, V8, pR1, DOI 10.1091/mbc.8.1.i; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Chang F, 1996, J CELL SCI, V109, P131; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Cid VJ, 2001, MOL BIOL CELL, V12, P1645, DOI 10.1091/mbc.12.6.1645; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; Cohen-Fix O, 2003, CURR BIOL, V13, pR603, DOI 10.1016/S0960-9822(03)00526-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Cueille N, 2001, J CELL SCI, V114, P2649; Dai W, 2003, FRONT BIOSCI-LANDMRK, V8, pD1128, DOI 10.2741/1129; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Edgington NP, 1999, MOL CELL BIOL, V19, P1369; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erikson E, 2004, J BIOL CHEM, V279, P32219, DOI 10.1074/jbc.M403840200; FANG G, 1988, MOL CELL, V2, P163; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; Frenz LM, 2000, J CELL SCI, V113, P3399; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Geymonat M, 2003, J BIOL CHEM, V278, P14591, DOI 10.1074/jbc.C300059200; Geymonat M, 2002, J BIOL CHEM, V277, P28439, DOI 10.1074/jbc.M202540200; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gruneberg U, 2003, TRENDS CELL BIOL, V13, P159, DOI 10.1016/S0962-8924(03)00034-5; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hanrahan J, 2003, MOL CELL, V12, P663, DOI 10.1016/j.molcel.2003.08.006; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofken T, 2002, EMBO J, V21, P4851, DOI 10.1093/emboj/cdf481; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; Hou MC, 2004, MOL CELL BIOL, V24, P3262, DOI 10.1128/MCB.24.8.3262-3276.2004; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jaspersen SL, 2000, CURR BIOL, V10, P615, DOI 10.1016/S0960-9822(00)00491-7; Jensen S, 2002, J CELL SCI, V115, P4977, DOI 10.1242/jcs.00189; Jensen S, 2002, CURR BIOL, V12, pR221, DOI 10.1016/S0960-9822(02)00756-X; Jensen S, 2002, CELL CYCLE, V1, P300, DOI 10.4161/cc.1.5.142; Jimenez J, 1998, J CELL BIOL, V143, P1617, DOI 10.1083/jcb.143.6.1617; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Li CX, 2000, J BIOL CHEM, V275, P14381, DOI 10.1074/jbc.275.19.14381; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lim HH, 2003, MOL BIOL CELL, V14, P4734, DOI 10.1091/mbc.E03-04-0238; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Menssen R, 2001, CURR BIOL, V11, P345, DOI 10.1016/S0960-9822(01)00095-1; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Mitchell DA, 2001, MOL CELL BIOL, V21, P488, DOI 10.1128/MCB.21.2.488-500.2001; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Park CJ, 2004, MOL BIOL CELL, V15, P1711, DOI 10.1091/mbc.E03-07-0461; Park CJ, 2003, GENETICS, V163, P21; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Ro HS, 2002, P NATL ACAD SCI USA, V99, P5436, DOI 10.1073/pnas.062059999; Ross KE, 2004, DEV CELL, V6, P729, DOI 10.1016/S1534-5807(04)00128-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Salimova E, 2000, J CELL SCI, V113, P1695; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shah R, 2001, GENETICS, V159, P965; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sohrmann M, 1996, GENE DEV, V10, P2707, DOI 10.1101/gad.10.21.2707; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stenmark H, 2001, GENOME BIOL, V2; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Theesfeld CL, 2003, MOL BIOL CELL, V14, P3280, DOI 10.1091/mbc.e03-03-0154; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Toyn JH, 1997, GENETICS, V145, P85; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Waizenegger IC, 2000, CELL, V103, P399, DOI 10.1016/S0092-8674(00)00132-X; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Xu SC, 2000, CURR BIOL, V10, P329, DOI 10.1016/S0960-9822(00)00382-1; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoshida S, 2002, CURR BIOL, V12, P944, DOI 10.1016/S0960-9822(02)00870-9; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2; 2001, NAT CELL BIOL, V3, pE12	180	50	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					217	229		10.1038/sj.onc.1208271	http://dx.doi.org/10.1038/sj.onc.1208271			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640837				2022-12-17	WOS:000226183100002
J	Xia, SJJ; Barr, FG				Xia, SJJ; Barr, FG			Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein	ONCOGENE			English	Article						PAX3-FKHR; rhabdomyosarcoma; transformation; growth suppression	ALVEOLAR RHABDOMYOSARCOMA; DNA-BINDING; CRYSTAL-STRUCTURE; FUSION PROTEIN; PAIRED DOMAIN; HOMEODOMAIN; FKHR; GENE	The 2;13 chromosomal translocation occurs in most casesof the cancer alveolar rhabdomyosarcoma ( ARMS), and juxtaposes the genes encoding the PAX3 and FKHR transcription factors. The resulting chimeric protein PAX3-FKHR is a potent transcriptional activator, and is hypothesized to function as a dominant acting oncogene. To investigate its biological function, PAX3-FKHR was transduced into three immortalized murine cell lines in either a constitutive or inducible manner. These cells only tolerate expression of low PAX3-FKHR levels, which is sufficient for transformation in NIH3T3 cells. In contrast, higher PAX3-FKHR levels, which are comparable to the endogenous level expressed in ARMS cells, result in growth suppression. To determine as to which PAX3 functional domains are needed for growth suppression and transformation, inactivating mutations were introduced into the paired box and homeodomain of PAX3-FKHR. In these experiments, the homeodomain is necessary for transformation, but not growth suppression; whereas the paired box is not required for transformation but mediates growth suppression. In summary, our findings demonstrate that the transforming and growth suppressive activities of PAX3-FKHR are dominant at different activity levels and are mediated by distinct functional domains. These findings are consistent with the hypothesis that distinct expression pathways are operative in these opposing phenotypic end points.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 505C, Philadelphia, PA 19104 USA	University of Pennsylvania	Barr, FG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 505C, 422 Curie Blvd, Philadelphia, PA 19104 USA.	barrfg@mail.med.upenn.edu			NCI NIH HHS [CA64202, CA71838] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071838, R01CA064202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Barr FG, 1997, J PEDIAT HEMATOL ONC, V19, P483, DOI 10.1097/00043426-199711000-00001; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bridge JA, 2002, GENE CHROMOSOME CANC, V33, P310, DOI 10.1002/gcc.10026; Bridge JA, 2000, GENE CHROMOSOME CANC, V27, P337, DOI 10.1002/(SICI)1098-2264(200004)27:4<337::AID-GCC1>3.0.CO;2-1; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; Lam PYP, 1999, MOL CELL BIOL, V19, P594; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; TSOKOS M, 1992, ARCH PATHOL LAB MED, V116, P847; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263	20	50	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6864	6871		10.1038/sj.onc.1207850	http://dx.doi.org/10.1038/sj.onc.1207850			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286710				2022-12-17	WOS:000223750700003
J	Vineis, P				Vineis, P			Individual susceptibility to carcinogens	ONCOGENE			English	Article						SNP; carcinogen metabolism; DNA repair; dose-response; public health	DNA-REPAIR; POLYMORPHISMS; CANCER; LUNG; POPULATIONS; CYP1A1; MEAT	The contribution of polymorphisms in carcinogen metabolizing genes to overall cancer rates may vary widely between groups with differing allele frequencies and with varying levels of carcinogenic exposure. Their effects are modified by interactions with each other and with other genes, particularly those involved in DNA repair. Studies on the combined effects of particular polymorphisms on colorectal and other cancers, and also on intermediate markers such as DNA adduct formation, are discussed. Such susceptibility genes are of considerable scientific interest, but do not confer high enough risks to be clinically relevant.	Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Canc Epidemiol Unit, Turin, Italy	Imperial College London; University of Turin	Vineis, P (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, Norfolk Pl, London W2 1PG, England.	p.vineis@imperial.ac.uk						Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; BERWICK M, 2002, BIOMARKERS ENV ASS D; Burnet NG, 1998, INT J CANCER, V79, P606, DOI 10.1002/(SICI)1097-0215(19981218)79:6<606::AID-IJC9>3.0.CO;2-Y; Dybdahl M, 1999, CANCER EPIDEM BIOMAR, V8, P77; EYFJORD JE, 2000, P WORKSH MOL EP NEW; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; Garte S, 1998, CARCINOGENESIS, V19, P1329, DOI 10.1093/carcin/19.8.1329; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; Le Marchand L, 2002, MUTAT RES-FUND MOL M, V506, P205, DOI 10.1016/S0027-5107(02)00167-7; Matullo G, 2003, CANCER EPIDEM BIOMAR, V12, P674; Nicas M, 1999, J OCCUP ENVIRON MED, V41, P535, DOI 10.1097/00043764-199907000-00002; Riboli E, 2002, IARC SCI PUBLICATION, V156; Taioli E, 1999, CANCER EPIDEM BIOMAR, V8, P727; Vineis P, 2004, INT J CANCER, V108, P2, DOI 10.1002/ijc.11467; Vineis P, 2003, INT J CANCER, V104, P650, DOI 10.1002/ijc.10995; Vineis P, 1996, CANCER CAUSE CONTROL, V7, P479, DOI 10.1007/BF00052675; Vineis P, 1999, IARC SCI PUBLICATION, V148; Vogelstein B., 1998, GENETIC BASIS HUMAN; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Weber WW, 1999, MOL DIAGN, V4, P299, DOI 10.1016/S1084-8592(99)80006-X; Ye Zheng, 2002, Med Sci Monit, V8, pCR558	21	50	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2004	23	38					6477	6483		10.1038/sj.onc.1207897	http://dx.doi.org/10.1038/sj.onc.1207897			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322518				2022-12-17	WOS:000223468800012
J	Brabender, J; Marjoram, P; Salonga, D; Metzger, R; Schneider, PM; Park, JM; Schneider, S; Holscher, AH; Yin, J; Meltzer, SJ; Danenberg, KD; Danenberg, PV; Lord, RV				Brabender, J; Marjoram, P; Salonga, D; Metzger, R; Schneider, PM; Park, JM; Schneider, S; Holscher, AH; Yin, J; Meltzer, SJ; Danenberg, KD; Danenberg, PV; Lord, RV			A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus	ONCOGENE			English	Article						Barrett's esophagus; esophageal adenocarcinoma; gene expression; quantititative real-time RT-PCR	MESSENGER-RNA EXPRESSION; ARTIFICIAL NEURAL NETWORKS; CDNA MICROARRAYS; LUNG-CANCER; DISTINGUISH; METAPLASIA; APOPTOSIS; DYSPLASIA; SEQUENCE; SYNTHASE	In order to identify genes or combination of genes that have the power to discriminate between premalignant Barrett's esophagus and Barrett's associated adenocarcinoma, we analysed a panel of 23 genes using quantitative real-time RT-PCR (qRT-PCR, Taqman(R)) and bioinformatic tools. The genes chosen were either known to be associated with Barrett's carcinogenesis or were filtered from a previous cDNA microarray study on Barrett's adenocarcinoma. A total of 98 tissues, obtained from 19 patients with Barrett's esophagus (BE group) and 20 patients with Barrett's associated esophageal adenocarcinoma (EA group), were studied. Triplicate analysis for the full 23 gene of interest panel, and analysis of an internal control gene, was performed for all samples, for a total of more than 9016 single PCR reactions. We found distinct classes of gene expression patterns in the different types of tissues. The most informative genes clustered in six different classes and had significantly different expression levels in Barrett's esophagus tissues compared to adenocarcinoma tissues. Linear discriminant analysis (LDA) distinguished four genetically different groups. The normal squamous esophagus tissues from patients with BE or EA were not distinguishable from one another, but Barrett's esophagus tissues could be distinguished from adenocarcinoma tissues. Using the most informative genes, obtained from a logistic regression analysis, we were able to completely distinguish between benign Barrett's and Barrett's adenocarcinomas. This study provides the first non-array parallel mRNA quantitation analysis of a panel of genes in the Barrett's esophagus model of multistage carcinogenesis. Our results suggest that mRNA expression quantitation of a panel of genes can discriminate between premalignant and malignant Barrett's disease. Logistic regression and LDAs can be used to further identify, from the complete panel, gene subsets with the power to make these diagnostic distinctions. Expression analysis of a limited number of highly selected genes may have clinical usefulness for the treatment of patients with this disease.	Univ Cologne, Dept Visceral & Vasc Surg, D-50931 Cologne, Germany; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA; Response Genet Inc, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; VA Med Ctr, Baltimore, MD 21201 USA; Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA	University of Cologne; University of Southern California; University of Southern California; University of Southern California; University System of Maryland; University of Maryland Baltimore; University of Southern California	Brabender, J (corresponding author), Univ Cologne, Dept Visceral & Vasc Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	jan.brabender@t-online.de	Marjoram, Paul/A-3066-2008	Lord, Reginald V N/0000-0001-7475-492X	NCI NIH HHS [CA95323, CA85069, CA77057, CA098450, CA01808, CA 71716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA095323, R21CA098450, R01CA071716, U01CA085069, R01CA001808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brabender J, 2002, J GASTROINTEST SURG, V6, P359, DOI 10.1016/S1091-255X(02)00003-3; Brabender J, 2003, BRIT J CANCER, V89, P1508, DOI 10.1038/sj.bjc.6601324; Brabender J, 2002, CLIN CANCER RES, V8, P438; Brabender J, 2001, J GASTROINTEST SURG, V5, P174, DOI 10.1016/S1091-255X(01)80031-7; Brabender J, 2001, J SURG RES, V99, P301, DOI 10.1006/jsre.2001.6186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; DUBOIT S, 2002, J AM STAT ASSOC, V8, P77; Eads CA, 1999, CANCER RES, V59, P2302; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; Lord RVN, 2001, SURGERY, V129, P267, DOI 10.1067/msy.2001.110856; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; SCHERF U, 2001, P ANN M AM ASS CANC, V42, pA3288; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Suda Yasuo, 1999, Gastric Cancer, V2, P165, DOI 10.1007/s101200050041; Terashima M, 2002, ANTICANCER RES, V22, P761; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Wilson KT, 1998, CANCER RES, V58, P2929; Woodward TA, 2000, ANTICANCER RES, V20, P2427; Xu Y, 2002, CANCER RES, V62, P3493; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	27	50	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	2004	23	27					4780	4788		10.1038/sj.onc.1207663	http://dx.doi.org/10.1038/sj.onc.1207663			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107828				2022-12-17	WOS:000221799200013
J	Drivdahl, R; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Plymate, SR				Drivdahl, R; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Plymate, SR			Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9	ONCOGENE			English	Article						SOX9; prostate; androgens; IGF; cancer	PROTEIN-RELATED PROTEIN-1; MANGANESE SUPEROXIDE-DISMUTASE; ANDROGEN RECEPTOR; CANCER CELLS; EPITHELIAL-CELLS; BINDING; EXPRESSION; GENES; SEX; KINASE	Overexpression of mac25 in the prostate cancer cell line M12 effects a dramatic reversal of the transformed phenotype. cDNA array analysis of RNA from cells overproducing the mac25 protein (M12/mac25) indicated upregulation of the sex determining transcription factor SOX9. In this study, we have confirmed increased expression of SOX9 in M12/mac25 cells and have further investigated the physiological effects of increased SOX9 production. Greatly increased levels of SOX9 RNA and mature protein were demonstrated in cells transfected with a SOX9 cDNA (M12/SOX9), and gel mobility shift assays confirmed binding of nuclear protein from these cells to an oligonucleotide containing the SOX9 consensus binding sequence. M12/SOX9 cells assumed the spindle-shaped morphology characteristic of M12/mac25 cells, suggesting that SOX9 mediates some effects of mac25. Elevated expression of SOX9 resulted in a decreased rate of cellular proliferation, cell cycle arrest in G0/G1, and increased sensitivity to apoptosis. Tumor development in athymic nude mice was inhibited by 80%. Finally, prostate-specific antigen and the androgen receptor, two genes whose expression is characteristic of differentiated cells, were both upregulated in M12/SOX9 cells. These data indicate that SOX9 contributes to growth regulation by mac25 via inhibition of cell growth and promotion of differentiation.	Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA; Univ Washington, Sch Med, Mol & Cell Biol Program, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Plymate, SR (corresponding author), Univ Washington, Harborview Med Ctr, Box 359755,325 9th Ave, Seattle, WA 98104 USA.	splymate@u.washington.edu			NCI NIH HHS [R01-CA56283, P01-CA85859] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Bowles J, 2001, GENOME BIOL, V2; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clarkson MJ, 2002, TRENDS ENDOCRIN MET, V13, P106, DOI 10.1016/S1043-2760(01)00541-0; Damon SE, 1998, ENDOCRINOLOGY, V139, P3456, DOI 10.1210/en.139.8.3456; Drivdahl RH, 2001, ENDOCRINOLOGY, V142, P1990, DOI 10.1210/en.142.5.1990; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1989, FOCUS, V10, P5; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.0.CO;2-N; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; Kanai Y, 1999, HUM MOL GENET, V8, P691, DOI 10.1093/hmg/8.4.691; Kato MV, 1996, ONCOGENE, V12, P1361; Kent J, 1996, DEVELOPMENT, V122, P2813; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KOMATSU K, 2001, BIOCHEM BIOPH RES CO, V276, P109; Koopman P, 2001, J EXP ZOOL, V290, P463, DOI 10.1002/jez.1089; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Marshall OJ, 2000, MOL GENET METAB, V71, P455, DOI 10.1006/mgme.2000.3081; Millikan LE, 1999, CLIN DERMATOL, V17, P353, DOI 10.1016/S0738-081X(99)00018-8; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Olney PN, 1999, AM J MED GENET, V84, P20, DOI 10.1002/(SICI)1096-8628(19990507)84:1<20::AID-AJMG5>3.3.CO;2-E; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; PEEHL DM, 1986, IN VITRO CELL DEV B, V22, P82; Plymate SR, 2003, ONCOGENE, V22, P1024, DOI 10.1038/sj.onc.1206210; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; Spokony RF, 2002, DEVELOPMENT, V129, P421; Sprenger CC, 1999, CANCER RES, V59, P2370; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tran CP, 2002, MOL CANCER RES, V1, P113; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	55	50	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4584	4593		10.1038/sj.onc.1207603	http://dx.doi.org/10.1038/sj.onc.1207603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077158				2022-12-17	WOS:000221799000008
J	Weinmann, M; Jendrossek, V; Handrick, R; Guner, D; Goecke, B; Belka, C				Weinmann, M; Jendrossek, V; Handrick, R; Guner, D; Goecke, B; Belka, C			Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner	ONCOGENE			English	Article						hypoxia; apoptosis; mitochondria; FADD; Bcl-2; caspase-8	DRUG-INDUCED APOPTOSIS; NEURONAL CELL-DEATH; TYROSINE KINASE LCK; IONIZING-RADIATION; CYTOCHROME-C; LYMPHOMA-CELLS; P53-DEPENDENT APOPTOSIS; DIFFERENTIAL REGULATION; CASPASE-3 ACTIVATION; SERUM DEPRIVATION	Dys-regulated growth and improper angiogenesis commonly lead to areas of hypoxia in human tumors. Hypoxia is known to be associated with a worse outcome since a lack of oxygen interferes with the efficacy of chemotherapy or radiotherapy. In parallel, hypoxia-induced apoptosis may also impose a selection pressure favoring growth of more resistant tumor cells. However, the mechanisms of hypoxia-induced apoptosis and the relative contribution of intrinsic and extrinsic apoptotic pathways are not understood. Therefore, Jurkat cell lines with defined defects in the extrinsic or intrinsic signaling cascades were used to evaluate the role of either pathway for induction of apoptosis under hypoxic conditions. Jurkat cells were incubated in hypoxia and the rate of apoptosis induction was determined by Western blotting, fluorescence microscopy and flow cytometry. Hypoxia-induced apoptosis was not affected by lack of caspase-8 or FADD, whereas overexpression of Bcl-2 or expression of dominant-negative caspase-9 mutant rendered the cells resistant to hypoxia-induced apoptosis. These results suggest that hypoxia-induced apoptosis mainly relies on intrinsic, mitochondrial pathways, whereas extrinsic pathways have no significant implications in this process. Thus, in human tumors, hypoxia will mainly lead to the selection of hypoxia-resistant cells with defects in mitochondrial apoptosis signaling pathways.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Charite Berlin, Dept Radiat Oncol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seylerstr 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Alarcon R M, 2001, Novartis Found Symp, V240, P115; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; Banasiak KJ, 1999, MOL BRAIN RES, V72, P214, DOI 10.1016/S0169-328X(99)00189-8; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Chao W, 2002, J BIOL CHEM, V277, P31639, DOI 10.1074/jbc.M204104200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Khurana P, 2002, NEUROCHEM RES, V27, P931, DOI 10.1023/A:1020347732741; Kim CY, 1997, CANCER RES, V57, P4200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KISCHKEL FC, 2001, J BIOL CHEM, V2, P2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 2002, J BIOL CHEM, V277, P42802, DOI 10.1074/jbc.M207765200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOPEZHERNANDEZ FJ, 2003, CELL DEATH DIFFER, V24, P24; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mogi M, 2001, LAB INVEST, V81, P177, DOI 10.1038/labinvest.3780225; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Steinbach JP, 2003, CELL DEATH DIFFER, V10, P823, DOI 10.1038/sj.cdd.4401252; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tsujimoto Yoshihide, 1997, Leukemia (Basingstoke), V11, P380; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yaniv G, 2002, CARDIOVASC RES, V54, P611, DOI 10.1016/S0008-6363(02)00264-X; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhu H, 2000, CELL DEATH DIFFER, V7, P773, DOI 10.1038/sj.cdd.4400721	64	50	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3757	3769		10.1038/sj.onc.1207481	http://dx.doi.org/10.1038/sj.onc.1207481			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15034549				2022-12-17	WOS:000221242500003
J	Choi, JA; Park, MT; Kang, CM; Um, HD; Bae, S; Lee, KH; Kim, TH; Kim, JH; Cho, CK; Lee, YS; Chung, HY; Lee, SJ				Choi, JA; Park, MT; Kang, CM; Um, HD; Bae, S; Lee, KH; Kim, TH; Kim, JH; Cho, CK; Lee, YS; Chung, HY; Lee, SJ			Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways	ONCOGENE			English	Article						12V-Ki-Ras; 12V-Ha-Ras; radiation-induced apoptosis; PI3K/Akt; Rac/p38 MAPK; Bax translocation	CYTOCHROME-C RELEASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-SURVIVAL; NIH-3T3 CELLS; CANCER CELLS; N-RAS; RESISTANCE; BAX; ONCOGENE; P38	It has been well known that Ras signaling is involved in various cellular processes, including proliferation, differentiation, and apoptosis. However, distinct cellular functions of Ras isozymes are not fully understood. Here we show the opposing roles of Ha-Ras and Ki-Ras genes in the modulation of cell sensitivity to ionizing radiation. Overexpression of active isoform of Ha-Ras (12V-Ha-Ras) in Rat2 cells increases resistance to the ionizing radiation. Constitutive activation of phosphoinositide-3-kinase (PI3K) and Akt is detected specifically in 12V-Ha-Ras-overexpressing cells. The specific PI3K inhibitor LY294002 inhibits PI3K/Akt signaling and potentiates the radiation-induced apoptosis, suggesting that activation of the PI3K/47;Akt signaling pathway is involved in the increased radio-resistance in cells overexpressing 12V-Ha-Ras. Overexpression of activated Ki-Ras (12V-Ki-Ras), on the other hand, markedly increases radiation sensitivity. The p38 mitogen-activated protein kinase (MAPK) activity is selectively enhanced by ionizing radiation in cells overexpressing 12V-Ki-Ras. The specific p38 MAPK inhibitor, PD169316, or dominant-negative p38 MAPK decreases radiation-induced cell death. We further show that the mechanism that underlies potentiation of cell death in cells overexpressing 12V-Ki-Ras involves Bax translocation to the mitochondrial membrane. Elevated Bax translocation following ionizing irradiation in 12V-Ki-Ras-overexpressing cells is completely inhibited by PD169316 or dominant-negative p38 MAPK. In addition, introduction of cells with RacN17, a dominant-negative mutant of Rac, resulted in a marked inhibition of radiation-induced Bax translocation and apoptotic cell death as well as p38 MAPK activation. Taken together, these findings explain the opposite effects of Ha-Ras and Ki-Ras on modulation of radiosensitivity, and suggest that differential activation of PI3K/Akt and Rac/p38 MAPK signaling by Ha-Ras and Ki-Ras may account for the opposing response to the ionizing radiation. These data provide an explanation for the diverse biological functions of Ras isozymes, and partly accounts for the differential response of transformed cells to anticancer treatments.	Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Expt Pathol, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Oncol Mol Lab, Seoul 139706, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea University; Hanyang University	Lee, SJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea.	sjlee@kcchsun.kcch.re.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Chung, Hee Yong/0000-0001-7580-0537				Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Bache M, 2001, INT J CANCER, V96, P110, DOI 10.1002/ijc.1002; Belka C, 2000, ANTICANCER RES, V20, P3243; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOS JL, 1989, CANCER RES, V49, P4682; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Choi JA, 2001, INT J ONCOL, V19, P837; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233; Fedorov YV, 2001, J CELL BIOL, V152, P1301, DOI 10.1083/jcb.152.6.1301; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Grana TM, 2002, CANCER RES, V62, P4142; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; HERMENS AF, 1992, CANCER RES, V52, P3073; Hosoi Y, 1998, INT J CANCER, V78, P642, DOI 10.1002/(SICI)1097-0215(19981123)78:5<642::AID-IJC19>3.0.CO;2-3; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kunz M, 2001, CELL GROWTH DIFFER, V12, P137; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; MCKENNA WG, 1990, CANCER RES, V50, P97; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nagase M, 2001, BIOSCI BIOTECH BIOCH, V65, P1741, DOI 10.1271/bbb.65.1741; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; Prior IA, 2001, J CELL SCI, V114, P1603; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Santillo M, 2001, CURR BIOL, V11, P614, DOI 10.1016/S0960-9822(01)00159-2; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshino T, 2001, EUR J IMMUNOL, V31, P2702, DOI 10.1002/1521-4141(200109)31:9<2702::AID-IMMU2702>3.0.CO;2-8	62	50	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					9	20		10.1038/sj.onc.1206982	http://dx.doi.org/10.1038/sj.onc.1206982			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712206				2022-12-17	WOS:000187895300002
J	DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, SJ; Freeman, JW				DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, SJ; Freeman, JW			Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines	ONCOGENE			English	Article						growth factors; ErbB-2; cell signaling; pancreatic cancer	CYCLIN D1; FACTOR-ALPHA; CONSTITUTIVE ACTIVATION; BREAST-CANCER; SIGNAL TRANSDUCERS; TYROSINE KINASES; CDK INHIBITORS; ABERRANT REGULATION; DEPENDENT KINASE; FACTOR RECEPTORS	Pancreatic ductal adenocarcinoma (PDAC) cell lines, MIA PaCa-2, and UK Pan-1, were used to investigate the role of ErbB2 in PDAC oncogenesis. Both these cell lines exhibit exogenous growth factor-independent proliferation that was attributed to the production of autocrine growth factors and/or overexpression of growth factor receptors. The exogenous growth factor-independent phenotype displayed by these PDAC cell lines was dependent on ErbB2 kinase activity since treatment of cells with tyrphostin AG879 prevented serum-free media (SFM) induction of cell proliferation. We determined that ErbB2 kinase contributed to aberrant cell cycle regulation in PDAC through the induction of cyclin D1 levels and the suppression of p21(Cip1) and p27(Kip1). Inhibition of ErbB2 kinase led to cell cycle arrest marked by an increased association of p27(Kip1) with cdk2 and reduced levels of phosphorylated pRb. We further observed constitutive STAT3 activation in the PDAC cell lines and an increase in STAT3 activation upon stimulating quiescent cells with SFM. Inhibitors of ErbB2 kinase blocked STAT3 activation, whereas inhibition of EGFR kinase led to a slight reduction of STAT3 activation. STAT3 was coimmunoprecipitated with ErbB2. SFM stimulation caused an increase in the association of ErbB2 and STAT3, which was blocked by inhibition of ErbB2 kinase. Expression of a STAT3 dominant negative prevented SFM-stimulated cell proliferation of MIA PaCa-2 cells, suggesting that activation of STAT3 by ErbB2 is required for a growth factor-independent phenotype of these cells. Consistent with this observation in PDAC cell lines, we found that most PDAC tumor specimens ( 10 of 11) showed constitutive activation of STAT3 and that ErbB2 was readily detected in most of these tumors ( nine of 11). We believe that these findings indicate a novel mechanism of oncogenesis in PDAC and may suggest future therapeutic strategies in the treatment of PDAC.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX 78229 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Georgetown Univ, Med Ctr, Dept Surg, Washington, DC 20007 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Roswell Park Cancer Institute; Georgetown University	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NCI NIH HHS [R01 CA69122, P30 CA 54174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069122, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Busse D, 2000, SEMIN ONCOL, V27, P3, DOI 10.1053/sonc.2000.19891; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Dugan MC, 1997, PANCREAS, V14, P229, DOI 10.1097/00006676-199704000-00003; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fralix KD, 2000, CANCER, V88, P2010, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; Friess H, 1999, ANN SURG, V230, P767, DOI 10.1097/00000658-199912000-00005; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JASKIEWICZ K, 1994, ANTICANCER RES, V14, P1919; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Klapper LN, 2000, ADV CANCER RES, V77, P25; KLOPPEL G, 1985, HISTOPATHOLOGY, V9, P841, DOI 10.1111/j.1365-2559.1985.tb02870.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mack L, 1997, HUM PATHOL, V28, P974, DOI 10.1016/S0046-8177(97)90014-9; Masuda M, 2002, CANCER RES, V62, P3351; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; SATOH K, 1993, CANCER, V72, P51, DOI 10.1002/1097-0142(19930701)72:1<51::AID-CNCR2820720112>3.0.CO;2-O; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; SOMERVILLE JE, 1992, J CLIN PATHOL, V45, P16, DOI 10.1136/jcp.45.1.16; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMANAKA Y, 1993, HUM PATHOL, V24, P1127, DOI 10.1016/0046-8177(93)90194-L; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	70	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7781	7795		10.1038/sj.onc.1206966	http://dx.doi.org/10.1038/sj.onc.1206966			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586404				2022-12-17	WOS:000186240200008
J	Trempat, P; Villalva, C; Laurent, G; Armstrong, F; Delsol, G; Dastugue, N; Brousset, P				Trempat, P; Villalva, C; Laurent, G; Armstrong, F; Delsol, G; Dastugue, N; Brousset, P			Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec	ONCOGENE			English	Article						chronic myeloid leukaemia; STI-571/Glivec; PDGFRA	GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; IMATINIB MESYLATE; DERMATOFIBROSARCOMA PROTUBERANS; BCR; STI571; INHIBITOR; EFFICACY; PDGFRA	Two cases of atypical chronic myeloid leukaemia (CML) carrying the t(4;22)(q12;q11) translocation involving the breakpoint cluster region (BCR) and platelet-derived growth factor a receptor (PDGFRA) genes have been recently characterized. We report a third case of atypical CML with the same translocation but with a distinct breakpoint fusing BCR exon 1 with PDGFRA exon 13. The patient had a clinical presentation of CML with progressive transformation in B-cell acute lymphoblastic leukaemia. The involvement of PDGFRA led us to treat the patient with the small organic compound imatinib mesylate/STI571 (Glivec) that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors. The patient subsequently achieved a rapid clinical and molecular response clearly demonstrating, for the first time, that Glivec is active against PDGFRA in vivo. Therefore, our study expands the list of Glivec targets and has direct biological and also clinical implications.	Purpan Hosp, Ctr Physiopathol Toulouse Purpan, INSERM, U563, Toulouse, France; Purpan Hosp, Dept Pathol, Toulouse, France; Purpan Hosp, Dept Haematol, Toulouse, France; Purpan Hosp, Dept Cytogenet, Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU de Toulouse; CHU de Toulouse	Brousset, P (corresponding author), CHU Purpan, INSERM, Anat Pathol Lab, U563, F-31059 Toulouse, France.							Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Magnusson MK, 2002, BLOOD, V100, P1088, DOI 10.1182/blood-2002-01-0165; Maki RG, 2002, INT J CANCER, V100, P623, DOI 10.1002/ijc.10535; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Petzer AL, 2002, BRIT J HAEMATOL, V117, P623, DOI 10.1046/j.1365-2141.2002.03523.x; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; Thijsen SFT, 1999, LEUKEMIA, V13, P1646, DOI 10.1038/sj.leu.2401565; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7	15	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5702	5706		10.1038/sj.onc.1206543	http://dx.doi.org/10.1038/sj.onc.1206543			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944919				2022-12-17	WOS:000184865900020
J	Waltermann, A; Kartasheva, NN; Dobbelstein, M				Waltermann, A; Kartasheva, NN; Dobbelstein, M			Differential regulation of p63 and p73 expression	ONCOGENE			English	Article						p53; p63; p73; E2F; TGF beta; cell density	GROWTH-FACTOR-BETA; P53 HOMOLOG P63; LARGE T-ANTIGEN; CELL-DENSITY; TRANSCRIPTION ANALYSES; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS; SPONTANEOUS TUMORS; E1B 55-KILODALTON; E4ORF6 PROTEINS	Two homologs of the tumor suppressor p53, named p63 and p 73, are each expressed from at least two start sites of mRNA synthesis, yielding full-length, transactivating (TA) isoforms, and also aminoterminally truncated (DeltaN) isoforms that act as antagonists to p53. The expression of TAp73-transcripts is induced by E2F and negatively regulated by transforming growth factor beta (TGFbeta). The DeltaNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity. Here, we have analysed the expression of p63 in comparison with p73. In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels. Accordingly, the 3' promoter of p73, but not that of p63, was activated by p53 in reporter assays. DeltaNp73 mRNA and DeltaNp73 protein, but not the p63 gene products, also accumulated when HaCat cells (lacking functional p53) were grown to high density. TAp73, but not TAp63, expression was suppressed by TGFbeta in these cells, and the TAp73, but not the TAp63, promoter was induced by E2F-1. Thus, in contrast to the functional similarities of their respective products, the expression levels of p63 and p 73 are regulated by different mechanisms. This might be responsible for the discordant biological roles of p63 and p73 in development, as well as their deviant expression characteristics in cancer.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cviko A, 2000, HUM PATHOL, V31, P740, DOI 10.1053/hupa.2000.8232; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; Koch P, 2001, CANCER RES, V61, P5941; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liefer KM, 2000, CANCER RES, V60, P4016; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nishi H, 1999, INT J ONCOL, V15, P1149; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Prabhu NS, 1998, INT J ONCOL, V13, P5; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Roth J, 1997, J VIROL, V71, P8933, DOI 10.1128/JVI.71.11.8933-8939.1997; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	61	50	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5686	5693		10.1038/sj.onc.1206859	http://dx.doi.org/10.1038/sj.onc.1206859			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944917				2022-12-17	WOS:000184865900018
J	Rodrigues, S; Attoub, S; Nguyen, QD; Bruyneel, E; Rodrigue, CM; Westley, BR; May, FEB; Thim, L; Mareel, M; Emami, S; Gespach, C				Rodrigues, S; Attoub, S; Nguyen, QD; Bruyneel, E; Rodrigue, CM; Westley, BR; May, FEB; Thim, L; Mareel, M; Emami, S; Gespach, C			Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells	ONCOGENE			English	Article						HER-CD533; EGFRvIIl; Iressa; src; TXA2-R; bile acids	EPIDERMAL-GROWTH-FACTOR; PLATELET-ACTIVATING-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR INVASION; EPITHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER	Trefoil peptides (TFFs) are now considered as scatter factors, proinvasive and angiogenic agents acting through cyclooxygenase-2 (COX-2)- and thromboxane A2 receptor (TXA2-R)-dependent signaling pathways. As expression and activation levels of the epidermal growth factor receptor (EGFR) predict the metastatic potential of human colorectal cancers, the purpose of this study was to establish whether the EGF receptor tyrosine kinase (EGFR-TK) contributes to cellular invasion induced by TFFs in kidney and colonic cancer cells. Both the dominant negative form of the EGFR (HER-CD533) and the EGFR-TK inhibitor ZD1839 (Iressa) abrogated cellular invasion induced by pS2, spasmolytic polypeptide (SP) and the src oncogene, but not by ITF and the TXA2-R. Similarly, EGFR-TK inhibition by ZD1839 reversed the invasive phenotype promoted by the constitutively activated form of the EGFR (EGFRvIII) and the EGFR agonists transforming growth factor alpha (TGFalpha), amphiregulin and EGF. We also provide evidence that TFFs, EGFRvIII, and TGFalpha trigger common proinvasive pathways using the P13'-kinase and Rho/Rho- kinase cascades. These findings identify the EGFR-TK as a key signaling element for pS2- and SP-mediated cellular invasion. It is concluded that although pS2, SP and ITF belong to the same family of inflammation- and cancer-associated regulatory peptides, they do not control identical signaling networks.	Hop St Antoine, INSERM, U482, Signal Transduct & Cellular Funct Diabet & Digest, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Newcastle Univ, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Newcastle University - UK; Novo Nordisk	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, Signal Transduct & Cellular Funct Diabet & Digest, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; CHINERY R, 1995, FEBS LETT, V357, P50, DOI 10.1016/0014-5793(94)01297-E; CHINERY R, 1995, CLIN SCI, V88, P401, DOI 10.1042/cs0880401; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DANTE R, 1994, LAB INVEST, V71, P188; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; Hoffmann W, 2002, INT REV CYTOL, V213, P147; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jacoby RF, 1996, CANCER RES, V56, P710; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Lal A, 2002, CANCER RES, V62, P3335; Lalani EN, 1999, LAB INVEST, V79, P537; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Maurizi M, 1996, BRIT J CANCER, V74, P1253, DOI 10.1038/bjc.1996.525; May FEB, 1997, J PATHOL, V182, P404; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; Moasser MM, 2001, CANCER RES, V61, P7184; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; ROSAM AC, 1986, NATURE, V319, P54, DOI 10.1038/319054a0; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SAITO Y, 1997, BACTERIAL TOXINS TOO, P85; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Taupin D, 1996, LAB INVEST, V75, P25; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; THEISINGER B, 1991, EUR J CANCER, V27, P770, DOI 10.1016/0277-5379(91)90186-H; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tong WM, 1998, BRIT J CANCER, V77, P1792, DOI 10.1038/bjc.1998.298; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; VAN BT, 1995, NATURE, V376, P781; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang DG, 1998, J CELL PHYSIOL, V177, P387, DOI 10.1002/(SICI)1097-4652(199812)177:3<387::AID-JCP2>3.3.CO;2-C; Wheeler M, 2001, MOL CELL BIOL, V21, P6660, DOI 10.1128/MCB.21.19.6660-6667.2001; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Williams R, 1996, J CELL SCI, V109, P63; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; Xie H, 1998, J CELL SCI, V111, P615; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YANG LJ, 1993, J BIOL CHEM, V268, P3739; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yoon JH, 2002, GASTROENTEROLOGY, V122, P985, DOI 10.1053/gast.2002.32410; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	98	50	50	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4488	4497		10.1038/sj.onc.1206685	http://dx.doi.org/10.1038/sj.onc.1206685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881705				2022-12-17	WOS:000184054700004
J	Bebien, M; Salinas, S; Becamel, C; Richard, W; Linares, L; Hipskind, RA				Bebien, M; Salinas, S; Becamel, C; Richard, W; Linares, L; Hipskind, RA			Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF	ONCOGENE			English	Article						c-fos; egr-1; mkp-1; ERK; SAPK; p38	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; TERNARY COMPLEX FACTORS; C-FOS EXPRESSION; HISTONE H3 PHOSPHORYLATION; N-TERMINAL KINASE; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; TRANSDUCTION PATHWAYS; SODIUM ARSENITE	Cellular stress activates multiple mitogen-activated protein kinase (MAPK) cascades and immediate-early gene (IEG) transcription. To address how these events are linked, we investigated the endogenous signaling/transcription factor network driving IEG activation by arsenite and anisomycin in the human osteosarcoma cell line HOS/TE-85. Induction of IEG transcription by both stresses corresponded temporally with the phosphorylation of the regulatory factors Elk-1 and cAMP response element-binding protein (CREB), along with activation of the extracellular signal-regulated kinase (ERK), stress-activated protein kinase (SAPK) and p38 MAPK cascades. To assess the role of the different cascades, they were selectively inhibited with PD98059, SP600125 and SB203580, respectively. This implicated all three cascades in Elk-1 phosphorylation after arsenite treatment, whereas ERK and SAPK inhibition diminished this, and IEG mRNA levels, downstream of anisomycin. SB blocked phosphorylation of both serum response factor (SRF) and CREB, and strongly reduced IEG activation by both stresses. Combining PD with SB further reduced arsenite induction of IEG transcription. Thus, all three MAPK cascades mediate anisomycin- and arsenite-induced signaling to IEG promoters in HOS cells through the differential targeting of Elk-1, SRF and CREB.	CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Hipskind, RA (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 24, 1919 Route Mende, F-34293 Montpellier, France.	hipskind@soleil.igm.cnrs-mop.fr	Linares, Laetitia LKL/F-9901-2018; Salinas, Sara/O-1150-2019; Salinas, Sara/O-1856-2013	Linares, Laetitia LKL/0000-0003-1661-2119; Salinas, Sara/0000-0003-4492-2093; Salinas, Sara/0000-0003-4492-2093				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHIOU HY, 1995, CANCER RES, V55, P1296; Chiou HY, 2001, AM J EPIDEMIOL, V153, P411, DOI 10.1093/aje/153.5.411; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GUBITS RM, 1988, ONCOGENE, V3, P163; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RANI AS, 1993, CARCINOGENESIS, V14, P947, DOI 10.1093/carcin/14.5.947; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUTHER U, 1989, ONCOGENE, V4, P861; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TINWELL H, 1991, ENVIRON HEALTH PERSP, V95, P205, DOI 10.2307/3431125; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	72	50	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1836	1847		10.1038/sj.onc.1206334	http://dx.doi.org/10.1038/sj.onc.1206334			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660819				2022-12-17	WOS:000181678200010
J	Masuda, Y; Nishida, A; Hori, K; Hirabayashi, T; Kajimoto, S; Nakajo, S; Kondo, T; Asaka, M; Nakaya, K				Masuda, Y; Nishida, A; Hori, K; Hirabayashi, T; Kajimoto, S; Nakajo, S; Kondo, T; Asaka, M; Nakaya, K			beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)	ONCOGENE			English	Article						beta-hydroxyisovalerylshikonin; apoptosis; DNA fragmentation; PLK1	CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; PROTEIN-KINASE; POTENT INDUCER; ANTICANCER DRUGS; DNA-DAMAGE; ACTIVATION; GENE; EXPRESSION; INDUCTION	beta-Hydroxyisovalerylshikonin (beta-HIVS), which was isolated from the plant, Lithospermum radix, induces apoptosis in various lines of human tumor cells. To identify genes involved in beta-HIVS-induced apoptotic process, we performed cDNA array analysis and found that beta-HIVS suppresses the expression of the gene for a polo-like kinase 1 (PLK1) that is involved in control of the cell cycle. When U937 and HL60 cells were treated with 10(-6) m beta-HIVS for 0.5 h, both the amount of PLK1 itself and the kinase activity of this enzyme were decreased. By contrast, Bcr-Abl-positive K562 cells were resistant to the induction of apoptosis by beta-HIVS and this compound did not suppress the kinase activity of PLK1 in these cells. However, simultaneous treatment of K562 cells with both beta-HIVS and STI571, which selectively inhibits the protein tyrosine kinase (PTK) activity of Bcr-Abl, strongly induced apoptosis. Moreover, beta-HIVS increased the inhibitory effect of STI571 on PTK activity. Treatment of K562 cells with antisense oligodeoxynucleotides (ODNs) specific for PLK1 sensitized these cells to the beta-HIVS-induced fragmentation of DNA. These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by beta-HIVS might play a critical role in the induction of apoptosis.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 0600815, Japan	Showa University; Hokkaido University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	nakaya@pharm.showa-u.ac.jp	Asaka, Masahiro/A-5948-2012; 堀, 孝一/AAU-8506-2021; Kondo, Takeshi/G-2103-2012; 堀, 孝一/K-5102-2019	堀, 孝一/0000-0002-0530-181X; Kondo, Takeshi/0000-0001-7455-5824; 堀, 孝一/0000-0002-0530-181X				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BHALLA K, 1993, LEUKEMIA, V7, P563; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHALIFOUR LE, 1994, ANAL BIOCHEM, V216, P299, DOI 10.1006/abio.1994.1045; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p697A; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; EVANS DL, 1993, CANCER RES, V53, P2133; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hashimoto S, 1999, J BIOCHEM-TOKYO, V125, P17, DOI 10.1093/oxfordjournals.jbchem.a022255; Hashimoto S, 2002, JPN J CANCER RES, V93, P944, DOI 10.1111/j.1349-7006.2002.tb01341.x; HURLE JM, 1981, EXP CELL RES, V133, P465, DOI 10.1016/0014-4827(81)90343-8; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; MASUDA Y, 1995, LEUKEMIA RES, V19, P549, DOI 10.1016/0145-2126(95)00031-I; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; Perkins C, 1998, CANCER RES, V58, P4561; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SAKAI I, 1993, BIOCHEM BIOPH RES CO, V191, P873, DOI 10.1006/bbrc.1993.1298; SAKAI I, 1994, BIOCHEM BIOPH RES CO, V205, P1305, DOI 10.1006/bbrc.1994.2807; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SUNKEL CE, 1988, J CELL SCI, V89, P25; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1997, CANCER RES, V57, P3097; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	50	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1012	1023		10.1038/sj.onc.1206200	http://dx.doi.org/10.1038/sj.onc.1206200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592388				2022-12-17	WOS:000180926100007
J	Lee, MS; Igawa, T; Yuan, TC; Zhang, XQ; Lin, FF; Lin, MF				Lee, MS; Igawa, T; Yuan, TC; Zhang, XQ; Lin, FF; Lin, MF			ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells	ONCOGENE			English	Article						prostate cancer; androgen independence; prostatic acid phosphatase; protein tyrosine phosphatase; ErbB-2; protein tvrosine kinase; PSA secretion; MAP kinases	IN-SITU HYBRIDIZATION; ANTIGEN MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; ACID-PHOSPHATASE; GROWTH-FACTOR; TYROSINE KINASE; RECEPTOR ACTIVATION; PROTEIN EXPRESSION; GENE-EXPRESSION; EGF RECEPTOR	The expression and secretion of prostate-specific antigen (PSA) are regulated by androgens in normal prostate secretory epithelial cells. In prostate cancer patients, the serum PSA level is usually elevated and cancer cells are initially responsive to androgens. However, those cancer cells become androgen-independent after androgen ablation therapy. In hormone-refractory, cancer patients, even in an androgen-deprived environment, the circulation level of PSA rebounds and is constitutively elevated through a yet unknown mechanism. Tyrosine phosphorylation of ErbB-2 is involved in regulating the androgen-responsive phenotype of prostate cancer cells, and it is at least partly regulated by the cellular form of prostatic acid phosphatase (PAc6) a prostate-unique protein tyrosine phosphatase. We investigated the ErbB-2 signal pathway in androgen-independent PSA secretion. LNCaP C-81 cells, which are androgen-independent LNCaP cells lacking endogenous PAcP expression with a hypertyrosine phosphorylated ErbB-2, secreted a higher level of PSA in conditioned media than did androgen-sensitive LNCaP C-33 parental cells. A restored expression of cellular PAcP in C-81 cells was concurrent with a decrease in tyrophosphorylation of ErbB-2 and reduction of PSA secretion. Moreover, transient transfection of C-33 cells with the wild-type ErbB-2 or a constitutively active mutant of MEK1 cDNA resulted in an increased level of secreted PSA. The elevation of secreted PSA level by the forced expression of ErbB-2 was inhibited by an MEK inhibitor, PD98059. In C-81 cells, the expression of a dominant negative mutant of ErbB-2 reduced the secreted level of PSA. The inhibition of ErbB-2 or mitogen-activated protein (MAP) kinases by specific inhibitors AG879, AG825, or PD98059 led to a decrease in PSA secretion. Taken together, our data clearly indicate that the ErbB-2 signal pathway via MAP kinases (ERK1/2) is involved in regulating the secretion of PSA by androgen-independent human prostate cancer LNCaP C-81 cells in an androgen-depleted environment.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sect Urol Surg, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 9845255 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@.unmc.edu		LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auclerc G, 2000, Oncologist, V5, P36, DOI 10.1634/theoncologist.5-1-36; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bubendorf L, 1999, CANCER RES, V59, P803; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gioeli D, 1999, CANCER RES, V59, P279; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; Hobisch A, 1998, CANCER RES, V58, P4640; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Johannessen LE, 2001, BIOCHEM J, V356, P87, DOI 10.1042/0264-6021:3560087; Karan D, 2001, CLIN CANCER RES, V7, P3472; Kimmelman AC, 2002, MOL CELL BIOL, V22, P5946, DOI 10.1128/MCB.22.16.5946-5961.2002; KURIYAMA M, 1982, J NATL CANCER I, V68, P99; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Lin MF, 2000, CELL BIOL INT, V24, P681, DOI 10.1006/cbir.2000.0433; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Mark HFL, 1999, EXP MOL PATHOL, V66, P170, DOI 10.1006/exmp.1999.2242; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Osman I, 2001, CLIN CANCER RES, V7, P2643; PAPSIDERO LD, 1980, CANCER RES, V40, P2428; PIERCE JH, 1991, ONCOGENE, V6, P1189; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; PRESS MF, 1990, ONCOGENE, V5, P953; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; QIAN XL, 1994, ONCOGENE, V9, P1507; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ross JS, 1997, CANCER-AM CANCER SOC, V79, P2162, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; Stenman UH, 1999, SEMIN CANCER BIOL, V9, P83, DOI 10.1006/scbi.1998.0086; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VELDSCHOLTE J, 1994, J STEROID BIOCHEM, V49, P341, DOI 10.1016/0960-0760(94)90277-1; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; Wen Y, 2000, CANCER RES, V60, P6841; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	74	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					781	796		10.1038/sj.onc.1206066	http://dx.doi.org/10.1038/sj.onc.1206066			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569372				2022-12-17	WOS:000180642100017
J	Albagli-Curiel, O				Albagli-Curiel, O			Ambivalent role of BCL6 in cell survival and transformation	ONCOGENE			English	Article						BCL6; B-cell lymphoma; germinal centre; cell survival; apoptosis	ZINC-FINGER PROTEIN; TUMOR-SUPPRESSOR GENE; NON-HODGKINS-LYMPHOMA; GERMINAL-CENTER FORMATION; ACID RECEPTOR-ALPHA; CENTER B-CELLS; SOMATIC HYPERMUTATION; PROMYELOCYTIC LEUKEMIA; GAGA FACTOR; TERMINAL DIFFERENTIATION	The BCL6 gene is often structurally altered and probably 'misregulated' in two different types of human B-cell non-Hodgkin lymphomas (BNHL) thought to arise from germinal centre B cells. BCL6 encodes a BTB/POZ and zinc finger protein whose biochemical properties support a role as a DNA-binding transcriptional repressor and disclose, in part, the underlying mechanisms. In contrast, the study of the 'oncogenic' structural alterations of BCL6 in BNHL and of its cellular functions gives rise to much more heterogeneous data with no obvious unifying picture so that how and even whether BCL6 contributes to lymphomagenesis remains unclear. This review will summarize the current knowledge about the 'oncogenic' alterations and cellular functions of BCL6 and, based on some results, will propose the following hypotheses: (1) In various systems, including in memory T cells and also in germinal centre B cells and possibly in certain postmitotic cells, BCL6 may act by stabilizing a particular stage of differentiation. (2) Both its ambivalent effects on cell survival and the heterogeneous consequences of its alterations in BNHL suggest that BCL6 can be oncogenic not only upon overexpression or persistent expression, as often proposed, but also, similar to some of its relatives, upon 'accidental' downregulation.	Inst Andre Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Albagli-Curiel, O (corresponding author), Inst Andre Lwoff, CNRS, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.	olivier.albagli@ujf-grenoble.fr						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Arima M, 2002, J IMMUNOL, V169, P829, DOI 10.4049/jimmunol.169.2.829; Artiga MJ, 2002, AM J PATHOL, V160, P1371, DOI 10.1016/S0002-9440(10)62564-3; Badenhorst P, 2001, DEVELOPMENT, V128, P4093; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Busturia A, 2001, DEVELOPMENT, V128, P2163; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Cattoretti G., 1997, Blood, V90, p175A; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; Chen WY, 2001, GENE CHROMOSOME CANC, V32, P281, DOI 10.1002/gcc.1191; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; DAI MS, 2002, J BIOL CHEM, V1, P1; Dalla-Favera R, 1999, CURR TOP MICROBIOL, V246, P257; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dickson BJ, 1998, CURR BIOL, V8, pR90, DOI 10.1016/S0960-9822(98)70054-5; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Hosokawa Y, 2001, BIOCHEM BIOPH RES CO, V283, P563, DOI 10.1006/bbrc.2001.4820; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Huynh KD, 2000, GENE DEV, V14, P1810; ICHII H, 2002, NAT IMMUNOL, V20, P20; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kojima S, 2001, DEVELOPMENT, V128, P57; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; LEMERCIER C, 2002, J BIOL CHEM, V19, P19; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Licht JD, 1996, ONCOGENE, V12, P323; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2000, BLOOD, V95, P1400, DOI 10.1182/blood.V95.4.1400.004k43_1400_1405; Lossos IS, 2001, LEUKEMIA LYMPHOMA, V42, P1343, DOI 10.1080/10428190127508; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Nakamura Y, 1996, LEUKEMIA, V10, P658; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pasqualucci L, 2000, BLOOD, V96, p703A; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TANG TT, 2002, J BIOL CHEM, V2, P2; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Ueda C, 2002, ONCOGENE, V21, P368, DOI 10.1038/sj.onc.1205099; Ueda C, 2002, BLOOD, V99, P2624, DOI 10.1182/blood-2001-11-0117; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang J, 1997, CANCER RES, V57, P351; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; Yoshida T, 1999, CARDIOVASC RES, V42, P670, DOI 10.1016/S0008-6363(99)00007-3; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642; Zan H, 2000, J IMMUNOL, V165, P830, DOI 10.4049/jimmunol.165.2.830; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zhang H, 2001, BBA-MOL CELL RES, V1540, P188, DOI 10.1016/S0167-4889(01)00128-8	99	50	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					507	516		10.1038/sj.onc.1206152	http://dx.doi.org/10.1038/sj.onc.1206152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555064				2022-12-17	WOS:000180538200004
J	Wiedemeyer, R; Westermann, F; Wittke, I; Nowock, J; Schwab, M				Wiedemeyer, R; Westermann, F; Wittke, I; Nowock, J; Schwab, M			Ataxin-2 promotes apoptosis of human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; ataxin-2; apoptosis; MYCN; amplification; SCA2	DRUG-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; N-MYC; CHILDHOOD NEUROBLASTOMAS; NUCLEAR-LOCALIZATION; INTERFERON-GAMMA; PROTEIN-KINASE; IFN-GAMMA; S-PHASE; EXPRESSION	Neuroblastoma is a highly heterogeneous tumor of young children. Although many advances have been made towards understanding the molecular mechanisms dictating the phenotypic heterogeneity, the prognosis of children with neuroblastoma, particularly of progressively growing variants, has remained dire. About 10% of neuroblastomas regress spontaneously, probably by apoptosis, while another 20% have amplified the MYCN gene resulting in a poor prognosis. In pursuit of identifying cell death-associated genes in neuroblastoma, we encountered the SCA2 gene, coding for ataxin-2, as an important player. Here, we report that enforced expression of wild-type ataxin-2, but not of mutant ataxin-2, sensitizes neuroblastoma cells for apoptosis. In line with this, higher levels of ataxin-2 were detected in apoptotic cells compared to nonapoptotic cells. Neuroblastoma tumors with amplified MYCN contain significantly less ataxin-2 protein than tumors without amplified MYCN. Collectively, our data suggest that ataxin-2 has an important role in regulating the susceptibility of neuroblastoma cells to apoptotic stimuli in vitro and in vivo.	German Canc Res Ctr, Dept Cytogenet, D-69121 Heidelberg, Germany; Univ Frankfurt, Sect Mol Neurogenet, D-60590 Frankfurt, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt	Schwab, M (corresponding author), German Canc Res Ctr, Dept Cytogenet, H0400,Neuenheimer Feld 280, D-69121 Heidelberg, Germany.		Westermann, Frank/F-7509-2013					Annicchiarico-Petruzzelli M, 2001, MED PEDIATR ONCOL, V36, P115; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; BERTHOLD F, 1990, KLIN PADIATR, V202, P262, DOI 10.1055/s-2007-1025531; Berthold F, 2000, DRUGS, V59, P1261, DOI 10.2165/00003495-200059060-00006; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Catchpoole DR, 2001, EUR J CANCER, V37, P2217, DOI 10.1016/S0959-8049(01)00273-8; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Eggert A, 2001, CANCER RES, V61, P1314; Estrada R, 1999, ACTA NEUROPATHOL, V97, P306, DOI 10.1007/s004010050989; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Huynh DP, 2000, NAT GENET, V26, P44, DOI 10.1038/79162; Ikeda H, 1996, AM J SURG PATHOL, V20, P649, DOI 10.1097/00000478-199606000-00001; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakagawara A, 1997, CANCER RES, V57, P4578; Nechiporuk T, 1998, HUM MOL GENET, V7, P1301, DOI 10.1093/hmg/7.8.1301; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WITTKE I, 2002, UNPUB	38	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					401	411		10.1038/sj.onc.1206150	http://dx.doi.org/10.1038/sj.onc.1206150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545161				2022-12-17	WOS:000180379100009
J	Perrotti, D; Calabretta, B				Perrotti, D; Calabretta, B			Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins	ONCOGENE			English	Article						BCR/ABL; STAT-5; hnRNP Al; leukemogenesis; CML	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; BCR-ABL; HNRNP A1; TRANSCRIPTION FACTORS; MESSENGER-RNAS; BETA-CATENIN; KINASE-C; V-ABL; EXPRESSION	Shuttling hnRNPs control the fate of eukaryotic mRNAs throughout their journey from the active site of transcription to that of translation; thus, gain or loss of their function in hematopoietic cells might result in altered hematopoiesis and/or be associated with the process of leukemogenesis. In BCR/ABL-expressing cells, there is a marked increase in the protein levels FUS, hnRNP A1 and hnRNP E2, three RNA-binding proteins involved in the regulation of mRNA processing, nucleocytoplasmic export, and translation. Ectopic expression and/or inhibition of the activity of these RNA-binding proteins affects proliferation, survival, and differentiation of normal and BCR/ABL-expressing cells, suggesting that enhanced expression/activity of certain RNA-binding proteins plays an important, but as yet unrecognized, role in BCR/ABL leukemogenesis. The identification of the mRNA subsets associated with RNA-binding proteins upregulated in BCR/ABL-expressing cells should functionally link the process of leukemogenesis with alteration of mRNA metabolism.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Calabretta, B (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Bluemle Life Sci Bldg,Room 630,233 S 10th St, Philadelphia, PA 19107 USA.	Bruno.Calabretta@mail.tju.edu	Perrotti, Danilo/E-3852-2011					Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BEDI A, 1994, BLOOD, V83, P2038; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; BIAMONTI G, 1993, J MOL BIOL, V230, P77, DOI 10.1006/jmbi.1993.1127; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CALVIO C, 1995, RNA, V1, P724; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHABOT B, 1997, MOL CELL BIOL, V19, P251; Chansky HA, 2001, CANCER RES, V61, P3586; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gouble A, 2002, CANCER RES, V62, P1489; Hamasaki M, 2001, ANTICANCER RES, V21, P979; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; KANTARJIAN HM, 1993, BLOOD, V82, P691; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Majewski M, 1999, CANCER RES, V59, P2815; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MICHAEL WM, 1995, CELL, V83, P415; Mills KI, 2000, BRIT J HAEMATOL, V108, P316; NAKAJIMA H, 2001, BLOOD, V98, P2077; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sueoka E, 1999, CANCER RES, V59, P1404; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zinszner H, 1997, J CELL SCI, V110, P1741; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	68	50	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8577	8583		10.1038/sj.onc.1206085	http://dx.doi.org/10.1038/sj.onc.1206085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476304				2022-12-17	WOS:000179734300007
J	Danaee, H; Nelson, HH; Karagas, MR; Schned, AR; Ashok, TDS; Hirao, T; Perry, AE; Kelsey, KT				Danaee, H; Nelson, HH; Karagas, MR; Schned, AR; Ashok, TDS; Hirao, T; Perry, AE; Kelsey, KT			Microsatellite instability at tetranucleotide repeats in skin and bladder cancer	ONCOGENE			English	Article						EMAST; ptch; microsatellite instability; p53; skin cancer; bladder cancer	BASAL-CELL CARCINOMA; WILD-TYPE P53; CYCLE CONTROL; HUMAN HOMOLOG; LUNG-CANCER; MUTATIONS; GENE; RADIATION; CARCINOGENESIS; IRRADIATION	Recently, a novel form of MSI has been described that occurs only at tetranucleotide repeat markers. This has been termed elevated microsatellite instability at selected tetranucleotide repeats (EMAST). EMAST has been related to alterations of the p53 gene, and to the nature of the repeat sequence. We initially tested whether loss of heterozygosity (LOH) at the p53 and the patched (ptch) genes was related to EMAST in a series of 61 non-melanoma skin cancer (NMSC) tumors. We then analysed a series of 57 primary bladder cancers for the presence of EMAST, testing whether this was related to mutation or expression of the p53 gene. In both NMSC and bladder tumors we found a high prevalence of EMAST (75.4 and 43.9%). In NMSC the prevalence of EMAST was higher in tumors that had either p53 or ptch LOH, although the difference was not statistically significant. There was a significant association of extensive EMAST (three or more loci) with mutations in p53 among the bladder cancer tumors, but no indication of elevated EMAST in tumors with abnormal p53 staining without mutation. The association of EMAST with p53 mutation was confined to non-invasive disease. Hence, EMAST likely reflects a particular pattern of somatic events that are interactive with p53 mutation, particularly common in skin cancer and limited to non-invasive disease in bladder cancer.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Dartmouth Coll, Sch Med, Dept Community & Family Med, Lebanon, NH 03756 USA; Dartmouth Coll, Sch Med, Dept Pathol, Lebanon, NH 03756 USA	Harvard University; Harvard T.H. Chan School of Public Health; Dartmouth College; Dartmouth College	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.		Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [T32CA009078, R01CA057494, R01CA082354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, P42ES005947, P42ES007373] Funding Source: NIH RePORTER; NCI NIH HHS [CA82354, CA09078, R01 CA082354, CA57494] Funding Source: Medline; NIEHS NIH HHS [P42ES5947, ES00002, P42ES07373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Ahrendt SA, 2000, CANCER RES, V60, P2488; Boland CR, 1998, CANCER RES, V58, P5248; Chuang YYE, 1999, CANCER RES, V59, P3073; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujii K, 1997, BIOCHEM BIOPH RES CO, V240, P269, DOI 10.1006/bbrc.1997.7603; Fujii K, 1999, JPN J CANCER RES, V90, P1351, DOI 10.1111/j.1349-7006.1999.tb00719.x; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karagas MR, 1998, ENVIRON HEALTH PERSP, V106, P1047, DOI 10.2307/3434150; Karagas MR, 1999, INT J CANCER, V81, P555, DOI 10.1002/(SICI)1097-0215(19990517)81:4<555::AID-IJC9>3.0.CO;2-R; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lichter MD, 2000, ARCH DERMATOL, V136, P1007, DOI 10.1001/archderm.136.8.1007; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; NAGASAWA H, 1988, TERATOGEN CARCIN MUT, V8, P25, DOI 10.1002/tcm.1770080104; Nelson HH, 1998, CANCER RES, V58, P1804; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Ren ZP, 1997, AM J PATHOL, V150, P1791; Shen TL, 1999, HUM PATHOL, V30, P284, DOI 10.1016/S0046-8177(99)90006-0; Sidransky D, 1996, ANNU REV MED, V47, P285; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Xu LH, 2001, INT J CANCER, V91, P200, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1031>3.0.CO;2-0	31	50	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4894	4899		10.1038/sj.onc.1205619	http://dx.doi.org/10.1038/sj.onc.1205619			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118368				2022-12-17	WOS:000176874800004
J	Digweed, M; Demuth, I; Rothe, S; Scholz, R; Jordan, A; Grotzinger, C; Schindler, D; Grompe, M; Sperling, K				Digweed, M; Demuth, I; Rothe, S; Scholz, R; Jordan, A; Grotzinger, C; Schindler, D; Grompe, M; Sperling, K			SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11	ONCOGENE			English	Review						ionizing irradiation; Fanconi anaemia; immortalization	STRAND BREAK REPAIR; FANCONI-ANEMIA; CELLULAR-RESPONSE; BRCA1; FIBROBLASTS; PHOSPHORYLATION; SUSCEPTIBILITY; PROTEINS; COMPLEX; BINDING	The accumulation of DNA repair proteins at the sites of DNA damage can be visualized in mutagenized cells at the single cell level as discrete nuclear foci by immunofluorescent staining. Formation of nuclear foci in irradiated human fibroblasts, as detected by antibodies directed against the DNA repair protein MRE11, is significantly disturbed by the presence of the viral oncogene, SV40 large T-antigen. The attenuation of foci formation was found in both T-antigen immortalized cells and in cells transiently expressing T-antigen, indicating that it is not attributable to secondary mutations but to T-antigen expression itself. ATM-mediated nibrin phosphorylation was not altered, thus the disturbance of MRE11 foci formation by T-antigen is independent of this event. The decrease in MRE11 foci was particularly pronounced in T-antigen immortalized cells from the Fanconi anaemia complementation group FA-D2. FA-D2 cells produce essentially no MRE11 DNA repair foci after ionizing irradiation and have a significantly increased cellular radiosensitivity at low radiation doses. The gene mutated in FA-D2 cells, FANCD2, codes for a protein which also locates to nuclear foci and may, therefore, be involved in MRE11 foci formation, at least in T-antigen immortalized cells. This finding possibly links Fanconi anaemia proteins to the frequently reported increased sensitivity of Fanconi anaemia cells to transformation by SV40. From a practical stand point these findings are particularly relevant to the many studies on DNA repair which exploit the advantages of SV40 immortalized cell lines. The interference of T-antigen with DNA repair processes, as demonstrated here, should be borne in mind when interpreting such studies.	Humboldt Univ, Charite, Inst Humangenet, D-13353 Berlin, Germany; Humboldt Univ, Charite, Klin Strahlenheilkunde, D-13353 Berlin, Germany; Humboldt Univ, Charite, Med Klin, Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, Inst Humangenet, D-97070 Wurzburg, Germany; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Oregon Health & Science University	Digweed, M (corresponding author), Humboldt Univ, Charite, Inst Humangenet, Augustenburger Pl 1, D-13353 Berlin, Germany.		Grötzinger, Carsten/B-6938-2008; Demuth, Ilja/ABD-5352-2021	Grötzinger, Carsten/0000-0001-9872-3087; Demuth, Ilja/0000-0002-4340-2523; Grompe, Markus/0000-0002-6616-4345				Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Digweed M, 1999, BIOESSAYS, V21, P649, DOI 10.1002/(SICI)1521-1878(199908)21:8<649::AID-BIES4>3.0.CO;2-O; DIGWEED M, 2002, IN PRESS CARCINOGENE, V23; DOSIK H, 1970, BLOOD-J HEMATOL, V36, P341, DOI 10.1182/blood.V36.3.341.341; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Lanson NA, 2000, NUCLEIC ACIDS RES, V28, P2882, DOI 10.1093/nar/28.15.2882; Liu JM, 1996, BIOCHEM BIOPH RES CO, V223, P685, DOI 10.1006/bbrc.1996.0956; LUBINIECKI AS, 1980, AM J HEMATOL, V8, P389, DOI 10.1002/ajh.2830080407; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Y, 2000, GENE DEV, V14, P927; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	24	50	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4873	4878		10.1038/sj.onc.1205616	http://dx.doi.org/10.1038/sj.onc.1205616			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118365				2022-12-17	WOS:000176874800001
J	Kubista, M; Rosner, M; Kubista, E; Bernaschek, G; Hengstschlager, M				Kubista, M; Rosner, M; Kubista, E; Bernaschek, G; Hengstschlager, M			Brca1 regulates in vitro differentiation of mammary epithelial cells	ONCOGENE			English	Article						Brca1; differentiation; mammary epithelial cells; breast cancer	SUPPRESSOR GENE BRCA1; BREAST-CANCER; DNA-DAMAGE; NEURONAL DIFFERENTIATION; NUCLEAR PHOSPHOPROTEIN; TUMOR-FORMATION; EXPRESSION; MOUSE; CYCLE; VARIANT	Murine Breal is widely expressed during development in different tissues. Why alterations of BRCA1 lead specifically to breast and ovarian cancer is currently not clarified. Here we show that Brca1 protein expression is upregulated during mammary epithelial differentiation of HC11 cells, during differentiation of C2C12 myoblasts into myotubes and during neuronal differentiation of N1E-115 cells. Ectopic overexpression of BRCA1 and downregulation of endogenous Brca1 expression specifically affect the regulation of mammary epithelial cell differentiation. Accelerated mammary epithelial cell differentiation upon high ectopic BRCA1 expression is not a consequence of the anti-proliferative capacity of this tumor suppressor and independent of functional p53. Overexpression of the BRCA1 variant lacking the large central exon 11 has no effects on mammary epithelial cell differentiation. These data provide new insights into the cellular role of Brca1.	Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chen YM, 1996, CANCER RES, V56, P3168; Daniel DC, 1999, CELL TISSUE RES, V298, P481, DOI 10.1007/s004410050070; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERLO GR, 1994, ONCOGENE, V9, P443; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Mixon M, 2000, ONCOGENE, V19, P5237, DOI 10.1038/sj.onc.1203905; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	40	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4747	4756		10.1038/sj.onc.1205580	http://dx.doi.org/10.1038/sj.onc.1205580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101413				2022-12-17	WOS:000176716300004
J	Coll, ML; Rosen, K; Ladeda, V; Filmus, J				Coll, ML; Rosen, K; Ladeda, V; Filmus, J			Increased Bcl-x(L) expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells	ONCOGENE			English	Article						Bcl-x(L); v-Src; anoikis; intestinal epithelial cells	ADVANCED COLORECTAL CANCERS; BCL-X; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; DOWN-REGULATION; ACTIVATED RAS; MAP KINASE; TRANSFORMATION; GROWTH; PP60(C-SRC)	Acquisition of resistance to anoikis (detachment-induced apoptosis) is considered to be a requirement for transformed intestinal epithelial cells to invade surrounding tissues and metastasize to distant organs. Increased Src kinase activity, which is a feature of a large proportion of colorectal cancers, has been identified as one of the factors that can contribute to anoikis resistance. However, the molecular mechanism by which high levels of Src activity contribute to anoikis resistance in intestinal epithelial cells is unknown. Here we show that high Src activity confers resistance to anoikis in intestinal epithelial cells, at least in part, by inducing Bcl-x(L) overexpression, and that this induction is mediated by the MEK/MAPK pathway. Based on the findings reported here. and on our previous study showing that Bcl-x(L), plays a critical role in ras-induced resistance to anoikis, we propose that the increased Bel-x(L) levels found in colorectal cancers play a significant role in the induction of resistance to anoikis during the progression of this disease.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cell & Mol Biol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	filmus@sten.sunnybrook.utoronto.ca		Loza Coll, Mariano/0000-0002-3123-1229; Rosen, Kirill/0000-0002-4317-9907				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Daigo Y, 1999, CANCER RES, V59, P4222; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Han NM, 1996, CLIN CANCER RES, V2, P1397; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JAMAL HH, 1994, ONCOGENE, V9, P417; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Krajewska M, 1996, CANCER RES, V56, P2422; Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pories SE, 1998, GASTROENTEROLOGY, V114, P1287, DOI 10.1016/S0016-5085(98)70435-4; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200	41	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2908	2913		10.1038/sj.onc.1205388	http://dx.doi.org/10.1038/sj.onc.1205388			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973652				2022-12-17	WOS:000175063700017
J	Li, M; Song, SM; Lippman, SM; Zhang, XK; Liu, XM; Lotan, R; Xu, XC				Li, M; Song, SM; Lippman, SM; Zhang, XK; Liu, XM; Lotan, R; Xu, XC			Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells	ONCOGENE			English	Article						retinoids; retinoic acid receptor-beta; cyclooxygenase-2; esophageal cancer	ACTIVATOR PROTEIN-1 ACTIVITY; UP-REGULATION; SELECTIVE-INHIBITION; EPITHELIAL-CELLS; APOPTOSIS; GROWTH; TRANSCRIPTION; ASPIRIN; N-(4-HYDROXYPHENYL)RETINAMIDE; DIFFERENTIATION	Since retinoic acid receptor (RAR)-beta mRNA is frequently lost during esophageal carcinogenesis and esophageal cancer cells that do not express RAR-beta are resistant to retinoic acid (RA), we stably transfected RAR-beta expression vector into an esophageal cancer cell line TE-8 and an antisense RAR-beta into TE-3 cells. Transfection of RAR-beta decreased cell growth and colony formation and induced apoptosis in TE-8 cells. Antisense RAR-beta-transfected TE-3 cells had a shorter doubling time and became resistant to RA. Induction of RAR-beta decreased COX-2 expression in RAR-beta transfected TE-8 cells, whereas antisense RAR-beta transfected TE-3 cells increased COX-2 expression. The inhibitory effect of RAR-beta on COX-2 expression was further enhanced in the presence of RA, which was blocked by an RAR antagonist. The synthetic retinoid N-(4-hydroxyphenyl)-retinamide, which does not bind effectively to RAR-beta, had no effect on COX-2 suppression. Furthermore, RA blocked bile acid-induced COX-2 expression and prostaglandin E-2 production only in the RAR-beta positive cells. Our data demonstrated that anticancer effect of RAR-beta may be related to its ability to suppress COX-2 expression and support that the loss of RAR-beta expression may contribute to esophageal carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Xu, XC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, 1515 Holcombe Blvd,Box 236, Houston, TX 77030 USA.	xxu@mdanderson.org						Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Carey M, 2000, TRANSCRIPTIONAL REGU; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford JL, 1999, CANCER RES, V59, P14; DE LUCA LM, 1991, FASEB J, V5, P2924; Dmitrovsky E, 1997, J NATL CANCER I, V89, P1179, DOI 10.1093/jnci/89.16.1179; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GOLDSTEIN SM, 1984, CANCER RES, V44, P120; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Li M, 2000, CANCER EPIDEM BIOMAR, V9, P545; Li M, 2001, INT J CANCER, V93, P218, DOI 10.1002/ijc.1322; Lin F, 2000, CANCER RES, V60, P3271; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MARNETT LJ, 1992, CANC RES, V52; Mestre JR, 1997, CANCER RES, V57, P2890; Mestre JR, 1997, ANN NY ACAD SCI, V833, P173, DOI 10.1111/j.1749-6632.1997.tb48605.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Souza RF, 2000, CANCER RES, V60, P5767; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Xu X.-C., 1999, HANDB EXP PHARM, P323; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zimmermann KC, 1999, CANCER RES, V59, P198	49	50	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					411	418		10.1038/sj.onc.1205106	http://dx.doi.org/10.1038/sj.onc.1205106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821953	Bronze			2022-12-17	WOS:000173311200009
J	Bader, AG; Schneider, ML; Bister, K; Hartl, M				Bader, AG; Schneider, ML; Bister, K; Hartl, M			TOJ3, a target of the v-jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1)	ONCOGENE			English	Article						jun oncogene; signal transduction; transcription factor AP-1; gene expression; target gene; nucleolar protein	DOXYCYCLINE-CONTROLLED EXPRESSION; CONDITIONAL CELL-TRANSFORMATION; C-JUN; FHA DOMAIN; STRUCTURAL-ANALYSIS; EMBRYO FIBROBLASTS; MOLECULAR-CLONING; GENE-EXPRESSION; AP-1 FUNCTION; FOS	Using the established quail cell line Q/d3 conditionally transformed by the v-jun oncogene, cDNA clones (TOJ2, TOJ3, TOJ5, TOJ6) were isolated by representational difference analysis (RDA) that correspond to genes which were induced immediately upon conditional activation of v-jun. One of these genes, TOJ3, is immediately and specifically activated after doxycycline-mediated v-jun induction, with kinetics similar to the induction of well characterized direct AP-I target genes. TOJ3 is neither activated upon conditional activation of v-myc, nor in cells or cell lines non-conditionally transformed by oncogenes other than v-jun. Sequence analysis revealed that the TOJ3-specific cDNA encodes a 530-amino acid protein with significant sequence similarities to the murine or human microspherule protein 1 (MCRS1, MSP58), a nucleolar protein that directly interacts with the ICP22 regulatory protein from herpes simplex virus 1 or with p120, a proliferation-related protein expressed at high levels in most human malignant tumor cells. Similar to its mammalian counterparts, the TOJ3 protein contains a bipartite nuclear localization motif and a forkhead associated domain (FHA). Using polyclonal antibodies directed against a recombinant amino-terminal TOJ3 protein segment, the activation of TOJ3 in jun-transformed fibroblasts was also demonstrated at the protein level by specific detection of a polypeptide with an apparent M-r of 65000. Retroviral expression of the TOJ3 gene in quail or chicken embryo fibroblasts induces anchor age-independent growth, indicating that the immediate activation of TOJ3 in fibroblasts transformed by the v-jun oncogene contributes to cell transformation.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Bister, K (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	klaus.bister@uibk.ac.at; markus.hartl@uibk.ac.at	Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1987, ONCOGENE, V1, P97; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; CURRAN T, 1991, TRANSCRIPTIONAL REGU, P797; Dang CV, 1999, MOL CELL BIOL, V19, P1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FREEMAN JW, 1988, CANCER RES, V48, P1244; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GROSSI M, 1991, ONCOGENE, V6, P1767; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOZAK P, 1995, EXP CELL RES, V216, P285, DOI 10.1006/excr.1995.1036; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JURDIC P, 1995, ONCOGENE, V11, P1699; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Li J, 2000, J CELL SCI, V113, P4143; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MOLDERS H, 1987, ONCOGENE, V1, P377; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Ren Y, 1998, EUR J BIOCHEM, V253, P734, DOI 10.1046/j.1432-1327.1998.2530734.x; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SU HY, 1991, ONCOGENE, V6, P1759; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WONG WY, 1992, ONCOGENE, V7, P2077; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	69	50	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7524	7535		10.1038/sj.onc.1204938	http://dx.doi.org/10.1038/sj.onc.1204938			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709724				2022-12-17	WOS:000171976900009
J	Takai, D; Yagi, Y; Wakazono, K; Ohishi, N; Morita, Y; Sugimura, T; Ushijima, T				Takai, D; Yagi, Y; Wakazono, K; Ohishi, N; Morita, Y; Sugimura, T; Ushijima, T			Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis	ONCOGENE			English	Article						DNA methylation; lung neoplasms; endothelin-1; serotonin IB receptor; MS-RDA	BRONCHIAL EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROSTATE-CANCER; GROWTH-FACTOR; CPG ISLANDS; GENE; ENDOTHELIN; HYPERMETHYLATION; AMPLIFICATION; PCR	Aberrantly hypermethylated genes in human lung cancers were searched for by a genome scanning technique, methylation-sensitive-representational difference analysis (MS-RDA). A total of 59 DNA fragments were isolated as those methylated more heavily in either/both of two lung squamous cell carcinoma cell lines, EBC-1 and LK-2, than in a primary culture of normal human bronchial epithelium, NHBE. Thirty-four DNA fragments, whose hypermethylation was confirmed in primary squamous cell carcinomas, were sequenced. By database searches, 17 of them were shown to be located within 2 kb of putative CpG islands, and five of the 17 DNA fragments had transcribed regions of known genes in their vicinities. By RT - PCR of the five genes in the carcinoma cell lines and NHBE, decreased expression of HTR1B (5-hydroxytryptamine receptor 1B) and EDN1 (endothelin-1) was observed. Sequencing after bisulfite modification showed that the CpG island in the promoter region of HTR1B was hypermethylated, while that of EDN1 was not. Demethylation and re-expression of HTR1B were observed after treatment of LK-2 cells with 5-aza-2'-deoxycytidine. In primary lung cancers, decreased mRNA expression of HTR1B was observed in 11 of 20 cases, and that of EDN1 was in 16 of 20 cases. Immunohistochemical analysis of endothelin-1 confirmed that its immunoreactivity was reduced in squamous cell carcinoma cells compared with that in normal bronchial epithelial cells. Considering that endothelin-1 induces apoptosis in melanoma cells and that silencing of endothelin receptor B is observed in prostate cancers, its reduced expression was speculated to confer a growth advantage to lung cancer cells. MS-RDA was shown to isolate DNA fragments that are hypermethylated and silenced, such as HTR1B, and those whose expressions are altered and the methylation statuses outside the promoter region are altered, such as EDN1.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138655, Japan	National Cancer Center - Japan; University of Tokyo	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817				Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; Baylin SB, 1998, ADV CANCER RES, V72, P141; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522; Eguchi K, 1997, CANCER RES, V57, P4913; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HARRIS CC, 1991, IARC SCI PUBL, V105, P294; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; Jakowlew SB, 1997, BBA-GENE STRUCT EXPR, V1353, P157, DOI 10.1016/S0167-4781(97)00068-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KADOKAMI Y, 1995, ANAL BIOCHEM, V226, P193, DOI 10.1006/abio.1995.1212; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; MARKEWITZ BA, 1995, AM J PHYSIOL-LUNG C, V268, pL192, DOI 10.1152/ajplung.1995.268.2.L192; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; McDowell DG, 1998, NUCLEIC ACIDS RES, V26, P3340, DOI 10.1093/nar/26.14.3340; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Nelson JB, 1997, CANCER RES, V57, P35; Nelson JB, 1996, CANCER RES, V56, P663; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; Sambrook J., 2000, MOL CLONING, V3rd; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	31	50	56	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7505	7513		10.1038/sj.onc.1204940	http://dx.doi.org/10.1038/sj.onc.1204940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709722				2022-12-17	WOS:000171976900007
J	Vikhanskaya, F; Bani, MR; Borsotti, P; Ghilardi, C; Ceruti, R; Ghisleni, G; Marabese, M; Giavazzi, R; Broggini, M; Taraboletti, G				Vikhanskaya, F; Bani, MR; Borsotti, P; Ghilardi, C; Ceruti, R; Ghisleni, G; Marabese, M; Giavazzi, R; Broggini, M; Taraboletti, G			p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis	ONCOGENE			English	Article						p73; angiogenesis; thrombospondin-1; VEGF; ovarian carcinoma	HUMAN BLADDER-CANCER; GROWTH-FACTOR GENE; CELL-LINES; MALIGNANT PROGRESSION; ENDOTHELIAL-CELLS; SUPPRESSOR GENE; C-JUN; EXPRESSION; P53; TRANSCRIPTION	Tumor neovascularization is controlled by a balance between positive and negative effectors, whose production can be regulated by oncogenes and tumor suppressor genes. The aim of this study was to investigate whether the angiogenic potential of tumors could also be controlled by p73, a gene homologous to the tumor suppressor p53, whose involvement in tumor angiogenesis is known. We have studied the production of proangiogenic (VEGF, FGF-2, PIGF and PDGF) and antiangiogenic (TSP-1) factors in two p73 overexpressing clones obtained from the human ovarian carcinoma cells A2780. TSP-1 was downregulated in both clones compared to mock transfected cells, both at mRNA bind protein level. Conversely, both clones showed an increased production of VEGF mRNA and protein. For both TSP-1 and VEGF, regulation of expression was partially due to modulation of the promoter activity, and was dependent on p53 status. Production of the other angiogenic factors FGF-2, PIGF and PDGF-B was also increased in p73 overexpressing clones. The two clones were more angiogenic than parental cells, as shown in vitro by their increased chemotactic activity for endothelial cells, and in vivo by the generation of more vascularized tumors. These findings suggest a potential role of p73 in tumor angiogenesis.	Mario Negri Inst Pharmacol Res, Dept Oncol, I-24125 Bergamo, Italy; Univ Milan, Ist Anat Patol Vet & Patol Aviare, I-20133 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Taraboletti, G (corresponding author), Mario Negri Inst Pharmacol Res, Dept Oncol, Via Gavazzeni 11, I-24125 Bergamo, Italy.		Giavazzi, Raffaella/ABB-9768-2020; Giavazzi, Raffaella/J-7424-2018; Borsotti, Patrizia/ABF-9679-2020; Bani, Maria Rosa/AAB-3397-2020; Taraboletti, Giulia/J-4089-2018; broggini, massimo/AAA-6460-2020; Marabese, Mirko/AAA-6876-2019; Ghilardi, Carmen/AAB-1599-2020	Giavazzi, Raffaella/0000-0001-5249-8208; Borsotti, Patrizia/0000-0002-9789-528X; Bani, Maria Rosa/0000-0001-8178-1432; Taraboletti, Giulia/0000-0001-8780-5001; Marabese, Mirko/0000-0001-9379-0301; Ghilardi, Carmen/0000-0002-3036-8557; Ghisleni, Gabriele/0000-0002-8116-110X; BROGGINI, MASSIMO/0000-0002-8138-9358				Bertin N, 1997, CANCER RES, V57, P396; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Chi SG, 1999, CANCER RES, V59, P2791; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Debernardis D, 1997, CANCER RES, V57, P870; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Holmgren L, 1998, ONCOGENE, V17, P819, DOI 10.1038/sj.onc.1201993; Hsu SC, 1996, CANCER RES, V56, P5684; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Levrero M, 2000, J CELL SCI, V113, P1661; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NAGY JA, 1995, CANCER RES, V55, P360; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Nomoto S, 1998, CANCER RES, V58, P1380; RAK J, 1995, CANCER RES, V55, P4575; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Takahashi H, 1998, CANCER RES, V58, P2076; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Taraboletti G, 2000, EXP CELL RES, V258, P384, DOI 10.1006/excr.2000.4936; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Vikhanskaya F, 2001, CANCER RES, V61, P935; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOLPERT OV, 1997, ONCOGENE, V14, P1497; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zwahlen D, 2000, INT J CANCER, V88, P66	44	50	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7293	7300		10.1038/sj.onc.1204896	http://dx.doi.org/10.1038/sj.onc.1204896			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704858				2022-12-17	WOS:000171894200001
J	David-Pfeuty, T; Nouvian-Dooghe, Y; Sirri, V; Roussel, P; Hernandez-Verdun, D				David-Pfeuty, T; Nouvian-Dooghe, Y; Sirri, V; Roussel, P; Hernandez-Verdun, D			Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells	ONCOGENE			English	Article						cyclin-dependent kinase 2; casein kinase II; wt p53; p21(WAFI CIPI); ribosomal RNA processing; untransformed and tumor-derived cells	CYCLIN-DEPENDENT KINASES; POLYMERASE-II TRANSCRIPTION; DNA-REPLICATION; S-PHASE; MAMMALIAN FIBROBLASTS; EPITHELIAL-CELLS; NUCLEAR-PROTEIN; PURINE ANALOGS; CDC28 MUTATION; CDK INHIBITORS	Two specific inhibitors of cyclin-dependent kinase 2 (Cdk2), roscovitine and olomoucine, have been shown recently to induce nuclear accumulation of wt p53 and nucleolar unravelling in interphase human untransformed IMR-90 and breast tumor-derived MCF-7 cells. Here, we show that the early response of MCF-7 cells to roscovitine is fully reversible since a rapid restoration of nucleolar organization followed by an induction of p21(WAF1/CIP1), a downregulation of nuclear wt p53 and normal cell cycle resumption occurs if the compound is removed after 4 h. Interestingly, similar reversible effects are also induced by the casein kinase II (CKII) inhibitor, 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole. Upon short-term treatment also, both compounds significantly, but reversibly, reduce the level of 45S precursor ribosomal RNA. Cells exposed to the two types of protein kinase inhibitors for longer times keep exhibiting altered nucleolar and wt p53 features, yet they strikingly differentiate in that most roscovitine-treated bells fail to ever accumulate high levels of p21(WAF1/CIP1) in contrast with DRB-treated ones. In both cases, however, the cells eventually fall into an irreversible state and die. Moreover, we found that constitutive overexpression of p21(WAF1/CIP1) alters the nucleolar unravelling process in the presence of DRB, but not of roscovitine, suggesting a role for this physiological Cdk inhibitor in the regulation of nucleolar function. Our data also support the notion that both roscovitine- and DRB-sensitive protein kinases, probably including Cdk2 and CKII, via their dual implication in the p53-Rb pathway and in ribosomal biogenesis, would participate in coupling cell growth with cell division.	Ctr Univ Orsay, CNRS, UMR 146, Inst Curie Rech, F-91405 Orsay, France; Inst Jacques Monod, UMR 7592, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	David-Pfeuty, T (corresponding author), Ctr Univ Orsay, CNRS, UMR 146, Inst Curie Rech, Batiment 110, F-91405 Orsay, France.	Therese.Pfeuty@curie.u-psud.fr						Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; GRANICK D, 1975, J CELL BIOL, V65, P398, DOI 10.1083/jcb.65.2.398; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Le Panse S, 1999, J CELL SCI, V112, P2145; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, ONCOGENE, V9, P2261; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHI K, 1994, J BIOL CHEM, V269, P6320; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Prives C, 1999, J PATHOL, V187, P112; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROUSSEL P, 1993, J CELL SCI, V104, P327; Sambrook J., 1982, MOL CLONING; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; WILSON GN, 1982, AM J HUM GENET, V34, P32; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	81	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					5951	5963		10.1038/sj.onc.1204741	http://dx.doi.org/10.1038/sj.onc.1204741			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593402				2022-12-17	WOS:000171056300002
J	Goodman, PA; Wood, CM; Vassilev, A; Mao, C; Uckun, FM				Goodman, PA; Wood, CM; Vassilev, A; Mao, C; Uckun, FM			Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia	ONCOGENE			English	Article; Proceedings Paper	42nd Annual Meeting of the American-Society-of-Hematology	DEC 01-05, 2000	SAN FRANCISCO, CA	Amer Soc Hematol		pro-B cell; B-cell ontogeny; SYK; exon skipping; acute lymphoblastic leukemia	CHILDRENS CANCER GROUP; SEVERE COMBINED IMMUNODEFICIENCY; MOLECULAR-CLONING; CLINICAL-SIGNIFICANCE; RECEPTOR STIMULATION; MEDIATED ACTIVATION; IKAROS ISOFORMS; MESSENGER-RNA; SH2 DOMAINS; PROTEIN	The cytoplasmic spleen tyrosine kinase (SYK) is a key regulator of signal transduction events, apoptosis and orderly cell cycle progression in B-lineage lymphoid cells, Although SYK has not been linked to a human disease, defective expression of the closely related T-cell tyrosine kinase ZAP-70 has been associated with severe combined immunodeficiency. Childhood CD19(+)CD10(-) pro-B cell acute lymphoblastic leukemia (ALL) is thought to originate from B-cell precursors with a maturational arrest at the pro-B cell stage and it is associated with poor prognosis, Since lethally irradiated mice reconstituted with SYK-deficient fetal liver-derived lymphohematopoietic progenitor cells show a block in B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression profiles of primary leukemic cells from children with pro-B cell ALL, Here we report that leukemic cells from pediatric CD19(+)CD10(-) pro-B cell ALL patients (but not leukemic cells from patients with CD19(+)CD10(+) common pre-pre-B cell ALL) have markedly reduced SYK activity, Sequencing of the reverse transcriptase-polymerase chain reaction (RT-PCR) products of the Syk mRNA in these pro-B leukemia cells revealed profoundly aberrant coding sequences with deletions or insertions, These mRNA species encode abnormal SYK proteins with a missing or truncated catalytic kinase domain, In contrast to pro-B leukemia cells, pre-pre-B leukemia cells from children with CD19+CD10+ common B-lineage ALL and EBV-transformed B-cell lines from healthy volunteers expressed wild-type Syk coding sequences, Examination of the genomic structure of the Syk gene by inter-exonic PCR and genomic cloning demonstrated that the deletions and insertions in the abnormal mRNA species of pro-B leukemia cells are caused by aberrant splicing resulting in either missplicing, exon skipping or inclusion of alternative exons, consistent with an abnormal posttranscriptional regulation of alternative splicing of Syk pre-mRNA, Our findings link for the first time specific molecular defects involving the Syk gene to an immunophenotypically distinct category of childhood ALL, To our knowledge, this is the first discovery of a specific tyrosine kinase deficiency in a human hematologic malignancy.	Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biochem, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA.	fatih_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BRUNGER AT, 1992, X PLOR VERSION 3 1; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GULBINS E, 1994, J IMMUNOL, V152, P2123; HARADA H, 1994, ONCOGENE, V9, P3313; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Latour S, 1998, EMBO J, V17, P2584, DOI 10.1093/emboj/17.9.2584; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LAW CL, 1994, J BIOL CHEM, V269, P12310; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1994, NATURE, V370, P249, DOI 10.1038/370249a0; Qin SF, 1998, FEBS LETT, V427, P139, DOI 10.1016/S0014-5793(98)00383-4; Reaman GH, 1999, J CLIN ONCOL, V17, P445, DOI 10.1200/JCO.1999.17.2.445; ROWLEY RB, 1995, J BIOL CHEM, V270, P12659, DOI 10.1074/jbc.270.21.12659; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tamiya S, 1998, BLOOD, V91, P3935; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Trigg ME, 1996, CANC MED, P2945; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; Uckun FM, 1997, LEUKEMIA LYMPHOMA, V27, P445, DOI 10.3109/10428199709058311; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; Uckun FM, 1998, BLOOD, V92, P810; Uckun FM, 1997, BLOOD, V89, P2488; Uckun FM, 1998, J CLIN ONCOL, V16, P527, DOI 10.1200/JCO.1998.16.2.527; YAGI S, 1994, BIOCHEM BIOPH RES CO, V200, P28, DOI 10.1006/bbrc.1994.1409; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	52	50	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3969	3978		10.1038/sj.onc.1204515	http://dx.doi.org/10.1038/sj.onc.1204515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494125				2022-12-17	WOS:000169681500005
J	Kishi, S; Wulf, G; Nakamura, M; Lu, KP				Kishi, S; Wulf, G; Nakamura, M; Lu, KP			Telomeric protein Pin2/TRF1 induces mitotic entry and apoptosis in cells with short telomeres and is down-regulated in human breast tumors	ONCOGENE			English	Article						apoptosis; cancer; cell cycle; Pin2/TRF1; telomeres; telomeric protein	ATAXIA-TELANGIECTASIA GENE; M-PHASE PHOSPHOPROTEINS; FISSION YEAST; PHOSPHORYLATED EPITOPE; PROLYL ISOMERIZATION; DEFICIENT MICE; FLOW-CYTOMETRY; ATM; LENGTH; INHIBITION	Telomeres are essential for cell survival and have been implicated in the mitotic control. The telomeric protein Pin2/TRF1 controls telomere elongation and its expression is tightly regulated during cell cycle. We previously reported that overexpression of Pin2/TRF1 affects mitotic progression. However, the role of Pin2/TRF1 at the interface between cell division and cell survival remains to be determined. Here we show that overexpression of Pin2 induced apoptosis in cells containing short telomeres, but not in cells with long telomeres, Furthermore, before entering apoptosis, Pin2-expressing cells first accumulated in mitosis and strongly stained with the mitosis-specific MPM2 antibody. Moreover, Pin2-induccd apoptosis is potentiated by arresting cells in mitosis, but suppressed by accumulating cells in G1, In addition, overexpression of Pin2 also resulted in activation of caspase-3, and its proapoptotic activity was significantly reduced by inhibition of caspase-3, These results indicate that up-regulation of Pin2/TRF1 can specifically induce entry into mitosis and apoptosis, likely via a mechanism related to activation of caspase-3, Significantly, we also found that, out of 51 human breast cancer tissues and 10 normal controls examined, protein levels of Pin2/TRF1 in tumors were significantly lower than in normal tissues, as detected by immunoblotting analysis and immunocytochemistry, Since down-regulation of Pin2/TRF1 allows cells to maintain long telomeres, these results suggest that down-regulation of Pin2/TRF1 may be important for cancer cells to extend their proliferative potential.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, HIM 1047,330 Brookline Ave, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 1999, GENETICS, V151, P1041; Aragona M, 2000, ONCOL REP, V7, P987; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Belloc F, 2000, CYTOMETRY, V40, P151, DOI 10.1002/(SICI)1097-0320(20000601)40:2<151::AID-CYTO9>3.0.CO;2-9; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Douglas RS, 1998, CYTOMETRY, V32, P57, DOI 10.1002/(SICI)1097-0320(19980501)32:1<57::AID-CYTO8>3.0.CO;2-C; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZIV Y, 1989, CANCER RES, V49, P2495	64	50	58	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1497	1508		10.1038/sj.onc.1204229	http://dx.doi.org/10.1038/sj.onc.1204229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313893				2022-12-17	WOS:000167595200010
J	Fukuchi, Y; Kizaki, H; Yamato, K; Kawamura, C; Umezawa, A; Hata, J; Nishihara, T; Ikeda, Y				Fukuchi, Y; Kizaki, H; Yamato, K; Kawamura, C; Umezawa, A; Hata, J; Nishihara, T; Ikeda, Y			Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells	ONCOGENE			English	Article						activin A; CML apoptosis; differentiation; Mcl-1	GLOBIN GENE-EXPRESSION; FSH-RELEASING PROTEIN; BCL-2 FAMILY-MEMBERS; ERYTHROID-DIFFERENTIATION; SIGNALING PATHWAY; PROLIFERATION; LEUKEMIA; INHIBIN; PURIFICATION; DELAYS	Activin A, one member of the transforming grow th factor (TGF)-beta superfamily, is known to be a commitment factor for cell death and differentiation. In the present study, we demonstrate that human chronic myeloid leukemia (CML) cell lines, KU812 and K562 cells, either induced apoptosis or differentiation, respectively, by treatment with activin A. During these cell fate decisive events caused by activin A, rapid and transient up-regulation of Mcl-1 nas observed in both cell lines, In activin A-induced apoptosis of KU812 cells, continuous up-regulation of Bas was observed. After the decrease in Mcl-1 expression had occurred, activation of caspase-9 and caspase-3 and cleavage of DFF45 were shown to take place in KU812 cells, resulting in the fragmentation of the genomic DNA of the cells. In contrast, the dean-regulation of Mcl-1 without up-regulation of Bas caused accumulation of hemoglobin (Hb) contents in activin A-treated K562 cells. Interestingly, erythropoietin (EPO) prevented activin A-induced apoptosis with continuous expression of Mcl-1 and caused KU812 cells to undergo erythroid differentiation. To address the role of Mcl-1 in activin A-treated CML cells, KU812 and K562 cells were stably transfected with cDNA encoding Mcl-1 (designated as KU812/mcl and K562/mcl cells). As in combined effect of activin A and EPO on the parental KU812 cells, activin A induced differentiation, but not apoptosis, of KU812/mcl cells without modulating Bas levels. Activin A-treated K562/mcl cells, as well as parental cells, were only differentiated to erythroid cells, These results suggest that Mcl-1 is an early inducible gene activated by the activin A signaling pathway for both cellular differentiation and apoptosis, and continuous expression of Mcl-1 mag be contributed to differentiation signals to the erythroid lineage in CML cells.	Keio Univ, Sch Med, Div Hematol, Dept Internal Med & Pathol,Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci,Dept Oral Funct, Sect Mol Cellular Oncol Microbiol, Tokyo 1138519, Japan; Kyushu Dent Coll, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan	Keio University; Tokyo Medical & Dental University (TMDU); Kyushu Dental University	Kizaki, H (corresponding author), Keio Univ, Sch Med, Div Hematol, Dept Internal Med & Pathol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Ando T, 1998, JPN J CANCER RES, V89, P1326, DOI 10.1111/j.1349-7006.1998.tb00530.x; BILEZIKJIAN LM, 1992, TRENDS ENDOCRIN MET, V3, P218, DOI 10.1016/1043-2760(92)90031-U; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; CHAMPLIN RE, 1985, BLOOD, V65, P1039; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; DEPAOLO LV, 1991, P SOC EXP BIOL MED, V198, P500; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FRIGON NL, 1992, BLOOD, V79, P765; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MIYAMOTO Y, 1990, BIOCHEM BIOPH RES CO, V168, P1149, DOI 10.1016/0006-291X(90)91149-M; MIZUGUCHI T, 1993, BLOOD, V81, P2891; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NISHIMURA M, 1991, BIOCHEM BIOPH RES CO, V181, P1042, DOI 10.1016/0006-291X(91)92042-I; Peters R, 1998, BLOOD, V92, P2041, DOI 10.1182/blood.V92.6.2041.418k34_2041_2052; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SHAO LE, 1992, BLOOD, V79, P773; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shiozaki M, 1998, BIOCHEM BIOPH RES CO, V242, P631, DOI 10.1006/bbrc.1997.8020; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; TALPAZ M, 1995, ANN INTERN MED, V122, P728, DOI 10.7326/0003-4819-122-9-199505010-00013; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang JM, 1999, MOL CELL BIOL, V19, P6195; YAMASHITA T, 1991, J BIOL CHEM, V266, P3888; Yamato K, 1997, MOL ENDOCRINOL, V11, P1044, DOI 10.1210/me.11.8.1044; YAMATO K, 1996, JPN J CLIN HEMATOL, V37, P564; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YU J, 1989, BLOOD, V73, P952; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	45	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					704	713		10.1038/sj.onc.1204142	http://dx.doi.org/10.1038/sj.onc.1204142			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314004				2022-12-17	WOS:000166806000006
J	Lamorte, L; Kamikura, DM; Park, M				Lamorte, L; Kamikura, DM; Park, M			A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein	ONCOGENE			English	Article						Crk; cytoskeleton; Gab1; JNK; Met tyrosine kinase; transformation	FOCAL ADHESION KINASE; ADAPTER PROTEIN CRK; TYROSINE PHOSPHORYLATION; SCATTER FACTOR; PROTOONCOGENE PRODUCT; COMPLEX-FORMATION; CARBOXY-TERMINUS; GRB2 BINDING; V-CRK; MIGRATION	Cell transformation is associated with anchorage independent growth and morphological changes characterized by reduced adhesion and spreading, The molecular signals that control these events are poorly understood. The Met receptor tyrosine kinase is deregulated in human tumors and an oncogenic derivative of this receptor transforms cells. In this paper we demonstrate that fibroblasts transformed by the Met oncoprotein display decreased cell spreading consistent with the loss of actin stress fibers and vinculin staining focal adhesions. In contrast to control cells, focal adhesion kinase, p130Cas and paxillin are weakly or not detectably tyrosine phosphorylated in Met transformed cells. Moreover, although paxillin and p130Cas associate with the Crk adapter protein in control cells, they fail to associate with Crk in Met transformed cells, yet these cells are motile and capable of wound closure to the same extent as control cells. In Met transformed cells, Crk predominantly associates with the CM and Gab1 docking proteins in a tyrosine phosphorylation dependent manner. The coupling of Gab1, but not Cbl, with Crk is retained in cells grown in suspension and enhances JNK activation. We propose that the loss of adhesion dependent signals required for cell cycle progression is compensated through Met induced Gab1/Crk signals.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hosp, Mol Oncol Grp, 687 Pine Ave W,Room H5-10, Montreal, PQ H3A 1A1, Canada.							Andoniou CE, 1996, ONCOGENE, V12, P1981; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cary LA, 1996, J CELL SCI, V109, P1787; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FERRACINI R, 1995, ONCOGENE, V10, P739; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Koochekpour S, 1997, CANCER RES, V57, P5391; Lo SS, 1999, MOL CARCINOGEN, V25, P150; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAWASDIKOSOLA S, 2000, BIOCHIM BIOPHYS ACTA, V1471, P1; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	55	50	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5973	5981		10.1038/sj.onc.1203977	http://dx.doi.org/10.1038/sj.onc.1203977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146548				2022-12-17	WOS:000165827900003
J	Hyun, JW; Choi, JY; Zeng, HH; Lee, YS; Kim, HS; Yoon, SH; Chung, MH				Hyun, JW; Choi, JY; Zeng, HH; Lee, YS; Kim, HS; Yoon, SH; Chung, MH			Leukemic cell line, KG-1 has a functional loss of hOGG1 enzyme due to a point mutation and 8-hydroxydeoxyguanosine can kill KG-1	ONCOGENE			English	Article						KG-1; 8-hydroxyguanine; hOGG1; mutation; cytotoxicity	REMOVES 8-HYDROXYGUANINE RESIDUES; OXIDATIVE DNA-DAMAGE; ESCHERICHIA-COLI; ENDONUCLEASE ACTIVITY; OGG1 GENE; GLYCOSYLASE; CLONING; REPAIR; EXCISION; PROTEIN	We tested the cytotoxic action of 8-hydroxyguanine (8ohG) by observing the viability of several leukemic cell lines (KG-1, U937, Jurkat and K 562) in the presence of 8-hydroxydeoxyguanosine (8ohdG), a nucleoside of 8ohG, It was found that 8ohdG showed cytotoxic action only to KG-1 and that only KG-1 showed a homozygous arginine 209 to glutamine mutation in the hOGG1 gene with an almost negligible hOGG1 enzyme activity, Possibly, the selective cytotoxicity in 8ohdG to KG-1 may be due to its low capacity to cope with an increase in the 8ohG level in DNA resulting from the incorporation of 8ohdG present in the culture media. The mutational impairment of hOGG1 in KG-1 is the first report in leukemic cell lines. Using KG-1 with impaired hOGG1, we demonstrated cytotoxicity of 8ohdG probably due to its incorporation into cellular DNA. This new property of KG-1 may allow it to serve as an useful tool for studies of OGG1, oxidative DNA damage and the cytotoxic action of 8ohG.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, Seoul 110744, South Korea; Beijing Med Univ, Sch Pharmaceut Sci, Beijing 100083, Peoples R China; Korea Canc Ctr Hosp, Lab Radiat Effect, Nowon Gu, Seoul 139706, South Korea	Seoul National University (SNU); Peking University; National Cancer Center - Korea (NCC)	Chung, MH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, 28 Yongon Dong, Seoul 110744, South Korea.							Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CALABRESI P, 1991, GOODMAN GILMANS PHAR, P1227; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Choi JY, 1999, FREE RADICAL BIO MED, V27, P848, DOI 10.1016/S0891-5849(99)00141-0; CHUNG MH, 1991, BIOCHEM BIOPH RES CO, V178, P1472, DOI 10.1016/0006-291X(91)91059-L; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Kim HS, 1996, MUTAT RES-DNA REPAIR, V363, P115, DOI 10.1016/0921-8777(96)00006-7; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; LEE YS, 1993, BIOCHEM BIOPH RES CO, V196, P1545, DOI 10.1006/bbrc.1993.2427; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TU CPD, 1980, GENE, V10, P177, DOI 10.1016/0378-1119(80)90135-3; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	25	50	52	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4476	4479		10.1038/sj.onc.1203787	http://dx.doi.org/10.1038/sj.onc.1203787			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002420	Green Published			2022-12-17	WOS:000089236800004
J	Lou, JR; Cao, WS; Bernardin, F; Ayyanathan, K; Rauscher, FJ; Friedman, AD				Lou, JR; Cao, WS; Bernardin, F; Ayyanathan, K; Rauscher, FJ; Friedman, AD			Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins	ONCOGENE			English	Article						CBF; CBF beta-SMMHC; AML1-ETO; cdk4; leukemia	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BINDING-FACTOR-BETA; TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; MURINE MYELOPEROXIDASE; FUSION TRANSCRIPT	Core Binding Factor (CBF) is required for the development of definitive hematopoiesis, and the CBF oncoproteins AML1-ETO, TEL-AML1, and CBF beta-SMMHC are commonly expressed in subsets of acute leukemia. CBF beta-SMMHC slows the G1 to S cell cycle transition in hematopoietic cells, but the mechanism of this effect is uncertain, We have sought to determine whether inhibition of CBF-mediated trans-activation is sufficient to stow proliferation. We demonstrate that activation of KRAB-AML1-ER, a protein containing the AML1 DNA-binding domain, the KRAB repression domain, and the Estrogen receptor ligand binding domain, also slows G1, if its DNA-binding domain is intact, Also, exogenous AML1 overcame CBF beta-SMMHC-induced inhibition of proliferation, Representational difference analysis (RDA) identified cdk4 RNA expression as an early target of KRAB-AML1 activation. Inhibition of CBF activities by KRAB-AML1-ER or CBF beta-SMMHC rapidly reduced endogenous cdk4 mRNA levels, even in cells proliferating at or near control rates as a result of exogenous cdk4 expression, Over-expression of cdk4, especially a variant which cannot bind p16(INK4a) overcame cell cycle inhibition resulting from activation of KRAB-AML1-ER, although cdk4 did not accelerate proliferation when expressed alone. These findings indicate that mutations which alter the expression of G1 regulatory proteins can overcome inhibition of proliferation by CBF oncoproteins.	Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; The Wistar Institute	Friedman, AD (corresponding author), Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Canc Res Bldg,Room 255,1650 Orleans St, Baltimore, MD 21231 USA.				NHLBI NIH HHS [HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; BAE SC, 1993, ONCOGENE, V8, P809; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Herman JG, 1996, CANCER RES, V56, P722; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V88, P5167; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Segade F, 1995, LIFE SCI, V58, P277, DOI 10.1016/0024-3205(95)02288-0; Sepehri S, 1997, GENOME RES, V7, P1006, DOI 10.1101/gr.7.10.1006; SMITH IM, 1993, ENERG FUEL, V7, P7, DOI 10.1021/ef00037a003; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	57	50	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2000	19	22					2695	2703		10.1038/sj.onc.1203588	http://dx.doi.org/10.1038/sj.onc.1203588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851069				2022-12-17	WOS:000087193000005
J	Manna, SK; Aggarwal, BB				Manna, SK; Aggarwal, BB			All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappa B, activated protein-1 and apoptosis in human lung cancer cells	ONCOGENE			English	Article						ATRA; TNF; NF-kappa B; AP-1; apoptosis	TUMOR-NECROSIS-FACTOR; LYMPHOMA U-937 CELLS; FACTOR-ALPHA; SURFACE EXPRESSION; CELLULAR-RESPONSE; GROWTH-INHIBITION; INTERFERON-GAMMA; HL-60 CELLS; LINE HL-60; DIFFERENTIATION	Retinoids modulate the growth and differentiation effects of TNF but the mechanism is not understood. In this study, we investigated the effect of all-tr all-trans-retinoic acid (ATRA) on the cell surface expression of TNF receptors and receptor-mediated signaling in various human lung cancer cell lines. ATRA treatment of cells that express wild-type p53 (A549 and H460), or null p53 (H1299), or mutant p53 (H596) increased the number of TNF receptors, as determined by the specific binding of I-125-labeled TNF to these cells, in a dose- and time-dependent manner. Treatment with 2 mu M ATRA for 24 h at 37 degrees C produced the maximal increase. Scatchard analysis indicated that the increase inducted by ATRA was due to an increase in receptor number and not to an increase in affinity. The upmodulation of TNF receptors nas also confirmed by covalent receptor-ligand cross-linking studies. The increase in TNF receptors sensitized H596 cells to TNF-induced activation of NF-kappa B, AP-1 and apoptosis, A549 cells, however, were completely resistant to TNF-induced activation of NF-kappa B, AP-1 and apoptosis, Treatment of these cells with as little as 0.5 mu M ATRA was effective in converting TNF-resistant cells to TNF-sensitive. Overall our results indicate that ATRA induces the TNF receptors in human lung cancer cells, which sensitizes them to TNF-induced signaling leading to activation of NF-kappa B, AP-1 and apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1992, TUMOR NECROSIS FACTO, P624; AMOS B, 1989, PHARM RETINOIDS SKIN, P26; BEAUPAIN R, 1990, ANTICANCER RES, V10, P1061; Benner S E, 1995, Oncology (Williston Park), V9, P205; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHAMBAUTGUERIN AM, 1995, J NEUROCHEM, V65, P537; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAN H, 1994, J BIOL CHEM, V269, P31424; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; DE LUCA LM, 1991, FASEB J, V5, P2924; DRACH J, 1993, CANCER RES, V53, P2100; FALK LA, 1991, BLOOD, V77, P1248; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gridley DS, 1996, ONCOL RES, V8, P485; HAN SK, 1994, AM J RESP CELL MOL, V11, P270, DOI 10.1165/ajrcmb.11.3.8086165; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Haridas V, 1998, J IMMUNOL, V160, P3152; HASS PE, 1985, J BIOL CHEM, V260, P2214; HEMMI H, 1987, BLOOD, V69, P501; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JETTEN AM, 1980, NATURE, V284, P626, DOI 10.1038/284626a0; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KILIAN PL, 1988, MONOKINES OTHER NONL, P203; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOTAN R, 1992, CANCER RES, V52, P4878; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MEHTA K, 1994, J LEUKOCYTE BIOL, V55, P336, DOI 10.1002/jlb.55.3.336; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Oridate N, 1995, J CELL BIOCHEM, P80; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PECK R, 1991, EUR J CANCER, V27, P53, DOI 10.1016/0277-5379(91)90061-H; Pestana ES, 1996, ACTA ONCOL, V35, P473, DOI 10.3109/02841869609109925; POGREBNIAK HW, 1991, J THORAC CARDIOV SUR, V102, P904, DOI 10.1016/S0022-5223(19)33941-8; PREWITT TW, 1994, J THORAC CARDIOV SUR, V107, P43; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; Sheski FD, 1999, J LAB CLIN MED, V133, P265, DOI 10.1016/S0022-2143(99)90083-5; SIDELL N, 1991, J IMMUNOL, V146, P3809; SIDELL N, 1988, CELL IMMUNOL, V115, P299, DOI 10.1016/0008-8749(88)90183-9; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2829; TOBLER A, 1987, BLOOD, V70, P1940; TOTPAL K, 1995, BLOOD, V85, P3547, DOI 10.1182/blood.V85.12.3547.bloodjournal85123547; TRINCHIERI G, 1987, BLOOD, V69, P1218; WINZEN R, 1992, J IMMUNOL, V148, P3454; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZHENG ZS, 1990, CANCER RES, V50, P1201; Zou CP, 1998, CLIN CANCER RES, V4, P1345	57	50	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2110	2119		10.1038/sj.onc.1203547	http://dx.doi.org/10.1038/sj.onc.1203547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815802				2022-12-17	WOS:000086728000004
J	Ala-aho, R; Johansson, N; Grenman, R; Fusenig, NE; Lopez-Otin, C; Kahari, VM				Ala-aho, R; Johansson, N; Grenman, R; Fusenig, NE; Lopez-Otin, C; Kahari, VM			Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1	ONCOGENE			English	Article						interferon-gamma; collagenase; squamous cell carcinoma; mitogen activated protein kinase; matrix metalloproteinase	NECROSIS-FACTOR-ALPHA; SQUAMOUS-CELL CARCINOMAS; GENE-EXPRESSION; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; MESSENGER-RNA; FIBROBLAST COLLAGENASE; RHEUMATOID-ARTHRITIS; BREAST CARCINOMAS; III PROCOLLAGENS	Collagenase-3 (MMP-13) is characterized by an exceptionally wide substrate specificity and restricted expression, MMP-13 is specifically expressed by transformed human keratinocytes in squamous cell carcinomas in who and its expression correlates with their invasion capacity. Here, we show, that interferon-gamma (IFN-gamma) markedly inhibits expression of MMP-13 by human cutaneous SCC cells (UT-SCC-7) and by ras-transformed human epidermal keratinocytes (A-5 cells) at the transcriptional level. In addition, IFN-gamma inhibits collagenase-1 (MMP-1) expression in these cells, IFN-gamma, abolished the enhancement of MMP-13 and MMP-1 expression by transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), and inhibited invasion of A-5 cells through type I collagen. IFN-gamma also rapidly and transiently activates extracellular signal-regulated kinase 1,2 (ERK1,2) and blocking ERK1,2 pathway (Raf/MEK1,2/ERK1,2) by specific MEK1,2 inhibitor PD98059 partially (by 50%) prevents Ser-727 phosphorylation of STAT1 and suppression of MMP-13 expression by IFN-gamma, Furthermore, Ser-727 phosphorylation of STAT1 by ERK1,2, or independently of ERK1,2 activation is associated with marked reduction in MMP-13 expression. These observations identify a novel role for IFN-gamma as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells, and show that inhibition of MMP-13 expression by IFN-gamma involves activation of ERK1,2 and STAT1.	Univ Turku, Medicity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Biochem Med, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Turku Univ, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Turku; University of Turku; University of Turku; Abo Akademi University; University of Turku; University of Turku; Helmholtz Association; German Cancer Research Center (DKFZ); University of Oviedo	Kahari, VM (corresponding author), Univ Turku, Medicity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland.		Kahari, Veli-Matti/T-4925-2019; López-Otín, Carlos/AAB-2106-2020; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; López-Otín, Carlos/0000-0001-6964-1904; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Arany I, 1998, CANCER LETT, V123, P173, DOI 10.1016/S0304-3835(97)00432-1; BOUKAMP P, 1990, CANCER RES, V50, P2840; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Heppner KJ, 1996, AM J PATHOL, V149, P273; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kauppila S, 1996, AM J PATHOL, V148, P539; KIM J, 1995, J IMMUNOL, V155, P2240; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Lee SH, 1998, BRIT J DERMATOL, V139, P186; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Makela M, 1998, BIOCHEM BIOPH RES CO, V253, P325, DOI 10.1006/bbrc.1998.9641; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Moers C, 1999, INT J CANCER, V80, P564, DOI 10.1002/(SICI)1097-0215(19990209)80:4<564::AID-IJC14>3.0.CO;2-X; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PYKE C, 1992, CANCER RES, V52, P1336; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; SCHUGER L, 1990, PATHOBIOLOGY, V58, P279, DOI 10.1159/000163597; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; Tartour E, 1998, J NATL CANCER I, V90, P287, DOI 10.1093/jnci/90.4.287; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wernicke D, 1996, J RHEUMATOL, V23, P590; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Xu XL, 1998, CANCER RES, V58, P2832; ZHU GG, 1993, CANCER RES, V53, P5028	63	50	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					248	257		10.1038/sj.onc.1203306	http://dx.doi.org/10.1038/sj.onc.1203306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645003				2022-12-17	WOS:000084844400010
J	Senga, T; Miyazaki, K; Machida, K; Iwata, H; Matsuda, S; Nakashima, I; Hamaguchi, M				Senga, T; Miyazaki, K; Machida, K; Iwata, H; Matsuda, S; Nakashima, I; Hamaguchi, M			Clustered cysteine residues in the kinase domain of v-Src: critical role for protein stability, cell transformation and sensitivity to herbimycin A	ONCOGENE			English	Article						v-Src; temperature sensitive; cysteine; herbimycin A; protein stability	ROUS-SARCOMA VIRUS; TYROSINE KINASE; C-SRC; PHOSPHORYLATION; P60SRC; GENE; INACTIVATION; INHIBITION; PP60C-SRC; MECHANISM	We have previously reported the activation of Src by mercuric chloride based on the sulfhydryl modification, To evaluate the significance of cysteine residues in v-Src, we replaced each cysteine to alanine by oligonucleotide-directed mutagenesis and examined its effect on cell transformation. Of ten cysteine residues scattered over v-Src, four cysteines clustered in kinase domain, Cys483, Cys487, Cys496 and Cys498, were important for protein stability and cell transformation, whereas those in SH2 domain were dispensable. A single mutation in Cys498 yielded suppression of kinase activity and a temperature-sensitivity in anchorage independent growth, Double mutation either in Cys483/Cys487 or in Cys496/ Cys498 yielded clear temperature-sensitivity in cell transformation and in stability of Src protein. Instability of Src protein was magnified by quadruple mutation in the cysteines, which decreased the half-life of Src to be less than one quarter of that of wild-type. In addition, both Cys483/Cyr487 and Cys496/Cys498 kinases became resistant to in vitro inactivation by herbimycin A, which directly inactivates v-Src in addition to its effect on HSP90, Taken together, our results strongly suggest that the cysteine clustered motif of v-Src are critical for protein stability, cell transformation and in vitro inactivation by herbimycin A.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.							BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARONEY AC, 1992, ONCOGENE, V7, P1207; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Pu MY, 1996, ONCOGENE, V13, P2615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	35	50	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					273	279		10.1038/sj.onc.1203296	http://dx.doi.org/10.1038/sj.onc.1203296			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645006				2022-12-17	WOS:000084844400013
J	Namba, K; Abe, M; Saito, S; Satake, M; Ohmoto, T; Watanabe, T; Sato, Y				Namba, K; Abe, M; Saito, S; Satake, M; Ohmoto, T; Watanabe, T; Sato, Y			Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31	ONCOGENE			English	Article						PEBP2/CBF; transcription factor; angiogenesis	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; RECEPTOR TYROSINE KINASE; MYOSIN HEAVY-CHAIN; DEFINITIVE HEMATOPOIESIS; PLASMINOGEN-ACTIVATOR; GROWTH-FACTOR; DNA-BINDING; PROTOONCOGENE PRODUCT; VASCULAR DEVELOPMENT	Mice lacking the AML1/PEBP2 alpha B/CBFa2 gene or PEBP2 beta/CBFb gene exhibit a defect in definitive hematopoiesis and die in utero because of hemorrhage in the central nervous system. Hematopoiesis in the embryo is considered to be tightly associated with vascular development, Here ive examined whether PEBP2/CBF plays any role in angiogenesis besides that in definitive hematopoiesis, We found that AML1/ PEBP2 alpha B/CBFa2, PEBP2 alpha A/CBFa1, and PEBP2 beta/ CBFb were expressed in a murine endothelial cell Line MISS31, The expression of these molecules as cell as the DNA binding activity of PEBP2/CBF were augmented by angiogenic growth factors such as bFGF and VEGF. Moreover, the expression of PEBP2 alpha/CBFa protein in endothelial tells was confirmed at the site of angiogenesis in vivo, To further clarify the role of PEBP2/CF in angiogenesis, we established permanent transfectants of PEBP2 beta-MYH11 gene, one that interacts with the runt domain of the alpha subunit and deregulates PEBP2/CBF in a dominant interfering manner. Proliferation, migration, and tube formation of the PEBP2 beta-MYH11 transfectants were significantly reduced in comparison with those activities of the mock transfectants. These results suggest that transcription factor PEBP2/CBF plays an important role in angiogenesis.	Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan	Tohoku University; Tohoku University; Okayama University	Sato, Y (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.							BAE SC, 1993, ONCOGENE, V8, P809; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CLAXTON DF, 1994, BLOOD, V83, P1850; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DICKSON MC, 1995, DEVELOPMENT, V121, P1945; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SATO Y, 1993, EXP CELL RES, V204, P223, DOI 10.1006/excr.1993.1028; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; WOTTON D, 1993, LEUKEMIA S, V2, pS55; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; YANG JT, 1993, DEVELOPMENT, V119, P1093	48	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					106	114		10.1038/sj.onc.1203257	http://dx.doi.org/10.1038/sj.onc.1203257			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644985				2022-12-17	WOS:000084844300012
J	Nomoto, S; Haruki, N; Takahashi, T; Masuda, A; Koshikawa, T; Takahashi, T; Fujii, Y; Osada, H; Takahashi, T				Nomoto, S; Haruki, N; Takahashi, T; Masuda, A; Koshikawa, T; Takahashi, T; Fujii, Y; Osada, H; Takahashi, T			Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers	ONCOGENE			English	Article						lung cancer; mitotic checkpoint; hMAD1; somatic mutation; genetic instability	SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; ARREST	We previously reported the presence of mitotic checkpoint impairment in about 40% of lung cancer cell lines. To gain an insight into the molecular basis of this impairment, we examined 49 lung cancer specimens for alterations in the hMAD1 mitotic checkpoint gene and identified a somatic, non-conservative missense mutation, which substitutes alanine (GCG) for threonine (GCG) at codon 299, together with a number of amino acid substituting, single nucleotide polymorphisms. This is the first demonstration of hMAD1 mutation in any type of human cancers. The present finding marks hMAD1 as a potential target, although with low frequency, for genetic alterations in lung cancer. Thus, further studies of hMAD1 dysfunction caused by other mechanisms appear to be warranted, as well as potential involvement of other components of the mitotic checkpoint.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; Gotoh K, 1999, CARCINOGENESIS, V20, P499, DOI 10.1093/carcin/20.3.499; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HIBI K, 1994, ONCOGENE, V9, P611; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Nagatake M, 1996, CANCER RES, V56, P2718; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Smith AL, 1996, BRIT J CANCER, V73, P203, DOI 10.1038/bjc.1996.36; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; WASHIMI O, 1995, CANCER RES, V55, P514	20	50	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7180	7183		10.1038/sj.onc.1203141	http://dx.doi.org/10.1038/sj.onc.1203141			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597320				2022-12-17	WOS:000083901900026
J	Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA				Fan, W; Richter, G; Cereseto, A; Beadling, C; Smith, KA			Cytokine response gene 6 induces p21 and regulates both cell growth and arrest	ONCOGENE			English	Article						cytokine; cell cycle; G1 and G2 progression	HUMAN INTERLEUKIN-2; TUMOR-SUPPRESSOR; DNA-REPLICATION; CYCLE; GADD45; P53; PROTEIN; EXPRESSION; INHIBITOR; INTERACTS	Cytokine response gene #6 (CR6), cloned from interleukin 2-stimulated T lymphocytes, is homologous to GADD45 and MyD118, genes which promote cell cycle arrest and apoptosis, To determine how this gene family could possibly mediate both cell survival/proliferation and cell cycle arrest/death, transfectants were generated so that the genes could be expressed ectopically, independently from their normal inducing agents. In cycling retinoblastoma protein-negative (pRb-) cells, ectopic CR6 expression blocked G2/M transition, but did not prevent G1/S transition so that endoreduplication resulted. By comparison, when CR6, GADD45, and MyD118 genes were expressed ectopically in proliferating pRb(+) cells, either G1/S or G2/M transition was effectively blocked, so that there was no endoreduplication, Consistent with these findings, in proliferating pRb-cells, ectopic expression of CR6 promoted the expression of both G1 and G2/M cyclins, By comparison, in pRb+ cells, the expression of G1 cyclins was increased, while expression of the mitotic cyclins was decreased. However, in pRb(+) cells, cyclin-dependent kinase activities associated with both G1 and G2/M cyclins were decreased. Moreover, ectopic expression of all three genes resulted in the expression of the CKI, p21, both in pRb- and pRb(+) cells. The physiologic induction of CR6 expression by IL2 in quiescent normal human T cells occurs transiently in the first half of G1, coordinately with the expression of p21, Therefore, this gene family regulates G1 and G2, and promotes either cell growth or arrest by a common mechanism.	Cornell Univ, Weill Med Coll & Grad Sch Med Sci, New York Presbyterian Cornell Med Ctr, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll & Grad Sch Med Sci, New York Presbyterian Cornell Med Ctr, 1300 York Ave, New York, NY 10021 USA.			Cereseto, Anna/0000-0003-4453-2597	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 32031-23] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CorreaBordes J, 1997, EMBO J, V16, P4657, DOI 10.1093/emboj/16.15.4657; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; HALL PA, 1995, ONCOGENE, V10, P2427; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; SMITH KA, 1983, J IMMUNOL, V131, P1808; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Vairapandi M, 1996, ONCOGENE, V12, P2579; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	33	50	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6573	6582		10.1038/sj.onc.1203054	http://dx.doi.org/10.1038/sj.onc.1203054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597261				2022-12-17	WOS:000083709200021
J	Hansen, GM; Justice, MJ				Hansen, GM; Justice, MJ			Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia	ONCOGENE			English	Article						leukemia or lymphoma; hematopoiesis; homeobox; mouse; retrovirus	ACUTE MYELOGENOUS LEUKEMIAS; PROTEIN-CODING REGIONS; HOMEOBOX GENE PRH; INSITU HYBRIDIZATION; MYELOID-LEUKEMIA; MULTIPLE GENES; LYMPHOMAS; IDENTIFICATION; DNA; LOCUS	AKXD recombinant inbred mice develop a variety of leukemias and lymphomas due to retrovirally mediated insertional activation of cellular proto-oncogenes. We describe a new retroviral insertion site that is the most frequent genetic alteration in AKXD B-cell leukemias. Multiple genes flank the site of viral insertion, but the expression of just two, Hex and mEg5, is significantly upregulated. Hex is a divergent homeobox gene that is transiently expressed in many hematopoietic lineages, suggesting an involvement in cellular differentiation. mEp5 is a member of the bim-C subfamily of kinesin related proteins that are necessary for spindle formation and stabilization during mitosis. Our data provide the first genetic evidence for the activation of these genes in leukemia, and suggest that unscheduled expression of Hex and mEg5 contributes to the development of B-cell leukemia. In addition, this work highlights the use of genomic approaches for the study of position effect mutations.	Baylor Coll Med, Dept Mol & Hum Genet, Houston, TX 77030 USA	Baylor College of Medicine	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Hum Genet, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA063229] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA63229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Beeman RW, 1997, INSECT MOL BIOL, V6, P83, DOI 10.1046/j.1365-2583.1997.00159.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CHATTOPADHYAY SK, 1980, P NATL ACAD SCI-BIOL, V77, P5774, DOI 10.1073/pnas.77.10.5774; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAVERIE JM, 1994, GENOMICS, V23, P575, DOI 10.1006/geno.1994.1545; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DUBE ID, 1991, BLOOD, V78, P2996; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Hansen GM, 1999, GENOMICS, V56, P228, DOI 10.1006/geno.1998.5708; Hawley RG, 1997, CANCER RES, V57, P337; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; IHLE JN, 1990, PROG CLIN BIOL RES, V352, P329; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LEVY ER, 1994, BLOOD, V83, P1348; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; *MOUS GEN DAT, 1999, MOUS GEN INF; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sarkar G, 1993, PCR Methods Appl, V2, P318; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; SUZUKAWA K, 1994, BLOOD, V84, P2681; TSICHLIS PN, 1990, J VIROL, V64, P2236, DOI 10.1128/JVI.64.5.2236-2244.1990; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; White JA, 1998, GENOMICS, V48, P270, DOI 10.1006/geno.1997.5157	54	50	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6531	6539		10.1038/sj.onc.1203023	http://dx.doi.org/10.1038/sj.onc.1203023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597256				2022-12-17	WOS:000083709200016
J	Balana, ME; Lupu, R; Labriola, L; Charreau, EH; Elizalde, PV				Balana, ME; Lupu, R; Labriola, L; Charreau, EH; Elizalde, PV			Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas	ONCOGENE			English	Article						progestin; heregulin; mouse mammary tumors; type I insulin-like growth factor receptor	BREAST-CANCER CELLS; NEU DIFFERENTIATION FACTOR; EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; MEDROXYPROGESTERONE ACETATE; TRANSDUCTION PATHWAYS; ESTROGEN-RECEPTOR; EPITHELIAL-CELLS; TUMOR-CELLS; EXPRESSION	The present study addressed links between progestin and heregulin (HRG) signaling pathways in mammary tumors. An experimental model of hormonal carcinogenesis, in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female Balb/c mice, was used. MPA induced an in vivo up-regulation of HRG mRNA expression in progestin-dependent (HD) tumor lines. Mammary tumor progression to a progestin-independent (HI) phenotype was accompanied by a high constitutive expression of HRG. The HRG message arose from the tumor epithelial cells. Primary cultures of malignant epithelial cells from a HD tumor line were used to investigate HRG involvement on cell proliferation. HRG induced a potent proliferative effect on these cells and potentiated MPA mitogenic effects. Blocking endogenous HRG synthesis by antisense oligodeoxynucleotides (ASODNs) to HRG mRNA inhibited MPA-induced cell growth, indicating that HRG acts as a mediator of MPA-induced growth. High levels of ErbB-2 and ErbB-3 expression and low ErbB-4 levels mere found in HD cells. Treatment of these cells with either MPA or HRG resulted in tyrosine phosphorylation of both ErbB-2 and ErbB-3. Furthermore, both HRG and MPA proliferative effects mere abolished when cells were treated with ASODNs to ErbB-2 mRNA, providing evidence for a critical role of ErbB-2 in HRG-induced growth. Finally, blocking type I insulin-like growth factor receptor (IGF-IR) expression with ASODN resulted in the complete inhibition of HRG proliferative effect, demonstrating that a functional IGF-IR is required for HRG mitogenic activity. These results provide the first evidence of interactions between progestins and HRB/ErbB signal transduction pathways in mammary cancer and the first demonstration that IGF-IR is required for HRG proliferative effects.	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Calif Berkeley, Lawrence Berkeley Natl Labs, Berkeley, CA 94710 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Elizalde, PV (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Labriola, Leticia/E-9059-2012; Labriola, Leticia/ABF-9079-2020	Labriola, Leticia/0000-0003-3899-6088; Labriola, Leticia/0000-0003-3899-6088; Elizalde, Patricia V./0000-0002-5923-9898				Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BACUS SS, 1993, CANCER RES, V53, P5251; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERLII R, 1995, MOL CELL BIOL, V15, P6496; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DRAN G, 1995, BREAST CANCER RES TR, V35, P173, DOI 10.1007/BF00668207; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra FK, 1996, INT J CANCER, V65, P812, DOI 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.3.CO;2-5; HAMBURGER AW, 1997, MOL CELL ENDOCRINOL, V138, P163; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Krane IM, 1996, ONCOGENE, V12, P1781; LANARI C, 1989, INT J CANCER, V43, P845, DOI 10.1002/ijc.2910430518; Lewis GD, 1996, CANCER RES, V56, P1457; Lowe WL, 1997, ENDOCRINOLOGY, V138, P2219, DOI 10.1210/en.138.6.2219; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; NORMANNO N, 1993, INT J ONCOL, V2, P903; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Tang CK, 1996, CANCER RES, V56, P3350; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; YOUNG JAT, 1985, NUCLEIC ACIDS RES, V13, P8883, DOI 10.1093/nar/13.24.8883	43	50	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6370	6379		10.1038/sj.onc.1203028	http://dx.doi.org/10.1038/sj.onc.1203028			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597237				2022-12-17	WOS:000083934100022
J	Zorbas, M; Sicurella, C; Bertoncello, I; Venter, D; Ellis, S; Mucenski, ML; Ramsay, RG				Zorbas, M; Sicurella, C; Bertoncello, I; Venter, D; Ellis, S; Mucenski, ML; Ramsay, RG			c-Myb is critical for murine colon development	ONCOGENE			English	Article						c-Myb; epithelium; gut; gene knockout; apoptosis	BCL-2 EXPRESSION; FORCED EXPRESSION; DOWN-REGULATION; CELL-DEATH; GASTROINTESTINAL-TRACT; INTESTINAL EPITHELIUM; POLYCYSTIC KIDNEY; MICE LACKING; BETA-CATENIN; APOPTOSIS	The mammalian colon develops from a simple tube of undifferentiated cells into a complex, highly ordered organ,,vith a continuously self-renewing epithelial layer, We have previously described c-Myb expression in the epithelia of murine and human colon crypts and documented increased expression in colorectal adenocarcinoma cells. To investigate the role of c-Myb in colonic epithelium development, we have used embryos with a disrupted c-myb gene, Prior to the in utero death of these embryos at E15, we excised colon tissue and transplanted it under the kidney capsule of recipient mice to allow further development and cyto-differentiation. Compared to the colons of wildtype and heterozygous littermates, the c-myb homozygous knockout colon is highly irregular with a disordered epithelium and abnormal crypts, In addition, the expression of Bcl-2, a known target of c-Myb, is reduced and apoptosis is increased, indicating a critical requirement for c-Myb in normal colon development.	Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia; Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Peter Maccallum Cancer Center; Cincinnati Children's Hospital Medical Center	Ramsay, RG (corresponding author), Peter MacCallum Canc Inst, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.		Bertoncello, Ivan/B-9235-2008; Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433; Ellis, Sarah/0000-0002-5772-6051				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BEDI A, 1995, CANCER RES, V55, P1811; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GABRIEL A, 1992, ANAT REC, V234, P281, DOI 10.1002/ar.1092340214; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL PA, 1994, J CELL SCI, V107, P3569; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IWANAGA T, 1995, ARCH HISTOL CYTOL, V58, P151, DOI 10.1679/aohc.58.151; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; KAMADA S, 1995, CANCER RES, V55, P354; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MCMAHON J, 1988, ONCOGENE, V3, P717; MELANI C, 1991, CANCER RES, V51, P2897; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NOVACK DV, 1994, AM J PATHOL, V145, P61; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Resnik E, 1997, NAT GENET, V16, P9, DOI 10.1038/ng0597-9; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1998, CANCER RES, V58, P5168; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9	46	50	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5821	5830		10.1038/sj.onc.1202971	http://dx.doi.org/10.1038/sj.onc.1202971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523863				2022-12-17	WOS:000083095100011
J	Yang, XL; Pater, A; Tang, SC				Yang, XL; Pater, A; Tang, SC			Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	ONCOGENE			English	Article						BAG-1; promoter; mutant p53; transactivation	APOPTOTIC PROTEIN BAG-1; HUMAN HSP70 PROMOTER; BAX GENE; NEGATIVE REGULATOR; DNA METHYLATION; SUPPRESSOR P53; CANCER-CELLS; EXPRESSION; BCL-2; MUTATIONS	BAG-1 is an anti-apoptotic protein that interacts with Bcl-2, BcL-X-L, Hsp70/Hsc70, Raf-1 and numerous hormone or growth factor receptors, Recently, BAG-1 has been found to be overexpressed in a variety of human cancer cell lines and some tumors. However, the molecular mechanism of BAG-1 upregulation is still unclear. In this study, me cloned 0.9 kb of human genomic DNA, BGEV, 5' flanking the BAG-1 open reading frame. BGEV subcloned into a promoterless luciferase reporter vector conferred high promoter activity in various human cancer cell lines. Deletion analysis of this sequence localized the region of maximal BAG-1 promoter activity from nucleotide positions -353 to -54, upstream of the first start codon CTG. Sequence analysis of the BAG-1 promoter region showed the absence of a TATA box but identified a CCAAT box, several GC boxes, a CpG island and several transcriptional factor binding sites, which may be important in the regulation of BAG-1 transcription. Most importantly, functional characterization of the BAG-1 promoter in vivo demonstrated that gain-of-function p53 mutants derived from human tumors upregulated the transcription of BAG-1 RNA and the expression of a reporter gene from the BAG-1 promoter. These results indicated that me have isolated the functional constitutive BAG-1 promoter. Furthermore, the data suggested that overexpression of BAG-1 in some tumors may be due to upregulation of the human BAG-1 promoter by mutant p53.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, St Johns, NF A1B 3V6, Canada; Newfoundland Canc Treatment & Res Fdn, Dr H Bliss Murphy Canc Ctr, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Yang, XL (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, 300 Prince Philip Dr, St Johns, NF A1B 3V6, Canada.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Baylin SB, 1998, ADV CANCER RES, V72, P141; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HALDAR S, 1994, CANCER RES, V54, P2095; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hirose Y, 1997, MOL CARCINOGEN, V19, P25, DOI 10.1002/(SICI)1098-2744(199705)19:1<25::AID-MC4>3.0.CO;2-M; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IKEGAKI N, 1994, CANCER RES, V54, P6; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; ORRENIUS S, 1995, J INTERN MED, V237, P529, DOI 10.1111/j.1365-2796.1995.tb00881.x; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	44	50	53	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4546	4553		10.1038/sj.onc.1202843	http://dx.doi.org/10.1038/sj.onc.1202843			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467399				2022-12-17	WOS:000082018600004
J	Ekman, S; Thuresson, ER; Heldin, CH; Ronnstrand, L				Ekman, S; Thuresson, ER; Heldin, CH; Ronnstrand, L			Increased mitogenicity of an alpha beta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding	ONCOGENE			English	Article						heterodimer; mitogenicity; PDGF receptor; phosphorylation; RasGAP	GROWTH-FACTOR RECEPTORS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; AUTOPHOSPHORYLATION SITES; TYROSINE KINASES; PHOSPHOLIPASE-C; ACTIVATION; IDENTIFICATION; PHOSPHORYLATION; PROTEINS	The different platelet-derived growth factor (PDGF) isoforms cause activation of their alpha and beta protein tyrosine kinase receptors through dimerization, Homodimerization as well as heterodimerization of receptors occur. It has been shown previously that the heterodimeric receptor complex mediates a stronger mitogenic response than either of the homodimeric complexes. In this report, me show that in cells expressing both PDGF alpha- and beta-receptors, stimulation with PDGF-AB, which leads to preferential heterodimer formation, leads to a very low degree of phosphorylation of Tyr771 in the beta-receptor. In contrast, Tyr771 is phosphorylated in a homodimeric complex of beta-receptors. Phosphorylated Tyr771 is a binding site for RasGAP; an analogous site is not present in the alpha-receptor, which lacks the ability to associate with RasGAP, The lowered phosphorylation of Tyr771 in the heterodimeric receptor complex correlates with lowered association with RasGAP, as well as with a more efficient activation of Ras and MAP kinase, which is consistent with the increased mitogenicity elicited by PDGF-AB, compared to PDGF-AA or PDGF-BB.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ekman, Simon/AAB-9387-2021; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ARVIDSSON AK, 1992, CELL GROWTH DIFFER, V3, P881; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAZENET CE, 1994, ONCOGENE, V9, P517; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	37	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2481	2488		10.1038/sj.onc.1202606	http://dx.doi.org/10.1038/sj.onc.1202606			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229199				2022-12-17	WOS:000079703300008
J	Plattner, R; Gupta, S; Khosravi-Far, R; Sato, KY; Perucho, M; Der, CJ; Stanbridge, EJ				Plattner, R; Gupta, S; Khosravi-Far, R; Sato, KY; Perucho, M; Der, CJ; Stanbridge, EJ			Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells	ONCOGENE			English	Article						Ras; ERK; JNK	NUCLEOTIDE DISSOCIATION STIMULATOR; EPITHELIAL-CELLS; PLASMA-MEMBRANE; IN-VITRO; C-JUN; GROWTH; IDENTIFICATION; SUFFICIENT; EXPRESSION; ONCOGENES	Although an important contribution of ERK and JNK mitogen-activated protein kinase (MAPK) activation in Ras transformation of rodent fibroblasts has been determined, their role in mediating oncogenic Ras transformation of human tumor cells remains to be established. We have utilized the human HT1080 fibrosarcoma and DLD-1 colon carcinoma cell lines, which contain endogenous mutated and oncogenic N- and K-ras alleles, respectively, to address this role. Study of these cells is advantageous over Ras-transformed rodent model cell systems for two key reasons. First, the ras mutations occurred naturally in the progression of the tumors from which the cell lines were derived, rather than due to overexpression of an exogenously introduced gene, Second, although these tumor cells possess defects in multiple genetic loci, it has been established that mutated Ras contributes significantly to the transformed phenotype of these cells. Clonal variant lines of HT1080 and DLD-1 have been isolated which have lost the oncogenic was allele and exhibit a corresponding impairment in growth transformation in vitro and in vivo. We found that upregulation of Raf/MEK/ERK and JNK correlated with expression of oncogenic Ras in HT1080, but not DLD-1 cells. Furthermore, inhibition of ERK activation in parental HT1080 cells caused the same changes in cell morphology and actin stress fiber organization seen with loss of expression of activated N-Ras(61K). Thus, we suggest that constitutive activation of the Raf/MEK/ERK and JNK pathways is necessary for Ras-induced transformation of HT1080 but not DLD-1 cells. These results emphasize that cell type differences exist in the signaling pathways by which oncogenic pas causes transformation.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol,Dept Pharmacol, Chapel Hill, NC 27599 USA; Burnham Inst, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Sanford Burnham Prebys Medical Discovery Institute	Stanbridge, EJ (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747; Perucho, Manuel/0000-0002-2169-2662	NCI NIH HHS [CA69515, CA42978, CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R01CA019401, R01CA069515, R37CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Graham SM, 1996, MOL CELL BIOL, V16, P6132; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hua VY, 1997, P NATL ACAD SCI USA, V94, P9614, DOI 10.1073/pnas.94.18.9614; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLDHAM SM, 1998, IN PRESS ONCOGENE; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; Wolthuis RMF, 1996, ONCOGENE, V13, P353	48	50	50	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1807	1817		10.1038/sj.onc.1202482	http://dx.doi.org/10.1038/sj.onc.1202482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086335				2022-12-17	WOS:000079090000004
J	Zohar, M; Teramoto, H; Katz, BZ; Yamada, KM; Gutkind, JS				Zohar, M; Teramoto, H; Katz, BZ; Yamada, KM; Gutkind, JS			Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation	ONCOGENE			English	Article						Rho A GTPase; Ras; small G-proteins; transformation; stress fibers; signal transduction	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; SMALL GTPASE RHO; RAS TRANSFORMATION; FAMILY GTPASES; TRANSCRIPTIONAL ACTIVATION; SERINE/THREONINE KINASE; ACTIN POLYMERIZATION; INDEPENDENT PATHWAYS; CYCLE PROGRESSION	The small GTP-binding Rho proteins control a variety of biological activities, including organization of the actin cytoskeleton, regulation of gene expression and cellular transformation. In contrast, Ras proteins do not induce actin stress fibers, but potently transform cells which exhibit a morphology clearly distinct from that caused by activated forms of Rho. To investigate whether nuclear signaling and oncogenic potential of Rho are a consequence of its profound effect on cytoskeletal organization, we replaced each amino acid in the Rho effector loop with those of Ras, or replaced conserved residues with others known to result in differential signaling capability when introduced into Ras and Rad. These Rho mutants did not gain the ability to induce the MAPK, JNK or p38 pathways but, surprisingly, all Rho effector loop mutants still continued to induce actin stress fiber formation. However, three of these Rho mutants, with substitutions of leucine-39, glutamic acid-39, or cysteine-42, lost the ability to stimulate gene transcription via the serum response factor (SRF) and failed to induce neoplastic transformation. Thus, these results indicate that cytoskeletal changes are not sufficient to induce the transformed phenotype, and that Rho-effector molecules regulating the actin cytostructure are distinct from those signaling to the nucleus and subverting normal growth control.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Yamada, Kenneth/0000-0003-1512-6805				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1996, CANCER SURV, V27, P311; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELF AJ, 1993, ONCOGENE, V8, P655; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	41	50	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					991	998		10.1038/sj.onc.1202022	http://dx.doi.org/10.1038/sj.onc.1202022			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747878				2022-12-17	WOS:000075560900007
J	Cheung, B; Hocker, JE; Smith, SA; Norris, MD; Haber, M; Marshall, GM				Cheung, B; Hocker, JE; Smith, SA; Norris, MD; Haber, M; Marshall, GM			Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation	ONCOGENE			English	Article						retinoic acid receptor beta; neuroblastoma; cell cycle; p21; prognosis	HUMAN LUNG-CANCER; RESISTANCE-ASSOCIATED PROTEIN; BINDING-PROTEINS; RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL PATTERN; UP-REGULATION; GENE; GROWTH; LINES	We have previously shown that ectopic overexpression of retinoic acid receptor (RAR) subtypes alpha, beta and gamma in human neuroblastoma cells had different effects on growth and retinoid sensitivity. Only overexpressed RAR beta induced profound growth inhibition in the absence of additional retinoid, and increased retinoid sensitivity. In this study, we measured mRNA expression levels of RAR alpha, beta, and gamma in 50 primary neuroblastoma tumor samples, and found a strong correlation between favorable patient prognosis and high-level RAR beta expression. Human neuroblastoma cells transfected with a vector expressing RARE demonstrated irreversible growth arrest following a 1 week exposure to all-trans-retinoic acid, whereas control cells continued to proliferate. In the absence of additional retinoid, RAR beta transfectants demonstrated a higher proportion of cells in the G(0)/G(1) phase of the cell cycle, increased p21(WAF1/CIP1) expression and specific binding to a retinoic acid response element. These were changes which we also observed in control neuroblastoma cells following retinoid treatment. Our data indicate that RAR beta is an important factor mediating the growth inhibitory effects of retinoids in neuroblastoma cells. The favorable effect of high-le vel RARE expression on prognosis in primary tumor tissue may occur through RAR beta effects on p21(WAF1/CIP1) expression and consequent G(0)/G(1) cell cycle arrest.	Sydney Childrens Hosp, Childrens Canc Inst Australia, Randwick, NSW 2031, Australia	Children's Cancer Institute	Marshall, GM (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Australia, High St, Randwick, NSW 2031, Australia.			Norris, Murray/0000-0002-0632-4589; Cheung, Belamy/0000-0001-8784-860X; Haber, Michelle/0000-0003-2036-8817				Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BORDOW SB, 1994, CANCER RES, V54, P5036; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; Brodeur Garrett M., 1997, P761; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; CLAGETTDAME M, 1993, ARCH BIOCHEM BIOPHYS, V300, P684, DOI 10.1006/abbi.1993.1095; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GEBERT JF, 1991, ONCOGENE, V6, P1859; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KIM YH, 1995, CANCER RES, V55, P5603; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUI Y, 1996, MOL CELL BIOL, V16, P1138; MACMILLAN RW, 1976, J PEDIATR SURG, V11, P461, DOI 10.1016/S0022-3468(76)80204-7; Mangelsdorf David J., 1994, P319; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V13, P437; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; ZHANG XK, 1994, CANCER RES, V54, P5663	49	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					751	759		10.1038/sj.onc.1201982	http://dx.doi.org/10.1038/sj.onc.1201982			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715277				2022-12-17	WOS:000075337200010
J	Tamir, Y; Bengal, E				Tamir, Y; Bengal, E			p53 Protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene	ONCOGENE			English	Article						p53; MyoD; cooperativity; muscle creatine kinase gene; muscle differentiation; transcriptional activation	WILD-TYPE P53; DNA-BINDING FUNCTION; CELL DIFFERENTIATION; SEQUENCE; EXPRESSION; ENHANCER; IDENTIFICATION; SUPPRESSOR; DISTINCT; ELEMENT	The p53 protein is a transcription factor involved in processes of cell growth and differentiation. The muscle creatine kinase (MCK) gene whose transcription is induced during muscle differentiation contains p53-binding sites. In this study we tested the involvement of p53 in the activation of MCK transcription during muscle differentiation of C2 cells. We have shown that the p53 protein is stabilized and its DNA binding and transcriptional activities are induced during muscle differentiation. At the stage of muscle-differentiation, p53 protein can induce the accurate transcription of a minimal p53-dependent MCK reporter gene. Moreover, p53 cooperates with MyoD in the induction of MCK transcription. The expression of a dominant negative p53 protein in muscle cells reduced the expression of endogenous MCK gene. The dominant negative p53 protein abolished the cooperativity of wild type p53 with MyoD. Amino and carboxy terminal residues of MyoD required for the cooperation with p53 in transcription were identified. The cooperativity between the two proteins occurs also at the stage of DNA binding. We suggest that p53 protein is activated during myoblast differentiation and participates with MyoD in the induction of MCK transcription.	Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, Efron St,POB 9649, IL-31096 Haifa, Israel.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; JACKSON P, 1995, GENE EXPRESSION, V5, P19; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu X, 1996, ONCOGENE, V13, P413; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PROKOCIMER M, 1994, BLOOD, V84, P2391; REGIMOVE N, 1993, ONCOGENE, V8, P1183; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	51	50	50	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					347	356		10.1038/sj.onc.1201929	http://dx.doi.org/10.1038/sj.onc.1201929			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690516				2022-12-17	WOS:000074947500009
J	Chang, DD; Park, NH; Denny, CT; Nelson, SF; Pe, M				Chang, DD; Park, NH; Denny, CT; Nelson, SF; Pe, M			Characterization of transformation related genes in oral cancer cells	ONCOGENE			English	Article						oncogenes; representational difference analysis; cDNA array hybridization; oral cancer; human papilloma virus	REPRESENTATIONAL DIFFERENCE ANALYSIS; TUMOR PROGRESSION; MESSENGER-RNA; EXPRESSION; CARCINOGENESIS; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; INDUCTION; CARCINOMA; ADHESION; PROTEIN	A cDNA representational difference analysis (cDNA-RDA) and an arrayed filter technique were used to characterize transformation-related genes in oral cancer. From an initial comparison of normal oral epithelial cells and a human papilloma virus (HPV)-immortalized oral epithelial cell line, we obtained 384 differentially expressed gene fragments and arrayed them on a filter. Two hundred and twelve redundant clones were identified by three rounds of back hybridization. Sequence analysis of the remaining clones revealed 99 unique clones corresponding to 69 genes. The expression of these transformation related gene fragments in three nontumorigenic HPV-immortalized oral epithelial cell lines and three oral cancer cell lines were simultaneously monitored using a cDNA array hybridization. Although there was a considerable cell line-to-cell line variability in the expression of these clones, a reliable prediction of their expression could be made from the cDNA array hybridization. Our study demonstrates the utility of combining cDNA-RDA and arrayed filters in high-throughput gene expression difference analysis. The differentially expressed genes identified in this study should be informative in studying oral epithelial cell carcinogenesis.	Univ Calif Los Angeles, Sch Dent, Dept Med Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Inst Dent Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Dent, Dept Med Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114	NCI NIH HHS [P0-1CA32737] Funding Source: Medline; NIDCR NIH HHS [R03-DE11728, R01-DE11229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011229, R03DE011728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BLOT WJ, 1988, CANCER RES, V48, P3282; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Gress TM, 1996, ONCOGENE, V13, P1819; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Itoh K, 1996, J BIOCHEM-TOKYO, V119, P385; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; KANNAN S, 1994, HISTOPATHOLOGY, V24, P531; KANNAN S, 1994, TUMOR BIOL, V15, P73, DOI 10.1159/000217877; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; KIM MS, 1993, CANCER RES, V53, P4811; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Lazarova Z, 1995, Exp Dermatol, V4, P121, DOI 10.1111/j.1600-0625.1995.tb00235.x; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Loda M, 1996, AM J PATHOL, V149, P1553; MathieuDaude F, 1996, NUCLEIC ACIDS RES, V24, P2080, DOI 10.1093/nar/24.11.2080; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; PARK NH, 1995, ONCOGENE, V10, P2145; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; STEELE C, 1993, CANCER RES, V53, P2330; TADOKORO K, 1989, ONCOGENE, V4, P499; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WOODS KV, 1993, J ORAL PATHOL MED, V22, P101, DOI 10.1111/j.1600-0714.1993.tb01038.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	40	50	53	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1921	1930		10.1038/sj.onc.1201715	http://dx.doi.org/10.1038/sj.onc.1201715			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591775				2022-12-17	WOS:000073079400003
J	Welsh, M; Zhou, SY; Frantz, JD; Trub, T; Reedquist, KA; Karlsson, T; Miyazaki, M; Cantley, LC; Band, H; Shoelson, SE				Welsh, M; Zhou, SY; Frantz, JD; Trub, T; Reedquist, KA; Karlsson, T; Miyazaki, M; Cantley, LC; Band, H; Shoelson, SE			Stimulation through the T cell receptor leads to interactions between SHB and several signaling proteins	ONCOGENE			English	Article						Shb; Jurkat T cells; T cell receptor; p36/38; SH2 domain; PTB domain	ANTIGEN RECEPTOR; TYROSINE KINASE; ZETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-1; ADAPTER PROTEIN; ACTIVATION; DOMAIN; PHOSPHOTYROSINE; ASSOCIATION	Shb is a recently described Src homology 2 (SH2) domain-containing adaptor protein. Here we show that Shb is expressed in lymphoid tissues, and is recruited into signaling complexes upon activation of Jurkat T cells. Grb2 binds proline-rich motifs in Shb via its SH3 domains, As a result, a number of proteins detected in anti-Shb and anti-Grb2 immunoprecipitates are shared, including phosphoproteins of 22, 36/38, 55/57 and 70 kDa. Shb-association with p22, which represents the T cell receptor associated zeta chain, occurs through the Shb SH2 domain. The central region of Shb binds p36/38. Since this interaction was inhibited by phosphotyrosine, this region of Shb is likely to contain a non-SH2 PTB (phosphotyrosine binding) domain. The Shb PTB domain tvas found to preferentially bind the sequence Asp-Asp-X-pTyr when incubated with a phosphopeptide library, A peptide corresponding to a phosphorylation site in 34 kDa Lnk inhibited association between Shb and p36/38. Overexpression of Shb in Jurkat cells led to increased basal phosphorylation of Shb-associated p36/38 and p70 proteins, Inactivation of the Shb SH2 domain by an R522K mutation resulted in a reduced stimulation of tyrosine phosphorylation of several proteins in response to CD3 crosslinking when expressed in Jurkat cells. Together, our results show three distinct domains of Shb all participate in the formulation of multimeric signaling complexes in activated T cells. These results indicate that the Shb protein functions in T cell receptor signaling.	Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Rheumatol & Immunol, Lymphocyte Biol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Signal Transduct, Boston, MA USA	Uppsala University; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Welsh, M (corresponding author), Biomedicum, Dept Med Cell Biol, Box 571, S-75123 Uppsala, Sweden.		Cantley, Lewis C/D-1800-2014; Miyazaki, Masaya/F-8520-2012; Welsh, Michael/AAF-8564-2020	Cantley, Lewis C/0000-0002-1298-7653; Miyazaki, Masaya/0000-0003-4031-7224; Welsh, Michael/0000-0002-5467-9755	NIAMS NIH HHS [AR36308] Funding Source: Medline; NIDDK NIH HHS [DK36836, DK45943] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045943, P30DK036836] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1996, ONCOGENE, V13, P955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; THOMPSON PA, 1992, ONCOGENE, V7, P719; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; TRUB T, 1995, J BIOL CHEM, V270, P18205; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELSH M, 1994, ONCOGENE, V9, P19; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	28	50	55	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					891	901		10.1038/sj.onc.1201607	http://dx.doi.org/10.1038/sj.onc.1201607			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484780				2022-12-17	WOS:000072053200008
J	LustigYariv, O; Schulze, E; Komitowski, D; Erdmann, V; Schneider, T; deGroot, N; Hochberg, A				LustigYariv, O; Schulze, E; Komitowski, D; Erdmann, V; Schneider, T; deGroot, N; Hochberg, A			The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?	ONCOGENE			English	Article						H19; IGF2; choriocarcinoma cell lines	GROWTH FACTOR-II; HUMAN EMBRYOGENESIS; MOUSE; RNA; RELAXATION	H19 is a paternally imprinted gene with unknown function, It is located in close proximity to the maternally imprinted IGF-2 gene on chromosome 11p15,5, In this study no consistent relationship between the expression of these two genes in clones derived from JEG-3 and JAr cell lines could be detected, Nor could a consistent relationship be detected between the expression levels of these two genes and between certain characteristic tumorigenic properties of these clones, We included in this study clones, expressing low H19 levels, which after transfection with an H19 expression construct highly expressed the H19 gene, In tumors, formed by the injection of cells of JAr or JEG-3 clones into nude mice, the H19 expression was high and irrelevant to the expression level in the cells before the injection, The same phenomenon was found for IGF-2 expression during tumorigenesis caused by cells of different JEG-3 clones and in some but not all JAr derived clones, Both H19 and IGF-2 are biallelicly expressed in all the JAr and JEG-3 clones, In summary, our observations point to the conclusion that H19 is not a tumor suppressor gene, However, its high expression in all the tumors formed after injection of cells of the JAr and JEG-3 clones, leaves its role, if any, in choriocarcinogenesis an open question.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV GOTTINGEN,ZOOL INST ENTWICKLUNGS BIOL,D-3400 GOTTINGEN,GERMANY; DKFZ,DEPT HISTODIAGNOST & PATHOMORPHOL,HEIDELBERG,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,DEPT CHEM,D-1000 BERLIN,GERMANY	Hebrew University of Jerusalem; University of Gottingen; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin								Adam GIR, 1996, DEVELOPMENT, V122, P839; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; AUSUBEL FM, 1993, CURRRENT PROTOCOLS M, V1; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DEGROOT N, 1994, TROPH RES, V8, P285; DoucRasy S, 1996, ONCOGENE, V12, P423; DUGIMONT T, 1995, MOL CELL, V85, P117; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FRESHNEY RI, 1990, CULTURE ANIMAL CELLS, P142; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hibi K, 1996, CANCER RES, V56, P480; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; Kondo M, 1996, ONCOGENE, V12, P1365; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RECHLER MM, 1990, PEPTIDE GROWTH FACTO, V1, P263; ROBERTSON EJ, 1995, DEV BIOL, V6, P293; Sambrook J, 1989, MOL CLONING LAB MANU; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	45	50	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					169	177		10.1038/sj.onc.1201175	http://dx.doi.org/10.1038/sj.onc.1201175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244352				2022-12-17	WOS:A1997XK37200005
J	Rosa, JL; Barbacid, M				Rosa, JL; Barbacid, M			A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70	ONCOGENE			English	Article						guanine nucleotide exchange factor; Ras-like small GTPases; protein transport; RCC1-like domains	TRANSPORT; RNA; CELLS; NEURONS; HOMOLOG; IMPORT; RCC1	We have recently identified an unusually large human protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins (EMBO J 15: 4262-4273, 1996), This protein, designated p532 based on its predicted molecular weight (EMBO J 15: 5738, 1996), contains multiple structural domains including two regions of seven internal repeats highly related to the cell cycle regulator RCC1, a guanine nucleotide exchange factor for the small GTP-binding protein Ran, seven beta-repeat domains characteristic of the beta subunit of heterotrimeric G proteins, three putative SH3 binding sites, a putative leucine-zipper and a carboxyterminal HECT domain characteristic of E3 ubiquitin-protein Ligases. Some of these domains are known to be involved in protein-protein interactions, suggesting the existence of p532-interacting proteins, To identify some of these proteins, we used the carboxy-terminal RCC1-like domain (RLD) of p532 in the yeast two-hybrid system, We report here the isolation of a clone that encodes the last 654 amino acid residues of the clathrin heavy chain, This interaction involves amino acid residues 1315-1557 of the clathrin heavy chain and the carboxy, but not the amino-terminal RLD of p532, p532 has been located in the cytosolic fraction as well as in the Golgi apparatus, The interaction between p532 and clathrin only occurs in the cytosol and is mediated by the formation of an ATP-dependent ternary complex with the heat shock protein, Hsp70, These observations suggest that p532 is involved in membrane transport processes.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Rosa, Jose Luis/K-6685-2014	Rosa, Jose Luis/0000-0002-6161-5688				BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BLACK MM, 1991, J NEUROSCI, V11, P1163; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NELSON KK, 1993, MOL CELL BIOL, V13, P521, DOI 10.1128/MCB.13.1.521; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; REN MD, 1995, MOL CELL BIOL, V15, P2117; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROSA JL, 1996, EMBO J, V15, P51738; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	27	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					1	6		10.1038/sj.onc.1201170	http://dx.doi.org/10.1038/sj.onc.1201170			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233772				2022-12-17	WOS:A1997XH58600001
J	Chlichlia, K; Busslinger, M; Peter, ME; Walczak, H; Krammer, PH; Schirrmacher, V; Khazaie, K				Chlichlia, K; Busslinger, M; Peter, ME; Walczak, H; Krammer, PH; Schirrmacher, V; Khazaie, K			ICE-proteases mediate HTLV-I tax-induced apoptotic T-cell death	ONCOGENE			English	Article						HTLV-I; tax; ER; inducible; apoptosis; CD95; APO-1; Fas; CD95 ligand; ICE	VIRUS TYPE-I; TUMOR-NECROSIS-FACTOR; FAS-LIGAND; MONOCLONAL-ANTIBODY; E1A PROTEINS; HIV-1 TAT; LEUKEMIA; ACTIVATION; LYMPHOCYTES; INDUCTION	The Tax protein of Human T-cell leukemia virus type 1 (HTLV-1) is important for the T-cell immortalizing properties of this virus in vitro and is considered to be responsible for the early stages of leukemogenesis in infected hosts, Tax can upregulate expression of TNF-alpha and TNF-beta, as well as potentiate apoptosis in activated T-cells and in serum starved murine fibroblasts. To examine the role of CD95 (APO-1/Fas) and ICE-proteases in Tax-mediated active T-cell death, Jurkat T cells expressing (APO(S)) or lacking (APO(R)) cell surface expression of CD95 (APO-1/Fas) were genetically modified to express hormone-inducible HTLV-1 Tax constructs, Hormone-inducible action of Tax alone was sufficient to promote programmed cell death in CD95-expressing Jurkat T-cell clones, In contrast, clones lacking CD95 surface expression were resistant to the antiproliferative action of Tax, Both APOS and APOR clones exhibited Tax-dependent upregulation of CD95 ligand and TNF-alpha. Blocking experiments suggested that while the apoptotic action of Tax critically required ICE-protease function it was largely independent of cell surface interaction of CD95 Ligand or TNF-alpha with their corresponding receptors, These observations strongly implicate ICE-proteases in Tax-induced T-cell death, and suggest a possible involvement of CD95 in this process.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; UNIV HEIDELBERG,DEPT SURG,SECT MOL DIAGNOST & THERAPY,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Ruprecht Karls University Heidelberg			Busslinger, Meinrad J./J-1249-2016; Walczak, Henning/AAV-2214-2020; Chlichlia, Katerina/Q-3948-2019	Busslinger, Meinrad J./0000-0002-9111-9351; Walczak, Henning/0000-0002-6312-4591; Chlichlia, Katerina/0000-0003-4952-0675; Peter, Marcus Ernst/0000-0003-3216-036X				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7197; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHLICHLIA K, 1995, ONCOGENE, V10, P269; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; DEBATIN KM, 1993, BLOOD, V81, P2972; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FUJITA M, 1995, ONCOGENE, V11, P15; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Guyot DJ, 1996, J ACQ IMMUN DEF SYND, V11, P317, DOI 10.1097/00042560-199604010-00001; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KALDEN JR, 1994, CLIN EXP IMMUNOL, V98, P1, DOI 10.1111/j.1365-2249.1994.tb06597.x; LASTER SM, 1988, J IMMUNOL, V141, P2629; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SETO K, 1995, ACTA NEUROPATHOL, V89, P483; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHACHLER E, 1989, BLOOD, V73, P194; TSCHACHLER E, 1993, BLOOD, V81, P95; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YIP MT, 1990, MOL BIOL MED, V7, P33; YOSHIKI Y, 1995, PHYTOCHEMISTRY, V38, P229, DOI 10.1016/0031-9422(94)00571-A; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	50	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2265	2272		10.1038/sj.onc.1201070	http://dx.doi.org/10.1038/sj.onc.1201070			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178902	Bronze			2022-12-17	WOS:A1997WY88300003
J	Mann, DJ; Higgins, T; Jones, NC; Rozengurt, E				Mann, DJ; Higgins, T; Jones, NC; Rozengurt, E			Differential control of cyclins D1 and D3 and the cdk inhibitor p27(Kip1) by diverse signalling pathways in Swiss 3T3 cells	ONCOGENE			English	Article						cyclin D1; cyclin D3; p27(Kip1); Swiss 3T3 cells; pRb	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; TRANSDUCTION PATHWAYS; REGULATED EXPRESSION; G(1); PROTEIN; P21; FIBROBLASTS; PHASE; ACCELERATION	Quiescent Swiss 3T3 cells can be induced to re-enter the cell cycle by stimulation of a variety of growth factor-dependent signal transduction cascades. We have utilised this cell system to investigate the point of convergence of mitogenic signalling by analysing the changes that distinct mitogens induce in the components of the cell cycle regulatory machinery (the G(1) cyclins, cdks and their inhibitors). In the presence of insulin, activation of cAMP-dependent protein kinase caused a dramatic post-transcriptional down-regulation of p27(Kip1), increase in cyclin D3 but had little effect on cyclin D1 levels, whilst activation of protein kinase C had a more modest effect on cyclin D3 and p27(Kip1) but caused a striking elevation in the expression of cyclin D1, The neuropeptide bombesin, when combined with insulin, caused increased expression of cyclin D1 and down-regulation of p27(Kip1) mRNA and protein. Thus each combination of mitogenic agents had different effects on the components responsible for regulating the orderly progression of the cell cycle. This outcome is incompatible with a single route to mitogenesis and demonstrates that different mitogens remain distinct in the signalling responses they initiate, only converging at the levels of the expression of the D-type cyclins and the inhibitor p27(Kip1).	IMPERIAL CANC RES FUND,GENE REGULAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,GROWTH REGULAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK								Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBERT DA, 1992, P NATL ACAD SCI USA, V89, P1597, DOI 10.1073/pnas.89.5.1597; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BATES S, 1994, ONCOGENE, V9, P71; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI Y, 1994, ONCOGENE, V9, P2261; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MASSUSHIME H, 1992, CELL, V71, P323; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	48	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1759	1766		10.1038/sj.onc.1201134	http://dx.doi.org/10.1038/sj.onc.1201134			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150381				2022-12-17	WOS:A1997WW16600001
J	Canelles, M; Delgado, MD; Hyland, KM; Lerga, A; Richard, C; Dang, CV; Leon, J				Canelles, M; Delgado, MD; Hyland, KM; Lerga, A; Richard, C; Dang, CV; Leon, J			Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells	ONCOGENE			English	Article						max; c-Myc mutants; K562; erythroid differentiation; apoptosis; okadaic acid	MURINE ERYTHROLEUKEMIA-CELLS; HL-60 PROMYELOCYTIC CELLS; OKADAIC ACID; GENE-EXPRESSION; ACTIVATES TRANSCRIPTION; RAS COTRANSFORMATION; FUNCTIONAL DOMAINS; CYCLE PROGRESSION; DOWN-REGULATION; DNA-BINDING	We have used the human leukemia cell line K562 as a model to study the role of c-myc in differentiation and apoptosis, We have generated stable transfectants of K562 constitutively expressing two c-Myc inhibitory mutants: D106-143, that carries a deletion in the transactivation domain of the protein, and In373, that carries an insertion in the DNA-interacting region, We show here that In373 is able to compete with c-Myc for Max binding and to inhibit the transformation activity of c-Myc, K562 cells can differentiate towards erythroid or myelomonocytic lineages, K562 transfected with c-myc mutants showed a higher expression of erythroid differentiation markers, without any detectable effects in the myelomonocytic differentiation, We also transfected K562 cells with a zinc-inducible max gene, Ectopic Max overexpression resulted in an increased erythroid differentiation, thus reproducing the effects of c-myc inhibitory mutants, We also studied the role of c-myc mutants and max in apoptosis of K562 induced by okadaic acid, a protein phosphatases inhibitor, The expression of D106-143 and In373 c-myc mutants and the overexpression of max reduced the apoptosis mediated by okadaic acid, The common biochemical activity of D106-143 and In373 is to bind Max and hence to titrate out c-Myc to form pen-functional Myc/Max Max diners, Similarly, Max overexpression would decrease the relative levels of c-Myc/Max with respect to Max/Max, The results support a model where a threshold of functional c-Myc/Max is required to maintain K562 cells in an undifferentiated state and to undergo drug-mediated apoptosis.	FAC MED,DEPT BIOL MOL,E-39011 SANTANDER,SPAIN; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205; HOSP UNIV MARQUES DE VALDECILLA,SERV HEMATOL,SANTANDER 39011,SPAIN	Johns Hopkins University; Hospital Universitario Marques de Valdecilla (HUMV)			Dang, Chi/Y-3375-2019; Canelles, Matilde/AAB-1011-2019; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Dang, Chi/0000-0002-4031-2522; Delgado, M. Dolores/0000-0003-4682-4040; Canelles, Matilde/0000-0003-2973-609X; Leon, Javier/0000-0001-5803-0112	NCI NIH HHS [CA51497] Funding Source: Medline; NIGMS NIH HHS [T32GM07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051497, R01CA051497, R37CA051497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER SJ, 1994, LEUKEMIA, V8, P1309; BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BENITO A, 1995, AM J PATHOL, V146, P481; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DELGADO MD, 1995, ONCOGENE, V10, P1659; DELGADO MD, 1992, CANCER RES, V52, P5948; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; GORUPPI S, 1994, ONCOGENE, V9, P1537; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZAV S, 1995, ONCOGENE, V11, P1079; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LERGA A, 1995, BIOCHEM BIOPH RES CO, V215, P889, DOI 10.1006/bbrc.1995.2547; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nguyen HQ, 1995, ONCOGENE, V11, P2439; OHMORI Y, 1993, ONCOGENE, V8, P379; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Sambrook J, 1989, MOL CLONING LAB MANU; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHENG B, 1994, J BIOL CHEM, V269, P12332	75	50	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1315	1327		10.1038/sj.onc.1200948	http://dx.doi.org/10.1038/sj.onc.1200948			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178892				2022-12-17	WOS:A1997WP10900007
J	Ide, H; Katoh, M; Sasaki, H; Yoshida, T; Aoki, K; Nawa, Y; Osada, Y; Sugimura, T; Terada, M				Ide, H; Katoh, M; Sasaki, H; Yoshida, T; Aoki, K; Nawa, Y; Osada, Y; Sugimura, T; Terada, M			Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs	ONCOGENE			English	Article						bone morphogenetic protein receptor; prostate cancer; human BMPR-IB	GROWTH-FACTOR-BETA; II RECEPTOR; MESSENGER-RNAS; IDENTIFICATION; ACTIVIN; FAMILY; CELLS	Bone metastasis is a common event in prostate cancer, and it is known that some of the bone morphogenetic proteins (BMPs) are expressed in prostate cancer cells, while no study on the expression of their receptors, BMPRs, has been reported, Here we report cloning and sequence analysis of the human BMPR-IB cDNA. We also analysed the expression of transcripts of three types of the BMPR genes in human tissues and prostate cancer cell lines, The BMPR-IB mRNA was present in various organs, but the highest level was found in the prostate. Moreover, the amount of BMPR-IB mRNA was significantly low in prostate cancer tissues after androgen withdrawal and was also low in prostate cancer cell lines. RT-PCR analysis showed that the BMPR-IB message was upregulated by androgen stimulation in the LNCaP cell line which expresses the androgen receptor, By contrast, the mRNA levels of BMPR-IA and BMPR-II were not significantly different among non-cancerous and cancerous prostate tissues. It was also suggested that human BMPR-IA and BMPR-IB might have different biological functions in the prostate, although their sequences were 85.3% identical in the serine-threonine kinase domain.	NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TOKYO 104,JAPAN; MIYAZAKI MED COLL,DEPT PARASITOL,MIYAZAKI 88916,JAPAN; MIYAZAKI MED COLL,DEPT UROL,MIYAZAKI 88916,JAPAN	National Cancer Center - Japan; University of Miyazaki; University of Miyazaki			Nawa, Yukifumi/I-1147-2019	Nawa, Yukifumi/0000-0002-0206-5196				BENTLEY H, 1992, BRIT J CANCER, V66, P1159, DOI 10.1038/bjc.1992.427; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Dawson N A, 1993, Oncology (Williston Park), V7, P17; Dawson NA, 1993, ONCOLOGY, V7, P17; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIU F, 1995, MOL CELL BIOL, V15, P3479; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; *STAT INF DEP, 1995, HLTH WELF STAT JAP, P76; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TILLEY WD, 1990, CANCER RES, V50, P5382; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1973, P NATL ACAD SCI USA, V70, P3511, DOI 10.1073/pnas.70.12.3511; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	27	50	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1377	1382		10.1038/sj.onc.1200964	http://dx.doi.org/10.1038/sj.onc.1200964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178898				2022-12-17	WOS:A1997WP10900013
J	Sitterlin, D; Tiollais, P; Transy, C				Sitterlin, D; Tiollais, P; Transy, C			The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain	ONCOGENE			English	Article						acute promyelocytic leukemia; PLZF; RAR alpha-PLZF chimera; DNA-binding activity; two-hybrid system	ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; TUMOR GENE-PRODUCT; T(15-17) TRANSLOCATION; FUSION PROTEINS; PML; CELLS; TRANSACTIVATION; SYSTEM; FAMILY	In most cases, Acute Promyelocytic Leukemia (APL) is associated with t(15;17) translocation which juxtaposes sequences from PML and retinoic acid receptor alpha (RAR alpha) genes. The generated PML-RAR alpha fusion interferes with wild type RAR alpha-mediated transcription and disrupts subnuclear compartments, known as PML bodies. Both defects are corrected by all trans retinoic acid (ATRA) therapy which induces differentiation of leukemic cells and clinical remission. In a rare APL syndrome associated,vith t(11;17), fusion of the RAR alpha gene with the PLZF gene, encoding a Zinc-finger protein produces two reciprocal RAR alpha chimeras, Although PLZF-RAR alpha and PML-RAR alpha are similar in their apparent dominant negative effects, t(11;17)-associated APL is refractory to ATRA therapy. In a yeast two-hybrid genetic screening, we isolated clones encoding the GAL4 transactivation domain fused to various parts of PLZF. Using these autonomously transactivating hybrids, similar in structure to the RAR alpha-PLZF fusion, we mapped the DNA-binding domain of PLZF to the last five Zinc-fingers, a region retained in RAR alpha-PLZF chimera and characterized a specific PLZF target sequence. Our data support the hypothesis that RAR alpha-PLZF chimera is not an inert product of reciprocal translocation and may thus contribute to ATRA unresponsiveness of t(11;17)-associated APL.	INST PASTEUR,UNITE REGULAT EXPRESS GENET,INSERM,U 163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DREXLER HG, 1995, LEUKEMIA, V9, P480; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; INOUYE C, 1994, DNA CELL BIOL, V13, P731, DOI 10.1089/dna.1994.13.731; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI JY, 1995, BLOOD S1, V86, pA262; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	35	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1067	1074		10.1038/sj.onc.1200916	http://dx.doi.org/10.1038/sj.onc.1200916			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070655				2022-12-17	WOS:A1997WM07000008
J	Lin, JC; Scherer, SW; Tougas, L; Traverso, G; Tsui, LC; Andrulis, IL; Jothy, S; Park, M				Lin, JC; Scherer, SW; Tougas, L; Traverso, G; Tsui, LC; Andrulis, IL; Jothy, S; Park, M			Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; chromosome 7q31; MET receptor tyrosine kinase; loss of heterozygosity	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CYSTIC-FIBROSIS LOCUS; EPITHELIAL-CELLS; SCATTER FACTOR; C-MET; MAMMARY-GLAND; FREQUENT LOSS; ALLELIC LOSS; RET PROTOONCOGENE	In breast cancer, loss of heterozygosity (LOH) has been described on the long arm of chromosome 7 at band q31, suggesting the presence of a tumor suppressor gene in this region. To define the deleted region, we analysed 73 cases of breast cancer and matched normal DNAs with 17 polymorphic markers. A minimal area of LOH was identified as the chromosomal interval flanked by markers D7S687 and metH, spanning a segment of 2 Mb on chromosome 7q31, Of the 73 breast cancer patients studied, all were informative for at least one marker in this region and nine patients showed LOH at one or more loci (12.3%). To define the physical size of the deletion and to ensure the correct interpretation of the LOH deletion studies, we redefined the physical map of markers within this region of 7q31, We present a new physical order for markers at 7q31. More significantly, we have mapped the minimum deletion of 7q31 in the breast cancers studied to date to a physical distance of 1000 kb, contained on a single YAC clone, which includes the MET receptor tyrosine kinase but no other known genes.	MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PATHOL,MONTREAL,PQ,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON,CANADA	McGill University; McGill University; McGill University; McGill University; University of Toronto; University of Toronto			Scherer, Stephen W./B-3785-2013; Andrulis, Irene L./E-7267-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; 				BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; DIRENZO MF, 1991, ONCOGENE, V6, P1997; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMPTON GM, 1994, CANCER RES, V54, P4586; HORN GT, 1990, CLIN CHEM, V36, P1614; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KERANGUEVEN F, 1995, ONCOL REP, V2, P89; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Latil A, 1995, CLIN CANCER RES, V1, P1385; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LITT M, 1993, BIOTECHNIQUES, V15, P280; MANIATIS T, 1992, MOL CLONING; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MULLER D, 1995, ONCOL REP, V2, P847; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; Poustka A, 1988, GENOMICS, V2, P337, DOI 10.1016/0888-7543(88)90023-7; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROMMENS JM, 1989, AM J HUM GENET, V45, P932; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO T, 1990, CANCER RES, V50, P7184; SCHERER S, 1991, P33; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YANG XM, 1995, LAB INVEST, V73, P483; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	60	50	50	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2001	2008						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934547				2022-12-17	WOS:A1996VR79500020
J	Chen, JH; Vercamer, C; Li, ZL; Paulin, D; Vandenbunder, B; Stehelin, D				Chen, JH; Vercamer, C; Li, ZL; Paulin, D; Vandenbunder, B; Stehelin, D			PEA3 transactivates vimentin promoter in mammary epithelial and tumor cells	ONCOGENE			English	Article						PEA3; vimentin; promoter; mammary tumor	ETS-RELATED PROTEIN; DIFFERENTIAL DISPLAY; TRANSCRIPTION FACTOR; METASTATIC DISEASE; BREAST CARCINOMAS; MOLECULAR-CLONING; MOUSE EMBRYO; EXPRESSION; GENE; ONCOGENE	We have used differential display RT-PCR method to detect the genes specifically activated or repressed between mammary tumor and normal mammary epithelial cells, One of the genes identified is vimentin, The vimentin gene is abundantly expressed in both human and mouse mammary tumor cells and its expression decreased dramatically in normal mammary epithelial cells. The expression of vimentin gene correlates with the expression of transcription factor PEA3, Since the promoters of human and mouse vimentin genes contain one PEA3 binding site we investigated the ability of PEA3 to transactivate the vimentin promoter in mouse mammary epithelial cell CLS1, mouse mammary tumor MMT and human mammary tumor cell lines MCF7 and MDA231, Our results suggest that PEA3 specifically transactivates vimentin promoter through PEA3 site, Among members of the ETS transcription factor family only Erg showed ability to transactivate vimentin promoter besides PEA3, Our results also suggest that NFkB site on the vimentin promoter may act as positive regulatory element for the transcription of vimentin, In metastatic mammary tumors derived from mice carrying the polyoma middle T or neu transgene, PEA3 is overexpressed and vimentin has been shown to play a key role in the motility of cells, Our results suggest that one of the roles of PEA3 in mammary tumor is to participate the activation of vimentin gene whose gene product in turn contributes to the metastatic potential of mammary tumors.	TZU CHI COLL MED,INST MED RES,HUALIEN,TAIWAN; UNIV PARIS 07,F-75005 PARIS 15,FRANCE; INST PASTEUR,SERV CENT MICROSCOPIE ELECT,F-75005 PARIS 15,FRANCE	Tzu Chi University; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chen, JH (corresponding author), INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE.		Li, Zhenlin/E-3937-2016	LI, Zhenlin/0000-0002-3706-4505				BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1993, ONCOGENE, V8, P3375; COCHARD P, 1984, J NEUROSCI, V4, P2080; COCUCCIGUYON E, 1994, CELL, V79, P679; Crepieux Pascale, 1993, Gene Expression, V3, P215; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DOMAGALA W, 1990, AM J PATHOL, V136, P219; DOMAGALA W, 1990, AM J PATHOL, V137, P1059; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUERST D O, 1989, Journal of Cell Biology, V109, P517; GOULD VE, 1990, AM J PATHOL, V137, P1143; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HIGASHINO F, 1995, ONCOGENE, V10, P1461; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARCHIONI M, 1993, MOL CELL BIOL, V13, P7399; MONTE D, 1994, ONCOGENE, V9, P1397; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; RAYMOND WA, 1989, J PATHOL, V158, P107, DOI 10.1002/path.1711580205; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1994, CANCER RES, V54, P3092; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYKS B, 1993, NATURE, V234, P191; WERNERT N, 1994, CANCER RES, V54, P5683; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YONGANATHAN T, 1992, EUR J BIOCHEM, V207, P195; ZAPORI D, 1990, CANCER J, V3, P164	44	50	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1667	1675						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895512				2022-12-17	WOS:A1996VM88700011
J	Ogawa, S; Kurokawa, M; Tanaka, T; Mitani, K; Inazawa, J; Hangaishi, A; Tanaka, K; Matsuo, Y; Minowada, J; Tsubota, T; Yazaki, Y; Hirai, H				Ogawa, S; Kurokawa, M; Tanaka, T; Mitani, K; Inazawa, J; Hangaishi, A; Tanaka, K; Matsuo, Y; Minowada, J; Tsubota, T; Yazaki, Y; Hirai, H			Structurally altered Evi-1 protein generated in the 3q21q26 syndrome	ONCOGENE			English	Article						Evi-1; inv(3)(q21q26); 3q21q26; syndrome CML; blastic crisis	ECOTROPIC VIRAL INTEGRATION; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; MURINE MYELOID TUMORS; ZINC FINGER GENE; COMMON SITE; EV11 GENE; EXPRESSION; REARRANGEMENTS; TRANSLOCATIONS	Overexpression of the Evi-1 gene appears to be a consistent feature of the 3q21q26 syndrome, an association of myeloid leukemias/myelodysplastic syndrome with a specific chromosomal aberration involving both 3q21 and 3q26, such as t(3;3)(q21;q26) or inv(3)(q21a26). The rearrangement in 3q26 has been reported to occur near the Evi-1 locus, implicating that it is the critical gene deregulated in the 3q21q26 syndrome, Here we present a structural abnormality of Evi-1 protein in a case with the 3q21q26 syndrome, In this case carrying typical inv(3)(q21q26), the 3q26 breakpoint is located within an intron of the Evi-1 gene, and resulted in overexpression of normally unexpressed, an aberrant form of Evi-1 protein, in which the C-terminal 44 amino acids of wild-type Evi-1 protein were truncated and replaced by five amino acids, The truncated Evi-1 protein is shown to increase AP1 activity when expressed in NIH3T3 cells as its wild-type counterpart, We also show that the origin of this peculiar type of rearrangement of the Evi-1 gene is not an artifact during establishment of the cell line, but is the event that occurred in the primary leukemic cells, Our results strongly support that the primary target for the 3q21q26 syndrome is the Evi-1 gene, and provide the first evidence that the structurally altered Evi-1 gene may be involved in the 3q21q26 syndrome.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KYOTO 602, JAPAN; HAYASHIBARA BIOCHEM LABS INC, FUJISAKI CELL CTR, OKAYAMA 702, JAPAN; OKAYAMA CITY HOSP, DEPT INTERNAL MED, OKAYAMA 700, JAPAN	University of Tokyo; Kyoto Prefectural University of Medicine; Hayashibara Biochemical Laboratories, Inc.			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BITTER MA, 1985, BLOOD, V66, P1362; BORDEREAUX D, 1990, ONCOGENE, V5, P925; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DREYFUS F, 1995, LEUKEMIA, V9, P203; FICHELSON S, 1992, LEUKEMIA, V6, P93; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P167, DOI 10.1016/0165-4608(89)90182-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LEVY ER, 1994, BLOOD, V83, P1348; Matsuo Y, 1991, Hum Cell, V4, P261; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, ONCOGENE RES, V2, P219; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA S, 1994, ONCOGENE, V9, P1669; OGAWA S, 1996, IN PRESS LEUKEMIA; OHYASHIKI JH, 1995, BLOOD, V85, P3713, DOI 10.1182/blood.V85.12.3713.bloodjournal85123713; OHYASHIKI K, 1994, LEUKEMIA, V8, P2169; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSELL M, 1993, LEUKEMIA, V7, P1654; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TANAKA T, 1991, BLOOD, V77, P2597	30	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					183	191						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700545				2022-12-17	WOS:A1996UX31900021
J	Ray, ME; Su, YA; Meltzer, PS; Trent, JM				Ray, ME; Su, YA; Meltzer, PS; Trent, JM			Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma	ONCOGENE			English	Article						malignant melanoma; chromosome 6; tumor suppression	LONG ARM; EXPRESSION; IDENTIFICATION; SEARCH	Melanocytic transformation is thought to occur by the sequential accumulation of genetic alterations, Evidence implicating human chromosome-6 as a site for a gene(s) involved in melanoma suppression comes from studies of LOH [loss of heterozygosity], cytogenetics and biologic reversion of tumorigenicity following the introduction of a normal chromosome 6 by microcell-mediated chromosome transfer (Trent et al., 1990), Using a tumorigenic melanoma cell line (UACC 903) and a chromosome-6 suppressed melanoma subline [UACC 903 (+6)], we have isolated a series of genes uniquely expressed in the suppressed subline, A modified PCR-based cDNA subtraction technique was used to generate subtracted cDNA sublibraries for both the parental and (+6) suppressed cells, A total of 32 randomly selected clones from the suppressed sublibrary were isolated and examined, with 24 detecting a transcript by Northern analysis, Of these 24 clones, 21 (88%) demonstrated elevated expressed by Northern analysis in the suppressed subline relative to the tumorigenic parental cell line, In 6/21 differentially expressed clones (29%), expression was exclusive to the suppressed subline, Partial sequence analysis and database searching of these clones indicated that 5/6 were novel with one representing a previously characterized gene, Chromosomal localization of the five novel clones was performed following PCR amplification of a human/rodent somatic cell hybrid mapping panel or fluorescent in situ hybridization, One cDNA (termed AIM1) was localized to a band-region of chromosome 6 frequently deleted in melanomas (6q21), This novel approach should facilitate the identification of genes whose expression is causally related to the suppressed phenotype.	NIH,NATL CTR HUMAN GENOME RES,CANC GENET LAB,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; *ANN CANC STAT REV, 1988, 882789 NIH NCI; BROWN T, 1993, CURRENT PROTOCOLS GR; ENGEBRECHT J, 1991, CURRENT PROTOCOLS; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HALABAN R, 1993, RECENT RES CANCER, V128, P133; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; KINGSTON RE, 1991, CURRENT PROTOCOLS; LASSAM N, 1992, ONCOGENE, V7, P51; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATHEW S, 1992, GENOMICS, V14, P775, DOI 10.1016/S0888-7543(05)80184-3; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MILLIKIN D, 1991, CANCER RES, V51, P5449; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WELCH DR, 1994, ONCOGENE, V9, P255	21	50	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2527	2533						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700511				2022-12-17	WOS:A1996UW48700006
J	Chang, CL; Strahler, JR; Thoraval, DH; Qian, MG; Hinderer, R; Hanash, SM				Chang, CL; Strahler, JR; Thoraval, DH; Qian, MG; Hinderer, R; Hanash, SM			A nucleoside diphosphate kinase A (nm23-H1) serine 120->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction	ONCOGENE			English	Article						NDP kinase; nm23-H1; neuroblastoma	REDUCED EXPRESSION; TUMOR-METASTASIS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; MESSENGER-RNA; GENE-PRODUCT; DROSOPHILA; CARCINOMA; CELLS; AUTOPHOSPHORYLATION	A high level of nucleoside diphosphate kinase A (NDPK A/nm23-H1) in neuroblastoma is associated with advanced stage disease. We have also found a serine 120-->glycine substitution in NDPK A and/or amplification of the nm23-H1 gene in advanced stage neuroblastomas. Serine 120, a highly conserved residue, is located in proximity to histidine 118 which forms a phosphorylated intermediate essential for NDPK activity. The effect of Ser120-->Gly substitution on the biochemical properties of NDPK A was investigated. Phosphate-transferase activity was lower in the recombinant mutant NDPK A and in the immunoprecipitated complex consisting of NDPK A and NDPK B prepared from a neuroblastoma tumor containing the mutation, relative to the wild-type. There was a significant decrease in the enzyme stability toward urea- or temperature-induced denaturation for the recombinant mutant NDPK A and in an immunoprecipitate from a tumor containing the mutation. Recombinant NDPK A containing the Ser120-->Gly mutation exhibited reduced hexameric and increased dimeric oligomerization relative to the wild-type. Moreover a 28 kDa cellular protein was detected, that co-precipitated with the mutant but not wild-type NDPK A. The altered properties of the mutant protein may have relevance to a role for NDPK A in neuroblastoma progression.	UNIV MICHIGAN, DEPT CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Chang, CL (corresponding author), UNIV MICHIGAN, DEPT PEDIAT, ANN ARBOR, MI 48109 USA.		Chang, Christina/B-9650-2009		NCI NIH HHS [CA32146, CA26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032146, P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R P, 1978, Methods Enzymol, V51, P376; AGARWAL RP, 1971, J BIOL CHEM, V246, P2258; AYHAN A, 1993, VIRCHOWS ARCH B, V63, P213, DOI 10.1007/BF02899264; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; DEAROLF C, 1988, DEV BIOL, V129, P139; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; FLORENES VA, 1992, CANCER RES, V52, P6088; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; KOYAMA K, 1984, J BIOCHEM-TOKYO, V95, P925, DOI 10.1093/oxfordjournals.jbchem.a134720; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAMORI S, 1993, INT J PANCREATOL, V14, P125; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URANO T, 1993, ONCOGENE, V8, P1371; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; ZHOU M, 1993, BRIT J CANCER, V68, P385, DOI 10.1038/bjc.1993.345; ZINYK DL, 1993, NAT GENET, V4, P195, DOI 10.1038/ng0693-195	52	50	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					659	667						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637723				2022-12-17	WOS:A1996TV59700023
J	STUART, AD; STEWART, JP; ARRAND, JR; MACKETT, M				STUART, AD; STEWART, JP; ARRAND, JR; MACKETT, M			THE EPSTEIN-BARR-VIRUS ENCODED CYTOKINE VIRAL INTERLEUKIN-10 ENHANCES TRANSFORMATION OF HUMAN B-LYMPHOCYTES	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; TRANSFORMATION; VIRAL INTERLEUKIN-10 VIABILITY; INTERFERON-GAMMA	INTERFERON-GAMMA; IN-VITRO; T-CELL; INFECTION; EXPRESSION; BLOOD; LEUKOCYTES; REGION	In vitro infection of human B lymphocytes with Epstein-Barr virus (EBV) results in their growth transformation and establishment of immortalised lymphoblastoid cell lines, The virus was recently found to encode homologue of the pleitropic cytokine interleukin-10 (IL-10), which has wide ranging effects on the immune system, We have investigated the effect of this virally encoded growth factor on the ability of EBV to immortalize B lymphocytes from tonsils and from adult and neonatal blood, Recombinant viral interleukin-10 (vIL-10) was found to increase dramatically the growth transformation of B cells from all three populations infected with either the highly transforming type 1 strain B95-8 or the less efficient type 2 strain BL16, This striking enhancement of transforming ability in the presence of viral ILIO may be in part due to increased viability of the B cells during infection and decreased levels of interferon-gamma, a cytokine known to inhibit EBV transformation, Thus viral 1L-10 influences a number of cell types of the immune system to allow the enhanced outgrowth of EBV transformed cells.	UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT VET PATHOL,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	STUART, AD (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,DEPT MOLEC BIOL,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Stewart, James/A-6034-2012	Stewart, James/0000-0002-8928-2037				ADLDINGER HK, 1985, VIROLOGY, V14, P221; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; BURDIN N, 1993, J EXP MED, V177, P295, DOI 10.1084/jem.177.2.295; CAYROL C, 1995, J VIROL, V69, P4206, DOI 10.1128/JVI.69.7.4206-4212.1995; De The G, 1980, VIRAL ONCOLOGY, P769; Geser A., 1983, EUR J CANCER CLIN ON, V19, P1394; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; HENLE G, 1979, EPSTEIN BARR VIRUS, P257; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; HUDSON GS, 1985, VIROLOGY, V147, P81, DOI 10.1016/0042-6822(85)90229-6; KIEFF E, 1990, VIROLOGY, P1889; KRUSE A, 1993, J INTERFERON RES, V13, P221, DOI 10.1089/jir.1993.13.221; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LOTZ M, 1985, EUR J IMMUNOL, V15, P520, DOI 10.1002/eji.1830150518; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MIYAZAKI I, 1993, J EXP MED, V178, P439, DOI 10.1084/jem.178.2.439; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSS DJ, 1972, J GEN VIROL, V17, P233, DOI 10.1099/0022-1317-17-2-233; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; PURTILO DT, 1981, CANCER RES, V41, P4226; RICKINSON AB, 1975, NATURE, V258, P236, DOI 10.1038/258236a0; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; Sambrook J., 1989, MOL CLONING LAB MANU; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; STEWART JP, 1992, VIROLOGY, V191, P773, DOI 10.1016/0042-6822(92)90253-L; STEWART JP, 1994, VIROLOGY, V200, P724, DOI 10.1006/viro.1994.1236; SWAMINATHAN S, 1993, J VIROL, V97, P7406; TAGA K, 1993, INT IMMUNOL, V5, P1599, DOI 10.1093/intimm/5.12.1599; THORLEYLAWSON DA, 1981, J IMMUNOL, V126, P829; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; WALLS EV, 1987, LYMPHOCYTES PRACTICA, P149; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WHITTINGHAM S, 1993, IMMUNOL CELL BIOL, V71, P259, DOI 10.1038/icb.1993.30; WIENER MS, 1973, BLOOD, V42, P939; WRIGHTHAM MN, 1995, IN PRESS VIROLOGY	42	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1711	1719						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478598				2022-12-17	WOS:A1995TD09400005
J	RAMOSMORALES, F; ROMERO, F; SCHWEIGHOFFER, F; BISMUTH, G; CAMONIS, J; TORTOLERO, M; FISCHER, S				RAMOSMORALES, F; ROMERO, F; SCHWEIGHOFFER, F; BISMUTH, G; CAMONIS, J; TORTOLERO, M; FISCHER, S			THE PROLINE-RICH REGION OF VAV BINDS TO GRB2, AND GRB3-3	ONCOGENE			English	Note						VAV; GRB2; GRB3-3; SH3; PROLINE-RICH; APOPTOSIS	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; RAS; PROTEIN; ACTIVATION; PROTOONCOGENE; ASSOCIATION; HOMOLOGY; GENE	Vav has structural features found in signaling proteins and is expressed only in hematopoietic cells. The recent development of mice Vav (-/-) has confirmed a major role of Vav in early blood cell development. We previously showed that Vav constitutively interacts with glutathione-S-transferase-Grb2. Coimmunoprecipitation experiments supported the idea of a complex formed by Vav-Grb2 in vivo. This complex is of potential interest in signaling of hematopoietic cells. In this work we localize the domains of Vav and Grb2 involved in this interaction. By the use of an in vivo genetic approach (the double hybrid system) and through in vitro experiments (glutathione-S-transferase fusion proteins) me furnish evidence that the interaction between Vav and Grb2 involves the C-SH3 domain of Grb2 and the proline-rich region located in the N-SH3 of Vav. Furthermore this was confirmed by the use of both Vav and Sos derived proline-rich peptides which blocked the binding. Tn addition me show that Vav also interacts with Grb3-3, a naturally occurring Grb2 isoform wich lacks functional SH2 domain.	UNIV SEVILLA,FAC BIOL,DEPT MICROBIOL,E-41080 SEVILLE,SPAIN; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE; CHU PITIE SALPETRIERE,CERVI,IMMUNOL CELLULARE & TISSULAIRE LAB,CNRS,URA 625,PARIS,FRANCE; INSERM,U248,F-75010 PARIS,FRANCE	University of Sevilla; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	RAMOSMORALES, F (corresponding author), HOP COCHIN,INST COCHIN GENET MOLEC,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.		Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008; Romero, Francisco/K-2101-2014	Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547; Romero, Francisco/0000-0002-9588-6881				ADAMS JM, 1992, ONCOGENE, V7, P611; Bartel PL, 1993, CELLULAR INTERACTION, P153; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P688; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sherman F., 1986, METHODS YEAST GENETI; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	41	50	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1665	1669						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478592				2022-12-17	WOS:A1995TC53500026
J	NGUYEN, H; MUSTAFA, A; HISCOTT, J; LIN, RT				NGUYEN, H; MUSTAFA, A; HISCOTT, J; LIN, RT			TRANSCRIPTION FACTOR IRF-2 EXERTS ITS ONCOGENIC PHENOTYPE THROUGH THE DNA-BINDING TRANSCRIPTION REGRESSION DOMAIN	ONCOGENE			English	Article						INTERFERON; TRANSCRIPTION; ONCOGENESIS; INTERFERON REGULATORY FACTORS	GENE REGULATORY ELEMENTS; IFN-INDUCIBLE GENES; PROTEIN-KINASE; BETA; INDUCTION; CHROMOSOME-2P21-P22; EXPRESSION; ACTIVATION; CELLS; PRKR	The Interferon Regulatory Factors-1 and -2 (IRF-1 and IRF-2) play a transcriptional role in the regulation of the IFN-beta gene as well as other immunoregulatory genes. IRF-1 serves as a transcriptional activator whereas IRF-2 acts as an antagonistic transcriptional repressor. IRF-1 and IRF-2 also play opposing functional roles in cell growth regulation, and are implicated as a potential antioncogene and oncogene, respectively. To analyse the relationship between DNA binding/transcriptional repression and oncogenic transformation, NIH3T3 cells expressing C-terminal deletions of IRF-2 were established and assayed for transformation by saturation density analysis, anchorage independent growth in soft agar and tumor formation in nude mice. Cells expressing an IRF-2 protein of at least 160 N-terminal amino acids were transformed in vitro and tumorigenic in vivo, thus mapping IRF-2 oncogenic activity to its DNA binding/ transcriptional repression domain, Overexpression of wild-type and truncated IRF-2 proteins resulted in reduced IFN-beta mRNA levels following induction by dsRNA. However, there was no effect of IRF-2 on IFN-beta inducibility by Sendai virus infection, suggesting the involvement of multiple IFN-beta induction pathways. In DNA binding assays, recombinant IRF-2 was found to preferentially bind to the IFN-beta PRDI site compared to IRF-1. These studies indicate that the transformed phenotype resulting from overexpression of IRF-2 may be due to constitutive engagement of the IRF-E recognition site, thus preventing DNA binding and transactivation of putative tumor suppressor genes by the IRF-1 anti-oncogene.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOLEC ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COHEN L, 1992, VIROLOGY, V191, P589, DOI 10.1016/0042-6822(92)90234-G; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DADDARIO M, 1990, J VIROL, V64, P6080, DOI 10.1128/JVI.64.12.6080-6089.1990; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; HANASH SM, 1995, GENES CHROM CANC, V8, P34; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1983, SCIENCE, V259, P971; HISCOTT J, 1995, IN PRESS SEMINARS VI, V6; KAMIJO R, 1994, CELL, V263, P1612; KIRCHOFF S, 1995, IN PRESS ONCOGENE; KOROMILAS AE, 1992, SCIENCE, V257, P1865; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITESIDE ST, 1994, J BIOL CHEM, V269, P27059; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; [No title captured]	34	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					537	544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630638				2022-12-17	WOS:A1995RN53000014
J	HART, AH; CORRICK, CM; TYMMS, MJ; HERTZOG, PJ; KOLA, I				HART, AH; CORRICK, CM; TYMMS, MJ; HERTZOG, PJ; KOLA, I			HUMAN ERG IS A PROTOONCOGENE WITH MITOGENIC AND TRANSFORMING ACTIVITY	ONCOGENE			English	Article						ETS; TRANSCRIPTION FACTORS; TUMOR; CHROMOSOME 21; CHROMOSOME TRANSLOCATION	ETS-RELATED GENE; DNA-BINDING; TRANSCRIPTION FACTOR; LEUKEMIA-VIRUS; DOWN-SYNDROME; C-ETS-1 PROTOONCOGENE; FLI-1 GENE; FAMILY; EXPRESSION; SEQUENCE	The ETS related gene, ERG, is one of 20 or more genes belonging to the ETS family of transcription factors, Translocation of the ERG gene t(21;22) results in the chimeric fusion transcript seen in approximately 10% of Ewings sarcomas, In addition, recent studies have shown that a reciprocal translocation t(21;16) of ERG gives rise to two aberrant transcripts seen in some forms of acute myeloid leukaemia. ln vitro studies have linked the up regulation of ERG expression with stromal cell independence in erythroleukemic clones and shown that the ERG related genes ETS1 and ETS2 have mitogenic and transforming activity when overexpressed in NIH3T3 cells, Interestingly ERGB/FLI-1, which is also involved in Ewings sarcoma translocations and shares a very high sequence identity with ERG has been reported to be unable to transform NIH3T3 cells, In this study we investigate the effects of overexpression of ERG on cell proliferation, factor dependence, growth in soft agar and tumorigenesis in nude mice, An ERG expression construct with the human ERG2 cDNA driven by the sheep metallothionein la promoter (sMTERG) was transfected into NIH3T3 cells. Clonal cell lines overexpressing ERG were established. The cell lines became morphologically altered, grew in low serum and serum free media and gave rise to colonies in soft agar suspension. Furthermore, we demonstrate that after subcutaneous injection these clones grow as solid tumors in nude mice, These data demonstrate that c-ERG is a proto-oncogene capable of transforming NM3T3 cells. Therefore, overexpression or inappropriate expression of ERG may contribute to oncogenesis.	MONASH UNIV, MONASH MED CTR, INST REPROD & DEV, MOLEC EMBRYOL & BIRTH DEFECTS LAB, CLAYTON, VIC 3168, AUSTRALIA	Monash University			Hart, Adam/C-1196-2011; Kola, Ismail/C-5254-2013; Hertzog, Paul/I-7053-2013	Hart, Adam/0000-0001-8129-3877; Hertzog, Paul/0000-0002-1373-8472				ASCIONE R, 1992, INT J ONCOL, V1, P631; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; ISELIUS L, 1990, HUM GENET, V85, P477; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOLA I, 1989, REPROD FERT DEVELOP, V1, P81, DOI 10.1071/RD9890081; KORENBERG JR, 1990, AM J HUM GENET, V47, P236; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; Maniatis T., 1982, MOL CLONING; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OHNO T, 1993, CANCER RES, V53, P5859; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V56, P1175; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROBISON LL, 1992, LEUKEMIA, V6, P5; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; TYMMS M, 1995, IN VITRO TRANSCRIPTI, P31; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1992, AM J PATHOL, V140, P119; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	50	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1423	1430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731694				2022-12-17	WOS:A1995QR65100021
J	LENG, P; BROWN, DR; SHIVAKUMAR, CV; DEB, S; DEB, SP				LENG, P; BROWN, DR; SHIVAKUMAR, CV; DEB, S; DEB, SP			N-TERMINAL-130 AMINO-ACIDS OF MDM2 ARE SUFFICIENT TO INHIBIT P53-MEDIATED TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article						MDM2; P53-MEDIATED TRANSACTIVATION	WILD-TYPE P53; GENE-EXPRESSION; BINDING-SITE; CELL-GROWTH; LUNG-CANCER; PROTEIN; MUTATIONS; ONCOGENE; FORMS; DNA	The human oncoprotein MDM2 binds with the tumor suppressor p53 and inhibits p53-directed transactivation. In this report we show that deletion of 336 amino acids from the C-terminus of human MDM2 does not decrease its efficiency to bind p53 in vivo and inhibit p53-directed transactivation. Even further deletion of MDM2 from the C-terminus up to amino acid 131 does not reduce its ability to inhibit p53-mediated transactivation. Since deletion up to amino acid 131 also deletes many antigenic sites of MDM2 and the truncated protein cannot be immunoprecipitated by the antibodies available to us, two internal deletions were made to define the p53-interaction domain. Internal deletion of four amino acids beginning at 110 residue (amino acids 110 to 113) did not reduce p53-binding or inhibition of p53-directed transactivation whereas internal deletion of amino acids 60 to 65 reduces but does not abolish these activities. Sequential deletion of amino acids from the N-terminus leads to sequential destruction of p53-binding and inhibition of transactivation capability of MDM2. Fourteen amino acids can be deleted from this end without any reduction of these activities. Deletion of 28 N-terminal amino acids residues drastically reduces, but does not abolish the p53-binding ability of the protein, as well as inhibition of p53-directed transactivation. Deletion of 58 amino acids from the N-terminus of the oncoprotein abolishes its ability to bind p53 in vivo and to inhibit p53-directed transactivation. These results locate the p53-binding domain of MDM2 within amino acids 14 to 154 and inhibition of transactivation domains of MDM2 within amino acid residues 14 to 130 suggesting possible p53-independent biological functions of the 491 amino acid long oncoprotein.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio				Leng, Roger/0000-0001-9652-4703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31498-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBS SP, 1994, ONCOGENE, V9, P1341; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P49; LADANYI M, 1993, CANCER RES, V53, P16; LENG P, 1985, INT J ONCOL, V6, P251; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Sambrook J., 1989, MOL CLONING LAB MANU; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	50	50	51	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1275	1282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731677				2022-12-17	WOS:A1995QR65100003
J	DELLARAGIONE, F; RUSSO, GL; OLIVA, A; MASTROPIETRO, S; MANCINI, A; BORRELLI, A; CASERO, RA; IOLASCON, A; ZAPPIA, V				DELLARAGIONE, F; RUSSO, GL; OLIVA, A; MASTROPIETRO, S; MANCINI, A; BORRELLI, A; CASERO, RA; IOLASCON, A; ZAPPIA, V			5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND P16(INK4) DEFICIENCY IN MULTIPLE TUMOR-CELL LINES	ONCOGENE			English	Article						5'-METHYLTHIOADENOSINE PHOSPHORYLASE; P16(INK4) GENE; TUMOR SUPPRESSOR GENE; HUMAN CANCERS; 9P21 CHROMOSOME	METHYLTHIOADENOSINE PHOSPHORYLASE; HUMAN GLIOMAS; CHROMOSOME-9; MALIGNANCY; DELETIONS; ABSENCE; ENZYME; GENE	5'-Deoxy-5'-methylthioadenosine phosphorylase (MTA-Pase) gene is localized at the 9p21 region linked to the recently identified putative tumor suppressor gene, p16(INK4), which appears implicated in the control of cell division cycle, The phosphorylase is a housekeeping enzyme involved in the purine and amino acid metabolism whose activity is evidentiable in all the normal tissues, Chromosomal deletions encompassing both MTAPase and p16(INK4) genes cause the total absence of the enzymatic activity only in malignant cells, thus resulting in defined metabolic differences between malignant and normal cells, MTAPase deficiency was investigated by direct radiochemical assay method and by immunochemical techniques in 35 different human malignant cell lines established from several tumor types, The enzyme-deficient cells derived from breast, lung, ovary and liver cancer, malignant melanomas, malignant gliomas and liposarcomas, Two of the MTAPase-deficient cell preparations (from a liver carcinoma and from a melanoma) are primary cultures thus directly representing the original cancer genotypes, Several of the MTAPase-negative cells were studied for p16(INK4) gene deletions and for p16(INK4) protein deficiency, In all the examined samples a full correlation exists between the lack of MTAPase and that of p16(INK4). A similar result was obtained analysing extracts of Vero cell line, which is a fibroblast MTAPase-negative cell line established from the kidney of a normal adult monkey, Conversely, Cos cells, which also are fibroblasts derived from monkey kidney, show both MTAPase and p16(INK4) protein, These results: (i) demonstrate that the phosphorylase deficiency is distributed among almost all the most important human cancers; (ii) confirm and extend the tumor types were p16(INK4) gene inactivation is observable and (iii) suggest that deletions at 9p21 (in humans) or at syntenic chromosomes (in other species) might represent a general mechanism of p16(INK4) gene loss of function and possibly, in turn, of cancer development and/or progression.	UNIV NAPLES 2,SCH MED,DEPT PEDIAT,NAPLES,ITALY; G PASCALE FDN,INST STUDY & TREATMENT TUMORS,NAPLES,ITALY; JOHNS HOPKINS UNIV,SCH MED,ONCOL CTR LABS,BALTIMORE,MD 21231	Universita della Campania Vanvitelli; IRCCS Fondazione Pascale; Johns Hopkins University	DELLARAGIONE, F (corresponding author), UNIV NAPLES 2,SCH MED,INST BIOCHEM MACROMOLEC,NAPLES,ITALY.		Iolascon, Achille/A-4461-2014; RUSSO, GIAN LUIGI/GQB-0962-2022	Casero, Robert/0000-0001-5653-3306; Borrelli, Antonella/0000-0002-4439-6882; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Della Ragione, Fulvio/0000-0002-0592-4283				BACKLUND PS, 1982, J BIOL CHEM, V257, P4196; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1994, SCIENCE, V265, P414; CARRERA CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2665, DOI 10.1073/pnas.81.9.2665; COLEMAN A, 1993, AM J HUM GENET S, V53, pA287; DELLARAGIONE F, 1986, J BIOL CHEM, V261, P2324; DELLARAGIONE F, 1990, J BIOL CHEM, V265, P6241; DELLARAGIONE F, 1992, BIOCHEM J, V281, P533, DOI 10.1042/bj2810533; DELLARAGIONE F, 1993, ADV EXP MED BIOL, V348, P31; DELLARAGIONE F, 1989, PHYSL POLYAMINES, P231; DELLARAGIONE F, 1981, J CHROMATOGR, V226, P2243; HEGI M, 1994, 59 COLD SPR HARB LAB, P85; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JONASSON J, 1977, J CELL SCI, V24, P217; KAMATANI N, 1981, P NATL ACAD SCI-BIOL, V78, P1219, DOI 10.1073/pnas.78.2.1219; KAMATANI N, 1981, BIOCHIM BIOPHYS ACTA, V675, P344, DOI 10.1016/0304-4165(81)90024-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P344, DOI 10.1126/science.8153613; NOBORI T, 1991, CANCER RES, V51, P3193; NOBORI T, 1992, CANCER RES, V53, P1098; NOBORI T, 1994, NATURE, V358, P753; OLOPADE OI, 1992, CANCER RES, V52, P2523; SAIKI RK, 1988, SCIENCE, V238, P487; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAGUCHI T, 1993, CANCER RES, V53, P4349; TRAWEEK ST, 1988, BLOOD, V71, P1568; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WORSHAM MJ, 1993, GENE CHROMOSOME CANC, V6, P58, DOI 10.1002/gcc.2870060111	29	50	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					827	833						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898924				2022-12-17	WOS:A1995QL03800003
J	SHAO, ZH; ROBBINS, PD				SHAO, ZH; ROBBINS, PD			DIFFERENTIAL REGULATION OF E2F AND SP1-MEDIATED TRANSCRIPTION BY G1 CYCLINS	ONCOGENE			English	Article						RETINOBLASTOMA PROTEIN; CYCLINS; SP1; E2F	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE-C; HUMAN CELL-CYCLE; RB PROTEIN; BINDING-ACTIVITY; RNA-POLYMERASE; CDC2 KINASE; PHOSPHORYLATION; EXPRESSION; PHASE	Cyclins have been demonstrated to mediate phosphorylation of the retinoblastoma tumor suppressor gene product (Rb) and/or to bind directly to Rb. Since Rb is a regulator of E2F and Sp1-mediated transcription, we have examined the effect of overexpression of cyclins on transcription mediated by E2F-dependent adenovirus E2 promoter and by Sp1 in a cotransfection assay in 3T3 cells. All the G1 cyclins tested, C, D1, D2, D3 and E, as well as cyclin A were able to stimulate E2 promoter activity to various levels with D3 showing the strongest stimulation. For stimulation of the E2 promoter by cyclins A, E and D-type cyclins was dependent upon the presence of functional E2F and ATF binding sites. Cyclin C, however, was able to stimulate both E2F and ATF-dependent transcription to the same level as the wild type E2 promoter. In addition, cyclin C was able to stimulate transcription mediated by Sp1, GAL4-Sp1 and GAL4-VP16, suggesting that cyclin C affects a general pathway of transcriptional activation. In contrast, cyclin D1 was able to repress specifically Sp1-mediated transcription through an Rb-independent pathway, These results suggest that cyclins can regulate transcription mediated by specific transcription factors in both positive and negative manners. Furthermore, the results demonstrate clear functional differences between the G1 cyclins, in particular, functional differences between the related D-type cyclins.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ADNANE S, 1995, IN PRESS ONCOGENE; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	58	50	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					221	228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838522				2022-12-17	WOS:A1995QC62400001
J	OGAWA, S; TOYOSHIMA, H; KOZUTSUMI, H; HAGIWARA, K; SAKAI, R; TANAKA, T; HIRANO, N; MANO, H; YAZAKI, Y; HIRAI, H				OGAWA, S; TOYOSHIMA, H; KOZUTSUMI, H; HAGIWARA, K; SAKAI, R; TANAKA, T; HIRANO, N; MANO, H; YAZAKI, Y; HIRAI, H			THE C-TERMINAL SH3 DOMAIN OF THE MOUSE C-CRK PROTEIN NEGATIVELY REGULATES TYROSINE-PHOSPHORYLATION OF CRK ASSOCIATED P130 IN RAT 3Y1 CELLS	ONCOGENE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; V-CRK; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ONCOGENE PRODUCT; ADAPTER PROTEIN; SARCOMA-VIRUS; RECEPTOR; KINASE	We have isolated the mouse c-crk cDNA from a mouse liver cDNA library. It encodes 304 amino acids and consists mainly of SH2/SH3 regions. In Northern blot analysis, the mouse c-crk mRNA is expressed ubiquitously in every tissue and organ, suggesting that the c-Crk protein may be a common signal transducing molecule among tissues. In contrast to the v-Crk protein, which has a single SH3 domain, the c-Crk protein contains two, the more N-terminal SH3(1) domain and the C-terminal SH3(2) domain. To elucidate functions of these SH3 domains, we have constructed two c-crk mutants, B-cuk and D-crk which lack the SH3(2) and the SH3(1) domain, respectively. These mutants were expressed in rat 3Y1 cells, and examined for their transforming ability in terms of morphological phenotypes and for tyrosine phosphorylation profiles of cells expressing the mutant proteins. Morphological alteration and increased tyrosine phosphorylation of 130-140 kDa proteins, the major component of which is the Crk-associated p130, were observed in cells expressing B-Crk as well as those expressing v-Crk, but little in cells expressing c-Crk even at a similar level of expression. Although a highly tyrosine-phosphorylated form of the p130 was coimmunoprecipitated with c-Crk as well as B-Crk, the relative level of tyrosine phosphorylation of the p130, which is normalized to the amount of Crk protein immunoprecipitated, was 10 to 20 times higher in B-Crk-expressing cells than in c-Crk- or D-Crk-expressing cells. The present results indicate that the SH3(2) domain of mouse c-Crk protein negatively regulates tyrosine phosphorylation of the p130, and that lack of the SH3(2) domain in B-Crk and v-Crk may contribute, at least partly, to their morphological alteration or transforming ability through increasing tyrosine phosphorylation of the p130.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI,JAPAN	University of Tokyo; Jichi Medical University				Sakai, Ryuichi/0000-0001-6833-1103				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GISH GD, 1992, CELL, V71, P359; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; POTTS MW, 1987, J VIROL, V60, P494; Potts W M, 1988, Oncogene Res, V3, P343; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P113; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1692; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	42	50	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1669	1678						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183562				2022-12-17	WOS:A1994NL81500019
J	WINKLER, C; WITTBRODT, J; LAMMERS, R; ULLRICH, A; SCHARTL, M				WINKLER, C; WITTBRODT, J; LAMMERS, R; ULLRICH, A; SCHARTL, M			LIGAND-DEPENDENT TUMOR-INDUCTION IN MEDAKAFISH EMBRYOS BY A XMRK RECEPTOR TYROSINE KINASE TRANSGENE	ONCOGENE			English	Article							TRANSIENT EXPRESSION; ORYZIAS-LATIPES; XIPHOPHORUS; MICE; MELANOMA; ONCOGENE; PROMOTER; GENE; OVEREXPRESSION; NEOPLASIA	Xmrk encodes a subclass I receptor tyrosine kinase (RTK) which has been cloned from the melanoma-inducing locus Tn of the poeciliid fish Xiphophorus. To demonstrate a high oncogenic potential in vivo we transferred the gene into early embryos of the closely related medakafish. Ectopic expression of the Xmrk oncogene under the control of a strong, constitutive promoter (CMVTk) led to the induction of embryonic tumors with high incidence, after short latency periods, and with a specific pattern of affected tissues. We demonstrate ligand-dependent transformation in vivo using a chimeric receptor consisting of the extracellular and transmembrane domains of the human EGF receptor (HER) and the cytoplasmatic domain of Xmrk. Expression of the chimeric receptor alone does not lead to kinase activation or induction of tumors. Coexpression of the chimera with its corresponding ligand, human transforming growth factor alpha (hTGF alpha), however, results in the activation of the chimeric RTK. In injected fish embryos the induction of the neoplastic growth is observed with similar incidence and tissue distribution as in embryos carrying the native Xmrk oncogene suggesting that the ligand as well as factors downstream of the RTK are required for tumor formation. In this study we show single-step induction of tumors by ectopic expression of RTKs in vivo substantiating the significance of autocrine stimulation in RTK induced tumors in vertebrates.	UNIV WURZBURG,BIOCTR,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Basel; Max Planck Society			Wittbrodt, Joachim/D-4735-2014; Winkler, Christoph/G-4822-2012	Wittbrodt, Joachim/0000-0001-8550-7377; Schartl, Manfred/0000-0001-9882-5948; Winkler, Christoph/0000-0003-4688-6241				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; CHONG SSC, 1989, THEOR APPL GENET, V78, P369, DOI 10.1007/BF00265299; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kirchen R. V, 1976, JAPANESE MEDAKA ITS; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MARCEY D, 1986, NATURE, V321, P380, DOI 10.1038/321380a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; TAKAGI H, 1992, CANCER RES, V52, P5171; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1989, CANCER RES, V49, P3713; WINKLER C, 1991, MOL GEN GENET, V226, P129, DOI 10.1007/BF00273596; Winkler Christoph, 1992, Molecular Marine Biology and Biotechnology, V1, P326; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YAMAMOTO TO, 1961, INT REV CYTOL, V12, P361	27	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1517	1525						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183545				2022-12-17	WOS:A1994NL81500001
J	CHUMAKOV, AM; MILLER, CW; CHEN, DL; KOEFFLER, HP				CHUMAKOV, AM; MILLER, CW; CHEN, DL; KOEFFLER, HP			ANALYSIS OF P53 TRANSACTIVATION THROUGH HIGH-AFFINITY BINDING-SITES	ONCOGENE			English	Article							LARGE T-ANTIGEN; WILD-TYPE P53; E1B-58KD TUMOR-ANTIGEN; CELL-CYCLE CONTROL; A MOUSE CELLS; SIMIAN VIRUS-40; TRANSFORMED-CELLS; TRANSCRIPTIONAL ACTIVATION; ALTERED PHOSPHORYLATION; SV40-TRANSFORMED CELLS	Alterations or elimination of the p53 protein is frequently occurring during human carcinogenesis. Overexpression of wild-type p53 has a profound growth-inhibitory effect on many cell lines, including strong and apparently non-sequence specific repression of a number of promoters. Consistent with the hypothesis that it acts as transcriptional regulator, wild-type p53 protein binds DNA and activates transcription of several promoters. We have studied DNA binding and transactivation (TA) properties of human wild-type and mutant p53 proteins representing four major mutational hotspots. DNA-gel retardation was used to detect specific p53-DNA complexes in nuclear extracts, with radiolabelled oligonucleotides representing high affinity p53-binding sites (HBS) as a probe. p53-specific complexes were identified by competition with unlabelled 'self' oligos and by double band-shifts in the presence of anti-p53 antibodies. To show transactivation by p53, TK promoter-driven CAT reporter gene was placed 3' of the p53-binding site. CAT activity was assayed after co-transfection of reporters with either wild-type (WT) or mutant p53 expression constructs into human cells that do not express p53 (SKOV3). We found that wild-type p53 has strong transactivating effect on the reporter. All mutants, with the exception of His273, were inactive in TA-assay. p53 is a target of several oncogenes found in DNA tumor viruses. We examined the effect of either SV40 T-ag or 55 kDa EIB protein of Ad5 on DNA binding and transactivation by p53 in transformed COS-1 and 293 cell lines, respectively. COS-1 extracts produced strong p53-dependent band-shift of the HBS oligos, that was doubleshifted by anti-p53 but not anti-T-ag antibodies, indicating that T-ag is not part of the complex. COS-1 cells had a high level of WT p53-dependent expression of transfected CAT reporter, indicating the presence of transactivation-competent p53, acting through the HBS element. In human Ad-transformed 293 cells, endogenous p53 was also transactivation competent and capable of DNA binding. In summary, we found efficient transactivation of HBS motif by WT and His273-p53. Studies of COS-1 and 293 cells suggest that a proportion of p53 in transformed cells display wild-type DNA binding and TA properties and that expression of transcriptionally inactive mutant p53 proteins in these cells does not interfere with WT-dependent transactivation.			CHUMAKOV, AM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI MED CTR, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHEN JD, 1992, ONCOGENE, V7, P1167; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1989, CURR TOP MICROBIOL I, V144, P37; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1990, MOL CELL ENDOCRINOL, V70, P1, DOI 10.1016/0303-7207(90)90053-B; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1989, ONCOGENE, V4, P643; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER CW, 1993, ONCOGENE, V8, P1815; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISHAUS E, 1990, ONCOGENE, V5, P137; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P636; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	53	50	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3005	3011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414502				2022-12-17	WOS:A1993MC09300014
J	FUNG, YKT; TANG, A; MURPHREE, AL; ZHANG, FH; QIU, WR; WANG, SW; SHI, XH; LEE, L; DRISCOLL, B; WU, KJ				FUNG, YKT; TANG, A; MURPHREE, AL; ZHANG, FH; QIU, WR; WANG, SW; SHI, XH; LEE, L; DRISCOLL, B; WU, KJ			THE RB GENE SUPPRESSES THE GROWTH OF NORMAL-CELLS	ONCOGENE			English	Article							HUMAN RETINOBLASTOMA GENE; WILMS-TUMOR-ASSOCIATION; LARGE T-ANTIGEN; SV40 LARGE-T; SUSCEPTIBILITY GENE; HUMAN CHROMOSOME-11; TUMORIGENIC EXPRESSION; CARCINOMA-CELLS; DNA-BINDING; PRODUCT	The suppression of tumor formation, first demonstrated by somatic cell hybrid and microcell fusion experiments, suggests the existence of a class of genes that selectively suppress the growth of tumor cells but not normal cells. The reintroduction of these genes into tumor cells presumably renders the cells responsive to in vivo growth inhibitory environment. As the inheritance of a defective retinoblastoma gene (Rb-1) allele results in a predisposition to the development of various cancers, and since inactivation of both alleles are observed in tumor cells, the Rb gene has been suspected to have the ability to suppress tumor growth. Data presented here demonstrated that different types of normal cells, which have a limited life span, were also growth arrested by a transfected Rb gene. Cell lines which are resistant to the growth suppression effect of the Rb gene in vitro, retain the ability to form tumors in nude mice even in the presence of a stable and highly expressed wild type Rb protein. We conclude that while the Rb gene can suppress the growth of many tumor cell lines, its growth suppression effect is not tumor specific.	CHILDRENS HOSP,DIV PATHOL & OPHTHALMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California	FUNG, YKT (corresponding author), CHILDRENS HOSP,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027, USA.				NATIONAL EYE INSTITUTE [R01EY007846] Funding Source: NIH RePORTER; NEI NIH HHS [EY07846] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HARRIS H, 1969, NATURE, V224, P1314; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUFOS A, 1984, NATURE, V309, P171; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUNCASTER MM, 1992, CANCER RES, V52, P654; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1980, CANCER GENET CYTOGEN, V2, P131, DOI 10.1016/0165-4608(80)90056-4; RULEY HE, 1985, CANCER CELL, V3, P257; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1988, ONCOGENE, V3, P471	47	50	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2659	2672						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378078				2022-12-17	WOS:A1993LX34300007
J	CHANG, JH; WILSON, LK; MOYERS, JS; ZHANG, K; PARSONS, SJ				CHANG, JH; WILSON, LK; MOYERS, JS; ZHANG, K; PARSONS, SJ			INCREASED LEVELS OF P21RAS-GTP AND ENHANCED DNA-SYNTHESIS ACCOMPANY ELEVATED TYROSYL PHOSPHORYLATION OF GAP-ASSOCIATED PROTEINS, P190 AND P62, IN C-SRC OVEREXPRESSORS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; EPIDERMAL GROWTH-FACTOR; RAS P21 GTPASE; SIGNAL TRANSDUCTION; MITOGENIC RESPONSIVENESS; CELLULAR PROTEINS; KINASE; TRANSFORMATION; RECEPTOR; CELLS	While examining the role of pp60c-src in cellular proliferation, we found that overexpression of c-src in C3H10T1/2 murine fibroblasts results in an augmented mitogenic response to epidermal growth factor (EGF) [Luttrell, D.K., Luttrell, L.M. & Parsons, S.J. (1988). Mol. Cell. Biol., 8, 497-501; Wilson, L.K., Luttrell, D.K., Parsons, S.J. (1989). Mol. Cell. Biol., 9, 1536-1544] and enhanced tyrosyl phosphorylation of specific cellular proteins [Wilson, L.K. & Parsons, S.J. (1990). 5, 1471-14801. Here we identify two of these proteins as the GAP (GTPase-activating protein of p21ras)associated proteins, p190 and p62. Evidence is presented to support the notion that, in 10T1/2 fibroblasts, p190 is a preferred substrate of pp6Oc-src, while p62 is preferentially phosphorylated by the EGF receptor. First, the phosphotyrosine content of p190 in quiescent cells is three- to fivefold higher in c-src overexpressors than in control cells and is not altered by growth factor treatment. In contrast, tyrosyl phosphorylation of p62 is undetectable in quiescent cells and transiently observable upon EGF addition. Second, the phosphotyrosine content of p190 in cells overexpressing defective pp60c-src is reduced in comparison with wild-type (wt) c-src overexpressors, while that of p62 is significantly less affected. Further studies revealed that tyrosyl phosphorylation of p190 and p62 is not required for GAP complex formation, as equal amounts of p190 and p62 proteins could be detected in GAP complexes from wt and variant c-src overexpressors both before and after EGF stimulation. However, analysis of GTP-bound p21ras revealed higher basal and EGF-stimulated levels in c-src overexpressors than in control cells. Taken together, these results suggest that one mechanism by which pp60c-src may contribute to early events in the EGF-induced mitogenic pathway in 10T1/2 fibroblasts is by increasing the level of GAP-associated p190 and p62 tyrosyl phosphorylation, which in turn results in higher levels of p21ras-GTP.	UNIV VIRGINIA,HLTH SCI CTR,CTR CANC,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,INST MOLEC BIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HEIDARAN MA, 1992, ONCOGENE, V7, P147; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1990, CELL, V56, P5; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PARSONS JT, 1990, TRENDS GENET, V6, P169; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	39	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					959	967						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681161				2022-12-17	WOS:A1993KT22000018
J	BOULUKOS, KE; ZIFF, EB				BOULUKOS, KE; ZIFF, EB			ADENOVIRUS 5 E1A PROTEINS DISRUPT THE NEURONAL PHENOTYPE AND GROWTH-FACTOR RESPONSIVENESS OF PC12 CELLS BY A CONSERVED REGION 1-DEPENDENT MECHANISM	ONCOGENE			English	Article							INTERMEDIATE FILAMENT PROTEIN; RETINOBLASTOMA GENE-PRODUCT; HUMAN CYCLIN-A; TRK PROTOONCOGENE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; FACTOR RECEPTORS; TERMINAL REGION; KINASE-ACTIVITY; NGF RECEPTOR	Expression in PC12 cells of adenovirus 5 E1a proteins dramatically changes cell morphology and disrupts neuronal differentiation. We demonstrate that the nerve growth factor (NGF) receptors, p140trk and p75NGFR, as well as the epidermal growth factor receptor are undetectable in E1a-expressing PC12 cells. This correlates with a repression of mRNAs for the chromaffin- and neuronal-specific proteins, tyrosine hydroxylase and peripherin, while more ubiquitously expressed genes remain unaffected. One possible mechanism of E1a action could thus be the repression of a coordinately regulated group of chromaffin- and/or neuronal-specific genes. Furthermore, we show that E1a conserved region 1, which binds p105Rb and p300, is necessary for this E1a-dependent effect. This indicates that cellular proteins interacting with E1a conserved region 1 may be implicated in growth arrest, expression of neuron-specific functions and orderly differentiation of PC12 cells in response to NGF.	NYU HOSP, HOWARD HUGHES MED INST, DEPT BIOCHEM, 1ST AVE, NEW YORK, NY 10016 USA; NYU HOSP, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649				BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GAYNOR RB, 1984, P NATL ACAD SCI-BIOL, V81, P1193, DOI 10.1073/pnas.81.4.1193; GIORDANO A, 1991, ONCOGENE, V6, P481; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARUYAMA K, 1987, ONCOGENE, V1, P361; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	53	50	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					237	248						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8093977				2022-12-17	WOS:A1993KN00600002
J	SZEBERENYI, J; ERHARDT, P; CAI, H; COOPER, GM				SZEBERENYI, J; ERHARDT, P; CAI, H; COOPER, GM			ROLE OF RAS IN SIGNAL TRANSDUCTION FROM THE NERVE GROWTH-FACTOR RECEPTOR - RELATIONSHIP TO PROTEIN-KINASE-C, CALCIUM AND CYCLIC-AMP	ONCOGENE			English	Article							PC12 CELLS; TRK PROTOONCOGENE; ADENYLATE-CYCLASE; ONCOGENE PRODUCT; PHOSPHOLIPASE-C; 3T3 CELLS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; INHIBITION	A dominant inhibitory ras mutant (Ha-ras Asn-17) has been used to investigate the role of Ras in nerve growth factor (NGF)-mediated signal transduction in PC12 cells. Expression of Ha-Ras Asn-17 blocks neuronal differentiation of these cells in response to NGF treatment. The Ha-Ras Asn-17 block was bypassed by treatment with NGF plus dibutyryl cAMP or NGF plus the Ca2+ ionophore ionomycin, but not by NGF plus 12-tetradecanoyl phorbol acetate (TPA). Direct stimulation of the cAMP or Ca2+ pathways thus appeared to act synergistically with a Ras-independent NGF signaling pathway. This Ras-independent pathway was also distinct from protein kinase C, since its activity was not affected by protein kinase C down-regulation. It thus appears that NGF stimulation generates a Ras-independent intracellular signal that contributes to neuronal differentiation independently of the cAMP, Ca2+ or protein kinase C second messenger systems Since TPA did not bypass the Ha-Ras Asn-17 block to differentiation, protein kinase C also did not appear to be sufficient for Ras-dependent pathways mediating NGF-induced differentiation. Down-regulation experiments further indicated that protein kinase C was not required for NGF induction of early response genes via either Ras-dependent or Ras-independent pathways. Moreover, the formation of inositol phosphates and mobilization of intracellular calcium in response to NGF was not inhibited in PC12 cells expressing the Ha-Ras Asn-17 protein. Therefore, although calcium was able to bypass the Ha-Ras Asn-17 block to PC12 differentiation, Ras activity was not required for activation of phospholipase C in response to NGF. It thus appears that both Ras-dependent and Ras-independent signaling pathways contribute to NGF-induced PC12 cell differentiation independently of the cAMP, calcium and protein kinase C second messenger systems.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; COPELAND NG, 1979, CELL, V16, P347, DOI 10.1016/0092-8674(79)90011-4; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1984, TRENDS NEUROSCI, V7, P91, DOI 10.1016/S0166-2236(84)80164-2; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VICENTINI LM, 1986, BIOCHEM J, V234, P555, DOI 10.1042/bj2340555; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	51	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2105	2113						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331931				2022-12-17	WOS:A1992JW66500002
J	CHINNADURAI, G				CHINNADURAI, G			ADENOVIRUS E1A AS A TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Review							RAT EMBRYO CELLS; TRANSCRIPTIONAL REPRESSION; FUNCTIONAL DOMAINS; EPITHELIAL-CELLS; TRANSFORMATION; INDUCTION; ONCOGENES; PROTEINS; TRANSACTIVATION; IMMORTALIZATION	The E1a gene of group C adenoviruses is one of the most studied transforming genes of DNA tumor viruses. These transforming genes have been conventionally considered as dominant oncogenes since they transform cells in vitro and many of the resulting transformed cell lines induce tumors in experimental animals. It now appears that, in addition to its well-known transforming activities, E1a possesses activities which suppress transformation, tumorigenesis and malignant progression (metastasis) of tumor cells. Thus, E1a appears to meet the definition of both a dominant oncogene and a tumor-suppressor gene.			CHINNADURAI, G (corresponding author), ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA-33616, CA-31719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5853; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY M, 1988, ONCOGENE, V2, P567; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LINDER S, 1992, IN PRESS ONCOGENE; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEEG PS, 1988, CANCER RES, V48, P6550; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	38	50	59	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1255	1258						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1535700				2022-12-17	WOS:A1992HZ97100001
J	ISHIZAKA, Y; SHIMA, H; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; SHIMA, H; SUGIMURA, T; NAGAO, M			DETECTION OF PHOSPHORYLATED RETTPC ONCOGENE PRODUCT IN CYTOPLASM	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; HUMAN TRK ONCOGENE; PROTO-ONCOGENE; CELL-LINE; TYROSINE KINASE; EXPRESSION; TRANSFORMATION; CLEAVAGE; ANTIGENS; CLONING	The product of the ret(TPC) oncogene, an activated form of the ret proto-oncogene found in human papillary thyroid carcinomas, was identified as a 57-kDa protein (p57retTPC) by Western blotting with a polyclonal antibody raised by an oligopeptide corresponding to the carboxy-terminal region of the ret proto-oncogene product. Subcellular fractionation experiments using NIH3T3 cell transformants induced by the ret(TPC) cDNA showed that p57retTPC was localized in a soluble cytoplasmic fraction, whereas the ret proto-oncogene products expressed in a neuroblastoma cell line were present in a membrane fraction. Immunostaining also demonstrated that p57retTPC is localized in the cytoplasm. Immunoprecipitation with antiphosphotyrosine antibody followed by Western blotting revealed that p57retTPC is constitutively phosphorylated, whereas the ret proto-oncogene products are not. These findings suggest that p57retTPC has an abererant tyrosine kinase activity resulting in autophosphorylation associated with change in its location.	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DEGRAAF FK, 1978, BIOCHEMISTRY-US, V17, P1137, DOI 10.1021/bi00599a031; DONGHI R, 1989, ONCOGENE, V4, P521; EMORI Y, 1986, J BIOL CHEM, V261, P9472; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLOW E, 1988, ANTIBODIES LABORATOR; IKEDA I, 1990, ONCOGENE, V5, P1291; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIZAKA Y, 1987, CARCINOGENESIS, V8, P1575, DOI 10.1093/carcin/8.11.1575; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ISHIZAKA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1331, DOI 10.1016/0006-291X(91)91719-S; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ITOH F, 1989, Tumor Research, V24, P1; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASAKI H, 1985, J MOL BIOL, V182, P217, DOI 10.1016/0022-2836(85)90340-7; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NODA T, 1987, J VIROL, V61, P2253, DOI 10.1128/JVI.61.7.2253-2263.1987; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4	32	50	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1441	1444						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620555				2022-12-17	WOS:A1992HZ97100025
J	YAN, ZF; HSU, S; WINAWER, S; FRIEDMAN, E				YAN, ZF; HSU, S; WINAWER, S; FRIEDMAN, E			TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1) INHIBITS RETINOBLASTOMA GENE-EXPRESSION BUT NOT PRB PHOSPHORYLATION IN TGF-BETA-1-GROWTH STIMULATED COLON-CARCINOMA CELLS	ONCOGENE			English	Note							SV40 LARGE-T; SUSCEPTIBILITY GENE; HEXAMETHYLENE BISACETAMIDE; RB GENE; PRODUCT; SUPPRESSION; DIFFERENTIATION; BINDING; CYCLE; TRANSCRIPTION	The response of the retinoblastoma (RB) gene and its product (pRB) to transforming growth factor-beta-1 (TGF-beta-1) was studied in three types of colon carcinoma cells derived from the same parental line. TGF-beta-1 was a growth inhibitor for two enterocytic-differentiated lines, a growth stimulator for two undifferentiated lines, and had no effect on two goblet cell-differentiated lines. TGF-beta-1 treatment for 3 days decreased RB gene expression and pRB level two- to threefold in each responsive line. When treated with TGF-beta-1 beginning in early G1, enterocytic cells were arrested in G1 and pRB remained under-phosphorylated and in low abundance. Neither goblet cell line exhibited these responses to TGF-beta-1 because they were shown to lack TGF-beta-1 type I and II receptors. Thus during colonocyte differentiation goblet cells lose responsiveness to TGF-beta-1 by down-regulating TGF-beta-1 receptors, while enterocytic cells retain and exhibit responsiveness to TGF-beta-1 through modulations of pRB. Both of the undifferentiated lines exhibited mixed responses to TGF-beta-1: a decrease in total amount of RB mRNA and pRB protein yet an increase in pRB phosphorylation consistent with increased cell cycling. Therefore, TGF-beta-1 controls RB function by two separable mechanisms, the regulation of pRB phosphorylation and the control of RB mRNA and protein level.	MEM SLOAN KETTERING CANC CTR,DEPT MED,GASTROENTEROL SERV,BOX 244,1275 YORK AVE,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Fan D, 1989, Cancer Commun, V1, P117; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAPUSCINSKI J, 1987, J BIOMOL STRUCT DYN, V5, P127, DOI 10.1080/07391102.1987.10506381; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHROY P, 1990, CANCER RES, V50, P261; SCHROY PC, 1988, CANCER RES, V48, P5487; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, ONCOGENE, V6, P1139	37	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					801	805						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565477				2022-12-17	WOS:A1992HQ68200027
J	ERLANDSSON, R; BOLDOG, F; PERSSON, B; ZABAROVSKY, ER; ALLIKMETS, RL; SUMEGI, J; KLEIN, G; JORNVALL, H				ERLANDSSON, R; BOLDOG, F; PERSSON, B; ZABAROVSKY, ER; ALLIKMETS, RL; SUMEGI, J; KLEIN, G; JORNVALL, H			THE GENE FROM THE SHORT ARM OF CHROMOSOME-3, AT D3F15S2, FREQUENTLY DELETED IN RENAL-CELL CARCINOMA, ENCODES ACYLPEPTIDE HYDROLASE	ONCOGENE			English	Note							ACYL-PEPTIDE HYDROLASE; ACID-RELEASING ENZYME; RAT-LIVER; SEQUENCE-ANALYSIS; LUNG-CANCER; PURIFICATION; ALPHA; DNF15S2; CLONING; LOCI	Loss or inactivation of a gene on the short arm of chromosome 3 may contribute to the genesis of renal cell carcinoma. A gene that corresponds to the most frequently lost RFLP site (D3F15S2) is expressed in a variety of human tissues, and at a particularly high level in the kidney. Its expression is markedly reduced in renal cell carcinoma. A database search showed that the gene product is closely related to or identical with acylpeptide hydrolase. The nucleotide identity between the rat acylpeptide hydrolase and the human gene at D3F15S2 is 88%, compatible with normal species differences. It is therefore likely that the human gene product is acylpeptide hydrolase. The renal cell carcinoma is then associated with a decrease of acylpeptide hydrolase activity. The gene may represent a tumor suppressor gene, whose loss contributes to the development of renal cell carcinoma. It might be speculated that it could act e.g. by affecting the activity of a small acetylated growth factor. Alternatively, its decreased expression may merely reflect the impairment of differentiation in RCC, compared to normal kidney. Loss of a linked but irrelevant gene by the 3p deletion is another possibility.	KAROLINSKA INST,DEPT CHEM 1,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	ERLANDSSON, R (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Zabarovsky, Eugene R/A-6645-2010; Allikmets, Rando/ABD-4533-2021		NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BODENMULLER H, 1981, NATURE, V293, P579, DOI 10.1038/293579a0; BOLDOG F, 1989, CANCER GENET CYTOGEN, V42, P295, DOI 10.1016/0165-4608(89)90098-8; BOLDOG F, IN PRESS GENES CHROM; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; GADE W, 1978, J BIOL CHEM, V253, P5012; HARRIS JI, 1959, BIOCHEM J, V71, P451, DOI 10.1042/bj0710451; JONES WM, 1985, BIOCHEM BIOPH RES CO, V126, P933, DOI 10.1016/0006-291X(85)90275-X; JONES WM, 1986, BIOCHEM BIOPH RES CO, V139, P244, DOI 10.1016/S0006-291X(86)80105-X; KAISER R, 1989, BIOCHEMISTRY-US, V28, P8432, DOI 10.1021/bi00447a024; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARKS N, 1983, J NEUROCHEM, V41, P201, DOI 10.1111/j.1471-4159.1983.tb13670.x; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; YOUNG LJS, 1988, HUM GENET, V79, P137, DOI 10.1007/BF00280552; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	50	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1293	1295						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861871				2022-12-17	WOS:A1991GV26000028
J	LEBEAU, J; LECHALONY, C; PROSPERI, MT; GOUBIN, G				LEBEAU, J; LECHALONY, C; PROSPERI, MT; GOUBIN, G			CONSTITUTIVE OVEREXPRESSION OF A 89 KDA HEAT-SHOCK PROTEIN GENE IN THE HBL100 HUMAN MAMMARY CELL-LINE CONVERTED TO A TUMORIGENIC PHENOTYPE BY THE EJ/T24 HARVEY-RAS ONCOGENE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; MOLECULAR-CLONING; PLATELET PROTEIN; TRANSCRIPTION; EXPRESSION; DNA; FIBROBLASTS; ACTIVATION	The non tumorigenic human mammary cell line HBL100 has been transformed by the EJ/T24 human bladder carcinoma Harvey(Ha)-ras oncogene. Six cell lines were established from transformed colonies. They all expressed a high level of the ras oncogene and were tumorigenic in athymic nude mice. During an in vivo passage in animals, tumour cells presenting a growth advantage were selected, and some of the tumours revealed an amplification of the transfected ras sequences. Using this model of human cell transformation, we have isolated a cDNA clone corresponding to a heat shock protein gene (hsp89-alpha). This gene, normally transcribed at a higher rate in response to serum stimulation, was found to be constitutively overexpressed in ras-transformed HBL100 cells. In contrast, a closely related hsp gene (hsp89-beta), remained sensitive to serum stimulation, in both untransformed and ras-transformed HBL100 cells. Thus, the regulation of the expression of the hsp89 genes, upon serum stimulation, involves ras-dependent and ras-independent pathways. Constitutive overexpression of the murine homolog of the hsp89-alpha was observed in NIH3T3 cells transformed by the three ras oncogenes, but not with some other oncogenes. Therefore, alteration of the hsp89-alpha gene expression is not a general characteristic of transformed cells, but seems to be linked to ras transformation.	INST CURIE,ONCOGENESE MOLEC LAB,26 RUE ULM,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	GOUBIN, G (corresponding author), INST CURIE,ONCOGENESE MOLEC LAB,26 RUE ULM,F-75005 PARIS,FRANCE.							BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BARNIER JV, 1987, EXP CELL RES, V170, P186, DOI 10.1016/0014-4827(87)90128-5; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTIAN BJ, 1990, CANCER RES, V50, P4779; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGAG N, 1990, ONCOGENE, V5, P1481; HAIRE RN, 1988, J CELL BIOL, V106, P883, DOI 10.1083/jcb.106.3.883; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HICKEY E, 1986, GENE, V43, P147, DOI 10.1016/0378-1119(86)90018-1; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1979, BIOCHIM BIOPHYS ACTA, V578, P1, DOI 10.1016/0005-2795(79)90106-5; LEGAGNEUX V, 1989, DIFFERENTIATION, V41, P42, DOI 10.1111/j.1432-0436.1989.tb00730.x; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; Maniatis T., 1982, MOL CLONING LAB MANU; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MOORE SK, 1989, J BIOL CHEM, V264, P5343; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OSHIMURA M, 1988, CANCER RES, V48, P1623; PROSPERI MT, 1987, ONCOGENE RES, V1, P121; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	47	50	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1125	1132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861862				2022-12-17	WOS:A1991GV26000005
J	BISCHOFF, FZ; STRONG, LC; YIM, SO; PRATT, DR; SICILIANO, MJ; GIOVANELLA, BC; TAINSKY, MA				BISCHOFF, FZ; STRONG, LC; YIM, SO; PRATT, DR; SICILIANO, MJ; GIOVANELLA, BC; TAINSKY, MA			TUMORIGENIC TRANSFORMATION OF SPONTANEOUSLY IMMORTALIZED FIBROBLASTS FROM PATIENTS WITH A FAMILIAL CANCER SYNDROME	ONCOGENE			English	Article							DIPLOID HUMAN-FIBROBLASTS; ANCHORAGE-INDEPENDENT GROWTH; MALIGNANT TRANSFORMATION; SKIN FIBROBLASTS; MORPHOLOGICAL TRANSFORMATION; RAS ONCOGENE; HUMAN-CELLS; DNA; TRANSFECTION; EXPRESSION	Immortal cell lines arose spontaneously during in vitro culture of initially normal fibroblasts, MDAH041 and MDAH087, from patients with Li-Fraumeni familial cancer syndrome. Fibroblasts from a control donor, MDAH170, maintained a normal morphology and senesced at 31 population doublings. The immortal fibroblasts have several properties of transformed cells. In addition to having acquired an altered morphology and chromosomal anomalies, MDAH041 and MDAH087 have escaped from senescence, growing beyond 300 and 100 population doublings (pd), respectively. As early as 50 pd, these cells can be transformed by an activated H-ras oncogene to form tumors in nude mice. However, MDAH041 immortal cells were resistant to tumorigenic transformation by transfection with the v-abl oncogene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PEDIAT,HOUSTON,TX 77030; ST JOSEPHS HOSP,STEHLIN FDN CANC RES,CANC RES LAB,HOUSTON,TX 77003; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [CA 09299, CA 34936, CA 42810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299, P01CA034936, R01CA042810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEDICT WF, 1984, CANCER RES, V44, P3471; BERG P, 1982, MOL APPL GENET, V1, P327; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHEN S, 1989, P NATL ACAD SCI USA, V86, P2008, DOI 10.1073/pnas.86.6.2008; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HURLIN PJ, 1987, CANCER RES, V47, P5752; HUSCHTSCHA LI, 1986, PROC R SOC SER B-BIO, V229, P1, DOI 10.1098/rspb.1986.0070; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1987, CANCER RES, V47, P4229; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MORGAN TL, 1986, IN VITRO CELL DEV B, V22, P317, DOI 10.1007/BF02623404; RULEY HE, 1984, CANCER CELL, V2, P481; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SILINSKAS KC, 1981, CANCER RES, V41, P1620; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; SUTHERLAND BM, 1980, CANCER RES, V40, P1934; WILLIAMS WR, 1985, FAM CANCER, P151; WILSON DM, 1989, CARCINOGENESIS, V10, P635, DOI 10.1093/carcin/10.4.635; WILSON DM, 1990, CANCER RES, V50, P5587; ZIMMERMAN RJ, 1983, CANCER RES, V43, P2183	27	50	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					183	186						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000218				2022-12-17	WOS:A1991FZ13400001
J	HORVATH, AR; ELMORE, MA; KELLIE, S				HORVATH, AR; ELMORE, MA; KELLIE, S			DIFFERENTIAL TYROSINE-SPECIFIC PHOSPHORYLATION OF INTEGRIN IN ROUS-SARCOMA VIRUS-TRANSFORMED CELLS WITH DIFFERING TRANSFORMED PHENOTYPES	ONCOGENE			English	Article									ROYAL COLL SURG ENGLAND,INST HUNTERIAN,DEPT BIOCHEM & CELL BIOL,LONDON WC2A 3PN,ENGLAND	Royal College of Surgeons of England			Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474; Horvath, Andrea/0000-0002-7474-3240				ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; AKIYAMA SK, 1990, CANCER RES, V50, P1601; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ANTLER AM, 1985, MOL CELL BIOL, V5, P263, DOI 10.1128/MCB.5.1.263; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BELL SM, 1990, J BIOL CHEM, V265, P1333; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ENRIETTO PJ, 1983, VIROLOGY, V127, P397, DOI 10.1016/0042-6822(83)90153-8; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FINCHAM VJ, 1982, VIROLOGY, V116, P72, DOI 10.1016/0042-6822(82)90404-4; GAVAZZI I, 1989, J CELL SCI, V94, P89; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KELLIE S, 1986, J CELL SCI, V82, P129; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEFF NT, 1982, J CELL BIOL, V95, P654, DOI 10.1083/jcb.95.2.654; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PERKINS RM, 1982, EXP CELL RES, V141, P231, DOI 10.1016/0014-4827(82)90211-7; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RADZIEJEWSKI C, 1989, BIOCHEMISTRY-US, V28, P9047, DOI 10.1021/bi00449a013; RESH MD, 1985, MOL CELL BIOL, V5, P916, DOI 10.1128/MCB.5.5.916; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; TAPLEY P, 1989, ONCOGENE, V4, P325; WAGNER DD, 1981, J BIOL CHEM, V256, P1708; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	57	50	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1349	1357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699197				2022-12-17	WOS:A1990EC24100011
J	SIEGFRIED, Z; ZIFF, EB				SIEGFRIED, Z; ZIFF, EB			TRANSCRIPTION ACTIVATION BY SERUM, PDGF, AND TPA THROUGH THE C-FOS DSE - CELL TYPE SPECIFIC REQUIREMENTS FOR INDUCTION	ONCOGENE			English	Article									NYU MED CTR,DEPT BIOCHEM,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University				Ziff, Edward/0000-0001-7389-8649	NATIONAL CANCER INSTITUTE [R01CA044042, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007827] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44042, P30 CA 16087] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EK B, 1982, J BIOL CHEM, V257, P486; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWENHAUPT K, 1978, CELL, V14, P337, DOI 10.1016/0092-8674(78)90119-8; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; METZ R, 1988, IN PRESS COND SPRING, V52; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLLOCH V, 1981, CELL, V23, P509, DOI 10.1016/0092-8674(81)90146-X; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YEE CL, 1985, AM J PATHOL, V119, P3261	53	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					3	11						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915902				2022-12-17	WOS:A1989U567400001
J	BYRD, PJ; GRAND, RJA; GALLIMORE, PH				BYRD, PJ; GRAND, RJA; GALLIMORE, PH			DIFFERENTIAL TRANSFORMATION OF PRIMARY HUMAN-EMBRYO RETINAL CELLS BY ADENOVIRUS E1 REGIONS AND COMBINATIONS OF E1A + RAS	ONCOGENE			English	Article											BYRD, PJ (corresponding author), MED SCH BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; BYRD PJ, 1982, J GEN VIROL, V60, P279, DOI 10.1099/0022-1317-60-2-279; BYRD PJ, 1982, NATURE, V298, P67; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GRABHAM PW, 1988, IN PRESS EXP EYE RES; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRAND RJA, 1987, ONCOGENE, V1, P305; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; JOCHEMSEN AG, 1986, J VIROL, V59, P684, DOI 10.1128/JVI.59.3.684-691.1986; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LOWY DR, 1986, CANCER SURV, V5, P275; MARSHALL CJ, 1984, CANCER SURV, V3, P183; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARASKEVA C, 1982, J VIROL, V44, P759, DOI 10.1128/JVI.44.2.759-764.1982; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RULEY HE, 1983, NATURE, V304, P609; SANTOS E, 1985, S SOC GENERAL MICROB, P291; SENNEAR AW, 1986, MOL CELL BIOL, V6, P1253; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STILLMAN B, 1986, CANCER SURV, V5, P389; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEINSTEIN IB, 1984, CANCER CELL, V1, P229; WOLFE J, 1984, EMBO J, V3, P1997, DOI 10.1002/j.1460-2075.1984.tb02081.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	49	50	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					477	484						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2967455				2022-12-17	WOS:A1988N434800009
J	Dubrez, L; Causse, S; Bonan, NB; Dumetier, B; Garrido, C				Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen			Heat-shock proteins: chaperoning DNA repair	ONCOGENE			English	Review							BASE EXCISION-REPAIR; HEAT-SHOCK-PROTEIN-70 HSP70 INHIBITOR; SMALL-MOLECULE INHIBITOR; SENSITIZES CANCER-CELLS; STRAND-BREAK REPAIR; HSP90 INHIBITOR; COLORECTAL-CANCER; TUMOR-CELLS; HOMOLOGOUS RECOMBINATION; 90-ALPHA HSP90-ALPHA	Cells are repeatedly exposed to environmental or endogenous stresses that can alter normal cell behavior and increase cell vulnerability. In order to ensure tissue integrity and function, cells cope with cellular injuries by adapting their metabolism, protecting essential intracellular constituents, inhibiting cell death signaling pathways and activating those devoted to damage repair. The molecular chaperones of the heat-shock protein (HSP) family are critical effectors of this adaptive response. They protect intracellular proteins from misfolding or aggregation, inhibit cell death signaling cascades and preserve the intracellular signaling pathways that are essential for cell survival. Most HSPs are rapidly overexpressed in response to cellular injuries including genotoxic stress. DNA damage can dramatically alter cell behavior and contribute to a number of diseases including developmental defects, neurodegenerative disorders, and cancer. Thus, the ability of cells to repair DNA damage is essential for preserving cell integrity. DNA damage activates a coordinated response that includes detecting DNA lesions before their transmission to daughter cells, blocking cell cycle progression and DNA replication and repairing the damage. Although the role of HSPs in proteins homeostasis and cell death, especially apoptosis has been widely reported, much less is known about their function in DNA repair. This review aims to present the role of HSPs in DNA repair signaling pathways.	[Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen] INSERM UMR 1231, Equipe Labellisee, Ligue Natl Canc, Dijon, France; [Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen] Lab Excellence LipSTIC, Dijon, France; [Dubrez, Laurence; Causse, Sebastien; Bonan, Natalia Borges; Dumetier, Baptiste; Garrido, Carmen] Univ Bourgogne Franche Comte, Dijon, France; [Garrido, Carmen] Anticanc Ctr Georges Francois Leclerc Unicancer, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Dubrez, L; Garrido, C (corresponding author), INSERM UMR 1231, Equipe Labellisee, Ligue Natl Canc, Dijon, France.; Dubrez, L; Garrido, C (corresponding author), Lab Excellence LipSTIC, Dijon, France.; Dubrez, L; Garrido, C (corresponding author), Univ Bourgogne Franche Comte, Dijon, France.; Garrido, C (corresponding author), Anticanc Ctr Georges Francois Leclerc Unicancer, Dijon, France.	ldubrez@u-bourgogne.fr; cgarrido@u-bourgogne.fr	Causse, Sebastien Zwe/AAZ-7365-2021; Laurence, Dubrez/P-9472-2019; Garrido, Carmen/G-1633-2018	Laurence, Dubrez/0000-0002-7030-2181; Garrido, Carmen/0000-0003-1368-1493; Causse, Sebastien/0000-0003-3246-3491; DUMETIER, Baptiste/0000-0001-9087-2344	Institut National du Cancer; Ligue Nationale Contre le Cancer; Conseil Regional de Bourgogne; French Government [ANR-11-LABX-0021, ANR-15-IDEX-0003]	Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); French Government	Our work was supported by grants from the Institut National du Cancer, Ligue Nationale Contre le Cancer, the Conseil Regional de Bourgogne, a French Government grants managed by the French National Research Agency under the program"Investissements d'Avenir" with reference ANR-11-LABX-0021 (LabEX LipSTIC) and ANR-15-IDEX-0003 (I-SITE-UBFC). We thank the "Fondation de France" (SC) and the European Union program FEDER.	ABE T, 1995, BIOCHEM BIOPH RES CO, V206, P548, DOI 10.1006/bbrc.1995.1078; Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Arrigo AP, 2017, CELL STRESS CHAPERON, V22, P517, DOI 10.1007/s12192-017-0765-1; Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004; Bases R, 2006, CELL STRESS CHAPERON, V11, P240, DOI 10.1379/CSC-185R.1; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Boudesco C, 2018, BLOOD, V132, P510, DOI 10.1182/blood-2017-12-819706; Bracher A, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00010; Brown MA, 2015, ONCOTARGET, V6, P4005, DOI 10.18632/oncotarget.2970; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Calderwood SK, 2019, CELL STRESS CHAPERON, V24, P1, DOI 10.1007/s12192-018-00966-w; Calini V, 2003, TOXICOL IN VITRO, V17, P561, DOI 10.1016/S0887-2333(03)00116-4; Campos EI, 2010, NAT STRUCT MOL BIOL, V17, P1343, DOI 10.1038/nsmb.1911; Causse SZ, 2019, ONCOGENE, V38, P2767, DOI 10.1038/s41388-018-0616-2; Chatterjee S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091978; Cheng AN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17126-2; Cho W, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00391-18; Choi EJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-17; Clerico EM, 2019, BIOCHEM J, V476, P1653, DOI 10.1042/BCJ20170380; Coban N, 2019, EXCLI J, V18, P195, DOI 10.17179/excli2018-1807; Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054; Condelli V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060532; Dahiya V, 2019, ADV PROTEIN CHEM STR, V114, P1, DOI 10.1016/bs.apcsb.2018.10.001; de Toda IM, 2015, BIOGERONTOLOGY, V16, P709, DOI 10.1007/s10522-015-9607-7; Dicks N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00011; Dorard C, 2011, NAT MED, V17, P1283, DOI 10.1038/nm.2457; Dote H, 2006, CANCER RES, V66, P9211, DOI 10.1158/0008-5472.CAN-06-2181; Duan YY, 2014, CELL STRESS CHAPERON, V19, P271, DOI 10.1007/s12192-013-0454-7; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; Echtenkamp FJ, 2016, MOL CELL, V64, P888, DOI 10.1016/j.molcel.2016.09.040; Elaimy AL, 2016, ONCOTARGET, V7, P82450, DOI 10.18632/oncotarget.12557; Ernst A, 2015, CANCER LETT, V365, P211, DOI 10.1016/j.canlet.2015.05.024; Fang QR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5503; Fewell SW, 2004, J BIOL CHEM, V279, P51131, DOI 10.1074/jbc.M404857200; Fu WM, 2014, CELL BIOL INT, V38, P272, DOI 10.1002/cbin.10193; Garrido C, 2012, M S-MED SCI, V28, P9, DOI 10.1051/medsci/2012281002; Gibert B, 2011, ONCOGENE, V30, P3672, DOI 10.1038/onc.2011.73; Goldfless SJ, 2006, MOL CELL, V21, P595, DOI 10.1016/j.molcel.2006.01.025; Gozzi G, 2019, CELL DEATH DIFFER; Gupta SD, 2019, EUR J MED CHEM, V178, P48, DOI 10.1016/j.ejmech.2019.05.073; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; Gvozdenov Z, 2019, COLD SPRING HARB PER; Ha K, 2011, MOL CANCER THER, V10, P1194, DOI 10.1158/1535-7163.MCT-11-0094; Heidinger-Pauli JM, 2008, MOL CELL, V31, P47, DOI 10.1016/j.molcel.2008.06.005; Heinrich JC, 2011, J CANCER RES CLIN, V137, P1349, DOI 10.1007/s00432-011-1005-1; Her J, 2018, J BIOL CHEM, V293, P10502, DOI 10.1074/jbc.TM118.000371; Huang KH, 2009, J MED CHEM, V52, P4288, DOI 10.1021/jm900230j; Huang QR, 2017, BLOOD, V129, P2737, DOI 10.1182/blood-2016-08-735886; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Imahori T, 2017, NEUROSCIENCE, V349, P1, DOI 10.1016/j.neuroscience.2017.02.036; Isaacs JS, 2016, ADV CANCER RES, V129, P107, DOI 10.1016/bs.acr.2015.09.003; Jang WJ, 2014, CANCER SCI, V105, P1245, DOI 10.1111/cas.12497; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Jez JM, 2003, CHEM BIOL, V10, P361, DOI 10.1016/S1074-5521(03)00075-9; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Kai M, 2003, ONCOL REP, V10, P1777; Kasioulis I, 2014, MOL BIOL CELL, V25, P1216, DOI 10.1091/mbc.E13-08-0471; Katsogiannou M, 2014, MOL CELL PROTEOMICS, V13, P3585, DOI 10.1074/mcp.M114.041228; Kenny GP, 1997, EUR J APPL PHYSIOL O, V76, P109, DOI 10.1007/s004210050221; Kenny MK, 2001, J BIOL CHEM, V276, P9532, DOI 10.1074/jbc.M009297200; Khuran N, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00225-18; Kim SH, 2012, J MED CHEM, V55, P7480, DOI 10.1021/jm3004619; Kim W, 2019, NEUROCHEM INT, V129, DOI 10.1016/j.neuint.2019.104477; Kimura A, 2016, ONCOTARGET, V7, P18415, DOI 10.18632/oncotarget.7821; Ko JC, 2012, REGUL TOXICOL PHARM, V64, P415, DOI 10.1016/j.yrtph.2012.10.003; Koll TT, 2008, MOL CANCER THER, V7, P1985, DOI 10.1158/1535-7163.MCT-07-2104; Kotoglou P, 2009, CELL STRESS CHAPERON, V14, P391, DOI 10.1007/s12192-008-0093-6; Lee Y, 2016, RADIOTHER ONCOL, V121, P162, DOI 10.1016/j.radonc.2016.08.029; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li Q, 2011, RADIAT RES, V176, P17, DOI 10.1667/RR2393.1; Li QQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00143-6; Li XK, 2013, ACS MED CHEM LETT, V4, P1042, DOI 10.1021/ml400204n; Litwin I, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120581; Liu YJ, 2019, CANCER RES, V79, P2923, DOI 10.1158/0008-5472.CAN-18-2540; Liu YH, 2016, ARCH BIOCHEM BIOPHYS, V594, P18, DOI 10.1016/j.abb.2016.02.018; Luengo TM, 2019, TRENDS CELL BIOL, V29, P164, DOI 10.1016/j.tcb.2018.10.004; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; Mattoo RUH, 2013, J BIOL CHEM, V288, P21399, DOI 10.1074/jbc.M113.479253; Mendez F, 2003, CELL STRESS CHAPERON, V8, P153, DOI 10.1379/1466-1268(2003)008<0153:HSPSOT>2.0.CO;2; Mittelman D, 2010, CELL STRESS CHAPERON, V15, P753, DOI 10.1007/s12192-010-0191-0; Miyata Y, 2013, ACS CHEM NEUROSCI, V4, P930, DOI 10.1021/cn300210g; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; Nadin SB, 2007, CANCER LETT, V252, P131, DOI 10.1016/j.canlet.2006.12.028; Naim V, 2009, CELL CYCLE, V8, P2907, DOI 10.4161/cc.8.18.9538; Castro GN, 2015, CELL STRESS CHAPERON, V20, P253, DOI 10.1007/s12192-014-0537-0; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Noguchi M, 2006, BIOCHEM BIOPH RES CO, V351, P658, DOI 10.1016/j.bbrc.2006.10.094; Nomura M, 2005, BIOCHEM BIOPH RES CO, V335, P900, DOI 10.1016/j.bbrc.2005.07.160; Obermann WMJ, 2018, J BIOL CHEM, V293, P16479, DOI 10.1074/jbc.RA118.003578; Oda T, 2007, BLOOD, V109, P5016, DOI 10.1182/blood-2006-08-038638; Olotu F, 2018, EXPERT OPIN DRUG DIS, V13, P903, DOI 10.1080/17460441.2018.1516035; Pannunzio NR, 2018, J BIOL CHEM, V293, P10512, DOI 10.1074/jbc.TM117.000374; Park C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7823; Park KC, 2000, ARCH DERMATOL RES, V292, P482, DOI 10.1007/s004030000173; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Quanz M, 2012, J BIOL CHEM, V287, P8803, DOI 10.1074/jbc.M111.320887; Rampelt H, 2012, EMBO J, V31, P4221, DOI 10.1038/emboj.2012.264; Rauch JN, 2014, J BIOL CHEM, V289, P1402, DOI 10.1074/jbc.M113.521997; Rerole AL, 2011, CANCER RES, V71, P484, DOI 10.1158/0008-5472.CAN-10-1443; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Rosenzweig R, 2019, NAT REV MOL CELL BIO; Rousaki A, 2011, J MOL BIOL, V411, P614, DOI 10.1016/j.jmb.2011.06.003; Sallmyr A, 2018, J BIOL CHEM, V293, P10536, DOI 10.1074/jbc.TM117.000375; Scaltriti M, 2011, MOL CANCER THER, V10, P817, DOI 10.1158/1535-7163.MCT-10-0966; Scharer OD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012609; Schmitt E, 2003, CANCER RES, V63, P8233; Schrank B, 2019, J CELL BIOL, V218, P2444, DOI 10.1083/jcb.201904202; Sekimoto T, 2010, MOL CELL, V37, P79, DOI 10.1016/j.molcel.2009.12.015; Soga S, 2003, CURR CANCER DRUG TAR, V3, P359, DOI 10.2174/1568009033481859; Solier S, 2012, P NATL ACAD SCI USA, V109, P12866, DOI 10.1073/pnas.1203617109; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Sottile ML, 2018, CELL STRESS CHAPERON, V23, P303, DOI 10.1007/s12192-017-0843-4; Sottile ML, 2015, INT J HYPERTHER, V31, P464, DOI 10.3109/02656736.2015.1026848; Stangl S, 2011, P NATL ACAD SCI USA, V108, P733, DOI 10.1073/pnas.1016065108; Stecklein SR, 2012, P NATL ACAD SCI USA, V109, P13650, DOI 10.1073/pnas.1203326109; Suhane T, 2015, EUKARYOT CELL, V14, P64, DOI 10.1128/EC.00159-14; Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103; Taherian A, 2008, BIOCHEM CELL BIOL, V86, P37, DOI [10.1139/O07-154, 10.1139/o07-154]; Thomas X, 2005, LEUKEMIA RES, V29, P1049, DOI 10.1016/j.leukres.2005.02.010; Wallace SS, 2014, DNA REPAIR, V19, P14, DOI 10.1016/j.dnarep.2014.03.030; Wang X, 2010, CANCER INVEST, V28, P635, DOI 10.3109/07357901003630983; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Wano C, 2004, EXP CELL RES, V298, P584, DOI 10.1016/j.yexcr.2004.04.048; Weatherbee JL, 2016, ONCOTARGET, V7, P43820, DOI 10.18632/oncotarget.9907; Whitaker AM, 2017, FRONT BIOSCI-LANDMRK, V22, P1493, DOI 10.2741/4555; Woodhead AJ, 2010, J MED CHEM, V53, P5956, DOI 10.1021/jm100060b; Wright WD, 2018, J BIOL CHEM, V293, P10524, DOI 10.1074/jbc.TM118.000372; Xu YM, 2013, CELL SIGNAL, V25, P1176, DOI 10.1016/j.cellsig.2013.01.017; Yamamori T, 2013, FEBS LETT, V587, P3348, DOI 10.1016/j.febslet.2013.08.030; Yamamoto Y, 2018, BRAIN RES, V1687, P82, DOI 10.1016/j.brainres.2018.03.001; Yamashita T, 2007, CELL CYCLE, V6, P2232, DOI 10.4161/cc.6.18.4653; Yang J, 2009, TOXICOLOGY, V265, P10, DOI 10.1016/j.tox.2009.09.001; Yang YH, 2019, CELL MOL LIFE SCI, V76, P381, DOI 10.1007/s00018-018-2957-y; Zabinsky RA, 2019, SEMIN CELL DEV BIOL, V88, P21, DOI 10.1016/j.semcdb.2018.05.015; Zaidi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035436; Zemanovic S, 2018, CELL REP, V25, P2605, DOI 10.1016/j.celrep.2018.11.015; Zhou X, 2015, HUM MOL GENET, V24, P3982, DOI 10.1093/hmg/ddv136	139	49	51	4	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					516	529		10.1038/s41388-019-1016-y	http://dx.doi.org/10.1038/s41388-019-1016-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31541194				2022-12-17	WOS:000509718300003
J	Ma, AH; Tang, M; Zhang, L; Wang, BS; Yang, ZJ; Liu, Y; Xu, GQ; Wu, L; Jing, TT; Xu, XL; Yang, SL; Liu, YZ				Ma, Aihui; Tang, Ming; Zhang, Li; Wang, Boshi; Yang, Zhaojuan; Liu, Yun; Xu, Guiqin; Wu, Lin; Jing, Tiantian; Xu, Xiaoli; Yang, Shengli; Liu, Yongzhong			USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis	ONCOGENE			English	Article							MULTIPLE-MYELOMA; STEM-CELLS; EXPRESSION; DEUBIQUITINATION; CARCINOMAS; SURVIVAL; RNA	Metastatic progression is the main cause of mortality in breast cancer, necessitating the determination of the molecular events driving this process for the development of new therapeutic approaches. Here, we demonstrate that hyperactivation of the deubiquitinase USP1 contributes to breast cancer metastasis. Upregulated USP1 expression in primary breast cancer specimens correlates with metastatic progression and poor prognosis in breast cancer patients. USP1 enhances the expression of a number of pro-metastatic genes in breast cancer cells, promotes cell migration and invasion in vitro, and facilitates lung metastasis of breast cancer cells. Moreover, USP1-mediated deubiquitination and stabilization of KPNA2 are revealed as the downstream events crucial for USP1-pro-metastatic function. Most importantly, pharmacological intervention of USP1 function by pimozide or ML323 significantly represses breast cancer metastasis in mice, suggesting a rationale for using USP1 inhibitors for treatment of patients with breast cancer. Taken together, our results establish USP1 as a promoter of breast cancer metastasis and provide evidence for the potential practice of USP1 targeting in the treatment of breast cancer.	[Ma, Aihui; Tang, Ming; Zhang, Li; Wang, Boshi; Yang, Zhaojuan; Liu, Yun; Xu, Guiqin; Wu, Lin; Jing, Tiantian; Xu, Xiaoli; Yang, Shengli; Liu, Yongzhong] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University	Liu, YZ (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China.	liuyzg@shsci.org		Liu, Yongzhong/0000-0002-1477-116X	National Natural Science Foundation of China [81572293, 31770976, 81672359]; Natural Science Foundation of Shanghai [18ZR1436800]; State Key Laboratory of Oncogenes and Related Genes [91-1705, 91-17-11]; Shanghai Cancer Institute [SB18-07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); State Key Laboratory of Oncogenes and Related Genes; Shanghai Cancer Institute	This work was supported by the National Natural Science Foundation of China (81572293, 31770976, and 81672359), Natural Science Foundation of Shanghai (18ZR1436800), the State Key Laboratory of Oncogenes and Related Genes (91-1705, 91-17-11), and Shanghai Cancer Institute (SB18-07).	Altan B, 2013, CARCINOGENESIS, V34, P2314, DOI 10.1093/carcin/bgt214; Auslander D, 2018, NAT METHODS, V15, P57, DOI [10.1038/nmeth.4505, 10.1038/NMETH.4505]; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Brown D, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms14944, 10.1038/ncomms15759]; Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dankof A, 2007, VIRCHOWS ARCH, V451, P877, DOI 10.1007/s00428-007-0513-5; Das DS, 2017, CLIN CANCER RES, V23, P4280, DOI 10.1158/1078-0432.CCR-16-2692; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Fujiwara T, 1998, GENOMICS, V54, P155, DOI 10.1006/geno.1998.5554; Gluz O, 2008, INT J CANCER, V123, P1433, DOI 10.1002/ijc.23628; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jensen JB, 2011, EUR UROL, V59, P841, DOI 10.1016/j.eururo.2011.01.048; Kane RC, 2006, CLIN CANCER RES, V12, P2955, DOI 10.1158/1078-0432.CCR-06-0170; Lee JK, 2016, NEURO-ONCOLOGY, V18, P37, DOI 10.1093/neuonc/nov091; Liang Q, 2014, NAT CHEM BIOL, V10, P298, DOI [10.1038/NCHEMBIO.1455, 10.1038/nchembio.1455]; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Mothi M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001949.pub3; Ni IBP, 2010, PATHOL RES PRACT, V206, P223, DOI 10.1016/j.prp.2009.11.006; Nicholson Benjamin, 2007, Future Oncol, V3, P191, DOI 10.2217/14796694.3.2.191; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403; Oestergaard VH, 2007, MOL CELL, V28, P798, DOI 10.1016/j.molcel.2007.09.020; Ogrunc M, 2016, CELL REP, V15, P1401, DOI 10.1016/j.celrep.2016.04.033; Rahme GJ, 2016, CANCER RES, V76, P2964, DOI 10.1158/0008-5472.CAN-15-2157; Raimondi M, 2016, CELL CYCLE, V15, P106, DOI 10.1080/15384101.2015.1121325; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rudland PS, 2000, CANCER RES, V60, P1595; Sampieri K, 2012, SEMIN CANCER BIOL, V22, P187, DOI 10.1016/j.semcancer.2012.03.002; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; TUETH MJ, 1993, SOUTH MED J, V86, P344, DOI 10.1097/00007611-199303000-00019; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Xiao ZN, 2016, CANCER METAST REV, V35, P589, DOI 10.1007/s10555-016-9640-2; Yu ZX, 2017, J EXP MED, V214, P3553, DOI 10.1084/jem.20170180; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang L, 2012, NAT CELL BIOL, V14, P717, DOI 10.1038/ncb2522	50	49	53	5	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2405	2419		10.1038/s41388-018-0590-8	http://dx.doi.org/10.1038/s41388-018-0590-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30531833				2022-12-17	WOS:000462588000013
J	Liu, Y; Li, F; Yang, YT; Xu, XD; Chen, JS; Chen, TL; Chen, HJ; Zhu, YB; Lin, JY; Li, Y; Xie, XM; Sun, XL; Ke, YQ				Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.			IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma	ONCOGENE			English	Article							FACTOR-BINDING PROTEIN-2; STEM-LIKE CELLS; HUMAN-MELANOMA CELLS; VASCULAR MIMICRY; GENE-EXPRESSION; GROWTH; CHEMORESISTANCE; IDENTIFICATION; MIGRATION; THERAPY	Vasculogenic mimicry (VM) refers to the fluid-conducting channels formed by aggressive tumor cells rather than endothelial cells (EC) with elevated expression of genes associated with vascularization. VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy. However, the molecular basis underlying VM formation remains unclear. Here we report that the insulin-like growth factor-binding protein 2 (IGFBP2) acts as a potent factor to enhance VM formation in glioma. Evidence showed that elevated IGFBP2 expression was positively related with VM formation in patients with glioma. Enforced expression of IGFBP2 increased network formation of glioma cells in vitro by activating CD144 and MMP2 (Matrix Metalloproteinase 2). U251 cells with stable knockdown of IGFBP2 led to decreased VM formation and tumor progression in orthotopic mouse model. Mechanistically, IGFBP2 interacts with integrin alpha 5 and beta 1 subunits and augments CD144 expression in a FAK/ERK pathway-dependent manner. Luciferase reporter and ChIP assay suggested that IGFBP2 activated the transcription factor SP1, which could bind to CD144 promoter. Thus, IGFBP2 acts as a stimulator of VM formation in glioma cells via enhancing CD144 and MMP2 expression.	[Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.] Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.] Educ Minist China, Engn Technol Res Ctr, Natl Key Clin Specialty, Guangzhou, Guangdong, Peoples R China; [Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.] Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Sun, XL; Ke, YQ (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.; Sun, XL; Ke, YQ (corresponding author), Educ Minist China, Engn Technol Res Ctr, Natl Key Clin Specialty, Guangzhou, Guangdong, Peoples R China.; Sun, XL; Ke, YQ (corresponding author), Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou, Guangdong, Peoples R China.	zjsunxinlin@163.com; kyquan@smu.edu.cn			National Natural Science Foundation of China [81772651, 81772652]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81772651 and No. 81772652)	Biernacka KM, 2013, ENDOCR-RELAT CANCER, V20, P741, DOI 10.1530/ERC-13-0077; Braghiroli MI, 2017, EXPERT REV ANTICANC, V12, P567; Chen XL, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-72; Chiao MT, 2011, CURR NEUROVASC RES, V8, P210, DOI 10.2174/156720211796558023; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Dvorak HF, 2015, CANCER J, V21, P237, DOI 10.1097/PPO.0000000000000124; El Hallani S, 2010, BRAIN, V133, P973, DOI 10.1093/brain/awq044; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540; Frommer KW, 2006, J MOL ENDOCRINOL, V37, P13, DOI 10.1677/jme.1.01955; Fuller GN, 1999, CANCER RES, V59, P4228; Gao S, 2016, CANCER RES, V76, P6543, DOI 10.1158/0008-5472.CAN-16-0438; Godard S, 2003, CANCER RES, V63, P6613; Guo P, 2005, AM J PATHOL, V166, P877, DOI 10.1016/S0002-9440(10)62308-5; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Huang YF, 2014, ENDOCR-RELAT CANCER, V21, P217, DOI 10.1530/ERC-13-0274; Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Kuhnl A, 2011, LEUKEMIA RES, V35, P1585, DOI 10.1016/j.leukres.2011.08.006; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Lai CY, 2012, CANCER RES, V72, P5111, DOI 10.1158/0008-5472.CAN-12-0624; Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85; Liu X, 2015, CANCER SCI, V106, P857, DOI 10.1111/cas.12684; Liu XM, 2011, J NEURO-ONCOL, V105, P173, DOI 10.1007/s11060-011-0578-5; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mei X, 2017, NEURO-ONCOLOGY, V42, P1; Mendes KN, 2010, INT J ONCOL, V37, P143, DOI 10.3892/ijo_00000662; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Norden AD, 2009, J NEURO-ONCOL, V92, P149, DOI 10.1007/s11060-008-9745-8; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Ping YF, 2011, CURR MOL MED, V11, P69, DOI 10.2174/156652411794474383; Renehan AG, 2000, BRIT J CANCER, V83, P1344, DOI 10.1054/bjoc.2000.1462; Russo VC, 2015, CYTOKINE GROWTH F R, V26, P329, DOI 10.1016/j.cytogfr.2014.12.001; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Sallinen SL, 2000, CANCER RES, V60, P6617; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Scully S, 2012, J NEUROSCI, V32, P12950, DOI 10.1523/JNEUROSCI.2017-12.2012; Seftor REB, 2001, CANCER RES, V61, P6322; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Uzoh CC, 2011, BRIT J CANCER, V104, P1587, DOI 10.1038/bjc.2011.127; Velez DO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01556-7; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang H, 2003, CANCER RES, V63, P4315; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141	51	49	52	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1815	1831		10.1038/s41388-018-0525-4	http://dx.doi.org/10.1038/s41388-018-0525-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30368528				2022-12-17	WOS:000461164400003
J	Wang, HN; Deng, GX; Ai, ML; Xu, ZJ; Mou, TY; Yu, J; Liu, H; Wang, S; Li, GX				Wang, Huanan; Deng, Guangxu; Ai, Meiling; Xu, Zhijun; Mou, Tingyu; Yu, Jiang; Liu, Hao; Wang, Shuang; Li, Guoxin			Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/beta-catenin signaling pathways in gastric cancer progression	ONCOGENE			English	Article							SHOCK-PROTEIN 90; HIGH-LEVEL EXPRESSION; LUNG-CANCER; PERITONEAL DISSEMINATION; CELL-PROLIFERATION; DOWN-REGULATION; POOR SURVIVAL; BETA-CATENIN; ER STRESS; METASTASIS	Hsp90ab1 is upregulated in numerous solid tumors, which is thought to induce the angiogenesis and promote cancer metastasis. However, it's actions in gastric cancer (GC) has not been exhibited. In this study, Hsp90ab1 was demonstrated to be overexpressed and correlated with the poor prognosis, proliferation and invasion of GC. Ectopic expression of Hsp90ab1 promoted the proliferation and metastasis of GC cells both in vitro in cell line models of GC and in vivo using two different xenograft mouse models, while opposite effects were observed in Hsp90ab1 silenced cells. Moreover, the underlining molecular mechanism was explored by the co-immunoprecipitation, immunofluorescence, GST pull-down and in vitro ubiquitination assay. Namely, Hsp90ab1 exerted these functions via the interaction of LRP5 and inhibited ubiquitin-mediated degradation of LRP5, an indispensable coreceptor of the Wnt/beta-catenin signaling pathway. In addition, the crosstalk between Hsp90ab1 and LRP5 contributed to the upregulation of multiple mesenchymal markers, which are also targets of Wnt/beta-catenin. Collectively, this study uncovers the details of the Hsp90ab1-LRP5 axis, providing novel insights into the role and mechanism of invasion and metastasis in GC.	[Wang, Huanan; Deng, Guangxu; Xu, Zhijun; Mou, Tingyu; Yu, Jiang; Liu, Hao; Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou 510515, Guangdong, Peoples R China; [Ai, Meiling; Wang, Shuang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Ai, Meiling] Guangzhou Med Univ, Dept Radiotherapy, Affiliated Canc Hosp & Inst, Guangzhou 510515, Guangdong, Peoples R China; [Wang, Shuang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University; Southern Medical University - China	Li, GX (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangdong Prov Engn Technol Res Ctr Minimally Inv, Guangzhou 510515, Guangdong, Peoples R China.; Wang, S (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Wang, S (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.	shuangw@126.com; gzliguoxin@163.com	Liu, Hao/I-9884-2019	Liu, Hao/0000-0003-1227-2954	State's Key Project of Research and Development Plan [2017YFC0108300, 2017YFC0108301]; National Natural Science Foundation of China [81672446]; Guangdong Provincial Science and Technology Key Project [2014A020215014]; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China [201402015]; Southern Medical University Clinical Research Start-Up Project [LC2016ZD003]; Guangzhou Science and Technology Project [201400000004-5]; Key Clinical Specialty Discipline Construction Program [[2011]170]	State's Key Project of Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Key Project; Research Fund of Public Welfare in the Health Industry; National Health and Family Planning Commission of China; Southern Medical University Clinical Research Start-Up Project; Guangzhou Science and Technology Project; Key Clinical Specialty Discipline Construction Program	This work was supported by the grants from the State's Key Project of Research and Development Plan (2017YFC0108300, 2017YFC0108301), National Natural Science Foundation of China (81672446), Guangdong Provincial Science and Technology Key Project (2014A020215014), Research Fund of Public Welfare in the Health Industry, the National Health and Family Planning Commission of China (201402015), the Southern Medical University Clinical Research Start-Up Project (LC2016ZD003), Guangzhou Science and Technology Project (201400000004-5) and the Key Clinical Specialty Discipline Construction Program ([2011]170).	Cai J, 2015, BRIT J CANCER, V113, P1720, DOI 10.1038/bjc.2015.367; Canella A, 2017, CLIN CANCER RES, V23, P6215, DOI 10.1158/1078-0432.CCR-16-3151; Casagolda D, 2010, J CELL SCI, V123, P2621, DOI 10.1242/jcs.067512; Chen DH, 2017, CELL PHYSIOL BIOCHEM, V42, P1025, DOI 10.1159/000478685; Chen Y, 2017, CLIN CANCER RES, V23, P1552, DOI 10.1158/1078-0432.CCR-16-1333; Cheng Q, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3168; Choi HJ, 2018, JNCI-J NATL CANCER I, V110, P400, DOI 10.1093/jnci/djx207; Correia AL, 2013, GENE DEV, V27, P805, DOI 10.1101/gad.211383.112; de la Mare JA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3190-z; DeBruine ZJ, 2017, GENE DEV, V31, P916, DOI 10.1101/gad.298331.117; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Fu YJ, 2011, INT J CANCER, V129, P1541, DOI 10.1002/ijc.26102; Giessrigl B, 2012, HUM MOL GENET, V21, P4615, DOI 10.1093/hmg/dds303; Gu Y, 2016, J PATHOL, V239, P60, DOI 10.1002/path.4697; Ha GH, 2013, CANCER LETT, V332, P63, DOI 10.1016/j.canlet.2013.01.013; Hamamoto R, 2014, CANCER LETT, V351, P126, DOI 10.1016/j.canlet.2014.05.014; Hu YF, 2016, J CLIN ONCOL, V34, P1350, DOI 10.1200/JCO.2015.63.7215; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; Jeon YK, 2007, J PATHOL, V213, P170, DOI 10.1002/path.2219; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kannan A, 2014, EUR J CANCER, V50, P204, DOI 10.1016/j.ejca.2013.08.016; Kim SH, 2015, HISTOPATHOLOGY, V67, P509, DOI 10.1111/his.12675; Knoblich K, 2014, CELL MOL LIFE SCI, V71, P1305, DOI 10.1007/s00018-013-1444-8; Kurashige J, 2015, CARCINOGENESIS, V36, P133, DOI 10.1093/carcin/bgu232; Li CF, 2008, CLIN CANCER RES, V14, P7822, DOI 10.1158/1078-0432.CCR-08-1369; Li S, 2017, ONCOL REP, V37, P849, DOI 10.3892/or.2016.5295; Liang L, 2013, GASTROENTEROLOGY, V144, P624, DOI 10.1053/j.gastro.2012.11.033; Liu SGH, 2015, MOL ONCOL, V9, P834, DOI 10.1016/j.molonc.2014.12.009; Lyou Y, 2017, BRIT J PHARMACOL, V174, P4589, DOI 10.1111/bph.13963; Marzook H, 2017, ONCOGENE, V36, P5263, DOI 10.1038/onc.2017.19; Meng J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0640-9; Ohkubo S, 2015, MOL CANCER THER, V14, P14, DOI 10.1158/1535-7163.MCT-14-0219; Okubo K, 2017, GASTRIC CANCER, V20, P802, DOI 10.1007/s10120-017-0705-x; Park S, 2017, REDOX BIOL, V13, P470, DOI 10.1016/j.redox.2017.07.010; Pavlakis N, 2016, J CLIN ONCOL, V34, P2728, DOI 10.1200/JCO.2015.65.1901; Perotti C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2193; Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511; Qiu SL, 2015, J PATHOL, V237, P330, DOI 10.1002/path.4579; Rong BX, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-70; Saveliev SV, 2013, ANAL CHEM, V85, P907, DOI 10.1021/ac302423t; Shi ZM, 2017, ONCOGENE, V36, P2577, DOI 10.1038/onc.2016.414; Singh A, 2015, J INVEST DERMATOL, V135, P1098, DOI 10.1038/jid.2014.460; Sun Y, 2018, THERANOSTICS, V8, P2044, DOI 10.7150/thno.23304; Tsutsumi S, 2009, FUTURE ONCOL, V5, P679, DOI 10.2217/FON.09.30; Verba KA, 2016, SCIENCE, V352, P1542, DOI 10.1126/science.aaf5023; Vinyoles M, 2017, ONCOGENE, V36, P429, DOI 10.1038/onc.2016.209; Wang KN, 2016, GUT, V65, P1619, DOI 10.1136/gutjnl-2015-309276; Wang L, 2016, GASTROENTEROLOGY, V150, P1183, DOI 10.1053/j.gastro.2016.01.034; Westekemper H, 2011, BRIT J OPHTHALMOL, V95, P853, DOI 10.1136/bjo.2010.183939; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wu SM, 2016, J PINEAL RES, V60, P142, DOI 10.1111/jpi.12295; Wu YK, 2015, INT J CLIN EXP PATHO, V8, P8252; Xiao HJ, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578-018-0221-7; Xiong XY, 2014, EXP CELL RES, V326, P78, DOI 10.1016/j.yexcr.2014.05.018; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Yang SS, 2017, BRIT J CANCER, V117, P1164, DOI 10.1038/bjc.2017.260; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Zhang B, 2015, CANCER LETT, V356, P704, DOI 10.1016/j.canlet.2014.10.016; Zhang P, 2017, BRIT J CANCER, V117, P525, DOI 10.1038/bjc.2017.181; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254; Zhao X, 2014, CELL DEATH DIFFER, V21, P1900, DOI 10.1038/cdd.2014.109; Zheng RS, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0234-3; Zhu XH, 2017, INT J CANCER, V141, P172, DOI 10.1002/ijc.30701	63	49	50	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1489	1507		10.1038/s41388-018-0532-5	http://dx.doi.org/10.1038/s41388-018-0532-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305727	hybrid, Green Published			2022-12-17	WOS:000459945800009
J	Stylianou, N; Lehman, ML; Wang, C; Fard, AT; Rockstroh, A; Fazli, L; Jovanovic, L; Ward, M; Sadowski, MC; Kashyap, AS; Buttyan, R; Gleave, ME; Westbrook, TF; Williams, ED; Gunter, JH; Nelson, CC; Hollier, BG				Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Fazli, Ladan; Jovanovic, Lidija; Ward, Micheal; Sadowski, Martin C.; Kashyap, Abhishek S.; Buttyan, Ralph; Gleave, Martin E.; Westbrook, Thomas F.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.			A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; ANDROGEN RECEPTOR; FREE SURVIVAL; CELL-CYCLE; TRANSITION; TUMOR; METASTASIS; PROGRESSION; REVEALS; EMT	The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial-mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations using reversible models of EMT, revealed the mesenchymal-to-epithelial reverting transition (MErT) to be enriched in clinical samples of metastatic castrate resistant prostate cancer (mCRPC). From this enrichment, a metastasis-derived gene signature was identified that predicted more rapid cancer relapse and reduced survival across multiple human carcinoma types. Additionally, the transcriptional profile of MErT is not a simple mirror image of EMT as tumour cells retain a transcriptional "memory" following a reversible EMT. This memory was also enriched in mCRPC samples. Cumulatively, our studies reveal the transcriptional profile of epithelial-mesenchymal plasticity and highlight the unique transcriptional properties of MErT. Furthermore, our findings provide evidence to support the association of epithelial plasticity with poor clinical outcomes in multiple human carcinoma types.	[Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Jovanovic, Lidija; Sadowski, Martin C.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Inst Hlth & Biomed Innovat, Fac Hlth,Sch Biomed Sci,Princess Alexandra Hosp,T, Brisbane, Qld, Australia; [Lehman, Melanie L.; Fazli, Ladan; Buttyan, Ralph; Gleave, Martin E.] Univ British Columbia, Dept Urol Sci, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Ward, Micheal] Univ Queensland, Sch Med, Translat Res Inst, Glycat & Diabet Complicat Grp,Mater Res Inst, Brisbane, Qld, Australia; [Kashyap, Abhishek S.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld, Australia; [Westbrook, Thomas F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Queensland University of Technology (QUT); University of British Columbia; Mater Research; University of Queensland; Queensland University of Technology (QUT); Baylor College of Medicine	Hollier, BG (corresponding author), Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Inst Hlth & Biomed Innovat, Fac Hlth,Sch Biomed Sci,Princess Alexandra Hosp,T, Brisbane, Qld, Australia.	b.hollier@qut.edu.au	Fard, Ati/AAX-4092-2021; Gunter, Jennifer H/B-8960-2016; Stylianou, Nataly/GOP-1782-2022; Williams, Elizabeth D/B-1538-2008	Gunter, Jennifer H/0000-0003-2447-5732; Williams, Elizabeth D/0000-0002-3364-6655; Taherian Fard, Atefeh/0000-0002-9126-4540; Gleave, Martin/0000-0003-4235-0167; Wang, Chenwei/0000-0002-2097-8634; Stylianou, Nataly/0000-0002-8006-5730; Sadowski, Martin/0000-0002-5267-1442	Australian Government Department of Health; Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; National Health and Medical Research Council of Australia [1100417]	Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Queensland Government National and International Research Alliance Program; Movember Foundation; Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This research was supported by funding from the Australian Government Department of Health, Queensland Government National and International Research Alliance Program funding to the Australian-Canadian Prostate Cancer Research Alliance as well as by the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award. This work was also supported by funding from the National Health and Medical Research Council of Australia (ID 1100417 to CC Nelson, BG Hollier, ML Lehman and ME Gleave).	Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bishop JL, 2015, ENDOCR-RELAT CANCER, V22, pR165, DOI 10.1530/ERC-15-0137; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chikaish Y, 2011, ANTICANCER RES, V31, P4451; Colditz J, 2016, MOL CELL BIOCHEM, V421, P139, DOI 10.1007/s11010-016-2794-y; Cooperberg MR, 2013, J CLIN ONCOL, V31, P1428, DOI 10.1200/JCO.2012.46.4396; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Du LT, 2016, CANCER MED-US, V5, P1962, DOI 10.1002/cam4.719; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Hoshino H, 2009, BIOCHEM BIOPH RES CO, V390, P1061, DOI 10.1016/j.bbrc.2009.10.117; HUBERT L, 1985, J CLASSIF, V2, P193, DOI 10.1007/BF01908075; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034; Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; LaTulippe E, 2002, CANCER RES, V62, P4499; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li HY, 2015, CELL SIGNAL, V27, P82, DOI 10.1016/j.cellsig.2014.09.018; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Ma ZF, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0042-9; Malek JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028561; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miao L, 2017, CANCER RES, V77, P3101, DOI 10.1158/0008-5472.CAN-16-2169; Nouri M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00370; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Pereira L, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00013; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773; Rokavec M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04234-2; Sadowski MC, 2014, ONCOTARGET, V5, P9362, DOI 10.18632/oncotarget.2433; Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032; Sethi S, 2011, AM J TRANSL RES, V3, P90; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979; Sieh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040217; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Ware KE, 2016, ONCOTARGET, V7, P50520, DOI 10.18632/oncotarget.10476; Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800; Ye X, 2017, NATURE, V547, pE1, DOI 10.1038/nature22816; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	69	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					913	934		10.1038/s41388-018-0488-5	http://dx.doi.org/10.1038/s41388-018-0488-5			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30194451	Green Published, hybrid			2022-12-17	WOS:000458624900001
J	Xu, YF; Liu, ZL; Pan, C; Yang, XQ; Ning, SL; Liu, HD; Guo, S; Yu, JM; Zhang, ZL				Xu, Yun-Fei; Liu, Zeng-Li; Pan, Chang; Yang, Xiao-Qing; Ning, Shang-Lei; Liu, Hong-Da; Guo, Sen; Yu, Jin-Ming; Zhang, Zong-Li			HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium	ONCOGENE			English	Article							EXPRESSION; CONTRIBUTES; PROGRESSION; INJURY	Perihilar cholangiocarcinoma (PHCCA) is the most common type of cholangiocarcinoma with low resection rate and high morbidity. The study of PHCCA biomarkers made progresses slowly compared with intrahepatic cholangiocarcinoma because of surgical complexity and low possibility of radical surgery, which resulted in the difficulty of specimen obtainment. To screen and identify new biomarkers in PHCCA, we constructed a retrospective cohort with 121 PHCCA patients and a prospective cohort consisting of 64 PHCCA patients, and screened the candidate biomarkers by immunohistochemistry and quantified PCR. In our study, expression of high mobility group box 1 (HMGB1) was demonstrated to be significantly associated with microvascular density (MVD) and unfavorable prognosis of PHCCA in both retrospective and prospective study. Moreover, HMGB1 concentrations in bile and serum of PHCCA patients and healthy controls were detected and compared. Postoperative serum HMGB1 and reflux cholangitis indicated recurrence and unfavorable prognosis of PHCCA. With experiments in vitro and in vivo, we demonstrated that intracellular HMGB1 could be released from PHCCA cells and induce invasion and angiogenesis with LPS stimulation. VEGFR2 expression in vessel endothelial cells was upregulated by the released HMGB1 from PHCCA, resulting in the ectopic angiogenesis. In conclusion, intracellular HMGB1 could be released from PHCCA cells and promote angiogenesis via elevating VEGFR2 in vessel endothelial cells. High expression of HMGB1 was associated with MVD and poor prognosis in clinical analyzation. Postoperative serum HMGB1 and cholangitis could predict high recurrence and unfavorable prognosis.	[Xu, Yun-Fei; Liu, Zeng-Li; Ning, Shang-Lei; Guo, Sen; Zhang, Zong-Li] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Shandong, Peoples R China; [Pan, Chang] Shandong Univ, Dept Emergency Med, Qilu Hosp, Jinan, Shandong, Peoples R China; [Pan, Chang] Shandong Univ, Chest Pain Ctr, Qilu Hosp, Jinan, Shandong, Peoples R China; [Yang, Xiao-Qing] Shandong Univ, Dept Pathol, Qianfoshan Hosp, Jinan, Shandong, Peoples R China; [Liu, Hong-Da] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Yu, Jin-Ming] Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; University of Jinan	Zhang, ZL (corresponding author), Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Shandong, Peoples R China.; Yu, JM (corresponding author), Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.	sdyujinming@163.com; zzlzzl1900@163.com	guo, sen/GWQ-3573-2022	Liu, Hongda/0000-0002-5977-9130	National Natural Science Foundation of China [81601668, 31701013]; Shandong Province Major Research and Design Program [2017GSF218059, 2016GSF201132]; Natural Science Foundation of Shandong [ZR2017BC032]; China Postdoctoral Science Foundation [2017M610167, 2017T100163]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Province Major Research and Design Program; Natural Science Foundation of Shandong(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The study was supported by National Natural Science Foundation of China (Grant Nos. 81601668 and 31701013), Shandong Province Major Research and Design Program (Grant Nos. 2017GSF218059 and 2016GSF201132), Natural Science Foundation of Shandong (Grant No. ZR2017BC032), and China Postdoctoral Science Foundation (Grant Nos. 2017M610167 and 2017T100163).	Avgousti DC, 2016, NATURE, V535, P173, DOI 10.1038/nature18317; DeOliveira ML, 2007, ANN SURG, V245, P755, DOI 10.1097/01.sla.0000251366.62632.d3; Dixelius J, 2006, CANCER RES, V66, P2089, DOI 10.1158/0008-5472.CAN-05-2217; Gnanasekar M, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/157103; Huebener P, 2015, J CLIN INVEST, V125, P539, DOI 10.1172/JCI76887; Kang R, 2017, CELL RES, V27, P916, DOI 10.1038/cr.2017.51; Kuniyasu H, 2005, AM J PATHOL, V166, P751, DOI 10.1016/S0002-9440(10)62296-1; Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031; Lillemoe Keith D, 2003, Semin Gastrointest Dis, V14, P208; Poser I, 2003, MOL CELL BIOL, V23, P2991, DOI 10.1128/MCB.23.8.2991-2998.2003; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013; Sia D, 2013, GASTROENTEROLOGY, V144, P829, DOI 10.1053/j.gastro.2013.01.001; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; Tang DL, 2011, ANTIOXID REDOX SIGN, V14, P1315, DOI 10.1089/ars.2010.3356; van Beijnum JR, 2013, ONCOGENE, V32, P363, DOI 10.1038/onc.2012.49; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Xu YF, 2015, WORLD J GASTROENTERO, V21, P3256, DOI 10.3748/wjg.v21.i11.3256; Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050; Yang H, 2015, MOL MED, V21, pS6, DOI 10.2119/molmed.2015.00087; Yang RK, 2009, AM J PHYSIOL-REG I, V297, pR362, DOI 10.1152/ajpregu.00184.2009; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Zhang QH, 2013, AUTOPHAGY, V9, P451, DOI 10.4161/auto.23691	24	49	49	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					868	880		10.1038/s41388-018-0485-8	http://dx.doi.org/10.1038/s41388-018-0485-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177842				2022-12-17	WOS:000458006300008
J	Han, JH; Wang, FY; Lan, YL; Wang, JB; Nie, CL; Liang, YJ; Song, RP; Zheng, TS; Pan, SH; Pei, TM; Xie, CM; Yang, GC; Liu, XR; Zhu, MX; Wang, Y; Liu, Y; Meng, FZ; Cui, YF; Zhang, B; Liu, YF; Meng, XZ; Zhang, JW; Liu, LX				Han, Jihua; Wang, Fengyue; Lan, Yaliang; Wang, Jiabei; Nie, Chunlei; Liang, Yingjian; Song, Ruipeng; Zheng, Tongsen; Pan, Shangha; Pei, Tiemin; Xie, Changming; Yang, Guangchao; Liu, Xirui; Zhu, Mingxi; Wang, Yan; Liu, Yao; Meng, Fanzheng; Cui, Yifeng; Zhang, Bo; Liu, Yufeng; Meng, Xianzhi; Zhang, Jiewu; Liu, Lianxin			KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling	ONCOGENE			English	Article							CANCER; PROLIFERATION; PROGRESSION; EXPRESSION; IL-6/STAT3; MICRORNA; MIRNA; TWIST	Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. The poor survival may be due to a high proportions of tumor recurrence and metastasis. Kinesin family member C1 (KIFC1) is highly expressed in a variety of neoplasms and is a potential marker for non-small cell lung cancer or ovarian adenocarcinoma metastasis. Nevertheless, the role of KIFC1 in HCC metastasis remains obscure. We investigated this in the present study using HCC cell lines and clinical specimens. Our results indicated that increased levels of KIFC1 were associated with poor prognosis and metastasis in HCC. In addition, KIFC1 induced epithelial-to-mesenchymal transition (EMT) and HCC metastasis both in vitro and in vivo. This tumorigenic effect depended on gankyrin; inhibiting gankyrin activity reversed EMT via activation of protein kinase B (AKT)/Twist family BHLH transcription factor 1 (AKT/TWIST1). We also found that KIFC1 was directly regulated by the microRNA miR-532-3p, whose downregulation was associated with metastatic progression in HCC. These results denote that a decrease in miR-532-3p levels results in increased KIFC1 expression in HCC, leading to metastasis via activation of the gankyrin/AKT/TWIST1 signaling pathway.	[Han, Jihua; Wang, Fengyue; Lan, Yaliang; Wang, Jiabei; Liang, Yingjian; Song, Ruipeng; Pan, Shangha; Pei, Tiemin; Xie, Changming; Yang, Guangchao; Liu, Xirui; Zhu, Mingxi; Wang, Yan; Liu, Yao; Meng, Fanzheng; Cui, Yifeng; Zhang, Bo; Liu, Yufeng; Meng, Xianzhi; Liu, Lianxin] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Key Lab Hepatosplen Surg,Minist Educ, Harbin, Heilongjiang, Peoples R China; [Han, Jihua; Nie, Chunlei; Zhang, Jiewu] Harbin Med Univ, Affiliated Hosp 3, Dept Head & Neck Surg, Harbin, Heilongjiang, Peoples R China; [Zheng, Tongsen] Harbin Med Univ, Affiliated Hosp 3, Dept Gastrointestinal Med Oncol, Harbin, Heilongjiang, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University	Meng, XZ; Liu, LX (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Key Lab Hepatosplen Surg,Minist Educ, Harbin, Heilongjiang, Peoples R China.; Zhang, JW (corresponding author), Harbin Med Univ, Affiliated Hosp 3, Dept Head & Neck Surg, Harbin, Heilongjiang, Peoples R China.	mengxianzhi@sina.com; drzhangjiewu@sohu.com; liulx@ems.hrbmu.edu.cn	zheng, tongsen/ABB-9572-2021	zheng, tongsen/0000-0002-7539-3924	National Key Program for Science and Technology Research and Development [2016YFC0106503, 2016YFC0106500, 2016YFC0905902]; Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province [2009td06]; Changjiang Scholars and Innovative Research Team in University [IRT1122]; National Natural Scientific Foundation of China [81602058, 81772588, 81773194]; Hei Longjiang Postdoctoral Foundation; China Postdoctoral Science Foundation [2018M630368]; Science and Technology Research Projects of Hei Longjiang Province [GC12C304-5]; Haiyan Research Fund of the Third Affiliated Hospital of Harbin Medical University [JJZD2017-03, JJQN2018-14]; Fundamental Research Funds for the Provincial Universities [2017LCZX24]; Foundation of the First Affiliated Hospital of Harbin Medical University [2018B017]; Innovative Research Program for Graduate of Harbin Medical University [YJSCX2015-17HYD]	National Key Program for Science and Technology Research and Development; Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province; Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Hei Longjiang Postdoctoral Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Science and Technology Research Projects of Hei Longjiang Province; Haiyan Research Fund of the Third Affiliated Hospital of Harbin Medical University; Fundamental Research Funds for the Provincial Universities; Foundation of the First Affiliated Hospital of Harbin Medical University; Innovative Research Program for Graduate of Harbin Medical University	This study was supported by National Key Program for Science and Technology Research and Development (grant no. 2016YFC0106503, no. 2016YFC0106500 and no. 2016YFC0905902), Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province (grant no. 2009td06), Changjiang Scholars and Innovative Research Team in University (grant no. IRT1122), the National Natural Scientific Foundation of China (grant no. 81602058, no. 81772588, no. 81773194), Hei Longjiang Postdoctoral Foundation, China Postdoctoral Science Foundation Grant (grant no. 2018M630368), the Science and Technology Research Projects of Hei Longjiang Province (grant no. GC12C304-5), Haiyan Research Fund of the Third Affiliated Hospital of Harbin Medical University (grant no. JJZD2017-03, no. JJQN2018-14), the Fundamental Research Funds for the Provincial Universities (grant no. 2017LCZX24), the Foundation of the First Affiliated Hospital of Harbin Medical University (grant no. 2018B017), Innovative Research Program for Graduate of Harbin Medical University (grant no. YJSCX2015-17HYD). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bai ZF, 2013, CANCER RES, V73, P4548, DOI 10.1158/0008-5472.CAN-12-4586; Benson EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141279; Chang RM, 2017, CLIN CANCER RES, V23, P2593, DOI 10.1158/1078-0432.CCR-16-0851; Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316; Fu J, 2011, HEPATOLOGY, V53, P181, DOI 10.1002/hep.24015; Goh GBB, 2015, BEST PRACT RES CL GA, V29, P919, DOI 10.1016/j.bpg.2015.09.007; Grinberg-Rashi H, 2009, CLIN CANCER RES, V15, P1755, DOI 10.1158/1078-0432.CCR-08-2124; Han J., 2017, IEEE J SOLID-ST CIRC, V1, P1; Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005; Kanaan Z, 2013, ANN SURG, V258, P400, DOI 10.1097/SLA.0b013e3182a15bcc; Li YH, 2015, CANCER BIOL THER, V16, P1316, DOI 10.1080/15384047.2015.1070980; Liu YF, 2016, J THORAC DIS, V8, P2911, DOI 10.21037/jtd.2016.10.67; Liu Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095043, 10.1371/journal.pone.0086026]; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Nath S, 2007, MOL BIOL CELL, V18, P1839, DOI 10.1091/mbc.E06-06-0524; Oue N, 2016, ONCOL REP, V36, P349, DOI 10.3892/or.2016.4781; Pawar S, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-53; Pei TM, 2015, ONCOTARGET, V6, P17206, DOI 10.18632/oncotarget.4043; Pospisilova S, 2016, NEOPLASMA, V63, P799, DOI 10.4149/neo_2016_518; Riahi MM, 2017, NEOPLASMA, V63, P1560; Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Serper M, 2017, GASTROENTEROLOGY, V152, P1954, DOI 10.1053/j.gastro.2017.02.040; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang JB, 2016, HEPATOLOGY, V64, P1606, DOI 10.1002/hep.28781; Wang WP, 2017, ONCOTARGET, V8, P5909, DOI 10.18632/oncotarget.13947; Wang WP, 2015, PATHOL RES PRACT, V211, P939, DOI 10.1016/j.prp.2015.09.010; Xiao YX, 2016, ONCOTARGET, V7, P48656, DOI 10.18632/oncotarget.8799; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu KM, 2009, CELL TISSUE RES, V337, P113, DOI 10.1007/s00441-009-0800-3; Zhao BS, 2013, ASIAN PAC J CANCER P, V14, P139, DOI 10.7314/APJCP.2013.14.1.139; Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705; Zhou SL, 2016, HEPATOLOGY, V63, P1560, DOI 10.1002/hep.28445; Zou H, 2015, HEPATOL INT, V9, P399, DOI 10.1007/s12072-015-9634-0	35	49	54	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					406	420		10.1038/s41388-018-0440-8	http://dx.doi.org/10.1038/s41388-018-0440-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30115976	Green Published, hybrid			2022-12-17	WOS:000455851200008
J	Wang, HJ; Pochampalli, M; Wang, LY; Zou, JX; Li, PS; Hsu, SC; Wang, BJ; Huang, SH; Yang, P; Yang, JC; Chu, CY; Hsieh, CL; Sung, SY; Li, CF; Tepper, CG; Ann, DK; Gao, AC; Evans, CP; Izumiya, Y; Chuu, CP; Wang, WC; Chen, HW; Kung, HJ				Wang, Hung-Jung; Pochampalli, Mamata; Wang, Ling-Yu; Zou, June X.; Li, Pei-Shan; Hsu, Sheng-Chieh; Wang, Bi-Juan; Huang, Shih-Han; Yang, Ping; Yang, Joy C.; Chu, Cheng-Ying; Hsieh, Chia-Ling; Sung, Shian-Ying; Li, Chien-Feng; Tepper, Clifford G.; Ann, David K.; Gao, Allen C.; Evans, Christopher P.; Izumiya, Yoshihiro; Chuu, Chi-Pin; Wang, Wen-Ching; Chen, Hong-Wu; Kung, Hsing-Jien			KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC	ONCOGENE			English	Article							PYRUVATE-KINASE M2; H3K36ME2 HISTONE DEMETHYLASE; GROUP PROTEIN EZH2; PROSTATE-CANCER; ANDROGEN RECEPTOR; ENZALUTAMIDE RESISTANCE; NUCLEAR TRANSLOCATION; CELL PROLIFERATION; JMJD5 PROMOTES; IDENTIFICATION	During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored. Here, we show that KDM8's oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions. Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1 alpha to upregulate glycolytic genes. Using shRNA knockdown, we validate KDM8's functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.	[Wang, Hung-Jung; Hsu, Sheng-Chieh; Gao, Allen C.] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan Township 35053, Miaoli County, Taiwan; [Wang, Hung-Jung; Li, Pei-Shan; Kung, Hsing-Jien] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan Township 35053, Miaoli County, Taiwan; [Pochampalli, Mamata; Wang, Ling-Yu; Zou, June X.; Chen, Hong-Wu; Kung, Hsing-Jien] Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA; [Hsu, Sheng-Chieh; Kung, Hsing-Jien] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30035, Taiwan; [Wang, Bi-Juan; Huang, Shih-Han; Chuu, Chi-Pin] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan Township 35053, Miaoli County, Taiwan; [Yang, Ping; Yang, Joy C.; Tepper, Clifford G.; Gao, Allen C.; Evans, Christopher P.] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; [Yang, Ping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Chu, Cheng-Ying; Hsieh, Chia-Ling; Sung, Shian-Ying; Ann, David K.; Kung, Hsing-Jien] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei, Taiwan; [Li, Chien-Feng] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan Township 35053, Miaoli County, Taiwan; [Ann, David K.] City Hope Natl Med Ctr, Dept Mol Pharmacol, Beckman Res Inst, Duarte, CA USA; [Evans, Christopher P.; Izumiya, Yoshihiro; Chen, Hong-Wu] Univ Calif Davis, Sch Med, Comprehens Canc Ctr, Sacramento, CA 95817 USA; [Wang, Wen-Ching] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; University of California System; University of California Davis; National Tsing Hua University; National Health Research Institutes - Taiwan; University of California System; University of California Davis; State Key Lab Oncology South China; Sun Yat Sen University; Taipei Medical University; National Health Research Institutes - Taiwan; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Davis; National Tsing Hua University	Wang, HJ (corresponding author), Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan Township 35053, Miaoli County, Taiwan.; Wang, HJ; Kung, HJ (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan Township 35053, Miaoli County, Taiwan.; Kung, HJ (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA.; Kung, HJ (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30035, Taiwan.; Kung, HJ (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei, Taiwan.	hjwang@nhri.org.tw; hkung@nhri.org.tw	Wang, Wen-Ching/ABI-2253-2020	Li, Chien-Feng/0000-0002-9527-7576; Wang, Wen-Ching/0000-0002-7422-3667; Wang, Ling-Yu/0000-0002-1413-817X	NIH, USA [CA114575, CA165263, CA206222]; NHRI, Taiwan [NHRI03A1-MGPP18-014, NHRI04A1-MGPP15-014, NHRI05A1-MGPP15-014]; MOHW of Taiwan [MOHW104-TDUM-212-13304]; MOST of Taiwan [MOST102-2320-B-400-018-MY3, MOST104-2321-B-400-009]; UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute [NCI P30CA093373]; National Core Facility Program for Biotechnology [MOST 105-2319-B-400-001]; NATIONAL CANCER INSTITUTE [P30CA093373, R01CA206222, R01CA165263] Funding Source: NIH RePORTER	NIH, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHRI, Taiwan(National Health Research Institutes - Taiwan); MOHW of Taiwan; MOST of Taiwan; UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute; National Core Facility Program for Biotechnology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants CA114575, CA165263, and CA206222 from NIH, USA; NHRI03A1-MGPP18-014, NHRI04A1-MGPP15-014, and NHRI05A1-MGPP15-014 from NHRI, Taiwan; MOHW104-TDUM-212-13304 from MOHW of Taiwan; MOST102-2320-B-400-018-MY3 and MOST104-2321-B-400-009 from MOST of Taiwan; The UCDCCC Genomics Shared Resource is funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373). We thank Taiwan Bioinformatics Institute Core Facility for assistances on using Oncomine (National Core Facility Program for Biotechnology, MOST 105-2319-B-400-001).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Alumkal JJ, 2012, CANCER DISCOV, V2, P979, DOI 10.1158/2159-8290.CD-12-0392; Amendola PG, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006632; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Choi SYC, 2016, CLIN CANCER RES, V22, P2721, DOI 10.1158/1078-0432.CCR-15-1624; Chu CH, 2014, J MED CHEM, V57, P5975, DOI 10.1021/jm500249n; Clermont PL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0074-4; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cui YY, 2014, ENDOCR-RELAT CANCER, V21, P435, DOI 10.1530/ERC-14-0107; DePrimo SE, 2002, GENOME BIOL, V3; Duan LL, 2015, CHEM BIOL, V22, P1185, DOI 10.1016/j.chembiol.2015.08.007; Duan ZJ, 2013, PROSTATE, V73, P455, DOI 10.1002/pros.22587; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; He ZM, 2016, J BIOL CHEM, V291, P4684, DOI 10.1074/jbc.M115.672642; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hsia DA, 2010, P NATL ACAD SCI USA, V107, P9671, DOI 10.1073/pnas.1000401107; Huang XB, 2015, BBA-MOL CELL RES, V1853, P2286, DOI 10.1016/j.bbamcr.2015.05.026; Huang XB, 2013, BIOCHIMIE, V95, P2114, DOI 10.1016/j.biochi.2013.08.002; Ishimura A, 2016, CELL TISSUE RES, V363, P723, DOI 10.1007/s00441-015-2276-7; Ishimura A, 2012, DEVELOPMENT, V139, P749, DOI 10.1242/dev.074138; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Keller KE, 2012, SCIENCE, V338, P1069, DOI 10.1126/science.1224409; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Li HF, 2013, MOL CANCER THER, V12, P2425, DOI 10.1158/1535-7163.MCT-13-0267; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Liu HL, 2017, P NATL ACAD SCI USA, V114, pE7717, DOI 10.1073/pnas.1706831114; Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Ma AH, 2006, CANCER RES, V66, P8439, DOI 10.1158/0008-5472.CAN-06-1636; Marcon E, 2014, CELL REP, V8, P297, DOI 10.1016/j.celrep.2014.05.050; Oh S, 2012, BIOCHEM BIOPH RES CO, V420, P61, DOI 10.1016/j.bbrc.2012.02.115; Ranasinghe WKB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054251; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Shafi AA, 2015, ONCOTARGET, V6, P31997, DOI 10.18632/oncotarget.5585; Shen J, 2017, EMBO REP, V18, P2131, DOI 10.15252/embr.201743892; Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147; Shin YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030393; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111; Wang L.-Y., 2013, NUCL SIGNALING PATHW; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wong N, 2014, CANCER INVEST, V32, P330, DOI 10.3109/07357907.2014.919306; Wu BH, 2016, ONCOTARGET, V7, P6847, DOI 10.18632/oncotarget.6867; Wu JY, 2017, CANCER LETT, V400, P18, DOI 10.1016/j.canlet.2017.04.021; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang P, 2012, MOL CELL BIOL, V32, P3121, DOI 10.1128/MCB.00204-12; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang YA, 2013, PROTEIN CELL, V4, P331, DOI 10.1007/s13238-013-2093-2; Youn MY, 2012, J BIOL CHEM, V287, P12994, DOI 10.1074/jbc.M111.323105; Zhang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.454; Zhang R, 2015, INT J CLIN EXP PATHO, V8, P6482; Zhao ZH, 2015, INT J CLIN EXP PATHO, V8, P10325; Zhu H, 2014, STEM CELLS, V32, P2098, DOI 10.1002/stem.1724; Zou JX, 2009, CANCER RES, V69, P3339, DOI 10.1158/0008-5472.CAN-08-3440	63	49	50	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					17	32		10.1038/s41388-018-0414-x	http://dx.doi.org/10.1038/s41388-018-0414-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30072740	Green Published, hybrid			2022-12-17	WOS:000454775900002
J	Kunz, M; Loffler-Wirth, H; Dannemann, M; Willscher, E; Doose, G; Kelso, J; Kottek, T; Nickel, B; Hopp, L; Landsberg, J; Hoffmann, S; Tuting, T; Zigrino, P; Mauch, C; Utikal, J; Ziemer, M; Schulze, HJ; Holzel, M; Roesch, A; Kneitz, S; Meierjohann, S; Bosserhoff, A; Binder, H; Schartl, M				Kunz, Manfred; Loeffler-Wirth, Henry; Dannemann, Michael; Willscher, Edith; Doose, Gero; Kelso, Janet; Kottek, Tina; Nickel, Birgit; Hopp, Lydia; Landsberg, Jenny; Hoffmann, Steve; Tueting, Thomas; Zigrino, Paola; Mauch, Cornelia; Utikal, Jochen; Ziemer, Mirjana; Schulze, Hans-Joachim; Holzel, Michael; Roesch, Alexander; Kneitz, Susanne; Meierjohann, Svenja; Bosserhoff, Anja; Binder, Hans; Schartl, Manfred			RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; METASTATIC MELANOMA; CUTANEOUS MELANOMA; PROGRESSION; VALIDATION; EVOLUTION; THICKNESS; THERAPY	Recent studies revealed trajectories of mutational events in early melanomagenesis, but the accompanying changes in gene expression are far less understood. Therefore, we performed a comprehensive RNA-seq analysis of laser-microdissected melanocytic nevi (n = 23) and primary melanoma samples (n = 57) and characterized the molecular mechanisms of early melanoma development. Using self-organizing maps, unsupervised clustering, and analysis of pseudotime (PT) dynamics to identify evolutionary trajectories, we describe here two transcriptomic types of melanocytic nevi (N1 and N2) and primary melanomas (M1 and M2). N1/M1 lesions are characterized by pigmentation-type and MITF gene signatures, and a high prevalence of NRAS mutations in M1 melanomas. N2/M2 lesions are characterized by inflammatory-type and AXL gene signatures with an equal distribution of wild-type and mutated BRAF and low prevalence of NRAS mutations in M2 melanomas. Interestingly, N1 nevi and M1 melanomas and N2 nevi and M2 melanomas, respectively, cluster together, but there is no clustering in a stage-dependent manner. Transcriptional signatures of M1 melanomas harbor signatures of BRAF/MEK inhibitor resistance and M2 melanomas harbor signatures of anti-PD-1 antibody treatment resistance. Pseudotime dynamics of nevus and melanoma samples are suggestive for a switch-like immune-escape mechanism in melanoma development with downregulation of immune genes paralleled by an increasing expression of a cell cycle signature in late-stage melanomas. Taken together, the transcriptome analysis identifies gene signatures and mechanisms underlying development of melanoma in early and late stages with relevance for diagnostics and therapy.	[Kunz, Manfred; Kottek, Tina; Ziemer, Mirjana] Univ Leipzig, Dept Dermatol Venereol & Allergol, Philipp Rosenthal Str 23-25, D-04103 Leipzig, Germany; [Loeffler-Wirth, Henry; Willscher, Edith; Doose, Gero; Hopp, Lydia; Hoffmann, Steve; Binder, Hans] Univ Leipzig, Interdisciplinary Ctr Bioinformat, Hartelstra 16-18, D-04107 Leipzig, Germany; [Dannemann, Michael; Kelso, Janet; Nickel, Birgit] Max Planck Inst Evolutionary Anthropol, Dept Evolutionary Genet, Deutsch Pl 6, D-04103 Leipzig, Germany; [Doose, Gero; Hoffmann, Steve] Univ Leipzig, Bioinformat Grp, Fac Math & Comp Sci, Hartelstr 16-18, D-04107 Leipzig, Germany; [Landsberg, Jenny] Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53127 Bonn, Germany; [Tueting, Thomas] Univ Magdeburg, Dept Dermatol, Leipziger Str 44, D-39120 Magdeburg, Germany; [Zigrino, Paola; Mauch, Cornelia] Univ Cologne, Dept Dermatol Venereol & Allergol, D-50937 Cologne, Germany; [Utikal, Jochen] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany; [Utikal, Jochen] Ruprecht Karl Univ Heidelberg, Dept Dermatol Venereol & Allergol, Univ Med Ctr Mannheim, D-68167 Mannheim, Germany; [Schulze, Hans-Joachim] Fachklin Hornheide, Dept Dermatol, Dorbaumstr 300, D-48157 Munster, Germany; [Holzel, Michael] Univ Bonn, Dept Clin Chem & Clin Pharmacol, Unit RNA Biol, D-53127 Bonn, Germany; [Roesch, Alexander] Univ Duisburg Essen, West German Canc Ctr, Dept Dermatol, Univ Hosp Essen, D-45122 Essen, Germany; [Roesch, Alexander] Univ Duisburg Essen, German Canc Consortium DKTK, D-45122 Essen, Germany; [Kneitz, Susanne; Meierjohann, Svenja; Schartl, Manfred] Univ Wurzburg, Dept Physiol Chem, Biozentrum, D-97074 Wurzburg, Germany; [Kneitz, Susanne; Meierjohann, Svenja; Schartl, Manfred] Univ Clin Wurzburg, Comprehens Canc Ctr Mainfranken, D-97080 Wurzburg, Germany; [Bosserhoff, Anja] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany; [Schartl, Manfred] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX 77843 USA; [Schartl, Manfred] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Leipzig University; Leipzig University; Max Planck Society; Leipzig University; University of Bonn; Otto von Guericke University; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Bonn; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Wurzburg; University of Wurzburg; University of Erlangen Nuremberg; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Kunz, M (corresponding author), Univ Leipzig, Dept Dermatol Venereol & Allergol, Philipp Rosenthal Str 23-25, D-04103 Leipzig, Germany.	Manfred.kunz@medizin.uni-leipzig.de	Bosserhoff, Anja/GNH-4801-2022; Landsberg, Jenny/AGI-0216-2022; Tüting, Thomas/AAJ-3610-2021; Landsberg, Jennifer/AAF-5113-2019; Hoffmann, Steve/E-1438-2013; Binder, Hans/U-5519-2018	Landsberg, Jenny/0000-0001-8029-3883; Tüting, Thomas/0000-0001-7146-0934; Zigrino, Paola/0000-0002-7470-0064; Binder, Hans/0000-0002-2242-4678; Loeffler-Wirth, Henry/0000-0001-8239-440X; Utikal, Jochen/0000-0001-5316-0241	Deutsche Krebshilfe, Melanomverbund [109716]	Deutsche Krebshilfe, Melanomverbund	MK, MD, AB, SM, and MS were supported by funding of the Deutsche Krebshilfe, Melanomverbund, grant number 109716.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bendall SC, 2014, CELL, V157, P714, DOI 10.1016/j.cell.2014.04.005; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Binder H, 2015, ENCY INFORM SCI TECH, V3rd, P1642, DOI [DOI 10.4018/978-1-4666-5888-2.CH157, 10.4018/978-1-4666-5888-2.ch157]; Binder H., 2013, SYST BIOMED, V1, P99, DOI [10.4161/sysb.25897, DOI 10.4161/SYSB.25897]; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Camp JG, 2017, NATURE, V546, P533, DOI 10.1038/nature22796; Campbell KR, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005212; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; Clarke LE, 2017, CANCER-AM CANCER SOC, V123, P617, DOI 10.1002/cncr.30385; Clarke LE, 2015, J CUTAN PATHOL, V42, P244, DOI 10.1111/cup.12475; Gerber T, 2017, ONCOTARGET, V8, P846, DOI 10.18632/oncotarget.13666; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Harbst K, 2012, CLIN CANCER RES, V18, P4026, DOI 10.1158/1078-0432.CCR-12-0343; Haymaker C, 2012, ONCOIMMUNOLOGY, V1, P735, DOI 10.4161/onci.20823; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Hulstaert E, 2017, ONCOTARGET, V8, P43470, DOI 10.18632/oncotarget.16478; Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820; Jonsson G, 2010, CLIN CANCER RES, V16, P3356, DOI 10.1158/1078-0432.CCR-09-2509; Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700; Keenen B, 2010, ONCOGENE, V29, P81, DOI 10.1038/onc.2009.304; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Loffler-Wirth H, 2015, BIOINFORMATICS, V31, P3225, DOI 10.1093/bioinformatics/btv342; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maurus K, 2017, ONCOGENE, V36, P5110, DOI 10.1038/onc.2017.135; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Reid JE, 2016, BIOINFORMATICS, V32, P2973, DOI 10.1093/bioinformatics/btw372; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008-5472.CAN-08-1794; Solus JF, 2013, ADV ANAT PATHOL, V20, P217, DOI 10.1097/PAP.0b013e3182976c94; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Toronen P, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-307; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Wirth H, 2012, BIODATA MIN, V5, DOI 10.1186/1756-0381-5-18; Wirth H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-306; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057	51	49	49	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6136	6151		10.1038/s41388-018-0385-y	http://dx.doi.org/10.1038/s41388-018-0385-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29995873				2022-12-17	WOS:000450883000003
J	Wang, PS; Chou, CH; Lin, CH; Yao, YC; Cheng, HC; Li, HY; Chuang, YC; Yang, CN; Ger, LP; Chen, YC; Lin, FC; Shen, TL; Hsiao, M; Lu, PJ				Wang, Po-Shun; Chou, Cheng-Han; Lin, Cheng-Han; Yao, Yun-Chin; Cheng, Hui-Chuan; Li, Hao-Yi; Chuang, Yu-Chung; Yang, Chia-Ning; Ger, Luo-Ping; Chen, Yu-Chia; Lin, Forn-Chia; Shen, Tang-Long; Hsiao, Michael; Lu, Pei-Jung			A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; REVEALS; ADENOCARCINOMA; INHIBITORS; PREDICTION; BIOMARKER; PATHWAY; GENES; BONE	Triple-negative breast cancer (TNBC) patients usually lead to poor prognosis and survival because of metastasis. The major sites for TNBC metastasis include the lungs, brain, liver, and bone. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts longer than 200 nucleotides and have been reported as important regulators in BC metastasis. However, the underlying mechanisms for lncRNAs regulating TNBC metastasis are not fully understood. Here we found that linc-ZNF469-3 was highly expressed in lung-metastatic LM2-4175 TNBC cells and overexpression of linc-ZNF469-3 enhanced invasion ability and stemness properties in vitro and lung metastasis in vivo. Furthermore, we found linc-ZNF469-3 physically interacted with miR-574-5p and overexpression of miR-574-5p attenuated ZEB1 expression. Importantly, endogenous high expressions of linc-ZNF469-3 and ZEB1 were correlated with tumor recurrence in TNBC patients with lung metastasis. Taken together, our findings suggested that linc-ZNF469-3 promotes lung metastasis of TNBC through miR-574-5p-ZEB1 signaling axis and may be used as potential prognostic marker for TNBC patients.	[Wang, Po-Shun; Chou, Cheng-Han; Lin, Cheng-Han; Yao, Yun-Chin; Cheng, Hui-Chuan; Li, Hao-Yi; Lu, Pei-Jung] Natl Cheng Kung Univ, Inst Clin Med, Med Coll, Tainan 70403, Taiwan; [Chuang, Yu-Chung; Yang, Chia-Ning] Natl Univ Kaohsiung, Dept Life Sci, Kaohsiung 81148, Taiwan; [Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 81362, Taiwan; [Chen, Yu-Chia] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung 81362, Taiwan; [Lin, Forn-Chia] Natl Cheng Kung Univ Hosp, Dept Radiat Oncol, Tainan 70403, Taiwan; [Shen, Tang-Long] Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei 10617, Taiwan; [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan; [Lu, Pei-Jung] Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan 70403, Taiwan	National Cheng Kung University; National University Kaohsiung; Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Taiwan University; Academia Sinica - Taiwan; Kaohsiung Medical University; National Cheng Kung University; National Cheng Kung University Hospital	Lu, PJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Med Coll, Tainan 70403, Taiwan.; Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan.; Hsiao, M (corresponding author), Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan.; Lu, PJ (corresponding author), Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan 70403, Taiwan.	mhsiao@gate.sinica.edu.tw; pjlu2190@mail.ncku.edu.tw	Shen, Tang-Long/C-7460-2011; Hsiao, Michael/U-6238-2019	Hsiao, Michael/0000-0001-8529-9213; Shen, Tang-Long/0000-0001-6264-3608; Wang, Po-Shun/0000-0002-2344-980X; Lin, Cheng-Han/0000-0001-5444-3999; Chou, Cheng-Han/0000-0003-0534-0373	Ministry of Science and Technology [MOST 103-2320-B-006-048, MOST 105-2320-B-006-054]; National Cheng Kung University Hospital [NCKUH-10605012, NCKUH-10601003]; Academia Sinica and Ministry of Science and Technology [MOST106-0210-01-15-02, MOST 107-0210-01-19-01]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Cheng Kung University Hospital; Academia Sinica and Ministry of Science and Technology	This work was supported by the Ministry of Science and Technology [MOST 103-2320-B-006-048 and MOST 105-2320-B-006-054 to PJL] and National Cheng Kung University Hospital [NCKUH-10605012 and NCKUH-10601003 to FCL and PJL]. Academia Sinica and Ministry of Science and Technology [MOST106-0210-01-15-02, MOST 107-0210-01-19-01 to Michael Hsiao]. Funding for open access charge: Ministry of Science and Technology [MOST 103-2320-B-006-048 and MOST 105-2320-B-006-054]. We thank the National Center for Genome Medicine for assisting with RNA sequencing and the Center for Genome Medicine, National Cheng Kung University for the support of lncRNA annotation and bioinformatic analyses. We also thank Dr. Myriam Gorospe (National Institutes of Health, Baltimore, MD, USA) for the plasmid pMS2 (24 x), pMS2-lincRNA-p21, and pMS2-GST, and Dr. Tang-Long Shen (National Taiwan University, Taipei, Taiwan) for MDA-MB-231 cell lines including parental, LM2-4175, BrM-831, and BoM-1833.	Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Biesiada M, 2016, METHODS, V103, P120, DOI 10.1016/j.ymeth.2016.03.010; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Chuang YC, 2015, MOL BIOSYST, V11, P723, DOI 10.1039/c4mb00620h; Cui Z, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-47; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Di Cecilia S, 2016, CANCER RES, V76, P5615, DOI 10.1158/0008-5472.CAN-15-1824; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Hsu CY, 2016, AM J RESP CRIT CARE, V193, P869, DOI 10.1164/rccm.201412-2226OC; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jiang YZ, 2016, CANCER RES, V76, P2105, DOI 10.1158/0008-5472.CAN-15-3284; Jin CJ, 2016, ONCOTARGET, V7, P51763, DOI 10.18632/oncotarget.10107; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee CC, 2017, RSC ADV, V7, P29871, DOI 10.1039/c7ra04099g; Lee S, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6374504; Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin AF, 2017, NAT CELL BIOL, V19, P238, DOI 10.1038/ncb3473; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Merola R, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0127-8; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Popenda M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks339; Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4; Redis RS, 2013, ONCOTARGET, V4, P1748, DOI 10.18632/oncotarget.1292; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038; van Kampen JGM, 2017, CANCER RES, V77, P2008, DOI 10.1158/0008-5472.CAN-16-2609; Velasco-Velazquez MA, 2011, AM J PATHOL, V179, P2, DOI 10.1016/j.ajpath.2011.03.005; Vennin C, 2015, ONCOTARGET, V6, P29209, DOI 10.18632/oncotarget.4976; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Xu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.149; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; Yuan SX, 2016, HEPATOLOGY, V63, P499, DOI 10.1002/hep.27893; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zhou R, 2016, SCI REP-UK, V6, DOI 10.1038/srep35714; Zhou R, 2015, ONCOTARGET, V6, P44609, DOI 10.18632/oncotarget.6338	57	49	55	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4662	4678		10.1038/s41388-018-0293-1	http://dx.doi.org/10.1038/s41388-018-0293-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755127				2022-12-17	WOS:000442514400003
J	Jiao, WJ; Chen, YJ; Song, HJ; Li, D; Mei, H; Yang, F; Fang, E; Wang, XJ; Huang, K; Zheng, LD; Tong, QS				Jiao, Wanju; Chen, Yajun; Song, Huajie; Li, Dan; Mei, Hong; Yang, Feng; Fang, Erhu; Wang, Xiaojing; Huang, Kai; Zheng, Liduan; Tong, Qiangsong			HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis	ONCOGENE			English	Article							INTELECTIN 1 SUPPRESSES; HEPARANASE EXPRESSION; NEUROBLASTOMA-CELLS; GASTRIC-CANCER; GENE-TRANSCRIPTION; GROWTH; INVASION; METASTASIS; ACTIVATION; ANGIOGENESIS	Recent studies reveal the emerging functions of enhancer RNAs (eRNAs) in gene expression. However, the roles of eRNAs in regulating the expression of heparanase (HPSE), an established endo-beta-D-glucuronidase essential for cancer invasion and metastasis, still remain elusive. Herein, through comprehensive analysis of publically available FANTOM5 expression atlas and chromatin interaction dataset, we identified a super enhancer and its derived eRNA facilitating the HPSE expression (HPSE eRNA) in cancers. Gain-of-function and loss-of-function experiments indicated that HPSE eRNA facilitated the in vitro and in vivo tumorigenesis and aggressiveness of cancer cells. Mechanistically, as a p300-regulated nuclear noncoding RNA, HPSE eRNA bond to heterogeneous nuclear ribonucleoprotein U (hnRNPU) to facilitate its interaction with p300 and their enrichment on super enhancer, resulting in chromatin looping between super enhancer and HPSE promoter, p300-mediated transactivation of transcription factor early growth response 1 (EGR1), and subsequent elevation of HPSE expression. In addition, rescue studies in HPSE overexpressing or silencing cancer cells indicated that HPSE eRNA exerted oncogenic properties via driving HPSE expression. In clinical cancer tissues, HPSE eRNA was highly expressed and positively correlated with HPSE levels, and served as an independent prognostic factor for poor outcome of cancer patients. Therefore, these findings indicate that as a novel noncoding RNA, HPSE eRNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis.	[Jiao, Wanju; Chen, Yajun; Zheng, Liduan] Huazhong Univ Sci & Technol, Union Hosp, Dept Pathol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China; [Song, Huajie; Li, Dan; Mei, Hong; Yang, Feng; Fang, Erhu; Wang, Xiaojing; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China; [Huang, Kai; Zheng, Liduan; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Clin Ctr Human Genom Res, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zheng, LD (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pathol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Clin Ctr Human Genom Res, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014	Tong, Qiangsong/0000-0002-2615-6404; Zheng, Liduan/0000-0001-5566-673X	National Natural Science Foundation of China [81272779, 81372667, 81472363, 81402301, 81402408, 81572423, 81672500, 81773094, 81772967]; Natural Science Foundation of Hubei Province [2014CFA012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province)	We appreciate Dr. Tso-Pang Yao for providing vectors. This work was granted by the National Natural Science Foundation of China (81272779, 81372667, 81472363, 81402301, 81402408, 81572423, 81672500, 81773094, and 81772967), and Natural Science Foundation of Hubei Province (2014CFA012).	Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bi HS, 2013, BBA-GEN SUBJECTS, V1830, P4899, DOI 10.1016/j.bbagen.2013.06.026; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; de Mestre AM, 2005, J BIOL CHEM, V280, P35136, DOI 10.1074/jbc.M503414200; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fang F, 2014, STEM CELLS, V32, P1805, DOI 10.1002/stem.1705; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; He B, 2014, P NATL ACAD SCI USA, V111, pE2191, DOI 10.1073/pnas.1320308111; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kim YW, 2013, BBA-GENE REGUL MECH, V1829, P963, DOI 10.1016/j.bbagrm.2013.04.006; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; Li D, 2015, ONCOTARGET, V6, P16168, DOI 10.18632/oncotarget.3753; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Masola V, 2014, CURR CANCER DRUG TAR, V14, P286, DOI 10.2174/1568009614666140224155124; Matsuoka Y, 2009, ONCOL REP, V22, P249, DOI 10.3892/or_00000431; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Puvvula PK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6323; Qu HX, 2016, SCI REP-UK, V6, DOI 10.1038/srep32628; Qu HX, 2015, HUM MOL GENET, V24, P2539, DOI 10.1093/hmg/ddv018; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Roshon MJ, 2005, TRANSGENIC RES, V14, P179, DOI 10.1007/s11248-004-8147-8; Shinyo Y, 2003, ANN ONCOL, V14, P1505, DOI 10.1093/annonc/mdg407; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Stadlmann S, 2003, EUR J CANCER, V39, P2229, DOI 10.1016/S0959-8049(03)00457-X; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zetser A, 2003, CANCER RES, V63, P7733; Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574; Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422; Zheng LD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.293; Zheng LD, 2016, ONCOTARGET, V7, P40314, DOI 10.18632/oncotarget.9739; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719; Zheng LD, 2013, MOL CANCER RES, V11, P182, DOI 10.1158/1541-7786.MCR-12-0534; Zheng LD, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-74; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33	53	49	51	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2728	2745		10.1038/s41388-018-0128-0	http://dx.doi.org/10.1038/s41388-018-0128-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29511351				2022-12-17	WOS:000432545100009
J	Bonnin, DAA; Havrda, MC; Lee, MC; Liu, H; Zhang, Z; Nguyen, LN; Harrington, LX; Hassanpour, S; Cheng, C; Israel, MA				Bonnin, D. A. Almiron; Havrda, M. C.; Lee, M. C.; Liu, H.; Zhang, Z.; Nguyen, L. N.; Harrington, L. X.; Hassanpour, S.; Cheng, C.; Israel, M. A.			Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; INDUCIBLE FACTOR-1-ALPHA; INSULIN-SECRETION; IL-6 SECRETION; NERVOUS-SYSTEM; TUMOR HYPOXIA; CANCER-CELLS; MOUSE MODEL; RAC1; GLIOBLASTOMA	High-grade gliomas (HGGs) include the most common and the most aggressive primary brain tumor of adults and children. Despite multimodality treatment, most high-grade gliomas eventually recur and are ultimately incurable. Several studies suggest that the initiation, progression, and recurrence of gliomas are driven, at least partly, by cancer stem-like cells. A defining characteristic of these cancer stem-like cells is their capacity to self-renew. We have identified a hypoxia-induced pathway that utilizes the Hypoxia Inducible Factor 1 alpha (HIF-1 alpha) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 -Signal Transducer and Activator of Transcription 3) axis to enhance the self-renewal of glioma stem-like cells. Hypoxia is a commonly found pathologic feature of HGGs. Under hypoxic conditions, HIF-1 alpha levels are greatly increased in glioma stem-like cells. Increased HIF-1 alpha activates the JAK1/2-STAT3 axis and enhances tumor stem-like cell self-renewal. Our data further demonstrate the importance of Vascular Endothelial Growth Factor (VEGF) secretion for this pathway of hypoxia-mediated self-renewal. Brefeldin A and EHT-1864, agents that significantly inhibit VEGF secretion, decreased stem cell self-renewal, inhibited tumor growth, and increased the survival of mice allografted with S100 beta-v-erbB/p53(-/-) glioma stem-like cells. These agents also inhibit the expression of a hypoxia gene expression signature that is associated with decreased survival of HGG patients. These findings suggest that targeting the secretion of extracellular, autocrine/paracrine mediators of glioma stem-like cell self-renewal could potentially contribute to the treatment of HGGs.	[Bonnin, D. A. Almiron; Havrda, M. C.; Liu, H.; Zhang, Z.; Cheng, C.; Israel, M. A.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Hanover, NH USA; [Bonnin, D. A. Almiron; Havrda, M. C.; Liu, H.; Zhang, Z.; Hassanpour, S.; Cheng, C.; Israel, M. A.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Hanover, NH USA; [Lee, M. C.] Dartmouth Coll, Dept Biol, Hanover, NH 03755 USA; [Nguyen, L. N.] Geisel Sch Med Dartmouth, Dept Pathol & Lab Med, Hanover, NH USA; [Nguyen, L. N.; Harrington, L. X.; Hassanpour, S.] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Hanover, NH USA; [Israel, M. A.] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH USA; [Israel, M. A.] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College	Israel, MA (corresponding author), Norris Cotton Canc Ctr Dartmouth, One Med Ctr Dr, Lebanon, NH 03756 USA.	Mark.A.Israel@Dartmouth.edu		Lee, Myung Chang/0000-0002-7051-5822	NIH; NSF; Cancer Center Core Grant from the National Cancer Institute [P30CA023108]; COBRE Grant from the National Institute of General Medical Sciences [P30GM10315-15]; Theodora B. Betz Foundation; Jordan and Kyra Memorial Foundation; Andrea Clark Nelson Medical Research Endowment; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Cancer Center Core Grant from the National Cancer Institute; COBRE Grant from the National Institute of General Medical Sciences; Theodora B. Betz Foundation; Jordan and Kyra Memorial Foundation; Andrea Clark Nelson Medical Research Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tor Tosteson and Dr Jiang Gui from the Biostatistics Shared Resource at Norris Cotton Cancer Center at Dartmouth for their consultation regarding statistical analysis, and Tabatha Richardson for her administrative support. Microarray processing and data normalization was carried out at Norris Cotton Cancer Center in the Genomics Shared Resource, which was established by equipment grants from the NIH and NSF and is supported in part by a Cancer Center Core Grant (P30CA023108) from the National Cancer Institute. Multiplex Luminex Cytokine Assay was performed in DartLab, the Immune Monitoring and Flow Cytometry Shared Resource at Norris Cotton Cancer Center, supported by a Cancer Center Core Grant (P30CA023108) from the National Cancer Institute and an Immunology COBRE Grant (P30GM10315-15) from the National Institute of General Medical Sciences. Financial support was generously provided by the Theodora B. Betz Foundation, the Jordan and Kyra Memorial Foundation and the Andrea Clark Nelson Medical Research Endowment. Support was generously provided by the Theodora B. Betz Foundation (M.A. Israel), the Jordan and Kyra Memorial Foundation (M.A. Israel), and the Andrea Clark Nelson Medical Research Endowment (M. A. Israel).	Agro L, 2015, BIO-PROTOCOL, V5, pe1659; Akbar H, 2007, J THROMB HAEMOST, V5, P1747, DOI 10.1111/j.1538-7836.2007.02646.x; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asahara S, 2013, DIABETOLOGIA, V56, P1088, DOI 10.1007/s00125-013-2849-5; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bonnin DAA, 2017, MOL CANCER THER, V16, P705, DOI 10.1158/1535-7163.MCT-16-0616; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Davila J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005458; Desire L, 2005, J BIOL CHEM, V280, P37516, DOI 10.1074/jbc.M507913200; Dwivedi S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-128; Dzaye ODA, 2016, J NEUROPATH EXP NEUR, V75, P429, DOI 10.1093/jnen/nlw016; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Finucane Mariel M, 2007, Epidemiol Perspect Innov, V4, P8, DOI 10.1186/1742-5573-4-8; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; Garabed RB, 2008, J R STAT SOC A STAT, V171, P699, DOI 10.1111/j.1467-985X.2008.00534.x; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goyal P, 2013, MOL HUM REPROD, V19, P528, DOI 10.1093/molehr/gat023; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Hamer PCDW, 2008, ONCOGENE, V27, P2091, DOI 10.1038/sj.onc.1210850; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harris MA, 2008, CANCER RES, V68, P10051, DOI 10.1158/0008-5472.CAN-08-0786; Havrda MC, 2006, THROMB HAEMOSTASIS, V96, P361, DOI 10.1160/TH06-04-0224; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hjelmeland AB, 2011, CELL DEATH DIFFER, V18, P829, DOI 10.1038/cdd.2010.150; Huang Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-304; Hwaiz R, 2015, BRIT J PHARMACOL, V172, P5347, DOI 10.1111/bph.13325; Hwaiz R, 2015, J LEUKOCYTE BIOL, V97, P975, DOI 10.1189/jlb.4A1214-603R; Jackson M, 2015, CARCINOGENESIS, V36, P177, DOI 10.1093/carcin/bgu243; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Kang SH, 2010, NEUROSURGERY, V67, P1386, DOI 10.1227/NEU.0b013e3181f1c0cd; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Li HZ, 2004, BIOINFORMATICS, V20, P208, DOI 10.1093/bioinformatics/bth900; Li JS, 2004, AM J PHYSIOL-ENDOC M, V286, pE818, DOI 10.1152/ajpendo.00307.2003; Li QW, 2003, J PHYSIOL-LONDON, V550, P431, DOI 10.1113/jphysiol.2003.039073; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu Q, 2015, INT J CLIN EXP MED, V8, P22073; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Man JH, 2014, CELL REP, V9, P1812, DOI 10.1016/j.celrep.2014.10.055; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854; Nordsmark M, 2005, RADIOTHER ONCOL, V77, P18, DOI 10.1016/j.radonc.2005.06.038; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sausville E A, 1996, Cancer J Sci Am, V2, P52; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Sondergaard KL, 2002, NEUROPATH APPL NEURO, V28, P210, DOI 10.1046/j.1365-2990.2002.00391.x; Spence AM, 2008, CLIN CANCER RES, V14, P2623, DOI 10.1158/1078-0432.CCR-07-4995; Stanley AC, 2014, IMMUNOL CELL BIOL, V92, P275, DOI 10.1038/icb.2013.90; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vordermark D, 2003, STRAHLENTHER ONKOL, V179, P801, DOI 10.1007/s00066-003-1150-9; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Weiss WA, 2003, CANCER RES, V63, P1589; Williams JA, 2009, AM J PHYSIOL-ENDOC M, V296, pE405, DOI 10.1152/ajpendo.90874.2008; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yun Z, 2014, ADV EXP MED BIOL, V772, P41, DOI 10.1007/978-1-4614-5915-6_2; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	92	49	49	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1107	1118		10.1038/onc.2017.404	http://dx.doi.org/10.1038/onc.2017.404			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29155422	hybrid, Green Published			2022-12-17	WOS:000425905700013
J	Guo, Y; Cui, J; Ji, Z; Cheng, C; Zhang, K; Zhang, C; Chu, M; Zhao, Q; Yu, Z; Zhang, Y; Fang, YX; Gao, WQ; Zhu, HH				Guo, Y.; Cui, J.; Ji, Z.; Cheng, C.; Zhang, K.; Zhang, C.; Chu, M.; Zhao, Q.; Yu, Z.; Zhang, Y.; Fang, Y-X; Gao, W-Q; Zhu, H. H.			miR-302/367/LATS2/YAP pathway is essential for prostate tumor- propagating cells and promotes the development of castration resistance	ONCOGENE			English	Article							HIPPO PATHWAY; ANDROGEN RECEPTOR; DOWN-REGULATION; CANCER; EXPRESSION; ANTIGEN; HYPERMETHYLATION; SUPPRESSION; REGULATORS; THERAPY	Clinical intervention for patients with advanced prostate cancer (PCa) remains challenging due to the inevitable recurrence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT). Cancer stem cells (CSCs) with serial tumor-propagating capacity are considered to be the driving force for PCa progression and recurrence. In this study, we report that the miR-302/367 cluster, a previously identified potent pluripotency regulator, is upregulated in prostate tumors. Specifically, the forced expression of the miR-302/367 cluster accelerates the in vitro and in vivo growth of PCa cells and their resistance to androgen ablation, whereas the knockdown of the miR-302/367 cluster using anti-sense RNA suppresses the incidence of formation, growth rate and endpoint weight of PCa cell tumors. Mechanistically, we find that LATS2, a key component of the tumor-suppressive Hippo signaling pathway, acts as a direct target of the miR-302/367 cluster in PCa cells. The downregulation of LATS2 by the miR-302/367 cluster reduces the phosphorylation and enhances the nuclear translocation of the YAP oncoprotein. Conversely, the restoration of LATS2 expression abrogates the tumor-promoting effects of forced miR-302/367 cluster expression. Collectively, the potent pluripotency regulator-triggered miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes castration resistance. Thus, targeting this signaling axis may represent a promising therapeutic strategy for CRPC.	[Guo, Y.; Cui, J.; Zhang, C.; Chu, M.; Fang, Y-X; Gao, W-Q; Zhu, H. H.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Ren Ji Med X Clin Stem Cell Res Ctr,State Key Lab, Shanghai, Peoples R China; [Ji, Z.; Cheng, C.; Zhang, K.; Gao, W-Q] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Ji, Z.; Cheng, C.; Zhang, K.; Gao, W-Q] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China; [Zhao, Q.; Yu, Z.; Zhang, Y.] Tongji Univ, Sch Med, Shanghai East Hosp, Res Ctr Translat Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University	Gao, WQ; Zhu, HH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Stem Cell Res Ctr, 160 Pujian Rd, Shanghai 200127, Peoples R China.	gao.weiqiang@sjtu.edu.cn; zhuhecrane@shsmu.edu.cn	Gao, Wei/GXH-0380-2022	ji, Zhongzhong/0000-0003-0562-2477; Chu, Mingliang/0000-0003-0559-8921	Chinese Ministry of Science and Technology [2017YFA0102900]; National Natural Science Foundation of China [81372189, 81630073]; Science and Technology Commission of Shanghai Municipality [16JC1405700]; KC Wong foundation; Shanghai Eastern Hospital Stem Cell Research Base Fund; State Key Laboratory of Oncogenes and Related Genes [90-16-03]; Shanghai Rising-Star Program [17QA1402100]; Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar) [QD2015002]; School of Medicine at Shanghai Jiao Tong University (Excellent Youth Scholar Initiation Grant) [16XJ11003]; Ren Ji Hospital [RJZZ14-010]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); KC Wong foundation; Shanghai Eastern Hospital Stem Cell Research Base Fund; State Key Laboratory of Oncogenes and Related Genes; Shanghai Rising-Star Program; Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar); School of Medicine at Shanghai Jiao Tong University (Excellent Youth Scholar Initiation Grant); Ren Ji Hospital	The study is supported by grants from the Chinese Ministry of Science and Technology (2017YFA0102900), the National Natural Science Foundation of China (81372189 and 81630073), the Science and Technology Commission of Shanghai Municipality (16JC1405700), the KC Wong foundation, and the Shanghai Eastern Hospital Stem Cell Research Base Fund to Wei-Qiang Gao, and Helen He Zhu received support from the State Key Laboratory of Oncogenes and Related Genes (90-16-03), Shanghai Rising-Star Program (17QA1402100), Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar) QD2015002), School of Medicine at Shanghai Jiao Tong University (Excellent Youth Scholar Initiation Grant 16XJ11003) and Ren Ji Hospital (Seed Project RJZZ14-010).	Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Badcock G, 1999, CANCER RES, V59, P4715; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen EJ, 2015, CLIN CANCER RES, V21, P1273, DOI 10.1158/1078-0432.CCR-14-1220; Chen L, 2015, COMP BIOCHEM PHYS D, V16, P83, DOI 10.1016/j.cbd.2015.08.002; Chu ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116197; Dai JL, 1996, STEROIDS, V61, P531; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Fang YX, 2010, MOL BIOTECHNOL, V45, P71, DOI 10.1007/s12033-010-9244-y; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; GERDES J, 1984, J IMMUNOL, V133, P1710; GROGAN TM, 1988, BLOOD, V71, P1157; Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hong AW, 2016, NAT REV GASTRO HEPAT, V13, P324, DOI 10.1038/nrgastro.2016.59; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Li WQ, 2011, CANCER RES, V71, P2162, DOI 10.1158/0008-5472.CAN-10-3268; Lu Y, 2014, CELL STEM CELL, V15, P92, DOI 10.1016/j.stem.2014.04.002; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Sebio A, 2015, CLIN CANCER RES, V21, P5002, DOI 10.1158/1078-0432.CCR-15-0411; Suzuki H, 1998, CANCER RES, V58, P204; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Torre LA, 2016, CA-CANCER J CLIN, V66, P182, DOI 10.3322/caac.21335; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2016, GYNECOL ONCOL, V141, P592, DOI 10.1016/j.ygyno.2015.11.034; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhang K, 2016, ONCOGENE, V35, P1271, DOI 10.1038/onc.2015.184; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao LY, 2016, SHOCK VIB, V2016, DOI 10.1155/2016/3891429; Zlotorynski Eytan, 2016, Nat Rev Cancer, V16, P481, DOI 10.1038/nrc.2016.78	48	49	51	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6336	6347		10.1038/onc.2017.240	http://dx.doi.org/10.1038/onc.2017.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28745315				2022-12-17	WOS:000414774800012
J	Torrente, L; Sanchez, C; Moreno, R; Chowdhry, S; Cabello, P; Isono, K; Koseki, H; Honda, T; Hayes, JD; Dinkova-Kostova, AT; de la Vega, L				Torrente, L.; Sanchez, C.; Moreno, R.; Chowdhry, S.; Cabello, P.; Isono, K.; Koseki, H.; Honda, T.; Hayes, J. D.; Dinkova-Kostova, A. T.; de la Vega, L.			Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses	ONCOGENE			English	Article							INTERACTING PROTEIN KINASE-2; TUMOR-SUPPRESSOR FUNCTION; TRANSCRIPTION FACTOR NRF2; DNA-DAMAGE RESPONSE; LUNG-CANCER; CELL-PROLIFERATION; MOLECULAR-MECHANISM; GENE-EXPRESSION; GROWTH ARREST; FEEDBACK LOOP	Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.	[Torrente, L.; Sanchez, C.; Moreno, R.; Chowdhry, S.; Cabello, P.; Hayes, J. D.; Dinkova-Kostova, A. T.; de la Vega, L.] Univ Dundee, Div Canc Res, Jacqui Wood Canc Ctr, Sch Med,Ninewells Hosp & Med Sch, James Arrott Dr, Dundee DD1 9SY, Scotland; [Koseki, H.] RIKEN Ctr Integrat Med Sci IMS, Dev Genet, Yokohama, Kanagawa, Japan; [Honda, T.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; [Honda, T.] SUNY Stony Brook, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA	University of Dundee; RIKEN; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	de la Vega, L (corresponding author), Univ Dundee, Div Canc Res, Jacqui Wood Canc Ctr, Sch Med,Ninewells Hosp & Med Sch, James Arrott Dr, Dundee DD1 9SY, Scotland.	l.delavega@dundee.ac.uk	de la Vega, Laureano/AAE-5456-2020	de la Vega, Laureano/0000-0003-2707-7414; Isono, Kyoichi/0000-0002-4609-8985; Hayes, John/0000-0002-2927-5548; Dinkova-Kostova, Albena/0000-0003-0316-9859; Torrente, Laura/0000-0003-0343-0287	Cancer Research UK [C52419/A22869]; Tenovus Scotland [T14/62]; Reata Pharmaceuticals; Stony Brook Foundation; Ninewells Cancer Campaign; Medical Research Institute of the University of Dundee; Cancer Research UK [22869, 13786] Funding Source: researchfish; Grants-in-Aid for Scientific Research [16H02622] Funding Source: KAKEN	Cancer Research UK(Cancer Research UK); Tenovus Scotland; Reata Pharmaceuticals; Stony Brook Foundation; Ninewells Cancer Campaign; Medical Research Institute of the University of Dundee; Cancer Research UK(Cancer Research UK); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Prof Donna D Zhang (University of Arizona) for providing plasmids; Prof Issay Kitabayashi (National Cancer Center Research Institute Tokyo) and Prof Masayuki Yamamoto (Tohoku University) for cell lines; Prof Shyam Biswal (Johns Hopkins University) for sharing their ChIP-seq data; Prof Stephen M Keyse (University of Dundee) for critical reading and insightful comments on the manuscript. We are extremely grateful to the Medical Research Institute of the University of Dundee, Cancer Research UK (C52419/A22869), the Ninewells Cancer Campaign, Tenovus Scotland (grant number T14/62), Reata Pharmaceuticals and Stony Brook Foundation for financial support.	Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Akaike Y, 2015, ONCOGENE, V34, P3463, DOI 10.1038/onc.2014.278; Al-Beiti MAM, 2008, AUST NZ J OBSTET GYN, V48, P329, DOI 10.1111/j.1479-828X.2008.00874.x; Ann EJ, 2016, CANCER RES, V76, P4728, DOI 10.1158/0008-5472.CAN-15-3310; Berber S, 2016, SCI REP-UK, V6, DOI 10.1038/srep19582; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Canet MJ, 2015, DRUG METAB DISPOS, V43, P93, DOI 10.1124/dmd.114.060103; Choi DW, 2013, MOL CELL, V51, P374, DOI 10.1016/j.molcel.2013.06.010; Chorley BN, 2012, NUCLEIC ACIDS RES, V40, P7416, DOI 10.1093/nar/gks409; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; de la Vega L, 2013, NUCLEIC ACIDS RES, V41, P5731, DOI 10.1093/nar/gkt262; de la Vega L, 2012, MOL CELL, V46, P472, DOI 10.1016/j.molcel.2012.03.003; de la Vega L, 2011, BBA-MOL CELL RES, V1813, P283, DOI 10.1016/j.bbamcr.2010.11.022; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Du W, 2013, CANCER LETT, V337, P58, DOI 10.1016/j.canlet.2013.05.016; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Garufi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.163; Giachino C, 2015, CANCER CELL, V28, P730, DOI 10.1016/j.ccell.2015.10.008; Giraud S, 2004, J VIROL, V78, P2984, DOI 10.1128/JVI.78.6.2984-2993.2004; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hailemariam K, 2010, J CELL SCI, V123, P3863, DOI 10.1242/jcs.073627; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Hofmann TG, 2005, J BIOL CHEM, V280, P29224, DOI 10.1074/jbc.M503921200; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Honda T, 2011, J MED CHEM, V54, P1762, DOI 10.1021/jm101445p; Iacovelli S, 2009, CELL PROLIFERAT, V42, P373, DOI 10.1111/j.1365-2184.2009.00601.x; Imberg-Kazdan K, 2013, GENOME RES, V23, P581, DOI 10.1101/gr.144774.112; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jin YM, 2012, NAT MED, V18, P580, DOI 10.1038/nm.2685; Kalra S, 2012, CANCER PREV RES, V5, P973, DOI 10.1158/1940-6207.CAPR-12-0041; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Kelleher MO, 2009, CARCINOGENESIS, V30, P1754, DOI 10.1093/carcin/bgp182; Kelly VP, 2000, CANCER RES, V60, P957; Kemmerer ZA, 2015, TOXICOL LETT, V238, P83, DOI 10.1016/j.toxlet.2015.07.004; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Lapin V, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.45; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee OH, 2007, J BIOL CHEM, V282, P36412, DOI 10.1074/jbc.M706517200; Li QK, 2011, J HUM GENET, V56, P230, DOI 10.1038/jhg.2010.172; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Munoz IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109752; Naidu SD, 2016, MOL CELL BIOL, V36, P2403, DOI 10.1128/MCB.00292-16; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Pi JB, 2007, FREE RADICAL BIO MED, V42, P1797, DOI 10.1016/j.freeradbiomed.2007.03.001; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Puca R, 2010, FREE RADICAL BIO MED, V48, P1338, DOI 10.1016/j.freeradbiomed.2010.02.015; Rada P, 2012, MOL CELL BIOL, V32, P3486, DOI 10.1128/MCB.00180-12; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P2498, DOI 10.1089/ars.2014.5843; Sasaki H, 2013, INT J MOL MED, V31, P1135, DOI 10.3892/ijmm.2013.1324; Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499; Saul VV, 2013, J MOL CELL BIOL, V5, P27, DOI 10.1093/jmcb/mjs053; Schulten HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153681; Shang YL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001527; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Sjolund J, 2014, P NATL ACAD SCI USA, V111, P7373, DOI 10.1073/pnas.1322275111; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743	74	49	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6204	6212		10.1038/onc.2017.221	http://dx.doi.org/10.1038/onc.2017.221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692050	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000414249800013
J	Vidal, E; Sayols, S; Moran, S; Guillaumet-Adkins, A; Schroeder, MP; Royo, R; Orozco, M; Gut, M; Gut, I; Lopez-Bigas, N; Heyn, H; Esteller, M				Vidal, E.; Sayols, S.; Moran, S.; Guillaumet-Adkins, A.; Schroeder, M. P.; Royo, R.; Orozco, M.; Gut, M.; Gut, I.; Lopez-Bigas, N.; Heyn, H.; Esteller, M.			A DNA methylation map of human cancer at single base-pair resolution	ONCOGENE			English	Article							EPIGENETIC LANDSCAPE; HYPOMETHYLATION; METHYLOME; REVEALS; SITES	Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination.	[Vidal, E.; Sayols, S.; Moran, S.; Heyn, H.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Vidal, E.] BIST, Ctr Genom Regulat CRG, Barcelona, Spain; [Vidal, E.; Guillaumet-Adkins, A.; Gut, M.; Gut, I.; Heyn, H.] UPF, Barcelona, Spain; [Guillaumet-Adkins, A.; Gut, M.; Gut, I.; Heyn, H.] BIST, Ctr Genom Regulat CRG, CNAG CRG, Barcelona, Spain; [Schroeder, M. P.; Lopez-Bigas, N.] IMIM Hosp, Med Res Inst, Res Program Biomed Informat, Biomed Genom Lab, Barcelona, Spain; [Schroeder, M. P.; Lopez-Bigas, N.] Univ Pompeu Fabra, Barcelona, Spain; [Royo, R.; Orozco, M.] Barcelona Inst Sci & Technol, IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona, Spain; [Orozco, M.] IRB Barcelona, Barcelona, Spain; [Orozco, M.] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain; [Lopez-Bigas, N.; Esteller, M.] ICREA, Barcelona, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; ICREA; University of Barcelona	Heyn, H; Esteller, M (corresponding author), Hosp Llobregat, Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Av Gran Via Hosp 199-203, Barcelona 08908, Catalonia, Spain.	hheyn@idibell.cat; mesteller@idibell.cat	Esteller, Manel/L-5956-2014; Lopez-Bigas, Nuria/F-6193-2011; Vidal, Enrique/R-5593-2019; Gut, Ivo/ABF-3188-2020; Moran, Sebastian/G-5293-2013	Esteller, Manel/0000-0003-4490-6093; Lopez-Bigas, Nuria/0000-0003-4925-8988; Vidal, Enrique/0000-0002-4217-1807; Gut, Ivo/0000-0001-7219-632X; Schroeder, Michael P/0000-0002-7563-509X; Moran, Sebastian/0000-0003-4192-8983; Sayols, Sergi/0000-0002-3877-4170; Heyn, Holger/0000-0002-3276-1889; Orozco Lopez, Modesto/0000-0002-8608-3278	Institute of Health Carlos III ISCIII Project [PI11/00321]; Spanish Cancer Research Network (RTICC) [RD12/0036/0039]; European Development Regional Fund; 'A way to achieve Europe' ERDF [SAF2014-55000-R]; Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR [2014SGR633]; Health and Science Departments of the Catalan government (Generalitat de Catalunya); European Community's Seventh Framework Program (FP7) [HEALTH-F5-2011-282510 - BLUEPRINT]	Institute of Health Carlos III ISCIII Project; Spanish Cancer Research Network (RTICC); European Development Regional Fund(European Commission); 'A way to achieve Europe' ERDF; Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation(Foundation CELLEX); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Health and Science Departments of the Catalan government (Generalitat de Catalunya); European Community's Seventh Framework Program (FP7)	This work was supported by Institute of Health Carlos III ISCIII Project no. PI11/00321, Spanish Cancer Research Network (RTICC) no. RD12/0036/0039; European Development Regional Fund, 'A way to achieve Europe' ERDF (SAF2014-55000-R), Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR 2014SGR633 grant; Health and Science Departments of the Catalan government (Generalitat de Catalunya) and European Community's Seventh Framework Program (FP7/2007-2013), grant HEALTH-F5-2011-282510 - BLUEPRINT. HH is a Miguel Servet (CP14/00229) ISCII researcher. ME and NLB are ICREA Research Professors.	Agirre X, 2015, GENOME RES, V25, P478, DOI 10.1101/gr.180240.114; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Burger L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt599; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Court F, 2014, GENOME RES, V24, P554, DOI 10.1101/gr.164913.113; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265; Hansen KD, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R83, 10.1186/gb-2012-13-10-r83]; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Heyn H, 2013, CANCER CELL, V23, P563, DOI 10.1016/j.ccr.2013.04.028; Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109; Heyn H, 2012, EPIGENETICS-US, V7, P542, DOI 10.4161/epi.20523; Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268; Ingley E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-21; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kretzmer H, 2015, NAT GENET, V47, P1316, DOI 10.1038/ng.3413; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Kumar N, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-21; Landau DA, 2014, CANCER CELL, V26, P813, DOI 10.1016/j.ccell.2014.10.012; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li H, 2011, BIOINFORMATICS, V27, P718, DOI 10.1093/bioinformatics/btq671; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Molaro A, 2011, CELL, V146, P1028, DOI 10.1016/j.cell.2011.08.016; Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541; Pujadas E, 2012, CELL, V148, P1123, DOI 10.1016/j.cell.2012.02.045; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schlesinger F, 2013, GENOME RES, V23, P1601, DOI 10.1101/gr.157271.113; Schroeder DI, 2013, P NATL ACAD SCI USA, V110, P6037, DOI 10.1073/pnas.1215145110; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433	49	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5648	5657		10.1038/onc.2017.176	http://dx.doi.org/10.1038/onc.2017.176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581523	Green Published, hybrid			2022-12-17	WOS:000412293600009
J	Pek, M; Yatim, SMJM; Chen, Y; Li, J; Gong, M; Jiang, X; Zhang, F; Zheng, J; Wu, X; Yu, Q				Pek, M.; Yatim, S. M. J. M.; Chen, Y.; Li, J.; Gong, M.; Jiang, X.; Zhang, F.; Zheng, J.; Wu, X.; Yu, Q.			Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer	ONCOGENE			English	Article							SYNTHETIC LETHAL INTERACTION; RECEPTOR TYROSINE KINASES; PANCREATIC-CANCER; MUTATION STATUS; DNA-DAMAGE; CELL-CYCLE; FOXM1; PROLIFERATION; SUPPRESSION; TRANSCRIPTION	Therapeutic strategies against KRAS mutant colorectal cancers are developed using cell line models, which do not accurately represent the transcriptome driven by oncogenic KRAS in tumors. We sought to identify a KRAS-associated gene signature from colorectal tumors to develop a precise treatment strategy. Integrative analysis of quantitative KRAS mutation detection and matched gene expression profiling in 55 CRC bulk tumors was carried out to define a gene signature enriched in CRC tumors with high KRAS mutation. The KRAS-associated gene signature identified exhibits functional enrichment in cell cycle and mitosis processes, and includes mitotic transcription factor, FOXM1. Combination treatment of CDK4/6 inhibitor Palbociclib and MEK inhibitor PD0325901 was tested in KRAS-mutant, BRAF-mutant CRC, normal colon epithelial lines and xenografts models to determine their efficacy and toxicity and to monitor the changes in the gene signature. Inhibiting CDK4/6, an upstream regulator of FOXM1, and MEK synergistically depleted FOXM1 and KRAS-associated gene signature, suggesting that CDK4/6 and MEK regulate the KRAS gene signature. The combined inhibition of CDK4/6 and MEK elicited a robust therapeutic response in KRAS-dependent and BRAF-mutant CRC, both in vitro and in vivo and this correlated with downregulation of the KRAS-associated gene signature. Our preclinical study demonstrated the efficacy of Palbociclib and PD0325901 combinatorial treatment selectively in KRAS-dependent and BRAF-mutant CRC but not in normal colon epithelial cells. The KRAS-associated gene signature could facilitate the identification of responsive metastatic CRC to this therapeutic strategy in clinical settings.	[Pek, M.; Yatim, S. M. J. M.; Chen, Y.; Gong, M.; Jiang, X.; Yu, Q.] ASTAR, Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Singapore, Singapore; [Pek, M.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Chen, Y.; Wu, X.] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China; [Chen, Y.; Wu, X.] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China; [Li, J.] ASTAR, Genome Inst Singapore, Computat Biol, Singapore, Singapore; [Zhang, F.; Zheng, J.] Nanyang Technol Univ, Sch Comp Engn, 50 Nanyang Ave, Singapore, Singapore; [Wu, X.] Guangdong Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Yu, Q.] Jinan Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Yu, Q.] Duke Natl Univ Singapore, Grad Med Sch Singapore, Canc & Stem Cell Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Sun Yat Sen University; Sun Yat Sen University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Jinan University; National University of Singapore	Yu, Q (corresponding author), Genome Inst Singapore, Canc Therapeut & Stratified Oncol, 60 Biopolis St,02-01, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg	Zheng, Jie/C-1356-2011; Zheng, Jie/AAX-1454-2021	Zheng, Jie/0000-0001-6774-9786; Yu, Qiang/0000-0003-2132-8278; Zhang, Fan/0000-0001-8377-0235	A*STAR of Singapore; International S&T Cooperation Program of China (ISTCP) [2013DFG32990]; National High Technology Research and Development Program (863) of China [2012AA02A520]	A*STAR of Singapore(Agency for Science Technology & Research (A*STAR)); International S&T Cooperation Program of China (ISTCP); National High Technology Research and Development Program (863) of China(National High Technology Research and Development Program of China)	This work was supported by the A*STAR of Singapore, International S&T Cooperation Program of China (ISTCP) (No. 2013DFG32990) and National High Technology Research and Development Program (863) of China (No. 2012AA02A520). We thank Puay Leng Lee for technical assistance in western blot analysis.	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137; Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hayes TK, 2016, CANCER CELL, V29, P75, DOI 10.1016/j.ccell.2015.11.011; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kosmidou V, 2014, HUM MUTAT, V35, P329, DOI 10.1002/humu.22496; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Russo A, 2005, ANN ONCOL, V16, P44, DOI 10.1093/annonc/mdi907; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tan Y, 2010, CELL PROLIFERAT, V43, P494, DOI 10.1111/j.1365-2184.2010.00699.x; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Ziemke EK, 2016, CLIN CANCER RES, V22, P405, DOI 10.1158/1078-0432.CCR-15-0829; Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016	43	49	51	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4975	4986		10.1038/onc.2017.120	http://dx.doi.org/10.1038/onc.2017.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459468				2022-12-17	WOS:000408768800003
J	Jungnickel, C; Schmidt, LH; Bittigkoffer, L; Wolf, L; Wolf, A; Ritzmann, F; Kamyschnikow, A; Herr, C; Menger, MD; Spieker, T; Wiewrodt, R; Bals, R; Beisswenger, C				Jungnickel, C.; Schmidt, L. H.; Bittigkoffer, L.; Wolf, L.; Wolf, A.; Ritzmann, F.; Kamyschnikow, A.; Herr, C.; Menger, M. D.; Spieker, T.; Wiewrodt, R.; Bals, R.; Beisswenger, C.			IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth	ONCOGENE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; BREAST-CANCER; EPITHELIAL-CELLS; MYELOID CELLS; HOST-DEFENSE; KAPPA-B; INFLAMMATION; RECEPTOR; COPD; METASTASIS	Chronic obstructive pulmonary disease (COPD) is associated with an increased risk for lung cancer and an aberrant microbiota of the lung. Microbial colonization contributes to chronic neutrophilic inflammation in COPD. Nontypeable Haemophilus influenzae (NTHi) is frequently found in lungs of stable COPD patients and is the major pathogen triggering exacerbations. The epithelial cytokine interleukin-17C (IL-17C) promotes the recruitment of neutrophils into inflamed tissues. The purpose of this study was to investigate the function of IL-17C in the pulmonary tumor microenvironment. We subjected mice deficient for IL-17C (IL-17C(-/-)) and mice double deficient for Toll-like receptor 2 and 4 (TLR-2/4(-/-)) to a metastatic lung cancer model. Tumor proliferation and growth as well as the number of tumor-associated neutrophils was significantly decreased in IL-17C(-/-) and TLR-2/4(-/-) mice exposed to NTHi. The NTHi-induced pulmonary expression of IL-17C was dependent on TLR-2/4. In vitro, IL-17C increased the NTHi-and tumor necrosis factor-alpha-induced expression of the neutrophil chemokines keratinocyte-derived chemokine and macrophage inflammatory protein 2 in lung cancer cells but did not affect proliferation. Human lung cancer samples stained positive for IL-17C, and in non-small cell lung cancer patients with lymph node metastasis, IL-17C was identified as a negative prognostic factor. Our data indicate that epithelial IL-17C promotes neutrophilic inflammation in the tumor microenvironment and suggest that IL-17C links a pathologic microbiota, as present in COPD patients, with enhanced tumor growth.	[Jungnickel, C.; Bittigkoffer, L.; Wolf, L.; Wolf, A.; Ritzmann, F.; Kamyschnikow, A.; Herr, C.; Bals, R.; Beisswenger, C.] Saarland Univ, Dept Internal Med Pulmonol Allergol & Resp Crit C, D-66421 Homburg, Germany; [Schmidt, L. H.; Wiewrodt, R.] Univ Hosp Munster, Dept Med Hematol Oncol & Pulmonol A, Munster, Germany; [Menger, M. D.] Saarland Univ, Inst Clin & Expt Surg, Med Ctr, Homburg, Germany; [Spieker, T.] Univ Hosp Muenster, Gerhard Domagk Inst Pathol, Munster, Germany	Universitatsklinikum des Saarlandes; University of Munster; Universitatsklinikum des Saarlandes; University of Munster	Beisswenger, C (corresponding author), Saarland Univ, Dept Internal Med Pulmonol Allergol & Resp Crit C, D-66421 Homburg, Germany.	christoph.beisswenger@uks.eu	Beisswenger, Christoph/GRO-6580-2022; Herr, Christian/AAH-5291-2021	Herr, Christian/0000-0001-9422-6569	Wilhelm-Sander-Stiftung	Wilhelm-Sander-Stiftung	We thank Anja Honecker for excellent technical assistance. This study was supported by grants from the Wilhelm-Sander-Stiftung to Christoph Beisswenger and Robert Bals.	Adcock IM, 2011, RESPIRATION, V81, P265, DOI 10.1159/000324601; Bellocq A, 1998, AM J PATHOL, V152, P83; Chang SH, 2014, P NATL ACAD SCI USA, V111, P5664, DOI 10.1073/pnas.1319051111; Chang SH, 2011, IMMUNITY, V35, P611, DOI 10.1016/j.immuni.2011.09.010; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; El Rayes T, 2015, P NATL ACAD SCI USA, V112, P16000, DOI 10.1073/pnas.1507294112; Friedrich M, 2015, MUCOSAL IMMUNOL, V8, P943, DOI 10.1038/mi.2014.124; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hattar K, 2013, CANCER IMMUNOL IMMUN, V62, P309, DOI 10.1007/s00262-012-1341-2; Herr C, 2015, EXP TOXICOL PATHOL, V67, P261, DOI 10.1016/j.etp.2015.01.002; Hess C, 2010, EUR RESPIR J, V35, P343, DOI 10.1183/09031936.00196408; Hoenderdos K, 2013, AM J RESP CELL MOL, V48, P531, DOI 10.1165/rcmb.2012-0492TR; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Johansen C, 2011, J BIOL CHEM, V286, P25487, DOI 10.1074/jbc.M111.240671; Jungnickel C, 2015, AM J PHYSIOL-LUNG C, V309, pL605, DOI 10.1152/ajplung.00116.2015; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Klein M, 2008, J INFECT DIS, V198, P1028, DOI 10.1086/591626; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kusagaya H, 2014, AM J RESP CELL MOL, V50, P30, DOI 10.1165/rcmb.2013-0130OC; Li D, 2014, ONCOGENE, V33, P2709, DOI 10.1038/onc.2013.248; Li D, 2014, ONCOGENE, V33, P1239, DOI 10.1038/onc.2013.75; Marsland BJ, 2014, NAT REV IMMUNOL, V14, P827, DOI 10.1038/nri3769; Moghaddam SJ, 2009, AM J RESP CELL MOL, V40, P443, DOI 10.1165/rcmb.2008-0198OC; Papi A, 2004, THORAX, V59, P679, DOI 10.1136/thx.2003.018291; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfeifer P, 2013, AM J RESP CELL MOL, V48, P415, DOI 10.1165/rcmb.2012-0232OC; Rad R, 2009, GASTROENTEROLOGY, V136, P2247, DOI 10.1053/j.gastro.2009.02.066; Ramirez-Carrozzi V, 2011, NAT IMMUNOL, V12, P1159, DOI 10.1038/ni.2156; REMMELE W, 1987, PATHOLOGE, V8, P138; Roos AB, 2015, AM J RESP CRIT CARE, V192, P428, DOI 10.1164/rccm.201409-1689OC; Schmidt LH, 2014, J THORAC ONCOL, V9, P1294, DOI 10.1097/JTO.0000000000000243; Sethi S, 2010, EUR RESPIR J, V35, P1209, DOI 10.1183/09031936.00081409; Song XY, 2014, IMMUNITY, V40, P140, DOI 10.1016/j.immuni.2013.11.018; Song XY, 2011, NAT IMMUNOL, V12, P1151, DOI 10.1038/ni.2155; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Teramukai S, 2009, EUR J CANCER, V45, P1950, DOI 10.1016/j.ejca.2009.01.023; Voss M, 2015, AM J PHYSIOL-LUNG C, V309, pL188, DOI 10.1152/ajplung.00388.2014; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wolf L, 2016, AM J PHYSIOL-LUNG C, V311, pL1015, DOI 10.1152/ajplung.00158.2016; Yadava K, 2016, AM J RESP CRIT CARE, V193, P975, DOI 10.1164/rccm.201504-0779OC; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208; Zulueta JJ, 2012, CHEST, V141, P1216, DOI 10.1378/chest.11-0101	47	49	58	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4182	4190		10.1038/onc.2017.28	http://dx.doi.org/10.1038/onc.2017.28			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346430				2022-12-17	WOS:000405835800009
J	Hulsurkar, M; Li, Z; Zhang, Y; Li, X; Zheng, D; Li, W				Hulsurkar, M.; Li, Z.; Zhang, Y.; Li, X.; Zheng, D.; Li, W.			Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1	ONCOGENE			English	Article							CORONARY-HEART-DISEASE; PROTEIN-KINASE-A; HISTONE DEACETYLASE; CARDIAC-HYPERTROPHY; HDAC INHIBITORS; VALPROIC ACID; IN-VITRO; CELLS; RECEPTOR; GENOMICS	Chronic behavioral stress and beta-adrenergic signaling have been shown to promote cancer progression, whose underlying mechanisms are largely unclear, especially the involvement of epigenetic regulation. Histone deacetylase-2 (HDAC2), an epigenetic regulator, is critical for stress-induced cardiac hypertrophy. It is unknown whether it is necessary for beta-adrenergic signaling promoted cancer progression. Using xenograft models, we showed that chronic behavioral stress and beta-adrenergic signaling promote angiogenesis and prostate cancer progression. HDAC2 was induced by beta-adrenergic signaling in vitro and in mouse xenografts. We next uncovered that HDAC2 is a direct target of cAMP response element-binding protein (CREB) that is activated by beta-adrenergic signaling. Notably, HDAC2 is necessary for beta-adrenergic signaling to induce angiogenesis. We further demonstrated that, upon CREB activation, HDAC2 represses thrombospondin-1 (TSP1), a potent angiogenesis inhibitor, through epigenetic regulation. Together, these data establish a novel pathway that HDAC2 and TSP1 act downstream of CREB activation in beta-adrenergic signaling to promote cancer progression.	[Hulsurkar, M.; Li, Z.; Zhang, Y.; Li, X.; Zheng, D.; Li, W.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, SRB 537C,1825 Pressler St, Houston, TX 77030 USA; [Hulsurkar, M.; Li, W.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Li, Z.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Breast & Thyroid Surg Ctr, Wuhan 430074, Peoples R China; [Zhang, Y.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China; [Li, X.] Taishan Med Univ, Liaocheng Clin Sch, Liaocheng Peoples Hosp, Liaocheng, Peoples R China; [Zheng, D.] Southern Med Univ, Nanfang Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China	University of Texas System; University of Texas Health Science Center Houston; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Shandong First Medical University & Shandong Academy of Medical Sciences; Southern Medical University - China	Li, W (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, SRB 537C,1825 Pressler St, Houston, TX 77030 USA.	wenliang.li@uth.tmc.edu	Hulsurkar, Mohit/L-9946-2019	Hulsurkar, Mohit/0000-0003-0595-6661	University of Texas System	University of Texas System	We are grateful to Dr Rebecca Berdeaux for providing us the CREB cDNA constructs. We are thankful to Drs Isaiah Fidler and Vihang Narkar for providing us PC3 and SVEC4-10 cells, respectively. We also would like to thank Dr Kendra Carmon for critical reading of this paper. This work was supported by a Rising STARS Award from University of Texas System (W Li).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Armaiz-Pena GN, 2013, BRAIN BEHAV IMMUN, V30, pS19, DOI 10.1016/j.bbi.2012.06.005; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Braadland PR, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00375; Byler TK, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-21; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; de Graaf C, 2008, J MED CHEM, V51, P4978, DOI 10.1021/jm800710x; Dishy V, 2001, NEW ENGL J MED, V345, P1030, DOI 10.1056/NEJMoa010819; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Govindan MV, 2010, J BIOL CHEM, V285, P4489, DOI 10.1074/jbc.M109.072728; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grytli HH, 2013, PROSTATE, V73, P250, DOI 10.1002/pros.22564; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Holmes S, 2013, CANCER EPIDEMIOL, V37, P881, DOI 10.1016/j.canep.2013.09.001; Kee HJ, 2006, CIRCULATION, V113, P51, DOI 10.1161/CIRCULATIONAHA.105.559724; Kong YL, 2006, CIRCULATION, V113, P2579, DOI 10.1161/CIRCULATIONAHA.106.625467; Krantz DS, 2002, ANNU REV PSYCHOL, V53, P341, DOI 10.1146/annurev.psych.53.100901.135208; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Li LN, 2014, ONCOTARGET, V5, P10840, DOI 10.18632/oncotarget.2535; Lia WL, 2014, P NATL ACAD SCI USA, V111, P1521, DOI 10.1073/pnas.1320638111; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Manna PP, 2004, CANCER RES, V64, P1026, DOI 10.1158/0008-5472.CAN-03-1708; Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Roberts W, 2010, BLOOD, V116, P4297, DOI 10.1182/blood-2010-01-265561; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sang M, 2016, ONCOTARGET, DOI 10.18632/oncotarget.9359.; Staton CA, 2004, INT J EXP PATHOL, V85, P233, DOI 10.1111/j.0959-9673.2004.00396.x; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Walchli T, 2015, NAT PROTOC, V10, P53, DOI 10.1038/nprot.2015.002; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang HM, 2013, ANN ONCOL, V24, P1312, DOI 10.1093/annonc/mds616; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wojtukiewicz MZ, 2001, NEOPLASIA, V3, P371, DOI 10.1038/sj.neo.7900184; Yang QW, 2007, CANCER RES, V67, P1716, DOI 10.1158/0008-5472.CAN-06-2595; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043	50	49	54	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1525	1536		10.1038/onc.2016.319	http://dx.doi.org/10.1038/onc.2016.319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27641328				2022-12-17	WOS:000397458100007
J	Englund, E; Bartoschek, M; Reitsma, B; Jacobsson, L; Escudero-Esparza, A; Orimo, A; Leandersson, K; Hagerling, C; Aspberg, A; Storm, P; Okroj, M; Mulder, H; Jirstrom, K; Pretras, K; Blom, AM				Englund, E.; Bartoschek, M.; Reitsma, B.; Jacobsson, L.; Escudero-Esparza, A.; Orimo, A.; Leandersson, K.; Hagerling, C.; Aspberg, A.; Storm, P.; Okroj, M.; Mulder, H.; Jirstrom, K.; Pretras, K.; Blom, A. M.			Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; EXPRESSION; COMPLEMENT; COMP; ACTIVATION; DOMAIN; BETA; ER	Cartilage oligomeric matrix protein (COMP) is a soluble pentameric protein expressed in cartilage and involved in collagen organization. Tissue microarrays derived from two cohorts of patients with breast cancer (n= 122 and n = 498) were immunostained, revealing varying expression of COMP, both in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Breast cancer cells, MDA-MB-231, stably expressing COMP were injected into the mammary fat pad of SCID (CB-17/Icr-Prkdc(scid)/Rj) mice. Tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control, mock-transfected, tumors. In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of matrix metalloprotease-9. Furthermore, microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. This observation was confirmed in vitro as COMP-expressing cells showed better survival as well as a higher rate of protein synthesis when treated with brefeldin A, compared with control cells. Further, COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect. Thus, in vitro measurement of cell respiration indicated decreased mitochondrial metabolism. In conclusion, COMP is a novel biomarker in breast cancer, which contributes to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.	[Englund, E.; Reitsma, B.; Escudero-Esparza, A.; Okroj, M.; Blom, A. M.] Lund Univ, Dept Translat Med, Div Med Prot Chem, Malmo, Sweden; [Bartoschek, M.; Pretras, K.] Lund Univ, Dept Lab Med, Div Translat Canc Res, Lund, Sweden; [Jacobsson, L.; Mulder, H.] Lund Univ, Unit Mol Metab, Dept Clin Sci Malmo, Lund, Sweden; [Orimo, A.] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo, Japan; [Leandersson, K.; Hagerling, C.] Lund Univ, Ctr Mol Pathol, Dept Lab Med, Malmo, Sweden; [Aspberg, A.] Lund Univ, Dept Clin Sci Lund, Div Rheumatol & Mol Skeletal Biol, Lund, Sweden; [Storm, P.] Lund Univ, Dept Clin Sci Malmo, Div Diabet & Endocrinol, Malmo, Sweden; [Okroj, M.] Med Univ Gdansk, UG MUG, Intercollegiate Fac Biotechnol, Dept Med Biotechnol, Gdansk, Poland; [Jirstrom, K.] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden	Lund University; Lund University; Lund University; Juntendo University; Lund University; Lund University; Lund University; Fahrenheit Universities; Medical University Gdansk; Lund University	Blom, AM (corresponding author), Lund Univ, Skane Univ Hosp, Wallenberg Lab, Div Med Prot Chem,Dept Translat Med, Inga Maria Nilssons St 53, S-20502 Malmo, Sweden.	anna.blom@med.lu.se	Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734; Pietras, Kristian/0000-0001-6738-4705; Storm, Petter/0000-0002-7655-3731; Mulder, Hindrik/0000-0002-6593-8417; Aspberg, Anders/0000-0002-6588-6944; Orimo, Akira/0000-0001-5330-7282	Cancerfonden; Swedish Research Council [K2012-66X-14928-09-5]; Swedish Government Funds for Clinical research; Foundation of Osterlund; Foundation of Crafoord; Foundation of Greta and Johan Kock; King Gustav V's 80th anniversary; Knut and Alice Wallenberg; Inga-Britt and Arne Lundberg; Royal Physiographic Society; Skane University Hospital; National Science Centre, Poland [2014/14/E/NZ6/00182]; Grants-in-Aid for Scientific Research [15K14385] Funding Source: KAKEN	Cancerfonden(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Government Funds for Clinical research; Foundation of Osterlund; Foundation of Crafoord; Foundation of Greta and Johan Kock; King Gustav V's 80th anniversary; Knut and Alice Wallenberg(Knut & Alice Wallenberg Foundation); Inga-Britt and Arne Lundberg; Royal Physiographic Society; Skane University Hospital; National Science Centre, Poland(National Science Centre, Poland); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Cancerfonden, the Swedish Research Council (K2012-66X-14928-09-5), the Swedish Government Funds for Clinical research (ALF) and the Foundations of Osterlund, Crafoord, Greta and Johan Kock, King Gustav V's 80th anniversary, Knut and Alice Wallenberg and Inga-Britt and Arne Lundberg, Royal Physiographic Society, as well as a grant from the Skane University Hospital. MO was supported by National Science Centre, Poland (2014/14/E/NZ6/00182).	Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Agarwal P, 2013, MATRIX BIOL, V32, P325, DOI 10.1016/j.matbio.2013.02.010; Anderson BO, 2008, CANCER-AM CANCER SOC, V113, P2221, DOI 10.1002/cncr.23844; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Borgquist S, 2008, J CLIN PATHOL, V61, P197, DOI 10.1136/jcp.2006.040378; Borgquist S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2146; Briggs MD, 2014, EUR J HUM GENET, V22, P1278, DOI 10.1038/ejhg.2014.30; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Englund E, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1734-7; Escudero-Esparza A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-43; Farina G, 2006, MATRIX BIOL, V25, P213, DOI 10.1016/j.matbio.2006.01.007; Furge K, 2012, PGSEA PARAMETRIC GEN; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Happonen KE, 2010, ARTHRITIS RHEUM-US, V62, P3574, DOI 10.1002/art.27720; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Hesselstrand R, 2008, ANN RHEUM DIS, V67, P1242, DOI 10.1136/ard.2007.082099; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kung LHW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117016; Lynch JM, 2012, CELL, V149, P1257, DOI 10.1016/j.cell.2012.03.050; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Otteby KE, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4410; Ryden L, 2005, J CLIN ONCOL, V23, P4695, DOI 10.1200/JCO.2005.08.126; Sodersten F, 2006, CONNECT TISSUE RES, V47, P85, DOI 10.1080/03008200600584124; Svensson KJ, 2011, INT J ONCOL, V39, P1421, DOI 10.3892/ijo.2011.1164; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203	31	49	50	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5585	5596		10.1038/onc.2016.98	http://dx.doi.org/10.1038/onc.2016.98			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065333				2022-12-17	WOS:000386998300002
J	Slany, RK				Slany, R. K.			The molecular mechanics of mixed lineage leukemia	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; MLL-REARRANGED LEUKEMIA; HOX GENE-EXPRESSION; ACUTE MYELOID-LEUKEMIA; PROTO-ONCOPROTEIN MLL; RNA-POLYMERASE-II; DEPENDENT KINASE INHIBITORS; METHYLTRANSFERASE ACTIVITY; 11Q23 TRANSLOCATIONS; FUSION PROTEINS	Mixed lineage leukemia caused by MLL fusion proteins is still a mostly incurable disease. Research on novel treatment strategies has gained momentum in the last years with the elucidation of the molecular mechanisms underlying the transforming potential of these powerful oncoproteins. This review summarizes the recent developments in this area including new attempts to treat MLL in a rational way by exploiting the biochemical vulnerabilities of the leukemogenic process.	[Slany, R. K.] Univ Erlangen Nurnberg, Dept Genet, Erwin Rommel St 3, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Erwin Rommel St 3, D-91058 Erlangen, Germany.	robert.slany@fau.de			Deutsche Forschungsgemeinschaft; Bavarian Ministry of Sciences, Research and the Arts in the framework of the Bavarian Molecular Biosystems Research Network; Emerging Fields Initiative of the FAU University Erlangen-Nurnberg (CYDER)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bavarian Ministry of Sciences, Research and the Arts in the framework of the Bavarian Molecular Biosystems Research Network; Emerging Fields Initiative of the FAU University Erlangen-Nurnberg (CYDER)	I would like to apologize to all colleagues whose work could not be cited because of space constraints. Research in the lab of the author is funded by: Deutsche Forschungsgemeinschaft, the Bavarian Ministry of Sciences, Research and the Arts in the framework of the Bavarian Molecular Biosystems Research Network and by the Emerging Fields Initiative of the FAU University Erlangen-Nurnberg (CYDER).	Anderson M, 2002, DEV GENES EVOL, V212, P107, DOI 10.1007/s00427-002-0213-8; Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Arai S, 2011, BLOOD, V117, P6304, DOI 10.1182/blood-2009-07-234310; Barretto Nisha N, 2014, J Exp Ther Oncol, V10, P293; Beldjord K, 2014, BLOOD, V123, P3739, DOI 10.1182/blood-2014-01-547695; BERGER R, 1982, LEUKEMIA RES, V6, P17, DOI 10.1016/0145-2126(82)90039-X; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Blachly JS, 2013, LEUKEMIA LYMPHOMA, V54, P2133, DOI 10.3109/10428194.2013.783911; Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016; Brown P, 2013, HEMATOL-AM SOC HEMAT, P596, DOI 10.1182/asheducation-2013.1.596; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Caslini C, 2007, CANCER RES, V67, P7275, DOI 10.1158/0008-5472.CAN-06-2369; Chang PY, 2010, J MOL BIOL, V400, P137, DOI 10.1016/j.jmb.2010.05.005; Chen CW, 2015, EXP HEMATOL, V43, P673, DOI 10.1016/j.exphem.2015.05.012; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Chen J, 2008, CANCER RES, V68, P6199, DOI 10.1158/0008-5472.CAN-07-6514; Chen L, 2013, LEUKEMIA, V27, P813, DOI 10.1038/leu.2012.327; Chessells JM, 2002, LEUKEMIA, V16, P776, DOI 10.1038/sj.leu.2402468; CHILDS C C, 1988, Hematologic Pathology, V2, P145; Cowell IG, 2012, P NATL ACAD SCI USA, V109, P8989, DOI 10.1073/pnas.1204406109; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Dawson MA, 2014, LEUKEMIA, V28, P311, DOI 10.1038/leu.2013.338; Denissov S, 2014, DEVELOPMENT, V141, P526, DOI 10.1242/dev.102681; Deshpande AJ, 2014, CANCER CELL, V26, P896, DOI 10.1016/j.ccell.2014.10.009; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Feng Y, 2010, BLOOD, V116, P4483, DOI 10.1182/blood-2010-03-276501; Garcia-Cuellar MP, 2014, LEUKEMIA, V28, P1427, DOI 10.1038/leu.2014.40; Garcia-Cuellar MP, 2015, HAEMATOLOGICA, V100, P905, DOI 10.3324/haematol.2015.124032; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/NCHEMBIO.1859, 10.1038/nchembio.1859]; Grembecka J, 2012, NAT CHEM BIOL, V8, P277, DOI [10.1038/NCHEMBIO.773, 10.1038/nchembio.773]; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guenther MG, 2008, GENE DEV, V22, P3403, DOI 10.1101/gad.1741408; He SH, 2014, J MED CHEM, V57, P1543, DOI 10.1021/jm401868d; Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Itzen F, 2014, NUCLEIC ACIDS RES, V42, P7577, DOI 10.1093/nar/gku449; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Jonkers I, 2015, NAT REV MOL CELL BIO, V16, P167, DOI 10.1038/nrm3953; KANEKO Y, 1986, BLOOD, V67, P484; Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912; Leach BI, 2013, STRUCTURE, V21, P176, DOI 10.1016/j.str.2012.11.011; Li ZJ, 2013, BLOOD, V121, P1422, DOI 10.1182/blood-2012-07-442004; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu H, 2014, CANCER CELL, V25, P530, DOI 10.1016/j.ccr.2014.03.008; Llano M, 2006, SCIENCE, V314, P461, DOI 10.1126/science.1132319; Maethner E, 2013, CELL REP, V3, P1553, DOI 10.1016/j.celrep.2013.03.038; McLean CM, 2014, LEUKEMIA, V28, P2131, DOI 10.1038/leu.2014.169; Mereau H, 2013, LEUKEMIA, V27, P1245, DOI 10.1038/leu.2013.10; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Mishra BP, 2014, CELL REP, V7, P1239, DOI 10.1016/j.celrep.2014.04.015; Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410; Monroe SC, 2011, EXP HEMATOL, V39, P77, DOI 10.1016/j.exphem.2010.09.003; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Mueller D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000249; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Muntean AG, 2008, BLOOD, V112, P4690, DOI 10.1182/blood-2008-01-134056; Murai MJ, 2014, BLOOD, V124, P3730, DOI 10.1182/blood-2014-01-550079; Nguyen AT, 2011, CELL RES, V21, P1370, DOI 10.1038/cr.2011.115; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okuda H, 2014, NUCLEIC ACIDS RES, V42, P4241, DOI 10.1093/nar/gkt1394; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Paggetti J, 2010, ONCOGENE, V29, P5019, DOI 10.1038/onc.2010.254; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pigneux A, 2015, LEUKEMIA, V29, P2375, DOI 10.1038/leu.2015.143; Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Pui CH, 2011, J CLIN ONCOL, V29, P551, DOI 10.1200/JCO.2010.30.7405; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Roderick JE, 2014, BLOOD, V123, P1040, DOI 10.1182/blood-2013-08-522698; ROWLEY JD, 1973, NEW ENGL J MED, V289, P220; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Shi AB, 2012, BLOOD, V120, P4461, DOI 10.1182/blood-2012-05-429274; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Smith E, 2011, GENE DEV, V25, P661, DOI 10.1101/gad.2015411; Spencer DH, 2015, LEUKEMIA, V29, P1279, DOI 10.1038/leu.2015.6; Srinivasan RS, 2004, LEUKEMIA, V18, P1364, DOI 10.1038/sj.leu.2403415; Sroczynska P, 2014, BLOOD, V123, P1870, DOI 10.1182/blood-2013-08-522094; STARK B, 1986, CANCER-AM CANCER SOC, V58, P1265, DOI 10.1002/1097-0142(19860915)58:6<1265::AID-CNCR2820580615>3.0.CO;2-6; Steffen PA, 2014, NAT REV MOL CELL BIO, V15, P340, DOI 10.1038/nrm3789; Stein EM, 2015, CURR OPIN HEMATOL, V22, P92, DOI 10.1097/MOH.0000000000000123; Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tomizawa D, 2007, LEUKEMIA, V21, P2258, DOI 10.1038/sj.leu.2404903; van der Linden MH, 2014, CELL CYCLE, V13, P834, DOI 10.4161/cc.27757; van der Linden MH, 2009, BLOOD, V114, P3764, DOI 10.1182/blood-2009-02-204214; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; VERMAELEN K, 1983, CANCER GENET CYTOGEN, V10, P105, DOI 10.1016/0165-4608(83)90111-5; Wang E, 2013, P NATL ACAD SCI USA, V110, P3901, DOI 10.1073/pnas.1301045110; Wang ES, 2014, HEMATOL-AM SOC HEMAT, P14, DOI 10.1182/asheducation-2014.1.14; Wang QF, 2011, BLOOD, V117, P6895, DOI 10.1182/blood-2010-12-324699; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Yokoyama A, 2008, CANCER CELL, V14, P36, DOI 10.1016/j.ccr.2008.05.003; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zeisig DT, 2005, ONCOGENE, V24, P5525, DOI 10.1038/sj.onc.1208699; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang Y, 2013, BLOOD, V122, P2888, DOI 10.1182/blood-2012-08-453662; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	129	49	51	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5215	5223		10.1038/onc.2016.30	http://dx.doi.org/10.1038/onc.2016.30			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26923329	Green Published			2022-12-17	WOS:000386053000001
J	Bernaudo, S; Salem, M; Qi, X; Zhou, W; Zhang, C; Yang, W; Rosman, D; Deng, Z; Ye, G; Yang, BB; Vanderhyden, B; Wu, Z; Peng, C				Bernaudo, S.; Salem, M.; Qi, X.; Zhou, W.; Zhang, C.; Yang, W.; Rosman, D.; Deng, Z.; Ye, G.; Yang, B. B.; Vanderhyden, B.; Wu, Z.; Peng, C.			Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/beta-catenin signaling	ONCOGENE			English	Article							OVARIAN-CANCER; EXPRESSION; TRANSCRIPTION; CARCINOMA; MECHANISM; INVASION; CELLS; TRANSFORMATION; ACTIVATION; PATHWAY	Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological malignancies owing to poor screening methods, non-specific symptoms and limited knowledge of the cellular targets that contribute to the disease. Cyclin G2 is an unconventional cyclin that acts to oppose cell cycle progression. Dysregulation of the cyclin G2 gene (CCNG2) in a variety of human cancers has been reported; however, the role of cyclin G2 in tumorigenesis remains unclear. In this study, we investigated the function of cyclin G2 in EOC. In vitro and in vivo studies using several EOC-derived tumor cell lines revealed that cyclin G2 inhibited cell proliferation, migration, invasion and spheroid formation, as well as tumor formation and invasion. By interrogating cDNA microarray data sets, we found that CCGN2 mRNA is reduced in several large cohorts of human ovarian carcinoma when compared with normal ovarian surface epithelium or borderline tumors of the ovary. Mechanistically, cyclin G2 was found to suppress epithelial-to-mesenchymal transition (EMT), as demonstrated by the differential regulation of various EMT genes, such as Snail, Slug, vimentin and E-cadherin. Moreover, cyclin G2 potently suppressed the Wnt/beta-catenin signaling pathway by downregulating key Wnt components, namely LRP6, DVL2 and beta-catenin, which could be linked to inhibition of EMT. Taken together, our novel findings demonstrate that cyclin G2 has potent tumor-suppressive effects in EOCs by inhibiting EMT through attenuating Wnt/beta-catenin signaling.	[Bernaudo, S.; Salem, M.; Qi, X.; Zhou, W.; Zhang, C.; Yang, W.; Rosman, D.; Ye, G.; Wu, Z.; Peng, C.] York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [Deng, Z.; Yang, B. B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Vanderhyden, B.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Wu, Z.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Deng, Z.] Jiangsu Univ, Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China	York University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Hong Kong University of Science & Technology; Jiangsu University	Peng, C (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	cpeng@yorku.ca			Canadian Institutes of Health Research (CIHR) [MOP-89931]; Natural Science and Engineering Foundation (NSERC) [203081-2009, 227937-2012]; NSERC; OGS; York University; Ovarian Cancer Canada	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Science and Engineering Foundation (NSERC); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); OGS(Ontario Graduate Scholarship); York University; Ovarian Cancer Canada	This study was supported by grants from Canadian Institutes of Health Research (CIHR) to CP (MOP-89931) and from Natural Science and Engineering Foundation (NSERC) to CP (203081-2009) and to BY (227937-2012). SB was a recipient of graduate scholarships from NSERC, OGS and York University. We thank Dr Mien-Chie Hung for SKOV3.ip1 cells and the tumor bank at Ottawa Hospital Research Institute for providing the ovarian cancer samples. The Ottawa Ovarian Cancer Tissue Bank is supported in part by Ovarian Cancer Canada.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Aguilar V, 2010, ENDOCRINOLOGY, V151, P5247, DOI 10.1210/en.2010-0461; Anglesio MS, 2008, MOL CANCER RES, V6, P1678, DOI 10.1158/1541-7786.MCR-08-0193; Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Chiu WT, 2015, ONCOTARGET, V6, P2349, DOI 10.18632/oncotarget.2957; Choi MG, 2009, J SURG RES, V157, P168, DOI 10.1016/j.jss.2008.06.020; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Ford CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054362; Fu G, 2011, ONCOGENE, V30, P3953, DOI 10.1038/onc.2011.127; Gajate C, 2002, J BIOL CHEM, V277, P41580, DOI 10.1074/jbc.M204644200; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Ito Y, 2003, ANTICANCER RES, V23, P2335; Jia Jin-Song, 2005, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V13, P254; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kasukabe T, 2005, BREAST CANCER RES, V7, pR1097, DOI 10.1186/bcr1344; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lau MT, 2011, ONCOGENE, V30, P2753, DOI 10.1038/onc.2011.6; Lili LN, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-49; Liu J, 2004, WORLD J GASTROENTERO, V10, P1357; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mourgues L, 2015, LEUKEMIA, V29, P1993, DOI 10.1038/leu.2015.112; Nadeem L, 2011, AM J PATHOL, V178, P1177, DOI 10.1016/j.ajpath.2010.11.066; Pease JC, 2012, BIOL OPEN, V1, P622, DOI 10.1242/bio.2012653; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Siragam V, 2012, ONCOTARGET, V3, P1370, DOI 10.18632/oncotarget.717; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Ye G, 2012, ADV OVARIAN CANC MAN, P6; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yoshihara K, 2009, CANCER SCI, V100, P1421, DOI 10.1111/j.1349-7006.2009.01204.x; Yuan H, 2013, CANCER RES, V73, P1581, DOI 10.1158/0008-5472.CAN-12-2377; Zhu LY, 2015, CANCER LETT, V363, P71, DOI 10.1016/j.canlet.2015.04.002	51	49	54	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4816	4827		10.1038/onc.2016.15	http://dx.doi.org/10.1038/onc.2016.15			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876206	hybrid, Green Published			2022-12-17	WOS:000383324700014
J	Li, Z; Hao, Q; Luo, J; Xiong, J; Zhang, S; Wang, T; Bai, L; Wang, W; Chen, M; Wang, W; Gu, L; Lv, K; Chen, J				Li, Z.; Hao, Q.; Luo, J.; Xiong, J.; Zhang, S.; Wang, T.; Bai, L.; Wang, W.; Chen, M.; Wang, W.; Gu, L.; Lv, K.; Chen, J.			USP4 inhibits p53 and NF-kappa B through deubiquitinating and stabilizing HDAC2	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; HISTONE DEACETYLASES; GENE-EXPRESSION; DNA-BINDING; ACETYLATION; ACTIVATION; APOPTOSIS; PHOSPHORYLATION; RECEPTOR; TARGETS	Histone deacetylases (HDACs) are major epigenetic modulators involved in a broad spectrum of human diseases including cancers. As HDACs are promising targets of cancer therapy, it is important to understand the mechanisms of HDAC regulation. In this study, we show that ubiquitin-specific peptidase 4 (USP4) interacts directly with and deubiquitinates HDAC2, leading to the stabilization of HDAC2. Accumulation of HDAC2 in USP4-overexpression cells leads to compromised p53 acetylation as well as crippled p53 transcriptional activation, accumulation and apoptotic response upon DNA damage. Moreover, USP4 targets HDAC2 to downregulate tumor necrosis factor TNF alpha-induced nuclear factor (NF)-kappa B activation. Taken together, our study provides a novel insight into the ubiquitination and stability of HDAC2 and uncovers a previously unknown function of USP4 in cancers.	[Li, Z.; Hao, Q.; Xiong, J.; Wang, T.] Xiamen Univ, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Li, Z.; Hao, Q.; Xiong, J.; Wang, T.] Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China; [Li, Z.; Hao, Q.; Xiong, J.; Wang, W.; Chen, M.; Wang, W.; Gu, L.; Chen, J.] State Ocean Adm, Inst Oceanog 3, Key Lab Breeding Base Marine Genet Resources, Xiamen 361005, Fujian, Peoples R China; [Luo, J.] Soochow Univ, Changzhou Tumor Hosp, Dept Radiotherapy, Changzhou, Peoples R China; [Zhang, S.] Soochow Univ, Sch Radiat Med & Protect, Suzhou, Peoples R China; [Zhang, S.] Soochow Univ, Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China; [Bai, L.] Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China; [Lv, K.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; [Lv, K.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Xiamen University; Xiamen University; State Oceanic Administration; Soochow University - China; Soochow University - China; Soochow University - China; Xiamen University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Chen, J (corresponding author), State Ocean Adm, Inst Oceanog 3, Key Lab Breeding Base Marine Genet Resources, Xiamen 361005, Fujian, Peoples R China.	chenjianming@tio.org.cn		Hao, Qiongyu/0000-0002-4720-767X	Scientific Research Foundation of Third Institute of Oceanography, SOA [2015011, 2014007]; China Ocean Mineral Resources RD Association [DY125-15-T-03, DY-125-15-T-08]; National Natural Science Foundation of China [81402518, 41201531, 31272684]; China Postdoctoral Science Foundation [2013M541853, 2014T70606]; Marine Public Welfare Project [201005022]; National Science Foundation [31171366]; special financial fund of innovative development of marine economic demonstration project [GD2012-D01-001]	Scientific Research Foundation of Third Institute of Oceanography, SOA; China Ocean Mineral Resources RD Association; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Marine Public Welfare Project; National Science Foundation(National Science Foundation (NSF)); special financial fund of innovative development of marine economic demonstration project	We thank all the members of the Jianming Chen laboratory for their help and assistance. This work was supported by the Scientific Research Foundation of Third Institute of Oceanography, SOA (No. 2015011), DY125-15-T-03 from China Ocean Mineral Resources R&D Association, the National Natural Science Foundation of China (81402518), grants from China Postdoctoral Science Foundation (No. 2013M541853), China Postdoctoral Science Foundation (No. 2014T70606), Marine Public Welfare Project 201005022, the National Science Foundation grant 31171366, the Scientific Research Foundation of Third Institute of Oceanography, SOA (No. 2014007), the National Natural Science Foundation of China (41201531), China Ocean Mineral Resources R&D Association (DY-125-15-T-08), the National Natural Science Foundation of China (31272684), special financial fund of innovative development of marine economic demonstration project, GD2012-D01-001.	Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek KH, 2006, CURR PROTEIN PEPT SC, V7, P171, DOI 10.2174/138920306776359740; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chang AA, 2005, ADV OTO-RHINO-LARYNG, V62, P92; Chen Y, 2011, NAT NEUROSCI, V14, P437, DOI 10.1038/nn.2780; Chung CH, 2006, CANCER RES, V66, P8210, DOI 10.1158/0008-5472.CAN-06-1213; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fan YH, 2011, CELL DEATH DIFFER, V18, P1547, DOI 10.1038/cdd.2011.11; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gong FD, 2013, MUTAT RES-FUND MOL M, V750, P23, DOI 10.1016/j.mrfmmm.2013.07.002; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Heideman MR, 2013, BLOOD, V121, P2038, DOI 10.1182/blood-2012-08-450916; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LeBoeuf M, 2010, DEV CELL, V19, P807, DOI 10.1016/j.devcel.2010.10.015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Milojevic T, 2006, MOL PHARMACOL, V69, P1083, DOI 10.1124/mol.105.015818; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ramakrishna S, 2011, CELL MOL LIFE SCI, V68, P15, DOI 10.1007/s00018-010-0504-6; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Segre CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wagner T, 2014, BBA-REV CANCER, V1846, P524, DOI 10.1016/j.bbcan.2014.07.010; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; Zhang J, 2011, GENE DEV, V25, P2610, DOI 10.1101/gad.170605.111; Zhang L, 2012, NAT CELL BIOL, V14, P717, DOI 10.1038/ncb2522; Zhang XN, 2011, EMBO J, V30, P2177, DOI 10.1038/emboj.2011.125; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou FF, 2012, J BIOL CHEM, V287, P11002, DOI 10.1074/jbc.M111.328187; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	52	49	51	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2902	2912		10.1038/onc.2015.349	http://dx.doi.org/10.1038/onc.2015.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411366	Green Published, hybrid			2022-12-17	WOS:000377473700010
J	Fedorenko, IV; Abel, EV; Koomen, JM; Fang, B; Wood, ER; Chen, YA; Fisher, KJ; Iyengar, S; Dahlman, KB; Wargo, JA; Flaherty, KT; Sosman, JA; Sondak, VK; Messina, JL; Gibney, GT; Smalley, KSM				Fedorenko, I. V.; Abel, E. V.; Koomen, J. M.; Fang, B.; Wood, E. R.; Chen, Y. A.; Fisher, K. J.; Iyengar, S.; Dahlman, K. B.; Wargo, J. A.; Flaherty, K. T.; Sosman, J. A.; Sondak, V. K.; Messina, J. L.; Gibney, G. T.; Smalley, K. S. M.			Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells	ONCOGENE			English	Article							E-CADHERIN; EXTRACELLULAR-MATRIX; ADAPTIVE RESISTANCE; DRUG-RESISTANCE; RAF INHIBITORS; B-RAF; BRAF(V600E); ACTIVATION; GROWTH; PHOSPHORYLATION	The mechanisms by which some melanoma cells adapt to Serine/threonine-protein kinase B-Raf (BRAF) inhibitor therapy are incompletely understood. In the present study, we used mass spectrometry-based phosphoproteomics to determine how BRAF inhibition remodeled the signaling network of melanoma cell lines that were BRAF mutant and PTEN null. Short-term BRAF inhibition was associated with marked changes in fibronectin-based adhesion signaling that were PTEN dependent. These effects were recapitulated through BRAF siRNA knockdown and following treatment with chemotherapeutic drugs. Increased fibronectin expression was also observed in mouse xenograft models as well as specimens from melanoma patients undergoing BRAF inhibitor treatment. Analysis of a melanoma tissue microarray showed loss of PTEN expression to predict for a lower overall survival, with a trend for even lower survival being seen when loss of fibronectin was included in the analysis. Mechanistically, the induction of fibronectin limited the responses of these PTEN-null melanoma cell lines to vemurafenib, with enhanced cytotoxicity observed following the knockdown of either fibronectin or its receptor alpha(5)beta(1) integrin. This in turn abrogated the cytotoxic response to BRAF inhibition via increased AKT signaling, which prevented the induction of cell death by maintaining the expression of the pro-survival protein Mcl-1. The protection conveyed by the induction of FN expression could be overcome through combined treatment with a BRAF and PI3K inhibitor.	[Fedorenko, I. V.; Koomen, J. M.; Wood, E. R.; Smalley, K. S. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Abel, E. V.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Fang, B.; Wood, E. R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Prote, Tampa, FL 33612 USA; [Chen, Y. A.; Fisher, K. J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL 33612 USA; [Iyengar, S.; Sondak, V. K.; Messina, J. L.; Gibney, G. T.; Smalley, K. S. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA; [Dahlman, K. B.; Sosman, J. A.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Wargo, J. A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Flaherty, K. T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Jefferson University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Smalley, KSM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	keiran.smalley@moffitt.org	Smalley, Inna/AAR-8638-2021; Smalley, Inna/G-9016-2015	Smalley, Inna/0000-0002-6796-9145; Smalley, Inna/0000-0002-6796-9145; Smalley, Keiran/0000-0003-1089-9307; Chen, yian/0000-0003-1468-3490	National Institutes of Health [R01 CA161107]; NATIONAL CANCER INSTITUTE [P30CA076292, P50CA168536, R01CA161107] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Gideon Bollag (Plexxikon) for providing vemurafenib and the PLX4720 chow; Noel Clark, Ashley Troutman, Kelli Noyd, Jayme O'Neal and Holly Crandell for assistance with IHC staining; Marta Perez and Monica Torres for assistance with xenograft studies; Agnieszka Kasprazak and Joseph Johnson for assistance with microscopy; and Laura Hall for assistance with qRT-PCR. The work in the Smalley laboratory is supported by R01 CA161107 from the National Institutes of Health.	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Boyd SC, 2013, J INVEST DERMATOL, V133, P1269, DOI 10.1038/jid.2012.421; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Fedorenko IV, 2011, BIOCHEM PHARMACOL, V82, P201, DOI 10.1016/j.bcp.2011.05.015; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Muro AF, 2008, AM J RESP CRIT CARE, V177, P638, DOI 10.1164/rccm.200708-1291OC; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Remily-Wood ER, 2011, PROTEOM CLIN APPL, V5, P383, DOI 10.1002/prca.201000115; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang JM, 1999, MOL CELL BIOL, V19, P6195; White ES, 2006, AM J RESP CRIT CARE, V173, P112, DOI 10.1164/rccm.200507-1058OC; Xiang Y, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005520; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	50	49	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1225	1235		10.1038/onc.2015.188	http://dx.doi.org/10.1038/onc.2015.188			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26073081	Green Accepted			2022-12-17	WOS:000371763100003
J	Chua, CY; Liu, Y; Granberg, KJ; Hu, L; Haapasalo, H; Annala, MJ; Cogdell, DE; Verploegen, M; Moore, LM; Fuller, GN; Nykter, M; Cavenee, WK; Zhang, W				Chua, C. Y.; Liu, Y.; Granberg, K. J.; Hu, L.; Haapasalo, H.; Annala, M. J.; Cogdell, D. E.; Verploegen, M.; Moore, L. M.; Fuller, G. N.; Nykter, M.; Cavenee, W. K.; Zhang, W.			IGFBP2 potentiates nuclear EGFR-STAT3 signaling	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR-BINDING PROTEIN-2; FACTOR RECEPTOR; EGF RECEPTOR; FACTOR-ALPHA; HUMAN GLIOMAS; GLIOBLASTOMA-MULTIFORME; PROGNOSTIC-SIGNIFICANCE; ASTROCYTIC GLIOMAS; MESSENGER-RNA	Insulin-like growth factor binding protein 2 (IGFBP2) is a pleiotropic oncogenic protein that has both extracellular and intracellular functions. Despite a clear causal role in cancer development, the tumor-promoting mechanisms of IGFBP2 are poorly understood. The contributions of intracellular IGFBP2 to tumor development and progression are also unclear. Here we present evidence that both exogenous IGFBP2 treatment and cellular IGEBP2 overexpression lead to aberrant activation of epidermal growth factor receptor (EGFR), which subsequently activates signal transducer and activator of transcription factor 3 (STAT3) signaling. Furthermore, we demonstrate that IGFBP2 augments the nuclear accumulation of EGFR to potentiate STAT3 transactivation activities, via activation of the nuclear EGFR signaling pathway. Nuclear IGFBP2 directly influences the invasive and migratory capacities of human glioblastoma cells, providing a direct link between intracellular (and particularly nuclear) IGFBP2 and cancer hallmarks. These activities are also consistent with the strong association between IGFBP2 and STAT3-activated genes derived from The Cancer Genome Atlas database for human glioma. A high level of all three proteins (IGFBP2, EGFR and STAT3) was strongly correlated with poorer survival in an independent patient data set. These results identify a novel tumor-promoting function for IGFBP2 of activating EGFR/STAT3 signaling and facilitating EGFR accumulation in the nucleus, thereby deregulating EGFR signaling by two distinct mechanisms. As targeting EGFR in glioma has been relatively unsuccessful, this study suggests that IGFBP2 may be a novel therapeutic target.	[Chua, C. Y.; Liu, Y.; Granberg, K. J.; Hu, L.; Annala, M. J.; Cogdell, D. E.; Verploegen, M.; Moore, L. M.; Fuller, G. N.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chua, C. Y.; Fuller, G. N.; Zhang, W.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Liu, Y.; Fuller, G. N.; Zhang, W.] ISB MDA Genome Data Anal Ctr, Canc Genome Atlas, Seattle, WA USA; [Liu, Y.; Fuller, G. N.; Zhang, W.] ISB MDA Genome Data Anal Ctr, Canc Genome Atlas, Houston, TX USA; [Granberg, K. J.; Annala, M. J.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Granberg, K. J.; Annala, M. J.; Nykter, M.] Univ Tampere, Inst Biomed Technol, FIN-33101 Tampere, Finland; [Haapasalo, H.] Fimlab Labs, Dept Pathol, Tampere, Finland; [Haapasalo, H.] Univ Tampere, FIN-33101 Tampere, Finland; [Verploegen, M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands; [Cavenee, W. K.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Tampere University; Tampere University; Radboud University Nijmegen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 85, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Verploegen, Maartje/GYA-0516-2022	Rautajoki, Kirsi Johanna/0000-0001-6549-7810; Chua, Corrine Ying Xuan/0000-0002-5724-8715; Fuller, Gregory/0000-0001-9447-2647; Nykter, Matti/0000-0001-6956-2843	US National Institutes of Health [CA098503, CA141432, CA143835, U24 CA143835]; Cancer Systems Informatics Center from the National Foundation for Cancer Research; NIH/NCI grant [P30CA016672]; Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program; Academy of Finland [259038]; NATIONAL CANCER INSTITUTE [R01CA141432, R01CA098503, U24CA143835, P30CA016672] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Systems Informatics Center from the National Foundation for Cancer Research; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program; Academy of Finland(Academy of Finland); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Oliver Bogler, Dr Zhimin Lu, Dr Frederick Lang, Dr Paul Chiao and Dr Tapio Visakorpi for their helpful comments and discussions and Kathryn L Hale, Department of Scientific Publications at MD Anderson Cancer Center, for editing the manuscript. We thank Ville Kytola for contributions to the immunohistochemical association analyses. This work was partially supported by grants from the US National Institutes of Health (CA098503, CA141432 and CA143835 to WZ and GNF and U24 CA143835 to WZ), by funding for the Cancer Systems Informatics Center from the National Foundation for Cancer Research (to WZ), by NIH/NCI grant P30CA016672 to MD Anderson Cancer Center supporting the Flow Cytometry and Cellular Imaging Core Facility and by the Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program and the Academy of Finland (grant 259038 to KG). WKC is a Fellow of the National Foundation for Cancer Research,	Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429; Azar WJ, 2014, ONCOGENE, V33, P578, DOI 10.1038/onc.2012.630; Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; Baxter RC, 2013, J CELL COMMUN SIGNAL, V7, P179, DOI 10.1007/s12079-013-0203-9; Becher OJ, 2008, J CHILD NEUROL, V23, P1205, DOI 10.1177/0883073808321766; Besnard V, 2001, BBA-MOL CELL RES, V1538, P47, DOI 10.1016/S0167-4889(00)00136-1; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Brand TM, 2011, DISCOV MED, V12, P419; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; CLEMMONS DR, 1990, TRENDS ENDOCRIN MET, V1, P412, DOI 10.1016/1043-2760(90)90102-9; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Demory ML, 2009, J BIOL CHEM, V284, P36592, DOI 10.1074/jbc.M109.000760; Dobrowolski R, 2012, NAT REV MOL CELL BIO, V13, P53, DOI 10.1038/nrm3244; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FERRER I, 1995, NEUROSCIENCE, V66, P189, DOI 10.1016/0306-4522(94)00584-R; Fuller GN, 1999, CANCER RES, V59, P4228; Ganesan A, 2012, PROTEIN SCI, V21, P918, DOI 10.1002/pro.2089; Gerrard DE, 1999, J ANIM SCI, V77, P1431; Giannopoulou E, 2006, IN VIVO, V20, P421; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Haapasalo H, 1996, BRIT J CANCER, V73, P620, DOI 10.1038/bjc.1996.107; Han S, 2014, BRIT J CANCER, V111, P1400, DOI 10.1038/bjc.2014.435; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Haynik DM, 2007, APPL IMMUNOHISTO M M, V15, P56, DOI 10.1097/01.pai.0000213133.09160.da; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; Hoeflich A, 2004, BIOCHEM BIOPH RES CO, V324, P705, DOI 10.1016/j.bbrc.2004.09.111; Holmes KM, 2012, P NATL ACAD SCI USA, V109, P3475, DOI 10.1073/pnas.1120375109; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; Housden BE, 2014, TRENDS BIOCHEM SCI, V39, P457, DOI 10.1016/j.tibs.2014.07.008; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Huynh H, 2011, BLOOD, V118, P3236, DOI 10.1182/blood-2011-01-331876; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Jahani-Asl A, 2013, CURR MOL MED, V13, P1241, DOI 10.2174/1566524011313080002; Joki T, 2000, CANCER RES, V60, P4926; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; KASER MR, 1992, MOL BRAIN RES, V16, P316, DOI 10.1016/0169-328X(92)90241-3; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LAZAR LM, 1992, J NEUROSCI, V12, P1688; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Li X, 2015, ONCOGENE, V34, P1619, DOI 10.1038/onc.2014.98; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Miyako K, 2009, MOL ENDOCRINOL, V23, P169, DOI 10.1210/me.2008-0168; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; Sallinen SL, 2000, CANCER RES, V60, P6617; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sarfstein R, 2013, ENDOCRINOLOGY, V154, P1672, DOI 10.1210/en.2012-2165; Scharf JG, 1996, HEPATOLOGY, V23, P818, DOI 10.1002/hep.510230424; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Scrideli CA, 2007, J NEURO-ONCOL, V83, P233, DOI 10.1007/s11060-007-9328-0; Shao H, 2003, CANCER RES, V63, P3923; Shono T, 2001, CANCER RES, V61, P4375; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stachowiak MK, 2003, J CELL BIOCHEM, V90, P662, DOI 10.1002/jcb.10606; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Terrien X, 2005, BIOCHEM J, V392, P457, DOI 10.1042/BJ20050517; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; TORP SH, 1993, EUR J CANCER, V29A, P1604, DOI 10.1016/0959-8049(93)90305-Y; TUZI NL, 1991, BRIT J CANCER, V63, P227, DOI 10.1038/bjc.1991.54; Waage IS, 2013, INT J SURG PATHOL, V21, P573, DOI 10.1177/1066896913492196; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Wang H, 2003, CANCER RES, V63, P4315; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; WOOD TL, 1992, DEVELOPMENT, V114, P59; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Xu KM, 2014, ONCOTARGET, V5, P1241, DOI 10.18632/oncotarget.1370; Yang DI, 2002, ANN NY ACAD SCI, V962, P8, DOI 10.1111/j.1749-6632.2002.tb04052.x; Yazawa T, 2009, AM J PATHOL, V175, P976, DOI 10.2353/ajpath.2009.081004; Zheng XG, 2007, CANCER SCI, V98, P674, DOI 10.1111/j.1349-7006.2007.00440.x; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	96	49	53	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					738	747		10.1038/onc.2015.131	http://dx.doi.org/10.1038/onc.2015.131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25893308	Green Accepted			2022-12-17	WOS:000370331300007
J	Min, KW; Liggett, JL; Silva, G; Wu, WW; Wang, R; Shen, RF; Eling, TE; Baek, SJ				Min, K-W; Liggett, J. L.; Silva, G.; Wu, W. W.; Wang, R.; Shen, R-F; Eling, T. E.; Baek, S. J.			NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway	ONCOGENE			English	Article							BETA SUPERFAMILY MEMBER; GROWTH-FACTOR-BETA; ACTIVATED GENE NAG-1; CELL-GROWTH; MOUSE MODEL; EXPRESSION; RECEPTOR; LOCALIZATION; APOPTOSIS; PROTEINS	Protein dynamics, modifications and trafficking are all processes that can modulate protein activity. Accumulating evidence strongly suggests that many proteins have distinctive roles dependent on cellular location. Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) is a transforming growth factor-beta (TGF-beta) superfamily protein that has a role in cancer, obesity and inflammation. NAG-1 is synthesized and cleaved into a mature peptide, which is ultimately secreted into the extracellular matrix (ECM). In this study, we have found that full-length NAG-1 is expressed in not only the cytoplasm and ECM, but also in the nucleus. NAG-1 is dynamically moved to the nucleus, exported into cytoplasm and further transported into the ECM. We have also found that nuclear NAG-1 contributes to inhibition of the Smad pathway by interrupting the Smad complex. Overall, our study indicates that NAG-1 is localized in the nucleus and provides new evidence that NAG-1 controls transcriptional regulation in the Smad pathway.	[Min, K-W; Liggett, J. L.; Silva, G.; Baek, S. J.] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, 2407 River Dr, Knoxville, TN 37996 USA; [Wu, W. W.; Wang, R.; Shen, R-F] US FDA, CBER, Facil Biotechnol Resources, Bethesda, MD 20014 USA; [Eling, T. E.] NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Min, K-W] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Medical University of South Carolina	Baek, SJ (corresponding author), Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, 2407 River Dr, Knoxville, TN 37996 USA.	sbaek2@utk.edu	Silva, Gabriel/D-7731-2017	Silva, Gabriel/0000-0002-5660-9769; Min, Kyung-Won/0000-0002-8718-3588	National Institutes of Health [R01CA108975]; Center of Excellence in Livestock Diseases and Human Health, University of Tennessee; CAPES Foundation, Brazil [BEX 3159/14-0]; NIH, NIEHS Intramural Research Program [Z01-ES010016-14]; NATIONAL CANCER INSTITUTE [R01CA108975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center of Excellence in Livestock Diseases and Human Health, University of Tennessee; CAPES Foundation, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NIH, NIEHS Intramural Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Xingya Wang (College of Pharmaceutical Science, Zhejiang Chinese Medical University, China) and Ms Misty Bailey (University of Tennessee) for their critical reading of the manuscript. We also thank Dr John Dunlap (Advanced Microscopy and Imaging Center at The University of Tennessee) for providing technical help on confocal microscopy. This work was supported by the National Institutes of Health (R01CA108975), and the Center of Excellence in Livestock Diseases and Human Health, University of Tennessee, to SJB and a grant (BEX 3159/14-0) from the CAPES Foundation, Brazil (GS). This research was also supported, in part, by the NIH, NIEHS Intramural Research Program (TEE) Z01-ES010016-14.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Baek SJ, 2006, GASTROENTEROLOGY, V131, P1553, DOI 10.1053/j.gastro.2006.09.015; Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; Baek SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200; Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bauskin AR, 2005, CANCER RES, V65, P2330, DOI 10.1158/0008-5472.CAN-04-3827; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, GENE, V237, P105, DOI 10.1016/S0378-1119(99)00309-1; Cekanova M, 2009, CANCER PREV RES, V2, P450, DOI 10.1158/1940-6207.CAPR-09-0057; Chan CP, 2010, J CELL SCI, V123, P1438, DOI 10.1242/jcs.067819; Chintharlapalli S, 2005, MOL PHARMACOL, V68, P1782, DOI 10.1124/mol.105.017046; Chrysovergis K, 2014, INT J OBESITY, V38, P1555, DOI 10.1038/ijo.2014.27; Felin JE, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-20; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI [10.2217/fon.09.67, 10.2217/FON.09.67]; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hutten S, 2007, TRENDS CELL BIOL, V17, P193, DOI 10.1016/j.tcb.2007.02.003; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnen H, 2012, CARDIOVASC PATHOL, V21, P499, DOI 10.1016/j.carpath.2012.02.003; Joshi JP, 2011, BIOCHEM PHARMACOL, V82, P1090, DOI 10.1016/j.bcp.2011.07.082; Kim JM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/641851; Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106; Kuo TF, 2011, FEBS J, V278, P4756, DOI 10.1111/j.1742-4658.2011.08409.x; L/nn P, 2010, MOL CELL, V40, P521; Lee HK, 2010, J CELL BIOCHEM, V111, P755, DOI 10.1002/jcb.22766; Lee SH, 2008, MOL CARCINOGEN, V47, P197, DOI 10.1002/mc.20374; Lee SH, 2008, MOL CANCER THER, V7, P3739, DOI 10.1158/1535-7163.MCT-08-0548; Lee SH, 2006, CARCINOGENESIS, V27, P972, DOI 10.1093/carcin/bgi268; Lee SH, 2005, BIOCHEM BIOPH RES CO, V328, P63, DOI 10.1016/j.bbrc.2004.12.138; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Macia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034868; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Min KW, 2012, TOXICOL APPL PHARM, V263, P225, DOI 10.1016/j.taap.2012.06.014; Nguyen BA, 2009, BMC BIOINFORMATICS, V10, P202, DOI [10.1186/1471-2105-10-202, DOI 10.1186/1471-2105-10-202]; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Planque Nathalie, 2006, Cell Commun Signal, V4, P7, DOI 10.1186/1478-811X-4-7; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shappell SB, 2003, CANCER RES, V63, P2256; Sharma M, 2012, J BIOL CHEM, V287, P819, DOI 10.1074/jbc.M111.299099; Shim M, 2005, J BIOL CHEM, V280, P18636, DOI 10.1074/jbc.M414613200; Shureiqi I, 2001, CANCER RES, V61, P6307; Sirover MA, 2012, J CELL BIOCHEM, V113, P2193, DOI 10.1002/jcb.24113; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Theodore M, 2008, J BIOL CHEM, V283, P8984, DOI 10.1074/jbc.M709040200; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016; Waldmann I, 2007, J BIOL CHEM, V282, P27685, DOI 10.1074/jbc.M703301200; Wang XY, 2013, BIOCHEM PHARMACOL, V85, P597, DOI 10.1016/j.bcp.2012.11.025; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Xu J, 2006, CIRC RES, V98, P342, DOI 10.1161/01.RES.0000202804.84885.d0; Yamaguchi K, 2004, J BIOL CHEM, V279, P49617, DOI 10.1074/jbc.M408796200; Yamaguchi K, 2008, MOL CANCER THER, V7, P2779, DOI 10.1158/1535-7163.MCT-08-0173; Yang MH, 2014, LIFE SCI, V100, P75, DOI 10.1016/j.lfs.2014.01.075; Zimmers TA, 2005, SHOCK, V23, P543, DOI 10.1097/01.shk.0000163393.55350.70; Zimmers TA, 2010, J CANCER RES CLIN, V136, P571, DOI 10.1007/s00432-009-0691-4	68	49	50	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					377	388		10.1038/onc.2015.95	http://dx.doi.org/10.1038/onc.2015.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893289	Green Accepted			2022-12-17	WOS:000369055300011
J	Wang, Z; Xu, D; Ding, HF; Kim, J; Zhang, J; Hai, T; Yan, C				Wang, Z.; Xu, D.; Ding, H-F; Kim, J.; Zhang, J.; Hai, T.; Yan, C.			Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR-3; GENE-EXPRESSION; ADAPTIVE-RESPONSE; TUMOR-SUPPRESSOR; METASTASIS; KINASE; TRANSACTIVATION; ADENOCARCINOMA; REPRESSION	Activating transcription factor 3 (ATF3) responds to diverse cellular stresses, and regulates oncogenic activities (for example, proliferation, survival and migration) through direct transcriptional regulation or protein-protein interactions. Although aberrant ATF3 expression is frequently found in human cancers, the role of ATF3 in tumorigenesis is poorly understood. Here, we demonstrate that ATF3 suppresses the development of prostate cancer induced by knockout of the tumor suppressor Pten in mouse prostates. Whereas the oncogenic stress elicited by Pten loss induced ATF3 expression in prostate epithelium, we found that ATF3 deficiency increased cell proliferation and promoted cell survival, leading to early onset of mouse prostatic intraepithelial neoplasia and the progression of prostate lesions to invasive adenocarcinoma. Importantly, the loss of ATF3 promoted activation of the oncogenic AKT signaling evidenced by high levels of phosphorylated AKT and S6 proteins in ATF3-null prostate lesions. In line with these in vivo results, knockdown of ATF3 expression in human prostate cancer cells by single guided RNA-mediated targeting activated AKT and increased matrix metalloproteinase-9 expression. Our results thus link ATF3 to the AKT signaling, and suggest that ATF3 is a tumor suppressor for the major subset of prostate cancers harboring dysfunctional Pten.	[Wang, Z.; Ding, H-F; Yan, C.] Georgia Regents Univ, GRU Canc Ctr, Augusta, GA 30912 USA; [Wang, Z.; Xu, D.; Yan, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Ding, H-F] Georgia Regents Unviers, Dept Pathol, Augusta, GA 30912 USA; [Kim, J.] Georgia Regents Unviers, Dept Biostat & Epidemiol, Augusta, GA 30912 USA; [Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH USA; [Hai, T.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Yan, C.] Georgia Regents Unviers, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Albany Medical College; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Case Western Reserve University; University System of Ohio; Ohio State University; University System of Georgia; Augusta University	Yan, C (corresponding author), Georgia Regents Univ, GRU Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA.	cyan@gru.edu	Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Yan, Chunhong/0000-0002-3974-7991; Ding, Han-Fei/0000-0001-5702-3439	NIH [R01CA139107, R01CA164006]; Department of Defense [W81XWH-07-1-0095]; NATIONAL CANCER INSTITUTE [R01CA164006, R01CA154625, R01CA139107] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R01CA139107, R01CA164006 and a Department of Defense award W81XWH-07-1-0095 to CY. We thank Dr George Church for providing sgRNA targeting reagents and Dr Honglin Li for providing NF-kappa B reagents.	Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen HH, 2004, MOL PHARMACOL, V65, P1130, DOI 10.1124/mol.65.5.1130; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gilchrist M, 2010, BLOOD, V115, P4734, DOI 10.1182/blood-2009-03-213512; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Huang CY, 2015, MOL NEUROBIOL, V51, P543, DOI 10.1007/s12035-014-8710-0; Huang XW, 2008, J BIOL CHEM, V283, P29795, DOI 10.1074/jbc.M802515200; Ishiguro T, 1996, CANCER RES, V56, P875; Jan YH, 2012, CANCER RES, V72, P5119, DOI 10.1158/0008-5472.CAN-12-1842; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu W, 2011, J BIOL CHEM, V286, P18949, DOI 10.1074/jbc.M111.232637; Liu YQ, 2013, CANCER LETT, V337, P66, DOI 10.1016/j.canlet.2013.05.022; Liu YP, 2013, CANCER RES, V73, P6194, DOI 10.1158/0008-5472.CAN-13-0518; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stearns ME, 2004, MOL CANCER RES, V2, P403; Svensson RU, 2011, AM J PATHOL, V179, P502, DOI 10.1016/j.ajpath.2011.03.014; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Varambally S, 2012, CANCER CELL, V8, P393; Wang HB, 2012, MOL CELL BIOL, V32, P3190, DOI 10.1128/MCB.00159-12; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wei SS, 2014, J BIOL CHEM, V289, P8947, DOI 10.1074/jbc.M113.503755; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311-06; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795	51	49	50	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4975	4984		10.1038/onc.2014.426	http://dx.doi.org/10.1038/onc.2014.426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531328	Green Accepted			2022-12-17	WOS:000361693000007
J	Erin, N; Podnos, A; Tanriover, G; Duymus, O; Cote, E; Khatri, I; Gorczynski, RM				Erin, N.; Podnos, A.; Tanriover, G.; Duymus, O.; Cote, E.; Khatri, I.; Gorczynski, R. M.			Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response	ONCOGENE			English	Article							SENSORY NEURONS PROMOTES; IMMUNE-RESPONSE; GENE-EXPRESSION; T-CELLS; INTERLEUKIN-10; CARCINOMA; RECEPTOR; MICE; GLYCOPROTEIN; SUPPRESSION	CD200 acts through its receptor (CD200R) to inhibit excessive inflammation. The role of CD200-CD200R1 interaction in tumor immunity is poorly understood. In this study, we examined the role of CD200-CD200R1 interaction in the progression and metastasis of highly aggressive 4THM murine-breast carcinoma using CD200 transgenic (CD200(tg)) and CD200R1 knock-out (CD200R1(-/-)) BALB/c mice. 4THM cells induce extensive visceral metastasis and neutrophil infiltration in affected tissues. CD200 overexpression in the host was associated with decreased primary tumor growth and metastasis, whereas lack of CD200R1 expression by host cells was associated with enhanced visceral metastasis. Absence of CD200R1 expression led to decreased tumor-infiltrating-cytotoxic T cells and increased the release of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6. In contrast, CD200 overexpression led to increased tumor-induced interferon-gamma and IL-10 response and decreased TNF-alpha and IL-6 release. Neutrophil infiltration of tissues was markedly decreased in CD200tg animals and increased in CD200R1(-/-) mice. These findings are contradictory to what has been reported in the EMT6 mouse breast-cancer model. Other distinguishing features of tumor elicited by EMT6 and 4THM cell injections were also examined. Visceral tissues from mice bearing EMT6 tumors showed a lack of neutrophil infiltration and decreased IL-6 release in CD200R1(-/-) mice. EMT6 and 4THM cells also differed in vimentin expression and in vitro migration rate, which was markedly lower in EMT6 tumors. These results support the hypothesis that CD200 expression can alter immune responses, and can inhibit metastatic growth of tumor cells that induce systemic and local inflammatory response. Increasing CD200 activity/signaling might be an important therapeutic strategy for treatment of aggressive breast carcinomas.	[Erin, N.; Duymus, O.] Akdeniz Univ, Sch Med, Dept Med Pharmacol, TR-07070 Antalya, Turkey; [Podnos, A.; Cote, E.; Khatri, I.; Gorczynski, R. M.] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada; [Tanriover, G.] Akdeniz Univ, Sch Med, Dept Histol & Embryol, TR-07070 Antalya, Turkey	Akdeniz University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Akdeniz University	Erin, N (corresponding author), Akdeniz Univ, Sch Med, Dept Med Pharmacol, B Blok Kat 1 Immunol, TR-07070 Antalya, Turkey.	nerin@akdeniz.edu.tr	Gorczynski, Reginald/AAA-1435-2019; Tanriover, Gamze/A-3196-2012; Erin, Nuray/B-8616-2012	Tanriover, Gamze/0000-0002-8002-5544; Erin, Nuray/0000-0002-6116-1970	TUBITAK (the scientific and technological research council of Turkey) [109S449]; Akdeniz University Research Units, Antalya, Turkey [2013.12.0103.001]; Canadian Cancer Society	TUBITAK (the scientific and technological research council of Turkey)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Akdeniz University Research Units, Antalya, Turkey(Akdeniz University); Canadian Cancer Society(Canadian Cancer Society (CCS))	This work was supported by funds from the TUBITAK (the scientific and technological research council of Turkey; project no: 109S449); Akdeniz University Research Units, Antalya, Turkey (project no: 2013.12.0103.001); and the Canadian Cancer Society (grant to RMG). We thank Nilufer Ekinci for her technical help.	Bao LL, 2011, AM J PATHOL, V178, P838, DOI 10.1016/j.ajpath.2010.10.029; Boudakov I, 2007, TRANSPLANTATION, V84, P251, DOI 10.1097/01.tp.0000269795.04592.cc; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Colmont CS, 2013, P NATL ACAD SCI USA, V110, P1434, DOI 10.1073/pnas.1211655110; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Erdman SE, 2003, CANCER RES, V63, P6042; Erin N, 2004, ANTICANCER RES, V24, P1003; Erin N, 2006, BREAST CANCER RES TR, V99, P351, DOI 10.1007/s10549-006-9219-7; Erin N, 2013, BREAST CANCER RES TR, V139, P677, DOI 10.1007/s10549-013-2584-0; Erin N, 2009, INT J CANCER, V124, P1503, DOI 10.1002/ijc.24131; Erin N, 2008, REGUL PEPTIDES, V151, P35, DOI 10.1016/j.regpep.2008.03.012; Geng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054959; Gorczynski R, 2004, J IMMUNOL, V172, P7744, DOI 10.4049/jimmunol.172.12.7744; Gorczynski RM, 2013, BREAST CANCER RES TR, V142, P271, DOI 10.1007/s10549-013-2735-3; Gorczynski RM, 2011, BREAST CANCER RES TR, V130, P49, DOI 10.1007/s10549-010-1259-3; Gorczynski RM, 2010, BREAST CANCER RES TR, V123, P405, DOI 10.1007/s10549-009-0667-8; Gorczynski RM, 2009, J IMMUNOL, V183, P1560, DOI 10.4049/jimmunol.0900200; Gorczynski RM, 2001, CLIN EXP IMMUNOL, V126, P220, DOI 10.1046/j.1365-2249.2001.01689.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kim HJ, 2009, J PROTEOME RES, V8, P1368, DOI 10.1021/pr8007573; Knutson KL, 2006, J IMMUNOL, V177, P1526, DOI 10.4049/jimmunol.177.3.1526; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kretz-Ronlmel A, 2008, J IMMUNOL, V180, P699, DOI 10.4049/jimmunol.180.2.699; Kundu N, 1996, JNCI-J NATL CANCER I, V88, P536, DOI 10.1093/jnci/88.8.536; Lin GH, 2012, J IMMUNOTHER, V35, P337, DOI 10.1097/CJI.0b013e318255ada3; Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X; Liu Y, 2013, NEURO-ONCOLOGY, V15, P891, DOI 10.1093/neuonc/not031; Maru Y, 2007, CELL ADHES MIGR, V1, DOI 10.4161/cam.1.2.4489; Memarian A, 2013, TUMOR BIOL, V34, P531, DOI 10.1007/s13277-012-0578-x; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Podnos A, 2012, BREAST CANCER RES TR, V136, P117, DOI 10.1007/s10549-012-2258-3; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Rygiel TP, 2012, ONCOGENE, V31, P2979, DOI 10.1038/onc.2011.477; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Stumpfova M, 2010, CANCER RES, V70, P2962, DOI 10.1158/0008-5472.CAN-09-4380; Talebian F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031442; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; West NR, 2013, BRIT J CANCER, V108, P155, DOI 10.1038/bjc.2012.524; Wong KK, 2012, CANCER RES, V72, P4931, DOI 10.1158/0008-5472.CAN-12-1390; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	54	49	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3860	3870		10.1038/onc.2014.317	http://dx.doi.org/10.1038/onc.2014.317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263452				2022-12-17	WOS:000358001600011
J	Zhou, J; Qu, Z; Yan, S; Sun, F; Whitsett, JA; Shapiro, SD; Xiao, G				Zhou, J.; Qu, Z.; Yan, S.; Sun, F.; Whitsett, J. A.; Shapiro, S. D.; Xiao, G.			Differential roles of STAT3 in the initiation and growth of lung cancer	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-2; TAX-MEDIATED TUMORIGENESIS; SQUAMOUS-CELL CARCINOMA; EPITHELIAL-CELLS; K-RAS; NUCLEAR-LOCALIZATION; SIGNAL TRANSDUCER; DNA METHYLATION; TRANSCRIPTION 3; BREAST-CANCER	Signal transducer and activator of transcription 3 (STAT3) is linked to multiple cancers, including pulmonary adenocarcinoma. However, the role of STAT3 in lung cancer pathogenesis has not been determined. Using lung epithelial-specific inducible knockout strategies, we demonstrate that STAT3 has contrasting roles in the initiation and growth of both chemically and genetically induced lung cancers. Selective deletion of lung epithelial STAT3 in mice before cancer induction by the smoke carcinogen, urethane, resulted in increased lung tissue damage and inflammation, K-Ras oncogenic mutations and tumorigenesis. Deletion of lung epithelial STAT3 after establishment of lung cancer inhibited cancer cell proliferation. Simultaneous deletion of STAT3 and expression of oncogenic K-Ras in mouse lung elevated pulmonary injury, inflammation and tumorigenesis, but reduced tumor growth. These studies indicate that STAT3 prevents lung cancer initiation by maintaining pulmonary homeostasis under oncogenic stress, whereas it facilitates lung cancer progression by promoting cancer cell growth. These studies also provide a mechanistic basis for targeting STAT3 to lung cancer therapy.	[Zhou, J.; Qu, Z.; Yan, S.; Sun, F.; Shapiro, S. D.; Xiao, G.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Zhou, J.; Qu, Z.; Yan, S.; Sun, F.; Xiao, G.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15213 USA; [Whitsett, J. A.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Neonatol Perinatal & Pulm Biol,Coll Med, Cincinnati, OH USA; [Shapiro, S. D.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, G (corresponding author), Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Inst Canc, Dept Microbiol & Mol Genet, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	xiaog2@upmc.edu	SUN, FAN/GWA-1524-2022; SUN, FAN/K-8683-2017; Yan, Shapei/AAB-1347-2021	SUN, FAN/0000-0002-3538-9701; 	National Institute of Health (NIH)/National Cancer Institute (NCI) [R01 CA172090, R21 CA175252, P30 CA047904]; American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship [RSG-06-066-01-MGO]; NATIONAL CANCER INSTITUTE [R21CA175252, R01CA172090, P30CA047904] Funding Source: NIH RePORTER	National Institute of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the National Institute of Health (NIH)/National Cancer Institute (NCI) grants R01 CA172090, R21 CA175252, P30 CA047904, as well as the American Lung Association (ALA) Lung Cancer Discovery Award and American Cancer Society (ACS) Fellowship RSG-06-066-01-MGO.	Ai T, 2012, INT J BIOL MARKER, V27, pE132, DOI 10.5301/JBM.2012.9146; Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Couto JP, 2012, P NATL ACAD SCI USA, V109, pE2361, DOI 10.1073/pnas.1201232109; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Dougan M, 2011, J CLIN INVEST, V121, P2436, DOI 10.1172/JCI44796; Fu J, 2010, ONCOGENE, V29, P6499, DOI 10.1038/onc.2010.374; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Matsuzaki Y, 2006, J IMMUNOL, V177, P527, DOI 10.4049/jimmunol.177.1.527; Mostertz W, 2010, JAMA-J AM MED ASSOC, V303, P535, DOI 10.1001/jama.2010.80; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Pan YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054565; Pectasides E, 2010, CLIN CANCER RES, V16, P2427, DOI 10.1158/1078-0432.CCR-09-2658; Peyser ND, 2013, ONCOTARGETS THER, V6, P999, DOI 10.2147/OTT.S47903; Qing GL, 2005, J BIOL CHEM, V280, P40578, DOI 10.1074/jbc.M508776200; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Qu ZX, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-23; Qu ZX, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-18; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Smith CJ, 2006, INHAL TOXICOL, V18, P667, DOI 10.1080/08958370600742821; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; WANG XR, 1995, CANCER LETT, V91, P33, DOI 10.1016/0304-3835(94)03715-U; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yan PR, 2009, NEOPLASIA, V11, P1036, DOI 10.1593/neo.09752; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104	48	49	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3804	3814		10.1038/onc.2014.318	http://dx.doi.org/10.1038/onc.2014.318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25284582	Green Accepted			2022-12-17	WOS:000358001600006
J	Kagawa, S; Natsuizaka, M; Whelan, KA; Facompre, N; Naganuma, S; Ohashi, S; Kinugasa, H; Egloff, AM; Basu, D; Gimotty, PA; Klein-Szanto, AJ; Bass, AJ; Wong, KK; Diehl, JA; Rustgi, AK; Nakagawa, H				Kagawa, S.; Natsuizaka, M.; Whelan, K. A.; Facompre, N.; Naganuma, S.; Ohashi, S.; Kinugasa, H.; Egloff, A. M.; Basu, D.; Gimotty, P. A.; Klein-Szanto, A. J.; Bass, A. J.; Wong, K-K; Diehl, J. A.; Rustgi, A. K.; Nakagawa, H.			Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities	ONCOGENE			English	Article							HUMAN ESOPHAGEAL KERATINOCYTES; TO-MESENCHYMAL TRANSITION; ZEB TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; TGF-BETA; PREMATURE SENESCENCE; SQUAMOUS CANCER; NOTCH; CARCINOMA; P53	Notch activity regulates tumor biology in a context-dependent and complex manner. Notch may act as an oncogene or a tumor-suppressor gene even within the same tumor type. Recently, Notch signaling has been implicated in cellular senescence. Yet, it remains unclear as to how cellular senescence checkpoint functions may interact with Notch-mediated oncogenic and tumor-suppressor activities. Herein, we used genetically engineered human esophageal keratinocytes and esophageal squamous cell carcinoma cells to delineate the functional consequences of Notch activation and inhibition along with pharmacological intervention and RNA interference experiments. When expressed in a tetracycline-inducible manner, the ectopically expressed activated form of Notch1 (ICN1) displayed oncogene-like characteristics inducing cellular senescence corroborated by the induction of G0/G1 cell-cycle arrest, Rb dephosphorylation, flat and enlarged cell morphology and senescence-associated beta-galactosidase activity. Notch-induced senescence involves canonical CSL/RBPJ-dependent transcriptional activity and the p16(INK4A)-Rb pathway. Loss of p16(INK4A) or the presence of human papilloma virus (HPV) E6/E7 oncogene products not only prevented ICN1 from inducing senescence but permitted ICN1 to facilitate anchorage-independent colony formation and xenograft tumor growth with increased cell proliferation and reduced squamous-cell differentiation. Moreover, Notch1 appears to mediate replicative senescence as well as transforming growth factor-beta-induced cellular senescence in non-transformed cells and that HPV E6/E7 targets Notch1 for inactivation to prevent senescence, revealing a tumor-suppressor attribute of endogenous Notch1. In aggregate, cellular senescence checkpoint functions may influence dichotomous Notch activities in the neoplastic context.	[Kagawa, S.; Natsuizaka, M.; Whelan, K. A.; Naganuma, S.; Ohashi, S.; Kinugasa, H.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA; [Kagawa, S.; Natsuizaka, M.; Whelan, K. A.; Naganuma, S.; Ohashi, S.; Kinugasa, H.; Gimotty, P. A.; Diehl, J. A.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Natsuizaka, M.] Hokkaido Univ, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan; [Facompre, N.; Basu, D.] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA; [Facompre, N.; Basu, D.] Univ Penn, Dept Head & Neck Surg, Philadelphia, PA 19104 USA; [Facompre, N.; Basu, D.] Philadelphia VA Med Ctr, Philadelphia, PA USA; [Naganuma, S.] Kochi Univ, Sch Med, Dept Pathol, Kochi 780, Japan; [Ohashi, S.] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Japan; [Kinugasa, H.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama 7008530, Japan; [Egloff, A. M.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Gimotty, P. A.] Univ Penn, Div Biostat, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Bass, A. J.; Wong, K-K] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Bass, A. J.; Wong, K-K] Dana Farber Canc Inst, Div Cellular & Mol Oncol, Boston, MA 02115 USA; [Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Hokkaido University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Kochi University; Kyoto University; Okayama University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; University of Pennsylvania	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, Dept Med, 956 BRB,421 Curie Blvd, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu	Gimotty, Phyllis/GWZ-4136-2022; Ohashi, Shinya/AAD-8920-2022	Gimotty, Phyllis/0000-0002-3850-9799; Natsuizaka, Mitsuteru/0000-0002-1819-1955	NIH [P01CA098101, U01CA143056, R01DK077005, K26 RR032714]; Pennsylvania CURE Program Grant [F32-CA174176, F32-DE024685, K08DE022842]; Trio/ACS Career Award; VA CPPF Grant [K07CA137140]; University of Pennsylvania University Research Foundation Award; University of Pennsylvania; Abramson Cancer Center Pilot Project Grant; American Cancer Society [RP-10-033-01-CCE]; NATIONAL CANCER INSTITUTE [P30CA016520, K07CA137140, F31CA174176, P01CA098101, U01CA143056, F32CA174146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR032714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE022842, F32DE024685, R21DE024396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077005, P30DK050306] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K26OD011179] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania CURE Program Grant; Trio/ACS Career Award; VA CPPF Grant; University of Pennsylvania University Research Foundation Award; University of Pennsylvania; Abramson Cancer Center Pilot Project Grant; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr Hiroshi Shirasawa (Chiba University, Chiba, Japan) for the gift of EN60 cells. We are grateful to the Molecular Pathology & Imaging, Molecular Biology/Gene Expression and Cell Culture Core Facilities of the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306) and of the NIH P01CA098101. This study was supported in part by NIH Grants P01CA098101 (to SK, MN, KAW, DB, HK, SN, SO, PAG, AJK-S, AB, K-KW, JAD, HN and AKR), U01CA143056 (to AKR), R01DK077005 (to HN), K26 RR032714 (to HN), Pennsylvania CURE Program Grant (to HN), F32-CA174176 (to KAW), F32-DE024685 to (NF), K08DE022842, Trio/ACS Career Award and VA CPPF Grant (to DB), K07CA137140 (to AME), University of Pennsylvania University Research Foundation Award (to HN), University of Pennsylvania, Abramson Cancer Center Pilot Project Grant (to HN), and the American Cancer Society RP-10-033-01-CCE (to AKR).	Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cui H, 2013, CANCER RES, V73, P3451, DOI 10.1158/0008-5472.CAN-12-3902; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dotto GP, 2009, NAT REV CANCER, V9, P587, DOI 10.1038/nrc2675; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Harada H, 2003, MOL CANCER RES, V1, P729; Hijioka H, 2010, INT J ONCOL, V36, P817, DOI 10.3892/ijo_00000558; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kim SH, 2006, CANCER RES, V66, P10415, DOI 10.1158/0008-5472.CAN-06-2104; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Li T, 2007, J NEUROSCI, V27, P10849, DOI 10.1523/JNEUROSCI.2152-07.2007; Lin S, 2012, MOL BIOL CELL, V23, P1569, DOI 10.1091/mbc.E11-10-0849; Ling H, 2013, CANCER RES, V73, P5963, DOI 10.1158/0008-5472.CAN-13-0409; LIU QY, 1995, ONCOGENE, V10, P619; Liu ZJ, 2012, ATHEROSCLEROSIS, V225, P296, DOI 10.1016/j.atherosclerosis.2012.04.010; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Maruo S, 2011, P NATL ACAD SCI USA, V108, P1919, DOI 10.1073/pnas.1019599108; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Mroz EA, 2008, CANCER RES, V68, P6049, DOI 10.1158/0008-5472.CAN-08-1279; Nakagawa H, 2003, GASTROINTESTINAL CAN, P241; Natsugoe S, 2002, CLIN CANCER RES, V8, P1838; Natsuizaka M, 2012, FASEB J, V26, P2620, DOI 10.1096/fj.11-198598; Natsuizaka M, 2010, CARCINOGENESIS, V31, P1344, DOI 10.1093/carcin/bgq108; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ohashi S, 2010, GASTROENTEROLOGY, V139, P2113, DOI 10.1053/j.gastro.2010.08.040; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Okawa T, 2007, GENE DEV, V21, P2788, DOI 10.1101/gad.1544507; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Oyama K, 2007, ONCOGENE, V26, P2353, DOI 10.1038/sj.onc.1210025; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Pascal T, 2005, FEBS LETT, V579, P3651, DOI 10.1016/j.febslet.2005.05.056; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Sashiyama H, 2001, INT J ONCOL, V19, P97; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Takaoka M, 2004, ONCOGENE, V23, P6760, DOI 10.1038/sj.onc.1207923; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Venkatesh D, 2011, ARTERIOSCL THROM VAS, V31, P876, DOI 10.1161/ATVBAHA.110.221945; Wang NJ, 2011, P NATL ACAD SCI USA, V108, P17761, DOI 10.1073/pnas.1114669108; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang YW, 2007, P NATL ACAD SCI USA, V104, P10613, DOI 10.1073/pnas.0703903104	67	49	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2347	2359		10.1038/onc.2014.169	http://dx.doi.org/10.1038/onc.2014.169			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931169	Green Accepted, Green Submitted			2022-12-17	WOS:000353824800008
J	Akalay, I; Tan, TZ; Kumar, P; Janji, B; Mami-Chouaib, F; Charpy, C; Vielh, P; Larsen, AK; Thiery, JP; Sabbah, M; Chouaib, S				Akalay, I.; Tan, T. Z.; Kumar, P.; Janji, B.; Mami-Chouaib, F.; Charpy, C.; Vielh, P.; Larsen, A. K.; Thiery, J. P.; Sabbah, M.; Chouaib, S.			Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CTL-MEDIATED LYSIS; INVASIVE PHENOTYPES; IMMUNE SURVEILLANCE; TUMOR; INHIBITION; SUPPRESSES; GENERATION; INDUCTION; ESCAPE	The molecular basis for the resistance of tumor cells to cell-mediated cytotoxicity remains poorly understood and thus poses a major challenge for cancer immunotherapy. The present study was designed to determine whether the WNT1-inducible signaling pathway protein 2 (WISP2, also referred to as CCN5), a key regulator of tumor cell plasticity, interferes with tumor susceptibility to cytotoxic T-lymphocyte (CTL)-mediated lysis. We found that silencing WISP2 signaling in human breast adenocarcinoma MCF7 cells impairs CTL-mediated cell killing by a mechanism involving stem cell marker Kruppel-like factor-4 (KLF-4) induction and microRNA-7 (miR-7) downregulation. Inhibition of transforming growth factor beta (TGF-beta) signaling using the A83-01 inhibitor in MCF7-shWISP2 cells resulted in a significant reversal of the epithelial-to-mesenchymal-transitioned (EMT) phenotype, the expression of KLF-4 and a partial recovery of target susceptibility to CTLs. More importantly, we showed that silencing KLF-4 was accompanied by a reduction in MCF7-shWISP2 resistance to CTLs. Using human breast cancer tissues, we demonstrated the coexpression of KLF-beta with EMT markers and TGF-beta pathway signaling components. More importantly, we found that KLF-4 expression was accompanied by miR-7 inhibition, which is partly responsible for impairing CTL-mediated lysis. Thus, our data indicate that WISP2 has a role in regulating tumor cell susceptibility through EMT by inducing the TGF-beta signaling pathway, KLF-4 expression and miR-7 inhibition. These studies indicate for the first time that WISP2 acts as an activator of CTL-induced killing and suggests that the loss of its function promotes evasion of immunosurveillance and the ensuing progression of the tumor.	[Akalay, I.; Mami-Chouaib, F.; Chouaib, S.] Inst Gustave Roussy, INSERM, U753, F-94805 Villejuif, France; [Tan, T. Z.; Kumar, P.; Thiery, J. P.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Janji, B.] Publ Res Ctr Hlth CRP Sante, Dept Oncol, Lab Expt Hematooncol, Luxembourg, Luxembourg; [Charpy, C.; Vielh, P.] Inst Cancerol Gustave Roussy, Lab Rech Translat Module Histocytopathol, Villejuif, France; [Charpy, C.; Vielh, P.] Inst Cancerol Gustave Roussy, Ctr Ressources Biol, Villejuif, France; [Larsen, A. K.; Sabbah, M.] INSERM, U938, Lab Canc Biol & Therapeut, Ctr Rech St Antoine, Paris, France; [Larsen, A. K.; Sabbah, M.] Univ Paris 06, Paris, France; [Thiery, J. P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Thiery, J. P.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Luxembourg Institute of Health; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; National University of Singapore; National University of Singapore	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U753, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	Salem.CHOUAIB@gustaveroussy.fr	Mami-Chouaib, Fathia/E-5267-2016; Tan, Tuan Zea/I-9227-2019; Sabbah, Michèle/GSN-8858-2022; Thiery, Jean Paul/M-9387-2019; Chouaib, Salem/F-7939-2016; Thiery, Jean Paul/H-1550-2011	Tan, Tuan Zea/0000-0001-6624-1593; Sabbah, Michèle/0000-0001-5368-9022; Thiery, Jean Paul/0000-0003-0478-5020; , Dr. Prashant Kumar/0000-0001-8975-5108; JANJI, Bassam/0000-0002-9763-0943	INSERM; la Ligue Nationale Contre le Cancer; l'Association de Recherche sur le Cancer; A*STAR Institute of Molecular Cell Biology; Cancer Science Institute National University of Singapore; CRP-Sante; Fondation Cancer, Luxembourg	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); l'Association de Recherche sur le Cancer; A*STAR Institute of Molecular Cell Biology(Agency for Science Technology & Research (A*STAR)); Cancer Science Institute National University of Singapore(National University of Singapore); CRP-Sante; Fondation Cancer, Luxembourg	This work was supported by grants from INSERM, la Ligue Nationale Contre le Cancer, l'Association de Recherche sur le Cancer, A*STAR Institute of Molecular Cell Biology, Cancer Science Institute National University of Singapore core grants, CRP-Sante and Fondation Cancer, Luxembourg.	Akalay I, 2013, AUTOPHAGY, V9, P1104, DOI 10.4161/auto.24728; Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432; Anichini A, 1999, J EXP MED, V190, P651, DOI 10.1084/jem.190.5.651; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Banerjee S, 2008, CANCER RES, V68, P7606, DOI 10.1158/0008-5472.CAN-08-1461; Chouaib S, 2003, J CLIN INVEST, V111, P595, DOI 10.1172/JCI200318044; Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316; Dorothee G, 2003, ONCOGENE, V22, P7192, DOI 10.1038/sj.onc.1206627; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; El Hage F, 2008, P NATL ACAD SCI USA, V105, P10119, DOI 10.1073/pnas.0802753105; El-Karim EA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-89; Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576; Frewer KA, 2013, BRIT J SURG, V100, P10; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086; Hamai A, 2010, TISSUE ANTIGENS, V75, P1, DOI 10.1111/j.1399-0039.2009.01401.x; Hasmim M, 2011, J IMMUNOL, V187, P4031, DOI 10.4049/jimmunol.1101011; Holzel M, 2013, NAT REV CANCER, V13, P365, DOI 10.1038/nrc3498; Hu D, 2011, J BIOL CHEM, V286, P6890, DOI 10.1074/jbc.M110.179952; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Magnon C, 2007, J CLIN INVEST, V117, P1844, DOI 10.1172/JCI30269; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; Reiman JM, 2010, CANCER RES, V70, P3005, DOI 10.1158/0008-5472.CAN-09-4041; Sabbah M, 2011, MOL CELL BIOL, V31, P1459, DOI 10.1128/MCB.01316-10; Shekhani MT, 2013, AM J STEM CELLS, V2, P52; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt96; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhang XH, 2012, ARTERIOSCL THROM VAS, V32, P1015, DOI 10.1161/ATVBAHA.111.244962	39	49	49	4	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2261	2271		10.1038/onc.2014.151	http://dx.doi.org/10.1038/onc.2014.151			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931170				2022-12-17	WOS:000353473000011
J	O'Flanagan, CH; Morais, VA; Wurst, W; De Strooper, B; O'Neill, C				O'Flanagan, C. H.; Morais, V. A.; Wurst, W.; De Strooper, B.; O'Neill, C.			The Parkinson's gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes	ONCOGENE			English	Article							MITOCHONDRIAL FISSION; OXIDATIVE STRESS; DISEASE; APOPTOSIS; MUTATIONS; PROTECTS; DYSFUNCTION; GROWTH; DRP1; PHOSPHORYLATION	PINK1 (phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-induced kinase 1), a Parkinson's disease-associated gene, was identified originally because of its induction by the tumor-suppressor PTEN. PINK1 promotes cell survival and potentially metastatic functions and protects against cell stressors including chemotherapeutic agents. However, the mechanisms underlying PINK1 function in cancer cell biology are unclear. Here, using several model systems, we show that PINK1 deletion significantly reduced cancer-associated phenotypes including cell proliferation, colony formation and invasiveness, which were restored by human PINK1 overexpression. Results show that PINK1 deletion causes major defects in cell cycle progression in immortalized mouse embryonic fibroblasts (MEFs) from PINK1(-/-) mice, and in BE(2)-M17 cells stably transduced with short hairpin RNA against PINK1. Detailed cell cycle analyses of MEF cell lines from several PINK1(-/-) mice demonstrate an increased proportion of cells in G2/M and decreased number of cells in G1 following release from nocodazole block. This was concomitant with increased double and multi-nucleated cells, a reduced ability to undergo cytokinesis and to re-enter G1, and significant alterations in cell cycle markers, including failure to increase cyclin D1, all indicative of mitotic arrest. PINK1(-/-) cells also demonstrated ineffective cell cycle exit following serum deprivation. Cell cycle defects associated with PINK1 deficiency occur at points critical for cell division, growth and stress resistance in cancer cells were rescued by ectopic expression of human PINK1 and demonstrated PINK1 kinase dependence. The importance of PINK1 for cell cycle control is further supported by results showing that cell cycle deficits induced by PINK1 deletion were linked mechanistically to aberrant mitochondrial fission and its regulation by dynamin-related protein-1 (Drp1), known to be critical for progression of mitosis. Our data indicate that PINK1 has tumor-promoting properties and demonstrates a new function for PINK1 as a regulator of the cell cycle.	[O'Flanagan, C. H.; O'Neill, C.] Natl Univ Ireland Univ Coll Cork, Sch Biochem & Cell Biol, BioSci Inst, Cork, Ireland; [Morais, V. A.; De Strooper, B.] VIB, Ctr Biol Dis, Leuven, Belgium; [Morais, V. A.; De Strooper, B.] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium; [Morais, V. A.; De Strooper, B.] Katholieke Univ Leuven, LIND, Leuven, Belgium; [Wurst, W.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Dev Genet, Munich, Germany; [Wurst, W.] Tech Univ Munich, Helmholtz Zentrum Munchen, Lehrstuhl Entwicklungsgenet, Munich, Germany; [Wurst, W.] German Ctr Neurodegenerat Dis DZNE, Munich, Germany; [De Strooper, B.] UCL, Inst Neurol, London, England	University College Cork; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of London; University College London	O'Neill, C (corresponding author), Natl Univ Ireland Univ Coll Cork, Sch Biochem & Cell Biol, BioSci Inst, Cork, Ireland.	c.oneill@ucc.ie	de+Strooper, Bart/Z-1638-2019	Wurst, Wolfgang/0000-0003-4422-7410; O'Neill, Cora/0000-0001-5386-7415	Health Research Board of Ireland; PhD Scholars' Programme in Cancer Biology; Science Foundation Ireland (SFI); FWO Foundation for Scientific Research Belgium, a Methusalem grant of the Flemish Government; KU Leuven; Helmholtz Alliance for Mental Health in an Ageing Society; SFI Programme Grant	Health Research Board of Ireland; PhD Scholars' Programme in Cancer Biology; Science Foundation Ireland (SFI)(Science Foundation Ireland); FWO Foundation for Scientific Research Belgium, a Methusalem grant of the Flemish Government; KU Leuven(KU Leuven); Helmholtz Alliance for Mental Health in an Ageing Society; SFI Programme Grant(Science Foundation Ireland)	We are grateful to Mark Cookson and Alexandra Beilina, National Institute on Aging, Bethesda, MD, USA for providing us with BE(2)-M17 cells transduced with control and PINK1 shRNA. We thank Rosemary O'Connor, School of Biochemistry and Cell Biology, University College Cork (UCC) for many helpful discussions, Sandra Yeomans UCC for technical assistance and Daniela Vogt-Weisenhorn, Helmholtz Centrum Munchen, for helpful input. This work was funded by the Health Research Board of Ireland, PhD Scholars' Programme in Cancer Biology. Support from Science Foundation Ireland (SFI) (RFP), the FWO Foundation for Scientific Research Belgium, a Methusalem grant of the Flemish Government and the KU Leuven, and the Helmholtz Alliance for Mental Health in an Ageing Society is also gratefully acknowledged. BDS is the Arthur Bax and Anna Vanluffelen Chair for Alzheimer's disease. The Molecular Cell Biology group, UCC, provided access to a Zeiss 510 Confocal microscope, funded by an SFI Programme Grant to Mary W McCaffrey.	Akundi RS, 2012, NEUROBIOL DIS, V45, P469, DOI 10.1016/j.nbd.2011.08.034; Akundi RS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016038; Arena G, 2013, CELL DEATH DIFFER, V20, P920, DOI 10.1038/cdd.2013.19; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Barbosa IA, 2012, BBA-REV CANCER, V1826, P238, DOI 10.1016/j.bbcan.2012.04.005; Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Berthier A, 2011, HUM PATHOL, V42, P75, DOI 10.1016/j.humpath.2010.05.016; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bonda DJ, 2010, NEUROPATH APPL NEURO, V36, P157, DOI 10.1111/j.1365-2990.2010.01064.x; Burgess DJ, 2011, NAT REV CANCER, V11, P692, DOI 10.1038/nrc3142; Cardona F, 2011, HUM MUTAT, V32, P369, DOI 10.1002/humu.21444; Chaiwatanasirikul KA, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.99; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Cho KA, 2004, J BIOL CHEM, V279, P42270, DOI 10.1074/jbc.M402352200; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; Dodson MW, 2007, CURR OPIN NEUROBIOL, V17, P331, DOI 10.1016/j.conb.2007.04.010; Favre C, 2010, ONCOGENE, V29, P3964, DOI 10.1038/onc.2010.146; Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199; Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114; Gispert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005777; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haque ME, 2008, P NATL ACAD SCI USA, V105, P1716, DOI 10.1073/pnas.0705363105; Heeman B, 2011, J CELL SCI, V124, P1115, DOI 10.1242/jcs.078303; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Herrup K, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt37; Horn SR, 2011, MOL BIOL CELL, V22, P1207, DOI 10.1091/mbc.E10-07-0567; Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849; Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310; Kawajiri S, 2010, FEBS LETT, V584, P1073, DOI 10.1016/j.febslet.2010.02.016; Kitada T, 2007, P NATL ACAD SCI USA, V104, P11441, DOI 10.1073/pnas.0702717104; Klinkenberg M, 2010, NEUROSCIENCE, V166, P422, DOI 10.1016/j.neuroscience.2009.12.068; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu WC, 2011, P NATL ACAD SCI USA, V108, P12920, DOI 10.1073/pnas.1107332108; Lutz AK, 2009, J BIOL CHEM, V284, P22938, DOI 10.1074/jbc.M109.035774; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Marongiu R, 2009, J NEUROCHEM, V108, P1561, DOI 10.1111/j.1471-4159.2009.05932.x; Martin SA, 2011, CANCER RES, V71, P1836, DOI 10.1158/0008-5472.CAN-10-2836; Mei Y, 2009, P NATL ACAD SCI USA, V106, P5153, DOI 10.1073/pnas.0901104106; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Mitra K, 2009, P NATL ACAD SCI USA, V106, P11960, DOI 10.1073/pnas.0904875106; Morais VA, 2009, EMBO MOL MED, V1, P99, DOI 10.1002/emmm.200900006; Muqit MMK, 2006, J NEUROCHEM, V98, P156, DOI 10.1111/j.1471-4159.2006.03845.x; Murata H, 2011, J BIOL CHEM, V286, P7182, DOI 10.1074/jbc.M110.179390; Park J, 2009, BIOCHEM BIOPH RES CO, V378, P518, DOI 10.1016/j.bbrc.2008.11.086; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105; Poole AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010054; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Rakovic A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016746; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Sandebring A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005701; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Staropoli JF, 2008, BIOESSAYS, V30, P719, DOI 10.1002/bies.20784; Sun XD, 2013, CELL CYCLE, V12, P1133, DOI 10.4161/cc.24215; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Wang HL, 2007, NEUROBIOL DIS, V28, P216, DOI 10.1016/j.nbd.2007.07.010; Wilhelmus MMM, 2012, FREE RADICAL BIO MED, V53, P983, DOI 10.1016/j.freeradbiomed.2012.05.040; Yamano K, 2011, NAT CELL BIOL, V13, P1026, DOI 10.1038/ncb2334; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697	70	49	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1363	1374		10.1038/onc.2014.81	http://dx.doi.org/10.1038/onc.2014.81			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681957	Green Published			2022-12-17	WOS:000350806500003
J	Moon, H; Lee, CS; Inder, KL; Sharma, S; Choi, E; Black, DM; Le Cao, KA; Winterford, C; Coward, JI; Ling, MT; Craik, DJ; Parton, RG; Russell, PJ; Hill, MM				Moon, H.; Lee, C. S.; Inder, K. L.; Sharma, S.; Choi, E.; Black, D. M.; Le Cao, K-A; Winterford, C.; Coward, J. I.; Ling, M. T.; Craik, D. J.; Parton, R. G.; Russell, P. J.; Hill, M. M.		Australian Prostate Canc BioResour	PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer	ONCOGENE			English	Article						PTRF; cavin-1; caveolin-1; caveolae; prostate cancer	RELEASE FACTOR PTRF; ANDROGEN RECEPTOR; SECRETED CAVEOLIN-1; STROMAL CAVEOLIN-1; SERUM CAVEOLIN-1; EXPRESSION; BREAST; GROWTH; INTERLEUKIN-6; FIBROBLASTS	Caveolin-1 has a complex role in prostate cancer and has been suggested to be a potential biomarker and therapeutic target. As mature caveolin-1 resides in caveolae, invaginated lipid raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the presence of cavin-1 in advanced prostate carcinoma, an expression pattern mirrored in the PC-3 cell line. In contrast, normal prostate epithelia expressed neither caveolin-1 nor cavin-1, while prostate stroma highly expressed both caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced prostate cancer, we found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis in an orthotopic prostate cancer xenograft mouse model. The expression of alpha-smooth muscle actin in stroma along with interleukin-6 (IL-6) in cancer cells was also decreased in tumors of mice bearing PC-3-cavin-1 tumor cells. To determine whether cavin-1 acts by neutralizing caveolin-1, we expressed cavin-1 in caveolin-1-negative prostate cancer LNCaP and 22Rv1 cells. Caveolin-1 but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. Cavin-1 co-expression reversed caveolin-1 effects in caveolin-1-positive LNCaP cells. Taken together, these results suggest that caveolin-1 in advanced prostate cancer is present outside of caveolae, because of the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-caveolar caveolin-1 microdomains partly via reduced IL-6 microenvironmental function. With circulating caveolin-1 as a potential biomarker for advanced prostate cancer, identification of the molecular pathways affected by cavin-1 could provide novel therapeutic targets.	[Moon, H.; Inder, K. L.; Choi, E.; Black, D. M.; Hill, M. M.] Univ Queensland, Diamantina Inst, Brisbane, Qld 4102, Australia; [Lee, C. S.; Sharma, S.] Univ Western Sydney, Sch Med, Discipline Pathol, Sydney, NSW, Australia; [Lee, C. S.; Sharma, S.] Univ Western Sydney, Mol Med Res Grp, Sydney, NSW, Australia; [Lee, C. S.; Sharma, S.] Liverpool Hosp, Dept Anat Pathol, Sydney, NSW, Australia; [Choi, E.] Univ Queensland, Sch Vet Sci, Brisbane, Qld 4102, Australia; [Le Cao, K-A] Univ Queensland, Queensland Facil Adv Bioinformat, Brisbane, Qld 4102, Australia; [Winterford, C.] Univ Queensland, Sch Med, Brisbane, Qld 4102, Australia; [Coward, J. I.] Translat Res Inst, Brisbane, Qld, Australia; [Ling, M. T.; Russell, P. J.] Queensland Univ Technol, Translat Res Inst, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia; [Ling, M. T.; Russell, P. J.] Queensland Univ Technol, Translat Res Inst, Inst Biomed Hlth & Innovat, Brisbane, Qld 4001, Australia; [Craik, D. J.; Parton, R. G.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4102, Australia	University of Queensland; Western Sydney University; Western Sydney University; Liverpool Hospital; University of Queensland; University of Queensland; University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Queensland	Hill, MM (corresponding author), Univ Queensland, Diamantina Inst, Translat Res Inst, Level 5,37 Kent St, Brisbane, Qld 4102, Australia.	m.hill2@uq.edu.au	Russell, Pamela J/G-1685-2010; Coward, Jermaine/C-1779-2012; Craik, David/B-1695-2010; Le Cao, Kim-Anh/B-6637-2013; Russell, Pamela/O-8504-2019; Hill, Michelle Mei Chih/G-4417-2010; Coward, Jermaine/F-2903-2016; Parton, Robert/C-5673-2009	Russell, Pamela J/0000-0002-3995-1239; Craik, David/0000-0003-0007-6796; Le Cao, Kim-Anh/0000-0003-3923-1116; Hill, Michelle Mei Chih/0000-0003-1134-0951; Coward, Jermaine/0000-0002-2309-9379; Parton, Robert/0000-0002-7494-5248; Lee, C. Soon/0000-0003-1058-5826; Moon, Hyeongsun/0000-0002-7479-1429	Association for International Cancer Research and Prostate Cancer Foundation Australia; National Health and Medical Research Council of Australia [569512]; NHMRC Project [631371]; NHMRC Australia Fellowship [569452]; University of Queensland International Postgraduate Research Scholarship; NHMRC Enabling [614296]; Prostate Cancer Foundation of Australia; Australian Cancer Research Foundation; Worldwide Cancer Research [10-0517] Funding Source: researchfish	Association for International Cancer Research and Prostate Cancer Foundation Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Project(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Australia Fellowship(National Health and Medical Research Council (NHMRC) of Australia); University of Queensland International Postgraduate Research Scholarship; NHMRC Enabling(National Health and Medical Research Council (NHMRC) of Australia); Prostate Cancer Foundation of Australia; Australian Cancer Research Foundation; Worldwide Cancer Research	S. We thank Duka Skalamera and Mareike Dahmer of the UQDI ARVEC facility for producing lentivirus, and the participants who kindly donated tissues to the Australian Prostate Cancer BioResource. This work was supported by project grants from the Association for International Cancer Research and Prostate Cancer Foundation Australia. MMH received a Career Development Award from the National Health and Medical Research Council of Australia (no. 569512). RGP was supported by NHMRC Project Grant 631371 and an NHMRC Australia Fellowship (569452). HM is supported by University of Queensland International Postgraduate Research Scholarship. The Australian Prostate Cancer BioResource is supported by an NHMRC Enabling Grant (no. 614296) and by an infrastructure grant from the Prostate Cancer Foundation of Australia. The ARVEC facility received support from the Australian Cancer Research Foundation.	Aboulaich N, 2004, BIOCHEM J, V383, P237, DOI 10.1042/BJ20040647; Aung CS, 2011, EUR J CELL BIOL, V90, P136, DOI 10.1016/j.ejcb.2010.06.004; Bai L, 2012, J CELL BIOCHEM, V113, P322, DOI 10.1002/jcb.23358; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Bennett N, 2009, IUBMB LIFE, V61, P961, DOI [10.1002/IUB.244, 10.1002/iub.244]; Bryant KG, 2011, INT J BIOCHEM CELL B, V43, P1318, DOI 10.1016/j.biocel.2011.04.019; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chung TDK, 1999, PROSTATE, V38, P199; Culig Z, 2012, MOL CELL ENDOCRINOL, V360, P52, DOI 10.1016/j.mce.2011.05.033; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Dorff TB, 2010, CLIN CANCER RES, V16, P3028, DOI 10.1158/1078-0432.CCR-09-3122; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Gould ML, 2010, PROSTATE, V70, P1609, DOI 10.1002/pros.21195; Gumulec J, 2012, ONCOL REP, V27, P831, DOI 10.3892/or.2011.1587; Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Hill MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043041; Hudes G, 2013, INVEST NEW DRUG, V31, P669, DOI 10.1007/s10637-012-9857-z; Hugo HJ, 2012, CANCER MICROENVIRON, V5, P83, DOI 10.1007/s12307-012-0098-7; Inder KL, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012245; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kuo SR, 2012, HYBRIDOMA, V31, P77, DOI 10.1089/hyb.2011.0100; Li LK, 2009, MOL CANCER RES, V7, P1781, DOI 10.1158/1541-7786.MCR-09-0255; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li X, 2008, CANCER SCI, V99, P1326, DOI 10.1111/j.1349-7006.2008.00816.x; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Luk SU, 2011, INT J CANCER, V128, P2182, DOI 10.1002/ijc.25546; Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130; McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Okamoto M, 1997, CANCER RES, V57, P141; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Skalamera D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051733; Skalamera D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020057; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Tahir SA, 2003, CLIN CANCER RES, V9, P3653; Tahir SA, 2001, CANCER RES, V61, P3882; Tahir SA, 2008, CANCER RES, V68, P731, DOI 10.1158/0008-5472.CAN-07-2668; Tahir SA, 2006, CLIN CANCER RES, V12, P4872, DOI 10.1158/1078-0432.CCR-06-0417; Wallner L, 2006, CANCER RES, V66, P3087, DOI 10.1158/0008-5472.CAN-05-3447; Wu CT, 2012, J MOL MED, V90, P1343, DOI 10.1007/s00109-012-0916-x; Xu XL, 2001, CANCER RES, V61, P7943; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873	49	49	50	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3561	3570		10.1038/onc.2013.315	http://dx.doi.org/10.1038/onc.2013.315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934189	Green Submitted			2022-12-17	WOS:000338941100008
J	Lee, EK; Diehl, JA				Lee, E. K.; Diehl, J. A.			SCFs in the new millennium	ONCOGENE			English	Review						Skp1; cullin 1; F-box; ubiquitin	E3 UBIQUITIN LIGASE; PHOSPHORYLATION-DEPENDENT UBIQUITINATION; BOX PROTEIN BETA-TRCP1; ALPHA-B-CRYSTALLIN; BETA-TRCP; TUMOR-SUPPRESSOR; CYCLIN D1; COP9 SIGNALOSOME; MTOR INHIBITOR; C-MYC	Substrate-specific degradation is a key feature of the ubiquitin proteasome system. Substrate specificity is typically directed by the E3 or ubiquitin ligase; such specificity can be conferred either by ligase modification or expression or conversely via modification of substrates that permit their recognition by a specific E3 ligase. The most well-known example of such complexes are the Cullin-RING ligases (CRLs). CRLs are composed of one of seven cullin-family scaffold proteins; the CRL serves as a scaffold that interacts directly with a RING-domain enzyme (Rbx1/2) through an extensive protein-protein interface within the globular C-terminal domain. At the N terminus, the cullin associates with an adaptor protein through cullin-repeat motifs. This adaptor, in turn, facilitates recruitment of a substrate-specifying factor that recruits the target to be ubiquitylated. The prototypical CRL is the cul1-containing complex, commonly referred to as the Skp1-Cul1-Fbox (SCF) ligase. SCF ligases contribute to the timely destruction of numerous substrates thereby ensuring normal cell growth. The importance of SCF function is highlighted by cancer-specific alterations in either the expression or the function of select F-box substrate-specific adaptors that results in neoplastic conversion. Herein, we discuss the current understanding of SCF function and contribution to cell biology.	[Lee, E. K.; Diehl, J. A.] Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA USA; [Lee, E. K.; Diehl, J. A.] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Abramson Family Canc Res Inst, 438 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			 [CA133154]; NATIONAL CANCER INSTITUTE [R01CA133154] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by CA133154.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Barbash O, 2011, ONCOGENE, V30, P1995, DOI 10.1038/onc.2010.584; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Beier F, 2012, BLOOD, V120, P2990, DOI 10.1182/blood-2012-03-418038; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Duda DM, 2012, MOL CELL, V47, P371, DOI 10.1016/j.molcel.2012.05.044; Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Emberley ED, 2012, J BIOL CHEM, V287, P29679, DOI 10.1074/jbc.M112.352484; Enchev RI, 2012, CELL REPORTS, V2, P616, DOI 10.1016/j.celrep.2012.08.019; Fischer ES, 2011, CELL, V147, P1024, DOI 10.1016/j.cell.2011.10.035; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; He Q, 2005, GENE DEV, V19, P1518, DOI 10.1101/gad.1322205; Hiramatsu Y, 2006, CANCER RES, V66, P8477, DOI 10.1158/0008-5472.CAN-06-1603; Hu R, 2010, PIGM CELL MELANOMA R, V23, P201, DOI 10.1111/j.1755-148X.2010.00668.x; Huang GC, 2011, J BIOL CHEM, V286, P10297, DOI 10.1074/jbc.M110.203729; Hulit J, 2006, CANCER RES, V66, P8529, DOI 10.1158/0008-5472.CAN-06-0149; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang H, 2005, MOL CELL, V18, P699, DOI 10.1016/j.molcel.2005.05.011; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kanarek N, 2010, GENE DEV, V24, P470, DOI 10.1101/gad.551610; Kim AY, 2008, J BIOL CHEM, V283, P33211, DOI 10.1074/jbc.M804440200; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Kudo Y, 2004, MOL CELL BIOL, V24, P8184, DOI 10.1128/MCB.24.18.8184-8194.2004; Kurz T, 2005, NATURE, V435, P1257, DOI 10.1038/nature03662; Lee TH, 2006, J BIOL CHEM, V281, P759, DOI 10.1074/jbc.M509855200; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsumoto ML, 2010, MOL CELL, V39, P477, DOI 10.1016/j.molcel.2010.07.001; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MIKOSHA A S, 1970, Problemy Endokria, V16, P90; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Nakamura M, 2002, FEBS LETT, V514, P193, DOI 10.1016/S0014-5793(02)02363-3; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Passmore LA, 2005, MOL CELL, V20, P855, DOI 10.1016/j.molcel.2005.11.003; Petroski MD, 2006, MOL CELL, V24, P523, DOI 10.1016/j.molcel.2006.10.010; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pierce NW, 2009, NATURE, V462, P615, DOI 10.1038/nature08595; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Shim EH, 2003, CANCER RES, V63, P1583; Spruck CH, 2002, CANCER RES, V62, P4535; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tanaka T, 2012, MOL ONCOL, V6, P267, DOI 10.1016/j.molonc.2012.01.003; Tang X, 2007, CELL, V129, P1165, DOI 10.1016/j.cell.2007.04.042; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vaites LP, 2011, MOL CELL BIOL, V31, P4513, DOI 10.1128/MCB.05733-11; van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Westbrook L, 2007, CANCER RES, V67, P11393, DOI 10.1158/0008-5472.CAN-06-4173; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2010, MOL CELL, V37, P784, DOI 10.1016/j.molcel.2010.02.025; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamoah K, 2008, P NATL ACAD SCI USA, V105, P12230, DOI 10.1073/pnas.0806155105; Yen HCS, 2008, SCIENCE, V322, P923, DOI 10.1126/science.1160462; Yen JL, 2012, MOL CELL, V48, P288, DOI 10.1016/j.molcel.2012.08.015; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zhang W, 2006, MOL CANCER RES, V4, P935, DOI 10.1158/1541-7786.MCR-06-0253; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhou XZ, 2003, J CELL BIOCHEM, V89, P19, DOI 10.1002/jcb.10496	103	49	50	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2011	2018		10.1038/onc.2013.144	http://dx.doi.org/10.1038/onc.2013.144			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23624913				2022-12-17	WOS:000334599100001
J	Antonov, AV; Krestyaninova, M; Knight, RA; Rodchenkov, I; Melino, G; Barlev, NA				Antonov, A. V.; Krestyaninova, M.; Knight, R. A.; Rodchenkov, I.; Melino, G.; Barlev, N. A.			PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome	ONCOGENE			English	Article						bioinformatics; computational oncology; survival	P73 TRANSCRIPTIONAL ACTIVITY; BREAST-CANCER; PROGNOSTIC MARKER; MICROARRAY DATA; ONLINE TOOL; P53; BIOMARKERS; RESOURCE; DATABASE; THERAPY	Multiple clinical studies have correlated gene expression with survival outcome in cancer on a genome-wide scale. However, in many cases, no obvious correlation between expression of well-known tumour-related genes (that is, p53, p73 and p21) and survival rates of patients has been observed. This can be mainly explained by the complex molecular mechanisms involved in cancer, which mask the clinical relevance of a gene with multiple functions if only gene expression status is considered. As we demonstrate here, in many such cases, the expression of the gene interaction partners (gene 'interactome') correlates significantly with cancer survival and is indicative of the role of that gene in cancer. On the basis of this principle, we have implemented a free online datamining tool (http://www.bioprofiling.de/PPISURV). PPISURV automatically correlates expression of an input gene interactome with survival rates on >40 publicly available clinical expression data sets covering various tumours involving about 8000 patients in total. To derive the query gene interactome, PPISURV employs several public databases including protein-protein interactions, regulatory and signalling pathways and protein post-translational modifications.	[Antonov, A. V.; Knight, R. A.; Melino, G.] Univ Leicester, Med Res Council, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Antonov, A. V.; Melino, G.; Barlev, N. A.] Technol Univ, Mol Pharmacol Lab, St Petersburg, Russia; [Krestyaninova, M.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Rodchenkov, I.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Barlev, N. A.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Barlev, N. A.] Russian Acad Sci, Inst Cytol, Gene Express Programme, St Petersburg 194064, Russia	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; University of Helsinki; University of Toronto; University of Rome Tor Vergata; University of Leicester; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Antonov, AV (corresponding author), Univ Leicester, Med Res Council, Toxicol Unit, Hodgkin Bldg,POB 138, Leicester LE1 9HN, Leics, England.	aa668@le.ac.uk; nb155@le.ac.uk	Barlev, Nikolai A/K-5268-2017	Barlev, Nikolai A/0000-0001-7111-2446; Krestyaninova, Maria/0000-0002-8705-8111	UK Medical Research Council (MRC); Russian Federal [14.B37.21.1967, 16.740.11.036, 11.G34.31.0069]; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Russian Federal; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the UK Medical Research Council (MRC) and funding from Russian Federal grants 14.B37.21.1967 (to AA) 16.740.11.036 (to NB) and 11.G34.31.0069 (to GM).	Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Antonov AV, 2010, NUCLEIC ACIDS RES, V38, pW78, DOI 10.1093/nar/gkq482; Barrett T, 2009, NUCLEIC ACIDS RES, V37, pD885, DOI 10.1093/nar/gkn764; Callagy GM, 2006, CLIN CANCER RES, V12, P2468, DOI 10.1158/1078-0432.CCR-05-2719; Castiglione F, 1999, ANTICANCER RES, V19, P4555; Ciardiello F, 2002, ANN ONCOL, V13, P501, DOI 10.1093/annonc/mdf191; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; Dietmann S, 2010, NUCLEIC ACIDS RES, V38, pW118, DOI 10.1093/nar/gkq515; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.1093/biomet/69.3.553; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Kerrien S, 2012, NUCLEIC ACIDS RES, V40, pD841, DOI 10.1093/nar/gkr1088; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Na II, 2007, J KOREAN MED SCI, V22, P393, DOI 10.3346/jkms.2007.22.3.393; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tandon S, 2010, CANCER EPIDEM BIOMAR, V19, P574, DOI 10.1158/1055-9965.EPI-09-0981; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Wu H, 2011, MOL CANCER RES, V9, P1780, DOI 10.1158/1541-7786.MCR-11-0157; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527	29	49	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1621	1628		10.1038/onc.2013.119	http://dx.doi.org/10.1038/onc.2013.119			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23686313				2022-12-17	WOS:000334344700002
J	Li, D; Beisswenger, C; Herr, C; Hellberg, J; Han, G; Zakharkina, T; Voss, M; Wiewrodt, R; Bohle, RM; Menger, MD; Schmid, RM; Stockel, D; Lenhof, HP; Bals, R				Li, D.; Beisswenger, C.; Herr, C.; Hellberg, J.; Han, G.; Zakharkina, T.; Voss, M.; Wiewrodt, R.; Bohle, R. M.; Menger, M. D.; Schmid, R. M.; Stoeckel, D.; Lenhof, H-P; Bals, R.			Myeloid cell RelA/p65 promotes lung cancer proliferation through Wnt/beta-catenin signaling in murine and human tumor cells	ONCOGENE			English	Article						lung cancer; NF-kappa B; inflammation; chronic obstructive disease; Wnt signaling pathway	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; IKK-BETA; INFLAMMATION; MACROPHAGES; WNT; TUMORIGENESIS; INHIBITION; PATHWAY; ANGIOGENESIS	Smoking is the most important risk factor for both lung cancer (LC) and chronic obstructive pulmonary disease. The aim of this study was to investigate the role of myeloid cell nuclear factor-kappa B in the regulation of tumor cell growth signaling. We subjected mice lacking myeloid RelA/p65 (rela(Delta-/-)) to a metastatic LC model. Cigarette smoke (CS) exposure significantly increased the proliferation of Lewis lung carcinoma cell tumors in wild-type mice. In CS-exposed rela(Delta-/-) mice, the tumor growth was largely inhibited. Transcriptome and pathway analysis of cancer tissue revealed a fundamental impact of myeloid cells on various growth signaling pathways, including the Wnt/beta-catenin pathway. In conclusion, myeloid RelA/p65 is necessary to link smoke-induced inflammation with LC growth and has a role in the activation of Wnt/beta-catenin signaling in tumor cells.	[Li, D.; Beisswenger, C.; Herr, C.; Hellberg, J.; Han, G.; Zakharkina, T.; Voss, M.; Bals, R.] Saarland Univ Hosp, Dept Internal Med Pulmonol 5, Homburg, Germany; [Wiewrodt, R.] Munster Univ Hosp, Dept Med A, Div Pulm, Munster, Germany; [Bohle, R. M.] Saarland Univ Hosp, Dept Pathol, Homburg, Germany; [Menger, M. D.] Univ Saarland, Inst Clin & Expt Surg, D-66421 Homburg, Saarland, Germany; [Schmid, R. M.] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany; [Stoeckel, D.; Lenhof, H-P] Univ Saarland, Ctr Bioinformat, D-66123 Saarbrucken, Germany	Universitatsklinikum des Saarlandes; University of Munster; Universitatsklinikum des Saarlandes; Saarland University; Technical University of Munich; Saarland University	Bals, R (corresponding author), Univ Saarland, Dept Internal Med Pulmonol 5, Kirrbergerstr 1, D-66421 Homburg, Saarland, Germany.	robert.bals@uks.eu	Herr, Christian/AAH-5291-2021; Beisswenger, Christoph/GRO-6580-2022	Herr, Christian/0000-0001-9422-6569	Deutsche Forschungsgemeinschaft [DFG Ba 1641/12]; Federal Ministry of Education and Research [FKZ 01G10881-0888]; LOEWE-Schwerpunkt	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); LOEWE-Schwerpunkt	This work was supported by Grants of the Deutsche Forschungsgemeinschaft (DFG Ba 1641/12), the Federal Ministry of Education and Research (FKZ 01G10881-0888), and the LOEWE-Schwerpunkt 'Tumor and Inflammation of the state of Hesse to RB. We thank Thomas Damm, Andreas Kamyschnikow and Anja Honecker for excellent technical support. We thank Professor Ingrid Forster for making the LysMcre animal available for this study.	Alalwani SM, 2010, EUR J IMMUNOL, V40, P1118, DOI 10.1002/eji.200939275; Algul H, 2007, J CLIN INVEST, V117, P1490, DOI 10.1172/JCI29882; Backes C, 2007, NUCLEIC ACIDS RES, V35, pW186, DOI 10.1093/nar/gkm323; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Berschneider B, 2011, INT J BIOCHEM CELL B, V43, P306, DOI 10.1016/j.biocel.2010.11.013; Blake JA, 2012, NUCLEIC ACIDS RES, V40, pD559, DOI 10.1093/nar/gkr1028; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hess C, 2010, EUR RESPIR J, V35, P343, DOI 10.1183/09031936.00196408; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu Mickey C-T, 2005, Future Oncol, V1, P67, DOI 10.1517/14796694.1.1.67; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kaler P, 2009, CANCER MICROENVIRON, V2, P69, DOI 10.1007/s12307-009-0030-y; Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lemjabbar-Alaoui H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000093; Li XG, 2008, NAT MED, V14, P863, DOI 10.1038/nm1783; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Moghaddam SJ, 2009, AM J RESP CELL MOL, V40, P443, DOI 10.1165/rcmb.2008-0198OC; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Papi A, 2004, THORAX, V59, P679, DOI 10.1136/thx.2003.018291; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Punturieri A, 2009, JNCI-J NATL CANCER I, V101, P554, DOI 10.1093/jnci/djp023; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Stathopoulos GT, 2008, MOL CANCER RES, V6, P364, DOI 10.1158/1541-7786.MCR-07-0309; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Takanami I, 1999, ONCOLOGY-BASEL, V57, P138, DOI 10.1159/000012021; Tennis M, 2007, J THORAC ONCOL, V2, P889, DOI 10.1097/JTO.0b013e318153fdb1; Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xu X, 2011, J THORAC ONCOL, V6, P716, DOI 10.1097/JTO.0b013e31820c5189; Yao PL, 2005, AM J RESP CELL MOL, V32, P540, DOI 10.1165/rcmb.2004-0223OC; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208; Zaynagetdinov R, 2011, J IMMUNOL, V187, P5703, DOI 10.4049/jimmunol.1100558; Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8	49	49	60	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1239	1248		10.1038/onc.2013.75	http://dx.doi.org/10.1038/onc.2013.75			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23563178				2022-12-17	WOS:000332631100004
J	Lee, TH; Park, JM; Leem, SH; Kang, TH				Lee, T-H; Park, J-M; Leem, S-H; Kang, T-H			Coordinated regulation of XPA stability by ATR and HERC2 during nucleotide excision repair	ONCOGENE			English	Article						XPA; ATR; HERC2; protein stability; posttranslational modification	PIGMENTOSUM GROUP-A; INDUCED DNA-DAMAGE; XERODERMA-PIGMENTOSUM; E3 LIGASE; PROTEIN; KINASE; PHOTOPRODUCTS; RECOGNITION; ACTIVATION; CELLS	ATR (ATM and Rad3-related) is an essential regulator of the nucleotide excision repair (NER) mechanism. For NER activation, ATR phosphorylates XPA, the rate-limiting factor in the NER pathway. However, the role of XPA phosphorylation at serine 196 by ATR has been elusive. Here we show that ATR-mediated XPA phosphorylation enhances XPA stability by inhibiting HERC2-mediated ubiquitination and subsequent degradation. We analyzed stabilization of XPA with substitutions of Ser 196 either to aspartate (S196D), a phosphomimetic mutation, or to alanine (S196A), a phosphodeficient mutation. Upon ultraviolet damage, ATR facilitated HERC2 dissociation from the XPA complex to induce XPA stabilization. However, this regulation was abrogated in S196A-complemented XPA-deficient cells due to persistent association of HERC2 with this XPA complex, resulting in enhanced ubiquitination of S196A. Conversely, the S196D substitution showed delayed degradation kinetics compared with the wild-type and less binding with HERC2, resulting in reduced ubiquitination of S196D. We also found that XPA phosphorylation enhanced the chromatin retention of XPA, the interaction with its binding partners following DNA damage. Taken together, our study presents a novel control mechanism in the NER pathway by regulating the steady-state level of XPA through posttranslational modifications by which ATR-mediated phosphorylation induces XPA stabilization by antagonizing HERC2-catalyzed XPA ubiquitination.	[Lee, T-H; Park, J-M; Leem, S-H; Kang, T-H] Dong A Univ, Dept Biol Sci, Pusan 604714, South Korea	Dong A University	Kang, TH (corresponding author), Dong A Univ, Dept Biol Sci, 840 Hadan 2 Dong, Pusan 604714, South Korea.	thkang@dau.ac.kr	Kang, Tae-Hong/Y-8294-2019	Kang, Tae-Hong/0000-0002-6013-900X; Lee, Tae-Hee/0000-0002-6263-6499	Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology (MEST) [2011-0013804, 2012-0003981]; Collaborative research Program of Nuclear Medical Sciences through the Dongnam Institute of Radiological & Medical Sciences; MEST and Busan Metropolitan city [2011-0593]	Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); Collaborative research Program of Nuclear Medical Sciences through the Dongnam Institute of Radiological & Medical Sciences; MEST and Busan Metropolitan city(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (MEST) (2011-0013804 and 2012-0003981). This study was also supported by 2011 Collaborative research Program of Nuclear Medical Sciences through the Dongnam Institute of Radiological & Medical Sciences funded by the MEST and Busan Metropolitan city (2011-0593).	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Auclair Y, 2008, P NATL ACAD SCI USA, V105, P17896, DOI 10.1073/pnas.0801585105; Bekker-Jensen S, 2010, NAT CELL BIOL, V12, P80, DOI 10.1038/ncb2008; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; D Bomgarden R, 2006, EMBO J, V25, P2605, DOI 10.1038/sj.emboj.7601123; Dzagnidze A, 2007, J NEUROSCI, V27, P9451, DOI 10.1523/JNEUROSCI.0523-07.2007; Gossage L, 2007, CANCER TREAT REV, V33, P565, DOI 10.1016/j.ctrv.2007.07.001; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Izawa N, 2011, CANCER RES, V71, P5621, DOI 10.1158/0008-5472.CAN-11-0385; Kang TH, 2008, J CELL SCI, V121, P3035, DOI 10.1242/jcs.026757; Kang TH, 2008, BBA-MOL CELL RES, V1783, P49, DOI 10.1016/j.bbamcr.2007.10.011; Kang TH, 2006, NAT CELL BIOL, V8, P863, DOI 10.1038/ncb1447; Kang TH, 2011, NUCLEIC ACIDS RES, V39, P3176, DOI 10.1093/nar/gkq1318; Kang TH, 2010, P NATL ACAD SCI USA, V107, P4890, DOI 10.1073/pnas.0915085107; Kang TH, 2009, CELL CYCLE, V8, P1665, DOI 10.4161/cc.8.11.8707; Kang TH, 2009, P NATL ACAD SCI USA, V106, P2864, DOI 10.1073/pnas.0812638106; Koberle B, 2006, DNA REPAIR, V5, P641, DOI 10.1016/j.dnarep.2005.12.001; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Li ZK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028326; Liu LR, 2010, J CELL PHYSIOL, V224, P585, DOI 10.1002/jcp.22205; Liu QH, 2000, GENE DEV, V14, P1448; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; Nguyen TA, 2010, DNA REPAIR, V9, P813, DOI 10.1016/j.dnarep.2010.04.005; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Perdiz D, 2000, J BIOL CHEM, V275, P26732; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Saijo M, 2011, J BIOL CHEM, V286, P5476, DOI 10.1074/jbc.M110.172916; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shell SM, 2009, J BIOL CHEM, V284, P24213, DOI 10.1074/jbc.M109.000745; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; States JC, 1998, HUM MUTAT, V12, P103, DOI 10.1002/(SICI)1098-1004(1998)12:2<103::AID-HUMU5>3.0.CO;2-6; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wu WW, 2010, CANCER RES, V70, P6384, DOI 10.1158/0008-5472.CAN-10-1304; Wu X, 2007, ONCOGENE, V26, P757, DOI 10.1038/sj.onc.1209828; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	46	49	50	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					19	25		10.1038/onc.2012.539	http://dx.doi.org/10.1038/onc.2012.539			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178497				2022-12-17	WOS:000329212000003
J	Pelosi, A; Careccia, S; Lulli, V; Romania, P; Marziali, G; Testa, U; Lavorgna, S; Lo-Coco, F; Petti, MC; Calabretta, B; Levrero, M; Piaggio, G; Rizzo, MG				Pelosi, A.; Careccia, S.; Lulli, V.; Romania, P.; Marziali, G.; Testa, U.; Lavorgna, S.; Lo-Coco, F.; Petti, M. C.; Calabretta, B.; Levrero, M.; Piaggio, G.; Rizzo, M. G.			miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; microRNA; PBX2	ACUTE PROMYELOCYTIC LEUKEMIA; MICRORNA; EXPRESSION; CELLS; ALPHA; RAS; TRANSFORMATION; HEMATOPOIESIS; DELTA-N-P73; PREDICTION	MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are involved in many complex cellular processes. Several miRNAs are differentially expressed in hematopoietic tissues and play important roles in normal differentiation, but, when aberrantly regulated, contribute to the abnormal proliferation and differentiation of leukemic cells. Recently, we reported that a small subset of miRNAs is differentially expressed in acute promyelocytic leukemia (APL) blasts and is modulated by treatment with all-trans-retinoic acid (ATRA). In particular, PML/RARa-positive blasts from APL patients display lower levels of miRNA let-7c, a member of the let-7 family, than normal promyelocytes and its expression increases after ATRA treatment. In this study, we investigated the effects of let-7c in acute myeloid leukemia (AML) cells. We found that ectopic expression of let-7c promotes granulocytic differentiation of AML cell lines and primary blasts. Moreover, we identified PBX2, a well-known homeodomain protein whose aberrant expression enhances HoxA9-dependent leukemogenesis, as a novel let-7c target that may contribute to the AML phenotype. Together, these studies raise the possibility that perturbation of the let-7c-PBX2 pathway may have a therapeutic value in AML.	[Pelosi, A.; Careccia, S.; Piaggio, G.; Rizzo, M. G.] Regina Elena Inst Canc Res, Dept Expt Oncol, Lab Mol Oncogenesis, I-00158 Rome, Italy; [Lulli, V.; Romania, P.; Marziali, G.; Testa, U.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Santa Lucia Fdn, Lab Neurooncohematol, Rome, Italy; [Petti, M. C.] Regina Elena Inst Canc Res, Dept Med Oncol, Div Hematol, Rome, Italy; [Calabretta, B.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Levrero, M.] Univ Roma La Sapienza, Dept Internal Med, I-00185 Rome, Italy; [Levrero, M.] Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Sapienza University Rome	Rizzo, MG (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via delle Messi dOro 156, I-00158 Rome, Italy.	rizzo@ifo.it	Careccia, Silvia/K-6475-2016; lavorgna, serena/O-8490-2016; Pelosi, Andrea/J-9690-2018; Marziali, Giovanna/J-9808-2016; Piaggio, Giulia/J-7214-2018; Testa, Ugo/J-6472-2016; Rizzo, Maria Giulia/B-2107-2018; Piaggio, Giulia/AAD-7336-2022; Romania, Paolo/K-3839-2018; Lulli, Valentina/J-9189-2016; Levrero, Massimo/G-5680-2016	Careccia, Silvia/0000-0001-7221-8170; lavorgna, serena/0000-0001-8812-2325; Pelosi, Andrea/0000-0003-2308-9215; Marziali, Giovanna/0000-0001-7450-1017; Piaggio, Giulia/0000-0003-2114-1892; Testa, Ugo/0000-0001-7900-8942; Rizzo, Maria Giulia/0000-0002-5009-2412; Romania, Paolo/0000-0001-6855-1464; Lulli, Valentina/0000-0002-2143-4436; Levrero, Massimo/0000-0002-4978-0875	NCI [CA95111]; AIL 'Alberto Landi'; Associazione Italiana Ricerca sul Cancro (AIRC); NATIONAL CANCER INSTITUTE [R01CA095111] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIL 'Alberto Landi'; Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Alessandro Fatica from 'Sapienza' University in Rome for a kind gift of lentiviral vector pRRLSIN-cPPT-PGK-GFP-WPRE and Dr Gianluca Bossi for kindly providing information on lentiviral utilization; Alessandra Boe for technical assistance for cell sorting and FACS analysis. We also acknowledge Dr Silvia Bacchetti for helpful comments on the manuscript. Associazione Italiana Leucemie (AIL) and Ministry of Health, Ricerca oncologica-Project of integrated program to MGR. G Piaggio was supported, in part, by Associazione Italiana Ricerca sul Cancro (AIRC). B Calabretta was supported, in part, by NCI grant CA95111. A Pelosi and S Careccia are PhD students University of Rome 'Sapienza'. A Pelosi is a recipient of a fellowship from AIRC. S Careccia is a recipient of the fellowship AIL 'Alberto Landi'.	Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Brown G, 2002, EXP CELL RES, V281, P28, DOI 10.1006/excr.2002.5654; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chaudhuri AA, 2012, P NATL ACAD SCI USA, V109, P4233, DOI 10.1073/pnas.1200677109; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Havelange V, 2010, AM J HEMATOL, V85, P935, DOI 10.1002/ajh.21863; Isken F, 2008, BRIT J HAEMATOL, V140, P153, DOI 10.1111/j.1365-2141.2007.06915.x; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Laurent A, 2008, INT J DEV BIOL, V52, P9, DOI 10.1387/ijdb.072304al; Leucci E, 2008, J PATHOL, V216, P440, DOI 10.1002/path.2410; Li X, 2012, NAT PROD COMMUN, V7, P181; Mainardi S, 2007, CELL DEATH DIFFER, V14, P1968, DOI 10.1038/sj.cdd.4402210; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104; Rizzo MG, 2004, LEUKEMIA, V18, P1804, DOI 10.1038/sj.leu.2403483; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107	34	49	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2013	32	31					3648	3654		10.1038/onc.2012.398	http://dx.doi.org/10.1038/onc.2012.398			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22964640	Green Accepted			2022-12-17	WOS:000322638400009
J	Lee, DW; Futami, M; Carroll, M; Feng, Y; Wang, Z; Fernandez, M; Whichard, Z; Chen, Y; Kornblau, S; Shpall, EJ; Bueso-Ramos, CE; Corey, SJ				Lee, D. W.; Futami, M.; Carroll, M.; Feng, Y.; Wang, Z.; Fernandez, M.; Whichard, Z.; Chen, Y.; Kornblau, S.; Shpall, E. J.; Bueso-Ramos, C. E.; Corey, S. J.			Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155	ONCOGENE			English	Article						SHIP-1; Akt; leukemia	CELL-SURVIVAL; BONE-MARROW; PTEN; GENE; TEC; HEMATOPOIESIS; PHOSPHATASES; PATHOGENESIS; AKT/PKB; TARGETS	The myelodysplastic syndromes (MDSs) comprise a group of disorders characterized by multistage progression from cytopenias to acute myeloid leukemia (AML). They display exaggerated apoptosis in early stages, but lose this behavior during evolution to AML. The molecular basis for loss of apoptosis is unknown. To investigate this critical event, we analyzed phosphatidylinositol (PI) 3'kinase signaling, implicated as a critical pathway of cell survival control in epithelial and hematological malignancies. PI 3'kinase activates Akt through its production of 3' phosphoinositides. In turn, the phosphoinositides are dephosphorylated by two lipid phosphatases, PTEN and SHIP-1, in myeloid cells. We studied primary MDS-enriched bone marrow cells and bone marrow sections by western blotting, immunohistochemistry, immunocytochemistry and quantitative PCR for components of the SHIP/PTEN/PI 3'kinase signaling circuit. We reported constitutively activated Akt, variable levels of PTEN and uniformly decreased SHIP-1 expression in MDS progenitor cells. Overexpression of SHIP-1, but not the phosphatase-deficient form, inhibited myeloid leukemic growth. Levels of microRNA (miR)-210 and miR-155 transcripts, which target SHIP-1, were increased in CD34(+) MDS cells compared with their normal counterparts. Direct binding of miR-210 to the 3' untranslated region of SHIP-1 was confirmed by luciferase reporter assay. Transfection of a myeloid cell line with miR-210 resulted in loss of SHIP-1 protein expression. These data suggest that miR-155 and miR-210/SHIP-1/Akt pathways could serve as clinical biomarkers for disease progression, and that miR-155 and miR-210 might serve as novel therapeutic targets in MDS. Oncogene (2012) 31, 4085-4094; doi:10.1038/onc.2011.579; published online 16 January 2012	[Futami, M.; Feng, Y.; Wang, Z.; Whichard, Z.; Chen, Y.; Corey, S. J.] Northeastern Univ, Feinberg Sch Med, Div Pediat, Chicago, IL 60611 USA; [Futami, M.; Feng, Y.; Wang, Z.; Whichard, Z.; Chen, Y.; Corey, S. J.] Northeastern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Carroll, M.] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Fernandez, M.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Kornblau, S.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Shpall, E. J.] Univ Texas MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA; [Lee, D. W.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Corey, SJ (corresponding author), Northeastern Univ, Dept Pediat, Childrens Mem Hosp & Robert H Lurie Comprehens Ca, Lurie 5-107,303 E Super St, Chicago, IL 60611 USA.	s-corey@northwestern.edu			NIH [KO2-HL03794, RO1-CA108992, PO1CA55164]; American Cancer Society [DHP-135]; Ladies Leukemia League; JP McCarthy Foundation; Leukemia SPORE [CA100632]; AA/MDS International Foundation; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA108992, P01CA055164, P50CA100632] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL003794] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Ladies Leukemia League; JP McCarthy Foundation; Leukemia SPORE; AA/MDS International Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Martin H Nguyen for technical assistance. We thank Drs Gerald Krystal for providing the cDNA for SHIP-1 and Maria-Magdalena Georgescu for control lysates. SJC was funded by the NIH Independent Scientist Award KO2-HL03794, RO1-CA108992, American Cancer Society Research Scholar Grant DHP-135, Ladies Leukemia League, JP McCarthy Foundation, NIH PO1CA55164 and Leukemia SPORE CA100632. Funding also came from the AA/MDS International Foundation to both SJC and MF.	Aul C, 1998, LEUKEMIA RES, V22, P93, DOI 10.1016/S0145-2126(97)00089-1; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Corey SJ, 2007, NAT REV CANCER, V7, P118, DOI 10.1038/nrc2047; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Fenaux P, 2004, SEMIN HEMATOL, V41, P6, DOI 10.1053/j.seminhematol.2004.02.002; Follo MY, 2007, CANCER RES, V67, P4287, DOI 10.1158/0008-5472.CAN-06-4409; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Gilby DC, 2007, LEUKEMIA, V21, P2390, DOI 10.1038/sj.leu.2404864; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Greenberg PL, 1998, LEUKEMIA RES, V22, P1123, DOI 10.1016/S0145-2126(98)00112-X; Hazen AL, 2009, BLOOD, V113, P2924, DOI 10.1182/blood-2008-02-138008; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Kalesnikoff J, 2004, REV PHYSIOL BIOCH P, V149, P87, DOI 10.1007/s10254-003-0016-y; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lakhanpal GK, 2010, BLOOD, V116, P428, DOI 10.1182/blood-2009-10-250217; Luo Jian-Min, 2004, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V12, P420; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Matsuda M, 2004, LEUKEMIA, V18, P1038, DOI 10.1038/sj.leu.2403301; Melcher M, 2008, J IMMUNOL, V180, P8048, DOI 10.4049/jimmunol.180.12.8048; Moody JL, 2004, BLOOD, V103, P4503, DOI 10.1182/blood-2003-09-3262; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nyakern M, 2006, LEUKEMIA, V20, P230, DOI 10.1038/sj.leu.2404057; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Pons A, 2009, LEUKEMIA LYMPHOMA, V50, P1854, DOI 10.3109/10428190903147645; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Rosenfeld C, 2000, LEUKEMIA, V14, P2, DOI 10.1038/sj.leu.2401618; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Ruschmann J, 2010, EXP HEMATOL, V38, P392, DOI 10.1016/j.exphem.2010.03.010; SATO K, 1994, LEUKEMIA, V8, P1663; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Thompson JE, 2007, EXP HEMATOL, V35, P21, DOI 10.1016/j.exphem.2006.08.017; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Whichard ZL, 2011, J BIOL CHEM, V286, P4742, DOI 10.1074/jbc.M110.166348; Worm J, 2009, NUCLEIC ACIDS RES, V37, P5784, DOI 10.1093/nar/gkp577; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4	45	49	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4085	4094		10.1038/onc.2011.579	http://dx.doi.org/10.1038/onc.2011.579			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22249254				2022-12-17	WOS:000308688900001
J	Rogers, AEJ; Le, JP; Sather, S; Pernu, BM; Graham, DK; Pierce, AM; Keating, AK				Rogers, A. E. J.; Le, J. P.; Sather, S.; Pernu, B. M.; Graham, D. K.; Pierce, A. M.; Keating, A. K.			Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology	ONCOGENE			English	Article						MerTK; receptor tyrosine kinase; glioblastoma multiforme; migration; focal adhesion kinase; morphology	ACUTE LYMPHOBLASTIC-LEUKEMIA; THERAPEUTIC TARGET; ADJUVANT TEMOZOLOMIDE; APOPTOTIC CELLS; TUMOR-GROWTH; AXL; CANCER; RADIOTHERAPY; METASTASIS; SURVIVAL	Glioblastoma multiforme (GBM) is an aggressive brain tumor, fatal within 1 year from diagnosis in most patients despite intensive multimodality therapy. The migratory and microscopically invasive nature of GBM as well as its resistance to chemotherapy renders conventional therapies inadequate in its treatment. Although Mer receptor tyrosine kinase (RTK) inhibition has been shown to decrease the long-term survival and improve the chemosensitivity of GBM in vitro, its role in malignant cellular migration has not been previously evaluated. In this study, we report for the first time a role for Mer RTK in brain tumor migration and show that Mer inhibition profoundly impedes GBM migration and alters cellular morphology. Our data demonstrate that Mer RTK inhibition results in altered signaling through focal adhesion kinase (FAK) and RhoA GTPase and a transformation of cytoskeletal organization, suggesting both molecular and structural mechanisms for the abrogation of migration. We also describe a novel and translational method of Mer RTK inhibition using a newly developed monoclonal antibody, providing proof of principle for future evaluation of Mer-targeted translational therapies in the treatment of GBM. Previous findings implicating Mer signaling in glioblastoma survival and chemotherapy resistance coupled with our discovery of the role of Mer RTK in GBM cellular migration support the development of novel Mer-targeted therapies for this devastating disease. Oncogene (2012) 31, 4171-4181; doi:10.1038/onc.2011.588; published online 19 December 2011	[Rogers, A. E. J.; Le, J. P.; Sather, S.; Pernu, B. M.; Graham, D. K.; Pierce, A. M.; Keating, A. K.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; [Rogers, A. E. J.; Graham, D. K.; Keating, A. K.] Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado	Keating, AK (corresponding author), Univ Colorado, Sch Med, Dept Pediat, MS 8302,12800 E 19th Ave,Rm P18-4105, Aurora, CO 80045 USA.	amy.keating@ucdenver.edu			NIH [R01 1CA137078, K12 HD068372]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068372] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA082086, R01CA137078, P30CA046934] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Rachel Linger, PhD for her expertise and insight into this project. We thank Jennifer Schlegel for production of the Mer add-back vector, the Advanced Light Microscopy Core Facility at the University of Colorado School of Medicine for their technical support in microscopy, and the University of Colorado Cancer Center Tissue Culture Core for their technical support in monoclonal antibody development. DKG is supported by NIH R01 1CA137078. AKK is generously supported by the St Baldrick's Foundation and the NIH K12 HD068372Child Health Research Career Development Award.	Chung H, 2011, J BIOL CHEM, V286, P13438, DOI 10.1074/jbc.M110.166751; Donson AM, 1999, J NEUROSURG, V90, P533, DOI 10.3171/jns.1999.90.3.0533; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goldberg L, 2006, CANCER RES, V66, P11709, DOI 10.1158/0008-5472.CAN-06-1878; Graham DK, 2006, CLIN CANCER RES, V12, P2662, DOI 10.1158/1078-0432.CCR-05-2208; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RMA, 2009, BLOOD, V114, P2678, DOI 10.1182/blood-2009-03-209247; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rochlitz C, 1999, LEUKEMIA, V13, P1352, DOI 10.1038/sj.leu.2401484; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Souhami L, 2004, INT J RADIAT ONCOL, V60, P853, DOI 10.1016/j.ijrobp.2004.04.011; Steinle M, 2011, RADIOTHER ONCOL, V101, P122, DOI 10.1016/j.radonc.2011.05.069; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Wu CW, 2002, ANTICANCER RES, V22, P1071; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632	27	49	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4171	4181		10.1038/onc.2011.588	http://dx.doi.org/10.1038/onc.2011.588			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22179835	Green Accepted			2022-12-17	WOS:000308975800001
J	Fan, H; Chen, L; Zhang, F; Quan, Y; Su, X; Qiu, X; Zhao, Z; Kong, KL; Dong, S; Song, Y; Chan, THM; Guan, XY				Fan, H.; Chen, L.; Zhang, F.; Quan, Y.; Su, X.; Qiu, X.; Zhao, Z.; Kong, K. L.; Dong, S.; Song, Y.; Chan, T. H. M.; Guan, X-Y			MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma	ONCOGENE			English	Article						DNMT3B; MTSS1; cell cycle; methylation; TSG; HCC	DE-NOVO METHYLATION; PERICENTROMERIC SATELLITE REGIONS; CANCER CELL-LINES; HUMAN HEPATOCARCINOGENESIS; BLADDER-CANCER; BREAST-CANCER; MESSENGER-RNA; CYCLIN-B; EXPRESSION; DNMT3B	DNA methyltransferase 3B (DNMT3B) mediates gene silencing via epigenetic mechanisms during hepatocellular carcinoma (HCC) progression. We aimed to identify novel targets of DNMT3B and their potential regulatory mechanisms in HCC. Metastasis suppressor 1 (MTSS1) was one of the DNMT3B targets and selected for further study. DNMT3B overexpression was detected in 81.25% of clinical HCC specimens and was negatively associated with MTSS1 in HCC cells and clinical samples. The underlying mechanism by which DNMT3B silences MTSS1 was studied using a combination of methylation-specific polymerase chain reaction (PCR) and bisulfite genome sequencing, chromatin immunoprecipitation-PCR and luciferase reporter assays. We found that the MTSS1 promoter region was sparsely methylated, and the methylation inhibitors failed to abolish DNMT3B-mediated MTSS1 silencing. DNMT3B protein bound directly to the 5'-flanking region (-865/-645) of the MTSS1 gene to inhibit its transcription. The functional role of MTSS1 was investigated using in vitro and in vivo tumorigenicity assays. As a result, MTSS1 exerted tumor suppressor effects and arrested cells in the G2/M phase, but not the G1/S phase of the cell cycle when it was depleted or overexpressed in HCC cells. Taken together, MTSS1, a novel target of DNMT3B, is repressed by DNMT3B via a DNA methylation-independent mechanism. MTSS1 was further characterized as a novel tumor suppressor gene in HCC. These findings highlight how DNMT3B regulates MTSS1, and such data may be useful for the development of new treatment options for HCC. Oncogene (2012) 31, 2298-2308; doi:10.1038/onc.2011.411; published online 12 September 2011	[Fan, H.; Zhang, F.; Quan, Y.; Su, X.; Qiu, X.] Southeast Univ, Sch Med, Key Lab Dev Genes & Human Dis, Minist Educ,Dept Med Genet & Dev Biol, Nanjing 210009, Peoples R China; [Chen, L.; Chan, T. H. M.; Guan, X-Y] Univ Hong Kong, State Key Lab Liver Canc, Pokfulam, Hong Kong, Peoples R China; [Chen, L.; Zhao, Z.; Kong, K. L.; Dong, S.; Song, Y.; Chan, T. H. M.; Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Chen, L.; Guan, X-Y] Sun Yat Sen Univ, State Key Lab Oncol So China, Dept Clin Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Southeast University - China; University of Hong Kong; University of Hong Kong; Sun Yat Sen University	Fan, H (corresponding author), Southeast Univ, Sch Med, Key Lab Dev Genes & Human Dis, Minist Educ,Dept Genet & Dev Biol, Nanjing 210009, Peoples R China.	fanh@seu.edu.cn; xyguan@hkucc.hku.hk	/A-3639-2009; Guan, Xin-Yuan/A-3639-2009	/0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017	National Natural Science Foundation of China [30971605]; HKU Li Ka Shing Faculty of Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); HKU Li Ka Shing Faculty of Medicine	This work was supported by The National Natural Science Foundation of China, No. 30971605, and in part by the Dr Cheng Yu Tung Fellowships 2007/08 under the HKU Li Ka Shing Faculty of Medicine. We are grateful to Professor Dianqing WU in UConn Health Center USA for providing siRNA expression vector. We are also grateful to Dr Stephanie Ma in Department of Pathology in University of Hong Kong for helping in MTSS1 antibody.	Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; Cross FR, 2005, MOL BIOL CELL, V16, P2129, DOI 10.1091/mbc.E04-10-0897; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Huang Xiu-yan, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P915, DOI 10.3760/cma.j.issn.1007-3418.2010.12.008; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jun Xu, 2005, Acta Genetica Sinica, V32, P1115; Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Oh BK, 2007, INT J MOL MED, V20, P65; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Shafiei F, 2008, ONCOGENE, V27, P2602, DOI 10.1038/sj.onc.1210917; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Simao TDA, 2006, HUM EXP TOXICOL, V25, P515, DOI 10.1191/0960327106het649oa; Takeshima H, 2006, J BIOCHEM, V139, P503, DOI 10.1093/jb/mvj044; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106; Wang J, 2007, CANCER RES, V67, P10647, DOI 10.1158/0008-5472.CAN-07-1337; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62	48	49	56	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2298	2308		10.1038/onc.2011.411	http://dx.doi.org/10.1038/onc.2011.411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21909138				2022-12-17	WOS:000303610800005
J	Li, H; Wittwer, T; Weber, A; Schneider, H; Moreno, R; Maine, GN; Kracht, M; Schmitz, ML; Burstein, E				Li, H.; Wittwer, T.; Weber, A.; Schneider, H.; Moreno, R.; Maine, G. N.; Kracht, M.; Schmitz, M. L.; Burstein, E.			Regulation of NF-kappa B activity by competition between RelA acetylation and ubiquitination	ONCOGENE			English	Article						NF-kappa B; RelA; p65; acetylation; ubiquitination; transcription	TRANSCRIPTION FACTOR; DEPENDENT TRANSCRIPTION; CANCER DEVELOPMENT; P65 SUBUNIT; PHOSPHORYLATION; ACTIVATION; ALPHA; INFLAMMATION; DEGRADATION; PROGRESSION	The nuclear factor (NF)-kappa B transcription factor has essential roles in inflammation and oncogenesis. Its ubiquitous RelA subunit is regulated by several post-translational modifications, including phosphorylation, ubiquitination and acetylation. Ubiquitination promotes the termination of RelA-dependent transcription, but its regulation is incompletely understood. Through mass spectrometry analysis of ubiquitinated RelA, we identified seven lysines that were attached to degradative and non-degradative forms of polyubiquitin. Interestingly, lysines targeted for acetylation were among the residues identified as ubiquitin acceptor sites. Mutation of these particular sites resulted in decreased polyubiquitination. Acetylation and ubiquitination were found to inhibit each other, consistent with their use of overlapping sites. Reconstitution of rela(-/-) fibroblasts with wild-type and mutant forms of RelA revealed that modifications at these residues can have activating and inhibitory functions depending on the target gene context. Altogether, this study elucidates that ubiquitination and acetylation can modulate each other and regulate nuclear NF-kappa B function in a gene-specific manner. Oncogene (2012) 31, 611-623; doi:10.1038/onc.2011.253; published online 27 June 2011	[Li, H.; Burstein, E.] UT SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; [Wittwer, T.; Moreno, R.; Schmitz, M. L.] Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; [Weber, A.; Kracht, M.] Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany; [Schneider, H.] Hannover Med Sch, Inst Biochem, D-3000 Hannover, Germany; [Maine, G. N.] William Beaumont Hosp, Dept Clin Pathol, Royal Oak, MI 48072 USA; [Burstein, E.] UT SW Med Ctr, Dept Mol Biol, Dallas, TX 75230 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Justus Liebig University Giessen; Justus Liebig University Giessen; Hannover Medical School; Beaumont Health; University of Texas System; University of Texas Southwestern Medical Center Dallas	Burstein, E (corresponding author), UT SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75230 USA.	Lienhard.Schmitz@biochemie.med.uni-giessen.de; ezra.burstein@utsouthwestern.edu	Burstein, Ezra/B-7247-2016; Li, Haiying/B-1879-2012; Schmitz, M. Lienhard/D-9328-2017	Burstein, Ezra/0000-0003-4341-6367; Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X	NIH [R01 DK073639]; CCFA; UTSW DOCS; DFG; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073639] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCFA; UTSW DOCS; DFG(German Research Foundation (DFG)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Zhijian 'James' Chen, Maria S Soengas and Marty W Mayo for providing cell lines that were utilized in these studies. We also thank Doris Newel and Oliver Dittrich for their technical assistance with the microarray experiments. This work was supported by an NIH R01 DK073639, a CCFA Senior Research Award and a UTSW DOCS Award to EB. The work of MLS and MK is supported by grants from the DFG.	BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Buerki C, 2008, NUCLEIC ACIDS RES, V36, P1665, DOI 10.1093/nar/gkn003; Burstein E, 2005, J BIOL CHEM, V280, P22222, DOI 10.1074/jbc.M501928200; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106; Fan YH, 2009, J BIOL CHEM, V284, P29290, DOI 10.1074/jbc.M109.018994; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Maine Gabriel N, 2009, Cold Spring Harb Protoc, V2009, DOI 10.1101/pdb.prot5318; Maine GN, 2010, NAT PROTOC, V5, P1447, DOI 10.1038/nprot.2010.109; Mao XC, 2009, GENE DEV, V23, P849, DOI 10.1101/gad.1748409; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Rothgiesser KM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-22; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Wright CW, 2009, SCIENCE, V323, P251, DOI 10.1126/science.1162818; Xu M, 2009, MOL CELL, V36, P302, DOI 10.1016/j.molcel.2009.10.002; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	40	49	51	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					611	623		10.1038/onc.2011.253	http://dx.doi.org/10.1038/onc.2011.253			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706061	Green Accepted			2022-12-17	WOS:000300221800007
J	Fenouille, N; Puissant, A; Tichet, M; Zimniak, G; Abbe, P; Mallavialle, A; Rocchi, S; Ortonne, JP; Deckert, M; Ballotti, R; Tartare-Deckert, S				Fenouille, N.; Puissant, A.; Tichet, M.; Zimniak, G.; Abbe, P.; Mallavialle, A.; Rocchi, S.; Ortonne, J-P; Deckert, M.; Ballotti, R.; Tartare-Deckert, S.			SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival	ONCOGENE			English	Article						melanoma; p53; signaling; tumor biology	INTEGRIN-LINKED KINASE; TUMOR-SUPPRESSOR P53; MALIGNANT-MELANOMA; THERAPEUTIC TARGET; CYSTEINE SPARC; UP-REGULATION; CANCER CELLS; E-CADHERIN; APOPTOSIS; EXPRESSION	Aberrant expression of Secreted Protein Acidic and Rich in Cysteine (SPARC)/osteonectin has been associated with an invasive tumor cell phenotype and poor outcome in human melanomas. Although it is known that SPARC controls melanoma tumorigenesis, the precise role of SPARC in melanoma cell survival is still unclear. Here, we show that SPARC has a cell-autonomous survival activity, which requires Akt-dependent regulation of p53. Suppression of SPARC by RNA interference in several human melanoma cells and xenografted A375 tumors triggers apoptotic cell death through the mitochondrial intrinsic pathway and activation of caspase-3. Cell death induced by depletion of SPARC is dependent on p53 and induction of Bax, and results in the generation of ROS. Stabilization of p53 in SPARC-depleted cells is associated with a decrease in Akt-mediated activating phosphorylation of MDM2. Inhibition of Akt signaling pathway is important for the observed changes as overexpression of constitutively active Akt protects cells against apoptosis induced by SPARC depletion. Conversely, increased expression of SPARC stimulates Akt and MDM2 phosphorylation, thus facilitating p53 degradation. Finally, we show that overexpression of SPARC renders cells more resistant to the p53-mediated cytotoxic effects of the DNA-damaging drug actinomycin-D. Our study indicates that SPARC functions through activation of Akt and MDM2 to limit p53 levels and that acquired expression of SPARC during melanoma development would confer survival advantages through suppression of p53-dependent apoptotic pathways. Oncogene (2011) 30, 4887-4900; doi: 10.1038/onc.2011.198; published online 20 June 2011	[Fenouille, N.; Tichet, M.; Zimniak, G.; Abbe, P.; Rocchi, S.; Ortonne, J-P; Ballotti, R.; Tartare-Deckert, S.] INSERM, Ctr Mediterraneene Med Mole C3M, U895, F-06204 Nice 3, France; [Fenouille, N.; Puissant, A.; Tichet, M.; Zimniak, G.; Abbe, P.; Mallavialle, A.; Rocchi, S.; Ortonne, J-P; Deckert, M.; Ballotti, R.; Tartare-Deckert, S.] Univ Nice Sophia Antipolis, Fac Med, Inst Signalisat & Pathol IFR50, Nice, France; [Mallavialle, A.; Deckert, M.] INSERM, U576, F-06204 Nice 3, France; [Rocchi, S.; Ballotti, R.; Tartare-Deckert, S.] Hop Archet, CHU Nice, Dept Dermatol, Nice, France; [Deckert, M.] Hop Archet, CHU Nice, Dept Clin Hematol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice	Tartare-Deckert, S (corresponding author), INSERM, Ctr Mediterraneene Med Mole C3M, U895, Equipe 1,151 Route St Antoine Ginestiere,BP 23194, F-06204 Nice 3, France.	tartare@unice.fr	BALLOTTI, Robert/F-8825-2013; PUISSANT, ALEXANDRE/O-9575-2016; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/T-3566-2019; Puissant, Alexandre/AAF-3875-2021; Rocchi, Stephane/O-4152-2016; Deckert, Marcel/M-4998-2016; Fenouille, Nina/AAI-1027-2021	PUISSANT, ALEXANDRE/0000-0002-3997-9282; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X; Puissant, Alexandre/0000-0002-3997-9282; Rocchi, Stephane/0000-0002-0943-1304; Tichet, Melanie/0000-0001-7128-4061; mallavialle, aude/0000-0002-9380-6788; BALLOTTI, Robert/0000-0002-7322-4908	INSERM (Institut National de la Santeet de la Recherche Medicale); ARC (Association pour la Recherche sur le Cancer) [1136]	INSERM (Institut National de la Santeet de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer)	This work was supported in part by INSERM (Institut National de la Santeet de la Recherche Medicale) and grant 1136 from ARC (Association pour la Recherche sur le Cancer). S Tartare-Deckert is a recipient of a Contrat d'Interface Clinique, Service de Dermatologie, CHU de Nice.	ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Arnold SA, 2009, J CELL COMMUN SIGNAL, V3, P255, DOI 10.1007/s12079-009-0072-4; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bailet O, 2009, CANCER RES, V69, P2748, DOI 10.1158/0008-5472.CAN-08-2690; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Chang W, 2010, J BIOL CHEM, V285, P8196, DOI 10.1074/jbc.M109.025684; Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Fenouille N, 2011, PIGM CELL MELANOMA R, V24, P219, DOI 10.1111/j.1755-148X.2010.00790.x; Fenouille N, 2010, CANCER RES, V70, P9659, DOI 10.1158/0008-5472.CAN-10-2034; Fukunaga-Kalabis M, 2008, CANCER MICROENVIRON, V1, P93, DOI 10.1007/s12307-008-0009-0; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Horie K, 2010, CANCER SCI, V101, P913, DOI 10.1111/j.1349-7006.2009.01476.x; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Khwaja FW, 2006, ONCOGENE, V25, P7650, DOI 10.1038/sj.onc.1209969; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; MIYASHITA T, 1995, CELL, V80, P293; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nie J, 2008, STEM CELLS, V26, P2735, DOI 10.1634/stemcells.2008-0212; Nie J, 2009, J CELL COMMUN SIGNAL, V3, P247, DOI 10.1007/s12079-009-0064-4; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Portela M, 2010, DEV CELL, V19, P562, DOI 10.1016/j.devcel.2010.09.004; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008-5472.CAN-08-1327; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Shi Q, 2007, ONCOGENE, V26, P4084, DOI 10.1038/sj.onc.1210181; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Smalley KSM, 2007, CANCER RES, V67, P209, DOI 10.1158/0008-5472.CAN-06-1538; Smit DJ, 2007, INT J CANCER, V121, P2653, DOI 10.1002/ijc.23039; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Sturm RA, 2002, CANCER RES, V62, P226; Tang MJ, 2007, J BIOL CHEM, V282, P34457, DOI 10.1074/jbc.M704459200; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weaver MS, 2008, J BIOL CHEM, V283, P22826, DOI 10.1074/jbc.M706563200; WEISS J, 1993, INT J CANCER, V54, P693, DOI 10.1002/ijc.2910540427; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	53	49	49	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	49					4887	4900		10.1038/onc.2011.198	http://dx.doi.org/10.1038/onc.2011.198			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21685937				2022-12-17	WOS:000298346400005
J	Crescenzi, E; Pacifico, F; Lavorgna, A; De Palma, R; D'Aiuto, E; Palumbo, G; Formisano, S; Leonardi, A				Crescenzi, E.; Pacifico, F.; Lavorgna, A.; De Palma, R.; D'Aiuto, E.; Palumbo, G.; Formisano, S.; Leonardi, A.			NF-kappa B-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells	ONCOGENE			English	Article						premature senescence; NF-kappa B; apoptosis; Fas; senescence-associated secretory phenotype	ONCOGENE-INDUCED SENESCENCE; IMMUNE-SYSTEM; DNA-DAMAGE; IN-VIVO; CELLULAR SENESCENCE; MEDIATED APOPTOSIS; CANCER-THERAPY; P53; PHENOTYPE; DEATH	Induction of a senescent phenotype in tumor cells has been linked to anticancer immune response, however, the molecular mechanisms mediating these phenomenon have not yet been determined. In this study, we present evidence that induction of premature senescence in human cancer cell lines induces Fas expression, and loss of resistance to Fas-induced apoptosis. Triggering of Fas by using the agonistic antibody CH11 or the recombinant ligand APO010, activates an apoptotic pathway responsible for cell death. Secretion of pro-inflammatory cytokines by the senescent cells, particularly TNF-alpha and IFN-gamma, mediates Fas upregulation. Indeed, treatment of proliferating cancer cell lines with TNF-alpha and IFN-gamma, upregulates Fas expression, while blocking TNF-alpha and IFN-gamma by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-kappa B has a central role in controlling the senescence-associated secretory phenotype (SASP) by the premature senescent cells, and that TNF-alpha and IFN-gamma, transcriptionally controlled by NF-kappa B, are the main mediators of Fas upregulation. Our data suggest the existence of an NF-kappa B- dependent autocrine loop, mediated by TNF-alpha and IFN-gamma, responsible for expression of Fas on the surface of senescent cells, and for their killing. Oncogene (2011) 30, 2707-2717; doi: 10.1038/onc.2011.1; published online 31 January 2011	[Lavorgna, A.; Palumbo, G.; Formisano, S.; Leonardi, A.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Crescenzi, E.; Pacifico, F.] Ist Endocrinol & Oncol Sperimentale, Naples, Italy; [De Palma, R.; D'Aiuto, E.] Univ Naples 2, Dipartimento Internist Clin & Sperimentale, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli	Leonardi, A (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	leonardi@unina.it	Pacifico, Francesco/AAX-3958-2020; leonardi, antonio/A-2887-2009; Lavorgna, Alfonso/A-5357-2012; Palumbo, Giuseppe/N-3136-2016	Pacifico, Francesco/0000-0001-9563-3596; leonardi, antonio/0000-0001-8636-9623; Palumbo, Giuseppe/0000-0001-9380-8436; CRESCENZI, ELVIRA/0000-0002-9258-8053; De Palma, Raffaele/0000-0001-9070-8878	MIUR [2008CCPKRP, 2007WJZZR2]	MIUR(Ministry of Education, Universities and Research (MIUR))	MIUR # 2008CCPKRP to AL; MIUR # 2007WJZZR2 to GP	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Chang BD, 1999, CANCER RES, V59, P3761; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Crescenzi E, 2008, CLIN CANCER RES, V14, P1877, DOI 10.1158/1078-0432.CCR-07-4298; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fluhr H, 2007, J CELL SCI, V120, P4126, DOI 10.1242/jcs.009761; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Gasser S, 2006, CANCER RES, V66, P3959, DOI 10.1158/0008-5472.CAN-05-4603; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Kimura M, 2003, CELL DEATH DIFFER, V10, P718, DOI 10.1038/sj.cdd.4401219; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Mirzayans R, 2005, RADIAT RES, V163, P53, DOI 10.1667/RR3280; NAUMANN M, 1993, ONCOGENE, V8, P2275; Neumann L, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.6; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Russo M, 2010, BIOCHEM PHARMACOL, V80, P674, DOI 10.1016/j.bcp.2010.03.011; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Soriani A, 2009, BLOOD, V113, P3503, DOI 10.1182/blood-2008-08-173914; te Poele RH, 2002, CANCER RES, V62, P1876; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verbrugge I, 2009, CLIN CANCER RES, V15, P2031, DOI 10.1158/1078-0432.CCR-08-2125; WAJAPEYEE N, 2008, CELL, V133, P1006; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22	39	49	51	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2707	2717		10.1038/onc.2011.1	http://dx.doi.org/10.1038/onc.2011.1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278794				2022-12-17	WOS:000291678500002
J	Hou, X; Liu, JE; Liu, W; Liu, CY; Liu, ZY; Sun, ZY				Hou, X.; Liu, J-E; Liu, W.; Liu, C-Y; Liu, Z-Y; Sun, Z-Y			A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation	ONCOGENE			English	Article						NUAK1; p53; LKB1; cell proliferation; phosphorylation	TUMOR INVASION; KINASE; LKB1; ARK5; IDENTIFICATION; ACTIVATION; GROWTH; CANCER; SENESCENCE; EXPRESSION	It has been suggested that adenosine monophosphate-activated protein kinase (AMPK) and 12 AMPK-related kinases (ARK), including novel (nua) kinase family 1 (NUAK1), are activated by master kinase LKB1, a major tumor suppressor. Apart from evidence to suggest that NUAK1 participates in induction of tumor survival, invasion and p53-independent cellular senescence, its detailed biological functions remain unclear. Here we showed that in the presence of wild-type LKB1, NUAK1 directly interacts with and phosphorylates p53 in vitro and in vivo. The phosphorylation of p53 induced by LKB1 required the kinase activity of NUAK1 and phosphorylation of NUAK1 at Thr211 by LKB1 was essential for its kinase activity, which leads to the conclusion that LKB1 activates NUAK1 and regulates phosphorylation of p53 through the NUAK1 kinase, at least partially. LKB1/NUAK1 activation leads to cell cycle arrest at the G(1)/S border by inducing expression of p21/WAF1. Under the regulation of LKB1, NUAK1 interacts with p53 in the nucleus and binds to the p53-responsive element of p21/WAF1 promoter. These findings have highlighted a novel role for NUAK1 in LKB1-related signaling pathways; NUAK1 can regulate cell proliferation and exert tumor suppression through direct interaction with p53. Oncogene (2011) 30, 2933-2942; doi:10.1038/onc.2011.19; published online 14 February 2011	[Hou, X.; Liu, J-E; Liu, W.; Liu, C-Y; Liu, Z-Y; Sun, Z-Y] Inner Mongolia Univ, Coll Life Sci, Hohhot 010021, Inner Mongolia, Peoples R China	Inner Mongolia University	Hou, X (corresponding author), Inner Mongolia Univ, Coll Life Sci, 235 Daxue W Rd, Hohhot 010021, Inner Mongolia, Peoples R China.	houxinliu@yahoo.com.cn	Liu, June/C-7871-2009		Science and Technology Foundation of Education Ministry of China [209025]; Inner Mongolia National Natural Science Foundation [2009ZD007]	Science and Technology Foundation of Education Ministry of China; Inner Mongolia National Natural Science Foundation	We thank Professor Tingmao Hu for helpful discussion. We are grateful to Dr Jinghua Yan for providing the plasmids. This study was supported by the Key Project of the Science and Technology Foundation of Education Ministry of China (209025) and the Key Project of the Inner Mongolia National Natural Science Foundation (2009ZD007).	Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kusakai G, 2004, J EXP CLIN CANC RES, V23, P263; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Niesler CU, 2007, EXP PHYSIOL, V92, P207, DOI 10.1113/expphysiol.2006.034736; ONCOGENE W, ONCOGENE; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Suzuki A, 2006, J BIOL CHEM, V281, P13915, DOI 10.1074/jbc.M511354200; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zeng PY, 2006, CANCER RES, V66, P10701, DOI 10.1158/0008-5472.CAN-06-0999	32	49	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2933	2942		10.1038/onc.2011.19	http://dx.doi.org/10.1038/onc.2011.19			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317932				2022-12-17	WOS:000292245100004
J	Huang, RY; Li, MY; Hsin, MKY; Underwood, MJ; Ma, LT; Mok, TSK; Warner, TD; Chen, GG				Huang, R-Y; Li, M-Y; Hsin, M. K. Y.; Underwood, M. J.; Ma, L. T.; Mok, T. S. K.; Warner, T. D.; Chen, G. G.			4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor	ONCOGENE			English	Article						lung cancer; NNK; thromboxane A(2); cell proliferation; CREB	ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; AIRWAY EPITHELIAL-CELLS; LIPID-PEROXIDATION; BCL-2 EXPRESSION; N-NITROSAMINES; CYCLOOXYGENASE-2; SYNTHASE; ADENOCARCINOMA; PROLIFERATION	The role of thromboxane A(2) (TxA(2)) in smoking-associated lung cancer is poorly understood. This study was conducted to study the role of TxA(2) in smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-promoted cell survival and growth in human lung cancer cells. We found that NNK increased TxA(2) synthase (TxAS) expression and thromboxane B-2 (TxB(2)) generation in cultured lung cancer cells, the result of which was supported by the increased level of TxAS in lung cancer tissues of smokers. Both TxAS-specific inhibitor furegrelate and TxA(2) receptor antagonist SQ29548 completely blocked NNK-mediated cell survival and growth via inducting apoptosis. TxA(2) receptor agonist U46619 reconstituted a near-full survival and growth response to NNK when TxAS was inhibited, affirming the role of TxA(2) receptor in NNK-mediated cell survival and growth. Suppression of cyclic adenosine monophosphate response element binding protein (CREB) activity by its small interference RNA blocked the effect of NNK. Phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) also had a positive role. Altogether, our results have revealed that NNK stimulates TxA(2) synthesis and activates its receptor in lung cancer cells. The increased TxA(2) may then activate CREB through PI3K/Akt and extracellular ERK pathways, thereby contributing to the NNK-promoted survival and growth of lung cancer cells. Oncogene (2011) 30, 106-116; doi: 10.1038/onc.2010.390; published online 6 September 2010	[Huang, R-Y; Li, M-Y; Hsin, M. K. Y.; Underwood, M. J.; Chen, G. G.] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Ma, L. T.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Mok, T. S. K.] Chinese Univ Hong Kong, Dept Clin Oncol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Warner, T. D.] Queen Mary Univ London, William Harvey Res Inst, London, England	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of London; Queen Mary University London	Chen, GG (corresponding author), Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	gchen@cuhk.edu.hk	Mok, Tony Shu Kam/B-2310-2019; Underwood, Malcolm John/L-6823-2016; Warner, Timothy D/A-1980-2009; Chen, George Gong/I-2757-2016; LI, Ming-Yue/I-2727-2016	Mok, Tony Shu Kam/0000-0002-8251-0551; Warner, Timothy D/0000-0003-3988-4408; 	CUHK [2007.2.045, 2008.2.038]	CUHK(Chinese University of Hong Kong)	We thank Suk Ying Chun, Ernest Chi Wai Chak and Billy Cheuk Sing Leung for their technical assistance. This study was supported by the CUHK direct grants (2007.2.045 and 2008.2.038).	Aggarwal S, 2008, CANCER RES, V68, P981, DOI 10.1158/0008-5472.CAN-06-0249; Amin S, 1996, CRIT REV TOXICOL, V26, P139, DOI 10.3109/10408449609017927; Aronov AM, 2007, J MED CHEM, V50, P1280, DOI 10.1021/jm061381f; Cailleteau C, 2008, ANAL BIOCHEM, V380, P26, DOI 10.1016/j.ab.2008.05.026; Calapai G, 2009, INHAL TOXICOL, V21, P1138, DOI 10.3109/08958370902798455; Cathcart MC, 2010, BBA-REV CANCER, V1805, P153, DOI 10.1016/j.bbcan.2010.01.006; Chen GG, 2006, CANCER LETT, V234, P193, DOI 10.1016/j.canlet.2005.03.032; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; COLEMAN RA, 1981, BRIT J PHARMACOL, V73, P773, DOI 10.1111/j.1476-5381.1981.tb16814.x; Daniel TO, 1999, CANCER RES, V59, P4574; de Leval X, 2006, J PHARMACOL EXP THER, V318, P1057, DOI 10.1124/jpet.106.101188; El-Bayoumy K, 1999, CANCER RES, V59, P1400; Ermert L, 2003, CLIN CANCER RES, V9, P1577; Fahn HJ, 1998, AM J RESP CELL MOL, V19, P901, DOI 10.1165/ajrcmb.19.6.3130; Grozio A, 2007, ANTI-CANCER AGENT ME, V7, P461; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; HOFFMANN D, 1994, J TOXICOL ENV HEALTH, V41, P1, DOI 10.1080/15287399409531825; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; Hung YH, 2009, CHEM-BIOL INTERACT, V179, P154, DOI 10.1016/j.cbi.2008.10.042; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Kim Y, 2006, CARCINOGENESIS, V27, P1410, DOI 10.1093/carcin/bgi340; Laag E, 2006, INT J CANCER, V119, P1547, DOI 10.1002/ijc.21987; Leung KC, 2009, EXP CELL RES, V315, P2974, DOI 10.1016/j.yexcr.2009.06.025; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Li MY, 2010, AM J RESP CELL MOL, V42, P113, DOI 10.1165/rcmb.2008-0463OC; Li XL, 2007, ARCH BIOCHEM BIOPHYS, V467, P20, DOI 10.1016/j.abb.2007.08.005; Li XL, 2009, CARCINOGENESIS, V30, P1606, DOI 10.1093/carcin/bgp161; Lu G, 2006, CANCER RES, V66, P11494, DOI 10.1158/0008-5472.CAN-06-1497; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; MCLEMORE TL, 1988, CANCER RES, V48, P3140; Merighi Stefania, 2006, Purinergic Signal, V2, P627, DOI 10.1007/s11302-006-9020-4; Miggin SM, 2001, BBA-MOL CELL RES, V1539, P147, DOI 10.1016/S0167-4889(01)00103-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Moussa O, 2008, ONCOGENE, V27, P55, DOI 10.1038/sj.onc.1210629; Moussa O, 2008, CANCER RES, V68, P4097, DOI 10.1158/0008-5472.CAN-07-6560; Nakahata N, 2008, PHARMACOL THERAPEUT, V118, P18, DOI 10.1016/j.pharmthera.2008.01.001; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Nishioka T, 2010, J CELL BIOCHEM, V109, P152, DOI 10.1002/jcb.22392; Parsons A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5569; Proulx LI, 2005, CLIN EXP IMMUNOL, V140, P46, DOI 10.1111/j.1365-2249.2005.02739.x; Sakai H, 2006, FEBS LETT, V580, P3368, DOI 10.1016/j.febslet.2006.05.007; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Stolimenov I, 2009, BIOCHEM SOC T, V37, P605, DOI 10.1042/BST0370605; Wei J, 2007, BIOCHEM PHARMACOL, V74, P787, DOI 10.1016/j.bcp.2007.06.008; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147	47	49	52	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					106	116		10.1038/onc.2010.390	http://dx.doi.org/10.1038/onc.2010.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818420				2022-12-17	WOS:000285959300010
J	Peng, A; Maller, JL				Peng, A.; Maller, J. L.			Serine/threonine phosphatases in the DNA damage response and cancer	ONCOGENE			English	Review						protein phosphatase; DNA damage; checkpoint; cancer	DOUBLE-STRAND BREAK; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR ACTIVITY; CHECKPOINT KINASE RAD53; CHK2 PROTEIN-KINASE; ACTIVATION IN-VIVO; WIP1 PHOSPHATASE; IONIZING-RADIATION; ATM ACTIVATION; DEPHOSPHORYLATES GAMMA-H2AX	The cellular response to DNA damage is a crucial surveillance mechanism that maintains genomic integrity and prevents cancer progression. Previous studies identified multiple Ser/Thr protein kinases that have pivotal roles in the activation of this response. It is interesting that a growing body of evidence suggests that these kinases and their substrates are under tight modulation by numerous Ser/Thr phosphatases. In this study, we review recent reports that reveal new functions and regulation of these phosphatases. Similar to the kinases in this pathway, phosphatases may also be intimately involved in cancer progression and present valuable targets for cancer therapy. Oncogene (2010) 29, 5977-5988; doi:10.1038/onc.2010.371; published online 13 September 2010	[Peng, A.; Maller, J. L.] Univ Colorado, Sch Med, Howard Hughes Med Inst, Aurora, CO 80045 USA; [Peng, A.; Maller, J. L.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Peng, A (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, 12801 E 17th Ave,RC1 S,Rm L1810122,MS 8303, Aurora, CO 80045 USA.	Aimin.Peng@unmc.edu; Jim.Maller@UCDENVER.edu			Howard Hughes Medical Institute	Howard Hughes Medical Institute(Howard Hughes Medical Institute)	We thank members of the Maller lab for stimulating discussions. This work was supported by the Howard Hughes Medical Institute. We apologize to colleagues whose relevant works are not cited here due to space limitations.	Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Austen B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bazzi M, 2010, MOL CELL BIOL, V30, P131, DOI 10.1128/MCB.01000-09; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buscemi G, 2006, MOL CELL BIOL, V26, P7832, DOI 10.1128/MCB.00534-06; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Chowdhury D, 2008, MOL CELL, V31, P33, DOI 10.1016/j.molcel.2008.05.016; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Douglas P, 2010, MOL CELL BIOL, V30, P1368, DOI 10.1128/MCB.00741-09; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feng JJ, 2009, MOL CELL BIOL, V29, P5696, DOI 10.1128/MCB.00191-09; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Freeman AK, 2010, CELL CYCLE, V9, P736, DOI 10.4161/cc.9.4.10613; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guillemain G, 2007, MOL CELL BIOL, V27, P3378, DOI 10.1128/MCB.00863-06; Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hamilton J, 2009, CANCER BIOL THER, V8, P1577, DOI 10.4161/cbt.8.16.8962; Haneda M, 2004, FEBS LETT, V567, P171, DOI 10.1016/j.febslet.2004.04.066; Heideker J, 2007, CELL CYCLE, V6, P3058, DOI 10.4161/cc.6.24.5100; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Keogh MC, 2006, NATURE, V441, P120, DOI 10.1038/nature04772; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lee DH, 2010, NAT STRUCT MOL BIOL, V17, P365, DOI 10.1038/nsmb.1769; Lee SJ, 2007, CELL DEATH DIFFER, V14, P1106, DOI 10.1038/sj.cdd.4402111; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Liang XB, 2006, INT J MOL MED, V17, P703; Liu Y, 2002, CANCER RES, V62, P6357; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lu G, 2008, CLIN EXP PHARMACOL P, V35, P107, DOI 10.1111/j.1440-1681.2007.04843.x; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Mi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004395; Mi J, 2009, MOL CANCER THER, V8, P135, DOI 10.1158/1535-7163.MCT-08-0457; Mochan TA, 2003, CANCER RES, V63, P8586; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nakada S, 2008, EMBO REP, V9, P1019, DOI 10.1038/embor.2008.162; Nazarov OB, 2003, RADIAT RES, V160, P309, DOI 10.1667/RR3043; O'Neill BM, 2007, P NATL ACAD SCI USA, V104, P9290, DOI 10.1073/pnas.0703252104; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Peng AM, 2010, CURR BIOL, V20, P387, DOI 10.1016/j.cub.2010.01.020; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Tang X, 2008, MOL CELL BIOL, V28, P2559, DOI 10.1128/MCB.01711-07; Travesa A, 2008, J BIOL CHEM, V283, P17123, DOI 10.1074/jbc.M801402200; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Wood JL, 2008, TRENDS CELL BIOL, V18, P451, DOI 10.1016/j.tcb.2008.07.006; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xia Y, 2009, J BIOL CHEM, V284, P17428, DOI 10.1074/jbc.M109.007823; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yan Y, 2010, ONCOGENE, V29, P4317, DOI 10.1038/onc.2010.187; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Yong WD, 2007, J BIOL CHEM, V282, P14690, DOI 10.1074/jbc.C700019200; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2003, CANCER BIOL THER, V2, pS16; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	100	49	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					5977	5988		10.1038/onc.2010.371	http://dx.doi.org/10.1038/onc.2010.371			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20838380				2022-12-17	WOS:000284108700001
J	Wang, M; Hossain, MS; Tan, W; Coolman, B; Zhou, J; Liu, S; Casey, PJ				Wang, M.; Hossain, M. S.; Tan, W.; Coolman, B.; Zhou, J.; Liu, S.; Casey, P. J.			Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth	ONCOGENE			English	Article						isoprenylcysteine carboxylmethyltransferase (Icmt); prenylation; farnesylation; autophagy; apoptosis; cancer therapy	PROGRAMMED CELL-DEATH; SMALL-MOLECULE INHIBITOR; CARBOXYL METHYLTRANSFERASE; PROTEIN PRENYLATION; K-RAS; OVARIAN; CYTOTOXICITY; MECHANISMS; HOMOLOG; LC3	Inhibition of isoprenylcysteine carboxylmethyltransferase (Icmt), which catalyzes the final step in the post-translational C-terminal processing of prenylated proteins, suppresses tumor cell growth and induces cell death. Icmt inhibition by either a small molecule inhibitor termed as cysmethynil or inhibitory RNA induces marked autophagy leading to cell death. HepG2 cells were used to investigate the function of autophagy in tumor cell death. Suppression of autophagy, either pharmacologically or through knockdown of the autophagy essential proteins, Atg5 or Atg1, inhibits not only cysmethynil-induced autophagy, but also apoptosis in HepG2 cells. The dependence of cysmethynil-induced apoptosis on autophagy was further shown using autophagy-deficient mouse embryonic fibroblast (MEF) cells. Atg5(-/-) MEF cells were found to be resistant to cysmethynil-induced apoptosis, whereas wild-type MEFs showed high sensitivity to apoptosis induction. These data indicate that inhibition of Icmt can elicit cell death through two linked mechanisms, autophagy and apoptosis, and that autophagy can be an active player upstream of apoptosis in cell types capable of apoptotic cell death, such as HepG2 and MEFs. Further, treatment of mice-bearing HepG2-derived tumors with cysmethynil resulted in marked inhibition of tumor growth; analysis of tumor tissue from these mice revealed markers consistent with autophagy induction and cell growth arrest. Oncogene (2010) 29, 4959-4970; doi: 10.1038/onc.2010.247; published online 12 July 2010	[Wang, M.; Hossain, M. S.; Tan, W.; Zhou, J.; Liu, S.; Casey, P. J.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Coolman, B.; Casey, P. J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA	National University of Singapore; Duke University	Wang, M (corresponding author), Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg	Hossain, Mohammad Sorowar/AAX-2009-2020	Hossain, Mohammad Sorowar/0000-0001-7143-2909; Wang, Mei/0000-0001-6887-6840; Casey, Patrick/0000-0002-7366-9309	Singapore Ministry of Health; Agency for Science, Technology, and Research	Singapore Ministry of Health(Ministry of Health-Singapore); Agency for Science, Technology, and Research(Agency for Science Technology & Research (A*STAR))	We are grateful to Noboru Mizushima for the generous gift of Atg5 knockout cells. This paper is dedicated to the spirit of Block C, an aging nursing school dormitory retrofitted as the Duke-NUS interim research facility in which some of these studies were conducted. Financial support was provided by awards from the Singapore Ministry of Health and the Agency for Science, Technology, and Research.	Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083; Anderson JL, 2005, J BIOL CHEM, V280, P29454, DOI 10.1074/jbc.M504982200; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Baron RA, 2007, BIOCHEMISTRY-US, V46, P554, DOI 10.1021/bi060344n; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Blum R, 2008, RECENT PAT ANTI-CANC, V3, P31; Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; CLIBY W, 1993, GYNECOL ONCOL, V50, P34, DOI 10.1006/gyno.1993.1160; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Di X, 2009, BIOCHEM PHARMACOL, V77, P1139, DOI 10.1016/j.bcp.2008.12.016; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; ECCLES DM, 1992, ONCOGENE, V7, P2069; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818; Gewirtz DA, 2009, RADIOTHER ONCOL, V92, P323, DOI 10.1016/j.radonc.2009.05.022; Gorka M, 2005, ANTI-CANCER DRUG, V16, P777; Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511; Juhasz G, 2003, FEBS LETT, V543, P154, DOI 10.1016/S0014-5793(03)00431-9; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kang C, 2007, GENE DEV, V21, P2161, DOI 10.1101/gad.1573107; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kramer K, 2003, MOL BIOL CELL, V14, P848, DOI 10.1091/mbc.E02-07-0390; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333; Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; Nair U, 2005, J BIOL CHEM, V280, P41785, DOI 10.1074/jbc.R500016200; Olie RA, 1998, CURR BIOL, V8, P955, DOI 10.1016/S0960-9822(98)70395-1; Roisin-Bouffay C, 2004, J BIOL CHEM, V279, P11489, DOI 10.1074/jbc.M312741200; SAITO H, 1993, CANCER RES, V53, P3382; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Sousa SF, 2008, CURR MED CHEM, V15, P1478, DOI 10.2174/092986708784638825; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood-2007-06-094060; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Wright LP, 2009, MOL CELL BIOL, V29, P1826, DOI 10.1128/MCB.01719-08; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	49	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4959	4970		10.1038/onc.2010.247	http://dx.doi.org/10.1038/onc.2010.247			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20622895				2022-12-17	WOS:000281578700010
J	Kiefel, H; Bondong, S; Erbe-Hoffmann, N; Hazin, J; Riedle, S; Wolf, J; Pfeifer, M; Arlt, A; Schafer, H; Muerkoster, SS; Altevogt, P				Kiefel, H.; Bondong, S.; Erbe-Hoffmann, N.; Hazin, J.; Riedle, S.; Wolf, J.; Pfeifer, M.; Arlt, A.; Schaefer, H.; Mueerkoester, S. Sebens; Altevogt, P.			L1CAM-integrin interaction induces constitutive NF-kappa B activation in pancreatic adenocarcinoma cells by enhancing IL-1 beta expression	ONCOGENE			English	Article						pancreatic tumour; L1CAM signalling; integrins	ADHESION MOLECULE L1; INTEGRIN-LINKED KINASE; CARCINOMA-CELLS; PRESENILIN/GAMMA-SECRETASE; THERAPEUTIC ANTIBODIES; MALIGNANT-MELANOMA; OVARIAN CARCINOMAS; COLORECTAL-CANCER; GENE-EXPRESSION; MIGRATION	L1 cell adhesion molecule (L1CAM) overexpression is often associated with bad prognosis in various human carcinomas. Recent studies also suggest a role of L1CAM in pancreatic ductal adenocarcinomas (PDAC). To further address its contribution, we expressed functional domains of L1CAM in PT45-P1 PDAC cells. We found that L1CAM that is full length (L1-FL), but neither the soluble ectodomain (L1ecto) nor the cytoplasmic part (L1cyt), could enhance cell proliferation or tumour growth in mice. Expression of L1-FL resulted in constitutive activation of NF-kappa B, which was abolished by L1CAM knockdown. We showed that the expression of IL-1 beta was selectively upregulated by L1-FL, and increased IL-1 beta levels were instrumental for sustained NF-kappa B activation. IL-1 beta production and NF-kappa B activation were abolished by knockdown of alpha 5-integrin and integrin-linked kinase, but insensitive to depletion of L1CAM cleavage proteinases. Supporting these data, PT45-P1 cells transduced with an L1CAM mutant deficient in integrin binding (L1-RGE) did not support the described L1-FL functions. Our results suggest that membranous L1CAM interacts with RGD-binding integrins, leading to sustained NF-kappa B activation by IL-1 beta production and autocrine/paracrine signalling. The unravelling of this novel mechanism sheds new light on the important role of L1CAM expression in PDAC cells. Oncogene (2010) 29, 4766-4778; doi:10.1038/onc.2010.230; published online 14 June 2010	[Kiefel, H.; Bondong, S.; Erbe-Hoffmann, N.; Hazin, J.; Riedle, S.; Wolf, J.; Pfeifer, M.; Altevogt, P.] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Arlt, A.; Schaefer, H.; Mueerkoester, S. Sebens] Univ Kiel, Clin Internal Med, Lab Mol Gastroenterol & Hepatol, Kiel, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Kiel	Altevogt, P (corresponding author), German Canc Res Ctr, D015,Neuenheimer Feld 280, D-69120 Baden Wurtemberg, Germany.	P.Altevogt@dkfz.de	Schäfer, Heiner/C-1055-2011; Sebens, Susanne/C-1222-2010; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059	Deutsche Krebshilfe (Schwerpunktprogramm: Invasion and Migration); Deutsche Forschungsgemeinschaft [SE-1831/2-1]; EU [PE-14034]; Medigene Inc. (Munich)	Deutsche Krebshilfe (Schwerpunktprogramm: Invasion and Migration)(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); EU(European Commission); Medigene Inc. (Munich)	We acknowledge the competent help of Dr Alex Stoeck (University of Michigan, Ann Arbor) in retroviral expression in the early phase of the study. We also thank Ramona Straub and Dagmar Leisner for excellent technical assistance. This study was supported by grants from Deutsche Krebshilfe (Schwerpunktprogramm: Invasion and Migration), the Deutsche Forschungsgemeinschaft project nr. SE-1831/2-1 to S.S. and the EU-FP6 framework program OVCAD project nr. PE-14034 to PA. Further financial support was received from a collaborative research grant from Medigene Inc. (Munich) to PA.	Arlt A, 2002, CANCER RES, V62, P910; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bao SD, 2008, CANCER RES, V68, P6043, DOI 10.1158/0008-5472.CAN-08-1079; Boo YJ, 2007, ANN SURG ONCOL, V14, P1703, DOI 10.1245/s10434-006-9281-8; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gast D, 2008, ONCOGENE, V27, P1281, DOI 10.1038/sj.onc.1210747; Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869; Gast D, 2008, EXP CELL RES, V314, P2411, DOI 10.1016/j.yexcr.2008.04.004; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Gouveia RM, 2008, J BIOL CHEM, V283, P28038, DOI 10.1074/jbc.M804991200; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Issa Y, 2009, J MOL MED, V87, P99, DOI 10.1007/s00109-008-0410-7; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kaifi JT, 2007, MODERN PATHOL, V20, P1183, DOI 10.1038/modpathol.3800955; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Maddaluno L, 2009, J EXP MED, V206, P623, DOI 10.1084/jem.20081211; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Muerkoester SS, 2009, INT J ONCOL, V34, P243, DOI 10.3892/ijo_00000146; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Novak-Hofer I, 2008, CANCER LETT, V261, P193, DOI 10.1016/j.canlet.2007.11.012; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Reidy M, 2006, J BIOMED MATER RES A, V77A, P542, DOI 10.1002/jbm.a.30590; Riedle S, 2009, BIOCHEM J, V420, P391, DOI 10.1042/BJ20081625; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Schniewind B, 2007, ONCOGENE, V26, P4850, DOI 10.1038/sj.onc.1210272; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Stoeck A, 2006, CANCER LETT, V239, P212, DOI 10.1016/j.canlet.2005.08.005; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3; Wolterink S, 2010, CANCER RES, V70, P2504, DOI 10.1158/0008-5472.CAN-09-3730	47	49	53	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4766	4778		10.1038/onc.2010.230	http://dx.doi.org/10.1038/onc.2010.230			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543863				2022-12-17	WOS:000281326400003
J	Zhao, TT; Le Francois, BG; Goss, G; Ding, K; Bradbury, PA; Dimitroulakos, J				Zhao, T. T.; Le Francois, B. G.; Goss, G.; Ding, K.; Bradbury, P. A.; Dimitroulakos, J.			Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins	ONCOGENE			English	Article						epidermal growth factor receptor mevalonate pathway; AKT; lovastatin; rho GTPases	GROWTH-FACTOR RECEPTOR; MEVALONATE PATHWAY; MTOR INHIBITORS; LUNG-CANCER; PHASE-III; COMBINATION; ERLOTINIB; GTPASES; TRIALS; RAS	We recently showed the ability of lovastatin to inhibit the function of the epidermal growth factor receptor (EGFR) and its downstream signaling of the phosphatidylinositol-3 kinase/AKT pathway. Combining lovastatin with gefitinib, a potent EGFR inhibitor, induced synergistic cytotoxicity in various tumor-derived cell lines. In this study, lovastatin treatment was found to inhibit ligand-induced EGFR dimerization in squamous cell carcinoma cells and its activation of AKT and its downstream targets 4E-binding protein 1 and S6 kinase 1. This inhibition was associated with global protein translational inhibition shown by a decrease in RNA associated polysome fractions. The effects of lovastatin on EGFR function were reversed by the addition of geranylgeranyl pyrophosphate, which functions as a protein membrane anchor. Lovastatin treatment induced actin cytoskeletal disorganization and the expression of geranylgeranylated rho family proteins that regulate the actin cytoskeleton, including rhoA. Lovastatin-induced rhoA was inactive as EGF stimulation failed to activate rhoA and inhibition of the rho-associated kinase, a target and mediator of rhoA function, with Y-27632 also showed inhibitory effects on EGFR dimerization. The ability of lovastatin to inhibit EGFR dimerization is a novel exploitable mechanism regulating this therapeutically relevant target. To explore the potential clinical significance of this combination, we evaluated the effect of statin on the overall survival (OS) and disease-specific survival (DSS) of patients with advanced non-small-cell lung cancer enrolled in the NCIC Clinical Trials Group phase III clinical trials BR21 (EGFR tyrosine kinase inhibitor erlotinib versus placebo) and BR18 (carboplatin and paclitaxel with or without the metalloproteinase inhibitor BMS275291). In BR18, use of statin did not affect OS or DSS. In BR21, patients showed a trend for improvement in OS (HR: 0.69, P = 0.098) and DSS (HR: 0.62, P = 0.048), but there was no statin x treatment interaction effect (P = 0.34 and P = 0.51 for OS and DSS, respectively). Oncogene (2010) 29, 4682-4692; doi:10.1038/onc.2010.219; published online 21 June 2010	[Zhao, T. T.; Le Francois, B. G.; Dimitroulakos, J.] Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; [Zhao, T. T.; Goss, G.] Ottawa Hosp, Res Inst, Dept Med Oncol, Ottawa, ON K1H 1C4, Canada; [Dimitroulakos, J.] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Dimitroulakos, J.] Univ Ottawa, Dept Biochem, Ottawa, ON, Canada; [Ding, K.; Bradbury, P. A.] Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Queens University - Canada; Canadian Cancer Trials Group	Dimitroulakos, J (corresponding author), Ottawa Hosp, Res Inst, Ctr Canc Therapeut, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 1C4, Canada.	jdimitroulakos@ohri.ca	Dimitroulakos, Jim/AAK-3398-2020		Canadian Institute of Health Research; Ontario Institute for Cancer Research	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research	Research support from the Canadian Institute of Health Research (JD) and the Ontario Institute for Cancer Research (JD) is greatly appreciated. We thank Dr D. Gray, Apotex Canada and AstraZeneca UK for generously providing the reagents used in this study.	Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Boulougouris P, 2001, ANTICANCER RES, V21, P2769; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Cabebe Elwyn, 2007, Curr Treat Options Oncol, V8, P15, DOI 10.1007/s11864-007-0022-4; Cicha I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.a3; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Dann SG, 2006, FEBS LETT, V580, P2821, DOI 10.1016/j.febslet.2006.04.068; Darenfed H, 2007, CELL MOTIL CYTOSKEL, V64, P97, DOI 10.1002/cm.20168; Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247; Dimitroulakos J, 2006, CLIN CANCER RES, V12, p4426S, DOI 10.1158/1078-0432.CCR-06-0089; Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Herbst RS, 2003, SEMIN ONCOL, V30, P34, DOI 10.1016/S0093-7754(03)00184-2; Herbst RS, 2002, EXPERT OPIN INV DRUG, V11, P837, DOI 10.1517/13543784.11.6.837; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; Mantha AJ, 2005, CLIN CANCER RES, V11, P2398, DOI 10.1158/1078-0432.CCR-04-1951; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Niknejad N, 2007, J BIOL CHEM, V282, P29748, DOI 10.1074/jbc.M705859200; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Pallet N, 2006, M S-MED SCI, V22, P947, DOI 10.1051/medsci/20062211947; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Thibault A, 1996, CLIN CANCER RES, V2, P483; Thomas AL, 2003, SEMIN ONCOL, V30, P32, DOI 10.1016/S0093-7754(03)00123-4	36	49	49	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4682	4692		10.1038/onc.2010.219	http://dx.doi.org/10.1038/onc.2010.219			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20562912	Bronze			2022-12-17	WOS:000281127400007
J	Post, SM; Quintas-Cardama, A; Terzian, T; Smith, C; Eischen, CM; Lozano, G				Post, S. M.; Quintas-Cardama, A.; Terzian, T.; Smith, C.; Eischen, C. M.; Lozano, G.			p53-dependent senescence delays E mu-myc-induced B-cell lymphomagenesis	ONCOGENE			English	Article						p53; apoptosis; senescence; lymphoma; mouse model	CYCLIN-DEPENDENT KINASES; IN-VIVO; TUMOR-SUPPRESSOR; HUMAN FIBROBLASTS; ONCOGENIC RAS; P53; P21; P21(CIP1/WAF1); P16(INK4A); INHIBITOR	The effect of p53-dependent cell-cycle arrest and senescence on E mu-myc-induced B-cell lymphoma development remains controversial. To address this question, we crossed E mu-myc mice with the p53(515C) mutant mouse, encoding the mutant p53R172P protein that retains the ability to activate the cell-cycle inhibitor and senescence activator p21. Importantly, this mutant lacks the ability to activate p53-dependent apoptotic genes. Hence, E mu-myc mice that harbor two p53(515C) alleles are completely defective for p53-dependent apoptosis. Both E mu-myc::p53(515C/515C) and E mu-myc::p53(515C/+) mice survive significantly longer than E mu-myc::p53(+/-) mice, indicating the importance of the p53-dependent non-apoptotic pathways in B-cell lymphomagenesis. In addition, the p53(515C) allele is deleted in several E mu-myc::p53(515C/+) lymphomas, further emphasizing the functionality of p53R172P in tumor inhibition. Lymphomas from both E mu-myc:: p53(515C/515C) and E mu-myc::p53(515C/+) mice retain the ability to upregulate p21, resulting in cellular senescence. Senescence-associated beta-galactosidase (SA beta-gal) activity was observed in lymphomas from E mu-myc::p53(+/+), E mu-myc::p53(515C/515C) and E mu-myc::p53(515C /+) mice but not in lymphomas isolated from E mu-myc::p53(+/-) mice. Thus, in the absence of p53-dependent apoptosis, the ability of p53R172P to induce senescence leads to a significant delay in B-cell lymphoma development. Oncogene (2010) 29, 1260-1269; doi:10.1038/onc.2009.423; published online 23 November 2009	[Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Unit 1010, Houston, TX 77030 USA; [Quintas-Cardama, A.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Smith, C.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Eischen, C. M.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, Unit 1010, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org			NCI Cancer Center [CA16672]; Ruth L Kirschstein NRSA fellowship [F32CA119616]; Dowdy P Hawn postdoctoral fellowship; NIH [CA82577]; NATIONAL CANCER INSTITUTE [F32CA119616, P30CA016672, R01CA082577] Funding Source: NIH RePORTER	NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L Kirschstein NRSA fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dowdy P Hawn postdoctoral fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tomoo Iwakuma, Arlette Audiffred and Kristina Castro for helpful discussions and technical assistance, and Dr Clifton Stephens for pathological analysis. We thank Drs Jim Jackson and Vinod Pant for review of this paper. Veterinary support and DNA sequencing core facilities were supported by NCI Cancer Center Support Grant CA16672. SMP is supported by a Ruth L Kirschstein NRSA fellowship F32CA119616 and is a recipient of the Dowdy P Hawn postdoctoral fellowship. This study was supported by NIH Grant CA82577 (to GL).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; BEENKEN SW, 1991, NUCLEIC ACIDS RES, V19, P4747, DOI 10.1093/nar/19.17.4747; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; DEIRY WS, 1993, CELL, V75, P817; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HSU B, 1995, ONCOGENE, V11, P175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; TAHARA H, 1995, ONCOGENE, V10, P835; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	36	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1260	1269		10.1038/onc.2009.423	http://dx.doi.org/10.1038/onc.2009.423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19935700	Green Accepted			2022-12-17	WOS:000275170600002
J	Chuan, YC; Iglesias-Gato, D; Fernandez-Perez, L; Cedazo-Minguez, A; Pang, ST; Norstedt, G; Pousette, A; Flores-Morales, A				Chuan, Y-C; Iglesias-Gato, D.; Fernandez-Perez, L.; Cedazo-Minguez, A.; Pang, S-T; Norstedt, G.; Pousette, A.; Flores-Morales, A.			Ezrin mediates c-Myc actions in prostate cancer cell invasion	ONCOGENE			English	Article						ezrin; c-Myc; metastasis; cell invasion; androgen	ANDROGEN RECEPTOR; GENE-EXPRESSION; AKT ACTIVITY; IN-VIVO; PROGRESSION; ACTIVATION; SUPPRESSOR; PATHWAYS; GROWTH; PTEN	The forced overexpression of c-Myc in mouse prostate and in normal human prostate epithelial cells results in tumor transformation with an invasive phenotype. How c-Myc regulates cell invasion is poorly understood. In this study, we have investigated the interplay of c-Myc and androgens in the regulation of prostate cancer cell invasion. We found that c-Myc induces cell invasion and anchorage-independent growth by regulating ezrin protein expression in the presence of androgens. The activity of the ezrin promoter is controlled by androgens through c-Myc, which binds to a phylogenetically conserved E-Box located in the proximal promoter region. Besides, we also show that ezrin is an important regulator of c-Myc protein levels. These effects are achieved through androgen-induced changes in ezrin phosphorylation, which results in the regulation of downstream signals. These downstream signals involve the modulation of Akt and GSK-3 beta activity resulting in increased c-Myc protein synthesis and inhibition of its degradation. In summary, we have shown a key role for ezrin as a mediator of c-Myc-induced tumorigenesis in prostate cancer cells. Oncogene (2010) 29, 1531-1542; doi:10.1038/onc.2009.442; published online 14 December 2009	[Chuan, Y-C] Univ Copenhagen, Fac Hlth Sci, Ctr Prot Res, Novo Nordisk Fdn, DK-2200 Copenhagen, Denmark; [Chuan, Y-C; Iglesias-Gato, D.; Norstedt, G.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Fernandez-Perez, L.] Univ Las Palmas GC, Dept Clin Sci, Las Palmas Gran Canaria, Spain; [Fernandez-Perez, L.] Canary Inst Canc Res, Las Palmas Gran Canaria, Spain; [Cedazo-Minguez, A.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Pang, S-T] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Surg,Div Urol, Tao Yuan, Taiwan; [Pousette, A.] Karolinska Inst, Androl Ctr, Stockholm, Sweden	Novo Nordisk Foundation; University of Copenhagen; Karolinska Institutet; Universidad de Las Palmas de Gran Canaria; Karolinska Institutet; Chang Gung Memorial Hospital; Chang Gung University; Karolinska Institutet	Chuan, YC (corresponding author), Univ Copenhagen, Fac Hlth Sci, Ctr Prot Res, Novo Nordisk Fdn, DK-2200 Copenhagen, Denmark.	yin.choy.chuan@cpr.ku.dk	Fernandez-Perez, Leandro/H-1493-2015; Cedazo-Minguez, Angel/C-6707-2012; Iglesias-Gato, Diego/R-1794-2016	Fernandez-Perez, Leandro/0000-0001-7802-465X; Cedazo-Minguez, Angel/0000-0003-4626-4864; Iglesias-Gato, Diego/0000-0002-8982-9936; Norstedt, Gunnar/0000-0002-7759-3241	Novo Nordisk Foundation Center for Protein Research; Karolinska Institutet, Cancerfonden [45576-B01-01XAB]; Swedish Research Council [VR- 529-2002-6766]; Robert Lundberg Memorial Foundation [2007Lund0045]	Novo Nordisk Foundation Center for Protein Research; Karolinska Institutet, Cancerfonden(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Robert Lundberg Memorial Foundation	We thank Maria Henriksson for providing the c-Myc expression plasmid. The work carried out in this study was in part supported by the Novo Nordisk Foundation Center for Protein Research, Karolinska Institutet, Cancerfonden (45576-B01-01XAB), Swedish Research Council (VR- 529-2002-6766) and the Robert Lundberg Memorial Foundation (2007Lund0045).	Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bonaccorsi L, 2000, ENDOCRINOLOGY, V141, P3172, DOI 10.1210/en.141.9.3172; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; D'Angelo R, 2007, MOL BIOL CELL, V18, P4780, DOI 10.1091/mbc.E06-12-1144; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; Hellerstedt BA, 2003, UROL ONCOL-SEMIN ORI, V21, P272, DOI 10.1016/S1078-1439(03)00046-2; Jenkins RB, 1997, CANCER RES, V57, P524; JOSHUA AM, 2007, BIOCH BIOPHYS ACTA; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Liu J, 2006, CURR TOP MICROBIOL, V302, P1; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Pang ST, 2004, ONCOL REP, V11, P1187; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; Prag S, 2007, MOL BIOL CELL, V18, P2935, DOI 10.1091/mbc.E06-11-1031; SADI MV, 1991, CANCER, V67, P3065, DOI 10.1002/1097-0142(19910615)67:12<3065::AID-CNCR2820671222>3.0.CO;2-U; Sawyer TK, 2004, EXPERT OPIN INV DRUG, V13, P1; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Sun JS, 2007, PROSTATE, V67, P692, DOI 10.1002/pros.20543; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791; Valdman A, 2005, EUR UROL, V48, P852, DOI 10.1016/j.eururo.2005.03.013; Vidal OM, 2007, MOL ENDOCRINOL, V21, P293, DOI 10.1210/me.2006-0096; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Williams K, 2005, PROSTATE, V63, P369, DOI 10.1002/pros.20200; Wu YM, 2004, CANCER RES, V64, P7311, DOI 10.1158/0008-5472.CAN-04-0972	40	49	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1531	1542		10.1038/onc.2009.442	http://dx.doi.org/10.1038/onc.2009.442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20010876				2022-12-17	WOS:000275392400011
J	Roidl, A; Foo, P; Wong, W; Mann, C; Bechtold, S; Berger, HJ; Streit, S; Ruhe, JE; Hart, S; Ullrich, A; Ho, HK				Roidl, A.; Foo, P.; Wong, W.; Mann, C.; Bechtold, S.; Berger, H. J.; Streit, S.; Ruhe, J. E.; Hart, S.; Ullrich, A.; Ho, H. K.			The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells	ONCOGENE			English	Article						cancer; FGFR4; mutation; oncogenesis; proliferation	FACTOR RECEPTOR 4; GROWTH-FACTOR RECEPTOR-3; KINASE GENE FAMILY; PROSTATE-CANCER; ARG388 ALLELE; PROGRESSION; MUTATIONS; EXPRESSION; PROLIFERATION; POLYMORPHISM	Mutational analysis of oncogenes is critical for our understanding of cancer development. Oncogenome screening has identified a fibroblast growth factor receptor 4 (FGFR4) Y367C mutation in the human breast cancer cell line MDA-MB453. Here, we investigate the consequence of this missense mutation in cancer cells. We show that MDA-MB453 cells harbouring the mutation are insensitive to FGFR4-specific ligand stimulation or inhibition with an antagonistic antibody. Furthermore, the FGFR4 mutant elicits constitutive phosphorylation leading to an activation of the mitogen-activated protein kinase cascade as shown by an enhanced Erk1/2 phosphorylation. Cloning and ectopic expression of the FGFR4 Y367C mutant in HEK293 cells revealed high pErk levels and enhanced cell proliferation. Based on these findings, we propose that FGFR4 may be a driver of tumour growth, particularly when highly expressed or stabilized and constitutively activated through genetic alterations. As such, FGFR4 presents an option for further mutational screening in tumours and is an attractive cancer target with the therapeutic potential. Oncogene (2010) 29, 1543-1552; doi:10.1038/onc.2009.432; published online 30 November 2009	[Ho, H. K.] ASTAR, Inst Med Biol, Singapore OncoGenome Programme, Singapore 138648, Singapore; [Roidl, A.; Mann, C.; Bechtold, S.; Berger, H. J.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Max Planck Society	Ho, HK (corresponding author), ASTAR, Inst Med Biol, Singapore OncoGenome Programme, 8A Biomed Grove,06-06 Immunos, Singapore 138648, Singapore.	hankiat.ho@imb.a-star.edu.sg			National Genome Research Network 2/CancerNet [01GS0435]; Agency for Science Technology and Research (A*STAR), Singapore	National Genome Research Network 2/CancerNet; Agency for Science Technology and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR))	We thank Heike Stubbe for excellent technical support and Dr Peter Czernilofsky for critically reading the manuscript. This work was supported by the National Genome Research Network 2/CancerNet, Grant Number: NGFN2/CancerNet no. 01GS0435, and the Agency for Science Technology and Research (A*STAR), Singapore.	Andrea R, 2003, AM J MED GENET A, V121A, P41, DOI 10.1002/ajmg.a.20101; Ansell A, 2009, ORAL ONCOL, V45, P23, DOI 10.1016/j.oraloncology.2008.03.007; Bange J, 2002, CANCER RES, V62, P840; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bignell G, 2006, GENE CHROMOSOME CANC, V45, P42, DOI 10.1002/gcc.20265; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ercolino T, 2008, CLIN ENDOCRINOL, V69, P253, DOI 10.1111/j.1365-2265.2008.03197.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fishman DA, 2001, CANCER RES, V61, P3194; Giri D, 1999, CLIN CANCER RES, V5, P1063; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ho HK, 2009, J HEPATOL, V50, P118, DOI 10.1016/j.jhep.2008.08.015; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Ma ZY, 2008, INT J CANCER, V123, P2574, DOI 10.1002/ijc.23578; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roidl A, 2009, CLIN CANCER RES, V15, P2058, DOI 10.1158/1078-0432.CCR-08-0890; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Ruhe JE, 2007, CANCER RES, V67, P11368, DOI 10.1158/0008-5472.CAN-07-2703; Sasaki H, 2008, ONCOL REP, V20, P1125, DOI 10.3892/or_00000119; SHAOUL E, 1995, ONCOGENE, V10, P1553; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Streit S, 2006, BRIT J CANCER, V94, P1879, DOI 10.1038/sj.bjc.6603181; Streit S, 2004, INT J CANCER, V111, P213, DOI 10.1002/ijc.20204; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587; Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; White KE, 2005, AM J HUM GENET, V76, P361, DOI 10.1086/427956; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	35	49	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1543	1552		10.1038/onc.2009.432	http://dx.doi.org/10.1038/onc.2009.432			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19946327				2022-12-17	WOS:000275392400012
